PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Liang, SQ; Buhrer, ED; Berezowska, S; Marti, TM; Xu, D; Froment, L; Yang, HT; Hall, SRR; Vassella, E; Yang, Z; Kocher, GJ; Amrein, MA; Riether, C; Ochsenbein, AF; Schmid, RA; Peng, RW				Liang, Shun-Qing; Buhrer, Elias D.; Berezowska, Sabina; Marti, Thomas M.; Xu, Duo; Froment, Laurene; Yang, Haitang; Hall, Sean R. R.; Vassella, Erik; Yang, Zhang; Kocher, Gregor J.; Amrein, Michael A.; Riether, Carsten; Ochsenbein, Adrian F.; Schmid, Ralph A.; Peng, Ren-Wang			mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; MAMMALIAN TARGET; STEM-CELLS; PHASE-II; EVEROLIMUS; DRUG; PHOSPHORYLATION; PROGRESSION; NSCLC; EMT	Oncogenic KRAS mutations comprise the largest subset of lung cancer defined by genetic alterations, but in the clinic no targeted therapies are available that effectively control mutational KRAS activation. Consequently, patients with KRASdriven tumors are routinely treated with cytotoxic chemotherapy, which is often transiently effective owing to development of drug resistance. In this study, we show that hyperactivated mammalian target of rapamycin (mTOR) pathway is a characteristic hallmark of KRAS-mutant lung adenocarcinoma after chemotherapy treatment, and that KRAS-mutant lung cancer cells rely on persistent mTOR signaling to resist chemotherapeutic drugs. Coherently, mTOR inhibition circumvents the refractory phenotype and restores sensitivity of resistant KRAS-mutant lung cancer cells to chemotherapy. Importantly, drug combinations of clinically approved mTOR inhibitors and chemotherapy drugs synergize in inhibiting cell proliferation of KRAS-mutant cancer cells in vitro and in vivo, and the efficacy of this combination treatment correlates with the magnitude of mTOR activity induced by chemotherapy alone. These results pinpoint mTOR as a mechanism of resistance to chemotherapy in KRAS-mutant lung cancer and validate a rational and readily translatable strategy that combines mTOR inhibitors with standard chemotherapy to treat KRAS-mutant adenocarcinoma, the most common and deadliest lung cancer subset.	[Liang, Shun-Qing; Marti, Thomas M.; Xu, Duo; Froment, Laurene; Yang, Haitang; Hall, Sean R. R.; Yang, Zhang; Kocher, Gregor J.; Schmid, Ralph A.; Peng, Ren-Wang] Bern Univ Hosp, Inselspital, Div Gen Thorac Surg, Bern, Switzerland; [Liang, Shun-Qing; Marti, Thomas M.; Xu, Duo; Froment, Laurene; Yang, Haitang; Hall, Sean R. R.; Yang, Zhang; Kocher, Gregor J.; Schmid, Ralph A.; Peng, Ren-Wang] Univ Bern, Dept BioMed Res DBMR, Bern, Switzerland; [Buhrer, Elias D.; Amrein, Michael A.; Riether, Carsten; Ochsenbein, Adrian F.] Univ Bern, Dept BioMed Res DBMR, Tumor Immunol, Bern, Switzerland; [Berezowska, Sabina; Vassella, Erik] Univ Bern, Inst Pathol, Bern, Switzerland; [Xu, Duo; Yang, Haitang; Yang, Zhang] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland; [Riether, Carsten; Ochsenbein, Adrian F.] Bern Univ Hosp, Inselspital, Dept Med Oncol, Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University of Bern; University of Bern; University of Bern; University of Bern; University Hospital of Bern	Schmid, RA; Peng, RW (corresponding author), Bern Univ Hosp, Inselspital, Div Gen Thorac Surg, Bern, Switzerland.; Schmid, RA; Peng, RW (corresponding author), Univ Bern, Dept BioMed Res DBMR, Bern, Switzerland.	Ralph.Schmid@insel.ch; Renwang.Peng@insel.ch	Liang, Shunqing/GXG-2346-2022; DUO, XU/AAC-8882-2021; Peng, Ren-Wang/AAM-8542-2021; Riether, Carsten/K-8603-2013; Liang, Shunqing/AHE-6842-2022; Berezowska, Sabina/AAJ-4557-2021; Riether, Carsten/ABC-7699-2021; Yang, Haitang/N-5141-2019; Kocher, Gregor Jan/GQZ-1359-2022; Yang, Haitang/AAS-6986-2020; Marti, Thomas/AAW-5232-2020	Liang, Shunqing/0000-0003-4664-6029; Peng, Ren-Wang/0000-0003-1199-6520; Riether, Carsten/0000-0001-7512-513X; Liang, Shunqing/0000-0003-4664-6029; Berezowska, Sabina/0000-0001-5442-9791; Riether, Carsten/0000-0001-7512-513X; Kocher, Gregor Jan/0000-0001-6531-2919; Yang, Haitang/0000-0002-8732-5910; Marti, Thomas/0000-0003-3005-220X; Amrein, Michael Alex/0000-0002-0378-8070; Ochsenbein, Adrian/0000-0003-1773-5436; Yang, Zhang/0000-0001-8592-5800; Schmid, Ralph Alexander/0000-0003-0699-079X	Swiss Cancer League [KFS-3772-08-2015]; Cancer League of the Canton of Bern; China Scholarship Council	Swiss Cancer League; Cancer League of the Canton of Bern; China Scholarship Council(China Scholarship Council)	We gratefully acknowledge Lung Cancer Center (LCC), Bern University Hospital and the Tissue Bank Bern (TBB), Institute of Pathology, University of Bern, in acquiring patient tissues. We thank Silvia Suardi and Jose Galvan (Institute of Pathology) and Colin Tieche and Ming Qiao (Division of General Thoracic Surgery) for technical assistance and help with data acquisition and analysis, Dr. med. Michael von Gunten (Pathologie Langgasse, Bern, Switzerland) and Dr. med. Mathias Gugger (Promed SA Laboratoire medical, Freiburg, Switzerland) for providing pre-chemotherapy biopsies, professor Marianne Geiser (Institute of Anatomy, University of Bern, Bern, Switzerland) and Dr. Yitzhak Zimmer (Department of Radiation Oncology, Bern University Hospital, Bern, Switzerland) for cell lines. This work was supported by Swiss Cancer League (#KFS-3772-08-2015; to R.-W. Peng), Cancer League of the Canton of Bern (to R-W. Peng), a PhD fellowship from China Scholarship Council (to S.-Q. Liang) and a MD-PhD fellowship from Swiss Cancer League (to E.D. Buhrer).	Bartucci M, 2012, CELL DEATH DIFFER, V19, P768, DOI 10.1038/cdd.2011.170; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Coffee EM, 2013, CLIN CANCER RES, V19, P2688, DOI 10.1158/1078-0432.CCR-12-2556; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Corcoran RB, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005753; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Farge T, 2017, CANCER DISCOV, V7, P716, DOI 10.1158/2159-8290.CD-16-0441; Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226; Goffin J, 2010, J THORAC ONCOL, V5, P260, DOI 10.1097/JTO.0b013e3181c6f035; Granville CA, 2007, CLIN CANCER RES, V13, P2281, DOI 10.1158/1078-0432.CCR-06-2570; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hegde GV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045647; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Kahan BD, 2000, LANCET, V356, P194, DOI 10.1016/S0140-6736(00)02480-6; Kawabata S, 2014, CELL REP, V7, P1824, DOI 10.1016/j.celrep.2014.05.039; Kawabata S, 2014, ONCOTARGET, V5, P1062, DOI 10.18632/oncotarget.1760; Kharbanda A, 2014, ONCOTARGET, V5, P8893, DOI 10.18632/oncotarget.2360; Langsch S, 2016, CANCER RES, V76, P4160, DOI 10.1158/0008-5472.CAN-15-2580; Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001; Liang SQ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.195; Liu LZ, 2007, CANCER RES, V67, P6325, DOI 10.1158/0008-5472.CAN-06-4261; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Papadimitrakopoulou VA, 2012, J THORAC ONCOL, V7, P1594, DOI 10.1097/JTO.0b013e3182614835; Pirazzoli V, 2014, CELL REP, V7, P999, DOI 10.1016/j.celrep.2014.04.014; Price KA, 2010, J THORAC ONCOL, V5, P1623, DOI 10.1097/JTO.0b013e3181ec1531; Ramalingam SS, 2013, J THORAC ONCOL, V8, P369, DOI 10.1097/JTO.0b013e318282709c; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Thoma CR, 2014, ADV DRUG DELIVER REV, V69, P29, DOI 10.1016/j.addr.2014.03.001; Vansteenkiste J, 2011, J THORAC ONCOL, V6, P2120, DOI 10.1097/JTO.0b013e3182307ede; Vasan N, 2014, CLIN CANCER RES, V20, P3921, DOI 10.1158/1078-0432.CCR-13-1762; Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382; Yoshizawa A, 2010, CLIN CANCER RES, V16, P240, DOI 10.1158/1078-0432.CCR-09-0986; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050; Zheng YY, 2013, CANCER CELL, V24, P59, DOI 10.1016/j.ccr.2013.05.021	46	28	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					622	636		10.1038/s41388-018-0479-6	http://dx.doi.org/10.1038/s41388-018-0479-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171261				2022-12-17	WOS:000457300300002
J	Li, H; Tian, ZF; Qu, YP; Yang, Q; Guan, HX; Shi, BY; Ji, MJ; Hou, P				Li, Heng; Tian, Zhufang; Qu, Yiping; Yang, Qi; Guan, Haixia; Shi, Bingyin; Ji, Meiju; Hou, Peng			SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis	ONCOGENE			English	Article							CELL-LINES; CANCER; NICOTINAMIDE; EXPRESSION; CARCINOMA; APOPTOSIS; SURVIVAL; TARGET; MTOR; S6K1	SIRT7 is an NAD(+)-dependent histone/non-histone deacetylase, which is highly expressed in different types of cancer including thyroid cancer; however, its biological function in thyroid cancer is still undiscovered. In this study, we found that SIRT7 expression was elevated in papillary thyroid cancers (PTCs), and demonstrated that SIRT7 knockdown dramatically inhibited the proliferation, colony formation, migration and invasion of thyroid cancer cells, and induced thyroid cancer cell cycle arrest and apoptosis. Conversely, SIRT7 re-expression markedly enhanced thyroid cancer cell growth, invasiveness and tumorigenic potential in nude mice. Further studies revealed that SIRT7 exerted an oncogenic function in thyroid tumorigenesis by phosphorylation of Akt and p70S6K1. Mechanistically, SIRT7 binds to the promoter of deleted in breast cancer-1 (DBC1), an endogenous inhibitor of SIRT1, and represses its transcription via deacetylation of H3K18Ac. This results in enhanced interactions between SIRT1 and Akt or p70S6K1, thereby promoting deacetylation and subsequent phosphorylation of Akt and p70S6K1 through a SIRT1-dependent manner. Altogether, our results show that DBC1 is a downstream target of SIRT7, and first uncover that SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via the modulation of DBC1/SIRT1 axis.	[Li, Heng; Qu, Yiping; Yang, Qi; Shi, Bingyin; Hou, Peng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China; [Li, Heng; Tian, Zhufang] Xian Cent Hosp, Dept Endocrinol, Xian 710003, Shaanxi, Peoples R China; [Guan, Haixia] China Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Shenyang 110001, Liaoning, Peoples R China; [Shi, Bingyin; Hou, Peng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China; [Ji, Meiju] Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Translat Med, Xian 710061, Shaanxi, Peoples R China	Xi'an Jiaotong University; China Medical University; Xi'an Jiaotong University; Xi'an Jiaotong University	Hou, P (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China.; Hou, P (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China.; Ji, MJ (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Translat Med, Xian 710061, Shaanxi, Peoples R China.	mjji0409@163.com; phou@xjtu.edu.cn			National Natural Science Foundation of China [81372217, 81572627, 81672645]; China International Medical Foundation [2016-N-07-12]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China International Medical Foundation	We would like to thank Drs. Haixia Guan (The First Affiliated Hospital of China Medical University, Shenyang, China) and Lei Ye (Ruijin Hospital, Shanghai, China) for kindly providing human thyroid cancer cell lines. This work was supported by the National Natural Science Foundation of China (no. 81372217, 81572627 and 81672645), and the China International Medical Foundation (no. 2016-N-07-12).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Ashraf N, 2006, BRIT J CANCER, V95, P1056, DOI 10.1038/sj.bjc.6603384; Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burns WR, 2010, SEMIN ONCOL, V37, P557, DOI 10.1053/j.seminoncol.2010.10.008; Chalkiadaki A, 2015, NAT REV CANCER, V15, DOI 10.1038/nrc3985; Chen SF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10734; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; de Nigris F, 2002, BRIT J CANCER, V86, P917, DOI 10.1038/sj.bjc.6600156; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Ford E, 2006, GENE DEV, V20, P1075, DOI 10.1101/gad.1399706; Frye R, 2002, BRIT J CANCER, V87, P1479, DOI 10.1038/sj.bjc.6600635; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Herranz D, 2013, ONCOGENE, V32, P4052, DOI 10.1038/onc.2012.407; Hong SK, 2014, J BIOL CHEM, V289, P13132, DOI 10.1074/jbc.M113.520734; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Kang H, 2011, MOL CELL, V44, P203, DOI 10.1016/j.molcel.2011.07.038; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JK, 2013, HEPATOLOGY, V57, P1055, DOI 10.1002/hep.26101; Kim LC, 2017, ONCOGENE, V36, P2191, DOI 10.1038/onc.2016.363; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Petrulea MS, 2015, CANCER TREAT REV, V41, P707, DOI 10.1016/j.ctrv.2015.06.005; Qu N, 2017, INT J ONCOL, V50, P1683, DOI 10.3892/ijo.2017.3951; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Shackelford R, 2013, ANTICANCER RES, V33, P3047; Shi J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.346; Shi J, 2015, ONCOTARGET, V6, P14344, DOI 10.18632/oncotarget.3852; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sundaresan NR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001465; Toker A, 2008, MOL CELL, V31, P6, DOI 10.1016/j.molcel.2008.06.007; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Yu HY, 2014, CLIN CANCER RES, V20, P3434, DOI 10.1158/1078-0432.CCR-13-2952; Yu J, 2017, CELL REP, V18, P1229, DOI 10.1016/j.celrep.2017.01.009; Zhang PY, 2016, NUCLEIC ACIDS RES, V44, P3629, DOI 10.1093/nar/gkv1504; Zhang S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09787; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515	41	28	31	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					345	359		10.1038/s41388-018-0434-6	http://dx.doi.org/10.1038/s41388-018-0434-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30093629				2022-12-17	WOS:000455851200004
J	Bai, J; Yeh, SY; Qiu, XF; Hu, LY; Zeng, J; Cai, YK; Zuo, L; Li, GH; Yang, GS; Chang, C				Bai, Jian; Yeh, Shuyuan; Qiu, Xiaofu; Hu, Linyi; Zeng, Jun; Cai, Yangke; Zuo, Li; Li, Gonghui; Yang, Guosheng; Chang, Chawnshang			TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; ORPHAN RECEPTORS; GENE-EXPRESSION; VIMENTIN; INVASION; PROLIFERATION; TUMORIGENESIS; SUPERFAMILY; GROWTH; LUNG	While TR4 nuclear receptor plays key roles to promote prostate cancer progression, its roles to alter the progression of clear cell renal cell carcinoma (ccRCC), remains unclear. Here, we demonstrate that TR4 can promote the ccRCC cell vasculogenic mimicry (VM) formation and its associated metastasis via modulating the miR490-3p/vimentin (VIM) signals. Mechanism dissection revealed that TR4 might increase the oncogene VIM expression via decreasing the miR-490-3p expression through direct binding to the TR4-response-elements (TR4REs) on the promoter region of miR-490-3p, which might then directly target the 3' UTR of VIM-mRNA to increase its protein expression. Preclinical studies using the in vivo mouse model with xenografted RCC Caki-1 cells into the sub-renal capsule of nude mice also found that TR4 could promote the ccRCC VM and its associated metastasis via modulating the miR490-3p/VIM signals. Together, results from preclinical studies using multiple RCC cell lines and the in vivo mouse model all conclude that TR4 may play a key role to promote ccRCC VM formation and metastasis and targeting the newly identified TR4/miR-490-3p/VIM signals with small molecules may help us to develop a new therapeutic approach to better suppress the ccRCC metastasis.	[Bai, Jian; Qiu, Xiaofu; Zeng, Jun; Cai, Yangke; Zuo, Li; Yang, Guosheng] Guangdong Second Prov Gen Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Bai, Jian; Yeh, Shuyuan; Qiu, Xiaofu; Hu, Linyi; Li, Gonghui; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Bai, Jian; Yeh, Shuyuan; Qiu, Xiaofu; Hu, Linyi; Li, Gonghui; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Bai, Jian; Yeh, Shuyuan; Qiu, Xiaofu; Hu, Linyi; Li, Gonghui; Chang, Chawnshang] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA; [Zuo, Li] Nanjing Med Univ, Peoples Affiliated Hosp 2, Dept Urol, Nanjing, Jiangsu, Peoples R China; [Chang, Chawnshang] China Med Univ & Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan	University of Rochester; University of Rochester; University of Rochester; Nanjing Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Yang, GS (corresponding author), Guangdong Second Prov Gen Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA.; Chang, C (corresponding author), China Med Univ & Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan.	2008yangguosheng@sina.com; chang@urmc.rochester.edu		Chang, Chawnshang/0000-0001-8510-3516	NIH [CA155477, CA156700]; George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence [DOH99-TD-B-111-004]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence	This work was supported by NIH grants (CA155477 and CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial, Research Center of Excellence (DOH99-TD-B-111-004 to China Medical University, Taichung, Taiwan). We thank Karen Wolf for help preparing the manuscript.	Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Chen K, 2016, BIOL CELL, V108, P41, DOI 10.1111/boc.201500033; Chen S, 2015, CANCER LETT, V362, P122, DOI 10.1016/j.canlet.2015.03.029; Chen XY, 2014, CLIN CANCER RES, V20, P2617, DOI 10.1158/1078-0432.CCR-13-3224; Chen YT, 2007, BRAIN RES, V1168, P72, DOI 10.1016/j.brainres.2007.06.069; Choi H, 2011, FEBS LETT, V585, P2763, DOI 10.1016/j.febslet.2011.08.002; Ciamporcero E, 2015, MOL CANCER THER, V14, P101, DOI 10.1158/1535-7163.MCT-14-0094; Collins LL, 2004, P NATL ACAD SCI USA, V101, P15058, DOI 10.1073/pnas.0405700101; Comperat E, 2012, Diagn Interv Imaging, V93, P221, DOI 10.1016/j.diii.2012.01.015; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Ding XF, 2015, INT J CANCER, V136, P955, DOI 10.1002/ijc.29049; Fuyuhiro Y, 2010, ANTICANCER RES, V30, P5239; Gilles C, 2003, CANCER RES, V63, P2658; Gu HH, 2014, BIOCHEM BIOPH RES CO, V444, P104, DOI 10.1016/j.bbrc.2014.01.020; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Lee YF, 2002, J STEROID BIOCHEM, V81, P291, DOI 10.1016/S0960-0760(02)00118-8; Li M, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-109; Lin SJ, 2014, CARCINOGENESIS, V35, P1399, DOI 10.1093/carcin/bgu052; Lin SJ, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-43; Liu QQ, 2016, J CELL MOL MED, V20, P1761, DOI 10.1111/jcmm.12851; Liu W, 2015, FEBS LETT, V589, P3148, DOI 10.1016/j.febslet.2015.08.034; Majid S, 2011, CANCER RES, V71, P2611, DOI 10.1158/0008-5472.CAN-10-3666; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mu XM, 2004, MOL CELL BIOL, V24, P5887, DOI 10.1128/MCB.24.13.5887-5899.2004; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Qiao LL, 2015, J CELL MOL MED, V19, P315, DOI 10.1111/jcmm.12496; Qiu XF, 2015, ONCOTARGET, V6, P15397, DOI 10.18632/oncotarget.3778; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Shen J, 2015, CANCER RES, V75, P754, DOI 10.1158/0008-5472.CAN-14-1301; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Song QC, 2014, CANCER RES, V74, P3031, DOI 10.1158/0008-5472.CAN-13-2193; Stadler WM, 2005, CANCER-AM CANCER SOC, V104, P2323, DOI 10.1002/cncr.21453; Trog D, 2008, AMINO ACIDS, V34, P539, DOI 10.1007/s00726-007-0007-4; UPTON MP, 1986, AM J SURG PATHOL, V10, P560, DOI 10.1097/00000478-198608000-00006; Yamasaki T, 2013, J UROLOGY, V190, P1059, DOI 10.1016/j.juro.2013.02.089; Yang DR, 2013, J BIOL CHEM, V288, P16476, DOI 10.1074/jbc.M112.448142; Zhang LY, 2013, J BIOL CHEM, V288, P4035, DOI 10.1074/jbc.M112.410506; Zhao Y, 2008, CELL BIOCHEM FUNCT, V26, P571, DOI 10.1002/cbf.1478; Zhou L, 2016, J UROLOGY, V196, P335, DOI 10.1016/j.juro.2016.02.2971; Zhu J, 2015, MOL CANCER THER, V14, P1445, DOI 10.1158/1535-7163.MCT-14-0971; Zoni E, 2015, CANCER RES, V75, P2326, DOI 10.1158/0008-5472.CAN-14-2155	46	28	28	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5901	5912		10.1038/s41388-018-0269-1	http://dx.doi.org/10.1038/s41388-018-0269-1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29973687				2022-12-17	WOS:000448943100007
J	Seidi, K; Jahanban-Esfahlan, R; Monhemi, H; Zare, P; Minofar, B; Adli, ADF; Farajzadeh, D; Behzadi, R; Abbasi, MM; Neubauer, HA; Moriggl, R; Zarghami, N; Javaheri, T				Seidi, Khaled; Jahanban-Esfahlan, Rana; Monhemi, Hassan; Zare, Peyman; Minofar, Babak; Adli, Amir Daei Farshchi; Farajzadeh, Davoud; Behzadi, Ramezan; Abbasi, Mehran Mesgari; Neubauer, Heidi A.; Moriggl, Richard; Zarghami, Nosratollah; Javaheri, Tahereh			NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth	ONCOGENE			English	Article							ANTI-ANGIOGENIC THERAPY; TISSUE FACTOR; TARGETING AGENTS; MOUSE MODEL; INFARCTION; STAPHYLOCOAGULASE; MICE; VESSELS; METASTASIS; ACTIVATION	Induction of selective thrombosis and infarction in tumor-feeding vessels represents an attractive strategy to combat cancer. Here we took advantage of the unique coagulation properties of staphylocoagulase and genetically engineered it to generate a new fusion protein with novel anti-cancer properties. This novel bi-functional protein consists of truncated coagulase (tCoa) and an NGR (GNGRAHA) motif that recognizes CD13 and alpha(v)beta(3) integrin receptors, targeting it to tumor endothelial cells. Herein, we report that tCoa coupled by its C-terminus to an NGR sequence retained its normal binding activity with prothrombin and alpha(v)beta(3) integrins, as confirmed in silico and in vitro. Moreover, in vivo biodistribution studies demonstrated selective accumulation of FITC-labeled tCoa-NGR fusion proteins at the site of subcutaneously implanted PC3 tumor xenografts in nude mice. Notably, systemic administration of tCoa-NGR to mice bearing 4T1 mouse mammary xenografts or PC3 human prostate tumors resulted in a significant reduction in tumor growth. These anti-tumor effects were accompanied by massive thrombotic occlusion of small and large tumor vessels, tumor infarction and tumor cell death. From these findings, we propose tCoa-NGR mediated tumor infarction as a novel and promising anti-cancer strategy targeting both CD13 and integrin alpha(v)beta(3) positive tumor neovasculature.	[Seidi, Khaled; Jahanban-Esfahlan, Rana; Adli, Amir Daei Farshchi; Zarghami, Nosratollah] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Biotechnol, Tabriz, Iran; [Monhemi, Hassan] Univ Neyshabour, Dept Chem, Khorasan Razavi Prov, Neyshabour, Iran; [Zare, Peyman] Univ Tabriz, Fac Vet Sci, Dept Pathobiol, Tabriz, Iran; [Minofar, Babak] Acad Sci Czech Republ, Ctr Nanobiol & Struct Biol, Inst Microbiol, Zamek 136, Nove Hrady 37333, Czech Republic; [Minofar, Babak] Univ South Bohemia, Fac Sci, Branisovska 1760, Ceske Budejovice 37005, Czech Republic; [Farajzadeh, Davoud] Azarbaijan Shahid Madani Univ, Fac Biol Sci, Dept Cellular & Mol Biol, Tabriz, Iran; [Behzadi, Ramezan] Pasture Inst Iran, North Res Ctr, Amol, Iran; [Abbasi, Mehran Mesgari] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran; [Neubauer, Heidi A.; Moriggl, Richard; Javaheri, Tahereh] Ludwig Boltzmann Inst Canc Res, A-1090 Vienna, Austria; [Neubauer, Heidi A.; Moriggl, Richard; Javaheri, Tahereh] Univ Vet Med Vienna, Inst Anim Breeding & Genet, A-1210 Vienna, Austria; [Moriggl, Richard] Med Univ Vienna, A-1090 Vienna, Austria; [Zarghami, Nosratollah] Tabriz Univ Med Sci, Fac Med, Dept Clin Biochem, Tabriz, Iran; [Zarghami, Nosratollah] Tabriz Univ Med Sci, Fac Med, Lab Med, Tabriz, Iran; [Zarghami, Nosratollah] Iranian Natl Sci Fdn, Tehran, Iran	Tabriz University of Medical Science; University of Tabriz; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of South Bohemia Ceske Budejovice; Azarbaijan Shahid Madani University; Tabriz University of Medical Science; Ludwig Boltzmann Institute; University of Veterinary Medicine Vienna; Medical University of Vienna; Tabriz University of Medical Science; Tabriz University of Medical Science	Zarghami, N (corresponding author), Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Biotechnol, Tabriz, Iran.; Javaheri, T (corresponding author), Ludwig Boltzmann Inst Canc Res, A-1090 Vienna, Austria.; Javaheri, T (corresponding author), Univ Vet Med Vienna, Inst Anim Breeding & Genet, A-1210 Vienna, Austria.; Zarghami, N (corresponding author), Tabriz Univ Med Sci, Fac Med, Dept Clin Biochem, Tabriz, Iran.; Zarghami, N (corresponding author), Tabriz Univ Med Sci, Fac Med, Lab Med, Tabriz, Iran.; Zarghami, N (corresponding author), Iranian Natl Sci Fdn, Tehran, Iran.	Zarghami@tbzmed.ac.ir; Tahereh.Javaheri@lbicr.lbg.ac.at	Farajzadeh, Davoud/AAQ-5732-2021; Zare, Peyman/ABE-6329-2020; Moriggl, Richard/H-8118-2019; Minofar, Babak/I-4326-2012; Farajzadeh, Davoud/W-2236-2017; Neubauer, Heidi A./AAD-8727-2019; Minofar, Babak/I-4326-2012	Zare, Peyman/0000-0003-1291-1808; Moriggl, Richard/0000-0003-0918-9463; Minofar, Babak/0000-0002-0188-0471; Farajzadeh, Davoud/0000-0002-9267-4277; Neubauer, Heidi/0000-0001-7372-7786; Minofar, Babak/0000-0001-8096-2194	Drug Applied Research Center, Tabriz University of Medical Sciences; Iran National Science Foundation (INSF) [90007316]	Drug Applied Research Center, Tabriz University of Medical Sciences; Iran National Science Foundation (INSF)(Iran National Science Foundation (INSF))	This study was funded by Drug Applied Research Center, Tabriz University of Medical Sciences (IR) and the Iran National Science Foundation (INSF) (Grant No: 90007316).	Adli ADF, 2018, CHEM BIOL DRUG DES, V91, P996, DOI 10.1111/cbdd.13166; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; Bieker R, 2009, BLOOD, V113, P5019, DOI 10.1182/blood-2008-04-150318; Brand C, 2016, ONCOTARGET, V7, P6774, DOI 10.18632/oncotarget.6725; Chen J, 2001, THROMB HAEMOSTASIS, V86, P334; Cheng AG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001036; Corti A, 2008, BLOOD, V112, P2628, DOI 10.1182/blood-2008-04-150862; Corti A, 2011, CURR PHARM BIOTECHNO, V12, P1128, DOI 10.2174/138920111796117373; Delano W.L., 2002, PYMOL MOL GRAPHICS S; Dreischaluck J, 2010, INT J ONCOL, V37, P1389, DOI 10.3892/ijo_00000790; Friedrich R, 2006, J BIOL CHEM, V281, P1188, DOI 10.1074/jbc.M507957200; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; Hashida H, 2002, GASTROENTEROLOGY, V122, P376, DOI 10.1053/gast.2002.31095; Hu PS, 2003, CANCER RES, V63, P5046; Huang FY, 2008, J ZHEJIANG UNIV-SC B, V9, P602, DOI 10.1631/jzus.B0820120; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; Huang ZJ, 2013, SCI WORLD J, DOI 10.1155/2013/637086; Huang Zheng-jie, 2012, Zhonghua Zhong Liu Za Zhi, V34, P249, DOI 10.3760/cma.j.issn.0253-3766.2012.04.003; Jahanban-Esfahlan R, 2018, J CELL PHYSIOL, V233, P2982, DOI 10.1002/jcp.26051; Jahanban-Esfahlan R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05326-9; Jahanban-Esfahlan R, 2018, J CELL PHYSIOL, V233, P2019, DOI 10.1002/jcp.25859; Jahanban-Esfahlan R, 2017, INT J HEMATOL, V105, P244, DOI 10.1007/s12185-016-2171-3; Javaheri T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.268; Kastrup CJ, 2008, NAT CHEM BIOL, V4, P742, DOI 10.1038/nchembio.124; Kazemi Z, 2016, MOL PHARMACOL, V89, P630, DOI 10.1124/mol.116.103267; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kessler T, 2005, CLIN CANCER RES, V11, P6317, DOI 10.1158/1078-0432.CCR-05-0389; Kubota Yoshiaki, 2012, Keio Journal of Medicine, V61, P47; Liu C, 2002, CANCER RES, V62, P5470; Liu ZF, 2008, DRUG DEVELOP RES, V69, P329, DOI 10.1002/ddr.20265; McAdow M, 2012, INFECT IMMUN, V80, P3389, DOI 10.1128/IAI.00562-12; Minas TZ, 2017, ONCOTARGET, V8, P34141, DOI 10.18632/oncotarget.9388; Minas TZ, 2015, ONCOTARGET, V6, P37678, DOI 10.18632/oncotarget.5520; MOJOVIC B, 1969, YALE J BIOL MED, V42, P11; Nierodzik ML, 2006, CANCER CELL, V10, P355, DOI 10.1016/j.ccr.2006.10.002; Nilsson F, 2001, CANCER RES, V61, P711; Panizzi P, 2006, J BIOL CHEM, V281, P1179, DOI 10.1074/jbc.M507956200; Panizzi P, 2004, CELL MOL LIFE SCI, V61, P2793, DOI 10.1007/s00018-004-4285-7; PENCIK J, 2015, NAT COMMUN, V6; Ran S, 1998, CANCER RES, V58, P4646; Seidi K, 2018, J CONTROL RELEASE, V275, P142, DOI 10.1016/j.jconrel.2018.02.020; Seidi K, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691001; SMITH DD, 1958, BRIT J EXP PATHOL, V39, P165; Thorpe PE, 2004, CLIN CANCER RES, V10, P415, DOI 10.1158/1078-0432.CCR-0642-03; Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038/nrc1628; van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014; Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Yokota N, 2014, J THROMB HAEMOST, V12, P71, DOI 10.1111/jth.12442	49	28	31	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3967	3980		10.1038/s41388-018-0213-4	http://dx.doi.org/10.1038/s41388-018-0213-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29662195	hybrid, Green Published			2022-12-17	WOS:000439101300005
J	Li, K; Zhang, TT; Wang, F; Cui, B; Zhao, CX; Yu, JJ; Lv, XX; Zhang, XW; Yang, ZN; Huang, B; Li, X; Hua, F; Hu, ZW				Li, Ke; zhang, Ting-ting; Wang, Feng; Cui, Bing; Zhao, Chen-xi; Yu, Jiao-jiao; Lv, Xiao-xi; Zhang, Xiao-wei; Yang, Zhao-na; Huang, Bo; Li, Xia; Hua, Fang; Hu, Zhuo-wei			Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression	ONCOGENE			English	Article							CELL-MIGRATION; BREAST-CANCER; DOUBLE-BLIND; TIP60; TRB3; PHOSPHORYLATION; PATHWAY; GROWTH; INVASION; KINASE	Metformin has beneficial effects of preventing and treating cancers on type 2 diabetic patients. However, the role of metformin in non-diabetic cancer patients and the precise molecular mechanisms against cancer have not yet been sufficiently elucidated. We recently reported that the pseudokinase protein TRIB3 acts as a stress sensor linking metabolic stressors to cancer promotion by inhibiting autophagy and ubiquitin-proteasomal degradation systems; genetically abrogating of TRIB3 expression reduces tumourigenesis and cancer progression. Thus, TRIB3 is a potential therapeutic target for diverse cancers. In this study, we found that metformin attenuates melanoma growth and metastasis by reducing TRIB3 expression in non-diabetic C57BL/6 mice and diabetic KK-Ay mice; overexpression of TRIB3 protects metformin from the activation of autophagic flux, the clearance of accumulated tumour-promoting factors and the attenuation of tumour progression. We further elucidated that TRIB3 acts as an adaptor to recruit lysine acetyltransferase 5 (KAT5) to SMAD3 and induce a phosphorylation-dependent K333 acetylation of SMAD3, which sustains transcriptional activity of SMAD3 and subsequently enhances TRIB3 transcription. Metformin suppresses SMAD3 phosphorylation and decreases the KAT5/SMAD3 interaction, to attenuate the KAT5-mediated K333 acetylation of SMAD3, reduce the SMAD3 transcriptional activity and subsequent TRIB3 expression, thereby antagonizes melanoma progression. Together, our study not only defines a molecular mechanism by which metformin protects against melanoma progression by disturbing the KAT5/TRIB3/SMAD3 positive feedback loop in diabetes and non-diabetes mice, but also suggests a candidate diverse utility of metformin in tumour prevention and therapy because of suppressing stress protein TRIB3 expression.	[Li, Ke; Wang, Feng; Cui, Bing; Zhao, Chen-xi; Yu, Jiao-jiao; Lv, Xiao-xi; Zhang, Xiao-wei; Yang, Zhao-na; Hua, Fang; Hu, Zhuo-wei] Chinese Acad Med Sci, Inst Mat Med, Immunol & Canc Pharmacol Grp, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China; [Li, Ke; Wang, Feng; Cui, Bing; Zhao, Chen-xi; Yu, Jiao-jiao; Lv, Xiao-xi; Zhang, Xiao-wei; Yang, Zhao-na; Huang, Bo; Hua, Fang; Hu, Zhuo-wei] Peking Union Med Coll, Beijing 100050, Peoples R China; [Li, Ke] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China; [zhang, Ting-ting; Li, Xia] Shandong Univ, Weihai 264209, Peoples R China; [Huang, Bo] Chinese Acad Med Sci, Inst Basic Med, Beijing 100050, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Materia Medica - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medicinal Biotechnology - CAMS; Shandong University; Chinese Academy of Medical Sciences - Peking Union Medical College	Hua, F; Hu, ZW (corresponding author), Chinese Acad Med Sci, Inst Mat Med, Immunol & Canc Pharmacol Grp, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China.; Hua, F; Hu, ZW (corresponding author), Peking Union Med Coll, Beijing 100050, Peoples R China.	huafang@imm.ac.cn; huzhuowei@imm.ac.cn	Cui, Bing/F-3599-2018	Cui, Bing/0000-0001-8374-7801; hu, zhuowei/0000-0001-9569-1016	National Key R&D Program of China [2017YFA0205400]; National Natural Science Foundation of China [81530093, 81773781, 81101595, 81472717, 81400140, 81503128]; Beijing Natural Science Foundation [7162133]; CAMS Innovation Found for Medical Sciences [2016-I2M1-007, 2016-I2M-1-011, 2016-I2M-3-008, 2016-I2M-1-008]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); CAMS Innovation Found for Medical Sciences	This work was supported by grants from National Key R&D Program of China (2017YFA0205400), from National Natural Science Foundation of China (81530093, 81773781 to Z.W.H.; 81101595, 81472717 to F.H.; 81400140 to K.L., 81503128 to X.X.L.), from Beijing Natural Science Foundation (7162133 to F.H.), and from CAMS Innovation Found for Medical Sciences (2016-I2M1-007 to Z.W.H., F.H. and C.X.Z.; 2016-I2M-1-011 to K.L.; 2016-I2M-3-008 to B.C. and J.J.Y.; 2016-I2M-1-008 to X.X.L.).	Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; Cerezo M, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12267; Cerezo M, 2013, MOL CANCER THER, V12, P1605, DOI 10.1158/1535-7163.MCT-12-1226-T; Chen GD, 2012, J INVEST DERMATOL, V132, P2632, DOI 10.1038/jid.2012.193; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Eyers PA, 2017, TRENDS CELL BIOL, V27, P284, DOI 10.1016/j.tcb.2016.11.002; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Gallagher EJ, 2015, PHYSIOL REV, V95, P727, DOI 10.1152/physrev.00030.2014; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Higurashi T, 2016, LANCET ONCOL, V17, P475, DOI 10.1016/S1470-2045(15)00565-3; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Hua F, 2015, AUTOPHAGY, V11, P1929, DOI 10.1080/15548627.2015.1084458; Hua F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8951; Hua F, 2011, J CELL SCI, V124, P3235, DOI 10.1242/jcs.082875; Inoue Y, 2007, ONCOGENE, V26, P500, DOI 10.1038/sj.onc.1209826; Izrailit J, 2013, P NATL ACAD SCI USA, V110, P1714, DOI 10.1073/pnas.1214014110; Jalving M, 2010, EUR J CANCER, V46, P2369, DOI 10.1016/j.ejca.2010.06.012; Janjetovic K, 2011, EUR J PHARMACOL, V668, P373, DOI 10.1016/j.ejphar.2011.07.004; Jiang ZH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-88; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kordes S, 2015, LANCET ONCOL, V16, P839, DOI 10.1016/S1470-2045(15)00027-3; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Lemercier C, 2003, J BIOL CHEM, V278, P4713, DOI 10.1074/jbc.M211811200; Li K, 2017, CANCER CELL, V31, P697, DOI 10.1016/j.ccell.2017.04.006; Li K, 2016, CANCER MED-US, V5, P1647, DOI 10.1002/cam4.706; Liang GZ, 2015, ONCOL LETT, V10, P1527, DOI 10.3892/ol.2015.3475; Martin MJ, 2012, CANCER DISCOV, V2, P344, DOI 10.1158/2159-8290.CD-11-0280; Matsumoto M, 2006, J CLIN INVEST, V116, P2464, DOI 10.1172/JCI27047; Montaudie H, 2017, PIGM CELL MELANOMA R, V30, P378, DOI 10.1111/pcmr.12576; Morales DR, 2015, ANNU REV MED, V66, P17, DOI 10.1146/annurev-med-062613-093128; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Niehr F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-76; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Parker BL, 2014, J BIOL CHEM, V289, P25890, DOI 10.1074/jbc.M114.556035; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Preston MA, 2014, EUR UROL, V66, P1012, DOI 10.1016/j.eururo.2014.04.027; Quinn BJ, 2013, TRENDS ENDOCRIN MET, V24, P469, DOI 10.1016/j.tem.2013.05.004; Sayed Rana, 2015, Asian Pac J Cancer Prev, V16, P6621; Shiota M, 2010, PROSTATE, V70, P540, DOI 10.1002/pros.21088; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Stades AME, 2004, J INTERN MED, V255, P179, DOI 10.1046/j.1365-2796.2003.01271.x; Takino T, 2016, CLIN EXP METASTAS, V33, P45, DOI 10.1007/s10585-015-9756-8; Tang PMK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14677; Tomcik M, 2016, ANN RHEUM DIS, V75, P609, DOI 10.1136/annrheumdis-2014-206234; Tomic T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.86; Tyteca S, 2006, MOL CELL, V24, P807, DOI 10.1016/j.molcel.2006.12.005; Wahdan-Alaswad R, 2016, CELL CYCLE, V15, P1046, DOI 10.1080/15384101.2016.1152432; Wang LK, 2012, NUCLEIC ACIDS RES, V40, pW376, DOI 10.1093/nar/gks437; Wennemers M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2934; Wu IJ, 2017, ARCH BIOCHEM BIOPHYS, V622, P26, DOI 10.1016/j.abb.2017.04.008; Wu LF, 2016, CELL, V167, P1705, DOI 10.1016/j.cell.2016.11.055; Xiao H, 2016, SCI REP-UK, V6, DOI 10.1038/srep28597; Xiao H, 2010, CARDIOVASC RES, V87, P504, DOI 10.1093/cvr/cvq066; Xu WH, 2017, INT J MACH LEARN CYB, V8, P1, DOI 10.1007/s13042-016-0600-5; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhou H, 2013, MOL MED REP, V8, P47, DOI 10.3892/mmr.2013.1453	58	28	31	6	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2967	2981		10.1038/s41388-018-0172-9	http://dx.doi.org/10.1038/s41388-018-0172-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29520103				2022-12-17	WOS:000433936300005
J	Zhao, YH; Hu, XD; Wei, L; Song, D; Wang, JJ; You, LF; Saiyin, H; Li, ZJ; Yu, WB; Yu, L; Ding, J; Wu, JX				Zhao, Yahui; Hu, Xiaoding; Wei, Li; Song, Dan; Wang, Juanjuan; You, Lifang; Saiyin, Hexige; Li, Zhaojie; Yu, Wenbo; Yu, Long; Ding, Jin; Wu, Jiaxue			PARP10 suppresses tumor metastasis through regulation of Aurora A activity	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA METASTASIS; ADP-RIBOSYLTRANSFERASE ARTD10; MESENCHYMAL TRANSITION; CANCER-THERAPY; KINASE; CELLS; POLY(ADP-RIBOSE); RIBOSYLATION; MIGRATION; TARGETS	ADP-ribosylation, including poly-ADP-ribosylation (PARylation) and mono-ADP-ribosylation (MARylation), is a multifunctional post-translational modification catalyzed by intracellular ADP-ribosyltransferases (ARTDs or PARPs). Although PARylation has been investigated most thoroughly, the function of MARylation is currently largely undefined. Here, we provide evidences that deficiency of PARP10, a mono-ADP-ribosyltransferase, markedly increased the migration and invasion of tumor cells through regulation of epithelial-mesenchymal transition (EMT), and PARP10 inhibited tumor metastasis in vivo, which was dependent on its enzyme activity. Mechanistically, we found that PARP10 interacted with and mono-ADP-ribosylated Aurora A, and inhibited its kinase activity, thereby regulating its downstream signaling. Moreover, the expression level of PARP10 was downregulated in intrahepatic metastatic hepatocellular carcinoma (HCC) compared with its corresponding primary HCC and adjacent non-tumorous tissues. Taken together, our results indicated that PARP10 has an important role in tumor metastasis suppression via negatively regulation of Aurora A activity.	[Zhao, Yahui; Hu, Xiaoding; Song, Dan; Wang, Juanjuan; You, Lifang; Saiyin, Hexige; Yu, Wenbo; Yu, Long; Wu, Jiaxue] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China; [Zhao, Yahui; Hu, Xiaoding; Song, Dan; Wang, Juanjuan; You, Lifang; Saiyin, Hexige; Yu, Wenbo; Yu, Long; Wu, Jiaxue] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China; [Wei, Li] 401 Hosp PLA, Dept Oncol, Qingdao, Peoples R China; [Li, Zhaojie] Shanghai Appl Prot Technol Co Ltd, Shanghai, Peoples R China; [Ding, Jin] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp Inst, Int Cooperat Lab Signal Transduct, Shanghai, Peoples R China	Fudan University; Fudan University; Naval Medical University	Wu, JX (corresponding author), Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China.; Wu, JX (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China.	jiaxue@fudan.edu.cn	wang, juanjuan/GYV-5540-2022	Hu, xiaoding/0000-0002-3144-1859; Wang, Juanjuan/0000-0001-5477-8860	national key research and development plan [2016YFC0902401]; National Natural Science Foundation of China [81272250, 81472619]; National Key Sci-Tech Special Project of China [2013ZX10002010-08]	national key research and development plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Sci-Tech Special Project of China	This work was supported by national key research and development plan (2016YFC0902401 to JW); the National Natural Science Foundation of China (81272250 and 81472619 to JW) and the National Key Sci-Tech Special Project of China (2013ZX10002010-08 to JW).	Chen T, 2017, NATURE COMMUN, V8, P1; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; Feijs KLH, 2013, NAT REV MOL CELL BIO, V14, P443, DOI 10.1038/nrm3601; Feijs KLH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-5; Forst AH, 2013, STRUCTURE, V21, P462, DOI 10.1016/j.str.2012.12.019; Gavert N, 2008, TRENDS MOL MED, V14, P199, DOI 10.1016/j.molmed.2008.03.004; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Herzog N, 2013, FEBS J, V280, P1330, DOI 10.1111/febs.12124; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Hu X, 2017, ONCOGENE, V36, P4047, DOI 10.1038/onc.2017.10; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kaufmann M, 2015, CURR TOP MICROBIOL, V384, P167, DOI 10.1007/82_2014_379; Kleine H, 2008, MOL CELL, V32, P57, DOI 10.1016/j.molcel.2008.08.009; Kleine H, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-28; Maier HJ, 2010, CANCER LETT, V295, P214, DOI 10.1016/j.canlet.2010.03.003; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Nicolae CM, 2014, J BIOL CHEM, V289, P13627, DOI 10.1074/jbc.M114.556340; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Tatsuka M, 2009, MOL CARCINOGEN, V48, P810, DOI 10.1002/mc.20525; Verheugd P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2672; Vyas S, 2014, NAT REV CANCER, V14, P502, DOI 10.1038/nrc3748; Wang JJ, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.34; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Wang XX, 2012, MOL CANCER RES, V10, P588, DOI 10.1158/1541-7786.MCR-11-0416; Wu D, 2016, HEPATOLOGY, V64, P1148, DOI 10.1002/hep.28708; Yan M, 2016, MED RES REV, V36, P1036, DOI 10.1002/med.21399; Yang N, 2017, ONCOGENE, V36, P3428, DOI 10.1038/onc.2016.490; Yu M, 2005, ONCOGENE, V24, P1982, DOI 10.1038/sj.onc.1208410; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zheng FM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10180	33	28	29	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2921	2935		10.1038/s41388-018-0168-5	http://dx.doi.org/10.1038/s41388-018-0168-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29515234				2022-12-17	WOS:000433936300002
J	Lombardo, G; Gili, M; Grange, C; Cavallari, C; Dentelli, P; Togliatto, G; Taverna, D; Camussi, G; Brizzi, MF				Lombardo, Giusy; Gili, Maddalena; Grange, Cristina; Cavallari, Claudia; Dentelli, Patrizia; Togliatto, Gabriele; Taverna, Daniela; Camussi, Giovanni; Brizzi, Maria Felice			IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the beta-catenin pathway	ONCOGENE			English	Article							STAT5/PPAR-GAMMA TRANSCRIPTIONAL COMPLEX; F-BOX PROTEIN; WNT/BETA-CATENIN; STEM-CELLS; SIGNALING PATHWAY; PROGENITOR-CELL; PROMOTES ANGIOGENESIS; HELICOBACTER-PYLORI; COLORECTAL-CANCER; POTENTIAL ROLE	The proangiogenic cytokine Interleukin-3 (IL-3) is released by inflammatory cells in breast and ovarian cancer tissue microenvironments and also acts as an autocrine factor for human breast and kidney tumor-derived endothelial cells (TECs). We have previously shown that IL-3-treated endothelial cells (ECs) release extracellular vesicles (EVs), which serve as a paracrine mechanism for neighboring ECs, by transferring active molecules. The impact of an anti-IL-3R-alpha blocking antibody on the proangiogenic effect of EVs released from TECs (anti-IL-3R-EVs) has therefore been investigated in this study. We have found that anti-IL-3R-EV treatment prevented neovessel formation and, more importantly, also induced the regression of in vivo TEC-derived neovessels. Two miRs that target the canonical wingless (Wnt)/beta-catenin pathway, at different levels, were found to be differentially regulated when comparing the miR-cargo of naive TEC-derived EVs (EVs) and anti-IL-3R-EVs. miR-214-3p, which directly targets beta-catenin, was found to be upregulated, whereas miR-24-3p, which targets adenomatous polyposis coli (APC) and glycogen synthase kinase-3 beta (GSK3 beta), was found to be downregulated. In fact, upon their transfer into the cell, low beta-catenin content and high levels of the two members of the "beta-catenin destruction complex" were detected. Moreover, c-myc downregulation was found in TECs treated with anti-IL-3R-EVs, pre-miR-214-3p-EVs and antago-miR-24-3p-EVs, which is consistent with network analyses of miR-214-3p and miR-24-3p gene targeting. Finally, in vivo studies have demonstrated the impaired growth of vessels in pre-miR-214-3p-EV- and antago-miR-24-3p-EV-treated animals. These effects became much more evident when combo treatment was applied. The results of the present study identify the canonical Wnt/beta-catenin pathway as a relevant mechanism of TEC-derived EV proangiogenic action. Furthermore, we herein provide evidence that IL-3R blockade may yield some significant advantages, than miR targeting, in inhibiting the proangiogenic effects of naive TEC-derived EVs by changing TEC-EV-miR cargo.	[Lombardo, Giusy; Gili, Maddalena; Grange, Cristina; Cavallari, Claudia; Dentelli, Patrizia; Togliatto, Gabriele; Camussi, Giovanni; Brizzi, Maria Felice] Univ Turin, Dept Med Sci, Turin, Italy; [Taverna, Daniela; Camussi, Giovanni; Brizzi, Maria Felice] Univ Torino, MBC, Dept Mol Biotechnol & Hlth Sci, Turin, Italy	University of Turin; University of Turin	Camussi, G; Brizzi, MF (corresponding author), Univ Turin, Dept Med Sci, Turin, Italy.; Camussi, G; Brizzi, MF (corresponding author), Univ Torino, MBC, Dept Mol Biotechnol & Hlth Sci, Turin, Italy.	giovanni.camussi@unito.it; mariafelice.brizzi@unito.it	Brizzi, Maria Felice/J-7882-2016; Togliatto, Gabriele/K-5668-2016; Camussi, Giovanni/J-7624-2016	Togliatto, Gabriele/0000-0002-3123-7823; Camussi, Giovanni/0000-0003-2795-232X; GRANGE, CRISTINA/0000-0002-6960-5476	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 2015.16973, IG 2015.17630]; Ministero dell'Istruzione, Universita e Ricerca (MIUR)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione, Universita e Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR))	This work has been supported by grants obtained by GC and MFB from the Associazione Italiana per la Ricerca sul Cancro (AIRC) projects IG 2015.16973 and IG 2015.17630 and by grants obtained by MFB from Ministero dell'Istruzione, Universita e Ricerca (MIUR) ex 60%. We thank Professor Paolo Provero from the University of Turin for his useful advice on using Ingenuity Pathway Analysis (IPA) Software.	Bastakoty D, 2016, FASEB J, V30, P3271, DOI 10.1096/fj.201600502R; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Brizzi MF, 2004, FASEB J, V18, P1249, DOI 10.1096/fj.03-1053fje; Brizzi MF, 2001, CIRCULATION, V103, P549, DOI 10.1161/01.CIR.103.4.549; Bruno S, 2017, TISSUE ENG PT A, V23, P1262, DOI [10.1089/ten.tea.2017.0069, 10.1089/ten.TEA.2017.0069]; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278; Cavallari C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08250-0; Chang HC, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-015-0242-3; Chiurillo MA, 2015, WORLD J EXP MED, V5, P84, DOI [DOI 10.5493/WJEM.V5.I2.84, 10.5493/wjem.v5.i2.84]; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Collino F, 2017, STEM CELL REV REP, V13, P226, DOI 10.1007/s12015-016-9713-1; D'Angelo B, 2016, ANTICANCER RES, V36, P5571, DOI 10.21873/anticanres.11142; Dai X, 2015, ADV DRUG DELIVER REV, V81, P184, DOI 10.1016/j.addr.2014.09.010; Dentelli P, 2005, ONCOGENE, V24, P6394, DOI 10.1038/sj.onc.1208786; Dentelli P, 2004, ONCOGENE, V23, P1681, DOI 10.1038/sj.onc.1207290; Dentelli P, 2011, ONCOGENE, V30, P4930, DOI 10.1038/onc.2011.204; Dentelli P, 1999, J IMMUNOL, V163, P2151; Dentelli P, 2010, ARTERIOSCL THROM VAS, V30, P1562, DOI 10.1161/ATVBAHA.110.206201; Dentelli P, 2009, ARTERIOSCL THROM VAS, V29, P114, DOI 10.1161/ATVBAHA.108.172247; Deregibus MC, 2007, BLOOD, V110, P2440, DOI 10.1182/blood-2007-03-078709; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Florea V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073146; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Gacche RN, 2013, PROG BIOPHYS MOL BIO, V113, P333, DOI 10.1016/j.pbiomolbio.2013.10.001; Gallo S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162417; Gao FB, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-25; Ghahhari NM, 2015, EUR J CANCER, V51, P1638, DOI 10.1016/j.ejca.2015.04.021; Giusti I, 2016, TUMOR BIOL, V37, P12743, DOI 10.1007/s13277-016-5165-0; Gomes FG, 2013, LIFE SCI, V92, P101, DOI 10.1016/j.lfs.2012.10.008; Grange C, 2006, ONCOL REP, V15, P381; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; GREENBERGER JS, 1983, FED PROC, V42, P2762; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He MY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122087; He SZ, 2015, LEUKEMIA LYMPHOMA, V56, P1406, DOI 10.3109/10428194.2014.956316; Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; Kharaziha P, 2012, BBA-REV CANCER, V1826, P103, DOI 10.1016/j.bbcan.2012.03.006; Kiewisz J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/854056; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Lee E, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.2; Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317; Lin HY, 2017, EBIOMEDICINE, V18, P62, DOI 10.1016/j.ebiom.2017.03.012; Liu NN, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2351-9; Lombardo G, 2016, SCI REP-UK, V6, DOI 10.1038/srep25689; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; METCALF D, 1986, BLOOD, V68, P46; Miki T, 2011, STEM CELL REV REP, V7, P836, DOI 10.1007/s12015-011-9275-1; Moldenhauer LM, 2015, STEM CELL RES, V14, P380, DOI 10.1016/j.scr.2015.04.002; Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219; Penfornis P, 2016, INT J CANCER, V138, P14, DOI 10.1002/ijc.29417; Pillai MM, 2014, BREAST CANCER RES TR, V146, P85, DOI 10.1007/s10549-014-3004-9; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Schepeler T, 2012, ONCOGENE, V31, P2750, DOI 10.1038/onc.2011.453; Song XW, 2015, ONCOTARGET, V6, P35579, DOI 10.18632/oncotarget.5758; Spano D, 2012, CLIN EXP METASTAS, V29, P381, DOI 10.1007/s10585-012-9457-5; Sun X, 2013, CELL SIGNAL, V25, P2805, DOI 10.1016/j.cellsig.2013.09.006; Takahashi RU, 2017, CLIN CHEM LAB MED, V55, P648, DOI 10.1515/cclm-2016-0708; Tickner JA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00127; Togliatto G, 2016, INT J OBESITY, V40, P102, DOI 10.1038/ijo.2015.123; Trombetta A, 2013, DIABETES, V62, P1245, DOI 10.2337/db12-0646; Uberti B, 2010, ONCOGENE, V29, P6581, DOI 10.1038/onc.2010.384; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Wang WF, 2015, LIFE SCI, V136, P28, DOI 10.1016/j.lfs.2015.06.025; Wang XJ, 2012, BIOCHEM BIOPH RES CO, V428, P525, DOI 10.1016/j.bbrc.2012.10.039; Yang K, 2016, LAB INVEST, V96, P116, DOI 10.1038/labinvest.2015.144; Zeoli A, 2008, BLOOD, V112, P350, DOI 10.1182/blood-2007-12-128215; Zhang B, 2015, STEM CELL TRANSL MED, V4, P513, DOI 10.5966/sctm.2014-0267	73	28	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1175	1191		10.1038/s41388-017-0034-x	http://dx.doi.org/10.1038/s41388-017-0034-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29238040	Green Published, hybrid			2022-12-17	WOS:000426505400004
J	Loskutov, YV; Griffin, CL; Marinak, KM; Bobko, A; Margaryan, NV; Geldenhuys, WJ; Sarkaria, JN; Pugacheva, EN				Loskutov, Yuriy V.; Griffin, Caryn L.; Marinak, Kristina M.; Bobko, Andrey; Margaryan, Naira V.; Geldenhuys, Werner J.; Sarkaria, Jann N.; Pugacheva, Elena N.			LPA signaling is regulated through the primary cilium: a novel target in glioblastoma	ONCOGENE			English	Article							LYSOPHOSPHATIDIC ACID; BREAST-CANCER; CELL-PROLIFERATION; PROTEIN; RECEPTORS; GROWTH; DIFFERENTIATION; SENSITIVITY; METASTASIS; ACTIVATION	The primary cilium is a ubiquitous organelle presented on most human cells. It is a crucial signaling hub for multiple pathways including growth factor and G-protein coupled receptors. Loss of primary cilia, observed in various cancers, has been shown to affect cell proliferation. Primary cilia formation is drastically decreased in glioblastoma (GBM), however, the role of cilia in normal astrocyte or glioblastoma proliferation has not been explored. Here, we report that loss of primary cilia in human astrocytes stimulates growth rate in a lysophosphatidic acid (LPA)-dependent manner. We show that lysophosphatidic acid receptor 1 (LPAR1) is accumulated in primary cilia. LPAR1 signaling through G alpha 12/G alpha q was previously reported to be responsible for cancer cell proliferation. We found that in ciliated cells, G alpha 12 and G alpha q are excluded from the cilium, creating a barrier against unlimited proliferation, one of the hallmarks of cancer. Upon loss of primary cilia, LPAR1 redistributes to the plasma membrane with a concomitant increase in LPAR1 association with G alpha 12 and G alpha q. Inhibition of LPA signaling with the small molecule compound Ki16425 in deciliated highly proliferative astrocytes or glioblastoma patient-derived cells/xenografts drastically suppresses their growth both in vitro and in vivo. Moreover, Ki16425 brain delivery via PEG-PLGA nanoparticles inhibited tumor progression in an intracranial glioblastoma PDX model. Overall, our findings establish a novel mechanism by which primary cilium restricts proliferation and indicate that loss of primary cilia is sufficient to increase mitogenic signaling, and is important for the maintenance of a highly proliferative phenotype. Clinical application of LPA inhibitors may prove beneficial to restrict glioblastoma growth and ensure local control of disease.	[Loskutov, Yuriy V.; Griffin, Caryn L.; Marinak, Kristina M.; Pugacheva, Elena N.] West Virginia Univ, Sch Med, WVU Canc Inst, Morgantown, WV 26506 USA; [Bobko, Andrey; Margaryan, Naira V.; Pugacheva, Elena N.] West Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA; [Geldenhuys, Werner J.] West Virginia Univ, Sch Med, Dept Pharmaceut Sci, Morgantown, WV USA; [Sarkaria, Jann N.] Mayo Clin, Rochester, MN USA; [Pugacheva, Elena N.] West Virginia Univ, Sch Med, Dept Radiat Oncol, Morgantown, WV 26506 USA	West Virginia University; West Virginia University; West Virginia University; Mayo Clinic; West Virginia University	Pugacheva, EN (corresponding author), West Virginia Univ, Sch Med, WVU Canc Inst, Morgantown, WV 26506 USA.; Pugacheva, EN (corresponding author), West Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA.; Pugacheva, EN (corresponding author), West Virginia Univ, Sch Med, Dept Radiat Oncol, Morgantown, WV 26506 USA.	epugacheva@hsc.wvu.edu		Whately, Kristina/0000-0002-5908-8145; Loskutov, Juergen/0000-0003-3472-4093	NIH/NCI [R21CA208875, R01CA148671]; NIGMS/NIH [U54GM104942]; WVU Cancer Institute Undergraduate Research Fellowship; "Let the Journey Begin" fund; WVCTSI [U54GM104942]; WVU Cancer Institute; NIH [P20RR016440, P20 RR016477, P30RR032138/P30GM103488]; NATIONAL CANCER INSTITUTE [R01CA148671, R21CA208875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104942] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); WVU Cancer Institute Undergraduate Research Fellowship; "Let the Journey Begin" fund; WVCTSI; WVU Cancer Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by grants R21CA208875 (E.N. P), R01CA148671 (E.N. P) from the NIH/NCI, U54GM104942 (W.J. G) from the NIGMS/NIH, WVU Cancer Institute Undergraduate Research Fellowship (C.L.G), and "Let the Journey Begin" fund established by Erin Dunmire, WVU Cancer Institute. Andrey Bobko is supported by startup funding from WVCTSI. Naira V. Margaryan is supported by U54GM104942 from WVCTSI. West Virginia University Microscope Imaging Facility is supported by the WVU Cancer Institute and NIH grants P20RR016440, P20 RR016477 and P30RR032138/P30GM103488.	Barzi M, 2011, J BIOL CHEM, V286, P8067, DOI 10.1074/jbc.M110.178772; Barzi M, 2010, J CELL SCI, V123, P62, DOI 10.1242/jcs.060020; Basten Sander G, 2013, Cilia, V2, P6, DOI 10.1186/2046-2530-2-6; Basten Sander G, 2013, Cilia, V2, P2, DOI 10.1186/2046-2530-2-2; Butowski N. A., 2016, CNS ONCOL, V6, P61; Cao ZM, 2009, ENDOCR RES, V34, P101, DOI 10.3109/07435800903204082; Carlson BL, 2011, CURR PROTOC PHARM, V14, P14; Carlson BL, 2009, INT J RADIAT ONCOL, V75, P212, DOI 10.1016/j.ijrobp.2009.04.026; Christensen ST, 2012, J PATHOL, V226, P172, DOI 10.1002/path.3004; Ezratty EJ, 2011, CELL, V145, P1129, DOI 10.1016/j.cell.2011.05.030; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Gan CP, 2014, ONCOTARGET, V5, P9626, DOI 10.18632/oncotarget.2437; Gastrointestinal Complications (PDQ(R)), 2002, HLTH PROF VERS; Geldenhuys W, 2015, PHARM DEV TECHNOL, V20, P497, DOI 10.3109/10837450.2014.892130; Goldsmith Zachariah G, 2011, Genes Cancer, V2, P563, DOI 10.1177/1947601911419362; Gonzalez-Gil I, 2015, MEDCHEMCOMM, V6, P13, DOI 10.1039/c4md00333k; Gradilone SA, 2013, CANCER RES, V73, P2259, DOI 10.1158/0008-5472.CAN-12-2938; Gschwind A, 2002, CANCER RES, V62, P6329; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Hassounah NB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068521; Hoang-Minh LB, 2016, ONCOTARGET, V7, P7029, DOI 10.18632/oncotarget.6854; Hoelzinger DB, 2008, J NEURO-ONCOL, V86, P297, DOI 10.1007/s11060-007-9480-6; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; Kasaharaa K, 2014, ACTA MED OKAYAMA, V68, P317; Kim S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9087; Koutcher JA, 2002, NEOPLASIA, V4, P480, DOI 10.1038/sj.neo.7900269; Kozyreva VK, 2016, MOL CANCER THER, V15, P1809, DOI 10.1158/1535-7163.MCT-15-0688; Li L, 2016, NAT CELL BIOL, V18, P418, DOI 10.1038/ncb3327; Loskutov YV, 2015, ONCOGENE, V34, P3662, DOI 10.1038/onc.2014.297; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; Marley A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070857; McDowell KA, 2011, CURR PHARM DESIGN, V17, P2411; Moser JJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-448; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Pal K, 2015, METHOD CELL BIOL, V127, P303, DOI 10.1016/bs.mcb.2014.12.003; Patel BR, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.45; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Portnoy S., 2008, P INT SOC MAG RESON, P3206; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Ries LAG., 2007, NIH PUB; Robbins DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002906; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; Sarkisian MR, 2014, J NEURO-ONCOL, V117, P15, DOI 10.1007/s11060-013-1340-y; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Schou KB, 2015, EMBO REP, V16, P1099, DOI 10.15252/embr.201540530; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; Shano S, 2008, NEUROCHEM INT, V52, P216, DOI 10.1016/j.neuint.2007.07.004; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Wang G, 2013, J CELL SCI, V126, P1355, DOI 10.1242/jcs.114918; Yang Y, 2013, EMBO REP, V14, P741, DOI 10.1038/embor.2013.80; Yoshimura K, 2011, GLIA, V59, P333, DOI 10.1002/glia.21105; Yuan K, 2010, J HISTOCHEM CYTOCHEM, V58, P857, DOI 10.1369/jhc.2010.955856; Yung YC, 2014, J LIPID RES, V55, P1192, DOI 10.1194/jlr.R046458; Zhu D, 2009, J CELL SCI, V122, P2760, DOI 10.1242/jcs.046276	56	28	28	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1457	1471		10.1038/s41388-017-0049-3	http://dx.doi.org/10.1038/s41388-017-0049-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321663	Green Accepted, Green Submitted			2022-12-17	WOS:000427459500005
J	Di Ruocco, F; Basso, V; Rivoire, M; Mehlen, P; Ambati, J; De Falco, S; Tarallo, V				Di Ruocco, F.; Basso, V.; Rivoire, M.; Mehlen, P.; Ambati, J.; De Falco, S.; Tarallo, V.			Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; POOR-PROGNOSIS; NONCODING RNAS; 7SL RNA; EXPRESSION; DICER; METASTASIS; INITIATION; ELEMENTS	Alu sequences are the most abundant short interspersed repeated elements in the human genome. Here we show that in a cell culture model of colorectal cancer (CRC) progression, we observe accumulation of Alu RNA that is associated with reduced DICER1 levels. Alu RNA induces epithelial-to-mesenchymal transition (EMT) by acting as a molecular sponge of miR-566. Moreover, Alu RNA accumulates as consequence of DICER1 deficit in colorectal, ovarian, renal and breast cancer cell lines. Interestingly, Alu RNA knockdown prevents DICER1 depletion-induced EMT despite global microRNA (miRNA) downregulation. Alu RNA expression is also induced by transforming growth factor-beta 1, a major driver of EMT. Corroborating this data, we found that non-coding Alu RNA significantly correlates with tumor progression in human CRC patients. Together, these findings reveal an unexpected DICER1-dependent, miRNA-independent role of Alu RNA in cancer progression that could bring mobile element transcripts in the fields of cancer therapeutic and prognosis.	[Di Ruocco, F.; De Falco, S.; Tarallo, V.] CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Angiogenesis Lab, 111 Pietro Castellino St, I-80131 Naples, Italy; [Basso, V.; Mehlen, P.] Univ Lyon, CNRS UMR5286, Equipe Labellisee La Ligue,Ctr Leon Berard,INSERM, LabEx DEVweCAN,Ctr Rech Cancerol Lyon,Apoptosis C, Lyon, France; [Rivoire, M.] Ctr Leon Berard, Surg Dept, Lyon, France; [Ambati, J.] Univ Virginia, Sch Med, Ctr Adv Vis Sci, Dept Ophthalmol, Charlottesville, VA 22908 USA; [Ambati, J.] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; [Ambati, J.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UNICANCER; Centre Leon Berard; University of Virginia; University of Virginia; University of Virginia	Tarallo, V (corresponding author), CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Angiogenesis Lab, 111 Pietro Castellino St, I-80131 Naples, Italy.	valeria.tarallo@igb.cnr.it		De Falco, Sandro/0000-0002-6501-1697; Tarallo, Valeria/0000-0002-6920-4402	Marie Curie Action [FP7-PEOPLE-2013-CIG 631311 CanAlu]; Italian Ministry of Scientific Research [PON 01_01434 REACT]; EU Horizon (TRANSCAN-2, project BeFIT); Nuovo-Soldati Cancer Research Foundation	Marie Curie Action(European Commission); Italian Ministry of Scientific Research(Ministry of Education, Universities and Research (MIUR)); EU Horizon (TRANSCAN-2, project BeFIT); Nuovo-Soldati Cancer Research Foundation	We thank the IGB integrated microscopy and FACS facilities and Grazia Mercadante for technical assistance, and Ivana Apicella, Valeria Cicatiello, Nagaraj Kerur and Monica Autiero for discussions. This work was supported by Marie Curie Action (FP7-PEOPLE-2013-CIG 631311 CanAlu) to VT, Italian Ministry of Scientific Research (PON 01_01434 REACT) and EU Horizon2020 (TRANSCAN-2, project BeFIT) to SDF, and Nuovo-Soldati Cancer Research Foundation to VB.	Alsaleh G, 2016, ARTHRITIS RHEUMATOL, V68, P1839, DOI 10.1002/art.39641; Baryakin DN, 2013, ACTA NATURAE, V5, P83, DOI 10.32607/20758251-2013-5-4-83-93; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106; Cordaux R, 2010, METHODS MOL BIOL, V628, P137, DOI 10.1007/978-1-60327-367-1_8; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deininger P, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-236; Drusco A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096670; Faggad A, 2012, HISTOPATHOLOGY, V61, P552, DOI 10.1111/j.1365-2559.2011.04110.x; Gomez I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018023; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; Hasler J, 2007, CELL MOL LIFE SCI, V64, P1793, DOI 10.1007/s00018-007-7084-0; Hewitt RE, 2000, J PATHOL, V192, P446; Hung T, 2015, SCIENCE, V350, P455, DOI 10.1126/science.aac7442; Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830; Kim J, 2007, SCIENCE, V317, P1220, DOI 10.1126/science.1140481; Kitagawa N, 2013, CANCER SCI, V104, P543, DOI 10.1111/cas.12126; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Leonova KI, 2013, P NATL ACAD SCI USA, V110, pE89, DOI 10.1073/pnas.1216922110; Liu CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep33947; Ma X., 2014, UROL ONCOL, V32, P46; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Pandey R, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-r117; PANNING B, 1994, VIROLOGY, V202, P408, DOI 10.1006/viro.1994.1357; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; SAKAMOTO K, 1991, J BIOL CHEM, V266, P3031; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shaikh TH, 1997, J MOL BIOL, V271, P222, DOI 10.1006/jmbi.1997.1161; Shibue T, 2013, CANCER CELL, V24, P481, DOI 10.1016/j.ccr.2013.08.012; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Tang RB, 2005, MOL CARCINOGEN, V42, P93, DOI 10.1002/mc.20057; Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036; Tsushima H, 2001, CLIN CANCER RES, V7, P1258; van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203; Wang W, 2016, MOL CELL ENDOCRINOL, V426, P91, DOI 10.1016/j.mce.2016.02.008; Xiang SY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-44; Zhang KL, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-63	41	28	28	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					627	637		10.1038/onc.2017.369	http://dx.doi.org/10.1038/onc.2017.369			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991230	Green Published, hybrid			2022-12-17	WOS:000423812200008
J	Piscitello, D; Varshney, D; Lilla, S; Vizioli, MG; Reid, C; Gorbunova, V; Seluanov, A; Gillespie, DA; Adams, PD				Piscitello, D.; Varshney, D.; Lilla, S.; Vizioli, M. G.; Reid, C.; Gorbunova, V; Seluanov, A.; Gillespie, D. A.; Adams, P. D.			AKT overactivation can suppress DNA repair via p70S6 kinase-dependent downregulation of MRE11	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; CELL-CYCLE CHECKPOINT; HEMATOPOIETIC-CELLS; TUMOR-SUPPRESSOR; DAMAGE RESPONSE; ACTIVATION; CANCER; PTEN; PATHWAY; TUMORIGENESIS	Deregulated AKT kinase activity due to PTEN deficiency in cancer cells contributes to oncogenesis by incompletely understood mechanisms. Here, we show that PTEN deletion in HCT116 and DLD1 colon carcinoma cells leads to suppression of CHK1 and CHK2 activation in response to irradiation, impaired G2 checkpoint proficiency and radiosensitization. These defects are associated with reduced expression of MRE11, RAD50 and NBS1, components of the apical MRE11/RAD50/NBS1 (MRN) DNA damage response complex. Consistent with reduced MRN complex function, PTEN-deficient cells fail to resect DNA double-strand breaks efficiently after irradiation and show greatly diminished proficiency for DNA repair via the error-free homologous recombination (HR) repair pathway. MRE11 is highly unstable in PTEN-deficient cells but stability can be significantly restored by inhibiting mTORC1 or p70S6 kinase (p70S6K), downstream kinases whose activities are stimulated by AKT, or by mutating a residue in MRE11 that we show is phosphorylated by p70S6K in vitro. In primary human fibroblasts, activated AKT suppresses MRN complex expression to escalate RAS-induced DNA damage and thereby reinforce oncogene-induced senescence. Taken together, our data demonstrate that deregulation of the PI3K-AKT/mTORC1/p70S6K pathways, an event frequently observed in cancer, exert profound effects on genome stability via MRE11 with potential implications for tumour initiation and therapy.	[Piscitello, D.; Lilla, S.] Beatson Inst Canc Res, Garscube Estate, Glasgow, Lanark, Scotland; [Varshney, D.] Univ Dundee, Sch Life Sci, Ctr Gene Regulat & Express, Dundee, Scotland; [Vizioli, M. G.; Reid, C.; Adams, P. D.] Univ Glasgow, Epigenet Canc & Ageing, Univ Ave, Glasgow G12 8QQ, Lanark, Scotland; [Gorbunova, V; Seluanov, A.] Univ Rochester, Dept Biol, Rochester, NY 14627 USA; [Gillespie, D. A.] Univ La Laguna, Fac Med, Ctr Invest Biomed Canarias, Inst Tecnol Biomed, Campus Ciencias Salud, Tenerife 38071, Spain	Beatson Institute; University of Dundee; University of Glasgow; University of Rochester; Universidad de la Laguna	Adams, PD (corresponding author), Univ Glasgow, Epigenet Canc & Ageing, Univ Ave, Glasgow G12 8QQ, Lanark, Scotland.; Gillespie, DA (corresponding author), Univ La Laguna, Fac Med, Ctr Invest Biomed Canarias, Inst Tecnol Biomed, Campus Ciencias Salud, Tenerife 38071, Spain.; Adams, PD (corresponding author), Sanford Burnham Prebys Med Discovery Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dgillesp@ull.es; p.adams@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; Adams, Peter/0000-0002-0684-1770; Seluanov, Andrei/0000-0003-3400-538X; Varshney, Dhaval/0000-0001-9197-9821; Gorbunova, Vera/0000-0001-8979-0333; Piscitello, Desiree/0000-0002-2510-4717	CRUK programme grant [C10652/A16566]; IMBRAIN Project [FP7-REGPOT-2012-CT2012-31637-IMBRAIN]; NIA [P01AG047200]; Cancer Research UK [16566] Funding Source: researchfish; NATIONAL INSTITUTE ON AGING [R01AG027237, P01AG047200, R03AG052365] Funding Source: NIH RePORTER	CRUK programme grant; IMBRAIN Project; NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Cancer Research UK(Cancer Research UK); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank members of the Gillespie and Adams labs for critical discussions. Work in the Adams lab was supported by the CRUK programme grant C10652/A16566. DA Gillespie acknowledges the IMBRAIN Project (FP7-REGPOT-2012-CT2012-31637-IMBRAIN: EU FP7 and Gobierno de Canarias) for financial support. V Gorbunova acknowledges the NIA P01AG047200.	Ali SM, 1999, BIODRUGS, V12, P138, DOI 10.2165/00063030-199912020-00006; Apweiler R, 2010, NUCLEIC ACIDS RES, V38, pD142, DOI 10.1093/nar/gkp846; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Buis J, 2008, CELL, V135, P85, DOI 10.1016/j.cell.2008.08.015; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Cristofalo VJ, 2004, MECH AGEING DEV, V125, P827, DOI 10.1016/j.mad.2004.07.010; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Guo F, 2013, LEUKEMIA, V27, P2040, DOI 10.1038/leu.2013.93; Harlow E, 1988, ANTIBODIES LAB MANUA; Henry MK, 2001, BLOOD, V98, P834, DOI 10.1182/blood.V98.3.834; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jastrzebski K, 2007, GROWTH FACTORS, V25, P209, DOI 10.1080/08977190701779101; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kennedy AL, 2011, MOL CELL, V42, P36, DOI 10.1016/j.molcel.2011.02.020; King FW, 2004, CELL CYCLE, V3, P634; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu PD, 2015, MOL CELL, V57, P648, DOI 10.1016/j.molcel.2015.01.005; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; McGarry DJ, 2016, ACS CHEM BIOL, V11, P3300, DOI 10.1021/acschembio.6b00742; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Olsen JV, 2005, MOL CELL PROTEOMICS, V4, P2010, DOI 10.1074/mcp.T500030-MCP200; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Robinson HMR, 2006, ONCOGENE, V25, P5359, DOI 10.1038/sj.onc.1209532; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; Seluanov Andrei, 2010, J Vis Exp, DOI 10.3791/2002; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tonic I, 2010, J BIOL CHEM, V285, P23790, DOI 10.1074/jbc.M110.104372; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wen Q, 2008, MOL BIOL CELL, V19, P1693, DOI 10.1091/mbc.E07-09-0975; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	49	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					427	438		10.1038/onc.2017.340	http://dx.doi.org/10.1038/onc.2017.340			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967905	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000423331600002
J	Ando, T; Charindra, D; Shrestha, M; Umehara, H; Ogawa, I; Miyauchi, M; Takata, T				Ando, T.; Charindra, D.; Shrestha, M.; Umehara, H.; Ogawa, I.; Miyauchi, M.; Takata, T.			Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer	ONCOGENE			English	Article							HIPPO PATHWAY; ONCOGENIC ACTIVITY; REGULATES YAP; SIZE-CONTROL; 1 TIMP-1; GROWTH; TEAD; PROGNOSIS; TAZ; TUMORIGENESIS	Tissue inhibitor of metalloproteinase-1 (TIMP-1), a member of the TIMP family (TIMP-1 to 4), is highly expressed in various types of cancer and forms a complex with its receptor CD63 and Integrin beta 1. However, the precise oncogenic mechanism of TIMP-1 remains unclear. Yes-associated protein (YAP) and transcriptional co-activator with PDZ binding motif (TAZ) are transcription co-activators enhancing the transcription of specific genes related to cell proliferation. But the mechanism of aberrant YAP/TAZ activation in cancer is not fully understood. Here, we showed that TIMP-1 activates YAP/TAZ as novel downstream targets to promote cell proliferation. The TIMP-1-CD63-Integrin beta 1 axis activates Src and promotes RhoA-mediated F-actin assembly, leading to LATS1/2 inactivation. This results in under-phosphorylation, protein stabilization and nuclear translocation of YAP/TAZ (YAP/TAZ activation); CTGF production; and cell proliferation. Furthermore, the TIMP-1-YAP/TAZ axis is aberrantly activated in various types of cancer cells or tissues. TIMP-1 knockdown inhibits cell proliferation through YAP/TAZ inactivation in cancer cells. This study found that TIMP-1 accelerates cell proliferation through YAP/TAZ activation in cancer, and suggests the TIMP-1-YAP/TAZ axis may be a novel potential drug target for cancer patients.	[Ando, T.; Charindra, D.; Shrestha, M.; Umehara, H.; Miyauchi, M.; Takata, T.] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Oral & Maxillofacial Pathobiol, Hiroshima, Japan; [Ogawa, I.] Hiroshima Univ Hosp, Ctr Oral Clin Examinat, Hiroshima, Japan	Hiroshima University; Hiroshima University	Takata, T (corresponding author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Oral & Maxillofacial Pathobiol, Basic Life Sci,Mimami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	ttakata@hiroshima-u.ac.jp	Ando, Toshinori/AAG-4033-2021; Ando, Toshinori/AAA-6401-2021; Shrestha, Madhu/HHC-3819-2022; Miyauchi, Mutsumi/G-5268-2019	Ando, Toshinori/0000-0002-3141-8173; Ando, Toshinori/0000-0002-3141-8173; 	JSPS KAKENHI [JP25293373, JP16H05503, 17K17084]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Professor Koichiro Ozawa (Department of Pharmacotherapy, Hiroshima University) for valuable discussion and Professor Makiko Fujii (Department of Global Dental Medicine and Molecular Oncology, Hiroshima University) for providing us HA-tagged YAP-WT vector and anti-HA antibody. This work was funded, in part, by JSPS KAKENHI Grant Number JP25293373 and JP16H05503 to (TT) and 17K17084 to (TA). Hanako Umehara currently belongs to department of advanced prosthodontics, Hiroshima University.	Aaberg-Jessen C, 2009, J NEURO-ONCOL, V95, P117, DOI 10.1007/s11060-009-9910-8; Ando T, 2017, SCI REP-UK, V7, DOI 10.1038/srep40187; Brodowska K, 2014, EXP EYE RES, V124, P67, DOI 10.1016/j.exer.2014.04.011; Chirco R, 2006, CANCER METAST REV, V25, P99, DOI 10.1007/s10555-006-7893-x; Crocker M, 2011, NEURO-ONCOLOGY, V13, P99, DOI 10.1093/neuonc/noq170; Dechaphunkul A, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/290854; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Egea V, 2012, P NATL ACAD SCI USA, V109, pE309, DOI 10.1073/pnas.1115083109; Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728; Eyckmans J, 2011, DEV CELL, V21, P35, DOI 10.1016/j.devcel.2011.06.015; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653; Grunnet M, 2013, SCAND J GASTROENTERO, V48, P899, DOI 10.3109/00365521.2013.812235; Honkavuori M, 2008, ANTICANCER RES, V28, P2715; Jackson HW, 2017, NAT REV CANCER, V17, P38, DOI 10.1038/nrc.2016.115; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Jung KK, 2006, EMBO J, V25, P3934, DOI 10.1038/sj.emboj.7601281; Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025; Kozlowski M, 2013, ADV MED SCI-POLAND, V58, P227, DOI 10.2478/ams-2013-0017; Liu G, 2015, ONCOGENE, V34, P3536, DOI 10.1038/onc.2014.281; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; Liu XW, 2005, CANCER RES, V65, P898; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Ma J, 2014, INT J CLIN EXP PATHO, V7, P246; Martin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12502; Mi W, 2015, ONCOGENE, V34, P3095, DOI 10.1038/onc.2014.251; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Oh WK, 2011, CANCER-AM CANCER SOC, V117, P517, DOI 10.1002/cncr.25394; Park HW, 2013, TRENDS PHARMACOL SCI, V34, P581, DOI 10.1016/j.tips.2013.08.006; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Plouffe SW, 2016, MOL CELL, V64, P993, DOI 10.1016/j.molcel.2016.10.034; Plouffe SW, 2015, TRENDS MOL MED, V21, P212, DOI 10.1016/j.molmed.2015.01.003; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Shanzer M, 2017, P NATL ACAD SCI USA, V114, P1678, DOI 10.1073/pnas.1610223114; Song GH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0427-7; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Striedinger K, 2008, NEOPLASIA, V10, P1204, DOI 10.1593/neo.08642; Tang Y, 2013, DEV CELL, V25, P402, DOI 10.1016/j.devcel.2013.04.011; Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228; Terpos E, 2010, LEUKEMIA RES, V34, P399, DOI 10.1016/j.leukres.2009.08.035; Toricelli M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-22; Wang L, 2016, NATURE, V540, P579, DOI 10.1038/nature20602; Xia YF, 2012, NAT CELL BIOL, V14, P257, DOI 10.1038/ncb2428; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yoo YJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep14018; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zanconato F, 2016, CURR OPIN PHARMACOL, V29, P26, DOI 10.1016/j.coph.2016.05.002; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810	57	28	28	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					263	270		10.1038/onc.2017.321	http://dx.doi.org/10.1038/onc.2017.321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925394				2022-12-17	WOS:000422631700012
J	Li, Y; Wang, L; Liu, J; Zhang, P; An, M; Han, C; Li, Y; Guan, X; Zhang, K				Li, Y.; Wang, L.; Liu, J.; Zhang, P.; An, M.; Han, C.; Li, Y.; Guan, X.; Zhang, K.			O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer	ONCOGENE			English	Article							GLCNAC TRANSFERASE; CHROMATIN-ASSOCIATION; STEM-CELLS; C-MYC; PHOSPHORYLATION; OGT; IDENTIFICATION; TARGET; GROWTH; DOMAIN	The Polycomb group transcriptional repressor Bmi-1 often overexpressed and participated in stem cells self-renewal and tumorigenesis initiating of prostate cancer. In this progression, Bmi-1 protein was regulated by transcription and post-translational modifications (PTMs). Nobly, the underlying PTMs regulation of Bmi-1 is poorly known. Here we use co-immunoprecipitation show that in C4-2 cell line, Bmi-1 directly interacted with OGT which is the only known enzyme catalyzed the O-GlcNAcylation in human. Furthermore, we identified that Ser255 is the site for Bmi-1 O-GlcNAcylation, and O-GlcNAcylation promoted Bmi-1 protein stability and its oncogenic activity. Finally, microarray analysis has characterized potential oncogenes associated pathway subject to repression via the OGT-Bmi-1 axis. Taken together, these results indicate that OGT-mediated O-GlcNAcylation at Ser255 stabilizes Bmi-1 and hence inhibits the TP53, PTEN and CDKN1A/CDKN2A pathway. The study not only uncovers a novel functional PTMs of Bmi-1 but also reveals a unique oncogenic role of O-GlcNAcylation in prostate cancer.	[Li, Y.; Wang, L.; Liu, J.; An, M.; Han, C.; Li, Y.; Guan, X.] Dalian Med Univ, Affiliated Hosp 1, Sino UK Regenerat Med Ctr, 222 Zhongshan Rd, Dalian 116011, Peoples R China; [Zhang, P.] Dalian Med Univ, Affiliated Hosp 1, Dept Pathol, Dalian, Peoples R China; [Zhang, K.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	Dalian Medical University; Dalian Medical University; University of California System; University of California San Diego	Liu, J (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Sino UK Regenerat Med Ctr, 222 Zhongshan Rd, Dalian 116011, Peoples R China.	liujing@dmu.edu.cn	Wang, Liang/O-8394-2019	Wang, Liang/0000-0003-1952-3525; Liu, Jing/0000-0002-0493-296X; Wang, Liang/0000-0003-2244-7535				Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Bansal N, 2016, CLIN CANCER RES, V22, P6176, DOI 10.1158/1078-0432.CCR-15-3107; Barlow Lamont J, 2013, Cancer Cell, V24, DOI 10.1016/j.ccr.2013.08.033; Bauer C, 2015, J BIOL CHEM, V290, P4801, DOI 10.1074/jbc.M114.605881; Bommi PV, 2010, CELL CYCLE, V9, P2663, DOI 10.4161/cc.9.13.12147; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Cao LX, 2011, J CELL BIOCHEM, V112, P2729, DOI 10.1002/jcb.23234; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9; Gambetta MC, 2015, CHROMOSOMA, V124, P429, DOI 10.1007/s00412-015-0513-1; Gambetta MC, 2009, SCIENCE, V325, P93, DOI 10.1126/science.1169727; Gu L, 2015, NAT GENET, V47, P22, DOI 10.1038/ng.3165; Hu P, 2010, FEBS LETT, V584, P2526, DOI 10.1016/j.febslet.2010.04.044; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Ito R, 2014, GENES CELLS, V19, P52, DOI 10.1111/gtc.12107; Iyer SPN, 2003, J BIOL CHEM, V278, P24608, DOI 10.1074/jbc.M300036200; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; Li DW, 2010, J CANCER RES CLIN, V136, P997, DOI 10.1007/s00432-009-0745-7; Liu L, 2006, ONCOGENE, V25, P4370, DOI 10.1038/sj.onc.1209454; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Malik R, 2009, J PROTEOME RES, V8, P4553, DOI 10.1021/pr9003773; Meng S, 2010, J BIOL CHEM, V285, P33219, DOI 10.1074/jbc.M110.133686; Moon JH, 2011, CELL RES, V21, P1305, DOI 10.1038/cr.2011.107; Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Schimpl M, 2010, BIOCHEM J, V432, P1, DOI 10.1042/BJ20101338; Silva J, 2006, CLIN CANCER RES, V12, P6929, DOI 10.1158/1078-0432.CCR-06-0788; Sinclair DAR, 2009, P NATL ACAD SCI USA, V106, P13427, DOI 10.1073/pnas.0904638106; Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114; Voncken JW, 1999, J CELL SCI, V112, P4627; Voncken JW, 2005, J BIOL CHEM, V280, P5178, DOI 10.1074/jbc.M407155200; Wu J, 2011, J CELL BIOCHEM, V112, P1938, DOI 10.1002/jcb.23114; Xie X, 2014, ONCOGENE, V33, P2040, DOI 10.1038/onc.2013.173; Yadav AK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-158; Yoo YA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12943; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	37	28	28	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6293	6305		10.1038/onc.2017.223	http://dx.doi.org/10.1038/onc.2017.223			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28714959				2022-12-17	WOS:000414774800008
J	Katschnig, AM; Kauer, MO; Schwentner, R; Tomazou, EM; Mutz, CN; Linder, M; Sibilia, M; Alonso, J; Aryee, DNT; Kovar, H				Katschnig, A. M.; Kauer, M. O.; Schwentner, R.; Tomazou, E. M.; Mutz, C. N.; Linder, M.; Sibilia, M.; Alonso, J.; Aryee, D. N. T.; Kovar, H.			EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; PROTEIN-COUPLED RECEPTOR; ACTIN CYTOSKELETON; BREAST-CANCER; TRANSCRIPTIONAL REGULATION; CELL-PROLIFERATION; DNA-BINDING; EXPRESSION; MRTF; METASTASIS	Ewing sarcoma (EWS) is a paediatric bone cancer with high metastatic potential. Cellular plasticity resulting from dynamic cytoskeletal reorganization, typically regulated via the Rho pathway, is a prerequisite for metastasis initiation. Here, we interrogated the role of the Ewing sarcoma driver oncogene EWS-FLI1 in cytoskeletal reprogramming. We report that EWS-FLI1 strongly represses the activity of the Rho-F-actin signal pathway transcriptional effector MRTFB, affecting the expression of a large number of EWS-FLI1-anticorrelated genes including structural and regulatory cytoskeletal genes. Consistent with this finding, chromatin immunoprecipitation sequencing (ChIP-seq) revealed strong overlaps in myocardin-related transcription factor B (MRTFB) and EWS-FLI1 chromatin occupation, especially for EWS-FLI1-anticorrelated genes. Binding of the transcriptional co-activator Yes-associated protein (YAP)-1, enrichment of TEAD-binding motifs in these shared genomic binding regions and overlapping transcriptional footprints of MRTFB and TEAD factors led us to propose synergy between MRTFB and the YAP/TEAD complex in the regulation of EWS-FLI1-anticorrelated genes. We propose that EWS-FLI1 suppresses the Rho-actin pathway by perturbation of a MRTFB/YAP-1/TEAD transcriptional module, which directly affects the actin-autoregulatory feedback loop. As spontaneous fluctuations in EWS-FLI1 levels of Ewing sarcoma cells in vitro and in vivo, associated with a switch between a proliferative, non-migratory EWS-FLI1-high and a non-proliferative highly migratory EWS-FLI1-low state, were recently described, our data provide a mechanistic basis for the underlying EWS-FLI1-dependent reversible cytoskeletal reprogramming of Ewing sarcoma cells.	[Katschnig, A. M.; Kauer, M. O.; Schwentner, R.; Tomazou, E. M.; Mutz, C. N.; Aryee, D. N. T.; Kovar, H.] St Anna Kinderkrebsforsch, Childrens Canc Res Inst, Zimmermannpl 10, A-1090 Vienna, Austria; [Linder, M.; Sibilia, M.] Med Univ Vienna, Inst Canc Res, Vienna, Austria; [Alonso, J.] Inst Invest Enfermedades Raras, Unidad Tumores Solidos Infantiles, Madrid, Spain; [Aryee, D. N. T.; Kovar, H.] Med Univ Vienna, Dept Paediat, Vienna, Austria	Saint Anna Children's Hospital; Medical University of Vienna; Instituto de Salud Carlos III; Instituto de Investigacion de Enfermedades Raras (IIER); Medical University of Vienna	Kovar, H (corresponding author), St Anna Kinderkrebsforsch, Childrens Canc Res Inst, Zimmermannpl 10, A-1090 Vienna, Austria.	heinrich.kovar@ccri.at	Alonso, Javier/B-6012-2013; Tomazou, Eleni M/J-1475-2014	Alonso, Javier/0000-0002-6287-8391; Tomazou, Eleni Marina/0000-0002-7497-4567; Sibilia, Maria/0000-0001-6129-5613; Schwentner, Raphaela/0000-0001-6839-0322	Austrian Science Fund [I1125-B19]; Liddy Shriver Initiative; European Commission [259348]	Austrian Science Fund(Austrian Science Fund (FWF)); Liddy Shriver Initiative; European Commission(European CommissionEuropean Commission Joint Research Centre)	This study was supported by the Austrian Science Fund grant I1125-B19, the Liddy Shriver Initiative and by the European Commission Framework Program 7 grant 259348 ('ASSET').	Amsellem V, 2005, EXP CELL RES, V304, P443, DOI 10.1016/j.yexcr.2004.10.035; Asparuhova MB, 2009, SCAND J MED SCI SPOR, V19, P490, DOI 10.1111/j.1600-0838.2009.00928.x; Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145; Bernstein M, 2006, ONCOLOGIST, V11, P503, DOI 10.1634/theoncologist.11-5-503; Bilke S, 2013, GENOME RES, V23, P1797, DOI 10.1101/gr.151340.112; Carrillo J, 2007, CLIN CANCER RES, V13, P2429, DOI 10.1158/1078-0432.CCR-06-1762; Chaturvedi A, 2014, MOL BIOL CELL, V25, P2695, DOI 10.1091/mbc.E14-01-0007; Chaturvedi Aashi, 2012, Genes Cancer, V3, P102, DOI 10.1177/1947601912457024; Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Franzetti GA, 2017, ONCOGENE, V36, P3505, DOI 10.1038/onc.2016.498; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hu QD, 2011, MOL CELL BIOL, V31, P3223, DOI 10.1128/MCB.01365-10; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; Kim T, 2017, EMBO J, V36, P520, DOI 10.15252/embj.201695137; Kovar H, 2010, GENOME MED, V2, DOI 10.1186/gm129; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lawlor Elizabeth R., 2015, Critical Reviews in Oncogenesis, V20, P155, DOI 10.1615/CritRevOncog.2015013553; Lee SM, 2010, J BIOL CHEM, V285, P22036, DOI 10.1074/jbc.M110.108878; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Liu CY, 2016, ONCOTARGET, V7, P13706, DOI 10.18632/oncotarget.7333; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; McCall MN, 2010, BIOSTATISTICS, V11, P242, DOI 10.1093/biostatistics/kxp059; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Miano JM, 2007, AM J PHYSIOL-CELL PH, V292, pC70, DOI 10.1152/ajpcell.00386.2006; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodenberg JM, 2010, AM J PHYSIOL-CELL PH, V299, pC1058, DOI 10.1152/ajpcell.00080.2010; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Schwentner R, 2015, NUCLEIC ACIDS RES, V43, P2780, DOI 10.1093/nar/gkv123; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Speight P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11642; Spraker HL, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00002; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan AL, 2011, MOL CELL BIOL, V31, P861, DOI 10.1128/MCB.00836-10; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Tomazou EM, 2015, CELL REP, V10, P1082, DOI 10.1016/j.celrep.2015.01.042; Toomey EC, 2010, ONCOGENE, V29, P4504, DOI 10.1038/onc.2010.205; Yu OM, 2016, MOL CELL BIOL, V36, P39, DOI 10.1128/MCB.00772-15; Yu OM, 2015, MOL PHARMACOL, V88, P171, DOI 10.1124/mol.115.097857; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	52	28	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5995	6005		10.1038/onc.2017.202	http://dx.doi.org/10.1038/onc.2017.202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28671673	Green Published, hybrid			2022-12-17	WOS:000413841400008
J	Kesanakurti, D; Maddirela, D; Banasavadi-Siddegowda, YK; Lai, TH; Qamri, Z; Jacob, NK; Sampath, D; Mohanam, S; Kaur, B; Puduvalli, VK				Kesanakurti, D.; Maddirela, D.; Banasavadi-Siddegowda, Y. K.; Lai, T-H; Qamri, Z.; Jacob, N. K.; Sampath, D.; Mohanam, S.; Kaur, B.; Puduvalli, V. K.			A novel interaction of PAK4 with PPAR gamma to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma	ONCOGENE			English	Article							ACTIVATED-RECEPTOR-GAMMA; OXYGEN SPECIES GENERATION; BREAST-CANCER CELLS; EXTRACELLULAR-MATRIX; DEPENDENT ACTIVATION; MALIGNANT GLIOMA; BETA-CATENIN; STEM-CELLS; KAPPA-B; INVASION	Tumor recurrence in glioblastoma (GBM) is, in part, attributed to increased epithelial-to-mesenchymal transition (EMT) and enhanced tumor cell dissemination in adjacent brain parenchyma after ionizing radiation (IR). EMT is associated with aggressive behavior, increased stem-like characteristics and treatment resistance in malignancies; however, the underlying signaling mechanisms that regulate EMT are poorly understood. We identified grade-dependent p21-activated kinases 4 (PAK4) upregulation in gliomas and further determined its role in mesenchymal transition and radioresistance. IR treatment significantly elevated expression and nuclear localization of PAK4 in correlation with induction of reactive oxygen species (ROS) and mesenchymal transition in GBM cells. Stable PAK4 overexpression promoted mesenchymal transition by elevating EMT marker expression in these cells. Of note, transcription factor-DNA-binding arrays and chromatin immunoprecipitation experiments identified the formation of a novel nuclear PAK4/PPAR gamma complex which was recruited to the promoter of Nox1, a peroxisome proliferator-activated receptor gamma (PPAR gamma) target gene. In addition, IR further elevated PAK4/PPAR gamma complex co-recruitment to Nox1 promoter, and increased Nox1 expression and ROS levels associated with mesenchymal transition in these cells. Conversely, specific PAK4 downregulation decreased PPAR gamma-mediated Nox1 expression and suppressed EMT in IR-treated cells. In vivo orthotopic tumor experiments showed inhibition of growth and suppression of IR-induced PPAR gamma and Nox1 expression by PAK4 downregulation in tumors. Our results provide the first evidence of a novel role for PAK4 in IR-induced EMT and suggest potential therapeutic efficacy of targeting PAK4 to overcome radioresistance in gliomas.	[Kesanakurti, D.; Puduvalli, V. K.] Ohio State Univ, Ctr Comprehens Canc, Dardinger Ctr Neurooncol & Neurosci, Div Neurooncol, 320W 10th Ave Starling Loving Hall Suite M410, Columbus, OH 43210 USA; [Kesanakurti, D.; Banasavadi-Siddegowda, Y. K.; Kaur, B.; Puduvalli, V. K.] Ohio State Univ, Ctr Comprehens Canc, Dardinger Ctr Neurooncol & Neurosci, Dept Neurosurg, 320W 10th Ave Starling Loving Hall Suite M410, Columbus, OH 43210 USA; [Maddirela, D.; Lai, T-H; Sampath, D.; Mohanam, S.] Ohio State Univ, Ctr Comprehens Canc, Div Hematol, 320W 10th Ave Starling Loving Hall Suite M410, Columbus, OH 43210 USA; [Maddirela, D.; Mohanam, S.] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL USA; [Qamri, Z.; Jacob, N. K.] Ohio State Univ, Ctr Comprehens Canc, Dept Radiat Oncol, 320W 10th Ave Starling Loving Hall Suite M410, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Illinois System; University of Illinois Peoria; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Kesanakurti, D (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Dardinger Ctr Neurooncol & Neurosci, Div Neurooncol, 320W 10th Ave Starling Loving Hall Suite M410, Columbus, OH 43210 USA.	Divya.Kesanakurti@osumc.edu; Vinay.Puduvalli@osumc.edu	Sampath, Deepa/T-5069-2019	/0000-0002-4730-6918; Sampath, Deepa/0000-0002-4366-8436	Ohio State University Pelotonia Fellowship; NCI [5K24CA160777]; Sanford/Rife Family Glioblastoma Research Fund; Snyder Nation Foundation; Ellen and John Hines Neuro-oncology Research Fund; NATIONAL CANCER INSTITUTE [K24CA160777, P30CA016058] Funding Source: NIH RePORTER	Ohio State University Pelotonia Fellowship; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Sanford/Rife Family Glioblastoma Research Fund; Snyder Nation Foundation; Ellen and John Hines Neuro-oncology Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jihong Xu, Krishna K Veeravalli and Bharath Chelluboina for technical help. We greatly appreciate Dr. Annie NY Cheung (University of Hong Kong, Hong Kong, China)) and Dr Audrey Minden (Rutgers University, NJ, USA) for kindly providing the PAK4-NLS-Mut and PAK4-K350M plasmids respectively, for our studies. We thank Drs Deepa Sampath and Rosa Lapalombella for manuscript review and helpful comments. This project was supported by the Ohio State University Pelotonia Fellowship (DK), NCI grant 5K24CA160777 (VKP), the Sanford/Rife Family Glioblastoma Research Fund, the Snyder Nation Foundation and the Ellen and John Hines Neuro-oncology Research Fund.	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Badiga AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020614; Baldassa S, 2010, J CELL PHYSIOL, V224, P722, DOI 10.1002/jcp.22172; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chattopadhyay N, 2000, J NEUROSCI RES, V61, P67, DOI 10.1002/1097-4547(20000701)61:1<67::AID-JNR8>3.0.CO;2-7; Chen L, 2006, J BIOL CHEM, V281, P24575, DOI 10.1074/jbc.M604147200; Dart AE, 2015, J CELL BIOL, V211, P863, DOI 10.1083/jcb.201501072; Davison CA, 2013, CANCER RES, V73, P3704, DOI 10.1158/0008-5472.CAN-12-2482; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Han EJ, 2013, INT J RADIAT ONCOL, V85, pE239, DOI 10.1016/j.ijrobp.2012.11.040; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Jin RS, 2014, J CELL SCI, V127, P3116, DOI 10.1242/jcs.147835; Kahlert UD, 2013, CANCER LETT, V331, P131, DOI 10.1016/j.canlet.2012.12.010; Kamata T, 2009, CANCER SCI, V100, P1382, DOI 10.1111/j.1349-7006.2009.01207.x; Kesanakurti D, 2013, ONCOGENE, V32, P5144, DOI 10.1038/onc.2012.546; Kesanakurti D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.182; Kim KY, 2006, BIOCHEM PHARMACOL, V72, P530, DOI 10.1016/j.bcp.2006.05.009; Komatsu D, 2008, ONCOGENE, V27, P4724, DOI 10.1038/onc.2008.102; Kubelt C, 2015, INT J ONCOL, V46, P2515, DOI 10.3892/ijo.2015.2944; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee JJ, 2012, ONCOGENE, V31, P3818, DOI 10.1038/onc.2011.543; Lee KS, 2006, J ALLERGY CLIN IMMUN, V118, P120, DOI 10.1016/j.jaci.2006.03.021; Lefterova MI, 2008, GENE DEV, V22, P2941, DOI 10.1101/gad.1709008; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Li XD, 2010, INT J BIOCHEM CELL B, V42, P70, DOI 10.1016/j.biocel.2009.09.008; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Liu F, 2012, J INVEST DERMATOL, V132, P2033, DOI 10.1038/jid.2012.119; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Mahabir R, 2014, NEURO-ONCOLOGY, V16, P671, DOI 10.1093/neuonc/not239; Masuda T, 2005, CLIN CANCER RES, V11, P4012, DOI 10.1158/1078-0432.CCR-05-0087; Meng J, 2014, ONCOTARGET, V5, P4683, DOI 10.18632/oncotarget.2088; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Minden Audrey, 2012, ISRN Oncol, V2012, P694201, DOI 10.5402/2012/694201; Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638; Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286-08; Park MT, 2014, CELL DEATH DIFFER, V21, P1185, DOI 10.1038/cdd.2014.34; Pestereva E, 2012, BRIT J CANCER, V106, P1702, DOI 10.1038/bjc.2012.161; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Sawayama H, 2014, CANCER RES, V74, P575, DOI 10.1158/0008-5472.CAN-13-1836; Schaefer KL, 2005, CANCER RES, V65, P2251, DOI 10.1158/0008-5472.CAN-04-3037; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Schwartzbaum JA, 2006, NAT CLIN PRACT NEURO, V2, P494, DOI 10.1038/ncpneuro0289; Siebzehnrubl FA, 2013, EMBO MOL MED, V5, P1196, DOI 10.1002/emmm.201302827; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tyagi N, 2016, CANCER LETT, V370, P260, DOI 10.1016/j.canlet.2015.10.028; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang X, 2013, ONCOGENE, V32, P5512, DOI 10.1038/onc.2013.217; Whale AD, 2013, ONCOGENE, V32, P2114, DOI 10.1038/onc.2012.233; Wu CH, 2012, J BIOL CHEM, V287, P25292, DOI 10.1074/jbc.M111.291195; Zarkoob H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064169; Zaytseva YY, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-90; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022	68	28	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5309	5320		10.1038/onc.2016.261	http://dx.doi.org/10.1038/onc.2016.261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28534509	Green Accepted			2022-12-17	WOS:000410671700009
J	Shakya, R; Tarulli, GA; Sheng, L; Lokman, NA; Ricciardelli, C; Pishas, KI; Selinger, CI; Kohonen-Corish, MRJ; Cooper, WA; Turner, AG; Neilsen, PM; Callen, DF				Shakya, R.; Tarulli, G. A.; Sheng, L.; Lokman, N. A.; Ricciardelli, C.; Pishas, K. I.; Selinger, C. I.; Kohonen-Corish, M. R. J.; Cooper, W. A.; Turner, A. G.; Neilsen, P. M.; Callen, D. F.			Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer	ONCOGENE			English	Article							WILD-TYPE; PROGNOSTIC-SIGNIFICANCE; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; MOUSE MODELS; GAIN; MUTATIONS; P63; INHIBITION; COMPLEX	Missense mutations in the TP53 tumor-suppressor gene inactivate its antitumorigenic properties and endow the incipient cells with newly acquired oncogenic properties that drive invasion and metastasis. Although the oncogenic effect of mutant p53 transcriptome has been widely acknowledged, the global influence of mutant p53 on cancer cell proteome remains to be fully elucidated. Here, we show that mutant p53 drives the release of invasive extracellular factors (the 'secretome') that facilitates the invasion of lung cancer cell lines. Proteomic characterization of the secretome from mutant p53-inducible H1299 human non-small cell lung cancer cell line discovered that the mutant p53 drives its oncogenic pathways through modulating the gene expression of numerous targets that are subsequently secreted from the cells. Of these genes, alpha-1 antitrypsin (A1AT) was identified as a critical effector of mutant p53 that drives invasion in vitro and in vivo, together with induction of epithelial-mesenchymal transition markers expression. Mutant p53 upregulated A1AT transcriptionally through the involvement with its family member p63. Conditioned medium containing secreted A1AT enhanced cell invasion, while an A1AT-blocking antibody attenuated the mutant p53-driven migration and invasion. Importantly, high A1AT expression correlated with increased tumor stage, elevated p53 staining and shorter overall survival in lung adenocarcinoma patients. Collectively, these findings suggest that A1AT is an indispensable target of mutant p53 with prognostic and therapeutic potential in mutant p53-expressing tumors.	[Shakya, R.; Sheng, L.; Pishas, K. I.; Turner, A. G.; Callen, D. F.] Univ Adelaide, Sch Med, Fac Hlth Sci, Ctr Personalised Canc Med,Canc Therapeut Lab, Level 3,Hanson Inst Bldg,Frome Rd, Adelaide, SA 5005, Australia; [Tarulli, G. A.] Univ Adelaide, Fac Hlth Sci, Sch Med, DRMCRL, Adelaide, SA, Australia; [Lokman, N. A.; Ricciardelli, C.] Univ Adelaide, Robinson Res Inst, Fac Hlth Sci, Sch Med,Discipline Obstet & Gynaecol, Adelaide, SA, Australia; [Lokman, N. A.] Univ Adelaide, Sch Mol & Biol Sci, Adelaide Prote Ctr, Adelaide, SA, Australia; [Selinger, C. I.] Royal Prince Alfred Hosp, Camperdown, NSW, Australia; [Kohonen-Corish, M. R. J.] Garvan Inst Med Res, Kinghorn Canc Ctr, Sydney, NSW, Australia; [Kohonen-Corish, M. R. J.] UNSW Australia, St Vincents Clin Sch, Sydney, NSW, Australia; [Kohonen-Corish, M. R. J.; Cooper, W. A.] Univ Western Sydney, Sch Med, Parramatta, NSW, Australia; [Cooper, W. A.] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Camperdown, NSW, Australia; [Cooper, W. A.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Neilsen, P. M.] Swinburne Univ Technol Sarawak Campus, Kuching, Sarawak, Malaysia	Hanson Institute; University of Adelaide; University of Adelaide; Robinson Research Institute; University of Adelaide; University of Adelaide; University of Sydney; Garvan Institute of Medical Research; University of New South Wales Sydney; Western Sydney University; University of Sydney; University of Sydney	Shakya, R (corresponding author), Univ Adelaide, Sch Med, Fac Hlth Sci, Ctr Personalised Canc Med,Canc Therapeut Lab, Level 3,Hanson Inst Bldg,Frome Rd, Adelaide, SA 5005, Australia.	reshma.shakya@adelaide.edu.au	Tarulli, Gerard A/D-8863-2013; Ricciardelli, Carmela/U-1814-2019; Ricciardelli, Carmela/K-2212-2015; Kohonen-Corish, Maija/Q-9763-2019	Ricciardelli, Carmela/0000-0001-7415-1854; Ricciardelli, Carmela/0000-0001-7415-1854; Kohonen-Corish, Maija/0000-0002-4073-1479; Lokman, Noor/0000-0002-2071-5308; Turner, Andrew/0000-0003-0374-1181; Neilsen, Paul/0000-0001-7937-3675; Tarulli, Gerard/0000-0002-1327-4655; Sheng, Lei/0000-0003-1814-809X; Shakya, Reshma/0000-0002-8154-432X	NHMRC Project [44107714, 44112162]; University of Adelaide Florey Medical Research Foundation Clinical Cancer Research Fellowship	NHMRC Project(National Health and Medical Research Council (NHMRC) of Australia); University of Adelaide Florey Medical Research Foundation Clinical Cancer Research Fellowship	We thank TCGA research network for publicly sharing their data. The results published here are in part based upon data generated by the TCGA project, which was established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov. We also thank Rebecca C Haycox for her technical assistance. This work was supported by the NHMRC Project grants (44107714 and 44112162). K Pishas acknowledges financial contributions from the University of Adelaide Florey Medical Research Foundation Clinical Cancer Research Fellowship.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Ahrendt SA, 2003, J NATL CANCER I, V95, P961, DOI 10.1093/jnci/95.13.961; Alamanova D, 2010, BMC BIOINFORMATICS, V11, P1; Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Aryee DNT, 2013, BRIT J CANCER, V109, P2696, DOI 10.1038/bjc.2013.635; Baker L, 2010, BRIT J CANCER, V102, P719, DOI 10.1038/sj.bjc.6605540; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang YH, 2012, MOL CELL PROTEOMICS, V11, P1320, DOI 10.1074/mcp.M112.017384; Chee JLY, 2013, CELL CYCLE, V12, P278, DOI 10.4161/cc.23054; Chen JT, 2000, ANTICANCER RES, V20, P2687; Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Coffill CR, 2012, EMBO REP, V13, P638, DOI 10.1038/embor.2012.74; Cordani M, 2016, CANCER LETT, V376, P303, DOI 10.1016/j.canlet.2016.03.046; Do PM, 2012, GENE DEV, V26, P830, DOI 10.1101/gad.181685.111; El-Akawi ZJ, 2008, NEUROENDOCRINOL LETT, V29, P482; El-Telbany Ahmed, 2012, Genes Cancer, V3, P467, DOI 10.1177/1947601912465177; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Frenzel E, 2015, J IMMUNOL, V195, P3605, DOI 10.4049/jimmunol.1500740; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grellety T, 2015, BMC CANCER, V15, P1; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; Janicke RU, 2008, CELL DEATH DIFFER, V15, P959, DOI 10.1038/cdd.2008.33; Katkoori VR, 2009, CLIN CANCER RES, V15, P2406, DOI 10.1158/1078-0432.CCR-08-1719; Kwon CH, 2014, BRIT J CANCER, V111, P1993, DOI 10.1038/bjc.2014.490; Kwon CH, 2015, ONCOTARGET, V6, P20312, DOI 10.18632/oncotarget.3964; LAINE A, 1990, CLIN CHIM ACTA, V190, P163, DOI 10.1016/0009-8981(90)90170-W; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lehmann BD, 2012, J CLIN ONCOL, V30, P3648, DOI 10.1200/JCO.2012.44.0412; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Miyake M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-322; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Neilsen PM, 2011, ONCOTARGET, V2, P1203; Noll JE, 2012, ONCOGENE, V31, P2836, DOI 10.1038/onc.2011.456; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Park SW, 2004, EXP MOL MED, V36, P211, DOI 10.1038/emm.2004.29; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Petrache I, 2006, AM J PATHOL, V169, P1155, DOI 10.2353/ajpath.2006.060058; Pishas KI, 2015, SCI REP-UK, V5, DOI 10.1038/srep11465; Polotskaia A, 2015, P NATL ACAD SCI USA, V112, pE1220, DOI 10.1073/pnas.1416318112; Rivlin N, 2014, P NATL ACAD SCI USA, V111, P7006, DOI 10.1073/pnas.1320428111; Russo D, 2013, BBA-MOL CELL RES, V1833, P1904, DOI 10.1016/j.bbamcr.2013.03.020; Samowitz WS, 2002, INT J CANCER, V99, P597, DOI 10.1002/ijc.10405; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Skaug V, 2000, CLIN CANCER RES, V6, P1031; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Trinidad AG, 2013, MOL CELL, V50, P805, DOI 10.1016/j.molcel.2013.05.002; Tseng IC, 2008, AM J PHYSIOL-CELL PH, V295, pC423, DOI 10.1152/ajpcell.00164.2008; Walerych D, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00289; Wang B, 2012, ACTA BIOCH BIOPH SIN, V44, P685, DOI 10.1093/abbs/gms053; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Yousef GM, 2003, BBA-GENE STRUCT EXPR, V1628, P88, DOI 10.1016/S0167-4781(03)00116-7; Zelvyte I, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-7; Zhang G, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0200-1	68	28	29	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4469	4480		10.1038/onc.2017.66	http://dx.doi.org/10.1038/onc.2017.66			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368395				2022-12-17	WOS:000406806000009
J	Tang, X; Ding, CK; Wu, J; Sjol, J; Wardell, S; Spasojevic, I; George, D; McDonnell, DP; Hsu, DS; Chang, JT; Chi, JT				Tang, X.; Ding, C-K; Wu, J.; Sjol, J.; Wardell, S.; Spasojevic, I.; George, D.; McDonnell, D. P.; Hsu, D. S.; Chang, J. T.; Chi, J-T			Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RENAL-CELL CARCINOMA; MALIGNANT-CELLS; TUMOR-CELLS; DEPRIVATION; GLUTAMINE; INHIBITION; PHENOTYPE; APOPTOSIS; PATHWAYS	Despite the advances in the diagnosis and treatment of breast cancer, breast cancers still cause significant mortality. For some patients, especially those with triple-negative breast cancer, current treatments continue to be limited and ineffective. Therefore, there remains an unmet need for a novel therapeutic approach. One potential strategy is to target the altered metabolic state that is rewired by oncogenic transformation. Specifically, this rewiring may render certain outside nutrients indispensable. To identify such a nutrient, we performed a nutrigenetic screen by removing individual amino acids to identify possible addictions across a panel of breast cancer cells. This screen revealed that cystine deprivation triggered rapid programmed necrosis, but not apoptosis, in the basal-type breast cancer cells mostly seen in TNBC tumors. In contrast, luminal-type breast cancer cells are cystine-independent and exhibit little death during cystine deprivation. The cystine addiction phenotype is associated with a higher level of cystine-deprivation signatures noted in the basal type breast cancer cells and tumors. We found that the cystine-addicted breast cancer cells and tumors have strong activation of TNF alpha and MEKK4-p38-Noxa pathways that render them susceptible to cystine deprivation-induced necrosis. Consistent with this model, silencing of TNFa and MEKK4 dramatically reduces cystine-deprived death. In addition, the cystine addiction phenotype can be abrogated in the cystine-addictive cells by miR-200c, which converts the mesenchymal-like cells to adopt epithelial features. Conversely, the introduction of inducers of epithelial-mesenchymal transition (EMT) in cystine-independent breast cancer cells conferred the cystine-addiction phenotype by modulating the signaling components of cystine addiction. Together, our data reveal that cystine-addiction is associated with EMT in breast cancer during tumor progression. These findings provide the genetic and mechanistic basis to explain how cystine deprivation triggers necrosis by activating pre-existing oncogenic pathways in cystine-addicted TNBC with prominent mesenchymal features.	[Tang, X.; Ding, C-K; Wu, J.; Chi, J-T] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA; [Tang, X.; Ding, C-K; Wu, J.; Hsu, D. S.; Chi, J-T] Duke Univ, Ctr Genom & Computat Biol, Durham, NC USA; [Tang, X.] Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA; [Sjol, J.; Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Wardell, S.; McDonnell, D. P.; Hsu, D. S.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA; [Spasojevic, I.; George, D.] Duke Univ, Dept Med, Durham, NC USA	Duke University; Duke University; Michigan Technological University; University of Texas System; University of Texas Health Science Center Houston; Duke University; Duke University	Chi, JT (corresponding author), Duke Univ, Ctr Genom & Computat Biol, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	jentsan.chi@duke.edu		Chi, Jen-Tsan/0000-0003-3433-903X; Ding, Chien-Kuang/0000-0001-9047-0222	NIH [CA125618, CA106520]; Department of Defense [W81XWH-12-1-0148, W81XWH-14-1-0309, W81XWH-15-1-0486]; NATIONAL CANCER INSTITUTE [R01CA106520, R01CA125618] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to acknowledge the financial support from the NIH (CA125618 and CA106520 to JTC) and Department of Defense (W81XWH-12-1-0148, W81XWH-14-1-0309, W81XWH-15-1-0486 to JTC). We appreciate the technical assistance of Ivan Spasojevic and the DCI's Pharmacokinetics and Investigational Chemotherapy share facility. We are also grateful to members of Chi lab for critical discussions and editing of the manuscript.	Arimoto K, 2008, NAT CELL BIOL, V10, P1324, DOI 10.1038/ncb1791; Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Chen JLY, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001093; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Dang L, 2010, NATURE, V465, P966, DOI 10.1038/nature09132; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gatza ML, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2899; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Harten SK, 2009, MOL BIOL CELL, V20, P1089, DOI 10.1091/mbc.E08-06-0566; Ho MY, 2012, MOL CANCER RES, V10, P1109, DOI 10.1158/1541-7786.MCR-12-0160; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Keenan MM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005599; Keenan MM, 2015, CANCER J, V21, P49, DOI 10.1097/PPO.0000000000000104; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; KREIS W, 1980, CANCER RES, V40, P634; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Kung HN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002229; Lampidis TJ, 2006, CANCER CHEMOTH PHARM, V58, P725, DOI 10.1007/s00280-006-0207-8; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Lucas JE, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000920; Moore T, 2013, J CHROMATOGR B, V929, P51, DOI 10.1016/j.jchromb.2013.04.004; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; Murphy JM, 2014, EMBO REP, V15, P155, DOI 10.1002/embr.201337970; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Ohtawa K, 1998, LEUKEMIA, V12, P1651, DOI 10.1038/sj.leu.2401139; Paranjape AN, 2016, ONCOGENE, V35, P5963, DOI 10.1038/onc.2015.498; Scott L, 2000, BRIT J CANCER, V83, P800, DOI 10.1054/bjoc.2000.1353; Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666; Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tang XH, 2016, CANCER RES, V76, P1892, DOI 10.1158/0008-5472.CAN-15-2328; Tang XH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005158; Tang XH, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0415-9; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Yoshikawa M, 2013, CANCER RES, V73, P1855, DOI 10.1158/0008-5472.CAN-12-3609-T; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang XJ, 2015, INT J ONCOL, V46, P1141, DOI 10.3892/ijo.2014.2809; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970	48	28	28	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4235	4242		10.1038/onc.2016.394	http://dx.doi.org/10.1038/onc.2016.394			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	27869167	Green Accepted			2022-12-17	WOS:000406360600001
J	Yu, L; Di, Y; Xin, L; Ren, Y; Liu, X; Sun, X; Zhang, W; Yao, Z; Yang, J				Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yao, Z.; Yang, J.			SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGF beta 1 response and breast cancer metastasis	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; NUCLEASE TUDOR-SN; TGF-BETA; TUMOR-SUPPRESSOR; ACETYLTRANSFERASE ACTIVITY; COACTIVATOR; ENHANCE; PROTEIN; REGULATOR; CARCINOMA	As an AEG-1/MTDH/LYRIC-binding protein, Staphylococcal nuclease domain-containing 1 (SND1) is upregulated in numerous human cancers where it has been assigned multiple functional roles. In this study, we discovered that SND1 was upregulated in breast cancer tissues, particularly the tissues from patients with distant metastases. The underlying molecular mechanisms demonstrated a novel role of SND1 in regulating the activity of transforming growth factor beta 1 (TGF beta 1) signaling pathway, which promotes metastasis in breast cancer. We illustrated that SND1 physically associated with and recruited the histone acetylase GCN5 to the promoter regions of Smad2/3/4, and consequently enhanced the gene transcriptional activation of Smad2/3/4, which are essential downstream regulators in the TGF beta 1 pathway. An electrophoretic mobility shift assay experiment further verified that SND1 could recognize the conserved domains (motifs 1 and 2) in the promoter regions of the Smad genes. Glutathione S-transferase (GST) pulldown assays indicated that the tudor domain of SND1 was responsible for the recruitment of GCN5, which increased histone H3K9 acetylation. Consistent with these results, a loss-of-function of SND1 reduced the protein level of Smads and the phosphorylation of R-Smads, thereby attenuating the R-Smad/Co-Smad depended transcription and, as a result, inhibited TGF beta signaling activation.	[Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yang, J.] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin, Peoples R China; [Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yao, Z.; Yang, J.] Tianjin Med Univ, Sch Basic Med Sci, Dept Immunol, Tianjin, Peoples R China; [Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yao, Z.; Yang, J.] Tianjin Med Univ, Res Ctr Basic Med Sci, Lab Mol Immunol, Tianjin, Peoples R China; [Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yao, Z.; Yang, J.] Tianjin Med Univ, Educ Minist China, Key Lab, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China; [Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yao, Z.; Yang, J.] Tianjin Med Univ, Tianjin Key Lab Cellular & Mol Immunol, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Yu, L; Yao, Z; Yang, J (corresponding author), Tianjin Med Univ, Educ Minist China, Key Lab, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.; Yu, L; Yao, Z; Yang, J (corresponding author), Tianjin Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol,Res Ctr Basic Med Sci, Dept Immunol,Lab Mol Immunol,Tianjin Key Lab Cell, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.	onoblivion@tmu.edu.cn; yaozhi@tijmu.edu.cn; yangj@tijmu.edu.cn	Yu, Lin/AAH-1131-2019	Yu, Lin/0000-0002-9972-3799	National Science Foundation for Distinguished Young Scholars of China [31125012]; National Natural Science Foundation of China [81202102, 81672592, 31370749, 31670759, 81572882]; Project for Innovative Research Team of Ministry of Education [IRT13085]; Project of Applicative Basic Research and Advanced Technology of Tianjin Municipal Science and Technology Commission [13JCQNJC12100]; Specialized Research Fund for the Doctoral Program of Higher Education [20121202120018]	National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project for Innovative Research Team of Ministry of Education; Project of Applicative Basic Research and Advanced Technology of Tianjin Municipal Science and Technology Commission; Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by grant from the National Science Foundation for Distinguished Young Scholars of China (31125012 to JY), grants from the National Natural Science Foundation of China (81202102 and 81672592 to LY, 31370749 and 31670759 to JY and 81572882 to ZY), grant from Project for Innovative Research Team of Ministry of Education (IRT13085 to JY), grants from Project of Applicative Basic Research and Advanced Technology of Tianjin Municipal Science and Technology Commission (13JCQNJC12100 to LY) and grant from Specialized Research Fund for the Doctoral Program of Higher Education (20121202120018 to LY).	Adams-Cioaba MA, 2009, BIOCHEM CELL BIOL, V87, P93, DOI 10.1139/O08-129; Bai X, 2016, ANGEW CHEM INT EDIT, V55, P7993, DOI 10.1002/anie.201602558; Borcherding N, 2015, CANCER RES, V75, P1972, DOI 10.1158/0008-5472.CAN-14-2761; Callebaut I, 1997, BIOCHEM J, V321, P125, DOI 10.1042/bj3210125; Cappellari M, 2014, ONCOGENE, V33, P3794, DOI 10.1038/onc.2013.360; Cerami Ethan G, 2011, Nucleic Acids Res, V39, pD685, DOI 10.1093/nar/gkq1039; Do TV, 2008, MOL CANCER RES, V6, P695, DOI 10.1158/1541-7786.MCR-07-0294; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Gao XJ, 2012, J BIOL CHEM, V287, P18130, DOI 10.1074/jbc.M111.311852; He YB, 2014, NAT NEUROSCI, V17, P943, DOI 10.1038/nn.3732; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jiang L, 2007, J BIOL CHEM, V282, P27923, DOI 10.1074/jbc.M704194200; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kannan N, 2014, CELL STEM CELL, V15, P118, DOI 10.1016/j.stem.2014.07.010; Kuruma H, 2009, AM J PATHOL, V174, P2044, DOI 10.2353/ajpath.2009.080776; Lee IH, 2014, ONCOGENE, V33, P4675, DOI 10.1038/onc.2014.69; Lee SG, 2013, ADV CANCER RES, V120, P1, DOI 10.1016/B978-0-12-401676-7.00001-2; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Li CL, 2008, NUCLEIC ACIDS RES, V36, P3579, DOI 10.1093/nar/gkn236; Liu L, 2015, NUCLEIC ACIDS RES, V43, P3873, DOI 10.1093/nar/gkv255; Liu X, 2011, CELL MOL IMMUNOL, V8, P88, DOI 10.1038/cmi.2010.47; Murphy SJ, 2016, CANCER RES, V76, P749, DOI 10.1158/0008-5472.CAN-15-2198; Nam JS, 2006, CANCER RES, V66, P6327, DOI 10.1158/0008-5472.CAN-06-0068; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Quintana AM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-30; Riss A, 2015, J BIOL CHEM, V290, P28997, DOI 10.1074/jbc.M115.668533; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Shaw N, 2007, NAT STRUCT MOL BIOL, V14, P779, DOI 10.1038/nsmb1269; Su C, 2015, J BIOL CHEM, V290, P7208, DOI 10.1074/jbc.M114.625046; Valineva T, 2005, J BIOL CHEM, V280, P14989, DOI 10.1074/jbc.M410465200; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Wang G, 2015, ONCOGENE, V35, P4388; Wang N, 2012, MOL BIOL REP, V39, P10497, DOI 10.1007/s11033-012-1933-0; [王旭 WANG Xu], 2010, [高分子通报, Polymer Bulletin], P1; Xie W, 2002, CANCER RES, V62, P497; Xu J, 2015, CANCER CELL, V27, P177, DOI 10.1016/j.ccell.2014.11.025; Yan XH, 2016, J BIOL CHEM, V291, P382, DOI 10.1074/jbc.M115.694281; Yang L, 2010, CANCER METAST REV, V29, P263, DOI 10.1007/s10555-010-9226-3; Yin J, 2013, ANAT REC, V296, P1568, DOI 10.1002/ar.22737; Yoo BK, 2011, HEPATOLOGY, V53, P1538, DOI 10.1002/hep.24216; Yu L, 2015, CANCER RES, V75, P1275, DOI 10.1158/0008-5472.CAN-14-2387	41	28	30	4	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3903	3914		10.1038/onc.2017.30	http://dx.doi.org/10.1038/onc.2017.30			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263968				2022-12-17	WOS:000404848200010
J	Cannistraci, A; Federici, G; Addario, A; Di Pace, AL; Grassi, L; Muto, G; Collura, D; Signore, M; De Salvo, L; Sentinelli, S; Simone, G; Costantini, M; Nanni, S; Farsetti, A; Coppola, V; De Maria, R; Bonci, D				Cannistraci, A.; Federici, G.; Addario, A.; Di Pace, A. L.; Grassi, L.; Muto, G.; Collura, D.; Signore, M.; De Salvo, L.; Sentinelli, S.; Simone, G.; Costantini, M.; Nanni, S.; Farsetti, A.; Coppola, V.; De Maria, R.; Bonci, D.			C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition	ONCOGENE			English	Article							ANDROGEN-RECEPTOR GENE; PROSTATE-CANCER; MICRORNA SIGNATURES; INCREASED SURVIVAL; C-MET; METASTASIS; EXPRESSION; GROWTH; PHOSPHORYLATION; PROGRESSION	Although a significant subset of prostate tumors remain indolent during the entire life, the advanced forms are still one of the leading cause of cancer-related death. There are not reliable markers distinguishing indolent from aggressive forms. Here we highlighted a new molecular circuitry involving microRNA and coding genes promoting cancer progression and castration resistance. Our preclinical and clinical data demonstrated that c-Met activation increases miR-130b levels, inhibits androgen receptor expression, promotes cancer spreading and resistance to hormone ablation therapy. The relevance of these findings was confirmed on patients' samples and by in silico analysis on an independent patient cohort from Taylor's platform. Data suggest c-Met/miR-130b axis as a new prognostic marker for patients' risk assessment and as an indicator of therapy resistance. Our results propose new biomarkers for therapy decision-making in all phases of the pathology. Data may help identify high-risk patients to be treated with adjuvant therapy together with alternative cure for castration-resistant forms while facilitating the identification of possible patients candidates for anti-Met therapy. In addition, we demonstrated that it is possible to evaluate Met/miR-130b axis expression in exosomes isolated from peripheral blood of surgery candidates and advanced patients offering a new non-invasive tool for active surveillance and therapy monitoring.	[Cannistraci, A.; Federici, G.; Addario, A.; Di Pace, A. L.; Grassi, L.; Signore, M.; Coppola, V.; Bonci, D.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy; [Federici, G.; Grassi, L.; De Salvo, L.; Sentinelli, S.; Simone, G.; Costantini, M.; Bonci, D.] Regina Elena Inst Canc Res, Rome, Italy; [Di Pace, A. L.] Sapienza Univ Rome, Histol & Med Embryol Sect, Dept Anat Histol Forens & Orthopaed Sci, Rome, Italy; [Muto, G.; Collura, D.] S Giovanni Bosco Hosp, Dept Urol, Turin, Italy; [Muto, G.] Campus Biomed Univ, Dept Urol, Rome, Italy; [Nanni, S.] Univ Cattolica, Inst Med Pathol, Rome, Italy; [Farsetti, A.] CNR, Inst Cell Biol & Neurobiol, Rome, Italy; [De Maria, R.] Univ Cattolica, Inst Gen Pathol, Largo Francesco Vito 1, I-00168 Rome, Italy; [De Maria, R.] Policlin Gemelli, Largo Francesco Vito 1, I-00168 Rome, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; University Campus Bio-Medico - Rome Italy; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Bonci, D (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.; De Maria, R (corresponding author), Univ Cattolica, Inst Gen Pathol, Largo Francesco Vito 1, I-00168 Rome, Italy.; De Maria, R (corresponding author), Policlin Gemelli, Largo Francesco Vito 1, I-00168 Rome, Italy.	ruggero.demaria@unicatt.it; desiree.bonci@iss.it	Signore, Michele/J-8563-2016; simone, giuseppe/K-9607-2016; Di Pace, Anna Laura/K-6494-2016; Addario, Antonio/AAC-4707-2022; Federici, Giulia/AAC-8820-2019; Bonci, Desiree/K-6488-2016; Farsetti, Antonella/I-8710-2018; De Maria, Ruggero/S-6385-2019; Coppola, Valeria/K-5120-2016	Signore, Michele/0000-0002-0262-842X; simone, giuseppe/0000-0002-4868-9025; Di Pace, Anna Laura/0000-0002-1712-9033; Addario, Antonio/0000-0001-8527-8738; Federici, Giulia/0000-0002-4684-0270; Bonci, Desiree/0000-0002-2472-5140; Farsetti, Antonella/0000-0002-8603-7925; De Maria, Ruggero/0000-0003-2255-0583; collura, devis/0000-0002-8964-5248; Coppola, Valeria/0000-0002-5745-2572; Muto, Giovanni/0000-0003-3593-6450	National Ministry of Health; Italy-USA microRNA program; Italian Association for Cancer (AIRC); Fondazione Roma	National Ministry of Health; Italy-USA microRNA program; Italian Association for Cancer (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma(Fondazione RomaEuropean Commission)	We thank Giuseppe Loreto and Tania Merlino for their technical support. We thank Alessandra Boe for cytofluorimetric analysis. This manuscript was supported by National Ministry of Health, Under-forty researcher (2012) and Italy-USA microRNA program to DB and the Italian Association for Cancer (AIRC) and Fondazione Roma funding to RDM.	Adolfsson J, 2008, BJU INT, V102, P10, DOI 10.1111/j.1464-410X.2008.07585.x; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Boeri M, 2011, P NATL ACAD SCI USA, V108, P3713, DOI 10.1073/pnas.1100048108; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; BRAWN PN, 1989, BRIT J CANCER, V59, P85, DOI 10.1038/bjc.1989.16; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Colangelo T, 2013, NEOPLASIA, V15, P1204, DOI 10.1593/neo.13998; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; D'Amico Anthony V, 2004, J Urol, V172, pS42, DOI 10.1097/01.ju.0000141845.99899.12; D'Amico AV, 2004, NEW ENGL J MED, V351, P125, DOI 10.1056/NEJMoa032975; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Dean M, 1987, Haematol Blood Transfus, V31, P464; Dong P, 2013, ONCOGENE, V32, P3286, DOI 10.1038/onc.2012.334; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Federici G, 2013, MOL CANCER RES, V11, P676, DOI 10.1158/1541-7786.MCR-12-0690; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gregory CW, 2001, CANCER RES, V61, P2892; Haas GP, 2008, CAN J UROL, V15, P3866; Nguyen HT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063219; ISAACS JT, 1981, CANCER RES, V41, P5070; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Knudsen BS, 2004, ADV CANCER RES, V91, P31, DOI 10.1016/S0065-230X(04)91002-0; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li BL, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0484-0; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Liu AM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000825; Ma S, 2010, CELL STEM CELL, V7, P694, DOI 10.1016/j.stem.2010.11.010; Maeda A, 2006, BIOCHEM BIOPH RES CO, V347, P1158, DOI 10.1016/j.bbrc.2006.07.040; Matias PM, 2002, J MED CHEM, V45, P1439, DOI 10.1021/jm011072j; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Mueller C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023780; Nanni S, 2006, MOL CANCER RES, V4, P79, DOI 10.1158/1541-7786.MCR-05-0098; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Pierobon M, 2015, ONCOGENE, V34, P805, DOI 10.1038/onc.2014.16; Reisinger K, 2003, J CELL SCI, V116, P225, DOI 10.1242/jcs.00237; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sozzi G, 2014, J CLIN ONCOL, V32, P768, DOI 10.1200/JCO.2013.50.4357; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; TILLEY WD, 1990, CANCER RES, V50, P5382; Varkaris A, 2011, EXPERT OPIN INV DRUG, V20, P1677, DOI 10.1517/13543784.2011.631523; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Verhoef EI, 2016, ONCOTARGET, V7, P31029, DOI 10.18632/oncotarget.8829; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555-006-9019-x; Zhao G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073803	58	28	28	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3718	3728		10.1038/onc.2016.505	http://dx.doi.org/10.1038/onc.2016.505			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192399				2022-12-17	WOS:000404349700007
J	Hasanov, E; Chen, G; Chowdhury, P; Weldon, J; Ding, Z; Jonasch, E; Sen, S; Walker, CL; Dere, R				Hasanov, E.; Chen, G.; Chowdhury, P.; Weldon, J.; Ding, Z.; Jonasch, E.; Sen, S.; Walker, C. L.; Dere, R.			Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL	ONCOGENE			English	Article							VON-HIPPEL-LINDAU; TUMOR-SUPPRESSOR PROTEIN; RENAL-CELL CARCINOMA; RNA-POLYMERASE-II; SKELETAL-MUSCLE PROGENITORS; AURORA-A KINASE; PROLINE HYDROXYLATION; PROLYL HYDROXYLATION; CANCER GENOMICS; PRIMARY CILIUM	The hypoxia-regulated tumor-suppressor von Hippel-Lindau (VHL) is an E3 ligase that recognizes its substrates as part of an oxygen-dependent prolyl hydroxylase (PHD) reaction, with hypoxia-inducible factor a (HIF alpha) being its most notable substrate. Here we report that VHL has an equally important function distinct from its hypoxia-regulated activity. We find that Aurora kinase A (AURKA) is a novel, hypoxia-independent target for VHL ubiquitination. In contrast to its hypoxia-regulated activity, VHL mono-, rather than poly-ubiquitinates AURKA, in a PHD-independent reaction targeting AURKA for degradation in quiescent cells, where degradation of AURKA is required to maintain the primary cilium. Tumor-associated variants of VHL differentiate between these two functions, as a pathogenic VHL mutant that retains intrinsic ability to ubiquitinate HIFa is unable to ubiquitinate AURKA. Together, these data identify VHL as an E3 ligase with important cellular functions under both normoxic and hypoxic conditions.	[Hasanov, E.; Chen, G.; Chowdhury, P.; Weldon, J.; Walker, C. L.; Dere, R.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX USA; [Hasanov, E.] Hacettepe Univ, Dept Basic Oncol, Canc Inst, Ankara, Turkey; [Chowdhury, P.; Walker, C. L.; Dere, R.] Baylor Coll Med, Ctr Precis Environm Hlth, One Baylor Plaza,BCM130, Houston, TX 77030 USA; [Ding, Z.] UT MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA; [Jonasch, E.] UT MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA; [Sen, S.] UT MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Hacettepe University; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Dere, R (corresponding author), Baylor Coll Med, Ctr Precis Environm Hlth, One Baylor Plaza,BCM130, Houston, TX 77030 USA.	ruhee.dere@bcm.edu	Hasanov, Elshad/AAO-8340-2021	Hasanov, Elshad/0000-0002-7195-0842	Robert A Welch Endowed Chair in Chemistry [BE-0023]; NATIONAL CANCER INSTITUTE [R01CA143811] Funding Source: NIH RePORTER	Robert A Welch Endowed Chair in Chemistry; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors would like to thank T Berry and S Bai for technical assistance. This work was supported by a Robert A Welch Endowed Chair in Chemistry (BE-0023) to CLW.	Anderson K, 2011, J BIOL CHEM, V286, P42027, DOI 10.1074/jbc.M111.303222; Basten Sander G, 2013, Cilia, V2, P6, DOI 10.1186/2046-2530-2-6; Basten Sander G, 2013, Cilia, V2, P2, DOI 10.1186/2046-2530-2-2; Boutet SC, 2007, CELL, V130, P349, DOI 10.1016/j.cell.2007.05.044; Boutet SC, 2010, MOL CELL, V40, P749, DOI 10.1016/j.molcel.2010.09.029; Carvallo L, 2010, J BIOL CHEM, V285, P29546, DOI 10.1074/jbc.M110.155812; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Coon TA, 2012, CELL CYCLE, V11, P721, DOI 10.4161/cc.11.4.19171; Dere R, 2015, J AM SOC NEPHROL, V26, P553, DOI 10.1681/ASN.2013090984; Ding ZY, 2014, CANCER RES, V74, P3127, DOI 10.1158/0008-5472.CAN-13-3213; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferchichi I, 2012, DIS MARKERS, V33, P333, DOI [10.1155/2012/804708, 10.3233/DMA-2012-00942]; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hamano K, 2002, J UROLOGY, V167, P713, DOI 10.1016/S0022-5347(01)69132-8; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Izawa Ichiro, 2015, Cilia, V4, P12, DOI 10.1186/s13630-015-0021-1; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kasap E, 2016, TUMOR BIOL, V37, P3071, DOI 10.1007/s13277-015-4131-6; Kuehn EW, 2007, CANCER RES, V67, P4537, DOI 10.1158/0008-5472.CAN-07-0391; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lai YL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016975; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Lolkema MP, 2008, EUR J HUM GENET, V16, P73, DOI 10.1038/sj.ejhg.5201930; Lolkema MP, 2007, FEBS LETT, V581, P4571, DOI 10.1016/j.febslet.2007.08.050; Martin B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067071; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Na X, 2003, EMBO J, V22, P4249, DOI 10.1093/emboj/cdg410; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Perera AD, 2000, CLIN CANCER RES, V6, P1518; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Randall JM, 2014, CANCER METAST REV, V33, P1109, DOI 10.1007/s10555-014-9533-1; Romain CV, 2014, ANTICANCER RES, V34, P2269; Sadowski M, 2012, IUBMB LIFE, V64, P136, DOI 10.1002/iub.589; Schodel J, 2016, EUR UROL, V69, P646, DOI 10.1016/j.eururo.2015.08.007; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Seeger-Nukpezah Tamina, 2013, Drug Discov Today Dis Mech, V10, pe135; Shabek N, 2012, MOL CELL, V48, P87, DOI 10.1016/j.molcel.2012.07.011; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Thoma CR, 2007, NAT CELL BIOL, V9, P588, DOI 10.1038/ncb1579; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Xie L, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000444; Xue J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035848; Zhou L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023936	53	28	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3450	3463		10.1038/onc.2016.495	http://dx.doi.org/10.1038/onc.2016.495			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114281	Green Published, hybrid			2022-12-17	WOS:000403340700009
J	Shahriari, K; Shen, F; Worrede-Mahdi, A; Liu, Q; Gong, Y; Garcia, FU; Fatatis, A				Shahriari, K.; Shen, F.; Worrede-Mahdi, A.; Liu, Q.; Gong, Y.; Garcia, F. U.; Fatatis, A.			Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche	ONCOGENE			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; NEUROENDOCRINE DIFFERENTIATION; BREAST-CANCER; TUMOR-GROWTH; PROGRESSION; FIBROBLASTS; EXPRESSION; MICE; ADENOCARCINOMA; IDENTIFICATION	The growth of disseminated tumor cells into metastatic lesions depends on the establishment of a favorable microenvironment in the stroma of the target organs. Here we show that mice treated with anakinra, an antagonist of the interleukin (IL)-1 beta receptor (IL-1R), or harboring a targeted deletion of IL-1R are significantly less prone to develop bone tumors when inoculated in the arterial circulation with human prostate cancer (PCa) cells expressing IL-1 beta. Interestingly, human mesenchymal stem cells exposed in vitro to medium conditioned by IL-1 beta-expressing cancer cells responded by upregulating S100A4, a marker of cancer-associated fibroblasts (CAFs), and this effect was blocked by anakinra. Analogously, the stroma adjacent to skeletal metastases generated in mice by IL-1 beta-expressing cancer cells showed a dramatic increase in S100A4, COX-2 and the alteration of 30 tumor-related genes as measured by Nanostring analysis. These effects were not observed in the stroma associated with the rare and much smaller metastases generated by the same cells in IL-1R knockout animals, confirming that tumor-secreted IL-1 beta generates skeletal CAFs and conditions the surrounding bone microenvironment. In skeletal lesions from patients with metastatic PCa, histological and molecular analyses revealed that IL-1 beta is highly expressed in cancer cells in which the androgen receptor (AR) is not detected (AR-), whereas this cytokine is uniformly absent in the AR-positive (AR+) metastatic cells. The stroma conditioned by IL-1 beta-expressing cancer cells served as a supportive niche also for coexisting IL-1 beta-lacking cancer cells, which are otherwise unable to generate tumors after independently seeding the skeleton of mice. This niche is established very early following tumor seeding and hints to a role of IL-1 beta in promoting early colonization of PCa at the skeletal level.	[Shahriari, K.; Shen, F.; Worrede-Mahdi, A.; Liu, Q.; Fatatis, A.] Drexel Univ, Coll Med, Dept Pharmacol & Physiol, 245N 15th St,NCB 8211, Philadelphia, PA 19102 USA; [Gong, Y.; Garcia, F. U.; Fatatis, A.] Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Garcia, F. U.] Eastern Reg Med Ctr, Canc Treatment Ctr Amer, Philadelphia, PA USA; [Fatatis, A.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Program Prostate Canc, Philadelphia, PA 19107 USA; [Liu, Q.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Drexel University; Drexel University; Jefferson University; University of Texas System; UTMD Anderson Cancer Center	Fatatis, A (corresponding author), Drexel Univ, Coll Med, Dept Pharmacol & Physiol, 245N 15th St,NCB 8211, Philadelphia, PA 19102 USA.	afatatis@drexelmed.edu		Worrede, Asurayya/0000-0003-2013-0112	NIH [F30CA192896-01]; Department of Defense [PC080987]; NATIONAL CANCER INSTITUTE [F30CA192896] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Olimpia Meucci (Department of Pharmacology and Physiology at Drexel University College of Medicine) for invaluable advice, Dr Kevin Kelly (Medical Oncology) and all the other members of the Greater Philadelphia Prostate Cancer Working Group at the Sidney Kimmel Cancer Center, Thomas Jefferson University for insightful discussions, Dr Ruth Birbe (Pathology) at Thomas Jefferson University for providing the human specimens of skeletal metastases and Danielle Jernigan (Fatatis laboratory) for critical reading of the manuscript. This work was supported by NIH F30CA192896-01 grant to KS and in part by Department of Defense PC080987 Idea Award to AF.	Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bersani F, 2014, CANCER RES, V74, P7229, DOI 10.1158/0008-5472.CAN-14-1809; Boye K, 2010, AM J PATHOL, V176, P528, DOI 10.2353/ajpath.2010.090526; Childs RW, 2015, NAT REV DRUG DISCOV, V14, P487, DOI 10.1038/nrd4506; Cindolo L, 2007, EUR UROL, V52, P1365, DOI 10.1016/j.eururo.2006.11.030; Cohen SB, 2004, RHEUM DIS CLIN N AM, V30, P365, DOI 10.1016/j.rdc.2004.01.005; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Dinarello CA, 2010, CANCER METAST REV, V29, P317, DOI 10.1007/s10555-010-9229-0; Drake JM, 2005, CLIN EXP METASTAS, V22, P674, DOI 10.1007/s10585-006-9011-4; Drake JM, 2010, CANCER BIOL THER, V9, P607, DOI 10.4161/cbt.9.8.11112; Eckhardt BL, 2012, NAT REV DRUG DISCOV, V11, P479, DOI 10.1038/nrd2372; FENTON MJ, 1992, INT J IMMUNOPHARMACO, V14, P401, DOI 10.1016/0192-0561(92)90170-P; Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Goel HL, 2008, ENDOCR-RELAT CANCER, V15, P657, DOI 10.1677/ERC-08-0019; Hemingway F, 2011, BONE, V48, P938, DOI 10.1016/j.bone.2010.12.023; Jamieson-Gladney WL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3016; Jiborn T, 1998, UROLOGY, V51, P585, DOI 10.1016/S0090-4295(97)00684-5; Kalos M, 2004, PROSTATE, V60, P246, DOI 10.1002/pros.20043; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Kim S, 2000, P NATL ACAD SCI USA, V97, P2731, DOI 10.1073/pnas.050588297; Klein CA, 2013, NATURE, V501, P365, DOI 10.1038/nature12628; Komiya A, 2009, INT J UROL, V16, P37, DOI 10.1111/j.1442-2042.2008.02175.x; Lewis AM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-48; Li HJ, 2012, CANCER DISCOV, V2, P840, DOI 10.1158/2159-8290.CD-12-0101; Liu QX, 2013, CANCER RES, V73, P3297, DOI 10.1158/0008-5472.CAN-12-3970; Madar S, 2013, TRENDS MOL MED, V19, P447, DOI 10.1016/j.molmed.2013.05.004; MICKEY DD, 1977, CANCER RES, V37, P4049; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pio R, 2014, ADV EXP MED BIOL, V772, P229, DOI 10.1007/978-1-4614-5915-6_11; Russell MR, 2009, ONCOGENE, V28, P412, DOI 10.1038/onc.2008.390; Shariff AH, 2006, UROLOGY, V68, P2, DOI 10.1016/j.urology.2006.02.002; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Shen F, 2016, MOL CANCER RES, V14, P518, DOI 10.1158/1541-7786.MCR-16-0013; Sheridan T, 2007, AM J SURG PATHOL, V31, P1351, DOI 10.1097/PAS.0b013e3180536678; Sun Y, 2009, AM J TRANSL RES, V1, P148; Tabassum DP, 2015, NAT REV CANCER, V15, P473, DOI 10.1038/nrc3971; Valdivia-Silva JE, 2009, CANCER LETT, V283, P176, DOI 10.1016/j.canlet.2009.03.040; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wai PY, 2008, CANCER METAST REV, V27, P103, DOI 10.1007/s10555-007-9104-9; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Weckermann D, 2001, J UROLOGY, V166, P699, DOI 10.1016/S0022-5347(05)66046-6; Wurth R, 2015, TRANSL ONCOL, V8, P358, DOI 10.1016/j.tranon.2015.07.002; Xu JC, 2001, CANCER RES, V61, P1563; Yu DD, 2015, ONCOTARGET, V6, P42687, DOI 10.18632/oncotarget.5883; Zhao Y, 2014, INT J BIOL SCI, V10, P614, DOI 10.7150/ijbs.8389	47	28	28	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2846	2856		10.1038/onc.2016.436	http://dx.doi.org/10.1038/onc.2016.436			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27991924	Green Accepted			2022-12-17	WOS:000401697800007
J	Li, Z; Bridges, B; Olson, J; Weinman, SA				Li, Z.; Bridges, B.; Olson, J.; Weinman, S. A.			The interaction between acetylation and serine-574 phosphorylation regulates the apoptotic function of FOXO3	ONCOGENE			English	Article							TRANSCRIPTION FACTOR FOXO3A; BREAST-CANCER; SIRT1; PROTEIN; DEACETYLATION; DEGRADATION; PROMOTES; STRESS; TUMORIGENESIS; METABOLISM	The multispecific transcription factor and tumor suppressor FOXO3 is an important mediator of apoptosis, but the mechanisms that control its proapoptotic function are poorly understood. There has long been evidence that acetylation promotes FOXO3driven apoptosis and recently a specific JNK (c-Jun N-terminal kinase)-dependent S574 phosphorylated form (p-FOXO3) has been shown to be specifically apoptotic. This study examined whether acetylation and S574 phosphorylation act independently or in concert to regulate the apoptotic function of FOXO3. We observed that both sirtuins 1 and 7 (SIRT1 and SIRT7) are able to deacetylate FOXO3 in vitro and in vivo, and that lipopolysaccharide (LPS) treatment of THP-1 monocytes induced a rapid increase of FOXO3 acetylation, partly by suppression of SIRT1 and SIRT7. Acetylation was required for S574 phosphorylation and cellular apoptosis. Deacetylation of FOXO3 by SIRT activation or SIRT1 or SIRT7 overexpression prevented its S574 phosphorylation and blocked apoptosis in response to LPS. We also found that acetylated FOXO3 preferentially bound JNK1, and a mutant FOXO3 lacking four known acetylation sites (K242, 259, 290 and 569R) abolished JNK1 binding and failed to induce apoptosis. This interplay of acetylation and phosphorylation also regulated cell death in primary human peripheral blood monocytes (PBMs). PBMs isolated from alcoholic hepatitis patients had high expression of SIRT1 and SIRT7 and failed to induce p-FOXO3 and apoptosis in response to LPS. PBMs from healthy controls had lower SIRT1 and SIRT7 and readily formed p-FOXO3 and underwent apoptosis when similarly treated. These results reveal that acetylation is permissive for generation of the apoptotic form of FOXO3 and the activity of SIRT1 and particularly SIRT7 regulate this process in vivo, allowing control of monocyte apoptosis in response to LPS.	[Li, Z.; Olson, J.; Weinman, S. A.] Univ Kansas, Med Ctr, Dept Internal Med, 3901 Rainbow Blvd,Mailstop 1018, Kansas City, KS 66160 USA; [Bridges, B.; Weinman, S. A.] Univ Kansas, Med Ctr, Ctr Liver, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Weinman, SA (corresponding author), Univ Kansas, Med Ctr, Dept Internal Med, 3901 Rainbow Blvd,Mailstop 1018, Kansas City, KS 66160 USA.	sweinman@kumc.edu	Li, Zhuan/C-3196-2014	LI, ZHUAN/0000-0002-1310-4584	National Institute on Alcoholism and Alcohol Abuse [AA012863]; Biomedical Research Training Program of the University of Kansas Medical Center; Hubert and Richard Hanlon Trust; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012863] Funding Source: NIH RePORTER	National Institute on Alcoholism and Alcohol Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Biomedical Research Training Program of the University of Kansas Medical Center; Hubert and Richard Hanlon Trust; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This study was supported by grant AA012863 from the National Institute on Alcoholism and Alcohol Abuse, a fellowship grant from the Biomedical Research Training Program of the University of Kansas Medical Center (to ZL) and by a grant from the Hubert and Richard Hanlon Trust. The human monocytes used in this study were provided by the University of Kansas Liver Center Tissue Bank. We thank Drs Charles Rice and Robert A Davey for providing reagents for these studies.	Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Caito S, 2010, FASEB J, V24, P3145, DOI 10.1096/fj.09-151308; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Chung YW, 2011, J BIOL CHEM, V286, P29681, DOI 10.1074/jbc.M111.264945; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Elmali N, 2007, INFLAMMATION, V30, P1, DOI 10.1007/s10753-006-9012-0; Flick F, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00029; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gao ZG, 2011, J BIOL CHEM, V286, P22227, DOI 10.1074/jbc.M111.228874; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098; Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2; Jin YH, 2008, BIOCHEM BIOPH RES CO, V368, P690, DOI 10.1016/j.bbrc.2008.01.114; Khongkow M, 2013, CARCINOGENESIS, V34, P1476, DOI 10.1093/carcin/bgt098; Lee SM, 2011, DIABETOLOGIA, V54, P1136, DOI 10.1007/s00125-011-2064-1; Li Z, 2016, CELL DEATH DIFFER, V23, P583, DOI 10.1038/cdd.2015.125; Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035; Lucey MR, 2009, NEW ENGL J MED, V360, P2758, DOI 10.1056/NEJMra0805786; MCKEEVER UM, 1983, LANCET, V2, P1492; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Nasrin N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008414; Ni HM, 2013, AM J PATHOL, V183, P1815, DOI 10.1016/j.ajpath.2013.08.011; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Ponugoti B, 2010, J BIOL CHEM, V285, P33959, DOI 10.1074/jbc.M110.122978; Rothgiesser KM, 2010, J CELL SCI, V123, P4251, DOI 10.1242/jcs.073783; Roychowdhury S, 2009, HEPATOLOGY, V49, P1326, DOI 10.1002/hep.22776; Sasaki T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004020; Satoh A, 2013, CELL METAB, V18, P416, DOI 10.1016/j.cmet.2013.07.013; Simic P, 2013, EMBO MOL MED, V5, P430, DOI 10.1002/emmm.201201606; Su JL, 2011, CANCER RES, V71, P6878, DOI 10.1158/0008-5472.CAN-11-0295; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tseng AHH, 2013, FREE RADICAL BIO MED, V63, P222, DOI 10.1016/j.freeradbiomed.2013.05.002; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang YF, 2015, CELL STRESS CHAPERON, V20, P805, DOI 10.1007/s12192-015-0599-7; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872; Zschoernig B, 2009, BIOCHEM BIOPH RES CO, V381, P372, DOI 10.1016/j.bbrc.2009.02.085	41	28	30	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1887	1898		10.1038/onc.2016.359	http://dx.doi.org/10.1038/onc.2016.359			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27669435	Green Accepted			2022-12-17	WOS:000398128900013
J	Obinata, D; Takayama, K; Fujiwara, K; Suzuki, T; Tsutsumi, S; Fukuda, N; Nagase, H; Fujimura, T; Urano, T; Homma, Y; Aburatani, H; Takahashi, S; Inoue, S				Obinata, D.; Takayama, K.; Fujiwara, K.; Suzuki, T.; Tsutsumi, S.; Fukuda, N.; Nagase, H.; Fujimura, T.; Urano, T.; Homma, Y.; Aburatani, H.; Takahashi, S.; Inoue, S.			Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth	ONCOGENE			English	Article							PYRROLE-IMIDAZOLE POLYAMIDE; ACYL-COA SYNTHETASE-5; GENE-EXPRESSION; TRANSCRIPTION FACTORS; DNA; PROGRESSION; IDENTIFICATION; SUPPRESSION; RECOGNITION; NETWORK	Androgen receptor (AR) functions as a ligand-dependent transcription factor to regulate its downstream signaling for prostate cancer progression. AR complex formation by multiple transcription factors is important for enhancer activity and transcriptional regulation. However, the significance of such collaborative transcription factors has not been fully understood. In this study, we show that Oct1, an AR collaborative factor, coordinates genome-wide AR signaling for prostate cancer growth. Using global analysis by chromatin immunoprecipitation sequencing (ChIP-seq), we found that Oct1 is recruited to AR-binding enhancer/promoter regions and facilitates androgen signaling. Moreover, a major target of AR/Oct1 complex, acyl-CoA synthetase 3 (ACSL3), contributes to tumor growth in nude mice, and its high expression is associated with poor prognosis in prostate cancer patients. Next, we examined the therapeutic effects of pyrrole-imidazole polyamides that target the Oct1-binding sequence identified in the center of the ACSL3 AR-binding site. We observed that treatment with Oct1 polyamide severely blocked the Oct1 binding at the ACSL3 enhancer responsible for its transcriptional activity and ACSL3 induction. In addition, Oct1 polyamides suppressed castration-resistant tumor growth and specifically repressed global Oct1 chromatin association and androgen signaling in prostate cancer cells, with few nonspecific effects on basal promoter activity. Thus, targeting Oct1 binding could be a novel therapeutic strategy for AR-activated castration-resistant prostate cancer.	[Obinata, D.; Takayama, K.; Urano, T.; Inoue, S.] Univ Tokyo, Grad Sch Med, Dept Antiaging Med, Tokyo, Japan; [Obinata, D.; Takahashi, S.] Nihon Univ, Sch Med, Dept Urol, Tokyo, Japan; [Takayama, K.; Urano, T.; Inoue, S.] Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo, Japan; [Takayama, K.; Inoue, S.] Tokyo Metropolitan Inst Gerontol, Dept Funct Biogerontr, Tokyo, Japan; [Fujiwara, K.] Nihon Univ, Sch Med, Dept Med, Div Gen Med, Tokyo, Japan; [Suzuki, T.] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi, Japan; [Tsutsumi, S.; Aburatani, H.] Univ Tokyo, RCAST, Genome Sci Div, Tokyo, Japan; [Fukuda, N.] Nihon Univ, Sch Med, Dept Med, Div Nephrol Hypertens & Endocrinol, Tokyo, Japan; [Nagase, H.] Chiba Canc Ctr, Res Inst, Lab Canc Genet, Chiba, Japan; [Fujimura, T.; Homma, Y.] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan; [Inoue, S.] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan	University of Tokyo; Nihon University; University of Tokyo; Tokyo Metropolitan Institute of Gerontology; Nihon University; Tohoku University; University of Tokyo; Nihon University; Chiba Cancer Center; University of Tokyo; Saitama Medical University	Inoue, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Antiaging Med, Bunkyo Ku, Tokyo 1138655, Japan.	sinoue@tmig.or.jp	Takayama, Kenichi/AAK-9238-2020; Urano, Tomohiko/AFS-9574-2022	Fukuda, Noboru/0000-0003-0098-054X; Nagase, Hiroki/0000-0002-3992-5399	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Japan Society for the Promotion of Science (JSPS), Japan [15K15353, 15K15581, 25293214, 15K10610]; MHLW, Japan; Nihon University Medical Alumni Association; Japanese Urological Association; Advanced Research for Medical Products Mining Program, NIBIO, Japan; Takeda Science Foundation; Mochida Memorial Research Foundation, Japan; Grants-in-Aid for Scientific Research [25112001, 16K09796] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MHLW, Japan; Nihon University Medical Alumni Association; Japanese Urological Association(Japanese Urological Association); Advanced Research for Medical Products Mining Program, NIBIO, Japan; Takeda Science Foundation(Takeda Science Foundation (TSF)); Mochida Memorial Research Foundation, Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank N Sasaki, T Oishi, S Takada, A Ito and E Sakamoto for technical assistance. This work was supported by grants of the Cell Innovation Program (SI) and P-Direct (SI) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; by Grants-in-Aid for SI (no. 15K15353), KT (no. 15K15581), TU (no. 25293214) and ST (no. 15K10610) from the Japan Society for the Promotion of Science (JSPS), Japan; by Grants-in-Aid (SI) from the MHLW, Japan; by the 2010 Research Grant of the 60th Anniversary Memorial Fund (DO) from Nihon University Medical Alumni Association; by the Young Researcher Promotion Grant (DO) from The Japanese Urological Association; by the Advanced Research for Medical Products Mining Program (SI), NIBIO, Japan; by grants from Takeda Science Foundation (SI and KT), by a grant from Mochida Memorial Research Foundation (KT), Japan.	Attard G, 2008, BRIT J CANCER, V99, P314, DOI 10.1038/sj.bjc.6604472; Barfeld SJ, 2014, ENDOCR-RELAT CANCER, V21, pT57, DOI 10.1530/ERC-13-0515; Bu SY, 2009, J BIOL CHEM, V284, P30474, DOI 10.1074/jbc.M109.036665; Chang YS, 2011, J CELL BIOCHEM, V112, P881, DOI 10.1002/jcb.22996; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Dervan PB, 2003, CURR OPIN STRUC BIOL, V13, P284, DOI 10.1016/S0959-440X(03)00081-2; Dervan PB, 2001, BIOORGAN MED CHEM, V9, P2215, DOI 10.1016/S0968-0896(01)00262-0; Fujimoto Y, 2007, J LIPID RES, V48, P1280, DOI 10.1194/jlr.M700050-JLR200; Gassler N, 2005, J PATHOL, V207, P295, DOI 10.1002/path.1831; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hendriksen PJM, 2006, CANCER RES, V66, P5012, DOI 10.1158/0008-5472.CAN-05-3082; Jariwala U, 2009, PROSTATE, V69, P392, DOI 10.1002/pros.20893; Jin Y, 2015, EMBO MOL MED, V7, P315, DOI 10.15252/emmm.201404181; Kim JY, 2014, MOL CELL, V54, P613, DOI 10.1016/j.molcel.2014.03.043; Maloberti PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015540; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsuda H, 2011, KIDNEY INT, V79, P46, DOI 10.1038/ki.2010.330; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Minekura H, 2001, GENE, V278, P185, DOI 10.1016/S0378-1119(01)00714-4; Monaco ME, 2010, TRANSL ONCOL, V3, P91, DOI 10.1593/tlo.09202; Murty MSRC, 2004, BIOL PHARM BULL, V27, P468, DOI 10.1248/bpb.27.468; Nagashima T, 2009, BIOL PHARM BULL, V32, P921, DOI 10.1248/bpb.32.921; Nickols NG, 2007, P NATL ACAD SCI USA, V104, P10418, DOI 10.1073/pnas.0704217104; Obinata D, 2012, INT J CANCER, V130, P1021, DOI 10.1002/ijc.26043; Raskatov JA, 2012, P NATL ACAD SCI USA, V109, P16041, DOI 10.1073/pnas.1214267109; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Takayama K, 2007, ONCOGENE, V26, P4453, DOI 10.1038/sj.onc.1210229; Takayama K, 2015, ONCOTARGET, V6, P2263, DOI 10.18632/oncotarget.2949; Takayama K, 2014, MOL ENDOCRINOL, V28, P2012, DOI 10.1210/me.2014-1171; Takayama K, 2014, CANCER RES, V74, P6542, DOI 10.1158/0008-5472.CAN-14-1030; Takayama K, 2013, INT J UROL, V20, P756, DOI 10.1111/iju.12146; Takayama K, 2013, EMBO J, V32, P1665, DOI 10.1038/emboj.2013.99; Tan PY, 2012, MOL CELL BIOL, V32, P399, DOI 10.1128/MCB.05958-11; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wang G, 2006, ONCOGENE, V25, P7311, DOI 10.1038/sj.onc.1209715; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wang XF, 2010, CANCER SCI, V101, P759, DOI 10.1111/j.1349-7006.2009.01435.x; Wu MH, 2011, INT J MOL MED, V27, P655, DOI 10.3892/ijmm.2011.624; Yamashita Y, 2000, ONCOGENE, V19, P5919, DOI 10.1038/sj.onc.1203981; Yang F, 2013, P NATL ACAD SCI USA, V110, P1863, DOI 10.1073/pnas.1222035110; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao HJ, 2005, PROSTATE, V63, P187, DOI 10.1002/pros.20158	47	28	28	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6350	6358		10.1038/onc.2016.171	http://dx.doi.org/10.1038/onc.2016.171			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27270436				2022-12-17	WOS:000390247000008
J	He, XH; Zhu, W; Yuan, P; Jiang, S; Li, D; Zhang, HW; Liu, MF				He, X-H; Zhu, W.; Yuan, P.; Jiang, S.; Li, D.; Zhang, H-W; Liu, M-F			miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells	ONCOGENE			English	Article							TRANSCRIPTIONAL REPRESSION; MICRORNA-155 PROMOTES; CANCER; TUMOR; TARGETS; TRASTUZUMAB; EXPRESSION; GROWTH; HER2; OVEREXPRESSION	ErbB2 is a vital breast cancer gene and its overexpression has a decisive role in breast tumor initiation and malignant progression. However, the molecular mechanisms that underlie ErbB2 dysregulation in breast cancer cells remain incompletely understood. In this study, we found that ErbB2 expression is inversely correlated with the level of miR-155, a well-documented oncogenic miRNA, in ErbB2-positive breast tumors. We further determined that miR-155 potently suppresses ErbB2 in breast cancer cells. Mechanistically, miR-155 acts to downregulate ErbB2 via two distinct mechanisms. First, miR-155 represses ErbB2 transcription by targeting HDAC2, a transcriptional activator of ErbB2. Second, miR-155 directly targets ErbB2 via a regulatory element in its coding region. Intriguingly, miR-155 is upregulated by trastuzumab and in turn leads to a reduction of ErbB2 expression in trastuzumab-treated ErbB2-positive breast cancer cells. Functional studies showed that miR-155 inhibits ErbB2-induced malignant transformation of human breast epithelial cells. Thus, our findings reveal an intriguing miR-155-ErbB2 context in regulating the malignant transformation of breast epithelial cells, and thereby indicate a novel mode of action for miR-155 in ErbB2-positive breast cancer.	[He, X-H; Yuan, P.; Jiang, S.; Liu, M-F] Univ Chinese Acad Sci, CAS Ctr Excellence Mol Cell Sci, Ctr RNA Res, State Key Lab Mol Biol, Shanghai, Peoples R China; [He, X-H; Yuan, P.; Jiang, S.; Liu, M-F] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Key Lab Mol Androl, Inst Biochem & Cell Biol, Shanghai, Peoples R China; [Zhu, W.; Zhang, H-W] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Li, D.] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Informat Ctr Life Sci, Shanghai, Peoples R China; [Liu, M-F] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Information Center for Life Sciences; ShanghaiTech University	Liu, MF (corresponding author), Chinese Acad Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	mfliu@sibcb.ac.cn		Jiang, Shuai/0000-0002-0572-4660; liu, mo fang/0000-0003-1800-466X	Ministry of Science and Technology of China [2012CB910803, 2014CB943103, 2014CB964802]; National Natural Science Foundation of China [31325008, 91419307, 81502267, 31300656]; Science and Technology Commission of the Shanghai Municipality [13ZR1464300, 16XD1404900]; Chinese Academy of Sciences [KJZD-EW-L01-2, 2013KIP202]; Foundation of Key Laboratory of Gene Engineering of the Ministry of Education	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of the Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Chinese Academy of Sciences(Chinese Academy of Sciences); Foundation of Key Laboratory of Gene Engineering of the Ministry of Education	We thank Dr Gao-Xiang Ge for suggestions and critical comments on the manuscript. This work was supported by grants from the Ministry of Science and Technology of China (2012CB910803, 2014CB943103 and 2014CB964802), the National Natural Science Foundation of China (31325008, 91419307, 81502267, and 31300656), the Science and Technology Commission of the Shanghai Municipality (13ZR1464300 and 16XD1404900), and the Chinese Academy of Sciences (KJZD-EW-L01-2 and 2013KIP202) and Foundation of Key Laboratory of Gene Engineering of the Ministry of Education.	Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; American Type Culture Collection, 2007, ATCC TECHN B, V8; Babar IA, 2011, CANCER BIOL THER, V12, P908, DOI 10.4161/cbt.12.10.17681; Cai ZK, 2015, MOL MED REP, V11, P533, DOI 10.3892/mmr.2014.2744; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dinami R, 2014, CANCER RES, V74, P4145, DOI 10.1158/0008-5472.CAN-13-2038; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Guarnieri DJ, 2008, ANN MED, V40, P197, DOI 10.1080/07853890701771823; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; Hicks DG, 2008, ARCH PATHOL LAB MED, V132, P1008, DOI 10.1043/1543-2165(2008)132[1008:TAATFE]2.0.CO;2; Higgs Gadareth, 2013, J Clin Bioinforma, V3, P17, DOI 10.1186/2043-9113-3-17; Huang SL, 2010, NUCLEIC ACIDS RES, V38, P7211, DOI 10.1093/nar/gkq564; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Koudelakova V, 2015, J MOL DIAGN, V17, P446, DOI 10.1016/j.jmoldx.2015.03.007; Krauss W C, 2000, Breast Dis, V11, P113; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu HQ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-51; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Melton C, 2010, NATURE, V463, P621, DOI 10.1038/nature08725; Mittendorf EA, 2009, CLIN CANCER RES, V15, P7381, DOI 10.1158/1078-0432.CCR-09-1735; Muller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215; Nofech-Mozes S, 2005, ADV ANAT PATHOL, V12, P256, DOI 10.1097/01.pap.0000184177.65919.5e; Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011; Pedersen IM, 2009, EMBO MOL MED, V1, P288, DOI 10.1002/emmm.200900028; Pinto AC, 2013, BREAST, V22, pS152, DOI 10.1016/j.breast.2013.07.029; Pouliot LM, 2012, CANCER RES, V72, P5945, DOI 10.1158/0008-5472.CAN-12-1400; Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429; Qin WX, 2013, FEBS LETT, V587, P1434, DOI 10.1016/j.febslet.2013.03.023; Sandhu SK, 2012, P NATL ACAD SCI USA, V109, P20047, DOI 10.1073/pnas.1213764109; Scott GK, 2002, MOL CANCER THER, V1, P385; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Wang L, 2014, CANCER RES, V74, P4720, DOI 10.1158/0008-5472.CAN-14-0960; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Wu L, 2008, MOL CELL, V29, P1, DOI 10.1016/j.molcel.2007.12.010; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhang XP, 2013, J CLIN ENDOCR METAB, V98, pE1305, DOI 10.1210/jc.2012-3602; Zhang YL, 2012, HEPATOLOGY, V56, P1631, DOI 10.1002/hep.25849; Zhao S, 2013, DEV CELL, V24, P13, DOI 10.1016/j.devcel.2012.12.006	50	28	28	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6015	6025		10.1038/onc.2016.132	http://dx.doi.org/10.1038/onc.2016.132			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27065318				2022-12-17	WOS:000388509400008
J	Shi, X; Wang, Q; Gu, J; Xuan, Z; Wu, JI				Shi, X.; Wang, Q.; Gu, J.; Xuan, Z.; Wu, J. I.			SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development	ONCOGENE			English	Article							CHROMATIN REMODELING COMPLEX; TUMOR-SUPPRESSOR; CEREBELLAR DEVELOPMENT; NEURAL DEVELOPMENT; CELL-PROLIFERATION; HEDGEHOG PATHWAY; CANCER; TRANSCRIPTION; BRG1; ACTIVATION	Recent large-scale genomic studies have classified medulloblastoma into four subtypes: Wnt, Shh, Group 3 and Group 4. Each is characterized by specific mutations and distinct epigenetic states. Previously, we showed that a chromatin regulator SMARCA4/Brg1 is required for Gli-mediated transcription activation in Sonic hedgehog (Shh) signaling. We report here that Brg1 controls a transcriptional program that specifically regulates Shh-type medulloblastoma growth. Using a mouse model of Shh-type medulloblastoma, we deleted Brg1 in precancerous progenitors and primary or transplanted tumors. Brg1 deletion significantly inhibited tumor formation and progression. Genome-wide expression analyses and binding experiments indicate that Brg1 specifically coordinates with key transcription factors including Gli1, Atoh1 and REST to regulate the expression of both oncogenes and tumor suppressors that are required for medulloblastoma identity and proliferation. Shh-type medulloblastoma displays distinct H3K27me3 properties. We demonstrate that Brg1 modulates activities of H3K27me3 modifiers to regulate the expression of medulloblastoma genes. Brg1-regulated pathways are conserved in human Shh-type medulloblastoma, and Brg1 is important for the growth of a human medulloblastoma cell line. Thus, Brg1 coordinates a genetic and epigenetic network that regulates the transcriptional program underlying the Shh-type medulloblastoma development.	[Shi, X.; Wang, Q.; Wu, J. I.] Univ Texas Southwestern Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Gu, J.; Xuan, Z.] Univ Texas Dallas, Ctr Syst Biol, Dept Biol Sci, Richardson, TX 75083 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas	Wu, JI (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jiang9.wu@utsouthwestern.edu			March of Dimes Foundation; American Cancer Society; NIMH; Department of Defense Visionary postdoc fellowship	March of Dimes Foundation(March of Dimes); American Cancer Society(American Cancer Society); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Department of Defense Visionary postdoc fellowship	We thank Drs Brent Orr (St. Jude Hospital), Wenzhe Niu and Zilai Zhang, and Mou Cao for technical support and Dr Chao Xing and the University of Texas Southwestern Sequencing Facility for performing the next-generation sequencing and RNA-seq analyses. We thank Drs Lin Gan and Jane Johnson for providing the Atoh1-Cre mice and Dr Ching-Ping Chang for providing human Brg1 shRNA constructs. This work was supported by grants from March of Dimes Foundation (JW), American Cancer Society (JW), NIMH (JW) and Department of Defense Visionary postdoc fellowship (XS).	Anne SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081769; Barakat MT, 2010, TRENDS MOL MED, V16, P337, DOI 10.1016/j.molmed.2010.05.003; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Corrales JMD, 2004, DEVELOPMENT, V131, P5581, DOI 10.1242/dev.01438; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dakubo GD, 2006, J NEURO-ONCOL, V79, P221, DOI 10.1007/s11060-006-9132-2; Dietrich N, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002494; Dubuc AM, 2013, ACTA NEUROPATHOL, V125, P373, DOI 10.1007/s00401-012-1070-9; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Flora A, 2009, SCIENCE, V326, P1424, DOI 10.1126/science.1181453; Fuccillo M, 2006, NAT REV NEUROSCI, V7, P772, DOI 10.1038/nrn1990; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; Hasselblatt M, 2014, ACTA NEUROPATHOL, V128, P453, DOI 10.1007/s00401-014-1323-x; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106; Hu GQ, 2011, GENOME RES, V21, P1650, DOI 10.1101/gr.121145.111; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jagani Z, 2010, NAT MED, V16, P1429, DOI 10.1038/nm.2251; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Johnson R, 2008, PLOS BIOL, V6, P2205, DOI 10.1371/journal.pbio.0060256; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klisch TJ, 2011, P NATL ACAD SCI USA, V108, P3288, DOI 10.1073/pnas.1100230108; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee EY, 2010, P NATL ACAD SCI USA, V107, P9736, DOI 10.1073/pnas.1004602107; Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li QT, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004524; Malatesta M, 2013, CANCER RES, V73, P6323, DOI 10.1158/0008-5472.CAN-12-4660; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Markant SL, 2013, CANCER RES, V73, P6310, DOI 10.1158/0008-5472.CAN-12-4258; Miller SA, 2010, MOL CELL, V40, P594, DOI 10.1016/j.molcel.2010.10.028; Moreno N, 2014, J NEUROSCI, V34, P13486, DOI 10.1523/JNEUROSCI.2560-14.2014; Natarajan S, 2013, CANCER RES, V73, P5381, DOI 10.1158/0008-5472.CAN-13-0033; Negrini S, 2013, TRENDS CELL BIOL, V23, P289, DOI 10.1016/j.tcb.2013.01.006; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Ooi L, 2006, J BIOL CHEM, V281, P38974, DOI 10.1074/jbc.M605370200; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Popov N, 2010, EPIGENETICS-US, V5, P685, DOI 10.4161/epi.5.8.12996; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Romero OA, 2014, CANCER DISCOV, V4, P292, DOI 10.1158/2159-8290.CD-13-0799; Rutkowski S, 2010, J CLIN ONCOL, V28, P4961, DOI 10.1200/JCO.2010.30.2299; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Sengupta R, 2012, CANCER RES, V72, P122, DOI 10.1158/0008-5472.CAN-11-1701; Sengupta S, 2014, ACTA NEUROPATHOL, V127, P593, DOI 10.1007/s00401-013-1205-7; Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113; Shi XM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6425; Smits M, 2012, CLIN CANCER RES, V18, P4048, DOI 10.1158/1078-0432.CCR-12-0399; Stankunas K, 2008, DEV CELL, V14, P298, DOI 10.1016/j.devcel.2007.11.018; SumiIchinose C, 1997, MOL CELL BIOL, V17, P5976, DOI 10.1128/MCB.17.10.5976; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Triscott J, 2013, CANCER RES, V73, P6734, DOI 10.1158/0008-5472.CAN-12-4331; Uziel T, 2006, CELL CYCLE, V5, P363, DOI 10.4161/cc.5.4.2475; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wang VY, 2001, NAT REV NEUROSCI, V2, P484, DOI 10.1038/35081558; Wang X, 2009, CANCER RES, V69, P8094, DOI 10.1158/0008-5472.CAN-09-0733; Wetmore C, 2001, CANCER RES, V61, P513; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Wu JI, 2012, ACTA BIOCH BIOPH SIN, V44, P54, DOI 10.1093/abbs/gmr099; Wu JI, 2009, CELL, V136, P200, DOI 10.1016/j.cell.2009.01.009; Yang H, 2010, GENESIS, V48, P407, DOI 10.1002/dvg.20633; Yu Y, 2013, CELL, V152, P248, DOI 10.1016/j.cell.2012.12.006; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340; Zhan XM, 2011, P NATL ACAD SCI USA, V108, P12758, DOI 10.1073/pnas.1018510108	76	28	28	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5746	5758		10.1038/onc.2016.108	http://dx.doi.org/10.1038/onc.2016.108			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065321				2022-12-17	WOS:000386998400006
J	Somarelli, JA; Schaeffer, D; Marengo, MS; Bepler, T; Rouse, D; Ware, KE; Hish, AJ; Zhao, Y; Buckley, AF; Epstein, JI; Armstrong, AJ; Virshup, DM; Garcia-Blanco, MA				Somarelli, J. A.; Schaeffer, D.; Marengo, M. S.; Bepler, T.; Rouse, D.; Ware, K. E.; Hish, A. J.; Zhao, Y.; Buckley, A. F.; Epstein, J. I.; Armstrong, A. J.; Virshup, D. M.; Garcia-Blanco, M. A.			Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ALTERNATIVE SPLICING REPORTERS; E-CADHERIN; IN-VIVO; PROSTATE-CANCER; TRANSGENIC MICE; DOWN-REGULATION; CELL CARCINOMA; BREAST-CANCER; COLONIZATION	The cascade that culminates in macrometastases is thought to be mediated by phenotypic plasticity, including epithelial-mesenchymal and mesenchymal-epithelial transitions (EMT and MET). Although there is substantial support for the role of EMT in driving cancer cell invasion and dissemination, much less is known about the importance of MET in the later steps of metastatic colonization. We created novel reporters, which integrate transcriptional and post-transcriptional regulation, to test whether MET is required for metastasis in multiple in vivo cancer models. In a model of carcinosarcoma, metastasis occurred via an MET-dependent pathway; however, in two prostate carcinoma models, metastatic colonization was MET independent. Our results provide evidence for both MET-dependent and MET-independent metastatic pathways.	[Somarelli, J. A.; Schaeffer, D.; Marengo, M. S.; Bepler, T.; Ware, K. E.; Garcia-Blanco, M. A.] Duke Univ, Med Ctr, Ctr RNA Biol, Durham, NC 27708 USA; [Somarelli, J. A.; Schaeffer, D.; Marengo, M. S.; Bepler, T.; Ware, K. E.; Garcia-Blanco, M. A.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA; [Rouse, D.] Duke Univ, Med Ctr, Dept Lab Anim Resources, Durham, NC USA; [Hish, A. J.; Armstrong, A. J.] Duke Univ, Med Ctr, Dept Med, Duke Canc Inst, Durham, NC 27710 USA; [Zhao, Y.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA; [Buckley, A. F.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Epstein, J. I.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; [Epstein, J. I.] Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USA; [Epstein, J. I.] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21287 USA; [Armstrong, A. J.] Duke Univ, Med Ctr, Solid Tumor Program, Durham, NC USA; [Armstrong, A. J.] Duke Univ, Med Ctr, Duke Prostate Ctr, Duke Canc Inst, Durham, NC USA; [Virshup, D. M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore; [Garcia-Blanco, M. A.] Duke Univ, Med Ctr, Duke Canc Inst, Program Mol Genet & Genom, Durham, NC USA; [Garcia-Blanco, M. A.] Univ Texas Med Branch, Dept Biochem & Mol Biol, 108 BSB, Galveston, TX 77555 USA; [Marengo, M. S.] Monsanto Co, Trait Delivery Program, Durham Site, Durham, NC USA; [Bepler, T.] MIT, Computat & Syst Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Duke University; Duke University; National University of Singapore; Duke University; University of Texas System; University of Texas Medical Branch Galveston; Monsanto; Massachusetts Institute of Technology (MIT)	Somarelli, JA (corresponding author), Duke Univ, Med Ctr, Ctr RNA Biol, Durham, NC 27708 USA.; Garcia-Blanco, MA (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, 108 BSB, Galveston, TX 77555 USA.	jason.somarelli@duke.edu; maragarc@utmb.edu	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; Buckley, Anne/0000-0003-1209-5791; Bepler, Tristan/0000-0001-5595-9954	National Institutes of Health (NIH) grant [R01 5R01-CA127727]; American Cancer Society Post-doctoral Fellowship [PF-11-036-01-DDC]; NIH T32 Training Grant [5T32CA009111]; NIH NRSA postdoctoral fellowship [F32-CA165482]; NIH NRSA Fellowship [1F32CA142095]; Duke Cancer Institute; Department of Orthopedics; Genitourinary Oncology Laboratory; NATIONAL CANCER INSTITUTE [F32CA142095, T32CA009111, F32CA165482, R01CA127727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063090] Funding Source: NIH RePORTER	National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society Post-doctoral Fellowship(American Cancer Society); NIH T32 Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH NRSA postdoctoral fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH NRSA Fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Duke Cancer Institute; Department of Orthopedics; Genitourinary Oncology Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health (NIH) grant R01 5R01-CA127727 to MAGB, American Cancer Society Post-doctoral Fellowship #PF-11-036-01-DDC to JAS, NIH T32 Training Grant #5T32CA009111 and an NIH NRSA postdoctoral fellowship (F32-CA165482) to DS, and NIH NRSA Fellowship 1F32CA142095 to MSM. JAS acknowledges support from the Duke Cancer Institute, The Department of Orthopedics and the Genitourinary Oncology Laboratory. We would like to acknowledge Dr Sebastian Oltean (Bristol University, UK) for his suggestion to develop the lineage-tracing reporter. We would also like to thank Dr Shelton Bradrick for helpful discussions. We acknowledge the Duke University Animal Pathology Core Facility, the Duke University Flow Cytometry Shared Resource and the Duke University Light Microscopy Core Facility.	Bonano VI, 2007, NAT PROTOC, V2, P2166, DOI 10.1038/nprot.2007.292; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; Chao Y, 2012, CANCER MICROENVIRON, V5, P19, DOI 10.1007/s12307-011-0085-4; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; De Gasperi R, 2008, GENESIS, V46, P308, DOI 10.1002/dvg.20400; Gao Y, 2015, ONCOTARGET, V6, P7828, DOI 10.18632/oncotarget.3488; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Han KS, 2015, MOL CANCER THER, V14, P1024, DOI 10.1158/1535-7163.MCT-14-0771; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Khan S, 2015, INT J BIOCHEM CELL B, V58, P1, DOI 10.1016/j.biocel.2014.10.028; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Kurahara H, 2012, J SURG ONCOL, V105, P655, DOI 10.1002/jso.23020; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Oltean S, 2008, CLIN EXP METASTAS, V25, P611, DOI 10.1007/s10585-008-9186-y; Oltean S, 2006, P NATL ACAD SCI USA, V103, P14116, DOI 10.1073/pnas.0603090103; Putzke AP, 2011, AM J PATHOL, V179, P400, DOI 10.1016/j.ajpath.2011.03.028; SAUER B, 1990, New Biologist, V2, P441; Schulten HJ, 2008, INT J GYNECOL CANCER, V18, P339, DOI 10.1111/j.1525-1438.2007.01004.x; Somarelli JA, 2013, RNA, V19, P116, DOI 10.1261/rna.035097.112; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wagner Eric J, 2004, Methods Mol Biol, V257, P29, DOI 10.1385/1-59259-750-5:029; Weinberg RA, 2014, CELL, V157, P267, DOI 10.1016/j.cell.2014.03.004; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Yori JL, 2010, J BIOL CHEM, V285, P16854, DOI 10.1074/jbc.M110.114546; Zhu YD, 2015, INTEGR CANCER THER, V14, P271, DOI 10.1177/1534735415572880	30	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4302	4311		10.1038/onc.2015.497	http://dx.doi.org/10.1038/onc.2015.497			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26751776	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000382152100002
J	Yagi, H; Asanoma, K; Ohgami, T; Ichinoe, A; Sonoda, K; Kato, K				Yagi, H.; Asanoma, K.; Ohgami, T.; Ichinoe, A.; Sonoda, K.; Kato, K.			GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; HIPPO SIGNALING PATHWAY; YES-ASSOCIATED PROTEIN; ALPHA-SUBUNIT; SIZE-CONTROL; G12 FAMILY; ORGAN SIZE; IDENTIFICATION; ESTABLISHMENT	G-protein-coupled receptors (GPCRs) and their ligands function in the progression of human malignancies. G alpha(12) and G alpha(13), encoded by GNA12 and GNA13, respectively, are referred to as the GEP oncogene and are implicated in tumor progression. However, the molecular mechanisms by which G alpha(12/13) activation promotes cancer progression are not fully elucidated. Here, we demonstrate elevated expression of G alpha 12/13 in human ovarian cancer tissues. G alpha(12/13) activation did not promote cellular migration in the ovarian cancer cell lines examined. Rather, G alpha(12/13) activation promoted cell growth. We used a synthetic biology approach using chimeric G proteins and GPCRs activated solely by artificial ligands to selectively trigger signaling pathways downstream of specific G proteins. We found that G alpha(12/13) promotes proliferation of ovarian cancer cells by activating the transcriptional coactivator YAP, a critical component of the Hippo signaling pathway. Furthermore, we reveal that inhibition of YAP by short hairpin RNA or a specific inhibitor prevented the growth of ovarian cancer cells. Therefore, YAP may be a suitable therapeutic target in ovarian cancer.	[Yagi, H.; Asanoma, K.; Ohgami, T.; Ichinoe, A.; Sonoda, K.; Kato, K.] Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Fukuoka, Japan	Kyushu University	Yagi, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yagih@med.kyushu-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [24791709, 26861332]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We are grateful to Ms Emiko Hori, Ms Yoko Miyanari and Research Support Center, Graduate School of Medical Science, Kyushu University for technical supports. This study was supported in part by a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (#24791709 and #26861332).	Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Galandrin S, 2007, TRENDS PHARMACOL SCI, V28, P423, DOI 10.1016/j.tips.2007.06.005; Gan CP, 2014, ONCOTARGET, V5, P9626, DOI 10.18632/oncotarget.2437; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Goldsmith Zachariah G, 2011, Genes Cancer, V2, P563, DOI 10.1177/1947601911419362; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; IMAI S, 1990, ONCOLOGY, V47, P177; Itamochi H, 2013, HUM CELL, V26, P121, DOI 10.1007/s13577-013-0062-y; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Miller E, 2012, CHEM BIOL, V19, P955, DOI 10.1016/j.chembiol.2012.07.005; Mo JS, 2012, GENE DEV, V26, P2138, DOI 10.1101/gad.197582.112; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Rajagopal S, 2010, NAT REV DRUG DISCOV, V9, P373, DOI 10.1038/nrd3024; Ramos A, 2012, TRENDS CELL BIOL, V22, P339, DOI 10.1016/j.tcb.2012.04.006; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Sudol M, 2012, SEMIN CELL DEV BIOL, V23, P827, DOI 10.1016/j.semcdb.2012.05.002; Tan WF, 2006, J BIOL CHEM, V281, P39542, DOI 10.1074/jbc.M609062200; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Worzfeld T, 2008, TRENDS PHARMACOL SCI, V29, P582, DOI 10.1016/j.tips.2008.08.002; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yang YM, 2015, ONCOGENE, V34, P2910, DOI 10.1038/onc.2014.218; Yotsumoto F, 2008, BIOCHEM BIOPH RES CO, V365, P555, DOI 10.1016/j.bbrc.2007.11.015; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210	45	28	29	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4471	4480		10.1038/onc.2015.505	http://dx.doi.org/10.1038/onc.2015.505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26804165				2022-12-17	WOS:000382153100005
J	Chu, PC; Yang, MC; Kulp, SK; Salunke, SB; Himmel, LE; Fang, CS; Jadhav, AM; Shan, YS; Lee, CT; Lai, MD; Shirley, LA; Bekaii-Saab, T; Chen, CS				Chu, P-C; Yang, M-C; Kulp, S. K.; Salunke, S. B.; Himmel, L. E.; Fang, C-S; Jadhav, A. M.; Shan, Y-S; Lee, C-T; Lai, M-D; Shirley, L. A.; Bekaii-Saab, T.; Chen, C-S			Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; K-RAS; DUCTAL ADENOCARCINOMA; GENE-EXPRESSION; HNRNP A1; EGF RECEPTOR; KINASE; TRANSCRIPTION; PROTEIN; MYC	Integrin-linked kinase (ILK) is a mediator of aggressive phenotype in pancreatic cancer. On the basis of our finding that knockdown of either KRAS or ILK has a reciprocal effect on the other's expression, we hypothesized the presence of an ILK-KRAS regulatory loop that enables pancreatic cancer cells to regulate KRAS expression. This study aimed to elucidate the mechanism by which this regulatory circuitry is regulated and to investigate the translational potential of targeting ILK to suppress oncogenic KRAS signaling in pancreatic cancer. Interplay between KRAS and ILK and the roles of E2F1, c-Myc and heterogeneous nuclear ribonucleoprotein as intermediary effectors in this feedback loop was interrogated by genetic manipulations through small interfering RNA/short hairpin RNA knockdown and ectopic expression, western blotting, PCR, promoter-luciferase reporter assays, chromatin immunoprecipitation and pull-down analyses. In vivo efficacy of ILK inhibition was evaluated in two murine xenograft models. Our data show that KRAS regulated the expression of ILK through E2F1-mediated transcriptional activation, which, in turn, controlled KRAS gene expression via hnRNPA1-mediated destabilization of the G-quadruplex on the KRAS promoter. Moreover, ILK inhibition blocked KRAS-driven epithelial-mesenchymal transition and growth factor-stimulated KRAS expression. The knockdown or pharmacological inhibition of ILK suppressed pancreatic tumor growth, in part, by suppressing KRAS signaling. These studies suggest that this KRAS-E2F1-ILK-hnRNPA1 regulatory loop enables pancreatic cancer cells to promote oncogenic KRAS signaling and to interact with the tumor microenvironment to promote aggressive phenotypes. This regulatory loop provides a mechanistic rationale for targeting ILK to suppress oncogenic KRAS signaling, which might foster new therapeutic strategies for pancreatic cancer.	[Chu, P-C; Yang, M-C; Kulp, S. K.; Salunke, S. B.; Himmel, L. E.; Fang, C-S; Jadhav, A. M.; Chen, C-S] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, 500W 12th Ave, Columbus, OH 43201 USA; [Chu, P-C; Lai, M-D; Chen, C-S] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan; [Chu, P-C; Chen, C-S] Acad Sinica, Inst Biol Chem, Taipei, Taiwan; [Himmel, L. E.] Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH USA; [Shan, Y-S] Natl Cheng Kung Univ, Coll Med, Dept Surg, Tainan, Taiwan; [Lee, C-T] Natl Cheng Kung Univ, Coll Med, Dept Pathol, Tainan, Taiwan; [Shirley, L. A.] Ohio State Univ, Coll Med, Dept Surg, Columbus, OH USA; [Bekaii-Saab, T.] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH USA	University System of Ohio; Ohio State University; National Cheng Kung University; Academia Sinica - Taiwan; University System of Ohio; Ohio State University; National Cheng Kung University; National Cheng Kung University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Chen, CS (corresponding author), Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, 500W 12th Ave, Columbus, OH 43201 USA.	chen.844@osu.edu	Lai, Ming-Derg/M-8028-2014; Jadhav, Appaso/ABC-8338-2020	Bekaii-Saab, Tanios/0000-0001-7721-1699; Jadhav, Appaso/0000-0002-4892-0792	Lucius A Wing Endowed Chair Fund; Ministry of Science and Technology [MOST 103-2320-B-001-017]; National Cheng Kung University College of Medicine; Ohio State University Wexner Medical Center; Comprehensive Cancer Center; National Institutes of Health [P30 CA016058]; Comparative Pathology and Mouse Phenotyping Shared Resource at The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	Lucius A Wing Endowed Chair Fund; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Cheng Kung University College of Medicine; Ohio State University Wexner Medical Center; Comprehensive Cancer Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Comparative Pathology and Mouse Phenotyping Shared Resource at The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Lucius A Wing Endowed Chair Fund (CSC), Ministry of Science and Technology grant MOST 103-2320-B-001-017 (PCC), Bi-institutional Collaborative Pancreatic Cancer Research grants from National Cheng Kung University College of Medicine (CSC) and The Ohio State University Wexner Medical Center and Comprehensive Cancer Center (TBS) and National Institutes of Health grant P30 CA016058, which supports, in part, the Comparative Pathology and Mouse Phenotyping Shared Resource at The Ohio State University Comprehensive Cancer Center.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Bommert KS, 2013, LEUKEMIA, V27, P441, DOI 10.1038/leu.2012.185; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cogoi S, 2006, NUCLEIC ACIDS RES, V34, P2536, DOI 10.1093/nar/gkl286; Cogoi S, 2010, J BIOL CHEM, V285, P22003, DOI 10.1074/jbc.M110.101923; Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 2011, ONCOGENE, V30, P4375, DOI 10.1038/onc.2011.177; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hsu EC, 2015, NEOPLASIA, V17, P497, DOI 10.1016/j.neo.2015.06.001; Jean-Philippe J, 2013, INT J MOL SCI, V14, P18999, DOI 10.3390/ijms140918999; Kalra J, 2010, ONCOGENE, V29, P6343, DOI 10.1038/onc.2010.366; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Lee SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067149; Lee SL, 2011, J MED CHEM, V54, P6364, DOI 10.1021/jm2007744; Liu TM, 2015, BLOOD, V125, P284, DOI 10.1182/blood-2014-06-583518; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; Meng P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.326; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Paramasivam M, 2009, NUCLEIC ACIDS RES, V37, P2841, DOI 10.1093/nar/gkp138; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Sawai H, 2006, ONCOGENE, V25, P3237, DOI 10.1038/sj.onc.1209356; Schaeffer DF, 2010, VIRCHOWS ARCH, V456, P261, DOI 10.1007/s00428-009-0866-z; Seidler B, 2008, P NATL ACAD SCI USA, V105, P10137, DOI 10.1073/pnas.0800487105; Serrano I, 2013, ONCOGENE, V32, P50, DOI 10.1038/onc.2012.30; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Stolzenberg-Solomon RZ, 2005, JAMA-J AM MED ASSOC, V294, P2872, DOI 10.1001/jama.294.22.2872; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Wang ZW, 2013, J CELL PHYSIOL, V228, P556, DOI 10.1002/jcp.24162; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Young A, 2009, ADV CANCER RES, V102, P1, DOI 10.1016/S0065-230X(09)02001-6; Zhou ZJ, 2013, INT J CANCER, V132, P1080, DOI 10.1002/ijc.27742	47	28	29	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3897	3908		10.1038/onc.2015.458	http://dx.doi.org/10.1038/onc.2015.458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26616862				2022-12-17	WOS:000381013100002
J	Park, UH; Kang, MR; Kim, EJ; Kwon, YS; Hur, W; Yoon, SK; Song, BJ; Park, JH; Hwang, JT; Jeong, JC; Um, SJ				Park, U-H; Kang, M-R; Kim, E-J; Kwon, Y-S; Hur, W.; Yoon, S. K.; Song, B-J; Park, J. H.; Hwang, J-T; Jeong, J-C; Um, S-J			ASXL2 promotes proliferation of breast cancer cells by linking ER alpha to histone methylation	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; H3K27 DEMETHYLASES; HISTOLOGIC GRADE; LSD1; TRANSCRIPTION; COACTIVATOR; MECHANISMS; CARCINOGENESIS; EPIGENETICS	Estrogen receptor alpha (ER alpha) has a pivotal role in breast carcinogenesis by associating with various cellular factors. Selective expression of additional sex comb-like 2 (ASXL2) in ER alpha-positive breast cancer cells prompted us to investigate its role in chromatin modification required for ERa activation and breast carcinogenesis. Here, we observed that ASXL2 interacts with ligand E2-bound ERa and mediates ERa activation. Chromatin immunoprecipitation-sequencing analysis supports a positive role of ASXL2 at ERa target gene promoters. ASXL2 forms a complex with histone methylation modifiers including LSD1, UTX and MLL2, which all are recruited to the E2-responsive genes via ASXL2 and regulate methylations at histone H3 lysine 4, 9 and 27. The preferential binding of the PHD finger of ASXL2 to the dimethylated H3 lysine 4 may account for its requirement for ERa activation. On ASXL2 depletion, the proliferative potential of MCF7 cells and tumor size of xenograft mice decreased. Together with our finding on the higher ASXL2 expression in ERa-positive patients, we propose that ASXL2 could be a novel prognostic marker in breast cancer.	[Park, U-H; Kwon, Y-S; Um, S-J] Sejong Univ, Dept Biosci & Biotechnol, 98 Kunja Dong,Cuungmuguan 614, Seoul 143747, South Korea; [Kang, M-R] Korea Res Inst Biosci & Biotechnol, Bioevaluat Ctr, Ochang, Cheongwon, South Korea; [Kim, E-J] Dankook Univ, Dept Mol Biol, Gyeonggi Do, South Korea; [Hur, W.; Yoon, S. K.] Catholic Univ, Liver Res Ctr, Seoul, South Korea; [Hur, W.; Yoon, S. K.] Catholic Univ, Coll Med, WHO Collaborating Ctr Viral Hepatitis, Seoul, South Korea; [Song, B-J] Catholic Univ, Coll Med, Seoul St Marys Hosp, Breast Ctr,Dept Surg, Seoul, South Korea; [Park, J. H.; Hwang, J-T] Korea Food Res Inst, Songnam, Gyeonggi Do, South Korea; [Jeong, J-C] Dongguk Univ, Coll Oriental Med, Dept Biochem Mol Biol & Internal Med, Kyungpook, South Korea	Sejong University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Dankook University; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital; Korea Food Research Institute (KFRI); Dongguk University	Um, SJ (corresponding author), Sejong Univ, Dept Biosci & Biotechnol, 98 Kunja Dong,Cuungmuguan 614, Seoul 143747, South Korea.	umsj@sejong.ac.kr			National R&D program for Cancer Control [1120210]; Korea Food Research Institute; Basic Science Research Program through NRF grant, Republic of Korea [2014R1A2A1A11052685]	National R&D program for Cancer Control(Ministry of Health & Welfare (MOHW), Republic of Korea); Korea Food Research Institute; Basic Science Research Program through NRF grant, Republic of Korea	This study was supported in part by a grant of the National R&D program for Cancer Control (1120210), a grant from the Korea Food Research Institute, and a grant of the Basic Science Research Program through NRF grant (2014R1A2A1A11052685), Republic of Korea.	Akhavantabasi S, 2010, MAMM GENOME, V21, P388, DOI 10.1007/s00335-010-9268-4; Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426; Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aravind L, 2012, CELL CYCLE, V11, P119, DOI 10.4161/cc.11.1.18475; Arteaga MF, 2013, CANCER CELL, V23, P376, DOI 10.1016/j.ccr.2013.02.014; Cho YS, 2006, J BIOL CHEM, V281, P17588, DOI 10.1074/jbc.M512616200; Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3; Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229; Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z; Farber CR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002038; Gage M, 2012, J SURG ONCOL, V105, P444, DOI 10.1002/jso.21856; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Glinsky GV, 2004, CLIN CANCER RES, V10, P2272, DOI 10.1158/1078-0432.CCR-03-0522; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Gozgit JM, 2007, BRIT J CANCER, V97, P809, DOI 10.1038/sj.bjc.6603926; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790; Horton JR, 2010, NAT STRUCT MOL BIOL, V17, P38, DOI 10.1038/nsmb.1753; Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109; Katoh M, 2013, BRIT J CANCER, V109, P299, DOI 10.1038/bjc.2013.281; Kawazu M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017830; Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Lai HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073983; Lai HL, 2012, J MOL CELL CARDIOL, V53, P734, DOI 10.1016/j.yjmcc.2012.08.014; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Park UH, 2011, J BIOL CHEM, V286, P1354, DOI 10.1074/jbc.M110.177816; Pollock JA, 2012, ACS CHEM BIOL, V7, P1221, DOI 10.1021/cb300108c; Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13; Shen YQ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-470; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Stratmann A, 2012, MOL CELL ENDOCRINOL, V348, P12, DOI 10.1016/j.mce.2011.09.028; Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	52	28	29	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3742	3752		10.1038/onc.2015.443	http://dx.doi.org/10.1038/onc.2015.443			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26640146				2022-12-17	WOS:000379622800012
J	Goto, K; Ishikawa, S; Honma, R; Tanimoto, K; Sakamoto, N; Sentani, K; Oue, N; Teishima, J; Matsubara, A; Yasui, W				Goto, K.; Ishikawa, S.; Honma, R.; Tanimoto, K.; Sakamoto, N.; Sentani, K.; Oue, N.; Teishima, J.; Matsubara, A.; Yasui, W.			The transcribed-ultraconserved regions in prostate and gastric cancer: DNA hypermethylation and microRNA-associated regulation	ONCOGENE			English	Article							GENE-EXPRESSION; NONCODING RNAS; DOWN-REGULATION; NEUROBLASTOMA; CARCINOMA; INVASION; DIFFERENTIATION; CONTRIBUTES; PROGRESSION; METASTASIS	The transcribed-ultraconserved regions (T-UCRs) are a novel class of non-coding RNAs, which are absolutely conserved (100%) between the orthologous regions of the human, rat and mouse genomes. Previous studies have described that several T-UCRs show differential expressions in cancers and might be involved in cancer development. We investigated the transcriptional levels of representative 26 T-UCRs and determined the regions that were differently expressed in prostate cancer (PCa) and gastric cancer (GC). A quantitative reverse transcription-polymerase chain reaction analysis revealed the downregulation of Uc. 158+A expression by a DNA methylation-associated mechanism, which was restored by 5-Aza-dC (5-aza-2'-deoxycytidine) treatment. Bisulfite genomic sequencing using cell lines and tissue samples demonstrated cancer-specific CpG hypermethylation in both GC and PCa. However, Uc. 416+A was only overexpressed in GC and we identified an miR-153 binding site in the possible regulatory region of Uc. 416+A using online databases. Along with a forced expression or knockdown of miR-153 in MKN-74 GC cells, the transcriptional levels of Uc. 416+A were significantly disturbed. A luciferase reporter gene assay supported the direct regulation of Uc. 416+A expression by miR-153. Furthermore, Uc. 416+A was associated with cell growth through the regulation of IGFBP6 (insulin-like growth factor-binding protein 6) in GC. These findings suggest an oncogenic role of Uc. 416+A in GC, which suggests that our approach would provide new insights into functional studies of T-UCRs in cancer biology.	[Goto, K.; Sakamoto, N.; Sentani, K.; Oue, N.; Yasui, W.] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Mol Pathol, Hiroshima, Japan; [Goto, K.; Teishima, J.; Matsubara, A.] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Urol, Hiroshima, Japan; [Ishikawa, S.; Honma, R.] Hiroshima Univ, Sch Med, Hiroshima, Japan; [Tanimoto, K.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Med, Hiroshima, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University	Yasui, W (corresponding author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Keiji, Tanimoto/U-1839-2019	Keiji, Tanimoto/0000-0003-4912-4197; Goto, Keisuke/0000-0002-3580-1401	Ministry of Education, Culture, Science, Sports and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; National Institute of Biomedical Innovation (Program for Promotion of Fundamental Studies in Health Sciences); National Cancer Center Research and Development Fund	Ministry of Education, Culture, Science, Sports and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); National Institute of Biomedical Innovation (Program for Promotion of Fundamental Studies in Health Sciences); National Cancer Center Research and Development Fund(National Cancer Center - Japan)	We thank Mr Shinichi Norimura for his excellent technical assistance. This work was carried out with the kind cooperation of the Research Center for Molecular Medicine of the Faculty of Medicine of Hiroshima University. We also thank the Analysis Center of Life Science of Hiroshima University for the use of their facilities. This work was supported, in part, by grants-in-aid for Cancer Research from the Ministry of Education, Culture, Science, Sports and Technology of Japan, and, in part, by a grant-in-aid for the Third Comprehensive. 10-Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of Japan, by the National Institute of Biomedical Innovation (Program for Promotion of Fundamental Studies in Health Sciences), and by the National Cancer Center Research and Development Fund.	Bach LA, 2005, GROWTH HORM IGF RES, V15, P185, DOI 10.1016/j.ghir.2005.04.001; Bach LA, 2013, CLIN SCI, V124, P215, DOI 10.1042/CS20120343; Baxter RC, 2014, NAT REV CANCER, V14, P329, DOI 10.1038/nrc3720; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Braconi C, 2011, P NATL ACAD SCI USA, V108, P786, DOI 10.1073/pnas.1011098108; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Fischbach NA, 2005, BLOOD, V105, P1456, DOI 10.1182/blood-2004-04-1583; Fu M, 2003, DEV DYNAM, V228, P1, DOI 10.1002/dvdy.10350; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; Goto K, 2013, MOL CLIN ONCOL, V1, P235, DOI 10.3892/mco.2012.46; Hudson RS, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-13; Hur H, 2014, MOL BIOTECHNOL, V56, P64, DOI 10.1007/s12033-013-9682-4; Kim TH, 2010, HISTOPATHOLOGY, V57, P734, DOI 10.1111/j.1365-2559.2010.03686.x; Liz J, 2014, MOL CELL, V55, P138, DOI 10.1016/j.molcel.2014.05.005; Lujambio A, 2010, ONCOGENE, V29, P6390, DOI 10.1038/onc.2010.361; Luo JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040127; Matsumura S, 2007, INT J CANCER, V120, P1689, DOI 10.1002/ijc.22433; Mestdagh P, 2010, ONCOGENE, V29, P3583, DOI 10.1038/onc.2010.106; Morgan R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-89; Naito Y, 2015, PATHOBIOLOGY, V82, P68, DOI 10.1159/000398809; Naito Y, 2014, ONCOL REP, V32, P1720, DOI 10.3892/or.2014.3333; Naito Y, 2014, CANCER SCI, V105, P228, DOI 10.1111/cas.12329; Oue N, 2003, CANCER SCI, V94, P901, DOI 10.1111/j.1349-7006.2003.tb01373.x; Oue N, 2014, ONCOGENE, V33, P3918, DOI 10.1038/onc.2013.364; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Oue N, 2015, CANCER SCI, V106, P951, DOI 10.1111/cas.12706; Oue N, 2014, INT J CANCER, V134, P1926, DOI 10.1002/ijc.28522; Sakamoto N, 2014, CANCER SCI, V105, P236, DOI 10.1111/cas.12330; Scaruffi P, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-441; Volpe MV, 2003, BIRTH DEFECTS RES A, V67, P550, DOI 10.1002/bdra.10086; Watters KM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-184; Wu ZQ, 2013, PROSTATE, V73, P596, DOI 10.1002/pros.22600; Xu JZ, 2011, INT J CANCER, V129, P2527, DOI 10.1002/ijc.25917; Xu Q, 2013, CARCINOGENESIS, V34, P539, DOI 10.1093/carcin/bgs374; Yuan Y, 2015, INT J CANCER, V136, P1333, DOI 10.1002/ijc.29103; Zhang L, 2013, CANCER RES, V73, P6435, DOI 10.1158/0008-5472.CAN-12-3308; Zhang ZL, 2015, ONCOTARGETS THER, V8, P357, DOI 10.2147/OTT.S78236	40	28	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3598	3606		10.1038/onc.2015.445	http://dx.doi.org/10.1038/onc.2015.445			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26640143	Green Submitted			2022-12-17	WOS:000379621500012
J	Ceccon, M; Merlo, MEB; Mologni, L; Poggio, T; Varesio, LM; Menotti, M; Bombelli, S; Rigolio, R; Manazza, AD; Di Giacomo, F; Ambrogio, C; Giudici, G; Casati, C; Mastini, C; Compagno, M; Turner, SD; Gambacorti-Passerini, C; Chiarle, R; Voena, C				Ceccon, M.; Merlo, M. E. Boggio; Mologni, L.; Poggio, T.; Varesio, L. M.; Menotti, M.; Bombelli, S.; Rigolio, R.; Manazza, A. D.; Di Giacomo, F.; Ambrogio, C.; Giudici, G.; Casati, C.; Mastini, C.; Compagno, M.; Turner, S. D.; Gambacorti-Passerini, C.; Chiarle, R.; Voena, C.			Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency	ONCOGENE			English	Article							ANAPLASTIC LYMPHOMA KINASE; LUNG-CANCER; ACQUIRED-RESISTANCE; CONFER RESISTANCE; DNA-REPLICATION; NUCLEAR EXPORT; INHIBITORS; MUTATIONS; SENSITIVITY; CRIZOTINIB	Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(2; 5; p23;q35) that produces the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphoma kinase). NPM-ALK-deregulated kinase activity drives several pathways that support malignant transformation of lymphoma cells. We found that in ALK-rearranged ALCL cell lines, NPM-ALK was distributed in equal amounts between the cytoplasm and the nucleus. Only the cytoplasmic portion was catalytically active in both cell lines and primary ALCL, whereas the nuclear portion was inactive because of heterodimerization with NPM1. Thus, about 50% of the NPM-ALK is not active and sequestered as NPM-ALK/NPM1 heterodimers in the nucleus. Overexpression or relocalization of NPM-ALK to the cytoplasm by NPM genetic knockout or knockdown caused ERK1/2 (extracellular signal-regulated protein kinases 1 and 2) increased phosphorylation and cell death through the engagement of an ATM/Chk2- and gamma H2AX (phosphorylated H2A histone family member X)-mediated DNA-damage response. Remarkably, human NPM-ALK-amplified cell lines resistant to ALK tyrosine kinase inhibitors (TKIs) underwent apoptosis upon drug withdrawal as a consequence of ERK1/2 hyperactivation. Altogether, these findings indicate that an excess of NPM-ALK activation and signaling induces apoptosis via oncogenic stress responses. A 'drug holiday' where the ALK TKI treatment is suspended could represent a therapeutic option in cells that become resistant by NPM-ALK amplification.	[Ceccon, M.; Mologni, L.; Bombelli, S.; Gambacorti-Passerini, C.] Univ Milano Bicocca, Dept Hlth Sci, Via Cadore 48, I-20900 Monza, Italy; [Merlo, M. E. Boggio; Poggio, T.; Varesio, L. M.; Menotti, M.; Manazza, A. D.; Di Giacomo, F.; Mastini, C.; Compagno, M.; Chiarle, R.; Voena, C.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Merlo, M. E. Boggio; Poggio, T.; Varesio, L. M.; Menotti, M.; Manazza, A. D.; Di Giacomo, F.; Mastini, C.; Compagno, M.; Chiarle, R.; Voena, C.] Citta Salute & Sci, CERMS, Turin, Italy; [Rigolio, R.] Univ Milano Bicocca, Surg & Translat Med Dept, Monza, Italy; [Ambrogio, C.] Ctr Nacl Invest Oncol, Mol Oncol Program, Madrid, Spain; [Giudici, G.] Univ Milano Bicocca, Pediat Clin, Tettamanti Res Ctr, Monza, Italy; [Casati, C.] MetaSystems Slr, Milan, Italy; [Compagno, M.; Chiarle, R.] Childrens Hosp, Dept Pathol, Boston, MA USA; [Compagno, M.; Chiarle, R.] Harvard Med Sch, Enders 1116-1,320 Longwood Ave, Boston, MA 02115 USA; [Turner, S. D.] Addenbrookes Hosp, Div Mol Histopathol, Cambridge, England; [Gambacorti-Passerini, C.] San Gerardo Hosp, Sect Haematol, Monza, Italy	University of Milano-Bicocca; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; University of Milano-Bicocca; University of Milano-Bicocca; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; San Gerardo Hospital	Gambacorti-Passerini, C (corresponding author), Univ Milano Bicocca, Dept Hlth Sci, Via Cadore 48, I-20900 Monza, Italy.; Chiarle, R (corresponding author), Harvard Med Sch, Enders 1116-1,320 Longwood Ave, Boston, MA 02115 USA.; Chiarle, R (corresponding author), Childrens Hosp Boston, Dept Pathol, Enders 1116-1,320 Longwood Ave, Boston, MA 02115 USA.	carlo.gambacorti@unimib.it; roberto.chiarle@childrens.harvard.edu	VOENA, Claudia/ADJ-6244-2022; Menotti, Matteo/AAA-9312-2022; Turner, Suzanne Dawn/K-4405-2013; Mologni, Luca/AAC-1065-2022	Turner, Suzanne Dawn/0000-0002-8439-4507; Mologni, Luca/0000-0002-6365-5149; Varesio, Lydia/0000-0001-6394-1607; Boggio Merlo, Maria Elena/0000-0002-1967-7308; Ambrogio, Chiara/0000-0003-4122-701X; Menotti, Matteo/0000-0002-1260-2389; Voena, Claudia/0000-0002-1324-1431; GAMBACORTI PASSERINI, CARLO/0000-0001-6058-515X; Poggio, Teresa/0000-0003-2560-8488	Regione Lombardia [ID14546A]; Fondazione Berlucchi Onlus Grant; FP7 ERC-StG [242965]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-12023]; Koch Institute/DFCC Bridge Project Fund; Ellison Foundation Boston; Worldwide Cancer Research Association [12-0216]; Grant for Oncology Innovation by Merck-Serono;  [R01 CA196703-01]; NATIONAL CANCER INSTITUTE [R01CA196703] Funding Source: NIH RePORTER	Regione Lombardia(Regione Lombardia); Fondazione Berlucchi Onlus Grant; FP7 ERC-StG; Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Koch Institute/DFCC Bridge Project Fund; Ellison Foundation Boston(Lawrence Ellison Foundation); Worldwide Cancer Research Association; Grant for Oncology Innovation by Merck-Serono; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Maria Stella Scalzo for technical support, Dr Emanuela Colombo for kindly providing MEFs that lack NPM1 (MEF NPM<SUP>-/-</SUP>p53<SUP>-/-</SUP>) and control fibroblasts (MEF p53<SUP>-/-</SUP>), Dr Guido Serini for the use of his confocal microscopy unit at the Candiolo Cancer Institute-IRCCS, Torino, Italy. We also thank Ariad Pharmaceutical, Pfizer, Astellas and Novartis that kindly provided all drugs used in this study. This work was supported by the Regione Lombardia (ID14546A) and Fondazione Berlucchi Onlus Grant 2014 (to CGP), and by grants FP7 ERC-2009-StG (Proposal No. 242965-'Lunely'); Associazione Italiana per la Ricerca sul Cancro (AIRC) Grant IG-12023; Koch Institute/DFCC Bridge Project Fund; Ellison Foundation Boston; Worldwide Cancer Research Association (former AICR) grant 12-0216; the Grant for Oncology Innovation by Merck-Serono and R01 CA196703-01 (to RC).	Amin AD, 2015, CANCER RES, V75, P2916, DOI 10.1158/0008-5472.CAN-14-3437; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Ceccon M, 2015, MOL CANCER RES, V13, P775, DOI 10.1158/1541-7786.MCR-14-0157; Ceccon M, 2013, MOL CANCER RES, V11, P122, DOI 10.1158/1541-7786.MCR-12-0569; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Cui YX, 2009, BLOOD, V113, P5217, DOI 10.1182/blood-2008-06-160168; Das A, 2015, EXP HEMATOL ONCOL, V4, DOI 10.1186/s40164-015-0002-5; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Dengler MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025139; Desplat V, 2005, CANCER-AM CANCER SOC, V103, P102, DOI 10.1002/cncr.20758; Doebele RC, 2012, CLIN CANCER RES, V18, P1472, DOI 10.1158/1078-0432.CCR-11-2906; Etchin J, 2013, BRIT J HAEMATOL, V161, P117, DOI 10.1111/bjh.12231; Friboulet L, 2014, CANCER DISCOV, V4, P662, DOI 10.1158/2159-8290.CD-13-0846; Funakoshi Y, 2013, INVEST NEW DRUG, V31, P1158, DOI 10.1007/s10637-013-9959-2; Gambacorti-Passerini C, 2011, NEW ENGL J MED, V364, P775, DOI 10.1056/NEJMc1013224; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Hapgood G, 2015, BLOOD, V126, P17, DOI 10.1182/blood-2014-10-567461; Hills SA, 2014, CURR BIOL, V24, pR435, DOI 10.1016/j.cub.2014.04.012; Ignatius Ou SH, 2014, J THORAC ONCOL, V9, P549, DOI DOI 10.1097/JTO.0000000000000094; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Katayama R, 2015, CLIN CANCER RES, V21, P2227, DOI 10.1158/1078-0432.CCR-14-2791; Katayama R, 2014, CLIN CANCER RES, V20, P5686, DOI 10.1158/1078-0432.CCR-14-1511; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Koop A, 2014, BRIT J DERMATOL, V170, P220, DOI 10.1111/bjd.12615; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Martinengo C, 2014, CANCER RES, V74, P6094, DOI 10.1158/0008-5472.CAN-14-0268; Maya-Mendoza A, 2015, MOL ONCOL, V9, P601, DOI 10.1016/j.molonc.2014.11.001; Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451; Mologni L, 2015, ONCOTARGET, V6, P5720, DOI 10.18632/oncotarget.3122; Mologni L, 2015, TRANSL LUNG CANCER R, V4, P5, DOI 10.3978/j.issn.2218-6751.2014.07.02; Mologni L, 2012, EXPERT OPIN INV DRUG, V21, P985, DOI 10.1517/13543784.2012.690031; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Pall G, 2015, CURR OPIN ONCOL, V27, P118, DOI 10.1097/CCO.0000000000000165; Passerini CG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt378; Piva R, 2006, BLOOD, V107, P689, DOI 10.1182/blood-2005-05-2125; Pulford K, 2004, J CELL PHYSIOL, V199, P330, DOI 10.1002/jcp.10472; Rassidakis GZ, 2005, LEUKEMIA, V19, P1663, DOI 10.1038/sj.leu.2403840; Shaw AT, 2014, NEW ENGL J MED, V370, P1189, DOI [10.1056/NEJMoa1311107, 10.1056/NEJMc1404894]; Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4; Suda K, 2012, LUNG CANCER, V76, P292, DOI 10.1016/j.lungcan.2011.11.007; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tipping AJ, 2001, BLOOD, V98, P3864, DOI 10.1182/blood.V98.13.3864; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Voena C, 2007, CANCER RES, V67, P4278, DOI 10.1158/0008-5472.CAN-06-4350; Voena C, 2012, EXPERT OPIN INV DRUG, V21, P1751, DOI 10.1517/13543784.2012.717930; Walker CJ, 2013, BLOOD, V122, P3034, DOI 10.1182/blood-2013-04-495374; Wei F, 2011, CURR MED CHEM, V18, P5476, DOI 10.2174/092986711798194388; Zdzalik D, 2014, J CANCER RES CLIN, V140, P589, DOI 10.1007/s00432-014-1589-3	54	28	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3854	3865		10.1038/onc.2015.456	http://dx.doi.org/10.1038/onc.2015.456			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26657151	Green Accepted, Green Submitted			2022-12-17	WOS:000380753200010
J	Manda, KR; Tripathi, P; Hsi, AC; Ning, J; Ruzinova, MB; Liapis, H; Bailey, M; Zhang, H; Maher, CA; Humphrey, PA; Andriole, GL; Ding, L; You, Z; Chen, F				Manda, K. R.; Tripathi, P.; Hsi, A. C.; Ning, J.; Ruzinova, M. B.; Liapis, H.; Bailey, M.; Zhang, H.; Maher, C. A.; Humphrey, P. A.; Andriole, G. L.; Ding, L.; You, Z.; Chen, F.			NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence	ONCOGENE			English	Article							CELL-PROLIFERATION; CANCER PROGRESSION; C-MYC; ACTIVATION; EXPRESSION; INVASION; STAT3; OSTEOCLASTOGENESIS; INTERLEUKIN-6; INFLAMMATION	Despite recent insights into prostate cancer (PCa)-associated genetic changes, full understanding of prostate tumorigenesis remains elusive owing to complexity of interactions among various cell types and soluble factors present in prostate tissue. We found the upregulation of nuclear factor of activated T cells c1 (NFATc1) in human PCa and cultured PCa cells, but not in normal prostates and non-tumorigenic prostate cells. To understand the role of NFATc1 in prostate tumorigenesis in situ, we temporally and spatially controlled the activation of NFATc1 in mouse prostate and showed that such activation resulted in prostatic adenocarcinoma with features similar to those seen in human PCa. Our results indicate that the activation of a single transcription factor, NFATc1 in prostatic luminal epithelium to PCa can affect expression of diverse factors in both cells harboring the genetic changes and in neighboring cells through microenvironmental alterations. In addition to the activation of oncogenes c-MYC and STAT3 in tumor cells, a number of cytokines and growth factors, such as IL1 beta, IL6 and SPP1 ( osteopontin, a key biomarker for PCa), were upregulated in NFATc1-induced PCa, establishing a tumorigenic microenvironment involving both NFATc1 positive and negative cells for prostate tumorigenesis. To further characterize interactions between genes involved in prostate tumorigenesis, we generated mice with both NFATc1 activation and Pten inactivation in prostate. We showed that NFATc1 activation led to acceleration of Pten null-driven prostate tumorigenesis by overcoming the PTEN loss-induced cellular senescence through inhibition of p21 activation. This study provides direct in vivo evidence of an oncogenic role of NFATc1 in prostate tumorigenesis and reveals multiple functions of NFATc1 in activating oncogenes, in inducing proinflammatory cytokines, in oncogene addiction, and in overcoming cellular senescence, which suggests calcineurin-NFAT signaling as a potential target in preventing PCa.	[Manda, K. R.; Ning, J.; Maher, C. A.; Ding, L.; Chen, F.] Washington Univ, Sch Med, Dept Med, Campus Box 8126,660 S Euclid Ave, St Louis, MO 63110 USA; [Tripathi, P.; Ruzinova, M. B.; Liapis, H.] Washington Univ, Dept Pathol & Immunol, St Louis, MO USA; [Hsi, A. C.; Ning, J.; Bailey, M.; Maher, C. A.; Ding, L.] Washington Univ, Genome Inst, St Louis, MO USA; [Zhang, H.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA USA; [Maher, C. A.; Andriole, G. L.; Ding, L.; Chen, F.] Washington Univ, Siteman Canc Ctr, St Louis, MO USA; [Humphrey, P. A.] Yale Univ, Dept Pathol, New Haven, CT USA; [Andriole, G. L.] Washington Univ, Dept Surg, St Louis, MO USA; [You, Z.] Tulane Univ, Dept Struct & Cellular Biol, New Orleans, LA 70118 USA; [Chen, F.] Washington Univ, Dept Cell Biol & Physiol, St Louis, MO USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Massachusetts System; University of Massachusetts Worcester; Siteman Cancer Center; Washington University (WUSTL); Yale University; Washington University (WUSTL); Tulane University; Washington University (WUSTL)	Chen, F (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8126,660 S Euclid Ave, St Louis, MO 63110 USA.	fchen@dom.wustl.edu		Bailey, Matthew H./0000-0003-4526-9727	DoD [PC130118]; NIH [DK087960, R01CA174714, R01CA180006, R01CA178383, U01HG006517]; NATIONAL CANCER INSTITUTE [R01CA178383, R01CA174714, R01CA180006] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG006517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087960] Funding Source: NIH RePORTER	DoD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs Gerald Crabtree and Minggui Pan for providing the TetO-NFATc1<SUP>Nuc</SUP> mice. FC is supported in part by grants from DoD (PC130118) and NIH (DK087960). ZY is supported in part by NIH R01CA174714. LD is supported in part by grants from NIH (R01CA180006, R01CA178383 and U01HG006517).	Alberti C, 2008, EUR REV MED PHARMACO, V12, P167; Arredouani MS, 2009, CLIN CANCER RES, V15, P5794, DOI 10.1158/1078-0432.CCR-09-0911; Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Carnero A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00252; Culig Z, 2014, AM J CLIN EXP UROL, V2, P231; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Foldynova-Trantirkova S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2581; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Huang HH, 2012, BIOCHEM BIOPH RES CO, V418, P186, DOI 10.1016/j.bbrc.2012.01.004; JANIK P, 1975, CANCER RES, V35, P3698; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jiang JF, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1015; Karlou M, 2010, NAT REV UROL, V7, P494, DOI 10.1038/nrurol.2010.134; Kavitha CV, 2014, MOL CARCINOGEN, V53, P169, DOI 10.1002/mc.21959; Kawahara T, 2015, PROSTATE, V75, P573, DOI 10.1002/pros.22937; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Lagunas L, 2009, J CELL BIOCHEM, V108, P237, DOI 10.1002/jcb.22245; Lee SJ, 2003, J MOL BIOL, V330, P749, DOI 10.1016/S0022-2836(03)00640-5; Lehen'kyi V, 2007, ONCOGENE, V26, P7380, DOI 10.1038/sj.onc.1210545; McCormick F, 2011, J SURG ONCOL, V103, P464, DOI 10.1002/jso.21749; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Nguyen DP, 2014, BJU INT, V113, P986, DOI 10.1111/bju.12452; Nilsson-Berglund LM, 2010, ARTERIOSCL THROM VAS, V30, P218, DOI 10.1161/ATVBAHA.109.199299; Ortega-Molina A, 2013, TRENDS ENDOCRIN MET, V24, P184, DOI 10.1016/j.tem.2012.11.002; Pan MG, 2013, CURR MOL MED, V13, P543; Pan MG, 2007, J IMMUNOL, V178, P4315, DOI 10.4049/jimmunol.178.7.4315; Phin S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00240; Rafiei S, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-605; Robbs BK, 2008, MOL CELL BIOL, V28, P7168, DOI 10.1128/MCB.00256-08; Suzman DL, 2014, THER ADV MED ONCOL, V6, P167, DOI 10.1177/1758834014529176; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Tripathi P, 2014, ONCOGENE, V33, P1840, DOI 10.1038/onc.2013.132; Vincent AJ, 2012, FEBS LETT, V586, P3429, DOI 10.1016/j.febslet.2012.07.063; Wang YQ, 2010, J AM SOC NEPHROL, V21, P1657, DOI 10.1681/ASN.2009121253; Wei Z, 2013, CELL SIGNAL, V25, P931, DOI 10.1016/j.cellsig.2013.01.011; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yiu GK, 2011, BIOCHEM J, V440, P157, DOI 10.1042/BJ20110530; Yiu GK, 2006, J BIOL CHEM, V281, P12210, DOI 10.1074/jbc.M600184200; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhang H, 2008, J CELL PHYSIOL, V215, P613, DOI 10.1002/jcp.21337; Zhao D, 2014, ONCOGENE, V34, P107	46	28	29	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3282	3292		10.1038/onc.2015.389	http://dx.doi.org/10.1038/onc.2015.389			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477312	Green Accepted			2022-12-17	WOS:000378306400007
J	Perotti, V; Baldassari, P; Molla, A; Vegetti, C; Bersani, I; Maurichi, A; Santinami, M; Anichini, A; Mortarini, R				Perotti, V.; Baldassari, P.; Molla, A.; Vegetti, C.; Bersani, I.; Maurichi, A.; Santinami, M.; Anichini, A.; Mortarini, R.			NFATc2 is an intrinsic regulator of melanoma dedifferentiation	ONCOGENE			English	Article							ACTIVATED T-CELLS; C-MYC EXPRESSION; NUCLEAR FACTOR; METASTATIC MELANOMA; THERAPEUTIC TARGET; MALIGNANT-MELANOMA; SIGNALING PATHWAY; INITIATING CELLS; ONCOGENIC BRAF; DIFFERENTIATION	Melanoma dedifferentiation, characterized by the loss of MITF and MITF regulated genes and by upregulation of stemness markers as CD271, is implicated in resistance to chemotherapy, target therapy and immunotherapy. The identification of intrinsic mechanisms fostering melanoma dedifferentiation may provide actionable therapeutic targets to improve current treatments. Here, we identify NFATc2 transcription factor as an intrinsic regulator of human melanoma dedifferentiation. In panels of melanoma cell lines, NFATc2 expression correlated inversely with MITF at both mRNA and protein levels. NFATc2(+/Hi) melanoma cell lines were CD271(+) and deficient for expression of melanocyte differentiation antigens (MDAs) MART-1, gp100, tyrosinase and of GPNMB, PGC1-alpha and Rab27a, all regulated by MITF. Targeting of NFATc2 by small interfering RNA, short hairpin RNA and by an NFATc2 inhibitor upregulated MITF, MDAs, GPNMB, PGC-1 alpha, tyrosinase activity and pigmentation and suppressed CD271. Mechanistically, we found that NFATc2 controls melanoma dedifferentiation by inducing expression in neoplastic cells of membrane-bound tumor necrosis factor-alpha (mTNF-alpha) and that melanoma-expressed TNF-alpha regulates a c-myc-Brn2 axis. Specifically, NFATc2, mTNF-alpha and expression of TNF receptors were significantly correlated in panels of cell lines. NFATc2 silencing suppressed TNF-alpha expression, and neutralization of melanoma-expressed TNF-alpha promoted melanoma differentiation. Moreover, silencing of NFATc2 and TNF-alpha neutralization downmodulated c-myc and POU3F2/Brn2. Brn2 was strongly expressed in NFATc2(+/Hi) MITFLo cell lines and its silencing upregulated MITF. Targeting of c-myc, by silencing or by a c-myc inhibitor, suppressed Brn2 and upregulated MITF and MART-1 in melanoma cells. The relevance of NFATc2-dependent melanoma dedifferentiation for immune escape was shown by cytolytic T-cell assays. NFATc2(Hi) MITFLo MDA(Lo) HLA-A2.1(+) melanoma cells were poorly recognized by MDA-specific and HLA-A2-restricted CTL lines, but NFATc2 targeting significantly increased CTL-mediated tumor recognition. Taken together, these results suggest that the expression of NFATc2 promotes melanoma dedifferentiation and immune escape.	[Perotti, V.; Baldassari, P.; Molla, A.; Vegetti, C.; Bersani, I.; Anichini, A.; Mortarini, R.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Human Tumors Immunobiol Unit, Via Venezian 1, I-20133 Milan, Italy; [Maurichi, A.; Santinami, M.] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Melanoma & Sarcoma Unit, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Mortarini, R (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Human Tumors Immunobiol Unit, Via Venezian 1, I-20133 Milan, Italy.	roberta.mortarini@istitutotumori.mi.it	Maurichi, Andrea/E-7030-2017; Perotti, Valentina/C-1049-2017; Maurichi, Andrea/AAX-5020-2020; Anichini, Andrea/K-1434-2016; Santinami, Mario/I-3795-2017; Mortarini, Roberta/C-9483-2017	Maurichi, Andrea/0000-0002-6503-5373; Perotti, Valentina/0000-0003-4506-2363; Maurichi, Andrea/0000-0002-6503-5373; Anichini, Andrea/0000-0001-5096-5538; Santinami, Mario/0000-0001-8436-4757; Mortarini, Roberta/0000-0001-7732-0561	Associazione Italiana per la Ricerca sul Cancro (A.I.R.C., Milan) [12020, 15860]	Associazione Italiana per la Ricerca sul Cancro (A.I.R.C., Milan)(Fondazione AIRC per la ricerca sul cancro)	We thank Dr L. De Cecco and Mr. E. Marchesi of the Functional Genomics Facility of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, for qPCR and gene expression analysis, Ms. G. Nicolini for the skillfull technical work. This investigation was supported by grant #12020 #15860 (to RM) from Associazione Italiana per la Ricerca sul Cancro (A.I.R.C., Milan).	Anichini A, 2006, CANCER RES, V66, P6405, DOI 10.1158/0008-5472.CAN-06-0854; Barral AM, 2000, MELANOMA RES, V10, P331, DOI 10.1097/00008390-200008000-00004; Bellei B, 2011, PIGM CELL MELANOMA R, V24, P309, DOI 10.1111/j.1755-148X.2010.00800.x; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bonvin E, 2012, MOL CELL BIOL, V32, P4674, DOI 10.1128/MCB.01067-12; Caballero FJ, 2007, BIOCHEM PHARMACOL, V73, P1013, DOI 10.1016/j.bcp.2006.12.001; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Cheli Y, 2014, ONCOTARGET, V5, P5272, DOI 10.18632/oncotarget.1967; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Denecker G, 2014, CELL DEATH DIFFER, V21, P1250, DOI 10.1038/cdd.2014.44; Flockhart RJ, 2009, BRIT J CANCER, V101, P1448, DOI 10.1038/sj.bjc.6605277; Furuta J, 2014, J INVEST DERMATOL, V134, P1369, DOI 10.1038/jid.2013.490; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Grazia G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.410; Harris RG, 2002, J BIOL CHEM, V277, P34815, DOI 10.1074/jbc.M109609200; Hartman ML, 2015, CELL MOL LIFE SCI, V72, P1249, DOI 10.1007/s00018-014-1791-0; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Kaminuma O, 2008, J IMMUNOL, V180, P319, DOI 10.4049/jimmunol.180.1.319; Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008-5472.CAN-14-1174; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Lawrence MC, 2011, J BIOL CHEM, V286, P1025, DOI 10.1074/jbc.M110.158675; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Mammucari C, 2005, DEV CELL, V8, P665, DOI 10.1016/j.devcel.2005.02.016; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Medyouf H, 2008, CELL CYCLE, V7, P297, DOI 10.4161/cc.7.3.5357; Menon DR, 2015, ONCOGENE, V34, P4448, DOI 10.1038/onc.2014.372; Minematsu H, 2011, CELL SIGNAL, V23, P1785, DOI 10.1016/j.cellsig.2011.06.013; Mognol GP, 2012, CELL CYCLE, V11, P1014, DOI 10.4161/cc.11.5.19518; Mortarini R, 2005, CANCER RES, V65, P3428, DOI 10.1158/0008-5472.CAN-04-3239; Mortarini R, 2003, CANCER RES, V63, P2535; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; NINOMIYATSUJI J, 1993, P NATL ACAD SCI USA, V90, P9611, DOI 10.1073/pnas.90.20.9611; Oliver JL, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12091; Perotti V, 2012, J INVEST DERMATOL, V132, P2652, DOI 10.1038/jid.2012.179; Pouryazdanparast P, 2012, MODERN PATHOL, V25, P1221, DOI 10.1038/modpathol.2012.75; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Romero P, 2006, ADV IMMUNOL, V92, P187, DOI 10.1016/S0065-2776(06)92005-7; Santini MP, 2001, P NATL ACAD SCI USA, V98, P9575, DOI 10.1073/pnas.161299698; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Shou JW, 2015, CANCER LETT, V361, P174, DOI 10.1016/j.canlet.2015.03.005; Singh G, 2010, J BIOL CHEM, V285, P27241, DOI 10.1074/jbc.M110.100438; Takada Y, 2007, ONCOGENE, V26, P1201, DOI 10.1038/sj.onc.1209906; Tam TTP, 2013, BIOCHEM BIOPH RES CO, V430, P722, DOI 10.1016/j.bbrc.2012.11.082; Tassi E, 2012, CLIN CANCER RES, V18, P3316, DOI 10.1158/1078-0432.CCR-11-2232; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85; Zhou YN, 2014, MOL BIOL CELL, V25, P2882, DOI 10.1091/mbc.E14-05-0998	51	28	29	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2862	2872		10.1038/onc.2015.355	http://dx.doi.org/10.1038/onc.2015.355			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387540				2022-12-17	WOS:000377473700006
J	Pieraccioli, M; Nicolai, S; Antonov, A; Somers, J; Malewicz, M; Melino, G; Raschella, G				Pieraccioli, M.; Nicolai, S.; Antonov, A.; Somers, J.; Malewicz, M.; Melino, G.; Raschella, G.			ZNF281 contributes to the DNA damage response by controlling the expression of XRCC2 and XRCC4	ONCOGENE			English	Article							C-MYC; REVEALS; SURVIVAL; GENES; IDENTIFICATION; ACTIVATION; NUCLEOLIN; NETWORK; BINDING; TOOL	ZNF281 is a zinc-finger factor involved in the control of cellular stemness and epithelial-mesenchymal transition (EMT). Here, we report that ZNF281 expression increased after genotoxic stress caused by DNA-damaging drugs. Comet assays demonstrated that DNA repair was delayed in cells silenced for the expression of ZNF281 and treated with etoposide. Furthermore, the expression of 10 DNA damage response genes was downregulated in cells treated with etoposide and silenced for ZNF281. In line with this finding, XRCC2 and XRCC4, two genes that take part in homologous recombination and non-homologous end joining, respectively, were transcriptionally activated by ZNF281 through a DNA-binding-dependent mechanism, as demonstrated by luciferase assays and Chromatin crosslinking ImmunoPrecipitation experiments. c-Myc, which also binds to the promoters of XRCC2 and XRCC4, was unable to promote their transcription or to modify ZNF281 activity. Of interest, bioinformatic analysis of 1971 breast cancer patients disclosed a significant correlation between the expression of ZNF281 and that of XRCC2. In summary, our data highlight, for the first time, the involvement of ZNF281 in the cellular response to genotoxic stress through the control exercised on the expression of genes that act in different repair mechanisms.	[Pieraccioli, M.; Nicolai, S.; Melino, G.; Raschella, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy; [Antonov, A.; Somers, J.; Malewicz, M.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Raschella, G.] Italian Natl Agcy New Technol Energy & Sustainabl, Res Ctr Casaccia, Radiat Biol & Human Hlth Unit, Via Anguillarese 301, I-00123 Rome, Lazio, Italy	University of Rome Tor Vergata; University of Leicester; Italian National Agency New Technical Energy & Sustainable Economics Development	Melino, G; Raschella, G (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.; Raschella, G (corresponding author), Italian Natl Agcy New Technol Energy & Sustainabl, Res Ctr Casaccia, Radiat Biol & Human Hlth Unit, Via Anguillarese 301, I-00123 Rome, Lazio, Italy.	melino@uniroma2.it; giuseppe.raschella@enea.it	Pieraccioli, Marco/K-4294-2018	Pieraccioli, Marco/0000-0003-3995-535X	AIRC IG Grant [2014-IG15653]; AIRC 5xmille Grant [9979]; Fondazione Roma NCDs grant awarded; AIRC 5xmille Grant; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_UP_A600_1109, MC_U132670600] Funding Source: researchfish	AIRC IG Grant(Fondazione AIRC per la ricerca sul cancro); AIRC 5xmille Grant(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma NCDs grant awarded; AIRC 5xmille Grant(Fondazione AIRC per la ricerca sul cancro); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by AIRC IG Grant (2014-IG15653), AIRC 5xmille Grant (2010-MCO no. 9979) and Fondazione Roma NCDs grant awarded to GM. SN was sponsored by a postdoctoral fellowship from AIRC 5xmille Grant. We thank Dr Eugenia Cordelli for assistance in the execution of Comet assays.	Adhikari D, 2014, MOL CELL ENDOCRINOL, V382, P480, DOI 10.1016/j.mce.2013.07.027; Amelio I, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.9; Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Antonov AV, 2014, ONCOGENE, V33, P1621, DOI 10.1038/onc.2013.119; Antonov AV, 2013, CELL DEATH DIFFER, V20, P367, DOI 10.1038/cdd.2012.137; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Calabretta B, 1997, ANTI-CANCER DRUG DES, V12, P373; Christmann M, 2013, NUCLEIC ACIDS RES, V41, P8403, DOI 10.1093/nar/gkt635; Chun J, 2013, MOL CELL BIOL, V33, P387, DOI 10.1128/MCB.00465-12; Cordelli E, 2012, ENVIRON MOL MUTAGEN, V53, P429, DOI 10.1002/em.21703; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Durut N, 2015, GENE, V556, P7, DOI 10.1016/j.gene.2014.09.023; Fidalgo M, 2012, P NATL ACAD SCI USA, V109, P16202, DOI 10.1073/pnas.1208533109; Fidalgo M, 2011, STEM CELLS, V29, P1705, DOI 10.1002/stem.736; Goldstein M, 2013, P NATL ACAD SCI USA, V110, P16874, DOI 10.1073/pnas.1306160110; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; John S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034252; Kakarougkas A, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130685; Koch HB, 2007, CELL CYCLE, V6, P205, DOI 10.4161/cc.6.2.3742; Law DJ, 1999, BIOCHEM BIOPH RES CO, V262, P113, DOI 10.1006/bbrc.1999.1180; Li ZZ, 2012, NEOPLASIA, V14, P1190, DOI 10.1593/neo.121258; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Luoto KR, 2010, CANCER RES, V70, P8748, DOI 10.1158/0008-5472.CAN-10-0944; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Murfuni I, 2013, ONCOGENE, V32, P610, DOI 10.1038/onc.2012.80; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; Phesse TJ, 2014, CELL DEATH DIFFER, V21, P956, DOI 10.1038/cdd.2014.15; Pieraccioli M, 2013, CELL CYCLE, V12, P2309, DOI 10.4161/cc.25405; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Sabatel H, 2011, BIOCHEM PHARMACOL, V82, P1371, DOI 10.1016/j.bcp.2011.07.105; Sabo A, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014191; Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415; Soucek L, 2002, CANCER CELL, V1, P406, DOI 10.1016/S1535-6108(02)00077-6; Wang F, 2013, CELL MOL LIFE SCI, V70, P3989, DOI 10.1007/s00018-012-1254-4; Yano K, 2008, CELL CYCLE, V7, P1321, DOI 10.4161/cc.7.10.5898; Yin XY, 2001, CANCER RES, V61, P6487	44	28	29	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2592	2601		10.1038/onc.2015.320	http://dx.doi.org/10.1038/onc.2015.320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26300006				2022-12-17	WOS:000376165700006
J	Park, SJ; Shim, JW; Park, HS; Eum, DY; Park, MT; Yi, JM; Choi, SH; Kim, SD; Son, TG; Lu, W; Kim, ND; Yang, K; Heo, K				Park, S-J; Shim, J. W.; Park, H. S.; Eum, D-Y; Park, M-T; Yi, J. Mi; Choi, S. H.; Kim, S. D.; Son, T. G.; Lu, W.; Kim, N. D.; Yang, K.; Heo, K.			MacroH2A1 downregulation enhances the stem-like properties of bladder cancer cells by transactivation of Lin28B	ONCOGENE			English	Article							INITIATING CELLS; HISTONE VARIANTS; SIDE POPULATION; LIN-28; EXPRESSION; RADIORESISTANCE; PROLIFERATION; PROGRESSION; REPRESSION; CARCINOMA	The histone variant, macroH2A1, has an important role in embryonic stem cell differentiation and tumor progression in various types of tumors. However, the regulatory roles of macroH2A1 on bladder cancer progression have not been fully elucidated. Here, we show that macroH2A1 knockdown promotes stem-like properties of bladder cancer cells. The knockdown of macroH2A1 in bladder cancer cells increased tumorigenicity, radioresistance, degeneration of reactive oxygen species, increased sphere formation capability and an increase in the proportion of side populations. We found that macroH2A1 is required for the suppression of Lin28B identified as a novel downstream target of macroH2A1 in bladder cancer. Loss of macroH2A1 expression significantly correlated with the elevated levels of Lin28B expression and subsequently inhibited the mature let-7 microRNA expression. Furthermore, the stable overexpression of Lin28B enhances the several phenotypes, including tumorigenicity and sphere-forming ability, which are induced by macroH2A1 depletion. Importantly, Lin28B expression was regulated by macroH2A1-mediated reciprocal binding of p300 and EZH2/SUV39H1. Our results suggest that Lin28B/let-7 pathway is tightly regulated by macroH2A1 and its cofactors, and have a pivotal role in the bladder tumor progression and the regulation of stem-like characteristics of bladder cancer cells.	[Park, S-J; Shim, J. W.; Park, H. S.; Eum, D-Y; Park, M-T; Yi, J. Mi; Choi, S. H.; Kim, S. D.; Son, T. G.; Yang, K.; Heo, K.] Dongnam Inst Radiol & Med Sci DIRAMS, Res Ctr, Jwadong Gil 40, Busan 619953, South Korea; [Park, S-J; Kim, N. D.] Pusan Natl Univ, Dept Pharm, Busan, South Korea; [Lu, W.] Univ So Calif, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Yang, K.] Dongnam Inst Radiol & Med Sci, Dept Radiat Oncol, Busan, South Korea; [Yang, K.] Korea Inst Radiol & Med Sci, Dept Radiat Oncol, Seoul, South Korea	Korea Institute of Radiological & Medical Sciences; Pusan National University; University of Southern California; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences	Yang, K; Heo, K (corresponding author), Dongnam Inst Radiol & Med Sci DIRAMS, Res Ctr, Jwadong Gil 40, Busan 619953, South Korea.	kmyang@dirams.re.kr; khjhk33@gmail.com		Heo, Kyu/0000-0001-8833-4731	National Research Foundation of Korea (DIRAMS) grant - Korea government (MSIP) [50590-2015]; (Basic Science Research Program) through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [NRF-2014 M2A2A 7043665]	National Research Foundation of Korea (DIRAMS) grant - Korea government (MSIP); (Basic Science Research Program) through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning	We thank Peter Jones for the UROtsa and LD611 cell lines. This work was supported by the National Research Foundation of Korea (DIRAMS) grant funded by the Korea government (MSIP) (50590-2015) and the (Basic Science Research Program) through the National Research Foundation of Korea (NRF) (NRF-2014 M2A2A 7043665) funded by the Ministry of Science, ICT & Future Planning.	Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X; Banaszynski LA, 2010, DEV CELL, V19, P662, DOI 10.1016/j.devcel.2010.10.014; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barrero MJ, 2013, CELL REP, V3, P1005, DOI 10.1016/j.celrep.2013.02.029; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Cai WY, 2013, J CELL SCI, V126, P2877, DOI 10.1242/jcs.123810; Chan KS, 2010, CURR OPIN UROL, V20, P393, DOI 10.1097/MOU.0b013e32833cc9df; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Cheng SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080053; Copley MR, 2013, NAT CELL BIOL, V15, P916, DOI 10.1038/ncb2783; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Dai B, 2007, STEM CELLS, V25, P2567, DOI 10.1634/stemcells.2007-0131; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Doyen CM, 2006, MOL CELL BIOL, V26, P1156, DOI 10.1128/MCB.26.3.1156-1164.2006; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; Gamble MJ, 2010, CELL CYCLE, V9, P2568, DOI 10.4161/cc.9.13.12144; Gaspar-Maia A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2582; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kim JM, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.40; King CE, 2011, CANCER RES, V71, P4260, DOI 10.1158/0008-5472.CAN-10-4637; Lee DF, 2012, CELL STEM CELL, V11, P179, DOI 10.1016/j.stem.2012.05.020; Li XF, 2012, J BIOL CHEM, V287, P23171, DOI 10.1074/jbc.M112.379412; Lu LG, 2012, CARCINOGENESIS, V33, P2119, DOI 10.1093/carcin/bgs243; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Novikov L, 2011, MOL CELL BIOL, V31, P4244, DOI 10.1128/MCB.05244-11; Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091; Pasque V, 2012, J CELL SCI, V125, P6094, DOI 10.1242/jcs.113019; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005; Sporn JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26; Sporn JC, 2012, AM J PATHOL, V180, P2516, DOI 10.1016/j.ajpath.2012.02.027; Svotelis A, 2010, CELL CYCLE, V9, P364, DOI 10.4161/cc.9.2.10465; Tanasijevic B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021512; Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Wang WJ, 2013, CANCER RES, V73, P1219, DOI 10.1158/0008-5472.CAN-12-1408; Wang YC, 2010, CARCINOGENESIS, V31, P1516, DOI 10.1093/carcin/bgq107; Wu CL, 2007, CANCER RES, V67, P8216, DOI 10.1158/0008-5472.CAN-07-0999; Xia ZB, 2013, MOL CANCER RES, V11, P1101, DOI 10.1158/1541-7786.MCR-13-0044; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	48	28	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1292	1301		10.1038/onc.2015.187	http://dx.doi.org/10.1038/onc.2015.187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028027	Green Published, hybrid			2022-12-17	WOS:000371763100009
J	Duvall-Noelle, N; Karwandyar, A; Richmond, A; Raman, D				Duvall-Noelle, N.; Karwandyar, A.; Richmond, A.; Raman, D.			LASP-1: a nuclear hub for the UHRF1-DNMT1-G9a-Snail1 complex	ONCOGENE			English	Article							METASTATIC BREAST-CANCER; E-CADHERIN REPRESSION; CHEMOKINE RECEPTORS; TUMOR-GROWTH; CELLS; SNAIL; EXPRESSION; LOCALIZATION; CARCINOMA; CXCR4	Nuclear LASP-1 (LIM and SH3 protein-1) has a direct correlation with overall survival of breast cancer patients. In this study, immunohistochemical analysis of a human breast TMA showed that LASP-1 is absent in normal human breast epithelium but the expression increases with malignancy and is highly nuclear in aggressive breast cancer. We investigated whether the chemokines and growth factors present in the tumor microenvironment could trigger nuclear translocation of LASP-1. Treatment of human breast cancer cells with CXCL12, EGF and HRG, and HMEC-CXCR2 cells with CXCL8 facilitated nuclear shuttling of LASP-1. Data from the biochemical analysis of the nuclear and cytosolic fractions further confirmed the nuclear translocation of LASP-1 upon chemokine and growth factor treatment. CXCL12-dependent nuclear import of LASP-1 could be blocked by CXCR4 antagonist, AMD-3100. Knock down of LASP-1 resulted in alterations in gene expression leading to an increased level of cell-junction and extracellular matrix proteins and an altered cytokine secretory profile. Three-dimensional cultures of human breast cancer cells on Matrigel revealed an altered colony growth, morphology and arborization pattern in LASP-1 knockdown cells. Functional analysis of the LASP-1 knockdown cells revealed increased adhesion to collagen IV and decreased invasion through the Matrigel. Proteomic analysis of immunoprecipitates of LASP-1 and subsequent validation approaches revealed that LASP-1 associated with the epigenetic machinery especially UHRF1, DNMT1, G9a and the transcription factor Snail1. Interestingly, LASP-1 associated with UHRF1, G9a, Snail1 and di- and tri-methylated histoneH3 in a CXCL12-dependent manner based on immunoprecipitation and proximity ligation assays. LASP-1 also directly bound to Snail1 which may stabilize Snail1. Thus, nuclear LASP-1 appears to functionally serve as a hub for the epigenetic machinery.	[Duvall-Noelle, N.; Karwandyar, A.; Richmond, A.; Raman, D.] Vanderbilt Univ, Sch Med, Dept Canc Biol, 436 Preston Res Bldg,23rd Ave South Pierce, Nashville, TN 37232 USA; [Richmond, A.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Raman, D (corresponding author), Vanderbilt Univ, Med Ctr, Dept Canc Biol, 436 Preston Res Bldg,23rd Ave South Pierce, Nashville, TN 37232 USA.	dayanidhi.raman@vanderbilt.edu			Department of Defense, IDEA grant [W81XWH-11-1-0413]; VICTR award - Vanderbilt Clinical and Translational Science Award (CTSA) grant from NCRR/NIH [UL1 TR000445]; NIH [CA-34590]; VA Merit Award; Career Scientist Award from the Tennessee Valley Healthcare System; Department of Veterans Affairs; Ingram Professorship; NATIONAL CANCER INSTITUTE [R23CA034590, R01CA034590] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002301] Funding Source: NIH RePORTER	Department of Defense, IDEA grant(United States Department of Defense); VICTR award - Vanderbilt Clinical and Translational Science Award (CTSA) grant from NCRR/NIH; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit Award(US Department of Veterans Affairs); Career Scientist Award from the Tennessee Valley Healthcare System; Department of Veterans Affairs(US Department of Veterans Affairs); Ingram Professorship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the Department of Defense, IDEA grant W81XWH-11-1-0413 (to DR), VICTR award, supported in part by Vanderbilt Clinical and Translational Science Award (CTSA) grant, UL1 TR000445 from NCRR/NIH (to DR), NIH grants CA-34590 (to AR), VA Merit Award (to AR), Career Scientist Award (to AR) from the Tennessee Valley Healthcare System and the Department of Veterans Affairs and Ingram Professorship (to AR).	Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Cipriano R, 2014, ONCOGENE, V33, P3298, DOI 10.1038/onc.2013.293; Cipriano R, 2013, ONCOTARGET, V4, P729, DOI 10.18632/oncotarget.1027; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; Frietsch JJ, 2010, BRIT J CANCER, V102, P1645, DOI 10.1038/sj.bjc.6605685; Fulton AM, 2009, CURR ONCOL REP, V11, P125, DOI 10.1007/s11912-009-0019-1; Goldberg-Bittman L, 2004, IMMUNOL LETT, V92, P171, DOI 10.1016/j.imlet.2003.10.020; Grunewald TGP, 2006, EXP CELL RES, V312, P974, DOI 10.1016/j.yexcr.2005.12.016; Grunewald TGP, 2007, BMC CANCER, V7, P1, DOI 10.1186/1471-2407-7-198; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Li HY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2680; Li XL, 2011, INT J RADIAT BIOL, V87, P263, DOI 10.3109/09553002.2011.530335; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Mihlan S, 2013, ONCOGENE, V32, P2107, DOI 10.1038/onc.2012.216; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Neel NF, 2008, THESIS; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Olmeda D, 2007, CANCER RES, V67, P11721, DOI 10.1158/0008-5472.CAN-07-2318; Orth MF, 2015, ONCOTARGET, V6, P26, DOI 10.18632/oncotarget.3083; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Raman D, 2009, METHOD ENZYMOL, V460, P297; Raman D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010050; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033; Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Ueda Y, 2006, CANCER RES, V66, P5665, DOI 10.1158/0008-5472.CAN-05-3579; Walser TC, 2006, CANCER RES, V66, P7701, DOI 10.1158/0008-5472.CAN-06-0709; Wikman H, 2014, ONCOTARGET, V5, P3076, DOI 10.18632/oncotarget.1832; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128	39	28	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1122	1133		10.1038/onc.2015.166	http://dx.doi.org/10.1038/onc.2015.166			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982273	Green Accepted			2022-12-17	WOS:000371351700006
J	Wu, DW; Chen, CY; Chu, CL; Lee, H				Wu, D-W; Chen, C-Y; Chu, C-L; Lee, H.			Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability	ONCOGENE			English	Article							PHOSPHORYLATION; EXPRESSION; SURVIVAL; MUTATION; CELLS; DEGRADATION; PROMOTES; PATHWAY	Tyrosine kinase inhibitors (TKIs) have been documented to have substantial clinical benefits to non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutation. TKI resistance occurs in nearly all patients who receive TKI-targeting therapy, resulting in a modest overall survival benefit. Therefore, establishing a biomarker for early prediction and exploring the mechanism of primary TKI resistance is essential for improving the therapeutic efficacy in non-small cell lung cancer patients. In this study, we provide evidence indicating that paxillin (PXN) overexpression may confer TKI resistance in EGFR-mutant lung cancer cells. Mechanistically, PXN-mediated extracellular signal-regulated kinases (ERK) activation is responsible for TKI resistance via decreased Bcl2-interacting mediator of cell death (BIM) and increased Mcl-1 expression due to modulating their protein stabilities by phosphorylation of BIM at serine 69 and Mcl-1 at threonine 163. The mechanistic action in the cell model was further confirmed by the observation of xenograft tumors in nude mice, revealing that the PXN-mediated TKI resistance was conquered by ERK inhibitor (AZD6244) and Bcl-2 family inhibitor (obatoclax), but the TKI resistance overcome by AZD6244 is more effective than that of obatoclax. Therefore, we suggest that PXN expression may be useful in predicting primary TKI resistance, and combining TKI with ERK inhibitors may clinically benefit EGFR-mutant non-small cell lung cancer patients whose tumors exhibit high PXN expression.	[Wu, D-W; Lee, H.] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Chen, C-Y; Chu, C-L] China Med Univ Hosp, Ctr Canc, Taichung, Taiwan; [Chen, C-Y] Chung Shan Med Univ Hosp, Dept Surg, Taichung 40201, Taiwan	Taipei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital	Lee, H (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Room 5,12F,3 Pk St, Taipei 115, Taiwan.	hl@tmu.edu.tw			National Health Research Institute [NHRI-EX103-10328BI]; National Science Council of Taiwan, ROC [NSC100-2314-B-038-043-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI-EX103-10328BI) and the National Science Council (NSC100-2314-B-038-043-MY3) of Taiwan, ROC.	Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Costa DB, 2007, LUNG CANCER, V58, P95, DOI 10.1016/j.lungcan.2007.05.017; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; Ewings KE, 2007, CELL CYCLE, V6, P2236, DOI 10.4161/cc.6.18.4728; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Huang MH, 2013, MOL ONCOL, V7, P112, DOI 10.1016/j.molonc.2012.09.002; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Kim HR, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-50; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Liao MM, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-44; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Ochi N, 2014, EXP CELL RES, V322, P168, DOI 10.1016/j.yexcr.2014.01.007; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Song JY, 2013, INVEST NEW DRUG, V31, P1458, DOI 10.1007/s10637-013-0030-0; Vela L, 2013, J BIOL CHEM, V288, P4935, DOI 10.1074/jbc.M112.422204; Wang J, 2011, J BIOL CHEM, V286, P22384, DOI 10.1074/jbc.M111.239566; Wu DW, 2014, ONCOGENE, V33, P4385, DOI 10.1038/onc.2013.389; Wu DW, 2012, AM J PATHOL, V181, P1796, DOI 10.1016/j.ajpath.2012.07.032; Zhao JF, 2009, MOL CANCER RES, V7, P1954, DOI 10.1158/1541-7786.MCR-09-0304	28	28	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					621	630		10.1038/onc.2015.120	http://dx.doi.org/10.1038/onc.2015.120			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25915848				2022-12-17	WOS:000369548800009
J	Berstad, MB; Cheung, LH; Berg, K; Peng, Q; Fremstedal, ASV; Patzke, S; Rosenblum, MG; Weyergang, A				Berstad, M. B.; Cheung, L. H.; Berg, K.; Peng, Q.; Fremstedal, A. S. V.; Patzke, S.; Rosenblum, M. G.; Weyergang, A.			Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL CARCINOMA; PHOTODYNAMIC THERAPY; ACQUIRED-RESISTANCE; ANTITUMOR-ACTIVITY; ENDOTHELIAL-CELLS; FACTOR-ALPHA; INTERNALIZATION; EXPRESSION; GELONIN	The number of epidermal growth factor receptor (EGFR)-targeting drugs in the development for cancer treatment is continuously increasing. Currently used EGFR-targeted monoclonal antibodies and tyrosine kinase inhibitors have specific limitations related to toxicity and development of resistance, and there is a need for alternative treatment strategies to maximize the clinical potential of EGFR as a molecular target. This study describes the design and production of a novel EGFR-targeted fusion protein, rGel/EGF, composed of the recombinant plant toxin gelonin and EGF. rGel/EGF was custom-made for administration by photochemical internalization (PCI), a clinically tested modality for cytosolic release of macromolecular therapeutics. rGel/EGF lacks efficient mechanisms for endosomal escape and is therefore minimally toxic as monotherapy. However, PCI induces selective and efficient cytosolic release of rGel/EGF in EGFR-expressing target cells by light-directed activation of photosensitizers accumulated selectively in tumor tissue. PCI of rGel/EGF was shown to be highly effective against EGFR-expressing cell lines, including head and neck squamous cell carcinoma (HNSCC) cell lines resistant to cetuximab (Erbitux). Apoptosis, necrosis and autophagy were identified as mechanisms of action following PCI of rGel/EGF in vitro. PCI of rGel/EGF was further shown as a highly tumor-specific and potent modality in vivo, with growth inhibitory effects demonstrated on A-431 squamous cell carcinoma (SCC) xenografts and reduction of tumor perfusion and necrosis induction in SCC-026 HNSCC tumors. Considering the small amount of rGel/EGF injected per animal (0.1 mg/kg), the presented in vivo results are highly promising and warrant optimization and production of rGel/EGF for further preclinical evaluation with PCI.	[Berstad, M. B.; Berg, K.; Fremstedal, A. S. V.; Patzke, S.; Weyergang, A.] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, N-0424 Oslo, Norway; [Cheung, L. H.; Rosenblum, M. G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Immunopharmacol & Targeted Therapy Lab, Houston, TX 77030 USA; [Peng, Q.] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0424 Oslo, Norway	University of Oslo; University of Texas System; UTMD Anderson Cancer Center; University of Oslo	Weyergang, A (corresponding author), Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, POB 4950, N-0424 Oslo, Norway.	anette.weyergang@rr-research.no	Weyergang, Anette/AAB-9938-2021; Weyergang, Anette/I-2934-2018; Patzke, Sebastian/G-9909-2019	Weyergang, Anette/0000-0003-0147-1763; Weyergang, Anette/0000-0003-0147-1763; Patzke, Sebastian/0000-0001-6821-197X; Berg, Kristian/0000-0002-7816-7543	South-Eastern Norway Regional Health Authority; NCI Grant [CA16672]; Norwegian Radium Hospital Legacies; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	South-Eastern Norway Regional Health Authority; NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Norwegian Radium Hospital Legacies; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kine Mari Bakke at the MRI Core Facility for technical assistance and valuable evaluation of the MRI results, Idun Dale Rein at The Flow Cytometry Core Facility (FCCF) for excellent technical expertise and sample analysis and Khalid A Mohamedali for fruitful discussion. We also thank Karen-Marie Heintz from the Department of Tumorbiology, Norwegian Radium Hospital and the RPPA Core Facility, MD Anderson Cancer Center for assistance in performing DNA fingerprinting assay. The project was supported by the South-Eastern Norway Regional Health Authority. Research was conducted, in part, by the Clayton Foundation for Research and supported by NCI Grant CA16672. Instrumentation for MRI, IVIS and flow cytometry has been financed by the Norwegian Radium Hospital Legacies.	Ahmad N, 2001, ONCOGENE, V20, P2314, DOI 10.1038/sj.onc.1204313; Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Amin DN, 2006, CANCER RES, V66, P2173, DOI 10.1158/0008-5472.CAN-05-3387; Ang KK, 2002, CANCER RES, V62, P7350; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Berg K, 1999, CANCER RES, V59, P1180; Berg K, 2011, PHOTOCH PHOTOBIO SCI, V10, P1637, DOI 10.1039/c1pp05128h; Bruell D, 2005, INT J MOL MED, V15, P305; Bull-Hansen B, 2014, J CONTROL RELEASE, V182, P58, DOI 10.1016/j.jconrel.2014.03.014; Cao Y, 2012, MOL CANCER THER, V11, P143, DOI 10.1158/1535-7163.MCT-11-0519; Cao Y, 2009, CANCER RES, V69, P8987, DOI 10.1158/0008-5472.CAN-09-2693; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; GRANDIS JR, 1993, CANCER RES, V53, P3579; Gregoire V, 2010, ANN ONCOL, V21, pv184, DOI 10.1093/annonc/mdq185; Hale ML, 2001, PHARMACOL TOXICOL, V88, P255, DOI 10.1034/j.1600-0773.2001.d01-113.x; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; Kim SM, 2010, CANCER LETT, V296, P150, DOI 10.1016/j.canlet.2010.04.006; Lackner MR, 2012, FUTURE ONCOL, V8, P999, DOI [10.2217/FON.12.86, 10.2217/fon.12.86]; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Lippman S M, 1995, Cancer Treat Res, V74, P89; Liu TF, 2005, CLIN CANCER RES, V11, P329; Martin CL, 2008, ORAL ONCOL, V44, P369, DOI 10.1016/j.oraloncology.2007.05.003; Martinez-Torrecuadrada JL, 2008, MOL CANCER THER, V7, P862, DOI 10.1158/1535-7163.MCT-07-0394; Norum OJ, 2009, PHOTOCHEM PHOTOBIOL, V85, P740, DOI 10.1111/j.1751-1097.2008.00477.x; Pastan I, 2007, ANNU REV MED, V58, P221, DOI 10.1146/annurev.med.58.070605.115320; PHILLIPS PC, 1994, CANCER RES, V54, P1008; Piette J, 2003, BIOCHEM PHARMACOL, V66, P1651, DOI 10.1016/S0006-2952(03)00539-2; Pirie CM, 2011, J BIOL CHEM, V286, P4165, DOI 10.1074/jbc.M110.186973; Rebucci M, 2011, INT J ONCOL, V38, P189, DOI 10.3892/ijo_00000838; Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220; ROSENBLUM MG, 1995, J INTERF CYTOK RES, V15, P547, DOI 10.1089/jir.1995.15.547; Selbo PK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006691; Selbo PK, 2010, J CONTROL RELEASE, V148, P2, DOI 10.1016/j.jconrel.2010.06.008; Selbo PK, 2000, INT J CANCER, V87, P853, DOI 10.1002/1097-0215(20000915)87:6<853::AID-IJC15>3.0.CO;2-0; Selbo PK, 2000, BBA-GEN SUBJECTS, V1475, P307, DOI 10.1016/S0304-4165(00)00082-9; Selbo PK, 2001, INT J CANCER, V92, P761, DOI 10.1002/1097-0215(20010601)92:5<761::AID-IJC1238>3.0.CO;2-4; STIRPE F, 1980, J BIOL CHEM, V255, P6947; Thomas SM, 2004, CLIN CANCER RES, V10, P7079, DOI 10.1158/1078-0432.CCR-04-0587; Veenendaal LM, 2002, P NATL ACAD SCI USA, V99, P7866, DOI [10.1073/pnas.122157899, 10.1073/pnas.162346299]; Vikdal M, 2013, PHOTOCHEM PHOTOBIOL, V89, P1185, DOI 10.1111/php.12126; Wang Q, 2005, EMBO REP, V6, P942, DOI 10.1038/sj.embor.7400491; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Weyergang A, 2008, MOL CANCER THER, V7, P1740, DOI 10.1158/1535-7163.MCT-08-0020; Weyergang A, 2014, J CONTROL RELEASE, V180, P1, DOI 10.1016/j.jconrel.2014.02.003; Weyergang A, 2013, BBA-GEN SUBJECTS, V1830, P2659, DOI 10.1016/j.bbagen.2012.11.010; Weyergang A, 2011, LASER SURG MED, V43, P721, DOI 10.1002/lsm.21084; Weyeyang A, 2007, BIOCHEM PHARMACOL, V74, P226, DOI 10.1016/j.bcp.2007.04.018; Zhou H, 2011, MOL CANCER THER, V10, P1276, DOI 10.1158/1535-7163.MCT-11-0161; Zhou XK, 2012, J CANCER RES CLIN, V138, P1081, DOI 10.1007/s00432-012-1181-7	51	28	28	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5582	5592		10.1038/onc.2015.15	http://dx.doi.org/10.1038/onc.2015.15			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25684137				2022-12-17	WOS:000364594000007
J	Haque, I; Banerjee, S; De, A; Maity, G; Sarkar, S; Majumdar, M; Jha, SS; McGragor, D; Banerjee, SK				Haque, I.; Banerjee, S.; De, A.; Maity, G.; Sarkar, S.; Majumdar, M.; Jha, S. S.; McGragor, D.; Banerjee, S. K.			CCN5/WISP-2 promotes growth arrest of triple-negative breast cancer cells through accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation	ONCOGENE			English	Article							DEPENDENT KINASE INHIBITOR; CDK INHIBITOR; INVASIVE PHENOTYPES; ONCOGENIC FUNCTION; TUMOR-CELLS; P27; EXPRESSION; CYCLE; ESTROGEN; DEGRADATION	The matricellular protein CCN5/WISP-2 represents a promising target in triple-negative breast cancer (TNBC) because treatment or induced activation of CCN5 in TNBC cells promotes cell growth arrest at the G0/G1 phase, reduces cell proliferation and delays tumor growth in the xenograft model. Our studies found that the p27(Kip1) tumor suppressor protein is upregulated and relocalized to the nucleus from cytoplasm by CCN5 in these cells and that these two events (upregulation and relocalization of p27(Kip1)) are critical for CCN5-induced growth inhibition of TNBC cells. In the absence of CCN5, p27(Kip1) resides mostly in the cytoplasm, which is associated with the aggressive nature of cancer cells. Mechanistically, CCN5 inhibits Skp2 expression, which seems to stabilize the p27(Kip1) protein in these cells. On the other hand, CCN5 also recruits FOXO3a to mediate the transcriptional regulation of p27(Kip1). The recruitment of FOXO3a is achieved by the induction of its expression and activity through shifting from cytoplasm to the nucleus. Our data indicate that CCN5 blocks PI3K/AKT signaling to dephosphorylate at S318, S253 and Thr32 in FOXO3a for nuclear relocalization and activation of FOXO3a. Moreover, inhibition of alpha 6 beta 1 receptors diminishes CCN5 action on p27(Kip1) in TNBC cells. Collectively, these data suggest that CCN5 effectively inhibits TNBC growth through the accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation, and thus, activation of CCN5 may have the therapeutic potential to kill TNBC.	[Haque, I.; Banerjee, S.; De, A.; Maity, G.; Sarkar, S.; Majumdar, M.; Jha, S. S.; McGragor, D.; Banerjee, S. K.] Vet Adm Med Ctr, Canc Res Unit, Kansas City, MO 64128 USA; [Haque, I.; Banerjee, S.; Maity, G.; Banerjee, S. K.] Univ Kansas, Med Ctr, Dept Med, Div Hematol & Oncol, Kansas City, MO USA; [Sarkar, S.; Banerjee, S. K.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, MO USA; [Sarkar, S.; Banerjee, S. K.] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, MO USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas; University of Kansas; University of Kansas	Banerjee, SK (corresponding author), Vet Adm Med Ctr, Canc Res Unit, Res Div 151, 4801 Linwood Blvd, Kansas City, MO 64128 USA.	sbanerjee2@kumc.edu	Banerjee, Sushanta/AAG-6534-2021; Haque, Inamul/I-2482-2019	Banerjee, Sushanta/0000-0002-7698-0717; Haque, Inamul/0000-0002-1307-9446	VA Merit Award; Veterans Affairs [I01BX001989] Funding Source: NIH RePORTER	VA Merit Award(US Department of Veterans Affairs); Veterans Affairs(US Department of Veterans Affairs)	These studies were supported by VA Merit Award grants (SKB and SB).	Alkarain A, 2004, J MAMMARY GLAND BIOL, V9, P67, DOI 10.1023/B:JOMG.0000023589.00994.5e; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Banerjee S, 2005, MOL CANCER RES, V3, P151, DOI 10.1158/1541-7786.MCR-04-0130; Banerjee S, 2003, NEOPLASIA, V5, P63, DOI 10.1016/S1476-5586(03)80018-0; Banerjee S, 2008, CANCER RES, V68, P7606, DOI 10.1158/0008-5472.CAN-08-1461; Banerjee S, 2006, MOL CARCINOGEN, V45, P871, DOI 10.1002/mc.20248; Banerjee SK, 2012, J CELL COMMUN SIGNAL, V6, P63, DOI 10.1007/s12079-012-0158-2; Barbareschi M, 2000, INT J CANCER, V89, P236, DOI 10.1002/1097-0215(20000520)89:3<236::AID-IJC5>3.3.CO;2-Q; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; De Paola F, 2002, J PATHOL, V196, P26, DOI 10.1002/path.1011; Dhar G, 2008, CANCER RES, V68, P4580, DOI 10.1158/0008-5472.CAN-08-0316; Dhar G, 2007, CANCER LETT, V254, P63, DOI 10.1016/j.canlet.2007.02.012; Dhar K, 2007, CANCER RES, V67, P1520, DOI 10.1158/0008-5472.CAN-06-3753; Fritah A, 2008, MOL CELL BIOL, V28, P1114, DOI 10.1128/MCB.01335-07; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Haque I, 2012, J BIOL CHEM, V287, P38569, DOI 10.1074/jbc.M112.389064; Haque I, 2011, J BIOL CHEM, V286, P43475, DOI 10.1074/jbc.M111.284158; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Mineta H, 1999, CANCER-AM CANCER SOC, V85, P1011, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1011::AID-CNCR1>3.0.CO;2-0; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Nakao T, 2008, CELL CYCLE, V7, P257, DOI 10.4161/cc.7.2.5148; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Oliveira LR, 2010, HISTOL HISTOPATHOL, V25, P371, DOI 10.14670/HH-25.371; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Reed W, 1999, VIRCHOWS ARCH, V435, P116, DOI 10.1007/s004280050408; Russo JW, 2010, J CELL COMMUN SIGNAL, V4, P119, DOI 10.1007/s12079-010-0098-7; Sabbah M, 2011, MOL CELL BIOL, V31, P1459, DOI 10.1128/MCB.01316-10; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Simpson PT, 2005, AM J SURG PATHOL, V29, P734, DOI 10.1097/01.pas.0000157295.93914.3b; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Tan P, 1997, CANCER RES, V57, P1259; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Troncone G, 2004, DIAGN CYTOPATHOL, V30, P375, DOI 10.1002/dc.20059; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wander SA, 2011, CLIN CANCER RES, V17, P12, DOI 10.1158/1078-0432.CCR-10-0752; Wei SO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047298; Zhang SW, 2013, J CELL BIOCHEM, V114, P354, DOI 10.1002/jcb.24371	55	28	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3152	3163		10.1038/onc.2014.250	http://dx.doi.org/10.1038/onc.2014.250			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25132260	Bronze			2022-12-17	WOS:000356101100007
J	Kohlmaier, A; Fassnacht, C; Jin, Y; Reuter, H; Begum, J; Dutta, D; Edgar, BA				Kohlmaier, A.; Fassnacht, C.; Jin, Y.; Reuter, H.; Begum, J.; Dutta, D.; Edgar, B. A.			Src kinase function controls progenitor cell pools during regeneration and tumor onset in the Drosophila intestine	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; STEM-CELL; C-SRC; TERMINAL DIFFERENTIATION; DEPENDENT REGULATION; BACTERIAL-INFECTION; TYROSINE KINASES; STAT3 ACTIVATION; CYCLE REGULATION; FACTOR RECEPTOR	Src non-receptor kinases have been implicated in events late in tumor progression. Here, we study the role of Src kinases in the Drosophila intestinal stem cell (ISC) lineage, during tissue homeostasis and tumor onset. The adult Drosophila intestine contains only two progenitor cell types, division-capable ISCs and their daughters, postmitotic enteroblasts (EBs). We found that Drosophila Src42a and Src64b were required for optimal regenerative ISC division. Conversely, activation of Src42a, Src64b or another nonreceptor kinase, Ack, promoted division of quiescent ISCs by coordinately stimulating G1/S and G2/M cell cycle phase progression. Prolonged Src kinase activation caused tissue overgrowth owing to cytokine receptor-independent Stat92E activation. This was not due to increased symmetric division of ISCs, but involved accumulation of weakly specified Notch(+) but division-capable EB-like cells. Src activation triggered expression of a mitogenic module consisting of String/Cdc25 and Cyclin E that was sufficient to elicit division not only of ISCs but also of EBs. A small pool of similarly division-capable transit-amplifying Notch(+) EBs was also identified in the wild type. Expansion of intermediate cell types that do not robustly manifest their transit-amplifying potential in the wild type may also contribute to regenerative growth and tumor development in other tissues in other organisms.	[Kohlmaier, A.; Fassnacht, C.; Jin, Y.; Reuter, H.; Begum, J.; Dutta, D.; Edgar, B. A.] Univ Heidelberg ZMBH Allianz, Deutsch Krebsforschungszentrum DKFZ, Zentrum Mol Biol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Edgar, BA (corresponding author), DKFZ ZMBH Alliance, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	b.edgar@zmbh.uni-heidelberg.de	Jin, Yinhua/AAU-5460-2021	Jin, Yinhua/0000-0003-4698-8555; Dutta, Devanjali/0000-0002-4993-9639; von Gugelberg (born Fassnacht), Christina/0000-0001-5379-2687	ERC [268515]; NIH [R01 GM51186]; DFG [SFB873]; Human Frontiers in Science Program Long-Term postdoctoral fellowship [LT00316/2008-L]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051186] Funding Source: NIH RePORTER	ERC(European Research Council (ERC)European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DFG(German Research Foundation (DFG)); Human Frontiers in Science Program Long-Term postdoctoral fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank David Ibbserson and the Deep Sequencing Core Facility of CellNetworks University of Heidelberg and the Fred Hutchinson Cancer Research Center Seattle for RNA and library preparations and sequencing. We thank Nicholas Harden, Yuh Nung Jan, Marco Milan, Steven Hou, Sarah Bray, Sol Sotillos and the Yale FlyTrap consortium (USA) for gifts of fly stocks. We are grateful to Sylvia Kreger for experimental support and Monika Langlotz (ZMBH) for help with FACS. We thank Juanita Reetz for critically reading of the manuscript. Work in BAE's laboratory was funded by ERC Grant 268515, NIH Grant R01 GM51186 and DFG Grant SFB873. AK was supported by a Human Frontiers in Science Program Long-Term postdoctoral fellowship (LT00316/2008-L).	Abdallah AM, 2013, DEV BIOL, V378, P141, DOI 10.1016/j.ydbio.2013.02.025; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Amcheslavsky A, 2009, CELL STEM CELL, V4, P49, DOI 10.1016/j.stem.2008.10.016; Apidianakis Y, 2009, P NATL ACAD SCI USA, V106, P20883, DOI 10.1073/pnas.0911797106; Baonza A, 2002, NAT CELL BIOL, V4, P976, DOI 10.1038/ncb887; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Beebe K, 2010, DEV BIOL, V338, P28, DOI 10.1016/j.ydbio.2009.10.045; Biteau B, 2008, CELL STEM CELL, V3, P442, DOI 10.1016/j.stem.2008.07.024; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Buchon N, 2013, CELL REP, V3, P1725, DOI 10.1016/j.celrep.2013.04.001; Buchon N, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-152; Buchon N, 2009, GENE DEV, V23, P2333, DOI 10.1101/gad.1827009; Buchon N, 2009, CELL HOST MICROBE, V5, P200, DOI 10.1016/j.chom.2009.01.003; Buttitta LA, 2007, CURR OPIN CELL BIOL, V19, P697, DOI 10.1016/j.ceb.2007.10.004; Buttitta LA, 2007, DEV CELL, V12, P631, DOI 10.1016/j.devcel.2007.02.020; Buttitta LA, 2010, J CELL BIOL, V189, P981, DOI 10.1083/jcb.200910006; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chau J, 2009, GENETICS, V182, P121, DOI 10.1534/genetics.109.100693; Choi NH, 2008, AGING CELL, V7, P318, DOI 10.1111/j.1474-9726.2008.00380.x; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Cordero JB, 2012, DEVELOPMENT, V139, P4524, DOI 10.1242/dev.078261; Cronin SJF, 2009, SCIENCE, V325, P340, DOI 10.1126/science.1173164; de Navascues J, 2012, EMBO J, V31, P2473, DOI 10.1038/emboj.2012.106; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; Enomoto M, 2013, EMBO REP, V14, P65, DOI 10.1038/embor.2012.185; Fernandez BG, 2014, ONCOGENE, V33, P2027, DOI 10.1038/onc.2013.155; Goulas S, 2012, CELL STEM CELL, V11, P529, DOI 10.1016/j.stem.2012.06.017; Guest ST, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-65; Herranz H, 2008, EMBO J, V27, P1633, DOI 10.1038/emboj.2008.84; Herranz H, 2012, GENE DEV, V26, P1602, DOI 10.1101/gad.192021.112; Herranz H, 2012, CURR BIOL, V22, P651, DOI 10.1016/j.cub.2012.02.050; Huang HL, 2014, DEV BIOL, V385, P211, DOI 10.1016/j.ydbio.2013.11.008; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Jiang HQ, 2011, CELL STEM CELL, V8, P84, DOI 10.1016/j.stem.2010.11.026; Jiang HQ, 2009, CELL, V137, P1343, DOI 10.1016/j.cell.2009.05.014; Jiang HQ, 2009, DEVELOPMENT, V136, P483, DOI 10.1242/dev.026955; Kapuria S, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003045; Kim M, 2004, MOL CELL BIOL, V24, P573, DOI 10.1128/MCB.24.2.573-583.2004; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010; Kohlmaier A, 2008, CURR OPIN CELL BIOL, V20, P699, DOI 10.1016/j.ceb.2008.10.002; Lee WC, 2009, DEVELOPMENT, V136, P2255, DOI 10.1242/dev.035196; Liu W, 2010, J CELL BIOCHEM, V109, P992, DOI 10.1002/jcb.22482; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Micchelli CA, 2006, NATURE, V439, P475, DOI 10.1038/nature04371; Nasmyth K, 2001, CELL, V107, P689, DOI 10.1016/S0092-8674(01)00604-3; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; O'Brien LE, 2011, CELL, V147, P603, DOI 10.1016/j.cell.2011.08.048; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; Ohlstein B, 2007, SCIENCE, V315, P988, DOI 10.1126/science.1136606; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269; Pedraza LG, 2004, ONCOGENE, V23, P4754, DOI 10.1038/sj.onc.1207635; Perdigoto CN, 2011, DEVELOPMENT, V138, P4585, DOI 10.1242/dev.065292; Pesin JA, 2008, ANNU REV CELL DEV BI, V24, P475, DOI 10.1146/annurev.cellbio.041408.115949; Prathapam T, 2006, P NATL ACAD SCI USA, V103, P2695, DOI 10.1073/pnas.0511186103; Prieto-Echagile V., 2011, J SIGNAL TRANSDUCT, V2011; Prokopenko SN, 2005, SEMIN CELL DEV BIOL, V16, P423, DOI 10.1016/j.semcdb.2005.02.005; Quesnelle KM, 2007, J CELL BIOCHEM, V102, P311, DOI 10.1002/jcb.21475; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Reis T, 2004, CELL, V117, P253, DOI 10.1016/S0092-8674(04)00247-8; Ren FF, 2013, CELL RES, V23, P1133, DOI 10.1038/cr.2013.101; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Schaeffer V, 2004, CURR BIOL, V14, P630, DOI 10.1016/j.cub.2004.03.040; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schoenherr JA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002725; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Sem KP, 2002, MOL CELL BIOL, V22, P3685, DOI 10.1128/MCB.22.11.3685-3697.2002; Shaw RL, 2010, DEVELOPMENT, V137, P4147, DOI 10.1242/dev.052506; Shcherbata HR, 2004, DEVELOPMENT, V131, P3169, DOI 10.1242/dev.01172; Shibutani ST, 2008, DEV CELL, V15, P890, DOI 10.1016/j.devcel.2008.10.003; Shindo M, 2008, DEVELOPMENT, V135, P1355, DOI 10.1242/dev.015982; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Sotillos S, 2013, DEVELOPMENT, V140, P1507, DOI 10.1242/dev.092320; Stewart RA, 2003, ONCOGENE, V22, P6436, DOI 10.1038/sj.onc.1206820; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Vidal M, 2007, CANCER RES, V67, P10278, DOI 10.1158/0008-5472.CAN-07-1376; Wang HY, 2007, NATURE, V449, P96, DOI 10.1038/nature06056; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zeng XK, 2010, GENESIS, V48, P607, DOI 10.1002/dvg.20661; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zielke N, 2008, GENE DEV, V22, P1690, DOI 10.1101/gad.469108; Zielke N, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012948; Zielke N, 2011, NATURE, V480, P123, DOI 10.1038/nature10579	98	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2371	2384		10.1038/onc.2014.163	http://dx.doi.org/10.1038/onc.2014.163			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24975577				2022-12-17	WOS:000353824800010
J	Walsh, LA; Roy, DM; Reyngold, M; Giri, D; Snyder, A; Turcan, S; Badwe, CR; Lyman, J; Bromberg, J; King, TA; Chan, TA				Walsh, L. A.; Roy, D. M.; Reyngold, M.; Giri, D.; Snyder, A.; Turcan, S.; Badwe, C. R.; Lyman, J.; Bromberg, J.; King, T. A.; Chan, T. A.			RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR SYSTEM; ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; VEGF EXPRESSION; MATRIX METALLOPROTEINASE-2; CONSTITUTIVE ACTIVATION; SUPPRESSOR GENES; INHIBITOR RECK; KAZAL MOTIFS; STAT3	Metastasis is the primary cause of cancer-related death in oncology patients. A comprehensive understanding of the molecular mechanisms that cancer cells usurp to promote metastatic dissemination is critical for the development and implementation of novel diagnostic and treatment strategies. Here we show that the membrane protein RECK (Reversion-inducing cysteine-rich protein with kazal motifs) controls breast cancer metastasis by modulating a novel, non-canonical and convergent signal transducer and activator of transcription factor 3 (STAT3)-dependent angiogenic program. Neoangiogenesis and STAT3 hyperactivation are known to be fundamentally important for metastasis, but the root molecular initiators of these phenotypes are poorly understood. Our study identifies loss of RECK as a critical and previously unknown trigger for these hallmarks of metastasis. Using multiple xenograft mouse models, we comprehensively show that RECK inhibits metastasis, concomitant with a suppression of neoangiogenesis at secondary sites, while leaving primary tumor growth unaffected. Further, with functional genomics and biochemical dissection we demonstrate that RECK controls this angiogenic rheostat through a novel complex with cell surface receptors to regulate STAT3 activation, cytokine signaling, and the induction of both vascular endothelial growth factor and urokinase plasminogen activator. In accordance with these findings, inhibition of STAT3 can rescue this phenotype both in vitro and in vivo. Taken together, our study uncovers, for the first time, that RECK is a novel regulator of multiple well-established and robust mediators of metastasis; thus, RECK is a keystone protein that may be exploited in a clinical setting to target metastatic disease from multiple angles.	[Walsh, L. A.; Roy, D. M.; Snyder, A.; Turcan, S.; Chan, T. A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Roy, D. M.] Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY USA; [Reyngold, M.; Chan, T. A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Giri, D.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Snyder, A.; Bromberg, J.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Badwe, C. R.] Weill Grad Sch Med Sci, New York, NY USA; [Lyman, J.; King, T. A.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave,Box 20, New York, NY 10065 USA.	chant@mskcc.org	Chan, Timothy A/ABD-5850-2021	Turcan, Sevin/0000-0002-0885-5607; Snyder Charen, Alexandra/0000-0002-2606-3523; Walsh, Logan/0000-0001-8771-2577	Department of Defense (DOD) [BC120568]; Frederick Adler Fund; Avon Foundation; Elsa Pardee foundation; MSKCC Metastasis Center; STARR Cancer Consortium; Canadian Institutes of Health Research PDF Award [MFE-127325]; HHMI Research Fellows Program; NIH MSTP grant [T32GM007739]; Ruth L. Kirschstein National Research Award (NRSA) from the National Cancer Institute [T32CA009512]; NIH [5T32CA160001]; NATIONAL CANCER INSTITUTE [P30CA008748, T32CA160001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER	Department of Defense (DOD)(United States Department of Defense); Frederick Adler Fund; Avon Foundation; Elsa Pardee foundation; MSKCC Metastasis Center; STARR Cancer Consortium; Canadian Institutes of Health Research PDF Award; HHMI Research Fellows Program; NIH MSTP grant; Ruth L. Kirschstein National Research Award (NRSA) from the National Cancer Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Agnes Viale and Russell Towers for technical assistance. We are indebted to Joan Massague (Memorial Sloan-Kettering Cancer Center) for generously providing cell lines and some constructs. We are grateful to the entire Tumour Procurement Service at MSKCC for facilitating tissue procurement and contributing valuable input. This work was supported by grants from the Department of Defense (DOD) (grant no. BC120568), the Frederick Adler Fund, the Avon Foundation, the Elsa Pardee foundation, the MSKCC Metastasis Center and the STARR Cancer Consortium (all to TAC). LAW was supported by The Canadian Institutes of Health Research PDF Award MFE-127325. DMR was supported by the HHMI Research Fellows Program and NIH MSTP grant T32GM007739. AS was supported by the Ruth L. Kirschstein National Research Award (NRSA) number T32CA009512 from the National Cancer Institute. ST was supported by an NIH T32 grant (5T32CA160001).	Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680; Bid HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035513; Bournazou Eirini, 2013, JAKSTAT, V2, pe23828, DOI 10.4161/jkst.23828; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Carbajo-Pescador S, 2013, BRIT J CANCER, V109, P83, DOI 10.1038/bjc.2013.285; Cardoso F, 2012, ANN ONCOL, V23, P11, DOI 10.1093/annonc/mds232; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chandana EPS, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-84; Chang CK, 2008, J CELL MOL MED, V12, P2781, DOI 10.1111/j.1582-4934.2008.00215.x; Chang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685; Cho CY, 2007, J CELL PHYSIOL, V213, P65, DOI 10.1002/jcp.21089; Choong PFM, 2003, CLIN ORTHOP RELAT R, pS46, DOI 10.1097/01.blo.0000093845.72468.bd; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; D'Haene N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067029; Cardeal LBD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033585; Dong QA, 2010, INT J EXP PATHOL, V91, P368, DOI 10.1111/j.1365-2613.2010.00724.x; Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Gu FM, 2011, WORLD J GASTROENTERO, V17, P3922, DOI 10.3748/wjg.v17.i34.3922; Han L, 2012, CNS NEUROSCI THER, V18, P573, DOI 10.1111/j.1755-5949.2012.00344.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Huang C, 2012, CYTOKINE GROWTH F R, V23, P25, DOI 10.1016/j.cytogfr.2012.01.003; Huang GY, 2014, STEM CELLS, V32, P1149, DOI 10.1002/stem.1609; Ishikawa S, 2004, CLIN CANCER RES, V10, P6579, DOI 10.1158/1078-0432.CCR-04-0272; Jeon HW, 2010, MOL CANCER THER, V9, P1361, DOI 10.1158/1535-7163.MCT-09-0717; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Kang SH, 2010, NEUROSURGERY, V67, P1386, DOI 10.1227/NEU.0b013e3181f1c0cd; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kim JH, 2010, BIOCHEM PHARMACOL, V79, P373, DOI 10.1016/j.bcp.2009.09.008; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Le QT, 2005, J CLIN ONCOL, V23, P8932, DOI 10.1200/JCO.2005.02.0206; Lee MMK, 2012, J IMMUNOL, V189, P5266, DOI 10.4049/jimmunol.1103359; Lin HY, 2013, BRIT J CANCER, V109, P731, DOI 10.1038/bjc.2013.349; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Noda M, 2010, FUTURE ONCOL, V6, P1105, DOI [10.2217/fon.10.80, 10.2217/FON.10.80]; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Onishi A, 2008, EXP CELL RES, V314, P377, DOI 10.1016/j.yexcr.2007.09.018; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Prabhu VV, 2012, ASIAN PAC J CANCER P, V13, P3539, DOI 10.7314/APJCP.2012.13.8.3539; Prendergast A, 2012, DEVELOPMENT, V139, P1141, DOI 10.1242/dev.072439; Rabien A, 2012, PROSTATE, V72, P948, DOI 10.1002/pros.21498; Roomi MW, 2009, ONCOL REP, V21, P1323, DOI 10.3892/or_00000358; Rosenkilde MM, 2004, APMIS, V112, P481, DOI 10.1111/j.1600-0463.2004.apm11207-0808.x; Sasahara RM, 2002, CANCER DETECT PREV, V26, P435, DOI 10.1016/S0361-090X(02)00123-X; Selander KS, 2004, CANCER RES, V64, P6924, DOI 10.1158/0008-5472.CAN-03-2516; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Shoushtari AN, 2011, NAT REV CLIN ONCOL, V8, P333, DOI 10.1038/nrclinonc.2011.65; Sriuranpong V, 2003, CANCER RES, V63, P2948; Tang LL, 2013, BIOMED PHARMACOTHER, V67, P179, DOI 10.1016/j.biopha.2012.10.003; Thummarati P, 2012, WORLD J GASTROENTERO, V18, P244, DOI 10.3748/wjg.v18.i3.244; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Zarogoulidis Paul, 2013, Immunome Res, V9, P16535, DOI 10.1186/2090-5009-9-1; Zeng L, 2010, CYTOKINE, V49, P294, DOI 10.1016/j.cyto.2009.11.015; Zhang B, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-427; Zhang CS, 2012, INT J BIOL SCI, V8, P451, DOI 10.7150/ijbs.4038; Zhao Y, 2008, BIOCHEM BIOPH RES CO, V369, P1215, DOI 10.1016/j.bbrc.2008.03.038; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	64	28	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2189	2203		10.1038/onc.2014.175	http://dx.doi.org/10.1038/onc.2014.175			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24931164	Green Accepted			2022-12-17	WOS:000353473000005
J	Zhang, J; Pan, YF; Ding, ZW; Yang, GZ; Tan, YX; Yang, C; Jiang, TY; Liu, LJ; Zhang, B; Han, T; Cao, D; Yang, T; Yang, N; Wu, MC; Dong, LW; Wang, HY				Zhang, J.; Pan, Y-F; Ding, Z-W; Yang, G-Z; Tan, Y-X; Yang, C.; Jiang, T-Y; Liu, L-J; Zhang, B.; Han, T.; Cao, D.; Yang, T.; Yang, N.; Wu, M-C; Dong, L-W; Wang, H-Y			RMP promotes venous metastases of hepatocellular carcinoma through promoting IL-6 transcription	ONCOGENE			English	Article							RNA-POLYMERASE-II; VIRUS X PROTEIN; NF-KAPPA-B; CANCER-CELLS; LIVER-CANCER; HEPATITIS-B; SERUM INTERLEUKIN-6; STEM-CELLS; EXPRESSION; PROLIFERATION	Hepatocellular carcinoma (HCC) is believed to arise from tumor-initiating cells (T-ICs), which are responsible for tumor relapse and metastases. Portal vein tumor thrombus (PVTT) is raised from HCC and strongly correlated to a poor prognosis. However, the mechanism underling the formation of PVTT is largely unknown. Herein, we provide evidence that RNA polymerase II subunit 5 (RPB5)-mediating protein (RMP) was progressively upregulated in PVTT and overexpressed RMP appeared to increase T-ICs self-renewal. Moreover, RMP promoted metastases of PVTT cells and HCC cells in vitro and in vivo. Knockdown of RMP attenuated T-ICs self-renewal and reversed epithelial-mesenchymal transition (EMT) in HCC and PVTT cells. The neutralizing assays suggested that interleukin-6 (IL-6) had an indispensable role in RMP regulating metastases and self-renewal of HCC cells. Furthermore, the transcription of IL-6 was verified to be modulated by RMP via interaction with p65 and RPB5, through which expanding the T-IC/cancer stem cell populations, as well as inducing EMT was promoted. These results suggested that RMP may promote PVTT formation by promoting IL-6 transcription. Thus, RMP serves as a potent factor contributed to develop PVTT and a promising therapeutic target for HCC patients.	[Zhang, J.; Pan, Y-F; Ding, Z-W; Yang, G-Z; Tan, Y-X; Yang, C.; Jiang, T-Y; Liu, L-J; Zhang, B.; Han, T.; Cao, D.; Dong, L-W; Wang, H-Y] Natl Ctr Liver Canc, Shanghai, Peoples R China; [Zhang, J.; Pan, Y-F; Ding, Z-W; Yang, G-Z; Tan, Y-X; Yang, C.; Jiang, T-Y; Liu, L-J; Zhang, B.; Han, T.; Cao, D.; Dong, L-W; Wang, H-Y] Second Mil Med Univ, Eastern Hepatobiliary Surg Inst, Int Cooperat Lab Signal Transduct, Shanghai 200438, Peoples R China; [Yang, T.; Yang, N.; Wu, M-C] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Surg, Shanghai 200438, Peoples R China; [Wang, H-Y] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200030, Peoples R China	Naval Medical University; Naval Medical University; Shanghai Jiao Tong University	Wang, HY (corresponding author), Second Mil Med Univ, Eastern Hepatobiliary Surg Inst, Int Cooperat Lab Signal Transduct, 225 Changhai Rd, Shanghai 200438, Peoples R China.	donliwei@126.com; hywangk@vip.sina.com	Yang, Tian/W-6668-2019; Yang, Tian/M-5484-2018	Yang, Tian/0000-0003-1544-0976; Dong, Li-Wei/0000-0003-2116-1674	National Natural Science Foundation of China [81370066, 81372355, 81001075, 91229205, BWS11J036]; Funds for Creative Research Groups of China [81221061]; State Key Project for Liver Cancer [2012ZX10002-009, 2013ZX10002-010]; Stem Cell and Medicine Research Center's Innovation Research Program of the Second Military Medical University [SCMRC1306]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Funds for Creative Research Groups of China(Science Fund for Creative Research Groups); State Key Project for Liver Cancer; Stem Cell and Medicine Research Center's Innovation Research Program of the Second Military Medical University	We thank Liang Tang, Dong-Ping Hu, Shan-Na Huang, Dan-Dan Huang, Shan-Hua Tang, Lin-Na Guo and Huan-Lin Sun for technical assistance. We thank Dr Xiao-Ni Kong for providing luciferase reporter constructs and Ad-caSTAT3 virus. This work was supported by grants from National Natural Science Foundation of China (81370066, 81372355, 81001075, 91229205, BWS11J036), the Funds for Creative Research Groups of China (81221061) and the State Key Project for Liver Cancer (2012ZX10002-009, 2013ZX10002-010), Stem Cell and Medicine Research Center's Innovation Research Program of the Second Military Medical University (SCMRC1306).	Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; dGM Acker J, 1997, J BIOL CHEM, V272, P16815; Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; He GB, 2013, CELL, V155, P384, DOI 10.1016/j.cell.2013.09.031; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Jang JW, 2012, CYTOKINE, V60, P686, DOI 10.1016/j.cyto.2012.07.017; Ji JF, 2012, SEMIN ONCOL, V39, P461, DOI 10.1053/j.seminoncol.2012.05.011; JOHNSON C, 2012, NATL GEOGR, V222, P6; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Nakagawa H, 2009, INT J CANCER, V125, P2264, DOI 10.1002/ijc.24720; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Parusel CT, 2006, DEVELOPMENT, V133, P621, DOI 10.1242/dev.02235; Portolani N, 2006, ANN SURG, V243, P229, DOI 10.1097/01.sla.0000197706.21803.a1; Spooren A, 2010, CELL SIGNAL, V22, P871, DOI 10.1016/j.cellsig.2010.01.018; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Theurillat JP, 2011, CANCER CELL, V19, P317, DOI 10.1016/j.ccr.2011.01.019; Wang Q, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-271; Wang T, 2010, BRIT J CANCER, V102, P1618, DOI 10.1038/sj.bjc.6605689; Wei WX, 2001, J BIOL CHEM, V276, P12266, DOI 10.1074/jbc.M009634200; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Wong VWS, 2009, INT J CANCER, V124, P2766, DOI 10.1002/ijc.24281; Xiang WQ, 2011, J HEPATOL, V54, P26, DOI 10.1016/j.jhep.2010.08.006; Yamashita T, 2010, CANCER RES, V70, P4687, DOI 10.1158/0008-5472.CAN-09-4210; Yang SJ, 2013, INT J BIOL SCI, V9, P637, DOI 10.7150/ijbs.6439; Yoon S, 2010, AUTOPHAGY, V6, P1125, DOI 10.4161/auto.6.8.13547; Zhang YQ, 2010, CLIN CANCER RES, V16, P1423, DOI 10.1158/1078-0432.CCR-09-2405	31	28	32	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1575	1583		10.1038/onc.2014.84	http://dx.doi.org/10.1038/onc.2014.84			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704835				2022-12-17	WOS:000351416800010
J	Wang, WL; Huang, HC; Kao, SH; Hsu, YC; Wang, YT; Li, KC; Chen, YJ; Yu, SL; Wang, SP; Hsiao, TH; Yang, PC; Hong, TM				Wang, W-L; Huang, H-C; Kao, S-H; Hsu, Y-C; Wang, Y-T; Li, K-C; Chen, Y-J; Yu, S-L; Wang, S-P; Hsiao, T-H; Yang, P-C; Hong, T-M			Slug is temporally regulated by cyclin E in cell cycle and controls genome stability	ONCOGENE			English	Article							REPRESSES E-CADHERIN; DEPENDENT KINASES; NEURAL CREST; EXPRESSION; CANCER; PROLIFERATION; DEGRADATION; INSTABILITY; TRANSCRIPTION; P27(KIP1)	The transcriptional repressor Slug is best known to control epithelial-mesenchymal transition (EMT) and promote cancer invasion/metastasis. In this study, we demonstrate that Slug is temporally regulated during cell cycle progression. At G1/S transition, cyclin E-cyclin-dependent kinase 2 mediates the phosphorylation of Slug at Ser-54 and Ser-104, resulting in its ubiquitylation and degradation. Non-phosphorylatable Slug is markedly stabilized at G1/S transition compared with wild-type Slug and greatly leads to downregulation of DNA synthesis and checkpoint-related proteins, including TOP1, DNA Ligase IV and Rad17, reduces cell proliferation, delays S-phase progression and contributes to genome instability. Our results indicate that Slug has multifaceted roles in cancer progression by controlling both EMT and genome stability.	[Wang, W-L; Kao, S-H; Wang, S-P; Yang, P-C] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Wang, W-L; Hong, T-M] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan 704, Taiwan; [Huang, H-C] Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei 10764, Taiwan; [Kao, S-H; Hsiao, T-H; Yang, P-C] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Hsu, Y-C; Li, K-C] Acad Sinica, Inst Stat Sci, Taipei 115, Taiwan; [Wang, Y-T; Chen, Y-J] Acad Sinica, Taiwan Int Grad Program, Chem Biol & Mol Biophys Program, Taipei 115, Taiwan; [Wang, Y-T; Chen, Y-J] Acad Sinica, Inst Chem, Taipei 115, Taiwan; [Yu, S-L] Natl Taiwan Univ, Coll Med, Dept Clin, Lab Sci & Med Biotechnol, Taipei 10764, Taiwan; [Yang, P-C] Natl Taiwan Univ, Coll Med, NTU Ctr Genom Med, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Cheng Kung University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University	Hong, TM (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, 138 Sheng Li Rd, Tainan 704, Taiwan.	tmhong@mail.ncku.edu.tw	Li, Ker-Chau/AAQ-4886-2021; Chen, Yu-Ju/E-9481-2015; Wang, Shu-Ping/S-4379-2018	Chen, Yu-Ju/0000-0002-3178-6697; Wang, Shu-Ping/0000-0002-5895-1269; YANG, PAN-CHYR/0000-0001-6330-6048; YU, SUNG-LIANG/0000-0003-4535-9036	Human Frontier Science Program long-term fellowship; National Science Council [NSC99-2628-B-006-031-MY3, NSC101-2325-B-006-018, NSC100-2321-B-002-071, NSC101-2321-B-002-068, NSC102-2811-B-002-069]; National Taiwan University [101R7601-2]	Human Frontier Science Program long-term fellowship(Human Frontier Science Program); National Science Council(Ministry of Science and Technology, Taiwan); National Taiwan University(National Taiwan University)	The proteomics data analysis by LTQ-Orbitrap XL hybrid mass spectrometer was performed by the Academia Sinica Common Mass Spectrometry Facilities located at the Institute of Biological Chemistry, Taipei, Taiwan. shRNA constructs were obtained from the National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taipei, Taiwan. We thank Szu-Hua Pan, Pei-Fang Hung and Shu-Wei Lin for technical assistance. S-PW is supported by a Human Frontier Science Program long-term fellowship. This work was supported by grants from the National Science Council (NSC99-2628-B-006-031-MY3, NSC101-2325-B-006-018, NSC100-2321-B-002-071, NSC101-2321-B-002-068 and NSC102-2811-B-002-069) and National Taiwan University (101R7601-2).	Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Baygi ME, 2010, TUMOR BIOL, V31, P297, DOI 10.1007/s13277-010-0037-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Hajra KM, 2002, CANCER RES, V62, P1613; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Liu J, 2010, PROSTATE, V70, P1768, DOI 10.1002/pros.21213; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; MAYOR R, 1995, DEVELOPMENT, V121, P767; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Sakaue-Sawano A, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-2; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Siu KT, 2012, CELL CYCLE, V11, P57, DOI 10.4161/cc.11.1.18775; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Turner FE, 2006, J BIOL CHEM, V281, P21321, DOI 10.1074/jbc.M509731200; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vernon AE, 2006, DEVELOPMENT, V133, P3359, DOI 10.1242/dev.02504; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Yuan A, 2002, J CLIN ONCOL, V20, P900, DOI 10.1200/JCO.20.4.900; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	32	28	28	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1116	1125		10.1038/onc.2014.58	http://dx.doi.org/10.1038/onc.2014.58			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662826				2022-12-17	WOS:000350122100005
J	Wolf, J; Muller-Decker, K; Flechtenmacher, C; Zhang, F; Shahmoradgoli, M; Mills, GB; Hoheisel, JD; Boettcher, M				Wolf, J.; Mueller-Decker, K.; Flechtenmacher, C.; Zhang, F.; Shahmoradgoli, M.; Mills, G. B.; Hoheisel, J. D.; Boettcher, M.			An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation	ONCOGENE			English	Article						In vivo RNAi screening; shRNA screen; tumor suppressor; SALL1; CDH1; EMT	EPITHELIAL-MESENCHYMAL TRANSITION; TOWNES-BROCKS-SYNDROME; EXPRESSION; CELLS; CARCINOMAS; MUTATIONS; MOESIN; GENES	The gold standard for determining the tumorigenic potential of human cancer cells is a xenotransplantation into immunodeficient mice. Higher tumorigenicity of cells is associated with earlier tumor onset. Here, we used xenotransplantation to assess the tumorigenic potential of human breast cancer cells following RNA interference-mediated inhibition of over 5000 genes. We identify 16 candidate tumor suppressors, one of which is the zinc-finger transcription factor SALL1. Analyzing this particular molecule in more detail, we show that inhibition of SALL1 correlates with reduced levels of CDH1, an important contributor to epithelial-to-mesenchymal transition. Furthermore, SALL1 expression led to an increased migration and more than twice as many cells expressing a cancer stem cell signature. Also, SALL1 expression correlates with the survival of breast cancer patients. These findings cast new light on a gene that has previously been described to be relevant during embryogenesis, but not carcinogenesis.	[Wolf, J.; Hoheisel, J. D.; Boettcher, M.] Deutsch Krebsforschungszentrum, Div Funct Genome Anal, D-69120 Heidelberg, Germany; [Mueller-Decker, K.] Deutsch Krebsforschungszentrum, Core Facil Tumor Models, D-69120 Heidelberg, Germany; [Flechtenmacher, C.] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany; [Zhang, F.; Shahmoradgoli, M.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Texas System; UTMD Anderson Cancer Center	Hoheisel, JD (corresponding author), Deutsch Krebsforschungszentrum, Div Funct Genome Anal, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	j.hoheisel@dkfz.de		Boettcher, Michael/0000-0003-0986-4465	DKFZ; DKFZ PhD scholarship; NIH [44RR024095, 44HG003355]	DKFZ(Helmholtz Association); DKFZ PhD scholarship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a grant from the DKFZ intramural funding program awarded to MB, and a DKFZ PhD scholarship awarded to JW. Lentiviral shRNA libraries were kindly provided and developed by Cellecta based on NIH-funded research grant support 44RR024095, 44HG003355.	Argos M, 2008, CANCER GENET CYTOGEN, V182, P69, DOI 10.1016/j.cancergencyto.2008.01.001; Bric A, 2009, CANCER CELL, V16, P324, DOI 10.1016/j.ccr.2009.08.015; Chien WW, 2011, INT J ONCOL, V38, P1741, DOI 10.3892/ijo.2011.985; Chin SF, 2007, ONCOGENE, V26, P1959, DOI 10.1038/sj.onc.1209985; de Celis JF, 2009, INT J DEV BIOL, V53, P1385, DOI 10.1387/ijdb.072408jd; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Fredebohm J, 2013, J CELL SCI, V126, P3380, DOI 10.1242/jcs.124768; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119; Hill VK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-51; Hsu TH, 2012, FEBS LETT, V586, P1287, DOI 10.1016/j.febslet.2012.03.020; Jing C, 2002, JNCI-J NATL CANCER I, V94, P482; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Karantzali E, 2011, J BIOL CHEM, V286, P1037, DOI 10.1074/jbc.M110.170050; Kiefer SM, 2010, DEVELOPMENT, V137, P3099, DOI 10.1242/dev.037812; Kohlhase J, 2000, HUM MUTAT, V16, P460, DOI 10.1002/1098-1004(200012)16:6<460::AID-HUMU2>3.0.CO;2-4; Krelin Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062124; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Loi S, 2010, P NATL ACAD SCI USA, V107, P10208, DOI 10.1073/pnas.0907011107; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; Netzer C, 2001, HUM MOL GENET, V10, P3017, DOI 10.1093/hmg/10.26.3017; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Wang CC, 2012, HISTOPATHOLOGY, V61, P78, DOI 10.1111/j.1365-2559.2012.04204.x; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061	34	28	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4273	4278		10.1038/onc.2013.515	http://dx.doi.org/10.1038/onc.2013.515			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24292671	Green Accepted, hybrid			2022-12-17	WOS:000341155800009
J	Rosenfeldt, MT; Bell, LA; Long, JS; O'Prey, J; Nixon, C; Roberts, F; Dufes, C; Ryan, KM				Rosenfeldt, M. T.; Bell, L. A.; Long, J. S.; O'Prey, J.; Nixon, C.; Roberts, F.; Dufes, C.; Ryan, K. M.			E2F1 drives chemotherapeutic drug resistance via ABCG2	ONCOGENE			English	Article						E2F1; ABCG2; cancer; drug sensitivity; multidrug transporters	MULTIDRUG-RESISTANCE; PROTEIN; CANCER; EXPRESSION; DEATH; TRANSCRIPTION; PHEOPHORBIDE; INHIBITION; APOPTOSIS; AUTOPHAGY	Multidrug resistance is a major barrier against successful chemotherapy, and this has been shown in vitro to be often caused by ATP-binding cassette (ABC) transporters. These transporters are frequently overexpressed in human cancers and confer an adverse prognosis in many common malignancies. The genetic factors, however, that initiate their expression in cancer are largely unknown. Here we report that the major multidrug transporter ABCG2 (BCRP/MXR) is directly and specifically activated by the transcription factor E2F1-a factor perturbed in the majority of human cancers. E2F1 regulates ABCG2 expression in multiple cell systems, and, importantly, we have identified a significant correlation between elevated E2F1 and ABCG2 expression in human lung cancers. We show that E2F1 causes chemotherapeutic drug efflux both in vitro and in vivo via ABCG2. Furthermore, the E2F1-ABCG2 axis suppresses chemotherapy-induced cell death that can be restored by the inhibition of ABCG2. These findings therefore identify a new axis in multidrug resistance and highlight a radical new function of E2F1 that is relevant to tumor therapy.	[Rosenfeldt, M. T.; Bell, L. A.; Long, J. S.; O'Prey, J.; Nixon, C.; Ryan, K. M.] Canc Res UK Beatson Inst, Tumour Cell Death Lab, Glasgow, Lanark, Scotland; [Roberts, F.] Univ Glasgow, Western Infirm, Dept Pathol, Glasgow G11 6NT, Lanark, Scotland; [Dufes, C.] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland	Beatson Institute; University of Glasgow; University of Strathclyde	Ryan, KM (corresponding author), Canc Res UK Beatson Inst Canc Res, Tumour Cell Death Lab, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.ryan@beatson.gla.ac.uk	Rosenfeldt, Mathias/ABE-4736-2022; Dufès, Christine/AAQ-1604-2021	Rosenfeldt, Mathias/0000-0001-7650-8458; Dufès, Christine/0000-0002-7963-6364; Ryan, Kevin M./0000-0002-1059-9681	Association for International Cancer Research and Cancer Research UK; Wellcome trust [ME0442]; Cancer Research UK [15816] Funding Source: researchfish; Worldwide Cancer Research [12-1262] Funding Source: researchfish	Association for International Cancer Research and Cancer Research UK; Wellcome trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	This work was supported by Association for International Cancer Research and Cancer Research UK, and by a Wellcome trust equipment grant (ME0442) to CD. We thank Doron Ginsberg, Kristian Helin, Douglas Ross and Karen Vousden for reagents.	Alla V, 2012, CELL CYCLE, V11, P3067, DOI 10.4161/cc.21476; Allen JD, 2002, MOL CANCER THER, V1, P417; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Bell HS, 2007, J CLIN INVEST, V117, P1008, DOI 10.1172/JCI28920; Bell LA, 2006, ONCOGENE, V25, P5656, DOI 10.1038/sj.onc.1209580; Bui-Xuan NH, 2010, J ETHNOPHARMACOL, V131, P95, DOI 10.1016/j.jep.2010.06.007; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575; Eymin B, 2001, ONCOGENE, V20, P1678, DOI 10.1038/sj.onc.1204242; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Helgason GV, 2010, CANCER RES, V70, P4074, DOI 10.1158/0008-5472.CAN-09-2876; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Natarajan K, 2012, BIOCHEM PHARMACOL, V83, P1084, DOI 10.1016/j.bcp.2012.01.002; Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Robey RW, 2009, ADV DRUG DELIVER REV, V61, P3, DOI 10.1016/j.addr.2008.11.003; Robey RW, 2004, CANCER RES, V64, P1242, DOI 10.1158/0008-5472.CAN-03-3298; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Stewart DJ, 2010, CRIT REV ONCOL HEMAT, V75, P173, DOI 10.1016/j.critrevonc.2009.11.006; Wu ZL, 2009, INT J BIOCHEM CELL B, V41, P2389, DOI 10.1016/j.biocel.2009.06.004; Zhang W, 2009, DRUG METAB DISPOS, V37, P737, DOI 10.1124/dmd.108.023309; Zhang YM, 2007, CANCER RES, V67, P9389, DOI 10.1158/0008-5472.CAN-07-0944; Zhang YM, 2009, CANCER RES, V69, P5867, DOI 10.1158/0008-5472.CAN-08-4866	27	28	30	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4164	4172		10.1038/onc.2013.470	http://dx.doi.org/10.1038/onc.2013.470			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24276245	hybrid, Green Accepted			2022-12-17	WOS:000340595700007
J	Pang, CL; Toh, SY; He, P; Teissier, S; Ben Khalifa, Y; Xue, Y; Thierry, F				Pang, C. L.; Toh, S. Y.; He, P.; Teissier, S.; Ben Khalifa, Y.; Xue, Y.; Thierry, F.			A functional interaction of E7 with B-Myb-MuvB complex promotes acute cooperative transcriptional activation of both S- and M-phase genes	ONCOGENE			English	Article						B-Myb-MuvB complex; HPV E7; B-Myb; FoxM1; mitosis; cervical carcinoma	HUMAN-PAPILLOMAVIRUS E7; CERVICAL-CANCER CELLS; DROSOPHILA-MYB; MITOTIC PATHWAY; CARCINOMA CELLS; E2 PROTEIN; EXPRESSION; FOXM1; PROGRESSION; SENESCENCE	High-risk human papillomaviruses are causative agents of cervical cancer. Viral protein E7 is required to establish and maintain the pro-oncogenic phenotype in infected cells, but the molecular mechanisms by which E7 promotes carcinogenesis are only partially understood. Our transcriptome analyses in primary human fibroblasts transduced with the viral protein revealed that E7 activates a group of mitotic genes via the activator B-Myb-MuvB complex. We show that E7 interacts with the B-Myb, FoxM1 and LIN9 components of this activator complex, leading to cooperative transcriptional activation of mitotic genes in primary cells and E7 recruitment to the corresponding promoters. E7 interaction with LIN9 and FoxM1 depended on the LXCXE motif, which is also required for pocket protein interaction and degradation. Using E7 mutants for the degradation of pocket proteins but intact for the LXCXE motif, we demonstrate that E7 functional interaction with the B-Myb-MuvB complex and pocket protein degradation are two discrete functions of the viral protein that cooperate to promote acute transcriptional activation of mitotic genes. Transcriptional level of E7 in patient's cervical lesions at different stages of progression was shown to correlate with those of B-Myb and FoxM1 as well as other mitotic gene transcripts, thereby linking E7 with cellular proliferation and progression in cervical cancer in vivo. E7 thus can directly activate the transcriptional levels of cell cycle genes independently of pocket protein stability.	[Pang, C. L.; Toh, S. Y.; He, P.; Teissier, S.; Xue, Y.; Thierry, F.] ASTAR, Inst Med Biol, Singapore 138648, Singapore; [Pang, C. L.] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; [Ben Khalifa, Y.] Inst Pasteur, Paris, France	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); National University of Singapore; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Thierry, F (corresponding author), ASTAR, Inst Med Biol, Immunos 06-05,8A Biomed Grove, Singapore 138648, Singapore.	francoise.thierry@imb.a-star.edu.sg		Toh, Shen Yon/0000-0002-6421-0862	Biomedical Sciences Institutes of A-star, Singapore	Biomedical Sciences Institutes of A-star, Singapore	We thank Dr DeCaprio for the generous gift of LIN9 and LIN54 antibodies and Birgit lane's lab for providing the primary human fibroblasts. We also thank Dr Perou for plasmid pBABE-B-Myb; Dr Teh for plasmid pSIN-CMV-FoxM1B; Dr Galloway for plasmids pLXSN-16E7, pLXSN-16E7D6 - 10 and pLXSN-16E7D21 - 24; Dr Manser for plasmid pXJ-Flag; Dr Colamonici for plasmid pEGFP-C3-LIN9; Dr Roman for plasmid pHA-p130; Dr Sage for shRNA vectors for pRB, p107 and p130. We would like to express our thanks to Dr Diana Lim from National University Hospital for providing us with the clinical specimens, Drs Zhi Liang and Jean-Pierre Abastado for help in the nanostring experiment design and analyses and John Connolly from SIgN Immunomonitoring Core. We would like to express our thanks to Dr Philipp Kaldis for valuable suggestions. We also greatly appreciate the careful reading of the manuscript by Dr Neil McCarthy of Insight Editing London. This work was supported by Biomedical Sciences Institutes of A-star, Singapore and Chai Ling Pang was a scholar of the National University of Singapore Graduate School for Integrative Science and Engineering.	Alvarez-Fernandez M, 2010, EMBO REP, V11, P452, DOI 10.1038/embor.2010.46; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Buitrago-Perez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041743; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Down CF, 2012, BBA-GENE REGUL MECH, V1819, P855, DOI 10.1016/j.bbagrm.2012.03.008; Fung SM, 2002, DEVELOPMENT, V129, P347; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Georlette D, 2007, GENE DEV, V21, P2880, DOI 10.1101/gad.1600107; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Katzen AL, 1998, GENE DEV, V12, P831, DOI 10.1101/gad.12.6.831; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Li Q, 2009, CANCER RES, V69, P3501, DOI 10.1158/0008-5472.CAN-08-3045; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Manak R, 2007, NAT CELL BIOL, V9, P581, DOI 10.1038/ncb1580; Martinez I, 2011, CANCER RES, V71, P5370, DOI 10.1158/0008-5472.CAN-11-1044; McLaughlin-Drubin ME, 2009, VIROLOGY, V384, P335, DOI 10.1016/j.virol.2008.10.006; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Peter M, 2010, J PATHOL, V221, P320, DOI 10.1002/path.2713; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Rashid NN, 2011, J GEN VIROL, V92, P2620, DOI 10.1099/vir.0.035352-0; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Shepard JL, 2005, P NATL ACAD SCI USA, V102, P13194, DOI 10.1073/pnas.0506583102; Shin MK, 2012, CANCER RES, V72, P5418, DOI 10.1158/0008-5472.CAN-12-2083; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Teh MT, 2002, CANCER RES, V62, P4773; Teissier S, 2010, ONCOGENE, V29, P5061, DOI 10.1038/onc.2010.246; Teissier S, 2007, J VIROL, V81, P9368, DOI 10.1128/JVI.00427-07; Thierry F, 2004, CANCER RES, V64, P895, DOI 10.1158/0008-5472.CAN-03-2349; Ueno T, 2006, ONCOGENE, V25, P4155, DOI 10.1038/sj.onc.1209445; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wells SI, 2003, P NATL ACAD SCI USA, V100, P7093, DOI 10.1073/pnas.1232309100; Xue Yuezhen, 2012, Open Virol J, V6, P163, DOI 10.2174/1874357901206010163	46	28	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4039	4049		10.1038/onc.2013.426	http://dx.doi.org/10.1038/onc.2013.426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24141769				2022-12-17	WOS:000340595300003
J	Santini, S; Stagni, V; Giambruno, R; Fianco, G; Di Benedetto, A; Mottolese, M; Pellegrini, M; Barila, D				Santini, S.; Stagni, V.; Giambruno, R.; Fianco, G.; Di Benedetto, A.; Mottolese, M.; Pellegrini, M.; Barila, D.			ATM kinase activity modulates ITCH E3-ubiquitin ligase activity	ONCOGENE			English	Article						Ataxia Telangiectasia; ATM kinase; ITCH E3-ubiquitin ligase; c-FLIP-L; c-Jun; protein ubiquitination and degradation	E3 UBIQUITIN LIGASES; INDUCED CELL-DEATH; C-FLIPL; ACTIVATION; PROTEIN; DEGRADATION; APOPTOSIS; CASPASE-8; PHOSPHORYLATION; PROLIFERATION	Ataxia Telangiectasia Mutated (ATM) kinase, a central regulator of the DNA damage response, regulates the activity of several E3-ubiquitin ligases, and the ubiquitination-proteasome system is a consistent target of ATM. ITCH is an E3-ubiquitin ligase that modulates the ubiquitination of several targets, therefore participating to the regulation of several cellular responses, such as the DNA damage response, tumor necrosis factor alpha (TNF alpha), Notch and Hedgehog signaling, and the differentiation of 'naive' lymphocytes into T helper type 2 cells. Here we uncover ATM as a novel positive modulator of ITCH E3-ubiquitin ligase activity. A single residue on ITCH protein, S161, which is part of an ATM SQ consensus motif, is required for ATM-dependent activation of ITCH. ATM activity enhances ITCH enzymatic activity, which in turn drives the ubiquitination and degradation of c-FLIP-L and c-Jun, previously identified as ITCH substrates. Importantly, ATM-deficient mice show resistance to hepatocyte cell death, similarly to Itch-deficient animals, providing in vivo genetic evidence for this circuit. Our data identify ITCH as a novel component of the ATM-dependent signaling pathway and suggest that the impairment of the correct functionality of ITCH caused by Atm deficiency may contribute to the complex clinical features linked to Ataxia Telangiectasia.	[Santini, S.; Stagni, V.; Fianco, G.; Barila, D.] Univ Roma Tor Vergata, Dept Biol, I-00143 Rome, Italy; [Santini, S.; Stagni, V.; Fianco, G.; Barila, D.] Ist Ricovero Cura Carattere, Lab Cell Signaling, Rome, Italy; [Giambruno, R.] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria; [Di Benedetto, A.; Mottolese, M.] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Pellegrini, M.] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy	University of Rome Tor Vergata; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome	Barila, D (corresponding author), Univ Roma Tor Vergata, Dept Biol, Fdn Santa Lucia Via Fosso Fiorano 64, I-00143 Rome, Italy.	daniela.barila@uniroma2.it	Pellegrini, manuela/AAC-1423-2022; Barilà, Daniela/K-8506-2016; Giambruno, Roberto/W-4868-2017; Giambruno, Roberto/AAI-6717-2021	Barilà, Daniela/0000-0002-6192-1562; Giambruno, Roberto/0000-0002-4566-261X; Giambruno, Roberto/0000-0002-4566-261X; Di Benedetto, Anna/0000-0002-9853-8671; stagni, venturina/0000-0002-3971-0398; pellegrini, manuela/0000-0001-6387-5187	Italian Telethon Foundation 'Comitato Telethon Fondazione Onlus' [GGP07252]; AIRC [IG10590, MFAG8904, IG8706]; Fondazione Santa Lucia	Italian Telethon Foundation 'Comitato Telethon Fondazione Onlus'(Fondazione Telethon); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Santa Lucia	We acknowledge Y Shiloh, Y Lerenthal, M Kastan, J Melino, M Rossi, S Polo, D Bohmann and J Tschopp for kindly providing reagents; G Cesareni for critical reading of the manuscript; A Totaro for technical support for point mutagenesis; and D Giaccari for helping with the in vivo experiments performed in compliance with the 'Tor Vergata' University Institutional Animal Care. This work has been supported by research grants from Italian Telethon Foundation 'Comitato Telethon Fondazione Onlus' (GGP07252) and by AIRC (IG10590) to DB, AIRC (MFAG8904) to MP and AIRC (IG8706) to MM. SS has been supported by Fondazione Santa Lucia.	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Barila D, 2003, MOL CELL BIOL, V23, P2790, DOI 10.1128/MCB.23.8.2790-2799.2003; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Bhatti S, 2011, CELL MOL LIFE SCI, V68, P2977, DOI 10.1007/s00018-011-0683-9; Biton S, 2006, J BIOL CHEM, V281, P17482, DOI 10.1074/jbc.M601895200; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Cheng Q, 2010, CELL CYCLE, V9, P472, DOI 10.4161/cc.9.3.10556; Daugherity EK, 2012, CELL CYCLE, V11, P1918, DOI 10.4161/cc.20259; Di Marcotullio L, 2011, ONCOGENE, V30, P65, DOI 10.1038/onc.2010.394; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Gao BX, 2006, J BIOL CHEM, V281, P29711, DOI 10.1074/jbc.M604596200; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Gilot D, 2005, CARCINOGENESIS, V26, P2086, DOI 10.1093/carcin/bgi187; Hansen TM, 2007, BIOCHEM BIOPH RES CO, V361, P33, DOI 10.1016/j.bbrc.2007.06.104; Kee Y, 2007, BIOCHEM BIOPH RES CO, V354, P329, DOI 10.1016/j.bbrc.2007.01.025; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Liu YC, 2007, SEMIN IMMUNOL, V19, P197, DOI 10.1016/j.smim.2007.02.003; Matei IR, 2006, IMMUNOL REV, V209, P142, DOI 10.1111/j.0105-2896.2006.00361.x; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60; Mongiardi MP, 2011, CELL CYCLE, V10, P4311, DOI 10.4161/cc.10.24.18663; Mouchantaf R, 2006, J BIOL CHEM, V281, P38738, DOI 10.1074/jbc.M605959200; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Mu JJ, 2007, J BIOL CHEM, V282, P17330, DOI 10.1074/jbc.C700079200; Mund T, 2009, EMBO REP, V10, P501, DOI 10.1038/embor.2009.30; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Schattenberg JM, 2011, J HEPATOL, V55, P1272, DOI 10.1016/j.jhep.2011.03.008; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stagni V, 2008, BLOOD, V111, P829, DOI 10.1182/blood-2007-04-085399; Stagni V, 2010, CARCINOGENESIS, V31, P1956, DOI 10.1093/carcin/bgq193; Stokes MP, 2007, P NATL ACAD SCI USA, V104, P19855, DOI 10.1073/pnas.0707579104; Weizman N, 2003, J BIOL CHEM, V278, P6741, DOI 10.1074/jbc.M211168200; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Yang C, 2006, MOL CELL, V21, P135, DOI 10.1016/j.molcel.2005.11.014; Yu JW, 2008, ONCOGENE, V27, P6216, DOI 10.1038/onc.2008.299	38	28	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1113	1123		10.1038/onc.2013.52	http://dx.doi.org/10.1038/onc.2013.52			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23435430	Green Accepted			2022-12-17	WOS:000331933800005
J	Harris, IS; Blaser, H; Moreno, J; Treloar, AE; Gorrini, C; Sasaki, M; Mason, JM; Knobbe, CB; Rufini, A; Halle, M; Elia, AJ; Wakeham, A; Tremblay, ML; Melino, G; Done, S; Mak, TW				Harris, I. S.; Blaser, H.; Moreno, J.; Treloar, A. E.; Gorrini, C.; Sasaki, M.; Mason, J. M.; Knobbe, C. B.; Rufini, A.; Halle, M.; Elia, A. J.; Wakeham, A.; Tremblay, M. L.; Melino, G.; Done, S.; Mak, T. W.			PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling	ONCOGENE			English	Article						oxidative stress; reactive oxygen species; antioxidant; protein tyrosine phosphatase; breast cancer	3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; BREAST-CANCER; TRANSCRIPTION FACTORS; REDOX REGULATION; APOPTOSIS; CELLS; PHOSPHORYLATION; METABOLISM; PEST; SGK	It is well known that protein tyrosine phosphatases (PTPs) that become oxidized due to exposure to reactive oxygen species (ROS) undergo a conformational change and are inactivated. However, whether PTPs can actively regulate ROS levels in order to prevent PTP inhibition has yet to be investigated. Here, we demonstrate that PTP non-receptor type 12 (PTPN12) protects cells against aberrant ROS accumulation and death induced by oxidative stress. Murine embryonic fibroblasts (MEFs) deficient in PTPN12 underwent increased ROS-induced apoptosis under conditions of antioxidant depletion. Cells lacking PTPN12 also showed defective activation of FOXO1/3a, transcription factors required for the upregulation of several antioxidant genes. PTPN12-mediated regulation of ROS appeared to be mediated by phosphoinositide-dependent kinase-1 (PDK1), which was hyperstimulated in the absence of PTPN12. As tight regulation of ROS to sustain survival is a key feature of cancer cells, we examined PTPN12 levels in tumors from a cohort of breast cancer patients. Patients whose tumors showed high levels of PTPN12 transcripts had a significantly poorer prognosis. Analysis of tissues from patients with various breast cancer subtypes revealed that more triple-negative breast cancers, the most aggressive breast cancer subtype, showed high PTPN12 expression than any other subtype. Furthermore, both human breast cancer cells and mouse mammary epithelial tumor cells engineered to lack PTPN12 exhibited reduced tumorigenic and metastatic potential in vivo that correlated with their elevated ROS levels. The involvement of PTPN12 in the antioxidant response of breast cancer cells suggests that PTPN12 may represent a novel therapeutic target for this disease.	[Harris, I. S.; Blaser, H.; Moreno, J.; Treloar, A. E.; Gorrini, C.; Sasaki, M.; Mason, J. M.; Knobbe, C. B.; Elia, A. J.; Wakeham, A.; Done, S.; Mak, T. W.] Univ Hlth Network, Princess Margaret Hosp, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada; [Harris, I. S.; Done, S.; Mak, T. W.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Moreno, J.; Done, S.] Univ Hlth Network, Lab Med Program, Toronto, ON M5G 2C1, Canada; [Moreno, J.; Done, S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Knobbe, C. B.] Univ Dusseldorf, Dept Neuropathol, Dusseldorf, Germany; [Rufini, A.; Melino, G.] Univ Leicester, MRC Toxicol Unit, Lab Apoptosis Canc, Leicester, Leics, England; [Halle, M.; Tremblay, M. L.] McGill Univ, Rosalind & Morris Goodman Canc Ctr, Dept Biochem, Montreal, PQ, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Heinrich Heine University Dusseldorf; University of Leicester; McGill University	Mak, TW (corresponding author), Univ Hlth Network, Princess Margaret Hosp, Campbell Family Inst Breast Canc Res, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.	tmak@uhnres.utoronto.ca	Knobbe-Thomsen, Christiane/J-4963-2014; Knobbe-Thomsen, Christiane B/D-3116-2019	Knobbe-Thomsen, Christiane/0000-0003-1231-0076; Gorrini, Chiara/0000-0002-5239-6671; Done, Susan/0000-0002-1770-988X; Harris, Isaac/0000-0002-6855-2763	Natural Sciences and Engineering Council of Canada; Canadian Institutes of Health Research [179815]; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	Natural Sciences and Engineering Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dr Anne Brustle and Dr Dirk Brenner for helpful discussions, Dr Han You and Dr Walbert Bakker for reagents and Dr Mary Saunders for insightful scientific editing. This work was supported by a PGS-D grant from the Natural Sciences and Engineering Council of Canada (ISH) and grant no. 179815 from the Canadian Institutes of Health Research (TWM).	Allred DC, 1998, MODERN PATHOL, V11, P155; Arpaia E, 2012, ONCOGENE, V31, P884, DOI 10.1038/onc.2011.288; Bailey HH, 1997, J NATL CANCER I, V89, P1789, DOI 10.1093/jnci/89.23.1789; Bakker WJ, 2007, MOL CELL, V28, P941, DOI 10.1016/j.molcel.2007.10.035; Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Cheng ZY, 2009, NAT MED, V15, P1307, DOI 10.1038/nm.2049; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; FORTELEONI G, 1988, TUMORI, V74, P665, DOI 10.1177/030089168807400608; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Karisch R, 2011, CELL, V146, P826, DOI 10.1016/j.cell.2011.07.020; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; Myatt SS, 2011, ANTIOXID REDOX SIGN, V14, P675, DOI 10.1089/ars.2010.3383; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Rogoff D, 2010, REDOX REP, V15, P64, DOI 10.1179/174329210X12650506623249; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Storz P, 2011, ANTIOXID REDOX SIGN, V14, P593, DOI 10.1089/ars.2010.3405; Streit S, 2006, CANCER GENET CYTOGEN, V170, P48, DOI 10.1016/j.cancergencyto.2006.05.013; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Vaughn AE, 2008, NAT CELL BIOL, V10, P1477, DOI 10.1038/ncb1807; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Yang KJ, 2008, J BIOL CHEM, V283, P1480, DOI 10.1074/jbc.M706361200; Yerushalmi R, 2012, BREAST CANCER RES TR, V132, P131, DOI 10.1007/s10549-011-1529-8	34	28	29	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1047	1054		10.1038/onc.2013.24	http://dx.doi.org/10.1038/onc.2013.24			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23435421				2022-12-17	WOS:000331933200012
J	Tripathi, V; Popescu, NC; Zimonjic, DB				Tripathi, V.; Popescu, N. C.; Zimonjic, D. B.			DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion	ONCOGENE			English	Article						E-cadherin; DLC1; Rho; invasion; prostate cancer	GTPASE-ACTIVATING PROTEIN; EPITHELIAL TUMOR-CELLS; HEPATOCELLULAR-CARCINOMA; ADHERENS JUNCTIONS; BREAST-CANCER; RHO/ROCK PATHWAY; GENE-EXPRESSION; FAMILY GTPASES; IN-VIVO; ADHESION	E-cadherin is a cell-cell adhesion molecule that acts as a suppressor of cancer cell invasion and its expression is downregulated in many advanced, poorly differentiated, human cancers. In this study, we found that the expression of DLC1 (deleted in liver cancer 1) tumor-suppressor gene in metastatic prostate carcinoma (PCA) cells increased the expression of E-cadherin and resulted in an elevated rate of cell-cell aggregation as measured by aggregation assay. DLC1-mediated increase in E-cadherin expression was not dependent on alpha-catenin, a DLC1-binding protein associated with E-cadherin, and/or cellular density. The increase of E-cadherin expression occurred at mRNA level and relied on DLC1 RhoGAP function, leading to suppression of high level of RhoA-GTP and RhoC-GTP activity in metastatic PCA cells. Application of Rho/ROCK inhibitors produced the same effect as introduction of DLC1. Knocking down of RhoA produced a moderate increase in E-cadherin whereas knocking down of RhoC resulted in a significant increase of E-cadherin. Downregulation of E-cadherin caused by constitutively active RhoA(V14) and RhoC(V14) could not be reversed by expression of DLC1 in DLC1-negative cell line. DLC1-mediated suppression of metastatic PCA cells invasion was comparable with the one associated with ectopic E-cadherin expression, or caused by suppression of Rho pathway either by Rho/ROCK inhibitors, or by shRNA repression. This study demonstrates that DLC1 expression positively regulates E-cadherin and suppresses highly metastatic PCA cell invasion by modulating Rho pathway, which appears as a feasible therapeutic target in cancers with high activity of RhoGTPases.	[Tripathi, V.; Popescu, N. C.; Zimonjic, D. B.] NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Expt Carcinogenesis Lab, NIH, Bldg 37,Room 4128B,37 Convent Dr,MSC 4262, Bethesda, MD 20892 USA.	popescun@mail.nih.gov	Zimonjic, Drazen/AAX-7513-2020		National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA	National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.	Annicotte JS, 2006, MOL CELL BIOL, V26, P7561, DOI 10.1128/MCB.00605-06; Asnaghi L, 2010, ONCOGENE, V29, P2760, DOI 10.1038/onc.2010.39; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Braga VMM, 2005, CURR OPIN CELL BIOL, V17, P466, DOI 10.1016/j.ceb.2005.08.012; Brouxhon S, 2007, CANCER RES, V67, P7654, DOI 10.1158/0008-5472.CAN-06-4415; Burbelo P, 2004, BREAST CANCER RES TR, V84, P43, DOI 10.1023/B:BREA.0000018422.02237.f9; Chang YWE, 2006, CANCER RES, V66, P11700, DOI 10.1158/0008-5472.CAN-06-1818; Cheng L, 1996, AM J PATHOL, V148, P1375; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Guan M, 2008, CANCER GENE THER, V15, P371, DOI 10.1038/cgt.2008.13; Guan M, 2006, CLIN CANCER RES, V12, P1412, DOI 10.1158/1078-0432.CCR-05-1906; Hajra KM, 2002, CANCER RES, V62, P1613; Healy KD, 2008, MOL CARCINOGEN, V47, P326, DOI 10.1002/mc.20389; Hodge JC, 2003, CANCER RES, V63, P1359; Jeong KJ, 2012, ONCOGENE, V31, P4279, DOI 10.1038/onc.2011.595; JIANG WG, 1995, CANCER RES, V55, P5043; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Koksal IT, 2002, PATHOLOGY, V34, P233, DOI 10.1080/00313020220131282; Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408; Li GR, 2011, P NATL ACAD SCI USA, V108, P17129, DOI 10.1073/pnas.1112122108; Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8; Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Mege RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Noe V, 2001, J CELL SCI, V114, P111; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104; Rashid MG, 2001, CANCER RES, V61, P489; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sawada K, 2008, METHOD ENZYMOL, V439, P395, DOI 10.1016/S0076-6879(07)00428-4; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Sequeira L, 2008, CLIN EXP METASTAS, V25, P569, DOI 10.1007/s10585-008-9173-3; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Thiolloy S, 2011, SEMIN CANCER BIOL, V21, P89, DOI 10.1016/j.semcancer.2010.12.008; Tripathi V, 2012, MOL CELL BIOL, V32, P2145, DOI 10.1128/MCB.06580-11; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wong CCL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002779; Wu M, 2010, CANCER-AM CANCER SOC, V116, P2768, DOI 10.1002/cncr.25181; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yam JWP, 2006, CANCER RES, V66, P8367, DOI 10.1158/0008-5472.CAN-05-2850; Zhou Q, 2009, MOL CANCER THER, V8, P1684, DOI 10.1158/1535-7163.MCT-09-0191; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246; Zimonjic DB, 2012, INT J ONCOL, V41, P393, DOI 10.3892/ijo.2012.1474	57	28	30	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					724	733		10.1038/onc.2013.7	http://dx.doi.org/10.1038/onc.2013.7			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23376848				2022-12-17	WOS:000331129200007
J	Zhai, C; Li, Y; Mascarenhas, C; Lin, Q; Li, K; Vyrides, I; Grant, CM; Panaretou, B				Zhai, C.; Li, Y.; Mascarenhas, C.; Lin, Q.; Li, K.; Vyrides, I.; Grant, C. M.; Panaretou, B.			The function of ORAOV1/LTO1, a gene that is overexpressed frequently in cancer: essential roles in the function and biogenesis of the ribosome	ONCOGENE			English	Article						ribosome biogenesis; translation; Fe - S cluster; squamous cell carcinoma	YEAST SACCHAROMYCES-CEREVISIAE; SQUAMOUS-CELL CARCINOMAS; NUCLEAR EXPORT; OXIDATIVE-STRESS; GLOBAL ANALYSIS; PROTEIN RLI1; ORAL-CANCER; TRANSLATION; 11Q13; ABCE1	ORAOV1 (oral cancer overexpressed) is overexpressed in many solid tumours, making a key contribution to the development of cancer, but the cellular role of ORAOV1 is unknown. The yeast orthologue of this protein is encoded by the hitherto uncharacterized essential gene, YNL260c. Expression of ORAOV1 restores viability to yeast cells lacking YNL260c. Under nonpermissive conditions, our conditional mutants of YNL260c are defective in the maturation of the 60S ribosomal subunit, whereas maturation of the 40S subunit is unaffected. Also, initiation of translation is abrogated when YNL260c function is lost. YNL260c is indispensible for life in oxygen, but is nonessential under anaerobic conditions. Consequently, the toxic affects of aerobic metabolism on biogenesis and function of the ribosome are alleviated by YNL260c, hence, we rename YNL260c as LTO1; required for biogenesis of the large ribosomal subunit and initiation of translation in oxygen. Lto1 is found in a complex with Rli1/ABCE1, an ATP-binding cassette (ABC)-ATPase bearing N-terminal [4Fe - 4S] clusters. Like Lto1, the Rli1/ABCE1 [4Fe - 4S] clusters are not required for viability under anaerobic conditions, but are essential in the presence of oxygen. Loss of Lto1 function renders cells susceptible to hydroperoxide pro-oxidants, though this type of sensitivity is specific to certain types of oxidative stress as the lto1 mutants are not sensitive to an agent that oxidizes thiols. These findings reflect a functional interaction between Lto1 and the Rli1/ABCE1 [4Fe - 4S] clusters, as part of a complex, which relieves the toxic effects of reactive oxygen species (ROS) on biogenesis and function of the ribosome. This complex also includes Yae1, which bridges the interaction between Lto1 and Rli1/ABCE1. Interactions between members of this complex were demonstrated both in vivo and in vitro. An increased generation of ROS is a feature shared by many cancers. The ORAOV1 complex could prevent ROS-induced ribosomal damage, explaining why overexpression of ORAOV1 is so common in solid tumours.	[Zhai, C.; Li, Y.; Lin, Q.; Li, K.; Vyrides, I.; Panaretou, B.] Kings Coll London, Inst Pharmaceut Sci, London SE1 9NH, England; [Mascarenhas, C.; Grant, C. M.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Li, K.] Chinese Acad Sci, Inst Hydrobiol, Wuhan, Peoples R China	University of London; King's College London; University of Manchester; Chinese Academy of Sciences; Institute of Hydrobiology, CAS	Panaretou, B (corresponding author), Kings Coll London, Inst Pharmaceut Sci, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England.	barry.panaretou@kcl.ac.uk	; Vyrides, Ioannis/D-1625-2016	Grant, Chris/0000-0002-0616-6576; Vyrides, Ioannis/0000-0001-8316-4577	National Natural Science Foundation of China [31100057]; BBSRC [BB/E00623X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E00623X/1] Funding Source: researchfish	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	CZ was partly supported by the National Natural Science Foundation of China (grant No.31100057). We thank Ed Hurt (University of Heidelberg, Germany) for providing ribosomal subunit reporter plasmids.	AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; Alhebshi A, 2012, MOL BIOL CELL, V23, P3582, DOI 10.1091/mbc.E12-05-0413; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; Barthelme D, 2007, J BIOL CHEM, V282, P14598, DOI 10.1074/jbc.M700825200; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Boal AK, 2005, BIOCHEMISTRY-US, V44, P8397, DOI 10.1021/bi047494n; Boal AK, 2009, P NATL ACAD SCI USA, V106, P15237, DOI 10.1073/pnas.0908059106; Chen ZQ, 2006, J BIOL CHEM, V281, P7452, DOI 10.1074/jbc.M510603200; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Hawle P, 2007, EUKARYOT CELL, V6, P521, DOI 10.1128/EC.00343-06; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Hu B, 2005, MOL MICROBIOL, V55, P1735, DOI 10.1111/j.1365-2958.2005.04531.x; Huang X, 2006, GENE CHROMOSOME CANC, V45, P1058, DOI 10.1002/gcc.20371; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; James P, 1996, GENETICS, V144, P1425; Janke C, 2004, YEAST, V21, P947, DOI 10.1002/yea.1142; Jiang L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-20; Jin YS, 1998, GENE CHROMOSOME CANC, V22, P312, DOI 10.1002/(SICI)1098-2264(199808)22:4<312::AID-GCC7>3.0.CO;2-Y; Khoshnevis S, 2010, EMBO REP, V11, P214, DOI 10.1038/embor.2009.272; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; LESE CM, 1995, GENE CHROMOSOME CANC, V12, P288, DOI 10.1002/gcc.2870120409; Li ZH, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000213; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mascarenhas C, 2008, MOL BIOL CELL, V19, P2995, DOI 10.1091/mbc.E07-11-1173; Mollapour M, 2007, MOL CELL BIOL, V27, P6446, DOI 10.1128/MCB.02205-06; Mroczek S, 2008, NUCLEIC ACIDS RES, V36, P2874, DOI 10.1093/nar/gkm1100; Pisarev AV, 2010, MOL CELL, V37, P196, DOI 10.1016/j.molcel.2009.12.034; ROSE MD, 1990, METHODS YEAST GENETI; Shoemaker CJ, 2011, P NATL ACAD SCI USA, V108, pE1392, DOI 10.1073/pnas.1113956108; Snoek ISI, 2006, FEMS YEAST RES, V6, P393, DOI 10.1111/j.1567-1364.2005.00007.x; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thorpe GW, 2004, P NATL ACAD SCI USA, V101, P6564, DOI 10.1073/pnas.0305888101; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Trotter EW, 2008, BIOCHEM J, V412, P73, DOI 10.1042/BJ20071634; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Yao W, 2007, MOL CELL, V26, P51, DOI 10.1016/j.molcel.2007.02.018; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; Zhai C, 2008, BIOCHEM J, V415, P455, DOI 10.1042/BJ20080209	44	28	30	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					484	494		10.1038/onc.2012.604	http://dx.doi.org/10.1038/onc.2012.604			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318452				2022-12-17	WOS:000330214600009
J	Xi, Y; Wei, Y; Sennino, B; Ulsamer, A; Kwan, I; Brumwell, AN; Tan, K; Aghi, MK; McDonald, DM; Jablons, DM; Chapman, HA				Xi, Y.; Wei, Y.; Sennino, B.; Ulsamer, A.; Kwan, I.; Brumwell, A. N.; Tan, K.; Aghi, M. K.; McDonald, D. M.; Jablons, D. M.; Chapman, H. A.			Identification of pY654-beta-catenin as a critical co-factor in hypoxia-inducible factor-1 alpha signaling and tumor responses to hypoxia	ONCOGENE			English	Article						hypoxia; signaling; transcription; tumor; epithelial	EPITHELIAL-MESENCHYMAL TRANSITION; BETA-CATENIN; ANTIANGIOGENIC THERAPY; GENE-EXPRESSION; CELL INVASION; C-SRC; ACTIVATION; METASTASIS; MET; MECHANISMS	Hypoxia is linked to epithelial-mesenchymal transition (EMT) and tumor progression in numerous carcinomas. Responses to hypoxia are thought to operate via hypoxia-inducible factors (HIFs), but the importance of co-factors that regulate HIF signaling within tumors is not well understood. Here, we elucidate a signaling pathway that physically and functionally couples tyrosine phosphorylation of beta-catenin to HIF1 alpha signaling and HIF1 alpha-mediated tumor EMT. Primary human lung adenocarcinomas accumulate pY654-beta-catenin and HIF1 alpha. All pY654-beta-catenin, and only the tyrosine phosphorylated form, was found complexed with HIF1 alpha and active Src, both within the human tumors and in lung tumor cell lines exposed to hypoxia. Phosphorylation of Y654, generated by hypoxia mediated, reactive oxygen species (ROS)-dependent Src kinase activation, was required for beta-catenin to interact with HIF1 alpha and Src, to promote HIF1 alpha transcriptional activity, and for hypoxia-induced EMT. Mice bearing hypoxic pancreatic islet adenomas, generated by treatment with anti-vascular endothelial growth factor antibodies, accumulate HIF1 alpha/pY654-beta-catenin complexes and develop an invasive phenotype. Concurrent administration of the ROS inhibitor N-acetylcysteine abrogated beta-catenin/HIF pathway activity and restored adenoma architecture. Collectively, the findings implicate accumulation of pY654-beta-catenin specifically complexed to HIF1 alpha and Src kinase as critically involved in HIF1 alpha signaling and tumor invasion. The findings also suggest that targeting ROS-dependent aspects of the pY654-beta-catenin/HIF1 alpha pathway may attenuate untoward biological effects of anti-angiogenic agents and tumor hypoxia.	[Xi, Y.; Wei, Y.; Ulsamer, A.; Kwan, I.; Brumwell, A. N.; Tan, K.; Chapman, H. A.] Univ Calif San Francisco, Div Pulm & Crit Care, Dept Med, San Francisco, CA 94143 USA; [Sennino, B.; McDonald, D. M.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Sennino, B.; McDonald, D. M.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Aghi, M. K.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Aghi, M. K.] Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; [Jablons, D. M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wei, Y (corresponding author), Univ Calif San Francisco, Div Pulm & Crit Care, 513 Parnassus Ave, San Francisco, CA 94143 USA.	ying.wei@ucsf.edu; hal.chapman@ucsf.edu	Ulsamer, A/H-7994-2014	Ulsamer, A/0000-0001-7808-1005	NIH [HL-44712, CA-125564]; NATIONAL CANCER INSTITUTE [R01CA125564] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712, P01HL024136, R01HL059157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS064167, R01NS079697] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Roshni Ray, Mazen Sidani, Toshina Ishiguro-Oonuma, Casey W Williamson, Thomas Kim, Yonghyun Kim, Yang Gao and Ronald Tsang for technical assistance; and Drs Miguel Ramalho Santos and Martin Brown for generous gifts of reagents. This work was supported by NIH Grants to HL-44712 and CA-125564 (HAC).	Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83; Grepin R, 2010, J ONCOL, V2010, DOI 10.1155/2010/835680; Hung JJ, 2009, THORAX, V64, P1082, DOI 10.1136/thx.2009.115691; Jiang BH, 1997, CANCER RES, V57, P5328; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Kaluz S, 2008, CLIN CHIM ACTA, V395, P6, DOI 10.1016/j.cca.2008.05.002; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; Kim KK, 2009, J CLIN INVEST, V119, P213, DOI 10.1172/JCI36940; Kim WY, 2009, J CLIN INVEST, V119, P2160, DOI 10.1172/JCI38443; Kim Y, 2009, J CELL BIOL, V184, P309, DOI 10.1083/jcb.200806067; Klimova T, 2008, CELL DEATH DIFFER, V15, P660, DOI 10.1038/sj.cdd.4402307; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Littlepage LE, 2010, CANCER RES, V70, P2224, DOI 10.1158/0008-5472.CAN-09-3515; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Lou YW, 2008, FEBS J, V275, P69, DOI 10.1111/j.1742-4658.2007.06173.x; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Luo DC, 2011, MOL CANCER RES, V9, P234, DOI 10.1158/1541-7786.MCR-10-0214; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Pham NA, 2009, INT J CANCER, V124, P280, DOI 10.1002/ijc.23912; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Setsukinai K, 2003, J BIOL CHEM, V278, P3170, DOI 10.1074/jbc.M209264200; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089; Ulsamer A, 2012, J BIOL CHEM, V287, P5164, DOI 10.1074/jbc.M111.322123; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zeng G, 2006, EXP CELL RES, V312, P3620, DOI 10.1016/j.yexcr.2006.08.003; Zhou GF, 2009, AM J PHYSIOL-LUNG C, V297, pL1120, DOI 10.1152/ajplung.00007.2009	45	28	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5048	5057		10.1038/onc.2012.530	http://dx.doi.org/10.1038/onc.2012.530			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23246962	Green Accepted			2022-12-17	WOS:000325937900006
J	Quizi, JL; Baron, K; Al-Zahrani, KN; O'Reilly, P; Sriram, RK; Conway, J; Laurin, AA; Sabourin, LA				Quizi, J. L.; Baron, K.; Al-Zahrani, K. N.; O'Reilly, P.; Sriram, R. K.; Conway, J.; Laurin, A-A; Sabourin, L. A.			SLK-mediated phosphorylation of paxillin is required for focal adhesion turnover and cell migration	ONCOGENE			English	Article						Ste20; kinase; paxillin; phosphorylation; migration	STE20-LIKE KINASE SLK; EARLY MOLECULAR EVENTS; MICROTUBULE CATASTROPHES; REGULATES ADHESION; ASSOCIATION; ACTIVATION; COMPLEX	Focal adhesion turnover is a complex process required for cell migration. We have previously shown that the Ste20-like kinase (SLK) is required for cell migration and efficient focal adhesion (FA) turnover in a FA kinase (FAK)-dependent manner. However, the role of SLK in this process remains unclear. Using a candidate substrate approach, we show that SLK phosphorylates the adhesion adapter protein paxillin on serine 250. Serine 250 phosphorylation is required for paxillin redistribution and cell motility. Mutation of paxillin serine 250 prevents its phosphorylation by SLK in vitro and results in impaired migration in vivo as evidenced by an accumulation of phospho-FAK-Tyr397 and altered FA turnover rates. Together, our data suggest that SLK phosphorylation of paxillin on serine 250 is required for FAK-dependent FA dynamics.	[Quizi, J. L.; Baron, K.; Al-Zahrani, K. N.; O'Reilly, P.; Sriram, R. K.; Sabourin, L. A.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Quizi, J. L.; Baron, K.; Al-Zahrani, K. N.; Sriram, R. K.; Conway, J.; Laurin, A-A; Sabourin, L. A.] Ottawa Hosp Res Inst, Canc Therapeut Program, Ottawa, ON K1H 8L6, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Sabourin, LA (corresponding author), Ottawa Hosp Res Inst, Canc Therapeut Program, 501 Smyth Rd,Box 926, Ottawa, ON K1H 8L6, Canada.	lsabourin@ohri.ca		Baron, Kyla/0000-0002-8859-9251; , Jillian/0000-0003-4354-0026	Canadian Institute for Health Research; Canadian Breast Cancer Foundation; OGSST	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); OGSST	This work was supported by the Canadian Institute for Health Research and the Canadian Breast Cancer Foundation. JLQ, KB and KNA-Z are the recipient of a Canadian Breast Cancer Foundation scholar award. LAS is the recipient of a CIHR scholar award. PO is the recipient of an OGSST studentship.	Abou Zeid Nancy, 2006, Cell Commun Signal, V4, P8, DOI 10.1186/1478-811X-4-8; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; Broussard JA, 2008, CURR OPIN CELL BIOL, V20, P85, DOI 10.1016/j.ceb.2007.10.009; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Brown MC, 2002, INT J BIOCHEM CELL B, V34, P855, DOI 10.1016/S1357-2725(01)00154-6; Canas Benito, 2006, Briefings in Functional Genomics & Proteomics, V4, P295, DOI 10.1093/bfgp/eli002; Delom F, 2006, PROTEOME SCI, V4, DOI 10.1186/1477-5956-4-15; Deramaudt TB, 2011, MOL BIOL CELL, V22, P964, DOI 10.1091/mbc.E10-08-0725; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Efimov A, 2009, CELL ADHES MIGR, V3, P285, DOI 10.4161/cam.3.3.8858; Efimov A, 2008, J CELL SCI, V121, P196, DOI 10.1242/jcs.012666; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Gilcrease MZ, 2007, CANCER LETT, V247, P1, DOI 10.1016/j.canlet.2006.03.031; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hoellerer MK, 2003, STRUCTURE, V11, P1207, DOI 10.1016/j.str.2003.08.010; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Loyet KM, 2005, MOL CELL PROTEOMICS, V4, P235, DOI 10.1074/mcp.R400011-MCP200; Manes S, 2000, IUBMB LIFE, V49, P89; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; O'Reilly PG, 2005, J BIOL CHEM, V280, P42383, DOI 10.1074/jbc.M510763200; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Romer LH, 2006, CIRC RES, V98, P606, DOI 10.1161/01.RES.0000207408.31270.db; Roovers K, 2009, ONCOGENE, V28, P2839, DOI 10.1038/onc.2009.146; Scheswohl Danielle M, 2008, J Mol Signal, V3, P1, DOI 10.1186/1750-2187-3-1; Storbeck CJ, 2009, MOL BIOL CELL, V20, P4174, DOI 10.1091/mbc.E08-07-0707; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Wagner S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001868; Webb DJ, 2003, CURR OPIN CELL BIOL, V15, P614, DOI 10.1016/S0955-0674(03)00105-4; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Webb DJ, 2005, J CELL SCI, V118, P4925, DOI 10.1242/jcs.02563; Wu Hsin-Yi, 2008, Chang Gung Med J, V31, P217; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zimerman B, 2004, CELL MOTIL CYTOSKEL, V58, P143, DOI 10.1002/cm.20005	36	28	29	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4656	4663		10.1038/onc.2012.488	http://dx.doi.org/10.1038/onc.2012.488			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23128389	Green Submitted			2022-12-17	WOS:000325072200007
J	Dalvai, M; Bellucci, L; Fleury, L; Lavigne, AC; Moutahir, F; Bystricky, K				Dalvai, M.; Bellucci, L.; Fleury, L.; Lavigne, A-C; Moutahir, F.; Bystricky, K.			H2A.Z-dependent crosstalk between enhancer and promoter regulates Cyclin D1 expression	ONCOGENE			English	Article						H2A.Z; chromatin; acetylation; enhancer; intragenic loop; cyclin D1	BREAST-CANCER CELLS; ESTROGEN-RECEPTOR-ALPHA; RNA-POLYMERASE-II; BETA-GLOBIN LOCUS; GENE-EXPRESSION; HISTONE H2A.Z; TRANSCRIPTIONAL ACTIVATION; CHROMOSOME CONFORMATION; CHROMATIN DYNAMICS; IN-VIVO	H2A.Z association with specific genomic loci is thought to contribute to a chromatin structure that promotes transcription activation. Acetylation of H2A.Z at promoters of oncogenes has been linked to tumorigenesis. The mechanism is unknown. Here, we show that in triple negative breast cancer cells, H2A.Z bound to the promoter of the constitutively, weakly expressed cyclin D1 oncogene (CCND1), a key regulator of cellular proliferation. Depleting the pool of H2A.Z stimulated transcription of CCND1 in the absence of its cognate transcription factor, the estrogen receptor (ER). During activation of CCND1, H2A.Z was released from the transcription start site (TSS) and downstream enhancer (enh2) sequences. Concurrently, acetylation of H2A.Z, H3 and H4 at the TSS was increased but only H2A.Z was acetylated at enh2. Acetylation of H2A.Z required the Tip60 acetyltransferase to be associated with the activated CCND1 on both TSS and enh2 sites. Depletion of Tip60 prevented CCND1 activation. Chromosome conformation capture experiments (3C) revealed specific contacts between the TSS and enh2 chromatin regions. These results suggest that release of a histone H2A.Z-mediated repression loop activates CCND1 for transcription. Our findings open new avenues for controlling and understanding aberrant gene expression associated with tumorigenesis.	[Dalvai, M.; Bellucci, L.; Fleury, L.; Lavigne, A-C; Moutahir, F.; Bystricky, K.] Univ Toulouse, LBME, F-31062 Toulouse, France; [Dalvai, M.; Bellucci, L.; Fleury, L.; Lavigne, A-C; Moutahir, F.; Bystricky, K.] CNRS, LBME, UMR 5099, Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bystricky, K (corresponding author), Univ Toulouse, LBME, 118 Route Narbonne, F-31062 Toulouse, France.	kerstin@biotoul.fr	Lavigne, Anne-Claire/O-8805-2015; Bystricky, Kerstin/AAA-3003-2020; BYSTRICKY, Kerstin/B-8670-2009	Bystricky, Kerstin/0000-0001-6717-3721; BYSTRICKY, Kerstin/0000-0001-6717-3721	Ligue Nationale Contre le Cancer; Institut National du Cancer (INCa) [34696]; Fondation pour la Recherche Medicale (FRM)	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	We would like to thank Dr Didier Trouche for the Tip60 expressing vector and insightful discussions, J Eeckhoute, Lille for sharing unpublished work, and David Laperriere, IRIC, Montreal, for expert advice on genome database use. This work was supported by the Ligue Nationale Contre le Cancer (fellowship to LB), the Institut National du Cancer (INCa grant no. 34696) and the Fondation pour la Recherche Medicale (FRM, fellowship to MD).	Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; Altaf M, 2009, BIOCHEM CELL BIOL, V87, P35, DOI 10.1139/O08-140; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; Barzily-Rokni M, 2011, NUCLEIC ACIDS RES, V39, P1326, DOI 10.1093/nar/gkq994; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Brookes E, 2009, EMBO REP, V10, P1213, DOI 10.1038/embor.2009.221; Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chambeyron S, 2004, CURR OPIN CELL BIOL, V16, P256, DOI 10.1016/j.ceb.2004.03.004; Chu S, 1997, MOL CELL ENDOCRINOL, V132, P195, DOI 10.1016/S0303-7207(97)00133-0; Dalvai M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011011; Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Deschenes J, 2007, J BIOL CHEM, V282, P17335, DOI 10.1074/jbc.C700030200; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Farris SD, 2005, J BIOL CHEM, V280, P25298, DOI 10.1074/jbc.M501784200; Fleury L, 2008, ONCOGENE, V27, P4075, DOI 10.1038/onc.2008.41; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gamble MJ, 2010, GENE DEV, V24, P21, DOI 10.1101/gad.1876110; Gevry N, 2009, GENE DEV, V23, P1522, DOI 10.1101/gad.1787109; Giamarchi C, 1999, ONCOGENE, V18, P533, DOI 10.1038/sj.onc.1202317; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; Hajkova P, 2008, NATURE, V452, P877, DOI 10.1038/nature06714; Henikoff S, 2005, ANNU REV CELL DEV BI, V21, P133, DOI 10.1146/annurev.cellbio.21.012704.133518; Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043; Iacovoni JS, 2010, EMBO J, V29, P1446, DOI 10.1038/emboj.2010.38; Ikura T, 2007, MOL CELL BIOL, V27, P7028, DOI 10.1128/MCB.00579-07; JENSEN EV, 1967, ARCH ANAT MICROSC MO, V56, P547; Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153; Jin CY, 2009, NAT GENET, V41, P941, DOI 10.1038/ng.409; Jin FL, 2011, P NATL ACAD SCI USA, V108, P5290, DOI 10.1073/pnas.1017214108; Keogh MC, 2006, GENE DEV, V20, P660, DOI 10.1101/gad.1388106; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kocanova S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000922; Lee S, 2010, J BIOL CHEM, V285, P21399, DOI 10.1074/jbc.M110.128413; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Lehn S, 2010, AM J PATHOL, V177, P2886, DOI 10.2353/ajpath.2010.100303; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000; March-Diaz R, 2008, PLANT J, V53, P475, DOI 10.1111/j.1365-313X.2007.03361.x; Mattera L, 2009, ONCOGENE, V28, P1506, DOI 10.1038/onc.2008.499; Mattera L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000983; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; Noordermeer D, 2011, NAT CELL BIOL, V13, P944, DOI 10.1038/ncb2278; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Ong CT, 2011, NAT REV GENET, V12, P283, DOI 10.1038/nrg2957; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Planas-Silva MD, 1999, CANCER RES, V59, P4788; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Serandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110; Shia WJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-217; Simonis M, 2006, NAT GENET, V38, P1348, DOI 10.1038/ng1896; Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Stadhouders R, 2012, EMBO J, V31, P986, DOI 10.1038/emboj.2011.450; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suganuma T, 2008, CELL, V135, P604, DOI 10.1016/j.cell.2008.10.036; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tobin NP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-417; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TOUITOU I, 1991, J STEROID BIOCHEM, V40, P231, DOI 10.1016/0960-0760(91)90187-A; Updike DL, 2006, PLOS GENET, V2, P1500, DOI 10.1371/journal.pgen.0020161; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Valdes-Mora F, 2012, GENOME RES, V22, P307, DOI 10.1101/gr.118919.110; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vogelmann J, 2011, NUCLEUS-PHILA, V2, P358, DOI 10.4161/nucl.2.5.17860; Voss TC, 2011, CELL, V146, P544, DOI 10.1016/j.cell.2011.07.006; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XW, 2001, CANCER RES, V61, P7025; Yun MY, 2011, CELL RES, V21, P564, DOI 10.1038/cr.2011.42	79	28	28	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4243	4251		10.1038/onc.2012.442	http://dx.doi.org/10.1038/onc.2012.442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23108396				2022-12-17	WOS:000324168000006
J	Khan, D; Sharathchandra, A; Ponnuswamy, A; Grover, R; Das, S				Khan, D.; Sharathchandra, A.; Ponnuswamy, A.; Grover, R.; Das, S.			Effect of a natural mutation in the 5 ' untranslated region on the translational control of p53 mRNA	ONCOGENE			English	Article						p53 mRNA; translational control; SNP; IRES; PTB; internal initiation	CELL-CYCLE; ENTRY SITE; POLYMORPHISM; MECHANISM; BINDING; TP53; PTB	Tumor-suppressor protein p53, the 'guardian of the genome', is critical in maintaining cellular homeostasis and genomic stability. Earlier, we have reported the discovery of internal ribosome entry sites (IRESs) within the p53 mRNA that regulate the translation of the full length and its N-terminal-truncated isoform, Delta N-p53. Polypyrimidine tract-binding protein (PTB) is an IRES trans-acting factor that positively regulates the IRES activities of both p53 isoforms by relocating from nucleus to the cytoplasm during stress conditions. Here we have demonstrated the putative contact points of PTB on the p53 IRES RNA. Studies on mutations that occur naturally in the 5' untranslated region (5' UTR) in p53 mRNA were lacking. We have investigated a naturally occurring C-to-T single-nucleotide polymorphism (SNP) first reported in human melanoma tumors. This SNP is at position 119 in the 5' UTR of p53 mRNA and we demonstrate that it has consequences on the translational control of p53. Introduction of this SNP has led to decrease in cap-independent translation from p53 5' UTR in bicistronic reporter assay. Further, the effects of this SNP on cap-independent translation have been studied in the context of p53 cDNA as well. Interestingly, the 5' UTR with this SNP has shown reduced binding to PTB that can be corroborated to its weaker IRES activity. Previously, it has been shown that G2-M checkpoint, DNA-damaging stress and oncogenic insult favor IRES-mediated translation. Under similar conditions, we demonstrate that this SNP interferes with the enhancement of the IRES activity of the 5' UTR. Taken together, the results demonstrate for the first time that SNP in the 5' UTR of the p53 mRNA might have a role in translational control of this critical tumor-suppressor gene.	[Khan, D.; Sharathchandra, A.; Ponnuswamy, A.; Grover, R.; Das, S.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Das, S (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	sdas@mcbl.iisc.ernet.in		Khan, Debjit/0000-0001-5568-3361; Arandkar, Sharathchandra/0000-0001-6160-6338	CSIR, India; IFCPAR	CSIR, India(Council of Scientific & Industrial Research (CSIR) - India); IFCPAR	We are grateful to Professor Robin Fahraeus (INSERM, France) for sharing the pcDNA3-GFP-hp-p53-5' UTR-cDNA construct with us. Professor Julian Downward (London Research Institute, UK) and Professor Annapoorni Rangarajan (Department of Molecular Reproduction and Developmental Genetics, IISc) are duly acknowledged for sharing the pBabe-H-Ras<SUP>V12</SUP> construct and anti-Ras antibody. We thank Professor K Somasundaram for sharing the WWP-Luciferase construct and Professor KN Balaji for providing anti-caspase-3 antibody. We also thank the FACS facility (Division of Biological Sciences, IISc) headed by Dr Omana Joy for the acquisition of the flow-cytometric data. We thank the present and past SD Lab members for critical discussion of the work and Ranjitha Tatineni for her help with the phylogenetic analysis. DK and SA are supported by pre-doctoral fellowships from CSIR, India. This work was partly supported by an Indo-French grant from IFCPAR to SD.	ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; Bellodi C, 2010, CANCER RES, V70, P6026, DOI 10.1158/0008-5472.CAN-09-4730; Bhattacharyya Sankar, 2006, RNA Biol, V3, P60; Bourougaa K, 2010, MOL CELL, V38, P78, DOI 10.1016/j.molcel.2010.01.041; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Grover R, 2009, ONCOGENE, V28, P2766, DOI 10.1038/onc.2009.138; Grover R, 2008, CELL CYCLE, V7, P2189, DOI 10.4161/cc.7.14.6271; Grover R, 2011, RNA BIOL, V8, P132, DOI 10.4161/rna.8.1.14260; Hellman LM, 2007, NAT PROTOC, V2, P1849, DOI 10.1038/nprot.2007.249; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Lewis SM, 2007, MOL BIOL CELL, V18, P1302, DOI 10.1091/mbc.E06-06-0515; Li XX, 2005, J BIOL CHEM, V280, P24245, DOI 10.1074/jbc.M414637200; Lim YP, 2007, ONCOGENE, V26, P1517, DOI 10.1038/sj.onc.1209952; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Montanaro L, 2010, CANCER RES, V70, P4767, DOI 10.1158/0008-5472.CAN-09-4024; Pudi R, 2004, J BIOL CHEM, V279, P29879, DOI 10.1074/jbc.M403417200; Ray AJ, 2002, INFECT CONT HOSP EP, V23, P474, DOI 10.1086/502090; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Soto JL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-36; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Yang DQ, 2006, ONCOGENE, V25, P4613, DOI 10.1038/sj.onc.1209483	28	28	29	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4148	4159		10.1038/onc.2012.422	http://dx.doi.org/10.1038/onc.2012.422			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23027126				2022-12-17	WOS:000323748500010
J	Santag, S; Jager, W; Karsten, CB; Kati, S; Pietrek, M; Steinemann, D; Sarek, G; Ojala, PM; Schulz, TF				Santag, S.; Jaeger, W.; Karsten, C. B.; Kati, S.; Pietrek, M.; Steinemann, D.; Sarek, G.; Ojala, P. M.; Schulz, T. F.			Recruitment of the tumour suppressor protein p73 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells	ONCOGENE			English	Article						KSHV; primary effusion lymphoma; LANA; p73; Nutlin-3; RETRA	DNA-SEQUENCES; TRANSCRIPTIONAL ACTIVATION; ENDOTHELIAL-CELLS; ONCOPROTEIN MDM2; GENE-EXPRESSION; P53 PATHWAY; APOPTOSIS; BINDING; VIRUS; INSTABILITY	Kaposi's Sarcoma Herpesvirus (KSHV) is the causative agent of Kaposi's Sarcoma (KS) and two rare lymphoproliferative disorders, primary effusion lymphoma (PEL) and the plasmablastic variant of multicentric Castleman's disease (MCD). The KSHV latency-associated nuclear antigen-1 (LANA), required for the replication and maintenance of latent viral episomal DNA, is involved in the transcriptional regulation of viral and cellular genes and interacts with different cellular proteins, including the tumour suppressor p53. Here, we report that LANA also recruits the p53-related nuclear transcription factor p73, which influences cellular processes like DNA damage response, cell cycle progression and apoptosis. Both the full-length isoform TAp73 alpha, as well as its dominant negative regulator Delta Np73 alpha, interact with LANA. LANA affects TAp73 alpha stability and sub-nuclear localisation, as well as TAp73 alpha-mediated transcriptional activation of target genes. We observed that the small-molecule inhibitor Nutlin-3, which disrupts the interaction of p53 and p73 with MDM2, induces apoptotic cell death in p53 wild-type, as well as p53-mutant PEL cell lines, suggesting a possible involvement of p73. The small-molecule RETRA, which activates p73 in the context of mutant p53, leads to the induction of apoptosis in p53-mutant PEL cell lines. RNAi-mediated knockdown of p73 confirmed that these effects depend on the presence of the p73 protein. Furthermore, both Nutlin-3 and RETRA disrupt the LANA-p73 interaction in different PEL cell lines. These results suggest that LANA modulates p73 function and that the LANA-p73 interaction may represent a therapeutic target to interfere with the survival of latently KSHV-infected cells.	[Santag, S.; Jaeger, W.; Karsten, C. B.; Kati, S.; Pietrek, M.; Schulz, T. F.] Hannover Med Sch, Inst Virol, D-30625 Hannover, Germany; [Steinemann, D.] Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany; [Sarek, G.; Ojala, P. M.] Univ Helsinki, Inst Biotechnol, Helsinki, Finland; [Sarek, G.; Ojala, P. M.] Univ Helsinki, Res Programs Unit, Genome Scale Biol Biomedicum Helsinki, Helsinki, Finland	Hannover Medical School; Hannover Medical School; University of Helsinki; University of Helsinki	Schulz, TF (corresponding author), Hannover Med Sch, Inst Virol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	schulz.thomas@mh-hannover.de	Karsten, Christina B./J-8689-2019; Schulz, Thomas/AAA-1634-2019; Karsten, Christina B./GNH-2673-2022; Ojala, Paivi M/J-3266-2014	Karsten, Christina B./0000-0003-1934-6442; Ojala, Paivi/0000-0001-9065-1832; Schulz, Thomas/0000-0001-8792-5345	DFG IRTG [1273]; EU Integrated Project INCA [LSHC-CT-18730]; collaborative research centre (CRC) 900 of the Deutsche Forschungsgemeinschaft	DFG IRTG(German Research Foundation (DFG)); EU Integrated Project INCA; collaborative research centre (CRC) 900 of the Deutsche Forschungsgemeinschaft	We thank Magdalena Weidner-Glunde for cloning of the GST fusion construct LANA N, as well as Eva Gellermann for cloning the GST fusion constructs C8a and C8b. This work was supported by the DFG IRTG 1273, the EU Integrated Project INCA (LSHC-CT-18730) and the collaborative research centre (CRC) 900 of the Deutsche Forschungsgemeinschaft.	Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Amin ARMR, 2007, CANCER RES, V67, P5617, DOI 10.1158/0008-5472.CAN-07-0655; An FQ, 2005, J BIOL CHEM, V280, P3862, DOI 10.1074/jbc.M407435200; Ben-Yehoyada M, 2003, J BIOL CHEM, V278, P34475, DOI 10.1074/jbc.M301051200; Busuttil V, 2010, P NATL ACAD SCI USA, V107, P18061, DOI 10.1073/pnas.1006163107; Cai QL, 2006, PLOS PATHOG, V2, P1002, DOI 10.1371/journal.ppat.0020116; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen WG, 2010, J VIROL, V84, P3898, DOI 10.1128/JVI.01321-09; D'Amours D, 2001, J CELL SCI, V114, P3771; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Godfrey A, 2005, BLOOD, V105, P2510, DOI 10.1182/blood-2004-08-3052; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Gwack Y, 2001, J VIROL, V75, P6245, DOI 10.1128/JVI.75.13.6245-6248.2001; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; Katano H, 2001, CANCER, V92, P3076, DOI 10.1002/1097-0142(20011215)92:12<3076::AID-CNCR10117>3.0.CO;2-D; Kliche S, 1998, J VIROL, V72, P8143, DOI 10.1128/JVI.72.10.8143-8149.1998; Kravchenko JE, 2008, P NATL ACAD SCI USA, V105, P6302, DOI 10.1073/pnas.0802091105; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Moll UM, 2004, MOL CANCER RES, V2, P371; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Ohsaki E, 2009, VIRUS RES, V139, P74, DOI 10.1016/j.virusres.2008.10.011; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pan HY, 2004, CANCER RES, V64, P4064, DOI 10.1158/0008-5472.CAN-04-0657; Park J, 2000, J VIROL, V74, P11977, DOI 10.1128/JVI.74.24.11977-11982.2000; Park JS, 2001, INT J CANCER, V91, P822, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1130>3.0.CO;2-0; Petre CE, 2007, J VIROL, V81, P1912, DOI 10.1128/JVI.01757-06; Platt GM, 1999, J VIROL, V73, P9789, DOI 10.1128/JVI.73.12.9789-9795.1999; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128/JVI.75.1.458-468.2001; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Rosenbluth JM, 2008, GENE DEV, V22, P2591, DOI 10.1101/gad.1727408; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Santarelli R, 2008, J VIROL, V82, P4562, DOI 10.1128/JVI.02400-07; Sarek G, 2013, ONCOGENE, V32, P1091, DOI 10.1038/onc.2012.118; Sarek G, 2007, J CLIN INVEST, V117, P1019, DOI 10.1172/JCI30945; Seo T, 2001, J VIROL, V75, P6193, DOI 10.1128/JVI.75.13.6193-6198.2001; Si HX, 2006, J VIROL, V80, P697, DOI 10.1128/JVI.80.2.697-709.2006; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Toh WH, 2010, CELL DEATH DIFFER, V17, P787, DOI 10.1038/cdd.2009.181; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Viejo-Borbolla A, 2005, J VIROL, V79, P13618, DOI 10.1128/JVI.79.21.13618-13629.2005; Viejo-Borbolla A, 2003, J VIROL, V77, P7093, DOI 10.1128/JVI.77.12.7093-7100.2003; Wang L, 2008, CANCER RES, V68, P4640, DOI 10.1158/0008-5472.CAN-07-5988; Wies E, 2008, BLOOD, V111, P320, DOI 10.1182/blood-2007-05-092288; Wong LY, 2004, J VIROL, V78, P10074, DOI 10.1128/JVI.78.18.10074-10085.2004; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	55	28	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3676	3685		10.1038/onc.2012.385	http://dx.doi.org/10.1038/onc.2012.385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22964633				2022-12-17	WOS:000322904400003
J	de Leeuw, R; Flach, K; Toaldo, CB; Alexi, X; Canisius, S; Neefjes, J; Michalides, R; Zwart, W				de Leeuw, R.; Flach, K.; Toaldo, C. Bentin; Alexi, X.; Canisius, S.; Neefjes, J.; Michalides, R.; Zwart, W.			PKA phosphorylation redirects ER alpha to promoters of a unique gene set to induce tamoxifen resistance	ONCOGENE			English	Article						estrogen receptor; breast cancer; protein kinase A; tamoxifen resistance; myc; ChIP-seq	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; PROTEIN-KINASE; NUCLEAR P21-ACTIVATED-KINASE-1; SERINE 305; CHIP-SEQ; ACTIVATION; EXPRESSION; TRANSCRIPTION; GROWTH	Protein kinase A (PKA)-induced estrogen receptor alpha (ER alpha) phosphorylation at serine residue 305 (ER alpha S305-P) can induce tamoxifen (TAM) resistance in breast cancer. How this phospho-modification affects ER alpha specificity and translates into TAM resistance is unclear. Here, we show that S305-P modification of ER alpha reprograms the receptor, redirecting it to new transcriptional start sites, thus modulating the transcriptome. By altering the chromatin-binding pattern, Ser305 phosphorylation of ER alpha translates into a 26-gene expression classifier that identifies breast cancer patients with a poor disease outcome after TAM treatment. MYC-target genes and networks were significantly enriched in this gene classifier that includes a number of selective targets for ER alpha S305-P. The enhanced expression of MYC increased cell proliferation in the presence of TAM. We demonstrate that activation of the PKA signaling pathway alters the transcriptome by redirecting ERa to new transcriptional start sites, resulting in altered transcription and TAM resistance.	[de Leeuw, R.; Toaldo, C. Bentin; Neefjes, J.; Michalides, R.] Netherlands Canc Inst, Dept Cell Biol, NL-1066 CX Amsterdam, Netherlands; [Flach, K.; Alexi, X.; Canisius, S.; Zwart, W.] Netherlands Canc Inst, Dept Mol Pathol, NL-1066 CX Amsterdam, Netherlands; [Canisius, S.] Netherlands Canc Inst, Dept Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Zwart, W (corresponding author), Netherlands Canc Inst, Dept Mol Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	w.zwart@nki.nl	Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211; de Leeuw, Renee/0000-0002-5550-7613; Zwart, Wilbert/0000-0002-9823-7289	Top Institute Pharma; KWF Dutch Cancer Society Fellowship	Top Institute Pharma; KWF Dutch Cancer Society Fellowship	We thank the Central Microarray Facility of the Netherlands Cancer Institute for processing the microarray samples. RL is in part supported by Top Institute Pharma. WZ is supported by a KWF Dutch Cancer Society Fellowship.	Al-Dhaheri MH, 2007, MOL ENDOCRINOL, V21, P439, DOI 10.1210/me.2006-0059; Bossis I, 2004, ENDOCRINOLOGY, V145, P5452, DOI 10.1210/en.2004-0900; Bostner J, 2010, CLIN CANCER RES, V16, P1624, DOI 10.1158/1078-0432.CCR-09-1733; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Callero MA, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/923250; Carascossa S, 2010, GENE DEV, V24, P708, DOI 10.1101/gad.568410; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chandra V, 2008, NATURE, V456, P350, DOI 10.1038/nature07413; Chen DS, 1999, MOL CELL BIOL, V19, P1002; de Leeuw R, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/232435; Dudek P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001859; Fan P, 2007, CANCER RES, V67, P1352, DOI 10.1158/0008-5472.CAN-06-1020; Ferlay J, 2010, IARC CANCERBASE; Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Holm C, 2009, J PATHOL, V217, P372, DOI 10.1002/path.2455; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Inoue A, 2004, J MOL ENDOCRINOL, V32, P649, DOI 10.1677/jme.0.0320649; Ji XW, 2006, NUCLEIC ACIDS RES, V34, pW551, DOI 10.1093/nar/gkl322; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kok M, 2011, BREAST CANCER RES TR, V125, P1, DOI 10.1007/s10549-010-0798-y; Krum SA, 2008, MOL ENDOCRINOL, V22, P2393, DOI 10.1210/me.2008-0100; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Louie MC, 2010, MOL CANCER RES, V8, P343, DOI 10.1158/1541-7786.MCR-09-0395; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; Lupien M, 2009, MOL CELL BIOL, V29, P3413, DOI 10.1128/MCB.00020-09; Madak-Erdogan Z, 2012, TOXICOL SCI, V125, P401, DOI 10.1093/toxsci/kfr300; Madak-Erdogan Z, 2011, MOL CELL BIOL, V31, P226, DOI 10.1128/MCB.00821-10; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567; Miller WR, 2002, ANN NY ACAD SCI, V968, P37, DOI 10.1111/j.1749-6632.2002.tb04325.x; Musgrove EA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002987; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Rayala SK, 2006, CANCER RES, V66, P5985, DOI 10.1158/0008-5472.CAN-06-0978; REINER GCA, 1986, CANCER RES, V46, P1124; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Robertson JFR, 2004, CANCER TREAT REV, V30, P695, DOI 10.1016/j.ctrv.2004.04.003; Robinson JLL, 2011, EMBO J, V30, P3019, DOI 10.1038/emboj.2011.216; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Skliris GP, 2009, BREAST CANCER RES TR, V118, P443, DOI 10.1007/s10549-008-0267-z; Skliris GP, 2010, ENDOCR-RELAT CANCER, V17, P589, DOI 10.1677/ERC-10-0030; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Suzuki T, 2007, ENDOCR-RELAT CANCER, V14, P279, DOI 10.1677/ERC-06-0005; Wang CY, 2011, MOL ENDOCRINOL, V25, P1527, DOI 10.1210/me.2011-1037; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Yi P, 2008, MOL CELL, V29, P465, DOI 10.1016/j.molcel.2007.12.030; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zwart W, 2007, EMBO J, V26, P3534, DOI 10.1038/sj.emboj.7601791	58	28	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3543	3551		10.1038/onc.2012.361	http://dx.doi.org/10.1038/onc.2012.361			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22907427				2022-12-17	WOS:000322220800007
J	Chander, H; Truesdell, P; Meens, J; Craig, AWB				Chander, H.; Truesdell, P.; Meens, J.; Craig, A. W. B.			Transducer of Cdc42-dependent actin assembly promotes breast cancer invasion and metastasis	ONCOGENE			English	Article						breast cancer; metastasis; invadopodia; F-BAR adaptor Toca-1	CDC42-INTERACTING PROTEIN 4; GROWTH-FACTOR-RECEPTOR; INVADOPODIA FORMATION; TUMOR-CELLS; N-WASP; CARCINOMA CELLS; PCH PROTEINS; BAR; CORTACTIN; SRC	Metastatic breast adenocarcinomas display activation signatures for signaling pathways that trigger cell motility and tissue invasion. Here, we report that the adaptor protein transducer of Cdc42-dependent actin assembly-1 (Toca-1) is expressed in highly invasive breast cancers and regulates their metastatic phenotypes. We show that Toca-1 localizes to the filamentous actin-rich core of invadopodial protrusions actively degrading the extracellular matrix (ECM). Toca-1 colocalizes with Cortactin, and we show that this interaction is mediated by the SH3 domain of Toca-1. Stable knockdown (KD) of Toca-1 expression in MDA-MB-231 cells led to a significant defect in epidermal growth factor (EGF)-induced cell migration and invasion. Toca-1 KD cells also showed significant defects in EGF- and Src-induced ECM digestion and formation of invadopodial membrane protrusions. To test the role of Toca-1 in metastasis, we achieved stable Toca-1 KD in both human and rat metastatic breast adenocarcinoma cell lines. Orthotopic tumor xenografting of control and Toca-1 KD cells in natural-killer /B-/T-cell-deficient mice revealed a significant defect in spontaneous lung metastases with Toca-1 silencing in vivo. In contrast, no defects in primary tumor growth or lung seeding following tail vein injection of Toca-1 KD cells was observed, suggesting that Toca-1 functions at an early step in the dissemination of metastatic breast tumor cells. Taken together, our results identify Toca-1 as a proinvasive protein in breast adenocarcinoma and a potential therapeutic target to limit tumor metastasis.	[Chander, H.; Truesdell, P.; Meens, J.; Craig, A. W. B.] Queens Canc Res Inst, Canc Biol & Genet Div, Kingston, ON, Canada; [Craig, A. W. B.] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Craig, AWB (corresponding author), Queens Univ, 18 Stuart St, Kingston, ON K7L 3N6, Canada.	andrew.craig@queensu.ca	Craig, Andrew/AAC-6923-2019; Craig, Andrew/G-2312-2017	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393	Canadian Breast Cancer Foundation (Ontario, Canada)	Canadian Breast Cancer Foundation (Ontario, Canada)	We greatfully acknowledge Stephanie Everingham, Jinghui Hu and Alka Mukhopadhyay for help in preparing key reagents, and Chandra Tayade for providing mice. Thanks to Sohail Ahmed, Phillipe Chavrier and Alan Mak for providing plasmids, and Leda Raptis and Doris Germain for providing cell lines. This research is supported by a grant from Canadian Breast Cancer Foundation (Ontario, Canada) to AWBC.	Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Aspenstrom P, 2006, TRENDS BIOCHEM SCI, V31, P670, DOI 10.1016/j.tibs.2006.10.001; Aspenstrom P, 2006, EXP CELL RES, V312, P2180, DOI 10.1016/j.yexcr.2006.03.013; Aspenstrom P, 2010, BBA-MOL CELL RES, V1803, P174, DOI 10.1016/j.bbamcr.2009.06.002; Bravo-Cordero JJ, 2011, CURR BIOL, V21, P635, DOI 10.1016/j.cub.2011.03.039; Bu WY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012153; Bu WY, 2009, J BIOL CHEM, V284, P11622, DOI 10.1074/jbc.M805940200; Campellone KG, 2012, J BIOL CHEM, V287, P20613, DOI 10.1074/jbc.M112.363473; Chitu V, 2007, TRENDS CELL BIOL, V17, P145, DOI 10.1016/j.tcb.2007.01.003; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; de Boer M, 2010, J NATL CANCER I, V102, P410, DOI 10.1093/jnci/djq008; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; DesMarais V, 2009, CELL MOTIL CYTOSKEL, V66, P303, DOI 10.1002/cm.20361; Devy L, 2009, CANCER RES, V69, P1517, DOI 10.1158/0008-5472.CAN-08-3255; Eckert MA, 2011, ONCOTARGET, V2, P562; Fricke Robert, 2010, Commun Integr Biol, V3, P89; Fricke R, 2009, CURR BIOL, V19, P1429, DOI 10.1016/j.cub.2009.07.058; Frittoli E, 2011, EUR J CELL BIOL, V90, P108, DOI 10.1016/j.ejcb.2010.04.007; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Giuliani C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000675; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Hu JH, 2011, J CELL SCI, V124, P1739, DOI 10.1242/jcs.078014; Hu JH, 2011, J BIOL CHEM, V286, P2261, DOI 10.1074/jbc.M110.157974; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Le Devedec SE, 2009, CLIN EXP METASTAS, V26, P673, DOI 10.1007/s10585-009-9267-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lizarraga F, 2009, CANCER RES, V69, P2792, DOI 10.1158/0008-5472.CAN-08-3709; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Pichot CS, 2010, CANCER RES, V70, P8347, DOI 10.1158/0008-5472.CAN-09-4149; Rakha EA, 2009, BREAST CANCER RES TR, V113, P411, DOI 10.1007/s10549-008-9952-1; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Rao YJ, 2010, P NATL ACAD SCI USA, V107, P8213, DOI 10.1073/pnas.1003478107; Rucci N, 2006, J PHARMACOL EXP THER, V318, P161, DOI 10.1124/jpet.106.102004; Shimada A, 2010, FEBS LETT, V584, P1111, DOI 10.1016/j.febslet.2010.02.058; Steffen A, 2008, CURR BIOL, V18, P926, DOI 10.1016/j.cub.2008.05.044; Stylli SS, 2008, J CLIN NEUROSCI, V15, P725, DOI 10.1016/j.jocn.2008.03.003; Suetsugu S, 2009, FEBS LETT, V583, P3401, DOI 10.1016/j.febslet.2009.10.019; Sun XL, 2009, CARCINOGENESIS, V30, P2109, DOI 10.1093/carcin/bgp251; Takano K, 2008, EMBO J, V27, P2817, DOI 10.1038/emboj.2008.216; Tsujita K, 2006, J CELL BIOL, V172, P269, DOI 10.1083/jcb.200508091; Valsecchi ME, 2012, CANCER-AM CANCER SOC, V118, P3484, DOI 10.1002/cncr.26661; Van Trappen PO, 2002, LANCET ONCOL, V3, P44, DOI 10.1016/S1470-2045(01)00621-0; Wang Q, 2009, P NATL ACAD SCI USA, V106, P12700, DOI 10.1073/pnas.0902974106; Wang WG, 2007, CANCER RES, V67, P3505, DOI 10.1158/0008-5472.CAN-06-3714; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Webb BA, 2006, EXP CELL RES, V312, P760, DOI 10.1016/j.yexcr.2005.11.032; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamamoto H, 2011, J UROLOGY, V185, P1930, DOI 10.1016/j.juro.2010.12.027	56	28	31	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3080	3090		10.1038/onc.2012.317	http://dx.doi.org/10.1038/onc.2012.317			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22824798				2022-12-17	WOS:000320705700008
J	Yao, Z; Jones, AWE; Fassone, E; Sweeney, MG; Lebiedzinska, M; Suski, JM; Wieckowski, MR; Tajeddine, N; Hargreaves, IP; Yasukawa, T; Tufo, G; Brenner, C; Kroemer, G; Rahman, S; Szabadkai, G				Yao, Z.; Jones, A. W. E.; Fassone, E.; Sweeney, M. G.; Lebiedzinska, M.; Suski, J. M.; Wieckowski, M. R.; Tajeddine, N.; Hargreaves, I. P.; Yasukawa, T.; Tufo, G.; Brenner, C.; Kroemer, G.; Rahman, S.; Szabadkai, G.			PGC-1 beta mediates adaptive chemoresistance associated with mitochondrial DNA mutations	ONCOGENE			English	Article						CDDP; chemoresistance; mitochondrial biogenesis; PGC-1; Complex-I; mitochondrial DNA	CANCER; COACTIVATORS; RESISTANCE; FAMILY; NEURODEGENERATION; PGC-1-ALPHA; BIOGENESIS; REGULATOR; CISPLATIN; APOPTOSIS	Primary mitochondrial dysfunction commonly leads to failure in cellular adaptation to stress. Paradoxically, however, nonsynonymous mutations of mitochondrial DNA (mtDNA) are frequently found in cancer cells and may have a causal role in the development of resistance to genotoxic stress induced by common chemotherapeutic agents, such as cis-diammine-dichloroplatinum(II) (cisplatin, CDDP). Little is known about how these mutations arise and the associated mechanisms leading to chemoresistance. Here, we show that the development of adaptive chemoresistance in the A549 non-small-cell lung cancer cell line to CDDP is associated with the hetero- to homoplasmic shift of a nonsynonymous mutation in MT-ND2, encoding the mitochondrial Complex-I subunit ND2. The mutation resulted in a 50% reduction of the NADH: ubiquinone oxidoreductase activity of the complex, which was compensated by increased biogenesis of respiratory chain complexes. The compensatory mitochondrial biogenesis was most likely mediated by the nuclear co-activators peroxisome proliferator-activated receptor gamma co-activator-1 alpha (PGC-1 alpha) and PGC-1 beta, both of which were significantly upregulated in the CDDP-resistant cells. Importantly, both transient and stable silencing of PGC-1 beta re-established the sensitivity of these cells to CDDP-induced apoptosis. Remarkably, the PGC-1 beta-mediated CDDP resistance was independent of the mitochondrial effects of the co-activator. Altogether, our results suggest that partial respiratory chain defects because of mtDNA mutations can lead to compensatory upregulation of nuclear transcriptional co-regulators, in turn mediating resistance to genotoxic stress.	[Yao, Z.; Jones, A. W. E.; Szabadkai, G.] UCL, Consortium Mitochondrial Res, Dept Cell & Dev Biol, London WC1E 6BT, England; [Fassone, E.; Rahman, S.] UCL Inst Child Hlth, Clin & Mol Genet Unit, London, England; [Fassone, E.] Univ Milan, IRCCS Fdn Ca Granda, Osped Maggiore Policlin, Dino Ferrari Ctr,Dept Neurol Sci, Milan, Italy; [Sweeney, M. G.] Natl Hosp Neurol & Neurosurg, Neurogenet Unit, London, England; [Lebiedzinska, M.; Suski, J. M.; Wieckowski, M. R.] M Nencki Inst Expt Biol, Dept Biochem, PL-02093 Warsaw, Poland; [Tajeddine, N.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Hargreaves, I. P.] UCL, Inst Neurol, London, England; [Yasukawa, T.] UCL, Wolfson Inst Biomed Res, London, England; [Tufo, G.; Brenner, C.] Univ Paris 11, INSERM, UMR S 769, Chatenay Malabry, France; [Kroemer, G.] Inst Gustave Roussy, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France; [Kroemer, G.] Univ Paris 05, Fac Med, Paris, France	University of London; University College London; University of London; University College London; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; University of London; University College London; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Szabadkai, G (corresponding author), UCL, Consortium Mitochondrial Res, Dept Cell & Dev Biol, Gower St, London WC1E 6BT, England.	g.szabadkai@ucl.ac.uk	Rahman, Shamima/M-7904-2019; Lebiedzińska-Arciszewska, Magdalena/AAC-5956-2021; KROEMER, Guido/B-4263-2013; Lebiedzińska-Arciszewska, Magdalena/AAA-3279-2022; Suski, Jan/AAP-9727-2021; Kroemer, Guido/AAY-9859-2020; Rahman, Shamima/C-5232-2008; Hargreaves, Iain/AAJ-6757-2020; Yao, Zhi/B-9047-2013; YAO, Zhi/C-6096-2009; Yasukawa, Takehiro/AAP-1335-2020	KROEMER, Guido/0000-0002-9334-4405; Lebiedzińska-Arciszewska, Magdalena/0000-0002-2725-5551; Rahman, Shamima/0000-0003-2088-730X; Yao, Zhi/0000-0001-6432-5734; Wieckowski, Mariusz/0000-0003-0789-4521; Szabadkai, Gyorgy/0000-0002-3006-3577; Suski, Jan/0000-0001-5657-2655; Yasukawa, Takehiro/0000-0001-9531-8780	Parkinson's UK [G-0905]; Medical Research Council (MRC-DTA); Polish Ministry of Science and Higher Education [NN407075137]; National Science Centre [DEC-2011/01/M/NZ3/02128]; Foundation for Polish Science; EU; European Regional Development Fund; Operational Programme "Innovative economy"; L'Oreal fellowship; Great Ormond Street Hospital Children's Charity; European Union (ApoSys); European Union (ArtForce); European Union (ChemoRes); Ligue contre le Cancer (Laboratoire labellise); Parkinson&quot;s UK [G-0905] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [V1220] Funding Source: researchfish	Parkinson's UK(Parkinson's UK); Medical Research Council (MRC-DTA); Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); National Science Centre(National Science Centre, Poland); Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); EU(European Commission); European Regional Development Fund(European Commission); Operational Programme "Innovative economy"; L'Oreal fellowship(L'Oreal Group); Great Ormond Street Hospital Children's Charity; European Union (ApoSys)(European CommissionEuropean Commission Joint Research Centre); European Union (ArtForce); European Union (ChemoRes); Ligue contre le Cancer (Laboratoire labellise); Parkinson&quot;s UK(Parkinson&apos;s UK); Great Ormond Street Hospital Childrens Charity	We thank the excellent technical help of M Rahman (UCL Biosciences Molecular Biology Unit), K Pearce (UCL Genomics), the access to the Arrayscan VTI HCS Reader and the help of G Keen, M Elrayess and J Staddon from Eisai Europe Ltd; Professors M Duchen, C Boshoff and JM Funes for reagents and advice; JW Taanman for providing the A549 rho0 cell line, and D Housenloy for the Akt antibodies. The work was supported by Parkinson's UK (G-0905) and the Medical Research Council (MRC-DTA) to GS, ZY and AJ MRW is supported by the Polish Ministry of Science and Higher Education under Grant NN407075137 and by the grant from the National Science Centre-decision number DEC-2011/01/M/NZ3/02128. JMS is a recipient of a PhD fellowship from the Foundation for Polish Science, EU, European Regional Development Fund and Operational Programme "Innovative economy". ML is recipient of a fellowship from the Foundation for Polish Science (Programme Start) and the L'Oreal fellowship (For Women in Science). SR is supported by Great Ormond Street Hospital Children's Charity. GK is supported by the European Union (ApoSys, ArtForce, ChemoRes) and the Ligue contre le Cancer (Laboratoire labellise).	Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bianchi K, 2006, CELL DEATH DIFFER, V13, P586, DOI 10.1038/sj.cdd.4401784; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Campanella M, 2009, BBA-BIOENERGETICS, V1787, P393, DOI 10.1016/j.bbabio.2009.02.023; Chandra D, 2011, BBA-BIOENERGETICS, V1807, P620, DOI 10.1016/j.bbabio.2010.10.023; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; CREWS S, 1979, NATURE, V277, P192, DOI 10.1038/277192a0; Cullen KJ, 2007, J BIOENERG BIOMEMBR, V39, P43, DOI 10.1007/s10863-006-9059-5; Di Re M, 2009, NUCLEIC ACIDS RES, V37, P5701, DOI 10.1093/nar/gkp614; Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI [10.1042/BSE0470115, 10.1042/bse0470115]; Efremov RG, 2010, NATURE, V465, P441, DOI 10.1038/nature09066; Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917; Galluzzi L, 2007, APOPTOSIS, V12, P803, DOI 10.1007/s10495-007-0720-1; Guerra F, 2011, HUM MOL GENET, V20, P2394, DOI 10.1093/hmg/ddr146; Guha M, 2010, MOL BIOL CELL, V21, P3578, DOI 10.1091/mbc.E10-03-0192; Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; Jones AWE, 2012, MITOCHONDRION, V12, P86, DOI 10.1016/j.mito.2011.09.009; Kajimura S, 2008, GENE DEV, V22, P1397, DOI 10.1101/gad.1666108; Kulawiec M, 2010, ENVIRON MOL MUTAGEN, V51, P427, DOI 10.1002/em.20582; Kulawiec M, 2009, CANCER BIOL THER, V8, P1378, DOI 10.4161/cbt.8.14.8751; Kwong JQ, 2007, J CELL BIOL, V179, P1163, DOI 10.1083/jcb.200704059; Lane N, 2011, BIOESSAYS, V16, P1; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lo S, 2005, INT J ONCOL, V27, P337; Mizutani S, 2009, CANCER SCI, V100, P1680, DOI 10.1111/j.1349-7006.2009.01238.x; Nakamaru-Ogiso E, 2010, FEBS LETT, V584, P883, DOI 10.1016/j.febslet.2010.01.004; Ohta S, 2006, ONCOGENE, V25, P4768, DOI 10.1038/sj.onc.1209602; Park CB, 2011, J CELL BIOL, V193, P809, DOI 10.1083/jcb.201010024; Ragan CI, 1988, MITOCHONDRIA PRACTIC, P79; Rahman S, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000411; Ruhanen H, 2010, BBA-MOL CELL RES, V1803, P931, DOI 10.1016/j.bbamcr.2010.04.008; Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019; Sen T, 2011, CANCER RES, V71, P1167, DOI 10.1158/0008-5472.CAN-10-1481; Spinazzola A, 2009, ADV EXP MED BIOL, V652, P69, DOI 10.1007/978-90-481-2813-6_6; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Suski JM, 2012, METHODS MOL BIOL, V810, P183, DOI 10.1007/978-1-61779-382-0_12; Traba J, 2012, CELL DEATH DIFFER, V19, P650, DOI 10.1038/cdd.2011.139; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002; Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05; Wallace DC, 2010, MITOCHONDRION, V10, P12, DOI 10.1016/j.mito.2009.09.006; Zechner C, 2010, CELL METAB, V12, P633, DOI 10.1016/j.cmet.2010.11.008	43	28	28	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2592	2600		10.1038/onc.2012.259	http://dx.doi.org/10.1038/onc.2012.259			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22777349				2022-12-17	WOS:000319274300011
J	Jin, C; Rajabi, H; Rodrigo, CM; Porco, JA; Kufe, D				Jin, C.; Rajabi, H.; Rodrigo, C. M.; Porco, J. A., Jr.; Kufe, D.			Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein	ONCOGENE			English	Article						MUC1-C; translation; AKT; mTOR; PDCD4; silvestrol	GROWTH-FACTOR RECEPTOR; MOLECULAR-MECHANISMS; CARCINOMA ANTIGEN; ACTIVATION; SURVIVAL; DEGRADATION; SILVESTROL; EXPRESSION; INHIBITORS; INITIATION	The oncogenic MUC1 C-terminal subunit (MUC1-C) subunit is aberrantly overexpressed in most human breast cancers by mechanisms that are not well understood. The present studies demonstrate that stimulation of non-malignant MCF-10A cells with epidermal growth factor (EGF) or heregulin (HRG) results in marked upregulation of MUC1-C translation. Growth factor-induced MUC1-C translation was found to be mediated by PI3K -> AKT, and not by MEK -> ERK1/2, signaling. We also show that activation of the mammalian target of rapamycin complex 1 (mTORC1)-> ribosomal protein S6 kinase 1 (S6K1) pathway decreases tumor suppressor programmed cell death protein 4 (PDCD4), an inhibitor of the eIF4A RNA helicase, and contributes to the induction of MUC1-C translation. In concert with these results, treatment of growth factor-stimulated MCF-10A cells with the eIF4A RNA helicase inhibitors, silvestrol and CR-1-31-B, blocked increases in MUC1-C abundance. The functional significance of the increase in MUC1-C translation is supported by the demonstration that MUC1-C, in turn, forms complexes with EGF receptor (EGFR) and promotes EGFR-mediated activation of the PI3K -> AKT pathway and the induction of growth. Compared with MCF-10A cells, constitutive overexpression of MUC1-C in breast cancer cells was unaffected by EGF stimulation, but was blocked by inhibiting PI3K -> AKT signaling. The overexpression of MUC1-C in breast cancer cells was also inhibited by blocking eIF4A RNA helicase activity with silvestrol and CR-1-31-B. These findings indicate that EGF-induced MUC1-C expression is mediated by the PI3K -> AKT pathway and the eIF4A RNA helicase, and that this response promotes EGFR signaling in an autoinductive loop. The findings also indicate that targeting the eIF4A RNA helicase is a novel approach for blocking MUC1-C overexpression in breast cancer cells. Oncogene (2013) 32, 2179-2188; doi:10.1038/onc.2012.236; published online 11 June 2012	[Jin, C.; Rajabi, H.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; [Rodrigo, C. M.; Porco, J. A., Jr.] Boston Univ, Dept Chem, Ctr Chem Methodol & Lib Dev, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Boston University	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute [CA97098, CA42802, CA100707]; National Institutes of Health Grant [GM-073855]; American Cancer Society [PF-11-077-01-CDD]; NATIONAL CANCER INSTITUTE [R01CA097098, P50CA100707, R01CA042802, R01CA166480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073855] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Cancer Institute Grants CA97098, CA42802 and CA100707; the National Institutes of Health Grant GM-073855 (JAP), and a postdoctoral fellowship from the American Cancer Society PF-11-077-01-CDD (CMR).	Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Bordeleau ME, 2008, J CLIN INVEST, V118, P2651, DOI 10.1172/JCI34753; Cencic R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005223; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Gerard B, 2007, ANGEW CHEM INT EDIT, V46, P7831, DOI 10.1002/anie.200702707; Hsieh AC, 2011, BRIT J CANCER, V105, P329, DOI 10.1038/bjc.2011.241; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Hwang BY, 2004, J ORG CHEM, V69, P3350, DOI 10.1021/jo040120f; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Joshi MD, 2009, MOL CANCER THER, V8, P3056, DOI 10.1158/1535-7163.MCT-09-0646; Kong D, 2009, CURR MED CHEM, V16, P2839, DOI 10.2174/092986709788803222; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Lucas DM, 2009, BLOOD, V113, P4656, DOI 10.1182/blood-2008-09-175430; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Newton R, 2000, BRIT J PHARMACOL, V130, P1353, DOI 10.1038/sj.bjp.0703431; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Parsyan A, 2011, NAT REV MOL CELL BIO, V12, P235, DOI 10.1038/nrm3083; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Rodrigo CM, 2012, J MED CHEM, V55, P558, DOI 10.1021/jm201263k; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Schatz JH, 2011, J EXP MED, V208, P1799, DOI 10.1084/jem.20110846; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wedeken L, 2011, J BIOL CHEM, V286, P42855, DOI 10.1074/jbc.M111.269456; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Workman P, 2010, CANCER RES, V70, P2146, DOI 10.1158/0008-5472.CAN-09-4355; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Yin L, 2007, J BIOL CHEM, V282, P257, DOI 10.1074/jbc.M610156200; Zhou YC, 2011, MOL PHARMACOL, V79, P886, DOI 10.1124/mol.110.070797	44	28	31	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2179	2188		10.1038/onc.2012.236	http://dx.doi.org/10.1038/onc.2012.236			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689062	Green Accepted			2022-12-17	WOS:000318062800007
J	Zhang, P; Guo, A; Possemato, A; Wang, C; Beard, L; Carlin, C; Markowitz, SD; Polakiewicz, RD; Wang, Z				Zhang, P.; Guo, A.; Possemato, A.; Wang, C.; Beard, L.; Carlin, C.; Markowitz, S. D.; Polakiewicz, R. D.; Wang, Z.			Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14	ONCOGENE			English	Article						PTPN14; p130Cas; tumorigenesis; colorectal cancer	HUMAN BREAST; TGF-BETA; SRC; RECEPTOR; ASSOCIATION; KINASE; PEZ; CAS; PHOSPHORYLATION; RESISTANCE	Protein tyrosine phosphatase nonreceptor type 14 (PTPN14) is frequently mutated in a variety of human cancers. However, the cell signaling pathways regulated by PTPN14 largely remain to be elucidated. Here, we identify a list of potential substrates of PTPN14 using a phospho-proteomic approach. We show that p130 Crk-associated substrate (p130Cas) is a direct substrate of PTPN14 and that PTPN14 specifically regulates p130Cas phosphorylation at tyrosine residue 128 (Y128) in colorectal cancer (CRC) cells. We engineered CRC cells homozygous for a p130Cas Y128F knock-in mutant and found that these cells exhibit significantly reduced migration and colony formation, impaired anchorage-independent growth, slower xenograft tumor growth in nude mice and have decreased phosphorylation of AKT. Furthermore, we demonstrate that SRC phosphorylates p130Cas Y128 and that CRC cell lines harboring high levels of pY128Cas are more sensitive to SRC family kinase inhibitor Dasatinib. These findings suggest that p130Cas Y128 phosphorylation may be exploited as a predictive marker for Dasatinib response in cancer patients. In aggregate, our studies reveal a novel signaling pathway that has an important role in colorectal tumorigenesis. Oncogene (2013) 32, 2087-2095; doi:10.1038/onc.2012.220; published online 18 June 2012	[Zhang, P.; Wang, C.; Wang, Z.] Case Western Reserve Univ, Dept Genet, Sch Med, Cleveland, OH 44106 USA; [Zhang, P.; Wang, C.; Beard, L.; Markowitz, S. D.; Wang, Z.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, Cleveland, OH 44106 USA; [Guo, A.; Possemato, A.; Polakiewicz, R. D.] Cell Signaling Technol Inc, Danvers, MA USA; [Beard, L.; Markowitz, S. D.] Case Western Reserve Univ, Dept Genet, Sch Med, Case Med Ctr, Cleveland, OH 44106 USA; [Wang, Z.] Cleveland Clin Fdn, Genom Med Inst, Cleveland, OH 44195 USA; [Carlin, C.] Case Western Reserve Univ, Dept Microbiol & Mol Biol, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University	Wang, Z (corresponding author), Case Western Reserve Univ, Dept Genet, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	zhenghe.wang@case.edu			National Institutes of Health [R01-CA127590, R01-HG004722]; Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [P50CA150964, R01CA127590, P30CA043703] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004722] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Yueting Chen for excellent technical assistance, Drs Susann Brady-Kalnay, Hua Luo and CK Qu for helpful discussions, and Anthony Scott for critical reading of the manuscript. This research was supported by grants from the National Institutes of Health Grant R01-CA127590, R01-HG004722 and a pilot grant from the Case Comprehensive Cancer Center.	Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Blanchetot C, 2005, METHODS, V35, P44, DOI 10.1016/j.ymeth.2004.07.007; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bohnacker T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000259; Brognard J, 2011, CURR OPIN GENET DEV, V21, P4, DOI 10.1016/j.gde.2010.10.012; Burnham MR, 1996, ONCOGENE, V12, P2467; Cabodi S, 2006, CANCER RES, V66, P4672, DOI 10.1158/0008-5472.CAN-05-2909; Montero JC, 2011, CLIN CANCER RES, V17, P5546, DOI 10.1158/1078-0432.CCR-10-2616; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; DORSSERS LCJ, 1993, MOL ENDOCRINOL, V7, P870, DOI 10.1210/me.7.7.870; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Hirata R, 2002, NAT BIOTECHNOL, V20, P735, DOI 10.1038/nbt0702-735; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Liang FB, 2007, MOL BIOSYST, V3, P308, DOI 10.1039/b700704n; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905; Patwardhan P, 2006, J BIOL CHEM, V281, P20689, DOI 10.1074/jbc.M602311200; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Riggins RB, 2003, MOL CANCER RES, V1, P428; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wadham C, 2000, J CELL SCI, V113, P3117; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wei XM, 2011, NAT GENET, V43, P442, DOI 10.1038/ng.810; Wyatt L, 2008, CELL CYCLE, V7, P2290, DOI 10.4161/cc.6443; Wyatt L, 2007, J CELL BIOL, V178, P1223, DOI 10.1083/jcb.200705035; Yarom N, 2011, DISCOV MED, V11, P95; Zhang P, 2011, MOL CANCER RES, V9, P1418, DOI 10.1158/1541-7786.MCR-11-0147; Zhang XD, 2008, NAT METHODS, V5, P163, DOI 10.1038/NMETH1170; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; Zhao YQ, 2010, P NATL ACAD SCI USA, V107, P2592, DOI 10.1073/pnas.0914884107	43	28	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2087	2095		10.1038/onc.2012.220	http://dx.doi.org/10.1038/onc.2012.220			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22710723	Green Accepted			2022-12-17	WOS:000317919900010
J	Du, W; Wright, BM; Li, X; Finke, J; Rini, BI; Zhou, M; He, H; Lal, P; Welford, SM				Du, W.; Wright, B. M.; Li, X.; Finke, J.; Rini, B. I.; Zhou, M.; He, H.; Lal, P.; Welford, S. M.			Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; macrophage migration inhibitory factor; MIF; src; p27; autocrine signaling	HYPOXIA-INDUCIBLE FACTORS; FACTOR MIF; GASTRIC-CANCER; UP-REGULATION; EXPRESSION; ACTIVATION; GENE; SRC; ANGIOGENESIS; PROGNOSIS	The macrophage migration inhibitory factor (MIF) is a hypoxia regulated gene that has a variety of tumorigenic functions. In clear cell renal carcinoma (CCRC), hypoxic signaling is constitutively active because of the frequent loss of function of the von Hippel-Lindau tumor suppressor protein. We therefore sought to assess the expression of MIF in CCRC and its biological functions. We stained tumor tissue microarrays comprising sections of 128 CCRC tumors and found MIF to be moderately or highly expressed in >98%. MIF expression was further found to be dramatically elevated in blood plasma of individuals with CCRC compared with healthy controls, suggesting that measurement of MIF levels in the blood may have utility as a diagnostic marker in CCRC. At a functional level, MIF has been reported to engage the CD74 and CD44 receptors and induce signal transduction. In CCRC cell lines, depletion of MIF, CD74 or CD44 by small hairpin RNA led to a significant reduction in growth rate, and clonogenic survival, coinciding with the degree of knockdown. Interruption of the MIF pathway also decreased tumorigenic potential. Biochemically, we found that in CCRC cells MIF signaling leads to activation of the mitogen-activated protein kinase pathway and to Src phosphorylation, which is critical for regulation of p27. Together, our studies establish MIF as a protumorigenic signaling molecule that functions in an autocrine fashion to promote renal cell carcinoma and may be useful as a minimally invasive marker of disease status. Oncogene (2013) 32, 1469-1474; doi:10.1038/onc.2012.143; published online 30 April 2012	[Du, W.; Wright, B. M.; Li, X.; Welford, S. M.] Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; [Finke, J.] Dept Mol Med, Cleveland, OH USA; [Rini, B. I.] Dept Solid Tumor Oncol, Cleveland, OH USA; [Zhou, M.; He, H.] Cleveland Clin Fdn, Dept Anat Pathol & Canc Biol, Cleveland, OH 44195 USA; [Lal, P.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA	Case Western Reserve University; Cleveland Clinic Foundation; University of Pennsylvania	Welford, SM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, BRB325,10900 Euclid Ave, Cleveland, OH 44106 USA.	scott.welford@case.edu			RSG from the American Cancer Society [121762-RSG-12-097-01-CCG];  [CA147387];  [P30CA43703]; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER	RSG from the American Cancer Society; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by CA147387, and by an RSG from the American Cancer Society (121762-RSG-12-097-01-CCG) to SMW. We thank Drs Amato Giaccia and Haifeng Yang for cell lines. Flow cytometry was performed in the CASE Comprehensive Cancer Center Cytometry and Microscopy Core facility, which is supported by P30CA43703.	American Cancer Society, 2011, CANC FACTS FIG 2011; Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011; Bach JP, 2008, ONCOLOGY-BASEL, V75, P127, DOI 10.1159/000155223; Bacher M, 2003, AM J PATHOL, V162, P11, DOI 10.1016/S0002-9440(10)63793-5; Baugh JA, 2006, BIOCHEM BIOPH RES CO, V347, P895, DOI 10.1016/j.bbrc.2006.06.148; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; He XX, 2006, GUT, V55, P797, DOI 10.1136/gut.2005.078113; He XX, 2009, MOL MED, V15, P1, DOI 10.2119/molmed.2008.00107; Hira E, 2005, CANCER, V103, P588, DOI 10.1002/cncr.20818; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koong AC, 2000, CANCER RES, V60, P883; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Legendre H, 2003, MODERN PATHOL, V16, P491, DOI 10.1097/01.MP.0000068235.45178.C1; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Li GQ, 2009, WORLD J GASTROENTERO, V15, P5541, DOI 10.3748/wjg.15.5541; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Lue H, 2007, ONCOGENE, V26, P5046, DOI 10.1038/sj.onc.1210318; Lue HQ, 2006, CELL SIGNAL, V18, P688, DOI 10.1016/j.cellsig.2005.06.013; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meyer-Siegler KL, 2002, CANCER-AM CANCER SOC, V94, P1449, DOI 10.1002/cncr.10354; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Nguyen MT, 2003, J IMMUNOL, V170, P3337, DOI 10.4049/jimmunol.170.6.3337; Onodera S, 2002, J BIOL CHEM, V277, P7865, DOI 10.1074/jbc.M106020200; Schrader J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-464; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Welford SM, 2006, GENE DEV, V20, P3366, DOI 10.1101/gad.1471106; Xia HHX, 2009, CANCER-AM CANCER SOC, V115, P5441, DOI 10.1002/cncr.24609	36	28	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1469	1474		10.1038/onc.2012.143	http://dx.doi.org/10.1038/onc.2012.143			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22543583				2022-12-17	WOS:000316455600013
J	Chen, PL; Chen, CF; Chen, Y; Guo, XE; Huang, CK; Shew, JY; Reddick, RL; Wallace, DC; Lee, WH				Chen, P-L; Chen, C-F; Chen, Y.; Guo, X. E.; Huang, C-K; Shew, J-Y; Reddick, R. L.; Wallace, D. C.; Lee, W-H			Mitochondrial genome instability resulting from SUV3 haploinsufficiency leads to tumorigenesis and shortened lifespan	ONCOGENE			English	Article						mitochondrial dysfunction; Suv3; animal model; tumorigenesis	TUMOR-SUPPRESSOR; DNA MUTATIONS; OXIDATIVE STRESS; RNA HELICASE; INACTIVATION; METABOLISM; TRANSCRIPTS; MAINTENANCE; STABILITY; INTEGRITY	Mitochondrial dysfunction has been a hallmark of cancer. However, whether it has a causative role awaits to be elucidated. Here, using an animal model derived from inactivation of SUV3, a mitochondrial helicase, we demonstrated that mSuv3+/- mice harbored increased mitochondrial DNA (mtDNA) mutations and decreased mtDNA copy numbers, leading to tumor development in various sites and shortened lifespan. These phenotypes were transmitted maternally, indicating the etiological role of the mitochondria. Importantly, reduced SUV3 expression was observed in human breast tumor specimens compared with corresponding normal tissues in two independent cohorts. These results demonstrated for the first time that maintaining mtDNA integrity by SUV3 helicase is critical for cancer suppression. Oncogene (2013) 32, 1193-1201; doi:10.1038/onc.2012.120; published online 7 May 2012	[Chen, P-L; Chen, C-F; Guo, X. E.; Wallace, D. C.; Lee, W-H] Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA; [Chen, Y.] Univ Calif Irvine, Sch Med, Dept Med, Irvine, CA 92697 USA; [Huang, C-K; Shew, J-Y; Lee, W-H] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Reddick, R. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Wallace, D. C.] Univ Calif Irvine, Sch Med, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Academia Sinica - Taiwan; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Irvine	Lee, WH (corresponding author), Univ Calif Irvine, Sch Med, Dept Biol Chem, 124 Sprague Hall, Irvine, CA 92697 USA.	plchen@uci.edu; whlee@uci.edu	Chen, Phang-Lang/J-5031-2013	Chen, Chi-Fen/0000-0002-6391-821X	NIH [AG027877, NS21328, AG13154]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328, R01NS041850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027877, R01AG024373, R01AG013154] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dennis Wang for his critical reading, Dr Tom Doetschman for providing 129/Sv mouse genomic library, Andrea Nikitin, Suna Cai and Weiwei Fan for their excellent assistance. This study was supported by grant NIH AG027877 to WHL and PLC, and NS21328 and AG13154 to DCW. Based on the UCI's policy, it is declared that WHL serves as a member of Board of Directors of GeneTex, Inc. This arrangement has been reviewed and approved by the UCI COI committee.	Alberici P, 2006, ONCOGENE, V25, P1841, DOI 10.1038/sj.onc.1209226; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Chen PL, 2005, MOL CELL BIOL, V25, P3535, DOI 10.1128/MCB.25.9.3535-3542.2005; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101; de Grey ADNJ, 2002, EUR J BIOCHEM, V269, P2003, DOI 10.1046/j.1432-1033.2002.02868.x; Dziembowski A, 2003, J BIOL CHEM, V278, P1603, DOI 10.1074/jbc.M208287200; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Golden TR, 2001, MECH AGEING DEV, V122, P1577, DOI 10.1016/S0047-6374(01)00288-3; GOLIK P, 1995, CURR GENET, V28, P217, DOI 10.1007/BF00309780; Guo XE, 2011, J BIOL CHEM, V286, P38783, DOI 10.1074/jbc.M111.257956; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Khidr L, 2008, J BIOL CHEM, V283, P27064, DOI 10.1074/jbc.M802991200; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lin XQ, 2007, MOL CELL BIOL, V27, P4905, DOI 10.1128/MCB.02396-06; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pereira M, 2007, MECH AGEING DEV, V128, P609, DOI 10.1016/j.mad.2007.09.001; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Rodriguez-Santiago B, 2001, EUR J HUM GENET, V9, P279, DOI 10.1038/sj.ejhg.5200629; Rowley PT, 2005, ANNU REV MED, V56, P539, DOI 10.1146/annurev.med.56.061704.135235; Shu ZY, 2004, BIOCHEMISTRY-US, V43, P4781, DOI 10.1021/bi0356449; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; STEPIEN PP, 1995, CURR GENET, V27, P234, DOI 10.1007/BF00326154; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988; Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314; Wallace DC, 2009, GENE DEV, V23, P1714, DOI 10.1101/gad.1784909; Wang DDH, 2009, J BIOL CHEM, V284, P20812, DOI 10.1074/jbc.M109.009605; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yui R, 2003, GENES GENET SYST, V78, P245; Zanssen S, 2005, PLOS MED, V2, P1082, DOI 10.1371/journal.pmed.0020401; Zheng L, 2002, ADV CANCER RES, V85, P13, DOI 10.1016/S0065-230X(02)85002-3	51	28	29	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1193	1201		10.1038/onc.2012.120	http://dx.doi.org/10.1038/onc.2012.120			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22562243	Green Accepted, Green Submitted			2022-12-17	WOS:000316428800013
J	Russo, A; O'Bryan, JP				Russo, A.; O'Bryan, J. P.			Intersectin 1 is required for neuroblastoma tumorigenesis	ONCOGENE			English	Article						scaffold protein; SH3 domains; EH domains; endocytosis; transformation; oncogenesis	PHOSPHOINOSITIDE 3-KINASE; ACTIVATING MUTATIONS; ALK KINASE; EXPRESSION; ENDOCYTOSIS; CELLS; GENE; RECEPTOR; GROWTH; PROTEINS	Intersectin 1 (ITSN1) is a scaffold protein that regulates diverse cellular pathways, including endocytosis and several signal transduction pathways, including phosphatidylinositol 3-kinase, Class II beta (PI3K-C2 beta). ITSN1's transforming potential in vitro suggests that this scaffold protein may be involved in human tumorigenesis. Herein, we demonstrate that ITSN1 is expressed in primary human neuroblastoma tumors and tumor cell lines and is necessary for their in vitro and in vivo tumorigenic properties. Silencing ITSN1 significantly inhibits the anchorage independent growth of tumor cells in vitro and tumor formation in xenograft assays independent of MYCN status. Overexpression of the ITSN1 target, PI3K-C2 beta, rescues the soft agar growth of ITSN1-silenced cells demonstrating the importance of the ITSN1-PI3K-C2 beta pathway in neuroblastoma tumorigenesis. These findings represent the first demonstration that the ITSN1-PI3K-C2 beta pathway has a requisite role in human cancer, specifically neuroblastomas.	[O'Bryan, J. P.] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	O'Bryan, JP (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 4091 COMRB,835 S Wolcott,E403 M-C 868, Chicago, IL 60612 USA.	obryanj@uic.edu		O'Bryan, John/0000-0001-5386-1080	National Institutes of Health [HL090651]; Department of Defense [PR080428]; Foundation Jerome Lejeune; St Baldrick's Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090651] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Foundation Jerome Lejeune; St Baldrick's Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Naohiko Ikegaki and Bernard Weissman for providing various neuroblastoma cell lines, and Drs Michael Hogarty and Wendy London and the Children's Oncology Group ANBL00B1 Neuroblastoma Biology Studies for providing the primary neuroblastoma tumor samples for analysis. We also thank Dr Ikegaki for providing advice on the xenograft assay, Dr Javed Khan for his helpful discussions regarding the Oncogenomics database, and members of the O'Bryan lab for comments on the manuscript. These studies were supported by grants to JPO from the National Institutes of Health (HL090651), Department of Defense (PR080428), the Foundation Jerome Lejeune, and the St Baldrick's Foundation.	Adams A, 2000, J BIOL CHEM, V275, P27414; Ambros PF, 2009, BRIT J CANCER, V100, P1471, DOI 10.1038/sj.bjc.6605014; Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Billottet C, 2006, ONCOGENE, V25, P6648, DOI 10.1038/sj.onc.1209670; Boller D, 2008, CLIN CANCER RES, V14, P1172, DOI 10.1158/1078-0432.CCR-07-0737; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Das M, 2007, MOL CELL BIOL, V27, P7906, DOI 10.1128/MCB.01369-07; Eggert A, 2000, KLIN PADIATR, V212, P200, DOI 10.1055/s-2000-9677; Eggert A, 2001, J CLIN ONCOL, V19, P689, DOI 10.1200/JCO.2001.19.3.689; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Izbicka Elzbieta, 2005, Curr Opin Investig Drugs, V6, P1200; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Katso RM, 2006, MOL BIOL CELL, V17, P3729, DOI 10.1091/mbc.E05-11-1083; Koutros S, 2010, CANCER RES, V70, P2389, DOI 10.1158/0008-5472.CAN-09-3575; Ma YJ, 2011, J NEUROSCI RES, V89, P1079, DOI 10.1002/jnr.22616; Ma YJ, 2010, BRAIN RES, V1351, P222, DOI 10.1016/j.brainres.2010.05.028; Malacombe M, 2006, EMBO J, V25, P3494, DOI 10.1038/sj.emboj.7601247; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Marras E, 2001, INT J ONCOL, V19, P395; Martin NP, 2006, MOL PHARMACOL, V70, P1643, DOI 10.1124/mol.106.028274; Mohney RP, 2003, J BIOL CHEM, V278, P47038, DOI 10.1074/jbc.M303895200; Momboisse F, 2010, CELL MOL NEUROBIOL, V30, P1327, DOI 10.1007/s10571-010-9580-2; O'Bryan JP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3152re10; Predescu SA, 2007, J BIOL CHEM, V282, P17166, DOI 10.1074/jbc.M608996200; Qian ZJ, 2002, P NATL ACAD SCI USA, V99, P14925, DOI 10.1073/pnas.222491799; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Wang JB, 2005, J BIOL CHEM, V280, P22883, DOI 10.1074/jbc.M414375200; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; Yu Y, 2008, HUM MOL GENET, V17, P3281, DOI 10.1093/hmg/ddn224	43	28	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	46					4828	4834		10.1038/onc.2011.643	http://dx.doi.org/10.1038/onc.2011.643			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22266851	Green Accepted			2022-12-17	WOS:000311210700003
J	Pradeep, CR; Zeisel, A; Kostler, WJ; Lauriola, M; Jacob-Hirsch, J; Haibe-Kains, B; Amariglio, N; Ben-Chetrit, N; Emde, A; Solomonov, I; Neufeld, G; Piccart, M; Sagi, I; Sotiriou, C; Rechavi, G; Domany, E; Desmedt, C; Yarden, Y				Pradeep, C-R; Zeisel, A.; Koestler, W. J.; Lauriola, M.; Jacob-Hirsch, J.; Haibe-Kains, B.; Amariglio, N.; Ben-Chetrit, N.; Emde, A.; Solomonov, I.; Neufeld, G.; Piccart, M.; Sagi, I.; Sotiriou, C.; Rechavi, G.; Domany, E.; Desmedt, C.; Yarden, Y.			Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions	ONCOGENE			English	Article						adhesion; breast cancer; EGF; HER2; hypoxia	CARCINOMA IN-SITU; LYSYL OXIDASE; ANOIKIS RESISTANCE; FACTOR-BETA; EXPRESSION; ERBB2; RECEPTOR; SURVIVAL; CELLS; HER2	The HER2/neu oncogene encodes a receptor-like tyrosine kinase whose overexpression in breast cancer predicts poor prognosis and resistance to conventional therapies. However, the mechanisms underlying aggressiveness of HER2 (human epidermal growth factor receptor 2)-overexpressing tumors remain incompletely understood. Because it assists epidermal growth factor (EGF) and neuregulin receptors, we overexpressed HER2 in MCF10A mammary cells and applied growth factors. HER2-overexpressing cells grown in extracellular matrix formed filled spheroids, which protruded outgrowths upon growth factor stimulation. Our transcriptome analyses imply a two-hit model for invasive growth: HER2-induced proliferation and evasion from anoikis generate filled structures, which are morphologically and transcriptionally analogous to preinvasive patients' lesions. In the second hit, EGF escalates signaling and transcriptional responses leading to invasive growth. Consistent with clinical relevance, a gene expression signature based on the HER2/EGF-activated transcriptional program can predict poorer prognosis of a subgroup of HER2-overexpressing patients. In conclusion, the integration of a three-dimensional cellular model and clinical data attributes progression of HER2-overexpressing lesions to EGF-like growth factors acting in the context of the tumor's microenvironment. Oncogene (2012) 31, 3569-3583; doi:10.1038/onc.2011.547; published online 5 December 2011	[Pradeep, C-R; Koestler, W. J.; Lauriola, M.; Ben-Chetrit, N.; Emde, A.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Zeisel, A.; Domany, E.] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; [Jacob-Hirsch, J.; Amariglio, N.; Rechavi, G.] Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, IL-69978 Tel Aviv, Israel; [Jacob-Hirsch, J.; Amariglio, N.; Rechavi, G.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Haibe-Kains, B.; Piccart, M.; Sotiriou, C.; Desmedt, C.] Inst Jules Bordet, Translat Res Unit, B-1000 Brussels, Belgium; [Haibe-Kains, B.] Univ Libre Bruxelles, Machine Learning Grp, Brussels, Belgium; [Solomonov, I.; Sagi, I.] Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; [Neufeld, G.] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc Res & Vasc Biol Ctr, IL-31096 Haifa, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Institut Jules Bordet; Universite Libre de Bruxelles; Weizmann Institute of Science; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotty Bldg,Room 302,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Neufeld, Gera/F-1524-2019; YARDEN, YOSEF/K-1467-2012; DOMANY, EYTAN/K-1560-2012; Desmedt, Christine/P-7438-2017; lauriola, mattia/N-6435-2014; Haibe-Kains, Benjamin/D-3702-2011	Desmedt, Christine/0000-0002-5223-5579; Haibe-Kains, Benjamin/0000-0002-7684-0079; lauriola, mattia/0000-0002-7966-0065	National Cancer Institute [CA72981]; M.D. Moross Institute for Cancer Research; Kekst Family Institute for Medical Genetics; Women's Health Research Center; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Harry and Jeanette Weinberg Women's Health Research Endowment; Oprah Winfrey Biomedical Research Fund; Arresto Biosciences; European Commission; German Research Foundation; NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); M.D. Moross Institute for Cancer Research; Kekst Family Institute for Medical Genetics; Women's Health Research Center; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Harry and Jeanette Weinberg Women's Health Research Endowment; Oprah Winfrey Biomedical Research Fund; Arresto Biosciences; European Commission(European CommissionEuropean Commission Joint Research Centre); German Research Foundation(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Carlos Arteaga and Ittai Ben-Porath for reagents and helpful insights. Our laboratories are supported by research grants from the National Cancer Institute (Grant CA72981), the M.D. Moross Institute for Cancer Research, Kekst Family Institute for Medical Genetics, Women's Health Research Center funded by Bennett-Pritzker Endowment Fund, Marvelle Koffler Program for Breast Cancer Research, Harry and Jeanette Weinberg Women's Health Research Endowment, Oprah Winfrey Biomedical Research Fund, Arresto Biosciences, the European Commission, and the German Research Foundation. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. ED is the incumbent of the Henry J Leir Professorial Chair.	Akiri G, 2003, CANCER RES, V63, P1657; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Balleine RL, 2008, CLIN CANCER RES, V14, P8244, DOI 10.1158/1078-0432.CCR-08-0939; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Cox DR, 1972, J R STAT SOC B, V4, P102; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Desmedt C, 2008, EUR J CANCER, V44, P2714, DOI 10.1016/j.ejca.2008.09.011; Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756; Ensslin MA, 2007, P NATL ACAD SCI USA, V104, P2715, DOI 10.1073/pnas.0610296104; Erler JT, 2009, CLIN EXP METASTAS, V26, P35, DOI 10.1007/s10585-008-9209-8; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Haibe-Kains B, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-394; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jechlinger M, 2009, GENE DEV, V23, P1677, DOI 10.1101/gad.1801809; Kirschmann DA, 2002, CANCER RES, V62, P4478; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; LONARDO F, 1990, New Biologist, V2, P992; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smigal C, 2006, CA-CANCER J CLIN, V56, P168, DOI 10.3322/canjclin.56.3.168; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tagliabue E, 2003, LANCET, V362, P527, DOI 10.1016/S0140-6736(03)14112-8; Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157; Therneau T.M., 2000, STAT BIOL HEALTH; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Valabrega G, 2005, ONCOGENE, V24, P3002, DOI 10.1038/sj.onc.1208478; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081	47	28	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	31					3569	3583		10.1038/onc.2011.547	http://dx.doi.org/10.1038/onc.2011.547			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22139081	Green Accepted			2022-12-17	WOS:000307245600001
J	Chen, Y; Yang, D; Li, S; Gao, Y; Jiang, R; Deng, L; Frankel, FR; Sun, B				Chen, Y.; Yang, D.; Li, S.; Gao, Y.; Jiang, R.; Deng, L.; Frankel, F. R.; Sun, B.			Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma	ONCOGENE			English	Article						Listeria monocytogenes; hepatocellular carcinoma; immunotherapy; epitope; cancer vaccines	T-CELL RESPONSES; ALPHA-FETOPROTEIN; IMMUNE-RESPONSES; CANCER-IMMUNOTHERAPY; ANTITUMOR IMMUNITY; DENDRITIC CELLS; TRANSGENIC MICE; PEPTIDE ELISA; IN-VIVO; PROTEIN	Live attenuated Listeria monocytogenes (LM) is a promising bacterial vector able to induce a T-cell response to tumor-associated antigens and demonstrates great potential for use in vaccine development. A novel recombinant LM-based vaccine (Lmdd (LM Delta dal Delta dat)-MPFG (multiple peptide fusing genes)) was developed with the ability to express and secrete hepatocellular carcinoma (HCC)-related tumor-associated antigens fragments due to the insertion of hepatitis B virus (HBV)-X protein (HBx)-derived epitopes HBx(52-60) and HBx(140-148), the universal T-helper epitope, alpha-fetoprotein (AFP) epitope AFP(158-166), and melanoma antigen gene (MAGE)-3(271-279) into the HBV core protein. Following immunization with the Lmdd-MPFG vaccine, macrophages exhibited uptake of the bacteria; the vaccine was then nearly cleared 3 days after the first administration. It disappeared even more quickly following subsequent vaccinations. However, recombinant Lmdd-MPFG allowed for the full development of an antitumor response towards the human leukocyte antigen (HLA)-A0201 epitopes of MPFG. Each epitope stimulated an augmented T-cell proliferation and enhanced the supernatant level of interferon (IFN)-gamma in vitro. In addition, IFN-gamma-producing CD8(+) T cells as well as in vivo cytolytic activity were significantly increased in HLA-A2 transgenic mice. Additionally, the Lmdd-MPFG developed a strong antitumor response, as indicated by the significant resistance of immunized mice to MPFG-positive Hepa1-6 cell challenge in both a prophylactic and therapeutic setting. Tumor regression was accompanied by an enhanced cytotoxic T lymphocyte response and a decrease of regulatory T cells in the tumor. Collectively, these results suggest that utilizing attenuated LM as a vaccine vector, able to carry the MPFG gene, presents a potentially feasible strategy for prevention of HCC. Oncogene (2012) 31, 2140-2152; doi:10.1038/onc.2011.395; published online 19 September 2011	[Chen, Y.; Yang, D.; Gao, Y.; Jiang, R.; Deng, L.; Sun, B.] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China; [Li, S.; Frankel, F. R.] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	Nanjing Medical University; University of Pennsylvania	Sun, B (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, 300 Guangzhou Rd, Nanjing, Jiangsu, Peoples R China.	sunbc@njmu.edu.cn	Jiang, Runqiu/T-8844-2018	Jiang, Runqiu/0000-0003-2720-1366	National Basic Research Program of China [2012CB910800]; National Natural Science Foundation [81072029, 30901750]; Major Research Plan of the National Natural Science Foundation [91029721]; New Century Excellent Talents in University, Ministry of Education [NCET-09-0160]; Natural Science Foundation of Jiangsu Province [BK201 0532]; Ministry of Health, China [W201001]; National Institutes of Health [R21-AI-071774]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI071774] Funding Source: NIH RePORTER	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Major Research Plan of the National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); New Century Excellent Talents in University, Ministry of Education(Program for New Century Excellent Talents in University (NCET)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Ministry of Health, China; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from National Basic Research Program of China (2012CB910800 to BS), the National Natural Science Foundation (81072029 to BS and 30901750 to YC), Major Research Plan of the National Natural Science Foundation (91029721 to BS), the New Century Excellent Talents in University, Ministry of Education (NCET-09-0160 to BS), Natural Science Foundation of Jiangsu Province (BK201 0532 to YC), Ministry of Health, China (W201001 to LD), and National Institutes of Health grant (R21-AI-071774 to FRF).	Alouf JE, 2000, INT J MED MICROBIOL, V290, P351; Badvie S, 2000, POSTGRAD MED J, V76, P4, DOI 10.1136/pmj.76.891.4; Bai X, 2011, CARCINOGENESIS, V32, P63, DOI 10.1093/carcin/bgq195; BERTOLETTI A, 1993, J VIROL, V67, P2376, DOI 10.1128/JVI.67.4.2376-2380.1993; Blasco H, 2007, J IMMUNOL METHODS, V325, P127, DOI 10.1016/j.jim.2007.06.011; Butterfield LH, 2001, J IMMUNOL, V166, P5300, DOI 10.4049/jimmunol.166.8.5300; Butterfield LH, 1999, CANCER RES, V59, P3134; Chen Y, 2009, CELL MOL IMMUNOL, V6, P269, DOI 10.1038/cmi.2009.36; Cheng ZQ, 1997, HEPATOLOGY, V26, P1351; Ding FX, 2009, HEPATOLOGY, V49, P1492, DOI 10.1002/hep.22816; Duvoux C, 1998, ANN CHIR, V52, P511; FRANKEL FR, 1995, J IMMUNOL, V155, P4775; Friedman RS, 2000, J VIROL, V74, P9987, DOI 10.1128/JVI.74.21.9987-9993.2000; Furukawa S, 2004, IMMUNOBIOLOGY, V209, P551, DOI 10.1016/j.imbio.2004.07.001; Gedde MM, 2000, INFECT IMMUN, V68, P999, DOI 10.1128/IAI.68.2.999-1003.2000; Greten TF, 2010, J IMMUNOTHER, V33, P211, DOI 10.1097/CJI.0b013e3181bb499f; Hussain SA, 2001, ANN ONCOL, V12, P161, DOI 10.1023/A:1008370324827; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kong J, 2007, ONCOL REP, V18, P279; Kursar M, 2002, J IMMUNOL, V168, P6382, DOI 10.4049/jimmunol.168.12.6382; Li ZX, 2008, J IMMUNOL, V180, P2504, DOI 10.4049/jimmunol.180.4.2504; Lin SM, 2005, GUT, V54, P1151, DOI 10.1136/gut.2004.045203; MACKANESS GB, 1969, J EXP MED, V129, P973, DOI 10.1084/jem.129.5.973; Menetrier-Caux C, 2009, CANCER RES, V69, P7895, DOI 10.1158/0008-5472.CAN-09-1642; Nieters A, 2005, CANCER, V103, P740, DOI 10.1002/cncr.20842; Olkhanud PB, 2009, CANCER RES, V69, P5996, DOI 10.1158/0008-5472.CAN-08-4619; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; Pamer EG, 1997, IMMUNOL REV, V158, P129, DOI 10.1111/j.1600-065X.1997.tb00999.x; Peters C, 2003, VACCINE, V21, P1187, DOI 10.1016/S0264-410X(02)00554-6; Ritter M, 2004, J HEPATOL, V41, P999, DOI 10.1016/j.jhep.2004.08.013; Sanyal AJ, 2010, ONCOLOGIST, V15, P14, DOI 10.1634/theoncologist.2010-S4-14; Sciaranghella G, 2011, VACCINE, V29, P476, DOI 10.1016/j.vaccine.2010.10.072; Seavey MM, 2009, CLIN CANCER RES, V15, P924, DOI 10.1158/1078-0432.CCR-08-2283; Shedlock DJ, 2003, J IMMUNOL, V170, P2053, DOI 10.4049/jimmunol.170.4.2053; Shen F, 1999, VACCINE, V17, P3039, DOI 10.1016/S0264-410X(99)00148-6; Shen XH, 2010, J CANCER RES CLIN, V136, P1745, DOI 10.1007/s00432-010-0833-8; Shen YN, 2010, INFECT IMMUN, V78, P2857, DOI 10.1128/IAI.01138-09; Singh R, 2006, EXPERT REV VACCINES, V5, P541, DOI 10.1586/14760584.5.4.541; Skoberne M, 2008, J CLIN INVEST, V118, P3990, DOI 10.1172/JCI31350; SMITH K, 1992, BIOCHIMIE, V74, P705, DOI 10.1016/0300-9084(92)90143-3; Song SX, 2007, VACCINE, V25, P4853, DOI 10.1016/j.vaccine.2006.12.029; Souders NC, 2006, DNA CELL BIOL, V25, P142, DOI 10.1089/dna.2006.25.142; Spears PA, 2008, INFECT IMMUN, V76, P4046, DOI 10.1128/IAI.00283-08; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Thompson RJ, 1998, INFECT IMMUN, V66, P3552, DOI 10.1128/IAI.66.8.3552-3561.1998; Vollmer CM, 1999, CANCER RES, V59, P3064; Wallecha A, 2009, CLIN VACCINE IMMUNOL, V16, P96, DOI 10.1128/CVI.00274-08; Williams JC, 2010, J IMMUNOL, V184, P6637, DOI 10.4049/jimmunol.0902784; Yamamoto K, 2006, CLIN EXP IMMUNOL, V144, P475, DOI 10.1111/j.1365-2249.2006.03092.x; Yoshimura K, 2006, CANCER RES, V66, P1096, DOI 10.1158/0008-5472.CAN-05-2307; Yoshimura K, 2007, CANCER RES, V67, P10058, DOI 10.1158/0008-5472.CAN-07-0573; Zerbini A, 2004, J HEPATOL, V40, P102, DOI 10.1016/S0168-8278(03)00484-7; Zhao XY, 2005, INFECT IMMUN, V73, P5789, DOI 10.1128/IAI.73.9.5789-5798.2005; Zhou L, 2010, J GASTROENTEROL, V45, P968, DOI 10.1007/s00535-010-0243-3; Zhou M, 2005, IMMUNOL LETT, V99, P113, DOI 10.1016/j.imlet.2005.02.007	56	28	30	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	17					2140	2152		10.1038/onc.2011.395	http://dx.doi.org/10.1038/onc.2011.395			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21927025				2022-12-17	WOS:000303415900003
J	Mannava, S; Omilian, AR; Wawrzyniak, JA; Fink, EE; Zhuang, D; Miecznikowski, JC; Marshall, JR; Soengas, MS; Sears, RC; Morrison, CD; Nikiforov, MA				Mannava, S.; Omilian, A. R.; Wawrzyniak, J. A.; Fink, E. E.; Zhuang, D.; Miecznikowski, J. C.; Marshall, J. R.; Soengas, M. S.; Sears, R. C.; Morrison, C. D.; Nikiforov, M. A.			PP2A-B56 alpha controls oncogene-induced senescence in normal and tumor human melanocytic cells	ONCOGENE			English	Article						senescence; PP2A; melanoma; C-MYC	C-MYC PROTEIN; BRAF MUTATIONS; PATHWAYS; PHOSPHORYLATION; PROLIFERATION; CIP2A; PP2A; IDENTIFICATION; SUPPRESSION; METABOLISM	Oncoprotein C-MYC is overexpressed in human metastatic melanomas and melanoma-derived cells where it is required for the suppression of oncogene-induced senescence (OIS). The genetic events that maintain high levels of C-MYC in melanoma cells and their role in OIS are unknown. Here we report that C-MYC in cells from several randomly chosen melanoma lines was upregulated at the protein level, and largely because of the increased protein stability. Of all known regulators of C-MYC stability, levels of B56 alpha subunit of the PP2A tumor suppressor complex were substantially suppressed in all human melanoma cells compared with normal melanocytes. Accordingly, immunohistochemical analysis revealed that the lowest and the highest amounts of PP2A-B56 alpha were predominantly detected in metastatic melanoma tissues and in primary melanomas from patients with good clinical outcome, respectively. Importantly, PP2A-B56 alpha overexpression suppressed C-MYC in melanoma cells and induced OIS, whereas depletion of PP2A-B56 alpha in normal human melanocytes upregulated C-MYC protein levels and suppressed BRAF(V600E)- and, less efficiently, NRAS(Q61R)-induced senescence. Our data reveal a mechanism of C-MYC overexpression in melanoma cells and identify a functional role for PP2A-B56 alpha in OIS of melanocytic cells. Oncogene (2012) 31, 1484-1492; doi:10.1038/onc.2011.339; published online 8 August 2011	[Mannava, S.; Wawrzyniak, J. A.; Fink, E. E.; Zhuang, D.; Nikiforov, M. A.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Omilian, A. R.; Morrison, C. D.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Miecznikowski, J. C.] Roswell Pk Canc Inst, Dept Biostat, Buffalo, NY 14263 USA; [Marshall, J. R.] Roswell Pk Canc Inst, Dept Canc Prevent & Populat Sci, Buffalo, NY 14263 USA; [Soengas, M. S.] Spanish Natl Canc Res Ctr, Mol Pathol Programme, Madrid, Spain; [Sears, R. C.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Centro Nacional de Investigaciones Oncologicas (CNIO); Oregon Health & Science University	Nikiforov, MA (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC L3-317,Elm & Carlton Str, Buffalo, NY 14263 USA.	Mikhail.nikiforov@roswellpark.org	Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299; Fink, Emily/0000-0003-2738-5732	NIH [R01 CA120244, ACS RSG-10-121-01, 5P30CA016056-34]; NATIONAL CANCER INSTITUTE [R01CA120244, P30CA016056, R01CA100855, R01CA129040] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Catherine Burkhart (Cleveland Biolabs) and Dr Shoshanna Zucker (Roswell Park Cancer Institute) for critical reading of the manuscript, Ms Carina Fung (University of Sydney) for the experimental help. This work was supported by the NIH R01 CA120244 and ACS RSG-10-121-01 grants to MAN. The work of JCM was supported in part by the NIH 5P30CA016056-34 grant.	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bansal R, 2010, CELL CYCLE, V9, P2782, DOI 10.4161/cc.9.14.12251; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Eilers M, 1999, MOL CELLS, V9, P1; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Haferkamp S, 2009, AGING-US, V1, P542, DOI 10.18632/aging.100051; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Mannava S, 2008, CELL CYCLE, V7, P2392, DOI 10.4161/cc.6390; Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Newson R, 2006, STATA J, V2, P45; Nikiforov MA, 2003, J BIOL CHEM, V278, P11094, DOI 10.1074/jbc.M212298200; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Smalley KSM, 2005, SEMIN CANCER BIOL, V15, P451, DOI 10.1016/j.semcancer.2005.06.002; Vaarala MH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-136; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258	47	28	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1484	1492		10.1038/onc.2011.339	http://dx.doi.org/10.1038/onc.2011.339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21822300	Green Accepted			2022-12-17	WOS:000302132000002
J	Akita, H; Nagano, H; Takeda, Y; Eguchi, H; Wada, H; Kobayashi, S; Marubashi, S; Tanemura, M; Takahashi, H; Ohigashi, H; Tomita, Y; Ishikawa, O; Mori, M; Doki, Y				Akita, H.; Nagano, H.; Takeda, Y.; Eguchi, H.; Wada, H.; Kobayashi, S.; Marubashi, S.; Tanemura, M.; Takahashi, H.; Ohigashi, H.; Tomita, Y.; Ishikawa, O.; Mori, M.; Doki, Y.			Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity	ONCOGENE			English	Article						pancreatic cancer; Ep-CAM; prognosis; invasion; surgery	CARCINOMA-ASSOCIATED ANTIGEN; ADHESION MOLECULE; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGET; POOR SURVIVAL; EXPRESSION; ADENOCARCINOMA; EPCAM; GEMCITABINE	The identification of molecular markers useful for predicting prognosis in pancreatic cancer patients is crucial for advances in disease management. The epithelial cell adhesion molecule (Ep-CAM) is known to express in most epithelial malignancies and was reported as a tumor marker or a candidate of molecular targeting therapy. However, the clinical significance of Ep-CAM expression in pancreatic cancer is not well-known. We determined the difference of malignant potential between parental and Ep-CAM-transfected pancreatic cancer cell lines by using proliferation, invasion and migration assay. Furthermore, we determined the relationship between tumoral Ep-CAM expression of resected specimens and clinical prognosis in 95 pancreatic cancer patients receiving radical surgery at two different cancer centers. One of the three Ep-CAM-transfected cell lines showed significantly low proliferation rate compared with the parental cell, while there was no difference in the other two cell lines. In invasion and migration assays, Ep-CAM-transfected cells showed significantly lower malignant potential than parental in all of the three cell lines. In 95 pancreatic cancer patients, 47 patients showed high-Ep-CAM expression, while 48 patients showed low, and there was no difference of clinicopathological features between Ep-CAM high and low-expression group. High-Ep-CAM expression group showed significantly good prognosis in overall survival (3-year survival; 56.2 versus 19.2%, P = 0.0018) as well as in disease-free survival (3-year survival; 40.3 versus 14.4%, P = 0.038) compared with low-expression group. In addition, the impact of Ep-CAM was observed strongly in LN-negative group when the influence of Ep-CAM was examined with dividing patients into LN-positive and negative group. In multivariate analysis, Ep-CAM expression was one of the independent prognostic factors as well as histology and lymph node metastasis. Ep-CAM expression was found to be related to the suppression of pancreatic cancer cell activity and the good prognosis in pancreatic cancer patients receiving the curative resection. Oncogene (2011) 30, 3468-3476; doi:10.1038/onc.2011.59; published online 14 March 2011	[Akita, H.; Nagano, H.; Takeda, Y.; Eguchi, H.; Wada, H.; Kobayashi, S.; Marubashi, S.; Tanemura, M.; Mori, M.; Doki, Y.] Osaka Univ, Grad Sch Med, Dept Surg, Suita, Osaka 5650871, Japan; [Takahashi, H.; Ohigashi, H.; Ishikawa, O.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Osaka, Japan; [Tomita, Y.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pathol & Cytol, Osaka, Japan	Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Medical Center for Cancer & Cardiovascular Diseases	Nagano, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Surg, 2-2,Yamadaoka E-2, Suita, Osaka 5650871, Japan.	hnagano@gesurg.med.osaka-u.ac.jp	Takahashi, Hidenori/I-1231-2019	Takahashi, Hidenori/0000-0003-4801-3540	Grants-in-Aid for Scientific Research [21590412] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Armstrong A, 2003, CANCER BIOL THER, V2, P320, DOI 10.4161/cbt.2.4.451; Balzar M, 1999, J MOL MED, V77, P699, DOI 10.1007/s001099900038; Balzar M, 1999, EXP CELL RES, V246, P108, DOI 10.1006/excr.1998.4263; Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Calabrese G, 2001, CYTOGENET CELL GENET, V92, P164, DOI 10.1159/000056891; Cirulli V, 1998, J CELL BIOL, V140, P1519, DOI 10.1083/jcb.140.6.1519; EDWARDS DP, 1986, CANCER RES, V46, P1306; Evans DB, 2008, J CLIN ONCOL, V26, P3496, DOI 10.1200/JCO.2007.15.8634; Fong D, 2008, J CLIN PATHOL, V61, P31, DOI 10.1136/jcp.2006.037333; Gastl G, 2000, LANCET, V356, P1981, DOI 10.1016/S0140-6736(00)03312-2; GEER RJ, 1993, AM J SURG, V165, P68, DOI 10.1016/S0002-9610(05)80406-4; Gonzalez B, 2009, STEM CELLS, V27, P1782, DOI 10.1002/stem.97; Gosens MJEM, 2007, MODERN PATHOL, V20, P221, DOI 10.1038/modpathol.3800733; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824; Jojovic M, 1998, HISTOCHEM J, V30, P723, DOI 10.1023/A:1003486630314; Kahlert C, 2009, BRIT J CANCER, V101, P457, DOI 10.1038/sj.bjc.6605136; KAYAHARA M, 1993, CANCER, V72, P2118, DOI 10.1002/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO;2-4; Kimura H, 2007, INT J ONCOL, V30, P171; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; Litvinov SV, 1996, AM J PATHOL, V148, P865; Manuyakorn A, 2010, J CLIN ONCOL, V28, P1358, DOI 10.1200/JCO.2009.24.5639; MOMBURG F, 1987, CANCER RES, V47, P2883; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; NITECKI SS, 1995, ANN SURG, V221, P59, DOI 10.1097/00000658-199501000-00007; Noda T, 2009, BRIT J CANCER, V100, P1647, DOI 10.1038/sj.bjc.6605064; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Ogawa M, 2004, HEPATOLOGY, V39, P528, DOI 10.1002/hep.20048; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Rao CG, 2005, INT J ONCOL, V27, P49; ROSS AH, 1986, BIOCHEM BIOPH RES CO, V135, P297, DOI 10.1016/0006-291X(86)90976-9; Rothenberg ML, 1996, ANN ONCOL, V7, P347; Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708; Schmidt M, 2008, CLIN CANCER RES, V14, P5849, DOI 10.1158/1078-0432.CCR-08-0669; Seligson DB, 2004, CLIN CANCER RES, V10, P2659, DOI 10.1158/1078-0432.CCR-1132-03; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Songun I, 2005, BRIT J CANCER, V92, P1767, DOI 10.1038/sj.bjc.6602519; Staley CA, 1996, AM J SURG, V171, P118, DOI 10.1016/S0002-9610(99)80085-3; Stoecklein NH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-165; Tai KY, 2007, ONCOGENE, V26, P3989, DOI 10.1038/sj.onc.1210176; Trzpis M, 2007, AM J PATHOL, V171, P386, DOI 10.2353/ajpath.2007.070152; Tsujie M, 2003, EXP CELL RES, V289, P143, DOI 10.1016/S0014-4827(03)00263-5; Varga M, 2004, CLIN CANCER RES, V10, P3131, DOI 10.1158/1078-0432.CCR-03-0528; Winter MJ, 2003, AM J PATHOL, V163, P2139, DOI 10.1016/S0002-9440(10)63570-5; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Zhang SL, 1998, CLIN CANCER RES, V4, P2669	50	28	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	31					3468	3476		10.1038/onc.2011.59	http://dx.doi.org/10.1038/onc.2011.59			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21399662				2022-12-17	WOS:000293508100007
J	Godshalk, SE; Paranjape, T; Nallur, S; Speed, W; Chan, E; Molinaro, AM; Bacchiocchi, A; Hoyt, K; Tworkoski, K; Stern, DF; Sznol, M; Ariyan, S; Lazova, R; Halaban, R; Kidd, KK; Weidhaas, JB; Slack, FJ				Godshalk, S. E.; Paranjape, T.; Nallur, S.; Speed, W.; Chan, E.; Molinaro, A. M.; Bacchiocchi, A.; Hoyt, K.; Tworkoski, K.; Stern, D. F.; Sznol, M.; Ariyan, S.; Lazova, R.; Halaban, R.; Kidd, K. K.; Weidhaas, J. B.; Slack, F. J.			A Variant in a MicroRNA complementary site in the 3 ' UTR of the KIT oncogene increases risk of acral melanoma	ONCOGENE			English	Article						melanoma; acral; microRNA; cancer risk; miR-221; KIT	CELL GROWTH-FACTOR; C-KIT; IMATINIB MESYLATE; EXPRESSION; DATABASE; CANCER; PROGRESSION; ACTIVATION; KINASE; CKIT	MicroRNAs (miRNAs) are small similar to 22nt single stranded RNAs that negatively regulate protein expression by binding to partially complementary sequences in the 3' untranslated region (3' UTRs) of target gene messenger RNAs (mRNA). Recently, mutations have been identified in both miRNAs and target genes that disrupt regulatory relationships, contribute to oncogenesis and serve as biomarkers for cancer risk. KIT, an established oncogene with a multifaceted role in melanogenesis and melanoma pathogenesis, has recently been shown to be upregulated in some melanomas, and is also a target of the miRNA miR-221. Here, we describe a genetic variant in the 3' UTR of the KIT oncogene that correlates with a greater than fourfold increased risk of acral melanoma. This KIT variant results in a mismatch in the seed region of a miR-221 complementary site and reporter data suggests that this mismatch can result in increased expression of the KIT oncogene. Consistent with the hypothesis that this is a functional variant, KIT mRNA and protein levels are both increased in the majority of samples harboring the KIT variant. This work identifies a novel genetic marker for increased heritable risk of melanoma. Oncogene (2011) 30, 1542-1550; doi: 10.1038/onc.2010.536; published online 29 November 2010	[Paranjape, T.; Nallur, S.; Chan, E.; Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; [Godshalk, S. E.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Speed, W.; Kidd, K. K.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; [Molinaro, A. M.] Yale Univ, Sch Publ Hlth, Div Biostat, New Haven, CT 06520 USA; [Bacchiocchi, A.; Hoyt, K.; Lazova, R.; Halaban, R.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; [Tworkoski, K.; Stern, D. F.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Sznol, M.] Yale Univ, Sch Med, Sect Med Oncol, New Haven, CT 06520 USA; [Ariyan, S.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University	Weidhaas, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, POB 208040, New Haven, CT 06520 USA.	joanne.weidhaas@yale.edu; frank.slack@yale.edu	Paranjape, Trupti/E-4338-2012; ravegnini, gloria/K-1330-2016	ravegnini, gloria/0000-0002-7774-402X; Slack, Frank/0000-0001-8263-0409; Sznol, Mario/0000-0002-4359-8749; Weidhaas, Joanne/0000-0002-5096-3281	National Cancer Institute [1 P50 CA121974]; National Center for Research Resources (NCRR), National Institutes of Health (NIH) [UL1 RR024139]; NIH roadmap for Medical Research;  [K08 CA124484]; NATIONAL CANCER INSTITUTE [P50CA121974, K08CA124484] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057672] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Research Resources (NCRR), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Yale SPORE in Skin Cancer funded by the National Cancer Institute grant number 1 P50 CA121974 (R Halaban, PI) and by a generous gift from Milstein-Meyer Center for Melanoma Research. JW is supported by K08 CA124484. AMM is supported by the CTSA Grant number UL1 RR024139 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH roadmap for Medical Research. The testing of the samples from the several world populations was supported by 1 P01 GM057672 (KK Kidd, PI).	Alexeev V, 2006, J INVEST DERMATOL, V126, P1102, DOI 10.1038/sj.jid.5700125; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; Ashida A, 2009, INT J CANCER, V124, P862, DOI 10.1002/ijc.24048; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Gershenwald JE, 2010, ANN SURG ONCOL, V17, P1475, DOI 10.1245/s10434-010-0986-3; Godshalk SE, 2008, CELL CYCLE, V7, P3595, DOI 10.4161/cc.7.22.7120; Halaban R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004563; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 1996, ONCOGENE, V13, P2339; Igoucheva O, 2009, BIOCHEM BIOPH RES CO, V379, P790, DOI 10.1016/j.bbrc.2008.12.152; Jazdzewski K, 2009, P NATL ACAD SCI USA, V106, P1502, DOI 10.1073/pnas.0812591106; Jiang XF, 2008, CLIN CANCER RES, V14, P7726, DOI 10.1158/1078-0432.CCR-08-1144; Koga Y, 2009, GENOME RES, V19, P1462, DOI 10.1101/gr.091447.109; LASSAM N, 1992, ONCOGENE, V7, P51; Lee CT, 2007, DNA CELL BIOL, V26, P209, DOI 10.1089/dna.2006.0545; Lutzky J, 2008, PIGM CELL MELANOMA R, V21, P492, DOI 10.1111/j.1755-148X.2008.00475.x; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; Meyle KD, 2009, HUM GENET, V126, P499, DOI 10.1007/s00439-009-0715-9; Mishra PJ, 2009, PHARMACOGENOMICS, V10, P399, DOI 10.2217/14622416.10.3.399; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; Rajeevan H, 2005, EVOL BIOINFORM, V1, P1; Ratner E, 2010, CANCER RES, V70, P6509, DOI 10.1158/0008-5472.CAN-10-0689; Rigel DS, 2010, ARCH DERMATOL, V146, P318, DOI 10.1001/archdermatol.2009.379; Saetrom P, 2009, CANCER RES, V69, P7459, DOI 10.1158/0008-5472.CAN-09-1201; Sayers EW, 2009, NUCLEIC ACIDS RES, V37, pD5, DOI 10.1093/nar/gkp967; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Smalley KSM, 2008, CANCER RES, V68, P5743, DOI 10.1158/0008-5472.CAN-08-0235; Smalley KSM, 2009, CANCER RES, V69, P3241, DOI 10.1158/0008-5472.CAN-08-4305; Smalley KSM, 2009, HISTOL HISTOPATHOL, V24, P643, DOI 10.14670/HH-24.643; Speed WC, 2009, PHARMACOGENOMICS J, V9, P283, DOI 10.1038/tpj.2009.10; Stefani G, 2007, EXPERT OPIN BIOL TH, V7, P1833, DOI 10.1517/14712598.7.12.1833; Went PT, 2004, J CLIN ONCOL, V22, P4514, DOI 10.1200/JCO.2004.10.125; ZAKUT R, 1993, ONCOGENE, V8, P2221	40	28	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1542	1550		10.1038/onc.2010.536	http://dx.doi.org/10.1038/onc.2010.536			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21119596	Green Accepted, Green Submitted			2022-12-17	WOS:000288998300005
J	Cordani, N; Pozzi, S; Martynova, E; Fanoni, D; Borrelli, S; Alotto, D; Castagnoli, C; Berti, E; Vigano, MA; Mantovani, R				Cordani, N.; Pozzi, S.; Martynova, E.; Fanoni, D.; Borrelli, S.; Alotto, D.; Castagnoli, C.; Berti, E.; Vigano, M. A.; Mantovani, R.			Mutant p53 subverts p63 control over KLF4 expression in keratinocytes	ONCOGENE			English	Article						KLF4; p63; mutant p53; keratinocytes	KRUPPEL-LIKE FACTOR-4; SQUAMOUS-CELL CARCINOMA; INDUCED DNA-DAMAGE; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; SKIN-CANCER; STEM-CELL; TRANSCRIPTIONAL CONTROL; CYCLE REGULATION; BREAST-CANCER	Genetic experiments established that p63 is crucial for the development and maintenance of pluri-stratified epithelia and KLF4 for the barrier function of the skin. KLF4 is one of the factors that reprogram differentiated cells to iPS. We investigated the relationship between p63 and KLF4 using RNA interference, overexpression, chromatin immunoprecipitation and transient transfections with reporter constructs. We find that p63 directly represses KLF4 in normal keratinocytes (KCs) by binding to upstream promoter sites. Unlike p63, KLF4 levels are high in the upper layers of human skin and increase upon differentiation of KCs in vitro. In HaCaT KCs, which harbor two mutant alleles of p53, inactivation of p63 and of mutant p53 leads to KLF4 repression. p63 and p53 mutants are bound to sites in the KLF4 core promoter. Importantly, expression of the H179Y and R282Q p53 mutants in primary KCs is sufficient to activate endogenous KLF4. Finally, immunohistochemical analysis of tissue arrays confirms increased coexpression of KLF4 and mutant p53 in squamous cell carcinomas. Our data indicate that suppression of KLF4 is part of the growth-promoting strategy of p63 in the lower layers of normal epidermis, and that tumor-predisposing p53 mutations hijack p63 to a different location on the promoter, turning it into an activator of this reprogramming factor. Oncogene (2011) 30, 922-932; doi:10.1038/onc.2010.474; published online 25 October 2010	[Cordani, N.; Pozzi, S.; Martynova, E.; Borrelli, S.; Vigano, M. A.; Mantovani, R.] Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy; [Fanoni, D.; Berti, E.] Univ Milan, Ist Sci Dermatol, IRCCS Fdn Osped Maggiore Policlin, I-20133 Milan, Italy; [Alotto, D.; Castagnoli, C.] Osped CTO, Dipartimento Chirurg Plast, Banca Cute, Turin, Italy; [Berti, E.] Univ Milano Bicocca, Milan, Italy	University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milano-Bicocca	Mantovani, R (corresponding author), Univ Milan, Dipartimento Sci Biomol & Biotecnol, Via Celoria 26, I-20133 Milan, Italy.	mantor@unimi.it	Cordani, Nicoletta/AAC-1978-2022; Berti, Emilio/F-5256-2012; Cordani, Nicoletta/ABG-8636-2020	Cordani, Nicoletta/0000-0002-3227-8280; Berti, Emilio/0000-0001-6753-4910; vigano, maria alessandra/0000-0003-2009-0384	European Union [EPISTEM LSHB-CT-2005-019067]; MIUR; Associazione Italiana per la Ricerca sul Cancro	European Union(European Commission); MIUR(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We thank V Yang (Emory University, USA) and C Ishioka (Tohoru U Jp) for gift of the KLF4-Luciferase vector and mutant p53 vectors, respectively. We thank K Vousden and P Muller (Beatson I, UK) for information on the p53 siRNA oligonucleotide. This work was supported by grants from the European Union (EPISTEM LSHB-CT-2005-019067), MIUR and Associazione Italiana per la Ricerca sul Cancro (to RM).	Aylon Y, 2007, CELL, V130, P597, DOI 10.1016/j.cell.2007.08.005; Barbaro V, 2007, J CELL BIOL, V177, P1037, DOI 10.1083/jcb.200703003; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Carroll DK, 2007, CELL CYCLE, V6, P255, DOI 10.4161/cc.6.3.3799; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen YJ, 2008, CANCER BIOL THER, V7, P777, DOI 10.4161/cbt.7.5.5768; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dai X, 2004, CURR OPIN GENET DEV, V14, P485, DOI 10.1016/j.gde.2004.07.002; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; de Gruijl FR, 2008, PHOTOCHEM PHOTOBIOL, V84, P382, DOI 10.1111/j.1751-1097.2007.00275.x; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Donzelli S, 2008, CURR GENOMICS, V9, P200, DOI 10.2174/138920208784340713; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; Furlan-Magaril M, 2009, METHODS MOL BIOL, V543, P253, DOI 10.1007/978-1-60327-015-1_17; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Ghaleb AM, 2007, ONCOGENE, V26, P2365, DOI 10.1038/sj.onc.1210022; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Huang CC, 2005, CANCER BIOL THER, V4, P1401, DOI 10.4161/cbt.4.12.2355; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Koster MI, 2004, DIFFERENTIATION, V72, P364, DOI 10.1111/j.1432-0436.2004.07208002.x; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004; Perez CA, 2007, CELL CYCLE, V6, P246, DOI 10.4161/cc.6.3.3801; Pfeifer GP, 2009, HUM GENET, V125, P493, DOI 10.1007/s00439-009-0657-2; Pozzi S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005008; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rinne T, 2006, AM J MED GENET A, V140A, P1396, DOI 10.1002/ajmg.a.31271; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Smith C, 2004, BIOCHEM J, V380, P757, DOI 10.1042/BJ20040077; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Swamynathan SK, 2008, INVEST OPHTH VIS SCI, V49, P3360, DOI 10.1167/iovs.08-1811; Swamynathan SK, 2007, MOL CELL BIOL, V27, P182, DOI 10.1128/MCB.00846-06; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Testoni B, 2006, CELL CYCLE, V5, P2805, DOI 10.4161/cc.5.23.3525; Tsai KY, 2004, AM J MED GENET C, V131C, P82, DOI 10.1002/ajmg.c.30037; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Vigano MA, 2007, CELL CYCLE, V6, P233, DOI 10.4161/cc.6.3.3802; Vigano MA, 2006, EMBO J, V25, P5105, DOI 10.1038/sj.emboj.7601375; Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243; Whitney EM, 2006, GENE EXPRESSION, V13, P85, DOI 10.3727/000000006783991908; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhou QB, 2009, CANCER RES, V69, P8284, DOI 10.1158/0008-5472.CAN-09-1345; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	72	28	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					922	932		10.1038/onc.2010.474	http://dx.doi.org/10.1038/onc.2010.474			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20972454				2022-12-17	WOS:000287695900004
J	Savaskan, NE; Seufert, S; Hauke, J; Trankle, C; Eyupoglu, IY; Hahnen, E				Savaskan, N. E.; Seufert, S.; Hauke, J.; Traenkle, C.; Eyuepoglu, I. Y.; Hahnen, E.			Dissection of mitogenic and neurodegenerative actions of cystine and glutamate in malignant gliomas	ONCOGENE			English	Article						glioma; tumor microenvironment; ionotropic glutamate signaling; glutamate/cystine transporter; excitotoxicity; xCT (SLC7A11)	X(C)(-) CYSTINE/GLUTAMATE ANTIPORTER; PRIMARY BRAIN-TUMORS; AMPA RECEPTORS; CELL-PROLIFERATION; IN-VIVO; GROWTH; RNA; TRANSPORT; CANCER; MICE	Malignant glioma represents one of the most aggressive and lethal human neoplasias. A hallmark of gliomas is their rapid proliferation and destruction of vital brain tissue, a process in which excessive glutamate release by glioma cells takes center stage. Pharmacologic antagonism with glutamate signaling through ionotropic glutamate receptors attenuates glioma progression in vivo, indicating that glutamate release by glioma cells is a prerequisite for rapid glioma growth. Glutamate has been suggested to promote glioma cell proliferation in an autocrine or paracrine manner, in particular by activation of the (RS)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrate (AMPA) subtype of glutamate receptors. Here, we dissect the effects of glutamate secretion on glioma progression. Glioma cells release glutamate through the amino-acid antiporter system X-c(-), a process that is mechanistically linked with cystine incorporation. We show that disrupting glutamate secretion by interfering with the system X-c(-) activity attenuates glioma cell proliferation solely cystine dependently, whereas glutamate itself does not augment glioma cell growth in vitro. Neither AMPA receptor agonism nor antagonism affects glioma growth in vitro. On a molecular level, AMPA insensitivity is concordant with a pronounced transcriptional downregulation of AMPA receptor subunits or overexpression of the fully edited GluR2 subunit, both of which block receptor activity. Strikingly, AMPA receptor inhibition in tumor-implanted brain slices resulted in markedly reduced tumor progression associated with alleviated neuronal cell death, suggesting that the ability of glutamate to promote glioma progression strictly requires the tumor microenvironment. Concerning a potential pharmacotherapy, targeting system X-c(-) activity disrupts two major pathophysiological properties of glioma cells, that is, the induction of excitotoxic neuronal cell death and incorporation of cystine required for rapid proliferation. Oncogene (2011) 30, 43-53; doi: 10.1038/onc.2010.391; published online 30 August 2010	[Savaskan, N. E.] Charite, Inst Cell Biol & Neurobiol, D-10117 Berlin, Germany; [Seufert, S.; Hauke, J.; Hahnen, E.] Univ Cologne, Inst Human Genet, D-50931 Cologne, Germany; [Seufert, S.; Hauke, J.; Hahnen, E.] Univ Cologne, Ctr Mol Med Cologne, Inst Genet, D-50931 Cologne, Germany; [Traenkle, C.] Univ Bonn, Inst Pharm, Dept Pharmacol & Toxicol, D-5300 Bonn, Germany; [Eyuepoglu, I. Y.] Univ Erlangen Nurnberg, Dept Neurosurg, Erlangen, Germany; [Hahnen, E.] Univ Hosp Erlangen, Inst Neuropathol, Erlangen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cologne; University of Cologne; University of Bonn; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Savaskan, NE (corresponding author), Charite, Inst Cell Biol & Neurobiol, Philippstr 12, D-10117 Berlin, Germany.	savaskan@gmx.net; eric.hahnen@uk-koeln.de	; Savaskan, Nicolai/D-2923-2018	Hauke, Jan/0000-0001-8236-4075; Savaskan, Nicolai/0000-0003-1348-094X	Wilhelm Sander-Stiftung; Institut Danone; International Human Frontiers Science Program; ELAN-Programm; Koln Fortune Programm; Center for Molecular Medicine Cologne (CMMC)	Wilhelm Sander-Stiftung; Institut Danone(Danone Nutricia); International Human Frontiers Science Program(Human Frontier Science Program); ELAN-Programm; Koln Fortune Programm; Center for Molecular Medicine Cologne (CMMC)	We thank Nadine Scheufler and Philip Rummel (both Erlangen) for experimental support. Jan Csupor (Berlin) is acknowledged for technical assistance. This study was supported by the 'Wilhelm Sander-Stiftung' (to EH), the 'Institut Danone' (to NES, IYE and EH), the 'International Human Frontiers Science Program' (to NES), the 'ELAN-Programm' (to IYE), the 'Koln Fortune Programm' (to EH) and the 'Center for Molecular Medicine Cologne (CMMC)' (to EH).	Behrens PF, 2000, J NEURO-ONCOL, V47, P11, DOI 10.1023/A:1006426917654; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Chung WJ, 2009, J NEUROCHEM, V110, P182, DOI 10.1111/j.1471-4159.2009.06129.x; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; De Groot JF, 2008, J NEURO-ONCOL, V88, P121, DOI 10.1007/s11060-008-9552-2; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; DONEVAN SD, 1993, NEURON, V10, P51, DOI 10.1016/0896-6273(93)90241-I; Eyupoglu IY, 2005, J NEUROSURG, V102, P738, DOI 10.3171/jns.2005.102.4.0738; Eyupoglu IY, 2005, J NEUROCHEM, V93, P992, DOI 10.1111/j.1471-4159.2005.03098.x; Eyupoglu LY, 2006, MOL CANCER THER, V5, P1248, DOI 10.1158/1535-7163.MCT-05-0533; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Jones DP, 2004, FASEB J, V18, P1246, DOI 10.1096/fj.03-0971fje; Liu RR, 2007, BIOCHEM BIOPH RES CO, V364, P528, DOI 10.1016/j.bbrc.2007.10.036; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Lu W, 2009, NEURON, V62, P254, DOI 10.1016/j.neuron.2009.02.027; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; Marcus HJ, 2010, J NEURO-ONCOL, V97, P11, DOI 10.1007/s11060-009-9990-5; Mawatari C, 1996, NEUROSCIENCE, V73, P201, DOI 10.1016/0306-4522(96)00025-5; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Patel SA, 2004, NEUROPHARMACOLOGY, V46, P273, DOI 10.1016/j.neuropharm.2003.08.006; Pham AN, 2010, J PHARMACOL EXP THER, V332, P949, DOI 10.1124/jpet.109.162248; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Robe PA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-372; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; Savaskan NE, 2007, CELL MOL LIFE SCI, V64, P230, DOI 10.1007/s00018-006-6412-0; Savaskan NE, 2009, J CELL PHYSIOL, V220, P531, DOI 10.1002/jcp.21795; Savaskan NE, 2008, NAT MED, V14, P629, DOI 10.1038/nm1772; Schwenk J, 2009, SCIENCE, V323, P1313, DOI 10.1126/science.1167852; Shih AY, 2006, J NEUROSCI, V26, P10514, DOI 10.1523/JNEUROSCI.3178-06.2006; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; van Vuurden DG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005953; Vanhoutte N, 2009, EXP NEUROL, V218, P56, DOI 10.1016/j.expneurol.2009.04.004; Ye ZC, 1999, CANCER RES, V59, P4383; Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999; Yoshida Y, 2006, PATHOL INT, V56, P262, DOI 10.1111/j.1440-1827.2006.01954.x; Zhuge J, 2006, FREE RADICAL BIO MED, V40, P63, DOI 10.1016/j.freeradbiomed.2005.08.012	42	28	31	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					43	53		10.1038/onc.2010.391	http://dx.doi.org/10.1038/onc.2010.391			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20802520				2022-12-17	WOS:000285959300004
J	Hartmann, C; Muller, N; Blaukat, A; Koch, J; Benhar, I; Wels, WS				Hartmann, C.; Mueller, N.; Blaukat, A.; Koch, J.; Benhar, I.; Wels, W. S.			Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response	ONCOGENE			English	Article						epidermal growth factor receptor; therapeutic antibody; phage display; peptide mimotope	GROWTH-FACTOR RECEPTOR; TUMOR-CELL GROWTH; MONOCLONAL-ANTIBODY; ERBB-2 RECEPTOR; CANCER; DISPLAY; TOXIN; INHIBITION; CARCINOMA; LIBRARIES	Aberrant activation of the epidermal growth factor receptor (EGFR) has been found in human cancers of various origins, and has been implicated in cancer pathogenesis. The therapeutic anti-EGFR antibodies cetuximab and matuzumab inhibit both ligand-induced receptor activation and growth of EGFR-expressing tumor cells. The efficacy of such EGFR-targeted therapies may be further enhanced by induction of functionally equivalent endogenous antibody responses. Here we describe novel peptide sequences selected from random peptide libraries for binding to single-chain antibody fragments of cetuximab or matuzumab. Two of these peptides characterized by KTL and YPLG motifs are recognized equally well by cetuximab and matuzumab, although nonoverlapping epitopes were previously reported for these antibodies. Immunization of experimental animals with synthetic KTL-and YPLG-containing peptides led to induction of antibodies that cross-react with human EGFR, and prevent binding of natural EGFR ligands, ligand-induced receptor activation and tumor cell growth in a manner similar to cetuximab and matuzumab. Our findings show that these peptide mimotopes can induce anti-EGFR antibodies with antitumoral activity, which may have implications for EGFR-specific cancer immunotherapy. Oncogene (2010) 29, 4517-4527; doi: 10.1038/onc.2010.195; published online 31 May 2010	[Hartmann, C.; Mueller, N.; Koch, J.; Wels, W. S.] Chemotherapeut Forschungsinst, D-60596 Frankfurt, Germany; [Blaukat, A.] Merck KGaA, Merck Serono Res, TA Oncol, Darmstadt, Germany; [Benhar, I.] Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, Ramat Aviv, Israel	Merck KGaA; EMD Serono Inc.; Tel Aviv University	Wels, WS (corresponding author), Chemotherapeut Forschungsinst, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	wels@em.uni-frankfurt.de		Benhar, Itai/0000-0002-0824-7177; Wels, Winfried/0000-0001-9858-3643	Merck KGaA	Merck KGaA(Merck & Company)	We thank Dr Jens Oliver Funk, Merck KGaA for support of this project; Thorsten Geyer, Georg-Speyer-Haus for preparing plasmid pIB-Tx-scFv(225); Dr John Mendelsohn, MD Anderson Cancer Center, Houston for monoclonal antibody cetuximab; Dr Nancy Hynes, Friedrich Miescher Institute, Basel for 15E anti-EGFR antibody; Christian Brendel, Georg-Speyer-Haus for help with CLSM experiments and Dr Stephen Hyland, Georg-Speyer-Haus and Dr Arne Sutter, Merck KGaA for helpful discussions. This work was supported in part by a grant from Merck KGaA.	Azemar M, 2000, INT J CANCER, V86, P269, DOI 10.1002/(SICI)1097-0215(20000415)86:2<269::AID-IJC18>3.0.CO;2-8; Baselga J, 2005, J CLIN ONCOL, V23, P5568, DOI 10.1200/JCO.2005.07.119; Benhar I, 2000, J MOL BIOL, V301, P893, DOI 10.1006/jmbi.2000.4021; Brandt O, 2009, CURR CHEM BIOL, V3, P171; Cochran JR, 2004, J IMMUNOL METHODS, V287, P147, DOI 10.1016/j.jim.2004.01.024; Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Groner B, 2004, CURR MOL MED, V4, P539, DOI 10.2174/1566524043360483; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; KETTLEBOROUGH CA, 1991, PROTEIN ENG, V4, P773, DOI 10.1093/protein/4.7.773; Leahy DJ, 2008, CANCER CELL, V13, P291, DOI 10.1016/j.ccr.2008.03.010; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Maurer-Gebhard M, 1998, CANCER RES, V58, P2661; Mayrose I, 2007, BIOINFORMATICS, V23, P3244, DOI 10.1093/bioinformatics/btm493; Mayrose I, 2007, NUCLEIC ACIDS RES, V35, P69, DOI 10.1093/nar/gkl975; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Partidos CD, 2000, CURR OPIN MOL THER, V2, P74; Rao S, 2008, BRIT J CANCER, V99, P868, DOI 10.1038/sj.bjc.6604622; Riemer AB, 2005, JNCI-J NATL CANCER I, V97, P1663, DOI 10.1093/jnci/dji373; Riemer AB, 2004, J IMMUNOL, V173, P394, DOI 10.4049/jimmunol.173.1.394; Sato J D, 1983, Mol Biol Med, V1, P511; Schmidt M, 1996, BRIT J CANCER, V74, P853, DOI 10.1038/bjc.1996.448; Schmidt M, 1999, ONCOGENE, V18, P1711, DOI 10.1038/sj.onc.1202489; Schmiedel J, 2008, CANCER CELL, V13, P365, DOI 10.1016/j.ccr.2008.02.019; Seiden MV, 2007, GYNECOL ONCOL, V104, P727, DOI 10.1016/j.ygyno.2006.10.019; Shomura H, 2004, BRIT J CANCER, V90, P1563, DOI 10.1038/sj.bjc.6601728; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120; WELS W, 1992, CANCER RES, V52, P6310; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	34	28	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4517	4527		10.1038/onc.2010.195	http://dx.doi.org/10.1038/onc.2010.195			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20514015				2022-12-17	WOS:000280862300003
J	Leone, V; Mansueto, G; Pierantoni, GM; Tornincasa, M; Merolla, F; Cerrato, A; Santoro, M; Grieco, M; Scaloni, A; Celetti, A; Fusco, A				Leone, V.; Mansueto, G.; Pierantoni, G. M.; Tornincasa, M.; Merolla, F.; Cerrato, A.; Santoro, M.; Grieco, M.; Scaloni, A.; Celetti, A.; Fusco, A.			CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1	ONCOGENE			English	Article						CREB1; CCDC6; HDAC1; RET/PTC1; papillary thyroid carcinomas	PAPILLARY THYROID-CARCINOMA; FACTOR RECEPTOR-BETA; GROWTH-FACTOR; GENE-TRANSCRIPTION; TRANSGENIC MICE; CELL-LINE; EXPRESSION; RET; REARRANGEMENTS; H4(D10S170)	RET/papillary thyroid carcinoma 1 (PTC1) oncogene is frequently activated in human PTCs. It is characterized by the fusion of the intracellular kinase-encoding domain of RET to the first 101 amino acids of CCDC6. The aim of our work is to characterize the function of the CCDC6 protein to better understand the function of its truncation, that results in the loss of the expression of one allele, in the process of thyroid carcinogenesis. Here, we report that CCDC6 interacts with CREB1 and represses its transcriptional activity by recruiting histone deacetylase 1 and protein phosphatase 1 proteins at the CRE site of the CREB1 target genes. Finally, we show an increased CREB1 phosphorylation and activity in PTCs carrying the RET/PTC1 oncogene. Consistently, an increased expression of two known CREB1 target genes, AREG and cyclin A, was observed in this subgroup of thyroid papillary carcinomas. Therefore, the repression of CREB1 activity by CCDC6 has a critical function in the development of human thyroid papillary carcinomas carrying RET/PTC1 activation. Oncogene (2010) 29, 4341-4351; doi:10.1038/onc.2010.179; published online 24 May 2010	[Fusco, A.] Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, Fac Med & Chirurg Napoli,CNR, I-80131 Naples, Italy; [Leone, V.; Mansueto, G.; Fusco, A.] Biotechnol Avanzate Napoli, NOGEC, CEINGE, Naples, Italy; [Leone, V.; Mansueto, G.; Fusco, A.] European Sch Mol Med, SEMM, Naples, Italy; [Scaloni, A.] CNR, Prote & Mass Spectrometry Lab, ISPAAM, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; CEINGE Biotecnologie Avanzate; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR)	Fusco, A (corresponding author), Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, Fac Med & Chirurg Napoli,CNR, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Cerrato, Aniello/AAY-1484-2020; Pierantoni, Giovanna Maria/O-7527-2015; Celetti, Angela/AAY-7172-2020; Mansueto, Gelsomina/AAD-6317-2021	Pierantoni, Giovanna Maria/0000-0003-4078-8528; Mansueto, Gelsomina/0000-0002-0544-5100; Scaloni, Andrea/0000-0001-9362-8515; Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) [CCPKRP_002]	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR))	This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC) and from the Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) (MERIT and PRIN 2008 CCPKRP_002). We are grateful to Konstantina Vergadou (Scientific Communication) for editing the text and Mario Berardone for artwork.	Bennett D, 2005, BIOCHEM SOC T, V33, P1444, DOI 10.1042/BST0331444; Berasain C, 2007, CANCER LETT, V254, P30, DOI 10.1016/j.canlet.2007.01.015; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; De Angelis R, 2003, FEBS LETT, V547, P15, DOI 10.1016/S0014-5793(03)00659-8; De Martino I, 2009, CANCER RES, V69, P1844, DOI 10.1158/0008-5472.CAN-08-4133; Dettori T, 2004, CANCER GENET CYTOGEN, V151, P171, DOI 10.1016/j.cancergencyto.2003.09.023; Drechsler M, 2007, ANN HEMATOL, V86, P353, DOI 10.1007/s00277-006-0247-5; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; Fedele M, 2005, ONCOGENE, V24, P3427, DOI 10.1038/sj.onc.1208501; Gao JX, 2009, BIOCHEM BIOPH RES CO, V379, P1, DOI 10.1016/j.bbrc.2008.11.135; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Han YB, 2007, ARCH ANDROLOGY, V53, P169, DOI 10.1080/01485010701314032; Hu XD, 2006, J NEUROCHEM, V98, P1841, DOI 10.1111/j.1471-4159.2006.04070.x; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kulkarni S, 2000, CANCER RES, V60, P3592; Luciani P, 2003, EUR J ENDOCRINOL, V148, P579, DOI 10.1530/eje.0.1480579; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Merolla F, 2007, ONCOGENE, V26, P6167, DOI 10.1038/sj.onc.1210446; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Pierantoni GM, 2006, CELL DEATH DIFFER, V13, P1554, DOI 10.1038/sj.cdd.4401839; Pierantoni GM, 2007, PROTEOMICS, V7, P3735, DOI 10.1002/pmic.200700148; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Puxeddu E, 2005, MUTAT RES-FUND MOL M, V570, P17, DOI 10.1016/j.mrfmmm.2004.09.010; SANTISTEBAN DA, 1994, J CHILD ADOLES SUBST, V3, P9, DOI 10.1300/J029v03n02_02; Santoro M, 1996, ONCOGENE, V12, P1821; Santoro M, 2006, EUR J ENDOCRINOL, V155, P645, DOI 10.1530/eje.1.02289; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; Sheils OM, 2000, J PATHOL, V192, P32; Talamo F, 2003, PROTEOMICS, V3, P440, DOI 10.1002/pmic.200390059; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Trinkle-Mulcahy L, 2006, CURR OPIN CELL BIOL, V18, P623, DOI 10.1016/j.ceb.2006.09.001; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Wang BJ, 2008, SCI CHINA SER C, V51, P487, DOI 10.1007/s11427-008-0068-y	40	28	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4341	4351		10.1038/onc.2010.179	http://dx.doi.org/10.1038/onc.2010.179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498639				2022-12-17	WOS:000280547900010
J	Orr, SJ; Gaymes, T; Ladon, D; Chronis, C; Czepulkowski, B; Wang, R; Mufti, GJ; Marcotte, EM; Thomas, NSB				Orr, S. J.; Gaymes, T.; Ladon, D.; Chronis, C.; Czepulkowski, B.; Wang, R.; Mufti, G. J.; Marcotte, E. M.; Thomas, N. S. B.			Reducing MCM levels in human primary T cells during the G(0)-> G(1) transition causes genomic instability during the first cell cycle	ONCOGENE			English	Article						cell cycle; MCM; chromosomal abnormalities; DNA damage; premature chromatid separation	MINICHROMOSOME MAINTENANCE PROTEINS; SISTER-CHROMATID COHESION; MOSAIC VARIEGATED ANEUPLOIDY; DNA-REPLICATION; S-PHASE; SACCHAROMYCES-CEREVISIAE; GENETIC INSTABILITY; MAMMALIAN-CELLS; CANCER-CELLS; RECOMBINATION	DNA replication is tightly regulated, but paradoxically there is reported to be an excess of MCM DNA replication proteins over the number of replication origins. Here, we show that MCM levels in primary human T cells are induced during the G(0)-> G(1) transition and are not in excess in proliferating cells. The level of induction is critical as we show that a 50% reduction leads to increased centromere separation, premature chromatid separation (PCS) and gross chromosomal abnormalities typical of genomic instability syndromes. We investigated the mechanisms involved and show that a reduction in MCM levels causes dose-dependent DNA damage involving activation of ATR & ATM and Chk1 & Chk2. There is increased DNA mis-repair by non-homologous end joining (NHEJ) and both NHEJ and homologous recombination are necessary for Mcm7-depleted cells to progress to metaphase. Therefore, a simple reduction in MCM loading onto DNA, which occurs in cancers as a result of aberrant cell cycle control, is sufficient to cause PCS and gross genomic instability within one cell cycle. Oncogene (2010) 29, 3803-3814; doi: 10.1038/onc.2010.138; published online 3 May 2010	[Orr, S. J.; Gaymes, T.; Ladon, D.; Chronis, C.; Czepulkowski, B.; Mufti, G. J.; Thomas, N. S. B.] Kings Coll London, Dept Haematol Med, Leukaemia Sci Labs, Rayne Inst, London SE5 9NU, England; [Wang, R.; Marcotte, E. M.] Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of London; King's College London; University of Texas System; University of Texas Austin	Thomas, NSB (corresponding author), Kings Coll London, Dept Haematol Med, Leukaemia Sci Labs, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	nicholas.s.thomas@kcl.ac.uk		Marcotte, Edward/0000-0001-8808-180X	Leukaemia Research Fund; Department of Trade and Industry (dti); British Society for Haematology; Welch and Packard Foundations; National Institutes of Health (NIH); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067779] Funding Source: NIH RePORTER	Leukaemia Research Fund; Department of Trade and Industry (dti); British Society for Haematology; Welch and Packard Foundations; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We sincerely thank Hye Kyung Hong, Kai Stoeber and Gareth Williams, UCL for the Mcm2 plasmid and advice on expressing recombinant Mcm2. We also thank our colleagues for helpful comments. This work was supported by grants from the Leukaemia Research Fund (LRF, now Leukaemia and Lymphoma Research (LLR)), Department of Trade and Industry (dti), the British Society for Haematology, the Welch and Packard Foundations and the National Institutes of Health (NIH).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Bailis JM, 2008, MOL CELL BIOL, V28, P1724, DOI 10.1128/MCB.01717-07; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Bruemmer D, 2003, BIOCHEM BIOPH RES CO, V303, P251, DOI 10.1016/S0006-291X(03)00343-7; Budman J, 2007, J BIOL CHEM, V282, P11950, DOI 10.1074/jbc.M610058200; Chong J P, 1996, Prog Cell Cycle Res, V2, P83; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; Crevel G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000833; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Feng DR, 2003, CANCER RES, V63, P7356; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; FRANCON P, 2006, ENCY LIFE SCI; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; Gaymes TJ, 2002, CANCER RES, V62, P2791; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Gillespie PJ, 2004, CURR BIOL, V14, P1598, DOI 10.1016/j.cub.2004.07.053; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; HOWELL RT, 1992, HUMAN CYTOGENETICS P, P209; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Kajii T, 1998, AM J MED GENET, V78, P245, DOI 10.1002/(SICI)1096-8628(19980707)78:3<245::AID-AJMG7>3.0.CO;2-O; Kajii T, 2001, AM J MED GENET, V104, P57, DOI 10.1002/ajmg.1580; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Lea NC, 2003, MOL CELL BIOL, V23, P2351, DOI 10.1128/MCB.23.7.2351-2361.2003; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lengronne A, 2006, MOL CELL, V23, P787, DOI 10.1016/j.molcel.2006.08.018; Liang DT, 1999, J CELL SCI, V112, P559; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Moldovan GL, 2006, MOL CELL, V23, P723, DOI 10.1016/j.molcel.2006.07.007; Nakanishi M, 2006, CANCER SCI, V97, P984, DOI 10.1111/j.1349-7006.2006.00289.x; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Shimada K, 2007, CELL, V128, P85, DOI 10.1016/j.cell.2006.11.045; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Shukla A, 2005, BIOCHEM BIOPH RES CO, V329, P1240, DOI 10.1016/j.bbrc.2005.02.106; Smith AE, 2009, GENOME RES, V19, P1325, DOI 10.1101/gr.085530.108; Stoeber K, 2001, J CELL SCI, V114, P2027; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Takahashi TS, 2004, NAT CELL BIOL, V6, P991, DOI 10.1038/ncb1177; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Williams GH, 2007, CURR OPIN CELL BIOL, V19, P672, DOI 10.1016/j.ceb.2007.10.005	52	28	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3803	3814		10.1038/onc.2010.138	http://dx.doi.org/10.1038/onc.2010.138			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440261	Green Accepted			2022-12-17	WOS:000279385200008
J	Liu, ZB; Hou, YF; Zhu, J; Hu, DL; Jin, W; Ou, ZL; Di, GH; Wu, J; Shen, ZZ; Shao, ZM				Liu, Z-B; Hou, Y-F; Zhu, J.; Hu, D-L; Jin, W.; Ou, Z-L; Di, G-H; Wu, J.; Shen, Z-Z; Shao, Z-M			Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner	ONCOGENE			English	Article						PA-MSHA vaccine; breast tumor; EGFR; mannose; sugar binding	UROPATHOGENIC ESCHERICHIA-COLI; GROWTH-FACTOR RECEPTOR; EPITHELIAL-CELLS; IN-VITRO; CARBOHYDRATE INTERACTIONS; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; ADHERENCE	To identify more therapeutic targets and clarify the detailed mechanisms of Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) on breast cancer cells both in vitro and in vivo. PA-MSHA was administered to epidermal growth factor receptor (EGFR)positive human breast cancer cell lines MDA-MB-231HM and MDA-MB-468 in vitro and to mice bearing tumor xenografts. The mannose cocultured test was used to detect the effect of mannose on PA-MSHA-induced cell proliferation, cell cycle arrest, apoptosis, and EGFR pathway signaling. We found that cells stimulated with PA-MSHA exhibited a downregulation of EGFR signaling. The addition of mannose partially inhibited the PA-MSHA-stimulated cell anti-proliferative effect, cell apoptosis, cell cycle arrest, activation of apoptosis-associated caspases, and even downregulation of the EGFR signaling pathway. In vivo, PA-MSHA treatment significantly suppressed mammary tumorigenesis in xenografts in mice and decreased lung metastasis in MDA-MB-231HM cell-transplanted mice. Tumor sample analyses confirmed inhibition of the EGFR pathway in the PA-MSHA-treated mice. In conclusion, this study showed that the involvement of the mannose-mediated EGFR pathway has a critical function in the preclinical rationale for the development of PA-MSHA for the treatment of human breast cancer. It also suggests the potentially beneficial use of PA-MSHA in adjuvant therapy for breast tumors with EGFR overexpression. Oncogene (2010) 29, 2996-3009; doi:10.1038/onc.2010.70; published online 15 March 2010	[Liu, Z-B; Hou, Y-F; Jin, W.; Ou, Z-L; Di, G-H; Wu, J.; Shen, Z-Z; Shao, Z-M] Fudan Univ, Dept Breast Surg, Breast Canc Inst, Canc Hosp, Shanghai 200032, Peoples R China; [Liu, Z-B; Hou, Y-F; Jin, W.; Ou, Z-L; Di, G-H; Wu, J.; Shen, Z-Z; Shao, Z-M] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Liu, Z-B; Hou, Y-F; Jin, W.; Ou, Z-L; Di, G-H; Wu, J.; Shen, Z-Z; Shao, Z-M] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China; [Zhu, J.; Hu, D-L] Shanghai Homejoy Pharmaceut Co Ltd, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University	Shao, ZM (corresponding author), Fudan Univ, Dept Breast Surg, Breast Canc Inst, Canc Hosp, 399 Ling Ling Rd, Shanghai 200032, Peoples R China.	zhimingshao@yahoo.com		Di, Genhong/0000-0003-1171-7907	Fudan University [EHF159201]; National Basic Research Program of China [2006CB910501]; National Natural Science Foundation of China [30371580, 30572109]; Shanghai Science and Technology Committee [06DJ14004, 06DZ19504, 08ZR1403500]	Fudan University; National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee)	We are grateful to Professor Xi-Liang Zha for providing technical assistance. This work was supported in part by the Key Discipline Innovation Personnel Training Program of Fudan University (Contract grant number: EHF159201), National Basic Research Program of China (Contract grant number: 2006CB910501), the National Natural Science Foundation of China (Contract grant numbers: 30371580 and 30572109), and the Shanghai Science and Technology Committee (Contract grant numbers: 06DJ14004, 06DZ19504, and 08ZR1403500).	Capdevila J, 2009, CANCER TREAT REV, V35, P354, DOI 10.1016/j.ctrv.2009.02.001; DUGUID JAMES P., 1968, ARCH IMMUNOL THER EXP, V16, P173; Duncan MJ, 2005, J BIOL CHEM, V280, P37707, DOI 10.1074/jbc.M501249200; ESHDAT Y, 1984, BIOL CELL, V51, P259, DOI 10.1111/j.1768-322X.1984.tb00307.x; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; HARPER M, 1978, J MED MICROBIOL, V11, P117, DOI 10.1099/00222615-11-2-117; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Jain RK, 2001, P NATL ACAD SCI USA, V98, P14748, DOI 10.1073/pnas.261606598; Johns TG, 2005, FASEB J, V19, P780, DOI 10.1096/fj.04-1766fje; Kang CS, 2006, CANCER GENE THER, V13, P530, DOI 10.1038/sj.cgt.7700932; Karlsson KA, 2001, ADV EXP MED BIOL, V491, P431; Kawashima N, 2009, J BIOL CHEM, V284, P6147, DOI 10.1074/jbc.M808171200; King SS, 2000, AM J VET RES, V61, P446, DOI 10.2460/ajvr.2000.61.446; Klumpp DJ, 2006, INFECT IMMUN, V74, P5106, DOI 10.1128/IAI.00376-06; KORHONEN TK, 1980, J BACTERIOL, V144, P800, DOI 10.1128/JB.144.2.800-805.1980; KORHONEN TK, 1981, INFECT IMMUN, V32, P796, DOI 10.1128/IAI.32.2.796-804.1981; Lage A, 2003, ANN MED, V35, P327, DOI 10.1080/07853890310010889; Liu B, 2009, AUTOPHAGY, V5, P432, DOI 10.4161/auto.5.3.7924; Liu B, 2009, AUTOPHAGY, V5, P253, DOI 10.4161/auto.5.2.7561; Liu ZB, 2009, J CELL BIOCHEM, V108, P195, DOI 10.1002/jcb.22241; McEwan NA, 2008, VET DERMATOL, V19, P221, DOI 10.1111/j.1365-3164.2008.00678.x; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; OFEK I, 1978, INFECT IMMUN, V22, P247, DOI 10.1128/IAI.22.1.247-254.1978; Schaerli P, 1998, CELL MOL LIFE SCI, V54, P129, DOI 10.1007/s000180050132; Schilling JD, 2001, J INFECT DIS, V183, pS36, DOI 10.1086/318855; Sharon N, 2006, BBA-GEN SUBJECTS, V1760, P527, DOI 10.1016/j.bbagen.2005.12.008; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; STEPINSKA M, 1995, FEMS IMMUNOL MED MIC, V12, P187, DOI 10.1016/0928-8244(95)00066-6; Wang JS, 2008, MOL CANCER RES, V6, P372, DOI 10.1158/1541-7786.MCR-07-0162; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278	31	28	42	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	20					2996	3009		10.1038/onc.2010.70	http://dx.doi.org/10.1038/onc.2010.70			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20228837				2022-12-17	WOS:000277890400010
J	Jacinto, FV; Ballestar, E; Esteller, M				Jacinto, F. V.; Ballestar, E.; Esteller, M.			Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation	ONCOGENE			English	Article						tumor suppressor genes; histone methyltransferase; DNA demethylating agents; CpG island; colon cancer	HUMAN CANCER; DEACETYLASE INHIBITION; COLORECTAL-CANCER; SET DOMAIN; METHYLATION; TRANSCRIPTION; PROTEINS; HYPERMETHYLATION; EPIGENETICS; PATTERNS	Understanding the mechanisms that link changes in DNA methylation with histone modifications is particularly relevant in the case of tumor suppressor genes that undergo transcriptional silencing in cancer cells in association with promoter CpG island hypermethylation. In this study, we show that two histone lysine methylation marks associated with active transcription, dimethylation of H3K79 (H3K79me2) and trimethylation of H3K4 (H3K4me3), are present in all the unmethylated promoters analysed, and both of them are lost when these promoters become hypermethylated. Most importantly, pharmacological and genetic interventions that cause DNA demethylation and partial recovery of gene transcription, result in the restoration of H3K4me3, but not of H3K79me2. We also show that DOT1L, the major H3K79 histone methyltransferase, is no longer recruited to the promoters that are demethylated after 5-azadeoxycytidine treatment or genetic deletion of DNA methyltransferases. Knock-down and transfection experiments for DOT1L show that this enzyme has a direct role in maintaining the euchromatic and active status of these genes when unmethylated. These findings suggest that DNA demethylating interventions alone are not able to restore a complete euchromatic status and a full transcriptional reactivation of the epigenetically silenced tumor suppressor genes, and reinforce the necessity of targeting multiple elements of the epigenetics machinery for a successful treatment of malignancies. Oncogene (2009) 28, 4212-4224; doi: 10.1038/onc.2009.267; published online 7 September 2009	[Jacinto, F. V.; Ballestar, E.; Esteller, M.] Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, Bellvitge Biomed Res Inst IDIBELL, Barcelona 8907, Catalonia, Spain; [Jacinto, F. V.] Univ Porto, Grad Program Areas Basic & Appl Biol, P-4100 Oporto, Portugal; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Universidade do Porto; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, Bellvitge Biomed Res Inst IDIBELL, 3rd Floor,Avda Gran Via 199-203,08907 Hosp Llobre, Barcelona 8907, Catalonia, Spain.	mesteller@iconcologia.net	Ballestar, Esteban/ABG-8561-2020; Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Ballestar, Esteban/0000-0002-1400-2440	European Union [HEALTH-F2-2007-200620, LSHG-CT-2006-037415, FIS PI08 1345, I + D + I MCYT08-03]; Consolider [MEC09-05]; Departments of the Spanish Government; Health Department of the Catalan Government; Spanish Association Against Cancer (AECC); FCT (Portuguese Foundation for Science and Technology) [SFRH/BD/11757/2003]; ICREA Funding Source: Custom	European Union(European Commission); Consolider(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Departments of the Spanish Government; Health Department of the Catalan Government; Spanish Association Against Cancer (AECC); FCT (Portuguese Foundation for Science and Technology)(Portuguese Foundation for Science and Technology); ICREA(ICREA)	We thank Dr Yi Zhang for providing us with the hDOT1L expression vector for the transfection experiments. Supported by the European Union Grants FP7 CANCERDIP (HEALTH-F2-2007-200620) and SMARTER (LSHG-CT-2006-037415), the Health (FIS PI08 1345) and Education and Science (I + D + I MCYT08-03 and Consolider MEC09-05) Departments of the Spanish Government, the Health Department of the Catalan Government and the Spanish Association Against Cancer (AECC). FVJ is funded by FCT (Portuguese Foundation for Science and Technology) SFRH/BD/11757/2003. ME is an ICREA (Institucio Catalana de Recerca i Estudis Avancats) Research Professor.	Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fahrner JA, 2002, CANCER RES, V62, P7213; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Garcia-Manero G, 2008, CURR OPIN ONCOL, V20, P705, DOI 10.1097/CCO.0b013e328313699c; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lopez-Serra L, 2008, BRIT J CANCER, V98, P1881, DOI 10.1038/sj.bjc.6604374; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Milne TA, 2005, CANCER RES, V65, P11367, DOI 10.1158/0008-5472.CAN-05-1041; Min JR, 2003, CELL, V112, P711, DOI 10.1016/S0092-8674(03)00114-4; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nguyen CT, 2002, CANCER RES, V62, P6456; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Oki Y, 2007, CRIT REV ONCOL HEMAT, V61, P140, DOI 10.1016/j.critrevonc.2006.07.010; Paz MF, 2003, CANCER RES, V63, P1114; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930	30	28	29	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4212	4224		10.1038/onc.2009.267	http://dx.doi.org/10.1038/onc.2009.267			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19734945				2022-12-17	WOS:000272876100007
J	Montano, X				Montano, X.			Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation	ONCOGENE			English	Article						SHP-1; trkA; phosphorylation; cell-cycle arrest; breast-cancer; p53	NERVE GROWTH-FACTOR; ACTIVATION LOOP TYROSINES; FACTOR RECEPTOR; PHOSPHATASE SHP-1; NF-Y; TRANSCRIPTIONAL REPRESSION; SIGNAL-TRANSDUCTION; TUMOR-SUPPRESSOR; ADAPTER PROTEIN; DNA-DAMAGE	The nerve growth factor (NGF) receptor, trkA, the tumour suppressor p53 and the phosphatase SHP-1 are critical in cell proliferation and differentiation. SHP-1 is a trkA phosphatase that dephosphorylates trkA at tyrosines (Y) 674 and 675. p53 can induce trkA activation and tyrosine phosphorylation in the absence of NGF stimulation. In breast cancer tumours trkA expression is associated with increased patient survival. TrkA protein expression is higher in breast-cancer cell lines than in normal breast epithelia. In cell lines (but not in normal breast epithelia) trkA is functional and can be NGF-stimulated to promote cell proliferation. This study investigates the functional relationship between trkA, p53 and SHP-1 in breast-cancer, and reveals that in wildtype (wt) trkA expressing breast-cancer cells both endogenous wtp53, activated by therapeutic agents, and transfected wtp53 repress expression of SHP-1 through the proximal CCAAT sequence of the SHP-1-P1-promoter and the transcription factor NF-Y. In these cells trkA-Y674/Y675 phosphorylation is detected when SHP-1 protein levels decrease in a wtp53-dependent manner. Proliferation and cell-cycle assays, with cells expressing endogenous or transfected wt-trkA and a temperature-sensitive p53 grown at 32 degrees C (when p53 is in the wt configuration), show suppressed cell proliferation. Suppression is not detected when grown at 37 degrees C (when p53 is in the mutant configuration). A release from suppression is observed when these cells are transiently transfected with wt-SHP-1 and grown at 32 degrees C. Suppression is also detected when, as control, wt-trkA-expressing cells are transiently transfected with SHP-1-siRNA, but not when a dominant-negative (DN) mutant trkA is used to abolish wt-trkA activity. Importantly, suppression is not seen with control trkA-negative breast-cancer cells (expressing wtp53, wt-SHP-1 and undetectable trkA), transfected with Y674F/Y675F mutant-trkA. BrdU-incorporation experiments reveal lack of incorporation in cells expressing wt-trkA and wtp53, or wt-trkA and SHP-1-siRNA. However, BrdU is incorporated in the presence of Y674F/Y675F mutant trkA or DN mutant trkA. These results indicate that p53 repression of SHP-1 expression leads to trkA-Y674/Y675 phosphorylation and trkA-dependent suppression of breast-cancer cell proliferation. These data provide an explanation as to why high trkA levels are associated with favourable prognosis. Oncogene (2009) 28, 3787-3800; doi:10.1038/onc.2009.143; published online 14 September 2009	Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Mol Signalling Grp, London SW7 2AZ, England	Imperial College London	Montano, X (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Mol Signalling Grp, Sir Alexander Fleming Bldg,Imperial Coll Rd, London SW7 2AZ, England.	xmontano@ich.ucl.ac.uk			Breast Cancer Campaign grant	Breast Cancer Campaign grant	Thanks to Tessa Crompton, Sue Outram, Anna Furmanski and Ayad Eddaoudi for helping with FACS analysis; Shanie Budham-Mahadeo for helping with luciferase assays; Ralf Kirschner, KurtEngeland, Finn Werner and David Mann for ChIP and BrdU incorporation protocols; Ben Neel and David Kaplan for wt-SHP-1, Delta-SHP-1 and anti-trk203-antibodies; Alison Sparks for sheep anti-p53-antibodies; Reiner Janicke for MCF7-p53-RNAi cells; Borek Vojtesek for MCF7-p53DD Derek Huntley for bioinformatics and particularly to David Bacon for technical help with photography and graphics. This research was supported by a Breast Cancer Campaign grant awarded to XM.	BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Browes C, 2001, FEBS LETT, V497, P20, DOI 10.1016/S0014-5793(01)02429-2; Brown A, 2000, ONCOGENE, V19, P3032, DOI 10.1038/sj.onc.1203619; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Carvalho I, 2005, BREAST CANCER RES, V7, pR788, DOI 10.1186/bcr1304; Concin N, 2003, BREAST CANCER RES TR, V79, P37, DOI 10.1023/A:1023351717408; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; El-Abaseri TB, 2006, CARCINOGENESIS, V27, P225, DOI 10.1093/carcin/bgi220; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Feki A, 2004, CRIT REV ONCOL HEMAT, V52, P103, DOI 10.1016/j.critrevonc.2004.07.002; Fraser SP, 2003, J CELL PHYSIOL, V195, P479, DOI 10.1002/jcp.10312; Gentry JJ, 2004, PROG BRAIN RES, V146, P25, DOI 10.1016/S0079-6123(03)46002-0; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Horvat A, 2001, J NEUROSCI, V21, P865, DOI 10.1523/JNEUROSCI.21-03-00865.2001; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; JAGJIT SG, 1998, J NEUROONCOL, V40, P19; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marsh HN, 2003, J CELL BIOL, V163, P999, DOI 10.1083/jcb.200309036; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Moll UM, 2004, MOL CANCER RES, V2, P371; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Montano X, 1997, ONCOGENE, V15, P245, DOI 10.1038/sj.onc.1201215; Mosesson Y, 2004, SEMIN CANCER BIOL, V14, P262, DOI 10.1016/j.semcancer.2004.04.005; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Olivier Magali, 2004, IARC Sci Publ, P247; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Reis JS, 2006, MODERN PATHOL, V19, P307, DOI 10.1038/modpathol.3800542; Roccato E, 2005, J BIOL CHEM, V280, P3382, DOI 10.1074/jbc.M407522200; Sakamoto Y, 2001, ONCOL REP, V8, P973; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; Spiesbach K, 2005, INT J CANCER, V114, P555, DOI 10.1002/ijc.20766; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; VAMBUTAS V, 1995, J BIOL CHEM, V270, P25629, DOI 10.1074/jbc.270.43.25629; Wasner M, 2003, GENE, V312, P225, DOI 10.1016/S0378-1119(03)00618-8; Wu CY, 2003, J CELL BIOCHEM, V90, P1026, DOI 10.1002/jcb.10727; Xie P, 2000, LEUKEMIA LYMPHOMA, V36, P595, DOI 10.3109/10428190009148408; Xu Y, 2001, GENE, V269, P141, DOI 10.1016/S0378-1119(01)00445-0; Yip SS, 2000, INT J CANCER, V88, P363, DOI 10.1002/1097-0215(20001101)88:3<363::AID-IJC7>3.0.CO;2-4; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677	62	28	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2009	28	43					3787	3800		10.1038/onc.2009.143	http://dx.doi.org/10.1038/onc.2009.143			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19749791				2022-12-17	WOS:000271248400003
J	Wolyniec, K; Wotton, S; Kilbey, A; Jenkins, A; Terry, A; Peters, G; Stocking, C; Cameron, E; Neil, JC				Wolyniec, K.; Wotton, S.; Kilbey, A.; Jenkins, A.; Terry, A.; Peters, G.; Stocking, C.; Cameron, E.; Neil, J. C.			RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress	ONCOGENE			English	Article						RUNX1; RUNX1-ETO; premature senescence	ONCOGENE-INDUCED SENESCENCE; ACUTE MYELOID-LEUKEMIA; CELLULAR SENESCENCE; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; MURINE FIBROBLASTS; TUMOR-SUPPRESSOR; PROTEIN-KINASE; RAS; P53	A role for the RUNX genes in cancer fail-safe processes has been suggested by their induction of senescence-like growth arrest in primary murine. broblasts and the failure of RAS-induced senescence in Runx2-deficient cells. We now show that RUNX1 induces senescence in human primary. broblasts. High-affinity DNA binding is necessary but not sufficient, as shown by the functional attenuation of the truncated RUNX1/AML1a isoform and the TEL-RUNX1 fusion oncoprotein. However, a similar phenotype was potently induced by the RUNX1-ETO (AML1-ETO) oncoprotein, despite its dominant-negative potential. A detailed comparison of H-RAS(V12), RUNX1 and RUNX1-ETO senescent phenotypes showed that the RUNX effectors induce earlier growth stasis with only low levels of DNA damage signaling and a lack of chromatin condensation, a marker of irreversible growth arrest. In human. broblasts, all effectors induced p53 in the absence of detectable p14(Arf), whereas only RUNX1-ETO induced senescence in p16(Ink4a)-null cells. Correlation was noted between induction of p53, reactive oxygen species and phospho-p38, whereas p38(MAPK) inhibition rescued cell growth markedly. These findings indicate a role for replication-independent pathways in RUNX and RUNX1-ETO senescence, and show that the context-specific oncogenic activity of RUNX1 fusion proteins is mirrored in their distinctive interactions with fail-safe responses. Oncogene ( 2009) 28, 2502-2512; doi: 10.1038/onc.2009.101; published online 18 May 2009	[Wolyniec, K.; Wotton, S.; Kilbey, A.; Jenkins, A.; Terry, A.; Cameron, E.; Neil, J. C.] Univ Glasgow, Inst Comparat Med, Fac Vet Med, Oncol Mol Lab, Glasgow G61 1QH, Lanark, Scotland; [Stocking, C.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany; [Peters, G.] London Res Inst, Lincolns Inn Fields Labs, London, England	University of Glasgow; Heinrich Pette Institute; University of Hamburg	Neil, JC (corresponding author), Univ Glasgow, Inst Comparat Med, Fac Vet Med, Oncol Mol Lab, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	J.C.Neil@vet.gla.ac.uk			Cancer Research UK; Leukemia Research Fund	Cancer Research UK(Cancer Research UK); Leukemia Research Fund	Primary support for this work was provided by Cancer Research UK and the Leukemia Research Fund. We thank Janice Rowe for excellent technical assistance and Scott Hiebert (Vanderbilt University) for generous supply of reagents and useful discussions.	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bernardin F, 2002, CANCER RES, V62, P3904; Blyth K, 2006, CANCER RES, V66, P2195, DOI 10.1158/0008-5472.CAN-05-3558; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Cammenga J, 2007, CANCER RES, V67, P537, DOI 10.1158/0008-5472.CAN-06-1903; Colavitti R, 2005, IUBMB LIFE, V57, P277, DOI 10.1080/15216540500091890; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Kilbey A, 2008, CELL CYCLE, V7, P2333; Kilbey A, 2007, CANCER RES, V67, P11263, DOI 10.1158/0008-5472.CAN-07-3016; Krejci O, 2008, BLOOD, V111, P2190, DOI 10.1182/blood-2007-06-093682; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; LENNY N, 1995, ONCOGENE, V11, P1761; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007-0061; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; Robinson KA, 1999, J NEUROSCI RES, V55, P724, DOI 10.1002/(SICI)1097-4547(19990315)55:6<724::AID-JNR7>3.3.CO;2-0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Swantek D, 2004, DEVELOPMENT, V131, P2281, DOI 10.1242/dev.01109; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tsuzuki S, 2007, PLOS MED, V4, P880, DOI 10.1371/journal.pmed.0040172; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wotton S, 2008, ONCOGENE, V27, P5856, DOI 10.1038/onc.2008.195; Wotton SF, 2004, ONCOGENE, V23, P5476, DOI 10.1038/sj.onc.1207729; Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104; Zhang RG, 2007, MOL CELL BIOL, V27, P2343, DOI 10.1128/MCB.02019-06	40	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2502	2512		10.1038/onc.2009.101	http://dx.doi.org/10.1038/onc.2009.101			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448675	Green Accepted			2022-12-17	WOS:000267806800003
J	Kashima, L; Toyota, M; Mita, H; Suzuki, H; Idogawa, M; Ogi, K; Sasaki, Y; Tokino, T				Kashima, L.; Toyota, M.; Mita, H.; Suzuki, H.; Idogawa, M.; Ogi, K.; Sasaki, Y.; Tokino, T.			CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappa B	ONCOGENE			English	Article						CHFR; NF-kappa B; IL-8; tumor suppressor; angiogenesis	MITOTIC CHECKPOINT PROTEIN; NECROSIS-FACTOR-ALPHA; CANCER-CELL-LINES; GENE-EXPRESSION; GASTRIC-CANCER; EPIGENETIC INACTIVATION; MICROTUBULE INHIBITORS; TRANSCRIPTION FACTORS; BREAST CANCERS; NUCLEAR-FACTOR	The mitotic checkpoint gene CHFR (checkpoint with forkhead and ring finger domains) is silenced in various human cancers by promoter hypermethylation, suggesting that CHFR is a tumor suppressor. Here, we show that CHFR functions as a negative regulator of the nuclear factor-kappa B (NF-kappa B) pathway. Expression of CHFR inhibited NF-kappa B reporter activity, whereas knockdown of CHFR activated reporter activity. These activities are independent of its RING finger domain. Furthermore, we found that CHFR physically interacts with p65 in cells. Electrophoretic mobility shift assays (EMSAs) and ELISA-based NF-kappa B-binding assays showed that CHFR negatively regulated transcriptional activity of p65. In addition, our data show that interleukin (IL)-8 is significantly downregulated by CHFR, and that the migration of human endothelial cells is suppressed in culture medium conditioned from CHFR-expressing cancer cells. Using a xenograft model, we show that neovascularization is suppressed by adenovirus-mediated transfer of CHFR. These results indicate that expression of CHFR markedly reduces the expression of IL-8 through the inhibition of NF-kappa B. As the NF-kappa B signaling pathway plays a critical role in the development and progression of cancer, our findings show the functional relationship between epigenetic alteration and inflammation/angiogenesis in human cancer cells, thereby showing several potential targets for therapeutic intervention. Oncogene (2009) 28, 2643 -2653; doi: 10.1038/onc.2009.123; published online 18 May 2009	[Kashima, L.; Toyota, M.; Mita, H.; Suzuki, H.; Idogawa, M.; Ogi, K.; Sasaki, Y.; Tokino, T.] Sapporo Med Univ, Dept Mol Biol, Canc Res Inst, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; [Toyota, M.; Suzuki, H.] Sapporo Med Univ, Dept Internal Med, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University	Tokino, T (corresponding author), Sapporo Med Univ, Dept Mol Biol, Canc Res Inst, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	tokino@sapmed.ac.jp	Idogawa, Masashi/B-5208-2008; Tokino, Takashi/AAI-9887-2021; Sasaki, Yasushi/AAA-3079-2019	Idogawa, Masashi/0000-0002-8507-1726; Sasaki, Yasushi/0000-0002-3500-8059	Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) [pcDNA3-Flag-p65]	Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This research was supported by a grant to TT (KAKENHI (20390519)) from the Grants-in-Aid for Scienti. c Research (B) program of the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT). We thank Dr Toshiharu Suzuki (Hokkaido University, Japan) for the pcDNA3-Flag-p65 construct.	AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cude K, 2007, J CELL BIOL, V177, P253, DOI 10.1083/jcb.200609166; Cuenca R E, 1992, Surg Oncol, V1, P323, DOI 10.1016/0960-7404(92)90094-2; Daniels MJ, 2004, NAT STRUCT MOL BIOL, V11, P1114, DOI 10.1038/nsmb837; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; Fukuda T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001776; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kang Dongmin, 2004, Methods Mol Biol, V280, P229; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kawai N, 2005, DEV BIOL, V277, P80, DOI 10.1016/j.ydbio.2004.09.007; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kontermann RE, 2008, J IMMUNOTHER, V31, P225, DOI 10.1097/CJI.0b013e31816a88f9; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Lee KH, 2004, ONCOLOGY-BASEL, V66, P210, DOI 10.1159/000077997; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Mumm JB, 2008, ONCOGENE, V27, P5913, DOI 10.1038/onc.2008.275; Nishikawa N, 2007, CANCER RES, V67, P9649, DOI 10.1158/0008-5472.CAN-06-4111; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Ogi K, 2005, CANCER BIOL THER, V4, P773, DOI 10.4161/cbt.4.7.1896; Privette LM, 2007, CANCER RES, V67, P6064, DOI 10.1158/0008-5472.CAN-06-4109; Privette LM, 2008, TRANSL ONCOL, V1, P57, DOI 10.1593/tlo.08109; Rakitina TV, 2003, CANCER RES, V63, P8600; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Sathe SS, 2004, P NATL ACAD SCI USA, V101, P192, DOI 10.1073/pnas.0306812101; Satoh A, 2003, CANCER RES, V63, P8606; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Starczynowski DT, 2007, ONCOGENE, V26, P2685, DOI 10.1038/sj.onc.1210089; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Wan FY, 2007, CELL, V131, P927, DOI 10.1016/j.cell.2007.10.009; Williams JL, 2008, CARCINOGENESIS, V29, P390, DOI 10.1093/carcin/bgm275; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Yuan A, 2005, FRONT BIOSCI-LANDMRK, V10, P853, DOI 10.2741/1579	48	28	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2643	2653		10.1038/onc.2009.123	http://dx.doi.org/10.1038/onc.2009.123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19448676				2022-12-17	WOS:000268211200003
J	Piao, C; Jin, M; Kim, HB; Lee, SM; Amatya, PN; Hyun, JW; Chang, IY; You, HJ				Piao, C.; Jin, M.; Kim, H. B.; Lee, S. M.; Amatya, P. N.; Hyun, J-W; Chang, I-Y; You, H. J.			Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2	ONCOGENE			English	Article						p53R2; MEK2; ERK1/2; invasion; transformation	CELL-CYCLE CHECKPOINT; HUMAN CANCER-CELLS; DNA-SYNTHESIS; THYMIDYLATE SYNTHASE; RENAL-FAILURE; R2 COMPONENT; MAP KINASE; DNTP POOLS; PROTEIN; REPAIR	The p53-dependent RR small subunit (p53R2) protein, a newly identified member of the ribonucleotide reductase family, plays a key role in the p53-dependent cellular response to DNA. Several recent studies have suggested that p53R2 also plays an important role in suppressing the invasive potential of human cancer cells. However, the cellular mechanism that regulates invasiveness remains largely unknown. In this study, we show that p53R2 interacts with MEK2 (extracellular signal-regulated kinase (ERK) kinase 2-mitogen-activated protein kinase (MAPK) kinase 2), the molecule immediately upstream of ERK in the Ras-Raf-MAPK signaling cascade. In co-immunoprecipitation and immunofluorescence analyses, we found that p53R2 and MEK2 interact physically in cultured mammalian cells, and that the p53R2 segment comprising amino acids 161-206 is critical for this interaction. Moreover, serum-induced phosphorylation of MEK1/2 and ERK1/2 was greatly augmented in human cancer cells expressing small-interfering RNA against p53R2. On the other hand, phosphorylation of MEK1/2 and ERK1/2 in human cancer cells was markedly attenuated by overexpression of p53R2. Furthermore, MEK2 was required for p53R2 knockdown-induced enhancement of the invasive ability and anchorage-independent growth of human lung cancer H1299 cells. Taken together, these findings show that p53R2 negatively modulates serum-induced MEK-ERK activity and inhibits the MEK-ERK-mediated malignancy potential of human cancer cells. Oncogene (2009) 28, 2173-2184; doi: 10.1038/onc.2009.84; published online 27 April 2009	[Piao, C.; Jin, M.; Kim, H. B.; Lee, S. M.; Amatya, P. N.; Chang, I-Y; You, H. J.] Chosun Univ, DNA Repair Res Ctr, Kwangju 501759, South Korea; [Piao, C.; Kim, H. B.; You, H. J.] Chosun Univ, Dept Pharmacol, Kwangju 501759, South Korea; [Jin, M.] Yanbian Univ, Sch Med, Dept Biochem, Yanji, Jilin, Peoples R China; [Hyun, J-W] Jeju Natl Univ, Coll Med, Dept Biochem, Cheju, Jeju Do, South Korea; [Chang, I-Y] Chosun Univ, Dept Anat, Kwangju 501759, South Korea	Chosun University; Chosun University; Yanbian University; Jeju National University; Chosun University	You, HJ (corresponding author), 2F Chosun Univ, Sch Med, DNA Repair Res Ctr, 375 Seosuk Dong, Kwangju 501759, South Korea.	hjyou@chosun.ac.kr		, Chunmei/0000-0002-2975-7336; You, Ho Jin/0000-0002-0530-4017	Ministry of Science and Technology, the Korean Government [M 1063901, M 20706000032]; Chosun University	Ministry of Science and Technology, the Korean Government(Ministry of Science & Technology (MOST), Republic of Korea); Chosun University	This research was supported by a Grant [ M 1063901] [ M 20706000032] from the Ministry of Science and Technology, the Korean Government and funds from the Chosun University, 2002.	Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Cao MY, 2003, CLIN CANCER RES, V9, P4553; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chen M, 2007, ONCOGENE, V26, P4817, DOI 10.1038/sj.onc.1210273; Devlin HL, 2008, MOL CANCER RES, V6, P808, DOI 10.1158/1541-7786.MCR-07-2027; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Fan HZ, 1998, CANCER RES, V58, P1650; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; Gautam A, 2003, ONCOGENE, V22, P2135, DOI 10.1038/sj.onc.1206232; Gautam A, 2006, CANCER RES, V66, P6497, DOI 10.1158/0008-5472.CAN-05-4462; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Liu XY, 2007, CLIN COLORECTAL CANC, V6, P374, DOI 10.3816/CCC.2007.n.007; Liu XY, 2006, CLIN CANCER RES, V12, P6337, DOI 10.1158/1078-0432.CCR-06-0799; Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Powell DR, 2005, PEDIATR NEPHROL, V20, P432, DOI 10.1007/s00467-004-1696-5; Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tsai MH, 2006, ONCOGENE, V25, P622, DOI 10.1038/sj.onc.1209082; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xu X, 2008, CANCER RES, V68, P2652, DOI 10.1158/0008-5472.CAN-07-5873; Xue LJ, 2007, CANCER RES, V67, P16, DOI 10.1158/0008-5472.CAN-06-3200; Xue LJ, 2006, CANCER RES, V66, P1900, DOI 10.1158/0008-5472.CAN-05-2656; Xue LJ, 2003, CANCER RES, V63, P980; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Yoshida T, 2006, INT J CANCER, V118, P1395, DOI 10.1002/ijc.21538; Zheng Z, 2007, NEW ENGL J MED, V356, P800, DOI 10.1056/NEJMoa065411; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43	37	28	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2009	28	21					2173	2184		10.1038/onc.2009.84	http://dx.doi.org/10.1038/onc.2009.84			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19398949				2022-12-17	WOS:000266451300006
J	Lee, SH; Lee, SJ; Chung, JY; Jung, YS; Choi, SY; Hwang, SH; Choi, D; Ha, NC; Park, BJ				Lee, S-H; Lee, S-J; Chung, J-Y; Jung, Y-S; Choi, S-Y; Hwang, S. H.; Choi, D.; Ha, N-C; Park, B-J			p53, secreted by K-Ras-Snail pathway, is endocytosed by K-Ras-mutated cells; implication of target-specific drug delivery and early diagnostic marker	ONCOGENE			English	Article						p53; Snail; secretion; endocytosis; diagnostic marker	COLON-CANCER CELLS; ANTI-P53 ANTIBODIES; NUCLEAR EXPORT; EXPRESSION; MUTATIONS; ACTIVATION; CHOLANGIOCARCINOMAS; RESTORATION; CLEARANCE; ONCOGENE	p53 is eliminated from K-Ras-mutated cancer cells through direct interaction with Snail. However, it is not achieved through proteasome-mediated degradation or transcriptional repression. Here we provide evidence that p53, binding with Snail, is exported from a K-Ras-mutated cell through a vesicle transport-like mechanism, independently using a p53-nuclear-exporting mechanism. Although we can detect p53 in culture media, a majority of p53 might be degraded by extracellular proteases. Thus, we can recover the secreted p53 in culture media by the inhibition of protease and endocytosis. In addition, a considerable amount of p53 is endocytosed by neighboring cells. As p53 resorption occurs in a K-Ras-dependent manner, treatment of recombinant p53 is detected in the whole-cell lysate of K-Ras-mutated cells, but not in that of wild-type cells. Using the property of p53, we can deliver the chemical (propidium iodine) into K-Ras mutated cells selectively. In contrast, Snail, a co-secreted protein with p53 in response to oncogenic K-Ras, shows resistance to endocytosis and protease, and results in remaining in the media. Thus, we can detect an autoantibody against Snail in the serum of a human cancer patient. Our finding can be used for a mutant K-Ras-specific anticancer drug delivery system and for the diagnosis of pancreatic, colon and lung cancers. Oncogene (2009) 28, 2005-2014; doi:10.1038/onc.2009.67; published online 6 April 2009	[Lee, S-H; Lee, S-J; Chung, J-Y; Jung, Y-S; Choi, S-Y; Park, B-J] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; [Hwang, S. H.] Pusan Natl Univ Hosp, Dept Lab Med, Pusan, South Korea; [Choi, D.] Shunchoonhyang Med Ctr, Seoul, South Korea; [Ha, N-C] Pusan Natl Univ, Coll Pharm, Dept Mfg Pharm, Pusan 609735, South Korea	Pusan National University; Pusan National University; Pusan National University Hospital; Pusan National University	Park, BJ (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.	bjpark1219@pusan.ac.kr	Lee, Sang Joon/AAG-2448-2019; Hwang, Sang-Hyun/C-3571-2008; Hwang, Sanghyun/L-5314-2019	Hwang, Sang-Hyun/0000-0003-3201-5728; Hwang, Sanghyun/0000-0003-3201-5728	Research Team for Longevity Life Sciences in Pusan National University; Pusan National University (PNU) [PNU-2008-101-2008-596-000]	Research Team for Longevity Life Sciences in Pusan National University; Pusan National University (PNU)	This work was supported by a research grant from the Research Team for Longevity Life Sciences in Pusan National University and by the Bio-Scientific Research Grant funded by the Pusan National University (PNU, Bio-Scientific Research Grant)(PNU-2008-101-2008-596-000).	Bergqvist M, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-66; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Genschel J, 2000, HUM MUTAT, V16, P451, DOI 10.1002/1098-1004(200012)16:6<451::AID-HUMU1>3.0.CO;2-9; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Koivusalo R, 2006, CANCER RES, V66, P11817, DOI 10.1158/0008-5472.CAN-06-2185; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; Lee SH, 2009, NEOPLASIA, V11, P22, DOI 10.1593/neo.81006; LEON M, 1995, ANTICANCER RES, V15, P859; LEVI S, 1991, CANCER RES, V51, P3497; Limpaiboon T, 2004, HEPATO-GASTROENTEROL, V51, P25; Nie LH, 2007, J BIOL CHEM, V282, P14616, DOI 10.1074/jbc.M610515200; Park BJ, 2006, CANCER RES, V66, P6913, DOI 10.1158/0008-5472.CAN-05-3740; Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Roy UKB, 2008, MOL CARCINOGEN, V47, P538, DOI 10.1002/mc.20414; Shin J, 2006, CELL PHYSIOL BIOCHEM, V17, P211, DOI 10.1159/000094126; Soussi T, 2000, CANCER RES, V60, P1777; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; TSUDA H, 1992, MOL CARCINOGEN, V6, P266, DOI 10.1002/mc.2940060408; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang GY, 2005, CA-CANCER J CLIN, V55, P352, DOI 10.3322/canjclin.55.6.352	30	28	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2005	2014		10.1038/onc.2009.67	http://dx.doi.org/10.1038/onc.2009.67			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19347028				2022-12-17	WOS:000266023900001
J	Rensen, WM; Roscioli, E; Tedeschi, A; Mangiacasale, R; Ciciarello, M; Di Gioia, SA; Lavia, P				Rensen, W. M.; Roscioli, E.; Tedeschi, A.; Mangiacasale, R.; Ciciarello, M.; Di Gioia, S. A.; Lavia, P.			RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner	ONCOGENE			English	Article						RanBP1; mitotic spindle microtubules; taxol; apoptosis; RanGTPase; caspase-3	INDUCED APOPTOSIS; MITOTIC SPINDLE; BINDING PROTEIN-1; IMPORTIN-BETA; CYCLIN B; MICROTUBULES; GTPASE; CHECKPOINT; MITOSIS; ACTIVATION	Mitotic microtubule (MT)-targeting drugs are widely used to treat cancer. The GTPase Ran regulates multiple processes, including mitotic spindle assembly, spindle pole formation and MT dynamics; Ran activity is therefore essential to formation of a functional mitotic apparatus. The RanBP1 protein, which binds Ran and regulates its interaction with effectors, is overexpressed in many cancer types. Several observations indicate that RanBP1 contributes to regulate the function of the mitotic apparatus: RanBP1 inactivation yields hyperstable MTs and induces apoptosis during mitosis, reminiscent of the effects of the MT-stabilizing drug taxol. Here we have investigated the influence of RanBP1 on spontaneous and taxol-induced apoptosis in transformed cells. We report that RanBP1 downregulation by RNA interference activates apoptosis in several transformed cell lines regardless of their p53 status, but not in the caspase-3-defective MCF-7 breast cancer cell line. Furthermore, RanBP1-interfered cells show an increased apoptotic response to taxol compared to their counterpart with normal or high RanBP1 levels, and this response is caspase-3 dependent. These results indicate that RanBP1 can modulate the outcome of MT-targeting therapeutic protocols.	[Rensen, W. M.; Roscioli, E.; Tedeschi, A.; Mangiacasale, R.; Ciciarello, M.; Di Gioia, S. A.; Lavia, P.] Univ Roma La Sapienza, IBPM Inst Mol Biol & Pathol, CNR Natl Res Council, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Lavia, P (corresponding author), Univ Roma La Sapienza, IBPM Inst Mol Biol & Pathol, CNR Natl Res Council, Via Apuli 4, I-00185 Rome, Italy.	patrizia.lavia@uniroma1.it	Lavia, Patrizia/AAL-3982-2021; Ciciarello, Marilena/AAA-7950-2022; Lavia, Patrizia/J-5793-2019; Ciciarello, Marilena/A-4401-2015	Ciciarello, Marilena/0000-0002-4744-507X; Lavia, Patrizia/0000-0003-3310-6701; Tedeschi, Antonio/0000-0001-7276-4550; Di Gioia, Silvio Alessandro/0000-0002-7235-5682	Italian Association for Cancer Research ( AIRC); MIUR-FIRB [RBIN04T7MT]; AIRC; ER; MIUR-FIRB	Italian Association for Cancer Research ( AIRC)(Fondazione AIRC per la ricerca sul cancro); MIUR-FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); AIRC(Fondazione AIRC per la ricerca sul cancro); ER; MIUR-FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB))	We thank Dr Christopher J Froelich (Northwestern University Medical School, Evanston, IL) for gifting the MCF-7/casp-3 cell line. We also thank Dr Giulia Guarguaglini for discussions and advice. This work was supported by the Italian Association for Cancer Research (AIRC) and by MIUR-FIRB ( grant RBIN04T7MT). WMR and MC were supported by AIRC, ER and RM by MIUR-FIRB research contracts.	Abe H, 2008, INT J CANCER, V122, P2391, DOI 10.1002/ijc.23400; Allan LA, 2007, MOL CELL, V26, P301, DOI 10.1016/j.molcel.2007.03.019; Alli E, 2002, CANCER RES, V62, P6864; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Battistoni A, 1997, J CELL SCI, V110, P2345; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bhat KMR, 2007, CLIN CANCER RES, V13, P2849, DOI 10.1158/1078-0432.CCR-06-3040; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BRITO DA, 2008, CELL MOTIL CYTOSKELE; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Ciciarello M, 2007, CELL MOL LIFE SCI, V64, P1891, DOI 10.1007/s00018-007-6568-2; Ciciarello M, 2004, J CELL SCI, V117, P6511, DOI 10.1242/jcs.01569; Clarke PR, 2008, NAT REV MOL CELL BIO, V9, P464, DOI 10.1038/nrm2410; De Luca A, 2003, CANCER RES, V63, P1430; Di Fiore B, 1999, J BIOL CHEM, V274, P10339, DOI 10.1074/jbc.274.15.10339; Di Fiore B, 2004, CELL CYCLE, V3, P305; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; DIMATTEO G, 1995, CELL GROWTH DIFFER, V6, P1213; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Giodini A, 2002, CANCER RES, V62, P2462; Gorlich D, 2003, EMBO J, V22, P1088, DOI 10.1093/emboj/cdg113; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; Hata T, 2005, CANCER RES, V65, P2899, DOI 10.1158/0008-5472.CAN-04-3981; Holland AJ, 2008, CANCER CELL, V14, P103, DOI 10.1016/j.ccr.2008.07.010; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Iancu C, 2000, CANCER RES, V60, P3537; Iancu C, 2001, J CELL SCI, V114, P909; Ibrado AM, 1998, LEUKEMIA, V12, P1930, DOI 10.1038/sj.leu.2401218; Impens F, 2008, ONCOGENE, V27, P4580, DOI 10.1038/onc.2008.96; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049; Jiang Y, 2003, ONCOGENE, V22, P8293, DOI 10.1038/sj.onc.1206873; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kalab P, 2008, J CELL SCI, V121, P1577, DOI 10.1242/jcs.005959; Kim M, 2005, MOL CELL BIOL, V25, P9232, DOI 10.1128/MCB.25.21.9232-9248.2005; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kurisetty VV, 2008, ONCOGENE, V27, P7139, DOI 10.1038/onc.2008.325; Li HY, 2007, CELL CYCLE, V6, P1886, DOI 10.4161/cc.6.15.4487; Lu KH, 2005, J ORTHOP RES, V23, P988, DOI 10.1016/j.orthres.2005.01.018; Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038/sj.cdd.4401012; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Perez de Castro I, 2007, CARCINOGENESIS, V28, P899, DOI 10.1093/carcin/bgm019; Plafker K, 2000, MOL CELL BIOL, V20, P3510, DOI 10.1128/MCB.20.10.3510-3521.2000; Rensen WM, 2008, FRONT BIOSCI-LANDMRK, V13, P4097, DOI 10.2741/2996; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Sillje HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070; Spankuch B, 2007, ONCOGENE, V26, P5793, DOI 10.1038/sj.onc.1210355; Spankuch B, 2006, CANCER RES, V66, P5836, DOI 10.1158/0008-5472.CAN-06-0343; Tanaka E, 2007, CLIN CANCER RES, V13, P1331, DOI 10.1158/1078-0432.CCR-06-1192; Tedeschi A, 2007, J CELL SCI, V120, P3748, DOI 10.1242/jcs.009308; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wong J, 2006, J CELL BIOL, V173, P879, DOI 10.1083/jcb.200511132; Xia F, 2008, MOL CELL BIOL, V28, P5299, DOI 10.1128/MCB.02039-07; Xia F, 2008, CANCER RES, V68, P1826, DOI 10.1158/0008-5472.CAN-07-5279; Yamada HY, 2006, MOL CANCER THER, V5, P2963, DOI 10.1158/1535-7163.MCT-06-0319; Yang XH, 2001, CANCER RES, V61, P348; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202	70	28	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1748	1758		10.1038/onc.2009.24	http://dx.doi.org/10.1038/onc.2009.24			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19270727	Bronze			2022-12-17	WOS:000265640400002
J	Li, NF; Kocher, HM; Salako, MA; Obermueller, E; Sandle, J; Balkwill, F				Li, N. F.; Kocher, H. M.; Salako, M. A.; Obermueller, E.; Sandle, J.; Balkwill, F.			A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells	ONCOGENE			English	Article						colony-stimulating factor 1 receptor; hTERT; immortalization; human epithelial cells	CSF-1 M-CSF; TELOMERASE; EXPRESSION; GROWTH; CYTOKINE; MARKER; P53	The receptor for macrophage colony-stimulating factor 1 receptor (CSF1R) is a product of the proto-oncogene c-fms and a member of the class III transmembrane tyrosine kinase receptor family. Earlier, we described increased mRNA expression of CSF1R in human telomerase reverse transcriptase (hTERT) immortalized human ovarian surface epithelial (IOSE) cell lines derived from a single donor. Here, we further describe that CSF1R is upregulated at both the mRNA and protein level in hTERT immortalized human normal OSE cells from two different donors and in hTERT immortalized human pancreatic ductal epithelial cells. CSF1R was not upregulated in hTERT immortalized epithelial clones that subsequently underwent senescence or in immortalized fibroblasts. Upon stimulation by the CSF1R ligand CSF1, the immortalized epithelial cell lines showed rapid internalization of CSF1R with concomitant down-modulation and colocalization of phosphorylated NF kappa Bp65 with hTERT protein, hTERT translocation into the nucleus and the binding of c-Myc to the hTERT promoter region. Reducing the expression of CSF1R using short hairpin interfering RNA abolished these effects and also decreased cell survival and the number of population doublings under suboptimal culture conditions. The telomerase inhibitor GRN163L confirmed a role for telomerase in the cleavage of the intracellular domain of CSF1R. On the basis of these findings, we suggest that CSF1R may be a critical factor facilitating hTERT immortalization of epithelial cells.	[Li, N. F.; Salako, M. A.; Obermueller, E.; Balkwill, F.] Barts & London Queen Marys Sch Med & Dent, Inst Canc, Ctr Canc & Inflammat, London EC1M 6BQ, England; [Li, N. F.; Kocher, H. M.; Salako, M. A.; Obermueller, E.; Sandle, J.; Balkwill, F.] Barts & London Queen Marys Sch Med & Dent, Canc Res UK Clin Ctr, London EC1M 6BQ, England; [Kocher, H. M.; Sandle, J.] Barts & London Queen Marys Sch Med & Dent, Inst Canc, Tumor Biol Ctr, London EC1M 6BQ, England	University of London; Queen Mary University London; Cancer Research UK; University of London; Queen Mary University London; University of London; Queen Mary University London	Balkwill, F (corresponding author), Barts & London Queen Marys Sch Med & Dent, Inst Canc, Ctr Canc & Inflammat, Charter House Sq, London EC1M 6BQ, England.	frances.balkwill@cancer.org.uk		LI, Ningfeng/0000-0001-5908-9976; Kocher, Hemant M/0000-0001-6771-1905; Balkwill, Frances/0000-0002-5587-9759	Medical Research Council [G0501974] Funding Source: Medline; MRC [G0501974] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akiyama M, 2003, CANCER RES, V63, P18; Hahn WC, 2002, MOL CELLS, V13, P351; Herbert BS, 2005, ONCOGENE, V24, P5262, DOI 10.1038/sj.onc.1208760; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KACINSKI BM, 1989, INT J RADIAT ONCOL, V17, P159, DOI 10.1016/0360-3016(89)90383-0; KACINSKI BM, 1990, INT J RADIAT ONCOL, V19, P619, DOI 10.1016/0360-3016(90)90488-6; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; Li NF, 2007, CELL PROLIFERAT, V40, P780, DOI 10.1111/j.1365-2184.2007.00462.x; Li NFF, 2004, LAB INVEST, V84, P923, DOI 10.1038/labinvest.3700093; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Rohrschneider LR, 1997, MOL REPROD DEV, V46, P96; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; SHERR CJ, 1988, J CELL BIOCHEM, V38, P179, DOI 10.1002/jcb.240380305; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Yang G, 2007, ONCOGENE, V26, P1492, DOI 10.1038/sj.onc.1209905	18	28	31	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					773	780		10.1038/onc.2008.412	http://dx.doi.org/10.1038/onc.2008.412			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	18997822				2022-12-17	WOS:000263076400014
J	Ayada, T; Taniguchi, K; Okamoto, F; Kato, R; Komune, S; Takaesu, G; Yoshimura, A				Ayada, T.; Taniguchi, K.; Okamoto, F.; Kato, R.; Komune, S.; Takaesu, G.; Yoshimura, A.			Sprouty4 negatively regulates protein kinase C activation by inhibiting phosphatidylinositol 4,5-biphosphate hydrolysis	ONCOGENE			English	Article						VEGF; phospholipase C; phosphatidylinositol; ERK; Ras	ENDOTHELIAL GROWTH-FACTOR; SUBSTRATE MARCKS PROTEIN; INDUCED ERK ACTIVATION; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; CELLS; RECEPTOR; FGF; TRANSLOCATION; ANGIOGENESIS	Sproutys have been shown to negatively regulate growth factor-induced extracellular signal-regulated kinase (ERK) activation, and suggested to be an anti-oncogene. However, molecular mechanism of the suppression has not yet been clarified completely. Sprouty4 inhibits vascular endothelial growth factor (VEGF)-A-induced ERK activation, but not VEGF-C-induced ERK activation. It has been shown that VEGF-A-mediated ERK activation is strongly dependent on protein kinase C (PKC), whereas that by VEGF-C is dependent on Ras. This suggests that Sprouty4 inhibits the PKC pathway more specifically than the Ras pathway. In this study, we confirmed that Sprouty4 suppressed various signals downstream of PKC, such as phosphorylation of MARCKS and protein kinase D (PKD), as well as PKC-dependent nuclear factor (NF)-kappa B activation. Furthermore, Sprouty4 suppressed upstream signals of PKC, such as Ca2+ mobilization, phosphatidylinositol 4,5-biphosphate (PIP2) breakdown and inositol 1,4,5-triphosphate (IP3) production in response to VEGF-A. Those effects were dependent on the C-terminal cysteine-rich region, but not on the N-terminal region of Sprouty4, which is critical for the suppression of fibroblast growth factor (FGF)-mediated ERK activation. Sprouty4 overexpression or deletion of the Sprouty4 gene did not affect phospholipase C (PLC) gamma-1 activation, which is an enzyme that catalyzes PIP2 hydrolysis. Moreover, Sprouty4 inhibited not only VEGF-A-mediated PIP2 hydrolysis but also inhibited the lysophosphatidic acid (LPA)-induced PIP2 breakdown that is catalyzed by PLC beta/epsilon activated by G-protein coupled receptor (GPCR). Taken together, Sprouty4 has broader suppression activity for various stimuli than previously thought; it may function as an inhibitor for various types of PLC-dependent signaling as well as for ERK activation.	[Yoshimura, A.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1608582, Japan; [Ayada, T.; Taniguchi, K.; Okamoto, F.; Kato, R.; Takaesu, G.; Yoshimura, A.] Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Fukuoka 812, Japan; [Ayada, T.; Komune, S.] Kyushu Univ, Grad Sch Med Sci, Dept Otorhinolaryngol, Fukuoka 812, Japan	Keio University; Kyushu University; Kyushu University	Yoshimura, A (corresponding author), Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	yoshimura@a6.keio.jp	Yoshimura, Akihiko/K-5515-2013	Takaesu, Giichi/0000-0002-1581-1055	Ministry of Education, Culture, Sports, Science and Technology of Japan; Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO); Takeda Science Foundation; Kato Memorial Trust for Nambyo Research; Mitsubishi Pharma Research Foundation; Nakatomi Foundation; Naito Foundation; Astellas Foundation for Research on Metabolic Disorders; Yakult Bioscience Research Foundation; Princess Takamatsu Cancer Research Fund	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO)(National Institute of Biomedical Innovation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Kato Memorial Trust for Nambyo Research(Kato Memorial Trust for Nambyo Research); Mitsubishi Pharma Research Foundation; Nakatomi Foundation; Naito Foundation(Naito Memorial Foundation); Astellas Foundation for Research on Metabolic Disorders; Yakult Bioscience Research Foundation; Princess Takamatsu Cancer Research Fund	We thank T Yoshioka and M Ohtsu for technical assistance, Dr Sasaki (Akita University), Dr Kawahara, Dr Okuno and Dr Yokomizo (Kyushu University) for reagents and discussions and Y Nishi for manuscript preparation. This study was supported by special Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO), the Takeda Science Foundation, the Kato Memorial Trust for Nambyo Research, the Mitsubishi Pharma Research Foundation, the Nakatomi Foundation, the Naito Foundation, Astellas Foundation for Research on Metabolic Disorders, the Yakult Bioscience Research Foundation and the Princess Takamatsu Cancer Research Fund.	Abe M, 2004, BIOCHEM BIOPH RES CO, V323, P1040, DOI 10.1016/j.bbrc.2004.08.198; Angrist M, 1996, NAT GENET, V14, P341, DOI 10.1038/ng1196-341; Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; Basson MA, 2006, DEV BIOL, V299, P466, DOI 10.1016/j.ydbio.2006.08.051; Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Brems H, 2007, NAT GENET, V39, P1120, DOI 10.1038/ng2113; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Fukunaga K, 2001, J BIOL CHEM, V276, P43025, DOI 10.1074/jbc.M108288200; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hempstead BL, 2004, J CLIN INVEST, V113, P811, DOI 10.1172/JCI200421309; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200; Kramer S, 1999, DEVELOPMENT, V126, P2515; Kuriyama M, 2004, BIOCHEM BIOPH RES CO, V325, P843, DOI 10.1016/j.bbrc.2004.10.102; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Maeng YS, 2006, CELL SIGNAL, V18, P994, DOI 10.1016/j.cellsig.2005.08.007; Minowada G, 1999, DEVELOPMENT, V126, P4465; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Ozdener F, 2002, MOL PHARMACOL, V62, P672, DOI 10.1124/mol.62.3.672; Qin LL, 2006, J BIOL CHEM, V281, P32550, DOI 10.1074/jbc.M604853200; Reich A, 1999, DEVELOPMENT, V126, P4139; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Sivak JM, 2005, DEV CELL, V8, P689, DOI 10.1016/j.devcel.2005.02.011; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; Taketomi T, 2005, NAT NEUROSCI, V8, P855, DOI 10.1038/nn1485; Taniguchi K, 2007, MOL CELL BIOL, V27, P4541, DOI 10.1128/MCB.01600-06; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Wang Y, 2008, GENE DEV, V22, P878, DOI 10.1101/gad.452908; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Yao YG, 2004, BIOCHEM BIOPH RES CO, V321, P648, DOI 10.1016/j.bbrc.2004.06.176; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	45	28	29	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1076	1088		10.1038/onc.2008.464	http://dx.doi.org/10.1038/onc.2008.464			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137008				2022-12-17	WOS:000263722900003
J	Jimeno, A; Chan, A; Cusatis, G; Zhang, X; Wheelhouse, J; Solomon, A; Chan, F; Zhao, M; Cosenza, SC; Reddy, MVR; Rudek, MA; Kulesza, P; Donehower, RC; Reddy, EP; Hidalgo, M				Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.; Cosenza, S. C.; Reddy, M. V. Ramana; Rudek, M. A.; Kulesza, P.; Donehower, R. C.; Reddy, E. P.; Hidalgo, M.			Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay	ONCOGENE			English	Article						pancreatic cancer; xenograft model; biomarker; ex vivo; cyclin B1; mitotic modulator	POLO-LIKE KINASE-1; CELL-DIVISION; CYCLIN B1; CHEMOTHERAPY SENSITIVITY; RESISTANCE ASSAYS; IN-VIVO; ARREST; OVEREXPRESSION; LEADS	The pupose of this study was to evaluate the activity of ON 01910.Na, a mitotic inhibitor, in in vitro and in vivo models of pancreatic cancer and to discover biomarkers predictive of efficacy. Successive in vitro and in vivo models were used; these included cell line-derived and patient-derived tumors from our PancXenoBank, a live collection of freshly generated pancreatic cancer xeno-grafts. ON 01910.Na showed equivalent activity to gemcitabine against pancreatic cancer cell lines in vitro. The activity of the agent correlated with suppression of phospho-CDC25C and cyclin B1. These markers were optimized for a fine-needle aspirate ex vivo rapid assay. Cyclin B1 mRNA evaluation yielded the most optimal combination of accuracy and reproducibility. Next, nine patient-derived tumors from the PancXenoBank were pro. led using the assay developed in cell lines and treated with ON01910.Na for 28 days. Two cases were cataloged as potential responders and seven as resistants. There was a correlation between the ex vivo assay and sensitivity to the tested agent, as the two cases prospectively identified as sensitive met prespecified criteria for response. Of the seven tumors of predictive resistant, only one was found to be sensitive to ON 01910.Na. In addition, there was a good correlation between cyclin B1 downregulation ex vivo and changes in cyclin B1 protein post-treatment. The novel mitotic inhibitor, ON 01910.Na, showed activity in preclinical model of pancreatic cancer. A rapid assay was rationally developed that not only identified cases sensitive to ON 01910.Na, but also anticipated the pharmacodynamic events occurring after in vivo exposure.	[Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.; Rudek, M. A.; Donehower, R. C.; Hidalgo, M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA; [Cosenza, S. C.; Reddy, M. V. Ramana; Reddy, E. P.] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19122 USA; [Kulesza, P.] Univ Alabama, Dept Pathol, Wallace Tumor Inst, Birmingham, AL 35294 USA	Johns Hopkins University; Johns Hopkins Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Alabama System; University of Alabama Birmingham	Hidalgo, M (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St,Room 1M88, Baltimore, MD 21231 USA.	mhidalg1@jhmi.edu	Cusatis, Gianluca/G-2539-2011; HIDALGO, MANUEL/I-4995-2015; Reddy, E. Premkumar/F-6233-2011	HIDALGO, MANUEL/0000-0002-3765-3318; 	Viragh Foundation; Onconova Inc; NATIONAL CANCER INSTITUTE [R01CA116554, P30CA006973] Funding Source: NIH RePORTER	Viragh Foundation; Onconova Inc; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by the Viragh Foundation and Onconova Inc.	Budirahardja Y, 2008, DEVELOPMENT, V135, P1303, DOI 10.1242/dev.019075; Dvory-Sobol H, 2006, EUR J CANCER, V42, P422, DOI 10.1016/j.ejca.2005.11.009; Gonczy P, 2008, NAT REV MOL CELL BIO, V9, P355, DOI 10.1038/nrm2388; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Hassan KA, 2002, CANCER RES, V62, P6414; Hidalgo M, 2006, MOL CANCER THER, V5, P1895, DOI 10.1158/1535-7163.MCT-05-0525; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jimeno A, 2006, CANCER RES, V66, P2385, DOI 10.1158/0008-5472.CAN-05-2882; Jimeno A, 2005, CANCER RES, V65, P3003, DOI 10.1158/0008-5472.CAN-04-3586; JIMENO A, 2008, J CLIN ONCOL; JIMENO A, 2008 ASCO ANN M OR P; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Korenaga D, 2002, SURGERY, V131, pS114, DOI 10.1067/msy.2002.119362; Li J, 2007, J CHROMATOGR B, V856, P198, DOI 10.1016/j.jchromb.2007.05.047; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Park M, 2000, CANCER RES, V60, P542; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Samson DJ, 2004, J CLIN ONCOL, V22, P3618, DOI 10.1200/JCO.2004.04.077; Schmidt M, 2006, MOL CANCER THER, V5, P809, DOI 10.1158/1535-7163.MCT-05-0455; Schrag D, 2004, J CLIN ONCOL, V22, P3631, DOI 10.1200/JCO.2004.05.065; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202	24	28	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					610	618		10.1038/onc.2008.424	http://dx.doi.org/10.1038/onc.2008.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	19029951	Green Accepted			2022-12-17	WOS:000262866500014
J	Hawkins, ED; Russell, SM				Hawkins, E. D.; Russell, S. M.			Upsides and downsides to polarity and asymmetric cell division in leukemia	ONCOGENE			English	Review						leukemia; lymphoma; Scribble; asymmetric cell divison; polarity; self-renewal	ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ACUTE MYELOID-LEUKEMIA; LETHAL-GIANT-LARVAE; NEUROBLAST SELF-RENEWAL; WNT-SIGNALING PATHWAY; NUCLEAR BETA-CATENIN; TUMOR-SUPPRESSOR; SPINDLE ORIENTATION; IN-VIVO	The notion that polarity regulators can act as tumor suppressors in epithelial cells is now well accepted. The function of these proteins in lymphocytes is less well explored, and their possible function as suppressors of leukemia has had little attention so far. We review the literature on lymphocyte polarity and the growing recognition that polarity proteins have an important function in lymphocyte function. We then describe molecular relationships between the polarity network and signaling pathways that have been implicated in leukemogenesis, which suggest mechanisms by which the polarity network might impact on leukemogenesis. We particularly focus on the possibility that disruption of polarity might alter asymmetric cell division ( ACD), and that this might be a leukemia-initiating event. We also explore the converse possibility that leukemic stem cells might be produced or maintained by ACD, and therefore that Dlg, Scribble and Lgl might be important regulators of this process.	[Hawkins, E. D.; Russell, S. M.] Peter MacCallum Canc Inst, Immune Signalling Lab, Div Res, Melbourne, Vic 3002, Australia; [Russell, S. M.] Swinburne Univ Technol, Ctr MicroPhoton, Fac Engn & Ind Sci, Hawthorn, Vic 3122, Australia	Peter Maccallum Cancer Center; Swinburne University of Technology	Russell, SM (corresponding author), Peter MacCallum Canc Inst, Immune Signalling Lab, Div Res, Melbourne, Vic 3002, Australia.	sarah.russell@petermac.org	Russell, Sarah M/B-9341-2009	Russell, Sarah M/0000-0001-5826-9641; Hawkins, Edwin/0000-0002-3686-8261				Affolter M, 2005, DEV CELL, V9, P19, DOI 10.1016/j.devcel.2005.06.003; Aggerholm A, 2000, EUR J HAEMATOL, V65, P109, DOI 10.1034/j.1600-0609.2000.90181.x; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Anderson AC, 2005, J IMMUNOL, V174, P890, DOI 10.4049/jimmunol.174.2.890; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Barnard AL, 2005, BLOOD, V106, P988, DOI 10.1182/blood-2004-07-2850; Beckmann J, 2007, BLOOD, V109, P5494, DOI 10.1182/blood-2006-11-055921; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Bhalerao S, 2005, CURR BIOL, V15, P1583, DOI 10.1016/j.cub.2005.07.061; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Blot V, 2004, J CELL SCI, V117, P3983, DOI 10.1242/jcs.01266; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Bromley SK, 2000, J IMMUNOL, V165, P15, DOI 10.4049/jimmunol.165.1.15; Buzzeo MP, 2007, LEUKEMIA, V21, P1619, DOI 10.1038/sj.leu.2404768; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485; Comer FI, 2007, CELL, V128, P239, DOI 10.1016/j.cell.2007.01.010; Congdon KL, 2008, CURR OPIN IMMUNOL, V20, P302, DOI 10.1016/j.coi.2008.05.003; Costello PS, 2002, NAT IMMUNOL, V3, P1082, DOI 10.1038/ni848; Cournailleau F, 2008, CURR OPIN CELL BIOL, V20, P462, DOI 10.1016/j.ceb.2008.03.007; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dollar GL, 2005, NATURE, V437, P1376, DOI 10.1038/nature04116; Dustin ML, 2002, ADV EXP MED BIOL, V512, P191; Ehebauer M, 2006, SCIENCE, V314, P1414, DOI 10.1126/science.1134042; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Fukuda R, 2005, P NATL ACAD SCI USA, V102, P15213, DOI 10.1073/pnas.0507184102; Gerard A, 2007, J CELL BIOL, V176, P863, DOI 10.1083/jcb.200608161; Giagulli C, 2004, IMMUNITY, V20, P25, DOI 10.1016/S1074-7613(03)00350-9; Giebel B, 2006, BLOOD, V107, P2146, DOI 10.1182/blood-2005-08-3139; Gong Y, 2004, NATURE, V430, P689, DOI 10.1038/nature02796; Gonzalez C, 2007, NAT REV GENET, V8, P462, DOI 10.1038/nrg2103; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933; Guo ZY, 2007, BLOOD, V109, P5463, DOI 10.1182/blood-2006-11-059071; Hardin J, 2008, CURR OPIN GENET DEV, V18, P362, DOI 10.1016/j.gde.2008.06.006; Heit B, 2008, NAT IMMUNOL, V9, P743, DOI 10.1038/ni.1623; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Januschke J, 2008, ONCOGENE, V27, P6994, DOI 10.1038/onc.2008.349; Javier RT, 2008, ONCOGENE, V27, P7031, DOI 10.1038/onc.2008.352; Jones P, 1998, BLOOD, V92, P1505, DOI 10.1182/blood.V92.5.1505.417k42_1505_1511; Kallay LM, 2006, J CELL BIOCHEM, V99, P647, DOI 10.1002/jcb.20992; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kiel MJ, 2008, NAT REV IMMUNOL, V8, P290, DOI 10.1038/nri2279; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Knoblich JA, 2008, CELL, V132, P583, DOI 10.1016/j.cell.2008.02.007; Krummel MF, 2006, NAT IMMUNOL, V7, P1143, DOI 10.1038/ni1404; Ladi E, 2006, NAT IMMUNOL, V7, P338, DOI 10.1038/ni1323; Langevin J, 2005, CURR BIOL, V15, P955, DOI 10.1016/j.cub.2005.04.054; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Lee CY, 2006, GENE DEV, V20, P3464, DOI 10.1101/gad.1489406; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lee OK, 2003, NAT CELL BIOL, V5, P987, DOI 10.1038/ncb1055; Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008-5472.CAN-05-3986; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; METCALF D, 1966, CANCER RES, V26, P483; Mikesch JH, 2007, LEUKEMIA, V21, P1638, DOI 10.1038/sj.leu.2404732; Mizumoto K, 2007, TRENDS CELL BIOL, V17, P465, DOI 10.1016/j.tcb.2007.08.004; Mizumoto K, 2007, DEV CELL, V12, P287, DOI 10.1016/j.devcel.2007.01.004; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777; Ngo NT, 2008, BRIT J HAEMATOL, V141, P771, DOI 10.1111/j.1365-2141.2008.07117.x; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; Nishio M, 2007, NAT CELL BIOL, V9, P36, DOI 10.1038/ncb1515; NORBERG B, 1977, LANCET, V1, P957; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Oliaro J, 2006, P NATL ACAD SCI USA, V103, P18685, DOI 10.1073/pnas.0602458103; Orgogozo V, 2002, DEVELOPMENT, V129, P4677; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Petropoulos K, 2008, J EXP MED, V205, P515, DOI 10.1084/jem.20071875; Rattis FM, 2004, CURR OPIN HEMATOL, V11, P88, DOI 10.1097/01.moh.0000133649.61121.ec; Real E, 2007, J IMMUNOL, V179, P5649, DOI 10.4049/jimmunol.179.9.5649; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roegiers F, 2005, MOL BIOL CELL, V16, P3480, DOI 10.1091/mbc.E05-03-0177; Roman-Gomez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood-2006-09-047043; Rothenberg EV, 2008, NAT REV IMMUNOL, V8, P9, DOI 10.1038/nri2232; Round JL, 2005, J EXP MED, V201, P419, DOI 10.1084/jem.20041428; Russell S, 2008, J CELL SCI, V121, P131, DOI 10.1242/jcs.021253; SAINTEMARIE G, 1965, BLOOD-J HEMATOL, V26, P765, DOI 10.1182/blood.V26.6.765.765; Sanada K, 2005, CELL, V122, P119, DOI 10.1016/j.cell.2005.05.009; Savona M, 2008, NAT REV CANCER, V8, P341, DOI 10.1038/nrc2368; Schlessinger K, 2007, J CELL BIOL, V178, P355, DOI 10.1083/jcb.200701083; SCHUMACHER HR, 1979, AM J HEMATOL, V7, P11, DOI 10.1002/ajh.2830070103; Siegrist SE, 2005, CELL, V123, P1323, DOI 10.1016/j.cell.2005.09.043; Sneddon JB, 2007, CELL STEM CELL, V1, P607, DOI 10.1016/j.stem.2007.11.009; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Steelman LS, 2008, LEUKEMIA, V22, P686, DOI 10.1038/leu.2008.26; Stephenson LM, 2007, MOL CELL BIOL, V27, P7574, DOI 10.1128/MCB.00439-07; Stinchcombe JC, 2007, ANNU REV CELL DEV BI, V23, P495, DOI 10.1146/annurev.cellbio.23.090506.123521; Takano H, 2004, J EXP MED, V199, P295, DOI 10.1084/jem.20030929; Tanegashima K, 2008, EMBO J, V27, P606, DOI 10.1038/emboj.2008.9; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Toyoshima F, 2007, DEV CELL, V13, P796, DOI 10.1016/j.devcel.2007.10.014; Van Keymeulen A, 2006, J CELL BIOL, V174, P437, DOI 10.1083/jcb.200604113; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Verburgh E, 2003, J CLIN ONCOL, V21, P273, DOI 10.1200/JCO.2003.04.182; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Wang SF, 2008, BLOOD, V111, P2878, DOI 10.1182/blood-2007-07-103119; Weerkamp F, 2006, LEUKEMIA, V20, P1197, DOI 10.1038/sj.leu.2404255; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Wikramanayake AH, 2003, NATURE, V426, P446, DOI 10.1038/nature02113; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Wu MF, 2007, CELL STEM CELL, V1, P541, DOI 10.1016/j.stem.2007.08.009; Xavier R, 2004, J CELL BIOL, V166, P173, DOI 10.1083/jcb.200309044; Xie T, 2007, DEVELOPMENT, V134, P2001, DOI 10.1242/dev.002022; Xue L, 2008, P NATL ACAD SCI USA, V105, P2022, DOI 10.1073/pnas.0712059105; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yin XY, 2007, J IMMUNOL, V179, P7358, DOI 10.4049/jimmunol.179.11.7358; Yoshida S, 2008, VIRUS GENES, V37, P9, DOI 10.1007/s11262-008-0234-0; Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003; ZIGMOND SH, 1981, J CELL BIOL, V89, P585, DOI 10.1083/jcb.89.3.585	142	28	28	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					7003	7017		10.1038/onc.2008.350	http://dx.doi.org/10.1038/onc.2008.350			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029941				2022-12-17	WOS:000261108200012
J	Huang, L; Verstrepen, L; Heyninck, K; Wullaert, A; Revets, H; De Baetselier, P; Beyaert, R				Huang, L.; Verstrepen, L.; Heyninck, K.; Wullaert, A.; Revets, H.; De Baetselier, P.; Beyaert, R.			ABINs inhibit EGF receptor-mediated NF-kappa B activation and growth of EGF receptor-overexpressing tumour cells	ONCOGENE			English	Article						ABIN; EGF receptor; NF-kappa B; proliferation; cancer	ADENOVIRAL GENE-TRANSFER; BREAST-CANCER; A20-BINDING INHIBITOR; TRANSCRIPTION FACTOR; THERAPEUTIC TARGET; BINDING-PROTEIN; CYCLIN D1; EXPRESSION; PHOSPHORYLATION; KINASE	The epidermal growth factor receptor (EGFR) is frequently overexpressed in various tumours of epidermal origin and is held responsible for tumourigenicity and tumour persistence. Increased nuclear factor (NF)-kappa B activity has been suggested to be involved in the malignant behaviour of EGFR-overexpressing cells. However, the mechanisms that regulate EGF-induced NF-kappa B activation are still largely unknown. Here we show that EGF can induce NF-kappa B-dependent gene expression independently from I kappa B alpha degradation or p100 processing in EGFR-overexpressing HEK293T cells. Moreover, EGF-induced NF-kappa B activation could be inhibited by overexpression of ABINs, which were previously identified as intracellular inhibitors of tumour necrosis factor, interleukin-1 and lipopolysaccharide-induced NF-kappa B activation. Knockdown of ABIN-1 by RNA interference boosted the NF-kappa B response upon EGF stimulation. The C-terminal ubiquitin-binding domain containing region of ABINs was crucial and sufficient for NF-kappa B inhibition. Adenoviral gene transfer of ABINs reduced constitutive NF-kappa B activity as well as the proliferation of EGFR-overexpressing A431 and DU145 human carcinoma cells. Altogether, these results demonstrate an important role for an ABIN-sensitive non-classical NF-kappa B signalling pathway in the proliferation of EGFR-overexpressing tumour cells, and indicate a potential use for ABIN gene therapy in the treatment of cancer.	[Huang, L.; Verstrepen, L.; Heyninck, K.; Wullaert, A.; Beyaert, R.] Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Oost Vlaanderen, Belgium; [Huang, L.; Revets, H.; De Baetselier, P.] Vrije Univ Brussel, Cellular & Mol Immunol Lab, Brussels, Belgium; [Huang, L.; Revets, H.; De Baetselier, P.] VIB, Dept Mol & Cellular Interact, Brussels, Belgium; [Huang, L.; Verstrepen, L.; Heyninck, K.; Wullaert, A.; Beyaert, R.] Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Ghent University	Beyaert, R (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Oost Vlaanderen, Belgium.	rudi.beyaert@dmbr.ugent.be	De Baetselier, Patrick/D-3866-2014; Huang, Lieven/B-4630-2008; Wullaert, Andy/R-1924-2019; Beyaert, Rudi/B-2589-2009; Wullaert, Andy/D-2975-2018	Wullaert, Andy/0000-0001-5012-654X; Wullaert, Andy/0000-0001-5012-654X; Beyaert, Rudi/0000-0002-5704-582X	Interuniversitaire Attractiepolen [IAP6/18]; 'Fonds voor Wetenschappelijk Onderzoek-Vlaanderen' (FWO-Vlaanderen); GOA of the University of Gent; IWT-Vlaanderen; Emmanuel Vanderschueren Stichting	Interuniversitaire Attractiepolen; 'Fonds voor Wetenschappelijk Onderzoek-Vlaanderen' (FWO-Vlaanderen)(FWO); GOA of the University of Gent; IWT-Vlaanderen(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Emmanuel Vanderschueren Stichting	This work was supported in part by grants from the 'Interuniversitaire Attractiepolen' (IAP6/18), the 'Fonds voor Wetenschappelijk Onderzoek-Vlaanderen' (FWO-Vlaanderen), the GOA of the University of Gent. LH is a predoctoral research fellow supported by the IWT-Vlaanderen and the Emmanuel Vanderschueren Stichting.	Adli M, 2006, J BIOL CHEM, V281, P26976, DOI 10.1074/jbc.M603133200; Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; Anto RJ, 2003, J BIOL CHEM, V278, P25490, DOI 10.1074/jbc.M301790200; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Chinnaiyan P, 2005, CANCER RES, V65, P3328, DOI 10.1158/0008-5472.CAN-04-3547; Damiano V, 2006, CLIN CANCER RES, V12, P577, DOI 10.1158/1078-0432.CCR-05-1943; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; El Bakkouri K, 2005, J BIOL CHEM, V280, P17938, DOI 10.1074/jbc.M413588200; El Sheikh SS, 2004, NEOPLASIA, V6, P846, DOI 10.1593/neo.04379; FAN Z, 1993, CANCER RES, V53, P4322; Gasparian AV, 2002, J CELL SCI, V115, P141; Grempler R, 2004, BIOCHEM J, V382, P471, DOI 10.1042/BJ20040160; Guo GZ, 2004, ONCOGENE, V23, P535, DOI 10.1038/sj.onc.1207149; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Haussler U, 2005, AM J PHYSIOL-RENAL, V289, pF808, DOI 10.1152/ajprenal.00434.2003; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Johnston JB, 2006, CURR MED CHEM, V13, P3483, DOI 10.2174/092986706779026174; Keutgens A, 2006, BIOCHEM PHARMACOL, V72, P1069, DOI 10.1016/j.bcp.2006.06.011; Kirkwood KS, 2003, J GASTROINTEST SURG, V7, P43; KONGER RL, 1993, J CELL PHYSIOL, V156, P515, DOI 10.1002/jcp.1041560310; Le Page C, 2005, PROSTATE, V65, P306, DOI 10.1002/pros.20291; Liptay S, 2003, INT J CANCER, V105, P735, DOI 10.1002/ijc.11081; Makino K, 2004, ONCOGENE, V23, P3883, DOI 10.1038/sj.onc.1207485; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; Meeran SM, 2008, FRONT BIOSCI-LANDMRK, V13, P2191, DOI 10.2741/2834; Miggin SM, 2006, J LEUKOCYTE BIOL, V80, P220, DOI 10.1189/jlb.1105672; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Olivier S, 2006, BIOCHEM PHARMACOL, V72, P1054, DOI 10.1016/j.bcp.2006.07.023; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; Papoutsopoulou S, 2006, NAT IMMUNOL, V7, P606, DOI 10.1038/ni1334; Peng D, 1996, CANCER RES, V56, P3666; Reid A, 2007, EUR J CANCER, V43, P481, DOI 10.1016/j.ejca.2006.11.007; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sclabas GM, 2003, J GASTROINTEST SURG, V7, P37, DOI 10.1016/S1091-255X(02)00088-4; Sethi G, 2007, ONCOGENE, V26, P7324, DOI 10.1038/sj.onc.1210544; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Strassheim D, 2004, J IMMUNOL, V172, P5727, DOI 10.4049/jimmunol.172.9.5727; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Van Laere SJ, 2007, BRIT J CANCER, V97, P659, DOI 10.1038/sj.bjc.6603906; Verstrepen L, 2008, J CELL MOL MED, V12, P316, DOI 10.1111/j.1582-4934.2007.00187.x; Wagner S, 2008, ONCOGENE, V27, P3739, DOI 10.1038/sj.onc.1211042; Weaver BK, 2007, MOL CELL BIOL, V27, P4603, DOI 10.1128/MCB.00223-07; Wullaert A, 2005, HEPATOLOGY, V42, P381, DOI 10.1002/hep.20785; Wullaert A, 2007, J BIOL CHEM, V282, P81, DOI 10.1074/jbc.M607481200; Wullaert A, 2006, TRENDS IMMUNOL, V27, P533, DOI 10.1016/j.it.2006.09.003; Yang C, 2008, BIOCHEM J, V410, P167, DOI 10.1042/BJ20070781; Zhang SL, 2002, BIOCHEM BIOPH RES CO, V297, P17, DOI 10.1016/S0006-291X(02)02086-7	65	28	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6131	6140		10.1038/onc.2008.208	http://dx.doi.org/10.1038/onc.2008.208			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18622428				2022-12-17	WOS:000260083100006
J	Liu, L; Guo, C; Dammann, R; Tommasi, S; Pfeifer, GP				Liu, L.; Guo, C.; Dammann, R.; Tommasi, S.; Pfeifer, G. P.			RASSF1A interacts with and activates the mitotic kinase Aurora-A	ONCOGENE			English	Article						RASSF1A; Aurora-A; centrosome; mitosis	TUMOR-SUPPRESSOR RASSF1A; ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE PROGRESSION; DEATH INDUCER C19ORF5; CENTROSOME SEPARATION; BINDING-PROTEIN; CHROMOSOME SEGREGATION; CANCER SUSCEPTIBILITY; MICROTUBULE STABILITY; SPINDLE FORMATION	The RAS association domain family 1A (RASSF1A) gene is located at chromosome 3p21.3 within a specific area of common heterozygous and homozygous deletions. RASSF1A frequently undergoes promoter methylation-associated inactivation in human cancers. Rassf1a(-/-) mice are prone to both spontaneous and carcinogen-induced tumorigenesis, supporting the notion that RASSF1A is a tumor suppressor. However, it is not fully understood how RASSF1A is involved in tumor suppression pathways. Here we show that overexpression of RASSF1A inhibits centrosome separation. RASSF1A interacts with Aurora-A, a mitotic kinase. Surprisingly, knockdown of RASSF1A by siRNA led to reduced activation of Aurora-A, whereas overexpression of RASSF1A resulted in increased activation of Aurora-A, suggesting that RASSF1A is involved in Aurora-A activation. Like other Aurora-A activators, RASSF1A was also a substrate of Aurora-A in vitro. The failure of recombinant RASSF1A to activate recombinant Aurora-A indicates that RASSF1A may not activate Aurora-A directly and suggests that RASSF1A may function as a scaffold to bring together Aurora-A and its activator(s). Inhibition of centrosome separation by RASSF1A overexpression is most likely a consequence of hyperstabilization of microtubules by this protein.	[Liu, L.; Guo, C.; Tommasi, S.; Pfeifer, G. P.] City Hope Canc Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; [Dammann, R.] Univ Giessen, Inst Genet, Giessen, Germany	City of Hope; Beckman Research Institute of City of Hope; Justus Liebig University Giessen	Pfeifer, GP (corresponding author), City Hope Canc Ctr, Beckman Res Inst, Div Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	gpfeifer@coh.org	Guo, Cai/E-8884-2010					ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boveri T, 1888, JENA Z NATURWISS, V22, P685; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Crane R, 2004, BIOL CELL, V96, P215, DOI 10.1016/j.biolcel.2003.09.008; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Ewart-Toland A, 2005, CARCINOGENESIS, V26, P1368, DOI 10.1093/carcin/bgi085; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Guse A, 2005, CURR BIOL, V15, P778, DOI 10.1016/j.cub.2005.03.041; Hachet V, 2007, DEV CELL, V12, P531, DOI 10.1016/j.devcel.2007.02.015; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Hutterer A, 2006, DEV CELL, V11, P147, DOI 10.1016/j.devcel.2006.06.002; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lerman MI, 2000, CANCER RES, V60, P6116; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Liu L, 2007, CELL CYCLE, V6, P1663, DOI 10.4161/cc.6.13.4435; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu LY, 2005, BIOCHEM BIOPH RES CO, V332, P670, DOI 10.1016/j.bbrc.2005.05.006; Liu LY, 2005, CANCER RES, V65, P4191, DOI 10.1158/0008-5472.CAN-04-3865; Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mortlock A, 2005, CURR TOP MED CHEM, V5, P199, DOI 10.2174/1568026053507651; Naruganahalli KS, 2006, CURR OPIN INVEST DR, V7, P1044; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Portier N, 2007, DEV CELL, V12, P515, DOI 10.1016/j.devcel.2007.01.019; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Rong R, 2007, ONCOGENE, V26, P7700, DOI 10.1038/sj.onc.1210575; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Satinover DL, 2004, P NATL ACAD SCI USA, V101, P8625, DOI 10.1073/pnas.0402966101; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Tommasi S, 2005, CANCER RES, V65, P92; Trieselmann N, 2003, J CELL SCI, V116, P4791, DOI 10.1242/jcs.00798; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Uzbekov R, 2002, BIOL CELL, V94, P275, DOI 10.1016/S0248-4900(02)01202-9; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; WATERS JC, 1993, J CELL BIOL, V122, P361, DOI 10.1083/jcb.122.2.361; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	72	28	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	47					6175	6186		10.1038/onc.2008.220	http://dx.doi.org/10.1038/onc.2008.220			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18641684				2022-12-17	WOS:000260083100010
J	Kim, MS; Chang, X; Nagpal, JK; Yamashita, K; Baek, JH; Dasgupta, S; Wu, G; Osada, M; Woo, JH; Westra, WH; Trink, B; Ratovitski, EA; Moon, C; Sidransky, D				Kim, M. S.; Chang, X.; Nagpal, J. K.; Yamashita, K.; Baek, J. H.; Dasgupta, S.; Wu, G.; Osada, M.; Woo, J-H; Westra, W. H.; Trink, B.; Ratovitski, E. A.; Moon, C.; Sidransky, D.			The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth	ONCOGENE			English	Article						NMDAR2A; promoter hypermethylation; colon cancer; 5-aza-2'-deoxycytidine; tumor suppressor; biomarker	DISCS LARGE; PROMOTER METHYLATION; GENE-EXPRESSION; HUMAN HOMOLOG; LUNG-CANCER; HUMAN BRAIN; NMDA; HYPERMETHYLATION; BIOMARKER; PATTERNS	N-methyl-D-aspartate receptors (NMDARs) are the predominant excitatory neurotransmitter receptors in the mammalian brain. We found that among the three NMDARs examined (NMDAR1, NMDAR2A, NMDAR2B), only NMDAR2A was silenced in colorectal carcinoma (CRC) cell lines at basal line and reactivated by the demethylating agent, 5-aza-2'-deoxycytidine. NMDAR2A was expressed in normal colon epithelium, while expression was hardly detectable in colon cancer tissues. Promoter methylation of NMDAR2A was confirmed by bisulfite sequencing and combined bisulfite restriction analysis in the CRC cell lines and primary tumors. Quantitative methylation-specific PCR demonstrated NMDAR2A promoter hypermethylation in 82 of 100 primary human CRC, 15 of 100 normal corresponding epithelial tissues and 1 of 11 (9%) normal colon mucosa samples obtained from patients without cancer. Moreover, forced expression of full-length NMDAR2A in CRC cell lines induced apoptosis and almost abolished the ability of the cells to form colonies in culture, while NMDAR2A knockdown increased cell growth. Thus, NMDAR2A is commonly hypermethylated in primary human CRC and possesses tumor-suppressive activity.	[Kim, M. S.; Chang, X.; Nagpal, J. K.; Yamashita, K.; Dasgupta, S.; Wu, G.; Osada, M.; Woo, J-H; Trink, B.; Ratovitski, E. A.; Moon, C.; Sidransky, D.] Johns Hopkins Univ, Dept Otolaryngol, Head & Neck Canc Res Div, Baltimore, MD 21231 USA; [Baek, J. H.] Johns Hopkins Univ, Inst Cell Engn, Dept Med Genet, Baltimore, MD 21231 USA; [Westra, W. H.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sidransky, D (corresponding author), Johns Hopkins Univ, Dept Otolaryngol, Head & Neck Canc Res Div, 1550 Orleans St, Baltimore, MD 21231 USA.	dsidrans@jhmi.edu						Anegawa NJ, 2000, MOL BRAIN RES, V77, P163, DOI 10.1016/S0169-328X(00)00050-4; Azim AC, 1995, GENOMICS, V30, P613, DOI 10.1006/geno.1995.1286; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Choi SW, 2004, J ORAL PATHOL MED, V33, P533, DOI 10.1111/j.1600-0714.2004.00226.x; Ebert MPA, 2005, NEOPLASIA, V7, P771, DOI 10.1593/neo.05235; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Fang JY, 2004, CELL RES, V14, P217, DOI 10.1038/sj.cr.7290222; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Gonzalez-Cadavid NF, 2000, J ANDROL, V21, P566; Gruber AD, 1999, CANCER RES, V59, P5488; Haraguchi K, 2000, GENES CELLS, V5, P905, DOI 10.1046/j.1365-2443.2000.00374.x; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jeronimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747; Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608; KIM MS, 2007, IN PRESS CLIN CANC R; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Ludford-Menting MJ, 2002, J BIOL CHEM, V277, P4477, DOI 10.1074/jbc.M108479200; Mandelker DL, 2005, CANCER RES, V65, P4963, DOI 10.1158/0008-5472.CAN-04-3923; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Palmisano WA, 2000, CANCER RES, V60, P5954; Pillozzi S, 2002, LEUKEMIA, V16, P1791, DOI 10.1038/sj.leu.2402572; Rootwelt T, 1998, J NEUROCHEM, V71, P1544; Said SI, 1996, P NATL ACAD SCI USA, V93, P4688, DOI 10.1073/pnas.93.10.4688; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Saur D, 2002, AM J PHYSIOL-GASTR L, V282, pG349, DOI 10.1152/ajpgi.00226.2001; Schito AM, 1997, NEUROSCI LETT, V239, P49, DOI 10.1016/S0304-3940(97)00853-7; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Stepulak A, 2005, P NATL ACAD SCI USA, V102, P15605, DOI 10.1073/pnas.0507679102; Weaver KD, 2006, CANCER INVEST, V24, P35, DOI 10.1080/07357900500449546; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yanai H, 2000, GENES CELLS, V5, P815, DOI 10.1046/j.1365-2443.2000.00368.x	36	28	31	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					2045	2054		10.1038/sj.onc.1210842	http://dx.doi.org/10.1038/sj.onc.1210842			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922030				2022-12-17	WOS:000254359100009
J	Satoh, K; Hovey, RC; Malewski, T; Warri, A; Goldhar, AS; Ginsburg, E; Saito, K; Lydon, JP; Vonderhaar, BK				Satoh, K.; Hovey, R. C.; Malewski, T.; Warri, A.; Goldhar, A. S.; Ginsburg, E.; Saito, K.; Lydon, J. P.; Vonderhaar, B. K.			Progesterone enhances branching morphogenesis in the mouse mammary gland by increased expression of Msx2	ONCOGENE			English	Article						progesterone; mammary gland; msx2; homeo-box genes; branching morphogenesis	EPITHELIAL-CELL PROLIFERATION; HEPATOCYTE GROWTH-FACTOR; SERUM-FREE CULTURE; HOMEOBOX GENES; BREAST-CANCER; RECEPTOR-B; IN-VITRO; HORMONE; MICE; PROLACTIN	Branching morphogenesis within the peripubertal mouse mammary gland is directed by progesterone (P). A role for the homeobox-containing transcription factor, Msx2, during branching morphogenesis is suggested from its ontogenic expression pro. le and hormonal regulation. Herein, we de. ne the spatio-temporal control of Msx2 expression, the regulation of its expression by P and its direct role in ductal branching morphogenesis. P induces Msx2 in the presence of estrogen (E) both in vitro and in vivo while absence of the P receptor (PR) decreased Msx2 expression. Stable transfection of PR into mouse mammary epithelial cells increased the endogenous expression of Msx2 and their ability to undergo branching morphogenesis in vitro. Furthermore, normal mammary cells stably-transfected with Msx2 demonstrated increased branching morphogenesis in vitro while transgenic mice expressing Msx2 in their mammary glands demonstrated enhanced lateral branching during early development. The action of P on branching morphogenesis appears to involve Bmp2/4. Together, these data demonstrate that P, acting through PR-A and the Bmp2/4 pathway, induces Msx2 to enhance ductal branching in the mammary glands.	Natl Canc Inst, Ctr Canc Res, Mammary Biol & Tumorigenesis Lab, Bethesda, MD USA; Baylor Coll Med, Dept Cell Biol, Houston, TX USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine	Vonderhaar, BK (corresponding author), NIH, Mol & Cellular Endocrinol Sect, Mammary Biol & Tumorigenesis Lab, Bldg 37 Room 1106a1,37 Convent Dr, Bethesda, MD 20892 USA.	bv10w@nih.gov	Malewski, Tadeusz/N-6883-2019; Malewski, Tadeusz/H-2915-2012; Malewski, Tadeusz/J-4930-2015	Malewski, Tadeusz/0000-0001-8061-435X; Malewski, Tadeusz/0000-0001-8061-435X; Warri, Anni/0000-0002-0535-847X	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008226, ZIABC008226] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Alappat S, 2003, CELL RES, V13, P429, DOI 10.1038/sj.cr.7290185; Atwood CS, 2000, J ENDOCRINOL, V167, P39, DOI 10.1677/joe.0.1670039; Aupperlee MD, 2005, ENDOCRINOLOGY, V146, P3577, DOI 10.1210/en.2005-0346; Bamberger AM, 1996, P NATL ACAD SCI USA, V93, P6169, DOI 10.1073/pnas.93.12.6169; Brisken C, 2000, GENE DEV, V14, P650; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Daniel CW, 1999, J MAMMARY GLAND BIOL, V4, P3, DOI 10.1023/A:1018796301609; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; Fernandez-Valdivia R, 2005, SEMIN REPROD MED, V23, P22, DOI 10.1055/s-2005-864031; Friedmann Y, 1996, DEV BIOL, V177, P347, DOI 10.1006/dbio.1996.0168; Gupta IR, 2000, J CELL SCI, V113, P269; HASLAM SZ, 1988, J STEROID BIOCHEM, V31, P9, DOI 10.1016/0022-4731(88)90199-9; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Ismail PM, 2002, MOL ENDOCRINOL, V16, P2475, DOI 10.1210/me.2002-0169; Kelly PA, 2002, MOL CELL ENDOCRINOL, V197, P127, DOI 10.1016/S0303-7207(02)00286-1; Lanari C, 2001, CANCER RES, V61, P293; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49; Lydon JP, 1996, J STEROID BIOCHEM, V56, P67, DOI 10.1016/0960-0760(95)00254-5; Malewski T, 2005, CANCER INVEST, V23, P222, DOI 10.1081/CNV-200055958; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Ruan WF, 2005, ENDOCRINOLOGY, V146, P1170, DOI 10.1210/en.2004-1360; Satoh K, 2004, J MAMMARY GLAND BIOL, V9, P195, DOI 10.1023/B:JOMG.0000037162.84758.b5; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Sunil N, 2002, ENDOCRINOLOGY, V143, P2953, DOI 10.1210/en.143.8.2953; Wang WD, 1996, MECH DEVELOP, V58, P203, DOI 10.1016/S0925-4773(96)00562-X; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Zhang HZ, 2002, ENDOCRINOLOGY, V143, P3427, DOI 10.1210/en.2002-220007	38	28	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7526	7534		10.1038/sj.onc.1210555	http://dx.doi.org/10.1038/sj.onc.1210555			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546050				2022-12-17	WOS:000251282100004
J	Jeng, YM; Cai-Ng, S; Li, A; Furuta, S; Chew, H; Chen, PL; Lee, EYH; Lee, WH				Jeng, Y-M; Cai-Ng, S.; Li, A.; Furuta, S.; Chew, H.; Chen, P-L; Lee, E-Y-H; Lee, W-H			Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation	ONCOGENE			English	Article						BRCA1; heterozygous mutant; ionizing radiation; ovarian tumor; haploinsufficiency	INDUCED MICRONUCLEUS FREQUENCIES; BREAST-CANCER RISK; MUTATION CARRIERS; SCREENING-TEST; EARLY-ONSET; DNA-REPAIR; GENE; LYMPHOCYTES; WOMEN; P53	BRCA1 mutation carriers have an 85% lifetime risk of breast cancer and 60% for ovarian cancer. BRCA1 facilitates DNA double-strand break repair, and dysfunction of BRCA1 leads to hypersensitivity to DNA damaging agents and consequently genomic instability of cells. In this communication, we have examined the tumor incidence and survival of Brca1 heterozygous female mice. Brca1 heterozygotes appear to have a shortened life span with 70% tumor incidence. Lymphoma, but not ovarian and mammary gland tumors, occurs commonly in these mice. After a whole-body exposure to ionizing radiation, Brca1 heterozygous mice have a 3-5- fold higher incidence specific to ovarian tumors, but not lymphoma, when compared with the Brca1+/+ mice. All the tumors from heterozygous mice examined retain the wild-type allele and the cancer cells express Brca1 protein, precluding the chromosomal mechanism for loss of heterozygosity of Brca1 locus. Although the manifestation of BRCA1 haploin sufficiency may be different between human and mouse, this study suggests that women carrying Brca1 mutations may be more prone to ovarian tumor formation after IR exposure than nonmutation carriers.	Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, Coll Med, 839 Med Sci Court,124 Sprague hall, Irvine, CA 92697 USA.	whlee@uci.edu	Chen, Phang-Lang/J-5031-2013; Furuta, Saori/P-9677-2018	Furuta, Saori/0000-0003-1121-0487; JENG, YUNG-MING/0000-0002-3878-4491	PHS HHS [R01 94170] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baeyens A, 2004, INT J RADIAT BIOL, V80, P745, DOI 10.1080/09553000400017937; Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Baria K, 2001, CANCER RES, V61, P5948; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; EASTON DF, 1995, AM J HUM GENET, V56, P265; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Friedenson B, 2000, MedGenMed, V2, pE9; Goldfrank D, 2006, CANCER EPIDEM BIOMAR, V15, P2311, DOI 10.1158/1055-9965.EPI-06-0176; Goss PE, 1998, J CLIN ONCOL, V16, P338, DOI 10.1200/JCO.1998.16.1.338; Greenblatt MS, 2001, CANCER RES, V61, P4092; Haffty BG, 2002, LANCET, V359, P1471, DOI 10.1016/S0140-6736(02)08434-9; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Kirova YM, 2005, CANCER-AM CANCER SOC, V104, P856, DOI 10.1002/cncr.21223; Kote-Jarai Z, 2006, BRIT J CANCER, V94, P308, DOI 10.1038/sj.bjc.6602912; Kotsopoulos J, 2007, BRIT J CANCER, V96, P118, DOI 10.1038/sj.bjc.6603528; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Metcalfe KA, 2005, GYNECOL ONCOL, V96, P222, DOI 10.1016/j.ygyno.2004.09.039; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Narod SA, 2006, LANCET ONCOL, V7, P402, DOI 10.1016/S1470-2045(06)70624-6; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rothfuss A, 2000, CANCER RES, V60, P390; Salim EI, 2003, CARCINOGENESIS, V24, P335, DOI 10.1093/carcin/24.2.335; Schildkraut JM, 1997, JNCI-J NATL CANCER I, V89, P932, DOI 10.1093/jnci/89.13.932; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shanley S, 2006, CLIN CANCER RES, V12, P7025, DOI 10.1158/1078-0432.CCR-06-1244; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; WAGNER EH, 1998, EFFECTIVE CLIN PRACT, V1, P1; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	47	28	28	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6160	6166		10.1038/sj.onc.1210451	http://dx.doi.org/10.1038/sj.onc.1210451			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420720				2022-12-17	WOS:000249401300006
J	Meng, LH; Kohn, KW; Pommier, Y				Meng, L-H; Kohn, K. W.; Pommier, Y.			Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21(WAF1/CIP1) in response to the novel anticancer agent, aminoflone (NSC 686288)	ONCOGENE			English	Article						p53; proteasome; Akt; apoptosis; histone H2AX; DNA damage	ATM-DEPENDENT PHOSPHORYLATION; MOLECULAR INTERACTION MAP; DNA-DAMAGE; AMINOFLAVONE NSC-686288; ADENOCARCINOMA CELLS; IONIZING-RADIATION; TOPOISOMERASE-I; P53 ACTIVATION; CANCER CELLS; KINASE	Aminoflavone (AF, NSC 686288) is beginning clinical trials. It induces replication-mediated histone H2AX phosphorylation, DNA-protein crosslinks and activates p53. Here, we studied p21(CIP1/WAF1) and Mdm2 responses to AF. Although p53 stabilization and phosphorylation at serine 15 increased with dose and time of exposure, Mdm2 and p21(CIP1/WAF1) protein levels displayed a biphasic response, as they accumulated at submicromolar doses and then decreased with increasing AF. As both Mdm2 and p21(CIP1/WAF1) mRNA levels increased with AF concentration without reduction at higher concentrations, we measured the half- lives of Mdm2 and p21(CIP1/WAF1) proteins. Mdm2 and p21(CIP1/WAF1) half-lives were shortened with increasing AF concentrations. Proteasomal degradation appears responsible for the decrease of both Mdm2 and p21(CIP1/WAF1), as MG-132 prevented their degradation and revealed AF-induced Mdm2 polyubiquitylation. AF also induced protein kinase B (Akt) activation, which was reduced with increasing AF concentrations. Suppression of Akt by small interfering RNA was associated with downregulation of Mdm2 and p21(CIP1/WAF1) and with enhanced apoptosis. These results suggest that the cellular responses to AF are determined at least in part by Mdm2 and p21(CIP1/WAF1) protein levels, as well as by Akt activity, leading either to cell cycle arrest when Mdm2 and p21(CIP1/WAF1) are elevated, or to apoptosis when Mdm2 and p21(CIP1/WAF1) are degraded by the proteasome and Akt insufficiently activated to protect against apoptosis.	NCI, Canc Res Ctr, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NCI, Canc Res Ctr, Mol Pharmacol Lab, NIH, 37 Convent Dr,Bldg 37,Room 5068, Bethesda, MD 20892 USA.	pommier@nih.gov	meng, linghua/Y-8110-2019		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC006150, ZIABC006150] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN C, 2006, J PHARM EXP THER; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fujiwara Y, 2006, BIOCHEM BIOPH RES CO, V340, P560, DOI 10.1016/j.bbrc.2005.12.039; Furuta T, 2006, ONCOGENE, V25, P2839, DOI 10.1038/sj.onc.1209313; Hayward RL, 2003, CLIN CANCER RES, V9, P2856; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim Y, 2002, IN VITRO CELL DEV-PL, V38, P1, DOI 10.1079/IVP2001243; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Kohn KW, 2005, BIOCHEM BIOPH RES CO, V331, P816, DOI 10.1016/j.bbrc.2005.03.186; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Li YH, 2002, J INFRARED MILLIM W, V21, P1; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Meng LH, 2005, CANCER RES, V65, P5337, DOI 10.1158/0008-5472.CAN-05-0003; Meng LH, 2004, CANCER RES, V64, P9086, DOI 10.1158/0008-5472.CAN-04-0313; Meng LH, 2006, CANCER RES, V66, P9656, DOI 10.1158/0008-5472.CAN-06-0796; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Milne D, 2004, FEBS LETT, V577, P270, DOI 10.1016/j.febslet.2004.09.081; Monks A, 1997, ANTI-CANCER DRUG DES, V12, P533; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; Pommier Y, 2005, CURR PHARM DESIGN, V11, P2855, DOI 10.2174/1381612054546716; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shieh SY, 2000, GENE DEV, V14, P289; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhao YQ, 2004, J CELL BIOCHEM, V91, P621, DOI 10.1002/jcb.10751	40	28	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4806	4816		10.1038/sj.onc.1210283	http://dx.doi.org/10.1038/sj.onc.1210283			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297446				2022-12-17	WOS:000248170400005
J	Kurosu, T; Tsuji, K; Kida, A; Koyama, T; Yamamoto, M; Miura, O				Kurosu, T.; Tsuji, K.; Kida, A.; Koyama, T.; Yamamoto, M.; Miura, O.			Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta	ONCOGENE			English	Article						BCR/ABL; imatinib; rottlerin; mitochondrial uncoupler; protein kinase C-delta	PERMEABILITY TRANSITION PORE; CHRONIC MYELOID-LEUKEMIA; DOMAIN MUTATIONS; RESISTANCE; INHIBITOR; ERYTHROPOIETIN; EVOLUTION; RESPONSES; COMPLEX; STI571	Although the BCR/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myeloid leukemia ( CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia ( ALL), relapse with emerging imatinib-resistance mutations in the BCR/ABL kinase domain poses a significant problem. Here, we demonstrate that rottlerin, a putative protein kinase C-delta ( PKC delta)-specific inhibitor, acts synergistically with imatinib to induce apoptosis of BCR/ABL-expressing K562 and Ton.B210 cells. However, rottlerin inhibited neither PKC delta nor BCR/ABL in these cells. On the other hand, rottlerin, previously characterized also as a mitochondrial uncoupler, transiently but significantly reduced mitochondrial membrane potential and gradually induced mitochondrial membrane permeabilization. Moreover, two other mitochondrial uncouplers, FCCP and DNP, very similarly induced apoptosis of BCR/ABL-expressing cells in a synergistic manner with imatinib. Imatinib synergistically enhanced mitochondrial membrane permeabilization induced by mitochondrial uncouplers, which led to release of cytochrome c into the cytoplasm and activation of caspases-3 and -9. Rottlerin also enhanced the cytotoxic effect of imatinib in leukemic cells from patients with CML blast crisis and Ph-positive ALL or a cell line expressing the imatinib-resistant E255K BCR/ABL mutant. The present study indicates that rottlerin synergistically enhances imatinib-induced apoptosis through its mitochondrial uncoupling effect independent of PKC delta and may contribute to the development of new treatment strategy to overcome the imatinib resistance and to cure the BCR/ABL expressing leukemias.	Tokyo Med & Dent Univ, Dept Hematol, Grad Sch Med, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Lab Mol Genet Hematol, Grad Sch Hlth Sci, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol, Grad Sch Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Yamamoto, Masahide/0000-0002-3142-8806; Miura, Osamu/0000-0002-0981-3054				Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Durrant D, 2004, BIOCHEM BIOPH RES CO, V321, P905, DOI 10.1016/j.bbrc.2004.07.049; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Hofmann WK, 2003, BLOOD, V102, P659, DOI 10.1182/blood-2002-06-1756; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Jin A, 2006, ONCOGENE, V25, P4332, DOI 10.1038/sj.onc.1209459; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Kreuzer KA, 2003, ANN HEMATOL, V82, P284, DOI 10.1007/s00277-003-0644-y; Kurosu T, 2003, ONCOGENE, V22, P4459, DOI 10.1038/sj.onc.1206755; Liao YF, 2005, LIFE SCI, V77, P707, DOI 10.1016/j.lfs.2005.01.010; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; Ni HY, 2003, BRIT J HAEMATOL, V121, P849, DOI 10.1046/j.1365-2141.2003.04368.x; O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Poncet D, 2003, APOPTOSIS, V8, P521, DOI 10.1023/A:1025546525894; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Roche-Lestienne C, 2003, NEW ENGL J MED, V348, P2265, DOI 10.1056/NEJMc035089; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Shah Neil P, 2005, Hematology Am Soc Hematol Educ Program, P183; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Temple MD, 2005, TRENDS CELL BIOL, V15, P319, DOI 10.1016/j.tcb.2005.04.003; Tillman DM, 2003, CANCER RES, V63, P5118; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; Willis SG, 2005, BLOOD, V106, P2128, DOI 10.1182/blood-2005-03-1036; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V319, P1272, DOI 10.1016/j.bbrc.2004.05.113; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	40	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					2975	2987		10.1038/sj.onc.1210117	http://dx.doi.org/10.1038/sj.onc.1210117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130834				2022-12-17	WOS:000246395400003
J	Efeyan, A; Collado, M; Velasco-Miguel, S; Serrano, M				Efeyan, A.; Collado, M.; Velasco-Miguel, S.; Serrano, M.			Genetic dissection of the role of p21(Cip1/Waf1) in p53-mediated tumour suppression	ONCOGENE			English	Article						p21; p53; cancer; cell cycle; apoptosis; tumour suppression	CYCLE ARREST; DNA-DAMAGE; P21; P53; INHIBITOR; CELLS; INACTIVATION; SENSITIVITY; DEFICIENCY; P21(WAF1)	Protein p21(Cip1/Waf1) is transcriptionally activated by the tumour suppressor p53 and previous studies have shown that p21 plays a role in tumour suppression. However, the involvement of p21 in p53-mediated tumour suppression remains to be directly demonstrated in vivo. Tumour suppression mediated by p53 can be measured by comparing tumour susceptibility in animals carrying two (wild-type mice) or three (super-p53 mice) copies of the p53 gene. We have taken advantage of this genetically defined system to measure p53-mediated cell-cycle arrest, apoptosis and tumorigenesis, in a p21 wild-type and in a p21-null context. The absence of p21 significantly impaired the enhanced p53-mediated cell-cycle arrest characteristic of super-p53 cells, but did not affect the enhanced apoptosis. Importantly, in an experimental model of fibrosarcoma induction, the absence of p21 significantly decreased the tumour suppression benefit of super-p53 mice. We conclude that cell-cycle arrest through p21 plays a significant role in mediating p53-dependent cancer protection.	Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Serrano, M (corresponding author), Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, 3 Melchor Fernandez Almagro St, Madrid 28029, Spain.	mserrano@cnio.es	Collado, Manuel/K-8140-2014; Efeyan, Alejo/J-8197-2016; Serrano, Manuel/H-2634-2015	Collado, Manuel/0000-0002-0330-0880; Efeyan, Alejo/0000-0002-3806-6799; Serrano, Manuel/0000-0001-7177-9312				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Bearss DJ, 2002, CANCER RES, V62, P2077; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fotedar R, 2004, CELL CYCLE, V3, P134; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; HARPER JW, 1993, CELL, V75, P805; Jackson JF, 2002, MOLEC METH PLAN ANAL, V21, P1; Jackson RJ, 2003, CANCER RES, V63, P3021; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Martin J A, 2001, Iowa Orthop J, V21, P1; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Samuel T, 2002, CELL CYCLE, V1, P162, DOI 10.4161/cc.1.3.118; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weinberg WC, 1999, CANCER RES, V59, P2050; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang WC, 2001, CANCER RES, V61, P565	32	28	29	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1645	1649		10.1038/sj.onc.1209972	http://dx.doi.org/10.1038/sj.onc.1209972			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964282				2022-12-17	WOS:000244782500014
J	Zhang, L; Wang, C				Zhang, L.; Wang, C.			Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain	ONCOGENE			English	Article						oncogene; rhabdomyosarcoma; transcription; chromosomal translocation	ALVEOLAR RHABDOMYOSARCOMA; TRANSCRIPTION FACTORS; FUSION PROTEIN; MYOGENIN GENE; EXPRESSION; DIFFERENTIATION; EMBRYOGENESIS; ACTIVATION; CELLS; TRANSLOCATION	Alveolar rhabdomyosarcoma (aRMS), an aggressive skeletal muscle cancer, carries a unique t(2;13) chromosomal translocation resulting in the formation of a chimeric transcription factor PAX3-FKHR. This fusion protein contains the intact DNA-binding domains (PD:paired box binding domain; HD: paired-type homeodomain) of Pax3 fused to the activation domain of FKHR. Cells expressing Pax3 and PAX3-FKHR show vastly different gene expression patterns, despite that they share the same DNA-binding domains. We present evidence of a gain of function mechanism that allows the fusion protein to recognize and transcriptionally activate response elements containing a PD-specific binding site. This DNA recognition specificity is in contrast to the requirement for Pax3-specific target sequences that must contain a composite of PD-and HD-binding sites. Domain swapping studies suggest that an increased structural flexibility could account for the relaxed DNA targeting specificity in PAX3-FKHR. Here, we identify myogenin gene as a direct target of PD- dependent PAX3-FKHR activation pathway in vitro and in vivo. We demonstrate that PAX3-FKHR could induce myogenin expression in undifferentiated myoblasts by a MyoD independent pathway, and that PAX3-FKHR is directly involved in myogenin expression in aRMS cells.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, C (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, 801 S Paulina St,Room 530E,M-C 860, Chicago, IL 60612 USA.	chiayeng@uic.edu			NATIONAL CANCER INSTITUTE [R01CA074907, R29CA074907] Funding Source: NIH RePORTER; NCI NIH HHS [CA074907, R29 CA074907, R01 CA074907, R01 CA074907-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; De Pitta C, 2006, INT J CANCER, V118, P2772, DOI 10.1002/ijc.21698; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Folpe AL, 2002, ADV ANAT PATHOL, V9, P198, DOI 10.1097/00125480-200205000-00003; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Hostein I, 2004, CANCER-AM CANCER SOC, V101, P2817, DOI 10.1002/cncr.20711; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Lam PYP, 1999, MOL CELL BIOL, V19, P594; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; Michelagnoli MP, 2003, MED PEDIATR ONCOL, V40, P1, DOI 10.1002/mpo.10201; Puri PL, 2000, GENE DEV, V14, P574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; Wang-Wuu S, 1988, Cancer Res, V48, P983; Weintraub M, 1997, Sarcoma, V1, P135, DOI 10.1080/13577149778218; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286	39	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1595	1605		10.1038/sj.onc.1209958	http://dx.doi.org/10.1038/sj.onc.1209958			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964289	Green Accepted			2022-12-17	WOS:000244782500009
J	Ivanova, IA; Dagnino, L				Ivanova, I. A.; Dagnino, L.			Activation of p38-and CRM1-dependent nuclear export promotes E2F1 degradation during keratinocyte differentiation	ONCOGENE			English	Article						keratinocyte; E2F; differentiation	TRANSCRIPTION FACTORS; EPIDERMAL-KERATINOCYTES; EXPRESSION PATTERNS; WOUND REPAIR; PROLIFERATION; PROTEIN; KINASE; FAMILY; PRB; LOCALIZATION	E2F factors modulate a plethora of cell functions, including proliferation, differentiation, DNA repair and apoptosis. We have shown that differentiation in primary epidermal keratinocytes leads to E2F1 downregulation via activation of protein kinase C and p38 mitogen-activated protein kinase. We now demonstrate that E2F1 downregulation in differentiating keratinocytes involves its ubiquitination, as well as proteasomal degradation subsequent to CRM1-dependent nuclear export. E2F1 nuclear export specifically in response to differentiation requires regions adjacent to the cyclin A-binding domain in the N-terminusof this protein. Significantly, inhibition of p38 interferes with nuclear export and degradation of E2F1 during differentiation, but has no effect on E2F1 in undifferentiated cells. Thus, induction of differentiation in epidermal keratinocytes activates a specific program for post-transcriptional downregulation of E2F1, which involves signaling through p38 and activation of nuclear export pathways.	Univ Western Ontario, Dept Physiol & Pharmacol & Regulatory Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Paediat, Child Hlth Res Inst, London, ON N6A 5C1, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159				Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Asher G, 2005, CELL CYCLE, V4, P1015, DOI 10.4161/cc.4.8.1900; Byrne C, 2003, J ANAT, V202, P113, DOI 10.1046/j.1469-7580.2003.00142.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chang WY, 2004, J BIOL CHEM, V279, P51343, DOI 10.1074/jbc.M408635200; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Gill RM, 2000, J CELL BIOL, V148, P1187, DOI 10.1083/jcb.148.6.1187; GOMEZ DA, 2000, J BIOL CHEM, V275, P13872; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Ivanova IA, 2006, ONCOGENE, V25, P430, DOI 10.1038/sj.onc.1208999; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Muller H, 1997, MOL CELL BIOL, V17, P5508; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Ruiz S, 2006, CELL CYCLE, V5, P625, DOI 10.4161/cc.5.6.2580; Vespa A, 2005, MOL BIOL CELL, V16, P4084, DOI 10.1091/mbc.e05-02-0087	25	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1147	1154		10.1038/sj.onc.1209894	http://dx.doi.org/10.1038/sj.onc.1209894			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924238				2022-12-17	WOS:000244406400005
J	Chao, C; Goluszko, E; Lee, YT; Kolokoltsov, AA; Davey, RA; Uchida, T; Townsend, CM; Hellmich, MR				Chao, C.; Goluszko, E.; Lee, Y-T; Kolokoltsov, A. A.; Davey, R. A.; Uchida, T.; Townsend, C. M., Jr.; Hellmich, M. R.			Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1 alpha expression and tumor growth	ONCOGENE			English	Article						Src kinase; gastrin receptor; gastrointestinal cancer	CHOLECYSTOKININ-B/GASTRIN RECEPTOR; COLORECTAL-CANCER; TYROSINE KINASE; PREMALIGNANT EPITHELIA; PANCREATIC-CARCINOMA; BARRETTS-ESOPHAGUS; COLON CANCER; CELL-GROWTH; GASTRIN; ACTIVATION	Gastrointestinal (GI) cancers ectopically express multiple splice variants of the cholecystokinin-2 (CCK2)/gastrin receptor; however, their relative contributions to the cancer phenotype are unknown. The aim of this study was to compare the effects of CCK2 receptor (CCK2R) and CCK2i4svR expression on cell growth both in vitro and in vivo using a human epithelial cell model, HEK239. In vitro, receptor variant expression did not affect cell proliferation either in the absence or presence of agonist. However, in vivo, the expression of CCK2i4svR, but not CCK2R, increases HEK293 tumor growth in a constitutive, Src-dependent manner. Enhanced tumorigenicity of CCK2i4svR is associated with an Src- dependent increase in the transcription factor, hypoxia-inducible factor-1 alpha, its downstream target, vascular endothelial growth factor and tumor micro-vessel density, suggesting that CCK2i4svR may contribute to the growth and spread of GI cancers through agonist-independent mechanisms that enhance tumor angiogenesis.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77550 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Hellmich, MR (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mhellmic@utmb.edu		Davey, Robert/0000-0001-9168-2892	NIDDK NIH HHS [R01 DK48345, R01 DK58119] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048345, R01DK058119] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; Chao C, 2005, J BIOL CHEM, V280, P33368, DOI 10.1074/jbc.M506337200; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Ding WQ, 2002, CANCER RES, V62, P947; Dockray G, 2005, PFLUG ARCH EUR J PHY, V449, P344, DOI 10.1007/s00424-004-1347-5; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guo Y S, 2000, J Hepatobiliary Pancreat Surg, V7, P276, DOI 10.1007/s005340070049; Harris JC, 2004, CANCER RES, V64, P1915, DOI 10.1158/0008-5472.CAN-03-2713; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Iravani S, 1998, LAB INVEST, V78, P365; Ishizawar RC, 2004, J BIOL CHEM, V279, P23773, DOI 10.1074/jbc.M312368200; Iwase K, 1997, GASTROENTEROLOGY, V113, P782, DOI 10.1016/S0016-5085(97)70172-0; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Kolokoltsov AA, 2005, J VIROL, V79, P756, DOI 10.1128/JVI.79.2.756-763.2005; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MCGREGOR DB, 1982, ANN SURG, V195, P219, DOI 10.1097/00000658-198202000-00017; McWilliams DF, 1998, GUT, V42, P795, DOI 10.1136/gut.42.6.795; MIYAKE A, 1995, BIOCHEM BIOPH RES CO, V208, P230, DOI 10.1006/bbrc.1995.1328; Moore TC, 2004, REGUL PEPTIDES, V120, P195, DOI 10.1016/j.regpep.2004.03.012; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Olszewska-Pazdrak B, 2004, J BIOL CHEM, V279, P40400, DOI 10.1074/jbc.C400208200; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SIRINEK KR, 1985, AM J SURG, V149, P35, DOI 10.1016/S0002-9610(85)80006-4; Smith AM, 2000, ALIMENT PHARM THERAP, V14, P1231, DOI 10.1046/j.1365-2036.2000.00842.x; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541; SMITH JP, 1995, AM J PHYSIOL-REG I, V268, pR135, DOI 10.1152/ajpregu.1995.268.1.R135; Smith JP, 1998, INT J ONCOL, V12, P411; Smith JP, 2002, INT J MOL MED, V10, P689; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; WINSETT OE, 1986, SURGERY, V99, P302; Wroblewski LE, 2002, BIOCHEM J, V365, P873, DOI 10.1042/BJ20020068	38	28	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1013	1019		10.1038/sj.onc.1209862	http://dx.doi.org/10.1038/sj.onc.1209862			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909104				2022-12-17	WOS:000244245400007
J	Joshi, PP; Kulkarni, MV; Yu, BK; Smith, KR; Norton, DL; van Veelen, W; Hoppener, JWM; Franklin, DS				Joshi, P. P.; Kulkarni, M. V.; Yu, B. K.; Smith, K. R.; Norton, D. L.; van Veelen, W.; Hoppener, J. W. M.; Franklin, D. S.			Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis	ONCOGENE			English	Article						MEN; RET; cell cycle; CDKI; tumorigenesis; proliferation	MEDULLARY-THYROID CARCINOMA; RET PROTOONCOGENE MUTATIONS; ENDOCRINE NEOPLASIA TYPE-2; ACTIVATED PROTEIN-KINASE; D-DEPENDENT KINASE; GROWTH-FACTOR; CELL-CYCLE; CONTACT INHIBITION; SIGNALING PATHWAY; MEN2B MUTATION	Multiple endocrine neoplasia type 2A (MEN2A) is predisposed by mutations in the RET proto-oncogene. Low expression of the cyclin-dependent kinase inhibitor (CDKI) p27(Kip1) is present in thyroid tumors, and recent evidence demonstrates p27 downregulation by the active RET mutant, RET/PTC1, found in papillary thyroid carcinoma. This implicates decreased p27 activity as an important event during thyroid tumorigenesis. However, p27(-/-) mice develop MEN-like tumors only in combination with loss of another CDKI, p18(Ink4c). This suggests that p18 and p27 functionally collaborate in suppression of tumorigenesis, that loss of both is critical in the development of MEN tumors and that both p18 and p27 are regulated by RET. We report that induction of the constitutively active MEN2A-specific RET mutant, RET2A(C634R), correlates with reduced p18/p27, and elevated cyctin D protein levels, leading to increased CDK activity, increased pRb phosphorylation and proliferation under growth arrest conditions. Mechanistically, RET2A represses p18/p27 mRNA levels while elevating cyclin D1 mRNA levels. RET2A expression also correlates with decreased p27 protein stability. RET2A-mediated regulation of p18 and p27, but not of cyclins D1 and D2, requires functional mitogen-activated protein kinase signaling. Additionally, RET2A-dependent p18 repression is required and sufficient to increase cell proliferation. Perhaps most significantly, MEN2A adrenal tumors also display these changes in cell cycle expression profile, demonstrating the biological relevance of our cell culture studies. Our results demonstrate for the first time that RET2A regulates p18, and suggest that loss of not only p27 but also of p18 expression is a key step in MEN tumorigenesis.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA; Univ Utrecht, Med Ctr, Dept Metab & Endocrine Dis, Utrecht, Netherlands	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Utrecht University	Franklin, DS (corresponding author), Purdue Univ, Dept Biol Sci, 205A Hansen Life Sci Res Bldg,201 S Univ St, W Lafayette, IN 47907 USA.	franklid@purdue.edu						ACTON D, 2004, J INTERN MED, V255, P696; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Buchwald PC, 2004, CLIN ENDOCRINOL, V60, P389, DOI 10.1111/j.1365-2265.2004.01995.x; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; CONDE E, 1992, ENDOCRINOLOGY, V131, P436, DOI 10.1210/en.131.1.436; Drosten M, 2004, JNCI-J NATL CANCER I, V96, P1231, DOI 10.1093/jnci/djh226; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 1996, ONCOGENE, V12, P481; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JUAN G, 1998, CURRENT PROTOCOLS CY, P791; Jung YD, 1999, CANCER RES, V59, P4804; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kawamoto Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/jbc.M312600200; Kim HS, 1998, J NEUROSCI, V18, P8247; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marsh DJ, 1997, HORM RES, V47, P168, DOI 10.1159/000185461; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schubert WH, 2001, J HYDROMETEOROL, V2, P3, DOI 10.1175/1525-7541(2001)002<0005:>2.0.CO;2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SOZZI G, 1991, ONCOGENE, V6, P339; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TISCHLER AS, 1989, INT J DEV NEUROSCI, V7, P439, DOI 10.1016/0736-5748(89)90004-X; TONG Q, 1995, ONCOGENE, V10, P1781; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Vitagliano D, 2004, CANCER RES, V64, P3823, DOI 10.1158/0008-5472.CAN-03-3918; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	54	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					554	570		10.1038/sj.onc.1209811	http://dx.doi.org/10.1038/sj.onc.1209811			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16953232				2022-12-17	WOS:000243731600008
J	Burks, J; Agazie, YM				Burks, J.; Agazie, Y. M.			Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3	ONCOGENE			English	Article						FGFR3; SHP2; alpha catenin; transformation; adhesion; migration	GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE PHOSPHATASES; E-CADHERIN; KINASE ACTIVATION; SKELETAL DYSPLASIA; INSULIN-RECEPTOR; BETA-CATENIN; P120 CATENIN; SH2 DOMAINS; MAP KINASE	The Src homology 2 phosphotyrosyl phosphatase (SHP2) is a nonreceptor-type phosphatase that acts as a positive transducer of receptor Tyr kinase (RTK) signaling, particularly the Ras-REK and PI3K-Akt pathways. Recently, we have demonstrated that SHP2 is required for cell transformation induced by the constitutively active fibroblast growth factor receptor 3 (K/E-FR3) (Oncogene, 22, 6909 -6918). In that study, we had detected a phosphotyrosyl protein of similar to 100 KDa (p100) in cells expressing dominant-negative SHP2 (R/ E-SHP2), but its identity and relevance in SHP2-meditaed transformation was not known. Here, we report the identification of p100 as alpha-catenin, a vinculin-related protein involved in adherens junction-mediated intercellular adhesion. We show that a-catenin becomes Tyr phosphorylated in intercellular adhesion-dependent manner and this event is counteracted by SHP2. Substrate trapping in intact cells and immunocomplex phosphatse assays confirmed that a-catenin is in deed an SHP2 substrate. Tyr phosphorylation of alpha-catenin enhances its translocation to the plasma membrane and its interaction with beta-catenin, leading to enhanced actin polymerization and stabilization of adherens junction-mediated intercellular adhesion, a phenomenon commensurate with loss of the transformation phenotype. Site-directed mutagenesis studies also suggested that Tyr phosphorylation of a-catenin enhances its inhibitory role on cell transformation. Based on our previous work and the current report, we demonstrate that mediation of cell transformation by SHP2 is a complex process that involves modulation of the Ras-ERK and PI3K-Akt signaling pathways, intercellular adhesion, focal adhesion and actin cytoskeletal reorganization. To our knowledge, this is the first report showing regulation of a-catenin function by Tyr phosphorylation and its inhibitory effect on cell transformation.	W Virginia Univ, Dept Mol Pharmacol & Biochem, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Agazie, YM (corresponding author), W Virginia Univ, Dept Mol Pharmacol & Biochem, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA.	yagazie@hsc.wvu.edu	Ladoux, Benoit/A-9879-2013					Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; ABERLE H, 1994, J CELL SCI, V107, P3655; Abutaily AS, 2003, J PATHOL, V201, P355, DOI 10.1002/path.1458; Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hu PQ, 2001, J INVEST DERMATOL, V117, P1059, DOI 10.1046/j.0022-202x.2001.01523.x; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Merdek KD, 2004, MOL CELL BIOL, V24, P2410, DOI 10.1128/MCB.24.6.2410-2422.2004; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; MORTON RA, 1993, CANCER RES, V53, P3585; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Ozawa M, 2001, J CELL SCI, V114, P503; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Saxton TM, 2000, NAT GENET, V24, P420, DOI 10.1038/74279; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Seki N, 2002, ARTERIOSCL THROM VAS, V22, P1081, DOI 10.1161/01.ATV.0000022878.37277.EC; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X	59	28	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7166	7179		10.1038/sj.onc.1209728	http://dx.doi.org/10.1038/sj.onc.1209728			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16767162				2022-12-17	WOS:000242046900006
J	Jannot, G; Simard, MJ				Jannot, G.; Simard, M. J.			Tumour-related microRNAs functions in Caenorhabditis elegans	ONCOGENE			English	Review						C. elegans; microRNA; miR-61; miR-84; oncogene	RNA; RAS; EXPRESSION; SEQUENCE; PATHWAY; MIR-48; ACTS; VAV1	Altering cell proliferation and differentiation are usually key events leading to cancer. As originally demonstrated by Sydney Brenner in 1960s, the nematode Caenorhabditis elegans represents an animal model of choice to study mechanisms important to maintain proper cellular behaviour. This round worm has helped to elucidate components as well as new cellular pathways required for animal development. Among them, the discovery of the programmed cell death and non-coding RNAs (microRNAs) controlling gene expression are two remarkable examples. Recently, two studies have demonstrated, once again, that using C. elegans can help gathering insights on cellular mechanisms leading to tumour formation. Two microRNAs, miR-84 and miR-61, control the expression of the oncogene orthologues Ras and Vav indicating their capacity to act as tumour suppressors. These observations demonstrate that uncovering the function of microRNAs is important to increase our understanding of cancer.	Univ Laval, Canc Res Ctr, Hotel Dieu Quebec, CHUQ, Quebec City, PQ G1R 2J6, Canada	Laval University	Simard, MJ (corresponding author), Univ Laval, Canc Res Ctr, Hotel Dieu Quebec, CHUQ, Quebec City, PQ G1R 2J6, Canada.	Martin.Simard@crhdq.ulaval.ca		Simard, Martin/0000-0002-3189-9309				Abbott AL, 2005, DEV CELL, V9, P403, DOI 10.1016/j.devcel.2005.07.009; Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Chang S, 2004, NATURE, V430, P785, DOI 10.1038/nature02752; DeNicola G, 2005, CANCER BIOL THER, V4, P509, DOI 10.4161/cbt.4.5.1781; Grad Y, 2003, MOL CELL, V11, P1253, DOI 10.1016/S1097-2765(03)00153-9; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Grosshans H, 2005, DEV CELL, V8, P321, DOI 10.1016/j.devcel.2004.12.019; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Johnston RJ, 2005, P NATL ACAD SCI USA, V102, P12449, DOI 10.1073/pnas.0505530102; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li M, 2005, DEV CELL, V9, P415, DOI 10.1016/j.devcel.2005.08.002; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Lin SY, 2003, DEV CELL, V4, P639, DOI 10.1016/S1534-5807(03)00124-2; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Poulin G, 2004, ONCOGENE, V23, P8340, DOI 10.1038/sj.onc.1208010; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Schumacher Bjorn, 2006, Future Oncol, V2, P145, DOI 10.2217/14796694.2.1.145; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; Sternberg PW., 2005, C ELEGANS RES COMMUN; Sundaram MV, 2005, GENE DEV, V19, P1825, DOI 10.1101/gad.1330605; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Yoo AS, 2005, SCIENCE, V310, P1330, DOI 10.1126/science.1119481	36	28	40	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6197	6201		10.1038/sj.onc.1209921	http://dx.doi.org/10.1038/sj.onc.1209921			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028599				2022-12-17	WOS:000241158900008
J	Palacios, G; Moll, UM				Palacios, G.; Moll, U. M.			Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo	ONCOGENE			English	Article						p53; apoptosis; mitochondria; E mu-Myc lymphoma	MEMBRANE PERMEABILIZATION; GENE-THERAPY; APOPTOSIS; TRANSLOCATION; DEATH; PROTEIN; CELLS; BAX; DISRUPTION; ACTIVATION	The complex apoptotic functions of the p53 tumor suppressor are central to its antineoplastic activity in vivo. Besides its well-known action as a transcriptional activator of apoptotic genes, p53 exerts a direct proapoptotic role at the mitochondria via protein-protein interactions with Bcl2 family members, thus executing the shortest known circuitry of p53 death signaling. We recently reported that exclusive delivery of p53 to mitochondria exerts a significant in vivo tumor suppressor activity in p53-null lymphomas. However, it was unknown whether mitochondrially targeted p53 has suppressor activities in tumors harboring missense mutants, which constitute the vast majority of p53 alterations in human tumors. Here, we show that targeting p53 to mitochondria does confer a significant growth disadvantage in B-lymphomas expressing various point mutants of p53, resulting in efficient apoptosis induction in vitro and in vivo in mice.	SUNY Stony Brook, Stony Brook Univ, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Moll, UM (corresponding author), SUNY Stony Brook, Stony Brook Univ, Dept Pathol, BSTL9,Room 134, Stony Brook, NY 11794 USA.	umoll@notes.cc.sunysb.edu						Arima Y, 2005, J BIOL CHEM, V280, P19166, DOI 10.1074/jbc.M410691200; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Essmann F, 2005, J BIOL CHEM, V280, P37169, DOI 10.1074/jbc.M502052200; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lim DS, 2006, HUM GENE THER, V17, P347, DOI 10.1089/hum.2006.17.347; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nemajerova A, 2005, FEBS LETT, V579, P6079, DOI 10.1016/j.febslet.2005.09.074; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Peng ZH, 2005, HUM GENE THER, V16, P1016, DOI 10.1089/hum.2005.16.1016; PETROS AM, 2004, FEBS LETT, P1; Roth JA, 2006, EXPERT OPIN BIOL TH, V6, P55, DOI 10.1517/14712598.6.1.55; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Sauthoff H, 2006, CANCER GENE THER, V13, P686, DOI 10.1038/sj.cgt.7700936; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Talos F, 2005, CANCER RES, V65, P9971, DOI 10.1158/0008-5472.CAN-05-1084; Yin SM, 2006, INT J ONCOL, V28, P781; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835	30	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6133	6139		10.1038/sj.onc.1209641	http://dx.doi.org/10.1038/sj.onc.1209641			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682948				2022-12-17	WOS:000241101200011
J	Bell, LA; O'Prey, J; Ryan, KM				Bell, L. A.; O'Prey, J.; Ryan, K. M.			DNA-binding independent cell death from a minimal proapoptotic region of E2F-1	ONCOGENE			English	Article						E2F; apoptosis; DNA binding	S-PHASE ENTRY; TRANSCRIPTION FACTORS E2F-1; RETINOBLASTOMA PROTEIN; E2F-DEPENDENT APOPTOSIS; E2F-1-INDUCED APOPTOSIS; P53-MEDIATED APOPTOSIS; MAMMALIAN-CELLS; MOUSE EMBRYOS; CYCLE ARREST; P53	The ability to induce cell cycle progression while evading cell death is a de. ning characteristic of cancer. Deregulation of E2F is a common event in most human cancers. Paradoxically, this can lead to both cell cycle progression and apoptosis. Although the way in which E2F causes cell cycle progression is well characterized, the pathways by which E2F induces cell death are less well defined. Many of the known mechanisms through which E2F induces apoptosis occur through regulation of E2F target genes. However, mutants of E2F-1 that lack the transactivation domain are still able to induce cell death. To further investigate this activity, we refined a transactivation independent mutant to identify a minimal apoptotic domain. This revealed that only 75 amino acids from within the DNA-binding domain of E2F-1 is sufficient for cell death and that this activity is also present in the DNA-binding domains of E2F-2 and E2F-3. However, analysis of this domain from E2F-1 revealed it does not bind DNA and is consequently unable to transactivate, repress or derepress E2F target genes. This provocative observation therefore defines a potential new mechanism of death from E2F and opens up new opportunities for inducing cell death in tumours for therapeutic gain.	Canc Res UK Beatson Labs, Tumour Cell Death Lab, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Ryan, KM (corresponding author), Canc Res UK Beatson Labs, Tumour Cell Death Lab, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.ryan@beatson.gla.ac.uk		Ryan, Kevin M./0000-0002-1059-9681				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brooks LA, 2002, BRIT J CANCER, V86, P263, DOI 10.1038/sj.bjc.6600033; Chen D, 2005, CELL DEATH DIFFER, V12, P358, DOI 10.1038/sj.cdd.4401536; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Ding Y, 1999, DNA Res, V6, P347, DOI 10.1093/dnares/6.5.347; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fogal V, 2005, CELL DEATH DIFFER, V12, P369, DOI 10.1038/sj.cdd.4401562; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Hershko T, 2005, CELL DEATH DIFFER, V12, P377, DOI 10.1038/sj.cdd.4401575; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; La Thangue NB, 2003, NAT CELL BIOL, V5, P587, DOI 10.1038/ncb0703-587; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Ryan KM, 2004, CANCER RES, V64, P4415, DOI 10.1158/0008-5472.CAN-04-1474; Ryan KM, 1997, BIOCHEM J, V325, P79, DOI 10.1042/bj3250079; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	64	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5656	5663		10.1038/sj.onc.1209580	http://dx.doi.org/10.1038/sj.onc.1209580			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16652153				2022-12-17	WOS:000240599100007
J	Rodriguez, JA; Lens, SMA; Span, SW; Vader, G; Medema, RH; Kruyt, FAE; Giaccone, G				Rodriguez, J. A.; Lens, S. M. A.; Span, S. W.; Vader, G.; Medema, R. H.; Kruyt, F. A. E.; Giaccone, G.			Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown	ONCOGENE			English	Article						Survivin; Borealin; INCENP; Aurora B; nuclear envelope breakdown; nuclear transport	B KINASE-ACTIVITY; AURORA-B; EXPORT SIGNALS; SURVIVIN; INCENP; SPINDLE; CANCER; EXPRESSION; CENTROMERE; PHOSPHORYLATION	As mitosis progresses, the chromosomal passenger proteins (CPPs) Survivin, Aurora B, INCENP and Borealin dynamically colocalize to mitotic structures. Chromosomal passenger proteins are already expressed during G2, whereas the nuclear envelope is only disassembled at the end of prophase. However, the mechanisms that modulate their nucleocytoplasmic localization before nuclear envelope breakdown (NEB) are poorly characterized. Using epitope-tagged proteins, we show that Aurora B, like Survivin, undergoes CRM1-mediated nucleocytoplasmic shuttling, although both proteins lack identifiable 'classical' nuclear transport signals. On the other hand, INCENP resides more stably in the nucleus and contains multiple nuclear localization signals. Finally, Borealin was detected in the nucleolus and the cytoplasm, but its cytoplasmic localization is not directly regulated by CRM1. Coexpression experiments indicate that the nuclear localization of Aurora B, but not of Survivin, is modulated by INCENP and that Survivin prevents the nucleolar accumulation of Borealin. Our data reveal that, in contrast to their closely related localization during mitosis, the nucleocytoplasmic localization of the CPPs before NEB is largely unrelated. Furthermore, the specific effect of INCENP and Survivin on the localization of Aurora B and Borealin, respectively, suggests that different complexes of CPPs may exist not only during mitosis, as recently reported, but also before NEB.	Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Netherlands Cancer Institute	Rodriguez, JA (corresponding author), Vrije Univ Amsterdam, Dept Med Oncol, Med Ctr, Acad Hosp, KRIGO BR232,Postbus 7057, NL-1007 MB Amsterdam, Netherlands.	ja.rodriguez@vumc.nl	Medema, Rene H/E-2981-2013; Giaccone, Giuseppe/E-8297-2017; Rodriguez, Jose Antonio/AAA-1125-2019; Medema, Rene H/G-5415-2011	Giaccone, Giuseppe/0000-0002-5023-7562; Rodriguez, Jose Antonio/0000-0002-2823-3733; Vader, Gerben/0000-0001-5729-0991; Medema, Rene/0000-0002-6754-0381; Kruyt, Frank/0000-0002-2445-9380				Adams RR, 2001, CHROMOSOMA, V110, P65, DOI 10.1007/s004120100130; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altura RA, 2003, BRIT J CANCER, V89, P1743, DOI 10.1038/sj.bjc.6601334; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Arnaoutov A, 2005, NAT CELL BIOL, V7, P626, DOI 10.1038/ncb1263; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Burke B, 2002, NAT REV MOL CELL BIO, V3, P487, DOI 10.1038/nrm860; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Krysan K, 2004, FASEB J, V18, P205, DOI 10.1096/fj.03-0369fje; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Mahotka C, 1999, CANCER RES, V59, P6097; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rodriguez JA, 2002, EXP CELL RES, V275, P44, DOI 10.1006/excr.2002.5492; Rodriguez JA, 2004, ONCOGENE, V23, P1809, DOI 10.1038/sj.onc.1207302; Saffery R, 1999, MAMM GENOME, V10, P415, DOI 10.1007/s003359901014; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Song JX, 2005, IMMUNITY, V22, P621, DOI 10.1016/j.immuni.2005.03.012; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tonini G, 2005, BRIT J CANCER, V92, P2225, DOI 10.1038/sj.bjc.6602632; Vader G, 2006, EMBO REP, V7, P85, DOI 10.1038/sj.embor.7400562; Vischioni B, 2004, ANN ONCOL, V15, P1654, DOI 10.1093/annonc/mdh436; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200	43	28	32	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4867	4879		10.1038/sj.onc.1209499	http://dx.doi.org/10.1038/sj.onc.1209499			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547492				2022-12-17	WOS:000239687100005
J	Joliot, V; Cormier, F; Medyouf, H; Alcalde, H; Ghysdael, J				Joliot, V.; Cormier, F.; Medyouf, H.; Alcalde, H.; Ghysdael, J.			Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis	ONCOGENE			English	Article						STAT5; p53; leukemia; lymphoma; B lymphocytes; oncogenic cooperation	IN-VIVO; SIGNAL TRANSDUCER; POLYCYTHEMIA-VERA; T-CELLS; MICE; TRANSCRIPTION; PROTEINS; LEUKEMIA; LEUKEMOGENESIS; PHOSPHATASE	Signal transducers and activator of transcription 5 (STAT5) A and B are transcriptional regulators that play a central role in cytokine signaling in the hematopoietic lineage and which are frequently activated in a persistent manner in human leukemia/lymphoma, as assessed by their constitutive tyrosine phosphorylation and DNA-binding activity. To study the intrinsic oncogenic properties of persistent STAT5 activation, we generated transgenic mice in which a constitutively activated point mutant of STAT5A, STAT5A(S711F), was expressed at physiological level in their lymphoid compartment. In this model, persistent STAT5 activation is weakly oncogenic, leading to the late emergence of clonal B-cell lymphoma/leukemia at a low incidence. In contrast, STAT5(S711F) was found to cooperate with the loss of function of the p53 tumor suppressor gene to both accelerate disease onset and to skew the large tumor spectrum that normally characterize p53-deficient mice to strongly favor B-cell lymphoma/leukemia. The emergence of STAT5A(S711F)-induced B-cell tumors is associated with the activation of STAT5 tyrosine phosphorylation and DNA-binding activity, indicating that activation of STAT5 oncogenic properties in transgenic STAT5A (TgSTAT5A) (S711F) mice involves the deregulation of STAT5 phosphorylation dynamics.	Ctr Univ Orsay, CNRS, Inst Curie, UMR 146, F-91405 Orsay, France; Univ Paris 07, UFR Biochim, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Ghysdael, J (corresponding author), Ctr Univ Orsay, CNRS, Inst Curie, UMR 146, Bat 110, F-91405 Orsay, France.	acques.ghysdael@curie.u-psud.fr	GHYSDAEL, Jacques/F-3377-2013	Medyouf, Hind/0000-0003-4652-9455; Cormier, Francoise/0000-0002-6904-5122				Abraham N, 2005, ONCOGENE, V24, P5252, DOI 10.1038/sj.onc.1208726; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Burchill MA, 2003, J IMMUNOL, V171, P5853, DOI 10.4049/jimmunol.171.11.5853; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carron C, 2000, BLOOD, V95, P3891; Chen Y, 2003, J BIOL CHEM, V278, P16520, DOI 10.1074/jbc.M210572200; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Fleming HE, 2004, J IMMUNOL, V173, P2542, DOI 10.4049/jimmunol.173.4.2542; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Goetz CA, 2005, J IMMUNOL, V174, P7753, DOI 10.4049/jimmunol.174.12.7753; Goetz CA, 2004, J IMMUNOL, V172, P4770, DOI 10.4049/jimmunol.172.8.4770; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kang JS, 2004, J IMMUNOL, V173, P2307, DOI 10.4049/jimmunol.173.4.2307; Kelly J, 2003, J IMMUNOL, V170, P210, DOI 10.4049/jimmunol.170.1.210; Kelly JA, 2003, J EXP MED, V198, P79, DOI 10.1084/jem.20021548; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lebigot I, 2003, BLOOD, V102, P4555, DOI 10.1182/blood-2003-06-2077; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Reddy J, 2005, ONCOGENE, V24, P732, DOI 10.1038/sj.onc.1208032; Sambroock J., 1989, MOL CLONING LAB MANU; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Sommer VH, 2004, LEUKEMIA, V18, P1288, DOI 10.1038/sj.leu.2403385; Sternberg DW, 2004, J CLIN ONCOL, V22, P361, DOI 10.1200/JCO.2004.10.124; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WeberNordt RM, 1996, BLOOD, V88, P809	51	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4573	4584		10.1038/sj.onc.1209480	http://dx.doi.org/10.1038/sj.onc.1209480			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16532027				2022-12-17	WOS:000239457500007
J	Lapi, E; Iovino, A; Fontemaggi, G; Soliera, AR; Iacovelli, S; Sacchi, A; Rechavi, G; Givol, D; Blandino, G; Strano, S				Lapi, E.; Iovino, A.; Fontemaggi, G.; Soliera, A. R.; Iacovelli, S.; Sacchi, A.; Rechavi, G.; Givol, D.; Blandino, G.; Strano, S.			S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation	ONCOGENE			English	Article						p73; p63; differentiation; transcription; keratinocytes; S100A2	DNA-DAMAGE; P73 GENE; EXPRESSION; P63; PROTEINS; IDENTIFICATION; FAMILY; CELLS; PROLIFERATION; NEUROBLASTOMA	The p53 paralogues p73, p63 and their respective truncated isoforms have been shown to be critical regulators of developmental and differentiation processes. Indeed, both p73- and p63-deficient mice exhibit severe developmental defects. Here, we show that S100A2 gene, whose transcript and protein are induced during keratinocyte differentiation of HaCaT cells, is a direct transcriptional target of p73 beta and Delta Np63 alpha and is required for proper keratinocyte differentiation. Transactivation assays reveal that p73b and DNp63a exert opposite transcriptional effects on S100A2 gene. While DNp63a is found in vivo onto S100A2 regulatory regions predominantly in proliferating cells, p73b is recruited in differentiating cells. Silencing of p73 impairs the induction of S100A2 during the differentiation of HaCaT cells. Moreover, silencing of p73 or S100A2 impairs the proper expression of keratinocyte differentiation markers. Of note, p53 family members do not trigger S100A2 gene expression in response to apoptotic doses of cisplatin and doxorubicin.	Regina Elena Inst Canc Res, Dept Expt Onocl, Mol Oncogenesis Lab, Rome, Italy; Chaim Sheba Med Ctr, Dept Pediat Hematol Oncol, Tel Hashomer, Israel; Rome Oncogenom Ctr, Rome, Italy; Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Chaim Sheba Medical Center; Weizmann Institute of Science	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Dept Expt Onocl, Mol Oncogenesis Lab, Via Messi Oro,156, Rome, Italy.	blandino@ifo.it	strano, sabrina/B-6743-2013; Fontemaggi, Giulia/K-9702-2016; Strano, Sabrina/K-9654-2016; Lapi, Eleonora/ABF-9748-2021; Blandino, Giovanni/B-1137-2013	strano, sabrina/0000-0002-6341-4230; Fontemaggi, Giulia/0000-0001-8332-8842; Lapi, Eleonora/0000-0003-4052-0361; Blandino, Giovanni/0000-0002-6970-2241; iacovelli, stefano/0000-0003-0806-6365	Telethon [GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Attardi LD, 2000, GENE DEV, V14, P704; Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; Blandino G, 2004, CELL CYCLE, V3, P886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Dale BA, 1997, J INVEST DERMATOL, V108, P179, DOI 10.1111/1523-1747.ep12334205; Dazard JE, 2003, ONCOGENE, V22, P2993, DOI 10.1038/sj.onc.1206537; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gupta S, 2003, J CLIN ONCOL, V21, P106, DOI 10.1200/JCO.2003.03.024; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Hibi K, 2003, CLIN CANCER RES, V9, P4282; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Maelandsmo GM, 1997, INT J CANCER, V74, P464, DOI 10.1002/(SICI)1097-0215(19970822)74:4<464::AID-IJC19>3.0.CO;2-9; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zaika AI, 1999, CANCER RES, V59, P3257	40	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3628	3637		10.1038/sj.onc.1209401	http://dx.doi.org/10.1038/sj.onc.1209401			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449968				2022-12-17	WOS:000238448300002
J	Pozzi, S; Rossetti, S; Bistulfi, G; Sacchi, N				Pozzi, S; Rossetti, S; Bistulfi, G; Sacchi, N			RAR-mediated epigenetic control of the cytochrome P450 Cyp26a1 in embryocarcinoma cells	ONCOGENE			English	Article						RAR alpha; RAR beta 2; Cyp26a1; epigenetic regulation; embryocarcinoma	RETINOIC ACID; DIFFERENTIATION; EXPRESSION; ALPHA; FEEDBACK; GENE	Retinoic acid (RA) is a signaling molecule that plays a pivotal role in major cellular processes and vertebrate development. RA action is mediated by specialized transcription factors, the nuclear RA receptors (RARs), which regulate the transcription of genes containing a RA-responsive element (RARE). Here we demonstrate that the genes for the RA-receptor RAR beta 2 and the cytochrome P450 RA-specific hydrolase Cyp26a1 involved in RA catabolism are coordinately regulated by RA. We found that both RAR beta 2 and Cyp26a1 genes are epigenetically silenced in the absence of DNA methylation in RAC65, a P19 embryocarcinoma cell line derivative carrying a dominant-negative RAR alpha mutant and resistant to the growth-inhibitory and differentiation effects of RA. In response to RA, RAR beta 2 transcription is epigenetically regulated by RAR alpha. Similarly, we found that Cyp26a1 transcription is epigenetically regulated by RAR beta 2. Knocking down RAR beta 2 transcription by RNA interference in wild-type P19 cells, with an intact RAR alpha, induced Cyp26a1 transcriptional repression in the absence of DNA methylation. Concomitantly, cells developed RA resistance and did not undergo RA-induced neuron differentiation. Apparently, RAR alpha, RAR beta 2 and Cyp26a1 are components of a RA-regulated gene network. Factors affecting an upstream gene of the network can trigger repressive chromatin changes-which are propagated in a domino fashion-at downstream genes of the network. This study also shows that chromatin inactivity, and consequent transcriptional silencing, can be achieved in the absence of DNA methylation.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Sacchi, N (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St,C&V Bldg,Rm 226, Buffalo, NY 14263 USA.	nicoletta.sacchi@roswellpark.org						Arney KL, 2004, J CELL SCI, V117, P4355, DOI 10.1242/jcs.01390; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Costa SL, 1996, EXP CELL RES, V225, P35, DOI 10.1006/excr.1996.0154; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Dobbs-McAuliffe B, 2004, MECH DEVELOP, V121, P339, DOI 10.1016/j.mod.2004.02.008; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KRUYT FAE, 1992, DIFFERENTIATION, V49, P27, DOI 10.1111/j.1432-0436.1992.tb00766.x; LAUDET V, 2002, NUCL RECEPTOR FACTS, P6; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Ozpolat B, 2002, AM J HEMATOL, V70, P39, DOI 10.1002/ajh.10099; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sirchia SM, 2002, CANCER RES, V62, P2455; Sonneveld E, 1999, DEV BIOL, V213, P390, DOI 10.1006/dbio.1999.9381; White KA, 2003, J BIOL CHEM, V278, P43889, DOI 10.1074/jbc.C300374200	25	28	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1400	1407		10.1038/sj.onc.1209173	http://dx.doi.org/10.1038/sj.onc.1209173			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16261163				2022-12-17	WOS:000235708200013
J	Wang, Y; Zhang, Z; Yao, R; Jia, D; Wang, D; Lubet, RA; You, M				Wang, Y; Zhang, Z; Yao, R; Jia, D; Wang, D; Lubet, RA; You, M			Prevention of lung cancer progression by bexarotene in mouse models	ONCOGENE			English	Article						chemoprevention; bexarotene; lung cancer; mouse models	RETINOID-X-RECEPTOR; SELECTIVE LIGAND LGD1069; MAMMARY-CARCINOMA; TARGRETIN; TUMORS; TAMOXIFEN; EFFICACY; MUTATION; KRAS2; TRIAL	Bexarotene (Targretin((R)), Ligand Pharmaceuticals Inc.) is a synthetic high-affinity RXR receptor agonist with limited affinity for RAR receptors. Bexarotene has shown efficacy in a phase I/II trial of non-small-cell lung cancers. However, the chemopreventive efficacy of bexarotene has not been determined in mouse lung cancer models. In this study, we have investigated the ability of bexarotene to inhibit lung tumor progression in the mutant A/J mouse models with genetic alterations in p53 or K-ras, two of the most commonly altered genes in human lung tumorigenesis. Mice were administered vinyl carbamate ( VC), a carcinogen, by a single intraperitoneal injection (i.p.) at 6 weeks of age. Bexarotene was given by gavage starting at 16 weeks after VC and was continued for 12 weeks. Although all mice developed lung tumors, only 7% of lung tumors were adenocarcinomas in wild-type mice, whereas 22 and 26% of lung tumors were adenocarcinomas in p53 transgenic or K-ras heterozygous deficient mice. Bexarotene inhibited both tumor multiplicity and tumor volume in mice of all three genotypes. Furthermore, bexarotene reduced the progression of adenoma to adenocarcinoma by similar to 50% in both p53(wt/wt)K-ras(ko/wt) and p53(wt/wt)K-ras(wt/wt) mice. Thus, bexarotene appears to be an effective preventive agent against lung tumor growth and progression.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA; Chemoprevent Agent Dev Res Grp, NCI, Rockville, MD USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554, N01CN25104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja HS, 2003, J BIOL REG HOMEOS AG, V17, P29; Bischoff ED, 1999, J NATL CANCER I, V91, P2118, DOI 10.1093/jnci/91.24.2118; Bischoff ED, 1998, CANCER RES, V58, P479; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; GARFINKEL L, 1991, CA-CANCER J CLIN, V41, P137, DOI 10.3322/canjclin.41.3.137; Gottardis MM, 1996, CANCER RES, V56, P5566; Herzog CR, 1997, J CELL BIOCHEM, P49; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofseth LJ, 2004, CHEST, V125, p83S, DOI 10.1378/chest.125.5_suppl.83S-a; Khuri FR, 2001, J CLIN ONCOL, V19, P2626, DOI 10.1200/JCO.2001.19.10.2626; Konopleva M, 2002, CURR OPIN HEMATOL, V9, P294, DOI 10.1097/00062752-200207000-00006; Lee KW, 2002, J ENDOCRINOL, V175, P33, DOI 10.1677/joe.0.1750033; Li J, 2003, ONCOGENE, V22, P1243, DOI 10.1038/sj.onc.1206192; Lubet RA, 2005, CARCINOGENESIS, V26, P441, DOI 10.1093/carcin/bgh338; MALKINSON AM, 1992, CANCER RES, V52, pS2670; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; NASONBURCHENAL K, 1999, HANDB EXP PHARM, V139, P301; Saini SPS, 2004, MOL PHARMACOL, V65, P292, DOI 10.1124/mol.65.2.292; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sherman SI, 1999, NEW ENGL J MED, V340, P1075, DOI 10.1056/NEJM199904083401404; STONER GD, 1991, EXP LUNG RES, V17, P405, DOI 10.3109/01902149109064428; Tong LZ, 1996, CANCER, V78, P1004, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1004::AID-CNCR10>3.0.CO;2-6; Wang Y, 2003, CANCER RES, V63, P4389; Wu KD, 2002, CANCER RES, V62, P6376; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zhang ZQ, 2004, ONCOGENE, V23, P3841, DOI 10.1038/sj.onc.1207496; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2000, CANCER RES, V60, P901	32	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1320	1329		10.1038/sj.onc.1209180	http://dx.doi.org/10.1038/sj.onc.1209180			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247446				2022-12-17	WOS:000235708200005
J	Yamada, HY; Gorbsky, GJ				Yamada, HY; Gorbsky, GJ			Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105	ONCOGENE			English	Article						TSSC5; protease associated; RING finger; ubiquitin ligase; UbcH6; 11p15.5	RETICULUM-ASSOCIATED DEGRADATION; CHROMOSOME 11P15.5; POLYSPECIFIC TRANSPORTER; IMPRINTED GENE; PROTEIN; IDENTIFICATION; KINETOCHORES; ASSOCIATION; PROTEOLYSIS; MUTATIONS	The region of human chromosome 11p15.5 is linked with Beckwith-Wiedemann syndrome that is associated with susceptibility to Wilms' tumor, rhabdomyosarcoma and hepatoblastoma. TSSC5 (tumor-suppressing subchromo-somal transferable fragment cDNA; also known as ORCTL2/IMPT1/BWR1A/SLC22A1L) is located in the region. The expression of TSSC5 and other genes in the region is regulated through paternal imprinting. Mutations and/or reduced expression of TSSC5 have been found in certain tumors. TSSC5 encodes an efflux transporter-like protein with 10 transmembrane domains, whose regulation may affect drug sensitivity, cellular metabolism and growth. Here, we present evidences indicating that RING105, a novel conserved RING-finger protein with a PA (protease-associated) domain and a PEST sequence, is a ubiquitin ligase for TSSC5 that can function in concert with the ubiquitin-conjugating enzyme UbcH6. The polyubiquitin target site on TSSC5 was mapped to a region in the 6th hydrophilic loop. Ectopic expression of RING105 in HeLa cells caused an accumulation of cells during G1 that was not observed with the expression of a form of RING105 in which a residue within the RING finger was mutated to inactivate its ligase activity. UbcH6-RING105 may de. ne a novel ubiquitin-proteasome pathway that targets TSSC5 in mammalian cells.	OMRF, Mol Cell & Dev Biol Res Program, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation	Yamada, HY (corresponding author), OMRF, Mol Cell & Dev Biol Res Program, 825 NE 13th St MS48, Oklahoma City, OK 73104 USA.	Hiroshi-yamada@omrf.ouhsc.edu		Yamada, Hiroshi/0000-0002-0536-5581; Gorbsky, Gary/0000-0003-3076-4725	NIGMS NIH HHS [R01-GM50412, R01 GM050412, R01 GM050412-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht S, 2004, INT J CANCER, V111, P627, DOI 10.1002/ijc.20280; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cooper PR, 1998, GENOMICS, V49, P38, DOI 10.1006/geno.1998.5221; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dao D, 1998, HUM MOL GENET, V7, P597, DOI 10.1093/hmg/7.4.597; Feinberg AP, 1999, CANCER RES, V59, p1743S; FEINBERG AP, 1994, J CELL SCI, P7; Gilon T, 2000, MOL CELL BIOL, V20, P7214, DOI 10.1128/MCB.20.19.7214-7219.2000; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirsch C, 2004, BBA-MOL CELL RES, V1695, P215, DOI 10.1016/j.bbamcr.2004.10.006; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Lee MP, 1998, CANCER RES, V58, P4155; Lewis A, 2004, CURR BIOL, V14, pR284, DOI 10.1016/j.cub.2004.03.026; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Mahon P, 2000, PROTEIN SCI, V9, P1930, DOI 10.1110/ps.9.10.1930; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Paulsen M, 1998, HUM MOL GENET, V7, P1149, DOI 10.1093/hmg/7.7.1149; Poirier K, 2003, J PATHOL, V201, P473, DOI 10.1002/path.1477; Ptak C, 2001, MOL CELL BIOL, V21, P6537, DOI 10.1128/MCB.21.19.6537-6548.2001; Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reece M, 1998, FEBS LETT, V433, P245, DOI 10.1016/S0014-5793(98)00907-7; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Sagne C, 1996, BIOCHEM J, V316, P825, DOI 10.1042/bj3160825; Schwienbacher C, 1998, P NATL ACAD SCI USA, V95, P3873, DOI 10.1073/pnas.95.7.3873; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Topper LM, 2001, J CELL BIOL, V154, P707, DOI 10.1083/jcb.200104130	37	28	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1330	1339		10.1038/sj.onc.1209167	http://dx.doi.org/10.1038/sj.onc.1209167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16314844	Green Accepted			2022-12-17	WOS:000235708200006
J	Embry, MR; Billiard, SM; Di Giulio, RT				Embry, MR; Billiard, SM; Di Giulio, RT			Lack of p53 induction in fish cells by model chemotherapeutics	ONCOGENE			English	Article						PLHC-1; rainbow trout; p53; chemotherapeutics; protein induction; apoptosis	FLOUNDER PLATICHTHYS-FLESUS; TUMOR-SUPPRESSOR PROTEIN; EUROPEAN FLOUNDER; DNA-DAMAGE; WILD-TYPE; MUTATION ANALYSIS; EPITHELIAL-CELLS; PRIMARY CULTURES; GENE; APOPTOSIS	Although p53 has been extensively studied in mammalian models, relatively little is known about its specific function in lower vertebrates. It has long been assumed that p53 pathways characterized in mammals apply to other vertebrates as well. Fish provide a useful model for the study of environmental carcinogenesis, and populations of fish inhabiting highly polluted environments provide information on the etiology of pollutant-mediated cancer. In this study, we investigated p53 protein and apoptosis induction in PLHC-1 ( desert topminnow hepatocellular carcinoma), RTL-W1 ( rainbow trout normal liver), and primary rainbow trout hepatocytes exposed to model chemotherapeutics. All of the chemicals used in these studies have been demonstrated to increase p53 protein levels and induce apoptosis in mammalian cell lines. In contrast, PLHC-1 p53 protein was not induced in response to any model mammalian p53 inducers following 24 h exposures. Additionally, both trout cell types demonstrated this same lack of p53 induction upon exposure to model chemotherapeutic drugs. PLHC-1 cells demonstrated an induction of apoptosis as measured by caspase-3 activation following exposure to all of the chemotherapeutics tested. Our results suggest that fish p53 may be activated differently from that of their mammalian counterparts, and that important differences may exist between phyla in the function and regulation of p53 as well as other mechanisms involved in environmental carcinogenesis.	Duke Univ, Ecotoxicol Lab, Nicholas Sch Environm & Earth Sci, Integrated Toxicol Program, Durham, NC USA	Duke University	Embry, MR (corresponding author), US EPA, Off Pollut Prevent & Tox Subst, Off Pesticide Programs, 1200 Penn Ave,NW,NW Mail Code 7507C, Washington, DC 20460 USA.	embry.michelle@epa.gov			NIEHS NIH HHS [ES07031, ES10356] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031, P42ES010356] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Cachot J, 2004, GENE, V324, P97, DOI 10.1016/j.gene.2003.09.052; Cachot J, 2000, MUTAT RES-GEN TOX EN, V464, P279, DOI 10.1016/S1383-5718(99)00205-3; Cachot J, 1998, COMP BIOCHEM PHYS C, V120, P351, DOI 10.1016/S0742-8413(98)00039-5; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Franklin TM, 2000, MAR ENVIRON RES, V50, P251, DOI 10.1016/S0141-1136(00)00091-X; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; FRITSCHE M, 1993, ONCOGENE, V8, P307; HIGHTOWER LE, 1988, J EXP ZOOL, V248, P290, DOI 10.1002/jez.1402480307; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Houser S, 2001, BIOCHEM BIOPH RES CO, V289, P998, DOI 10.1006/bbrc.2001.6073; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kazianis S, 1998, GENE, V212, P31, DOI 10.1016/S0378-1119(98)00144-9; Krause MK, 1997, GENE, V189, P101, DOI 10.1016/S0378-1119(96)00841-4; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; LEE LEJ, 1993, CELL BIOL TOXICOL, V9, P279, DOI 10.1007/BF00755606; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marechal V, 1997, PATHOL BIOL, V45, P824; Matsubara H, 1999, INT J ONCOL, V14, P1081; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Okamura M, 2004, ANTICANCER RES, V24, P655; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PART P, 1993, J EXP BIOL, V175, P219; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Sandbacka M, 2000, COMP BIOCHEM PHYS C, V127, P307, DOI 10.1016/S0742-8413(00)00156-0; Schlenk D, 1998, AQUAT TOXICOL, V43, P121, DOI 10.1016/S0166-445X(98)00050-2; Sekelsky JJ, 2000, J CELL BIOL, V150, pF31, DOI 10.1083/jcb.150.2.F31; Sueiro RA, 2000, MUTAT RES-GEN TOX EN, V468, P63, DOI 10.1016/S1383-5718(00)00040-1; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wang YX, 1999, FEBS LETT, V445, P269, DOI 10.1016/S0014-5793(99)00136-2; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	44	28	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2004	2010		10.1038/sj.onc.1209238	http://dx.doi.org/10.1038/sj.onc.1209238			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16434976				2022-12-17	WOS:000236359700003
J	Liu, S; Ishikawa, H; Tsuyama, N; Li, FJ; Abroun, S; Otsuyama, KI; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM				Liu, S; Ishikawa, H; Tsuyama, N; Li, FJ; Abroun, S; Otsuyama, KI; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM			Increased susceptibility to apoptosis in CD45(+) myeloma cells accompanied by the increased expression ofVDAC1	ONCOGENE			English	Article						apoptosis; Ca2+; CD45; myeloma; ROS; VDAC1	DEPENDENT ANION CHANNEL; TYROSINE PROTEIN-KINASE; PLASMA-CELLS; CYTOCHROME-C; BONE-MARROW; ACTIVATION; BCL-2; SRC; PROLIFERATION; FAMILY	Expression of CD45 is quite variable in human myeloma cells and cell lines, such as U266, and CD45(+) U266 proliferates in response to a growth factor, interleukin-6. Here, we show that CD45(+) myeloma cell lines were more sensitive to various apoptotic stimuli, such as oxidative stress and endoplasmic reticulum ( ER)-stress, than CD45(-) cells. Reactive oxygen species and calcium ion seemed to be involved in the susceptibility to apoptosis of CD45(+) U266. The activation of the src family kinases associated with CD45 phosphatase played an important role in the augmented apoptosis in CD45(+) U266 by oxidative stress. These results indicate that the CD45- expression renders myeloma cells competent for not only mitogenic but also apoptotic stimuli, resulting in either proliferation or apoptosis of CD45(+) myeloma cells dependently upon the circumstantial stimuli. Furthermore, voltage-dependent anion channel ( VDAC) 1 was identified as a gene highly expressed in CD45(+) U266 by cDNA subtraction. The increased expression of VDAC1 seemed to augment the sensitivity to the ER-stress because the VDAC1-transfected U266 was more susceptible to the thapsigargininduced apoptosis. Thus, CD45 expression accompanied by the increased VDAC1 expression sensitizes myeloma cells to the various extracellular stimuli that trigger apoptosis via the mitochondrial pathways.	Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, Lab Cellular Signal Anal, Ube, Yamaguchi 755, Japan	Yamaguchi University	Ishikawa, H (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, Lab Cellular Signal Anal, 1-1-1 Minami Kogushi, Ube, Yamaguchi 755, Japan.	hishika@yamaguchi-u.ac.jp	ABROUN, SAEID/GPF-5006-2022					Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Abroun S, 2004, BLOOD, V103, P2291, DOI 10.1182/blood-2003-07-2187; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Decaudin D, 1997, CANCER RES, V57, P62; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fujii R, 1999, BRIT J HAEMATOL, V105, P131, DOI 10.1046/j.1365-2141.1999.01281.x; Ishikawa H, 2002, BLOOD, V99, P2172, DOI 10.1182/blood.V99.6.2172; Joshua D, 1996, BRIT J HAEMATOL, V94, P76, DOI 10.1046/j.1365-2141.1996.d01-1784.x; Justement L B, 2001, Int Rev Immunol, V20, P713, DOI 10.3109/08830180109045587; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KAWANO MM, 1995, BLOOD, V85, P487; KAWANO MM, 1993, BLOOD, V82, P564; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li FJ, 2005, BLOOD, V105, P3295, DOI 10.1182/blood-2004-10-4083; Lipton SA, 1998, CELL CALCIUM, V23, P165, DOI 10.1016/S0143-4160(98)90115-4; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Mahmoud MS, 1998, BLOOD, V92, P3887, DOI 10.1182/blood.V92.10.3887.422a48_3887_3897; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; NAMBA M, 1989, IN VITRO CELL DEV B, V25, P723; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Schneider U, 1997, BRIT J HAEMATOL, V97, P56, DOI 10.1046/j.1365-2141.1997.d01-2115.x; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SHIMIZU S, 1993, LEUKEMIA, V7, P274; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Takagi-Morishita Y, 2003, BIOL REPROD, V68, P1178, DOI 10.1095/biolreprod.102.007997; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	43	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					419	429		10.1038/sj.onc.1208982	http://dx.doi.org/10.1038/sj.onc.1208982			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16247487				2022-12-17	WOS:000234714100010
J	Stuart, JR; Kawai, H; Tsai, KKC; Chuang, EY; Yuan, ZM				Stuart, JR; Kawai, H; Tsai, KKC; Chuang, EY; Yuan, ZM			c-Abl regulates early growth response protein (EGR1) in response to oxidative stress	ONCOGENE			English	Article						c-Abl; EGR1; oxidative stress; tyrosine kinase	FINGER TRANSCRIPTION FACTOR; TYROSINE KINASE; IONIZING-RADIATION; DNA-DAMAGE; ACTIVATION; GENE; EXPRESSION; P53; UPSTREAM; CELLS	c-Abl is a tyrosine kinase that can act as a regulator of cell growth and apoptosis in response to stress. Using cell lines expressing c-Abl in an inducible manner, we identified genes whose expression was regulated by c-Abl kinase activity. Microarray analysis indicated that Early Growth Response-1 (EGR1) gene expression is induced by c-Abl kinase activity, which was confirmed at the message and protein levels. Promoter mapping experiments revealed that c-Abl utilizes three distal serum response elements (SREs) in the EGR1 promoter, which are transactivated by mitogen/extracellular receptor kinase (MEK/ERK) signaling. PD 95089, a specific inhibitor of MEK/ERK signaling, attenuated c-Abl-mediated upregulation of EGR1 expression in a dose-dependent manner. Similar results were obtained by using a dominant-negative mutant of mitogen/extracellular kinase. Significantly, hydrogen peroxide-induced EGR1 expression appears to be mediated by c-Abl, as cells expressing dominant negative c-Abl, and c-Abl(-/-) murine embryonic fibroblasts, are completely defective in hydrogen peroxide-induced EGR1 expression. In addition, c-Abl-induced apoptosis is partially mitigated by EGR1 activity, as cells devoid of EGR1 expression undergo reduced rates of c-Abl-induced apoptosis. Together, these results indicate that c-Abl promotes the induction of EGR1 through the MEK/ERK pathway in regulating apoptotic response to oxidative stress.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA	Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave,HSPH-1,Room 508, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Tsai, Kun-Chih/C-1371-2010	Tsai, Kelvin/0000-0002-1612-2868; Kawai, Hidehiko/0000-0003-2213-7166	NCI NIH HHS [R29 CA85679] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085679] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Cibelli G, 2002, J NEUROSCI RES, V67, P450, DOI 10.1002/jnr.10141; DANIEL R, 1995, ONCOGENE, V10, P1607; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; GOGA A, 1995, ONCOGENE, V11, P791; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Jones N, 2003, J CELL PHYSIOL, V196, P326, DOI 10.1002/jcp.10308; Kaufmann K, 2001, BIOL CHEM, V382, P1077, DOI 10.1515/BC.2001.135; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Park JO, 2002, J CLIN INVEST, V110, P403, DOI 10.1172/JCI200215548; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437	33	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8085	8092		10.1038/sj.onc.1208953	http://dx.doi.org/10.1038/sj.onc.1208953			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091742				2022-12-17	WOS:000233809400001
J	Young, T; Mei, F; Liu, JS; Bast, RC; Kurosky, A; Cheng, XD				Young, T; Mei, F; Liu, JS; Bast, RC; Kurosky, A; Cheng, XD			Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defned human ovarian cancer model	ONCOGENE			English	Article						caspase 4; mass spectrometry; ovarian cancer; proteomics; ras; transformation	EPITHELIAL-CELLS; CATHEPSIN-D; POLYACRYLAMIDE-GELS; SIGNALING PATHWAY; MASS-SPECTROMETRY; GENE-MUTATIONS; CALPAIN; EXPRESSION; CARCINOMA; IDENTIFICATION	RAS is a small GTP binding protein mutated in approximately 30% human cancer. Despite its important role in the initiation and progression of human cancer, the underlying mechanism of RAS-induced human epithelial transformation remains elusive. In this study, we probe the cellular and molecular mechanisms of RAS-mediated transformation, by pro. ling two human ovarian epithelial cell lines. One cell line was immortalized with SV40T/t antigens and the human catalytic subunit of telomerase ( T29), while the second cell line was transformed with an additional oncogenic ras(V12) allele ( T29H). In total, 32 proteins associated with RAS-mediated transformation have been identified using peptide mass fingerprinting. These protein targets are involved in several cellular pathways, including metabolism, redox balance, calcium signaling, apoptosis, and cellular methylation. One such target, the 40kDa procaspase 4 is significantly upregulated at the protein level in RAS-transformed T29H cells, related directly to signaling through MEK, but not PI3 kinase. Cellular caspase 4 activity is, however, suppressed in the T29H cells, suggesting that the maturation process of caspase 4 is abrogated in RAS-transformed T29H cells. Consistent with this notion, transformed T29H cells were less susceptible to the toxic effects of anti-Fas antibody than were immortalized, nontransformed T29 cells, associated with less activation of caspase 4. This study demonstrates that functional proteomic analysis of a genetically defined cancer model provides a powerful approach toward systematically identifying cellular targets associated with oncogenic transformation.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	xcheng@utmb.edu	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R24CA088317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066170, R01GM060170] Funding Source: NIH RePORTER; NCI NIH HHS [R24CA88317, R24 CA088317] Funding Source: Medline; NHLBI NIH HHS [N01HV28184, N01-HV-28184] Funding Source: Medline; NIEHS NIH HHS [ES06676, P30 ES006676] Funding Source: Medline; NIGMS NIH HHS [GM060170, R01 GM066170, R01 GM060170] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; ARGILES JM, 1988, MOL CELL BIOCHEM, V81, P3; Balabanov S, 2001, EUR J BIOCHEM, V268, P5977, DOI 10.1046/j.0014-2956.2001.02546.x; Bao JJ, 2002, CANCER RES, V62, P7264; BERCHUCK A, 1990, CANCER RES, V50, P4087; Bernard K, 2003, CANCER RES, V63, P6716; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOS JL, 1989, CANCER RES, V49, P4682; CALAF G, 1994, BREAST CANCER RES TR, V29, P169, DOI 10.1007/BF00665678; Cao QJ, 2001, INT J GYNECOL PATHOL, V20, P346, DOI 10.1097/00004347-200110000-00006; Demoz M, 1999, J CELL BIOCHEM, V73, P370, DOI 10.1002/(SICI)1097-4644(19990601)73:3<370::AID-JCB8>3.0.CO;2-N; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jones MB, 2002, PROTEOMICS, V2, P76, DOI 10.1002/1615-9861(200201)2:1<76::AID-PROT76>3.3.CO;2-F; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li G, 2002, P NATL ACAD SCI USA, V99, P13254, DOI 10.1073/pnas.202355799; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Losch A, 2004, GYNECOL ONCOL, V92, P545, DOI 10.1016/j.ygyno.2003.11.016; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; Martin CA, 2002, AM J PHYSIOL-GASTR L, V282, pG92, DOI 10.1152/ajpgi.2002.282.1.G92; MATTHAEI KI, 1987, JNCI-J NATL CANCER I, V79, P805; Ostergaard M, 1997, CANCER RES, V57, P4111; Park KS, 2002, INT J CANCER, V97, P261, DOI 10.1002/ijc.1585; Patton SE, 1998, CANCER RES, V58, P2253; Rich JN, 2001, CANCER RES, V61, P3556; ROGERS J, 1990, ADV EXP MED BIOL, V269, P195; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Varras MN, 1999, ONCOLOGY-BASEL, V56, P89, DOI 10.1159/000011946; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Yu LR, 2000, ELECTROPHORESIS, V21, P3058, DOI 10.1002/1522-2683(20000801)21:14<3058::AID-ELPS3058>3.0.CO;2-U	43	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6174	6184		10.1038/sj.onc.1208753	http://dx.doi.org/10.1038/sj.onc.1208753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940260	Green Accepted			2022-12-17	WOS:000231718100011
J	Hsieh, SY; Chen, WY; Yeh, TS; Sheen, IS; Huang, SF				Hsieh, SY; Chen, WY; Yeh, TS; Sheen, IS; Huang, SF			High-frequency Alu-mediated genomic recombination/deletion within the caspase-activated DNase gene in human hepatoma	ONCOGENE			English	Article						DNA fragmentation factor B; CAPN; caspase-activated Dnase; CAD; Alu repetitive elements; hepatoma	CHROMATIN CONDENSATION; REPEATS; INHIBITOR; REARRANGEMENTS; FRAGMENTATION; NEUROBLASTOMA; SEQUENCES; ELEMENTS; HETEROZYGOSITY; TUMORIGENICITY	The Alu repetitive elements, which constitute 10% of human genome, may serve as bridges for genomic recombination. However, their roles in tumorigenesis remain to be elucidated. Caspase-activated DNase (CAD), whose gene (hCAD) is mapped at chromosome 1p36, a region frequently displaying hemizygote deletion in many human cancers, is the key enzyme for nucleosome fragmentation during apoptosis. Recently, we detected many aberrant mRNAs for hCAD in many human hepatoma cells. To elucidate the genetic basis leading to the mRNA aberration, we used PCR-based chromosome walking to clone the corresponding genomic DNA identifying a novel Alu/Alu homologous recombination/ deletion within hCAD in HepG2 and Hep3B cells. We then detected similar recombination events in 13 out of the 20 hepatoma tissues and in eight of the para-cancerous cirrhotic livers. The recombination was inclined to occur in males (P = 0.031) and had marginal association with high-grade hepatoma (P = 0.070) and tumor recurrence (P = 0.070). The recombination caused exon-3 deletion, which in turn led to exon-3 skipping or replacement with a partial Alu-sequence, and consequential C-truncation of CAD. Our findings of high frequency of Alu-mediated hCAD deletion in human hepatoma not only underscore the implication of hCAD in hepatocarcinogenesis, but also highlight the potential roles of human repetitive sequences in mediating genome instability in human cancers.	Chang Gung Mem Hosp, Liver Res Unit, Taoyuan 333, Taiwan; Chang Gung Mem Hosp, Clin Proteom Ctr, Taoyuan 333, Taiwan; Chang Gung Mem Hosp, Sch Med, Dept Microbiol & Immunol, Taoyuan 333, Taiwan; Chang Gung Mem Hosp, Dept Gen Surg, Taoyuan 333, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; National Health Research Institutes - Taiwan	Hsieh, SY (corresponding author), Chang Gung Mem Hosp, Liver Res Unit, 5 Fu Hsin Rd, Taoyuan 333, Taiwan.	siming@adm.cgmh.org.tw	Huang, Shiu-Feng Kathy/E-3977-2010					BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHENG NC, 1995, ONCOGENE, V10, P291; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsieh SY, 1997, P NATL ACAD SCI USA, V94, P3206, DOI 10.1073/pnas.94.7.3206; Hsieh SY, 2003, BRIT J CANCER, V88, P210, DOI 10.1038/sj.bjc.6600695; Jeffs AR, 1998, HUM MOL GENET, V7, P767, DOI 10.1093/hmg/7.5.767; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kolomietz E, 2001, BLOOD, V97, P3581, DOI 10.1182/blood.V97.11.3581; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; Lin CH, 2001, CANCER RES, V61, P4238; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lobachev KS, 2000, EMBO J, V19, P3822, DOI 10.1093/emboj/19.14.3822; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nagase H, 2003, CELL DEATH DIFFER, V10, P142, DOI 10.1038/sj.cdd.4401139; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Rohlfs EM, 2000, GENE CHROMOSOME CANC, V28, P300, DOI 10.1002/1098-2264(200007)28:3<300::AID-GCC8>3.0.CO;2-1; Rowold DJ, 2000, GENETICA, V108, P57, DOI 10.1023/A:1004099605261; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; SIMON D, 1991, ONCOGENE, V6, P765; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Stenger JE, 2001, GENOME RES, V11, P12, DOI 10.1101/gr.158801; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; TANAKA K, 1993, ONCOGENE, V8, P2253; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yeh SH, 2001, GASTROENTEROLOGY, V121, P699, DOI 10.1053/gast.2001.27211; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	38	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6584	6589		10.1038/sj.onc.1208803	http://dx.doi.org/10.1038/sj.onc.1208803			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007181				2022-12-17	WOS:000232204100012
J	Fung, MM; Chu, YL; Fink, JL; Wallace, A; McGuire, KL				Fung, MM; Chu, YL; Fink, JL; Wallace, A; McGuire, KL			IL-2- and STAT5-regulated cytokine gene expression in cells expressing the Tax protein of HTLV-1	ONCOGENE			English	Article						IL-2; human; HTLV-1; T cell; Tax	JAK-STAT PATHWAY; IL-2 RECEPTOR; SERINE PHOSPHORYLATION; T-CELLS; CONSTITUTIVE ACTIVATION; BINDING PROTEIN; LEUKEMIA-CELLS; GROWTH-FACTOR; INTERLEUKIN-2; LYMPHOCYTES	Interleukin-2 (IL-2) mediates cell cycle progression and antiapoptosis in human T cells via several signal transduction pathways. The Tax protein of the human T-cell leukemia virus type I (HTLV-1) deregulates cell growth and alters the role of IL-2 in infected cells. However, Tax-immortalized cells stay dependent on IL-2, suggesting that events besides HTLV-1 gene expression are required for leukemia to develop. Here, IL-2-dependent and -independent events were analysed in a human T cell line immortalized by Tax. These studies show that, of the signaling pathways evaluated, only STAT5 remains dependent. Microarray analyses revealed several genes, including il-5, il-9 and il-13, are uniquely upregulated by IL-2 in the presence of Tax. Bioinformatics and supporting molecular biology show that some of these genes are STAT5 targets, explaining their IL-2 upregulation. These results suggest that IL-2 and viral proteins work together to induce gene expression, promoting the hypothesis that deregulation via the constitutive activation of STAT5 may lead to the IL-2-independent phenotype of HTLV-1-transformed cells.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA; Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA	California State University System; San Diego State University; University of California System; University of California San Diego; Scripps Research Institute	McGuire, KL (corresponding author), San Diego State Univ, Dept Biol, 5500 Campanile Dr, San Diego, CA 92182 USA.	kmcguire@sunstroke.sdsu.edu	Fink, Lynn/C-2031-2008	Fink, Lynn/0000-0003-2912-6048	NCRR NIH HHS [P41 RR08605-08] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008605] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Boer AK, 2002, BLOOD, V100, P467, DOI 10.1182/blood.V100.2.467; Chung HK, 2003, BLOOD, V102, P4130, DOI 10.1182/blood-2003-04-1043; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Fung MM, 2003, CELL SIGNAL, V15, P625, DOI 10.1016/S0898-6568(03)00003-2; Gaffen SL, 2001, CYTOKINE, V14, P63, DOI 10.1006/cyto.2001.0862; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; HERTZ GZ, 1990, COMPUT APPL BIOSCI, V6, P81; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; HOUSSIAU FA, 1993, J IMMUNOL, V150, P2634; Iacobelli M, 1999, J IMMUNOL, V162, P3308; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KELLEHER K, 1991, BLOOD, V77, P1436; Kim HP, 2001, IMMUNITY, V15, P159, DOI 10.1016/S1074-7613(01)00167-4; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li-Weber M, 2001, EUR J IMMUNOL, V31, P3694, DOI 10.1002/1521-4141(200112)31:12<3694::AID-IMMU3694>3.0.CO;2-S; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Lu LR, 1998, EUR J IMMUNOL, V28, P805, DOI 10.1002/(SICI)1521-4141(199803)28:03<805::AID-IMMU805>3.0.CO;2-G; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; Matsushita K, 1997, LEUKEMIA RES, V21, P211, DOI 10.1016/S0145-2126(96)00109-9; McGuire KL, 1997, J IMMUNOL, V159, P1319; MCGUIRE KL, 1999, RECENT RES DEV IMMUN, V1, P149; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MURATA K, 1992, CANCER, V69, P966, DOI 10.1002/1097-0142(19920215)69:4&lt;966::AID-CNCR2820690422&gt;3.0.CO;2-H; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Ogata M, 1998, AM J HEMATOL, V59, P242, DOI 10.1002/(SICI)1096-8652(199811)59:3<242::AID-AJH11>3.3.CO;2-F; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROBB RJ, 1984, IMMUNOL TODAY, V5, P203, DOI 10.1016/0167-5699(84)90224-X; Robek MD, 1998, J VIROL, V72, P4458, DOI 10.1128/JVI.72.5.4458-4462.1998; Rohwer F, 1996, J IMMUNOL, V157, P643; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Skinnider BF, 2002, LEUKEMIA LYMPHOMA, V43, P1203, DOI 10.1080/10428190290026259; Skinnider BF, 2001, INT ARCH ALLERGY IMM, V126, P267, DOI 10.1159/000049523; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; Waldele K, 2004, J VIROL, V78, P6081, DOI 10.1128/JVI.78.12.6081-6090.2004; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; Ye JX, 2003, BLOOD, V102, P3963, DOI 10.1182/blood-2003-05-1490; YOSHIDA M, 1994, AIDS RES HUM RETROV, V10, P1193, DOI 10.1089/aid.1994.10.1193	61	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4624	4633		10.1038/sj.onc.1208507	http://dx.doi.org/10.1038/sj.onc.1208507			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15735688				2022-12-17	WOS:000230304500002
J	Wong, CF; Barnes, LM; Dahler, AL; Smith, L; Popa, C; Serewko-Auret, MM; Saunders, NA				Wong, CF; Barnes, LM; Dahler, AL; Smith, L; Popa, C; Serewko-Auret, MM; Saunders, NA			E2F suppression and Sp1 overexpression are sufficient to induce the differentiation-specific marker, transglutaminase type 1, in a squamous cell carcinoma cell line	ONCOGENE			English	Article						squamous cell carcinoma; differentiation therapy; keratinocytes; E2F; Sp1	HUMAN EPIDERMAL-KERATINOCYTES; TRANSCRIPTION FACTOR E2F; SKIN TUMOR-DEVELOPMENT; EPITHELIAL-CELLS; GENE-EXPRESSION; CULTURED-CELLS; RETINOIC ACID; IN-VITRO; PROMOTER; BINDING	Recently, E2F function has expanded to include the regulation of differentiation in human epidermal keratinocytes (HEKs). We extend these findings to report that in HEKs, Sp1 is a differentiation-specific activator and a downstream target of E2F-mediated suppression of the differentiation-specific marker, transglutaminase type 1 (TG-1). Deletion of elements between -0.084 to -0.034 kb of the TG-1 promoter disabled E2F1-induced suppression of promoter activity. Electrophoretic mobility shift assays (EMSAs) demonstrated that Sp1 and Sp3 bound this region. Protein expression analysis suggested that squamous differentiation was accompanied by increased Sp1/Sp3 ratio. Cotransfection of proliferating HEKs or the squamous cell carcinoma (SCC) cell line, KJD-1/SV40, with an E2F inhibitor (E2Fd/n) and Sp1 expression plasmid was sufficient to activate the TG-1 promoter. The suppression of Sp1 activity by E2F in differentiated cells appeared to be indirect since we found no evidence of an Sp1/E2F coassociation on the TG-1 promoter fragment. Moreover, E2F inhibition in the presence of a differentiation stimulus induced Sp1 protein. These data demonstrate that (i) Sp1 can act as a differentiation stimulus, (ii) E2F-mediated suppression of differentiation-specific markers is indirect via Sp1 inhibition and (iii) a combination of E2F inhibition and Sp1 activation could form the basis of a differentiation therapy for SCCs.	Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Programme,Epithelial Pathobiol Grp, Woolloongabba, Qld 4102, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4067, Australia	University of Queensland; University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Programme,Epithelial Pathobiol Grp, 4th Floor,Bldg 1,R Wing,Ipswich Rd, Woolloongabba, Qld 4102, Australia.	nsaunders@circ.uq.edu.au	saunders, nicholas/AAJ-6101-2020; McTaggart, Jill/G-4696-2010	saunders, nicholas/0000-0002-2478-3420; McTaggart, Jill/0000-0002-9000-8529				ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Dahler AL, 1998, J CELL PHYSIOL, V177, P474, DOI 10.1002/(SICI)1097-4652(199812)177:3<474::AID-JCP10>3.3.CO;2-D; Dahler AL, 2001, J INVEST DERMATOL, V116, P266, DOI 10.1046/j.1523-1747.2001.01243.x; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dicker AJ, 2000, EXP CELL RES, V258, P352, DOI 10.1006/excr.2000.4944; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Guo CS, 2003, J BIOL CHEM, V278, P22615, DOI 10.1074/jbc.M301943200; Guy CT, 1996, MOL CELL BIOL, V16, P685; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Jang SI, 2002, J BIOL CHEM, V277, P42268, DOI 10.1074/jbc.M205593200; Jessen BA, 2000, J INVEST DERMATOL, V115, P113, DOI 10.1046/j.1523-1747.2000.00027.x; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KHANNA KK, 1995, ONCOGENE, V11, P609; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lee JH, 1996, J BIOL CHEM, V271, P4561; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; Park GT, 1999, J BIOL CHEM, V274, P26599, DOI 10.1074/jbc.274.37.26599; Phillips Marjorie A, 2004, BMC Dermatol, V4, P2, DOI 10.1186/1471-5945-4-2; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Popa C, 2004, DIFFERENTIATION, V72, P185, DOI 10.1111/j.1432-0436.2004.07205001.x; Popa C, 1999, BRIT J DERMATOL, V141, P460; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; Serewko MM, 2002, CANCER RES, V62, P3759; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong CF, 2004, BIOCHEM BIOPH RES CO, V324, P497, DOI 10.1016/j.bbrc.2004.09.084; Wong CF, 2003, J BIOL CHEM, V278, P28516, DOI 10.1074/jbc.M301246200; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; WU RL, 1994, J BIOL CHEM, V269, P28450	45	28	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3525	3534		10.1038/sj.onc.1208372	http://dx.doi.org/10.1038/sj.onc.1208372			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735752				2022-12-17	WOS:000229038800014
J	da Costa, RMA; Riou, L; Paquola, A; Menck, CFM; Sarasin, A				da Costa, RMA; Riou, L; Paquola, A; Menck, CFM; Sarasin, A			Transcriptional profiles of unirradiated or UV-irradiated human cells expressing either the cancer-prone XPB/CS allele or the noncancer-prone XPB/TTD allele	ONCOGENE			English	Article						DNA repair; nucleotide excision repair; xeroderma pigmentosum; trichothiodystrophy; microarray; UV light	DNA-REPAIR; XERODERMA-PIGMENTOSUM; TISSUE TRANSGLUTAMINASE; COCKAYNE-SYNDROME; TRICHOTHIODYSTROPHY; GENE; ACTIVATION; DISORDERS; PROTEINS; HELICASE	Xeroderma pigmentosum (XP) and trichothiodystrophy (TTD) syndromes are characterized by deficiency in nucleotide excision repair pathway, but with distinguished clinical manifestations. While XP patients exhibit a high frequency of skin cancer, TTD patients are not cancer prone. The relation between lack of DNA repair and their clinical manifestations was investigated through analysis of the transcriptional profile of 12 600 transcripts in two isogenic cell lines with different capabilities of DNA repair. These cell lines result from a stable transfection of the XPB-TTD allele into XP complementation group B fibroblasts, from an XP patient who also have clinical abnormalities corresponding to Cockayne's syndrome (CS). The microarray assays performed under normal growth conditions showed the expression of distinct groups of genes in each cell line. The UVC-transcription modulation of these cells revealed the changes in 869 transcripts. Some of these transcripts had similar modulation pattern in both cells, although with eventually different time patterns for induction or repression. However, some different 'UVC signature' for each cell line was also found, that is, transcripts that were specifically UV regulated depending on the DNA repair status of the cell. These results provide a detailed portrait of expression profiles that may potentially unravel the causes of the different phenotypes of XP/CS and TTD patients. Published online 20 December 2004.	Inst Gustave Roussy, CNRS, UPR2169, Lab Genet Instabil & Canc, F-94805 Villejuif, France; Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, BR-05508900 Sao Paulo, Brazil; CEA, DRR, DSV, SEGG,Dept Radiobiol & Radiopathol, F-92625 Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Universidade de Sao Paulo; CEA	Sarasin, A (corresponding author), Inst Gustave Roussy, CNRS, UPR2169, Lab Genet Instabil & Canc, Rue Camille Desmoulins, F-94805 Villejuif, France.	sarasin@igr.fr	Costa, Renata/G-4248-2012; Menck, Carlos FM/G-6321-2011	Costa, Renata/0000-0002-9196-6462; Menck, Carlos FM/0000-0003-1941-0694; RIOU, Lydia/0000-0002-3878-7844				Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; Chen BS, 2002, CURR BIOL, V12, pR620, DOI 10.1016/S0960-9822(02)01134-X; Claverie JM, 1999, HUM MOL GENET, V8, P1821, DOI 10.1093/hmg/8.10.1821; Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017; Durante W, 2003, J CELL PHYSIOL, V195, P373, DOI 10.1002/jcp.10274; Ehrhart JC, 2003, PHOTOCH PHOTOBIO SCI, V2, P825, DOI 10.1039/b302281a; Ena P, 2003, CLIN EXP DERMATOL, V28, P493, DOI 10.1046/j.1365-2230.2003.01335.x; Gallego MP, 2003, BIOCHIMIE, V85, P1073, DOI 10.1016/j.biochi.2003.11.005; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Gentile M, 2003, NUCLEIC ACIDS RES, V31, P4779, DOI 10.1093/nar/gkg675; Gross SR, 2003, J INVEST DERMATOL, V121, P412, DOI 10.1046/j.1523-1747.2003.12353.x; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Haroon ZA, 1999, LAB INVEST, V79, P1679; Houseweart MK, 2003, CELL DEATH DIFFER, V10, P1329, DOI 10.1038/sj.cdd.4401309; Itin PH, 2001, J AM ACAD DERMATOL, V44, P891, DOI 10.1067/mjd.2001.114294; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; Kyng KJ, 2003, ONCOGENE, V22, P1135, DOI 10.1038/sj.onc.1206187; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Riou L, 1999, HUM MOL GENET, V8, P1125, DOI 10.1093/hmg/8.6.1125; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Stary A, 1996, CANCER SURV, V26, P155; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vaughan ATM, 2002, APOPTOSIS, V7, P173, DOI 10.1023/A:1014374717773; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yoshida Y, 2003, MECH DEVELOP, V120, P629, DOI 10.1016/S0925-4773(03)00020-0; Younes A, 2003, CANCER-AM CANCER SOC, V98, P458, DOI 10.1002/cncr.11524	38	28	28	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1359	1374		10.1038/sj.onc.1208288	http://dx.doi.org/10.1038/sj.onc.1208288			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608684				2022-12-17	WOS:000227092600006
J	Hentges, KE; Weiser, KC; Schountz, T; Woodward, LS; Morse, HC; Justice, MJ				Hentges, KE; Weiser, KC; Schountz, T; Woodward, LS; Morse, HC; Justice, MJ			Evi3, a zinc-finger protein related to EBFAZ, regulates EBF activity in B-cell leukemia	ONCOGENE			English	Article						Evi3; EBF; Pax-5; mb-1; B29; B-cell leukemia	ANTIGEN RECEPTOR; FUNCTIONAL-CHARACTERIZATION; RETROVIRAL INTEGRATION; LYMPHOCYTE DEVELOPMENT; TARGET GENES; MOUSE; CD19; IDENTIFICATION; CLONING; TRANSCRIPTION	Retroviral insertions that activate proto-oncogenes are a primary cause of tumors in certain strains of mice. The AKXD recombinant inbred mice are predisposed to a variety of leukemias and lymphomas as a result of viral integration. One common insertion site, the ecotropic viral insertion site 3 ( Evi3), has been implicated in most B-cell tumors in the AKXD-27 strain. The Evi3 gene encodes a zinc-finger protein with sequence similarity to the Early B-cell Factor-Associated Zinc-finger gene (EBFAZ). We show that the Evi3 gene is overexpressed in several tumors with viral insertions at Evi3, which results in the upregulation of Early B-cell Factor (EBF)-target gene expression, suggesting that Evi3 modulates EBF activity. Reconstitution of primary leukemia cells showed that these tumors express high densities of the B-cell surface proteins CD19 and CD38, which are EBF targets. Using a transactivation assay, we show that the terminal six zinc-fingers of Evi3 are required for modi. cation of EBF activity. This is the first evidence that Evi3 expression in tumors alters the level of EBF target genes, and the first characterization of the Evi3 protein domains required for modulation of EBF activity. Further, these data imply that Evi3 misexpression initiates tumorigenesis by perturbing B-cell development via an interaction with EBF.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Interdepartmental Program Cell & Mol Biol, Houston, TX 77030 USA; NIAID, Immunopathol Lab, NIH, Rockville, MD USA	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Room S413,1 Baylor Plaza, Houston, TX 77030 USA.	mjustice@bcm.tmc.edu	Schountz, Tony/I-2161-2017	Hentges, Kathryn/0000-0001-8917-3765; Morse, Herbert/0000-0002-9331-3705	NCI NIH HHS [R01 CA63229] Funding Source: Medline; NICHD NIH HHS [F32 HD42436] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD042436] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA063229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akerblad P, 1999, MOL CELL BIOL, V19, P392; Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; Bond HM, 2004, BLOOD, V103, P2062, DOI 10.1182/blood-2003-07-2388; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; Donis-Hernandez FR, 2001, EUR J IMMUNOL, V31, P1261, DOI 10.1002/1521-4141(200104)31:4<1261::AID-IMMU1261>3.0.CO;2-H; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; Gisler R, 2000, BLOOD, V96, P1457, DOI 10.1182/blood.V96.4.1457.h8001457_1457_1464; Gisler R, 1999, MOL IMMUNOL, V36, P1067, DOI 10.1016/S0161-5890(99)00092-9; Greenbaum S, 2002, SEMIN IMMUNOL, V14, P405, DOI 10.1016/S1044532302000751; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; Hase H, 2004, BLOOD, V103, P2257, DOI 10.1182/blood-2003-08-2694; Hasegawa M, 2001, J IMMUNOL, V167, P3190, DOI 10.4049/jimmunol.167.6.3190; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; JUSTICE MJ, 1994, J VIROL, V68, P1293, DOI 10.1128/JVI.68.3.1293-1300.1994; KRONENBERG M, 1985, NATURE, V313, P647, DOI 10.1038/313647a0; Lund FE, 1999, J IMMUNOL, V162, P2693; Lund FE, 1996, J IMMUNOL, V157, P1455; Maier H, 2002, SEMIN IMMUNOL, V14, P415, DOI 10.1016/S1044532302000763; MUCENSKI ML, 1988, J VIROL, V62, P839, DOI 10.1128/JVI.62.3.839-846.1988; MUCENSKI ML, 1987, ONCOGENE RES, V2, P33; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Schountz T, 1996, J IMMUNOL, V157, P3893; Shim S, 2002, NUCLEIC ACIDS RES, V30, P3107, DOI 10.1093/nar/gkf437; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Sigvardsson M, 2002, MOL CELL BIOL, V22, P8539, DOI 10.1128/MCB.22.24.8539-8551.2002; Smith EMK, 2002, J IMMUNOL, V169, P261, DOI 10.4049/jimmunol.169.1.261; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Wang SS, 1997, J NEUROSCI, V17, P4149; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652; Xu YK, 2002, J IMMUNOL, V169, P6910, DOI 10.4049/jimmunol.169.12.6910; ZHOU LJ, 1991, J IMMUNOL, V147, P1424	39	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1220	1230		10.1038/sj.onc.1208243	http://dx.doi.org/10.1038/sj.onc.1208243			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580294				2022-12-17	WOS:000226898700009
J	Delgado, JP; Parouchev, A; Allain, JE; Pennarun, L; Gauthier, LR; Dutrillaux, AM; Dutrillaux, B; Di Santo, J; Capron, F; Boussin, FD; Weber, A				Delgado, JP; Parouchev, A; Allain, JE; Pennarun, L; Gauthier, LR; Dutrillaux, AM; Dutrillaux, B; Di Santo, J; Capron, F; Boussin, FD; Weber, A			Long-term controlled immortalization of a primate hepatic progenitor cell line after Simian virus 40 T-Antigen gene transfer	ONCOGENE			English	Article						hepatic progenitors; primate; immortalization	IN-VITRO; TELOMERASE ACTIVITY; LIVER-REGENERATION; EPITHELIAL-CELLS; STEM-CELLS; EXPRESSION; GROWTH; TRANSFORMATION; MODEL; RATS	Hepatoblasts are bipotent progenitors of both hepatocytes and cholangiocytes. The lack of stable in vitro culture systems for such cells makes it necessary to generate liver progenitor cell lines by means of immortalization. In this study, we describe the long-term behaviour of a clone of simian foetal hepatic progenitor cells immortalized by Simian virus 40 (SV40) large T-antigen (T-Ag) flanked by loxP sites. Immortalization was associated with the reexpression of telomerase activity, which decreased at late passages ( population doubling 120) after more than a year in culture. This decrease was concomitant to telomere shortening and karyotypic instability. However, the chromosomes carrying the p53 gene remained intact and long-term immortalized progenitor cells maintained contact inhibition and proliferative properties. They also displayed the features of a normal bipotent phenotype. We constructed a retroviral vector expressing an inducible Cre recombinase and transferred it into the immortalized progenitors. Activation of the Cre recombinase by 4-hydroxy-tamoxifen induced SV40 T-Ag excision, leading to the death of cells expressing Cre recombinase. Immortalized progenitors at late passages stopped growing and eventually disappeared after transplantation into the livers of immunocompromised mice. These cells provide a novel model to study hepatic differentiation and carcinogenesis.	Univ Paris 11, Hop Kremlin Bicetre, INSERM, EMI 0020, F-94276 Le Kremlin Bicetre, France; CEA, DSV DRR, Lab Radiopathol, F-92265 Fontenay Aux Roses, France; Inst Curie, CNRS, Lab Instabil Genome & Canc, F-75005 Paris, France; Inst Pasteur, INSERM, EPI 0101, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Weber, A (corresponding author), Univ Paris 11, Hop Kremlin Bicetre, INSERM, EMI 0020, 80 Ave Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	anne.weber@kb.inserm.fr	Di Santo, James P/M-4298-2014; Delgado, jean Paul/B-6325-2009; Gauthier, Laurent/ABC-7614-2021	Di Santo, James P/0000-0002-7146-1862; Gauthier, Laurent/0000-0003-4644-7660; Boussin, francois/0000-0003-3778-4403; Pennarun, Gaelle/0000-0001-9881-9345				Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Allain JE, 2002, P NATL ACAD SCI USA, V99, P3639, DOI 10.1073/pnas.062038599; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1998, CIBA F SYMP, V211, P160; BLUMRICH M, 1994, EUR J CELL BIOL, V64, P339; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Colucci F, 1999, J IMMUNOL, V162, P2761; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dabeva MD, 1998, CANCER RES, V58, P5825; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; DUTRILLAUX B, 1979, CYTOGENET CELL GENET, V23, P77, DOI 10.1159/000131305; Dutrillaux B, 1981, PRATIQUE ANAL CHROMO; Erez N, 2004, EXP CELL RES, V294, P366, DOI 10.1016/j.yexcr.2003.11.033; Grompe M, 1999, SEMIN LIVER DIS, V19, P7, DOI 10.1055/s-2007-1007093; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; HOFFSCHIR F, 1988, CYTOGENET CELL GENET, V49, P264, DOI 10.1159/000132674; Hultdin M, 1998, NUCLEIC ACIDS RES, V26, P3651, DOI 10.1093/nar/26.16.3651; Kakuo S, 1999, BIOCHEM BIOPH RES CO, V263, P308, DOI 10.1006/bbrc.1999.1385; Kim BH, 2000, EXP MOL MED, V32, P29, DOI 10.1038/emm.2000.6; Kobayashi N, 2000, SCIENCE, V287, P1258, DOI 10.1126/science.287.5456.1258; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Laconi S, 2001, AM J PATHOL, V158, P771, DOI 10.1016/S0002-9440(10)64019-9; Laconi S, 1999, J HEPATOL, V31, P1069, DOI 10.1016/S0168-8278(99)80320-1; Leblanc V, 2002, M S-MED SCI, V18, P577, DOI 10.1051/medsci/2002185577; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; Mahieu-Caputo D, 2004, HUM GENE THER, V15, P1219, DOI 10.1089/hum.2004.15.1219; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Pani P, 1999, J HEPATOL, V31, P354, DOI 10.1016/S0168-8278(99)80235-9; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Pommier JP, 1997, VIROLOGY, V231, P148, DOI 10.1006/viro.1997.8512; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Shimizu Y, 2003, MECH AGEING DEV, V124, P237, DOI 10.1016/S0047-6374(02)00186-0; STEENSEL B, 1997, NATURE, V385, P740; Steinert S, 2002, EXP CELL RES, V272, P146, DOI 10.1006/excr.2001.5409; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Thomas D, 2003, EUR J CANCER, V39, P2200, DOI 10.1016/S0959-8049(03)00618-X; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; Vallier L, 2001, P NATL ACAD SCI USA, V98, P2467, DOI 10.1073/pnas.041617198; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WOODWORTH CD, 1988, MOL CELL BIOL, V8, P4492, DOI 10.1128/MCB.8.10.4492; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	54	28	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					541	551		10.1038/sj.onc.1208089	http://dx.doi.org/10.1038/sj.onc.1208089			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15608689				2022-12-17	WOS:000226420400002
J	Li, J; Sahagian, GG				Li, J; Sahagian, GG			Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor	ONCOGENE			English	Article						breast cancer; apoptosis; lysosomal trafficking; TGF-beta; uPAR; retinoic acid	GROWTH-FACTOR-II; SQUAMOUS-CELL CARCINOMA; LYSINE-BASED STRUCTURE; MOUSE MAMMARY-TUMOR; BREAST-CANCER CELLS; TGF-BETA-RII; 6-PHOSPHATE RECEPTOR; IN-VIVO; TRANSFORMING GROWTH-FACTOR-BETA-1; MICROSATELLITE INSTABILITY	The mannose 6-phosphate/IGF-2 receptor has been proposed to be a tumor suppressor gene on the basis of loss of heterozygosity and mutations in tumors from cancer patients. To test this hypothesis, the receptor was expressed in 66cl4, a mouse mammary tumor cell line deficient in the receptor. Expression of the receptor corrected the abnormal lysosomal trafficking phenotype displayed by these cells. Receptor expression had no apparent effect on growth or invasiveness of the cells in vitro but effectively inhibited formation of mammary tumors in BALB/c mice. Analysis of cell proliferation and apoptosis in tumors indicated that the primary effect of the receptor was to inhibit cell proliferation. Proliferation indices for receptor-deficient and receptor-expressing tumors, as determined by BrdU incorporation, were 24.6 and 7.6%, respectively. No significant effect of receptor expression on apoptosis was observed. Receptor expression similarly inhibited tumor growth in BALB/c scid mice indicating that cytotoxic T cells and other components of the immune system missing in scid mice are not involved in the receptor's tumor suppressing effect. These findings establish a role for the receptor as a bona. de tumor suppressor gene and together with previous studies, suggest an important role for the receptor in human and rodent cancers.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Sahagian, GG (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	gary.sahagian@tufts.edu			NCI NIH HHS [R01-CA66575] Funding Source: Medline; NIDDK NIH HHS [P30DK34928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Beck S, 2002, PROTEOMICS, V2, P247, DOI 10.1002/1615-9861(200203)2:3<247::AID-PROT247>3.0.CO;2-K; BRAULKE T, 1988, BIOCHEM BIOPH RES CO, V150, P1287, DOI 10.1016/0006-291X(88)90769-3; Caligo MA, 2000, ONCOL REP, V7, P1371; Calin GA, 2000, INT J CANCER, V89, P230, DOI 10.1002/1097-0215(20000520)89:3<230::AID-IJC4>3.0.CO;2-J; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; Chen ZH, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-18; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DOLE M, 1994, CANCER RES, V54, P3253; FILSON AJ, 1993, DEVELOPMENT, V118, P731; Gamma A, 2000, LUNG CANCER-J IASLC, V30, P91, DOI 10.1016/S0169-5002(00)00130-6; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Ghahary A, 1999, J CELL PHYSIOL, V180, P61, DOI 10.1002/(SICI)1097-4652(199907)180:1<61::AID-JCP7>3.0.CO;2-R; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Hale AJ, 1996, EUR J BIOCHEM, V237, P884; Hankins GR, 1996, ONCOGENE, V12, P2003; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; Jamieson TA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-4; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Kang JX, 1999, CELL GROWTH DIFFER, V10, P591; KIESS W, 1988, J BIOL CHEM, V263, P9339; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; Leboulleux S, 2001, EUR J ENDOCRINOL, V144, P163, DOI 10.1530/eje.0.1440163; Lee JS, 2003, INT J CANCER, V107, P564, DOI 10.1002/ijc.11453; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P7523; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; McKinnon T, 2001, J CLIN ENDOCR METAB, V86, P3665, DOI 10.1210/jc.86.8.3665; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; O'Gorman DB, 1999, CANCER RES, V59, P5692; O'Gorman DB, 2002, ENDOCRINOLOGY, V143, P4287, DOI 10.1210/en.2002-220548; Oka Y, 2002, HEPATOLOGY, V35, P1153, DOI 10.1053/jhep.2002.32669; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; SAHAGIAN GG, 1981, P NATL ACAD SCI-BIOL, V78, P4289, DOI 10.1073/pnas.78.7.4289; Seitz S, 2003, GENE CHROMOSOME CANC, V37, P29, DOI 10.1002/gcc.10196; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Tao K, 2001, INT J ONCOL, V19, P1333; TONG PY, 1988, J BIOL CHEM, V263, P2585; Wang SN, 1997, CANCER RES, V57, P2543; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; Zavras AI, 2003, CANCER RES, V63, P296	47	28	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9359	9368		10.1038/sj.onc.1208039	http://dx.doi.org/10.1038/sj.onc.1208039			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543235				2022-12-17	WOS:000225764100007
J	Joers, A; Jaks, V; Kase, J; Maimets, T				Joers, A; Jaks, V; Kase, J; Maimets, T			p53-dependent transcription can exhibit both on/off and graded response after genotoxic stress	ONCOGENE			English	Article						p53; transcription; DNA damage; GFP; flow cytometry	P53 PROTEIN; GENE-EXPRESSION; ACTIVATION; APOPTOSIS; MDM-2; TRANSACTIVATION; PARTICIPATION; ACCUMULATION; DEFICIENT; MEDIATOR	The p53 protein is a central player in cellular response to DNA damage. Induction of p53 by DNA-damaging agents involves elevation of its steady-state level and activation of its potency as a transcription factor. In the cell population, these responses can occur either homogeneously (where every single cell responds simultaneously and similarly to its neighbor) or heterogeneously (where only some cells of a population respond and the number of these increases with increasing dose of inducer). We have studied here the p53 response to DNA-damaging agents (camptothecin, mitomycin C) in individual cells. We show that the level of p53 protein is increased in every single cell of the population homogeneously, while the p53-dependent transcription can be subject to an on/off-type response. Depending on the structure of the target promoter, p53-dependent transcription can be regulated according to the binary or graded model. The on/off-type transcriptional activation pattern of p53 defines two distinct subpopulations of cells after DNA damage.	Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia; Estonian Bioctr, EE-51010 Tartu, Estonia	University of Tartu; Estonian Biocentre	Joers, A (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, Riia 23, EE-51010 Tartu, Estonia.	ajoers@ebc.ee	Jaks, Viljar/H-2467-2012; Maimets, Toivo/E-9268-2017	Jaks, Viljar/0000-0002-2221-6262; Maimets, Toivo/0000-0001-6461-3365; Roostalu, Johanna/0000-0002-6757-0468; Joers, Arvi/0000-0003-2083-3977				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Biggar SR, 2001, EMBO J, V20, P3167, DOI 10.1093/emboj/20.12.3167; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; de Krom M, 2002, MOL CELL, V9, P1319, DOI 10.1016/S1097-2765(02)00558-0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Graubert TA, 1998, NUCLEIC ACIDS RES, V26, P2849, DOI 10.1093/nar/26.12.2849; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rossi FMV, 2000, MOL CELL, V6, P723, DOI 10.1016/S1097-2765(00)00070-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	40	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6175	6185		10.1038/sj.onc.1207864	http://dx.doi.org/10.1038/sj.onc.1207864			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208667				2022-12-17	WOS:000223399000001
J	Carnero, A; Beach, DH				Carnero, A; Beach, DH			Absence of p21(WAF1) cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation	ONCOGENE			English	Article						oncogenic cooperation; c-myc; ras; waf1; PI3k	SKIN CARCINOGENESIS; EMBRYO FIBROBLASTS; TUMOR SUPPRESSION; TRANSGENIC MICE; ACTIVATED RAS; HA-RAS; P53; TRANSFORMATION; APOPTOSIS; CELLS	The absence of p21(waf1) combined with an ectopic expression of c-myc prevents ras-induced senescence in mouse embryo fibroblasts. Extension of lifespan after c-myc transduction into p21-null cells was followed at later passages by apoptosis of a large fraction of c-myc-overexpressing p21-null cells. This apoptotic effect could be overridden by inactivation of the p53 tumor suppressor or oncogenic Pas expression. Ras-induced inhibition of apoptosis is mediated by PI3K activation. These results suggest a functional relationship between Pas and myc that may explain their oncogenic cooperation. The number of foci formed by myc + Pas increased cooperatively in the absence of p21(waf1). Thus, the reciprocal cooperation between myc and ras in a p21-null background during cellular immortalization lead to increased oncogenic cooperation between Pas and myc.	CNIO, Expt Therapeut Programme, Madrid, Spain; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	Centro Nacional de Investigaciones Oncologicas (CNIO); University of London; University College London	Carnero, A (corresponding author), CNIO, Expt Therapeut Programme, Madrid, Spain.	acarnero@cnio.es	IBIS, CANCER/P-3323-2015	Carnero, Amancio/0000-0003-4357-3979				Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; HARVEY M, 1993, ONCOGENE, V8, P2457; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LANGDON WY, 1989, ONCOGENE RES, V4, P253; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Michieli P, 1996, ONCOGENE, V12, P775; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tsuneoka M, 2000, ONCOGENE, V19, P115, DOI 10.1038/sj.onc.1203232; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WEINBERG RA, 1989, CANCER RES, V49, P3713; Weinberg WC, 1999, CANCER RES, V59, P2050; WEINBERG WC, 1995, ONCOGENE, V10, P2271; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	42	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					6006	6011		10.1038/sj.onc.1207839	http://dx.doi.org/10.1038/sj.onc.1207839			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15195145				2022-12-17	WOS:000222941100016
J	Mishra, SK; Yang, ZB; Mazumdar, A; Talukder, AH; Larose, L; Kumar, R				Mishra, SK; Yang, ZB; Mazumdar, A; Talukder, AH; Larose, L; Kumar, R			Metastatic tumor antigen 1 short form (MTA1s) associates with casein kinase I-gamma 2, an estrogen-responsive kinase	ONCOGENE			English	Article						metastasis-associated protein-1 short form; casein kinase I-gamma 2; estrogen response element	PROTEIN-KINASE; BETA-CATENIN; RECEPTOR-ALPHA; I EPSILON; PHOSPHORYLATION; EXPRESSION; COMPLEX; CLONING; FAMILY; NURD	Recent studies have shown that metastasis-associated protein-1 short form (MTA1s) - metastatic tumor antigen 1 short form sequesters estrogen receptor-alpha (ER-alpha) in the cytoplasm of breast cancer cells. Using a yeast two-hybrid screening to clone MTA1s-interacting proteins, we identified casein kinase I-gamma 2 (CKI-gamma2, a ubiquitously expressed cytoplasmic kinase) as an MTA1s-binding protein. We show that MTA1s interacts with CKI-gamma2 both in vitro and in vivo and colocalizes in the cytoplasm. In addition, we found that CKI-gamma2 can phosphorylate MTA1s, but not ER, in an antiestrogen-dependent manner and that estrogen stimulates CKI-gamma2 activity that could be effectively blocked by a specific inhibitor of CKI. CKI-gamma2 could further potentiate the ER corepressive function of MTA1s. Kinase dead CK1-gamma2 could not repress estrogen-induced ER transactivation functions. Results from mutagenesis studies suggest that substitution of the serine residue at 321 to alanine, which is a possible CKI-gamma2 phopshorylation site in MTA1s, results in a significant reduction in the ability of MTA1s to repress ER transactivation. These findings identified MTA1s as a target of CKI-gamma2, and provided new evidence to suggest that CKI-gamma2 phosphorylates and modulates the functions of MTA1s, and that these extranuclear effects of estrogen might have important implications in regulating the functions of MTA1s in human mammary epithelial and cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2B2, Canada	University of Texas System; UTMD Anderson Cancer Center; McGill University	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol 108, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org		Mishra, Sandip/0000-0002-0776-6581	NCI NIH HHS [CA90970, CA098823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098823, R01CA090970] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; Bioukar EB, 1999, J BIOL CHEM, V274, P21457, DOI 10.1074/jbc.274.30.21457; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; DAHMUS ME, 1981, J BIOL CHEM, V256, P1239; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Dubois T, 2001, J BIOL CHEM, V276, P18757, DOI 10.1074/jbc.M010005200; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Kitabayashi AN, 1997, GENOMICS, V46, P133, DOI 10.1006/geno.1997.4991; Kleene R, 1999, J CELL SCI, V112, P2539; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; Kreegipuu A, 1998, FEBS LETT, V430, P45, DOI 10.1016/S0014-5793(98)00503-1; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Kumar R, 2003, CELL, V113, P142, DOI 10.1016/S0092-8674(03)00274-5; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; SIMKOWSKI KW, 1980, J BIOL CHEM, V255, P6456; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tzeng DZ, 1996, BIOCHEM BIOPH RES CO, V223, P554, DOI 10.1006/bbrc.1996.0933; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	34	28	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4422	4429		10.1038/sj.onc.1207569	http://dx.doi.org/10.1038/sj.onc.1207569			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15077195				2022-12-17	WOS:000221661300008
J	Coupier, I; Baldeyron, U; Rousseau, A; Mosseri, V; Pages-Berhouet, S; Caux-Moncoutier, V; Papadopoulo, D; Stoppa-Lyonnet, D				Coupier, I; Baldeyron, U; Rousseau, A; Mosseri, V; Pages-Berhouet, S; Caux-Moncoutier, V; Papadopoulo, D; Stoppa-Lyonnet, D			Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations	ONCOGENE			English	Article						BRCA1 heterozygous carriers; missense mutation; DNA end-joining; double-strand break repair	OVARIAN-CANCER FAMILIES; DAMAGE RESPONSE; GENE; SUSCEPTIBILITY; REARRANGEMENTS; ASSOCIATION; RAD51; RISK	Germ-line mutations of the BRCA1 and BRCA2 genes, when they lead to a truncated protein, confer a high risk of breast and ovarian cancer. However, the role of BRCA1 missense mutations in cancer predisposition is unclear. Functional assays may be very helpful to more clearly define the biological effect of these mutations, and could therefore be useful in clinical practice. A recent study using a Host Cell End-Joining assay showed that a truncating mutation results in impaired fidelity of DSB repair by DNA end-joining. In the present study, we examined the fidelity of DSB repair in four lymphoblastoid cell lines with BRCA1 missense mutations. The fidelity of DNA end-joining was impaired in the four cell lines studied compared to the normal control cell line. The fidelity of end-joining was similar to that of a truncated mutation control cell line for one cell line and slightly higher for the other cell lines.	Inst Curie, Serv Genet Oncol, Med Sect, F-75248 Paris 05, France; Inst Curie, INSERM, U509, Sect Rech, Paris, France; Inst Curie, CNRS, UMR 218, Sect Rech, F-75231 Paris, France; Inst Curie, Serv Biostat, Med Sect, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Stoppa-Lyonnet, D (corresponding author), Inst Curie, Serv Genet Oncol, Med Sect, 26 Rue Ulm, F-75248 Paris 05, France.	dominique.stoppa-lyonnet@curie.net	Baldeyron, Céline/F-6990-2019	Baldeyron, Céline/0000-0003-2311-1523				Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; Casilli F, 2002, HUM MUTAT, V20, P218, DOI 10.1002/humu.10108; Chen JJ, 1999, CANCER RES, V59, p1752S; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; Fleming MA, 2003, P NATL ACAD SCI USA, V100, P1151, DOI 10.1073/pnas.0237285100; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Gad S, 2002, ONCOGENE, V21, P6841, DOI 10.1038/sj.onc.1205685; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Roberts SA, 1999, AM J HUM GENET, V65, P784, DOI 10.1086/302544; Rothfuss A, 2000, CANCER RES, V60, P390; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wagner T, 1999, GENOMICS, V62, P369, DOI 10.1006/geno.1999.6026; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	26	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					914	919		10.1038/sj.onc.1207191	http://dx.doi.org/10.1038/sj.onc.1207191			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647443				2022-12-17	WOS:000188486600006
J	Wright, KO; Messing, EM; Reeder, JE				Wright, KO; Messing, EM; Reeder, JE			DBCCR1 mediates death in cultured bladder tumor cells	ONCOGENE			English	Article						bladder neoplasm; DBCCR1; tumor suppressor gene; chromosme 9	HOMOZYGOUS DELETION; SUPPRESSOR REGION; CANCER; 9Q32-33; GENE; DEFINITION; EXPRESSION; CARCINOMA; GROWTH; LOCUS	Chromosome 9, which is often partially or fully reduced to homozygosity in bladder cancer cells, harbors several tumor suppressor loci including deleted in bladder cancer chromosome region 1 (DBCCR1) at 9q32-33. To study DBCCR1 function, stable cell lines, inducible for DBCCR1 expression by tetracycline, were made, but the DBCCR1 protein was not expressed at detectable levels. To understand the fate of DBCCR1-expressing cells, human bladder tumor cells were transiently transfected with an expression vector containing DBCCR1 fused to enhanced green fluorescent protein (EGFP). Initially, DBCCR1-expressing cells demonstrated diffuse cytoplasmic green fluorescence with nuclear exclusion patterns. After time, the intensity level of green fluorescence increased and a granular distribution of protein became visible in the cells. At this point, cells rounded up and detached from the tissue culture dish. Cells transfected with a control vector, containing only EGFP, and partial DBCCR1-EGFP fusion constructs did not demonstrate this behavior. DBCCR1-mediated cell death in cultured tumor cells was independent of caspase-3 activation and did not result in detectable DNA strand breaks by TUNEL staining that are hallmarks of the classical apoptotic pathway.	Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, Rochester, NY USA	University of Rochester; University of Rochester	Reeder, JE (corresponding author), Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA.	Jay_Reeder@urmc.patholo-gy.rochester.edu		Reeder, Jay/0000-0002-7125-6893	NCI NIH HHS [CA33148-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1993, ONCOGENE, V8, P1083; COMPTON M, 1992, CANCER METAST REV, V2, P105; CREAGH E, 2001, BIOCH SOC T, V29; DEVLIN J, 1994, ONCOGENE, V9, P2757; Easton RM, 1997, J NEUROSCI, V17, P9656; Fujiwara H, 2001, J HUM GENET, V46, P372, DOI 10.1007/s100380170056; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122; Howard CM, 2000, CANCER RES, V60, P2737; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; KEEN AJ, 1994, ONCOGENE, V9, P2083; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li WW, 1997, CANCER RES, V57, P2193; MICKEY D, 1982, J UROLOGY, V27, P23307; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Nishiyama H, 2001, ONCOGENE, V20, P2956, DOI 10.1038/sj.onc.1204432; RUPPERT JM, 1993, CANCER RES, V53, P5093; Sowden MP, 1998, NUCLEIC ACIDS RES, V26, P1644, DOI 10.1093/nar/26.7.1644; Stadler WM, 2001, CLIN CANCER RES, V7, P1676; Tang Dean G, 1996, Pathol Oncol Res, V2, P117; Weng LP, 1999, CANCER RES, V59, P5808	25	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					82	90		10.1038/sj.onc.1206642	http://dx.doi.org/10.1038/sj.onc.1206642			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712213				2022-12-17	WOS:000187895300009
J	Wu, MC; Ho, SM				Wu, MC; Ho, SM			PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model	ONCOGENE			English	Article						peroxisome; androgen independency; prostate neoplasm; epigenetic regulation of gene expression; 5-aza-2 '-deoxycytidine; bisulfite genomic sequencing	HUMAN PROSTATE-CANCER; ARBITRARILY PRIMED-PCR; HUMAN TUMOR-CELLS; CPG ISLAND; METHYLATION DIFFERENCES; EPIGENETIC REGULATION; EPITHELIAL-CELLS; MEMBRANE-PROTEIN; SUPPRESSOR GENE; RECEPTOR GENE	Transcriptional silencing of antitumor genes via CpG island methylation could be a mechanism mediating prostate cancer (PCa) progression from an androgen-sensitive (AS) to an androgen-insensitive (AI) state. We have used the (m) under bar ethylation-(s) under bar ensitive (r) under bar estriction (f) under bar ingerprinting (MSRF) technique to identify novel CpG-rich sequences that are differentially methylated between the genome of the AS PCa cell line LNCaP and that of an AI subline LNCaPCS generated by maintaining LNCaP in medium with charcoal-stripped (CS) serum for over 30 passages. One such sequence identified was located on a 5' CpG island that was found to span part of the promoter, exon 1, and part of intron 1 of the (p) under bar eroxisomal (m) under bar embrane (p) under bar rotein 24 kDa (PMP24) gene. Using semiquantitative RT-PCR and bisulfite genomic sequencing, we established an inverse relationship between mRNA expression and methylation of the 5' CpG island of PMP24. PMP24 mRNA was absent in LNCaPCS and the androgen receptor-negative PC-3 cell line; both exhibited dense methylation in the said CpG island. In contrast, PMP24 mRNA was expressed in LNCaP and normal prostatic epithelial cells (NPrECs) whose PMP24 5' CpG island remained unmethylated. Treatment of LNCaPCS and PC-3 with the demethylating agent 5-aza-2'-deoxycytidine (5-AZAdC) reactivated PMP24 mRNA expression. Transient transfection of PMP24 into LNCaPCS and PC-3 cells induced a significant reduction in cell growth and soft-agar colony formation potential, suggesting that PMP24 gene product has antitumor properties. These results demonstrate the utility of MSRF in the identification of novel, differentially methylated DNA sequences in the genome and suggest that hypermethylation-mediated silencing of PMP24 is an epigenetic event involved in PCa progression to androgen independence.	Univ Massachusetts, Sch Med, Dept Surg, Div Urol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Interdisciplinary Grad Program, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Div Urol, Rm 504,Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	Shuk-Mei.Ho@umassmed.edu			NCI NIH HHS [CA94221, CA62269] Funding Source: Medline; NIDDK NIH HHS [DK61084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094221, R01CA062269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BRYANT DD, 1995, BIOCHEM MOL MED, V55, P22, DOI 10.1006/bmme.1995.1027; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Davies Catherine S, 2002, Methods Mol Biol, V200, P43; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; El Yaagoubi M, 1998, BIOCHEM MOL BIOL INT, V46, P321; Esteller M, 2000, CANCER RES, V60, P129; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1997, CANCER RES, V57, P594; GRAFF JR, 1995, CANCER RES, V55, P5195; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; HAYATSU H, 1970, J AM CHEM SOC, V92, P724, DOI 10.1021/ja00706a062; Huang THM, 1997, CANCER RES, V57, P1030; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jarrard DF, 1997, CLIN CANCER RES, V3, P2121; Jarrard DF, 1998, CANCER RES, V58, P5310; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; Johnson TL, 2001, PLANT PHYSIOL, V127, P731, DOI 10.1104/pp.010262; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kibel AS, 2001, PROSTATE, V48, P248, DOI 10.1002/pros.1104; Kohno T, 1998, HUM GENET, V102, P258, DOI 10.1007/s004390050689; Kuzmin I, 2002, CANCER RES, V62, P3498; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lau KM, 2000, CANCER RES, V60, P3175; Lauer C, 1999, CARCINOGENESIS, V20, P985, DOI 10.1093/carcin/20.6.985; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; Liang GG, 2002, METHODS, V27, P150, DOI 10.1016/S1046-2023(02)00068-3; Liang GN, 2000, CANCER RES, V60, P4907; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Lou W, 1999, CANCER RES, V59, P2329; MARSHALL KG, 1995, JAMA-J AM MED ASSOC, V274, P607, DOI 10.1001/jama.1995.03530080023020; Masters C, 1998, MOL CELL BIOCHEM, V187, P85, DOI 10.1023/A:1006863123068; Mobley JA, 2003, CANCER EPIDEM BIOMAR, V12, P775; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190; Nelson JB, 1997, CANCER RES, V57, P35; Newling DWW, 1996, EUR UROL, V29, P69; Reguenga C, 1999, BBA-GENE STRUCT EXPR, V1445, P337, DOI 10.1016/S0167-4781(99)00061-5; Robbins SE, 1996, PROSTATE, V29, P362; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; SALMON SE, 1978, NEW ENGL J MED, V298, P1321, DOI 10.1056/NEJM197806152982401; SCHER HI, 1995, UROLOGY, V46, P142, DOI 10.1016/S0090-4295(99)80182-4; Schmitt JF, 2002, MOL ENDOCRINOL, V16, P213, DOI 10.1210/me.16.2.213; Singal R, 2001, CANCER RES, V61, P4820; Singh S, 2003, CANCER RES, V63, P2306; Syed V, 2001, CANCER RES, V61, P6768; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Taplin ME, 2001, J CLIN ENDOCR METAB, V86, P3467, DOI 10.1210/jc.86.8.3467; Tekur S, 2001, MOL CARCINOGEN, V30, P1, DOI 10.1002/1098-2744(200101)30:1<1::AID-MC1008>3.0.CO;2-X; Toyota M, 1999, CANCER RES, V59, P2307; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Verkaik NS, 1999, INT J CANCER, V80, P439; WANG RYH, 1980, NUCLEIC ACIDS RES, V8, P4777, DOI 10.1093/nar/8.20.4777; Zheng SL, 2001, HUM GENET, V108, P430, DOI 10.1007/s004390100513	58	28	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					250	259		10.1038/sj.onc.1207076	http://dx.doi.org/10.1038/sj.onc.1207076			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712230				2022-12-17	WOS:000187895300026
J	Lefevre, G; Calipel, A; Mouriaux, F; Hecquet, C; Malecaze, F; Mascarelli, F				Lefevre, G; Calipel, A; Mouriaux, F; Hecquet, C; Malecaze, F; Mascarelli, F			Opposite long-term regulation of c-Myc and p27(Kip1)through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells	ONCOGENE			English	Article						choroidal melanoma; proliferation; Raf-1; antisense strategy	ACTIVATED PROTEIN-KINASE; UVEAL MELANOMA; UP-REGULATION; IN-VITRO; APOPTOSIS; GROWTH; CYCLE; INHIBITION; EXPRESSION; MUTATIONS	Although there is no current evidence for ras gene mutation in choroidal melanoma, there is an increasing body of evidence indicating that deregulated intracellular signalling pathways are involved in choroidal melanoma pathogenesis. The various components of the linear Raf/MEK/ERK signalling pathway have been implicated in various tumours. We therefore investigated the role of Raf-1 and the MEK/ERK module in the proliferation of human normal choroidal melanocytes (NCM) and cells from the ocular choroidal melanoma (OCM-1) cell line. OCM-1 cells proliferated four times faster than NCM. High basal activation of the MEK/ERK module was observed in unstimulated OCM-1 cells, whereas rapid and persistent activation was detected after serum stimulation, throughout the 24-h period of culture. In contrast, the activation of MEK/ERK was barely detectable in unstimulated NCM and occurred late (6 h) after the stimulation of cell proliferation. Inhibition of Raf-1 and MEK1/2 activation by pharmacological approaches and of the production of Raf-1 and ERK1/2 by antisense oligonucleotide approaches demonstrated that Raf-1 and the MEK/ERK module controlled proliferation in OCM-1 cells, but not in NCM. OCM-1 cells produced very low levels of p27(Kip1), whereas NCM produced constant, high levels of p27(Kip1). The inhibition of Raf-1 or MEK1/2 induced a large increase in p27(Kip1) in OCM-1 cells, associated with an arrest of cell proliferation. Levels of c-Myc production were high and constant in OCM-1 cells and low in NCM, in contrast to what was observed for p27(Kip1). The inhibition of both Raf-1 and MEK1/2 induced a decrease in c-Myc production and downregulated c-Myc activity by preventing c-Myc phosphorylation in OCM-1 cells. We conclude that Raf-1 and the MEK/ERK module control the production of both p27(Kip1) and c-Myc, and the activation of c-Myc for OCM-1 cell proliferation.	Inst Biomed Cordeliers, IFR58, INSERM, U450, F-75006 Paris, France; CHRU, Hop Purpan, Serv Ophtalmol, F-31000 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; CHU de Toulouse	Mascarelli, F (corresponding author), Inst Biomed Cordeliers, IFR58, INSERM, U450, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	Mouriaux, Frederic/T-1440-2019; Mascarelli, Frederic/L-8916-2018					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barry OP, 2001, J BIOL CHEM, V276, P15537, DOI 10.1074/jbc.M010847200; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHUANG CF, 1994, FEBS LETT, V346, P229, DOI 10.1016/0014-5793(94)00480-3; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; HU DN, 1993, INVEST OPHTH VIS SCI, V34, P2210; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; KANMITCHELL J, 1989, INVEST OPHTH VIS SCI, V30, P829; Kimura A, 1999, CANCER RES, V59, P5133; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; MARSHALL CJ, 1995, METHOD ENZYMOL, V255, P273; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MOOY CM, 1991, BRIT J CANCER, V64, P411, DOI 10.1038/bjc.1991.319; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mouriaux F, 1998, INVEST OPHTH VIS SCI, V39, P876; Mouriaux F, 2000, INVEST OPHTH VIS SCI, V41, P2837; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Pyrhonen S, 1998, EUR J CANCER, V34, pS27; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SOPARKER CN, 1993, INVEST OPHTH VIS SCI, V34, P2203; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev	34	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8813	8822		10.1038/sj.onc.1207099	http://dx.doi.org/10.1038/sj.onc.1207099			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654778				2022-12-17	WOS:000186982200002
J	Fassl, S; Leisser, C; Huettenbrenner, S; Maier, S; Rosenberger, G; Strasser, S; Grusch, M; Fuhrmann, G; Leuhuber, K; Polgar, D; Stani, J; Tichy, B; Nowotny, C; Krupitza, G				Fassl, S; Leisser, C; Huettenbrenner, S; Maier, S; Rosenberger, G; Strasser, S; Grusch, M; Fuhrmann, G; Leuhuber, K; Polgar, D; Stani, J; Tichy, B; Nowotny, C; Krupitza, G			Transferrin ensures survival of ovarian carcinoma cells when apoptosis is induced by TNF alpha, FasL, TRAIL, or Myc	ONCOGENE			English	Article						transferrin; apoptosis; TNF alpha; myc; survival; ovarian cancer	TUMOR-NECROSIS-FACTOR; PYRIDOXAL ISONICOTINOYL HYDRAZONE; FERRITIN HEAVY-CHAIN; C-MYC; HEMATOPOIETIC-CELLS; H-FERRITIN; RIBONUCLEOTIDE REDUCTASE; BENZAMIDE RIBOSIDE; GENE-EXPRESSION; GROWTH-FACTOR	The activation of Myc induces apoptosis of human ovarian adenocarcinoma N.1 cells when serum factors are limited. However, the downstream mechanism that is triggered by Myc is unknown. Myc-activation and treatment with the proapoptotic ligands TNFalpha, FasL, and TRAIL induced H-ferritin expression under serum-deprived conditions. H-ferritin chelates intracellular iron and also intracellular iron sequestration by deferoxamine-induced apoptosis of N.1 cells. Supplementation of serum-free medium with holo-transferrin blocked apoptosis of N.1 cells that was induced by Myc-activation or by treatment with TNFalpha, FasL, and TRAIL, whereas apotransferrin did not prevent apoptosis. This suggests that intracellular iron depletion was a trigger for apoptosis and that transferrin-bound iron rescued N.1 cells. Furthermore, apoptosis of primary human ovarian carcinoma cells, which was induced by TNFalpha, FasL, and TRAIL, was also inhibited by holotransferrin. The data suggest that Myc-activation, FasL, TNFalpha, and TRAIL disturbed cellular iron homeostasis, which triggered apoptosis of ovarian carcinoma cells and that transferrin iron ensured survival by re-establishing this homeostasis.	Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria; Univ Vienna, Inst Zool, A-1090 Vienna, Austria; Univ Vienna, Dept Obstet & Gynaecol, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Krupitza, G (corresponding author), Univ Vienna, Inst Clin Pathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Grusch, Michael/C-1183-2008	Grusch, Michael/0000-0001-5486-9340; Krupitza, Georg/0000-0003-2949-7906				Alcantara O, 2001, EXP HEMATOL, V29, P1060, DOI 10.1016/S0301-472X(01)00683-X; ASKEW DS, 1991, ONCOGENE, V6, P1915; Baik MG, 1998, INT J MOL MED, V2, P39; BARNES D, 1979, NATURE, V281, P388, DOI 10.1038/281388a0; Buss JL, 2003, BIOCHEM PHARMACOL, V65, P161, DOI 10.1016/S0006-2952(02)01512-5; Davidson MG, 1998, EXP EYE RES, V66, P207, DOI 10.1006/exer.1997.0413; Desole MS, 1998, NEUROSCI LETT, V247, P1, DOI 10.1016/S0304-3940(98)00260-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ferreira C, 2001, BLOOD, V98, P525, DOI 10.1182/blood.V98.3.525; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; Grusch M, 1999, CELL DEATH DIFFER, V6, P736, DOI 10.1038/sj.cdd.4400546; Grusch M, 2002, CELL DEATH DIFFER, V9, P169, DOI 10.1038/sj.cdd.4400937; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Honda KI, 2001, INT J MOL MED, V8, P135; Hua WH, 1995, J STEROID BIOCHEM, V55, P279, DOI 10.1016/0960-0760(95)00187-5; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawabata H, 2001, BLOOD, V98, P1949, DOI 10.1182/blood.V98.6.1949; Kawabata H, 2001, BLOOD, V98, P2714, DOI 10.1182/blood.V98.9.2714; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kovar J, 1997, PATHOBIOLOGY, V65, P61, DOI 10.1159/000164105; Kovar J, 2001, IN VITRO CELL DEV-AN, V37, P450; Krupitza G, 1998, CELL DEATH DIFFER, V5, P758, DOI 10.1038/sj.cdd.4400417; KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511; Kyriakou D, 1998, EUR J HAEMATOL, V60, P21; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; Leardi A, 1998, BRIT J HAEMATOL, V102, P746, DOI 10.1046/j.1365-2141.1998.00834.x; Lesnikov V, 2001, EXP HEMATOL, V29, P477, DOI 10.1016/S0301-472X(00)00687-1; Leung Y. M., 1993, Biological Signals, V2, P117; Lin FB, 1998, ARCH BIOCHEM BIOPHYS, V352, P51, DOI 10.1006/abbi.1998.0588; Lok CN, 1998, BIOL SIGNAL RECEPT, V7, P157; Maclean K, 2001, J CELL BIOCHEM, V82, P171, DOI 10.1002/jcb.1111; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; Pang JHS, 1996, J CLIN INVEST, V97, P2204, DOI 10.1172/JCI118661; Quirk SM, 2000, BIOL REPROD, V63, P49, DOI 10.1095/biolreprod63.1.49; Richardson DR, 1997, BLOOD, V89, P3025, DOI 10.1182/blood.V89.8.3025; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; Rosenberger G, 2000, LIFE SCI, V67, P3131, DOI 10.1016/S0024-3205(00)00901-2; ROUAULT TA, 1987, P NATL ACAD SCI USA, V84, P6335, DOI 10.1073/pnas.84.18.6335; SALMERON A, 1995, J IMMUNOL, V154, P1675; Shi YF, 1997, J IMMUNOL, V159, P5318; Simonitsch I, 1998, BRIT J CANCER, V78, P862, DOI 10.1038/bjc.1998.594; SLOTMAN BJ, 1988, ANTICANCER RES, V8, P417; Sunstrom NAS, 2000, BIOTECHNOL PROGR, V16, P698, DOI 10.1021/bp000102t; Szekeres T, 1997, CRIT REV CL LAB SCI, V34, P503, DOI 10.3109/10408369709006424; Tanaka T, 1997, BBA-MOL CELL RES, V1357, P91, DOI 10.1016/S0167-4889(97)00016-5; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; WU S, 1992, AM J OBSTET GYNECOL, V166, P997, DOI 10.1016/0002-9378(92)91379-O; WU S, 1993, CANCER RES, V53, P1939; Yuan XM, 1999, FREE RADICAL RES, V30, P221, DOI 10.1080/10715769900300241	56	28	31	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8343	8355		10.1038/sj.onc.1207047	http://dx.doi.org/10.1038/sj.onc.1207047			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614458				2022-12-17	WOS:000186541500013
J	Zhang, YJ; Finegold, MJ; Porteu, F; Kanteti, P; Wu, MX				Zhang, YJ; Finegold, MJ; Porteu, F; Kanteti, P; Wu, MX			Development of T-cell lymphomas in E mu-IEX-1 mice	ONCOGENE			English	Article						IEX-1; antiapoptosis; T-cell lymphoma; transgenic mice	IMMEDIATE-EARLY GENE; NF-KAPPA-B; P53 TUMOR-SUPPRESSOR; EARLY-RESPONSE GENE; TRANSGENIC MICE; PROTEIN EXPRESSION; IEX-1; APOPTOSIS; SURVIVAL; BCL-2	Inhibition of apoptosis or abnormal cell survival can result in tumorigenesis by facilitating the insurgence of various mutations. Immediate-early response gene X-1 (IEX-1), protects T cells from apoptosis induced by the ligation of Fas or the T-cell receptor (TCR)/CD3 complex in Emu-IEX-1 mice that direct the gene expression in both T and B cell lineages under the control of the Emu enhancer. Consistent with a biased effect of IEX-1 towards T cells, Emu-IEX-1 mice selectively developed T-cell lymphomas in the spleen, when they aged, which may be associated with increased levels of IEX-1 phosphorylation in T cells compared to B cells. The lymphomas were single positive (CD4(+)CD8(-), CD4(-)CD8(+)), double positive (CD4(+)CD8(-)), or double negative (CD4(-)CD8(-)) T cells. They resulted from aberrantly clonal expansions of T cells expressing a specific TCR, as suggested by the TCR repertoire analysis using a panel of monoclonal antibodies recognizing TCR Vbeta chain, as well as by TCR beta gene rearrangements. The study provides, for the first time, unambiguous evidence of the oncogenic potential of IEX-1 in a cell-specific manner. The animal model may help our understanding of peripheral T-cell lymphoma development.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Boston Univ, Med Ctr, Dept Mol & Cell Biol, Boston, MA 02118 USA; Inst Cochin Genet Mol, Dept Hematol, INSERM, U567,CNRS,UMR 8104, F-75014 Paris, France; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	Baylor College of Medicine; Boston University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wu, MX (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, 50 Blossom St,Wellman 224, Boston, MA 02114 USA.		PORTEU, Françoise/I-8445-2016	PORTEU, Françoise/0000-0002-2403-4163	NIAID NIH HHS [AI45003] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045003] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; CHARLES CH, 1993, ONCOGENE, V8, P797; Chuang PI, 2002, BLOOD, V99, P3350, DOI 10.1182/blood.V99.9.3350; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Huang YH, 2002, ONCOGENE, V21, P6819, DOI 10.1038/sj.onc.1205854; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; Kondratyev AD, 1996, CANCER RES, V56, P1498; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; PEZZELLA F, 1990, LANCET, V336, P1510, DOI 10.1016/0140-6736(90)93216-C; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; SEITE P, 1993, LEUKEMIA, V7, P410; STRASSER A, 1993, ONCOGENE, V8, P1; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; WU MX, 1995, P NATL ACAD SCI USA, V92, P1525, DOI 10.1073/pnas.92.5.1525; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	37	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6845	6851		10.1038/sj.onc.1206707	http://dx.doi.org/10.1038/sj.onc.1206707			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534530				2022-12-17	WOS:000185843400004
J	Remenyik, E; Wikonkal, NM; Zhang, WG; Paliwal, V; Brash, DE				Remenyik, E; Wikonkal, NM; Zhang, WG; Paliwal, V; Brash, DE			Antigen-specific immunity does not mediate acute regression of UVB-induced p53-mutant clones	ONCOGENE			English	Article						Rag1; knockout; sunburn cells; apoptosis; epidermal thickness; immune surveillance	MOUSE SKIN CARCINOGENESIS; EARLY ADAPTIVE RESPONSES; ULTRAVIOLET-IRRADIATION; PERSISTENT HYPERPLASIA; INDUCED APOPTOSIS; HAIRLESS MICE; LYMPHOCYTES-T; P53 MUTATIONS; NKT CELLS; CANCER	Chronic irradiation of human or murine epidermis with ultraviolet B (UVB) induces clones of p53-mutant keratinocytes. Clones precede and parallel the induction of carcinomas, suggesting that they are an early stage of UVB carcinogenesis. In the absence of UVB, these clones rapidly regress. For UVB-induced murine skin tumors and papillomas, regression is known to involve antigen-specific immunity. To determine whether antigen-specific immunity influences the creation, expansion, or regression of p53-mutant clones, we studied Rag1 knockout mice deficient in the recombination activating gene 1 required for development of B, alphabetaT, gammadeltaT, and natural killer T cells. Since tissue homeostasis could affect proliferation or persistence of clones, we also examined the effect of Rag1 on UVB-induced hyperplasia and apoptosis. Mice were irradiated with UVB daily for 7-11 weeks to create p53-mutant clones, and then retained in the absence of UV. After UV ended, epidermal thickness decreased and p53-mutant clones observed in the epidermal sheets regressed, with no significant differences between Rag1(-/-) and wild type. During the initial chronic UVB irradiation, increasing irradiation time increased both the number and size of p53-mutant clones, with no significant difference between genotypes. We conclude that antigen-specific immunity is not involved in the initiation, expansion, or acute regression of p53-mutant clones.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT USA; Yale Univ, Yale Canc Ctr, New Haven, CT USA; Univ Debrecen, Med & Hlth Sci Ctr, Dept Dermatol, H-4012 Debrecen, Hungary; Semmelweis Univ, Sch Med, Dept Dermatol, H-1085 Budapest, Hungary	Yale University; Yale University; Yale University; University of Debrecen; Semmelweis University	Brash, DE (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St,HRT 309, New Haven, CT 06520 USA.	douglas.brash@yale.edu		Zhang, Wengeng/0000-0002-1000-4692	NATIONAL CANCER INSTITUTE [R01CA078735] Funding Source: NIH RePORTER; NCI NIH HHS [CA78735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS EJ, 1971, J NATL CANCER I, V47, P653; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Berton TR, 1997, J INVEST DERMATOL, V109, P340, DOI 10.1111/1523-1747.ep12335984; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1998, CANCER SURV, V32, P69; BURNS FJ, 1976, CANCER RES, V36, P1422; Carnaud C, 1999, J IMMUNOL, V163, P4647; Daugelat S, 1996, IMMUNOL LETT, V50, P81, DOI 10.1016/0165-2478(96)02523-0; DAYNES RA, 1981, J INVEST DERMATOL, V77, P77, DOI 10.1111/1523-1747.ep12479260; DEFABO EC, 1979, PHOTOCHEM PHOTOBIOL, V30, P385, DOI 10.1111/j.1751-1097.1979.tb07372.x; DEGRUIJL FR, 1993, CANCER RES, V53, P53; FISHER MS, 1977, P NATL ACAD SCI USA, V74, P1688, DOI 10.1073/pnas.74.4.1688; FISHER MS, 1982, SCIENCE, V216, P1133, DOI 10.1126/science.6210958; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kemp CJ, 1999, CARCINOGENESIS, V20, P2051, DOI 10.1093/carcin/20.11.2051; KRIPKE ML, 1974, J NATL CANCER I, V53, P1333, DOI 10.1093/jnci/53.5.1333; KRIPKE ML, 1976, J NATL CANCER I, V57, P211, DOI 10.1093/jnci/57.1.211; Lu YP, 1999, CANCER RES, V59, P4591; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moodycliffe AM, 2000, NAT IMMUNOL, V1, P521, DOI 10.1038/82782; NOONAN FP, 1990, PHOTOCHEM PHOTOBIOL, V52, P801, DOI 10.1111/j.1751-1097.1990.tb08685.x; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Rebel H, 2001, CANCER RES, V61, P977; Ren ZP, 1996, ONCOGENE, V12, P765; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; STRICKLAND PT, 1987, CANCER RES, V47, P6294; STRICKLAND PT, 1986, ENVIRON HEALTH PERSP, V68, P131, DOI 10.2307/3430257; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; TODA KI, 1986, J CLIN LAB IMMUNOL, V20, P129; Ullrich SE, 2000, BIOCHEMICAL MODULATION OF SKIN REACTIONS, P281; Ullrich SE, 2002, FRONT BIOSCI-LANDMRK, V7, pD684, DOI 10.2741/ullrich; Zhang WG, 2001, P NATL ACAD SCI USA, V98, P13948, DOI 10.1073/pnas.241353198; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	36	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6369	6376		10.1038/sj.onc.1206657	http://dx.doi.org/10.1038/sj.onc.1206657			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508517				2022-12-17	WOS:000185535300007
J	Renou, JP; Bierie, B; Miyoshi, K; Cui, YZ; Djiane, J; Reichenstein, M; Shani, M; Hennighausen, L				Renou, JP; Bierie, B; Miyoshi, K; Cui, YZ; Djiane, J; Reichenstein, M; Shani, M; Hennighausen, L			Identification of genes differentially expressed in mouse mammary epithelium transformed by an activated beta-catenin	ONCOGENE			English	Article						mammary gland; beta-catenin; transdifferentiation; metaplasia; microarrays Mammochip	LYSOSOMAL CYSTEINE PROTEASES; CRE RECOMBINASE; DEPENDENT EXPRESSION; GLAND INVOLUTION; BREAST-CANCER; HAMSTER CELLS; CATHEPSIN-L; PROTEIN; SPECIFICITY; ADIPOCYTES	beta-Catenin is an executor of Wnt signaling and it can control cell fate and specification. Deletion of exon 3 from the endogenous beta-catenin gene in differentiating mammary alveolar epithelium of the mouse results in the generation of an activated protein that lacks amino acids 5-80. This is accompanied by a loss of mammary epithelial differentiation and a transdifferentiation process to squamous metaplasias. To further understand the molecular process of transdifferentiation, the expression of genes in mammary tissue was profiled in the absence and presence of activated of beta-catenin. Microarrays were generated that carry about 8500 cDNA clones with approximately 6000 obtained from mammary tissue. Mutant tissues, which had undergone either partial (TD1) or complete (TD2) squamous transdifferentiation, were compared with wild-type mammary tissue. Four groups of genes were identified. Group I contained genes whose expression was induced in both mutant tissues. Groups 2 and 3 contained genes that were active preferentially in TD2 and TD1, respectively. Group 4 contained genes suppressed in both samples. Using this approach, known and unknown genes activated in the transdifferentiation process were identified. A new 20 kDa protein (PANE1) induced upon transdifferentiation was nuclear in nonconfluent cells and cytoplasmic in confluent or dividing cells. Lastly, stabilization of beta-catenin resulted in the retention of differentiated epithelium upon involution and altered activities of several proteases in transdifferentiated mammary epithelium.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; INRA, Jouy En Josas, France; Univ Tokushima, Dept Biochem, Sch Dent, Tokushima 770, Japan; Agr Res Org, Volcani Ctr, IL-50250 Bet Dagan, Israel	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Tokushima University; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Room 101, Bethesda, MD 20892 USA.			Miyoshi, Keiko/0000-0001-6910-4172; Hennighausen, Lothar/0000-0001-8319-9841; Reichenstein, Moshe/0000-0003-4957-004X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; CALABRO MA, 1982, LIPIDS, V17, P397, DOI 10.1007/BF02535218; Campana WM, 1999, BBA-GEN SUBJECTS, V1427, P392, DOI 10.1016/S0304-4165(99)00036-7; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; DANESCH U, 1992, J BIOL CHEM, V267, P7185; DUFOUR E, 1988, BIOSCIENCE REP, V8, P185, DOI 10.1007/BF01116463; Humphreys RC, 2002, ENDOCRINOLOGY, V143, P3641, DOI 10.1210/en.2002-220224; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Larsen LB, 1996, J DAIRY RES, V63, P119, DOI 10.1017/S0022029900031599; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; LYNCH CJ, 1993, AM J PHYSIOL, V265, pC234, DOI 10.1152/ajpcell.1993.265.1.C234; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; McMurtrie EB, 1997, GENOMICS, V45, P623, DOI 10.1006/geno.1997.4959; McTernan PG, 2002, J CLIN ENDOCR METAB, V87, P2407, DOI 10.1210/jc.87.5.2407; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Park DS, 2001, J BIOL CHEM, V276, P48389, DOI 10.1074/jbc.M108210200; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; Polakis P, 2000, GENE DEV, V14, P1837; Rossman TG, 1997, MUTAT RES-REV MUTAT, V386, P307, DOI 10.1016/S1383-5742(97)00013-6; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Sol-Church K, 2000, BBA-GENE STRUCT EXPR, V1491, P289, DOI 10.1016/S0167-4781(00)00030-0; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097	33	28	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4594	4610		10.1038/sj.onc.1206596	http://dx.doi.org/10.1038/sj.onc.1206596			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881717				2022-12-17	WOS:000184054700016
J	Budunova, IV; Kowalczyk, D; Perez, P; Yao, YJ; Jorcano, JL; Slaga, TJ				Budunova, IV; Kowalczyk, D; Perez, P; Yao, YJ; Jorcano, JL; Slaga, TJ			Glucocorticoid receptor functions as a potent suppressor of mouse skin carcinogenesis	ONCOGENE			English	Article						glucocorticoid receptor; transgenic mice; skin carcinogenesis; NF-kappa B	NF-KAPPA-B; TRANSGENIC TG.AC MICE; CELL-CYCLE; TRANSCRIPTION FACTORS; TUMOR PROMOTION; ONCOGENIC RAS; ORNITHINE DECARBOXYLASE; PAPILLOMA DEVELOPMENT; DNA-BINDING; EXPRESSION	Glucocorticoids are effective inhibitors of epidermal proliferation and skin tumorigenesis. Glucocorticoids affect cellular functions via glucocorticoid receptor (GR), a well-known transcription factor. Recently, we generated skin-targeted transgenic mice overexpressing GR under control of the keratin5 promoter (K5-GR mice). To test the hypothesis that GR plays a role as a tumor suppressor in skin, we bred K5-GR transgenic mice with Tg.AC transgenic mice, which express v-Ha-ras oncogene in the skin, and compared the susceptibility of F1 offspring to TPA-induced skin carcinogenesis. GR overexpression in the epidermis dramatically inhibited skin tumor development. In K5-GR/ras+ double transgenic mice papillomas developed later and the average number of tumors per animal was 15% (in males) and 40% (in females) of the number seen in wild type (w.t./ras+) littermates. In addition, the papillomas in w.t./ras+ animals were eight to nine times larger. GR overexpression resulted in a decrease in keratinocyte proliferation combined with a modest increase in apoptosis and differentiation of keratinocytes in K5-GR/ras+ papillomas. Our data clearly indicate that interference of GR transgenic protein with nuclear factor kappa B (NF-kappaB) transcription factor had resulted in NF-kappaB blockage in K5-GR/ras + tumors. We discuss the role of NF-kappaB blockage in tumor-suppressor effect of GR.	AMC Canc Res Ctr, Denver, CO 80214 USA; CSIC, Inst Biomed Valencia, E-46010 Valencia, Spain; CIEMAT, Project Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain	AMC Cancer Research Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Budunova, IV (corresponding author), AMC Canc Res Ctr, 1600 Pierce St, Denver, CO 80214 USA.	budunovai@amc.org	Perez, Paloma/K-8841-2017	Perez, Paloma/0000-0002-7166-2824	NATIONAL CANCER INSTITUTE [R01CA079065] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-79065-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Battalora MS, 2001, CARCINOGENESIS, V22, P651, DOI 10.1093/carcin/22.4.651; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Binder RL, 1998, CANCER RES, V58, P4314; Budunova IV, 1997, MOL CARCINOGEN, V18, P177, DOI 10.1002/(SICI)1098-2744(199703)18:3<177::AID-MC7>3.3.CO;2-U; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cannon RE, 1997, MOL CARCINOGEN, V20, P108, DOI 10.1002/(SICI)1098-2744(199709)20:1<108::AID-MC12>3.0.CO;2-5; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; DIGIOVANNI J, 1992, CARCINOGENESIS, V13, P525, DOI 10.1093/carcin/13.4.525; DIGIOVANNI J, 1988, CARCINOGENESIS, V9, P1445, DOI 10.1093/carcin/9.8.1445; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FISCHER SM, 1989, CANCER RES, V49, P6693; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HENNINGS H, 1987, MULTISTEP MODELS CAR, P59; Honchel R, 2001, MOL CARCINOGEN, V30, P99, DOI 10.1002/1098-2744(200102)30:2<99::AID-MC1018>3.3.CO;2-Z; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Ma SH, 1997, GENE EXPRESSION, V6, P361; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; NAITO M, 1988, CARCINOGENESIS, V9, P639, DOI 10.1093/carcin/9.4.639; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; NESNOW S, 1986, ENVIRON HEALTH PERSP, V68, P19, DOI 10.1289/ehp.866819; Park JH, 2001, INT J ONCOL, V18, P997; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; Perez P, 2001, FASEB J, V15, P2030, DOI 10.1096/fj.00-0772fje; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Samuelsson MKR, 1999, MOL ENDOCRINOL, V13, P1811, DOI 10.1210/me.13.11.1811; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHWARZ JA, 1977, CHEM-BIOL INTERACT, V17, P331, DOI 10.1016/0009-2797(77)90096-5; SLAGA TJ, 1984, MODELS MECH ETIOLOGY, P497; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; Spiegelman VS, 1997, MOL CARCINOGEN, V20, P99, DOI 10.1002/(SICI)1098-2744(199709)20:1<99::AID-MC11>3.3.CO;2-O; STRAWHECKER JM, 1992, CARCINOGENESIS, V13, P2075, DOI 10.1093/carcin/13.11.2075; Takuwa N, 2001, MOL CELL ENDOCRINOL, V177, P25, DOI 10.1016/S0303-7207(01)00439-7; Terada Y, 2001, KIDNEY INT, V59, P1706, DOI 10.1046/j.1523-1755.2001.0590051706.x; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; VERMA AK, 1983, CANCER RES, V43, P3045	56	28	29	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3279	3287		10.1038/sj.onc.1206383	http://dx.doi.org/10.1038/sj.onc.1206383			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761498				2022-12-17	WOS:000183040000010
J	Goodman, PA; Burkhardt, N; Juran, B; Tibbles, HE; Uckun, FM				Goodman, PA; Burkhardt, N; Juran, B; Tibbles, HE; Uckun, FM			Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia	ONCOGENE			English	Article						CpG island; methylation-specific; PCR; T-lineage leukemia	LYMPHOMA B-CELLS; HUMAN BREAST-CANCER; DNA METHYLATION; CPG ISLANDS; PHOSPHOLIPASE C-GAMMA-2; RECEPTOR STIMULATION; MEDIATED ACTIVATION; INDUCED APOPTOSIS; BINDING PROTEINS; MYELOID-LEUKEMIA	Sequence analysis of the noncoding first exon (exon 1) of the Syk gene demonstrated the presence of a previously cloned CpG island (GenBank #Z 65706). Transient transfection analysis in Daudi cells demonstrated promoter activity (18-fold increase over parental luciferase plasmid) for a 348 bp BstXI-BsrBI fragment containing this island. This region exhibits a high GC content (similar to75%), contains several SP1 binding sites and a potential initiator sequence, but lacks a strong TATA consensus. Bisulfite sequencing and methylation-specific PCR (MSP) of this region demonstrated that the Syk promoter CpG island was largely unmethylated in B-lineage leukemia cell lines, control peripheral blood cells, human thymocytes and CD3(+) T lymphocytes. However, dense methylation was seen in four T-lineage leukemia cell lines, Jurkat, H9, Molt 3 and HUT 78. MSP screening of leukemia cells from six T-lineage acute lymphoblastic leukemia (ALL) patients demonstrated methylation of the Syk promoter CpG island in one T-lineage ALL patient. Promoter methylation was correlated with reduced to absent expression of Syk mRNA and SYK protein in the T-lineage leukemia cell lines. Treatment of the leukemia lines Ha and Molt 3, with the methylation inhibitor, 5-aza-2'-deoxycytidine (5-aza-CdR) resulted in increased Syk mRNA expression. The presence of a methylated promoter sequence in these T-lineage leukemia cell lines and in one T-lineage patient suggests a potential role for SYK as a tumor suppressor in T-ALL.	Parker Hughes Inst, Dept Mol Oncol, St Paul, MN 55113 USA; Parker Hughes Canc Ctr, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Mol Genet, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Biochem, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Parker Hughes Inst, Dept Mol Oncol, 2699 Patton Rd, St Paul, MN 55113 USA.	faith_uckun@mercury.ih.org		Uckun, Fatih M./0000-0001-9334-183X				Akanuma D, 1999, ORAL ONCOL, V35, P476, DOI 10.1016/S1368-8375(99)00020-2; ALCALAY M, 1988, NUCLEIC ACIDS RES, V16, P9527, DOI 10.1093/nar/16.20.9527; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Baylin SB, 1998, ADV CANCER RES, V72, P141; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1999, J IMMUNOL, V163, P2610; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Cornall RJ, 2000, P NATL ACAD SCI USA, V97, P1713, DOI 10.1073/pnas.97.4.1713; Craig NL, 1996, CURR TOP MICROBIOL, V204, P27; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLATAU E, 1983, CANCER RES, V43, P4901; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Glavac Damjan, 1996, Pfluegers Archiv European Journal of Physiology, V431, pR193, DOI 10.1007/BF02346334; Goodman PA, 2002, LEUKEMIA LYMPHOMA, V43, P1627, DOI 10.1080/1042819021000002965; Goodman PA, 2001, ONCOGENE, V20, P3969, DOI 10.1038/sj.onc.1204515; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; GULBINS E, 1994, J IMMUNOL, V152, P2123; Guo SX, 2000, LEUKEMIA RES, V24, P39, DOI 10.1016/S0145-2126(99)00158-7; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KOEFFLER HP, 1980, BLOOD, V56, P344; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Law CL, 1996, MOL CELL BIOL, V16, P1305; Li HL, 1997, J BIOL CHEM, V272, P18200, DOI 10.1074/jbc.272.29.18200; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MallickWood CA, 1996, P NATL ACAD SCI USA, V93, P9704, DOI 10.1073/pnas.93.18.9704; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; MINOWADA J, 1981, J CANCER RES CLIN, V101, P91, DOI 10.1007/BF00405069; MINOWADA J, 1972, J NATL CANCER I, V49, P891; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Okamura S, 1999, ONCOL RES, V11, P281; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; Qin SF, 1998, FEBS LETT, V427, P139, DOI 10.1016/S0014-5793(98)00383-4; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Stellwagen AE, 1997, EMBO J, V16, P6823, DOI 10.1093/emboj/16.22.6823; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; Stewart ZA, 2001, BREAST CANCER RES, V3, P5, DOI 10.1186/bcr261; Stirzaker C, 1997, CANCER RES, V57, P2229; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tibbles HE, 2001, J BIOL CHEM, V276, P17815, DOI 10.1074/jbc.M011405200; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; UCKUN FM, 1989, BLOOD, V73, P1000; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; Uckun FM, 1997, BLOOD, V89, P2488; UCKUN FM, 1985, J IMMUNOL, V135, P3817; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Yeivin A, 1993, EXS, V64, P523; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Yuan YF, 2001, CANCER RES, V61, P5558; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810	84	28	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2504	2514		10.1038/sj.onc.1206313	http://dx.doi.org/10.1038/sj.onc.1206313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717427				2022-12-17	WOS:000182383500013
J	Mulherkar, R; Kirtane, BM; Ranichandani, A; Mansukhani, NP; Kannan, S; Naresh, KN				Mulherkar, R; Kirtane, BM; Ranichandani, A; Mansukhani, NP; Kannan, S; Naresh, KN			Expression of enhancing factor/phospholipase A(2) in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis	ONCOGENE			English	Article						enhancing factor; secretory phospholipase A(2); transgenic mice; epidermal growth factor; squamous cell carcinoma; hair follicle	MOUSE SMALL-INTESTINES; GROWTH-FACTOR RECEPTOR; TRANSGENIC MICE; PHOSPHOLIPASE A(2); HAIR-FOLLICLES; KERATIN GENE; STEM-CELLS; DIFFERENTIATION; LOCALIZATION; PROTEIN	Enhancing factor (EF), a growth factor modulator, is the mouse homologue of human secretory group 11 phospholipase A(2). EF exhibits growth-promoting activity in vitro, in the presence of epidermal growth factor, and also brings about phenotypic transformation of normal cells. In order to ascertain the role of EF in vivo, a human keratin-14 promoter was used to drive the expression of EF ectopically to squamous epithelial cells. The founder mouse and its progeny showed abnormal whiskers and a scaly, beaded tail. In these mice, keratinization pattern of the epidermis was disturbed and parakeratosis and acanthosis were noted. The transgenic mice, TgK14-EF, expressed EF in the suprabasal layers of tail epidermis as well as in the epithelial cells of hair follicle and sebaceous glands of skin. Expression of EF along with hyperplasia was also observed in other squamous epithelia such as buccal mucosa, tongue and oesophagus. TgK14-EF mice homozygous for the transgene showed delayed and scanty hair growth although the mice were healthy and fertile. The hemizygous TgK14-EF mice were sensitive to a two-stage chemical carcinogenesis and developed a higher number of papillomas than their normal littermates over the course of the experiment. The conversion rate of papilloma to carcinoma was two fold higher in the transgenic mice.	Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, ACTREC, Genet Engn Lab,Canc Res Inst, Kharghar 410208, Navi Mumbai, India; Tata Mem Hosp, Tata Mem Ctr, Dept Pathol, Bombay 400012, Maharashtra, India	Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Tata Memorial Hospital	Mulherkar, R (corresponding author), Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, ACTREC, Genet Engn Lab,Canc Res Inst, Kharghar 410208, Navi Mumbai, India.			Naresh, Kikkeri N/0000-0003-3807-3638				COHEN S, 1963, J INVEST DERMATOL, V40, P1; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DEO MG, 1983, INDIAN J BIOCHEM BIO, V20, P228; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GREEN MR, 1983, DEV BIOL, V100, P506, DOI 10.1016/0012-1606(83)90243-9; JIANG CK, 1991, J INVEST DERMATOL, V96, P162, DOI 10.1111/1523-1747.ep12460939; Kadam S, 1999, BIOCHEM J, V340, P237, DOI 10.1042/0264-6021:3400237; KAISER E, 1990, CLIN BIOCHEM, V23, P349, DOI 10.1016/0009-9120(90)90051-U; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kiguchi K, 2000, ONCOGENE, V19, P4243, DOI 10.1038/sj.onc.1203778; LAVKER RM, 1993, J INVEST DERMATOL, V101, P16; MORRIS RJ, 1986, CANCER RES, V46, P3061; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1986, J CELL PHYSIOL, V127, P183, DOI 10.1002/jcp.1041270122; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; ROOP DR, 1988, CANCER RES, V48, P3245; Shibata MA, 1997, MOL CARCINOGEN, V18, P160, DOI 10.1002/(SICI)1098-2744(199703)18:3<160::AID-MC5>3.0.CO;2-J; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WAGLE A, 1989, CELL BIOL INT REP, V13, P309, DOI 10.1016/0309-1651(89)90154-9; Xie W, 1998, CELL GROWTH DIFFER, V9, P313	27	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1936	1944		10.1038/sj.onc.1206229	http://dx.doi.org/10.1038/sj.onc.1206229			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673199				2022-12-17	WOS:000181967700004
J	Demoulin, JB; Louahed, J; Dumoutier, L; Stevens, M; Renauld, JC				Demoulin, JB; Louahed, J; Dumoutier, L; Stevens, M; Renauld, JC			MAP kinase activation by interleukin-9 in lymphoid and mast cell lines	ONCOGENE			English	Article						cytokines; ERK; proliferation	INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GAMMA-CHAIN; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; IL-9 RECEPTOR; PROLIFERATION; PROTEIN; RAS	Interleukin-9 (IL-9) stimulates the proliferation of mast cells and lymphocytes. In the present study, we showed that IL-9 induced a transient phosphorylation of MEK, ERK2 and p90/RSK in murine lymphoid and mast cell lines. ERK2 in vitro kinase activity was also increased upon IL-9 stimulation. Similar results were obtained with IL-4, which had not been previously reported to activate these kinases in hematopoietic cells. Analysis of IL-9 receptor mutants showed that activation of the pathway was correlated with proliferation and with phosphorylation of the adaptor protein SHC, but not IRS2 or GAB2. The MEK inhibitor PD98059 reduced the mitogenic response to IL-4 and IL-9. In addition, expression of a dominant-negative RAS variant blocked ERK phosphorylation and significantly decreased Ba/F3 cell growth in the presence of IL-9, but did not affect expression of pim-1, a STAT target gene. In summary, these results indicate that IL-9 can transiently activate the mitogen-activated protein kinase pathway, which contributes to growth stimulation of hematopoietic cell tines.	Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Expt Med Univ, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	Renauld, JC (corresponding author), Univ Catholique Louvain, Ludwig Inst Canc Res, Ave Hippocrate 74, B-1200 Brussels, Belgium.	Jean-Christophe.Renauld@bru.licr.org	Demoulin, Jean-Baptiste/E-5847-2010; Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131; Demoulin, Jean-Baptiste/0000-0002-8016-6689; Dumoutier, Laure/0000-0002-6645-684X				Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Demoulin JB, 2000, FEBS LETT, V482, P200, DOI 10.1016/S0014-5793(00)02059-7; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; Demoulin JB, 1998, CYTOKINES CELL MOL T, V4, P243; Demoulin JB, 2000, CANCER RES, V60, P3971; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Demoulin JB, 2001, CELL GROWTH DIFFER, V12, P169; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gadina M, 2000, J BIOL CHEM, V275, P26959; Gingras S, 2000, MOL ENDOCRINOL, V14, P229, DOI 10.1210/me.14.2.229; Gomez J, 1996, J IMMUNOL, V157, P2272; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Lemoli RM, 1996, BLOOD, V87, P3852, DOI 10.1182/blood.V87.9.3852.bloodjournal8793852; Louahed J, 2001, BLOOD, V97, P1035, DOI 10.1182/blood.V97.4.1035; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; MIYAZAWA K, 1992, BLOOD, V80, P1685; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; Renauld Jean-Christophe, 1998, P313; Richard M, 2000, P NATL ACAD SCI USA, V97, P767, DOI 10.1073/pnas.97.2.767; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rohrschneider LR, 2000, GENE DEV, V14, P505; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Vink A, 1999, J EXP MED, V189, P1413, DOI 10.1084/jem.189.9.1413; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Xiao H, 2002, J BIOL CHEM, V277, P8091, DOI 10.1074/jbc.M106650200; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zamorano J, 1998, J IMMUNOL, V161, P859; Zhu YX, 1997, J BIOL CHEM, V272, P21334, DOI 10.1074/jbc.272.34.21334	43	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1763	1770		10.1038/sj.onc.1206253	http://dx.doi.org/10.1038/sj.onc.1206253			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660812	Bronze			2022-12-17	WOS:000181678200003
J	Sonderegger, CK; Vogt, PK				Sonderegger, CK; Vogt, PK			Binding of the corepressor TLE1 to Qin enhances Qin-mediated transformation of chicken embryo fibroblasts	ONCOGENE			English	Article						corepressor; TLE1; FoxG1; oncogenic transformation; chicken embryo fibroblasts	TRANSCRIPTIONAL REPRESSION; ONCOGENIC TRANSFORMATION; GROUCHO; PROTEIN; EXPRESSION; AML1; OLIGOMERIZATION; IDENTIFICATION; INTERACTS; HOMOLOGS	The oncoprotein Qin is a member of the winged helix family of transcriptional regulators. The region C-terminal to its winged helix DNA-binding domain is required for transformation of chicken embryo fibroblasts. We isolated the corepressor TLE1 as a binding partner for Qin in a yeast two-hybrid screen and localized the TLE1-binding region to a 60 amino-acid stretch directly C-terminal of the winged helix domain of Qin. We show in vivo interaction of full-length Qin and TLE1 in a mammalian two-hybrid system. Coexpression of TLE1-binding Qin and TLE1 induces phosphorylation of TLEI. The DNA-binding activity of Qin is not required for this function. Binding of Qin to TLE1 correlates with Qin-induced transformation. Addition of the TLE1-binding motif WRPW to the C-terminus of a transformation-defective Qin deletion mutant restores binding to TLE1 and significantly enhances transformation. Expression of TLE1 in CEF by the retroviral vector RCAS enhances cell growth and induces formation of agar colonies.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; AOKI M, 2002, COMMUNICATION; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Chang HW, 1996, ONCOGENE, V13, P441; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; DUFF RG, 1969, VIROLOGY, V39, P18, DOI 10.1016/0042-6822(69)90344-4; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; Ma Y, 2000, ONCOGENE, V19, P4815, DOI 10.1038/sj.onc.1203834; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; NISHIZAWA M, 2002, UNPUB; Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; SONDEREGGER CK, 2003, IN PRESS ONCOGENE; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Yao J, 1998, DEV GROWTH DIFFER, V40, P133; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	33	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1749	1757		10.1038/sj.onc.1206308	http://dx.doi.org/10.1038/sj.onc.1206308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660810				2022-12-17	WOS:000181678200001
J	Nasr, AF; Nutini, M; Palombo, B; Guerra, E; Alberti, S				Nasr, AF; Nutini, M; Palombo, B; Guerra, E; Alberti, S			Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene	ONCOGENE			English	Article						DNA methylation; gene amplification; genome instability; p53; Trop-1	WILD-TYPE P53; CHROMOSOME INSTABILITY; COLON-CANCER; MUTANT P53; HOMOLOGOUS RECOMBINATION; METHYLTRANSFERASE GENE; RETINOBLASTOMA GENE; COLORECTAL-CANCER; CELLS; EXPRESSION	p53 and DNA methylation play key roles in the maintenance of genome stability. In this work, we demonstrate that the two mechanisms are linked and that p53 plays a role in the maintenance of the DNA methylation levels. The loss of p53 was shown to induce loss of DNA methylation in the TROP1 gene, a human cancer-expressed locus that undergoes amplification when hypomethylated. This demethylation was reverted by the reintroduction of a wild-type TP53 (wt TP53) in the TP53-null cells. Using a gene-amplification assay in vivo, we demonstrate that the loss of p53 leads to a demethylation-dependent TROP1 gene amplification. The induction of gene amplification was reverted by the expression of a wtTP53 gene or by in vitro methylation of the transfected DNA with the Sss I DNA methylase. Taken together, these findings demonstrate that the inactivation of TP53 induces loss of DNA methylation and DNA methylation-dependent gene amplification.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Expt Oncol Lab, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Alberti, S (corresponding author), Univ G DAnnunzio, Sch Med, Inst Med & Aging, Chieti, Italy.		Alberti, Saverio/M-4511-2014	Alberti, Saverio/0000-0002-4647-6042; Guerra, Emanuela/0000-0002-7091-8621				Ahuja N, 1997, CANCER RES, V57, P3370; ALBERTI S, 1994, P NATL ACAD SCI USA, V91, P5833, DOI 10.1073/pnas.91.13.5833; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BLANDINO G, 1995, ONCOGENE, V10, P731; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Calabrese G, 2001, CYTOGENET CELL GENET, V92, P164, DOI 10.1159/000056891; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; GOETZ SE, 1985, SCIENCE, V228, P187; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORI T, 1983, MUTAT RES, V121, P47, DOI 10.1016/0165-7992(83)90085-4; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639; PERRY ME, 1992, MUTAT RES, V276, P189, DOI 10.1016/0165-1110(92)90008-W; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sambrook J, 1989, MOL CLONING LAB MANU; Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; STRNAD J, 1989, CANCER RES, V49, P314; Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590; WAHL GM, 1984, NATURE, V307, P516, DOI 10.1038/307516a0; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zheng L, 2002, CANCER RES, V62, P2498	49	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1668	1677		10.1038/sj.onc.1206248	http://dx.doi.org/10.1038/sj.onc.1206248			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642870				2022-12-17	WOS:000181580500009
J	Presneau, N; Mes-Masson, AM; Ge, B; Provencher, D; Hudson, TJ; Tonin, PN				Presneau, N; Mes-Masson, AM; Ge, B; Provencher, D; Hudson, TJ; Tonin, PN			Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines	ONCOGENE			English	Article						ovarian cancer; cell lines; DNA microarray; chromosome 17; gene expression	ALLELIC LOSS; MICROARRAY ANALYSIS; DELETION UNIT; TUMORS DISTAL; FREQUENT LOSS; P53 GENE; BREAST; REGION; CANDIDATE; HETEROZYGOSITY	Oligonucleotide microarray analysis was applied to assess the expression profile of 332 probe sets representing 308 genes or expressed sequence tags (ESTs) that map to chromosome 17 in order to address epigenetic events that result in alterations in gene expression in epithelial ovarian cancer (EOC). Expression profiles were generated from 12 primary cultures derived from normal ovarian surface epithelium (NOSE) and four long-term cultures (TOV-81D, TOV-112D, TOV-21G and OV-90) derived from EOCs that have been previously characterized and shown to mimic features of the tumoral cells from which they were derived. The expression values of all 332 probe sets is highly correlated across the 12 NOSEs (89% correlation coefficients > 0.90). In two-way comparisons, differential patterns of gene expression were observed for 157 probe sets for which the expression value of at least one EOC cell tine fell outside the limits of the range of expression of the 12 NOSEs. When compared to NOSEs, four genes displayed similar differential patterns of gene expression across all four EOC cell lines, and 26 genes displayed similar differential patterns of gene expression across the three EOC cell lines (TOV-112D, TOV-21G and OV-90) representing tumoral cells derived from the most aggressive disease. A total of 17 genes displayed differential patterns of gene expression greater than threefold in at least one EOC cell line in comparison to NOSE, and three genes were differentially expressed greater than threefold across all aggressive cell lines. The analysis of a selected number of genes by RT-PCR revealed patterns of gene expression comparable to those observed by microarray analysis in the majority of samples tested. Comparison of expression profiles of differentially expressed genes identified by microarray analysis in two-way comparisons of the EOC cell lines and the NOSEs with published reports revealed 10 genes previously implicated in ovarian tumorigenesis and 18 in tumorigenesis of other types of cancer. The differential pattern of gene expression of genes that map to both the p and q arm of chromosome 17 is consistent with the hypothesis that a number of genes that map to this chromosome are implicated in the etiology of ovarian cancer.	McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3G 1A4, Canada; McGill Univ, Ctr Hlth, Montreal Genome Ctr, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; CHU Montreal, Notre Dame Hosp, Ctr Rech, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University	Tonin, PN (corresponding author), Montreal Gen Hosp, Room L10-120,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	patricia.tonin@mcgill.ca	Pillay, Nischalan/F-9536-2012	Mes-Masson, Anne-Marie/0000-0002-6498-266X				Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; CLIBY W, 1993, CANCER RES, V53, P2393; Davidson B, 1999, CLIN EXP METASTAS, V17, P799, DOI 10.1023/A:1006723011835; Davidson B, 2001, EUR J CANCER, V37, P2040, DOI 10.1016/S0959-8049(01)00235-0; Dion F, 2000, ONCOGENE, V19, P1466, DOI 10.1038/sj.onc.1203463; ECCLES DM, 1990, ONCOGENE, V5, P1599; ECCLES DM, 1992, BRIT J CANCER, V65, P40, DOI 10.1038/bjc.1992.8; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; GODWIN AK, 1994, AM J HUM GENET, V55, P666; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hoff C, 2000, GENOMICS, V70, P26, DOI 10.1006/geno.2000.6353; JACOBS IJ, 1993, CANCER RES, V53, P1218; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kikkawa F, 1997, CANCER LETT, V120, P109, DOI 10.1016/S0304-3835(97)00295-4; Konishi H, 1998, ONCOGENE, V17, P2095, DOI 10.1038/sj.onc.1202128; KRUK PA, 1990, LAB INVEST, V63, P132; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; LEE JH, 1990, CANCER RES, V50, P2724; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Lucito R, 2000, GENOME RES, V10, P1726, DOI 10.1101/gr.138300; MANDAI M, 1994, CANCER RES, V54, P1825; Manderson EN, 2002, GENOME RES, V12, P112, DOI 10.1101/gr.174202; Merajver SD, 1995, CLIN CANCER RES, V1, P539; Mertens F, 1997, CANCER RES, V57, P2765; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OKAMOTO A, 1991, CANCER RES, V51, P5171; Papp J, 1996, BRIT J CANCER, V74, P1592, DOI 10.1038/bjc.1996.594; Phelan CM, 1998, CANCER RES, V58, P1004; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; Pieretti M, 1995, INT J CANCER, V64, P434, DOI 10.1002/ijc.2910640614; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; Schneider J, 1996, ANTICANCER RES, V16, P1197; Schneider J, 2000, BRIT J CANCER, V82, P1662; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tangir J, 1996, ONCOGENE, V12, P735; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; Teng DHF, 2001, GENOMICS, V74, P352, DOI 10.1006/geno.2001.6551; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; TSAO SW, 1991, ANTICANCER RES, V11, P1975; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405	46	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1568	1579		10.1038/sj.onc.1206219	http://dx.doi.org/10.1038/sj.onc.1206219			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629520	Bronze			2022-12-17	WOS:000181411900014
J	Brachat, A; Pierrat, B; Xynos, A; Brecht, K; Simonen, M; Brungger, A; Heim, J				Brachat, A; Pierrat, B; Xynos, A; Brecht, K; Simonen, M; Brungger, A; Heim, J			A microarray-based, integrated approach to identify novel regulators of cancer drug response and apoptosis	ONCOGENE			English	Article						apoptosis; microarray; hemoglobin; camptothecin; methotrexate; cisplatin	GP49B INHIBITORY RECEPTOR; GENE-EXPRESSION; ADENYLATE KINASE; DNA-DAMAGE; IDENTIFICATION; PROTEIN; SENSITIVITY; CYCLOPHILIN; CLONING; STRESS	DNA microarrays are powerful tools for the analysis of gene expression on a genomic scale. The importance of individual regulatory events for the process under study can however not be deduced unequivocally without additional experiments. We devised a strategy to identify central regulators of cancer drug responses by combining the results of microarray experiments with efficient methods for phenotypic testing of candidate genes. We exposed murine FL5.12 pro-B cells to cisplatin, camptothecin, methotrexate or paclitaxel, respectively and analysed the patterns of gene expression with cDNA microarrays. Drug-specific regulatory events as well as intersections between different apoptotic pathways, including previously studied responses to staurosporine and interleukin-3 (IL-3) deprivation, were identified. Genes shared by at least three pathways were chosen for further analysis. Ectopic expression of three such genes, TEAP, GP49B, and Lipin1 was found to have an anti-proliferative effect on pro-B cells. Interestingly, we identified hemoglobin alpha as a strong pro-apoptotic regulator. While hemoglobin-expressing cells were growing normally in the presence of IL-3, they displayed accelerated apoptosis with similar kinetics as Bax overexpressing cells upon IL-3 removal. The proapoptotic effect of hemoglobin was suppressed by Bcl-2 and was characterized by enhanced stimulation of caspase activity.	Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland; Novartis Pharma AG, Mol & Cellular Biol Sr Sci Expert Lab, CH-4002 Basel, Switzerland	Novartis; Novartis	Heim, J (corresponding author), Novartis Pharma AG, Oncol Res, K-125-13-16, CH-4002 Basel, Switzerland.	jutta.heim@pharma.novartis.com		Brachat, Arndt/0000-0001-5768-3429				Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Beinert T, 2000, J LEUKOCYTE BIOL, V67, P369, DOI 10.1002/jlb.67.3.369; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Brachat A, 2000, ONCOGENE, V19, P5073, DOI 10.1038/sj.onc.1203882; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Carrier A, 1999, IMMUNOGENETICS, V50, P255, DOI 10.1007/s002510050601; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; Dunn SE, 1997, CANCER RES, V57, P2687; Ferrante K, 1999, CANCER CHEMOTH PHARM, V43, pS61, DOI 10.1007/s002800051100; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lehar SM, 1996, ONCOGENE, V12, P1181; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Matsuda S, 1996, ONCOGENE, V12, P705; Matsumoto Y, 2001, J IMMUNOL, V166, P781, DOI 10.4049/jimmunol.166.2.781; Meguro T, 2001, J NEUROCHEM, V77, P1128, DOI 10.1046/j.1471-4159.2001.00313.x; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; SWIFT S, 1999, CUR PROTO IMMUNOL S, V28; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang LL, 2000, J IMMUNOL, V164, P5215, DOI 10.4049/jimmunol.164.10.5215; Yang WM, 2001, EMBO J, V20, P4814, DOI 10.1093/emboj/20.17.4814; Yoneda T, 1998, MOL BRAIN RES, V62, P187, DOI 10.1016/S0169-328X(98)00249-6	32	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8361	8371		10.1038/sj.onc.1206016	http://dx.doi.org/10.1038/sj.onc.1206016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447701				2022-12-17	WOS:000179323900016
J	Pim, D; Thomas, M; Banks, L				Pim, D; Thomas, M; Banks, L			Chimeric HPV E6 proteins allow dissection of the proteolytic pathways regulating different E6 cellular target proteins	ONCOGENE			English	Article						HPV; E6; PDZ; Dlg; MAGI-1	HUMAN-PAPILLOMAVIRUS TYPE-16; LARGE TUMOR-SUPPRESSOR; RECURRENT RESPIRATORY PAPILLOMATOSIS; P53 IN-VITRO; DISCS LARGE; MUTATIONAL ANALYSIS; CERVICAL-CANCER; PDZ DOMAINS; PROGNOSTIC-SIGNIFICANCE; TRANSFORMING FUNCTION	The ability of HPV E6 oneoproteins to induce the degradation of PDZ domain-containing MAGUK proteins correlates with their malignant potential. We previously showed that the HPV-6 E6 protein, when pro-tided with the PDZ-binding domain from HPV-18 E6, acquires the ability to bind the Discs Large (Dlg) turnour suppressor and target it for degradation. Based on this finding we have extended this analysis to E6 proteins from a variety of different papillomavirus types. Cloning a PDZ-binding sequence onto the C-terminus of E6 proteins derived from low-risk mucosal, and low and high-risk cutaneous papillomavirus types, enables them to bind Dlg and a second MAGUK family member, MAGI-1. This renders the mucosally-derived low-risk chimaeric HPV E6 proteins capable of targeting Dlg for degradation, but they are unable to induce significant levels of degradation of MAGI-1. In contrast, none of the E6 proteins derived from cutaneous papillomavirus types induce significant degradation of either MAGI-1 or Dlg when provided with a PDZ-binding domain. These results demonstrate significant differences, both between mucosal and cutaneous HPV E6 proteins and in the pathways required for Dlg and MAGI-1 degradation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Pim, D (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99,Area Sci Pk, I-34012 Trieste, Italy.	pim@icgeb.org.it						BARNES W, 1988, GYNECOL ONCOL, V29, P267, DOI 10.1016/0090-8258(88)90225-9; Be XB, 2001, BIOCHEMISTRY-US, V40, P1293, DOI 10.1021/bi0019592; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BURNETT AF, 1992, GYNECOL ONCOL, V47, P343, DOI 10.1016/0090-8258(92)90137-8; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Das K, 2000, J VIROL, V74, P812, DOI 10.1128/JVI.74.2.812-816.2000; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Elbel M, 1997, VIROLOGY, V239, P132, DOI 10.1006/viro.1997.8860; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Gao QS, 2002, CANCER RES, V62, P3315; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Inoue T, 1998, MOL CARCINOGEN, V21, P215; ISHIWATARI H, 1994, J MED VIROL, V44, P243, DOI 10.1002/jmv.1890440306; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Petersen BL, 1998, J LARYNGOL OTOL, V112, P1101, DOI 10.1017/S0022215100142586; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; PIM D, 1994, ONCOGENE, V9, P1869; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rabah R, 2001, PEDIATR DEVEL PATHOL, V4, P68, DOI 10.1007/s100240010105; Rady PL, 1998, LARYNGOSCOPE, V108, P735, DOI 10.1097/00005537-199805000-00021; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; ZHANG JW, 1995, GYNECOL ONCOL, V57, P170, DOI 10.1006/gyno.1995.1120	46	28	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8140	8148		10.1038/sj.onc.1206026	http://dx.doi.org/10.1038/sj.onc.1206026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444549				2022-12-17	WOS:000179231400007
J	Modugno, M; Tagliabue, E; Ardini, E; Berno, V; Galmozzi, E; De Bortoli, M; Castronovo, V; Menard, S				Modugno, M; Tagliabue, E; Ardini, E; Berno, V; Galmozzi, E; De Bortoli, M; Castronovo, V; Menard, S			p53-dependent downregulation of metastasis-associated laminin receptor	ONCOGENE			English	Article						p53; laminin receptor; transcriptional regulation; AP-2; promoter	WILD-TYPE P53; GENE-EXPRESSION; OVARIAN-CARCINOMA; BREAST-CARCINOMA; CELL-GROWTH; PROTEIN; PRECURSOR; PROMOTER; ESTROGEN; CANCER	Based on observations suggesting a role for the tumor suppressor protein p53 in regulating expression of the 67-kDa laminin receptor precursor, 37LRP, we analysed the 37LRP promoter activity in a wild-type p53 (wt p53) ovarian carcinoma cell line and in a cisplatin-resistant subline with mutated p53. We observed an increased promoter activity in wt p53 cells as compared to the mutated-p53 line when the first intron of the 37LRP gene was present in the reporter construct. Cotransfection experiments showed that the promoter is downregulated by both wt and mutated p53. Deletion analysis of the first intron localized an enhancer activity in the first 5' 214 bp that upregulates both 37LRP and SV40 promoter activity and is repressed by both wt and mutant p53. Cotransfection, mutagenesis and gel-shift experiments identified a functional AP-2 cis-acting element in this intron region that is repressed by increased levels of both wt and mutated p53. Coimmunoprecipitation studies revealed AP-2 in physical association in vivo with both wt and mutated p53, indicating for the first time that interaction of p53 with AP-2 is involved in the repression mechanism and in the regulation of genes involved in cancer growth and progression.	Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Inst Canc Res & Treatment, Candiolo, Italy; Metastasis Res Lab, B-4000 Liege, Belgium	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Fondazione del Piemonte per l'Oncologia	Menard, S (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.		Tagliabue, Elda/B-9377-2017; Berno, Valeria/AAN-3997-2020; De Bortoli, Michele/B-5418-2013; menard, sylvie mm/C-7940-2011	Tagliabue, Elda/0000-0001-9877-2903; Berno, Valeria/0000-0001-5848-494X; De Bortoli, Michele/0000-0002-6666-9052; Galmozzi, Enrico/0000-0001-8831-2401				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Buto S, 1998, J CELL BIOCHEM, V69, P244, DOI 10.1002/(SICI)1097-4644(19980601)69:3<244::AID-JCB2>3.0.CO;2-R; Buto S, 1997, INT J BIOL MARKER, V12, P1; CASTRONOVO V, 1990, BIOCHEM BIOPH RES CO, V68, P1110; Clausse N, 1998, BIOCHEM BIOPH RES CO, V251, P564, DOI 10.1006/bbrc.1998.9431; DiLeo A, 1995, EUR J CANCER, V31A, P2248, DOI 10.1016/0959-8049(95)00481-5; Foley J, 1996, CANCER RES, V56, P4056; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Jackers P, 1996, ONCOGENE, V13, P495; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANDOWSKI TH, 1995, BIOCHEMISTRY-US, V34, P11276, DOI 10.1021/bi00035a037; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Loging WT, 1999, ONCOGENE, V18, P7608, DOI 10.1038/sj.onc.1203135; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARTIGNONE S, 1992, CLIN EXP METASTAS, V10, P379, DOI 10.1007/BF00133466; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.3.CO;2-O; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; Nadji M, 1999, CANCER-AM CANCER SOC, V85, P432, DOI 10.1002/(SICI)1097-0142(19990115)85:2<432::AID-CNCR22>3.0.CO;2-J; Pal S, 2001, CANCER RES, V61, P6952; Perego P, 1996, CANCER RES, V56, P556; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; PERREM K, 1995, ONCOGENE, V11, P1299; RAGHUNATH PN, 1993, J BIOL REG HOMEOS AG, V7, P22; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; Righetti SC, 1996, CANCER RES, V56, P689; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAO KS, 1995, CANCER RES, V55, P4367; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	37	28	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7478	7487		10.1038/sj.onc.1205957	http://dx.doi.org/10.1038/sj.onc.1205957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386810				2022-12-17	WOS:000178618200003
J	Abramovich, C; Chavez, EA; Lansdorp, PM; Humphries, RK				Abramovich, C; Chavez, EA; Lansdorp, PM; Humphries, RK			Functional characterization of multiple domains involved in the subcellular localization of the hematopoietic Pbx interacting protein (HPIP)	ONCOGENE			English	Article						hematopoietic Pbx interacting protein; cellular localization; nuclear import; nuclear export; microtubules	NUCLEAR EXPORT SIGNAL; IN-VIVO; GENE-EXPRESSION; CELLS CAUSES; HOX; BINDING; CRM1; OVEREXPRESSION; PREP1; ASSOCIATION	We have previously reported the cloning of the Hematopoietic Pbx Interacting Protein (HPIP), a novel protein discovered through its interaction with Pbx1. HPIP is expressed in early hematopoietic precursors, can bind all members of the Pbx family and can inhibit the transcriptional activation of the oncogene E2A-Pbx. To further understand the function of HPIP, we have analysed its cellular localization and characterized its functional localization domains. Using fluorescence microscopy to follow the distribution of different HPIP sequences fused to GFP, we found that HPIP localizes predominantly to cytoskeletal fibers but has the potential ability to shuttle between the nucleus and the cytosol. The cytoskeletal localization of HPIP is mediated by an N-terminal leucine rich region (between as 190-218) and can be disrupted by the microtubule destabilizing drug vincristine. The HPIP C-terminal domain (aa 443731) bears a nuclear export activity that is blocked by the CRM1 inhibitor Leptomycin B. In addition, we found two basic amino acid regions located between as 485505 and as 695-720 that contain nuclear import activities attenuated by nuclear export. These observations support a model in which the constitutive attachment of HPIP to the cytoskeleton could be modified by changes in functional domains implicated in nuclear export, import and cytoskeleton binding sequences, allowing the molecule to shuttle between the nucleus and the cytosol.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 2B5, Canada	British Columbia Cancer Agency; University of British Columbia	Humphries, RK (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.			Humphries, Richard/0000-0003-0540-7005; Lansdorp, Peter/0000-0001-7435-1071	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065430] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65430] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramovich C, 2000, J BIOL CHEM, V275, P26172, DOI 10.1074/jbc.M001323200; Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Buske C, 2001, BLOOD, V97, P2286, DOI 10.1182/blood.V97.8.2286; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; CORSETTI MT, 1995, J CELL SCI, V108, P187; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Graf L, 2001, BIOL BLOOD MARROW TR, V7, P486, DOI 10.1053/bbmt.2001.v7.pm11669215; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; LEE KK, 2002, J BIOL CHEM, V22, P22; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Selleri L, 2001, DEVELOPMENT, V128, P3543; Shen WF, 1999, MOL CELL BIOL, V19, P3051; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Veraksa A, 2000, MOL GENET METAB, V69, P85, DOI 10.1006/mgme.2000.2963; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	33	28	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6766	6771		10.1038/sj.onc.1205784	http://dx.doi.org/10.1038/sj.onc.1205784			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360403				2022-12-17	WOS:000178315800006
J	Amini, S; Clavo, A; Nadraga, Y; Giordano, A; Khalili, K; Sawaya, BE				Amini, S; Clavo, A; Nadraga, Y; Giordano, A; Khalili, K; Sawaya, BE			Interplay between cdk9 and NF-kappa B factors determines the level of HIV-1 gene transcription in astrocytic cells	ONCOGENE			English	Article						HIV-1 transcription; NF-kappa B; cdk9	HUMAN-IMMUNODEFICIENCY-VIRUS; TAR-INDEPENDENT TRANSACTIVATION; RNA-POLYMERASE-II; FACTOR P-TEFB; IN-VITRO; CELLULAR PROTEIN; PUR-ALPHA; CYCLIN T1; ACTIVATION; KINASE	Basal transcription of the HIV-1 genome is controlled by a variety of ubiquitous and inducible regulatory factors, some with the ability to associate with the viral DNA sequences within the promoter spanning the long terminal repeat (LTR). In this report we demonstrate that activation of the HIV-1 promoter through the inducible DNA binding NF-kappaB transcription factors can be affected by cdk9 in human astrocytic cells. Our results show that ectopic expression of cdk9, but not its mutant variant which lacks the domain responsible for its kinase activity, augments transcription of the LTR. Moreover, we demonstrate that induction of the NF-kappaB pathway by PMA, or overexpression of its subunits including p50/p65 have a negative effect on the ability of cdk9 to stimulate viral gene transcription in these cells. Results from band-shift experiments demonstrated significant suppression of p50/p65 association to its DNA target motif by cdk9. Further, data from GST pull-down and combined immunoprecipitation/Western blot analysis of the protein extracts from cells expressing cdk9, p50 and p65 have revealed the interaction of cdk9 with both p50 and p65 in the absence of DNA containing the kappaB motif. All of these observations led us to conclude that the interaction of cdk9 with the NF-kappaB factors can determine the ability of NF-kappaB to modulate HIV-1 gene transcription.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Temple Univ, Sbarro Inst Canc Res, Coll Sci & Technol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, 1900 N 12Th St 015-96,Room 203, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BANDRES JC, 1994, J VIROL, V68, P3243, DOI 10.1128/JVI.68.5.3243-3249.1994; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Gallia GL, 1999, P NATL ACAD SCI USA, V96, P11572, DOI 10.1073/pnas.96.20.11572; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Hiscott J, 1997, J LEUKOCYTE BIOL, V62, P82, DOI 10.1002/jlb.62.1.82; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; LINDHOLM P F, 1990, New Biologist, V2, P1034; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Rostasy K, 2000, J NEUROVIROL, V6, P537, DOI 10.3109/13550280009091954; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	27	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5797	5803		10.1038/sj.onc.1205754	http://dx.doi.org/10.1038/sj.onc.1205754			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173051				2022-12-17	WOS:000177463400016
J	Alarcon-Vargas, D; Tansey, WP; Ronai, Z				Alarcon-Vargas, D; Tansey, WP; Ronai, Z			Regulation of c-myc stability by selective stress conditions and by MEKK1 requires aa 127-189 of c-myc	ONCOGENE			English	Article						c-myc; stress kinases; MEKK1; protein stability; cytokines; TNF alpha	RECEPTOR-INTERACTING PROTEIN; CELL-LINE; PHOSPHORYLATION; TRANSACTIVATION; STABILIZATION; EXPRESSION; DEGRADATION; ACTIVATION; KINASE; JNK	C-myc availability is central for its ability to serve as a regulator of cell growth and death. Here we study the regulation of c-myc protein stability and identify domains of c-myc that are important for its stabilization in response to stress kinases activated following selective stress conditions. UV-irradiation elicited an increase in c-myc protein levels, which could be attenuated by inhibitors of stress kinases but also by actinomycin D-inhibitor of transcription. Inhibition of protein synthesis results in a noticeable decrease in c-myc levels, further pointing to the short half-life of the protein. However, in combination with tumor necrosis factor-alpha (TNF-alpha), cycloheximide efficiently increases steady-state levels of C-myc, suggesting that selective stress conditions are required to increase c-myc protein stability. Expression of MEKK1, an upstream regulator of protein kinases that has been implicated in mediating the response to diverse stress conditions, also results in an efficient increase in the half-life of c-myc protein. To map c-myc domains that are responsive to stress kinases, we monitored changes in the level of c-myc deletion mutants following MEKK1 expression. Of the seven c-myc deletion mutants analysed, the domain spanning amino acids 127-189 was found to be required for MEKK1-dependent increase in c-myc stability. In all, the present study identifies a novel domain that is important for the regulation of c-myc stability by stress kinases in response to selective stress conditions.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Cold Spring Harbor Laboratory	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419, P01CA013106, F31CA085197] Funding Source: NIH RePORTER; NCI NIH HHS [CA85197, CA13106, CA78419] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Dang CV, 1999, MOL CELL BIOL, V19, P1; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Gavine PR, 1999, ONCOGENE, V18, P7552, DOI 10.1038/sj.onc.1203102; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Herbst A, 2000, MOL BIOL REP, V27, P203, DOI 10.1023/A:1011008018565; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Kim JW, 2001, J BIOL CHEM, V276, P27064, DOI 10.1074/jbc.M009364200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Park IC, 1998, CANCER LETT, V125, P17, DOI 10.1016/S0304-3835(97)00450-3; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; PULVERER BJ, 1994, ONCOGENE, V9, P59; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SETH A, 1991, J BIOL CHEM, V266, P23521; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; WATERS CM, 1991, ONCOGENE, V6, P797; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	45	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4384	4391		10.1038/sj.onc.1205543	http://dx.doi.org/10.1038/sj.onc.1205543			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080469				2022-12-17	WOS:000176317100004
J	Sarker, M; Ruiz-Ruiz, C; Robledo, G; Lopez-Rivas, A				Sarker, M; Ruiz-Ruiz, C; Robledo, G; Lopez-Rivas, A			Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells	ONCOGENE			English	Article						MAPK; TRAIL; apoptosis; MCF-7 cells; mitochondria	CYTOCHROME-C; TUMOR-CELLS; IN-VIVO; T-CELLS; DEATH; CASPASE-3; BCL-2; CHEMOTHERAPY; SENSITIVITY; LYMPHOCYTES	We studied the role of the mitogen-activated protein kinase (MAPK) pathway in the regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in breast tumor MCF-7 cells. We found that addition of a protein kinase C (PKC) activator to MCF-7 cultures prevented TRAIL-induced apoptosis, by inhibiting a step downstream of both caspase-8 activation and BID cleavage. TRAIL-induced translocation of Bax from cytosol to mitochondria, release of cytochrome c from mitochondria and activation of caspase-9 were all inhibited by PKC activation. PKC-mediated prevention of mitochondrial apoptotic events; and apoptosis was found to be dependent on the MAPK pathway. Since TRAIL is a ligand of potential use in antineoplastic clinical trials, our findings may provide relevant information in cancer therapy.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.		Ruiz-Ruiz, Carmen/I-8792-2017; Lopez-Rivas, Abelardo/E-5115-2015	Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Lopez-Rivas, Abelardo/0000-0002-9351-9690				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; ILLERA VA, 1993, J IMMUNOL, V151, P2965; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jarvis WD, 1999, INVEST NEW DRUG, V17, P227, DOI 10.1023/A:1006328303451; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	34	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4323	4327		10.1038/sj.onc.1205523	http://dx.doi.org/10.1038/sj.onc.1205523			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082620				2022-12-17	WOS:000176174200015
J	Stein, T; Crighton, D; Boyle, JM; Varley, JM; White, RJ				Stein, T; Crighton, D; Boyle, JM; Varley, JM; White, RJ			RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome	ONCOGENE			English	Article						E6; p53; Li-Fraumeni; mdm2; RNA polymerase III; transcription	WILD-TYPE P53; TATA-BINDING-PROTEIN; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; HUMAN TUMORS; DNA-BINDING; REPRESSION; CANCER; GROWTH	RNA polymerase (pol) III synthesizes essential small RNAs, including tRNA and 5S rRNA. Wild-type p53 can repress pol III transcription both in vitro and in vivo. Many tumours carry substitutions in p53 which have selective effects on its functions. We identify tumour-derived mutations that compromise the ability of p53 to regulate pol III transcription. Furthermore, substitution R175H, the most common mutation in cancers, converts p53 from a repressor to an activator of pol III. Oncoproteins neutralize p53 in some tumours; we show that human papillomavirus E6 and cellular hdm2 can both release pol III from repression by p53. These data suggest that the restraining influence of p53 on pol III will be lost in many tumours. In addition to these features of sporadic cancers, some individuals inherit mutant forms of p53 and consequently suffer from Li-Fraumeni syndrome, showing genetic predisposition to certain malignancies. We find that pol III transcriptional activity is often highly elevated in primary fibroblasts from Li-Fraumeni patients, especially if the germline p53 mutation is followed by loss of the remaining allele. Our data suggest that p53 status can have a profound effect upon pol III transcription and hence on the biosynthetic capacity of cells.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Paterson Inst Canc Res, Canc Res UK Dept Canc Genet, Manchester M20 9BX, Lancs, England	University of Glasgow; Paterson Institute for Cancer Research	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	rwhite@bio.gla.ac.uk	Stein, Torsten/G-1147-2012	Stein, Torsten/0000-0002-9946-1549				AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Boyle JM, 1998, BRIT J CANCER, V77, P2181, DOI 10.1038/bjc.1998.364; Brown TRP, 2000, GENE EXPRESSION, V9, P15; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONCHOWER LA, 1992, NATURE, V356, P215; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Eichhorn K, 2001, J BIOL CHEM, V276, P21158, DOI 10.1074/jbc.M102295200; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOH HS, 1995, CANCER RES, V55, P5217; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1996, ONCOGENE, V12, P2437; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Varley JM, 2001, ONCOGENE, V20, P2647, DOI 10.1038/sj.onc.1204369; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WANG HD, 1995, MOL CELL BIOL, V15, P6720; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; Zhao RB, 2000, GENE DEV, V14, P981	87	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2961	2970		10.1038/sj.onc.1205372	http://dx.doi.org/10.1038/sj.onc.1205372			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082526				2022-12-17	WOS:000175262700003
J	Koch, CA; Huang, SC; Zhuang, ZP; Stolle, C; Azumi, N; Chrousos, GP; Vortmeyer, AO; Pacak, K				Koch, CA; Huang, SC; Zhuang, ZP; Stolle, C; Azumi, N; Chrousos, GP; Vortmeyer, AO; Pacak, K			Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma	ONCOGENE			English	Article						RET; MEN 2; VHL; pheochromocytoma; deletion	HIPPEL-LINDAU-DISEASE; TUMOR-SUPPRESSOR GENE; RET PROTOONCOGENE; SPORADIC PHEOCHROMOCYTOMAS; GERMLINE MUTATIONS; SHORT ARM; HETEROZYGOSITY; EVENTS; ALLELE; 1P	Multiple endocrine neoplasia type 2 (MEN 2) is an inherited cancer syndrome that includes pheochromocytoma. Germline mutations in RET are responsible for MEN 2 but the precise pathogenetic mechanisms of tumorigenesis are unknown. We have recently identified possible mechanisms of tumor formation in patients with MEN 2A-related pheochromocytoma. Two of nine tumors investigated, however, did not reveal either of these mechanisms. In the present study, we therefore searched for other possible mechanisms underlying the pathogenesis of MEN 2A-related pheochromocytoma. Hereditary pheochromocytoma also occurs in patients with von Hippel-Lindau (VHL) disease, a syndrome consisting of tumors caused by inactivation of the VHL tumor suppressor gene. A subset of sporadic pheochromocytomas have somatic mutations in RET or VHL, suggesting that both genes contribute to pheochromocytoma pathogenesis in a subset of tumors. It is unknown, however; whether VHL gene alterations would be associated with tumorigenesis in hereditary, MEN 2-related pheochromocytoma. We therefore investigated four pheochromocytomas from patients with MEN 2A and RET germline mutations for the presence of allelic deletion and/or somatic mutation of the VHL gene. LOH analysis using the polymorphic markers D3S1038 and D3S1110 that map to the VHL gene locus 3p25/26, revealed evidence for somatic VHL gene deletion in all four MEN 2A-related pheochromocytomas. Mutation analysis of the VHL gene showed frameshift mutations in two tumors and a splice acceptor mutation in one tumor. The remaining tumor did show LOH but not mutation of the VHL gene. These results suggest that somatic genetic alterations of the VHL gene may play a role in the tumorigenesis of some MEN 2A-related pheochromocytomas.	NICHHD, PREB, NIH, Bethesda, MD 20892 USA; NINCDS, Surg Neurol Branch, Mol Pathogenesis Unit, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Georgetown Univ, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Pennsylvania; Georgetown University	Koch, CA (corresponding author), NICHHD, PREB, NIH, Bldg 10,Rm 9D42, Bethesda, MD 20892 USA.	kochc@exchange.nih.gov	Koch, Christian A/A-4699-2008	Koch, Christian A/0000-0003-3127-5739; Koch, Christian/0000-0003-0678-1242	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000615, ZIAHD000618] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD000618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BELDJORD C, 1995, J CLIN ENDOCR METAB, V80, P2063, DOI 10.1210/jc.80.7.2063; Bender BU, 2000, J CLIN ENDOCR METAB, V85, P4568, DOI 10.1210/jc.85.12.4568; Benn DE, 2000, CANCER RES, V60, P7048; Brauch H, 1997, J CLIN ENDOCR METAB, V82, P4101, DOI 10.1210/jc.82.12.4101; CHOYKE PL, 1995, RADIOLOGY, V194, P629, DOI 10.1148/radiology.194.3.7862955; CROSSEY PA, 1994, HUM GENET, V93, P53; CROSSEY PA, 1995, J MED GENET, V32, P885, DOI 10.1136/jmg.32.11.885; Dannenberg H, 2000, AM J PATHOL, V157, P353, DOI 10.1016/S0002-9440(10)64547-6; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang SC, 2000, CANCER RES, V60, P6223; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LINDOR NM, 1995, J CLIN ENDOCR METAB, V80, P627, DOI 10.1210/jc.80.2.627; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; MOLEY JF, 1992, CANCER RES, V52, P770; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Prowse AH, 1997, AM J HUM GENET, V60, P765; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; Vargas MP, 1997, HUM PATHOL, V28, P411, DOI 10.1016/S0046-8177(97)90028-9; Walther MM, 1999, J UROLOGY, V162, P659, DOI 10.1097/00005392-199909010-00004; ZEIGER MA, 1995, GENE CHROMOSOME CANC, V13, P151, DOI 10.1002/gcc.2870130303; Zhuang Z, 1998, Cell Vis, V5, P43	30	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					479	482		10.1038/sj.onc.1205133	http://dx.doi.org/10.1038/sj.onc.1205133			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821960				2022-12-17	WOS:000173311200016
J	Yasunaga, Y; Nakamura, K; Ko, DJ; Srivstava, S; Moul, JW; Sesterhenn, IA; McLeod, DG; Rhim, JS				Yasunaga, Y; Nakamura, K; Ko, DJ; Srivstava, S; Moul, JW; Sesterhenn, IA; McLeod, DG; Rhim, JS			A novel human cancer culture model for the study of prostate cancer	ONCOGENE			English	Article						human prostate cancer cell line; immortalization; telomerase	HUMAN PAPILLOMAVIRUS DNA; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; EXPRESSION; ADENOCARCINOMA; PROGRESSION; ACTIVATION; PHENOTYPE; TISSUE; LINES	Research into molecular and genetic mechanisms underlying prostate carcinogenesis would be greatly advanced by in vitro models of prostate tumors representing primary tumors. We have successfully established an immortalized human prostate epithelial (HPE) cell culture derived from a primary tumor with telomerase. The actively proliferating early passaged RC-58T cells were transduced through infection with a retrovirus vector expressing the human telomerase catalytic subunit (hTERT). A high level of telomerase was detected in RC-58T/hTERT cells but not RC-58T cells. RC-58T/hTERT cells are currently growing well at passage 50, whereas RC-58T cells senesced at passage 7. RC-58T/hTERT cells exhibit transformed morphology. More importantly, these immortalized cells showed anchorage-independent growth as they formed colonies in soft agar and grew above the agar laver. Expression of androgen-regulated prostate specific gene NKX3.1 and epithelial specific cytokeratin 8 (CK8) but not prostate specific antigen (PSA) and androgen receptor was detected in RC-58T/hTERT cells. Prostate stem cell antigen (PSCA) and p16 were also expressed in this cell line. RC-58T/hTERT cells showed growth inhibition when exposed to retinoic acid and transforming growth factor (TGF)-beta1 known potent inhibitors of prostate epithelial cell growth. A number of chromosome alterations were observed including the loss of chromosomes Y, 3p, 10p, 17p, 18q and the gain of chromosomes 16 and 20. These results demonstrate that this primary tumor-derived HPE cell line retained its transformed phenotypes and should allow studies to elucidate molecular and genetic alterations involved in prostate cancer. This is the first documented case of an established human prostate cancer cell line from a primary tumor of a prostate cancer patient with telomerase.	Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, Bethesda, MD 20814 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20307 USA; Walter Reed Army Med Ctr, Dept Surg, Serv Urol, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Rhim, JS (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.							Alers JC, 2000, LAB INVEST, V80, P931, DOI 10.1038/labinvest.3780096; ANWAR K, 1992, CANCER RES, V52, P5991; Bright RK, 1997, CANCER RES, V57, P995; Brothman AR, 1999, PROSTATE, V38, P303; Burger AM, 1998, INT J ONCOL, V13, P1043; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; Gibbs M, 1999, AM J HUM GENET, V64, P776, DOI 10.1086/302287; Greider CW, 1999, TRENDS GENET, V15, P109, DOI 10.1016/S0168-9525(98)01681-3; Hukku B, 2000, CANCER GENET CYTOGEN, V120, P117, DOI 10.1016/S0165-4608(00)00216-8; Ittmann MM, 1998, ONCOL REP, V5, P1329; Iype PT, 1998, INT J ONCOL, V12, P257; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; MCNICOL PJ, 1990, J CLIN MICROBIOL, V28, P409, DOI 10.1128/JCM.28.3.409-412.1990; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Peehl DM, 1989, GROWTH FACTORS, V1, P237, DOI 10.3109/08977198908998000; Perinchery G, 1999, INT J CANCER, V83, P610, DOI 10.1002/(SICI)1097-0215(19991126)83:5<610::AID-IJC7>3.0.CO;2-2; Ratsch SB, 2001, RADIAT RES, V155, P143, DOI 10.1667/0033-7587(2001)155[0143:MGCARF]2.0.CO;2; Rhim JS, 2000, PROSTATE CANCER P D, V3, P229, DOI 10.1038/sj.pcan.4500470; Sauter G, 1998, PATHOLOGE, V19, P63, DOI 10.1007/s002920050256; Serth J, 1999, CANCER RES, V59, P823; Sommerfeld HJ, 1996, CANCER RES, V56, P218; STEUER AF, 1977, J NATL CANCER I, V58, P917, DOI 10.1093/jnci/58.4.917; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Xu LL, 2000, J UROLOGY, V163, P972, DOI 10.1016/S0022-5347(05)67867-6; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141	29	28	31	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					8036	8041		10.1038/sj.onc.1205002	http://dx.doi.org/10.1038/sj.onc.1205002			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753687				2022-12-17	WOS:000172288700013
J	Greenland, C; Touriol, C; Chevillard, G; Morris, SW; Bai, RY; Duyster, J; Delsol, G; Allouche, M				Greenland, C; Touriol, C; Chevillard, G; Morris, SW; Bai, RY; Duyster, J; Delsol, G; Allouche, M			Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis	ONCOGENE			English	Article						anaplastic large cell lymphoma; ALK; tyrosine kinase; chemotherapy; apoptosis	RECEPTOR TYROSINE KINASE; NON-HODGKINS-LYMPHOMA; FACTOR I RECEPTOR; ANAPLASTIC LYMPHOMA; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; POSITIVE LYMPHOMA; LEUKEMIC-CELLS; FRENCH SOCIETY	Anaplastic large cell lymphomas (ALCLs), are frequently associated with, the t(2;5)(p23;q35) translocation, leading to the expression of NPM-ALK, a fusion protein linking nucleophosmin and anaplastic lymphoma kinase, a receptor tyrosine kinase. In ALCLs, dimerization of NPM-ALK leads to constitutive autophosphorylation and activation of the kinase, necessary for NPM-ALK oncogenicity.. To investigate whether NPM-ALK, like other oncogenic tyrosine kinases, can, inhibit drug-induced apoptosis, we permanently transfected NPM-ALK into Jurkat T-cells. As, in ALCLs, NPM-ALK was expressed as, a constitutively kinase-active 80 kDa protein, and could be detected by immunocytochemistry in nucleoli, nuclei and cytoplasm. Doxorubicin-induced apoptosis (assessed by cell morphology and annexin V-FITC binding), was significantly inhibited in two independent NPM-ALK-expressing clones (5.2 +/- 1.8 and 7.5 +/- 0.8%, apoptosis), compared to control vector-transduced cells (36 +/- 6.7%). Similar results were observed with etoposide. In contrast, Fas-induced apoptosis, was not inhibited. Cytochrome c release into the cytosol was delayed in doxorubicin-, but not anti-Fas-treated transfectant cells, indicating that apoptosis inhibition occurred upstream of mitochondrial events. Using NPM-ALK mutants, we demonstrated that inhibition of drug-induced apoptosis: (1) requires functional kinase activity, (2) does not involve phospholipase C-gamma, essential for NPM-ALK-mediated mitogenicity and (3) appears to: be phosphoinositide 3-kinase independent, despite a strong Akt/PKB activation observed in wild type NPM-ALK-expressing cells. These results suggest that the NPM-ALK antiapoptotic and mitogenic pathways are distinct.	CHU Purpan, CNRS UPR2163, UPCM, F-31059 Toulouse 03, France; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-8000 Munich, Germany	CHU de Toulouse; St Jude Children's Research Hospital; Technical University of Munich; University of Munich	Allouche, M (corresponding author), CHU Purpan, CNRS UPR2163, UPCM, Ave Grande Bretagne, F-31059 Toulouse 03, France.	allouche@cict.fr	TOURIOL, Christian/O-8949-2014	TOURIOL, Christian/0000-0003-1219-4693	NCI NIH HHS [CA21765, CA69129] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA069129] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Brugieres L, 2000, ANN ONCOL, V11, P53, DOI 10.1023/A:1008352726155; Brugieres L, 1998, BLOOD, V92, P3591; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; Collins P, 2000, NAT REV NEUROSCI, V1, P156, DOI 10.1038/35044513; DELSOL G, 1988, AM J PATHOL, V130, P59; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Hernandez L, 1999, BLOOD, V94, P3265; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jain SK, 1996, BLOOD, V88, P1542; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lamant L, 1996, BLOOD, V87, P284; Lamant L, 1999, BLOOD, V93, P3088; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mason DY, 1998, CANCER RES, V58, P1057; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; McGahon AJ, 1998, BRIT J HAEMATOL, V101, P539, DOI 10.1046/j.1365-2141.1998.00745.x; MORGAN R, 1989, BLOOD, V73, P2155; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Ollendorff V, 1999, J BIOL CHEM, V274, P26922, DOI 10.1074/jbc.274.38.26922; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Ross TS, 1999, J BIOL CHEM, V274, P22328, DOI 10.1074/jbc.274.32.22328; Sanchez-Alcazar JA, 2000, CELL DEATH DIFFER, V7, P1090, DOI 10.1038/sj.cdd.4400740; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Villunger A, 1997, CANCER RES, V57, P3331; Warmuth M, 1999, ANN HEMATOL, V78, P49, DOI 10.1007/s002770050473; Wellmann A, 1997, FASEB J, V11, P965, DOI 10.1096/fasebj.11.12.9337149; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YIN DX, 1995, CANCER RES, V55, P4922	74	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7386	7397		10.1038/sj.onc.1204870	http://dx.doi.org/10.1038/sj.onc.1204870			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704868				2022-12-17	WOS:000171894200011
J	Fujimura, Y; Siddique, H; Lee, L; Rao, VN; Reddy, ESP				Fujimura, Y; Siddique, H; Lee, L; Rao, VN; Reddy, ESP			EWS-ATF-1 chimeric protein in soft tissue clear cell sarcoma associates with CREB-binding protein and interferes with p53-mediated trans-activation function	ONCOGENE			English	Article						EWS-ATF-1; CBP; p53; Ewing's sarcoma; clear cell sarcoma	ACUTE MYELOID-LEUKEMIA; RNA-POLYMERASE-II; CHROMOSOME-TRANSLOCATION; EWINGS-SARCOMA; MALIGNANT-MELANOMA; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; GENE FUSION; EWS GENE; MYXOID LIPOSARCOMA	The recurrent t(12;22) (q13;q12) chromosomal translocation associated with soft tissue clear cell sarcoma results in a chimeric protein EWS-ATF-1 that acts as a constitutive transcriptional activator. The CBP/p300 transcriptional coactivator, which links various transcriptional factors to basal transcription apparatus, participates in transcriptional activation, growth and cell cycle control and differentiation. In this study, we show that EWS-ATF-1 associates constitutively with CBP both in vitro and in vivo. Both EWS and ATF-1 fusion domains are needed for this interaction. Here, we demonstrate that EWS-ATF-1 represses p53/CBP-mediated transactivation function. Overexpression of CBP can counteract this repressive effect of EWS-ATF-1. Taken together, these findings suggest that one of the mechanisms by which EWS-ATF-1 may cause tumors is through targeting CBP/p300 resulting in the loss of function of p53. This novel mechanism may be responsible for the development of these and other related solid tumors.	Med Coll Penn & Hahnemann Univ, Sch Med, Program Canc Genet, Canc Ctr,Dept Biochem, Philadelphia, PA 19102 USA; SAIC, Frederick, MD 21702 USA	Drexel University; Science Applications International Corporation (SAIC); SAIC-Frederick	Reddy, ESP (corresponding author), Med Coll Penn & Hahnemann Univ, Sch Med, Program Canc Genet, Canc Ctr,Dept Biochem, Broad & Vine,MS 481, Philadelphia, PA 19102 USA.				NCI NIH HHS [R01 CA58642, R01 CA 85343, CA 57322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085343, R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BROWN AD, 1995, ONCOGENE, V10, P1749; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN AL, 1984, CANCER RES, V44, P1265; Fujimura Y, 1996, ONCOGENE, V12, P159; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kung AL, 2000, GENE DEV, V14, P272; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	52	28	28	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6653	6659		10.1038/sj.onc.1204684	http://dx.doi.org/10.1038/sj.onc.1204684			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709699				2022-12-17	WOS:000171551600001
J	Schmidt, M; Fan, Z				Schmidt, M; Fan, Z			Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells	ONCOGENE			English	Article						chemotherapy; chemoprotection; Rb; cell cycle; CDK	HUMAN PAPILLOMAVIRUS TYPE-16; EPIDERMAL GROWTH-FACTOR; G(1) ARREST; RETINOBLASTOMA PROTEIN; E7 ONCOPROTEIN; CDK INHIBITORS; GENE; DIFFERENTIATION; P27(KIP1); BINDING	Inactivation of the retinoblastoma (Rb) protein caused by gene mutation, association with oncoproteins from small DNA viruses, mutational inactivation of p16(Ink4a), or overexpression of cyclin D is a common feature of many human cancer cells and is causally associated with the aberrant proliferation control of cancer cells; whereas normal cells maintain an integrated cell cycle machinery and are subject to cell cycle checkpoint control by cyclin-dependent kinase (CDK) inhibitors (CKIs). To determine whether this difference can be translated into a therapeutic advantage to protect normal cells from adverse cytotoxicity caused by chemotherapy, we established cell model systems for ecdysone-inducible expression of p16(Ink4a), p21(Waf1), and p27(Kip1) in one CKI-responsive cell line (A431 human vulvar epidermoid carcinoma cells with functional Rb) and one CKI-unresponsive cell line (SiHa human cervical cancer cells with nonfunctional Rb). Expression of p16(Ink4a), p21(Waf1), or p27(Kip1) in both SiHa and A431 cells strongly inhibited CDK2 activity, indicating functional expression of the CDK inhibitors in both cell lines. However, only in A431 cells did expression of p16(Ink4a), p21(Waf1), or p27(Kip1) cause Rb dephosphorylation, arrest cell cycle traversal, and potently inhibit cell proliferation. Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) in SiHa cells failed to cause Rb dephosphorylation or to arrest cell cycle traversal, and such induction only minimally inhibited cell proliferation. We then compared the chemosensitivity of clones derived from these two cell lines when the CKIs were and were not induced. Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells. Our results support a novel chemotherapy strategy for treating patients with Rb pathway-impaired cancers by concurrent administration of chemotherapy with CKIs as chemoprotective agents for normal cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 36, Houston, TX 77030 USA.				NCI NIH HHS [CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Boyer SN, 1996, CANCER RES, V56, P4620; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; Davis ST, 2001, SCIENCE, V291, P134, DOI 10.1126/science.291.5501.134; Dellas A, 1998, ANTICANCER RES, V18, P3991; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Fueyo J, 1998, INT J ONCOL, V12, P665; Funk JO, 1998, TRENDS BIOCHEM SCI, V23, P337; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; JONES RE, 1990, J BIOL CHEM, V265, P12782; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; KWOK TT, 1994, CANCER RES, V54, P2834; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; MUNGER K, 1992, CANCER SURV, V12, P197; Ruan S, 1998, CANCER RES, V58, P1538; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; SCHMIDT M, 2001, IN PRESS MOL PHARM; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; StCroix B, 1996, NAT MED, V2, P1204; Stone S, 1996, CANCER RES, V56, P3199; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; Wu XP, 1996, ONCOGENE, V12, P1397; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	41	28	42	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6164	6171		10.1038/sj.onc.1204814	http://dx.doi.org/10.1038/sj.onc.1204814			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593424				2022-12-17	WOS:000171206300007
J	Malabarba, MG; Milia, E; Faretta, M; Zamponi, R; Pelicci, PG; Di Fiore, PP				Malabarba, MG; Milia, E; Faretta, M; Zamponi, R; Pelicci, PG; Di Fiore, PP			A repertoire library that allows the selection of synthetic SH2s with altered binding specificities	ONCOGENE			English	Article						SH2; phosphotyrosine; scaffold library; scaffold engineering	AFFINITY PHOSPHOTYROSYL PEPTIDE; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; CRYSTAL-STRUCTURES; DOMAIN; PROTEIN; KINASE; BIOSENSORS; COMPLEXES; RESIDUES	Tyrosine phosphorylation is one of the major mechanisms involved in the intracellular propagation of external signals. Strategies aimed at interfering with this process might allow the control of several cellular phenotypes. SH2 domains mediate protein-protein interactions by recognizing phosphotyrosine (pY) residues in the context of specific phosphopeptides. We created an SH2-scaffolded repertoire library by randomly mutagenizing five critical amino acid positions in the specificity-determining region of the PLC gamma C-terminal SH2 domain. Synthetic SH2 domains were selected from the library using biotinylated phosphopeptides; derived from a natural PLC gamma -SH2 ligand as well as unrelated SH2 ligands. The isolated SH2s displayed high binding affinity constants for the selecting peptides and were capable of interacting with the corresponding proteins.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; IFOM, FIRC Inst Mol Oncol, I-20090 Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Di Fiore, PP (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pdifiore@ieo.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Di Fiore, Pier Paolo/K-2130-2012; Faretta, Mario/H-8946-2012; Zamponi, Raffaella/V-5683-2018; Malabarba, Maria Grazia/L-4805-2015	Di Fiore, Pier Paolo/0000-0002-2252-0950; Faretta, Mario/0000-0003-1678-5781; Malabarba, Maria Grazia/0000-0002-9457-2047; Zamponi, Raffaella/0000-0002-3313-1387				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; Bradshaw JM, 2000, J MOL BIOL, V299, P521; Breeze AL, 1996, EMBO J, V15, P3579, DOI 10.1002/j.1460-2075.1996.tb00727.x; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Ikeda M, 1996, GENE, V181, P167, DOI 10.1016/S0378-1119(96)00497-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAROSE L, 1993, ONCOGENE, V8, P2493; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morton TA, 1998, METHOD ENZYMOL, V295, P268; NARULA SS, 1995, STRUCTURE, V3, P1061, DOI 10.1016/S0969-2126(01)00242-8; Ogura K, 1999, J MOL BIOL, V289, P439, DOI 10.1006/jmbi.1999.2792; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; SALCINI AE, 1994, ONCOGENE, V9, P2827; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Shoelson SE, 1997, CURR OPIN CHEM BIOL, V1, P227, DOI 10.1016/S1367-5931(97)80014-2; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	28	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5186	5194		10.1038/sj.onc.1204654	http://dx.doi.org/10.1038/sj.onc.1204654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526507				2022-12-17	WOS:000170464000012
J	Fuhrmann, G; Leisser, C; Rosenberger, G; Grusch, M; Huettenbrenner, S; Halama, T; Mosberger, I; Sasgary, S; Cerni, C; Krupitza, G				Fuhrmann, G; Leisser, C; Rosenberger, G; Grusch, M; Huettenbrenner, S; Halama, T; Mosberger, I; Sasgary, S; Cerni, C; Krupitza, G			Cdc25A phosphatase suppresses apoptosis induced by serum deprivation	ONCOGENE			English	Article						Cdc25; apoptosis; survival; Akt; Raf1; c-myc; signal transduction	CELL-CYCLE REGULATION; S-PHASE ENTRY; C-MYC; PROTEIN-KINASES; TNF-ALPHA; ACTIVATION; INDUCTION; PHOSPHORYLATION; EXPRESSION; 14-3-3-PROTEINS	The phosphatase Cdc25A was shown to be a target of the transcription factor c-Myc. Myc-induced apoptosis appeared dependent on Cdc25A expression and Cdc25A over-expression could substitute for Myc-triggered apoptosis. These findings suggested that an important downstream component of Myc-mediated apoptosis was identified. However and in contrast, we recently reported that during TNF alpha -induced apoptosis, which required c-Myc function, Cdc25A was down-regulated in a human carcinoma cell line. We now provide evidence that Cdc25A rendered the non-transformed rat embryonic cell line 423 refractory to apoptosis, which was induced by serum deprivation and in absence of detectable c-myc levels. The survival promoting activity of cdc25A was abolished upon infection of cells with a full-length cdc25A antisense construct. To identify the signaling proteins mediating the survival function of the phosphatase, cdc25A- and akt- over-expressing pooled clones were exposed to selected chemicals, which inhibit or activate key proteins in signaling pathways. Inhibition of apoptosis by SU4984, NF023 and Rapamycin placed Cdc25A and Akt function downstream of FGF.R, PDGF.R, and compensated G-protein- and PP2A-activity. Interestingly, upon treatment with LY-294002, cdc25A- and akt- over-expressing clones exhibited similar apoptotic patterns as control cells, which indicates that neither Akt- nor Cdc25A-mediated survival functions are dependent on PI.3 kinase activity in rat 423 cells. In cdc25A-overexpressing cells increased levels of serine 473 phosphorylated Akt were found, which coprecipitated with Cdc25A and Raf1. Since activation of proteins requires dephosphorylation of particular residues in addition to site-specific phosphorylation, the antiapoptotic effect of Cdc25A might derive from its participation in a multimeric protein complex with phosphoAkt and Raf1, two prominent components of survival pathways.	Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria; Univ Vienna, Dept Gen Dermatol, A-1090 Vienna, Austria; Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Krupitza, G (corresponding author), Univ Vienna, Inst Clin Pathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Grusch, Michael/C-1183-2008	Grusch, Michael/0000-0001-5486-9340; Krupitza, Georg/0000-0003-2949-7906				CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Das G, 1999, SCAND J IMMUNOL, V49, P307, DOI 10.1046/j.1365-3083.1999.00486.x; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Grusch M, 1999, CELL DEATH DIFFER, V6, P736, DOI 10.1038/sj.cdd.4400546; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jaworowski A, 1999, IMMUNOL CELL BIOL, V77, P90, DOI 10.1046/j.1440-1711.1999.00798.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JOLLES J, 1993, DEMENTIA, V4, P81, DOI 10.1159/000107301; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Krupitza G, 1998, CELL DEATH DIFFER, V5, P758, DOI 10.1038/sj.cdd.4400417; KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Simonitsch I, 1998, BRIT J CANCER, V78, P862, DOI 10.1038/bjc.1998.594; Spitkovsky D, 1996, ONCOGENE, V12, P2549; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xia K, 1999, MOL CELL BIOL, V19, P4819	45	28	30	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4542	4553		10.1038/sj.onc.1204499	http://dx.doi.org/10.1038/sj.onc.1204499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494150				2022-12-17	WOS:000170074900012
J	Barette, C; Jariel-Encontre, I; Piechaczyk, M; Piette, J				Barette, C; Jariel-Encontre, I; Piechaczyk, M; Piette, J			Human cyclin C protein is stabilized by its associated kinase cdk8, independently of its catalytic activity	ONCOGENE			English	Article						cyclin C; cdk8; degradation; proteasome; ubiquitin	RNA-POLYMERASE-II; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE; TRANSCRIPTIONAL CONTROL; RAPID DEGRADATION; MEDIATOR COMPLEX; MAMMALIAN-CELLS; MESSENGER-RNA; CLN FUNCTION; DNA-REPAIR	Cyclin C belongs to the cyclin family of proteins that control cell cycle transitions through activation of specific catalytic subunits, the cyclin-dependent kinases (CDKs), However, there is as yet no evidence, for any role of cyclin C and its partner, cdk8, in cell cycle regulation. Rather, the cyclin C-cdk8 complex was found associated with the RNA polymerase II transcription machinery. The periodic degradation of bona fide cyclins is crucial for cell-cycle progression and depends on the catalytic activity of the associated CDK. Here we,ve show that endogenous cyclin C protein is quite stable with a half-life of 4 h, In contrast, exogenously expressed cyclin C is very unstable (half-life 15 min) and degraded by the ubiquitin-proteasome pathway. Co-expression with its associated cdk, however, strongly stabilizes cyclin C and results in a protein half-life near that of endogenous cyclin C. In stark contrast to data reported for other members of the cyclin family, both catalytically active and inactive cdk8 induce cyclin C stabilization. Moreover, this stabilization is accompanied in both cases by phosphorylation of the cyclin,which is not detectable when unstable. Our results indicate that cyclin C has apparently diverged from other cyclins in the regulation of its stability by its CDK partner.	CNRS, UMR 5535, Inst Genet Mol, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piette, J (corresponding author), CNRS, UMR 5535, Inst Genet Mol, IFR24,1919 Route Mende, F-34293 Montpellier 5, France.		PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597; BARETTE, Caroline/0000-0003-0999-7751				Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; CARLSON M, 1984, GENETICS, V107, P19; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Hautbergue G, 1999, MOL CELL BIOL, V19, P2527; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirst M, 1999, MOL CELL, V3, P673, DOI 10.1016/S1097-2765(00)80360-3; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; Lania L, 1999, J CELL PHYSIOL, V179, P134, DOI 10.1002/(SICI)1097-4652(199905)179:2<134::AID-JCP3>3.0.CO;2-O; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Rickert P, 1999, ONCOGENE, V18, P1093, DOI 10.1038/sj.onc.1202399; Rickert P, 1996, ONCOGENE, V12, P2631; Sambrook J, 1989, MOL CLONING LAB MANU; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; STRICH R, 1989, P NATL ACAD SCI USA, V86, P10018, DOI 10.1073/pnas.86.24.10018; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; SUROSKY RT, 1994, MOL CELL BIOL, V14, P3446, DOI 10.1128/MCB.14.5.3446; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158	53	28	28	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					551	562		10.1038/sj.onc.1204129	http://dx.doi.org/10.1038/sj.onc.1204129			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313987				2022-12-17	WOS:000166755000002
J	Blagosklonny, MV				Blagosklonny, MV			Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors	ONCOGENE			English	Review						p53; VHL; HIF-1 alpha; mdm-2; beta-catenin	INDUCIBLE FACTOR 1-ALPHA; DNA-DAMAGE; PROTEIN; HYPOXIA; GENE; TRANSCRIPTION; STABILIZATION; ACTIVATION; STABILITY; PROMOTES	Recently it has been shown that the VHL tumor suppressor targets the hypoxia-inducible transcription factor (HIF-1) for ubiquitin-dependent degradation by the proteasome, Past mysteries of the p53 tumor suppressor help to solve the present puzzles of the VHL tumor suppressor. Thus, Mdm-2 targets the p53 tumor suppressor for ubiquitin-dependent degradation by the proteasome, but, in addition, the p53 transcription factor induces Mdm-2, thus, establishing a feedback loop. Hypoxia or DNA damage by abrogating binding of HIF-1 with VHL and p53 with Mdm-2, respectively, leads to stabilization and accumulation transcriptionally active HIF-1 and p53, More detailed analysis depicts the VHL/HIF-1 pair as the p53/mdm-2 pair that is turned upside down, suggesting that VHL may be a HIF-1-inducible gene of the feedback loop. The extended model proposes that an oncoprotein and a tumor suppressor due to transactivation coupled with feedback protein degradation might form functional pairs (Rb/E7, E2F/Rb, E2F/Mdm-2, catenin/APC, p27, cyclin D1, Rb/gankyrin), thus, predicting missing links.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blagosklonny, MV (corresponding author), NCI, Med Branch, NIH, Bethesda, MD 20892 USA.							An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Renbaum P, 1996, HUM GENET, V98, P666, DOI 10.1007/s004390050281; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salnikow K, 2000, CANCER RES, V60, P38; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhong H, 1999, CANCER RES, V59, P5830; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	37	28	30	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					395	398		10.1038/sj.onc.1204055	http://dx.doi.org/10.1038/sj.onc.1204055			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313969	Bronze			2022-12-17	WOS:000166411000014
J	Manenti, G; Peissel, B; Gariboldi, M; Falvella, FS; Zaffaroni, D; Allaria, B; Pazzaglia, S; Rebessi, S; Covelli, V; Saran, A; Dragani, TA				Manenti, G; Peissel, B; Gariboldi, M; Falvella, FS; Zaffaroni, D; Allaria, B; Pazzaglia, S; Rebessi, S; Covelli, V; Saran, A; Dragani, TA			A cancer modifier role for parathyroid hormone-related protein	ONCOGENE			English	Article						linkage disequilibrium; skin cancer	CHEMICAL CARCINOGENESIS; SKIN CARCINOGENESIS; MICE; GROWTH; PEPTIDE; HYPERCALCEMIA; RESISTANCE; CARCINOMA; GENETICS; LINES	The parathyroid hormone-related protein (PTHrP) gene (Pthlh) maps in the distal region of mouse chromosome 6 that contains a quantitative trait locus associated with genetic predisposition to skin tumorigenesis. Here, we report a genetic polymorphism located in the osteostatin encoding region of the Pthlh gene and that produces Thr/ Pro PTHrP variants. Pthlh(Thr) and Pthlh(Pro) alleles were significantly linked with resistance and susceptibility to skin carcinogenesis in phenotypically selected Car-R and Car-S outbred mice. Transfection of human NCI-H520 squamous cell carcinoma cells with the Pthlh(Pro) allele resulted in cells growing in clusters, tending to pile up, and growing at a significantly faster rate in nude mice than non-transfected and Pthlh(Thr)-transfected cells. These results point to the role of the Pthlh gene as a cancer modifier gene in skin tumorigenesis.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, ICU, I-20133 Milan, Italy; ENEA CR Casaccia, Rome, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.		Dragani, Tommaso A./K-4493-2016; Manenti, Giacomo/J-3339-2017; Zaffaroni, Daniela/I-8731-2017; Peissel, Bernard/E-8187-2017; Gariboldi, Manuela/K-4744-2016	Dragani, Tommaso A./0000-0001-5915-4598; Manenti, Giacomo/0000-0002-4887-4482; Zaffaroni, Daniela/0000-0002-6995-2216; Peissel, Bernard/0000-0001-9233-3571; Gariboldi, Manuela/0000-0001-8406-165X; Saran, Anna/0000-0002-5587-064X				BANGRAZI C, 1990, CARCINOGENESIS, V11, P1711, DOI 10.1093/carcin/11.10.1711; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Dragani TA, 1997, NAT GENET, V17, P7, DOI 10.1038/ng0997-7; Hastings RH, 1999, CHEST, V116, p68S, DOI 10.1378/chest.116.suppl_1.68S; Hastings RH, 1997, AM J PHYSIOL-LUNG C, V272, pL394, DOI 10.1152/ajplung.1997.272.3.L394; Hastings RH, 1996, AM J PHYSIOL-LUNG C, V270, pL353, DOI 10.1152/ajplung.1996.270.3.L353; HEATH DA, 1990, LANCET, V335, P66, DOI 10.1016/0140-6736(90)90537-F; Henderson JE, 1996, J CELL PHYSIOL, V169, P33, DOI 10.1002/(SICI)1097-4652(199610)169:1<33::AID-JCP4>3.0.CO;2-F; HOLICK MF, 1994, P NATL ACAD SCI USA, V91, P8014, DOI 10.1073/pnas.91.17.8014; Iwamura M, 1999, CANCER, V86, P1028, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1028::AID-CNCR19>3.0.CO;2-G; Kremer R, 1996, AM J PHYSIOL-CELL PH, V271, pC164, DOI 10.1152/ajpcell.1996.271.1.C164; LI X, 1993, CANCER RES, V53, P2980; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Manenti G, 1999, GENOME RES, V9, P639; Manenti G, 1997, CARCINOGENESIS, V18, P1917, DOI 10.1093/carcin/18.10.1917; MANGIN M, 1990, GENE, V95, P195, DOI 10.1016/0378-1119(90)90362-U; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; PEISSEL B, 2000, IN PRESS MAMM GENOME; Saran A, 1996, CARCINOGENESIS, V17, P2463, DOI 10.1093/carcin/17.11.2463; *SAS I, 1988, SAS; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; Takai E, 1996, CANCER-AM CANCER SOC, V78, P1384, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1384::AID-CNCR3>3.0.CO;2-L; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133	24	28	30	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5324	5328		10.1038/sj.onc.1203916	http://dx.doi.org/10.1038/sj.onc.1203916			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103933	Bronze			2022-12-17	WOS:000165302300003
J	Poirel, H; Lopez, RG; Lacronique, V; Della Valle, V; Mauchauffe, M; Berger, R; Ghysdael, J; Bernard, OA				Poirel, H; Lopez, RG; Lacronique, V; Della Valle, V; Mauchauffe, M; Berger, R; Ghysdael, J; Bernard, OA			Characterization of a novel ETS gene, TELB, encoding a protein structurally and functionally related to TEL	ONCOGENE			English	Article						transcriptional repression; ETS; TEL	FUSION PROTEIN; HUMAN LEUKEMIA; OLIGOMERIZATION; REPRESSOR; KINASE; BETA	The TEL/ETV6 gene is located at 12p13 and is frequently involved in chromosomal translocations in human malignancies usually resulting in the expression of fusion proteins between the amino terminal part of TEL, and either unrelated transcription factors or protein tyrosine kinases. We report here a novel gene named TELB which is located on human chromosomal band 6p21 and encodes a protein highly related to TEL, TELB is widely expressed in different tissues and, similarly to TEL encodes a sequence-specific transcriptional repressor.	Ctr Etud Polymorphisme Humain, U434, INSERM, F-75010 Paris, France; CNRS, UMR 146, Inst Curie, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Bernard, OA (corresponding author), Ctr Etud Polymorphisme Humain, U434, INSERM, 27 Rue Juliette Dodu, F-75010 Paris, France.		Bernard, Olivier A./E-5721-2016; GHYSDAEL, Jacques/F-3377-2013; Penard-Lacronique, Virginie/R-1938-2019; Penard-Lacronique, Virginie/E-5729-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747				Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392	13	28	29	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4802	4806		10.1038/sj.onc.1203830	http://dx.doi.org/10.1038/sj.onc.1203830			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032031				2022-12-17	WOS:000089528800015
J	Reddy, TR; Xu, WD; Wong-Staal, F				Reddy, TR; Xu, WD; Wong-Staal, F			General effect of Sam68 on Rev/Rex regulated expression of complex retroviruses	ONCOGENE			English	Article						Sam68; HTLV-1; EIA V; Rev-MS2; transactivation	INFECTIOUS-ANEMIA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; NUCLEAR EXPORT SIGNALS; HIV-1 REV PROTEIN; I REX; MESSENGER-RNA; LEPTOMYCIN-B; TYPE-1 REV; VIRAL-RNA; IDENTIFICATION	We have previously demonstrated that overexpression of Sam68 functionally substitutes for, as well as synergizes with, HIV-1 Rev in RRE-mediated gene expression and virus replication. In addition, C-terminal deletion mutants of Sam68 exhibit a transdominant negative phenotype in HIV replication. We now report that Sam68 also enhances the activities of Rev-like proteins of other complex retroviruses (e.g. HTLV-1 and EIAV) on their respective RNA targets. Furthermore, we demonstrate that Sam68 can function alone as well as synergize with Rev-MS2 and/or Rex-MS2 chimeric proteins on expression mediated by the corresponding RRE-MS2 fusion RNA element. Additionally, dominant negative mutants of Sam68 also repressed the synergistic activation of Sam68 with Rex, E-Rev, and/or Rev-MS2/ Rex-MS2 on their corresponding RNA targets. Thus, Sam68 may play an important role in the post-transcriptional regulation of all complex retroviruses.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Reddy, TR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.				NIAID NIH HHS [AI46240] Funding Source: Medline; NIGMS NIH HHS [GM56089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046240] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Cullen BR, 1998, VIROLOGY, V249, P203, DOI 10.1006/viro.1998.9331; FELBER B K, 1989, New Biologist, V1, P318; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRIDELL RA, 1993, J VIROL, V67, P7317, DOI 10.1128/JVI.67.12.7317-7323.1993; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; Hope TJ, 1997, CHEM BIOL, V4, P335, DOI 10.1016/S1074-5521(97)90124-1; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; LEWIS N, 1990, J VIROL, V64, P1690, DOI 10.1128/JVI.64.4.1690-1697.1990; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MANCUSO VA, 1994, J VIROL, V68, P1998, DOI 10.1128/JVI.68.3.1998-2001.1994; MARTARANO L, 1994, J VIROL, V68, P3102, DOI 10.1128/JVI.68.5.3102-3111.1994; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Reddy TR, 2000, ONCOGENE, V19, P3110, DOI 10.1038/sj.onc.1203637; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; UNGE T, 1991, P NATL ACAD SCI USA, V88, P7145, DOI 10.1073/pnas.88.16.7145; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xu Yuan, 1996, Journal of Biomedical Science, V3, P82, DOI 10.1007/BF02255535	24	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4071	4074		10.1038/sj.onc.1203749	http://dx.doi.org/10.1038/sj.onc.1203749			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962565				2022-12-17	WOS:000088825300014
J	Fu, SL; Waha, A; Vogt, PK				Fu, SL; Waha, A; Vogt, PK			Identification and characterization of genes upregulated in cells transformed by v-Jun	ONCOGENE			English	Article						v-Jun; oncogenic transformation; transcriptional activation; transcriptional targets	CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING ACTIVITY; C-JUN; PROTEIN-KINASE; LIM DOMAIN; TRANSCRIPTIONAL ACTIVATION; CELLULAR-TRANSFORMATION; TRANSACTIVATION DOMAIN; LEUCINE ZIPPER; MESSENGER-RNAS	The transcription factor Jun (c-Jun) functions as a recipient of extracellular growth signals and converts them into patterns of gene expression. An oncogenic variant of c-Jun was isolated from the acutely transforming retrovirus ASV17, Overexpression of this viral Jun (v-Jun) induces transformation of chicken embryo fibroblasts (CEF) in culture and fibrosarcomas in chickens. v-Jun is constitutively active form of c-Jun and transforms cells presumably by deregulating the expression of specific target genes. In this report, we describe six genes whose transcripts are upregulated in v-Jun-transformed CEF, Three of these genes show homology to known mammalian genes, to MAP kinase phosphatase 2 (MKP-2), to reversion-induced LIM protein (RIL) and to cytokine-inducible SH2-containing protein (CIS), Northern blot analysis, using CEF infected with various Jun mutants or an estrogen-regulatable Jun chimera, revealed distinct induction patterns of individual targets by v-jun, The chicken RIL homolog showed an expression pattern tightly correlated with the activity of v-Jun, Its expression is also transformation-dependent, suggesting a role for this gene in v-Jun transformation, The newly identified v-Jun targets can serve as molecular markers in the v-Jun transformation process.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, BCC239,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DeRisi J, 1996, NAT GENET, V14, P457; DUESBERG PH, 1977, P NATL ACAD SCI USA, V74, P4320, DOI 10.1073/pnas.74.10.4320; DUFF RG, 1969, VIROLOGY, V39, P18, DOI 10.1016/0042-6822(69)90344-4; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; Guy PM, 1999, MOL BIOL CELL, V10, P1973, DOI 10.1091/mbc.10.6.1973; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIESS M, 1995, ONCOGENE, V10, P61; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lavery DJ, 1997, P NATL ACAD SCI USA, V94, P6831, DOI 10.1073/pnas.94.13.6831; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; MORGAN IM, 1994, ONCOGENE, V9, P2793; NEIL JC, 1981, P NATL ACAD SCI-BIOL, V78, P1906, DOI 10.1073/pnas.78.3.1906; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; TSUCHIE H, 1989, ONCOGENE, V4, P1281; USUI H, 1994, J NEUROSCI, V14, P4915; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vogt P K, 1981, Haematol Blood Transfus, V26, P424; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; Yokoyama A, 1997, BIOCHEM BIOPH RES CO, V239, P746, DOI 10.1006/bbrc.1997.7547; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	57	28	31	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3537	3545		10.1038/sj.onc.1203691	http://dx.doi.org/10.1038/sj.onc.1203691			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918612				2022-12-17	WOS:000088346500010
J	Clarke, D; Vegiopoulos, A; Crawford, A; Mucenski, M; Bonifer, C; Frampton, J				Clarke, D; Vegiopoulos, A; Crawford, A; Mucenski, M; Bonifer, C; Frampton, J			In vitro differentiation of c-myb(-/-) ES cells reveals that the colony forming capacity of unilineage macrophage precursors and myeloid progenitor commitment are c-Myb independent	ONCOGENE			English	Article						c-Myb; knockout; ES cell differentiation; haemopoietic progenitors	MULTIPLE HEMATOPOIETIC LINEAGES; EMBRYONIC STEM-CELLS; TRANSCRIPTION FACTOR GATA-1; MICE LACKING; ERYTHROID DEVELOPMENT; YOLK-SAC; GENE; LEUKEMIA; MOUSE; MEGAKARYOCYTE	Mice homozygous for an inactivated c-myb allele exhibit embryonic (primitive) blood formation but die at about day 15 of gestation because of a failure to generate adult (definitive) haemopoiesis. Recently, it has been shown that commitment to definitive haemopoiesis does occur in vivo, but that some point in the subsequent development towards the differentiated lineages is compromised. Here we have asked whether it is possible to demonstrate this same distinction between the development of primitive and definitive haemopoiesis during the in vivo differentiation of c-myb null ES cells, and whether this can be used to define more precisely at which developmental stage the absence of c-Myb blocks the adult haemopoietic lineages. We investigated the kinetics of progenitor formation and commitment to differentiation using a combination of colony forming assays and analysis of RNA and surface antigen expression. Primitive unilineage macrophage and erythroid precursor commitment could develop in the absence of c-Myb. No precursors characteristic of definitive haemopoiesis were detected; nevertheless, we could show the expression of programme of transcription and surface antigens which is consistent with the appearance of definitive progenitors blocked at an early multipotential stage.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; Univ Leeds, St James Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Childrens Hosp, Div Pulm Biol, Cincinnati, OH 45229 USA	University of Oxford; Saint James's University Hospital; University of Leeds; Cincinnati Children's Hospital Medical Center	Frampton, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.		Bonifer, Constanze/B-3000-2009	Bonifer, Constanze/0000-0002-4267-0825				Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; Elefanty AG, 1997, BLOOD, V90, P1435, DOI 10.1182/blood.V90.4.1435.1435_1435_1447; Elwood NJ, 1998, BLOOD, V91, P3756; Faust N, 1997, EXP HEMATOL, V25, P432; FAUST N, 1994, DNA CELL BIOL, V13, P901, DOI 10.1089/dna.1994.13.901; Frampton J, 1997, MOL B INT U, P287; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; LONG MW, 1981, BLOOD, V58, P1032; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1999, CURR BIOL, V9, P833, DOI 10.1016/S0960-9822(99)80368-6; Naito M, 1996, J LEUKOCYTE BIOL, V59, P133, DOI 10.1002/jlb.59.2.133; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V12, P123; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Palis J, 1999, DEVELOPMENT, V126, P5073; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shavit JA, 1998, GENE DEV, V12, P2164, DOI 10.1101/gad.12.14.2164; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; Suwabe N, 1998, BLOOD, V92, P4108, DOI 10.1182/blood.V92.11.4108.423k29_4108_4118; TAKAHASHI K, 1989, J LEUKOCYTE BIOL, V45, P87, DOI 10.1002/jlb.45.2.87; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WILES MV, 1991, DEVELOPMENT, V111, P259; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890	43	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3343	3351		10.1038/sj.onc.1203661	http://dx.doi.org/10.1038/sj.onc.1203661			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918591				2022-12-17	WOS:000088198100002
J	Skalski, V; Lin, ZY; Choi, BY; Brown, KR				Skalski, V; Lin, ZY; Choi, BY; Brown, KR			Substrate specificity of the p53-associated 3 '-5 ' exonuclease	ONCOGENE			English	Article						p53; 3 '-5 ' exonuclease; mismatches; DNA double-strand breaks	DNA-REPLICATION FIDELITY; C-TERMINAL DOMAIN; P53 CORE DOMAIN; WILD-TYPE; 3'-TO-5' EXONUCLEASE; POLYMERASE-ALPHA; N-TERMINUS; PROTEIN; REPAIR; DAMAGE	p53 exhibits 3'-5' exonuclease activity and the significance of this biochemical function is currently not defined. In order to gain information about the potential role(s) of this exonuclease activity, recombinant and wild-type human p53 was examined for excision of nucleotides from defined synthetic DNA substrates. p53 removes nucleotides threefold faster from single-strand DNA than from DNA duplexes, exhibits a 1.5-fold preference for 3'-terminals of DNA that contain a single nucleotide mispair (mismatch) as compared to correctly paired DNA and efficiently excises nucleotides from 3'-ends of blunt and cohesive (staggered) DNA double-strand breaks, The p53 exonuclease is predominantly non-processive on DIVA which is 17 nucleotides long (or shorter) and processive on the longer 30-mers, The processivity of nucleotide excision is decreased in the presence of 50 mM potassium phosphate and eliminated when full-length p53 is replaced with the core domain, comprised of amino acids 82-292, Photoaffinity labeling indicates that (1) p53 monomers, rather than dimers, bind to single-strand forms of these oligomers; (2) complexes between p53 and 30-mers are more stable than those formed with 17-mers, The stability of these complexes determines processivity during nucleotide removal and modulates the 3'-5' exonuclease activity of p53. The relevance of substrate specificity of the p53 exonuclease to DNA repair is discussed.	Univ Toronto, Div Expt Therapeut, Ontario Canc Inst, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Skalski, V (corresponding author), Univ Toronto, Div Expt Therapeut, Ontario Canc Inst, Princess Margaret Hosp, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Brown, Kevin/0000-0002-5514-2538				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BELYAKOVA NV, 1993, EUR J BIOCHEM, V217, P493, DOI 10.1111/j.1432-1033.1993.tb18269.x; BRYANT PE, 1994, INT J RADIAT BIOL, V66, P597, DOI 10.1080/09553009414551681; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Chuang YYE, 1999, CANCER RES, V59, P3073; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HARPER JW, 1993, CELL, V75, P805; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; KASTAN MB, 1991, CANCER RES, V51, P6304; KOLESNIKOV VA, 1981, FEBS LETT, V132, P101, DOI 10.1016/0014-5793(81)80437-1; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; KUKHANOVA M, 1995, J BIOL CHEM, V270, P23055, DOI 10.1074/jbc.270.39.23055; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LALUMIERE M, 1995, BACULOVIRUS EXPRESSI, P161; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LOEB LA, 1990, MUTAT RES, V238, P297, DOI 10.1016/0165-1110(90)90021-3; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NICHOLAS AL, 1994, MOL CELL BIOL, V14, P170; NISHINO H, 1995, ONCOGENE, V11, P263; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Pelicano H., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P28; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; Rogers S G, 1980, Methods Enzymol, V65, P201; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Shevelev IV, 1996, MUTAT RES-FUND MOL M, V352, P51, DOI 10.1016/0027-5107(95)00230-8; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TARUNINA M, 1993, ONCOGENE, V8, P3165; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; ZU L, 1999, BIOCHEM BIOPH RES CO, V259, P262	47	28	29	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3321	3329		10.1038/sj.onc.1203649	http://dx.doi.org/10.1038/sj.onc.1203649			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918588				2022-12-17	WOS:000088019300010
J	Zochodne, B; Truong, AHL; Stetler, K; Higgins, RR; Howard, J; Dumont, D; Berger, SA; Ben-David, Y				Zochodne, B; Truong, AHL; Stetler, K; Higgins, RR; Howard, J; Dumont, D; Berger, SA; Ben-David, Y			Epo regulates erythroid proliferation and differentiation through distinct signaling pathways: implication for erythropoiesis and Friend virus-induced erythroleukemia	ONCOGENE			English	Article						erythropoiesis; epo; Fli-1; signal transduction; Friend erythroleukemia	COLONY-STIMULATING FACTOR; MURINE LEUKEMIA-VIRUS; STEM-CELL-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; STAT5 ACTIVATION; DNA-BINDING; F-MULV	We have recently isolated the erythroleukemic cell line, HB60-5 that proliferates in the presence of erythropoietin (Epo) and stem cell factor (SCF), but undergoes terminal differentiation in the presence of Epo alone. Ectopic expression of the ets related transcription factor Fli-1 in these cells resulted in the establishment of the Epo-dependent cell line HB60-ED that proliferates in the presence of Epo, In this study, me utilized these two cell lines to examine the signal transduction pathways that are activated in response to Epo and SCF stimulation, We demonstrate that Epo, but not SCF, phosphorylates STAT-5 in both HB60-5 and HB60-ED cells. Interestingly, SCF activates the Shc/ras pathway in HB60-5 cells while Epo does not. However, both Epo and SCF are capable of activating the Shc/ras pathway in HB60-ED cells, Furthermore, enforced expression of gp55 in HB60-5 cells by means of infection with the Spleen Focus Forming virus-P (SFFV-P), confers Epo independent growth, which is associated with the up-regulation of Fli-1, Activation of the Shc/ras pathway is readily detected in gp55 expressing cells in response to both Epo and SCF, and is associated with a block in STAT-SE tyrosine phosphorylation, These results suggest that STAT-5 activation, in the absence of Shc/ras activation, plays a role in erythroid differentiation. Moreover, Fli-1 is capable of switching Epo-induced differentiation to Epo-induced proliferation, suggesting that this ets factor regulated genes whose products modulate the Epo-Epo-R signal transduction pathway.	Univ Toronto, Sunnybrook & Womens Coll, Dept Med Biophys, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Immunol, Hlth Network, Arthrit & Immune Disorder Network, Toronto, ON M5G 2M9, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Dept Med Biophys, Hlth Sci Ctr, 2075 Bayview Ave,S Wing, Toronto, ON M4N 3M5, Canada.							BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAVID YB, 1988, ONCOGENE, V3, P179; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; HANKINS WD, 1989, ANN NY ACAD SCI, V554, P21, DOI 10.1111/j.1749-6632.1989.tb22405.x; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; JacobsHelber SM, 1997, J BIOL CHEM, V272, P6850, DOI 10.1074/jbc.272.11.6850; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; OHagan RC, 1996, ONCOGENE, V13, P1323; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Sattler M, 1997, J BIOL CHEM, V272, P10248; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Tamir A, 1999, MOL CELL BIOL, V19, P4452; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; Yamamura Y, 1998, MOL CELL BIOL, V18, P1172, DOI 10.1128/MCB.18.3.1172; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	52	28	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2296	2304		10.1038/sj.onc.1203590	http://dx.doi.org/10.1038/sj.onc.1203590			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822380				2022-12-17	WOS:000086974300004
J	Teixeira, LT; Kiyokawa, H; Peng, XD; Christov, KT; Frohman, LA; Kineman, RD				Teixeira, LT; Kiyokawa, H; Peng, XD; Christov, KT; Frohman, LA; Kineman, RD			p27(Kip1)-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation	ONCOGENE			English	Article						pituitary adenoma; p27; growth hormone; IGF-I; hepatocyte hyperplasia; splenocyte hyperplasia	KINASE INHIBITOR P27(KIP1); HUMAN PITUITARY-ADENOMAS; RAT ANTERIOR-PITUITARY; HGRH TRANSGENIC MICE; GENE-EXPRESSION; CELL-CYCLE; ELEVATED LEVELS; FACTOR-I; TUMORS; HYPERPLASIA	p27(Kip1) (p27) controls cell cycle progression by binding to and inhibiting the activity of cyclin dependent kinases, Disruption of the p27 gene in mice (p27-/-) results in increased body growth with a disproportionate enlargement of the spleen, thymus, testis, ovary and pituitary, The increase in pituitary size is due to selective hyperplasia of the intermediate lobe (IL) while the anterior lobe (AL) is not overtly affected. p27 heterozygous mice (p27+/-), as well as p27-/- mice, are hypersensitive to radiation- and chemical-induced tumors compared to wildtype (p27+/+) littermates. Therefore, unlike classical tumor suppressors, only a reduction in p27 levels is necessary to predispose tissues to secondary tumor promoters. Consistent with these studies is the fact that the p27 gene sequence and mRNA levels appear normal in human pituitary adenomas while p27 protein levels are decreased, Therefore, a reduction in p27 levels could be sufficient to sensitize pituitary cells to tumorigenic factors, To test this hypothesis, metallothionein promoter-driven, human growth hormone-releasing hormone (MT-hGHRH) transgenic mice, that exhibit somatotrope hyperplasia before 9 months of age and subsequent adenoma formation with 30-40% penetrance, were crossbred with p27+/- mice for two successive generations to produce p27+/+, p27+/- and p27-/- mice that expressed the hGHRH At 10-12 weeks of age, p27-/- and p27+/+, hGHRH mice were larger than their p27+/+ littermates and displayed characteristic hyperplasia of the IL and AL, respectively, Expression of the hGHRH transgene in both p27+/- and p27-/- mice selectively expanded the population of somatotropes within the AL, where pituitaries of p27+/-, hGHRH and p27-/-, hGHRH mice were two- and fivefold larger than p27+/+, hGHRH pituitaries, respectively, There was also a synergistic effect of hGHRH transgene expression and p27-deficiency on liver, spleen and ovarian growth, At 6-8 months of age, 83% of p27+/-, hGHRH mice displayed macroscopic AL (>100 mg), while all pituitaries from p27+/+, hGHRH mice remained hyperplastic (<20 mg), In contrast to the dramatic effects of p27-deficiency on hGHRH-induced organ growth, elimination of p53, by crossbreeding MT-hGHRH mice to p53-deficient mice, did not augment the hyperplastic/tumorigenic effects of hGHRH transgene expression, Taken together these results demonstrate that reduction in p27 expression is sufficient to sensitize somatotropes to the proliferative actions of excess GHRH, resulting in the earlier appearance and increased penetrance of hGHRH-induced pituitary tumors.	Univ Illinois, Dept Med MC 640, Chicago, IL 60612 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60612 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kineman, RD (corresponding author), Univ Illinois, Dept Med MC 640, 1819 W Polk, Chicago, IL 60612 USA.		Kineman, Rhonda D/H-2221-2011; Peng, Xiao-ding/B-2478-2012	Kineman, Rhonda D/0000-0001-7322-1152; Peng, Xiao-ding/0000-0002-9214-0136	NIDDK NIH HHS [DK-30667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030667, R01DK030667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASA SL, 1990, P SOC EXP BIOL MED, V193, P232; Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798; Bamberger AM, 1999, VIRCHOWS ARCH, V434, P423, DOI 10.1007/s004280050361; Bamberger CM, 1999, EUR J ENDOCRINOL, V140, P250, DOI 10.1530/eje.0.1400250; BILEZIKJIAN LM, 1987, MOL ENDOCRINOL, V1, P137, DOI 10.1210/mend-1-2-137; BILLESTRUP N, 1987, MOL ENDOCRINOL, V1, P300, DOI 10.1210/mend-1-4-300; BLAZAR BR, 1995, EXP HEMATOL, V23, P1397; Blevins LS, 1998, ONCOLOGY-NY, V12, P1307; BRAR AK, 1989, ENDOCRINOLOGY, V125, P801, DOI 10.1210/endo-125-2-801; BRAR AK, 1991, ENDOCRINOLOGY, V129, P3274, DOI 10.1210/endo-129-6-3274; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; Dahia PLM, 1998, ONCOGENE, V16, P69, DOI 10.1038/sj.onc.1201516; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FROHMAN LA, 1968, ENDOCRINOLOGY, V82, P1125, DOI 10.1210/endo-82-6-1125; FROHMAN LA, 1990, ENDOCRINOLOGY, V127, P2149, DOI 10.1210/endo-127-5-2149; Green VL, 1997, EUR J ENDOCRINOL, V136, P382, DOI 10.1530/eje.0.1360382; HAMMER RE, 1985, NATURE, V315, P413, DOI 10.1038/315413a0; HARWOOD JP, 1984, MOL CELL ENDOCRINOL, V37, P277, DOI 10.1016/0303-7207(84)90097-2; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; HERMAN V, 1993, J CLIN ENDOCR METAB, V77, P50, DOI 10.1210/jc.77.1.50; Ikeda H, 1997, BRIT J CANCER, V76, P1119, DOI 10.1038/bjc.1997.521; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jin L, 1997, AM J PATHOL, V151, P509; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lavia P, 1999, BIOESSAYS, V21, P221; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY A, 1994, CLIN ENDOCRINOL, V41, P809, DOI 10.1111/j.1365-2265.1994.tb02797.x; Lidhar K, 1999, J CLIN ENDOCR METAB, V84, P3823, DOI 10.1210/jc.84.10.3823; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; Lloyd RV, 1997, AM J PATHOL, V150, P401; LLOYD RV, 1992, AM J PATHOL, V141, P895; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P433, DOI 10.1210/endo-123-1-433; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; Medina DL, 1999, ENDOCRINOLOGY, V140, P87, DOI 10.1210/en.140.1.87; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; Miller TL, 1999, ENDOCRINOLOGY, V140, P4152, DOI 10.1210/en.140.9.4152; MILLER TL, 1997, 79 ANN END SOC P179, P154; Mori T, 1998, LAB ANIM SCI, V48, P64; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Prives C, 1999, J PATHOL, V187, P112; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Rutanen EM, 1998, GYNECOL ENDOCRINOL, V12, P399, DOI 10.3109/09513599809012842; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiozawa T, 1998, MOL HUM REPROD, V4, P899, DOI 10.1093/molehr/4.9.899; Snibson KJ, 1999, LIVER, V19, P242, DOI 10.1111/j.1478-3231.1999.tb00042.x; Soos T J, 1998, Results Probl Cell Differ, V22, P111; SOTO JL, 1995, ENDOCRINOLOGY, V136, P3863, DOI 10.1210/en.136.9.3863; Takeuchi S, 1998, J ENDOCRINOL, V157, P337, DOI 10.1677/joe.0.1570337; Tanaka C, 1997, J CLIN ENDOCR METAB, V82, P3141, DOI 10.1210/jc.82.9.3141; THAPAR K, 1996, NEUROSURGERY, V38, P763; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Xu X, 1999, BIOCHEMISTRY-US, V38, P8713	68	28	29	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 6	2000	19	15					1875	1884		10.1038/sj.onc.1203490	http://dx.doi.org/10.1038/sj.onc.1203490			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773877				2022-12-17	WOS:000086424300003
J	Miyata, Y; Yahara, I				Miyata, Y; Yahara, I			p53-independent association between SV40 large T antigen and the major cytosolic heat shock protein, HSP90	ONCOGENE			English	Article						stress protein; tumor antigen; molecular chaperone; SV40; p53; geldanamycin	LARGE-TUMOR-ANTIGEN; ROUS-SARCOMA VIRUS; 90-KDA STRESS PROTEIN; CASEIN KINASE-II; MOLECULAR CHAPERONE; GLUCOCORTICOID RECEPTOR; SV40-TRANSFORMED CELLS; TRANSFORMING PROTEIN; TYROSINE KINASE; DNA-REPLICATION	The simian double strand DNA tumor virus SV40 encodes the 90-kDa multi-functional protein, large T antigen (LT). LT functions by binding to DNA, as well as to many cellular target proteins such as p53 and retinoblastoma protein (pRB). We report here the identification of a cellular heat shock protein, HSP90, as a previously undescribed LT-associated protein. Immunoprecipitates by anti-HSP90 antibodies from LT-expressing cell lysates contained LT protein, as revealed by Western blotting. Conversely, anti-LT antibody co-immunoprecipitated HSP90. Co-immunoprecipitation of HSP90 and LT was observed even after complete immune-depletion of p53, indicating that the association of LT with HSP90 is p53-independent. LT-HSP90 complexes can be reconstituted from purified HSP90 and unfolded-LT in vitro in an ATP-independent manner but not from HSP90 and native LT, suggesting that non-mature conformation of LT is required for the efficient association with HSP90. Moreover, geldanamycin, an anti-tumor drug that specifically binds and inhibits HSP90, reduced the intracellular concentration of LT by destabilizing newly synthesized LT. The above results suggest that HSP90 associates with immature forms of LT both in vivo and in vitro, and thus might assist LT in the formation of a functional, mature structure.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Miyata, Y (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kitashirakawa Oiwake Cho, Kyoto 6068502, Japan.		Miyata, Y/X-7111-2019					ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DIXON RAF, 1985, J VIROL, V53, P1001, DOI 10.1128/JVI.53.3.1001-1004.1985; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Hedge Ramanujan S., 1995, Journal of Cellular Physiology, V165, P186; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JEOUNG DI, 1991, GENE DEV, V5, P2235, DOI 10.1101/gad.5.12a.2235; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KELLEY WL, 1994, TRENDS BIOCHEM SCI, V19, P277, DOI 10.1016/0968-0004(94)90003-5; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Tjian R, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P103; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Yahara I, 1998, ANN NY ACAD SCI, V851, P54, DOI 10.1111/j.1749-6632.1998.tb08976.x; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	57	28	29	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1477	1484		10.1038/sj.onc.1203475	http://dx.doi.org/10.1038/sj.onc.1203475			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723140				2022-12-17	WOS:000085942700014
J	Hofmann, TG; Hehner, SP; Droge, W; Schmitz, ML				Hofmann, TG; Hehner, SP; Droge, W; Schmitz, ML			Caspase-dependent cleavage and inactivation of the Vav1 proto-oncogene product during apoptosis prevents IL-2 transcription	ONCOGENE			English	Article						apoptosis; caspase; IL-2; NF-kappa B; Vav	T-CELL RECEPTOR; POLY(ADP-RIBOSE) POLYMERASE; SIGNAL-TRANSDUCTION; DEATH; ACTIVATION; PROTOONCOGENE; REQUIREMENT; THYMOCYTES; EXCHANGE; PATHWAYS	Here we identify the hematopoietic proto-oncogene Vav1 as a caspase substrate during apoptosis in lymphoid cells. Cleavage of Vav1 is prevented by the caspase inhibitors zDEVD and zVAD as well as by expression of CrmA, Vav1 is cleaved in vivo at the evolutionary conserved caspase consensus cleavage site (DLYDC)-C-161, generating the carboxy-terminal cleavage product Vav1p76 of intermediate stability. In vitro caspase assays reveal cleavage of Vav1 at position 161 either by apoptotic cell lysates or by recombinant caspase-3, Mutation of Asp 161 to Ala leads to the usage of the adjacent alternative cleavage sequence DQID(150)D. Mutation of both cleavage sites at position 150 and 161 protects Vav1 from caspase-mediated proteolysis in vitro and in vivo. The cleavage product Vav1p76 is capable of activating JNK in T-cells, but fails to induce the phosphorylation of p38/HOG1, Vav1p76 displays a diminished capacity to activate the transcription factors NF-AT, AP-1 and NF-kappa B, and thus completely fails to activate IL-2 transcription. Since Vav1 is essential for IL-2 production and plays a central role for cytoskeletal reorganization, its proteolytic inactivation during apoptosis affects multiple downstream targets.	German Canc Res Ctr, Dept Immunochem, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schmitz, ML (corresponding author), German Canc Res Ctr, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				Baichwal V. R., 1997, CURR BIOL, V7, P94; Cantrell D, 1998, CURR BIOL, V8, pR535, DOI 10.1016/S0960-9822(07)00341-7; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Cosulich SC, 1997, EMBO J, V16, P6182, DOI 10.1093/emboj/16.20.6182; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Germani A, 1999, MOL CELL BIOL, V19, P3798; Gomez J, 1998, CRIT REV IMMUNOL, V18, P185, DOI 10.1615/CritRevImmunol.v18.i3.20; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Katzav S, 1995, CRIT REV ONCOGENESIS, V6, P87; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Salojin KV, 1999, J IMMUNOL, V163, P844; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Song JS, 1999, J IMMUNOL, V163, P802; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Varadhachary AS, 1997, P NATL ACAD SCI USA, V94, P5778, DOI 10.1073/pnas.94.11.5778; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WU J, 1995, MOL CELL BIOL, V15, P4337; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	54	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1153	1163		10.1038/sj.onc.1203406	http://dx.doi.org/10.1038/sj.onc.1203406			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713703				2022-12-17	WOS:000085567800005
J	Glukhova, L; Lavialle, C; Fauvet, D; Chudoba, I; Danglot, G; Angevin, E; Bernheim, A; Goguel, AF				Glukhova, L; Lavialle, C; Fauvet, D; Chudoba, I; Danglot, G; Angevin, E; Bernheim, A; Goguel, AF			Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene	ONCOGENE			English	Article						chromosome 7 polysomy; 7q31 chromosomal region; papillary renal cell carcinoma; MET receptor tyrosine kinase	TUMORS; PROTOONCOGENE; GENE; DNA; HYBRIDIZATION; CYTOGENETICS; DUPLICATION; PARAMETERS; FEATURES; ALLELE	Molecular cytogenetic analysis of several sporadic papillary renal cell carcinomas and of their xenografts in immunodeficient mice had previously allowed us to delimit a minimal overrepresented region of chromosome 7 shaped by all of them to band 7q31, We have refined the location of the overlapping region to the junction of the subbands 7q31.2 and 7q31.3 by reverse painting with two differently labelled probes prepared from the small chromosome 7 derivatives microdissected from the cells of two distinct tumours, This small region was shown to contain the MET proto-oncogene, present at three to four copies per cell as determined by Southern blot analysis, The increased copy number of the MET gene was found to be associated with its overexpression at the mRNA level. However, no change in MET copy number or expression level was observed in the cells from two xenografted tumours serially transplanted into immunodeficient mice, as compared to those from the corresponding initial tumours. Our results indicate that expression of the MET proto-oncogene above a critical threshold is required for the maintenance of the tumorigenic phenotype of at least some papillary renal cell carcinomas, but does not further increase during tumour progression.	Inst Gustave Roussy, Lab Cytogenet & Genet Oncol, UMR 1599, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, Lab Genet Oncol, UMR 1599, F-94805 Villejuif, France; Inst Gustave Roussy, Unite Immunotherapie, F-94805 Villejuif, France; Inst Human Genet & Anthropol, D-07740 Jena, Germany	UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Goguel, AF (corresponding author), Inst Gustave Roussy, Lab Cytogenet & Genet Oncol, UMR 1599, PR2,39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Lavialle, Christian/O-2329-2019; Lavialle, Christian/B-3775-2009	ANGEVIN, Eric/0000-0001-6249-7209				Amin MB, 1997, AM J SURG PATHOL, V21, P621, DOI 10.1097/00000478-199706000-00001; Angevin E, 1999, LAB INVEST, V79, P879; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bentz M, 1996, CYTOGENET CELL GENET, V75, P17, DOI 10.1159/000134448; Bernues M, 1995, CANCER GENET CYTOGEN, V84, P123, DOI 10.1016/0165-4608(95)00044-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chudoba I, 1996, ONCOL REP, V3, P829; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655, DOI 10.1097/00000478-198210000-00007; GALDEMARD C, 1995, ONCOGENE, V10, P2331; Glukhova L, 1998, GENE CHROMOSOME CANC, V22, P171, DOI 10.1002/(SICI)1098-2264(199807)22:3<171::AID-GCC2>3.3.CO;2-K; Goguel AF, 1996, ANN GENET-PARIS, V39, P64; HAAF T, 1992, CYTOGENET CELL GENET, V60, P12, DOI 10.1159/000133284; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KOVACS G, 1993, HISTOPATHOLOGY, V22, P1, DOI 10.1111/j.1365-2559.1993.tb00061.x; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; LAGER DJ, 1995, CANCER, V76, P669, DOI 10.1002/1097-0142(19950815)76:4<669::AID-CNCR2820760420>3.0.CO;2-U; Lin JC, 1998, ONCOGENE, V16, P833, DOI 10.1038/sj.onc.1201599; Lin JC, 1996, ONCOGENE, V13, P2001; MACIEIRACOELHO A, 1982, EXP CELL RES, V141, P325, DOI 10.1016/0014-4827(82)90220-8; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sambrook J, 1989, MOL CLONING LAB MANU; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SLIM R, 1994, CYTOGENET CELL GENET, V65, P104, DOI 10.1159/000133611; WEISS LM, 1995, AM J CLIN PATHOL, V103, P624; WILHELM M, 1995, WORLD J UROL, V13, P143; Zbar B, 1998, ADV CANCER RES, V75, P163, DOI 10.1016/S0065-230X(08)60742-3; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	35	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					754	761		10.1038/sj.onc.1203397	http://dx.doi.org/10.1038/sj.onc.1203397			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698493				2022-12-17	WOS:000085192100005
J	Reichert, TE; Nagashima, S; Kashii, Y; Stanson, J; Gao, G; Dou, QP; Whiteside, TL				Reichert, TE; Nagashima, S; Kashii, Y; Stanson, J; Gao, G; Dou, QP; Whiteside, TL			Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression	ONCOGENE			English	Article						human carcinoma; IL-2 expression; cell cycle; antisense oligonucleotide; p27	NATURAL-KILLER-CELLS; IL-2 RECEPTOR; BETA-CHAIN; FUNCTIONAL INTERLEUKIN-2; CANCER-PATIENTS; DOWN-REGULATION; GAMMA-CHAIN; TUMOR-CELLS; IN-SITU; PROLIFERATION	Human carcinomas were shown to express mRNA and protein for IL-2R alpha, beta and gamma chains. Recently, human carcinomas were also shown to constitutively express protein and mRNA for IL-2 in vivo and in vitro. Here ape report that the expression levels of cytoplasmic IL-2 as well as IL-2R beta- and gamma-chain in human carcinoma cells change during the cell cycle progression, Carcinoma cells synchronized in the G2/M phase of the cell cycle expressed significantly more intracytoplasmic IL-2 as web as IL-2R beta and gamma proteins than tumor cells in the G0/G1 phase, The level of mRNA for IL-2 was 5-10-fold higher in the M phase than in the G0/G1-phase, as shown by quantitative competitive RT-PCR, Expression of the cyclin-dependent kinase (CDK) inhibitor p27(kip1) in these carcinoma cells was found to be high in the G0/G1 phase, nearly absent in the S phase, and it increased again in the G2/M phase of the cell cycle, In synchronized cells, the decrease in p27 expression coincided with high levels of expression of IL-2. Using the IL-2 specific antisense oligonucleotide to block synthesis of endogenous IL-2 in tumor cells, we observed increased levels of p27 as well as p21. The antisense oligonucleotides specific for p27 or p21 blocked expression of these proteins but not of IL-2. Thus, endogenous IL-2 is important in regulating expression of p27 as well as p21 and, therefore, in controlling cell cycle progression of tumor cells, while its own expression remains independent of the CDK inhibitors.	Univ Pittsburgh, Pittsburgh Canc Inst, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Otolaryngol, Sch Med, Pittsburgh, PA 15213 USA; H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Biol, Tampa, FL 33612 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Whiteside, TL (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Sch Med, Biomed Sci Tower,W 1041,211 Lothrop St, Pittsburgh, PA 15213 USA.			Dou, Qingping/0000-0002-6465-1473	NCI NIH HHS [R0-1 CA 63513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS B, 1994, MOL BIOL CELL, P911; ALILECHE A, 1994, INT IMMUNOL, V6, P1585; ALILECHE A, 1993, ONCOGENE, V8, P1791; ARZT E, 1992, J CLIN INVEST, V90, P1944, DOI 10.1172/JCI116072; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; CHEN K, 1987, LAB INVEST, V56, P114; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIACCI C, 1993, J CLIN INVEST, V92, P527, DOI 10.1172/JCI116598; DUPREZ V, 1988, J BIOL CHEM, V263, P12860; HATAKEYAMA M, 1990, PEPTIDE GROWTH FACTO, V1, P523; HEMAR A, 1994, EUR J IMMUNOL, V24, P1951, DOI 10.1002/eji.1830240902; HEO DS, 1989, CANCER RES, V49, P5167; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; Lai P, 1996, CLIN CANCER RES, V2, P161; LIN WC, 1995, J IMMUNOL, V155, P4805; Liu JB, 1997, J IMMUNOL, V159, P812; MCMILLAN DN, 1995, INT J CANCER, V60, P766, DOI 10.1002/ijc.2910600606; Miyazaki M, 1998, BIOCHEM BIOPH RES CO, V246, P873, DOI 10.1006/bbrc.1998.8712; NAKANISHI K, 1992, P NATL ACAD SCI USA, V89, P3551, DOI 10.1073/pnas.89.8.3551; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OCONNOR PM, 1995, CELL CYCLE MAT METHO, P63; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PLAISANCE S, 1992, INT IMMUNOL, V4, P739, DOI 10.1093/intimm/4.7.739; PLAISANCE S, 1993, INT IMMUNOL, V5, P843; RABINOWICH H, 1992, J IMMUNOL, V149, P340; RALPH P, 1984, J IMMUNOL, V133, P2442; Reichert TE, 1998, J HISTOCHEM CYTOCHEM, V46, P603, DOI 10.1177/002215549804600506; Reichert TE, 1999, BRIT J CANCER, V81, P822, DOI 10.1038/sj.bjc.6690770; RIMOLDI D, 1993, ANTICANCER RES, V13, P555; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; SANETO RP, 1986, P NATL ACAD SCI USA, V83, P9221, DOI 10.1073/pnas.83.23.9221; SEIGEL LJ, 1984, SCIENCE, V223, P175, DOI 10.1126/science.6318318; SHIMIZU Y, 1991, CANCER RES, V51, P6153; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; SUMINAMI Y, 1995, J IMMUNOTHER, V17, P238, DOI 10.1097/00002371-199505000-00006; Suminami Y, 1998, ONCOGENE, V16, P1309, DOI 10.1038/sj.onc.1201640; TAKESHITA T, 1989, J EXP MED, V169, P1323, DOI 10.1084/jem.169.4.1323; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WEIDMANN E, 1992, CANCER RES, V52, P5963; WHITESIDE TL, 1995, CURR OPIN IMMUNOL, V7, P704, DOI 10.1016/0952-7915(95)80080-8; YASUMURA S, 1994, INT J CANCER, V59, P225, DOI 10.1002/ijc.2910590215	44	28	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					514	525		10.1038/sj.onc.1203391	http://dx.doi.org/10.1038/sj.onc.1203391			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698521				2022-12-17	WOS:000085104200005
J	Turpin, E; Dalle, B; de Roquancourt, A; Plassa, LF; Marty, M; Janin, A; Beuzard, Y; de The, H				Turpin, E; Dalle, B; de Roquancourt, A; Plassa, LF; Marty, M; Janin, A; Beuzard, Y; de The, H			Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers	ONCOGENE			English	Article						TSG101; p53; stress , tumor grading; splicing; breast cancer	SUSCEPTIBILITY GENE TSG101; POOR-PROGNOSIS; TRANSCRIPTS; MUTATIONS; HETEROZYGOSITY; REARRANGEMENTS; METASTASIS; HYPOXIA; RNA	The TSG101 gene, identified through insertional mutagenesis, is localized in a region that exhibits LOH in human cancers, suggesting that TSG101 might be a tumor suppressor gene. Numerous studies have then shown the presence of abnormal transcripts in various tumors which appear to result from aberrant splicing of the gene, rather than from intragenic deletions. Moreover, many studies demonstrated that these aberrantly spliced transcripts mere not found in matched normal tissues, We have analysed TSG101 transcripts in 85 breast cancer samples and found that abnormal splicing of the gene is tightly correlated with tumor grade and p53 mutation. In addition, stress induced the appearance of these abnormal transcripts in primary lymphocytes. Hence, TSG101 splicing defects, while unrelated to the oncogenic process per se, could reflect the cellular environment of the tumor cells. The proposed role of stress and hypoxia to select p53 mutant cells could account for the tight association with p53 status.	Hop St Louis, Lab Biochim B, F-75475 Paris 10, France; Hop St Louis, Anat Pathol Lab, F-75475 Paris, France; Hop St Louis, Serv Oncol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Turpin, E (corresponding author), Hop St Louis, Lab Biochim B, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.							BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Carney ME, 1998, J SOC GYNECOL INVEST, V5, P281, DOI 10.1016/s1071-5576(98)00018-5; Chang JG, 1999, BRIT J CANCER, V79, P445, DOI 10.1038/sj.bjc.6690069; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLES C, 1992, CANCER RES, V52, P5291; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; KNOWLES MA, 1994, CANCER RES, V54, P531; LAMOND AI, 1995, CURR BIOL, V5, P862, DOI 10.1016/S0960-9822(95)00174-6; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lin PM, 1998, BRIT J HAEMATOL, V102, P753, DOI 10.1046/j.1365-2141.1998.00815.x; Lin SY, 1998, J GASTROEN HEPATOL, V13, P1111, DOI 10.1111/j.1440-1746.1998.tb00585.x; LISUKA M, 1995, GENES CHROM CANC, V13, P40; Oh Y, 1998, ONCOGENE, V17, P1141, DOI 10.1038/sj.onc.1202029; SAITOH S, 1994, ONCOGENE, V9, P2869; Sato T, 1997, CANCER LETT, V115, P47, DOI 10.1016/S0304-3835(97)04705-8; Silvestrini R, 1996, CLIN CANCER RES, V2, P2007; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Valgardsdottir R, 1997, APMIS, V105, P121, DOI 10.1111/j.1699-0463.1997.tb00550.x; Wagner KU, 1998, ONCOGENE, V17, P2761, DOI 10.1038/sj.onc.1202529; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Willeke F, 1998, MOL CARCINOGEN, V23, P195; WINQVIST R, 1995, CANCER RES, V55, P2660	32	28	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7834	7837		10.1038/sj.onc.1203196	http://dx.doi.org/10.1038/sj.onc.1203196			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618725				2022-12-17	WOS:000084256900014
J	Van Keymeulen, A; Bartek, J; Dumont, JE; Roger, PP				Van Keymeulen, A; Bartek, J; Dumont, JE; Roger, PP			Cyclin D3 accumulation and activity integrate and rank the comitogenic pathways of thyrotropin and insulin in thyrocytes in primary culture	ONCOGENE			English	Article						cell cycle; cyclins D; p27(kipl); cAMP; thyroid; synergy	THYROID EPITHELIAL-CELLS; GROWTH-FACTOR-I; CDK-ACTIVATING KINASE; G1 PHASE PROGRESSION; RETINOBLASTOMA PROTEIN; DEPENDENT KINASE; SUBCELLULAR-LOCALIZATION; INHIBITOR P27(KIP1); MITOGENIC PATHWAYS; SIGNALING CASCADES	The proliferation of most normal cells depends on the synergistic interaction of several growth factors and hormones, but the cell cycle basis for this combined requirement remains largely uncharacterized, We have addressed the question of the requirement for insulin/IGF-1 also observed in many cell culture systems in the physiologically relevant system of primary cultures of dog thyroid epithelial cells stimulated by TSH, which exerts its mitogenic activity only via cAMP, The induction of cyclin A and cdc2, the phosphorylation of cdk2, the nuclear translocation of cdk4 and the assembly of cyclin D3-cdk4 complexes required the synergy of TSH and insulin. Cyclin D3 (the most abundant cyclin D) was necessary for the proliferation stimulated by TSH in the presence of insulin as shown by microinjection of a neutralizing antibody, Cyclin D3 accumulation and activity mere differentially regulated by insulin and TSH, which points out this cyclin as an integrator that ranks these comitogenic pathways as supportive and activatory, respectively. Paradoxically TSH alone strongly repressed cyclin D3 accumulation. This inhibition was overridden by insulin, which markedly stimulated cyclin D3 mRNA and protein accumulation, but failed to assemble cyclin D3-cdk4 complexes in the absence of TSH. TSH unmasked the DCS-22 epitope of cyclin D3 and assembled cyclin D3-cdk4 in the presence of insulin. These data demonstrate that cyclin D synthesis and cyclin D-cdk assembly can be dissociated and complementarily regulated by different agents and signalling pathways.	Free Univ Brussels, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Danish Canc Soc, Div Canc Biol, DK-2100 Copenhagen, Denmark	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Danish Cancer Society	Roger, PP (corresponding author), Free Univ Brussels, Inst Interdisciplinary Res, 808 Route Lennik,Campus Erasme, B-1070 Brussels, Belgium.		Bartek, Jiri/G-5870-2014	Roger, Pierre/0000-0002-5812-1783				Baptist M, 1996, J CELL PHYSIOL, V166, P256; BAPTIST M, 1995, EXP CELL RES, V221, P160, DOI 10.1006/excr.1995.1363; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Burikhanov R, 1996, J BIOL CHEM, V271, P29400, DOI 10.1074/jbc.271.46.29400; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheung NW, 1996, J CLIN ENDOCR METAB, V81, P1179, DOI 10.1210/jc.81.3.1179; Coppee F, 1998, ONCOGENE, V17, P631, DOI 10.1038/sj.onc.1201966; Coulonval K, 1997, EXP CELL RES, V233, P395, DOI 10.1006/excr.1997.3582; de Asua L J, 1977, Proc Natl Acad Sci U S A, V74, P3845; Deleu S, 1999, MOL CELL ENDOCRINOL, V149, P41, DOI 10.1016/S0303-7207(99)00005-2; DELEU S, 1999, IN PRESS J CELL PHYS; Depoortere F, 1996, J CELL SCI, V109, P1759; Depoortere F, 1998, J CELL BIOL, V140, P1427, DOI 10.1083/jcb.140.6.1427; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAMY F, 1989, J CELL PHYSIOL, V138, P568, DOI 10.1002/jcp.1041380318; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; REUSE S, 1991, EXP CELL RES, V196, P210, DOI 10.1016/0014-4827(91)90253-Q; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROGER P, 1988, J CLIN ENDOCR METAB, V66, P1158, DOI 10.1210/jcem-66-6-1158; Roger PP, 1997, EUR J ENDOCRINOL, V137, P579, DOI 10.1530/eje.0.1370579; ROGER PP, 1987, EXP CELL RES, V172, P282, DOI 10.1016/0014-4827(87)90387-9; ROGER PP, 1987, J CELL PHYSIOL, V130, P58, DOI 10.1002/jcp.1041300110; ROGER PP, 1992, J CELL BIOL, V117, P383, DOI 10.1083/jcb.117.2.383; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TAKAHASHI SI, 1991, J BIOL CHEM, V266, P7834; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMAS GA, 1994, J PATHOL, V173, P355, DOI 10.1002/path.1711730411; TOMINAGA T, 1994, ENDOCRINOLOGY, V135, P1212, DOI 10.1210/en.135.3.1212; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; Ward AC, 1996, BIOCHEM BIOPH RES CO, V224, P10, DOI 10.1006/bbrc.1996.0976; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1998, CANCER RES, V58, P5053; WERNER H, 1994, VITAM HORM, V48, P1, DOI 10.1016/S0083-6729(08)60495-1; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	58	28	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7351	7359		10.1038/sj.onc.1203164	http://dx.doi.org/10.1038/sj.onc.1203164			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602491				2022-12-17	WOS:000084119400021
J	Liu, XF; Baker, E; Eyre, HJ; Sutherland, GR; Zhou, MD				Liu, XF; Baker, E; Eyre, HJ; Sutherland, GR; Zhou, MD			gamma-Heregulin: a fusion gene of DOC-4 and neuregulin-1 derived from a chromosome translocation	ONCOGENE			English	Article						gamma-heregulin; neuregulin-1; DOC-4; gene localization; MDA-MB-175 cell line	NEU DIFFERENTIATION FACTOR; CARDIAC DEVELOPMENT; IDENTIFICATION; RECEPTOR; LIGANDS; DOMAIN; ERBB2	gamma-Heregulin was identified as an isoform resulting from alternate splicing of the neuregulin-1 gene, after cloning of its cDNA from the MDA-MB-175 breast cancer cell line, gamma-Heregulin was shown to promote growth of cultured MDA-MB-175 cells resulting from activation of its cognate ErbB tyrosine kinase reporters. We show here that gamma-heregulin is transcribed from a fusion gene resulting from a chromosome translocation in MDA-MB-175 cells. The fusion chromosome is described as dic(8:11)(8qter-->8p12::11q13-->11pter). As a result, the 5' end of the gamma-heregulin gene is derived from the stress-induced gene, DOC-4 (11q13), while the 3' end is from the neuregulin-1 gene (8p12). Thus, expression of gamma-heregulin is under the control of the DOC-4 promoter, By contrast with MDA-MB-175 cells, RT-PCR failed to detect a gamma-heregulin transcript in either E9.5 to E13.5 embryonic mouse tissues, adult mouse tissues or other human tumour cell lines. We conclude, therefore, that gamma-heregulin is not a native isoform of the neuregulin-1 gene, but a novel growth factor that may contribute to tumour cell proliferation.	Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia	Victor Chang Cardiac Research Institute; University of New South Wales Sydney; Womens & Childrens Hospital Australia	Zhou, MD (corresponding author), Victor Chang Cardiac Res Inst, 384 Victoria St, Darlinghurst, NSW 2010, Australia.		Sutherland, Grant Robert/D-2606-2012					CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Chausovsky A, 1998, MOL BIOL CELL, V9, P3195, DOI 10.1091/mbc.9.11.3195; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Liu XF, 1998, P NATL ACAD SCI USA, V95, P13024, DOI 10.1073/pnas.95.22.13024; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELLESTOR F, 1994, HUM GENET, V94, P346; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	17	28	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7110	7114		10.1038/sj.onc.1203136	http://dx.doi.org/10.1038/sj.onc.1203136			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597312				2022-12-17	WOS:000083901900018
J	Choi, S; Park, S				Choi, S; Park, S			Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates Fyn binding to the Tyr-615 site by enhancing tyrosine kinase activity	ONCOGENE			English	Article						Eph; receptor tyrosine kinase; Fyn	NEURAL CREST MIGRATION; RETINAL AXON GUIDANCE; COMMISSURAL AXONS; LIGAND ACTIVATION; PROTEIN-KINASES; IN-VITRO; RECEPTOR; FAMILY; ELF-1; CELLS	Eph-related receptors and their ephrin ligands are highly conserved protein families which play important roles in targeting axons and migrating cells. In this study we have examined the functional roles of two major autophosphorylation sites, Tyr-615 and Tyr-838, in the EphA8 receptor. Two-dimensional phosphopeptide mapping analysis demonstrated that Tyr-615 and Tyr-838 constitute major autophosphorylation sites in EphA8. Tyr-615 was phosphorylated to the highest stoichiometry, suggesting that phosphorylation at this site may have a physiologically important role. Upon conservative mutation of Tyr-838 located in the tyrosine kinase domain, the catalytic activity of EphA8 was strikingly reduced both in vitro and in vivo, whereas a mutation at Tyr-615 in the juxtamembrane domain did not impair the tyrosine kinase activity. In vitro binding experiments revealed that phosphorylation at Tyr-615 in EphA8 mediates the preferential binding to Fyn-SH2 domain rather than Src and Ras GTPase-activating protein (Ras GAP)-SH2 domains. Additionally, a high level of EphA8 was detected in Fyn immunoprecipitates in intact cells, indicating that EphA8 and Fyn can physically associate in vivo. In contrast, the association of full-length Fyn to EphA8 containing mutation at either Tyr-615 or Tyr-838 was greatly reduced. These data indicate that phosphorylation of Tyr-615 is critical for determining the association with Fyn whereas the integrity of Tyr-838 phosphorylation is required for efficient phosphorylation at Tyr-615 as well as other major sites. Finally, it was observed that cell attachment responses are attenuated by overexpression of wild type EphA8 receptor but to much less extent by EphA8 mutants lacking phosphorylation at either Tyr-615 or Tyr-838. Furthermore, transient expression of kinase-inactive Fyn in EphA8-overexpressing cells blocked cell attachment responses attenuated by the EphA8 signaling. We therefore propose that Fyn kinase is one of the major downstream targets for the EphA8 signaling pathway leading to a modification of cell adhesion, and that autophosphorylation at Tyr-838 is critical for positively regulating the EphA8 signaling event.	Hallym Univ, Inst Environm & Life Sci, Chunchon 200702, Kangwon Do, South Korea	Hallym University	Park, S (corresponding author), Hallym Univ, Inst Environm & Life Sci, 1 Okcheon Dong, Chunchon 200702, Kangwon Do, South Korea.							[Anonymous], 1997, Cell, V90, P403; BARE DJ, 1993, ONCOGENE, V8, P1429; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; Gao PP, 1998, P NATL ACAD SCI USA, V95, P5329, DOI 10.1073/pnas.95.9.5329; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; INGRAHAM CA, 1992, ONCOGENE, V7, P95; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Park S, 1997, ONCOGENE, V14, P533, DOI 10.1038/sj.onc.1200857; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1994, ONCOGENE, V9, P2433; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	45	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5413	5422		10.1038/sj.onc.1202917	http://dx.doi.org/10.1038/sj.onc.1202917			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498895				2022-12-17	WOS:000082718600006
J	Ahmad, N; Gupta, S; Mukhtar, H				Ahmad, N; Gupta, S; Mukhtar, H			Involvement of retinoblastoma (Rb) and E2F transcription factors during photodynamic therapy of human epidermoid carcinoma cells A431	ONCOGENE			English	Article						photodynamic therapy; cell cycle; retinoblastoma (pRb); E2F	MOUSE LYMPHOMA-CELLS; CYCLE PROGRESSION; INDUCED ABLATION; CANCER-CELLS; NITRIC-OXIDE; APOPTOSIS; INDUCTION; PROTEINS; KINASE; PHOTOSENSITIZERS	Photodynamic therapy (PDT), a promising new therapeutic modality for the management of a variety of solid malignancies and many non-malignant diseases, is a bimodal therapy using a porphyrin based photosensitizing chemical and visible light. The proper understanding of the mechanism of PDT-mediated cancer cell-kill may result in improving the efficacy of this treatment modality. Earlier we have shown (PI oc. Natl, Acad. Sci, USA; 95: 6977-6982, 1998) that silicon phthalocyanine (Pc4)-PDT results in an induction of the cyclin kinase inhibitor WAF1/CIP1/p21 which, by inhibiting cyclins (E and DI) and cyclin dependent kinases (cdk2 and cdk6), results in a G0/G1-phase arrest followed by apoptosis in human epidermoid carcinoma cells A431. We have also demonstrated the generation of nitric oxide during PDT-mediated apoptosis (Cancer Res.; 58: 1785-1788, 1998), Retinoblastoma (pRb) and E2F family transcription factors are important proteins, which regulate the G1-->S transition in the cell cycle. Here, we pro, ide evidence for the involvement of pRb-E2F/DP machinery as an important contributor of PDT-mediated cell cycle arrest and apoptosis, Western blot analysis demonstrated a decrease in the hyper-phosphorylated form of pRb at 3, 6 and 12 h post-PDT with a relative increase in hypo-phosphorylated pRb, Western blot analysis also revealed that PDT-caused decrease in phosphorylation of pRb occurs at serine-780, The ELISA data demonstrated a time dependent accumulation of hypo-phosphorylated pRb by PDT, This response was accompanied with down-regulation in the protein expression of all five E2F (1-5) family transcription factors, and their heterodimeric partners DP1 and DP2, These results suggest that Pc4-PDT of A431 cells results in a down regulation of hyper-phosphorylated pRb protein with a relative increase in hypo-phosphorylated pRb that, in turn, compromises with the availability of free E2F, We suggest that these events result in a stoppage of the cell cycle progression at G1-->S transition thereby leading to a G0/G1 phase arrest and a subsequent apoptotic cell death, These data provide an evidence for the involvement of pRb-E2F/DP machinery in PDT-mediated cell cycle arrest leading to apoptosis.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.			Gupta, Sanjay/0000-0002-9492-3249	NCI NIH HHS [P30 CA 43703, R01 CA51802, P01 CA 48735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, P01CA048735, R01CA051802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; BenHur E, 1997, PHOTOCHEM PHOTOBIOL, V65, P456, DOI 10.1111/j.1751-1097.1997.tb08589.x; Bowen C, 1998, CANCER RES, V58, P3275; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Goldberg Y, 1996, ONCOGENE, V12, P893; Gomer CJ, 1996, CANCER RES, V56, P2355; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V54, P1093, DOI 10.1111/j.1751-1097.1991.tb02133.x; Granville DJ, 1997, CELL DEATH DIFFER, V4, P623, DOI 10.1038/sj.cdd.4400286; Gupta S, 1998, CANCER RES, V58, P1785; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Ishida A, 1997, J BIOL CHEM, V272, P10050; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; LUNA MC, 1994, CANCER RES, V54, P1374; Luo Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P528, DOI 10.1111/j.1751-1097.1996.tb03079.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; Separovic D, 1997, CANCER RES, V57, P1717; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TOM R, 1997, J NATL CANCER I, V89, P112; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x	41	28	33	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1891	1896		10.1038/sj.onc.1202493	http://dx.doi.org/10.1038/sj.onc.1202493			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086343				2022-12-17	WOS:000079090000012
J	Li, YW; Bhuiyan, M; Mohammad, RM; Sarkar, FH				Li, YW; Bhuiyan, M; Mohammad, RM; Sarkar, FH			Induction of apoptosis in breast cancer cells by TPA	ONCOGENE			English	Article						apoptosis; breast cancer; TPA	POLY(ADP-RIBOSE) POLYMERASE; GROWTH ARREST; P53; EXPRESSION; PROTEINASE; MATRIX; DEATH; CYCLOOXYGENASE-2; IDENTIFICATION; SUPPRESSION	Bcl-2, Fax and p53 gene products have been linked to programmed cell death pathways. p21(WAF1) has been shown to mediate p53-induced cell cycle arrest and to inhibit cyclin-dependent kinase activity. We have analysed the expression of these genes and apoptosis induced by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in several human breast cancer cell line. We found up-regulation of p2l(WAF1) and Bax expressions, however, the expressions of p53 and Bcl-2 genes remained unchanged in TPA-treated cells. Furthermore, DNA ladder formation and PARP cleavage were observed after treatment for 24 h, indicating apoptotic cell death. Flow cytometry with 7-amino actinomycin D staining showed that the number of apoptotic cells increased with longer treatment of TPA. From these results, we conclude that TPA is not only a tumor promoter, but also induces apoptosis in breast cancer cells. TPA-induced apoptosis appears to be mediated through a p53-independent pathway, and the up-regulation of p21(WAF1) and Bax may be the molecular mechanisms by which TPA induces apoptosis.	Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; CORNELIUS LA, 1995, J INVEST DERMATOL, V105, P170, DOI 10.1111/1523-1747.ep12317080; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HARPER JW, 1993, CELL, V75, P241; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang P, 1997, CANCER RES, V57, P3407; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KAPILA S, 1995, J DENT RES, V74, P1328, DOI 10.1177/00220345950740061301; KARGMAN SL, 1995, CANCER RES, V55, P2556; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kitada S, 1996, ONCOGENE, V12, P187; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lund LR, 1996, DEVELOPMENT, V122, P181; MIYASHITA T, 1995, CELL, V80, P293; Mohammad RM, 1998, CLIN CANCER RES, V4, P445; Parker S. L., 1996, CA CANC J CLIN, V65, P5; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Quarrie LH, 1996, J CELL PHYSIOL, V168, P559, DOI 10.1002/(SICI)1097-4652(199609)168:3<559::AID-JCP8>3.0.CO;2-O; RAWDANOWICZ TJ, 1994, J CLIN ENDOCR METAB, V79, P530, DOI 10.1210/jc.79.2.530; Reddy BS, 1996, CANCER RES, V56, P4566; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SANO H, 1995, CANCER RES, V55, P3785; SEDLAK ML, 1995, P NATL ACAD SCI USA, V92, P7934; Sundareshan P, 1997, CANCER LETT, V113, P17, DOI 10.1016/S0304-3835(96)04552-1; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	33	28	36	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2915	2920		10.1038/sj.onc.1202218	http://dx.doi.org/10.1038/sj.onc.1202218			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879997				2022-12-17	WOS:000077286400011
J	Braun, K; Holzl, G; Soucek, T; Geisen, C; Moroy, T; Hengstschlager, M				Braun, K; Holzl, G; Soucek, T; Geisen, C; Moroy, T; Hengstschlager, M			Investigation of the cell cycle regulation of cdk3-associated kinase activity and the role of cdk3 in proliferation and transformation	ONCOGENE			English	Article						Cdk3; cell cycle; p27; c-Myc; E2F	DEPENDENT KINASES; THYMIDINE KINASE; C-MYC; PROTEIN-KINASES; RETINOBLASTOMA PROTEIN; GENE; COMPLEXES; FAMILY; E2F; TRANSACTIVATION	The G1-S transition in mammalian cells has been demonstrated to require the cyclin-dependent kinases cdk2, cdk3 and cdk4/6. Here we show that a novel kinase activity associated with cdk3 fluctuates throughout the cell cycle differently from the expression of cyclin D1-, E- and A-associated kinase activities. Cdk3 kinase activity is neither affected by p16 (in contrast to cdk4/6) nor by E2F-1 (in contrast to cdk2), but is downregulated upon transient p27 expression. We found cdk3 to bind to p21 and p27, We provide evidence that p27 could be involved in the regulation of the cell cycle fluctuation of cdk3 activity: cdk3 protein does not fluctuate and interaction of cdk3 with p27, but not with p21, is lost when cdk3 kinase becomes active during the cell cycle. In Myc-overexpressing cells, but not in normal Rat1 cells, constitutive ectopic expression of cdk3 induces specific upregulation of cdk3-associated kinase activity that is still cell cycle phase dependent. Ectopic cdk3, but not cdk2, enhances Myc-induced proliferation and anchorage-independent growth associated with Myc activation, without effects on cyclin D1, E- and A protein expression or kinase activities. High levels of cdk3 in Myc-overexpressing cells trigger up- and deregulation of E2F-dependent transcription without inducing the E2F-DNA binding capacity. In contrast to all other studied positive G1 regulators, cdk3 is unable to cooperate with ras in fibroblast transformation suggesting a function of cdk3 in G1 progression that is different from cyclin Dor E-associated kinase activities. Our data provide first insights into the regulation of cdk3-associated kinase activity and suggest a model how cdk3 participates in the regulation of the G1-S transition.	Univ Vienna, Dept Prenatal Diagnosis & Therapy, A-1090 Vienna, Austria; Univ Klinikum Esses, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Dept Prenatal Diagnosis & Therapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Moroy, Tarik/D-9923-2011					BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BULLRICH F, 1995, CANCER RES, V55, P1199; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DOU QP, 1994, J BIOL CHEM, V269, P1306; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengstschlager M, 1996, DNA CELL BIOL, V15, P41, DOI 10.1089/dna.1996.15.41; Hengstschlager M, 1996, ONCOGENE, V12, P1635; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; NEVINS JR, 1992, SCIENCE, V258, P424; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pusch O, 1997, DNA CELL BIOL, V16, P737, DOI 10.1089/dna.1997.16.737; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Sherbet G.V., 1997, GENETICS CANC; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VLACH J, 1996, EMBO J, V15, P6596; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	38	28	30	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2259	2269		10.1038/sj.onc.1202145	http://dx.doi.org/10.1038/sj.onc.1202145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811456				2022-12-17	WOS:000076698200011
J	Zancai, P; Cariati, R; Rizzo, S; Boiocchi, M; Dolcetti, R				Zancai, P; Cariati, R; Rizzo, S; Boiocchi, M; Dolcetti, R			Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G(1) regulatory proteins: p27(Kip1) up-regulation is a relevant early event	ONCOGENE			English	Article						retinoic acid; cell cycle; p27(kip1); B lymphocytes; EBV	DEPENDENT KINASE INHIBITOR; ACUTE PROMYELOCYTIC LEUKEMIA; BREAST-CANCER CELLS; IN-VITRO; DIFFERENTIATION THERAPY; CARCINOMA CELLS; DNA-REPLICATION; DOWN-REGULATION; CDK INHIBITOR; HL-60 CELLS	EBV-immortalized lymphoblastoid B cell lines (LCLs) are a suitable in vitro model for the study of EBV-related lymphoproliferative disorders of immunosuppressed patients, We have previously shown that 9-cis-, 13-cis- and all-trans-retinoic acid (RA) powerfully inhibit LCL proliferation at concentrations corresponding to therapeutically achievable plasma levels (10(-6) M). Herein we show that RA-induced LCL accumulation in the G(0)/G(1) phases correlated with the loss of the catalytic activity of all three G(1)-associated CDKs (CDK2, CDK4 and CDK6) and with increased levels of underphosphorylated pRb and, in some LCLs, p130, LCLs arrested in G(0)/G(1) by RA also showed a significant decrease in the protein levels of cyclins D2, D3 and A, together with a reduction in the amount of cyclin D associated with CDK4 and CDK6, probably accounting for the inhibition of the relative kinase activity. In addition, RA-treated LCLs showed a marked upregulation of the CDK inhibitor (CKI) p27(Kip-1) at the protein but not mRNA level, which correlated with a progressive increase of p27(Kip-1) in CDK2 complexes (more than 2.5-fold) and with a reduction in the active phosphorylated form of CDK2, p27(Kip-1) may also contribute to the inhibition of CDK4 kinase activity, as the amount of CDK4-associated p27(Kip-1) was increased by 50% after RA exposure. p27(Kip-1) up-regulation stably persisted for more than one week after RA withdrawal concomitantly with the maintenance of the proliferative block. Moreover, neutralization of TGF beta did not affect the growth inhibitory activity of RA, suggesting that LCL growth arrest induced by these retinoids is probably not mediated by a pathway directly involving TGF beta. Overall, these results demonstrate that RA treatment of EBV-immortalized B lymphocytes is associated with multiple effects on G(1) regulatory proteins, including p27(Kip1) up-regulation, decreased levels of cyclins D2, D3 and A, and inhibition of CDK2, CDK4 and CDK6 activity, which ultimately result in reduced pRb phosphorylation and G(0)/G(1) growth arrest.	Ctr Riferimento Oncol, Div Expt Oncol 1, I-33081 Aviano, PN, Italy	IRCCS Aviano (CRO)	Boiocchi, M (corresponding author), Ctr Riferimento Oncol, Div Expt Oncol 1, I-33081 Aviano, PN, Italy.		Dolcetti, Riccardo/O-3832-2015; Rizzo, Silvana/AAW-1132-2020	Dolcetti, Riccardo/0000-0003-1625-9853; Rizzo, Silvana/0000-0002-7156-1783				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; ASIEDU C, 1995, CANCER RES, V55, P3716; Blanchard DA, 1997, J IMMUNOL, V158, P3054; Bouchard C, 1997, J IMMUNOL, V159, P4155; CASTAIGNE S, 1990, BLOOD, V76, P1704; FALK LA, 1991, BLOOD, V77, P1248; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Florenes VA, 1996, ONCOGENE, V13, P2447; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; KALEMKERIAN GP, 1994, CELL GROWTH DIFFER, V5, P55; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MIYATAKE S, 1995, J EXP MED, V182, P401, DOI 10.1084/jem.182.2.401; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; NALESNIK MA, 1988, AM J PATHOL, V133, P173; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Peng D, 1996, CANCER RES, V56, P3666; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SHAO ZM, 1995, ONCOGENE, V11, P493; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; URBANI L, 1995, EXP CELL RES, V219, P159, DOI 10.1006/excr.1995.1216; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang QM, 1996, CANCER RES, V56, P264; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1994, SEMIN HEMATOL, V31, P1; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	47	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1827	1836		10.1038/sj.onc.1202089	http://dx.doi.org/10.1038/sj.onc.1202089			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778049				2022-12-17	WOS:000076303300009
J	Hitomi, M; Shu, JY; Agarwal, M; Agarwal, A; Stacey, DW				Hitomi, M; Shu, JY; Agarwal, M; Agarwal, A; Stacey, DW			p21(Waf1) inhibits the activity of cyclin dependent kinase 2 by preventing its activating phosphorylation	ONCOGENE			English	Article						prostaglandin A2; cyclin; cyclin dependent kinase; gadd45; gadd153; p27(Kip1); p21(Waf1); p53	GROWTH ARREST; POTENTIAL MEDIATOR; PROSTAGLANDIN A(2); CDK2 ACTIVITY; DNA-DAMAGE; P53; P21; P27(KIP1); GENE; CLONING	Prostaglandin A2 (PGA2), a potent inhibitor of the growth of many cell types, inhibits G1 phase cyclin dependent kinases (cdk). Although PGA2 suppresses cyclin D1 and elevates p21(Waf1) levels, it was the failure of cdk2 to become activated by phosphorylation which correlated best with growth inhibition. In kinetic studies, cdk2 activation was inhibited efficiently only if p21(Waf1) levels increased prior to the activating phosphorylation; suggesting that p21(Waf1) had blocked this phosphorylation. This model was confirmed in cells from p21(Waf1) knockout mice where PGA2 was completely unable to block the activating phosphorylation of cdk2, or inhibit cdk2 activity. As expected, growth inhibition of p21(Waf1-/-) cells was not observed at PGA2 concentrations which inhibited cdk2 activity and growth of p21Waf1-/- cells.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hitomi, M (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NIGMS NIH HHS [GM52271] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN TM, 1992, ONCOGENE, V7, P1541; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOWE PH, 1993, J BIOL CHEM, V268, P21448; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Maniatis T., 1982, MOL CLONING; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; PRICE BD, 1993, ONCOGENE, V8, P3055; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sambrook J., 1989, MOL CLONING; Shu JY, 1996, ONCOGENE, V13, P2421; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	41	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					959	969		10.1038/sj.onc.1202005	http://dx.doi.org/10.1038/sj.onc.1202005			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747875	Bronze			2022-12-17	WOS:000075560900004
J	Omri, B; Blancher, C; Neron, B; Marty, MC; Rutin, J; Molina, TJ; Pessac, B; Crisanti, P				Omri, B; Blancher, C; Neron, B; Marty, MC; Rutin, J; Molina, TJ; Pessac, B; Crisanti, P			Retinal dysplasia in mice lacking p56(lck)	ONCOGENE			English	Article						Lck; neuroretina; dysplasia	TYROSINE KINASE; INDUCED RETINOPATHY; NEURAL RETINA; NEURONS; FYN; RAT; LCK; PROTOONCOGENE; EXPRESSION; LSTRA	The product of the proto-oncogene p56(lck) is a nonreceptor tyrosine kinase member of the Src family. It is found in T cells (Marth ef al,, 1985, 1988) and in the mouse brain (Omri et al., 1996; Van Tan et al., 1996). In this report, we describe experiments showing that Lck is present in the mouse retina neurons. Lck gene expression was identified after isolating and sequencing the specific 5' and 3' part of the cDNA obtained by RT-PCR. In adult retina Lck immunoreactivity was most abundant in photoreceptor cells and within the outer plexiform layers. Staining was also observed in the inner nuclear and plexiform layers. In transgenic mice, the disruption of the Lck gene had serious consequences on the organization of the retina causing retinal dysplasia. These mice have partial retinal detachment with infolding and rosette formation in the photoreceptor sheet. These retinal abnormalities observed in Lck deficient mice lead to the loss of normal architecture of the photoreceptor and the inner nuclear layers, and provide an important role of Lck protein in the retina development. The lack of the Lck protein produces a spectrum of retinal pathology that resembles human retinopathy of prematurity (ROP).	CNRS, UPR 9035, F-75270 Paris 06, France; Hotel Dieu, Fac Med Broussais, Dept Pathol, F-75270 Paris, France; Univ Paris 06, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Sorbonne Universite	Crisanti, P (corresponding author), CNRS, UPR 9035, F-75270 Paris 06, France.		Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754				CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; FISCHER S, 1987, BIOCHEM BIOPH RES CO, V143, P819, DOI 10.1016/0006-291X(87)90322-6; FLEXNER RA, 1981, J HOPKINS HOSP B, V2, P115; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; HAMMER ME, 1986, AM J OPHTHALMOL, V102, P1; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; INGRAHAM CA, 1992, ONCOGENE, V7, P95; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Omri B, 1996, J NEUROCHEM, V67, P1360; OMRI B, 1994, INT IMMUNOL, V6, P377, DOI 10.1093/intimm/6.3.377; PENN JS, 1992, CURR EYE RES, V11, P939, DOI 10.3109/02713689209033492; POPOFF N, 1969, J ULTRA MOL STRUCT R, V29, P535, DOI 10.1016/S0022-5320(69)90072-0; QUINN GE, 1990, DOC OPHTHALMOL, V74, P223, DOI 10.1007/BF02482612; RAJAOFETRA N, 1992, DEV BRAIN RES, V67, P237, DOI 10.1016/0165-3806(92)90224-K; SADDA SR, 1994, INVEST OPHTH VIS SCI, V35, P1202; SILVERSTEIN AM, 1971, AM J OPHTHALMOL, V72, P13, DOI 10.1016/0002-9394(71)91586-8; SIRA BS, 1985, SURV OPHTHALMOL, V33, P1; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; TSO MOM, 1969, ARCH PATHOL, V88, P664; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; VanTan H, 1996, J NEUROCHEM, V67, P2306; YAGI T, 1994, DEV GROWTH DIFFER, V36, P543; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZIERLER S, 1988, RETINOPATHY PREMATUR, P23	28	28	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2351	2356		10.1038/sj.onc.1201761	http://dx.doi.org/10.1038/sj.onc.1201761			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620552				2022-12-17	WOS:000073428000007
J	Riordan, FA; Bravery, CA; Mengubas, K; Ray, N; Borthwick, NJ; Akbar, AN; Hart, SM; Hoffbrand, AV; Mehta, AB; Wickremasinghe, RG				Riordan, FA; Bravery, CA; Mengubas, K; Ray, N; Borthwick, NJ; Akbar, AN; Hart, SM; Hoffbrand, AV; Mehta, AB; Wickremasinghe, RG			Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells	ONCOGENE			English	Article						apoptosis; leukaemia; Philadelphia chromosome; bcr/abl; herbimycin A; etoposide	ABL TYROSINE KINASE; PH(1)-POSITIVE LEUKEMIA-CELLS; CHRONIC MYELOID-LEUKEMIA; CANCER-THERAPY; DEATH; PROTEIN; LINES; BCL-2; INHIBITOR; GROWTH	Philadelphia chromosome (Ph)-positive leukaemia cells express the chimeric bcr/abl oncoprotein, whose deregulated protein tyrosine kinase (PTK) activity antagonizes the induction of apoptosis by DNA damaging agents, Treatment of Ph-positive K562, TOM 1 and KCL-22 cells with etoposide for 2d induced cytosolic vacuolation, but not nuclear condensation or DNA fragmentation, The bcr/abl kinase-selective inhibitor herbimycin A increased the induction of nuclear apoptosis by etoposide or gamma-radiation. The concentration of herbimycin required to synergize with etoposide was similar to that required to decrease the level of tyrosine phosphorylated proteins or of the protein tyrosine kinase activity of anti-abl immune complexes in K562 cells, The ability of herbimycin A to sensitize K562, TOM 1 or KCL-22 cells to apoptosis induction correlated with its ability to decrease the cellular content of phosphotyrosyl proteins in these Philadelphia-positive lines. Enhancement of nuclear apoptosis by herbimycin was not attributable to downregulation of the bcl-2 or bcl-X-L anti-apoptotic proteins, In contrast, herbimycin protected Philadelphia-negative HL60 cells from apoptosis induction by etoposide and did not affect killing of NC37 and CEM cells, The data suggest that the induction of apoptosis is blocked in cells expressing the bcr/abl oncoprotein and that herbimycin A increases induction of programmed cell death following DNA damage, Selective PTK inhibitors may therefore be of value in securing the genetic death of Ph-positive leukaemia cells.	Royal Free Hosp, Sch Med, Dept Hematol, London NW3 2QG, England; Royal Free Hosp, Sch Med, Dept Clin Immunol, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Wickremasinghe, RG (corresponding author), Royal Free Hosp, Sch Med, Dept Hematol, Pond St, London NW3 2QG, England.		Mehta, Atul/GPC-7364-2022	Akbar, Arne/0000-0002-3763-9380				BEDI A, 1994, BLOOD, V83, P2036; BERGAMASCHI G, 1993, LEUKEMIA, V7, P2012; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; BLAGOSKLONNY MV, 1996, LEUKEMIA, V12, P101; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARK RE, 1995, LEUKEMIA LYMPHOMA, V19, P189, DOI 10.3109/10428199509107888; CORY S, 1994, NATURE, V367, P317, DOI 10.1038/367317a0; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; EVANS JPM, 1987, LEUKEMIA, V1, P524; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GinestierVerne C, 1996, ANAL CELL PATHOL, V11, P115; HONMA Y, 1992, CANCER RES, V52, P4017; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LOTEM J, 1992, BLOOD, V80, P1750; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; NALDINI L, 1986, MOL CELL BIOL, V6, P1803, DOI 10.1128/MCB.6.5.1803; Nishii K, 1996, ONCOGENE, V13, P2225; OBRIEN SG, 1994, LEUKEMIA, V8, P2156; OKABE M, 1993, LEUKEMIA LYMPHOMA, V12, P41, DOI 10.3109/10428199309059570; OKABE M, 1994, LEUKEMIA RES, V18, P213, DOI 10.1016/0145-2126(94)90117-1; OKABE M, 1992, BLOOD, V80, P1330; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; *PROM CORP, 1993, PROM TECHN MAN LUC R; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1996, LEUKEMIA RES, V20, P109, DOI 10.1016/0145-2126(95)00135-2; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SATO S, 1994, LEUKEMIA RES, V18, P221, DOI 10.1016/0145-2126(94)90118-X; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SMETSERS TFCM, 1995, LEUKEMIA, V9, P118; SMETSERS TFCM, 1995, BLOOD, V85, P597; STEUBE KG, 1995, LEUKEMIA, V9, P1841; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; TWENTYMAN PR, 1989, BRIT J HAEMATOL, V71, P19, DOI 10.1111/j.1365-2141.1989.tb06268.x; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VAERMAN JL, 1995, BLOOD, V86, P3891, DOI 10.1182/blood.V86.10.3891.bloodjournal86103891; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368	52	28	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1533	1542		10.1038/sj.onc.1201680	http://dx.doi.org/10.1038/sj.onc.1201680			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569020				2022-12-17	WOS:000072743200003
J	Gloushankova, N; Ossovskaya, V; Vasiliev, J; Chumakov, P; Kopnin, B				Gloushankova, N; Ossovskaya, V; Vasiliev, J; Chumakov, P; Kopnin, B			Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes	ONCOGENE			English	Article						p53; ras; morphological transformation	P-GLYCOPROTEIN FUNCTION; TATA-BINDING PROTEIN; MAP KINASE KINASE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; WILD-TYPE; FUNCTION MUTATIONS; TUMOR-ANTIGEN; DOMAINS; GENE	p53 plays an important role in restriction of abnormal cell proliferation, Loss of this safeguard function induced by p53 mutations seems to be a key mechanism in oncogenesis, It cannot be excluded however, that in addition to elimination of p53-dependent checkpoints and/or apoptosis p53 mutations may cause additional effects that contribute to oncogenic transformation. In order to analyse the effects of 7 wild-type (wt) and mutant p53 on expression of res-induced morphological transformation we used the method of computer-assisted morphometry, The following parameters were determined: a) the area covered by the spread cells; b) dispersion and c) elongation of cell contours, The last two indices characterise cell shape, Elongation indicates the degree of bipolarity of cell contour and dispersion the degree of its multipolarity. Transformation of Rat1 and mouse 10(3) fibroblasts by N-rasasp12 oncocgene, was accompanied by dramatic decrease of cell area and increase of dispersion and elongation. IAR-2 discoid epitheliocytes expressing exogenous res oncogene transformed into polarised cells with decreased cell area, Fluorescent microscopic examination of actin cytoskeleton stained with rhodamine-phalloidin had shown that res-induced transformation of IAR-2 cells is characterised by disappearance of circumferential actin bundle and straight fibers, Neither did we reveal actin stress-fibers in the ras-transformed Rat1 cells, Transduction of p53 cDNAs caused no significant changes in morphometric parameters of non-transformed parental Rat1, IAR-2 and 10(3) cells, but some of the p53 mutants modified cell shape of ras-transformed cells, p53-His273, unlike other tested p53 mutants (Tyr141, His194, Trp248), induced partial reversion of morphological transformation in both Rat1 fibroblasts and IAR-2 epitheliocytes. Its expression led to increase of average cell area, decrease of dispersion and elongation indices, and re-appearance of actin bundles, Exogenous wild-type p53 also caused some reversion of transformed phenotype of Rat/ras cells, but its effect was weaker than that of the p53-His273. In contrast, another p53 mutant p53-His175 was able to enhance ras-induced morphological transformation in p53-deficient murine 10(3) fibroblasts that is consistent with possible involvement of some gain of function activity of mutant p53 in modulation of cell shape, Possible pathways that might be responsible for p53-induced changes of cell morphology are discussed.	RUSSIAN ACAD SCI,ENGELHARDT INST MOL BIOL,MOSCOW,RUSSIA; RUSSIAN ACAD SCI,CANC RES CTR,INST CANCEROGENESIS,MOSCOW,RUSSIA	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences			Chumakov, Peter M/E-7731-2014; Kopnin, Boris/R-8240-2019; Gloushankova, Natalya/S-2577-2019	Kopnin, Boris/0000-0003-3100-2212; Gloushankova, Natalya/0000-0002-2044-2063; Chumakov, Peter/0000-0002-8078-2908				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BROWN AF, 1989, CELL BIOL INT REP, V13, P357, DOI 10.1016/0309-1651(89)90162-8; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dunn G. A., 1986, J CELL SCI, V108, P1659; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FUKASAWA K, 1995, ONCOGENE, V11, P1447; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSIAO M, 1994, AM J PATHOL, V145, P702; JENKINS JR, 1984, NATURE, V312, P851; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOPNIN BP, 1995, ONCOL RES, V7, P299; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACHESKY LM, 1996, TRENDS CELL BIOL, V6, P394; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MONTESANO R, 1975, INT J CANCER, V16, P550, DOI 10.1002/ijc.2910160405; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARK DJ, 1994, ONCOGENE, V9, P1899; PERREM K, 1995, ONCOGENE, V11, P1299; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ransone Lynn J., 1993, Gene Expression, V3, P37; SCHENENBERGER CA, 1991, J CELL BIOL, V112, P873; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, CANCER RES, V51, P5232; STROMSKAYA TP, 1995, FEBS LETT, V368, P373, DOI 10.1016/0014-5793(95)00662-S; Thomas M, 1996, ONCOGENE, V13, P265; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAICHUK TA, 1993, P RUSSIAN ACAD SCI, V330, P386; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	52	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2985	2989		10.1038/sj.onc.1201483	http://dx.doi.org/10.1038/sj.onc.1201483			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416842				2022-12-17	WOS:A1997YK37700011
J	PaasinenSohns, A; Holtta, E				PaasinenSohns, A; Holtta, E			Cells transformed by ODC, c-Ha-ras and v-src exhibit MAP kinase Erk-independent constitutive phosphorylation of Sos, Raf and c-Jun activation domain, and reduced PDGF receptor expression	ONCOGENE			English	Article						transformation; ODC; Ras; Src; MAP kinase; c-Jun phosphorylation	NUCLEOTIDE EXCHANGE FACTOR; NIH 3T3 CELLS; ORNITHINE DECARBOXYLASE ACTIVITY; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; TYROSINE KINASE; ONCOGENIC TRANSFORMATION; PHOSPHOTYROSINE PHOSPHATASE; TRANSCRIPTIONAL ACTIVITY	While it is known that the constitutive activity of a variety of signal transduction molecules leads to cell transformation, a key unresolved question is whether these wirings converge to a common intermediate(s) that dictates transformation, In this study, we investigated whether NIH3T3 and Rat-1 cells transformed by human ornithine decarboxylase (ODC), c-Ha-ras(Val12) and temperature-sensitive v-src oncogene display common alteration(s) in the components that relay PDGF-mediated signals in normal fibroblasts. The ras- and ODC-transformed cells did not show constitutively elevated tyrosine phosphorylation of the phospholipase Cy-l (PLC gamma-1), RasGTPase-activating protein (GAP), phosphotyrosine phosphatase Syp, She proteins, and phosphatidylinositol 3-kinase (PI3-K) or activation of the MAP kinase (Erk1 and Erk2), p70 S6 kinase or the Janus protein tyrosine kinase (JAK) and signal transducer and activator of transcription (STAT) protein-1 pathways. Instead, the Ras nucleotide exchange factor Sos-1 and Raf-l kinase exhibited constitutive phosphorylations, as deduced from their electrophoretic mobility shifts in polyacrylamide gels, Hence a kinase distinct from Erk1 and Erk2, previously known to feedback phosphorylate Sos-1 and Raf-l, is responsible for the phosphorylation of these molecules in the transformants. We also demonstrate that the ras- and ODC-transformed cells exhibit loss of both the PDGF alpha- and beta-receptors, while the v-Src-transformants show a predominant reduction in the beta-receptors. Moreover, all the transformed cell lines were found to display a constitutive increase in phosphorylation of c-Jun on serines 63 and 73, which appears to be governed by an as yet unknown kinase.	UNIV HELSINKI,HAARTMAN INST,DEPT PATHOL,FIN-00014 HELSINKI,FINLAND	University of Helsinki								Alessandrini A, 1996, J BIOL CHEM, V271, P31612, DOI 10.1074/jbc.271.49.31612; ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; AUVINEN M, 1997, IN PRESS CANC RES, V57; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BARONDELAGE S, 1994, J BIOL CHEM, V15, P18686; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BAZENET CE, 1993, ONCOGENE, V9, P517; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GAZDAR AF, 1976, NATURE, V262, P696, DOI 10.1038/262696a0; Greulich H, 1996, ONCOGENE, V12, P1689; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; HOLTTA E, 1994, BIOCHEM SOC T, V22, P853; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEHTOLA L, 1991, CELL REGUL, V2, P651, DOI 10.1091/mbc.2.8.651; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEGG AE, 1988, CANCER RES, V48, P759; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; RAKE JB, 1991, J BIOL CHEM, V266, P5348; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TOMASKA L, 1993, BIOCHEM J, V293, P215, DOI 10.1042/bj2930215; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VAZRIL C, 1995, MOL CELL BIOL, V15, P1244; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	89	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1953	1966		10.1038/sj.onc.1201366	http://dx.doi.org/10.1038/sj.onc.1201366			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365242				2022-12-17	WOS:A1997YA87200010
J	Sivak, LE; Tai, KF; Smith, RS; Dillon, PA; Brodeur, GM; Carroll, WL				Sivak, LE; Tai, KF; Smith, RS; Dillon, PA; Brodeur, GM; Carroll, WL			Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines	ONCOGENE			English	Article						N-myc promoter; neuroblastoma; autoregulation	HUMAN C-MYC; GENE AMPLIFICATION; MAMMALIAN-CELLS; NEURO-BLASTOMA; NEGATIVE AUTOREGULATION; DIFFERENTIAL EXPRESSION; REGULATORY ELEMENTS; BURKITT-LYMPHOMA; TRANSGENIC MICE; CYCLIN D1	Amplification of the N-myc gene is a significant adverse prognostic factor in neuroblastoma, a common childhood tumor, In non-transformed cells, myc expression is controlled through an autoregulatory circuit, through which elevated Myc protein levels lead to down-regulation of myc transcription, The precise mechanism of myc gene autoregulation is unknown, Loss of c-myc autoregulation has been documented in transformed cells from a number of different lineages, but N-myc autoregulation has not yet been investigated, In neuroblastoma, the increased N-Myc protein produced by amplified tumors mould be expected to silence N-myc transcription if the autoregulatory loop were intact, To determine whether N-myc autoregulation is operative in human neuroblastoma, and to localize cis-acting elements which mediate N-myc autosuppression, we transfected a series of N-myc 5' promoter constructs into a panel of human neuroblastoma cell lines carrying one or multiple copies of N-myc, The transfected promoter was equally amplified lines, Significant promoter activity in the presence of abundant Myc protein in amplified neuroblastoma Lines indicates that autoregulation is disabled in this subset of tumors, To investigate,whether single-copy lines produce insufficient N-Myc protein to trigger autosuppression yet retain an intact autoregulatory circuit, we transfected neuroblastoma lines with 5' promoter constructs in the presence of a c- or N-myc expression vector, Overexpression of c- or N-Myc resulted in diminution of activity of both the transfected promoter and the endogenous N-myc gene in single-copy, but not amplified lines, Using a series of 5' promoter-deletion minigenes, we localized a cis-acting element required for autoregulation close to the transcription start sites, While the precise mechanism of autosuppression remains unknown, we demonstrated that Myc is incapable of silencing the adenovirus major late promoter (AdMLP) in neuroblastoma cells, indicating that Myc suppression of its own promoter and the AdMLP involve distinct components, These studies provide the first systematic investigation of autoregulation in neuroblastoma, and indicate that single-copy neuroblastoma lines produce insufficient N-Myc protein to activate downstream effector(s) of autosuppression; the autoregulatory circuit is otherwise intact, Amplified lines, in contrast, have lost autoregulation.	UNIV UTAH, SCH MED, ECCLES INST HUMAN GENET, HUNTSMAN CANC INST, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT PATHOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT PEDIAT, SALT LAKE CITY, UT 84112 USA; JOHNS HOPKINS UNIV, DIV PEDIAT SURG, BALTIMORE, MD USA; CHILDRENS HOSP PHILADELPHIA, DIV PEDIAT HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Johns Hopkins University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1986, NATURE, V321, P702; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BARTRAM CR, 1987, EUR J PEDIATR, V146, P162, DOI 10.1007/BF02343225; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BERTLING W, 1987, J BIOCHEM BIOPH METH, V14, P223, DOI 10.1016/0165-022X(87)90011-X; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BUCKLE RS, 1996, ONCOGENE, V10; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CROUCH DH, 1990, ONCOGENE, V5, P683; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Goldman SC, 1996, AM J PATHOL, V148, P1381; GRADY EF, 1987, CANCER RES, V47, P2931; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HILLER S, 1991, ONCOGENE, V6, P969; JAKOBVITS A, 1985, NATURE, V318, P1188; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MA A, 1991, MOL CELL BIOL, V11, P440, DOI 10.1128/MCB.11.1.440; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NEPVEU A, 1987, ONCOGENE, V1, P243; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SLAVC I, 1990, CANCER RES, V50, P1459; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416; VOGAN K, 1993, CANCER RES, V53, P5269; WADA RK, 1992, ONCOGENE, V7, P711; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG YS, 1992, ONCOGENE, V7, P1241; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	65	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1937	1946		10.1038/sj.onc.1201363	http://dx.doi.org/10.1038/sj.onc.1201363			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365240				2022-12-17	WOS:A1997YA87200008
J	Carpentier, A; Balitrand, N; RochetteEgly, C; Shroot, B; Degos, L; Chomienne, C				Carpentier, A; Balitrand, N; RochetteEgly, C; Shroot, B; Degos, L; Chomienne, C			Distinct sensitivity of neuroblastoma cells for retinoid receptor agonists: evidence for functional receptor heterodimers	ONCOGENE			English	Article						neuroblastoma; retinoic acid; retinoid receptor agonist; retinoic acid receptor	INDUCED GRANULOCYTIC DIFFERENTIATION; NEURO-BLASTOMA CELLS; BINDING PROTEIN-II; RAR-ALPHA; ACID RECEPTORS; 13-CIS-RETINOIC ACID; CHILDRENS-CANCER; RXR HETERODIMERS; WILD-TYPE; PHASE-I	Retinoic acid (RA) plays a major role in embryogenesis of the nervous system and has been reported to induce differentiation in neuroblastoma cell lines. To identify RA signaling pathways involved in such differentiation processes, two RA-sensitive neuroblastoma cell lines (LA-N-5 and SH-SY5Y) were extensively studied. Northern blot experiments determined that of the three RAR mRNAs, only RAR alpha was significantly expressed, with respectively weak or undetectable levels of RAR gamma and RAR beta. RXRs (alpha and beta) receptors were weakly expressed, Western blotting analysis confirmed the constitutive expression of RAR alpha and absence of RAR beta and weak levels of RXR alpha. Treatment with all-trans-RA up-regulated RAR alpha and induced a drastic increase of RAR beta (both at the RNA and protein level). To further characterize the function of RAR alpha, RAR beta and RXR alpha in NB cells, nuclear extracts from LA-N-5 cells were analysed by EMSA studies. Three specific retarded complexes were observed which were significantly decreased or shifted in the presence of monoclonal antibodies to RAR alpha, RAR beta and RXR alpha. RA treatment dramatically induced a DR5-binding RXR alpha-RAR beta heterodimer. Treatment with combinations of RAR alpha or RAR beta agonists with a RXR alpha agonist or with a RAR alpha agonist alone, induced neurite-outgrowth supporting the probability that both RXR alpha-RAR alpha or RXR alpha-RAR beta heterodimers are involved in RA-mediated differentiation of NB cells. The availability of novel synthetic RA-specific receptor ligands should provide the possibility of tissue specific therapeutic regimes.	UNIV PARIS 07, HOP ST LOUIS,CNRS,EP 107,INST HEMATOL, LAB BIOL CELLULAIRE HEMATOPOIET, F-75475 PARIS 10, FRANCE; IGBMC, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; CIRD, GALDERMA, F-06902 SOPHIA ANTIPOLIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Galderma R&D SNC				Carpentier, Antoine/0000-0003-2926-0060; CHOMIENNE, Christine/0000-0001-5513-5752				BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Calabresse C, 1995, LEUKEMIA, V9, P2049; CARNEY DN, 1988, SEMIN ONCOL, V15, P199; CASTLE VP, 1992, J CLIN INVEST, V90, P1857, DOI 10.1172/JCI116062; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FINKLESTEIN JZ, 1992, MED PEDIATR ONCOL, V20, P307, DOI 10.1002/mpo.2950200407; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Gudas Lorraine J., 1994, P443; HIGUCHI T, 1991, CANCER RES, V51, P3958; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEROY P, 1991, P NATL ACAD SCI USA, V87, P4804; Li C, 1994, Prog Clin Biol Res, V385, P221; LOVAT PE, 1993, NEUROSCI LETT, V162, P109, DOI 10.1016/0304-3940(93)90572-3; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Manohar CF, 1996, TUMOR BIOL, V17, P34, DOI 10.1159/000217965; MARSHALL GM, 1995, ONCOGENE, V11, P485; MARSHALL GM, 1994, ANTICANCER RES, V14, P437; NERVI C, 1990, CELL GROWTH DIFFER, V1, P535; PLUM LA, 1995, ARCH BIOCHEM BIOPHYS, V319, P457, DOI 10.1006/abbi.1995.1317; REDFERN CPF, 1994, BIOCHEM J, V304, P147, DOI 10.1042/bj3040147; REES JL, 1989, BIOCHEM J, V259, P917, DOI 10.1042/bj2590917; Reynolds CP, 1994, ADV NEUROBLASTOMA RE, V4, P237; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; ROSOLEN A, 1992, EUR CYTOKINE NETW, V2, P81; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROUSSELOT P, 1994, ONCOGENE, V9, P545; ROY DY, 1995, MOL CELL BIOL, V15, P6481; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SIDELL N, 1982, J NATL CANCER I, V68, P589; SMITH MA, 1992, J CLIN ONCOL, V10, P1666, DOI 10.1200/JCO.1992.10.11.1666; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615	51	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	1997	15	15					1805	1813		10.1038/sj.onc.1201335	http://dx.doi.org/10.1038/sj.onc.1201335			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362447				2022-12-17	WOS:A1997XZ72500007
J	Chalk, JG; Barr, FG; Mitchell, CD				Chalk, JG; Barr, FG; Mitchell, CD			Translin recognition site sequences flank chromosome translocation breakpoints in alveolar rhabdomyosarcoma cell lines	ONCOGENE			English	Article							PAX3-FKHR FUSION PROTEIN; GENE; PAX3; HYBRID; DIFFERENTIATION; REARRANGEMENT; CLUSTER; REGION	Alveolar rhabdomyosarcoma is characterized by a t(2;13)(q35;q14) chromosome translocation, which leads to the fusion of the PAX3 and the FKHR genes, The resulting fusion gene encodes a chimeric protein which has aberrant transcriptional activity, We report the molecular definition of the genomic breakpoints on both derivative chromosomes in one case and the derivative chromosome 13 breakpoints in two other cases, The DNA sequences adjacent to the breakpoints on the derivative chromosome 13 are remarkable for their resemblance to recognition sequences for the protein translin. Gel shift analyses confirm that these sequences bind translin, These findings suggest that translin may not only be important in the genesis of chromosomal translocations in lymphoid malignancy, but also in translocations found in solid tumours.	UNIV OXFORD, JOHN RADCLIFFE HOSP, DEPT PAEDIAT, OXFORD OX3 9DU, ENGLAND; UNIV PENN, DIV PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DIV LAB MED, PHILADELPHIA, PA 19104 USA	University of Oxford; University of Pennsylvania; University of Pennsylvania					NATIONAL CANCER INSTITUTE [R29CA061935] Funding Source: NIH RePORTER; NCI NIH HHS [CA61935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; CHEN SJ, 1989, ONCOGENE, V4, P195; COWELL JK, 1989, CYTOGENET CELL GENET, V52, P1, DOI 10.1159/000132827; DAVIS RJ, 1995, HUM MOL GENET, V4, P2355, DOI 10.1093/hmg/4.12.2355; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; MACINA RA, 1995, GENOMICS, V26, P1, DOI 10.1016/0888-7543(95)80076-X; MITCHELL CD, 1991, ONCOGENE, V6, P89; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAN Z, 1992, HUM GENET, V90, P435; SORENSEN PHB, 1995, CANCER RES, V55, P1385	18	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1199	1205		10.1038/sj.onc.1201285	http://dx.doi.org/10.1038/sj.onc.1201285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294613				2022-12-17	WOS:A1997XU99100009
J	Collins, LR; Ricketts, WA; Olefsky, JM; Brown, JH				Collins, LR; Ricketts, WA; Olefsky, JM; Brown, JH			The G(12) coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain	ONCOGENE			English	Article						G alpha(12); Shc; AP-1; thrombin	INDUCE NEOPLASTIC TRANSFORMATION; NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; TYROSINE-KINASE; SIGNAL TRANSDUCTION; ASTROCYTOMA-CELLS; ADAPTER PROTEIN; RAS; ACTIVATION; PATHWAY	Our previous studies in 1321N1 astrocytoma cells demonstrate that thrombin stimulates Ras-dependent mitogenesis through the pertussis toxin insensitive G protein G(12). While the direct effecters of G(12) are unknown, G alpha(12) can transform fibroblasts, utilize Ras and Rac dependent signaling pathways and stimulate GTP loading of Ras. Here we have examined the role of the Shc adaptor protein in mitogenic signaling by the thrombin receptor in 1321N1 cells. As has been reported in other systems, thrombin stimulation results in tyrosine phosphorylation of Shc in 1321N1 cells. We also show that transient expression of G alpha(12) results in tyrosine phosphorylation of Shc, thereby identifying Shc as the most proximal G(12) effector to date. In addition, we demonstrate by microinjection that thrombin stimulated mitogenesis requires Shc and occurs specifically through the Shc SH2 domain. Expression of the SH2 domain of Shc also inhibits G alpha(12) mediated induction of an AP-1 dependent reporter gene demonstrating that G(12) utilizes Shc to propagate downstream signals. Our data indicate that Shc is essential for stimulation of Ras dependent mitogenesis and gene expression by the G(12) coupled thrombin receptor.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NIDDK NIH HHS [DK33651] Funding Source: Medline; NIGMS NIH HHS [F31 GM17277, GM36927] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927, R56GM036927, F31GM017277] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASU T, 1994, ONCOGENE, V9, P3483; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	33	28	30	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					595	600		10.1038/sj.onc.1201220	http://dx.doi.org/10.1038/sj.onc.1201220			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247313				2022-12-17	WOS:A1997XN25500011
J	Chiba, N; Watanabe, T; Nomura, S; Tanaka, Y; Minowa, M; Niki, M; Kanamaru, R; Satake, M				Chiba, N; Watanabe, T; Nomura, S; Tanaka, Y; Minowa, M; Niki, M; Kanamaru, R; Satake, M			Differentiation dependent expression and distinct subcellular localization of the protooncogene product, PEBP2 beta/CBF beta, in muscle development	ONCOGENE			English	Article						PEBP2 beta/CBF beta; transcription factor; acute myeloid leukemia; muscle development; immunohistochemistry	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; SKELETAL-MUSCLE; E-CADHERIN; AML1 GENE; FUSION TRANSCRIPT; DNA-BINDING; PROTEIN; RUNT; DOMAIN	The Pebpb2/Cbfb gene encodes the non-DNA binding subunit of the heterodimeric transcription factor, PEBP2/CBF. To examine the expression of the PEBP2 beta/CBF beta protein in vivo, we carried out immunohistochemistry using the tissues from adult mice as well as embryos, Although PEBP2 beta/CBF beta was detected in various tissues to various degrees, interesting features of expression were observed in the skeletal myogenic cells. Here PEBP2 beta/CBF beta was found mainly to occur as cytoplasmic staining and the intensity of this staining increased depending on the differentiation stage of the cells, In the undifferentiated myoblasts PEBP2 beta/CBF beta was undetectable, whereas moderate levels of PEBP2 beta/CBF beta were detected in the elongated and aligned myocytes. PEBP2 beta/CBF beta appeared to accumulate further when the cells fused to each other to become multinucleated myotubes, Once the muscle fibers were established, PEBP2 beta/CBF beta was relocated onto or around the Z-lines. PEBP2 beta/CBF beta was also detected in the cytoplasm of cardiac myocytes and in the smooth muscle cells of the digestive tract. In all the above, the skeletal myotubes were the only case that showed both nuclear and cytoplasmic staining of PEBP2 beta/CBF beta. Thus, we could show differentiation dependent pattern of PEBP2 beta/CBF beta expression in muscle development and establish PEBP2 beta/CBF beta to be a cytoplasmic as well as nuclear protein in vivo.	TOHOKU UNIV,DEPT MOL IMMUNOL,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; TOHOKU UNIV,DEPT CLIN ONCOL,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN	Tohoku University; Tohoku University; Osaka University								ABERLE H, 1994, J CELL SCI, V107, P3655; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOBER E, 1994, DEVELOPMENT, V120, P603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEVLIN RB, 1978, CELL, V13, P599, DOI 10.1016/0092-8674(78)90211-8; ERICKSON P, 1992, BLOOD, V80, P1825; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; MARUYAMA K, 1965, J BIOCHEM-TOKYO, V58, P13, DOI 10.1093/oxfordjournals.jbchem.a128158; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MORRIS EJ, 1994, J CELL SCI, V107, P377; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051, DOI 10.1128/MCB.14.12.8051	42	28	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2543	2552		10.1038/sj.onc.1201109	http://dx.doi.org/10.1038/sj.onc.1201109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191054				2022-12-17	WOS:A1997XA94900006
J	Cadoret, A; Bertrand, F; BaronDelage, S; Levy, P; Courtois, G; Gespach, C; Capeau, J; Cherqui, G				Cadoret, A; Bertrand, F; BaronDelage, S; Levy, P; Courtois, G; Gespach, C; Capeau, J; Cherqui, G			Down-regulation of NF-kappa B activity and NF-kappa B p65 subunit expression by ras and polyoma middle T oncogenes in human colonic Caco-2 cells	ONCOGENE			English	Article						Ha-ras; polyoma middle T; NF-kappa B; p65 subunit; Caco-2 cells	PROTEIN-KINASE-C; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; P50 SUBUNIT; ADHESION MOLECULE-1; GROWTH-FACTOR; ACTIVATION; GENE; PROMOTER; ALPHA	The products of ras and src proto-oncogenes are frequently activated in a constitutive state in human colorectal cancer, In this study we attempted to establish whether the tumorigenic progression induced by oncogenic activation of p21(ras) or pp60(c-src) in human colonic cells is associated with alterations of the activity and expression of nuclear factor kappa B (NF-kappa B), a transcription factor suspected to participate in the development of cancer, To this end, we used Caco-2 cells made highly tumorigenic by transfection with an activated Val-12 human Ha-ras gene or with the polyoma middle T (PyMT) oncogene, a constitutive activator of pp60(c-src) tyrosine kinase activity, Compared with control vector-transfected Caco-2 cells, both oncogene-transfected cell lines exhibited: (i) decreased constitutive NF-kappa B DNA-binding activity and NF-kappa B-mediated reporter gene expression, without alteration of their response to TNF-alpha for activation of these parameters; (ii) reduced NF-kappa B cytosolic stores along with a decreased p65 expression due, at least in part, to destabilization of p65 mRNA; (iii) a decrease in adhesion to extracellular matrix component-coated substrata which was partially corrected when stimulating NF-kappa B transcriptional activity with TNF-alpha. These results indicate that the tumorigenic progression induced by oncogenic p21(ras) or PyMT/pp60(c-src) in human colonic Caco-2 cells is associated with a down-regulation of p65 expression and NF-kappa B activity which could be responsible for the reduced adhesive properties of these cells after oncogene transfection.	UNIV PARIS 06, BIOL CELLULAIRE LAB, INSERM U402, F-75571 PARIS 12, FRANCE; INST PASTEUR, CNRS URA 1149, UNITE BIOL MOL EXPRESS GEN, F-75724 PARIS, FRANCE; HOP ST ANTOINE, INSERM, U55, F-75571 PARIS 12, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Cadoret, Axelle/L-2529-2017	Cadoret, Axelle/0000-0002-4283-6864; COURTOIS, Gilles/0000-0003-3117-9595				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARGON J, 1992, J BIOL CHEM, V267, P16056; BaronDelage S, 1996, AM J PHYSIOL-GASTR L, V270, pG314, DOI 10.1152/ajpgi.1996.270.2.G314; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DELAGE S, 1993, CANCER RES, V53, P2762; deWit H, 1996, EXP HEMATOL, V24, P228; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HEMAR A, 1991, J IMMUNOL, V146, P2409; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JELINEK MA, 1992, ONCOGENE, V7, P1687; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOONG AC, 1994, CANCER RES, V54, P5273; KOWALIK TF, 1993, P NATL ACAD SCI USA, V90, P1107, DOI 10.1073/pnas.90.3.1107; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEVY P, 1996, IN PRESS BR J CANC; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; MUNOZ E, 1994, J VIROL, V68, P8035; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; NODA M, 1988, J BIOL CHEM, V263, P18574; PEREZ JR, 1994, MOL CELL BIOL, V14, P5326, DOI 10.1128/MCB.14.8.5326; ROUSSET M, 1980, JNCI-J NATL CANCER I, V65, P885; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIRINIAN MI, 1993, ONCOGENE, V8, P157; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; UEBERLA K, 1993, J ACQ IMMUN DEF SYND, V6, P227; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEISER MM, 1990, LAB INVEST, V62, P325; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995	56	28	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1589	1600		10.1038/sj.onc.1200992	http://dx.doi.org/10.1038/sj.onc.1200992			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129150				2022-12-17	WOS:A1997WQ54800010
J	Zhang, R; Zhang, H; Zhu, WM; Pardee, AB; Coffey, RJ; Liang, P				Zhang, R; Zhang, H; Zhu, WM; Pardee, AB; Coffey, RJ; Liang, P			Mob-1, a Ras target gene, is overexpressed in colorectal cancer	ONCOGENE			English	Article						ras oncogene; chemokines; colorectal cancer; cell transformation	DIFFERENTIAL DISPLAY; MESSENGER-RNA; EXPRESSION; CELLS; INDUCTION; PROTEINS	Mutations in the ras oncogenes have been linked to many different cancers, In contrast to the extensive body of knowledge related to the genetics of ras activation, relatively little is known of the transcriptional events triggered by ras, In previous work we have used differential display to identify Mob-1, a member of alpha-chemokine family, as one of the immediate transcriptional targets following Ras activation, Here, we provide additional experimental evidence to support this finding by the use of an inducible H-ras expression system, the treatment of Ras farnesyl transferase inhibitor and activation of endogenous Ras by serum growth factors, We further demonstrate that IP-10, the human homolog of Mob-1, is overexpressed in the majority of colorectal cancers.	VANDERBILT UNIV,DEPT CELL BIOL,SCH MED,VANDERBILT CANC CTR,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED & CELL BIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,VET AFFAIRS MED CTR,NASHVILLE,TN 37232; DANA FARBER CANC INST,DIV CELL GROWTH & REGULAT,BOSTON,MA 02115	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Harvard University; Dana-Farber Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA046413, R01CA061232] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA46413, R01 CA61232] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; DURKIN JP, 1986, MOL CELL BIOL, V6, P1386, DOI 10.1128/MCB.6.5.1386; GODWIN AK, 1990, ONCOGENE, V5, P1231; KIARIS H, 1995, INT J ONCOL, V7, P413; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MARTINEZ J, 1991, GENE DEV, V5, P152; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; OLDHAM S, 1996, IN PRESS P NATL ACAD; STOECKLE M Y, 1990, New Biologist, V2, P313; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANGURI P, 1990, J BIOL CHEM, V265, P15049	17	28	28	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1607	1610		10.1038/sj.onc.1200957	http://dx.doi.org/10.1038/sj.onc.1200957			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129152				2022-12-17	WOS:A1997WQ54800012
J	Paulson, R; Jackson, J; Immergluck, K; Bishop, JM				Paulson, R; Jackson, J; Immergluck, K; Bishop, JM			The DFer gene of Drosophila melanogaster encodes two membrane associated proteins that can both transform vertebrate cells	ONCOGENE			English	Article						tyrosine kinase; Drosophila melanogaster; oncogenes; cell transformation; FPS/FES	FUJINAMI SARCOMA-VIRUS; TYROSINE KINASE FER; FPS-GENE; C-FPS; CELLULAR-LOCALIZATION; MYRISTYLATION SIGNAL; NUCLEOTIDE-SEQUENCE; RETROVIRAL VECTORS; TRANSCRIPT FERT; AMINO-ACIDS	The vertebrate gene FER encodes two protein-tyrosine kinases with molecular weights of 51 000 and 94 000 and distinctive aminotermini, The larger kinase is expressed ubiquitously among vertebrate tissues, whereas expression of the smaller kinase appears to be limited to spermatogenic cells in the testes, Here we show that Drosophila melanogaster contains an apparent ortholog of FER (DFer) that also produces two mRNAs by separate initiation of transcription, and two proteins with molecular weights of 45 000 and 92 000, Both proteins are in part loosely associated with cytoplasmic membranes, Both can transform avian and rodent cells with roughly equal potency, when expressed from retroviral vectors, Fusing the myristoylation signal from the SRC protein-tyrosine kinase to the aminoterminus of the DFer protein increased the strength of attachment to membranes but augmented transformation only marginally, The results provide the first demonstration of neoplastic transformation by a protein-tyrosine kinase of Drosophila and by FER from any species, The products of Drosophila and vertebrate FER may be part of similar signaling pathways in the two species.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, GW HOOPER FDN, SAN FRANCISCO, CA 94143 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute					NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER; NCI NIH HHS [(CA44338)] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FA, 1990, CURRENT PROTOCOLS MO; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BISHOP JM, 1970, CELL, V42, P182; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; GARAPIN AC, 1970, J VIROL, V6, P589, DOI 10.1128/JVI.6.5.589-598.1970; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; GROFFEN J, 1982, SCIENCE, V216, P1136, DOI 10.1126/science.6281890; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; HOFFMANN FM, 1989, CURR TOP MICROBIOL, V147, P1; HOLLAND GD, 1990, J VIROL, V64, P2226, DOI 10.1128/JVI.64.5.2226-2235.1990; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATZEN AL, 1991, MOL CELL BIOL, V11, P226, DOI 10.1128/MCB.11.1.226; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KIM L, 1995, MOL CELL BIOL, V15, P4553; LETWIN K, 1988, ONCOGENE, V3, P621; MCMAHON M, 1991, MOL CELL BIOL, V11, P4760, DOI 10.1128/MCB.11.9.4760; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSS P, 1984, J VIROL, V52, P557, DOI 10.1128/JVI.52.2.557-565.1984; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pawson T, 1988, Adv Exp Med Biol, V234, P55; PENHALLOW RC, 1995, J BIOL CHEM, V270, P23362, DOI 10.1074/jbc.270.40.23362; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; RAMAKRISHNA NR, 1993, DEVELOPMENT, P95; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; WILKS AF, 1988, ONCOGENE, V3, P289; WOOLFORD J, 1984, VIROLOGY, V135, P168, DOI 10.1016/0042-6822(84)90127-2; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	44	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					641	652		10.1038/sj.onc.1200875	http://dx.doi.org/10.1038/sj.onc.1200875			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038371				2022-12-17	WOS:A1997WG43000002
J	Jenkins, TD; Nakagawa, H; Rustgi, AK				Jenkins, TD; Nakagawa, H; Rustgi, AK			The association of Epstein-Barr virus DNA with esophageal squamous cell carcinoma	ONCOGENE			English	Article						Epstein-Barr virus; esophageal cancer; genomic sequence	LYMPHOEPITHELIOMA-LIKE CARCINOMA; NASOPHARYNGEAL CARCINOMA; GASTRIC ADENOCARCINOMA; HUMAN PAPILLOMAVIRUS; RAS MUTATIONS; CYCLIN D1; EXPRESSION; GENE; CANCER; AMPLIFICATION	The Epstein-Barr virus (EBV), a member of the herpesviruses, is a double stranded 170 kilobase DNA virus important in many human benign and malignant conditions. It has been implicated in the pathogenesis of proliferative diseases of lymphocytes and tumors of epithelial derivation. The etiology and pathogenesis of esophageal squamous cell carcinoma (ESCC) is thought to involve a combination of genetic and environmental events which lead to epithelial cell transformation. The aim of this study was to determine whether an association exists between EBV and ESCC. DNA was extracted from 16 human ESCC cell lines and microdissected tumor specimens from 60 patients. The polymerase chain reaction was used to amplify a 400 base pair fragment corresponding to the BamHIW fragment repeat sequence of EBV. Southern blotting, utilizing an oligonucleotide probe specific for the BamH1W sequence, was used to confirm positive results and increase sensitivity of detection. 5/60 tumor samples and 1/16 ESCC cell Lines were positive for the EBV sequence. Positive tumor samples were estimated to contain one copy of EBV per 20 cellular genomes. Given the role of EBV in other tumors of epithelial derivation, it is possible that EBV may contribute to the molecular pathogenesis of ESCC.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HEMATOL ONCOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NIDDK NIH HHS [DK40561, T2DK07191D21] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191, P30DK040561] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRICHACEK B, 1984, JNCI-J NATL CANCER I, V72, P809; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUTLER AE, 1989, AM J SURG PATHOL, V13, P632, DOI 10.1097/00000478-198908000-00002; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHANG FJ, 1992, GASTROENTEROLOGY, V103, P1336, DOI 10.1016/0016-5085(92)91526-A; CHOI PHK, 1993, CANCER-AM CANCER SOC, V72, P2873, DOI 10.1002/1097-0142(19931115)72:10<2873::AID-CNCR2820721003>3.0.CO;2-A; COHEN JI, 1993, ANN INTERN MED, V118, P45; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HAFIZ MA, 1985, OBSTET GYNECOL, V66, P829; HARN HJ, 1995, HUM PATHOL, V26, P267, DOI 10.1016/0046-8177(95)90056-X; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HOLLSTEIN MC, 1988, CANCER RES, V48, P5119; HUI PK, 1994, HUM PATHOL, V25, P947, DOI 10.1016/0046-8177(94)90017-5; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KIEFF E, 1995, NEW ENGL J MED, V333, P724, DOI 10.1056/NEJM199509143331110; KIEFF E, 1990, VIROLOGY, P1889; KITCHEN VS, 1990, GUT, V31, P1223, DOI 10.1136/gut.31.11.1223; LABRECQUE LG, 1995, CANCER RES, V55, P39; LEWENSOHNFUCHS I, 1994, ANTICANCER RES, V14, P1281; LIU QY, 1995, ONCOGENE, V10, P619; MCGUIRE LJ, 1988, AM J PATHOL, V131, P385; MIN KW, 1991, AM J CLIN PATHOL, V96, P219, DOI 10.1093/ajcp/96.2.219; MORI M, 1994, ARCH PATHOL LAB MED, V118, P998; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; Oikawa Ou, 1995, Hokkaido Journal of Medical Science, V70, P729; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PATHMANATHAN R, 1995, AM J PATHOL, V146, P1355; ROWLANDS DC, 1993, BRIT J CANCER, V68, P1014, DOI 10.1038/bjc.1993.472; SHIBATA D, 1992, AM J PATHOL, V140, P769; SHIBATA D, 1991, AM J PATHOL, V139, P469; SWANSON SA, 1988, MODERN PATHOL, V1, P359; TOGAWA K, 1994, GASTROENTEROLOGY, V107, P128, DOI 10.1016/0016-5085(94)90070-1; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Wong Fen-Hwa, 1992, Chinese Journal of Microbiology and Immunology (Taipei), V25, P59; YOUNG LS, 1992, CANCER SURV, V7, P507	38	28	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1809	1813						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895528				2022-12-17	WOS:A1996VM88700027
J	Rabault, B; Roussel, MF; Quang, CT; Ghysdael, J				Rabault, B; Roussel, MF; Quang, CT; Ghysdael, J			Phosphorylation of Ets1 regulates the complementation of a CSF-1 receptor impaired in mitogenesis	ONCOGENE			English	Article						Ets1; phosphorylation; mitogenesis; mitogen-activated protein kinase	TRANSCRIPTION FACTORS; PROTEIN-KINASE; MAP KINASE; GENE; CELLS; ACTIVATION; EXPRESSION; FAMILY; MYC; IDENTIFICATION	Ets1, the founder member of the Ets transcription factor family, is involved in a variety of developmental and cellular processes, Previous studies have shown that serine phosphorylation of Ets1 inhibits its DNA binding activity, suggesting that phosphorylation is important in the regulation of Ets1 function. To further examine Ets1 phosphorylation, we ectopically expressed Ets1 in fibroblasts and stimulated these cells with serum, Using two-dimensional tryptic phosphopeptide analysis and site-directed mutagenesis, we found that Ets1 was phosphorylated on threonine 38, a residue conserved in several Ets proteins, Substitution of this residue with alanine enhanced CSF-1-dependent colony formation in semi-solid medium of NIH3T3 cells expressing a mitogenically defective CSF-1 receptor [Y809F], Threonine 38 is part of a consensus amino-acid sequence frequently recognized and targeted by members of the MAP kinase family, Moreover, this residue is phosphorylated in vitro by recombinant ERK2, which suggests that the kinase which phosphorylates threonine 38 in vivo is a member of the MAP kinase family, In addition, phosphorylation on threonine 38 seems to negatively regulate Ets1 activity in response to growth-factor stimulation.	CTR UNIV ORSAY, INST CURIE, CNRS UMR 146, LAB ONCOL VIRALE & CELLULAIRE, F-91405 ORSAY, FRANCE; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; St Jude Children's Research Hospital			Roussel, Martine F/F-1469-2016; GHYSDAEL, Jacques/F-3377-2013; QUANG, christine TRAN/G-7508-2016	Roussel, Martine F/0000-0002-1740-8139; 	NCI NIH HHS [CA-56819, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056819, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P995; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; FISHER CL, 1991, J IMMUNOL, V146, P1743; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Yang BS, 1996, MOL CELL BIOL, V16, P538	26	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					877	881						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761310				2022-12-17	WOS:A1996VD43300024
J	Guan, RJ; Moss, SF; Arber, N; Krajewski, S; Reed, JC; Holt, PR				Guan, RJ; Moss, SF; Arber, N; Krajewski, S; Reed, JC; Holt, PR			30 KDa phosphorylated form of Bcl-2 protein in human colon	ONCOGENE			English	Article						Bcl-2; protein phosphorylation; colon cancer; apoptosis; programmed cell death	CELL-DEATH; GENE	Bcl-2 expression was studied in a human colon cell line (HT-29) and in human colonic biopsies by Western and Northern blotting, Polyclonal antibodies raised against the Bcl-2 protein detected the expected 26 KDa protein in human colon, However, although Bcl-2 mRNA was present, the 26 KDa Bcl-2 protein was absent in HT-29 cells, Instead, a 30 KDa protein band strongly reacting with anti-Bcl-2 antibodies was found in HT-29 cells, and also in human colon, tonsil, and some other tissues, Alkaline phosphatase shifted the 30 KDa protein to the 26 KDa position in a time-dependent manner. P-32-labeling of HT-29 cells showed that the 30 KDa protein was phosphorylated, A 27 KDa phosphorylated protein was also immunoprecipitated by anti-Bcl-2 antibody, Phosphopeptide mapping showed that the 27 KDa protein contained a minimum of 3 and the 30 KDa protein at least an additional four phosphorylation sites, Phosphoamino acid analysis revealed that both the 30 KDa and 27 KDa proteins were phosphorylated on serine residues, These findings strongly suggest that the 30 KDa protein is a phosphorylated form of Bcl-2, which is widely distributed in human tissues.	UNIV COLOGNE, ST LUKES ROOSEVELT HOSP CTR, DEPT MED, DIV GASTROENTEROL, NEW YORK, NY 10025 USA; LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	Mount Sinai St. Luke's; Mount Sinai West; Sanford Burnham Prebys Medical Discovery Institute				holt, peter/0000-0002-8469-2766; Arber, Nadir/0000-0001-5283-6991				ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BAXTER GD, 1992, J IMMUNOL, V148, P1949; BEDI A, 1995, CANCER RES, V55, P1811; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; MAY WS, 1994, J BIOL CHEM, V269, P26865; MOSS SF, 1995, GASTROENTEROLOGY, V108, pA511, DOI 10.1016/0016-5085(95)26359-4; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROBAYE B, 1994, ELECTROPHORESIS, V15, P503, DOI 10.1002/elps.1150150168; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WANG HG, 1994, ONCOGENE, V9, P2751; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	29	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2605	2609						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700519				2022-12-17	WOS:A1996UW48700014
J	Jacobs, H; Ossendorp, F; deVries, E; Ungewiss, K; vonBoehmer, H; Borst, J; Berns, A				Jacobs, H; Ossendorp, F; deVries, E; Ungewiss, K; vonBoehmer, H; Borst, J; Berns, A			Oncogenic potential of a pre-T cell receptor lacking the TCR beta variable domain	ONCOGENE			English	Article						lymphomagenesis; T cell receptor; transgenic mice; lymphopoiesis; T cell development; oncogene	TRANSGENIC MICE; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; C-MYC; GENE; ALPHA; CHAIN; PROTEINS; MUTANT; REARRANGEMENT	In transgenic mice expressing a mutated T cell receptor (TCR) beta chain lacking the variable domain (Delta V-TCR beta) T cell differentiation is arrested at the CD4(+) CD8(+) thymocyte stage, Here, we report that these transgenic animals develop CD4(+), CD8(+), IL-2 receptor alpha-positive T cell lymphomas at a very high incidence. Introduction of a normal TCR beta gene into the Delta V-TCR beta transgenic mice drastically reduces the tumor incidence, while crossing the Delta V-TCR beta transgene onto a recombinase-deficient RAG-1(-/-) background does not prevent tumor development, Therefore, the induction of T cell lymphomas is a property of the mutated TCR beta chain, The Delta V- TCR beta chain appears at the cell surface as a disulfide-linked Delta V-TCR beta/pT alpha dimer in association with CD3 gamma and -epsilon, but not with CD3 delta. This mutated preTCR/CD3 complex is shown to induce pre-T cell proliferation and differentiation, but does not permit formation of a normally sized CD4(+)8(+) thymic compartment, Delta V-TCR beta transgenic mice frequently show an expansion of CD4(+)8(+), IL-2 receptor alpha(+) pre-T cells early in life, These cells likely represent the population that is subject to oncogenic transformation.	NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Netherlands Cancer Institute; Netherlands Cancer Institute				Jacobs, Heinz/0000-0001-6227-9850; Borst, Jannie/0000-0002-8043-5009				BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; COGNE M, 1989, RES IMMUNOL, V140, P487; CUYPERS HT, 1984, CELL, V37, P141; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DODEMONT HJ, 1982, EMBO J, V1, P167, DOI 10.1002/j.1460-2075.1982.tb01142.x; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HASER WG, 1987, J EXP MED, V166, P1186, DOI 10.1084/jem.166.4.1186; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KAPPES DJ, 1995, CURR OPIN IMMUNOL, V7, P441, DOI 10.1016/0952-7915(95)80086-7; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; Maniatis T., 1982, MOL CLONING LAB MANU; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSSENDORP F, 1992, J IMMUNOL, V148, P3714; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; SELIGMANN M, 1979, IMMUNOL REV, V48, P146; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	38	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2089	2099						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668334				2022-12-17	WOS:A1996UP28300007
J	Roemer, K; MuellerLantzsch, N				Roemer, K; MuellerLantzsch, N			p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis	ONCOGENE			English	Article						programmed cell death; transcription; transfection; MDM-2	WILD-TYPE P53; GENE-EXPRESSION; CELL-GROWTH; PROTEIN; SUPPRESSION; DNA; INHIBITION; CARCINOMA; ONCOGENE; KINASES	p53 is multifunctional, To assess exactly what function is critical for the prevention of neoplastic transformation has proven difficult, Mutants with substitutions at positions 22 and 23 promised to address the relevance of transcription transactivation since they seemed to be defective specifically for this function, We report here that p53 mutant Q22, S23 [p53 (22,23)] is not only impaired for transactivation but for the repression of the fos promoter and SV40 early promoter, Furthermore, whereas p53 (22,23) fails to efficiently transactivate reporter genes in two p53-negative cell lines, it stimulates reporters and suppresses proliferation in two wild-type (wt) p53-positive cell lines strongly above the levels induced by the transfection procedure alone, This transactivation is refractory to inhibition by MDM-2, Finally, p53 (22,23) expressed from large plasmid quantity (1 mu g) is crippled for the mediation of apoptosis in p53-negative Hep3B hepatocarcinoma cells, Nevertheless, at a quantity of only 10 ng, both mutant and wt p53 plasmids but not control plasmid, are able to induce some cell death which is not inhibitable by MDM-2, Thus, a correlation exists between p53's functions to regulate promoters and to efficiently mediate apoptosis in Hep3B cells.			Roemer, K (corresponding author), UNIV SAARLAND,DEPT VIROL,INST MED MICROBIOL,BLDG 47,D-66421 HOMBURG,GERMANY.							ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1995, MOL CELL BIOL, V15, P6474; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PERREM K, 1995, ONCOGENE, V11, P1299; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RENZING J, 1995, ONCOGENE, V10, P1865; ROLLEY N, 1995, ONCOGENE, V11, P763; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; VAN MEIR EG, 1994, CANCER RES, V54, P649; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4; YEE PR, 1994, GENE DEV, V8, P190; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	65	28	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2069	2079						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668332				2022-12-17	WOS:A1996UP28300005
J	LeCouter, JE; Whyte, PFM; Rudnicki, MA				LeCouter, JE; Whyte, PFM; Rudnicki, MA			Cloning and expression of the Rb-related mouse p130 mRNA	ONCOGENE			English	Article						p130; cDNA; mouse	RETINOBLASTOMA GENE FAMILY; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTOR E2F; PROTEIN; DIFFERENTIATION; INTERACTS; CONTAINS; MUTATION; PRODUCT; MEMBER	The mouse p130 cDNA was cloned from a thymus-derived library using the human p130 cDNA as a probe. The 4515-bp mouse cDNA encodes a putative 1092 aa protein with predicted molecular mass of 123kD. Comparison of mouse and human sequences reveals the mouse protein lacks 43 aa in a conserved domain, relative to the human sequence, located amino-terminal to the pocket region. Northern analysis of P19 embryonal carcinoma (EC) and RA-induced P19 cultures indicates p130 mRNA is not expressed at detectable levels in undifferentiated stem cells and is strongly upregulated after post-mitotic neurons begin to accumulate. Northern analysis of adult mouse tissues indicated that the 4.8 kb p130 mRNA is expressed ubiquitously, however, a putative 9-truncated 1.7 kb isoform is detected solely in testis. Forced expression of mouse p130 induced growth suppression of P19 EC cells and Western analysis of transfected P19 cells suggested the cloned cDNA encodes the full-length p130 protein.	MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,CANC RES GRP,HAMILTON,ON L8S 4K1,CANADA	McMaster University								ADRA CN, 1988, SOMAT CELL MOLEC GEN, V14, P69, DOI 10.1007/BF01535050; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANNON GJ, 1993, GENE DEV, V7, P2366; HARLOW E, 1988, ANTIBODIES LAB MANUA, P483; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; KAWASAKI E, 1990, PCR PROTOCOLS GUIDE, P22; KIM KK, 1995, GENOMICS, V28, P520, DOI 10.1006/geno.1995.1184; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Maniatis T., 1982, MOL CLONING; MAYOL X, 1993, ONCOGENE, V8, P2561; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; RUDNICKI MA, 1987, TERATOCARCINOMAS EMB, P32; SAVATIER P, 1994, ONCOGENE, V9, P809; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLACK RS, 1993, ONCOGENE, V8, P1585; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x	42	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1433	1440						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622859				2022-12-17	WOS:A1996UF07600007
J	Kirsch, KH; Korradi, Y; Johnson, JP				Kirsch, KH; Korradi, Y; Johnson, JP			Mader: A novel nuclear protein over expressed in human melanomas	ONCOGENE			English	Article						delayed early response gene; proline rich; MUC18	MESSENGER-RNA DEGRADATION; HUMAN-MALIGNANT MELANOMA; TUMOR PROGRESSION; CELL-ADHESION; SEQUENCE; IDENTIFICATION; STIMULATION; ACTIVATION; ANTIGEN; DOMAINS	Mader is a novel delayed early response gene encoding a nuclear protein. Upregulation of the Mader 2.7 kb mRNA requires protein synthesis and can be induced in a variety of human cell lines by serum stimulation and in freshly isolated lymphocytes by mitogens. mRNA levels reach a maximum by 2 h and return to basal levels by 6 h. Mader is highly conserved as cross-hybridizing DNA sequences were observed in species as diverse as Rhesus and S. cerevisiae. The Mader protein of approximately 55 kD has two proline rich domains and contains 15 potential phosphorylation sites, a nuclear localization signal, and multiple S(T)PXX motifs that are characteristic of regulatory DNA binding proteins. Monoclonal antibodies produced against Mader confirm that it is localized to the nucleus. These features of Mader suggest that it may play a role in growth regulation. Although Mader mRNA can be detected in most cell lines, only occasional immunoreactive cells were detected in normal human tissues. In contrast, uniform strong nuclear staining was observed in all malignant melanomas examined. The fact that only one of six benign melanocytic nevi examined showed evidence of Mader expression suggests that over-expression of Mader protein may be associated with the malignant transformation of melanocytes.	UNIV MUNICH,INST IMMUNOL,D-80336 MUNICH,GERMANY	University of Munich				Kirsch, Kathrin/0000-0003-1532-1715				ALBELDA SM, 1990, CANCER RES, V50, P6757; ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; GARRIGUES HJ, 1986, J CELL BIOL, V103, P1699, DOI 10.1083/jcb.103.5.1699; GRANA X, 1995, ONCOGENE, V11, P211; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Johnson JP, 1996, CURR TOP MICROBIOL, V213, P95; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KELLY K, 1983, CELL, V35, P306; KLEIN CE, 1991, J INVEST DERMATOL, V96, P281, DOI 10.1111/1523-1747.ep12464485; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIU L, 1995, ONCOGENE, V11, P405; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSHALL MA, 1991, MOL CELL BIOL, V11, P55, DOI 10.1128/MCB.11.1.55; MARTINPADURA I, 1991, CANCER RES, V51, P2239; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGREGOR JM, 1993, BRIT J DERMATOL, V128, P606, DOI 10.1111/j.1365-2133.1993.tb00253.x; MENDELSOHL J, 1995, MOL BASIS CANC; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P983; OHTA M, 1994, CANCER RES, V54, P5269; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REED JA, 1995, CANCER RES, V55, P2713; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; [No title captured]	44	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					963	971						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649813				2022-12-17	WOS:A1996UA88400003
J	KhannaGupta, A; Lopingco, MC; Savinelli, T; Zibello, T; Berliner, N; Perkins, AS				KhannaGupta, A; Lopingco, MC; Savinelli, T; Zibello, T; Berliner, N; Perkins, AS			Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dcl3	ONCOGENE			English	Article						G-CSF; myeloid leukemia; evil	COLONY-STIMULATING FACTOR; ZINC FINGER GENE; TRANSFORMING GENE; GRANULOCYTIC DIFFERENTIATION; EXPRESSION; SEQUENCE; LEUKEMIA; BINDING; PROTEIN; DNA	Evil is a myeloid-specific protooncogene that encodes 145 kDa and 88 kDa proteins via alternative splicing, Overexpression of the gene via retroviral insertion in murine tumors or chromosomal rearrangement in human tumors is associated with myeloid leukemias and myelodysplasias; however, the mechanism by which such overexpression leads to transformation is not clear, It has been postulated that overexpression of evil acts to block normal myelopoiesis. In attempts to assess the effect of overexpression of evil on myelopoiesis, we chose to utilize the IL-3-dependent murine 32Dcl3 cell line, which has been shown to differentiate in culture in response to G-CSP. Previous experiments with this cell line, which Ne have confirmed, showed that overexpression of evil, mediated by retroviral vector transfer, caused a block to G-CSF-induced cell survival and differentiation, We report here that the naive 32Dcl3 cell line contains a rearrangement of the evil locus and constitutively overexpresses evil mRNA and protein; this expression is downregulated only slightly during G-CSF-induced myeloid maturation, The steady state levels, molecular weight and DNA binding characteristics of the EVI1 protein in these cells is comparable to that seen in NFS 58, a myeloid leukemia cell line with retroviral insertion at evil, The observed ability of the murine 32Dcl3 cells to fully differentiate in the presence of G-CSF while evil continues to be expressed indicates that, at the levels expressed in naive 32Dcl3, evil does not block G-CSF-induced survival and differentiation, Thus, retroviral insertions at evil may have been selected for in 32Dcl3 cells due to effects other than that on G-CSF-induced cell survival.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06520 USA	Yale University; Yale University					NIDDK NIH HHS [DK42347] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042347] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORDEREAUX D, 1990, ONCOGENE, V5, P925; CHATTOPADHYAY SK, 1980, J VIROL, V36, P499, DOI 10.1128/JVI.36.2.499-505.1980; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; GREENBERGER JS, 1983, FED PROC, V42, P2762; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY ER, 1994, BLOOD, V83, P1348; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; OVAL J, 1992, LEUKEMIA, V6, P446; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROVERA G, 1987, ONCOGENE, V1, P29; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1994, J BIOL CHEM, V269, P24020; VALTIERI M, 1987, J IMMUNOL, V138, P3829	35	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					563	569						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637713				2022-12-17	WOS:A1996TV59700013
J	RAMSAY, RG; MORRICE, N; VANEEDEN, P; KANAGASUNDARAM, V; NOMURA, T; DEBLAQUIERE, J; ISHII, S; WETTENHALL, R				RAMSAY, RG; MORRICE, N; VANEEDEN, P; KANAGASUNDARAM, V; NOMURA, T; DEBLAQUIERE, J; ISHII, S; WETTENHALL, R			REGULATION OF C-MYB THROUGH PROTEIN-PHOSPHORYLATION AND LEUCINE-ZIPPER INTERACTIONS	ONCOGENE			English	Article						C-MYB; CASEIN KINASE II; LEUCINE ZIPPERS; DNA BINDING	DNA-BINDING; IN-VITRO; ACTIVATION; TRUNCATION; PROTOONCOGENE; ONCOPROTEINS; KINASES	c-Myb function is modulated in part by a negative regulation domain which encompasses a leucine zipper (LZ). When E. coli-expressed c-Myb with wild type or mutated LZ proteins are assessed for DNA binding activity, the mutant form is substantially better at DNA binding than the wild type (WT) form. In contrast, the DNA binding activity of the WT protein is increased to an equivalent level of activity of the LZ-mutant when both are expressed in rabbit reticulocyte lysates (RRL) or insect cells. The possibility that phosphorylation overcomes the negative influence of the LZ was investigated. E. coli-expressed mutant, but not wild type c-Myb proteins, were shown to be substrates for Casein Kinase II (CKII) and cAMP-dependent Protein Kinase (PKA). The phosphorylation sites for CKII and PKA were serines 11 and 12, and 8 and 116, respectively. Serines 11 and 12 were found to be phosphorylated in recombinant wild type and mutant c-Myb expressed in insect cells and DNA binding was markedly reduced following phosphatase treatment. Substitution of serines 11 and 12 with glutamic acid and alanine in E. coli-expressed Myb demonstrated that these amino terminal residues influence the negative effect on DNA binding exerted by the LZ. Collectively, these observations support the notion that phosphorylation of serines 11 and 12 positively modulate DNA binding.	LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, PARKVILLE, VIC 3050, AUSTRALIA; UNIV MELBOURNE, DEPT BIOCHEM, PARKVILLE, VIC 3050, AUSTRALIA; LA TROBE UNIV, CTR PROT & ENZYME TECHNOL, BUNDOORA, VIC 3083, AUSTRALIA; RIKEN, TSUKUBA LIFE SCI CTR, TSUKUBA, IBARAKI, JAPAN	Ludwig Institute for Cancer Research; University of Melbourne; La Trobe University; RIKEN			van Eeden, Pauline/O-8713-2014; Ishii, Shunsuke/A-5271-2016; van Eeden, Pauline/H-4952-2014; Ramsay, Robert G/C-3291-2015	Ishii, Shunsuke/0000-0002-6530-2478; Ramsay, Robert G/0000-0001-5003-0433				AZIZ N, 1993, ONCOGENE, V8, P2259; BADING H, 1989, ONCOGENE, V4, P33; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; FAVIER D, 1994, ONCOGENE, V9, P305; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HUNTER T, 1988, COLD SPRING HARB SYM, V53, P131, DOI 10.1101/SQB.1988.053.01.019; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KARIN M, 1994, ONCOGENE, V9, P305; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Ramsay R G, 1995, Methods Mol Biol, V37, P369; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; Weston K M, 1990, Semin Cancer Biol, V1, P371; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186	25	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					2113	2120						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478531				2022-12-17	WOS:A1995TF29700022
J	ROUQUET, N; ALLEMAND, I; MOLINA, T; BENNOUN, M; BRIAND, P; JOULIN, V				ROUQUET, N; ALLEMAND, I; MOLINA, T; BENNOUN, M; BRIAND, P; JOULIN, V			FAS-DEPENDENT APOPTOSIS IS IMPAIRED BY SV40 T-ANTIGEN IN TRANSGENIC LIVER	ONCOGENE			English	Article						T-ANTIGEN; APOPTOSIS; FAS-RECEPTOR; CARCINOGENESIS	GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; MICE; ANTIBODY; GENE; PHOSPHORYLATION; EXPRESSION; DOMAIN; LENS	A transgenic mouse model for hepatocarcinoma has been previously produced by targeting SV40 T-antigen expression to the liver. To evaluate the perturbation of cell death occurring during hepatocarcinogenesis, we examined the Fas-induced apoptosis on hepatocytes expressing T-antigen. Whereas anti-Fas antibody induced apoptosis in primary cultured normal hepatocytes, they imparted a weak cytotoxicity on primary cultured hepatocytes expressing T-antigen. This resistance of hepatic Fas-mediated apoptosis appears to result in an enhancement of a protective mechanism involving the protein kinase C signaling pathway rather than in a down-regulation of Fas-antigen expression. We further demonstrated that anti-Fas antibody does not have as efficient a lethal effect in T-antigen transgenic mice as in wild-type mice, The livers of transgenic mice injected with anti-Fas mAbs showed large intact regions with a few scattered apoptotic bodies: these regions strictly corresponded with carcinoma nodules, expressing high level of T-antigen. Our results describe a novel function for SV40 T-antigen which could contribute to viral pathogenesis by protecting infected cells against the host apoptotic defense mechanism.	INST COCHIN GENET MOLEC, INSERM, U380, F-75014 PARIS, FRANCE; UNIV PARIS, RECH & HISTOPATHOL LAB, F-75006 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754; allemand, isabelle/0000-0002-8861-7632; JOULIN, Virginie/0000-0003-1091-7819				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; CHEN JD, 1992, ONCOGENE, V7, P1167; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GILL BM, 1994, IMMUNOL REV, V142, P113, DOI 10.1111/j.1600-065X.1994.tb00885.x; GRELL M, 1994, EUR J IMMUNOL, V24, P2563, DOI 10.1002/eji.1830241045; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; GUO MW, 1994, BIOCHEM BIOPH RES CO, V203, P1438, DOI 10.1006/bbrc.1994.2346; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; LEIST M, 1995, J IMMUNOL, V154, P1307; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MEEK DW, 1992, BIOCHEM J, V287, P1; MITA E, 1994, BIOCHEM BIOPH RES CO, V204, P468, DOI 10.1006/bbrc.1994.2483; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SAMBROOK J, 1989, MOL CLONIGN LABORATO; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WONG GHW, 1994, J IMMUNOL, V152, P1751	39	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1061	1067						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566965				2022-12-17	WOS:A1995RX18000008
J	TANIGUCHI, T; SCHOFIELD, AE; SCARLETT, JL; MORISON, IM; SULLIVAN, MJ; REEVE, AE				TANIGUCHI, T; SCHOFIELD, AE; SCARLETT, JL; MORISON, IM; SULLIVAN, MJ; REEVE, AE			ALTERED SPECIFICITY OF IGF2 PROMOTER IMPRINTING DURING FETAL DEVELOPMENT AND ONSET OF WILMS-TUMOR	ONCOGENE			English	Article						IMPRINTING; IGF2; PROMOTER; FETAL TISSUE; WILMS TUMOR	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN SYNDROME; FACTOR GENES; RELAXATION	The specificity of IGF2 promoter imprinting was examined in embryonal tissues and Wilms tumour. In several fetal tissues of approximately 12 weeks gestation, IGF2 was found to be monoallelically expressed from all IGF2 promoters i.e. P1, P2, P3 and P4. However, in tissues of slightly older gestation age (15-17 weeks) relaxation of imprinting at the P1 promoter was evident, although the P2-P4 promoters remained imprinted. These data indicate that early in embryogenesis a population of cells exists in which all IGF2 promoters are imprinted, but that as development proceeds the imprinting of the P1 promoter is relaxed. The pattern of IGF2 promoter imprinting was also analysed in Wilms tumour. In some tumours, the pattern of promoter imprinting was identical to that found in early fetal kidney, indicating that this tumour originates within early embryonic kidney tissue. In contrast, in tumours in which relaxation of imprinting had occurred, imprinting relaxation affected all IGF2 promoters. This aberrant pattern of promoter imprinting, which was not detected in fetal kidney, provides further evidence that pathological relaxation of IGF2 imprinting is involved in the genesis of Wilms tumour.	UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,DUNEDIN,NEW ZEALAND	University of Otago			Sullivan, Michael/B-5459-2012; Morison, Ian M/A-1236-2008	Morison, Ian M/0000-0003-3616-0025; Sullivan, Michael/0000-0002-8606-5889				ADAMS SM, 1991, FOCUS, V13, P56; BELL GI, 1985, P NATL ACAD SCI USA, V82, P6450, DOI 10.1073/pnas.82.19.6450; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; JANSEN M, 1985, FEBS LETT, V179, P243, DOI 10.1016/0014-5793(85)80527-5; Jansen M, 1990, GROWTH FACTORS GENES; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REED ML, 1994, NAT GENET, V6, P1; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; SCOTT J, 1985, NATURE, V317, P261; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WAGSTAFF J, 1993, AM J HUM GENET, V53, P105; WEKSBERG R, 1993, HUM MOL GENET, V2, P549, DOI 10.1093/hmg/2.5.549; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	32	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					751	756						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651739				2022-12-17	WOS:A1995RQ46900017
J	MONTANER, S; RAMOS, A; PERONA, R; ESTEVE, P; CARNERO, A; LACAL, JC				MONTANER, S; RAMOS, A; PERONA, R; ESTEVE, P; CARNERO, A; LACAL, JC			OVEREXPRESSION OF PKC-XI IN NIH3T3 CELLS DOES NOT INDUCE CELL-TRANSFORMATION NOR TUMORIGENICITY AND DOES NOT ALTER NF-KAPPA-B ACTIVITY	ONCOGENE			English	Article						PKC-XI; CELL TRANSFORMATION; NF-KAPPA-B	PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; RAT FIBROBLASTS; ZETA-ISOFORM; ACTIVATION; GROWTH; ONCOGENE; BINDING; EPSILON	Signal transduction is the major mechanism by which cells communicate among themselves through extracellular stimuli. Among the different Structural components involved in signal transduction, protein kinases are one of the key elements in the process. Protein kinase C is a multimember family of kinases which has been involved in the regulation of diverse cellular functions. Regulation of cell growth in fibroblasts has been reported to be one of such functions, In particular the PKC zeta isoenzyme has been postulated to be transforming to NIH3T3 cells (Berra et al., 1993) and to serve as an effector for Ras proteins through the regulation of the NF kappa B transcription factor (Dominguez et al., 1993) and direct interaction (Diaz-Meco et al., 1994). We have investigated the effects of overexpressing the mouse wild-type PKC zeta in NIH3T3 cells. When compared to the parental NIH3T3 cells, we have found (1) no significant effect on cell morphology; (2) no difference in growth properties in the absence of serum or in the presence of individual growth factors such as insulin, phorbol esters or PDGF; (3) no growth in soft agar nor tumorigenic activity in nude mice. In addition cells stably overexpressing the PKC zeta kinase did not interfere or amplify the induction of NF kappa B activity by tumor necrosis factor alfa (TNF-alpha) nor altered NF kappa B activity in transient expression of cells treated with TNF-alpha. Thus, mammalian PKC zeta is most likely not directly involved in the regulation of cell proliferation in fibroblasts nor affects directly or indirectly the activation of NF kappa B.	CSIC,INST INVEST BIOMED,MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Lacal, Juan Carlos/AAL-2235-2020; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARNERO A, 1994, ONCOGENE, V9, P1387; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; EXTON JH, 1990, J BIOL CHEM, V265, P1; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LACAL JC, 1994, ONCOL REP, V1, P667; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; SINGHAL RL, 1994, CANCER RES, V54, P5574; TOKER A, 1994, J BIOL CHEM, V269, P32358; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159	36	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2213	2220						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784066				2022-12-17	WOS:A1995RB70300017
J	PHAM, CD; ARLINGHAUS, RB; ZHENG, CF; GUAN, KL; SINGH, B				PHAM, CD; ARLINGHAUS, RB; ZHENG, CF; GUAN, KL; SINGH, B			CHARACTERIZATION OF MEK1 PHOSPHORYLATION BY THE V-MOS PROTEIN	ONCOGENE			English	Note						MOS ONCOGENE; MAP KINASE KINASE; PROTEIN KINASE ACTIVATION; PHOSPHORYLATION SITES	MAP KINASE-KINASE; MAMMALIAN SOMATIC-CELLS; XENOPUS-OOCYTES; IN-VITRO; METAPHASE ARREST; ONCOGENE PRODUCT; 3T3 CELLS; ACTIVATION; MATURATION; INDUCTION	Activation of MAP kinase/Erk Kinase (MEK) via direct phosphorylation by Mos may be crucial for cellular transformation by the activated c-mos or v-mos gene, Recent studies on a number of different protein kinases showed that phosphorylation within a subdomain of the catalytic domain may represent a common mode of activation, In this regard, activation of MEK1 by Raf involves phosphorylation of serine residues 218 and 222, Here we show that recombinant kinase-inactive MEK1 is phosphorylated by v-Mos with equal efficiency at both Ser 218 and Ser 222 in vitro, Tryptic phosphopeptide analysis of glutathione-S-transferase (GST)-MEK1 K97R and its alanine-for-serine mutants indicated that Ser 222 is the preferred phosphorylation site. Wild-type GST-MEK1 was phosphorylated at the same sites but contained a significantly lower amount of doubly phosphorylated species then its K97R kinase-inactive mutant, The ratio of GST-MEK1 species phosphorylated at two serines to those phosphorylated at one serine was similar in auto-phosphorylated and v-Mos-phosphorylated GST-MEK1, Consistent with the in vitro data, phosphopeptide mapping of MEK1 immunoprecipitated from mos transformed cells showed an increased amount of singly phosphorylated phosphopeptide compared to nontransformed cells, MEK1 was found to be more highly activated in NM3T3 cells transformed by an activated c-mos or v-mos gene than in cells growing normally in medium containing serum, Our data indicate that Mos activates MEK1 in vitro as well as in vivo by phosphorylating Ser 222.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC PATHOL, HOUSTON, TX 77030 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, INST GERONTOL, ANN ARBOR, MI 48109 USA	University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA 45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GOTOH Y, 1994, ONCOGENE, V9, P1891; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIU JX, 1990, ONCOGENE, V5, P171; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1992, MOL CARCINOGEN, V6, P182, DOI 10.1002/mc.2940060303; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	35	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1683	1688						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731726				2022-12-17	WOS:A1995QU68100028
J	BOURS, V; AZARENKO, V; DEJARDIN, E; SIEBENLIST, U				BOURS, V; AZARENKO, V; DEJARDIN, E; SIEBENLIST, U			HUMAN RELB (I-REL) FUNCTIONS AS A KAPPA-B SITE-DEPENDENT TRANSACTIVATING MEMBER OF THE FAMILY OF REL-RELATED PROTEINS	ONCOGENE			English	Article							DNA-BINDING SUBUNIT; V-REL; TRANSCRIPTION ACTIVATOR; ONCOPROTEIN BCL-3; PROTO-ONCOGENE; CLONING; P50; GENE; EXPRESSION; HOMOLOGY	RelB belongs to the family of Rel-related proteins, dimers of which determine NF-kappa B activity. The murine RelB protein has been reported to be a dimerizing partner in kappa B-binding complexes which are capable of transactivation. On the other hand, the I-Rel protein, the presumed human homolog of RelB, was proposed to be an inhibitor whose presence in dimeric complexes interfered with their kappa B binding and therefore interfered also with transactivation. We demonstrate that human RelB (I-Rel) forms with p50 and p52 (p50B) kappa B-binding heterodimeric complexes which potently transactivate kappa B-dependent constructs in transfection studies. It is concluded that human RelB (I-Rel) and murine RelB can both function as transactivators and that no significant species-specific differences exist.	UNIV LIEGE,METASTASIS RES LAB,B-4000 LIEGE,BELGIUM	University of Liege	BOURS, V (corresponding author), NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892, USA.		Dejardin, Emmanuel/AAE-9076-2021					BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bours V, 1992, Curr Top Microbiol Immunol, V182, P411; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V148, P1; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464	30	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1699	1702						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183565				2022-12-17	WOS:A1994NL81500022
J	CROWE, AJ; MCGLADE, J; PAWSON, T; HAYMAN, MJ				CROWE, AJ; MCGLADE, J; PAWSON, T; HAYMAN, MJ			PHOSPHORYLATION OF THE SHC PROTEINS ON TYROSINE CORRELATES WITH THE TRANSFORMATION OF FIBROBLASTS AND ERYTHROBLASTS BY THE V-SEA TYROSINE KINASE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTORS; VIRUS; GAP; SRC; DOMAINS; S13; IDENTIFICATION; RETROVIRUS; EXPRESSION	The S13 avian erythroblastosis viral genome encodes an oncogenic tyrosine kinase, termed env-sea, that is capable of transforming fibroblasts and erythroblasts, Although the tyrosine kinase activity of the env-sea protein has been shown to be necessary for transformation, no substrates for this enzyme have been detected in vivo. Here we demonstrate that the recently described she proteins are phosphorylated on tyrosine residues in both S13 transformed fibroblasts and erythroblasts. Furthermore, using an S13 temperature sensitive mutant, we show that the phosphorylation of the she proteins occurs concomitantly with the activation of the tyrosine kinase activity of the env-sea protein. These observations make the phosphorylation of the she proteins a good candidate for being involved in oncogenic signaling by the env-sea oncoprotein.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013		NCI NIH HHS [CA42573, CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1987, PATHOL IMMUNOPATH R, V6, P390, DOI 10.1159/000157065; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAMPS MP, 1988, ONCOGENE, V2, P305; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kowenz E, 1987, Haematol Blood Transfus, V31, P199; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, ELL, V70, P359; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	28	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					537	544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290264				2022-12-17	WOS:A1994MW24800021
J	DEGROOT, RP; DELMAS, V; SASSONECORSI, P				DEGROOT, RP; DELMAS, V; SASSONECORSI, P			DNA BENDING BY TRANSCRIPTION FACTORS CREM AND CREB	ONCOGENE			English	Article							CYCLIC-AMP; BINDING-PROTEINS; GENE-TRANSCRIPTION; SOMATOSTATIN GENE; C-FOS; ELEMENT; ACTIVATION; SITE; PROMOTER; IDENTIFICATION	DNA bending is postulated to be a major determinant of gene expression and has been shown to be specifically induced by some regulatory proteins with DNA-binding properties. Here we show that nuclear factors which naturally bind to CREs (cAMP-responsive elements) are able to induce bending in the sequences flanking this recognition site. In our assays we used a permutated binding site/gel retardation assay and bacterially generated nuclear factors. We have been studying the cAMP-responsive-element modulator (CREM) gene, which encodes both repressors (CREM alpha, beta and gamma) and an activator (CREM tau) of cAMP-responsive transcription by alternative splicing. Tn addition, two alternative DNA-binding domains can be encoded in different CREM isoforms. No differences in induction of DNA bending by the CREM proteins with the two DNA binding domains were detected. The activator CREB induced DNA bending in a fashion similar to CREM. Importantly, we show that phosphorylation of CREM or CREB alters their mobilities in a regular gel shift assay as well as enhances the angle of DNA bending induced by these proteins.	INST CHIM BIOL,FAC MED,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Delmas, veronique/0000-0001-7368-3664				ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	47	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					463	468						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290258				2022-12-17	WOS:A1994MW24800013
J	HUANG, AP; WRIGHT, JA				HUANG, AP; WRIGHT, JA			FIBROBLAST GROWTH-FACTOR MEDIATED ALTERATIONS IN DRUG-RESISTANCE, AND EVIDENCE OF GENE AMPLIFICATION	ONCOGENE			English	Article							DIHYDROFOLATE-REDUCTASE GENE; RIBONUCLEOTIDE REDUCTASE; CELL-LINES; DNA AMPLIFICATION; TUMOR PROGRESSION; AUTOCRINE GROWTH; FACTOR RECEPTOR; 3T3 CELLS; CAD GENE; TRANSFORMATION	We have investigated the drug resistance and gene amplification potential of NIH3T3 cells transfected with sequences coding for K-FGF, a known oncogene product, or bFGF, a non-oncogene member of the fibroblast growth factor family. Resistance to methotrexate, N-(phosphonacetyl)-L-aspartate and hydroxyurea was observed with K-fgf transfectants, due to amplification of dihydrofolate reductase, CAD or ribonucleotide reductase R2 genes, respectively. In keeping with the increase in gene amplification frequency, cells transfected with the K-fgf gene also exhibited a marked increase in CAD gene amplification rate, as determined by fluctuation analysis in the presence of N-(phosphonacetyl)-L-asparate. Cells transfected with bFGF encoding cDNA also exhibited a significant elevation in N-(phosphonacetyl)-L-aspartate resistance, and CAD gene amplification. Treatment with suramin, which interferes with the interaction of fibroblast growth factors with their cell surface receptors, did not decrease the drug resistance properties of K-fgf transfected cells. These observations with suramin and the findings with bFGF, which lacks a conventional signal sequence for secretion, suggests that the growth factor-mediated effects on drug resistance and gene amplification occur through an intracellular as opposed to autocrine mode of action. The finding that aberrant growth factor expression regulates gene amplification opens up new possibilities for investigating intracellular mechanisms relevant to this process and also describes new functions for the altered expression of K-FGF and bFGF, which are relevant to mechanisms of malignant progression.	UNIV MANITOBA, MANITOBA INST CELL BIOL, 100 OLIVIA ST, WINNIPEG R3E 0V9, MB, CANADA	University of Manitoba								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BLAM SB, 1988, ONCOGENE, V3, P129; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; Brigstock DR, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104815; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHANG ACY, 1978, NATURE, V275, P617, DOI 10.1038/275617a0; CILLO C, 1987, CANCER RES, V47, P2604; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DAMEN JE, 1991, BIOCHIM BIOPHYS ACTA, V1097, P103, DOI 10.1016/0925-4439(91)90092-N; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DREWS RE, 1992, MOL CELL BIOL, V12, P198, DOI 10.1128/MCB.12.1.198; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3280, DOI 10.1128/MCB.5.11.3280; EGAN SE, 1991, ENVIRON HEALTH PERSP, V93, P91, DOI 10.2307/3431175; EGAN SE, 1990, ANTICANCER RES, V10, P1341; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDS RG, 1981, J CELL PHYSIOL, V106, P309, DOI 10.1002/jcp.1041060218; HILL RP, 1990, CANCER METAST REV, V9, P137, DOI 10.1007/BF00046340; HUANG SS, 1988, J BIOL CHEM, V263, P12608; Issandou M, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000289; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; LAROCCA RV, 1990, CANCER CELL-MON REV, V2, P106; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luria SE, 1943, GENETICS, V28, P491; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MCINTYRE P, 1988, ANAL BIOCHEM, V174, P209, DOI 10.1016/0003-2697(88)90537-4; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; NOWELL PC, 1986, CANCER RES, V46, P2203; OTTO E, 1989, J BIOL CHEM, V264, P3390; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RODECK U, 1991, CANCER CELL-MON REV, V3, P308; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAMUEL SK, 1992, EMBO J, V11, P1599, DOI 10.1002/j.1460-2075.1992.tb05205.x; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1990, Critical Reviews in Oncogenesis, V2, P35; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Schwarz LC, 1990, GROWTH FACTORS, V3, P115, DOI 10.3109/08977199009108274; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; STARK GR, 1990, GENE REARRANGEMENT F, P99; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; TAYLOR WR, 1993, EXP CELL RES, V204, P295, DOI 10.1006/excr.1993.1036; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, 1984, MOL CELL BIOL, V4, P1050, DOI 10.1128/MCB.4.6.1050; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	67	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					491	499						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7904743				2022-12-17	WOS:A1994MW24800016
J	HILDT, E; URBAN, S; LAUER, U; HOFSCHNEIDER, PH; KEKULE, AS				HILDT, E; URBAN, S; LAUER, U; HOFSCHNEIDER, PH; KEKULE, AS			ER-LOCALIZATION AND FUNCTIONAL EXPRESSION OF THE HBV TRANSACTIVATOR MHBS(T)	ONCOGENE			English	Article							HEPATITIS-B-VIRUS; HUMAN HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL TRANSACTIVATOR; NUCLEOTIDE-SEQUENCE; SURFACE-ANTIGEN; DNA; REGION; INTEGRATION	In two recently reported cases, integrated hepatitis B virus (HBV) DNAs cloned from hepatocellular carcinoma were found to express a transcriptional transactivator from 3'-terminally truncated HBV surface (preS/S) genes. In this study, we characterized the transactivator at the protein level. Expression of a 3'-truncated preS2/S gene in Spodoptera frugiperda (Sf9) insect cells resulted in a C-terminally truncated middle surface protein of 76 amino acids (MHBs(t76)), which was found to be associated with membranes of the endoplasmic reticulum and retained from Golgi processing and secretion, Accordingly, the microsome fraction of MHBs(t76)-expressing Sf9 cells displayed transactivator activity after electric field-mediated transfer into Chang liver cells. In contrast to full-length MHBs, MHBs(t76) is unglycosylated, and glycosylation is not required for transactivation as shown by mutation of the glycosylation site at asparagine-4. Since highly purified MHBs(t76) derived from an E. coli expression system also showed transactivator activity, it is concluded that unglycosylated MHBs(t76) protein is the authentic transactivating factor. As the transactivator protein derives from inactive MHbs by rearrangements of integrated HBV DNA, it may be important for HBV-associated liver carcinogenesis.			HILDT, E (corresponding author), MAX PLANCK INST BIOCHEM, DEPT VIRUS RES, D-82152 MARTINSRIED, GERMANY.		Hildt, Eberhard/A-1040-2015					BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; EBLE BE, 1990, J VIROL, V64, P1414, DOI 10.1128/JVI.64.3.1414-1419.1990; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1991, CURR TOP MICROBIOL, V168, P61; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARTELSCHENK S, 1991, BIOCHIM BIOPHYS ACTA, V1115, P108, DOI 10.1016/0304-4165(91)90019-D; Heermann KH, 1991, MOL BIOL HEPATITIS B, P109; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; MATSUBARA K, 1991, MOL BIOL HEPATITIS B, P245; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; MIMMS LT, 1990, VIROLOGY, V176, P604, DOI 10.1016/0042-6822(90)90031-L; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1992, VIROLOGY, V187, P663, DOI 10.1016/0042-6822(92)90469-6; NEURATH AR, 1987, MOL IMMUNOL, V24, P975, DOI 10.1016/0161-5890(87)90009-5; OZOLS J, 1990, METHOD ENZYMOL, V182, P225; SAMBROOK J, 1989, MOL CLONING LABORATO, P1402; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUTER V, 1992, UNPUB J CLIN INVEST; SCULLY LJ, 1988, VIRAL HEPATITIS LIVE, P365; SHERKER AH, 1991, ANNU REV MICROBIOL, V45, P475; Summers MD, 1987, MANUAL METHODS BACUL; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WILL H, 1985, P NATL ACAD SCI USA, V82, P891, DOI 10.1073/pnas.82.3.891	31	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3359	3367						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247538				2022-12-17	WOS:A1993MG78200020
J	WARNER, LC; HACK, N; EGAN, SE; GOLDBERG, HJ; WEINBERG, RA; SKORECKI, KL				WARNER, LC; HACK, N; EGAN, SE; GOLDBERG, HJ; WEINBERG, RA; SKORECKI, KL			RAS IS REQUIRED FOR EPIDERMAL GROWTH FACTOR-STIMULATED ARACHIDONIC-ACID RELEASE IN RAT-1 FIBROBLASTS	ONCOGENE			English	Article							PROTEIN-KINASE-C; FACTOR RECEPTORS; MAP KINASE; CYTOSOLIC PHOSPHOLIPASE-A2; SIGNAL TRANSDUCTION; MESANGIAL CELLS; 3T3 CELLS; TYROSINE PHOSPHORYLATION; THYROID-CELLS; MESSENGER-RNA	Previous studies have provided suggestive evidence for an interaction between ras activation and signalling pathways involved in agonist-stimulated arachidonic acid release in a variety of cell systems. In order to clarify this interaction, we have measured epidermal growth factor (EGF)-stimulated arachidonic acid release in rat-1 fibroblasts transfected with the N-17 dominant negative mutation of ras. Cells transfected with the N-17 ras mutant, display a markedly attenuated arachidonic acid-release response to EGF, compared to sham-transfected and non-transfected cells. In contrast, the response to phorbol myristate acetate (PMA) was not attenuated in the N-17-mutant expressing cells. No differences were detected between sham-transfected and N-17 mutant expressing cells in levels of immunodetectable EGF receptor, cytosolic phospholipase A(2) or mitogen-activated protein (MAP) kinase. Attenuation of EGF-stimulated arachidonic acid release in the N-17 mutant expressing cells, was accompanied by a marked diminution in EGF-stimulated tyrosine phosphorylation of MAP kinase. We conclude that the signalling pathway involved in epidermal growth factor-stimulated arachidonic acid release is similar to the signalling pathway for mitogenic responses to epidermal growth factor and requires ras activation, likely followed by a downstream cascade of kinases eventuating in MAP kinase activation.	UNIV TORONTO,DEPT MED,DIV NEPHROL,MRC,MEMBRANE BIOL GRP,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO M5S 1A8,ON,CANADA; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	University of Toronto; University of Toronto; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; BOS JL, 1989, CANCER RES, V49, P4682; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P83; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gan B S, 1989, Proc West Pharmacol Soc, V32, P269; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HACK N, 1990, BIOSCIENCE REP, V10, P353, DOI 10.1007/BF01117235; HACK N, 1991, BIOCHEM J, V275, P563, DOI 10.1042/bj2750563; Hack N., 1991, Journal of Basic and Clinical Physiology and Pharmacology, V2, P161; HACK N, IN PRESS J BIOL CHEM; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HARRIS RC, 1990, FASEB J, V4, P1654, DOI 10.1096/fasebj.4.6.2138579; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS BL, 1988, BIOCHEM J, V249, P587, DOI 10.1042/bj2490587; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MENE P, 1991, AM J PHYSIOL, V260, P159; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PANAYOTOU G, 1992, MOL CELL BIOL, V12, P991; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SELVA E, 1993, J BIOL CHEM, V268, P2250; SHARMA SV, 1992, ONCOGENE, V7, P193; SHARP JD, 1991, J BIOL CHEM, V266, P14850; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZOR U, 1990, BIOCHIM BIOPHYS ACTA, V1091, P385	65	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3249	3255						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247528				2022-12-17	WOS:A1993MG78200007
J	ISHIKAWA, H; ASANO, M; KANDA, T; KUMAR, S; GELINAS, C; ITO, Y				ISHIKAWA, H; ASANO, M; KANDA, T; KUMAR, S; GELINAS, C; ITO, Y			2 NOVEL FUNCTIONS ASSOCIATED WITH THE REL ONCOPROTEINS - DNA-REPLICATION AND CELL-SPECIFIC TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article							NF-KAPPA-B; V-REL; C-REL; BINDING-PROTEIN; ONCOGENIC TRANSFORMATION; GENE-EXPRESSION; SUBUNIT; FAMILY; HOMOLOGY; ELEMENTS	The v-Rel oncoprotein and its cellular homolog c-Rel belong to the Rel/kappaB family of transcription factors. Members of this family share extensive sequence similarity in their N-terminal halves, a region referred to as the Rel Homology Region (RHR), bind to NF-kappaB DNA motifs and form heterodimers with one another. Whereas c-Rel activates transcription of kappaB-linked genes, v-Rel behaves as a dominant-interfering mutant of c-Rel- and kappaB-mediated transcription activation. Here we describe two novel activities of the Rel oncoproteins. One induces kappaB-site dependent stimulation of polyomavirus (Py) DNA replication and maps to the N-terminus of the RHR, a region where no transcription activation function was detected. This activity is common to v-Rel, c-Rel, p52 (p49/lyt10), RelA (p65) and the p50 subunit of NF-kappaB. The second promotes transcriptional activation in undifferentiated F9 cells and maps 3' to the RHR, a region essential for the transforming activity of v-Rel.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Kyoto University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center			Kanda, Teru/J-7313-2019	Kanda, Teru/0000-0002-1391-3349				BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DIFFLEY JFX, 1990, TRENDS GENET, V6, P427, DOI 10.1016/0168-9525(90)90305-P; DOUGHERTY JP, 1989, J VIROL, V63, P3209, DOI 10.1128/JVI.63.7.3209-3212.1989; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIM KJ, 1979, J IMMUNOL, V122, P549; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEE JH, 1991, ONCOGENE, V6, P665; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYUHAS O, 1990, J BIOL CHEM, V265, P11465; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORRISON LE, 1992, ONCOGENE, V7, P1137; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WASYLYK C, 1990, ONCOGENE, V5, P1055	58	28	28	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2889	2896						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414493				2022-12-17	WOS:A1993MC09300001
J	SAKAMOTO, K; HOWARD, T; OGRYZKO, V; XU, NZ; CORSICO, CC; JONES, DH; HOWARD, B				SAKAMOTO, K; HOWARD, T; OGRYZKO, V; XU, NZ; CORSICO, CC; JONES, DH; HOWARD, B			RELATIVE MITOGENIC ACTIVITIES OF WILD-TYPE AND RETINOBLASTOMA BINDING-DEFECTIVE SV40 T-ANTIGENS IN SERUM-DEPRIVED AND SENESCENT HUMAN-DIPLOID FIBROBLASTS	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; SUPPRESSOR GENE-PRODUCT; LARGE TUMOR-ANTIGEN; SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR; SV40-TRANSFORMED CELLS; INTERLEUKIN-2 RECEPTOR; CELLULAR PROTEINS; SODIUM-BUTYRATE; RB PROTEIN	A novel gene transfer approach was used to investigate whether the retinoblastoma (Rb)-binding domain of simian virus 40 (SV40) T antigen is required for efficient T antigen-mediated stimulation of DNA synthesis is quiescent or senescent human embryo fibroblasts. In senescent cells, comparison between wild-type T antigen and a mutant defective in Rb binding (Glu-107-->Lys) revealed the latter to have almost-equal-to 15-fold lower activity. In contrast, comparison of wild-type and Rb- T antigens in serum-deprived quiescent cells revealed a much smaller (1.8-fold) difference. Surprisingly, an 18-fold differential could be induced by treating quiescent cells with the differentiating agent sodium butyrate. These results suggest that the role of Rb in control of the cell cycle is strongly dependent on the physiological state of the cell and the mechanism of growth arrest.	NICHHD,MOLEC GROWTH REGULAT LAB,BLDG 6,ROOM 416,BETHESDA,MD 20892; NIH,HOWARD HUGHES MED INST,RES SCHOLARS PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA			Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCHMAN AR, 1980, DNA TUMOR VIRUSES, P799; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORDIS CM, 1990, P NATL ACAD SCI USA, V87, P1169, DOI 10.1073/pnas.87.3.1169; FOSS FM, 1989, ONCOGENE RES, V5, P13; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIORDANO T, 1990, EXP CELL RES, V192, P193; GOLDSTEIN S, 1989, NUCLEIC ACIDS RES, V17, P3959, DOI 10.1093/nar/17.10.3959; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; ISAACS WB, 1991, CANCER RES, V51, P4716; JONES DH, 1990, BIOTECHNIQUES, V8, P17; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KOSAKA M, 1991, EXP CELL RES, V192, P46, DOI 10.1016/0014-4827(91)90155-N; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; PADMANABHAN R, 1988, ANAL BIOCHEM, V170, P341, DOI 10.1016/0003-2697(88)90640-9; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAKAMOTO K, 1991, J BIOL CHEM, V266, P3031; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1048, P59, DOI 10.1016/0167-4781(90)90022-T; THOMAS NSB, 1991, ONCOGENE, V6, P317; TSUDO M, 1987, P NATL ACAD SCI USA, V84, P4215, DOI 10.1073/pnas.84.12.4215; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116	55	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1887	1893						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390037				2022-12-17	WOS:A1993LG68200021
J	TAMAGNONE, L; PARTANEN, J; ARMSTRONG, E; LASOTA, J; OHGAMI, K; TAZUNOKI, T; LAFORGIA, S; HUEBNER, K; ALITALO, K				TAMAGNONE, L; PARTANEN, J; ARMSTRONG, E; LASOTA, J; OHGAMI, K; TAZUNOKI, T; LAFORGIA, S; HUEBNER, K; ALITALO, K			THE HUMAN RYK CDNA SEQUENCE PREDICTS A PROTEIN CONTAINING 2 PUTATIVE TRANSMEMBRANE SEGMENTS AND A TYROSINE KINASE CATALYTIC DOMAIN	ONCOGENE			English	Note							GENE	The human ryk tyrosine kinase cDNA was originally identified as a PCR-amplified cDNA fragment (JTK5) from K562 leukemia cells and found to represent a ubiquitously expressed gene (Partanen et al., 1990). The open reading frame of human ryk, reported here, encodes a novel type of putative tyrosine kinase of 607 amino acid residues, having two potential transmembrane domains and homology to receptor tyrosine kinases, such as met (HGF/SF-R) and IGF-1R, in its catalytic domain. The gene maps to human chromosome 3q11-25. Expression of the 3.4 kb ryk mRNA was found in all human adult tissues examined.	UNIV HELSINKI,DEPT PATHOL,MOLEC CANC BIOL LAB,POB 21,SF-00014 HELSINKI,FINLAND; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	University of Helsinki; Jefferson University			Tamagnone, Luca/J-8948-2018; Alitalo, Kari K/J-5013-2014	Tamagnone, Luca/0000-0002-2884-7946; Alitalo, Kari K/0000-0002-7331-0902; Partanen, Juha/0000-0001-8850-4825	NATIONAL CANCER INSTITUTE [P01CA021124] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASLER K, 1988, CELL, V54, P299; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; HUEBNER K, 1993, IN PRESS HUM GENETIC; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBURTH D, 1992, GENOMICS, V14, P59, DOI 10.1016/S0888-7543(05)80283-6; ULLRICH A, 1990, CELL, V61, P243; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	21	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					2009	2014						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390040				2022-12-17	WOS:A1993LG68200034
J	KOLCH, W; HEIDECKER, G; TROPPMAIR, J; YANAGIHARA, K; BASSIN, RH; RAPP, UR				KOLCH, W; HEIDECKER, G; TROPPMAIR, J; YANAGIHARA, K; BASSIN, RH; RAPP, UR			RAF REVERTANT CELLS RESIST TRANSFORMATION BY NONNUCLEAR ONCOGENES AND ARE DEFICIENT IN THE INDUCTION OF EARLY RESPONSE GENES BY TPA AND SERUM	ONCOGENE			English	Article							PROTEIN KINASE-C; NIH 3T3 CELLS; SIGNAL TRANSDUCTION; V-RAF; TYROSINE PHOSPHORYLATION; NEGATIVE AUTOREGULATION; EXTRACELLULAR SIGNALS; NUCLEOTIDE-SEQUENCE; FLAT REVERTANTS; AUTO-REGULATION	A revertant cell line was generated from v-raf transformed NIH/3T3 fibroblasts. These cells, termed CHP25, express a functional v-raf oncogene. However, they are non-tumorigenic, do not form colonies in soft agar and possess a flat morphology. CHP25 cell are resistant to re-transformation by sis, ras, tyrosine kinase as well as serine/threonine kinase-encoding oncogenes suggesting that Raf functions downstream of most membrane associated signal transducers. In contrast to v-raf transformed cells, in which the endogenous Raf-1 protein kinase is constitutively activated, v-Raf in CHP25 cells does not activate endogenous Raf-1 kinase. Since mitogen regulation of Raf-1 kinase in CHP25 cells is intact, we conclude that CHP25 cells are blocked at the level of Raf-1 substrate phosphorylation. Consistent with this interpretation CHP25 cells show specific alterations of early gene induction. The serum induction of c-fos and junD as well as the serum and TPA (12-O-tetradecanoylphorbol-13-acetate) induction of junB and egr-1 are almost completely abolished. Only v-fos can transform CHP25, whereas c-fos, v-myc, c-jun and junB are ineffective. These data suggest that the lesion responsible for the revertant phenotype of CHP25 cells is the inability to activate the AP-1 complex. We conclude that Raf-1 signaling is essential for transformation of NIH/3T3 cells by peripheral oncogenes and for regulation of a subset of early response genes by TPA and serum growth factors.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kolch, Walter/ABF-2102-2021	Troppmair, Jakob/0000-0002-0611-3837; Kolch, Walter/0000-0001-5777-5016				APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIARDIELLO F, 1988, CANCER RES, V48, P2483; Cleveland J L, 1988, Oncogene Res, V3, P357; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DESSUREAULT J, 1990, J CELL BIOCHEM, V43, P293, DOI 10.1002/jcb.240430309; GERFAUX J, 1990, MOL CARCINOGEN, V3, P103, DOI 10.1002/mc.2940030208; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1992, IN PRESS ADV CANCER; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NOSE K, 1989, MOL CARCINOGEN, V2, P208, DOI 10.1002/mc.2940020407; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROEBROEK AJM, 1986, VIRUS RES, V6, P15, DOI 10.1016/0168-1702(86)90053-5; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VARNUM BC, 1989, ONCOGENE, V4, P119; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WISDOM R, 1990, MOL CELL BIOL, V10, P5626, DOI 10.1128/MCB.10.11.5626; YAMADA H, 1990, MOL CELL BIOL, V10, P1822, DOI 10.1128/MCB.10.4.1822; YANAGIHARA K, 1990, ONCOGENE, V5, P1179; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	71	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					361	370						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426742				2022-12-17	WOS:A1993KN00600015
J	VASTRIK, I; KOSKINEN, PJ; ALITALO, R; MAKELA, TP				VASTRIK, I; KOSKINEN, PJ; ALITALO, R; MAKELA, TP			ITERNATIVE MESSENGER-RNA FORMS AND OPEN READING FRAMES OF THE MAX GENE	ONCOGENE			English	Note							DNA-BINDING; MYC	The max gene encodes a heterodimeric partner of Myc. We have recently identified an alternative max mRNA (DELTAmax) that contains an additional internal exon introducing an in-frame translational termination. Here we have studied the expression of human max mRNAs by Northern blotting analysis. In addition to the major 2.3-kb mRNA form, four bands were identified. Our results indicate that these bands represent differentially spliced mRNA forms, which contain altogether three open reading frames. In addition to the previously identified Max and DELTAMax proteins, sequence analysis of a 3.5-kb mRNA form predicted a protein that resembles DELTAMax in structure. Like DELTAMax, this protein enhanced the number of transformed foci in the ras-myc co-transformation assay. Although the 3.5-kb mRNA represents a minor form in actively proliferating cells, a shift from the major 2.3-kb mRNA to the 3.5-kb form was observed in response to high cell densitiy or acidification of the growth medium. Our results indicate the presence of several differentially spliced mRNA forms of the max gene, and suggest a possible mechanism for the production of functionally distinct Max proteins.	UNIV HELSINKI, DEPT PATHOL, CANC BIOL LAB, SF-00290 HELSINKI 29, FINLAND; UNIV HELSINKI, CENT HOSP, TRANSPLANTAT LAB, SF-00290 HELSINKI 29, FINLAND	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	VASTRIK, I (corresponding author), UNIV HELSINKI, DEPT VIROL, CANC BIOL LAB, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND.		Vastrik, Imre/C-2690-2009; makela, tomi/B-3734-2009; Koskinen, Päivi J/G-8939-2014	makela, tomi/0000-0002-4869-8044; 				BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLACKWOOD EM, 1992, IN PRESS CURR OPIN G; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SPENCER CA, 1991, ADV CANCER RES, V56, P1; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111	13	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					503	507						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426752				2022-12-17	WOS:A1993KN00600031
J	DANISH, R; ELAWAR, O; WEBER, BL; LANGMORE, J; TURKA, LA; RYAN, JJ; CLARKE, MF				DANISH, R; ELAWAR, O; WEBER, BL; LANGMORE, J; TURKA, LA; RYAN, JJ; CLARKE, MF			C-MYB EFFECTS ON KINETIC EVENTS DURING MEL CELL-DIFFERENTIATION	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; FRIEND-ERYTHROLEUKEMIA CELLS; HUMAN LYMPHOCYTES-T; ERYTHROID-DIFFERENTIATION; GENE-EXPRESSION; GLOBIN GENES; V-MYB; TRANSFORMING GENE; DNA-POLYMERASE; MESSENGER-RNA	During dimethylsulfoxide (DSMO)-induced differentation of Friend mouse erythroleukemia (MEL) cells there is a biphasic fall in c-myb mRNA levels. We have previously shown that constitutive expression of c-myb blocks differentiation. To delineate more accurately the point at which Myb blocks differentiation, MEL cells were transfected with a human c-myb construct under the control of the beta-globin promoter and enhancers. In concert with endogenous DMSO-induced globin transcription during MEL cell differentiation, the beta-globin c-myb transcription unit of the transfected plasmid is activated after 3-5 days of culture in media containing DMSO. Here we describe c-myb-transformed MEL clones which undergo delayed expression of the exogenous c-myb following 3-5 days of culture in DMSO. In contrast to wild-type MEL cells, both clones failed to display phenotypic markers of differentiation and continued to proliferate for up to 10 days of culture. These data suggest that the late fall in c-myb levels may be required in order for differentiation to occur. Additionally, we suggest that constitutive expression of c-myb does not block early commitment events such as activation of histone Hl', subsequent chromatin condensation, and alteration of proliferation-related gene expression. Taken together, these results show that c-myb acts very late in the process of differentiation.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,C570 MSRB II,1150 W MED CTR DR,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NCI NIH HHS [CA46657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFFOLTER M, 1987, MOL CELL BIOL, V7, P3663, DOI 10.1128/MCB.7.10.3663; ALONSO A, 1988, EMBO J, V7, P3003, DOI 10.1002/j.1460-2075.1988.tb03163.x; APPELS R, 1972, J MOL BIOL, V70, P425, DOI 10.1016/0022-2836(72)90550-5; BALCAREK JM, 1983, J BIOL CHEM, V258, P622; BANCHEV T, 1988, EXP CELL RES, V17, P1; BEHRINGER RR, 1987, P NATL ACAD SCI USA, V84, P7056, DOI 10.1073/pnas.84.20.7056; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BERGMANN DG, 1981, J VIROL, V40, P450, DOI 10.1128/JVI.40.2.450-455.1981; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BOETTIGER D, 1984, J VIROL, V49, P841, DOI 10.1128/JVI.49.3.841-847.1984; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DOENECKE D, 1986, J MOL BIOL, V187, P461, DOI 10.1016/0022-2836(86)90446-8; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GJERSET R, 1982, P NATL ACAD SCI-BIOL, V79, P2333, DOI 10.1073/pnas.79.7.2333; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; GUSELLA JF, 1980, BLOOD, V56, P481; GUSELLA JF, 1982, J CELL PHYSIOL, V113, P179, DOI 10.1002/jcp.1041130127; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUBER HE, 1987, J BIOL CHEM, V262, P16224; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KEPPEL F, 1977, P NATL ACAD SCI USA, V74, P653, DOI 10.1073/pnas.74.2.653; KEUHL WM, 1988, CURR TOP MICROBIOL I, V141, P318; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LENNOX RW, 1984, HISTONE GENES STRUCT, P373; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PRAGNELL IB, 1977, EXP CELL RES, V108, P269, DOI 10.1016/S0014-4827(77)80034-7; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; ROCHE J, 1985, NATURE, V314, P197, DOI 10.1038/314197a0; ROSS J, 1972, P NATL ACAD SCI USA, V69, P3620, DOI 10.1073/pnas.69.12.3620; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; RUIZCARRILLO A, 1976, ARCH BIOCHEM BIOPHYS, V174, P273, DOI 10.1016/0003-9861(76)90346-5; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH BJ, 1984, EUR J BIOCHEM, V138, P309, DOI 10.1111/j.1432-1033.1984.tb07916.x; SOUZA LM, 1980, J VIROL, V36, P325, DOI 10.1128/JVI.36.2.325-336.1980; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WATSON ML, 1958, J BIOPHYS BIOCHEM CY, V4, P475, DOI 10.1083/jcb.4.4.475; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	66	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					901	907						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1533276				2022-12-17	WOS:A1992HP64200009
J	STRAUSS, M; HERING, S; LIEBER, A; HERRMANN, G; GRIFFIN, BE; ARNOLD, W				STRAUSS, M; HERING, S; LIEBER, A; HERRMANN, G; GRIFFIN, BE; ARNOLD, W			STIMULATION OF CELL-DIVISION AND FIBROBLAST FOCUS FORMATION BY ANTISENSE REPRESSION OF RETINOBLASTOMA PROTEIN-SYNTHESIS	ONCOGENE			English	Article							LARGE T-ANTIGENS; GENE-PRODUCT; SUSCEPTIBILITY GENE; OSTEO-SARCOMA; HUMAN CANCER; EXPRESSION; VIRUS; CYCLE; SV40; PHOSPHORYLATION	Circumstantial evidence supports a role for the retinoblastoma susceptibility gene, Rb-1, in the maintenance of normal cell growth, in that loss of its function results in abnormal growth and malignancy. Here we report that a high rate of mitosis and efficient dense focus formation in human embryonic lung fibroblasts (HEL cells) is induced by antisense oligonucleotide-directed inhibition of synthesis of p105-Rb, the product of the Rb-1 gene. mRNA specific for p105-Rb is truncated at the site of base pairing with the antisense oligonucleotide, and no synthesis of p105-Rb is observed. The rate of mitosis is considerably increased and the frequency of dense focus formation is extremely high in treated cells. However, although phosphothioate oligodeoxyribonucleotides taken up by the cells remain stable for at least 4 weeks, the recipient cells do not become immortal; nor are they able to induce tumor formation in nude mice. Thus, loss of Rb-1 function is not sufficient per se to allow malignant transformation.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; INST CANC RES,W-1115 BERLIN,GERMANY	Imperial College London	STRAUSS, M (corresponding author), INST MOLEC BIOL,MOLEK ZELLGENET ABT,ROBERT ROSSLE STR 10,W-1115 BERLIN,GERMANY.							AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GREIGEL S, 1990, INT J CANCER, V46, P125; HANSEN MF, 1988, CELL, V53, P172, DOI 10.1016/0092-8674(88)90376-5; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STRAUSS M, 1990, ONCOGENE, V5, P1223; STRAUSS M, 1990, CANCER CELL-MON REV, V2, P360; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOKOTA J, 1988, ONCOGENE, V3, P471	37	28	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					769	773						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565472				2022-12-17	WOS:A1992HQ68200021
J	INGRAHAM, CA; COOKE, MP; CHUANG, YN; PERLMUTTER, RM; MANESS, PF				INGRAHAM, CA; COOKE, MP; CHUANG, YN; PERLMUTTER, RM; MANESS, PF			CELL TYPE AND DEVELOPMENTAL REGULATION OF THE FYN PROTOONCOGENE IN NEURAL RETINA	ONCOGENE			English	Article								The product of the proto-oncogene c-fyn (p59fyn) is a non-receptor tyrosine kinase of unknown function. The expression of the p59fyn tyrosine kinase was analysed by immunoperoxidase staining of the different neuronal cell types in the developing chick neural retina. p59fyn was primarily localized in the cell bodies of mature retinal neurons. p59fyn immunoreactivity was most abundant in cell bodies of differentiated ganglion, amacrine and photoreceptor cells. The onset of p59fyn expression in developing photoreceptors occurred coordinately with terminal neuronal differentiation. p59fyn was also found within the outer plexiform layer, which contains synaptic terminals of the photoreceptors. At embryonic stages prior to photoreceptor differentiation, p59fyn was most highly concentrated in the cell bodies of differentiating ganglion and amacrine cells. p59fyn autokinase activity in retinal extracts decreased concomitant with the final stages of maturation of retinal neurons, suggesting that the p59fyn kinase is developmentally regulated. Thus, the expression of p59fyn is regulated in both a developmental and cell type-specific manner. The existence of p59fyn in some of the same neuronal cells as p60c-src suggests the possibility of functional redundancy of these non-receptor tyrosine kinases.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM, CHAPEL HILL, NC 27599 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT IMMUNOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, DIV MED GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NCI NIH HHS [CA45682] Funding Source: Medline; NEI NIH HHS [EY08975] Funding Source: Medline; NINDS NIH HHS [NS26620] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045682] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026620] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARCLAY AN, 1981, IMMUNOLOGY, V44, P727; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, IN PRESS CELL; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1987, PEPTIDES PHOSPHORYLA; Dowling J.E., 1987, RETINA APPROACHABLE; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUGHES WF, 1974, ANAT REC, V179, P297, DOI 10.1002/ar.1091790302; KAHN AJ, 1974, DEV BIOL, V38, P30, DOI 10.1016/0012-1606(74)90256-5; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; LEMMON V, 1986, J NEUROSCI, V6, P2987; LINSER P, 1979, P NATL ACAD SCI USA, V76, P6476, DOI 10.1073/pnas.76.12.6476; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTH JD, 1989, J IMMUNOL, V142, P2430; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; PEARSON R, 1972, AVIAN BRAIN; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHORES CG, 1989, J NEUROSCI RES, V24, P59, DOI 10.1002/jnr.490240109; SINCLAIR CM, 1986, BRAIN RES, V398, P91, DOI 10.1016/0006-8993(86)91254-0; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TOWLE AC, 1984, J HISTOCHEM CYTOCHEM, V32, P766, DOI 10.1177/32.7.6145741; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEBB M, 1984, J NEUROCHEM, V43, P1061, DOI 10.1111/j.1471-4159.1984.tb12844.x; WONG ROL, 1987, J COMP NEUROL, V255, P159, DOI 10.1002/cne.902550202	39	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					95	100						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741169				2022-12-17	WOS:A1992HC22700013
J	KEEGAN, K; MEYER, S; HAYMAN, MJ				KEEGAN, K; MEYER, S; HAYMAN, MJ			STRUCTURAL AND BIOSYNTHETIC CHARACTERIZATION OF THE FIBROBLAST GROWTH-FACTOR RECEPTOR-3 (FGFR-3) PROTEIN	ONCOGENE			English	Article							EARLY XENOPUS EMBRYOS; TYROSINE KINASE; MAMMALIAN-CELLS; MESSENGER-RNAS; EXPRESSION; GENE; PHOSPHOTYROSINE; DIFFERENTIATION; IDENTIFICATION; TRANSLOCATION	Recently an additional member of the fibroblast growth factor receptor family, FGFR-3, was isolated. In this report, the structure and biosynthesis of the FGFR-3 protein product are investigated. In vitro transcription and translation of the three immunoglobulin-like domain form of FGFR-3 demonstrated the primary translation product to be approximately 97 kDa. However when analysed in COS-1 cells, this form of the receptor directed the expression of three polypeptides with apparent molecular weights of 97 kDa, 125 kDa and 135 kDa. Pulse-chase analysis, treatment of the cells with N-linked glycosylation inhibitors and digestion of these proteins with endoglycosidases demonstrated that the difference in molecular weights was the result of varying degrees of glycosylation. The 97 kDa protein was determined to be a non-glycosylated, cytoplasmic protein, whereas the 125-kDa protein was found to be a membrane-associated glycoprotein that is the biosynthetic precursor of the mature 135 kDa glycoprotein.	SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [R01 CA-42573, P01 CA-28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HAYMAN MJ, 1978, VIROLOGY, V85, P241, DOI 10.1016/0042-6822(78)90428-2; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; HUYLEBROECK D, 1988, GENE, V66, P163, DOI 10.1016/0378-1119(88)90354-X; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAMPS MP, 1988, ONCOGENE, V2, P305; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMMELMAN D, 1988, SCIENCE, V242, P1053; KNIGHT J, 1988, ONCOGENE, V2, P317; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINKHART TA, 1981, DEV BIOL, V86, P18; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TARENTINO A, 1985, BIOCHEMISTRY-US, V261, P4465; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TIARA M, 1987, P NATL ACAD SCI USA, V84, P2980; TOGARI A, 1985, J NEUROSCI, V5, P307; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012	45	28	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2229	2236						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1662791				2022-12-17	WOS:A1991GX73500008
J	BHATIA, K; HUPPI, K; MCKEITHAN, T; SIWARSKI, D; MUSHINSKI, JF; MAGRATH, I				BHATIA, K; HUPPI, K; MCKEITHAN, T; SIWARSKI, D; MUSHINSKI, JF; MAGRATH, I			MOUSE BCL-3 - CDNA STRUCTURE, MAPPING AND STAGE-DEPENDENT EXPRESSION IN LYMPHOCYTES-B	ONCOGENE			English	Note							LIGHT CHAIN GENE; CELL-CYCLE CONTROL; CHROMOSOME-TRANSLOCATION; LEUKEMIA; DIFFERENTIATION; BREAKPOINT; LYMPHOMAS; SEQUENCE; CLONING; ACTIVATION	Human B-cell chronic lymphocytic leukemias (CLLs) are malignancies of mature B lymphocytes. A subset of these tumors is associated with a non-random t(14; 19) translocation (Ueshima et al., 1985). Recently a gene (bcl-3) has been identified in the region adjacent to the chromosome 19 breakpoint in this translocation (McKeithan et al., 1987; Ohno et al., 1990). We now report the isolation of cDNA clones of mouse bcl-3. The mouse bcl-3-coding region is 1746 bp long and exhibits 80% identity with human bcl-3 at both the nucleotide and amino acid level. The bcl-3 locus maps to the proximal end of mouse chromosome 7, which is syntenic to human chromosome 19. The bcl-3 probe readily detects particularly abundant amounts of a 1.8 kb mRNA in mouse tumors consisting of follicular center mature B cells and large pre-B cells, but not in small pre-B cells. The bcl-3 pattern of expression is distinctive in the spectrum of B-cell maturation in that bcl-3 transcripts are particularly abundant in B-cell lines immortalized just prior to Ig switch. The bcl-3 pattern of expression also bears close resemblance to that of bcl-2 (Gurfinkel et al., 1987), which is frequently associated with human B follicular lymphomas {t(14;18)} and some chronic lymphocytic leukemias (Adachi et al., 1989; 1990; Adachi & Tsujimoto, 1989).	UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; NCI,GENET LAB,BETHESDA,MD 20892	University of Chicago; University of Chicago; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BHATIA, K (corresponding author), NCI,PEDIAT BRANCH,LYMPHOMA BIOL SECT,BETHESDA,MD 20892, USA.			McKeithan, Timothy/0000-0003-2242-3074	NATIONAL CANCER INSTITUTE [R29CA049207] Funding Source: NIH RePORTER; NCI NIH HHS [CA49207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADACHI M, 1989, ONCOGENE, V4, P1073; CAVANNA JS, 1990, GENOMICS, V7, P12, DOI 10.1016/0888-7543(90)90513-T; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; GAUWERKY CE, 1989, P NATL ACAD SCI USA, V86, P8867, DOI 10.1073/pnas.86.22.8867; Green EL, 1981, GENETICS PROBABILITY, P77; GURFINKEL N, 1987, EUR J IMMUNOL, V17, P567, DOI 10.1002/eji.1830170421; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; MUSHINSKI JF, 1987, CANCER INVEST, V5, P345; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; SAUNDERS AM, 1990, GENOMICS, V8, P525, DOI 10.1016/0888-7543(90)90040-2; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263	20	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1569	1573						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923524				2022-12-17	WOS:A1991GX27400011
J	VELLARD, M; SORET, J; VIEGASPEQUIGNOT, E; GALIBERT, F; VANCONG, N; DUTRILLAUX, B; PERBAL, B				VELLARD, M; SORET, J; VIEGASPEQUIGNOT, E; GALIBERT, F; VANCONG, N; DUTRILLAUX, B; PERBAL, B			C-MYB PROTOONCOGENE - EVIDENCE FOR INTERMOLECULAR RECOMBINATION OF CODING SEQUENCES	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; HUMAN ACUTE LEUKEMIAS; GENE V-MYB; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; CHICKEN DNA; DIFFERENTIAL EXPRESSION; INSITU HYBRIDIZATION; ONC GENES	We have characterized a novel chicken c-myb exon whose sequences are specifically expressed in thymic cells. In situ hybridization experiments indicate that this thymus-specific coding exon is localized on a small chromosome, distinct from the large acrocentric chromosome 3 on which we recently mapped the bulk of 15 exons, common to the c-myb mRNA species expressed in hematopoietic cells of both B and T lineages. These observations indicate that intermolecular recombination is required for the tissue-specific expression of the c-myb proto-oncogene. We also show that these thymus-specific sequences are conserved in human DNA and lie on chromosome 17q25, whereas the human c-myb locus is localized on chromosome 6q22-23. Sequencing data obtained from genomic DNA and PCR analyses performed with c-myb mRNA species expressed in chicken thymic cells strongly suggest that a repeated decameric sequence plays a key role in the recombination process.	CTR UNIV ORSAY,INST CURIE,BATIMENT 110,F-91405 ORSAY,FRANCE; INST CURIE,F-75005 PARIS,FRANCE; CTR HAYEM,F-75010 PARIS,FRANCE; UNIV PARIS 06,F-75230 PARIS 05,FRANCE; HOP NECKER ENFANTS MALAD,F-75730 PARIS 15,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite								BADING H, 1908, ONCOGENE, V3, P257; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BLICK M, 1984, BLOOD, V64, P1234; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CHINSKY J, 1985, P NATL ACAD SCI USA, V82, P565, DOI 10.1073/pnas.82.2.565; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P4714, DOI 10.1073/pnas.79.15.4714; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOZIER C, 1986, NUCLEIC ACIDS RES, V14, P1928, DOI 10.1093/nar/14.4.1928; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DUTRILLAUX B, 1971, CR ACAD SCI D NAT, V272, P2638; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HILDEBRAND M, 1988, P NATL ACAD SCI USA, V85, P372, DOI 10.1073/pnas.85.2.372; HOLLIDAY R, 1989, TRENDS GENET, V5, P355, DOI 10.1016/0168-9525(89)90150-9; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; JANSSEN JWG, 1986, CYTOGENET CELL GENET, V41, P129, DOI 10.1159/000132217; KAHN PM, 1971, ARCH BIOCHEM BIOPHYS, V145, P470; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MAVILIO F, 1986, P NATL ACAD SCI USA, V83, P4394, DOI 10.1073/pnas.83.12.4394; MCMAHON J, 1988, ONCOGENE, V3, P717; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NGUYEN VC, 1986, ANN GENET-PARIS, V29, P20; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; Perbal B., 1988, PRACTICAL GUIDE MOL; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROYBURMAN P, 1983, INT J CANCER, V32, P185, DOI 10.1002/ijc.2910320208; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SORET J, 1988, FEBS LETT, V232, P227, DOI 10.1016/0014-5793(88)80422-8; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; SORET J, 1985, J VIROL, V55, P227; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; URBANEK P, 1988, NUCLEIC ACIDS RES, V16, P11521, DOI 10.1093/nar/16.24.11521; UZAN G, 1987, CYTOGENET CELL GENET, V46, P707; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; VLACH J, 1989, BIOCHEM BIOPH RES CO, V158, P737, DOI 10.1016/0006-291X(89)92783-6; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	60	28	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					505	514						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1840680				2022-12-17	WOS:A1991FR93900003
J	WU, J; ZHU, JQ; HAN, KK; ZHU, DX				WU, J; ZHU, JQ; HAN, KK; ZHU, DX			THE ROLE OF THE C-FMS ONCOGENE IN THE REGULATION OF HL-60 CELL-DIFFERENTIATION	ONCOGENE			English	Article									INSERM,U16,F-59045 LILLE,FRANCE; NANJING UNIV,DEPT BIOCHEM,NANJING 210008,PEOPLES R CHINA	Institut National de la Sante et de la Recherche Medicale (Inserm); Nanjing University								CAYRE Y, 1987, P NATL ACAD SCI USA, V84, P7619, DOI 10.1073/pnas.84.21.7619; CHEN BDM, 1984, J CELL SCI, V70, P147; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DELAMARTER JF, 1987, NUCLEIC ACIDS RES, V15, P2389, DOI 10.1093/nar/15.5.2389; Gait M. J, 1984, OLIGONUCLEOTIDE SYNT; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HONMA Y, 1980, BIOCHEM BIOPH RES CO, V95, P507, DOI 10.1016/0006-291X(80)90813-X; KREIPE H, 1986, DIFFERENTIATION, V33, P56, DOI 10.1111/j.1432-0436.1986.tb00410.x; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; YAM LT, 1971, AM J CLIN PATHOL, V55, P283; YEN A, 1987, EXP CELL RES, V168, P247, DOI 10.1016/0014-4827(87)90432-0	20	28	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					873	877						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2141686				2022-12-17	WOS:A1990DP55300013
J	CROOK, T; GREENFIELD, I; HOWARD, J; STANLEY, M				CROOK, T; GREENFIELD, I; HOWARD, J; STANLEY, M			ALTERATIONS IN GROWTH-PROPERTIES OF HUMAN PAPILLOMA-VIRUS TYPE-16 IMMORTALIZED HUMAN CERVICAL KERATINOCYTE CELL-LINE CORRELATE WITH AMPLIFICATION AND OVEREXPRESSION OF C-MYC ONCOGENE	ONCOGENE			English	Note									UNIV CAMBRIDGE, DEPT PATHOL, TENNIS COURT RD, CAMBRIDGE CB2 1QP, ENGLAND; UNIV CAMBRIDGE, IMPERIAL CANC RES FUND, TUMOUR VIRUS GRP, CAMBRIDGE CB2 1QP, ENGLAND	University of Cambridge; University of Cambridge								BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROOK T, 1989, P NATL ACAD SCI USA, V86, P5713, DOI 10.1073/pnas.86.15.5713; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; DUTRILLAUX B, 1981, HUM GENET, V57, P93; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRESHNEY IR, 1984, CULTURE ANIMAL CELLS, P129; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; MCKAY RDG, 1973, CHROMOSOMA, V44, P1, DOI 10.1007/BF00372569; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RIOU G, 1987, LANCET, V1, P761; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; YOUNG LS, 1989, BRIT MED J, V298, P14, DOI 10.1136/bmj.298.6665.14; YUNIS JJ, 1973, CHROMOSOMA, V44, P15, DOI 10.1007/BF00372570; YUNIS JJ, 1976, SCIENCE, V191, P1268, DOI 10.1126/science.1257746	20	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1990	5	4					619	622						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2158040				2022-12-17	WOS:A1990DB85300025
J	CAMPO, MS; MCCAFFERY, RE; DOHERTY, I; KENNEDY, IM; JARRETT, WFH				CAMPO, MS; MCCAFFERY, RE; DOHERTY, I; KENNEDY, IM; JARRETT, WFH			THE HARVEY RAS-1 GENE IS ACTIVATED IN PAPILLOMAVIRUS-ASSOCIATED CARCINOMAS OF THE UPPER ALIMENTARY CANAL IN CATTLE	ONCOGENE			English	Article											CAMPO, MS (corresponding author), BEATSON INST CANC RES,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND.							ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; CAMPO MS, 1985, EMBO J, V4, P1819, DOI 10.1002/j.1460-2075.1985.tb03856.x; CAMPO MS, 1980, NATURE, V286, P180, DOI 10.1038/286180a0; CAMPO MS, 1987, CANCER SURV, V6, P39; CAMPO MS, 1986, CIBA F SYMP, V120, P117; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EVANS IA, 1982, P ROY SOC EDINB B, V81, P65, DOI 10.1017/S0269727000003249; EVANS WC, 1982, P ROY SOC EDINB B, V81, P29, DOI 10.1017/S0269727000003237; FUJITA J, 1988, J NATL CANCER I, V80, P37, DOI 10.1093/jnci/80.1.37; HUNTER T, 1984, JNCI-J NATL CANCER I, V73, P773; Jarrett W. F. H., 1985, Advances in Viral Oncology, V5, P83; JARRETT WFH, 1978, NATURE, V274, P215, DOI 10.1038/274215a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MCCAFFERY RE, 1989, ONCOGENE, V4, P1441; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; POPESCU NC, 1987, J VIROL, V51, P1682; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RIOU G, 1984, CR ACAD SCI III-VIE, V299, P575; RIOU G, 1988, ONCOGENE, V3, P329; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SEERDOF K, 1987, EMBO J, V6, P139; SMITH KT, 1989, ONCOGENE, V4, P409; SMITH KT, 1988, VIROLOGY, V164, P39, DOI 10.1016/0042-6822(88)90617-4; SMITH KT, 1989, IN PRESS UCLA S PAPI; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANDIDOS DA, 1984, TRANSCRIPTION TRANSL, P1; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0	38	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					303	308						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2156207				2022-12-17	WOS:A1990CW41500007
J	FORREST, D; MUNOZ, A; RAYNOSCHEK, C; VENNSTROM, B; BEUG, H				FORREST, D; MUNOZ, A; RAYNOSCHEK, C; VENNSTROM, B; BEUG, H			REQUIREMENT FOR THE C-TERMINAL DOMAIN OF THE V-ERBA ONCOGENE PROTEIN FOR BIOLOGICAL FUNCTION AND TRANSCRIPTIONAL REPRESSION	ONCOGENE			English	Article									KAROLINSKA INST,CTR MOLEC BIOL,DEPT MOLEC BIOL,S-10401 STOCKHOLM 60,SWEDEN; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; UNIV AUTONOMA MADRID,FAC MED,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Karolinska Institutet; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Autonomous University of Madrid			Munoz, Alberto/O-6393-2014	Munoz, Alberto/0000-0003-3890-4251				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BENTZEN D, 1987, MOL CELL BIOL, V7, P2416; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1981, VIROLOGY, V111, P201, DOI 10.1016/0042-6822(81)90665-6; BEUG H, 1980, P NATL ACAD SCI-BIOL, V77, P6683, DOI 10.1073/pnas.77.11.6683; BEUG H, 1985, MODERN TRENDS HUMAN, V6, P290; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FREAKE HC, 1988, MOL ENDOCRINOL, V2, P986, DOI 10.1210/mend-2-10-986; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOROWITZ ZD, 1989, MOL ENDOCRINOL, V3, P148, DOI 10.1210/mend-3-1-148; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KAHN P, 1986, 12 S COMP RES LEUK R; KIM HRC, 1988, MOL CELL BIOL, V8, P4416, DOI 10.1128/MCB.8.10.4416; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; Oppenheimer J. H., 1983, MOL BASIS THYROID HO; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VENNSTROM B, 1980, J VIROL, V36, P575; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	49	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					309	316						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1969136				2022-12-17	WOS:A1990CW41500008
J	DE, BK; SRINIVASAN, A				DE, BK; SRINIVASAN, A			DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND HUMAN LYMPHOTROPIC VIRUS (HTLV) TYPE-I OR TYPE-II DUAL INFECTIONS BY POLYMERASE CHAIN-REACTION	ONCOGENE			English	Note									WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute	DE, BK (corresponding author), CTR DIS CONTROL,RETROVIRUS DIS BRANCH,ATLANTA,GA 30333, USA.							BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BARTHOLOMEW C, 1987, JAMA-J AM MED ASSOC, V257, P2604, DOI 10.1001/jama.257.19.2604; BLASER MJ, 1986, REV INFECT DIS, V8, P21; CARMAN WF, 1989, J VIROL METHODS, V23, P272; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CURRAN JW, 1985, SCIENCE, V229, P1352, DOI 10.1126/science.2994217; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GAZDAR AF, 1980, BLOOD, V55, P409; GETCHELL JP, 1987, J INFECT DIS, V155, P612, DOI 10.1093/infdis/155.4.612; GOLDE DW, 1978, BLOOD, V52, P1068; HOXIE JA, 1985, SCIENCE, V229, P1400, DOI 10.1126/science.2994222; KALYANARAMAN VS, 1985, EMBO J, V4, P1455, DOI 10.1002/j.1460-2075.1985.tb03802.x; KANNER SB, 1987, J INFECT DIS, V155, P617, DOI 10.1093/infdis/155.4.617; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOBAYASHI N, 1984, EMBO J, V3, P1339, DOI 10.1002/j.1460-2075.1984.tb01974.x; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KWOK S, 1988, J INFECT DIS, V158, P1193, DOI 10.1093/infdis/158.6.1193; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; Maniatis T., 1982, MOL CLONING; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS G, 1988, HUMAN RETROVIRUSES A; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; RANDO RF, 1987, ONCOGENE, V1, P13; ROBERGUROFF M, 1987, JAMA-J AM MED ASSOC, V255, P3133; ROSENBLATT JD, 1988, SEMIN HEMATOL, V25, P230; SCHOCHETMAN G, 1988, J INFECT DIS, V158, P1154, DOI 10.1093/infdis/158.6.1154; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SRINIVASAN A, 1988, ARCH VIROL, V98, P135; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0	35	28	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1533	1535						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2594369				2022-12-17	WOS:A1989CB65900019
J	DASGUPTA, P; LINNENBACH, AJ; GIACCIA, AJ; STAMATO, TD; REDDY, EP				DASGUPTA, P; LINNENBACH, AJ; GIACCIA, AJ; STAMATO, TD; REDDY, EP			MOLECULAR-CLONING OF THE BREAKPOINT REGION ON CHROMOSOME-6 IN CUTANEOUS MALIGNANT-MELANOMA - EVIDENCE FOR DELETION IN THE C-MYB LOCUS AND TRANSLOCATION OF A SEGMENT OF CHROMOSOME-12	ONCOGENE			English	Article									WISTAR INST, 36TH ST SPRUCE, PHILADELPHIA, PA 19104 USA	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA044463, P01CA025875] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44463, CA 25875] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANSUBEL FM, 1987, CURRENT PROTOCOLS MO, P221; BALABAN G, 1984, CANCER GENET CYTOGEN, V11, P429, DOI 10.1016/0165-4608(84)90024-4; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BECHER R, 1983, CANCER RES, V43, P5010; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; GIACCIA AJ, 1989, UNPUB; GROFFEN J, 1989, PROG NUCLEIC ACID RE, V36, P281; HALUSKA FG, 1989, PROG NUCLEIC ACID RE, V36, P269; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HERLYN M, 1987, LAB INVEST, V56, P461; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; LIOTTA LA, 1987, PIGM CELL RES, V1, P5, DOI 10.1111/j.1600-0749.1987.tb00528.x; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MANIATIS T, 1982, MOL CLONING LABORATO, P109; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SMITH HO, 1976, NUCLEIC ACIDS RES, V3, P2387, DOI 10.1093/nar/3.9.2387; TRENT JM, 1989, CANCER RES, V49, P420	23	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1989	4	10					1201	1205						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2677917				2022-12-17	WOS:A1989AU50800006
J	MORELLO, D; ASSELIN, C; LAVENU, A; MARCU, KB; BABINET, C				MORELLO, D; ASSELIN, C; LAVENU, A; MARCU, KB; BABINET, C			TISSUE-SPECIFIC POST-TRANSCRIPTIONAL REGULATION OF C-MYC EXPRESSION IN NORMAL AND H-2K/HUMAN C-MYC TRANSGENIC MICE	ONCOGENE			English	Article									SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	MORELLO, D (corresponding author), INST PASTEUR,UNITE GENET MAMMIFERES,DEPT IMMUNOL,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.				NCI NIH HHS [CA 36246] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036246] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; ASSELIN C, 1989, IN PRESS ONC RES; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BREGEGERE F, 1981, NATURE, V292, P78, DOI 10.1038/292078a0; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1988, ONCOGENE, V3, P387; FAUSTO N, 1987, S FUNDAM CANCER RES, V39, P69; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MARCU KB, 1986, CURR TOP MICROBIOL, V132, P345; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MORELLO D, 1989, ONCOGENE RES, V4, P111; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PANDURO A, 1987, GENE DEV, V1, P1172, DOI 10.1101/gad.1.10.1172; PAUL J, 1969, CELL TISSUE KINET, V2, P283, DOI 10.1111/j.1365-2184.1969.tb00238.x; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; SCHNEIDERSCHAULIES J, 1987, EUR J IMMUNOL, V17, P713, DOI 10.1002/eji.1830170521; STARNAUD R, 1988, ONCOGENE, V3, P553; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	45	28	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					955	961						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668846				2022-12-17	WOS:A1989AJ29700002
J	BEIMLING, P; MOELLING, K				BEIMLING, P; MOELLING, K			ISOLATION AND CHARACTERIZATION OF THE TAX PROTEIN OF HTLV-I	ONCOGENE			English	Note									MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,D-1000 BERLIN 33,FED REP GER	Max Planck Society								ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN ISY, 1985, SCIENCE, V230, P570, DOI 10.1126/science.2996140; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUHISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277; GALLO R, 1988, NATURE, V333, P504, DOI 10.1038/333504a0; GERSTEN DM, 1978, J IMMUNOL METHODS, V24, P305, DOI 10.1016/0022-1759(78)90133-3; GILMOUR DS, 1985, MOL CELL BIOL, V5, P2009, DOI 10.1128/MCB.5.8.2009; GOH WC, 1985, SCIENCE, V227, P1227, DOI 10.1126/science.2983419; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLBROOK NJ, 1984, NUCLEIC ACIDS RES, V12, P5005, DOI 10.1093/nar/12.12.5005; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KIYOKAWA T, 1985, VIROLOGY, V147, P462, DOI 10.1016/0042-6822(85)90149-7; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE TH, 1984, SCIENCE, V226, P57, DOI 10.1126/science.6089350; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545	43	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					511	516						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2785666				2022-12-17	WOS:A1989U567700017
J	BOS, TJ; RAUSCHER, FJ; CURRAN, T; VOGT, PK				BOS, TJ; RAUSCHER, FJ; CURRAN, T; VOGT, PK			THE CARBOXY TERMINUS OF THE VIRAL JUN ONCOPROTEIN IS REQUIRED FOR COMPLEX-FORMATION WITH THE CELLULAR FOS PROTEIN	ONCOGENE			English	Article									UNIV SO CALIF,SCH MED,DEPT MICROBIOL,2011 ZONAL AVE,HMR 401,LOS ANGELES,CA 90033; ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110	University of Southern California			Curran, Tom/C-1164-2008; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Curran, Tom/F-5234-2018	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Vogt, Peter K/0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [F32CA008411, R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564, CA 08411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BALL AR, 1988, IN PRESS COLD SPRING, V53; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1988, IN PRESS COLD SPRING, V53; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, IN PRESS ONCOGENE; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0	22	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					123	126						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2494630				2022-12-17	WOS:A1989U567500001
J	WEISINGER, G; REMMERS, EF; HEARING, P; MARCU, KB				WEISINGER, G; REMMERS, EF; HEARING, P; MARCU, KB			MULTIPLE NEGATIVE ELEMENTS UPSTREAM OF THE MURINE C-MYC GENE SHARE NUCLEAR FACTOR BINDING-SITES WITH SV40 AND POLYOMA ENHANCERS	ONCOGENE			English	Article									SUNY STONY BROOK, DEPT BIOCHEM, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Remmers, Elaine F/0000-0002-9522-1249	NCI NIH HHS [NCI CA36246] Funding Source: Medline; NCPDCID CDC HHS [NCI-44673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036246] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCPDCID CDC HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; CREMISI C, 1986, J VIROL, V59, P761, DOI 10.1128/JVI.59.3.761-763.1986; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; IRANI MH, 1983, CELL, V32, P783, DOI 10.1016/0092-8674(83)90064-8; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADESCH T, 1986, NUCLEIC ACIDS RES, V14, P8209, DOI 10.1093/nar/14.20.8209; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; LANG RB, 1982, NUCLEIC ACIDS RES, V10, P611, DOI 10.1093/nar/10.2.611; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJUMDAR A, 1984, P NATL ACAD SCI-BIOL, V81, P6100, DOI 10.1073/pnas.81.19.6100; Maniatis T., 1982, MOL CLONING; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MOSTHAF L, 1985, NATURE, V315, P597, DOI 10.1038/315597a0; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; Ptashne M., 1986, A GENETIC SWITCH; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SASSONECORSI P, 1987, ONCOGENE RES, V1, P113; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STRUHL K, 1985, NATURE, V317, P822, DOI 10.1038/317822a0; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; WEINBERGER J, 1988, MOL CELL BIOL, V8, P988, DOI 10.1128/MCB.8.2.988; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	51	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1988	3	6					635	646						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577865				2022-12-17	WOS:A1988R646000003
J	BARSAGI, D; GOMPERTS, BD				BARSAGI, D; GOMPERTS, BD			STIMULATION OF EXOCYTOTIC DE-GRANULATION BY MICROINJECTION OF THE RAS ONCOGENE PROTEIN INTO RAT MAST-CELLS	ONCOGENE			English	Article									UNIV LONDON UNIV COLL,DEPT EXPTL PATHOL,LONDON WC1E 6JJ,ENGLAND	University of London; University College London	BARSAGI, D (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [R01CA039811] Funding Source: NIH RePORTER; NCI NIH HHS [CA07896, CA39811] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CAPON DJ, 1982, NATURE, V304, P479; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOMPERTS BD, 1983, BIOCHEM J, V210, P737, DOI 10.1042/bj2100737; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HORSFIELD GI, 1965, J PATHOL BACTERIOL, V90, P599, DOI 10.1002/path.1700900228; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; KAGAYAMA M, 1974, J CELL BIOL, V62, P519, DOI 10.1083/jcb.62.2.519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUNOFF D, 1973, J CELL BIOL, V57, P252; LAWSON D, 1977, J CELL BIOL, V72, P242, DOI 10.1083/jcb.72.2.242; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MUELLER R, 1982, NATURE, V299, P640; NEUMANSILBERBERG FS, 1984, CELL, V37, P1027; PAPAGEORGE A, 1982, J VIROL, V44, P509, DOI 10.1128/JVI.44.2.509-519.1982; PAPAGEORGE AG, 1984, MOL CELL BIOL, V4, P23, DOI 10.1128/MCB.4.1.23; PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; PREISS J, 1986, J BIOL CHEM, V261, P8597; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; ROHLICH P, 1971, J CELL BIOL, V51, P465, DOI 10.1083/jcb.51.2.465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SWANSON ME, 1986, J CELL BIOL, V103, P485, DOI 10.1083/jcb.103.2.485; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WANG K, 1982, METHOD ENZYMOL, V85, P514; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WONG G, 1986, CANCER RES, V46, P6029; YAMADA K, 1987, BIOCHEM J, V247, P95, DOI 10.1042/bj2470095	57	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					463	469						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078954				2022-12-17	WOS:A1988Q773900016
J	BADING, H; GERDES, J; SCHWARTING, R; STEIN, H; MOELLING, K				BADING, H; GERDES, J; SCHWARTING, R; STEIN, H; MOELLING, K			NUCLEAR AND CYTOPLASMIC DISTRIBUTION OF CELLULAR MYB PROTEIN IN HUMAN HEMATOPOIETIC-CELLS EVIDENCED BY MONOCLONAL-ANTIBODY	ONCOGENE			English	Article									MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,D-1000 BERLIN 33,FED REP GER; FREE UNIV BERLIN,KLINIKUM STEGLITZ,INST PATHOL,D-1000 BERLIN 45,FED REP GER	Max Planck Society; Free University of Berlin								ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BADING H, 1987, ONCOGENE, V1, P395; BADING H, 1987, MODERN TRENDS HUMAN, V7, P488; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; CRAIG RW, 1984, CANCER RES, V44, P442; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; ENGLEMAN EG, 1981, J IMMUNOL, V127, P2124; GERDES J, 1984, J IMMUNOL, V133, P1710; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GROSSO LE, 1984, BIOCHEM BIOPH RES CO, V119, P473, DOI 10.1016/S0006-291X(84)80273-9; HABESHAW JA, 1983, LANCET, V1, P498; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KADIN ME, 1986, BLOOD, V68, P1042; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLINMAN DM, 1986, J EXP MED, V163, P1292, DOI 10.1084/jem.163.5.1292; MAVILIO F, 1986, P NATL ACAD SCI USA, V83, P4394, DOI 10.1073/pnas.83.12.4394; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; PENMAN S, 1969, FUNDAMENTAL TECHNIQU, P35; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STEIN H, 1984, ADV CANCER RES, V42, P67, DOI 10.1016/S0065-230X(08)60456-X; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, LAB INVEST, V52, P676; STEIN H, 1985, BLOOD, V66, P848; Stein H, 1986, Verh Dtsch Ges Pathol, V70, P127; STEIN H, 1985, RECENT ADV HAEMATOLO, V4, P127; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	48	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					257	265						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060791				2022-12-17	WOS:A1988Q436700003
J	CARDIFF, RD; GUMERLOCK, PH; SOONG, MM; DANDEKAR, S; BARRY, PA; YOUNG, LJT; MEYERS, FJ				CARDIFF, RD; GUMERLOCK, PH; SOONG, MM; DANDEKAR, S; BARRY, PA; YOUNG, LJT; MEYERS, FJ			C-H-RAS-1 EXPRESSION IN 7,12-DIMETHYL BENZANTHRACENE-INDUCED BALB/C MOUSE MAMMARY HYPERPLASIAS AND THEIR TUMORS	ONCOGENE			English	Article									UNIV CALIF DAVIS,SACRAMENTO MED CTR,MED CTR,DEPT INTERNAL MED,SACRAMENTO,CA 95817	University of California System; University of California Davis	CARDIFF, RD (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT PATHOL,DAVIS,CA 95616, USA.				NATIONAL CANCER INSTITUTE [R01CA036493] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA36493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHLEY RL, 1982, J NATL CANCER I, V69, P639; ASHLEY RL, 1980, CANCER RES, V40, P4232; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BLAIR PB, 1962, BIOLOGICAL INTERACTI, P371; CARDIFF RD, 1977, CANCER, V39, P2734, DOI 10.1002/1097-0142(197706)39:6<2734::AID-CNCR2820390661>3.0.CO;2-U; CARDIFF RD, 1984, ADV CANCER RES, V42, P167, DOI 10.1016/S0065-230X(08)60458-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DELLAPENNA D, 1986, ANAL BIOCHEM, V152, P329, DOI 10.1016/0003-2697(86)90417-3; DEOME KB, 1959, CANCER RES, V19, P515; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DIPPLE A, 1979, CANCER RES, V39, P1154; DIPPLE A, 1978, CHEM-BIOL INTERACT, V20, P17, DOI 10.1016/0009-2797(78)90077-7; DIPPLE A, 1983, CANCER RES, V43, P4132; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FAULKIN LJ, 1966, J NATL CANCER I, V36, P289; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARDNER MB, 1980, J NATL CANCER I, V64, P1251; GOODMAN JI, 1986, TIPS, P354; GRAHAM R, 1976, VIROLOGY, V52, P456; GUMERLOCK PH, 1988, UNPUB J IMMUNOLOGIC; HARPER JR, 1986, MOL CELL BIOL, V6, P3144, DOI 10.1128/MCB.6.9.3144; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; IYER AP, 1981, J NATL CANCER I, V66, P893; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MEDINA D, 1976, CANCER RES, V36, P2589; MEDINA D, 1978, BREAST CANCER, V2, P47; MEDINA D, 1973, METHOD CANCER RES, V7, P3; MILLER EC, 1976, CHEM CARCINOGENS, P737; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; PATHAK VK, 1987, J NATL CANCER I, V78, P327; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WISER MF, 1986, ANAL BIOCHEM, V155, P71, DOI 10.1016/0003-2697(86)90226-5; WONG G, 1986, CANCER RES, V46, P6029; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	50	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					205	213						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842717				2022-12-17	WOS:A1988Q053400012
J	BROWNELL, E; FELL, HP; TUCKER, PW; VANKESSEL, AHMG; HAGEMEIJER, A; RICE, NR				BROWNELL, E; FELL, HP; TUCKER, PW; VANKESSEL, AHMG; HAGEMEIJER, A; RICE, NR			REGIONAL LOCALIZATION OF THE HUMAN C-REL LOCUS USING TRANSLOCATION CHROMOSOME ANALYSIS	ONCOGENE			English	Article									ONCOGEN,SEATTLE,WA 98121; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,GRAD PROGRAM IMMUNOL,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT MICROBIOL,DALLAS,TX 75235; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Erasmus University Rotterdam	BROWNELL, E (corresponding author), NCI,FREDERICK CANC RES FACIL,BRI BASIC RES PROGRAM,FREDERICK,MD 21701, USA.		van Kessel, Ad Geurts/A-2810-2010		NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AURIAS A, 1986, HUM GENET, V72, P210, DOI 10.1007/BF00291879; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; CLAFLIN JL, 1978, IMMUNOGENETICS, V6, P379, DOI 10.1007/BF01563929; Davis MM, 1985, ATAXIA TELANGIECTASI, P197; DENDUNNEN JT, 1985, HUM GENET, V70, P217, DOI 10.1007/BF00273445; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; FELL HP, 1986, SCIENCE, V232, P491, DOI 10.1126/science.3961491; GIBSON DM, 1978, J IMMUNOL, V121, P1585; GOTTLIEB PD, 1974, J EXP MED, V140, P1432, DOI 10.1084/jem.140.5.1432; HERZOG NK, 1986, J VIROL, V57, P371, DOI 10.1128/JVI.57.1.371-375.1986; ITAKURA K, 1972, TRANSPLANTATION, V13, P239, DOI 10.1097/00007890-197203000-00007; LARSON RA, 1987, P NATL ACAD SCI US, V84, P2970; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; PETTENATI MJ, 1987, P NATL ACAD SCI USA, V84, P2970, DOI 10.1073/pnas.84.9.2970; SUKHATME VP, 1985, J EXP MED, V161, P429, DOI 10.1084/jem.161.2.429; YUNIS JJ, 1987, ONCOGENE, V1, P59; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	20	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					527	529						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3287280				2022-12-17	WOS:A1988N434800016
J	STORER, RD; ALLEN, HL; KRAYNAK, AR; BRADLEY, MO				STORER, RD; ALLEN, HL; KRAYNAK, AR; BRADLEY, MO			RAPID INDUCTION OF AN EXPERIMENTAL METASTATIC PHENOTYPE IN 1ST PASSAGE RAT EMBRYO CELLS BY COTRANSFECTION OF EJ C-HA-RAS AND C-MYC ONCOGENES	ONCOGENE			English	Article											STORER, RD (corresponding author), MERCK SHARP & DOHME RES LABS,W POINT,PA 19486, USA.							BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; FOULDS L, 1964, CELLULAR CONTROL MEC, P242; Kuhn T, 2012, STRUCTURE SCI REVOLU, V4th, DOI DOI 10.7208/CHICAGO/9780226458144.001.0001; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; MANIATIS T, 1983, MOL CLONING LABORATO; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STORER RD, 1986, CANCER RES, V46, P1458; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	18	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					141	147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285293				2022-12-17	WOS:A1988M086000007
J	OPPER, M; SCHULER, G; MECHLER, BM				OPPER, M; SCHULER, G; MECHLER, BM			HEREDITARY SUPPRESSION OF LETHAL (2) GIANT LARVAE MALIGNANT-TUMOR DEVELOPMENT IN DROSOPHILA BY GENE-TRANSFER	ONCOGENE			English	Article									UNIV MAINZ, INST GENET, POB 3980, D-6500 MAINZ, GERMANY	Johannes Gutenberg University of Mainz								Bridges CB, 1938, J HERED, V29, P11, DOI 10.1093/oxfordjournals.jhered.a104399; BRYANT PJ, 1984, Q REV BIOL, V59, P387, DOI 10.1086/414040; CLINE TW, 1976, GENETICS S16, V83; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; GATEFF E, 1969, NATL CANCER I MONOGR, P365; HADORN E, 1955, LETHALFAKTOREN; HAENLIN M, 1985, CELL, V40, P827, DOI 10.1016/0092-8674(85)90342-3; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LEWIS EB, 1945, GENETICS, V30, P137; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LUTZELSCHWAB R, 1986, MOL GEN GENET, V204, P58, DOI 10.1007/BF00330187; Maniatis T., 1982, MOL CLONING; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHERER G, 1982, J MOL BIOL, V157, P435, DOI 10.1016/0022-2836(82)90470-3; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917	27	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1987	1	2					91	96						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	2830580				2022-12-17	WOS:A1987J635200001
J	Huo, FC; Zhu, ZM; Zhu, WT; Du, QY; Liang, J; Mou, J				Huo, Fu-Chun; Zhu, Zhi-Man; Zhu, Wen-Tao; Du, Qiu-Ying; Liang, Jia; Mou, Jie			METTL3-mediated m(6)A methylation of SPHK2 promotes gastric cancer progression by targeting KLF2	ONCOGENE			English	Article								N6-methyladenosine (m(6)A) RNA methylation is profoundly involved in epigenetic regulation, especially for carcinogenesis and tumor progression. Mounting evidence suggests that methyltransferase METTL3 regulates malignant behaviors of gastric cancer (GC). However, the clinical significance and biological implication of SPHK2 and its related m(6)A modification in GC remain unclear. In this study, quantitative real-time PCR (qRT-PCR), western blot and immunohistochemistry were utilized to detect the expression profiles and prognostic significance of SPHK2 in GC. Here, we showed that increased SPHK2 was signified a poor prognosis of GC patients. Phosphorylation and ubiquitination assays were used to investigate the possible mechanisms of SPHK2-mediated KLF2 expression. SPHK2 can promote the phosphorylation of KLF2, which triggers the ubiquitination and degradation of KLF2 protein in GC. Methylated RNA immunoprecipitation (MeRIP) was performed to uncover the m(6)A modification of SPHK2 mRNA. METTL3 promotes translation of SPHK2 mRNA via an m(6)A-YTHDF1-dependent manner. Functionally, SPHK2 facilitates GC cell proliferation, migration and invasion by inhibiting KLF2 expression. SPHK2/KLF2 regulates the cell proliferation, migration, and invasion induced by METTL3 in GC. Overall, our findings reveal that METTL3-mediated m(6)A modification of SPHK2 contributes to GC progression, which extends the understanding of the importance m(6)A methylation in GC and represents a potential target for GC therapy.	[Huo, Fu-Chun; Zhu, Wen-Tao; Du, Qiu-Ying; Liang, Jia; Mou, Jie] Xuzhou Med Univ, Dept Pathol, Xuzhou, Jiangsu, Peoples R China; [Zhu, Zhi-Man] Jiangsu Coll Nursing, Dept Basic Med, Huaian, Peoples R China; [Mou, Jie] Xuzhou Med Univ, Jiangsu Key Lab New Drug & Clin Pharm, Xuzhou, Jiangsu, Peoples R China; [Mou, Jie] Xuzhou Med Univ, Sch Pharm, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University	Mou, J (corresponding author), Xuzhou Med Univ, Dept Pathol, Xuzhou, Jiangsu, Peoples R China.; Mou, J (corresponding author), Xuzhou Med Univ, Jiangsu Key Lab New Drug & Clin Pharm, Xuzhou, Jiangsu, Peoples R China.; Mou, J (corresponding author), Xuzhou Med Univ, Sch Pharm, Xuzhou, Jiangsu, Peoples R China.	mou.jie@xzhmu.edu.cn						Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Bialkowska AB, 2017, DEVELOPMENT, V144, P737, DOI 10.1242/dev.145441; Bornschein J, 2014, FRONT BIOSCI-LANDMRK, V19, P312, DOI 10.2741/4210; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Britten CD, 2017, CLIN CANCER RES, V23, P4642, DOI 10.1158/1078-0432.CCR-16-2363; Chen Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1671-5; Chu JH, 2014, BIOMED PHARMACOTHER, V68, P1089, DOI 10.1016/j.biopha.2014.10.001; Costamagna G, 2012, ANN ITAL CHIR, V83, P183; Dong JL, 2018, BIOMED PHARMACOTHER, V105, P922, DOI 10.1016/j.biopha.2018.06.052; Hasanifard L, 2019, J CELL PHYSIOL, V234, P8162, DOI 10.1002/jcp.27612; He HB, 2019, BIOCHEM BIOPH RES CO, V517, P581, DOI 10.1016/j.bbrc.2019.07.058; Huo FC, 2019, CELL DEATH DIFFER, V26, P994, DOI 10.1038/s41418-018-0178-4; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Kao SH, 2017, ONCOGENE, V36, P5916, DOI 10.1038/onc.2017.302; Li XB, 2018, CANCER GENE THER, V25, P58, DOI 10.1038/s41417-017-0007-9; Lian YF, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0333-9; Liang JY, 2018, J CONTROL RELEASE, V286, P348, DOI 10.1016/j.jconrel.2018.07.039; Lin S, 2019, OPEN MED-WARSAW, V14, P25, DOI 10.1515/med-2019-0005; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu H, 2016, LIFE SCI, V151, P23, DOI 10.1016/j.lfs.2016.02.098; Liu W, 2016, TUMOR BIOL, V37, P6331, DOI 10.1007/s13277-015-4480-1; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; Marfe G, 2015, MINI-REV MED CHEM, V15, P300, DOI 10.2174/1389557515666150227105415; Matsubara J, 2011, ONCOLOGY-BASEL, V81, P291, DOI 10.1159/000334462; Pham DH, 2014, ONCOGENE, V33, P5559, DOI 10.1038/onc.2013.502; Qiu WW, 2016, ONCOTARGET, V7, P39907, DOI 10.18632/oncotarget.9530; Rane MJ, 2019, EBIOMEDICINE, V40, P743, DOI 10.1016/j.ebiom.2019.01.021; Shi WN, 2017, ONCOTARGET, V8, P39605, DOI 10.18632/oncotarget.17174; Shimada H, 2014, GASTRIC CANCER, V17, P26, DOI 10.1007/s10120-013-0259-5; Sun E, 2016, TUMOR BIOL, V37, P473, DOI 10.1007/s13277-015-3818-z; Wang BS, 2018, AM J MENS HEALTH, V13, DOI 10.1177/1557988318816907; Wang L, 2019, EUR REV MED PHARMACO, V23, P201, DOI [10.26355/eurrev_201908_18648, 10.26355/eurrev_201908_1864d]; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang QQ, 2019, AM J TRANSL RES, V11, P4895; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wei J, 2016, WORLD J GASTROENTERO, V22, P7478, DOI 10.3748/wjg.v22.i33.7478; Xiao GQ, 2018, ONCOL RES, V26, P1183, DOI 10.3727/096504018X15151495109394; Xie P, 2011, BIOCHEM BIOPH RES CO, V407, P254, DOI 10.1016/j.bbrc.2011.03.016; Xue KC, 2017, EUR REV MED PHARMACO, V21, P3794; Xun C, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0205-y; Yang DD, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00115; Yuan XH, 2020, EUR REV MED PHARMACO, V24, P673, DOI 10.26355/eurrev_202001_20044; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033	45	27	27	3	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2968	2981		10.1038/s41388-021-01753-1	http://dx.doi.org/10.1038/s41388-021-01753-1		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33758320				2022-12-17	WOS:000631804500001
J	Chen, T; Wang, XL; Li, C; Zhang, HW; Liu, Y; Han, DW; Li, YM; Li, Z; Luo, D; Zhang, N; Zheng, MZ; Chen, B; Wang, LJ; Zhao, WJ; Yang, QF				Chen, Tong; Wang, Xiaolong; Li, Chen; Zhang, Hanwen; Liu, Ying; Han, Dianwen; Li, Yaming; Li, Zheng; Luo, Dan; Zhang, Ning; Zheng, Meizhu; Chen, Bing; Wang, Lijuan; Zhao, Wenjing; Yang, Qifeng			CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation	ONCOGENE			English	Article							NUCLEAR FACTOR-I; CIRCULAR RNA; PROLIFERATION; BINDING; INTERACTS; ROLES	Emerging evidence has demonstrated that circular RNAs (circRNAs) play critical roles in the development and progression of human cancer. However, the biological functions and underlying mechanisms of circRNAs in triple-negative breast cancer (TNBC) remain to be investigated. In our present study, we found that the novel circRNA circHIF1A was significantly overexpressed in breast cancer tissues and that it was associated with metastasis, poor prognosis, and the TNBC subtype. Gain- and loss-of-function experiments were conducted to investigate the biological roles of circHIF1A in TNBC. Overexpression of circHIF1A significantly promoted TNBC growth and metastasis in vitro and in vivo, while knockdown of circHIF1A exerted the opposite effects. Mechanistically, circHIF1A modulated the expression and translocation of NFIB through posttranscriptional and posttranslational modifications, resulting in the activation of the AKT/STAT3 signaling pathway and inhibition of P21. The RNA binding protein FUS could regulate the biogenesis of circHIF1A by interacting with the flanking intron, and FUS was transcriptionally regulated by NFIB, thus forming the circHIF1A/NFIB/FUS positive feedback loop. Moreover, circHIF1A could be packaged into exosomes and was upregulated in the plasma of breast cancer patients. Our findings indicated that circHIF1A played a critical role in the growth and metastasis of TNBC via a positive feedback loop and that circHIF1A could be a promising biomarker for breast cancer diagnosis and a potential therapeutic target for TNBC treatment.	[Chen, Tong; Wang, Xiaolong; Li, Chen; Zhang, Hanwen; Liu, Ying; Han, Dianwen; Li, Yaming; Li, Zheng; Luo, Dan; Zhang, Ning; Yang, Qifeng] Shandong Univ, Qilu Hosp, Dept Breast Surg, Gen Surg, Jinan, Shandong, Peoples R China; [Zheng, Meizhu] Shandong First Med Univ, Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Breast Surg, Jinan, Shandong, Peoples R China; [Chen, Bing; Wang, Lijuan; Zhao, Wenjing; Yang, Qifeng] Shandong Univ, Pathol Tissue Bank, Qilu Hosp, Jinan, Shandong, Peoples R China; [Yang, Qifeng] Shandong Univ, Res Inst Breast Canc, Jinan, Shandong, Peoples R China	Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong University; Shandong University	Yang, QF (corresponding author), Shandong Univ, Qilu Hosp, Dept Breast Surg, Gen Surg, Jinan, Shandong, Peoples R China.; Yang, QF (corresponding author), Shandong Univ, Pathol Tissue Bank, Qilu Hosp, Jinan, Shandong, Peoples R China.; Yang, QF (corresponding author), Shandong Univ, Res Inst Breast Canc, Jinan, Shandong, Peoples R China.	qifengy_sdu@163.com	Zhang, Ning/GNP-1966-2022; yang, qiang/GYJ-0971-2022; Zhang, Ning/GOJ-8058-2022; Zhang, Hanwen/CAG-1998-2022	Zhang, Ning/0000-0002-6430-4236; Li, Chen/0000-0001-6994-1253; Yang, Qifeng/0000-0003-0576-8513	National Key Research and Development Program [2020YFA0712400, 2018YFC0114705]; Special Foundation for Taishan Scholars [ts20190971]; National Natural Science Foundation of China [81672613, 81874119, 82072912, 82004122]; Shandong Provincial Natural Science Foundation, China [ZR2019LZL003, ZR201911010260, ZR201911050391]; Special Support Plan for National High Level Talents (Ten Thousand Talents Program) [W01020103]; Foundation from Clinical Research Center of Shandong University [2020SDUCRCA015]; Qilu Hospital Clinical New Technology Developing Foundation [2018-7, 2019-3]	National Key Research and Development Program; Special Foundation for Taishan Scholars; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation, China(Natural Science Foundation of Shandong Province); Special Support Plan for National High Level Talents (Ten Thousand Talents Program); Foundation from Clinical Research Center of Shandong University; Qilu Hospital Clinical New Technology Developing Foundation	This work was supported by National Key Research and Development Program (No. 2020YFA0712400; No. 2018YFC0114705), Special Foundation for Taishan Scholars (No. ts20190971), National Natural Science Foundation of China (No. 81672613; No. 81874119; No. 82072912; No. 82004122), Shandong Provincial Natural Science Foundation, China (No. ZR2019LZL003, No. ZR201911010260, No. ZR201911050391), Special Support Plan for National High Level Talents (Ten Thousand Talents Program W01020103), Foundation from Clinical Research Center of Shandong University (No.2020SDUCRCA015), Qilu Hospital Clinical New Technology Developing Foundation (No. 2018-7; No. 2019-3).	Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Chan SH, 2014, ONCOGENE, V33, P4496, DOI 10.1038/onc.2014.10; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; de Rinaldis E, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-643; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dong YP, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0370-2; Du WW, 2017, EUR HEART J, V38, P1402, DOI 10.1093/eurheartj/ehw001; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Errichelli L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14741; Fanale D, 2018, ADV EXP MED BIOL, V1087, P109, DOI 10.1007/978-981-13-1426-1_9; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hentze MW, 2013, EMBO J, V32, P923, DOI 10.1038/emboj.2013.53; Hong HQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2183-z; Hu YP, 2019, AGING-US, V11, P8068, DOI 10.18632/aging.102122; Ji DG, 2019, BIOCHEM BIOPH RES CO, V512, P176, DOI 10.1016/j.bbrc.2019.03.049; Jin B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01173-x; Kobayashi H, 2016, BBA-GENE REGUL MECH, V1859, P71, DOI 10.1016/j.bbagrm.2015.08.007; Lagier-Tourenne C, 2010, HUM MOL GENET, V19, pR46, DOI 10.1093/hmg/ddq137; Li J, 2019, J CELL BIOCHEM, V120, P7725, DOI 10.1002/jcb.28046; Li JQ, 2015, AM J CANCER RES, V5, P472; Li ZH, 2018, CANCER LETT, V432, P237, DOI 10.1016/j.canlet.2018.04.035; Liang HF, 2017, AM J CANCER RES, V7, P1566; Liu RZ, 2019, J PATHOL, V247, P186, DOI 10.1002/path.5182; Liu ZY, 2019, CANCER SCI, V110, P86, DOI 10.1111/cas.13833; Liu ZH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1287-1; Moon HG, 2011, MOL ONCOL, V5, P538, DOI 10.1016/j.molonc.2011.08.002; Pan B, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01096; Sang YT, 2019, MOL THER, V27, P1638, DOI 10.1016/j.ymthe.2019.05.011; Sato S, 2005, GASTROENTEROLOGY, V129, P1225, DOI 10.1053/j.gastro.2005.07.025; Shao SQ, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109582; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Wang AH, 2019, EUR REV MED PHARMACO, V23, P8310, DOI 10.26355/eurrev_201910_19142; WANG S, 2019, MOL CANCER, V18; Wu CQ, 2018, ONCOL REP, V40, P1565, DOI 10.3892/or.2018.6574; Xie MY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01208-3; Xue DW, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1072-5; Yang R, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0933-7; Yang Z, 2020, GASTRIC CANCER, V23, P449, DOI 10.1007/s10120-019-01019-6; Yang ZG, 2017, MOL THER, V25, P2062, DOI 10.1016/j.ymthe.2017.05.022; Yasuda K, 2017, J CELL BIOL, V216, P1015, DOI 10.1083/jcb.201608022; Yu T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0776-8; Zhang XO, 2016, GENOME RES, V26, P1277, DOI 10.1101/gr.202895.115; Zhang XN, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0959-5; Zhang ZR, 2018, EBIOMEDICINE, V34, P267, DOI 10.1016/j.ebiom.2018.07.036; Zheng XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01183-9	49	27	28	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2756	2771		10.1038/s41388-021-01739-z	http://dx.doi.org/10.1038/s41388-021-01739-z		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33714984				2022-12-17	WOS:000628485300004
J	Ren, SL; Gaykalova, DA; Guo, T; Favorov, AV; Fertig, EJ; Tamayo, P; Callejas-Valera, JL; Allevato, M; Gilardi, M; Santos, J; Fukusumi, T; Sakai, A; Ando, M; Sadat, S; Liu, C; Xu, GR; Fisch, KM; Wang, ZY; Molinolo, AA; Gutkind, JS; Ideker, T; Koch, WM; Califano, JA				Ren, Shuling; Gaykalova, Daria A.; Guo, Theresa; Favorov, Alexander, V; Fertig, Elana J.; Tamayo, Pablo; Callejas-Valera, Juan Luis; Allevato, Mike; Gilardi, Mara; Santos, Jessica; Fukusumi, Takahito; Sakai, Akihiro; Ando, Mizuo; Sadat, Sayed; Liu, Chao; Xu, Guorong; Fisch, Kathleen M.; Wang, Zhiyong; Molinolo, Alfredo A.; Gutkind, J. Silvio; Ideker, Trey; Koch, Wayne M.; Califano, Joseph A.			HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; INTEGRATION SITES; GENE-EXPRESSION; PROTEIN; HEAD; INHIBITION; E6; TRANSCRIPTION; REPLICATION; CARCINOMAS	The dominant paradigm for HPV carcinogenesis includes integration into the host genome followed by expression of E6 and E7 (E6/E7). We explored an alternative carcinogenic pathway characterized by episomal E2, E4, and E5 (E2/E4/E5) expression. Half of HPV positive cervical and pharyngeal cancers comprised a subtype with increase in expression of E2/E4/E5, as well as association with lack of integration into the host genome. Models of the E2/E4/E5 carcinogenesis show p53 dependent enhanced proliferation in vitro, as well as increased susceptibility to induction of cancer in vivo. Whole genomic expression analysis of the E2/E4/E5 pharyngeal cancer subtype is defined by activation of the fibroblast growth factor receptor (FGFR) pathway and this subtype is susceptible to combination FGFR and mTOR inhibition, with implications for targeted therapy.	[Ren, Shuling; Callejas-Valera, Juan Luis; Allevato, Mike; Gilardi, Mara; Santos, Jessica; Fukusumi, Takahito; Sakai, Akihiro; Ando, Mizuo; Sadat, Sayed; Liu, Chao; Wang, Zhiyong; Molinolo, Alfredo A.; Gutkind, J. Silvio; Califano, Joseph A.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Ren, Shuling] Capital Med Univ, Beijing Friendship Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Gaykalova, Daria A.; Guo, Theresa; Koch, Wayne M.] Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; [Favorov, Alexander, V; Fertig, Elana J.] Johns Hopkins Med Inst, Dept Oncol, Div Oncol Biostat, Baltimore, MD 21205 USA; [Favorov, Alexander, V] Russian Acad Sci, Vavilov Inst Gen Genet, Lab Syst Biol & Computat Genet, Moscow, Russia; [Tamayo, Pablo; Xu, Guorong; Fisch, Kathleen M.; Ideker, Trey] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Callejas-Valera, Juan Luis] Sanford Res, Canc Biol & Immunotherapies Grp, Sioux Falls, SD USA; [Califano, Joseph A.] Univ Calif San Diego, Dept Surg, Div Otolaryngol Head & Neck Surg, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Capital Medical University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Russian Academy of Sciences; Vavilov Institute of General Genetics; University of California System; University of California San Diego; Sanford Health; University of California System; University of California San Diego	Califano, JA (corresponding author), Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.; Califano, JA (corresponding author), Univ Calif San Diego, Dept Surg, Div Otolaryngol Head & Neck Surg, La Jolla, CA 92093 USA.	jcalifano@ucsd.edu	Favorov, Alexander V/K-2699-2018; Guo, Theresa/AFU-3555-2022; Gutkind, J. Silvio/J-1201-2016; Guo, Theresa/AAF-2216-2021	Favorov, Alexander V/0000-0003-2595-1091; Gutkind, J. Silvio/0000-0002-5150-4482; Tamayo, Pablo/0000-0002-9360-4668; Santos, Jessica/0000-0002-4721-2292; Allevato, Michael/0000-0003-1846-7189; Ideker, Trey/0000-0002-1708-8454; Guo, Theresa/0000-0002-1689-3275; Liu, Chao/0000-0003-2184-9102	National Institute of Dental and Craniofacial Research; NIH [P30 CA006973, R01 DE023347]; UC San Diego Clinical and Translational Research Institute Grant [UL1TR001442]; Russian Basic Research Foundation (RBRF) [17-00-00208]; Russian Academy of Sciences Project [0112-2019-0001]	National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UC San Diego Clinical and Translational Research Institute Grant; Russian Basic Research Foundation (RBRF); Russian Academy of Sciences Project	We would like to thank Dennis Young, Joseph Aguilera for valuable advice and support. This work has been supported by National Institute of Dental and Craniofacial Research and NIH (R01 DE023347, JAC), the UC San Diego Clinical and Translational Research Institute Grant (UL1TR001442, KMF), NIH (P30 CA006973, AVF), Russian Basic Research Foundation (RBRF) (17-00-00208, AVF), and Russian Academy of Sciences Project (0112-2019-0001, AVF).	Akagi K, 2014, GENOME RES, V24, P185, DOI 10.1101/gr.164806.113; Amornphimoltham P, 2008, CLIN CANCER RES, V14, P8094, DOI 10.1158/1078-0432.CCR-08-0703; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Babina IS, 2017, NAT REV CANCER, V17, P318, DOI 10.1038/nrc.2017.8; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Boulenouar S, 2010, CARCINOGENESIS, V31, P473, DOI 10.1093/carcin/bgp281; Callejas-Valera JL, 2016, CARCINOGENESIS, V37, P1014, DOI 10.1093/carcin/bgw086; Campo MS, 2010, VIROLOGY, V407, P137, DOI 10.1016/j.virol.2010.07.044; Chen ZG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020183; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Crow JM, 2012, NATURE, V486, pS12, DOI 10.1038/486S12a; Davy CE, 2002, J VIROL, V76, P9806, DOI 10.1128/JVI.76.19.9806-9818.2002; Davy C, 2009, VIROLOGY, V394, P266, DOI 10.1016/j.virol.2009.08.035; de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Egawa N, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006282; Gammoh N, 2009, ONCOGENE, V28, P2299, DOI 10.1038/onc.2009.78; Gaykalova DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093102; Gleber-Netto FO, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124762; Graham SV, 2016, J VIROL, V90, P8384, DOI 10.1128/JVI.00502-16; Graham SV, 2010, FUTURE MICROBIOL, V5, P1493, DOI [10.2217/fmb.10.107, 10.2217/FMB.10.107]; Guo T, 2016, INT J CANCER, V139, P373, DOI 10.1002/ijc.30081; Halavaty KK, 2014, VIROLOGY, V452, P223, DOI 10.1016/j.virol.2014.01.013; Iglesias-Bartolome R, 2013, CANCER DISCOV, V3, P722, DOI 10.1158/2159-8290.CD-13-0239; Iglesias-Bartolome R, 2012, CELL STEM CELL, V11, P401, DOI 10.1016/j.stem.2012.06.007; Jemal A, 2013, JNCI-J NATL CANCER I, V105, P175, DOI 10.1093/jnci/djs491; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu Y, 2016, ONCOTARGET, V7, P5852, DOI 10.18632/oncotarget.6809; Martinez-Zapien D, 2016, NATURE, V529, P541, DOI 10.1038/nature16481; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Muller Mandy, 2012, Open Virol J, V6, P173, DOI 10.2174/1874357901206010173; Muller M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002761; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Olthof NC, 2015, INT J CANCER, V136, pE207, DOI 10.1002/ijc.29112; Parfenov M, 2014, P NATL ACAD SCI USA, V111, P15544, DOI 10.1073/pnas.1416074111; Prescott EL, 2014, J VIROL, V88, P12599, DOI 10.1128/JVI.02029-14; Ranieri D, 2015, INT J CANCER, V137, P61, DOI 10.1002/ijc.29373; Rundhaug Joyce E, 2010, Cancers (Basel), V2, P436, DOI 10.3390/cancers2020436; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schwartz S, 2013, VIROLOGY, V445, P187, DOI 10.1016/j.virol.2013.04.034; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Tan CL, 2015, CELL CYCLE, V14, P1459, DOI 10.1080/15384101.2015.1021519; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Walter V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056823; Wang K, 2010, NUCLEIC ACIDS RES, V38; Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009; Wesche J, 2011, BIOCHEM J, V437, P199, DOI 10.1042/BJ20101603; Zhang LF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0361-x; Zhang YX, 2016, CLIN CANCER RES, V22, P4735, DOI 10.1158/1078-0432.CCR-16-0323	53	27	28	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6327	6339		10.1038/s41388-020-01431-8	http://dx.doi.org/10.1038/s41388-020-01431-8		AUG 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32848210	Green Published, hybrid			2022-12-17	WOS:000563171800002
J	Lin, RR; Zhan, M; Yang, LH; Wang, H; Shen, H; Huang, S; Huang, XC; Xu, SW; Zhang, ZJ; Li, WJ; Liu, Q; Shi, YS; Chen, W; Yu, JX; Wang, J				Lin, Ruirong; Zhan, Ming; Yang, Linhua; Wang, Hui; Shen, Hui; Huang, Shuai; Huang, Xince; Xu, Sunwang; Zhang, Zijie; Li, Weijian; Liu, Qiang; Shi, Yongsheng; Chen, Wei; Yu, Jianxiu; Wang, Jian			Deoxycholic acid modulates the progression of gallbladder cancer through N-6-methyladenosine-dependent microRNA maturation	ONCOGENE			English	Article							BILE-ACIDS; CHOLANGIOCYTE PROLIFERATION; NUCLEAR-RNA; MESSENGER; METABOLISM; APOPTOSIS; N6-METHYLADENOSINE; INFLAMMATION; ACTIVATION; ENDOCRINE	Bile acids (BAs), well-defined signaling molecules with diverse metabolic functions, play important roles in cellular processes associated with many cancers. As one of the most common BAs, deoxycholic acid (DCA) is originally synthesized in the liver, stored in the gallbladder, and processed in the gut. DCA plays crucial roles in various tumors; however, functions and molecular mechanisms of DCA in gallbladder cancer (GBC) still remain poorly characterized. Here, we analyzed human GBC samples and found that DCA was significantly downregulated in GBC, and reduced levels of DCA was associated with poor clinical outcome in patients with GBC. DCA treatment impeded tumor progression by halting cell proliferation. DCA decreased miR-92b-3p expression in an m(6)A-dependent posttranscriptional modification manner by facilitating dissociation of METTL3 from METTL3-METTL14-WTAP complex, which increased the protein level of the phosphatase and tensin homolog, a newly identified target of miR-92b-3p, and subsequently inactivated the PI3K/AKT signaling pathway. Our findings revealed that DCA might function as a tumor suppressive factor in GBC at least by interfering with miR-92b-3p maturation, and suggested that DCA treatment could provide a new therapeutic strategy for GBC.	[Lin, Ruirong; Zhan, Ming; Yang, Linhua; Wang, Hui; Shen, Hui; Huang, Shuai; Huang, Xince; Xu, Sunwang; Zhang, Zijie; Li, Weijian; Chen, Wei; Wang, Jian] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Biliary Pancreat Surg, Shanghai 200127, Peoples R China; [Liu, Qiang; Shi, Yongsheng] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Pathol, Shanghai 200127, Peoples R China; [Yu, Jianxiu] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China; [Yu, Jianxiu; Wang, Jian] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Basic Clin Res Ctr, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Wang, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Biliary Pancreat Surg, Shanghai 200127, Peoples R China.; Yu, JX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China.; Yu, JX; Wang, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Basic Clin Res Ctr, Shanghai 200127, Peoples R China.	Jianxiu.Yu@gmail.com; dr_wangjian@126.com		Wang, Jian/0000-0002-5335-8845; Lin, Ruirong/0000-0003-1675-8724; Zhang, ZiJie/0000-0002-2513-3091	National Natural Science Foundation of China [81974370, 81773184, 81472240]; Shanghai Outstanding Academic Leaders Plan (2016); High-Level Collaborative Innovation Team Incentive Program of Shanghai Municipal Education Commission (2018)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Outstanding Academic Leaders Plan (2016); High-Level Collaborative Innovation Team Incentive Program of Shanghai Municipal Education Commission (2018)	The authors acknowledge the grants from National Natural Science Foundation of China (81974370, 81773184, and 81472240 to JW), Shanghai Outstanding Academic Leaders Plan (2016 to JW), and High-Level Collaborative Innovation Team Incentive Program of Shanghai Municipal Education Commission (2018 to JW).	Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Alpini G, 1997, AM J PHYSIOL-GASTR L, V273, pG518, DOI 10.1152/ajpgi.1997.273.2.G518; Alpini G, 1999, GASTROENTEROLOGY, V116, P179, DOI 10.1016/S0016-5085(99)70242-8; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; Bokar JA, 1997, RNA, V3, P1233; Broeders EPM, 2015, CELL METAB, V22, P418, DOI 10.1016/j.cmet.2015.07.002; Chavez-Talavera O, 2017, GASTROENTEROLOGY, V152, P1679, DOI 10.1053/j.gastro.2017.01.055; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Cheng L, 2019, J CELL BIOCHEM, V120, P17405, DOI 10.1002/jcb.29005; Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Du YZ, 2018, NUCLEIC ACIDS RES, V46, P5195, DOI 10.1093/nar/gky156; Gafar AA, 2016, PEERJ, V4, DOI 10.7717/peerj.2445; Geula S, 2015, SCIENCE, V347, P1002, DOI 10.1126/science.1261417; Goldberg AA, 2011, ONCOTARGET, V2, P761; Graf D, 2002, GASTROENTEROLOGY, V122, P1411, DOI 10.1053/gast.2002.32976; Hohenester S, 2010, J HEPATOL, V53, P918, DOI 10.1016/j.jhep.2010.05.015; Horowitz NS, 2007, GYNECOL ONCOL, V107, P344, DOI 10.1016/j.ygyno.2007.07.072; Hou JJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1082-3; Houten SM, 2006, EMBO J, V25, P1419, DOI 10.1038/sj.emboj.7601049; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Huang WD, 2006, SCIENCE, V312, P233, DOI 10.1126/science.1121435; Hundal R, 2014, CLIN EPIDEMIOL, V6, P99, DOI 10.2147/CLEP.S37357; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jonsson AL, 2017, NAT REV CARDIOL, V14, P79, DOI 10.1038/nrcardio.2016.183; Keitel V, 2008, WORLD J GASTROENTERO, V14, P5620, DOI 10.3748/wjg.14.5620; Kim DH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12179; Konig A, 2014, J HEPATOL, V61, P867, DOI 10.1016/j.jhep.2014.05.018; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Kovacs P, 2019, CANCERS, V11, DOI 10.3390/cancers11091255; Lefebvre P, 2009, PHYSIOL REV, V89, P147, DOI 10.1152/physrev.00010.2008; Li K, 2019, FLOW MEAS INSTRUM, V69, DOI 10.1016/j.flowmeasinst.2019.101590; Li TG, 2014, PHARMACOL REV, V66, P948, DOI 10.1124/pr.113.008201; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Liu RP, 2014, HEPATOLOGY, V60, P908, DOI 10.1002/hep.27085; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Miko E, 2018, BBA-BIOENERGETICS, V1859, P958, DOI 10.1016/j.bbabio.2018.04.002; Neuschwander-Tetri BA, 2015, LANCET, V385, P956, DOI 10.1016/S0140-6736(14)61933-4; Pan T, 2013, TRENDS BIOCHEM SCI, V38, P204, DOI 10.1016/j.tibs.2012.12.006; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Pols TWH, 2011, CELL METAB, V14, P747, DOI 10.1016/j.cmet.2011.11.006; Pols TWH, 2011, J HEPATOL, V54, P1263, DOI 10.1016/j.jhep.2010.12.004; Rolo AP, 2004, TOXICOL SCI, V79, P196, DOI 10.1093/toxsci/kfh078; Shapiro H, 2018, J EXP MED, V215, P383, DOI 10.1084/jem.20171965; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stinton LM, 2012, GUT LIVER, V6, P172, DOI 10.5009/gnl.2012.6.2.172; Sun Y, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919855859; Tang W, 2019, CLIN CANCER RES, V25, P5972, DOI 10.1158/1078-0432.CCR-19-0094; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Wang X, 2016, NATURE, V534, P575, DOI 10.1038/nature18298; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wang XD, 2015, 2015 5TH INTERNATIONAL CONFERENCE ON ELECTRIC UTILITY DEREGULATION AND RESTRUCTURING AND POWER TECHNOLOGIES (DRPT 2015), P161, DOI 10.1109/DRPT.2015.7432219; Wang YQ, 2017, HEPATOLOGY, V65, P2005, DOI 10.1002/hep.29076; Wistuba II, 2004, NAT REV CANCER, V4, P695, DOI 10.1038/nrc1429; Wolpin BM, 2010, NEW ENGL J MED, V362, P1335, DOI 10.1056/NEJMe1001183; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Xu SW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13420-x; Zhang JL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09712-x; Zhang W, 2020, J CELL BIOCHEM, V121, P1998, DOI 10.1002/jcb.29434; Zhao X, 2014, CELL RES, V24, P1403, DOI 10.1038/cr.2014.151; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015	62	27	27	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4983	5000		10.1038/s41388-020-1349-6	http://dx.doi.org/10.1038/s41388-020-1349-6		JUN 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32514152	hybrid, Green Published			2022-12-17	WOS:000538969800001
J	Dong, XS; Chen, RQ				Dong, Xuesen; Chen, Ruiqi			Understanding aberrant RNA splicing to facilitate cancer diagnosis and therapy	ONCOGENE			English	Review							NEUROENDOCRINE PROSTATE-CANCER; CIRCULAR RNA; SR PROTEIN; TRANSCRIPTION; MECHANISMS; RESISTANCE; VARIANTS; TARGET; INSTABILITY; RECOGNITION	Almost all genes in normal cells undergo alternative RNA splicing to generate a greater extent of diversification of gene products for normal cellular functions. RNA splicing is tightly regulated and closely interplays with genetic and epigenetic machinery. While DNA polymorphism and somatic mutations modulate alternative splicing patterns, RNA splicing also controls genomic stability, chromatin organization, and transcriptome. Tumor cells, in turn, often take advantage of aberrant RNA splicing to develop, grow and progress into therapy-resistant tumors. Understanding alternative RNA splicing in tumor cells would, therefore, provide us opportunities to gain further insights into tumor biology, identify diagnostic or prognosis biomarkers, as well as to design effective therapeutic means to control tumor progression. Here, we provide an overview of RNA splicing mechanisms and use prostate cancer as an example to review recent advancements in our understanding of RNA splicing in cancer progression and therapy resistance. We also discuss emerging diagnostic and therapeutic potentials of RNA splicing events or RNA splicing factors.	[Dong, Xuesen] Univ British Columbia, Fac Med, Dept Urol Sci, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada; [Dong, Xuesen] Vancouver Gen Hosp, Vancouver Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada; [Chen, Ruiqi] Univ Toronto, Fac Med, 27 Kings Coll Circle 8, Toronto, ON M5S 1A1, Canada	University of British Columbia; University of British Columbia; University of Toronto	Dong, XS (corresponding author), Univ British Columbia, Fac Med, Dept Urol Sci, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.; Dong, XS (corresponding author), Vancouver Gen Hosp, Vancouver Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	xdong@prostatecentre.com	Dong, Xuesen/AGF-9228-2022	Dong, Xuesen/0000-0002-3115-3371	Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) [PJT-156150, MOP-137007] Funding Source: Medline	Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)		Aartsma-Rus A, 2017, NUCLEIC ACID THER, V27, P67, DOI 10.1089/nat.2017.0665; Agrawal AA, 2018, CURR OPIN GENET DEV, V48, P67, DOI 10.1016/j.gde.2017.10.010; Aguilera A, 2012, MOL CELL, V46, P115, DOI 10.1016/j.molcel.2012.04.009; Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Araki S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116929; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Bryzgunova OE, 2015, ACTA NATURAE, V7, P48, DOI 10.32607/20758251-2015-7-3-48-54; Busch A, 2012, WIRES RNA, V3, P1, DOI 10.1002/wrna.100; Calarco JA, 2009, CELL, V138, P898, DOI 10.1016/j.cell.2009.06.012; Cao SB, 2019, ONCOGENE, V38, P7060, DOI 10.1038/s41388-019-0947-7; Cato L, 2019, CANCER CELL, V35, P401, DOI 10.1016/j.ccell.2019.01.008; Chan YA, 2014, TRENDS GENET, V30, P245, DOI 10.1016/j.tig.2014.03.005; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chen K, 2017, CLIN CANCER RES, V23, P3428, DOI 10.1158/1078-0432.CCR-16-2020; Chen RQ, 2018, BJU INT, V122, P560, DOI 10.1111/bju.14207; Chen SJ, 2019, CELL, V176, P831, DOI 10.1016/j.cell.2019.01.025; Chen Z, 2018, P NATL ACAD SCI USA, V115, P6810, DOI 10.1073/pnas.1718811115; Corrionero A, 2011, GENE DEV, V25, P445, DOI 10.1101/gad.2014311; Dredge BK, 2005, EMBO J, V24, P1608, DOI 10.1038/sj.emboj.7600630; Dvinge H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0168-9; Effenberger KA, 2016, RNA, V22, P350, DOI 10.1261/rna.053108.115; Escobar-Hoyos L, 2019, ANNU REV CANC BIOL, V3, P167, DOI 10.1146/annurev-cancerbio-030617-050407; Etxebarria A, 2009, J BIOL CHEM, V284, P4200, DOI 10.1074/jbc.M808050200; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Fan LL, 2018, P NATL ACAD SCI USA, V115, pE4584, DOI 10.1073/pnas.1802415115; Gan Y, 2018, EBIOMEDICINE, V31, P267, DOI 10.1016/j.ebiom.2018.05.002; Giannakouros T, 2011, FEBS J, V278, P570, DOI 10.1111/j.1742-4658.2010.07987.x; Gonatopoulos-Pournatzis T, 2018, MOL CELL, V72, P510, DOI 10.1016/j.molcel.2018.10.008; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hua YM, 2008, AM J HUM GENET, V82, P834, DOI 10.1016/j.ajhg.2008.01.014; Ilagan JO, 2015, GENOME RES, V25, P14, DOI 10.1101/gr.181016.114; Irimia M, 2014, CELL, V159, P1511, DOI 10.1016/j.cell.2014.11.035; Jangi M, 2014, GENE DEV, V28, P637, DOI 10.1101/gad.235770.113; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jensen MA, 2014, NAT STRUCT MOL BIOL, V21, P189, DOI 10.1038/nsmb.2756; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kaida D, 2007, NAT CHEM BIOL, V3, P576, DOI 10.1038/nchembio.2007.18; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kim J, 2017, ONCOGENE, V36, P4072, DOI 10.1038/onc.2017.50; Kim N, 2012, NAT REV GENET, V13, P204, DOI 10.1038/nrg3152; Kim S, 2011, P NATL ACAD SCI USA, V108, P13564, DOI 10.1073/pnas.1109475108; Kornblihtt AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI 10.1016/j.ceb.2005.04.014; Kotake Y, 2007, NAT CHEM BIOL, V3, P570, DOI 10.1038/nchembio.2007.16; Krawczak M, 2007, HUM MUTAT, V28, P150, DOI 10.1002/humu.20400; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Laugesen A, 2019, MOL CELL, V74, P8, DOI 10.1016/j.molcel.2019.03.011; Laurent B, 2015, MOL CELL, V57, P957, DOI 10.1016/j.molcel.2015.01.010; Lee AR, 2019, CANCER SCI, V110, P245, DOI 10.1111/cas.13869; Lee AR, 2018, EBIOMEDICINE, V35, P167, DOI 10.1016/j.ebiom.2018.08.011; Lee AR, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00093; Lee AR, 2017, ONCOTARGET, V8, P27966, DOI 10.18632/oncotarget.15854; Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li YN, 2019, EUR UROL, V76, P157, DOI 10.1016/j.eururo.2019.03.011; Li YN, 2019, PROSTATE, V79, P96, DOI 10.1002/pros.23715; Li YN, 2017, ONCOTARGET, V8, P66878, DOI 10.18632/oncotarget.19916; Li YA, 2017, EUR UROL, V71, P68, DOI 10.1016/j.eururo.2016.04.028; Lim KH, 2011, P NATL ACAD SCI USA, V108, P11093, DOI 10.1073/pnas.1101135108; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Lippert MJ, 2011, P NATL ACAD SCI USA, V108, P698, DOI 10.1073/pnas.1012363108; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Luo JD, 2019, MOL THER-NUCL ACIDS, V18, P916, DOI 10.1016/j.omtn.2019.10.015; Luo J, 2018, EUR UROL, V73, P715, DOI 10.1016/j.eururo.2017.11.038; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Muraki M, 2004, J BIOL CHEM, V279, P24246, DOI 10.1074/jbc.M314298200; Nadiminty N, 2015, MOL CANCER THER, V14, P1884, DOI 10.1158/1535-7163.MCT-14-1057; Ni JZ, 2007, GENE DEV, V21, P708, DOI 10.1101/gad.1525507; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Orban TI, 2003, J CLIN PATHOL-MOL PA, V56, P191, DOI 10.1136/mp.56.4.191; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Paschalis A, 2018, NAT REV CLIN ONCOL, V15, P663, DOI 10.1038/s41571-018-0085-0; Pradeepa MM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002717; Prasad J, 1999, MOL CELL BIOL, V19, P6991; Rahman L, 2002, GENOMICS, V80, P245, DOI 10.1006/geno.2002.6826; Raj B, 2011, MOL CELL, V43, P843, DOI 10.1016/j.molcel.2011.08.014; Rickman DS, 2017, NAT MED, V23, P664, DOI 10.1038/nm.4341; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; Rostovtseva TK, 2009, J BIOL CHEM, V284, P34390, DOI 10.1074/jbc.M109.021873; Roybal GA, 2010, NUCLEIC ACIDS RES, V38, P6664, DOI 10.1093/nar/gkq494; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Scotti MM, 2016, NAT REV GENET, V17, P19, DOI 10.1038/nrg.2015.3; Seiler M, 2018, CELL REP, V23, P282, DOI 10.1016/j.celrep.2018.01.088; Seiler M, 2018, NAT MED, V24, P497, DOI 10.1038/nm.4493; Shepard PJ, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-10-242; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shimojo M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43100-1; Sollier J, 2014, MOL CELL, V56, P777, DOI 10.1016/j.molcel.2014.10.020; Stockley J, 2015, SCI REP-UK, V5, DOI 10.1038/srep13426; Sun GQ, 2010, MOL CELL BIOL, V30, P1997, DOI 10.1128/MCB.01116-09; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021; Wagener N, 2008, INT J CANCER, V123, P1545, DOI 10.1002/ijc.23683; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang ZF, 2008, RNA, V14, P802, DOI 10.1261/rna.876308; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Xu D, 2015, CANCER RES, V75, P3663, DOI 10.1158/0008-5472.CAN-15-0381; Yang YJ, 2016, CLIN CANCER RES, V22, P1744, DOI 10.1158/1078-0432.CCR-15-1606; Yokoi A, 2011, FEBS J, V278, P4870, DOI 10.1111/j.1742-4658.2011.08387.x; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Zhang XT, 2015, CLIN CANCER RES, V21, P4698, DOI 10.1158/1078-0432.CCR-15-0157; Zhou W, 2016, J CELL SCI, V129, P1963, DOI 10.1242/jcs.179465; Zibetti C, 2010, J NEUROSCI, V30, P2521, DOI 10.1523/JNEUROSCI.5500-09.2010	113	27	27	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2231	2242		10.1038/s41388-019-1138-2	http://dx.doi.org/10.1038/s41388-019-1138-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31819165				2022-12-17	WOS:000519440400001
J	Struve, N; Binder, ZA; Stead, LF; Brend, T; Bagley, SJ; Faulkner, C; Ott, L; Muller-Goebel, J; Weik, AS; Hoffer, K; Krug, L; Rieckmann, T; Bussmann, L; Henze, M; Morrissette, JJD; Kurian, KM; Schuller, U; Petersen, C; Rothkamm, K; O'Rourke, DM; Short, SC; Kriegs, M				Struve, Nina; Binder, Zev A.; Stead, Lucy F.; Brend, Tim; Bagley, Stephen J.; Faulkner, Claire; Ott, Leonie; Mueller-Goebel, Justus; Weik, Anna-Sophie; Hoffer, Konstantin; Krug, Leonie; Rieckmann, Thorsten; Bussmann, Lara; Henze, Marvin; Morrissette, Jennifer J. D.; Kurian, Kathreena M.; Schueller, Ulrich; Petersen, Cordula; Rothkamm, Kai; O'Rourke, Donald M.; Short, Susan C.; Kriegs, Malte			EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; VARIANT III EGFRVIII; PROGNOSTIC-SIGNIFICANCE; ADJUVANT TEMOZOLOMIDE; PAIRED PRIMARY; EXPRESSION; GENE; MUTATIONS; THERAPY; CELLS	The oncogene epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed in glioblastomas (GBM) but its impact on therapy response is still under controversial debate. Here we wanted to test if EGFRvIII influences the sensitivity towards the alkylating agent temozolomide (TMZ). Therefore, we retrospectively analyzed the survival of 336 GBM patients, demonstrating that under standard treatment, which includes TMZ, EGFRvIII expression is associated with prolonged survival, but only in patients with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylated tumors. Using isogenic GBM cell lines with endogenous EGFRvIII expression we could demonstrate that EGFRvIII increases TMZ sensitivity and results in enhanced numbers of DNA double-strand breaks and a pronounced S/G2-phase arrest after TMZ treatment. We observed a higher expression of DNA mismatch repair (MMR) proteins in EGFRvIII+ cells and patient tumor samples, which was most pronounced for MSH2 and MSH6. EGFRvIII-specific knockdown reduced MMR protein expression thereby increasing TMZ resistance. Subsequent functional kinome profiling revealed an increased activation of p38- and ERK1/2-dependent signaling in EGFRvIII expressing cells, which regulates MMR protein expression downstream of EGFRvIII. In summary, our results demonstrate that the oncoprotein EGFRvIII sensitizes a fraction of GBM to current standard of care treatment through the upregulation of DNA MMR.	[Struve, Nina; Ott, Leonie; Mueller-Goebel, Justus; Weik, Anna-Sophie; Hoffer, Konstantin; Krug, Leonie; Rieckmann, Thorsten; Bussmann, Lara; Henze, Marvin; Petersen, Cordula; Rothkamm, Kai; Kriegs, Malte] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr Hamburg, Hubertus Wald Tumorzentrum, Lab Radiobiol & Expt Radiat Oncol, Hamburg, Germany; [Binder, Zev A.; O'Rourke, Donald M.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Stead, Lucy F.; Brend, Tim; Short, Susan C.] St James Univ Hosp, Leeds Inst Med Res St Jamess, Wellcome Trust Brenner Bldg, Leeds, W Yorkshire, England; [Bagley, Stephen J.] Univ Penn, Dept Med, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; [Faulkner, Claire] Southmead Hosp, Bristol Genet Lab, Bristol, Avon, England; [Krug, Leonie; Rieckmann, Thorsten; Bussmann, Lara] Univ Med Ctr Hamburg Eppendorf, Dept Otorhinolaryngol & Head & Neck Surg, Hamburg, Germany; [Henze, Marvin; Petersen, Cordula] Univ Med Ctr Hamburg Eppendorf, Dept Radiotherapy & Radiooncol, Hamburg, Germany; [Morrissette, Jennifer J. D.] Hosp Univ Penn, Dept Pathol & Lab Med, Div Precis & Computat Diagnost, 3400 Spruce St, Philadelphia, PA 19104 USA; [Kurian, Kathreena M.] Univ Bristol, Bristol Brain Tumour Res Ctr, Bristol, Avon, England; [Schueller, Ulrich] Childrens Canc Ctr Hamburg, Res Inst, Hamburg, Germany; [Schueller, Ulrich] Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, Hamburg, Germany; [Schueller, Ulrich] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Pennsylvania; Pennsylvania Medicine; Saint James's University Hospital; University of Pennsylvania; Pennsylvania Medicine; Southmead Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Pennsylvania; Pennsylvania Medicine; University of Bristol; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Struve, N (corresponding author), Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr Hamburg, Hubertus Wald Tumorzentrum, Lab Radiobiol & Expt Radiat Oncol, Hamburg, Germany.	ni.struve@uke.de	Petersen, Cordula/AAW-9789-2020; Ott, Leonie/ABA-2973-2020; O'Rourke, Donald/AAC-3376-2021; Rothkamm, Kai/A-2164-2014	Short, Susan/0000-0003-4423-7256; Rothkamm, Kai/0000-0001-7414-5729; Kurian, Kathreena/0000-0003-0303-3716; Stead, Lucy/0000-0002-9550-4150; Rieckmann, Thorsten/0000-0001-8426-107X; Bussmann, Lara/0000-0001-6302-0859; Brend, Tim/0000-0001-9703-7042	Brigitte and Dr. Konstanze Wegener-Stiftung; Wilhelm-Sander-Stiftung; Forschungsforderungsfonds des Fachbereichs Medizin des Universitatsklinikums Hamburg-Eppendorf; Federal Ministry of Education and Research (BMBF) [02NUK032]; Cancer Research UK [CRUK/21600]; Brain Tumour Charity [TBTC13/192]; Medical Research Council [MR/K015214/1]; University of Leeds Academic Fellowship; Templeton Family Research Fund; Maria and Gabriele Troiano Brain Cancer Immunotherapy Fund; National Institutes of Health [NIH 2R01-NS042645-11A1]; Fordergemeinschaft Kinderkrebs-Zentrum Hamburg; Projekt DEAL	Brigitte and Dr. Konstanze Wegener-Stiftung; Wilhelm-Sander-Stiftung; Forschungsforderungsfonds des Fachbereichs Medizin des Universitatsklinikums Hamburg-Eppendorf; Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Cancer Research UK(Cancer Research UK); Brain Tumour Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Leeds Academic Fellowship; Templeton Family Research Fund; Maria and Gabriele Troiano Brain Cancer Immunotherapy Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fordergemeinschaft Kinderkrebs-Zentrum Hamburg; Projekt DEAL	This work was supported by the Brigitte and Dr. Konstanze Wegener-Stiftung (MK), Wilhelm-Sander-Stiftung (MK), Forschungsforderungsfonds des Fachbereichs Medizin des Universitatsklinikums Hamburg-Eppendorf (NS) and the Federal Ministry of Education and Research (BMBF grant 02NUK032; MK, KR), Cancer Research UK (CRUK/21600; SCS, TB), The Brain Tumour Charity (TBTC13/192; SCS, TB), Medical Research Council (MR/K015214/1; SCS, TB), University of Leeds Academic Fellowship (LFS), The Templeton Family Research Fund (ZAB), The Maria and Gabriele Troiano Brain Cancer Immunotherapy Fund (ZAB, DOR) and the National Institutes of Health (NIH 2R01-NS042645-11A1; DOR). U.S. is supported by the Fordergemeinschaft Kinderkrebs-Zentrum Hamburg. Open access funding provided by Projekt DEAL.	Arni S, 2017, ONCOTARGET, V8, P68599, DOI 10.18632/oncotarget.19803; Bienkowski M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065444; Binder ZA, 2018, CANCER CELL, V34, P163, DOI 10.1016/j.ccell.2018.06.006; Boyd PS, 2016, NANOSCALE, V8, P20037, DOI 10.1039/c6nr05880a; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brown PD, 2008, J CLIN ONCOL, V26, P5603, DOI 10.1200/JCO.2008.18.0612; Cominelli M, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv041; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Dosch J, 1998, CARCINOGENESIS, V19, P567, DOI 10.1093/carcin/19.4.567; Dunn J, 2009, BRIT J CANCER, V101, P124, DOI 10.1038/sj.bjc.6605127; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Faulkner C, 2015, BRIT J NEUROSURG, V29, P23, DOI 10.3109/02688697.2014.950631; Felsberg J, 2017, CLIN CANCER RES, V23, P6846, DOI 10.1158/1078-0432.CCR-17-0890; Felsberg J, 2011, INT J CANCER, V129, P659, DOI 10.1002/ijc.26083; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; Gazzoli I, 2003, MOL CELL BIOL, V23, P7992, DOI 10.1128/MCB.23.22.7992-8007.2003; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Ito M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062351; Kaina B, 2002, INT J CLIN PHARM TH, V40, P354; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kriegs M, 2015, RADIOTHER ONCOL, V115, P120, DOI 10.1016/j.radonc.2015.02.018; Lei XF, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh098; Li G, 2012, J NEURO-ONCOL, V108, P395, DOI 10.1007/s11060-012-0842-3; Liu L, 2005, J MOL MED, V83, P917, DOI 10.1007/s00109-005-0700-2; McFaline-Figueroa JL, 2015, CANCER RES, V75, P3127, DOI 10.1158/0008-5472.CAN-14-3616; Mojas N, 2007, GENE DEV, V21, P3342, DOI 10.1101/gad.455407; Montano N, 2011, NEOPLASIA, V13, P1113, DOI 10.1593/neo.111338; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Nasrallah MP, 2019, ACAD PATHOL, V6, DOI 10.1177/2374289519848353; O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984; Peereboom DM, 2010, J NEURO-ONCOL, V98, P93, DOI 10.1007/s11060-009-0067-2; Portnow J, 2009, CLIN CANCER RES, V15, P7092, DOI 10.1158/1078-0432.CCR-09-1349; Qi ST, 2011, ONCOL REP, V26, P1479, DOI 10.3892/or.2011.1428; Quiros S, 2010, CELL CYCLE, V9, P168, DOI 10.4161/cc.9.1.10363; Reardon DA, 2017, NEURO-ONCOLOGY, V19, P965, DOI 10.1093/neuonc/now257; Riedel M, 2016, ONCOTARGET, V7, P61988, DOI 10.18632/oncotarget.11328; Sanson M, 2009, J CLIN ONCOL, V27, P4150, DOI 10.1200/JCO.2009.21.9832; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Shinojima N, 2003, CANCER RES, V63, P6962; Smrdel U, 2016, RADIOL ONCOL, V50, P394, DOI 10.1515/raon-2015-0041; Struve N, 2015, ONCOTARGET, V6, P33867, DOI 10.18632/oncotarget.5293; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; van den Bent M, 2017, CANCER CHEMOTH PHARM, V80, P1209, DOI 10.1007/s00280-017-3451-1; van den Bent MJ, 2015, NEURO-ONCOLOGY, V17, P935, DOI 10.1093/neuonc/nov013; Wachsberger PR, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00013; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Weller M, 2014, INT J CANCER, V134, P2437, DOI 10.1002/ijc.28576; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Yip S, 2009, CLIN CANCER RES, V15, P4622, DOI 10.1158/1078-0432.CCR-08-3012; Zheng QF, 2014, NEURO-ONCOLOGY, V16, P1229, DOI 10.1093/neuonc/nou046	53	27	27	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3041	3055		10.1038/s41388-020-1208-5	http://dx.doi.org/10.1038/s41388-020-1208-5		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32066879	hybrid, Green Published			2022-12-17	WOS:000514052700003
J	Mukhopadhyay, H; Lee, NY				Mukhopadhyay, Himadri; Lee, Nam Y.			Multifaceted roles of TAK1 signaling in cancer	ONCOGENE			English	Review							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; TGF-BETA; IKK ACTIVATION; CELL-SURVIVAL; PATHWAY; GROWTH; STRESS; EXPRESSION; PHOSPHORYLATION	Context-specific signaling is a prevalent theme in cancer biology wherein individual molecules and pathways can have multiple or even opposite effects depending on the tumor type. TAK1 represents a particularly notable example of such signaling diversity in cancer progression. Originally discovered as a TGF-beta-activated kinase, over the years it has been shown to respond to numerous other stimuli to phosphorylate a wide range of downstream targets and elicit distinct cellular responses across cell and tissue types. Here we present a comprehensive review of TAK1 signaling and provide important therapeutic perspectives related to its function in different cancers.	[Mukhopadhyay, Himadri; Lee, Nam Y.] Univ Arizona, Coll Med, Deparment Pharmacol, Tucson, AZ 85721 USA; [Lee, Nam Y.] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA; [Lee, Nam Y.] Univ Arizona, Canc Ctr, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona	Lee, NY (corresponding author), Univ Arizona, Coll Med, Deparment Pharmacol, Tucson, AZ 85721 USA.; Lee, NY (corresponding author), Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA.; Lee, NY (corresponding author), Univ Arizona, Canc Ctr, Tucson, AZ 85721 USA.	namlee@email.arizona.edu			NIGMS NIH HHS [R01 GM128055] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed N, 2011, NAT IMMUNOL, V12, P1176, DOI 10.1038/ni.2157; Ajibade AA, 2012, IMMUNITY, V36, P43, DOI 10.1016/j.immuni.2011.12.010; Augeri DJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0511-9; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Besse A, 2007, J BIOL CHEM, V282, P3918, DOI 10.1074/jbc.M608867200; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Blanco S, 2007, MOL CELL BIOL, V27, P7273, DOI 10.1128/MCB.00025-07; Buglio D, 2012, BLOOD, V120, P347, DOI 10.1182/blood-2011-07-369397; Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864; Cai PCH, 2014, ONCOTARGET, V5, P7549, DOI 10.18632/oncotarget.2273; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Choo MK, 2006, MOL CANCER THER, V5, P2970, DOI 10.1158/1535-7163.MCT-06-0379; Chowdhury SM, 2017, ULTRASONOGRAPHY, V36, P171, DOI 10.14366/usg.17021; Dai L, 2012, IUBMB LIFE, V64, P825, DOI 10.1002/iub.1078; Dasgupta B, 2016, TRENDS PHARMACOL SCI, V37, P192, DOI 10.1016/j.tips.2015.11.007; dos Santos DMC, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4525-0; Ear T, 2010, J IMMUNOL, V184, P3897, DOI 10.4049/jimmunol.0902958; Freudlsperger C, 2013, ONCOGENE, V32, P1549, DOI 10.1038/onc.2012.171; Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamidi A, 2012, J BIOL CHEM, V287, P123, DOI 10.1074/jbc.M111.285122; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashimoto K, 2016, ANTIOXID REDOX SIGN, V25, P953, DOI 10.1089/ars.2016.6663; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Hirata Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010205; Hoffmann A, 2005, J BIOL CHEM, V280, P27271, DOI 10.1074/jbc.M503368200; Huang HL, 2015, ONCOTARGET, V6, P995, DOI 10.18632/oncotarget.2739; HuangFu WC, 2006, J BIOL CHEM, V281, P28802, DOI 10.1074/jbc.M603627200; Inagaki M, 2008, J BIOL CHEM, V283, P33080, DOI 10.1074/jbc.M807574200; Inokuchi S, 2010, P NATL ACAD SCI USA, V107, P844, DOI 10.1073/pnas.0909781107; Inokuchi-Shimizu S, 2014, J CLIN INVEST, V124, P3566, DOI 10.1172/JCI74068; Iriondo O, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04460-w; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Jeon SM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.81; Jiang LL, 2016, CANCER RES, V76, P1101, DOI 10.1158/0008-5472.CAN-15-1770; Kajino-Sakamoto R, 2010, J IMMUNOL, V185, P4729, DOI 10.4049/jimmunol.0903587; Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001; Kim SI, 2012, KIDNEY RES CLIN PRAC, V31, P94, DOI 10.1016/j.krcp.2012.04.322; Lam CRI, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.339; Lam CRI, 2011, CELL DEATH DIFFER, V18, P1120, DOI 10.1038/cdd.2010.182; Lamothe B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051228; Lin PF, 2015, INT J CLIN EXP PATHO, V8, P14449; Liu W, 2007, CLIN CANCER RES, V13, P5028, DOI 10.1158/1078-0432.CCR-07-0300; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McNew KL, 2016, MOL CANCER RES, V14, P1204, DOI 10.1158/1541-7786.MCR-16-0173; Melisi D, 2011, JNCI-J NATL CANCER I, V103, P1190, DOI 10.1093/jnci/djr243; Melvin A, 2011, CELL CYCLE, V10, P879, DOI 10.4161/cc.10.6.14910; Mihaly SR, 2014, CELL DEATH DIFFER, V21, P1667, DOI 10.1038/cdd.2014.123; Morioka S, 2012, BLOOD, V120, P3846, DOI 10.1182/blood-2012-03-416198; Naito H, 2019, DEV CELL, V48, P151, DOI 10.1016/j.devcel.2018.12.002; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Ogura Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10123; Ohkawara B, 2004, GENE DEV, V18, P381, DOI 10.1101/gad.1166904; Omori E, 2008, J BIOL CHEM, V283, P26161, DOI 10.1074/jbc.M804513200; Park MH, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020015; Ray DM, 2012, BRIT J CANCER, V107, P129, DOI 10.1038/bjc.2012.214; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Roh YS, 2014, J GASTROENTEROL, V49, P185, DOI 10.1007/s00535-013-0931-x; Safina A, 2008, ONCOGENE, V27, P1198, DOI 10.1038/sj.onc.1210768; Safina A, 2011, MOL CANCER RES, V9, P1042, DOI 10.1158/1541-7786.MCR-10-0196; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Sakurai H, 2012, TRENDS PHARMACOL SCI, V33, P522, DOI 10.1016/j.tips.2012.06.007; Santoro R, 2017, DRUG RESIST UPDATE, V33-35, P36, DOI 10.1016/j.drup.2017.10.004; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shah N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04121-y; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shinohara H, 2005, J EXP MED, V202, P1423, DOI 10.1084/jem.20051591; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Smit L, 2004, J BIOL CHEM, V279, P17232, DOI 10.1074/jbc.M307801200; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Stoppani J, 2002, AM J PHYSIOL-ENDOC M, V283, pE1239, DOI 10.1152/ajpendo.00278.2002; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Syed V, 2016, J CELL BIOCHEM, V117, P1279, DOI 10.1002/jcb.25496; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Taylor EB, 2008, J BIOL CHEM, V283, P9787, DOI 10.1074/jbc.M708839200; Terada Y, 1999, KIDNEY INT, V56, P1258, DOI 10.1046/j.1523-1755.1999.00704.x; Totzke J, 2017, CELL CHEM BIOL, V24, P1029, DOI 10.1016/j.chembiol.2017.07.011; Vallet-Regi M, 2018, MOLECULES, V23, DOI 10.3390/molecules23010047; Wei YX, 2016, INT J CLIN EXP MED, V9, P10891; Wen J, 2013, ANN THORAC SURG, V95, P285, DOI 10.1016/j.athoracsur.2012.09.050; Wu M, 2012, CANCER RES, V72, P2833, DOI 10.1158/0008-5472.CAN-11-2724; Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yang L, 2013, GASTROENTEROLOGY, V144, P1042, DOI 10.1053/j.gastro.2013.01.056; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Yang Y, 2017, MOL MED REP, V16, P3103, DOI 10.3892/mmr.2017.6998; Yu Y, 2008, J BIOL CHEM, V283, P24497, DOI 10.1074/jbc.M802825200; Zhang DM, 2016, CELL SIGNAL, V28, P1742, DOI 10.1016/j.cellsig.2016.08.008; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073	97	27	29	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1402	1413		10.1038/s41388-019-1088-8	http://dx.doi.org/10.1038/s41388-019-1088-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31695153	Green Accepted			2022-12-17	WOS:000513289600002
J	Thomsen, MK; Skouboe, MK; Boularan, C; Vernejoul, F; Lioux, T; Leknes, SL; Berthelsen, MF; Riedel, M; Cai, HQ; Joseph, JV; Perouzel, E; Tiraby, M; Vendelbo, MH; Paludan, SR				Thomsen, Martin K.; Skouboe, Morten K.; Boularan, Cedric; Vernejoul, Fabienne; Lioux, Thierry; Leknes, Siv L.; Berthelsen, Martin F.; Riedel, Maria; Cai, Huiqiang; Joseph, Justin, V; Perouzel, Eric; Tiraby, Michele; Vendelbo, Mikkel H.; Paludan, Soren R.			The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma	ONCOGENE			English	Article							INTERFERON-ALPHA; CANCER; DNA; ACTIVATION; INFLAMMATION; IMMUNITY; CELLS; HEPATOCYTES; CONTRIBUTES; REGRESSION	Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the incidence of HCC is increasing. Recently, cancer immunotherapy has emerged as an efficient treatment against some cancers. Here we have used a mouse model of mutagen-induced HCC to explore the therapeutic usefulness of targeting the DNA-activated STING pathway in HCC. STING-deficient mice exhibited unaltered initial development of HCC, but had higher number of large tumors at late stages of disease. In the liver of STING-deficient HCC mice, we observed reduced levels of phospho-STAT1, autophagy, and cleaved caspase3. These responses were activated in the liver by treatment with a cyclic dinucleotide (CDN) STING agonist. Importantly, CDN treatment of mice after HCC development efficiently reduced tumor size. Initiation of CDN treatment at an even later stage of disease to allow HCC detection by MR scanning revealed that the majority of tumors regressed in response to CDN, but new tumors were also detected, which were unresponsive to CDN treatment. Overall, the modulation of the STING pathway affects the development of HCC, and holds promise for a use as a treatment of this disease, most likely in combination with other immunomodulatory treatments such as PD1 inhibitors or with standard of care.	[Thomsen, Martin K.; Skouboe, Morten K.; Vendelbo, Mikkel H.; Paludan, Soren R.] Univ Aarhus, Dept Biomed, Hoegh Guldberg Gade 10, Aarhus C, Denmark; [Thomsen, Martin K.; Leknes, Siv L.; Berthelsen, Martin F.; Riedel, Maria; Cai, Huiqiang; Joseph, Justin, V] Univ Aarhus, Dept Clin Med, Palle Juul Jensens Blvd 82, DK-8200 Aarhus N, Denmark; [Boularan, Cedric; Vernejoul, Fabienne; Lioux, Thierry; Perouzel, Eric; Tiraby, Michele] InvivoGen, Toulouse, France; [Vendelbo, Mikkel H.] Aarhus Univ Hosp, Dept Nucl Med, Aarhus, Denmark; [Vendelbo, Mikkel H.] Aarhus Univ Hosp, PET Ctr, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University	Thomsen, MK; Paludan, SR (corresponding author), Univ Aarhus, Dept Biomed, Hoegh Guldberg Gade 10, Aarhus C, Denmark.; Thomsen, MK (corresponding author), Univ Aarhus, Dept Clin Med, Palle Juul Jensens Blvd 82, DK-8200 Aarhus N, Denmark.	mkt@clin.au.dk; srp@biomed.au.dk	Thomsen, Martin/AAU-5014-2021	Thomsen, Martin/0000-0002-5055-7531; Vendelbo, Mikkel Holm/0000-0003-0431-2522; Riedel, Maria/0000-0002-6545-0243; Skouboe, Morten Kelder/0000-0001-9358-5500	Danish Medical Research Council [12-124330, DFF-6110-00068]; Lundbeck Foundation [R198-2015-171]; InvivoGen; Danish Cancer Society [R146-A9394-16-S2, R204-A12490]; Ministry of health [4-1612-236/7]; AUFF NOVA [E-2o15-FLS-9-8]	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden); InvivoGen; Danish Cancer Society(Danish Cancer Society); Ministry of health; AUFF NOVA	We thank Mette Simonsen for assistant with scanning, Latifa Bakiri for thoroughly reading and comments on the manuscript, and Kirsten S Petersen for technical assistance. This work was funded by the Danish Medical Research Council (grants nos: 12-124330 and DFF-6110-00068), the Lundbeck Foundation (grant no R198-2015-171), and an unrestricted research grant from InvivoGen (all to SRP). MKT was funded by a fellowship sponsored by InvivoGen, Danish Cancer Society (R146-A9394-16-S2 and R204-A12490), Ministry of health (4-1612-236/7), and AUFF NOVA (E-2o15-FLS-9-8).	Ahn J, 2015, ONCOGENE, V34, P5302, DOI 10.1038/onc.2014.457; Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4723; Ariff B, 2009, WORLD J GASTROENTERO, V15, P1289, DOI 10.3748/wjg.15.1289; Bakiri L, 2013, MOL ONCOL, V7, P206, DOI 10.1016/j.molonc.2013.01.005; Chen DS, 2018, P NATL ACAD SCI USA, V115, P3930, DOI 10.1073/pnas.1717190115; Cheon H, 2014, SEMIN ONCOL, V41, P156, DOI 10.1053/j.seminoncol.2014.02.002; Corrales L, 2015, CLIN CANCER RES, V21, P4774, DOI 10.1158/1078-0432.CCR-15-1362; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Diner EJ, 2013, CELL REP, V3, P1355, DOI 10.1016/j.celrep.2013.05.009; Gao P, 2014, CELL REP, V8, P1668, DOI 10.1016/j.celrep.2014.08.010; Gulen MF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00573-w; Haanen JBAG, 2015, PROG TUMOR RES, V42, P55, DOI 10.1159/000437178; Hou J, 2014, CANCER CELL, V25, P49, DOI 10.1016/j.ccr.2013.11.011; Iurescia S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00711; Jessy Thomas, 2011, J Nat Sci Biol Med, V2, P43, DOI 10.4103/0976-9668.82318; Larkin B, 2017, J IMMUNOL, V199, P397, DOI 10.4049/jimmunol.1601999; Lau L, 2015, SCIENCE, V350, P568, DOI 10.1126/science.aab3291; Li K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020404; Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139; Lucas ED, 2018, J IMMUNOL, V45, P520; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Muhlbauer M, 2006, J HEPATOL, V45, P520, DOI 10.1016/j.jhep.2006.05.007; Ohkuri T, 2014, CANCER IMMUNOL RES, V2, P1199, DOI 10.1158/2326-6066.CIR-14-0099; Paludan SR, 2019, NAT REV IMMUNOL, V19, P141, DOI 10.1038/s41577-018-0117-0; Paludan SR, 2015, MICROBIOL MOL BIOL R, V79, P225, DOI 10.1128/MMBR.00061-14; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Prabakaran T, 2018, EMBO J, V37, DOI 10.15252/embj.201797858; Rasmussen SB, 2011, J IMMUNOL, V187, P5268, DOI 10.4049/jimmunol.1100949; Sakamaki A, 2017, WORLD J GASTROENTERO, V23, P3797, DOI 10.3748/wjg.v23.i21.3797; Schlageter M, 2014, WORLD J GASTROENTERO, V20, P15955, DOI 10.3748/wjg.v20.i43.15955; Schoggins JW, 2014, NATURE, V505, P691, DOI 10.1038/nature12862; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Skouboe MK, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006976; Sokolowska O, 2018, ARCH IMMUNOL THER EX, V66, P125, DOI 10.1007/s00005-017-0481-7; Sze A, 2013, CELL HOST MICROBE, V14, P422, DOI 10.1016/j.chom.2013.09.009; Takahashi A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03555-8; Thomsen MK, 2016, HEPATOLOGY, V64, P746, DOI 10.1002/hep.28685; vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022-1759(96)00056-7; Wang H, 2017, P NATL ACAD SCI USA, V114, P1637, DOI 10.1073/pnas.1621363114; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Yeung JT, 2013, CLIN CANCER RES, V19, P1816, DOI 10.1158/1078-0432.CCR-12-2861; Young A, 2018, CANCER IMMUNOL RES, V6, P1445, DOI 10.1158/2326-6066.CIR-18-0487; Yu YS, 2019, J CLIN INVEST, V129, P546, DOI 10.1172/JCI121842; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhang CX, 2019, CELL DEATH DIFFER, V26, P2314, DOI 10.1038/s41418-019-0302-0; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051; Zhu QF, 2014, J IMMUNOL, V193, P4779, DOI 10.4049/jimmunol.1402051	47	27	27	3	31	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1652	1664		10.1038/s41388-019-1108-8	http://dx.doi.org/10.1038/s41388-019-1108-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740782				2022-12-17	WOS:000514923000003
J	Zhangyuan, GY; Wang, F; Zhang, HT; Jiang, RQ; Tao, XW; Yu, DC; Jin, KP; Yu, WW; Liu, Y; Yin, Y; Shen, JT; Xu, QF; Zhang, WJ; Sun, BC				Zhangyuan, Guangyan; Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Tao, Xuewen; Yu, Decai; Jin, Kangpeng; Yu, WeiWei; Liu, Yang; Yin, Yin; Shen, Jintao; Xu, Qinfeng; Zhang, Wenjie; Sun, Beicheng			VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX COMPONENTS; GROWTH-FACTOR RECEPTOR; STROMAL VERSICAN; CANCER; EXPRESSION; HYALURONAN; MIGRATION; CELLS; PROGRESSION; ATTACHMENT	Versican has been reported to participate in carcinogenesis in several malignant tumors. However, the accurate role of VersicanV1, a predominant isoform of Versican in liver, remains an enigma in hepatocellular carcinoma (HCC). The expression of VersicanV1 in HCC tissues and adjacent tissues was detected by Reverse Transcription-Polymerase Chain Reaction (RT-PCR), Western Blot (WB) and inmumohistochemistry (IHC). Gain and loss of function assays were performed to examine the role of VersicanV1 in proliferation and metastasis of HCC. Measurement of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in vitro and PET-CT (positron emission tomography/computed tomography) analysis in vivo were applied to evaluate the effects of VersicanV1 on glycolysis. RNA sequencing, Co-IP (Co-immunoprecipitation) and MS (mass spectrometry) were utilized to investigate the molecular mechanisms. Our current study reveals that VersicanV1, regulated by direct interaction with Linc01225, is significantly upregulated in HCC tissues and correlates with poor prognosis. Both in vitro and in vivo experiments show that knockdown of VersicanV1 in HCC cells attenuates cancer cells malignancy. Further studies identify the positive role of VersicanV1 in aerobic glycolysis. Mechanistic investigation discovers the activation of EGFR-PI3K-AKT pathway in HCC cells expressing high VersicanV1. Moreover, EGF-like motif is indispensable for VersicanV1 to promote Warburg effect of HCC cells and subsequently, proliferation, invasion, and metastasis ability via activation of EGFR-PI3K-AKT axis. In sum, our research highlights a novel role of VersicanV1 in the progression of HCC, suggesting that VersicanV1 is an indicator for prognosis and a potential therapeutic target of HCC.	[Zhangyuan, Guangyan; Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Tao, Xuewen; Zhang, Wenjie; Sun, Beicheng] Nanjing Med Univ, Dept Hepatobiliary Surg, Drum Tower Clin Med Coll, Nanjing, Peoples R China; [Zhangyuan, Guangyan; Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Tao, Xuewen; Yu, Decai; Jin, Kangpeng; Yu, WeiWei; Liu, Yang; Yin, Yin; Zhang, Wenjie; Sun, Beicheng] Nanjing Univ, Med Sch, Dept Hepatobiliary Surg, Affiliated Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China; [Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Jin, Kangpeng; Liu, Yang; Zhang, Wenjie; Sun, Beicheng] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China; [Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Jin, Kangpeng; Liu, Yang; Zhang, Wenjie; Sun, Beicheng] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Shen, Jintao; Xu, Qinfeng] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Nucl Med, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing University; Nanjing Medical University; Nanjing Medical University; Nanjing University	Zhang, WJ; Sun, BC (corresponding author), Nanjing Med Univ, Dept Hepatobiliary Surg, Drum Tower Clin Med Coll, Nanjing, Peoples R China.; Zhang, WJ; Sun, BC (corresponding author), Nanjing Univ, Med Sch, Dept Hepatobiliary Surg, Affiliated Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.; Zhang, WJ; Sun, BC (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China.; Zhang, WJ; Sun, BC (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.	drzhangwj@163.com; sunbc@nju.edu.cn		Yin, Yin/0000-0001-8113-4278; Sun, Beicheng/0000-0002-8657-7024; Zhangyuan, Guangyan/0000-0002-6298-8304; Jiang, Runqiu/0000-0002-6995-9557; YU, Decai/0000-0002-3006-2531	National Key Research and Development Program of China [2016YFC0905900]; State Key Program of the National Natural Science Foundation [81430062]; Innovative Research Groups of the National Natural Science Foundation [81521004]; National Natural Science Foundation [81702344]; TianQing Liver Disease Research Fund [TQGB20180095]; Research Innovation Program for Postgraduate of Jiangsu Province [SJKY19_1379]	National Key Research and Development Program of China; State Key Program of the National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Innovative Research Groups of the National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); TianQing Liver Disease Research Fund; Research Innovation Program for Postgraduate of Jiangsu Province	This work was supported by grants from the National Key Research and Development Program of China (Grant Number 2016YFC0905900 to BS), State Key Program of the National Natural Science Foundation (Grant Number 81430062 to BS), Innovative Research Groups of the National Natural Science Foundation (Grant Number 81521004 to BS), National Natural Science Foundation (Grant Number 81702344 to WZ), TianQing Liver Disease Research Fund (Grant Number: TQGB20180095 to WZ) and the Research Innovation Program for Postgraduate of Jiangsu Province (Grant Number SJKY19_1379 to GZ). BS is Yangtze River Scholar of Distinguished Professor.	Asano K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17613-6; Bhattacharyya S, 2014, ONCOGENE, V33, P5467, DOI 10.1038/onc.2013.483; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Casey RC, 2003, CLIN EXP METASTAS, V20, P143, DOI 10.1023/A:1022670501667; Cattaruzza S, 2002, J BIOL CHEM, V277, P47626, DOI 10.1074/jbc.M206521200; Chen Y, 2005, J PROTEOME RES, V4, P998, DOI 10.1021/pr049754t; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Desjardins M, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-70; Domenzain-Reyna C, 2009, J BIOL CHEM, V284, P12306, DOI 10.1074/jbc.M807108200; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Du WW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013828; Edwards IJ, 2012, NAT REV UROL, V9, P196, DOI 10.1038/nrurol.2012.19; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fanhchaksai K, 2016, INT J CANCER, V138, P630, DOI 10.1002/ijc.29804; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hope C, 2017, J IMMUNOL, V199, P1933, DOI 10.4049/jimmunol.1700529; Hope C, 2016, BLOOD, V128, P680, DOI 10.1182/blood-2016-03-705780; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kodama J, 2007, ANN ONCOL, V18, P269, DOI 10.1093/annonc/mdl370; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Mitsui Y, 2017, MOL CANCER RES, V15, P884, DOI 10.1158/1541-7786.MCR-16-0444; Nara Y, 1997, HISTOCHEM J, V29, P21, DOI 10.1023/A:1026460700592; Nikitovic D, 2006, IUBMB LIFE, V58, P47, DOI 10.1080/15216540500531713; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Onken J, 2014, J NEURO-ONCOL, V120, P73, DOI 10.1007/s11060-014-1545-8; Pappas AG, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1537427; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Pukkila M, 2007, J CLIN PATHOL, V60, P267, DOI 10.1136/jcp.2005.034181; Ricciardelli C, 2002, CLIN CANCER RES, V8, P1054; Ricciardelli C, 1998, CLIN CANCER RES, V4, P963; Sakko AJ, 2003, CANCER RES, V63, P4786; Suwiwat S, 2004, CLIN CANCER RES, V10, P2491, DOI 10.1158/1078-0432.CCR-03-0146; Touab M, 2002, AM J PATHOL, V160, P549, DOI 10.1016/S0002-9440(10)64874-2; Voutilainen K, 2003, INT J CANCER, V107, P359, DOI 10.1002/ijc.11423; Wang RY, 2013, GASTROENTEROLOGY, V145, pe1431; Wang X, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.26; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Worns MA, 2014, NAT REV GASTRO HEPAT, V11, P447, DOI 10.1038/nrgastro.2014.10; Wu YJ, 2005, CELL RES, V15, P483, DOI 10.1038/sj.cr.7290318; Wu YJ, 2004, J CELL SCI, V117, P2227, DOI 10.1242/jcs.01057; Xia LM, 2014, HEPATOLOGY, V59, P958, DOI 10.1002/hep.26735; Xiang YY, 2006, J BIOL CHEM, V281, P19358, DOI 10.1074/jbc.M512980200; Yarden Y, 2007, CELL, V131, DOI 10.1016/j.cell.2007.11.013	47	27	30	3	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1213	1230		10.1038/s41388-019-1052-7	http://dx.doi.org/10.1038/s41388-019-1052-7			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31605014				2022-12-17	WOS:000526714600004
J	Qi, M; Dai, D; Liu, J; Li, ZQ; Liang, PP; Wang, Y; Cheng, L; Zhan, YH; An, ZF; Song, YY; Yang, YN; Yan, XH; Xiao, H; Shao, HJ				Qi, Miao; Dai, Dan; Liu, Jin; Li, Zhongqi; Liang, Panpan; Wang, Yue; Cheng, Lu; Zhan, Yihong; An, Zhifeng; Song, Yaoyao; Yang, Yana; Yan, Xiaohui; Xiao, Hui; Shao, Huanjie			AIM2 promotes the development of non-small cell lung cancer by modulating mitochondrial dynamics	ONCOGENE			English	Article							NF-KAPPA-B; DNA SENSOR; FISSION; INFLAMMASOME; FUSION; PHOSPHORYLATION; PROLIFERATION; TUMORIGENESIS; PROGRESSION; EXPRESSION	Mitochondrial fusion and fission dynamics fine-tune cellular calcium homeostasis, ATP production capacity and ROS production and play important roles in cell proliferation and migration. Dysregulated mitochondrial dynamics is closely related to tumor development, but the mechanism of mitochondrial dynamics dysregulation and its role in the development of lung cancer remains unclear. Here, we demonstrate that the DNA sensor protein absent in melanoma 2 (AIM2) is highly expressed in non-small cell lung cancer (NSCLC) cells and that high AIM2 expression is associated with poor prognosis in patients with NSCLC. High expression of AIM2 contributes to tumor cell growth and proliferation independent of inflammasome activation in vitro and in vivo. Further studies have shown that AIM2 colocalizes with mitochondria in NSCLC cells and that AIM2 knockdown leads to enhanced mitochondrial fusion and decreased cell proliferation. Mechanistic studies have shown that AIM2 downregulation promotes MFN2 upregulation, thereby enhancing mitochondrial fusion. Moreover, we found that mitochondrial fusion driven by AIM2 knockdown leads to a decrease of cellular reactive oxygen species (ROS) production, which further causes inactivation of the MAPK/ERK signaling pathway. Together, we discovered a novel function of AIM2 in promoting NSCLC development by regulating mitochondrial dynamics and revealed its underlying mechanism. Our work provides new intervention targets for the treatment of NSCLC.	[Qi, Miao; Dai, Dan; Liu, Jin; Li, Zhongqi; Liang, Panpan; Wang, Yue; Cheng, Lu; Zhan, Yihong; An, Zhifeng; Song, Yaoyao; Yang, Yana; Yan, Xiaohui; Xiao, Hui; Shao, Huanjie] Shaanxi Normal Univ, Coll Life Sci, Natl Engn Lab Resource Developing Endangered Chin, Key Lab,Minist Educ Med Resources & Nat Pharmaceu, Xian 710119, Shaanxi, Peoples R China	Shaanxi Normal University	Shao, HJ (corresponding author), Shaanxi Normal Univ, Coll Life Sci, Natl Engn Lab Resource Developing Endangered Chin, Key Lab,Minist Educ Med Resources & Nat Pharmaceu, Xian 710119, Shaanxi, Peoples R China.	hshao@snnu.edu.cn			National Natural Science Foundation of China [81872250]; Natural Science Foundation of Shaanxi Province, China [2016JM8102]; key industrial chain projects of Shaanxi Province [2019TD-033]; program of Innovative Research Team for the Central Universities [GK201701005]; Student Innovation Training Program, Shaanxi Normal University [201810718056, 201910718048]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shaanxi Province, China(Natural Science Foundation of Shaanxi Province); key industrial chain projects of Shaanxi Province; program of Innovative Research Team for the Central Universities; Student Innovation Training Program, Shaanxi Normal University	We are thankful for financial support of National Natural Science Foundation of China (81872250), the Natural Science Foundation of Shaanxi Province, China (2016JM8102), the key industrial chain projects of Shaanxi Province (2019TD-033), the program of Innovative Research Team for the Central Universities (GK201701005), and the Student Innovation Training Program (201810718056, 201910718048), Shaanxi Normal University. The authors like to thank Dr Ling Guo and Yaohui Ren for assistance with TEM.	Arciuch VGA, 2012, ANTIOXID REDOX SIGN, V16, P1150, DOI 10.1089/ars.2011.4085; Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Azim HA, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0538-7; Berman SB, 2008, CELL DEATH DIFFER, V15, P1147, DOI 10.1038/cdd.2008.57; Brown AP, 2007, CANCER CHEMOTH PHARM, V59, P671, DOI 10.1007/s00280-006-0323-5; Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58; Cai JY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.370; Che TF, 2015, ONCOTARGET, V6, P37349, DOI 10.18632/oncotarget.5736; Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026; Chen HC, 2017, CELL METAB, V26, P39, DOI 10.1016/j.cmet.2017.05.016; Chen IF, 2006, MOL CANCER THER, V5, P1, DOI 10.1158/1535-7163.MCT-05-0310; Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb1161; Chen Y, 2013, SCIENCE, V340, P471, DOI 10.1126/science.1231031; Deheshi S, 2015, J NEUROCHEM, V133, P684, DOI 10.1111/jnc.13090; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Farshchian M, 2017, ONCOTARGET, V8, P45825, DOI 10.18632/oncotarget.17573; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Inoue-Yamauchi A, 2012, BIOCHEM BIOPH RES CO, V421, P81, DOI 10.1016/j.bbrc.2012.03.118; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kondo Y, 2012, CANCER SCI, V103, P782, DOI 10.1111/j.1349-7006.2012.02211.x; Kong H, 2015, TUMOR BIOL, V36, P7501, DOI 10.1007/s13277-015-3473-4; Lei H, 2009, J BIOL CHEM, V284, P6329, DOI 10.1074/jbc.M808426200; Lennon FE, 2014, EXPERT OPIN INV DRUG, V23, P675, DOI 10.1517/13543784.2014.899350; Li J, 2017, ONCOGENE, V36, P4901, DOI 10.1038/onc.2017.98; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Loson OC, 2013, MOL BIOL CELL, V24, P659, DOI 10.1091/mbc.E12-10-0721; Lugrin J, 2018, IMMUNOL REV, V281, P99, DOI 10.1111/imr.12618; Ma LM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1447-y; Ma XM, 2016, ONCOTARGET, V7, P36185, DOI 10.18632/oncotarget.9154; Ponomareva L, 2013, MOL CANCER RES, V11, P1193, DOI 10.1158/1541-7786.MCR-13-0145; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Shao HJ, 2013, MOL CANCER THER, V12, P2640, DOI 10.1158/1535-7163.MCT-13-0066; Simula L, 2017, SEMIN CANCER BIOL, V47, P29, DOI 10.1016/j.semcancer.2017.06.007; Stack JH, 2005, J IMMUNOL, V175, P2630, DOI 10.4049/jimmunol.175.4.2630; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Trotta AP, 2017, CELL MOL LIFE SCI, V74, P1999, DOI 10.1007/s00018-016-2451-3; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Willems PHGM, 2015, CELL METAB, V22, P207, DOI 10.1016/j.cmet.2015.06.006; Wilson JE, 2015, NAT MED, V21, P906, DOI 10.1038/nm.3908; Xia MH, 2014, INT J ONCOL, V45, P2341, DOI 10.3892/ijo.2014.2669; Yan XH, 2018, BIOCHEM PHARMACOL, V150, P72, DOI 10.1016/j.bcp.2018.01.031; Yeo W, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1334-6; Zhang JH, 2019, REDOX BIOL, V22, DOI 10.1016/j.redox.2019.101116; Zhang MD, 2019, J CELL PHYSIOL, V234, P20161, DOI 10.1002/jcp.28617; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494	48	27	28	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2707	2723		10.1038/s41388-020-1176-9	http://dx.doi.org/10.1038/s41388-020-1176-9		JAN 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32005973				2022-12-17	WOS:000510346700001
J	Ding, KK; Ji, JX; Zhang, X; Huang, B; Chen, AJ; Zhang, D; Li, XG; Wang, XY; Wang, J				Ding, Kaikai; Ji, Jianxiong; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Li, Xingang; Wang, Xinyu; Wang, Jian			RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation	ONCOGENE			English	Article							TRANSCRIPTIONAL COACTIVATOR TAZ; LENTIVIRUS-MEDIATED INHIBITION; CELL-PROLIFERATION; HEPATOCELLULAR-CARCINOMA; DESTRUCTION COMPLEX; CANCER GROWTH; HIPPO; SUPPRESSES; KNOCKDOWN; PATHWAY	Increasing evidence demonstrates that ubiquitin specific protease 39 (USP39) plays an oncogenic role in various human tumors. Here, using expression analysis of the publicly available Oncomine database, clinical glioma patient samples, and glioma cells, we found that USP39 was overexpressed in human gliomas. Knockdown of USP39 in glioma cells demonstrated that the protein promoted cell growth, invasion and migration in vitro and in a tumor model in nude mice. To identify mediators of USP39 growth-promoting properties, we used luciferase reporter constructs under transcriptional control of various promoters specific to seven canonical cancer-associated pathways. Luciferase activity from a synthetic TEAD-dependent YAP/TAZ-responsive reporter, as a direct readout of the Hippo signaling pathway, was decreased by 92% in cells with USP39 knockdown, whereas the luciferase activities from the other six cancer pathways, including MAPK/ERK, MAPK/JNK, NF kappa B, Notch, TGF beta, and Wnt, remained unchanged. TAZ protein expression however was decreased independent of canonical Hippo signaling. Immunohistochemistry revealed a positive correlation between USP39 and TAZ proteins in orthotopic xenografts derived from modified glioma cells expressing USP39 shRNAs and primary human glioma samples (p < 0.05). Finally, loss of USP39 decreased TAZ pre-mRNA splicing efficiency in glioma cells in vitro, which led to reduced levels of TAZ protein. In summary, USP39 has oncogenic properties that increase TAZ protein levels by inducing maturation of its mRNA. USP39 therefore provides a novel therapeutic target for the treatment of human glioma.	[Ding, Kaikai; Ji, Jianxiong; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Li, Xingang; Wang, Xinyu; Wang, Jian] Shandong Univ, Dept Neurosurg, Qilu Hosp, Jinan 250012, Shandong, Peoples R China; [Ding, Kaikai; Ji, Jianxiong; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Li, Xingang; Wang, Xinyu; Wang, Jian] Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan 250012, Shandong, Peoples R China; [Ding, Kaikai; Ji, Jianxiong; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Li, Xingang; Wang, Xinyu; Wang, Jian] Shandong Key Lab Brain Funct Remodeling, Jinan 250012, Shandong, Peoples R China; [Wang, Jian] Univ Bergen, Dept Biomed, N-5009 Bergen, Norway	Shandong University; Shandong University; University of Bergen	Wang, XY; Wang, J (corresponding author), Shandong Univ, Dept Neurosurg, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.; Wang, XY; Wang, J (corresponding author), Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan 250012, Shandong, Peoples R China.; Wang, XY; Wang, J (corresponding author), Shandong Key Lab Brain Funct Remodeling, Jinan 250012, Shandong, Peoples R China.; Wang, J (corresponding author), Univ Bergen, Dept Biomed, N-5009 Bergen, Norway.	wangxinyu@sdu.edu.cn; jian.wang@sdu.edu.cn	Wang, Xin/GYU-1129-2022; Huang, Bin/AAT-4514-2021; Chen, Anjing/GYE-2355-2022		National Natural Science Foundation of China [81701329, 81702474]; Department of Science & Technology of Shandong Province [2016GSF201060, 2017CXGC1502, 2018GSF118082]; Special Foundation for Taishan Scholars [ts20110814, tshw201502056, tsqn20161067]; Shandong Provincial Natural Science Foundation [ZR2017MH116, ZR2017MH015]; China Postdoctoral Science Foundation [2018M642666]; Jinan Science and Technology Bureau of Shandong Province [201704096]; University of Bergen; K.G. Jebsen Brain Tumor Research Centre	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science & Technology of Shandong Province; Special Foundation for Taishan Scholars; Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jinan Science and Technology Bureau of Shandong Province; University of Bergen; K.G. Jebsen Brain Tumor Research Centre	We appreciate the assistance from other members of the lab. This work was supported by the National Natural Science Foundation of China (81701329 and 81702474), the Department of Science & Technology of Shandong Province (2016GSF201060, 2017CXGC1502, and 2018GSF118082), the Special Foundation for Taishan Scholars (ts20110814, tshw201502056, and tsqn20161067), the Shandong Provincial Natural Science Foundation (ZR2017MH116 and ZR2017MH015), the China Postdoctoral Science Foundation (2018M642666), the Jinan Science and Technology Bureau of Shandong Province (201704096), the University of Bergen, and the K.G. Jebsen Brain Tumor Research Centre.	An Y, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0669-4; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Cai J, 2017, BIOCHEM BIOPH RES CO, V486, P184, DOI 10.1016/j.bbrc.2017.03.025; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Chen J, 2017, CANCER DISCOV, V7, P766, DOI 10.1158/2159-8290.CD-16-0908; Choi W, 2018, CANCER RES, V78, P3306, DOI 10.1158/0008-5472.CAN-17-3487; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Deel MD, 2018, CLIN CANCER RES, V24, P2616, DOI 10.1158/1078-0432.CCR-17-1207; Diamantopoulou Z, 2017, CANCER CELL, V31, P621, DOI 10.1016/j.ccell.2017.03.007; Ehmer U, 2016, MOL CANCER RES, V14, P127, DOI 10.1158/1541-7786.MCR-15-0305; Fraile JM, 2017, J BIOL CHEM, V292, P4164, DOI 10.1074/jbc.M116.762757; Gan ZH, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0121-z; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Huang Y, 2016, ONCOTARGET, V7, P22016, DOI 10.18632/oncotarget.7882; Ji JX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0548-3; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li KY, 2016, CANCER BIOMARK, V16, P137, DOI 10.3233/CBM-150549; Li WJ, 2016, ONCOTARGET, V7, P82686, DOI 10.18632/oncotarget.12625; Lin ZF, 2016, MOL CELL BIOCHEM, V422, P97, DOI 10.1007/s11010-016-2809-8; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Lygerou Z, 1999, MOL CELL BIOL, V19, P2008; Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553; Miranda MZ, 2017, J BIOL CHEM, V292, P14902, DOI 10.1074/jbc.M117.780502; Nallet-Staub F, 2014, J INVEST DERMATOL, V134, P123, DOI 10.1038/jid.2013.319; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Rios Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001271; Schwartzbaum JA, 2006, NAT CLIN PRACT NEURO, V2, P494, DOI 10.1038/ncpneuro0289; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; van Leuken RJ, 2008, CELL CYCLE, V7, P2710, DOI 10.4161/cc.7.17.6553; Wang HB, 2013, ONCOL REP, V30, P2871, DOI 10.3892/or.2013.2798; Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539; Wang XB, 2016, MOL MED REP, V14, P301, DOI 10.3892/mmr.2016.5252; Wen PY, 2016, NAT REV NEUROL, V12, P69, DOI 10.1038/nrneurol.2015.242; Xing ZY, 2018, ONCOL LETT, V15, P5443, DOI [10.3892/ol.2018.808061, 10.3892/ol.2018.8061]; Xu Y, 2018, MOL MED REP, V17, P4729, DOI 10.3892/mmr.2018.8421; Yuan XW, 2017, ONCOL REP, V37, P2398, DOI 10.3892/or.2017.5454; Yuan XW, 2015, ONCOL REP, V34, P823, DOI 10.3892/or.2015.4065; Zhang H, 2016, TUMOR BIOL, V37, P11321, DOI 10.1007/s13277-016-4995-0; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhao Y, 2016, TUMOR BIOL, V37, P13167, DOI 10.1007/s13277-016-5212-x	46	27	28	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2019	38	37					6414	6428		10.1038/s41388-019-0888-1	http://dx.doi.org/10.1038/s41388-019-0888-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6FR	31332287	hybrid, Green Published			2022-12-17	WOS:000485778800002
J	Schade, AE; Oser, MG; Nicholson, HE; DeCaprio, JA				Schade, Amy E.; Oser, Matthew G.; Nicholson, Hilary E.; DeCaprio, James A.			Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB	ONCOGENE			English	Article							DEPENDENT KINASE 4/6; FAMILY-MEMBERS; B-MYB; COMPLEX; P130; E2F; PHOSPHORYLATION; MECHANISMS; PROMOTER; DISTINCT	The retinoblastoma protein (RB) restricts cell cycle gene expression and entry into the cell cycle. The RB-related protein p130 forms the DREAM (DP, RB-like, E2F, and MuvB) complex and contributes to repression of cell cycle-dependent genes during quiescence. Although both RB and DREAM bind and repress an overlapping set of E2F-dependent gene promoters, it remains unclear whether they cooperate to restrict cell cycle entry. To test the specific contributions of RB and DREAM, we generated RB and p130 knockout cells in primary human fibroblasts. Knockout of both p130 and RB yielded higher levels of cell cycle gene expression in GO and G1 cells compared to cells with knockout of RB alone, indicating a role for DREAM and RB in repression of cell cycle genes. We observed that RB had a dominant role in E2F-dependent gene repression during mid to late G1 while DREAM activity was more prominent during GO and early G1. Cyclin D-Cyclin-Dependent Kinase 4 (CDK4)-dependent phosphorylation of p130 occurred during early G1, and led to the release of p130 and MuvB from E2F4 and decreased p130 and MuvB binding to cell cycle promoters. Specific inhibition of CDK4 activity by palbociclib blocked DREAM complex disassembly during cell cycle entry. In addition, sensitivity to CDK4 inhibition was dependent on RB and an intact DREAM complex in both normal cells as well as in palbociclib-sensitive cancer cell lines. Although RB knockout cells were partially resistant to CDK4 inhibition, RB and p130 double knockout cells were significantly more resistant to palbociclib treatment. These results indicate that DREAM cooperates with RB in repressing E2F-dependent gene expression and cell cycle entry and supports a role for DREAM as a therapeutic target in cancer.	[Schade, Amy E.; DeCaprio, James A.] Harvard Univ, Grad Sch Arts & Sci, Div Med Sci, Program Virol, Boston, MA 02115 USA; [Schade, Amy E.; Oser, Matthew G.; Nicholson, Hilary E.; DeCaprio, James A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Oser, Matthew G.; DeCaprio, James A.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Oser, Matthew G.; DeCaprio, James A.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	DeCaprio, JA (corresponding author), Harvard Univ, Grad Sch Arts & Sci, Div Med Sci, Program Virol, Boston, MA 02115 USA.; DeCaprio, JA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; DeCaprio, JA (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.; DeCaprio, JA (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	james_decaprio@dfci.harvard.edu		Nicholson, Hilary/0000-0002-3393-3013; Schade, Amy/0000-0002-0342-8251	US Public Health Service [R01CA63113, R01CA173023, P01CA050661, F31CA220800, K08CA222657]; Harvard Landry Biology Consortium Fellowship; NATIONAL CANCER INSTITUTE [K08CA222657, F31CA220800, R01CA173023, P01CA203655, R01CA063113, F32CA220849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR069625] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Harvard Landry Biology Consortium Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by US Public Health Service grants R01CA63113, R01CA173023, and P01CA050661 to JAD; F31CA220800 to AES; K08CA222657 to MGO; and a Harvard Landry Biology Consortium Fellowship to AES.	Aka JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031532; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Boichuk S, 2013, CANCER RES, V73, P5120, DOI 10.1158/0008-5472.CAN-13-0579; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Burke JR, 2014, J MOL BIOL, V426, P245, DOI 10.1016/j.jmb.2013.09.031; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Corona SP, 2018, DRUG DES DEV THER, V12, P321, DOI 10.2147/DDDT.S137783; Davis PK, 2001, BIOTECHNIQUES, V30, P1322, DOI 10.2144/01306rv01; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Fischer M, 2017, CRIT REV BIOCHEM MOL, V52, P638, DOI 10.1080/10409238.2017.1360836; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Guiley KZ, 2015, GENE DEV, V29, P961, DOI 10.1101/gad.257568.114; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hesbacher S, 2016, ONCOTARGET, V7, P32956, DOI 10.18632/oncotarget.8793; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Ho VM, 2009, ONCOGENE, V28, P1393, DOI 10.1038/onc.2008.491; Jorda R, 2018, J MED CHEM, V61, P9105, DOI 10.1021/acs.jmedchem.8b00049; Lara MF, 2008, MOL CARCINOGEN, V47, P209, DOI 10.1002/mc.20376; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Liban TJ, 2016, J MOL BIOL, V428, P3960, DOI 10.1016/j.jmb.2016.08.017; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; MacDonald J, 2017, MOL CANCER RES, V15, P371, DOI 10.1158/1541-7786.MCR-16-0323-T; Mages CFS, 2017, ELIFE, V6, DOI 10.7554/eLife.26876; Marceau AH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12301; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; Muller GA, 2014, NUCLEIC ACIDS RES, V42, P10331, DOI 10.1093/nar/gku696; Muller GA, 2012, NUCLEIC ACIDS RES, V40, P1561, DOI 10.1093/nar/gkr793; Narasimha AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02872; Odajima J, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006429; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Ortiz AB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188068; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rashid NN, 2016, VIROL J, V13, DOI 10.1186/s12985-015-0460-8; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Schmit F, 2009, FEBS J, V276, P5703, DOI 10.1111/j.1742-4658.2009.07261.x; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Takahashi Y, 2000, GENE DEV, V14, P804; Tang B, 2015, SCI REP-UK, V5, DOI 10.1038/srep13563; TOBEY RA, 1988, EXP CELL RES, V179, P400, DOI 10.1016/0014-4827(88)90279-0; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714	56	27	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4962	4976		10.1038/s41388-019-0767-9	http://dx.doi.org/10.1038/s41388-019-0767-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30833638	Green Accepted			2022-12-17	WOS:000472145900006
J	John, B; Naczki, C; Patel, C; Ghoneum, A; Qasem, S; Salih, Z; Said, N				John, Bincy; Naczki, Christine; Patel, Chirayu; Ghoneum, Alia; Qasem, Shadi; Salih, Ziyan; Said, Neveen			Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC	ONCOGENE			English	Article							BINDING PROTEIN BETA; ADIPOSE TRIGLYCERIDE LIPASE; C/EBP-BETA; CHEMOKINE GENES; EXPRESSION; INFLAMMATION; METASTASIS; LIPOLYSIS; PATHWAYS; SURVIVAL	Ovarian cancer (OvCa) exhibits a specific predilection for metastasis to the omentum. Our earlier studies highlighted the tumour-suppressor effect of secreted protein acidic and rich in cysteine (SPARC) in OvCa through multi-faceted roles inhibiting cancer cell interactions within the peritoneal milieu. The goal of this study is to investigate the role of SPARC in OvCa interactions with omental adipocytes and its role in OvCa colonization in the omentum. We employed multi-pronged approach using primary omental adipocytes from Sparc knockout mice, genetically engineered human omental adipocytes in 3D co-cultures with OvCa cells, as well as treatment with recombinant SPARC protein. We show that SPARC suppresses multistep cascade in OvCa omental metastasis. SPARC inhibited in vivo and adipocyte-induced homing, proliferation, and invasion of OvCa cells. SPARC suppressed metabolic programming of both adipocytes and OvCa cells and exerted an inhibitory effect of adipocyte differentiation and their phenotypic switch to cancer-associated phenotype. Mechanistic studies revealed that this effect is mediated through inhibition of cEBP beta-NFkB-AP-1 transcription machinery. These findings define a novel and functionally important role of SPARC in OvCa and not only bridge the knowledge gap but highlight the need to consider SPARC protein expression in therapeutic development.	[John, Bincy; Naczki, Christine; Patel, Chirayu; Ghoneum, Alia; Said, Neveen] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27109 USA; [Qasem, Shadi; Salih, Ziyan; Said, Neveen] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27103 USA; [Said, Neveen] Wake Forest Univ, Bowman Gray Sch Med, Dept Urol, Winston Salem, NC 27103 USA; [Qasem, Shadi] Univ Kentucky, Coll Med, Surg Pathol, Lexington, KY USA; [Salih, Ziyan] Univ Louisville, Sch Med, Dept Pathol & Lab Med, Louisville, KY 40202 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Kentucky; University of Louisville	Said, N (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27109 USA.; Salih, Z; Said, N (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27103 USA.; Said, N (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Urol, Winston Salem, NC 27103 USA.; Salih, Z (corresponding author), Univ Louisville, Sch Med, Dept Pathol & Lab Med, Louisville, KY 40202 USA.	ziyan.salih@louisville.edu; nsaid@wakehealth.edu		Patel, Chirayu/0000-0003-0649-0090	Marsha Rivkin Pilot Award; WFBMC Department of Pathology Research Pilot Funds;  [R01 CA193437];  [P30CA012197]; NATIONAL CANCER INSTITUTE [P30CA012197, R01CA193437] Funding Source: NIH RePORTER	Marsha Rivkin Pilot Award; WFBMC Department of Pathology Research Pilot Funds; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by Marsha Rivkin Pilot Award, WFBMC Department of Pathology Research Pilot Funds and R01 CA193437 (NS) and P30CA012197 to the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC).	Al-Hassan NN, 2012, NEOPLASIA, V14, P259, DOI 10.1593/neo.12442; Barbolina MV, 2009, CANCER TREAT RES, V149, P319, DOI 10.1007/978-0-387-98094-2_15; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Bradshaw AD, 2003, P NATL ACAD SCI USA, V100, P6045, DOI 10.1073/pnas.1030790100; Cheville NF, 2014, VET PATHOL, V51, P28, DOI 10.1177/0300985813505114; Chinnaiyan P, 2012, CANCER RES, V72, P5878, DOI 10.1158/0008-5472.CAN-12-1572-T; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973; De Pergola G, 2013, J OBES, V2013, DOI 10.1155/2013/291546; Delany AM, 2003, ENDOCRINOLOGY, V144, P2588, DOI 10.1210/en.2002-221044; Delany AM, 2009, J CELL COMMUN SIGNAL, V3, P227, DOI 10.1007/s12079-009-0076-0; Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323; Doerstling SS, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00216; Ebadi M, 2014, NUTRIENTS, V6, P5280, DOI 10.3390/nu6115280; Esteves CL, 2014, J CLIN ENDOCR METAB, V99, pE160, DOI 10.1210/jc.2013-1708; Ewing SJ, 2008, CELL DEATH DIFFER, V15, P1734, DOI 10.1038/cdd.2008.105; Fontana L, 2007, DIABETES, V56, P1010, DOI 10.2337/db06-1656; Gharpure KM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04987-y; Grisouard J, 2012, INNATE IMMUN-LONDON, V18, P25, DOI 10.1177/1753425910386632; Guo L, 2012, CELL DEATH DIFFER, V19, P1917, DOI 10.1038/cdd.2012.75; Guo L, 2015, J BIOL CHEM, V290, P755, DOI 10.1074/jbc.R114.619957; Harjes U, 2017, ONCOGENE, V36, P912, DOI 10.1038/onc.2016.256; Hein S, 2009, ONCOL REP, V22, P177, DOI 10.3892/or_00000422; Hernandez L, 2010, CANCER RES, V70, P4005, DOI 10.1158/0008-5472.CAN-09-3912; Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363; House CD, 2017, CANCER RES, V77, P6927, DOI 10.1158/0008-5472.CAN-17-0366; Howe LR, 2013, CLIN CANCER RES, V19, P6074, DOI 10.1158/1078-0432.CCR-12-2603; Huber R, 2012, CELL SIGNAL, V24, P1287, DOI 10.1016/j.cellsig.2012.02.007; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Jakobs A, 2016, J BIOL CHEM, V291, P26098, DOI 10.1074/jbc.M116.748129; Ji CB, 2011, J BIOENERG BIOMEMBR, V43, P367, DOI 10.1007/s10863-011-9361-8; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Ladanyi A, 2018, ONCOGENE, V37, P2285, DOI 10.1038/s41388-017-0093-z; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Liu D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03590-5; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Naczki C, 2018, CANCERS, V10, DOI 10.3390/cancers10100385; Nie J, 2011, CONNECT TISSUE RES, V52, P99, DOI 10.3109/03008207.2010.483747; Nie J, 2009, J CELL COMMUN SIGNAL, V3, P247, DOI 10.1007/s12079-009-0064-4; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Oyesanya RA, 2008, FASEB J, V22, P2639, DOI 10.1096/fj.07-101428; Piconese S, 2011, J AUTOIMMUN, V37, P300, DOI 10.1016/j.jaut.2011.09.002; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Rahman SM, 2012, J BIOL CHEM, V287, P34349, DOI 10.1074/jbc.M112.410613; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rozenberg JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078179; Said N, 2005, AM J PATHOL, V167, P1739, DOI 10.1016/S0002-9440(10)61255-2; Said N, 2013, J CARCINOGENE MUTAGE, V4, P151; Said N, 2007, MOL CANCER RES, V5, P1015, DOI 10.1158/1541-7786.MCR-07-0001; Said N, 2007, AM J PATHOL, V170, P1054, DOI 10.2353/ajpath.2007.060903; Said N, 2013, J CLIN INVEST, V123, P4089, DOI 10.1172/JCI71241; Said N, 2012, J CLIN INVEST, V122, P1503, DOI 10.1172/JCI61392; Said N, 2011, J CLIN INVEST, V121, P132, DOI 10.1172/JCI42912; Said NA, 2008, NEOPLASIA, V10, P1092, DOI 10.1593/neo.08672; Said NA, 2007, NEOPLASIA, V9, P23, DOI 10.1593/neo.06658; Schweiger M, 2006, J BIOL CHEM, V281, P40236, DOI 10.1074/jbc.M608048200; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Tucker SL, 2014, CLIN CANCER RES, V20, P3280, DOI 10.1158/1078-0432.CCR-14-0445; Vaysse C, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0015-9; Yeung TL, 2015, AM J PHYSIOL-CELL PH, V309, pC444, DOI 10.1152/ajpcell.00188.2015; Zhang WL, 2014, J BIOL CHEM, V289, P32178, DOI 10.1074/jbc.M114.601096; Zhang ZQ, 2010, J BIOL CHEM, V285, P33092, DOI 10.1074/jbc.M110.130377; Zhang ZJ, 2014, INT J MOL SCI, V15, P17242, DOI 10.3390/ijms151017242	64	27	29	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4366	4383		10.1038/s41388-019-0728-3	http://dx.doi.org/10.1038/s41388-019-0728-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30765860	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000469339100012
J	Balamurugan, K; Mendoza-Villanueva, D; Sharan, S; Summers, GH; Dobrolecki, LE; Lewis, MT; Sterneck, E				Balamurugan, Kuppusamy; Mendoza-Villanueva, Daniel; Sharan, Shikha; Summers, Glenn H.; Dobrolecki, Lacey E.; Lewis, Michael T.; Sterneck, Esta			C/EBP delta links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes	ONCOGENE			English	Article						Hypoxia; IL-6; Breast cancer; Cancer stem cells; C/EBP; CEBPD; Inflammation; FBXW7; NOTCH; MYC	TUMOR-INITIATING CELLS; EXPRESSION; IDENTIFICATION; INFLAMMATION; METASTASIS; CARCINOMA; PATHWAY; MODELS; DRIVER	To improve cancer patient outcome significantly, we must understand the mechanisms regulating stem-like cancer cells, which have been implicated as a cause of metastasis and treatment resistance. The transcription factor C/EBP delta can exhibit pro- and anti-tumorigenic activities, but the mechanisms underlying the complexity of its functions are poorly understood. Here we identify a role for breast cancer cell intrinsic C/EBP delta in promoting phenotypes that have been associated with cancer stem cells (CSCs). While C/EBP delta expression is not abundant in most metastatic breast cancers, our data support a pro-tumorigenic role of C/EBP delta when expressed in subsets of tumor cells and/or through transient activation by the tumor microenvironment or loss of substrate adhesion. Using genetic mouse models and human breast cancer cell lines, we show that deletion or depletion of C/EBP delta reduced expression of stem cell factors and stemnness markers, sphere formation and self-renewal, along with growth of tumors and established experimental metastases in vivo. C/EBP delta is also known as a mediator of the innate immune response, which is enhanced by hypoxia and interleukin-6 (IL-6) signaling, two conditions that also play important roles in cancer progression. Our mechanistic data reveal C/EBP delta as a link that engages two positive feedback loops, in part by directly targeting the IL-6 receptor (IL6RA) gene, and, thus, amplifying IL-6 and HIF-1 signaling. This study provides a molecular mechanism for the synergism of tumor microenvironmental conditions in cancer progression with potential implications for the targeting of CSCs.	[Balamurugan, Kuppusamy; Mendoza-Villanueva, Daniel; Sharan, Shikha; Sterneck, Esta] NCI, Lab Cell & Dev Signaling, Ctr Canc Res, Frederick, MD 21702 USA; [Summers, Glenn H.] Leidos Biomed Res Inc, Lab Anim Sci Program, Frederick, MD 21702 USA; [Dobrolecki, Lacey E.; Lewis, Michael T.] Baylor Coll Med, Dept Mol & Cellular Biol, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Dobrolecki, Lacey E.; Lewis, Michael T.] Baylor Coll Med, Dept Radiol, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Mendoza-Villanueva, Daniel] Mission Bio, San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine; Baylor College of Medicine	Balamurugan, K; Sterneck, E (corresponding author), NCI, Lab Cell & Dev Signaling, Ctr Canc Res, Frederick, MD 21702 USA.	kuppusamyb@mail.nih.gov; sternecg@mail.nih.gov	Lewis, Michael T/A-9572-2009; Kuppusamy, Balamurugan/AAC-6020-2022	Sterneck, Esta/0000-0001-7716-8766	Intramural Research Program of the NIH, National Cancer Institute; Frederick Cancer Institute (NIH) [HHSN261200800001E]; BCRF Founders Fund Grant [CPRIT DP150069]; V-Foundation grant [T2014-010]; NATIONAL CANCER INSTITUTE [ZIABC010307] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Frederick Cancer Institute (NIH); BCRF Founders Fund Grant; V-Foundation grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are thankful for superb support through services provided by Leidos Biomedical Research, Inc., FNLCR (Laboratory Animal Sciences Program, Protein Expression Laboratory, Illustrations, and Graphical Support); and the NCI/CCR cores (Small Animal Imaging, Flow Cytometry, Optical Microscopy, and Analysis Laboratory); and Data Management Services, Inc. for assistance with Statistics. We thank Linda Miller, Suzanne Specht, Rena Mao, and the student interns for their valuable contributions; Heidi Dowst for providing clinical information related to the PDX models; and all the investigators who kindly shared their valuable reagents (see Methods) or provided critical comments on the manuscript. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, in part with Federal Funds from the Frederick Cancer Institute (NIH) under contract no. HHSN261200800001E. LED and MTL were supported by BCRF Founders Fund Grant CPRIT DP150069 and V-Foundation grant T2014-010. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Balamurugan K, 2016, INT J CANCER, V138, P1058, DOI 10.1002/ijc.29519; Balamurugan K, 2013, INT J BIOL SCI, V9, P917, DOI 10.7150/ijbs.7224; Balamurugan K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2677; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Brower V, 2016, JNCI-J NATL CANCER I, V108, P2; Chang Q, 2014, SEMIN IMMUNOL, V26, P48, DOI 10.1016/j.smim.2014.01.007; Chen JC, 2014, CELL, V159, P402, DOI 10.1016/j.cell.2014.09.021; Cojoc Monica, 2013, Onco Targets Ther, V6, P1347, DOI 10.2147/OTT.S36109; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; Dobrolecki LE, 2016, CANCER METAST REV, V35, P547, DOI 10.1007/s10555-016-9653-x; Espinoza I, 2013, ONCOTARGETS THER, V6, P1249, DOI 10.2147/OTT.S36162; Fallah Y, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7030053; Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Gwak JM, 2017, ONCOTARGET, V8, P36305, DOI 10.18632/oncotarget.16750; Harrison H, 2013, CANCER RES, V73, P1420, DOI 10.1158/0008-5472.CAN-12-2505; Kageyama Y, 2004, FASEB J, V18, P1028, DOI 10.1096/fj.03-1233fje; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Lagadec C, 2014, STEM CELLS, V32, P135, DOI 10.1002/stem.1537; Litvak V, 2009, NAT IMMUNOL, V10, P437, DOI 10.1038/ni.1721; Luo M, 2015, CURR PHARM DESIGN, V21, P1301, DOI 10.2174/1381612821666141211120604; Mamlouk S, 2013, INT J CANCER, V132, P2721, DOI 10.1002/ijc.27901; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mathieu J, 2011, CANCER RES, V71, P4640, DOI 10.1158/0008-5472.CAN-10-3320; Mendoza-Villanueva D, 2016, ONCOGENE, V35, P6166, DOI 10.1038/onc.2016.156; Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340; Min Y, 2011, ONCOGENE, V30, P4901, DOI 10.1038/onc.2011.187; Min YF, 2017, ONCOTARGET, V8, P50582, DOI 10.18632/oncotarget.16410; Mitra A, 2015, ONCOTARGET, V6, P10697, DOI 10.18632/oncotarget.4037; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rustighi A, 2014, EMBO MOL MED, V6, P99, DOI 10.1002/emmm.201302909; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sarkar TR, 2012, MOL CELL BIOL, V32, P320, DOI 10.1128/MCB.05790-11; Seymour T, 2015, INT J MOL SCI, V16, P27288, DOI 10.3390/ijms161126024; Tabassum DP, 2015, NAT REV CANCER, V15, P473, DOI 10.1038/nrc3971; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang YH, 2015, ONCOTARGET, V6, P31069, DOI 10.18632/oncotarget.5209; Watanabe M, 2014, CYTOM PART A, V85, P206, DOI 10.1002/cyto.a.22422; Wei W, 2015, ENDOCR-RELAT CANCER, V22, pR135, DOI 10.1530/ERC-14-0447; Wei W, 2014, STEM CELLS, V32, P2571, DOI 10.1002/stem.1752; Yamaguchi J, 2015, KIDNEY INT, V88, P262, DOI 10.1038/ki.2015.21; Yan WX, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-62; Yang AM, 2017, CANCER RES, V77, P6641, DOI 10.1158/0008-5472.CAN-16-3452; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081; Zou J, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-3; 2012, ONCOGENE, V31, P2614, DOI DOI 10.1038/ONC.2011.439	49	27	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3765	3780		10.1038/s41388-018-0516-5	http://dx.doi.org/10.1038/s41388-018-0516-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30262865	Green Accepted			2022-12-17	WOS:000468035600001
J	Tenvooren, I; Jenks, MZ; Rashid, H; Cook, KL; Muhlemann, JK; Sistrunk, C; Holmes, J; Wang, K; Bonin, K; Hodges, K; Lo, HW; Shaikh, A; Camarillo, IG; Lelievre, SA; Seewaldt, V; Vidi, PA				Tenvooren, Iliana; Jenks, Monica Z.; Rashid, Hamza; Cook, Katherine L.; Muhlemann, Joelle K.; Sistrunk, Christopher; Holmes, Julia; Wang, Kevin; Bonin, Keith; Hodges, Kurt; Lo, Hui-Wen; Shaikh, Ayaz; Camarillo, Ignacio G.; Lelievre, Sophie A.; Seewaldt, Victoria; Vidi, Pierre-Alexandre			Elevated leptin disrupts epithelial polarity and promotes premalignant alterations in the mammary gland	ONCOGENE			English	Article							BREAST-CANCER RISK; CELL POLARITY; GROWTH-FACTOR; NUCLEAR-ORGANIZATION; SIGNALING PATHWAYS; CIRCULATING LEVELS; NORMAL-WEIGHT; OBESITY; ADIPONECTIN; AFADIN	Obesity is a highly prevalent and modifiable breast cancer risk factor. While the role of obesity in fueling breast cancer progression is well established, the mechanisms linking obesity to breast cancer initiation are poorly understood. A hallmark of breast cancer initiation is the disruption of apical polarity in mammary glands. Here we show that mice with diet-induced obesity display mislocalization of Par3, a regulator of cellular junctional complexes defining mammary epithelial polarity. We found that epithelial polarity loss also occurs in a 3D coculture system that combines acini with human mammary adipose tissue, and establish that a paracrine effect of the tissue adipokine leptin causes loss of polarity by overactivation of the PI3K/Akt pathway. Leptin sensitizes non-neoplastic cells to proliferative stimuli, causes mitotic spindle misalignment, and expands the pool of cells with stem/progenitor characteristics, which are early steps for cancer initiation. We also found that normal breast tissue samples with high leptin/adiponectin transcript ratio characteristic of obesity have an altered distribution of apical polarity markers. This effect is associated with increased epithelial cell layers. Our results provide a molecular basis for early alterations in epithelial architecture during obesity-mediated cancer initiation.	[Tenvooren, Iliana; Jenks, Monica Z.; Rashid, Hamza; Holmes, Julia; Lo, Hui-Wen; Vidi, Pierre-Alexandre] Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; [Cook, Katherine L.] Wake Forest Sch Med, Dept Surg, Winston Salem, NC 27157 USA; [Cook, Katherine L.; Vidi, Pierre-Alexandre] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA; [Muhlemann, Joelle K.] Wake Forest Univ, Dept Biol, Winston Salem, NC 27109 USA; [Sistrunk, Christopher; Seewaldt, Victoria] City Hope Natl Med Ctr, Dept Populat Sci, Duarte, CA 91010 USA; [Wang, Kevin; Bonin, Keith] Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA; [Hodges, Kurt] Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45219 USA; [Shaikh, Ayaz] Indiana Univ Sch Med, IU Hlth Arnett Hosp, Lafayette, IN 47905 USA; [Camarillo, Ignacio G.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Lelievre, Sophie A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; City of Hope; Wake Forest University; University System of Ohio; University of Cincinnati; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Vidi, PA (corresponding author), Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA.; Vidi, PA (corresponding author), Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA.	pvidi@wakehealth.edu		LELIEVRE, Sophie/0000-0001-6606-2501; Muhlemann, Joelle/0000-0003-2431-4357; Sistrunk, Christopher/0000-0002-5951-1361; Cook, Katherine/0000-0001-6241-0214	National Institute of Health [R00CA163957]; Walther Cancer Foundation; Wake Forest Center for Molecular Signaling (CMS); National Cancer Institute's Cancer Center Support Grant [P30CA012197]; NATIONAL CANCER INSTITUTE [R01CA158668, R01CA192914, P30CA012197, R00CA163957] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Walther Cancer Foundation; Wake Forest Center for Molecular Signaling (CMS); National Cancer Institute's Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kenneth Grant for assistance with electron microscopy and Dr. Fei Xing for assistance with stem cell analyses. The CA-Akt construct was a gift from Dr. Mong-Hong Lee (MD Anderson Cancer Center). NuMA B1C11 antibodies were kindly provided by Dr. J. Nickerson (University of Massachusetts). This work was funded by the National Institute of Health (R00CA163957 to PAV), the Walther Cancer Foundation (to SAL, PAV, and IGC), the Wake Forest Center for Molecular Signaling (CMS; to PAV and KB), and the National Cancer Institute's Cancer Center Support Grant award number P30CA012197 issued to the Wake Forest Baptist Comprehensive Cancer Center. SAL, VS, and PAV are members of the International Breast Cancer & Nutrition (IBCN) program.	Ando S, 2012, NAT REV ENDOCRINOL, V8, P263, DOI 10.1038/nrendo.2011.184; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Bartella V, 2008, CANCER RES, V68, P4919, DOI 10.1158/0008-5472.CAN-08-0642; Bissell MJ, 1999, CANCER RES, V59, p1757S; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carminati M, 2016, NAT STRUCT MOL BIOL, V23, P155, DOI 10.1038/nsmb.3152; Carpenter RL, 2015, ONCOGENE, V34, P546, DOI 10.1038/onc.2013.582; Cecchini RS, 2012, CANCER PREV RES, V5, P583, DOI 10.1158/1940-6207.CAPR-11-0482; Chandramouly G, 2007, J CELL SCI, V120, P1596, DOI 10.1242/jcs.03439; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Dietze EC, 2015, NAT REV CANCER, V15, P248, DOI 10.1038/nrc3896; Dubois V, 2014, NUTR CANCER, V66, P645, DOI 10.1080/01635581.2014.894104; Elloul S, 2014, MOL CANCER RES, V12, P464, DOI 10.1158/1541-7786.MCR-13-0398; Esper RM, 2015, CANCER PREV RES, V8, P1174, DOI 10.1158/1940-6207.CAPR-14-0334; Fan Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120775; Fang LH, 2007, CELL RES, V17, P100, DOI 10.1038/sj.cr.7310145; Feigin ME, 2014, CANCER RES, V74, P3180, DOI 10.1158/0008-5472.CAN-13-3415; Grafton MMG, 2011, INTEGR BIOL-UK, V3, P451, DOI [10.1039/c0ib00132e, 10.1039/c0ib00132c]; Grossmann ME, 2012, BIOCHIMIE, V94, P2164, DOI 10.1016/j.biochi.2012.06.013; Gunter MJ, 2009, JNCI-J NATL CANCER I, V101, P48, DOI 10.1093/jnci/djn415; Hao Y, 2010, CURR BIOL, V20, P1809, DOI 10.1016/j.cub.2010.09.032; Hu X, 2002, J NATL CANCER I, V94, P1704, DOI 10.1093/jnci/94.22.1704; Hursting SD, 2012, CANCER PREV RES, V5, P1260, DOI 10.1158/1940-6207.CAPR-12-0140; Ibarra-Drendall C, 2012, BREAST CANCER RES TR, V132, P487, DOI 10.1007/s10549-011-1609-9; Kim CS, 2006, INT J OBESITY, V30, P1347, DOI 10.1038/sj.ijo.0803259; Lelievre SA, 2010, J MAMMARY GLAND BIOL, V15, P49, DOI 10.1007/s10911-010-9168-y; Macara IG, 2014, CURR BIOL, V24, pR815, DOI 10.1016/j.cub.2014.06.068; Macis D, 2014, INT J EPIDEMIOL, V43, P1226, DOI 10.1093/ije/dyu088; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Matsubara M, 2002, EUR J ENDOCRINOL, V147, P173, DOI 10.1530/eje.0.1470173; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6; Niu DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067456; Ogden Cynthia L, 2015, NCHS Data Brief, P1; Ooshio T, 2010, J BIOL CHEM, V285, P5003, DOI 10.1074/jbc.M109.043760; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pierobon M, 2013, BREAST CANCER RES TR, V137, P307, DOI 10.1007/s10549-012-2339-3; Rangel MC, 2016, BREAST CANCER RES TR, V156, P211, DOI 10.1007/s10549-016-3746-7; Ray A, 2017, CYTOKINE GROWTH F R, V38, P80, DOI 10.1016/j.cytogfr.2017.11.002; Renehan AG, 2015, NAT REV CANCER, V15, P484, DOI 10.1038/nrc3967; Roignot J, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013789; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Saxena NK, 2013, J MAMMARY GLAND BIOL, V18, P309, DOI 10.1007/s10911-013-9308-2; Schwartz GF, 2008, CANCER, V113, P2627, DOI 10.1002/cncr.23903; Sumis A, 2016, ENDOCR-RELAT CANCER, V23, P839, DOI 10.1530/ERC-16-0359; Takai Y, 2008, ANNU REV CELL DEV BI, V24, P309, DOI 10.1146/annurev.cellbio.24.110707.175339; Teixeira TFS, 2012, NUTR RES, V32, P637, DOI 10.1016/j.nutres.2012.07.003; Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13; Vidi PA, 2012, J CELL SCI, V125, P350, DOI 10.1242/jcs.089177; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Wheatley KE, 2011, J OBES, V2011, DOI 10.1155/2011/265417; Wu MH, 2009, BRIT J CANCER, V100, P578, DOI 10.1038/sj.bjc.6604913; Xue GD, 2013, JNCI-J NATL CANCER I, V105, P393, DOI 10.1093/jnci/djs648; Zeidan A, 2007, J PHARMACOL EXP THER, V322, P1110, DOI 10.1124/jpet.107.122440	57	27	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3855	3870		10.1038/s41388-019-0687-8	http://dx.doi.org/10.1038/s41388-019-0687-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30670780	Green Accepted			2022-12-17	WOS:000468035600007
J	Louault, K; Bonneaud, TL; Seveno, C; Gomez-Bougie, P; Nguyen, F; Gautier, F; Bourgeois, N; Loussouarn, D; Kerdraon, O; Barille-Nion, S; Jezequel, P; Campone, M; Amiot, M; Juin, PP; Souaze, F				Louault, K.; Bonneaud, T. L.; Seveno, C.; Gomez-Bougie, P.; Nguyen, F.; Gautier, F.; Bourgeois, N.; Loussouarn, D.; Kerdraon, O.; Barille-Nion, S.; Jezequel, P.; Campone, M.; Amiot, M.; Juin, P. P.; Souaze, F.			Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers	ONCOGENE			English	Article							BCL-2; CARCINOMA; DETERMINANT; SENSITIVITY; APOPTOSIS; FEATURES; IMPACT; IL-6	Selective inhibition of BCL-2 is expected to enhance therapeutic vulnerability in luminal estrogen receptor-positive breast cancers. We show here that the BCL-2 dependency of luminal tumor cells is nevertheless mitigated by breast cancer-associated fibroblasts (bCAFs) in a manner that defines MCL-1 as another critical therapeutic target. bCAFs favor MCL-1 expression and apoptotic resistance in luminal cancer cells in a IL-6 dependent manner while their own, robust, survival also relies on MCL-1. Studies based on ex vivo cultures of human luminal breast cancer tissues further argue that the contribution of stroma-derived signals to MCL-1 expression shapes BCL-2 dependency. Thus, MCL-1 inhibitors are beneficial for targeted apoptosis of breast tumor ecosystems, even in a subtype where MCL-1 dependency is not intrinsically driven by oncogenic pathways.	[Louault, K.; Bonneaud, T. L.; Seveno, C.; Nguyen, F.; Gautier, F.; Bourgeois, N.; Barille-Nion, S.; Jezequel, P.; Campone, M.; Juin, P. P.; Souaze, F.] Univ Nantes, Univ Angers, INSERM, CRCINA,Team 8, Nantes, France; [Louault, K.; Bonneaud, T. L.; Seveno, C.; Gomez-Bougie, P.; Gautier, F.; Bourgeois, N.; Kerdraon, O.; Barille-Nion, S.; Jezequel, P.; Campone, M.; Amiot, M.; Juin, P. P.; Souaze, F.] SIRIC ILIAD, Nantes, France; [Gomez-Bougie, P.; Amiot, M.] Univ Nantes, Univ Angers, INSERM, CRCINA,Team 10, Nantes, France; [Nguyen, F.] Nantes Atlantic Coll Vet Med Food Sci & Engn, ONIRIS, Anim Canc, Nantes, France; [Gautier, F.; Kerdraon, O.; Jezequel, P.; Campone, M.; Juin, P. P.] ICO Rene Gauducheau, St Herblain, France; [Loussouarn, D.] CHU Nantes, Serv Anat Pathol, Nantes, France; [Juin, P. P.; Souaze, F.] CNRS GDR3697 Micronit, Tours, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Nantes Universite; CHU de Nantes	Juin, PP; Souaze, F (corresponding author), Univ Nantes, Univ Angers, INSERM, CRCINA,Team 8, Nantes, France.; Juin, PP; Souaze, F (corresponding author), SIRIC ILIAD, Nantes, France.; Juin, PP (corresponding author), ICO Rene Gauducheau, St Herblain, France.; Juin, PP; Souaze, F (corresponding author), CNRS GDR3697 Micronit, Tours, France.	philippe.juin@univ-nantes.fr; frederique.souaze@univ-nantes.fr	JUIN, Philippe/Q-1338-2019; souazé, frédérique/AAE-6478-2021; JUIN, Philippe P/H-3636-2014; Barille-nion, sophie/W-8103-2019	JUIN, Philippe/0000-0002-4997-3888; JUIN, Philippe P/0000-0002-4997-3888; Barille-nion, sophie/0000-0001-5171-9937; Nguyen, Frederique/0000-0001-7203-2982; Gomez Bougie, Patricia/0000-0002-4846-4782; Frederique, Souaze/0000-0003-0476-2603; Louault, Kevin/0000-0002-2325-5757	CIFRE grant (ANRT contract) [20150995]; Ligue contre le cancer; Odyssea; Canceropole Grand Ouest (MATURE project 2017-18); ARC [R15083NN]; ANR [15-CE18-0008]; INCa; DGOS (SIRIC ILIAD, INCa-DGOS Inserm) [12558]	CIFRE grant (ANRT contract)(French National Research Agency (ANR)); Ligue contre le cancer(Ligue nationale contre le cancer); Odyssea; Canceropole Grand Ouest (MATURE project 2017-18); ARC(Australian Research Council); ANR(French National Research Agency (ANR)); INCa(Institut National du Cancer (INCA) France); DGOS (SIRIC ILIAD, INCa-DGOS Inserm)	This research was performed within the framework of a CIFRE grant (ANRT contract #20150995) for K. Louault at CRCINA and ONCOTHEREX. T.L Bonneaud was supported by a fellowship from Ligue contre le cancer. This work was supported by Odyssea, Canceropole Grand Ouest (MATURE project 2017-18), ARC (R15083NN), ANR (15-CE18-0008), INCa and DGOS (SIRIC ILIAD, INCa-DGOS Inserm-12558).	Campbell KJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0035-2; Campone M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-110; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Denys H, 2008, CANCER LETT, V266, P263, DOI 10.1016/j.canlet.2008.02.068; Dousset C, 2017, BRIT J HAEMATOL, V179, P684, DOI 10.1111/bjh.14251; Foight GW, 2014, ACS CHEM BIOL, V9, P1962, DOI 10.1021/cb500340w; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Hendrayani SF, 2016, ONCOTARGET, V7, P41974, DOI 10.18632/oncotarget.9633; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Jezequel P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0550-y; Juin P, 2013, NAT REV CANCER, V13, P455, DOI 10.1038/nrc3538; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Kumar S, 2017, BLOOD, V130, P2401, DOI 10.1182/blood-2017-06-788786; Labovsky V, 2016, TUMOR BIOL, V37, P13377, DOI 10.1007/s13277-016-5268-7; Lagares D, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3765; Leu CM, 2003, ONCOGENE, V22, P7809, DOI 10.1038/sj.onc.1207084; Ma YF, 2017, ADV CLIN EXP MED, V26, P421, DOI 10.17219/acem/62120; Marusyk A, 2016, CANCER RES, V76, P6495, DOI 10.1158/0008-5472.CAN-16-1457; Merino D, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7049; Mertens JC, 2013, CANCER RES, V73, P897, DOI 10.1158/0008-5472.CAN-12-2130; Montero J, 2018, CELL DEATH DIFFER, V25, P56, DOI 10.1038/cdd.2017.183; Oakes SR, 2012, P NATL ACAD SCI USA, V109, P2766, DOI 10.1073/pnas.1104778108; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Qiao AX, 2016, FRONT MED-PRC, V10, P33, DOI 10.1007/s11684-016-0431-5; Romagnoli M, 2007, LEUKEMIA, V21, P1070, DOI 10.1038/sj.leu.2404602; Ryan J, 2013, METHODS, V61, P156, DOI 10.1016/j.ymeth.2013.04.006; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sansone P, 2017, CANCER RES, V77, P1927, DOI 10.1158/0008-5472.CAN-16-2129; Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442; Seveno C, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3214; Trecesson SD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01079-1; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Winslow S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0530-2; Xiao Y, 2015, MOL CANCER THER, V14, P1837, DOI 10.1158/1535-7163.MCT-14-0928; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Young AIJ, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0781-6	39	27	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3261	3273		10.1038/s41388-018-0635-z	http://dx.doi.org/10.1038/s41388-018-0635-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30631150	hybrid, Green Published			2022-12-17	WOS:000465557200011
J	Zhang, L; Cheng, FL; Wei, YJ; Zhang, LJ; Guo, DS; Wang, BF; Li, W				Zhang, Lei; Cheng, Fangling; Wei, Yiju; Zhang, Lijun; Guo, Dongsheng; Wang, Baofeng; Li, Wei			Inhibition of TAZ contributes radiation-induced senescence and growth arrest in glioma cells	ONCOGENE			English	Article							IONIZING-RADIATION; GLIOBLASTOMA-MULTIFORME; HIPPO PATHWAY; GENE; EXPRESSION; PROGRESSION; SUBTYPES; THERAPY	Glioblastoma (GBM) is the most aggressive brain tumor and resistant to current available therapeutics, such as radiation. To improve the clinical efficacy, it is important to understand the cellular mechanisms underlying tumor responses to radiation. Here, we investigated long-term cellular responses of human GBM cells to ionizing radiation. Comparing to the initial response within 12 hours, gene expression modulation at 7 days after radiation is markedly different. While genes related to cell cycle arrest and DNA damage responses are mostly modulated at the initial stage; immune-related genes are specifically affected as the long-term effect. This later response is associated with increased cellular senescence and inhibition of transcriptional coactivator with PDZ-binding motif (TAZ). Mechanistically, TAZ inhibition does not depend on the canonical Hippo pathway, but relies on enhanced degradation mediated by the beta-catenin destruction complex in the Wnt pathway. We further showed that depletion of TAZ by RNAi promotes radiation-induced senescence and growth arrest. Pharmacological activation of the beta-catenin destruction complex is able to promote radiation-induced TAZ inhibition and growth arrest in these tumor cells. The correlation between senescence and reduced expression of TAZ as well as beta-catenin also occurs in human gliomas treated by radiation. Collectively, these findings suggested that inhibition of TAZ is involved in radiation-induced senescence and might benefit GBM radiotherapy.	[Zhang, Lei; Wei, Yiju; Li, Wei] Penn State Coll Med, Div Pediat Hematol Oncol, Dept Pediat, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA; [Zhang, Lei] Huazhong Univ Sci & Technol, Hepat Surg Ctr, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Cheng, Fangling; Guo, Dongsheng; Wang, Baofeng] Huazhong Univ Sci & Technol, Dept Neurosurg, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Zhang, Lijun] Penn State Coll Med, Inst Personalized Med, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA; [Zhang, Lijun; Li, Wei] Penn State Coll Med, Dept Biochem & Mol Biol, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Li, W (corresponding author), Penn State Coll Med, Div Pediat Hematol Oncol, Dept Pediat, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA.; Li, W (corresponding author), Penn State Coll Med, Dept Biochem & Mol Biol, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA.	weili@pennstatehealth.psu.edu	Zhang, Lei/AAJ-2148-2020	Li, Wei/0000-0001-5696-4309; Zhang, Lei/0000-0002-2227-0613	National Natural Science Foundation of China [81472364]; National Institutes of Health [K22 5K22CA190440]; American Cancer Society-Institutional Research Grant [124171-IRG-13-043-01]; Four Diamonds Fund for Pediatric Cancer Research; NATIONAL CANCER INSTITUTE [K22CA190440] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society-Institutional Research Grant(American Cancer Society); Four Diamonds Fund for Pediatric Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Brian J. Lorah, Kim Powell, Bryan E. Achey and Steven P. Leibig in the Division of Health Physics, Yuka Imamura Kawasawa in the Institute for Personalized Medicine of Penn State College of Medicine for technical support. We thank Dong Kuang and Yan-Bing Chen in Department of Pathology of Tongji Hospital, Tongji Medical College, HUST for pathologic analysis. This work was supported by the National Natural Science Foundation of China 81472364 (to B.W.), the National Institutes of Health Grant K22 5K22CA190440 (to W.L.), the American Cancer Society-Institutional Research Grant 124171-IRG-13-043-01 (to W.L.), and the Four Diamonds Fund for Pediatric Cancer Research (to W.L.).	Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Bassi CL, 2008, HUM EXP TOXICOL, V27, P919, DOI 10.1177/0960327108102045; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; BURGER PC, 1983, J NEUROSURG, V58, P159, DOI 10.3171/jns.1983.58.2.0159; Camphausen KV, 2005, CANCER RES, V65, P10389, DOI 10.1158/0008-5472.CAN-05-1904; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Godoy PRDV, 2013, MUTAT RES-GEN TOX EN, V756, P46, DOI 10.1016/j.mrgentox.2013.06.010; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Jin HH, 2017, EUR J PHARM SCI, V96, P323, DOI 10.1016/j.ejps.2016.10.002; Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li W, 2014, CANCER CELL, V26, P48, DOI 10.1016/j.ccr.2014.05.001; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Liu ZJ, 2019, ONCOGENE, V38, P120, DOI 10.1038/s41388-018-0425-7; Lv DG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01731-w; Ma H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.412; Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057; Otomo T, 2004, J RADIAT RES, V45, P53, DOI 10.1269/jrr.45.53; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Quick QA, 2006, J NEUROSURG, V105, P111, DOI 10.3171/jns.2006.105.1.111; Schosserer M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00278; Tihan T, 2006, HUM PATHOL, V37, P272, DOI 10.1016/j.humpath.2005.11.010; Tsai MH, 2007, CANCER RES, V67, P3845, DOI 10.1158/0008-5472.CAN-06-4250; VAN MEIR EG, 1994, CANCER RES, V54, P649; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang J, 2017, J CLIN INVEST, V127, P3075, DOI 10.1172/JCI89092; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Xie Q, 2013, CANCER RES, V73, P3615, DOI 10.1158/0008-5472.CAN-12-3793; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zamorano L, 1989, Acta Neurochir Suppl (Wien), V46, P90; Zhang LH, 2015, ONCOGENE, V34, P600, DOI 10.1038/onc.2013.593	34	27	27	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2788	2799		10.1038/s41388-018-0626-0	http://dx.doi.org/10.1038/s41388-018-0626-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542117	Green Accepted			2022-12-17	WOS:000464121600009
J	Xu, C; Wang, YF; Tu, Q; Zhang, ZY; Chen, MR; Mwangi, J; Li, YX; Jin, Y; Zhao, XD; Lai, R				Xu, Cheng; Wang, Yunfei; Tu, Qiu; Zhang, Zhiye; Chen, Mengrou; Mwangi, James; Li, Yaxiong; Jin, Yang; Zhao, Xudong; Lai, Ren			Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation	ONCOGENE			English	Article							DEFENSE PEPTIDE LL-37; IN-VIVO; GROWTH; GEMCITABINE; THERAPY; PROLIFERATION; MECHANISMS; RESISTANCE; APOPTOSIS; PROMOTES	Pancreatic cancer remains one of the deadliest human cancers despite current advances in conventional therapeutics including surgery and adjuvant therapies. Here, we showed that LZ1, a peptide derived from a snake venom cathelicidin, significantly inhibited growth of pancreatic cancer cells by inducing autophagy-dependent cell death both in vitro and in vivo. The LZ1-induced cell death was blocked by pharmacological or genetic inhibition of autophagy. In orthotopic model of pancreatic cancer, systemic administration of LZ1 (1-4 mg/kg) exhibited remarkable antitumor efficacy, significantly prolonged mice survival, and showed negligible adverse effects by comparison with gemcitabine (20 mg/kg). Mechanistic studies revealed that LZ1 acts through binding to nucleolin, whose expression on cell surface is frequently increased in pancreatic cancer cells. LZ1 binding triggers degradation of surface-expressed nucleolin. This leads to activation of 5'-AMP kinase which results in suppression of mTORC1 activity and induction of autophagic flux. These data suggest that LZ1, targeting nucleolin-AMPK-autophagy axis, is a promising lead for the development of therapeutic agents against pancreatic cancer.	[Xu, Cheng; Wang, Yunfei; Tu, Qiu; Zhang, Zhiye; Mwangi, James; Zhao, Xudong; Lai, Ren] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China; [Xu, Cheng; Wang, Yunfei; Mwangi, James] Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming 650204, Yunnan, Peoples R China; [Chen, Mengrou; Lai, Ren] Nanjing Agr Univ, Life Sci Coll, Nanjing 210095, Jiangsu, Peoples R China; [Mwangi, James; Lai, Ren] Chinese Acad Sci, Sino African Joint Res Ctr, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China; [Li, Yaxiong] Kunming Med Univ, Yanan Affiliated Hosp, Dept Cardiovasc Surg, Kunming 650041, Yunnan, Peoples R China; [Jin, Yang] Oslo Univ Hosp, Inst Canc Genet & Informat, Oslo, Norway	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Nanjing Agricultural University; Chinese Academy of Sciences; Kunming Institute of Zoology; Kunming Medical University; University of Oslo	Zhao, XD; Lai, R (corresponding author), Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.; Lai, R (corresponding author), Nanjing Agr Univ, Life Sci Coll, Nanjing 210095, Jiangsu, Peoples R China.; Lai, R (corresponding author), Chinese Acad Sci, Sino African Joint Res Ctr, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.; Jin, Y (corresponding author), Oslo Univ Hosp, Inst Canc Genet & Informat, Oslo, Norway.	yangj@ibv.uio.no; zhaoxudong@mail.kiz.ac.cn; rlai@mail.kiz.ac.cn	Jin, Yang/GXF-7896-2022	Jin, Yang/0000-0002-7996-048X; zhao, zhao xu dong/0000-0001-9126-7365; Zhang, Zhiye/0000-0002-1661-2277	National Natural Science Foundation of China [21761142002, 81770464]; Ministry of Science and Technology [2018ZX09301043-003]; Chinese Academy of Science [QYZDJ-SSWSMC012, SAJC201606]; Chinese Academy of Science (West Light Foundation); Chinese Academy of Science (Youth Innovation Promotion Association) [2017432]; Yunnan Provincial Science and Technology Department [2017FB038, 2015BC005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Chinese Academy of Science(Chinese Academy of Sciences); Chinese Academy of Science (West Light Foundation); Chinese Academy of Science (Youth Innovation Promotion Association); Yunnan Provincial Science and Technology Department	This work was supported by National Natural Science Foundation of China (21761142002 and 81770464), Ministry of Science and Technology (2018ZX09301043-003), Chinese Academy of Science (QYZDJ-SSWSMC012, SAJC201606, the West Light Foundation and Youth Innovation Promotion Association (2017432)) and Yunnan Provincial Science and Technology Department (2017FB038, 2015BC005).	Benedetti E, 2015, ONCOTARGET, V6, P42091, DOI 10.18632/oncotarget.5990; Berger CM, 2015, BIOCHIMIE, V113, P78, DOI 10.1016/j.biochi.2015.03.023; Cavalcante LD, 2014, EUR J PHARMACOL, V741, P8, DOI [10.1010/j.ejphar.2014.07.041, 10.1016/j.ejphar.2014.07.041]; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Destouches D, 2011, CANCER RES, V71, P3296, DOI 10.1158/0008-5472.CAN-10-3459; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; Farin K, 2011, CANCER RES, V71, P2140, DOI 10.1158/0008-5472.CAN-10-2887; Galzio R, 2012, J CELL BIOCHEM, V113, P571, DOI 10.1002/jcb.23381; Gilles ME, 2016, CANCER RES, V76, P7181, DOI 10.1158/0008-5472.CAN-16-0300; Goldshmit Y, 2014, ONCOTARGET, V5, P8602, DOI 10.18632/oncotarget.2343; Hamma-Kourbali Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-212; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; He XQ, 2016, EBIOMEDICINE, V13, P248, DOI 10.1016/j.ebiom.2016.10.022; Hidalgo M, 2015, PANCREATOLOGY, V15, P8, DOI 10.1016/j.pan.2014.10.001; Hovanessian AG, 2006, CELL RES, V16, P174, DOI 10.1038/sj.cr.7310024; Huang Y, 2006, BLOOD, V107, P3564, DOI 10.1182/blood-2005-07-2961; Khanbolooki S, 2006, MOL CANCER THER, V5, P2251, DOI 10.1158/1535-7163.MCT-06-0075; Kim MP, 2008, CLIN CANCER RES, V14, P1284, DOI 10.1158/1078-0432.CCR-07-2247; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Krust B, 2001, P NATL ACAD SCI USA, V98, P14090, DOI 10.1073/pnas.221467298; Krust B, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-333; Li FF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01565-6; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Mongelard F, 2007, TRENDS CELL BIOL, V17, P80, DOI 10.1016/j.tcb.2006.11.010; Nazli O, 2000, HEPATO-GASTROENTEROL, V47, P1750; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; Paglin S, 2001, CANCER RES, V61, P439; Palmieri D, 2015, P NATL ACAD SCI USA, V112, P9418, DOI 10.1073/pnas.1507087112; Qin JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9471; Ren SX, 2012, CANCER RES, V72, P6512, DOI 10.1158/0008-5472.CAN-12-2359; Reyes-Reyes EM, 2010, CANCER RES, V70, P8617, DOI 10.1158/0008-5472.CAN-10-0920; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Said EA, 2005, FEBS J, V272, P4646, DOI 10.1111/j.1742-4658.2005.04870.x; Said EA, 2002, J BIOL CHEM, V277, P37492, DOI 10.1074/jbc.M201194200; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Shen SS, 2012, AUTOPHAGY, V8, P1, DOI 10.4161/auto.8.1.16618; Shi S, 2012, CANCER LETT, V317, P127, DOI 10.1016/j.canlet.2011.11.029; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soundararajan S, 2008, CANCER RES, V68, P2358, DOI 10.1158/0008-5472.CAN-07-5723; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wang H, 2013, EUR J PHARMACOL, V707, P1, DOI 10.1016/j.ejphar.2013.03.028; Wu WKK, 2010, INT J CANCER, V127, P1741, DOI 10.1002/ijc.25489; Yang AN, 2018, CANCER DISCOV, V8, P276, DOI 10.1158/2159-8290.CD-17-0952; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017	50	27	28	5	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1832	1844		10.1038/s41388-018-0556-x	http://dx.doi.org/10.1038/s41388-018-0556-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30356139				2022-12-17	WOS:000461164400004
J	Simhadri, S; Vincelli, G; Huo, YY; Misenko, S; Foo, TK; Ahlskog, J; Sorensen, CS; Oakley, GG; Ganesan, S; Bunting, SF; Xia, B				Simhadri, Srilatha; Vincelli, Gabriele; Huo, Yanying; Misenko, Sarah; Foo, Tzeh Keong; Ahlskog, Johanna; Sorensen, Claus S.; Oakley, Gregory G.; Ganesan, Shridar; Bunting, Samuel F.; Xia, Bing			PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; HOMOLOGOUS RECOMBINATION; BRCA1-PALB2 INTERACTION; CANCER; PHOSPHORYLATION; PROTEIN; PARTNER; SUPPRESSION; INSTABILITY; EXPRESSION	The G2/M checkpoint inhibits mitotic entry upon DNA damage, thereby preventing segregation of broken chromosomes and preserving genome stability. The tumor suppressor proteins BRCA1, PALB2 and BRCA2 constitute a BRCA1-PALB2-BRCA2 axis that is essential for homologous recombination (HR)-based DNA doublestrand break repair. Besides HR, BRCA1 has been implicated in both the initial activation and the maintenance of the G2/M checkpoint, while BRCA2 and PALB2 have been shown to be critical for its maintenance. Here we show that all three proteins can play a significant role in both checkpoint activation and checkpoint maintenance, depending on cell type and context, and that PALB2 links BRCA1 and BRCA2 in the checkpoint response. The BRCA1-PALB2 interaction can be important for checkpoint activation, whereas the PALB2-BRCA2 complex formation appears to be more critical for checkpoint maintenance. Interestingly, the function of PALB2 in checkpoint response appears to be independent of CHK1 and CHK2 phosphorylation. Following ionizing radiation, cells with disengaged BRCA1-PALB2 interaction show greatly increased chromosomal abnormalities due apparently to combined defects in HR and checkpoint control. These findings provide new insights into DNA damage checkpoint control and further underscore the critical importance of the proper cooperation of the BRCA and PALB2 proteins in genome maintenance.	[Simhadri, Srilatha; Vincelli, Gabriele; Huo, Yanying; Foo, Tzeh Keong; Ganesan, Shridar; Xia, Bing] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA; [Simhadri, Srilatha; Vincelli, Gabriele; Huo, Yanying; Foo, Tzeh Keong; Xia, Bing] Rutgers Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ 08903 USA; [Simhadri, Srilatha; Ganesan, Shridar] Rutgers Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA; [Misenko, Sarah; Bunting, Samuel F.] Rutgers State Univ, Sch Arts & Sci, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; [Ahlskog, Johanna; Sorensen, Claus S.] Univ Copenhagen, BRIC, Copenhagen, Denmark; [Oakley, Gregory G.] Univ Nebraska, Med Ctr, Coll Dent, Dept Oral Biol, Lincoln, NE 68583 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; University of Copenhagen; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center	Xia, B (corresponding author), Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA.; Xia, B (corresponding author), Rutgers Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ 08903 USA.	xiabi@cinj.rutgers.edu	Foo, Tzeh Keong/AAE-5830-2021	Foo, Tzeh Keong/0000-0003-0168-7054; Sorensen, Claus/0000-0001-6022-9710; HUO, YANYING/0000-0003-4747-4951	National Institutes of Health [R01CA138804, R01CA188096, R01CA190858, R01CA169182]; New Jersey Commission for Cancer Research (NJCCR); NATIONAL CANCER INSTITUTE [R01CA188096, R01CA138804, R01CA169182, R01CA190858] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New Jersey Commission for Cancer Research (NJCCR); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs. J. Jonkers (Netherlands Cancer Institute) and D. Boothman (UT Southwestern Medical Center) for provision of the KB2 mouse mammary tumor cells and isogenic HCT116 cells, respectively. This work was supported by the National Institutes of Health (R01CA138804 and R01CA188096 to BX, R01CA190858 to SFB and R01CA169182 to SG). GV was supported by a postdoctoral fellowship and SM by a predoctoral fellowship from the New Jersey Commission for Cancer Research (NJCCR).	Apostolou P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/747318; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cavanagh H, 2015, HERED CANCER CLIN PR, V13, DOI 10.1186/s13053-015-0038-x; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cotta-Ramusino C, 2011, SCIENCE, V332, P1313, DOI 10.1126/science.1203430; Couch FJ, 2014, SCIENCE, V343, P1466, DOI 10.1126/science.1251827; Cruz-Garcia A, 2014, CELL REP, V9, P451, DOI 10.1016/j.celrep.2014.08.076; Davis TW, 1998, CANCER RES, V58, P767; Evers B, 2010, CLIN CANCER RES, V16, P99, DOI 10.1158/1078-0432.CCR-09-2434; Foo TK, 2017, ONCOGENE, V36, P4161, DOI 10.1038/onc.2017.46; Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Juan G, 1998, CYTOMETRY, V32, P71, DOI 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Lin HR, 2003, J BIOL CHEM, V278, P35979, DOI 10.1074/jbc.M210659200; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Lu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10086; Ma JL, 2012, MOL CELL BIOL, V32, P1506, DOI 10.1128/MCB.06271-11; Menzel T, 2011, EMBO REP, V12, P705, DOI 10.1038/embor.2011.99; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Murphy AK, 2014, J CELL BIOL, V206, P493, DOI 10.1083/jcb.201404111; Oliver AW, 2009, EMBO REP, V10, P990, DOI 10.1038/embor.2009.126; Orthwein A, 2015, NATURE, V528, P422, DOI 10.1038/nature16142; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Shabbeer S, 2013, ONCOGENE, V32, P5005, DOI 10.1038/onc.2012.522; Simhadri S, 2014, J BIOL CHEM, V289, P24617, DOI 10.1074/jbc.M114.566141; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tischkowitz M, 2010, CANCER RES, V70, P7353, DOI 10.1158/0008-5472.CAN-10-1012; Venkitaraman AR, 2014, SCIENCE, V343, P1470, DOI 10.1126/science.1252230; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018	45	27	27	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1585	1596		10.1038/s41388-018-0535-2	http://dx.doi.org/10.1038/s41388-018-0535-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30337689	Green Accepted, Green Submitted			2022-12-17	WOS:000460423800001
J	Chen, TL; Chen, JS; Zhu, YB; Li, Y; Wang, Y; Chen, HJ; Wang, JH; Li, X; Liu, Y; Li, BS; Sun, XL; Ke, YQ				Chen, Taoliang; Chen, Jiansheng; Zhu, Yubo; Li, Yan; Wang, Yun; Chen, Huajian; Wang, Jihui; Li, Xiao; Liu, Yang; Li, Baisheng; Sun, Xinlin; Ke, Yiquan			CsD163, a novel therapeutic target, regulates the proliferation and stemness of glioma cells via casein kinase 2	ONCOGENE			English	Article							MACROPHAGE SCAVENGER RECEPTOR; PROTEIN-KINASE; HUMAN GLIOBLASTOMA; CANCER; CD163; EXPRESSION; BRAIN; CK2; ANTIGEN; CD133	Glioma is a devastating cancer with a dismal prognosis and there is an urgent need to discover novel glioma-specific antigens for glioma therapy. Previous studies have identified CD163-positive tumour cells in certain solid tumours, but CD163 expression in glioma remains unknown. In this study, via an analysis of public datasets, we demonstrated that CD163 overexpression in glioma specimens correlated with an unfavourable patient prognosis. CD163 expression was increased in glioma cells, especially primary glioma cells. The loss of CD163 expression inhibited both cell cycle progression and the proliferation of glioblastoma multiforme (GBM) cell lines and primary glioma cells. CD163 interacted directly with casein kinase 2 (CK2) and CD163 silencing reduced AKT/GSK3 beta/beta-catenin/cyclin D1 pathway activity via CK2. Moreover, CD163 was upregulated in CD133-positive glioma stem cells (GSCs), and CD163 downregulation decreased the expression of GSC markers, including CD133, ALDH1A1, NANOG and OCT4. The knockdown of CD163 impaired GSC stemness by inhibiting the CK2/AKT/GSK3 beta/beta-catenin pathway. Finally, a CD163 antibody successfully induced complement-dependent cytotoxicity against glioma cells. Our findings indicate that CD163 contributes to gliomagenesis via CK2 and provides preclinical evidence that CD163 and the CD163 pathway might serve as a therapeutic target for glioma.	[Chen, Taoliang; Chen, Jiansheng; Zhu, Yubo; Li, Yan; Wang, Yun; Chen, Huajian; Wang, Jihui; Li, Xiao; Liu, Yang; Li, Baisheng; Sun, Xinlin; Ke, Yiquan] Southern Med Univ, Dept Neurosurg,Zhujiang Hosp,Minist China, Natl Key Clin Specialty,Engn Technol Res Ctr Educ, Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou 510282, Guangdong, Peoples R China; [Wang, Yun] Xinjiang Med Univ, Hosp 1, Dept Neurosurg, Urumqi 830054, Peoples R China; [Li, Baisheng] Huizhou Cent Peoples Hosp, Dept Neurosurg, Huizhou 516001, Peoples R China	Southern Medical University - China; Xinjiang Medical University	Sun, XL; Ke, YQ (corresponding author), Southern Med Univ, Dept Neurosurg,Zhujiang Hosp,Minist China, Natl Key Clin Specialty,Engn Technol Res Ctr Educ, Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou 510282, Guangdong, Peoples R China.	zjsunxinlin@163.com; kyquan@smu.edu.cn			Natural Science Foundation of China [81772651, 81772652]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Natural Science Foundation of China (nos. 81772651 and 81772652).	Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860; BIGNER SH, 1985, NEUROL CLIN, V3, P769, DOI 10.1016/S0733-8619(18)31008-9; Binnemars-Postma K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050979; Boussiotis VA, 2018, ONCOGENE, V37, P1121, DOI 10.1038/s41388-017-0024-z; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Calvert JG, 2007, J VIROL, V81, P7371, DOI 10.1128/JVI.00513-07; Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408; Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178; Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604; Dixit D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.10; Fabriek BO, 2009, BLOOD, V113, P887, DOI 10.1182/blood-2008-07-167064; He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Jensen TO, 2010, J CLIN ONCOL, V28; Kaminska B, 2009, INT J ONCOL, V35, P1091, DOI 10.3892/ijo_00000424; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Lai SS, 2016, J HEPATOL, V64, P352, DOI 10.1016/j.jhep.2015.09.025; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lin KY, 2010, ANN SURG ONCOL, V17, P1695, DOI 10.1245/s10434-010-0911-9; Lisi L, 2017, NEUROSCI LETT, V645, P106, DOI 10.1016/j.neulet.2017.02.076; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Lu X, 2011, ADV EXP MED BIOL, V714, P129, DOI 10.1007/978-94-007-0782-5_6; Ma CY, 2018, MED MOL MORPHOL, V51, P13, DOI 10.1007/s00795-017-0165-8; Natsume A, 2008, DRUG DES DEV THER, V3, P7; Nitta RT, 2015, ONCOGENE, V34, P3688, DOI 10.1038/onc.2014.299; Noubissi FK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091587; Olsen BB, 2010, ONCOGENE, V29, P6016, DOI 10.1038/onc.2010.337; Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158; Ostuni R, 2015, TRENDS IMMUNOL, V36, P229, DOI 10.1016/j.it.2015.02.004; Pallares J, 2009, AM J PATHOL, V174, P287, DOI 10.2353/ajpath.2009.080552; Ponce DP, 2011, J CELL PHYSIOL, V226, P1953, DOI 10.1002/jcp.22527; Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923; Prosniak M, 2013, CLIN CANCER RES, V19, P3776, DOI 10.1158/1078-0432.CCR-12-1940; Qi L, 2016, ONCOTARGET, V7, P71673, DOI 10.18632/oncotarget.12317; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Rasper M, 2010, NEURO-ONCOLOGY, V12, P1024, DOI 10.1093/neuonc/noq070; Reardon DA, 2016, CANCER IMMUNOL RES, V4, P124, DOI 10.1158/2326-6066.CIR-15-0151; Reardona DA, 2017, NEURO-ONCOLOGY, V19, P21, DOI 10.1093/neuonc/nox036.071; Ritter M, 2001, EUR J IMMUNOL, V31, P999, DOI 10.1002/1521-4141(200104)31:4<999::AID-IMMU999>3.0.CO;2-R; Sanchez-Torres C, 2003, ARCH VIROL, V148, P2307, DOI 10.1007/s00705-003-0188-4; Shabo I, 2008, INT J CANCER, V123, P780, DOI 10.1002/ijc.23527; Shabo I, 2011, ADV EXP MED BIOL, V714, P141, DOI 10.1007/978-94-007-0782-5_7; Shabo I, 2009, INT J CANCER, V125, P1826, DOI 10.1002/ijc.24506; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tang YY, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0222-5; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xi G, 2016, ONCOGENE, V35, P241, DOI 10.1038/onc.2015.78; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038	57	27	28	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1183	1199		10.1038/s41388-018-0515-6	http://dx.doi.org/10.1038/s41388-018-0515-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30258108				2022-12-17	WOS:000459249800003
J	Fang, LS; Wu, SS; Zhu, X; Cai, JC; Wu, JH; He, ZJ; Liu, L; Zeng, MS; Song, EW; Li, J; Li, MF; Guan, HY				Fang, Lishan; Wu, Shanshan; Zhu, Xun; Cai, Junchao; Wu, Jueheng; He, Zhenjian; Liu, Lei; Zeng, Musheng; Song, Erwei; Li, Jun; Li, Mengfeng; Guan, Hongyu			MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-beta pathway in NSCLC	ONCOGENE			English	Article							LONG NONCODING RNA; CANCER STATISTICS; CELL; 11Q13; GENE; AMPLIFICATION; PROGRESSION; EXPRESSION; PTEN; INVASION	Non-small cell lung cancer (NSCLC) remains a major cause of death worldwide. As metastatic disease is primarily responsible for the poor clinical outcome of NSCLC, it is important to understand the process, and its underlying molecular mechanism as well, via which NSCLC cells disseminate. In this study, we identified a new competing endogenous RNA (ceRNA), namely, the MYEOV transcript, and found that it is upregulated in NSCLC and associated with a poor prognosis of the disease. We further uncovered that the MYEOV ceRNA plays a critical role in the invasion and metastasis of NSCLC cells. Intriguingly, the MYEOV ceRNA exerted its pro-metastatic function independent of its protein-coding capacity, but in a miR-30c-2-3p binding-dependent manner. Further experiments demonstrated that the MYEOV ceRNA sequestered miR30c-2-3p from binding its targets TGFBR2 and USP15 mRNAs, which in turn leading to constitutive activation of TGF-beta signaling and tumor progression in NSCLC. By identifying a new layer of regulatory modality for TGF-beta signaling, our findings extend the current understanding on the molecular mechanism mediating NSCLC progression and highlight a potential role of MYEOV transcript to serve as the therapeutic target.	[Fang, Lishan; Wu, Shanshan; Zhu, Xun; Cai, Junchao; Wu, Jueheng; Liu, Lei; Li, Mengfeng] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China; [Fang, Lishan] Sun Yat Sen Univ, Cent Lab, Affiliated Hosp 8, Shenzhen, Peoples R China; [Wu, Shanshan; Cai, Junchao; Wu, Jueheng; Liu, Lei; Li, Mengfeng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China; [Zhu, Xun] Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Guangdong, Peoples R China; [He, Zhenjian] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China; [Zeng, Musheng] Sun Yat Sen Univ, Dept Expt Res, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China; [Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Surg, Guangzhou, Guangdong, Peoples R China; [Li, Jun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Guangdong, Peoples R China; [Guan, Hongyu] Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, MF (corresponding author), Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou, Guangdong, Peoples R China.; Li, MF (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China.; Guan, HY (corresponding author), Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.	limf@mail.sysu.edu.cn; ghongy@mail.sysu.edu.cn	LIU, LEI/AAL-7491-2021; LIU, LEI/AAY-2012-2020	LIU, LEI/0000-0003-4898-5665; Fang, Lishan/0000-0002-0183-861X	Natural Science Foundation of China [81490752]; Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81621004]; Guangzhou science and technology plan [201803010039]; "Guangdong Te Zhi program" youth science and technology talent of project [2015TQ01R281]; Guangdong Natural Science Funds for Distinguished Young Scholar [2014A030306023]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou science and technology plan; "Guangdong Te Zhi program" youth science and technology talent of project; Guangdong Natural Science Funds for Distinguished Young Scholar	This work was supported by The Natural Science Foundation of China (No. 81490752); The Foundation for Innovative Research Groups of the National Natural Science Foundation of China (No. 81621004); Guangzhou science and technology plan (No. 201803010039). "Guangdong Te Zhi program" youth science and technology talent of project (No. 2015TQ01R281); Guangdong Natural Science Funds for Distinguished Young Scholar (2014A030306023).	Anumanthan G, 2005, BRIT J CANCER, V93, P1157, DOI 10.1038/sj.bjc.6602831; Brown LA, 2006, GYNECOL ONCOL, V100, P264, DOI 10.1016/j.ygyno.2005.08.026; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Cai JC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15870; Cai JC, 2013, CANCER RES, V73, P5402, DOI 10.1158/0008-5472.CAN-13-0297; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; de Almeida RA, 2006, J BIOL CHEM, V281, P695, DOI 10.1074/jbc.M511467200; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; Enright AJ, 2004, GENOME BIOL, V5; Fang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9640; Finger EC, 2008, CARCINOGENESIS, V29, P528, DOI 10.1093/carcin/bgm289; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Horie M, 2017, MOL CANCER RES, V15, P1354, DOI 10.1158/1541-7786.MCR-17-0191; Hui ABY, 2005, CANCER RES, V65, P8125, DOI 10.1158/0008-5472.CAN-05-0648; Janssen JWG, 2002, J HUM GENET, V47, P460, DOI 10.1007/s100380200065; Janssen JWG, 2002, INT J CANCER, V102, P608, DOI 10.1002/ijc.10765; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Leyden J, 2006, BRIT J CANCER, V94, P1204, DOI 10.1038/sj.bjc.6603054; Li J, 2008, CLIN CANCER RES, V14, P6996, DOI 10.1158/1078-0432.CCR-08-0754; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mathew LK, 2014, CANCER DISCOV, V4, P53, DOI 10.1158/2159-8290.CD-13-0291; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Moreaux J, 2010, EXP HEMATOL, V38, P1189, DOI 10.1016/j.exphem.2010.09.002; Moss AC, 2006, BIOCHEM BIOPH RES CO, V345, P216, DOI 10.1016/j.bbrc.2006.04.094; Pao W, 2012, NAT MED, V18, P349, DOI 10.1038/nm.2697; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Rodrigo JP, 2009, J PATHOL, V217, P516, DOI 10.1002/path.2462; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shukla K, 2015, MOL ONCOL, V9, P1106, DOI 10.1016/j.molonc.2015.01.008; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takita J, 2011, CANCER SCI, V102, P1645, DOI 10.1111/j.1349-7006.2011.01995.x; Tan XC, 2018, J CLIN INVEST, V128, P3198, DOI 10.1172/JCI122740; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang Y, 2013, DEV CELL, V25, P69, DOI 10.1016/j.devcel.2013.03.002; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Ying Z, 2017, J CLIN INVEST, V127, P1725, DOI 10.1172/JCI90439; Yu Q, 2000, GENE DEV, V14, P163; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	47	27	28	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					896	912		10.1038/s41388-018-0484-9	http://dx.doi.org/10.1038/s41388-018-0484-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30181549	hybrid, Green Published			2022-12-17	WOS:000458006300010
J	Su, WJ; Hong, LX; Xu, X; Huang, S; Herpai, D; Li, LS; Xu, YX; Truong, L; Hu, WY; Wu, XH; Xiao, CC; Zhang, W; Han, JH; Debinski, W; Xiang, R; Sun, PQ				Su, Weijun; Hong, Lixin; Xu, Xin; Huang, Shan; Herpai, Denise; Li, Lisheng; Xu, Yingxi; Lan Truong; Hu, Wen-Yuan; Wu, Xiaohua; Xiao, Changchun; Zhang, Wei; Han, Jiahuai; Debinski, Waldemar; Xiang, Rong; Sun, Peiqing			miR-30 disrupts senescence and promotes cancer by targeting both p16(INK4A) and DNA damage pathways	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; DOUBLE-STRAND BREAK; RAS-INDUCED SENESCENCE; SMALL RNAS; CHROMATIN IMMUNOPRECIPITATION; MESSENGER-RNAS; CHD7; MICRORNAS; REPAIR; TUMORIGENESIS	miR-30 is a microRNA frequently overexpressed in human cancers. However, the biological consequence of miR-30 overexpression in cancer has been unclear. In a genetic screen, miR-30 was found to abrogate oncogenic-induced senescence, a key tumor-suppressing mechanism that involves DNA damage responses, activation of p53 and induction of p16(INK4A). In cells and mouse models, miR-30 disrupts senescence and promotes cancer by suppressing 2 targets, CHD7 and TNRC6A. We show that while CHD7 is a transcriptional coactivator essential for induction of p16(INK4A) in senescent cells, TNRC6A, a miRNA machinery component, is required for expression and functionality of DNA damage response RNAs (DDRNAs) that mediate DNA damage responses and p53 activation by orchestrating histone modifications, chromatin remodeling and recruitment of DNA damage factors at damaged sites. Thus, miR-30 inhibits both p16(INK4A) and p53, 2 key senescence effectors, leading to efficient senescence disruption. These findings have identified novel signaling pathways mediating oncogene-induced senescence and tumor-suppression, and revealed the molecular and cellular mechanisms underlying the oncogenic activity of miR-30. Thus, the miR-30/CHD7/TNRC6A pathway is potentially a novel diagnostic biomarker and therapeutic target for cancer.	[Su, Weijun; Huang, Shan; Herpai, Denise; Zhang, Wei; Debinski, Waldemar; Sun, Peiqing] Wake Forest Sch Med, Wake Forest Comprehens Canc Ctr, Dept Canc Biol, Winston Salem, NC 27101 USA; [Su, Weijun; Xu, Yingxi; Xiang, Rong] Nankai Univ, Sch Med, Tianjin, Peoples R China; [Hong, Lixin; Xu, Yingxi; Lan Truong; Wu, Xiaohua; Sun, Peiqing] Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA; [Hong, Lixin; Li, Lisheng; Han, Jiahuai] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China; [Xu, Xin] 2 Peoples Hosp Wuxi City, Wuxi, Peoples R China; [Herpai, Denise; Debinski, Waldemar] Wake Forest Sch Med, Wake Forest Comprehens Canc Ctr, Brain Tumor Ctr Excellence, Winston Salem, NC USA; [Hu, Wen-Yuan] Biosettia Inc, San Diego, CA USA; [Xiao, Changchun] Scripps Res Inst, Dept Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Xiao, Changchun] Scripps Res Inst, Dept Microbial Sci, La Jolla, CA 92037 USA; [Zhang, Wei] Wake Forest Sch Med, Wake Forest Comprehens Canc Ctr, Ctr Canc Genom & Precis Oncol, Winston Salem, NC USA	Wake Forest University; Nankai University; Scripps Research Institute; Xiamen University; Wake Forest University; Scripps Research Institute; Scripps Research Institute; Wake Forest University	Sun, PQ (corresponding author), Wake Forest Sch Med, Wake Forest Comprehens Canc Ctr, Dept Canc Biol, Winston Salem, NC 27101 USA.; Sun, PQ (corresponding author), Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA.	psun@wakehealth.edu	Xu, Yingxi/HGA-1792-2022	Li, Lisheng/0000-0002-0793-272X	Overseas Collaboration Fund from National NSF of China [31428013]; NIH/NCI [CA106768, CA131231, CA172115, P30CA012197]; Thomas K. Hearn Brain Tumor Center; International Postdoctoral Exchange Fellowship Program by Office of China Postdoctoral Council [20140027]; NATIONAL CANCER INSTITUTE [R01CA172115, R01CA106768, P30CA012197, R01CA131231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080677] Funding Source: NIH RePORTER	Overseas Collaboration Fund from National NSF of China; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Thomas K. Hearn Brain Tumor Center; International Postdoctoral Exchange Fellowship Program by Office of China Postdoctoral Council; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. Joanna Wysocka for CHD7 cDNA, and Tumor Tissue and Pathology, Biostatistics and Bioinformatics, Cell & Viral Vector Laboratory and Cellular Imaging Shared Resources of WFBCCC. This study was supported by Overseas Collaboration Fund from National NSF of China 31428013 (PS, RX), NIH/NCI grants CA106768, CA131231, CA172115 (PS), P30CA012197, and Thomas K. Hearn Brain Tumor Center. WS is supported by International Postdoctoral Exchange Fellowship Program by Office of China Postdoctoral Council (20140027).	Bajpai R, 2010, NATURE, V463, P958, DOI 10.1038/nature08733; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Caldwell ME, 2012, ONCOGENE, V31, P1599, DOI 10.1038/onc.2011.350; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; di Fagagna FD, 2014, TRENDS CELL BIOL, V24, P171, DOI 10.1016/j.tcb.2013.09.008; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DiGiovanni J, 1991, MODIFICATION TUMOR D, V33, P192; Engelen E, 2011, NAT GENET, V43, P607, DOI 10.1038/ng.825; Eystathioy T, 2002, MOL BIOL CELL, V13, P1338, DOI 10.1091/mbc.01-11-0544; Fabbri M, 2008, CANCER J, V14, P1, DOI 10.1097/PPO.0b013e318164145e; Faraonio R, 2012, CELL DEATH DIFFER, V19, P713, DOI 10.1038/cdd.2011.143; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; Francia S, 2012, NATURE, V488, P231, DOI 10.1038/nature11179; Gertsenstein M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011260; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hong LX, 2010, CANCER RES, V70, P8547, DOI 10.1158/0008-5472.CAN-10-1938; Hurd EA, 2007, MAMM GENOME, V18, P94, DOI 10.1007/s00335-006-0107-6; Jongmans MCJ, 2006, J MED GENET, V43, P306, DOI 10.1136/jmg.2005.036061; Kim MS, 2010, J PATHOL, V221, P139, DOI 10.1002/path.2683; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Kwong J, 2013, MOL CELL BIOL, V33, P3780, DOI 10.1128/MCB.00784-13; Kwong J, 2009, J BIOL CHEM, V284, P11237, DOI 10.1074/jbc.M808327200; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Meister G, 2005, CURR BIOL, V15, P2149, DOI 10.1016/j.cub.2005.10.048; Meister G, 2013, NAT REV GENET, V14, P447, DOI 10.1038/nrg3462; Mukhopadhyay A, 2008, NAT PROTOC, V3, P698, DOI 10.1038/nprot.2008.38; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011; Schnetz MP, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001023; Schnetz MP, 2009, GENOME RES, V19, P590, DOI 10.1101/gr.086983.108; Srikantan S, 2011, CELL CYCLE, V10, P3211, DOI 10.4161/cc.10.19.17050; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Wang HL, 2012, J BIOL CHEM, V287, P21471, DOI 10.1074/jbc.M112.355354; Wang QH, 2016, CANCER RES, V76, P1904, DOI 10.1158/0008-5472.CAN-15-2334; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wei W, 2012, CELL, V149, P101, DOI 10.1016/j.cell.2012.03.002; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Xu Y, 2012, MOL CELL, V48, P723, DOI 10.1016/j.molcel.2012.09.026; Yoshizuka N, 2012, MOL CELL BIOL, V32, P606, DOI 10.1128/MCB.06301-11; Zamudio JR, 2014, CELL, V156, P920, DOI 10.1016/j.cell.2014.01.041; Zeng PY, 2006, BIOTECHNIQUES, V41, P694, DOI 10.2144/000112297; Zhao T, 2010, AM J PHYSIOL-ENDOC M, V299, pE110, DOI 10.1152/ajpendo.00192.2010	49	27	29	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5618	5632		10.1038/s41388-018-0358-1	http://dx.doi.org/10.1038/s41388-018-0358-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29907771	Green Accepted			2022-12-17	WOS:000447619100003
J	Jung, JH; Jung, DB; Kim, H; Lee, H; Kang, SE; Srivastava, SK; Yun, MY; Kim, SH				Jung, Ji Hoon; Jung, Deok-Beom; Kim, Hyunseok; Lee, Hyemin; Kang, Shi-Eun; Srivastava, Sanjay K.; Yun, Miyong; Kim, Sung-Hoon			Zinc finger protein 746 promotes colorectal cancer progression via c-Myc stability mediated by glycogen synthase kinase 3 beta and F-box and WD repeat domain-containing 7	ONCOGENE			English	Article							PARKINSONS-DISEASE; CELLS; EXPRESSION; TARGET; APOPTOSIS; ONCOGENE; PATHWAY; PHOSPHORYLATION; IDENTIFICATION; PROLIFERATION	To elucidate the underlying oncogenic mechanism of zinc finger protein 746 (ZNF746), current study was conducted in colorectal cancers (CRCs). Herein, ZNF746 was overexpressed in HCT116, SW620, and SW480 cells, which was supported by CRC tissue microarray and TCGA analysis. Also, DNA microarray revealed the differentially expressed gene profile particularly related to cell cycle genes and c-Myc in ZNF746 depleted HCT116 cells. Furthermore, ZNF746 enhanced the stability of c-Myc via their direct binding through nuclear colocalization by immunoprecipitation and immunofluorescence, while ZNF746 and c-Myc exist mainly in nucleoplasm. Conversely, ZNF746 depletion attenuated phosphorylation of c-Myc (S62) and glycogen synthase kinase 3 beta (GSK3 beta) (S9) and also activated p-c-Myc (T58), which was reversed by GSK3 inhibitors such as SB-216763 and Enza. Also, c-Myc degradation by ZNF746 depletion was blocked by knockdown of F-box/WD repeat-containing protein 7 (FBW7) ubiquitin ligase or proteosomal inhibitor MG132. Additionally, the growth of ZNF746 depleted HCT116 cancer cells was retarded with decreased expression of ZNF746 and c-Myc. Overall, these findings suggest that ZNF746 promotes CRC progression via c-Myc stability mediated by GSK3 and FBW7.	[Jung, Ji Hoon; Jung, Deok-Beom; Lee, Hyemin; Kim, Sung-Hoon] Kyung Hee Univ, Coll Korean Med, Korean Med Tumor Ecosyst Regulat Res Ctr, Seoul, South Korea; [Kang, Shi-Eun; Yun, Miyong] Kyung Hee Univ, Dept Otorhinolaryngol Head & Neck Surg, Sch Med, Seoul, South Korea; [Kim, Hyunseok] NJ Univ Hosp, Univ Hosp Newark, 150 Bergen St, Newark, NJ 07103 USA; [Srivastava, Sanjay K.] Texas Tech Univ, Hlth Sci Ctr, Dept Biomed Sci, Amarillo, TX 79106 USA; [Srivastava, Sanjay K.] Texas Tech Univ, Canc Biol Ctr, Hlth Sci Ctr, Amarillo, TX 79106 USA	Kyung Hee University; Kyung Hee University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo	Kim, SH (corresponding author), Kyung Hee Univ, Coll Korean Med, Korean Med Tumor Ecosyst Regulat Res Ctr, Seoul, South Korea.; Yun, MY (corresponding author), Kyung Hee Univ, Dept Otorhinolaryngol Head & Neck Surg, Sch Med, Seoul, South Korea.	myyun91@khu.ac.kr; sungkim7@khu.ac.kr	Srivastava, Sanjay K./AAE-7635-2020; YUN, MIYONG/S-9433-2019	kim, sunghoon/0000-0003-2423-1973	National Research Foundation of Korea (NRF) grant [2017R1A2A1A17069297]	National Research Foundation of Korea (NRF) grant	This work was supported by the National Research Foundation of Korea (NRF) grant (no. 2017R1A2A1A17069297) and also we appreciate Dr. Han YH in KIRMAS for pcDNA3 reporter, 5'-V5-Myc, HA-FBW7, HA-Myc (S62A), and HA-Myc(T58A) and Dr. Lee ES for c-Myc mutant plasmids used in this project.	Aslan JE, 2009, MOL CELL, V34, P497, DOI 10.1016/j.molcel.2009.04.011; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bommer GT, 2007, CANCER CELL, V11, P391, DOI 10.1016/j.ccr.2007.04.015; Center MM, 2009, CANCER EPIDEM BIOMAR, V18, P1688, DOI 10.1158/1055-9965.EPI-09-0090; Chen BJ, 2014, INT J BIOL SCI, V10, P1084, DOI 10.7150/ijbs.10190; Chen TC, 2016, TOXICOL IN VITRO, V31, P1, DOI 10.1016/j.tiv.2015.11.002; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Conrad T, 2017, METHODS MOL BIOL, V1468, P1, DOI 10.1007/978-1-4939-4035-6_1; de Mello RA, 2013, WORLD J GASTROENTERO, V19, P6315, DOI 10.3748/wjg.v19.i38.6315; Farrell AS, 2013, MOL CELL BIOL, V33, P2930, DOI 10.1128/MCB.01455-12; Gao SP, 2016, TUMOR BIOL, V37, P1279, DOI 10.1007/s13277-015-3878-0; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Geng JH, 2016, J ALZHEIMERS DIS, V49, P1161, DOI 10.3233/JAD-150423; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang HL, 2014, CURR PHARM DESIGN, V20, P6543, DOI 10.2174/1381612820666140826153203; Ji LL, 2014, INT J CLIN EXP PATHO, V7, P1124; Karuppagounder SS, 2014, SCI REP-UK, V4, DOI 10.1038/srep04874; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; Kim B, 2014, ONCOL REP, V31, P73, DOI 10.3892/or.2013.2801; Koch HB, 2007, CELL CYCLE, V6, P205, DOI 10.4161/cc.6.2.3742; Koukourakis GV, 2011, CLIN TRANSL ONCOL, V13, P710, DOI 10.1007/s12094-011-0720-z; Kumar Manoj, 2012, Acta Biomed, V83, P220; Li M, 2017, ONCOL REP, V37, P1627, DOI 10.3892/or.2017.5432; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Mansi L, 2011, B CANCER, V98, P1019, DOI 10.1684/bdc.2011.1380; McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037; MORELLO D, 1989, ONCOGENE, V4, P955; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; Robson S, 2006, RECENT PAT ANTI-CANC, V1, P305, DOI 10.2174/157489206778776934; ROTHBERG PG, 1987, SEMIN SURG ONCOL, V3, P152, DOI 10.1002/ssu.2980030305; Roy UKB, 2008, MOL CARCINOGEN, V47, P947, DOI 10.1002/mc.20451; Schwamborn JC, 2009, CELL, V136, P913, DOI 10.1016/j.cell.2008.12.024; Schweiger T, 2014, ANN SURG ONCOL, V21, P946, DOI 10.1245/s10434-013-3386-7; Shin JH, 2011, CELL, V144, P689, DOI 10.1016/j.cell.2011.02.010; SPENCER CA, 1991, ADV CANCER RES, V56, P1; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Wang XH, 2016, GASTRIC CANCER, V19, P116, DOI 10.1007/s10120-015-0467-2; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Won SH, 2012, PHYTOTHER RES, V26, P669, DOI 10.1002/ptr.3616; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yuge R, 2015, AM J PATHOL, V185, P399, DOI 10.1016/j.ajpath.2014.10.014	47	27	27	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3715	3728		10.1038/s41388-018-0225-0	http://dx.doi.org/10.1038/s41388-018-0225-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29628506				2022-12-17	WOS:000437975200008
J	Lopez-Delisle, L; Pierre-Eugene, C; Louis-Brennetot, C; Surdez, D; Raynal, V; Baulande, S; Boeva, V; Grossetete-Lalami, S; Combaret, V; Peuchmaur, M; Delattre, O; Janoueix-Lerosey, I				Lopez-Delisle, Lucille; Pierre-Eugene, Cecile; Louis-Brennetot, Caroline; Surdez, Didier; Raynal, Virginie; Baulande, Sylvain; Boeva, Valentina; Grossetete-Lalami, Sandrine; Combaret, Valerie; Peuchmaur, Michel; Delattre, Olivier; Janoueix-Lerosey, Isabelle			Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis	ONCOGENE			English	Article							ANAPLASTIC LYMPHOMA KINASE; ETS TRANSCRIPTION FACTORS; RECEPTOR TYROSINE KINASE; INHIBITOR PF-06463922; THERAPEUTIC TARGET; UP-REGULATION; RET; MUTATIONS; CANCER; EXPRESSION	Activating mutations of the ALK receptor occur in a subset of neuroblastoma tumors. We previously demonstrated that Alk mutations cooperate with MYCN overexpression to induce neuroblastoma in mice and identified Ret as being strongly upregulated in MYCN/Alk(mu)t tumors. By a genetic approach in vivo, we now document an oncogenic cooperation between activated Ret and MYCN overexpression in neuroblastoma formation. We show that MYCN/Ret(M919T) tumors exhibit histological features and expression profiles close to MYCN/Alk(mut) tumors. We show that RET transcript levels decrease precedes RET protein levels decrease upon ALK inhibition in neuroblastoma cell lines. Etv5 was identified as a candidate transcription factor regulating Ret expression from murine MYCN/Alk(mut) tumor transcriptomic data. We demonstrate that ETV5 is regulated both at the protein and mRNA levels upon ALK activation or inhibition in neuroblastoma cell lines and that this regulation precedes RET modulation. We document that ALK activation induces ETV5 protein upregulation through stabilization in a MEK/ERK- dependent manner. We show that RNAi-mediated inhibition of ETV5 decreases RET expression. Reporter assays indicate that ETV5 is able to drive RET gene transcription. ChIP-seq analysis confirmed ETV5 binding on the RET promoter and identified an enhancer upstream of the promoter. Finally, we demonstrate that combining RET and ALK inhibitors reduces tumor growth more efficiently than each single agent in MYCN and Alk(F1178L)-driven murine neuroblastoma. Altogether, these results define the ERK-ETV5-RET pathway as a critical axis driving neuroblastoma oncogenesis downstream of activated ALK.	[Lopez-Delisle, Lucille; Pierre-Eugene, Cecile; Louis-Brennetot, Caroline; Surdez, Didier; Raynal, Virginie; Grossetete-Lalami, Sandrine; Delattre, Olivier; Janoueix-Lerosey, Isabelle] PSL Res Univ, INSERM, U830, Equipe Labellisee Ligue Canc,Inst Curie, Paris, France; [Raynal, Virginie; Baulande, Sylvain] Inst Curie Res Ctr, Inst Curie Genom Excellence ICGex, Paris, France; [Boeva, Valentina] Univ Paris 05, CNRS, UMR 8104, Inst Cochin,INSERM,U1016,UMR S1016, Paris, France; [Boeva, Valentina] PSL Res Univ, INSERM, U900, Inst Curie,Mines ParisTech, Paris, France; [Combaret, Valerie] Ctr Leon Berard, Lab Rech Translat, Lyon, France; [Peuchmaur, Michel] Hop Univ Robert Debre, AP HP, Dept Pathol, Paris, France; [Peuchmaur, Michel] Univ Diderot Paris 7, Paris Sorbonne Cite, Paris, France; [Delattre, Olivier; Janoueix-Lerosey, Isabelle] Inst Curie, SIREDO Care Innovat & Res Children Adolescents &, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; MINES ParisTech; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Janoueix-Lerosey, I (corresponding author), PSL Res Univ, INSERM, U830, Equipe Labellisee Ligue Canc,Inst Curie, Paris, France.; Janoueix-Lerosey, I (corresponding author), Inst Curie, SIREDO Care Innovat & Res Children Adolescents &, Paris, France.	janoueix@curie.fr	Surdez, Didier/ABG-4565-2020; Boeva, Valentina/C-2855-2017; Janoueix-Lerosey, Isabelle/G-1758-2018	Boeva, Valentina/0000-0002-4382-7185; Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; BAULANDE, Sylvain/0000-0003-3104-1684; delattre, olivier/0000-0002-8730-2276; Lopez-Delisle, Lucille/0000-0002-1964-4960; LOUIS, Caroline/0000-0002-4952-3828	Institut National du Cancer [PRT-K 14061]; Ligue Nationale contre le Cancer (Equipe labellisee); Association Hubert Gouin "Enfance et Cancer"; Les Bagouz a Manon, les amis de Claire; la Federation Enfants et Sante et la Societe Francaise de Lutte contre les Cancers et les Leucemies de l'Enfant et l'Adolescent; Fondation pour la Recherche Medicale [FDT20140930966]; Institut Curie-SIRIC (Site de Recherche Integree en Cancerologie) program; ATIP-Avenir program; "Who am I?" program; Agence Nationale de la Recherche ("Investissements d'Avenir" program) [ANR-10-EQPX-03, ANR-10-INBS-09-08]; Canceropole Ile-de-France; SiRIC-Curie program-SiRIC [INCa-DGOS-4654]	Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); Association Hubert Gouin "Enfance et Cancer"; Les Bagouz a Manon, les amis de Claire; la Federation Enfants et Sante et la Societe Francaise de Lutte contre les Cancers et les Leucemies de l'Enfant et l'Adolescent; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut Curie-SIRIC (Site de Recherche Integree en Cancerologie) program; ATIP-Avenir program; "Who am I?" program; Agence Nationale de la Recherche ("Investissements d'Avenir" program)(French National Research Agency (ANR)); Canceropole Ile-de-France(Region Ile-de-France); SiRIC-Curie program-SiRIC	The U830 Inserm laboratory is supported by grants from the Institut National du Cancer (PRT-K 14061), the Ligue Nationale contre le Cancer (Equipe labellisee), the Association Hubert Gouin "Enfance et Cancer", Les Bagouz a Manon, les amis de Claire, la Federation Enfants et Sante et la Societe Francaise de Lutte contre les Cancers et les Leucemies de l'Enfant et l'Adolescent. LL-D was the recipient of a fellowship of the Fondation pour la Recherche Medicale (FDT20140930966). DS is supported by the Institut Curie-SIRIC (Site de Recherche Integree en Cancerologie) program. VB is supported by the ATIP-Avenir and the "Who am I?" programs. High-throughput sequencing has been performed by the ICGex NGS platform of the Institut Curie supported by the grants ANR-10-EQPX-03 (Equipex) and ANR-10-INBS-09-08 (France Genomique Consortium) from the Agence Nationale de la Recherche ("Investissements d'Avenir" program), by the Canceropole Ile-de-France and by the SiRIC-Curie program-SiRIC Grant "INCa-DGOS-4654". We thank Jean-Luc Baert (Institut de Recherche Interdisciplinaire de Lille, Lille, France) for providing us with the pcDNA3-ETV5 plasmid and Matthias Fischer for providing the ALK status of tumors from the GSE49711 dataset. We thank D Gentien and his team from the translational department of Institut Curie for Affymetrix profiling experiments. We are grateful to the animal facilities team of the Institut Curie and especially to I Grandjean and C Jouhanneau. We thank the Experimental Pathology Department of Institut Curie for their valuable help and the SIRIC-Curie for help in image analyses. We acknowledge our colleagues F Tirode and W Richer for assistance in the analysis of Affymetrix data.	Ashoor H, 2013, BIOINFORMATICS, V29, P2979, DOI 10.1093/bioinformatics/btt524; Baert JL, 2007, ONCOGENE, V26, P415, DOI 10.1038/sj.onc.1209801; Berry T, 2012, CANCER CELL, V22, P117, DOI 10.1016/j.ccr.2012.06.001; Boeva V, 2017, NAT GENET, V49, P1408, DOI 10.1038/ng.3921; Bresler SC, 2014, CANCER CELL, V26, P682, DOI 10.1016/j.ccell.2014.09.019; Bresler SC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002950; Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43; Cazes A, 2014, ONCOTARGET, V5, P2688, DOI 10.18632/oncotarget.1883; Chatterjee S, 2016, CELL, V167, P355, DOI 10.1016/j.cell.2016.09.005; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Fontanet P, 2013, J NEUROSCI, V33, P15940, DOI 10.1523/JNEUROSCI.0928-13.2013; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Guan J, 2016, DIS MODEL MECH, V9, P941, DOI 10.1242/dmm.024448; Hallberg B, 2016, ANN ONCOL, V27, P4, DOI 10.1093/annonc/mdw301; Infarinato NR, 2016, CANCER DISCOV, V6, P96, DOI 10.1158/2159-8290.CD-15-1056; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Lambertz I, 2015, CLIN CANCER RES, V21, P3327, DOI 10.1158/1078-0432.CCR-14-2024; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lin S, 2006, J BIOL CHEM, V281, P16716, DOI 10.1074/jbc.M602221200; Liu YR, 2003, DEV BIOL, V261, P10, DOI 10.1016/S0012-1606(03)00359-2; Lu BC, 2009, NAT GENET, V41, P1295, DOI 10.1038/ng.476; Mano H, 2012, CANCER DISCOV, V2, P495, DOI 10.1158/2159-8290.CD-12-0009; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Mazot P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033581; Medina-Rivera A, 2015, NUCLEIC ACIDS RES, V43, pW50, DOI 10.1093/nar/gkv362; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Reiff T, 2011, DEVELOPMENT, V138, P4699, DOI 10.1242/dev.072157; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Schulte JH, 2011, CLIN CANCER RES, V17, P5082, DOI 10.1158/1078-0432.CCR-10-2809; Shaw AT, 2013, NAT REV CANCER, V13, P772, DOI 10.1038/nrc3612; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Simon L, 2007, EXP CELL RES, V313, P3090, DOI 10.1016/j.yexcr.2007.05.002; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; Tyagi G, 2009, BIOL REPROD, V81, P258, DOI 10.1095/biolreprod.108.075200; Vitari AC, 2011, NATURE, V474, P403, DOI 10.1038/nature10005; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wood AC, 2017, CLIN CANCER RES, V23, P2856, DOI 10.1158/1078-0432.CCR-16-1114; Zhang WQ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0694-1	49	27	30	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1417	1429		10.1038/s41388-017-0039-5	http://dx.doi.org/10.1038/s41388-017-0039-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321660	Green Published, hybrid			2022-12-17	WOS:000427459500002
J	Morath, I; Jung, C; Leveque, R; Chen, LF; Toillon, RA; Warth, A; Orian-Rousseau, V				Morath, Iris; Jung, Christian; Leveque, Romain; Chen Linfeng; Toillon, Robert-Alain; Warth, Arne; Orian-Rousseau, Veronique			Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer	ONCOGENE			English	Article							GROWTH-FACTOR; SIGNALING PLATFORM; EGF RECEPTOR; C-MET; EXPRESSION; CYTOSKELETON; EZRIN; METASTASIS; ACTIVATION; PROTEINS	Members of the CD44 family of transmembrane glycoproteins control cell signaling pathways from numerous cell surface receptors, including receptor tyrosine kinases (RTKs). The decisive factor (ligand, RTKs or both) that controls the recruitment of specific CD44 isoforms is still unknown. We investigated this question by using the EGFR signaling pathway, in which one receptor can be activated by a broad range of ligands. By means of siRNA-mediated downregulation of CD44 expression and blocking experiments, we identified CD44v6 as a co-receptor for EGF- and ER-induced ErbB1 activation and for NRG1-induced ErbB3 and ErbB4 activation. In contrast, TGFa is independent of all CD44 isoforms, even though it addresses the same receptor pairs as EGF. Moreover, the heparin-sulfated CD44v3 isoform is required for HB-EGF-induced EGFR signaling. These data suggest that specific CD44 isoforms are recruited in a ligand-dependent manner as co-receptors in the EGFR signaling pathways and that the specificity is determined by the ligand and not by the receptors themselves. The in vivo relevance of this interplay between CD44 isoforms and EGFR ligands is underlined by the decreased metastatic spreading of mammary carcinomas in mice treated with a CD44v6-specific peptide. Most importantly, we found a clear correlation between the presence of CD44v6/ErbB1 complexes in breast cancer patients and lymph node metastases.	[Morath, Iris; Jung, Christian; Orian-Rousseau, Veronique] Karlsruhe Inst Technol, Inst Toxicol & Genet, Karlsruhe, Germany; [Leveque, Romain; Toillon, Robert-Alain] Univ Lille, INSERM, U908, CPAC, Lille, France; [Chen Linfeng] Dana Farber Canc Inst, Boston, MA 02115 USA; [Warth, Arne] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Harvard University; Dana-Farber Cancer Institute; Ruprecht Karls University Heidelberg	Orian-Rousseau, V (corresponding author), Karlsruhe Inst Technol, Inst Toxicol & Genet, Karlsruhe, Germany.	veronique.orian-rousseau@kit.edu	Jung, Christian/AAN-4537-2021; Toillon, Robert-Alain/Q-2286-2018; Orian-Rousseau, Veronique/H-5735-2013	Jung, Christian/0000-0001-8325-250X; Toillon, Robert-Alain/0000-0001-5483-2118; Orian-Rousseau, Veronique/0000-0003-2939-9257	Mildred Scheel Foundation	Mildred Scheel Foundation(Deutsche Krebshilfe)	The authors are very thankful to Selma Huber and the animal facility of the Institute of Toxicology and Genetics for their excellent work and help with the animal experiments. This work was supported by a grant from Mildred Scheel Foundation.	ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Bennett R, 2001, J HISTOCHEM CYTOCHEM, V49, P67, DOI 10.1177/002215540104900107; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; Diaz LK, 2005, CLIN CANCER RES, V11, P3309, DOI 10.1158/1078-0432.CCR-04-2184; Ellis IR, 2007, EXP CELL RES, V313, P732, DOI 10.1016/j.yexcr.2006.11.016; Foekens JA, 1999, INT J CANCER, V84, P209, DOI 10.1002/(SICI)1097-0215(19990621)84:3<209::AID-IJC2>3.0.CO;2-9; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ilangumaran S, 1999, LEUKEMIA LYMPHOMA, V35, P455, DOI 10.1080/10428199909169610; Kivisaari AK, 2010, BRIT J DERMATOL, V163, P726, DOI 10.1111/j.1365-2133.2010.09924.x; Konig H, 1996, EMBO J, V15, P4030, DOI 10.1002/j.1460-2075.1996.tb00776.x; Konstantinovsky S, 2012, CLIN EXP METASTAS, V29, P527, DOI 10.1007/s10585-012-9468-2; Lynch CC, 2007, CANCER RES, V67, P6760, DOI 10.1158/0008-5472.CAN-07-0026; Matsuo I, 2013, CURR OPIN GENET DEV, V23, P399, DOI 10.1016/j.gde.2013.02.004; Matzke A, 2005, CANCER RES, V65, P6105, DOI 10.1158/0008-5472.CAN-05-0207; Matzke-Ogi A, 2016, GASTROENTEROLOGY, V150, P513, DOI 10.1053/j.gastro.2015.10.020; Minuti G, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.06.22; Misra S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00201; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Olaku V, 2011, MOL BIOL CELL, V22, P2777, DOI 10.1091/mbc.E11-02-0134; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Orian-Rousseau W, 2007, MOL BIOL CELL, V18, P76, DOI 10.1091/mbc.E06-08-0674; Orian-Rousseau V, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00154; Orian-Rousseau V, 2014, ADV CANCER RES, V123, P231, DOI 10.1016/B978-0-12-800092-2.00009-5; Orian-Rousseau V, 2010, EUR J CANCER, V46, P1271, DOI 10.1016/j.ejca.2010.02.024; Orian-Rousseau V, 2008, ADV CANCER RES, V101, P63, DOI 10.1016/S0065-230X(08)00404-1; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Raymond E, 2000, DRUGS, V60, P15, DOI 10.2165/00003495-200060001-00002; Rodig SJ, 2010, CURR OPIN INVEST DR, V11, P1477; Rowinsky E, 2000, DRUGS, V60, P41; Sherman L, 1998, GENE DEV, V12, P1058, DOI 10.1101/gad.12.7.1058; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Tremmel M, 2009, BLOOD, V114, P5236, DOI 10.1182/blood-2009-04-219204; Tsatas D, 2002, J CLIN NEUROSCI, V9, P282, DOI 10.1054/jocn.2001.1063; Volz Y, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150093; Wan X, 2009, ONCOGENE, V28, P3401, DOI 10.1038/onc.2009.206; Wu WKK, 2009, ANTICANCER RES, V29, P229; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	48	27	27	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1472	1484		10.1038/s41388-017-0030-1	http://dx.doi.org/10.1038/s41388-017-0030-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321661				2022-12-17	WOS:000427459500006
J	Zhou, Y; Wang, L; Ban, X; Zeng, T; Zhu, Y; Li, M; Guan, XY; Li, Y				Zhou, Y.; Wang, L.; Ban, X.; Zeng, T.; Zhu, Y.; Li, M.; Guan, X-Y; Li, Y.			DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma	ONCOGENE			English	Article							CANCER CELL; DOWN-REGULATION; BREAST-CANCER; GENE; EXPRESSION; FAMILY; HEP27; ACTIVATION; PROTEINS; INVASION	Esophageal squamous cell carcinoma (ESCC) is highly prevailing in Asia and it is ranked in the most aggressive squamous cell carcinomas. High-frequency loss of heterozygosity occurred in chromosome 14q11.2 in many tumors including ESCC, suggesting that one or more tumor-suppressor genes might exist within this region. In this study, we identified the tumor-suppressing role of DHRS2 (short-chain dehydrogenase/reductase family, member 2) at 14q11.2 in ESCCs. Downregulation of DHRS2 occurred in 30.8% of primary ESCC tumor tissues vs paired non-tumorous tissues. DHRS2 downregulation was associated significantly with ESCC invasion, lymph nodes metastasis and clinical staging (P<0.001). Survival analysis revealed that DHRS2 downregulation was significantly associated with worse outcome of patients with ESCC. In vitro and in vivo studies indicated that both DHRS2 variants could suppress cell proliferation and cell motility. Moreover, we demonstrated that DHRS2 could reduce reactive oxygen species and decrease nicotinamide adenine dinucleotide phosphate (oxidized/reduced), increase p53 stability and decrease Rb phosphorylation; it also decreased p38 mitogen-activated protein kinase phosphorylation and matrix metalloproteinase 2. In summary, these findings demonstrated that DHRS2 had an important part in ESCC development and progression.	[Zhou, Y.; Wang, L.; Ban, X.; Zeng, T.; Zhu, Y.; Li, M.; Guan, X-Y; Li, Y.] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Zhou, Y.] Guangdong Esophageal Canc Inst, Guangzhou, Guangdong, Peoples R China; [Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; University of Hong Kong	Guan, XY; Li, Y (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.	xyguan@hku.hk; liy6@mail.sysu.edu.cn	/A-3639-2009	/0000-0003-1874-9805	National Natural Science Foundation of China [81472255, 81472250]; Guangdong Esophageal Cancer Institute [M201511]; Guangdong Science and Technology Foundation [2016A020214008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Esophageal Cancer Institute; Guangdong Science and Technology Foundation	This research was supported by the National Natural Science Foundation of China (81472255 and 81472250); Guangdong Esophageal Cancer Institute Funding (M201511); Guangdong Science and Technology Foundation (2016A020214008).	Alberghina L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.513; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Binker MG, 2009, BIOCHEM BIOPH RES CO, V379, P445, DOI 10.1016/j.bbrc.2008.12.080; Bjorkqvist AM, 1999, BRIT J CANCER, V81, P1111, DOI 10.1038/sj.bjc.6690816; Bray JE, 2009, CHEM-BIOL INTERACT, V178, P99, DOI 10.1016/j.cbi.2008.10.058; Chiu WT, 2010, NEUROBIOL DIS, V37, P118, DOI 10.1016/j.nbd.2009.09.015; Crean D, 2012, MOL CELL BIOCHEM, V366, P231, DOI 10.1007/s11010-012-1300-4; Deblec-Rychter M, 2001, GENE CHROMOSOME CANC, V32, P26; Deisenroth C, 2010, MOL CELL BIOL, V30, P3981, DOI 10.1128/MCB.01284-09; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; El-Rifai W, 2000, GENE CHROMOSOME CANC, V27, P387, DOI 10.1002/(SICI)1098-2264(200004)27:4<387::AID-GCC8>3.0.CO;2-C; Fang L, 2016, CANCER BIOL THER, V17, P664, DOI 10.1080/15384047.2016.1190485; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; GABRIELLI F, 1995, EUR J BIOCHEM, V232, P473, DOI 10.1111/j.1432-1033.1995.473zz.x; Gabrielli F, 2012, GENE, V511, P461, DOI 10.1016/j.gene.2012.09.013; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Guan XY, 2001, CANCER RES, V61, P3806; Hu L, 2016, TUMOR BIOL, V37, P837, DOI 10.1007/s13277-015-3880-6; Hurd TR, 2012, TRENDS CELL BIOL, V22, P107, DOI 10.1016/j.tcb.2011.11.002; Li J, 2014, INT J BIOL SCI, V10, P142, DOI 10.7150/ijbs.7727; Li Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060027; Li Y, 2011, CANCER RES, V71, P6106, DOI 10.1158/0008-5472.CAN-10-4291; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Monge M, 2009, CARCINOGENESIS, V30, P1288, DOI 10.1093/carcin/bgp119; Nishikawa M, 2008, CANCER LETT, V266, P53, DOI 10.1016/j.canlet.2008.02.031; Oppermann U, 2007, ANNU REV PHARMACOL, V47, P293, DOI 10.1146/annurev.pharmtox.47.120505.105316; Pelicano H, 2009, CANCER RES, V69, P2375, DOI 10.1158/0008-5472.CAN-08-3359; Pellegrini S, 2002, BBA-GENE STRUCT EXPR, V1574, P215, DOI 10.1016/S0167-4781(01)00323-2; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Shafqat N, 2006, CELL MOL LIFE SCI, V63, P1205, DOI 10.1007/s00018-006-6013-y; Shao JY, 2001, ANTICANCER RES, V21, P3021; Shi ZZ, 2014, CLIN TRANSL ONCOL, V16, P606, DOI 10.1007/s12094-013-1124-z; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Tochhawng L, 2013, MITOCHONDRION, V13, P246, DOI 10.1016/j.mito.2012.08.002; Wang J, 2017, INT J CANCER, V140, P2484, DOI 10.1002/ijc.30680; Wang P, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0012-z; Wong ML, 2006, INT J ONCOL, V28, P767; Wu XQ, 2007, MOL CELL ENDOCRINOL, V265, P71, DOI 10.1016/j.mce.2006.12.006	38	27	29	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1086	1094		10.1038/onc.2017.383	http://dx.doi.org/10.1038/onc.2017.383			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106393	Green Published, hybrid			2022-12-17	WOS:000425905700011
J	Kelly, NJ; Varga, JFA; Specker, EJ; Romeo, CM; Coomber, BL; Uniacke, J				Kelly, N. J.; Varga, J. F. A.; Specker, E. J.; Romeo, C. M.; Coomber, B. L.; Uniacke, J.			Hypoxia activates cadherin-22 synthesis via eIF4E2 to drive cancer cell migration, invasion and adhesion	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; DOWN-REGULATION; STEM-CELLS; EXPRESSION; GLIOBLASTOMA; METASTASIS; SNAIL; PROTEINS; NECROSIS	Hypoxia is a driver of cell movement in processes such as development and tumor progression. The cellular response to hypoxia involves a transcriptional program mediated by hypoxia-inducible factors, but translational control has emerged as a significant contributor. In this study, we demonstrate that a cell-cell adhesion molecule, cadherin-22, is upregulated in hypoxia via mTORC1-independent translational control by the initiation factor eIF4E2. We identify new functions of cadherin-22 as a hypoxia-specific cell-surface molecule involved in cancer cell migration, invasion and adhesion. Silencing eIF4E2 or cadherin-22 significantly impaired MDA-MB-231 breast carcinoma and U87MG glioblastoma cell migration and invasion only in hypoxia, while reintroduction of the respective exogenous gene restored the normal phenotype. Cadherin-22 was evenly distributed throughout spheroids and required for their formation and support of a hypoxic core. Conversely, E-cadherin translation was repressed by hypoxia and only expressed in the oxygenated cells of U87MG spheroids. Furthermore, immunofluorescence on paraffin-embedded human tissue from 40 glioma and 40 invasive ductal breast carcinoma patient specimens revealed that cadherin-22 expression colocalized with areas of hypoxia and significantly correlated with tumor grade and progression-free survival or stage and tumor size, respectively. This study broadens our understanding of tumor progression and metastasis by highlighting cadherin-22 as a potential new target of cancer therapy to disable hypoxic cancer cell motility and adhesion.	[Kelly, N. J.; Varga, J. F. A.; Specker, E. J.; Romeo, C. M.; Uniacke, J.] Univ Guelph, Dept Mol & Cellular Biol, 50 Stone Rd East, Guelph, ON N1G 2W1, Canada; [Coomber, B. L.] Univ Guelph, Dept Biomed Sci, Ontario Vet Coll, Guelph, ON, Canada	University of Guelph; University of Guelph	Uniacke, J (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, 50 Stone Rd East, Guelph, ON N1G 2W1, Canada.	juniacke@uoguelph.ca	Varga, Joseph/ABD-2277-2021	Varga, Joseph/0000-0001-8516-225X	Canadian Institutes of Health Research [PJT 152925]; Cancer Research Society	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society	We thank Terry Van Raay for the use of his microscope, Scott Ryan and John Vessey for the use of their cryostat, and Marc Coppolino for technical advice and reagents. This work was funded by grants from the Canadian Institutes of Health Research (PJT 152925) and the Cancer Research Society to JU.	Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beasley GM, 2009, CANCER-AM CANCER SOC, V115, P4766, DOI 10.1002/cncr.24509; Bhat M, 2015, NAT REV DRUG DISCOV, V14, P261, DOI 10.1038/nrd4505; Blaschuk OW, 2009, EUR J PHARMACOL, V625, P195, DOI 10.1016/j.ejphar.2009.05.033; Chaudary N, 2009, LAB INVEST, V89, P587, DOI 10.1038/labinvest.2009.16; Chen J, 2010, BRIT J CANCER, V102, P351, DOI 10.1038/sj.bjc.6605486; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DeLeeuw WJF, 1997, J PATHOL, V183, P404, DOI 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Espina V, 2013, WOMENS HEALTH, V9, P157, DOI [10.2217/whe.13.5, 10.2217/WHE.13.5]; Feng MY, 2015, P NATL ACAD SCI USA, V112, P2145, DOI 10.1073/pnas.1424907112; FRANKO AJ, 1979, RADIAT RES, V79, P439, DOI 10.2307/3575173; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Grabmaier K, 2004, ONCOGENE, V23, P5624, DOI 10.1038/sj.onc.1207764; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Ho JJD, 2016, CELL REP, V14, P1293, DOI 10.1016/j.celrep.2016.01.036; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hwang-Verslues WW, 2011, ONCOGENE, V30, P2463, DOI 10.1038/onc.2010.618; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Indovina P, 2008, ANTICANCER RES, V28, P1013; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Kitamura T, 2007, NAT GENET, V39, P467, DOI 10.1038/ng1997; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Krishnamachary B, 2003, CANCER RES, V63, P1138; Kuehn BM, 2010, JAMA-J AM MED ASSOC, V303, P925, DOI 10.1001/jama.2010.236; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Lundgren K, 2009, BRIT J CANCER, V101, P1769, DOI 10.1038/sj.bjc.6605369; Martinez-Gonzalez A, 2012, B MATH BIOL, V74, P2875, DOI 10.1007/s11538-012-9786-1; Perotti A, 2009, ANN ONCOL, V20, P741, DOI 10.1093/annonc/mdn695; Piche B, 2011, AM J CANCER RES, V1, P233; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rom E, 1998, J BIOL CHEM, V273, P13104, DOI 10.1074/jbc.273.21.13104; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Rorth P, 2009, ANNU REV CELL DEV BI, V25, P407, DOI 10.1146/annurev.cellbio.042308.113231; Russell J, 2009, INT J RADIAT ONCOL, V73, P1177, DOI 10.1016/j.ijrobp.2008.12.004; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Sugimoto K, 1996, J BIOL CHEM, V271, P11548, DOI 10.1074/jbc.271.19.11548; Tee AR, 2004, FEBS LETT, V564, P58, DOI 10.1016/S0014-5793(04)00313-8; Timpano S, 2016, J BIOL CHEM, V291, P10772, DOI 10.1074/jbc.M116.717363; Uniacke J, 2014, CANCER RES, V74, P1379, DOI 10.1158/0008-5472.CAN-13-2278; Uniacke J, 2012, NATURE, V486, P126, DOI 10.1038/nature11055; Vinci M, 2015, JOVE-J VIS EXP, DOI 10.3791/52686; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wu J, 2003, J ENDOCRINOL, V176, P381, DOI 10.1677/joe.0.1760381; Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482; Zhong H, 1999, CANCER RES, V59, P5830; Zhou J, 2009, TUMOR BIOL, V30, P130, DOI 10.1159/000225242; Zhu Y, 2013, ANAT REC, V296, P1850, DOI 10.1002/ar.22821	60	27	27	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					651	662		10.1038/onc.2017.372	http://dx.doi.org/10.1038/onc.2017.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991229	Green Accepted			2022-12-17	WOS:000423812200010
J	Rowson-Hodel, AR; Wald, JH; Hatakeyama, J; O'Neal, WK; Stonebraker, JR; VanderVorst, K; Saldana, MJ; Borowsky, AD; Sweeney, C; Carraway, KL				Rowson-Hodel, A. R.; Wald, J. H.; Hatakeyama, J.; O'Neal, W. K.; Stonebraker, J. R.; VanderVorst, K.; Saldana, M. J.; Borowsky, A. D.; Sweeney, C.; Carraway, K. L., III			Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer	ONCOGENE			English	Article							SIALOMUCIN COMPLEX; PANCREATIC-CANCER; MUC4/SIALOMUCIN COMPLEX; INTRAMEMBRANE MODULATOR; MESENCHYMAL TRANSITION; TRANSGENIC MICE; EXPRESSION; GROWTH; HER2; OVEREXPRESSION	Mucin-4 (Muc4) is a large cell surface glycoprotein implicated in the protection and lubrication of epithelial structures. Previous studies suggest that aberrantly expressed Muc4 can influence the adhesiveness, proliferation, viability and invasiveness of cultured tumor cells, as well as the growth rate and metastatic efficiency of xenografted tumors. Although it has been suggested that one of the major mechanisms by which Muc4 potentiates tumor progression is via its engagement of the ErbB2/HER2 receptor tyrosine kinase, other mechanisms exist and remain to be delineated. Moreover, the requirement for endogenous Muc4 for tumor growth progression has not been previously explored in the context of gene ablation. To assess the contribution of endogenous Muc4 to mammary tumor growth properties, we first created a genetically engineered mouse line lacking functional Muc4 (Muc4(ko)), and then crossed these animals with the NDL (Neu DeLetion mutant) model of ErbB2-induced mammary tumorigenesis. We observed that Muc4ko animals are fertile and develop normally, and adult mice exhibit no overt tissue abnormalities. In tumor studies, we observed that although some markers of tumor growth such as vascularity and cyclin D1 expression are suppressed, primary mammary tumors from Muc4(ko)/NDL female mice exhibit similar latencies and growth rates as Muc4(wt)/NDL animals. However, the presence of lung metastases is markedly suppressed in Muc4(ko)/NDL mice. Interestingly, histological analysis of lung lesions from Muc4(ko)/NDL mice revealed a reduced association of disseminated cells with platelets and white blood cells. Moreover, isolated cells derived from Muc4(ko)/NDL tumors interact with fewer blood cells when injected directly into the vasculature or diluted into blood from wild type mice. We further observed that blood cells more efficiently promote the viability of non-adherent Muc4(wt)/NDL cells than Muc4(ko)/NDL cells. Together, our observations suggest that Muc4 may facilitate metastasis by promoting the association of circulating tumor cells with blood cells to augment tumor cell survival in circulation.	[Rowson-Hodel, A. R.; Wald, J. H.; Hatakeyama, J.; VanderVorst, K.; Saldana, M. J.; Sweeney, C.; Carraway, K. L., III] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Res Bldg 3,Room 1100B,4645 2nd Ave, Sacramento, CA 95817 USA; [Rowson-Hodel, A. R.; Wald, J. H.; Hatakeyama, J.; VanderVorst, K.; Saldana, M. J.; Sweeney, C.; Carraway, K. L., III] Univ Calif Davis, Sch Med, UC Davis Comprehens Canc Ctr, Res Bldg 3,Room 1100B,4645 2nd Ave, Sacramento, CA 95817 USA; [O'Neal, W. K.; Stonebraker, J. R.] Univ North Carolina Chapel Hill, Sch Med, UNC Cyst Fibrosis Res Ctr, Marsico Lung Inst, Chapel Hill, NC USA; [Borowsky, A. D.] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of California System; University of California Davis	Carraway, KL (corresponding author), Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Res Bldg 3,Room 1100B,4645 2nd Ave, Sacramento, CA 95817 USA.; Carraway, KL (corresponding author), Univ Calif Davis, Sch Med, UC Davis Comprehens Canc Ctr, Res Bldg 3,Room 1100B,4645 2nd Ave, Sacramento, CA 95817 USA.	klcarraway@ucdavis.edu	Rowson-Hodel, Ashley/AAE-2619-2022	Rowson-Hodel, Ashley/0000-0003-0531-9929; Hatakeyama, Jason/0000-0001-8690-5107	NIH [R01 CA166412, R01 CA118384, P01 HL110873, T32 CA108459, F31 CA210467, F31 CA165758, P30 CA093373, P30 DK065988]; Department of Defense fellowship [W81XWH-111-0065]; Cystic Fibrosis Foundation [BOUCHE15R0]; NATIONAL CANCER INSTITUTE [R01CA166412, T32CA108459, R01CA118384, P30CA093373] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL110873] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense fellowship(United States Department of Defense); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We wish to thank the histology core facility at UC Davis for embedding services and slide preparation, the UC Davis animal facilities for routine management of mouse colonies, the UC Davis Mouse Biology Program for breeding assistance, and Lakmal Kotelawala, Maxine Umeh-Garcia, and Heather Workman for technical assistance. These studies were supported by NIH grants R01 CA166412 (KLC), R01 CA118384 (CS), and P01 HL110873 (WKO), NIH fellowships and training grants T32 CA108459 (ARRH), F31 CA210467 (KVV), and F31 CA165758 (JH), NIH Center grants P30 CA093373 and P30 DK065988, Department of Defense fellowship W81XWH-111-0065 (JHW), and a grant from the Cystic Fibrosis Foundation BOUCHE15R0 (WKO).	Boimel PJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3108; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Damsgaard CT, 2009, J IMMUNOL METHODS, V340, P95, DOI 10.1016/j.jim.2008.10.005; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; Fujita N, 2012, J BIOCHEM, V152, P407, DOI 10.1093/jb/mvs108; Funes M, 2006, J BIOL CHEM, V281, P19310, DOI 10.1074/jbc.M603225200; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Gil-Bernabe AM, 2012, BLOOD, V119, P3164, DOI 10.1182/blood-2011-08-376426; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hauselmann I, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00028; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hu QY, 2015, ADV MATER, V27, P7043, DOI 10.1002/adma.201503323; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Kumar R, 2001, SEMIN ONCOL, V28, P27, DOI 10.1016/S0093-7754(01)90279-9; Labelle M, 2012, CANCER DISCOV, V2, P1091, DOI 10.1158/2159-8290.CD-12-0329; Li JH, 2016, J CONTROL RELEASE, V228, P38, DOI 10.1016/j.jconrel.2016.02.036; Li JH, 2016, BIOMATERIALS, V76, P52, DOI 10.1016/j.biomaterials.2015.10.046; Lorusso G, 2012, SEMIN CANCER BIOL, V22, P226, DOI 10.1016/j.semcancer.2012.03.007; Lundmark A, 2015, SCI REP-UK, V5, DOI 10.1038/srep18475; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mitjavila-Garcia MT, 2002, DEVELOPMENT, V129, P2003; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Mohanty S, 2010, EXPT METASTASIS ASSA, pe1942; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1711; Ponnusamy MP, 2008, BRIT J CANCER, V99, P520, DOI 10.1038/sj.bjc.6604517; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Ponnusamy MP, 2011, J OVARIAN RES, V4, DOI 10.1186/1757-2215-4-7; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Rachagani S, 2012, CARCINOGENESIS, V33, P1953, DOI 10.1093/carcin/bgs225; Rowson-Hodel AR, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1572-7; Rowson-Hodel AR, 2016, CANCER LETT, V375, P62, DOI 10.1016/j.canlet.2016.02.042; Senapati S, 2011, CLIN CANCER RES, V17, P267, DOI 10.1158/1078-0432.CCR-10-1937; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Tan M, 1997, CANCER RES, V57, P1199; Wald JH, 2017, ONCOGENE, V36, P5158, DOI 10.1038/onc.2017.126; Workman HC, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2364; Workman HC, 2009, CANCER RES, V69, P2845, DOI 10.1158/0008-5472.CAN-08-2089; Yokdang N, 2016, ONCOGENE, V35, P2932, DOI 10.1038/onc.2015.345; Zhang J, 2005, J CELL PHYSIOL, V204, P166, DOI 10.1002/jcp.20277; Zhang J, 2006, CURR EYE RES, V31, P1011, DOI 10.1080/02713680601052155; Zhao QC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-154; Zhi XF, 2014, CANCER LETT, V346, P104, DOI 10.1016/j.canlet.2013.12.021	56	27	28	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					197	207		10.1038/onc.2017.327	http://dx.doi.org/10.1038/onc.2017.327			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28892049	Green Accepted, Green Submitted			2022-12-17	WOS:000422631700006
J	Tu, Q; Hao, J; Zhou, X; Yan, L; Dai, H; Sun, B; Yang, D; An, S; Lv, L; Jiao, B; Chen, C; Lai, R; Shi, P; Zhao, X				Tu, Q.; Hao, J.; Zhou, X.; Yan, L.; Dai, H.; Sun, B.; Yang, D.; An, S.; Lv, L.; Jiao, B.; Chen, C.; Lai, R.; Shi, P.; Zhao, X.			CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A	ONCOGENE			English	Article							ONCOGENIC K-RAS; DUCTAL ADENOCARCINOMA; INDUCED SENESCENCE; ACINAR-CELLS; TGF-BETA; TRANSCRIPTION; P15(INK4B); COOPERATE; MOUSE; PROGRESSION	Pancreatic cancer is among the deadliest malignancies; however, the genetic events that lead to pancreatic carcinogenesis in adults remain unclear. In vivo models in which these genetic alterations occur in adult animals may more accurately reflect the features of human cancer. In this study, we demonstrate that inactivation of Cdkn2b (p15ink4b) is necessary for induction of pancreatic cancer by oncogenic KRAS(G12D) expression and inactivation of Tp53 and Cdkn2a in adult mouse pancreatic ductal cells (P60 or older). KRAS(G12D) overexpression in these cells activated transforming growth factor-beta signaling and expression of CDKN2B, which, along with CDKN2A, led to cellular senescence and protected cells from KRAS-mediated transformation via inhibition of retinoblastoma phosphorylation. These results show a critical role of CDKN2B inactivation in pancreatic carcinogenesis, and provide a useful adult animal model by genetic engineering via lentiviral delivery.	[Tu, Q.; Zhou, X.; Yan, L.; Dai, H.; Sun, B.; Yang, D.; An, S.; Chen, C.; Lai, R.; Zhao, X.] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming Inst Zool, 32 East Jiaochang Rd, Kunming 650223, Yunnan, Peoples R China; [Tu, Q.; Zhou, X.; Sun, B.; Yang, D.; An, S.] Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming, Yunnan, Peoples R China; [Hao, J.; Jiao, B.; Shi, P.] Chinese Acad Sci, Kunming Inst Zool, Lab Evolutionary & Funct Genom, State Key Lab Genet Resources & Evolut, Kunming, Yunnan, Peoples R China; [Yan, L.; Lv, L.; Zhao, X.] Chinese Acad Sci, Kunming Primate Res Ctr, Kunming, Yunnan, Peoples R China; [Zhao, X.] Soochow Univ, KIZ SU Joint Lab Anim Model & Drug Dev, Coll Pharmaceut Sci, Suzhou, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; Soochow University - China	Shi, P; Zhao, X (corresponding author), Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming Inst Zool, 32 East Jiaochang Rd, Kunming 650223, Yunnan, Peoples R China.	ship@mail.kiz.ac.cn; zhaoxudong@mail.kiz.ac.cn	Shi, Peng/B-3372-2008	Shi, Peng/0000-0002-4075-4902; Sun, Bin/0000-0002-5663-4294; zhao, zhao xu dong/0000-0001-9126-7365	'Strategic Priority Research Program' of the Chinese Academy of Sciences [XDB13020400, XDA 01040403]; National Natural Science Foundation of China (NSFC) [81472862]; Top Talents Program of Yunnan Province, China [2012HA014]	'Strategic Priority Research Program' of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Top Talents Program of Yunnan Province, China	We thank Dr Ronald Depinho, Dr Gerry Chu and Dr Haoqiang Ying for constructive opinions on this study. We thank Dr Antonio Lavarone for the useful discussion on the regulation of CDKN2B. We thank Dr Jumin Zhou for manuscript revision. We thank Yujie Xia for technical assistance with the histological analysis. This work was supported by by the 'Strategic Priority Research Program' of the Chinese Academy of Sciences (grant no. XDB13020400 to PS and XDA 01040403 to XZ), the National Natural Science Foundation of China (NSFC, 81472862) and the Top Talents Program of Yunnan Province, China (2012HA014) to XZ.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Bailey JM, 2016, ONCOGENE, V35, P4282, DOI 10.1038/onc.2015.441; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Ben-Chetrit N, 2013, CELL ADHES MIGR, V7, P33, DOI 10.4161/cam.22263; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Brembeck FH, 2001, GASTROENTEROLOGY, V120, P1720, DOI 10.1053/gast.2001.24846; DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Gallardo T, 2007, GENESIS, V45, P413, DOI 10.1002/dvg.20310; Gopinathan A, 2015, DIS MODEL MECH, V8, P1185, DOI 10.1242/dmm.021055; Guerra C, 2013, MOL ONCOL, V7, P232, DOI 10.1016/j.molonc.2013.02.002; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Houbracken I, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-74; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Ji BA, 2009, GASTROENTEROLOGY, V137, P1072, DOI 10.1053/j.gastro.2009.05.052; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kohn D. F., 1997, ANESTHESIA ANALGESIA; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Logsdon CD, 2009, CLIN GASTROENTEROL H, V7, pS40, DOI 10.1016/j.cgh.2009.07.040; McNeal AS, 2015, CANCER DISCOV, V5, P1072, DOI 10.1158/2159-8290.CD-15-0196; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Niola F, 2013, J CLIN INVEST, V123, P405, DOI 10.1172/JCI63811; Patel RK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030619; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schuster K, 2014, MOL CANCER RES, V12, P912, DOI 10.1158/1541-7786.MCR-13-0620-T; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Singh SK, 2013, GUT, V62, P1364, DOI 10.1136/gutjnl-2012-302793; Tanaka H, 2010, CANCER SCI, V101, P341, DOI 10.1111/j.1349-7006.2009.01410.x; Tang Y, 2015, ONCOL LETT, V9, P55, DOI 10.3892/ol.2014.2684; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang LH, 2012, GENOME RES, V22, P208, DOI 10.1101/gr.123109.111; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Ying HQ, 2016, GENE DEV, V30, P355, DOI 10.1101/gad.275776.115	49	27	27	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					128	138		10.1038/onc.2017.316	http://dx.doi.org/10.1038/onc.2017.316			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28892048	Green Published, hybrid			2022-12-17	WOS:000422625000013
J	Kwun, HJ; Wendzicki, JA; Shuda, Y; Moore, PS; Chang, Y				Kwun, H. J.; Wendzicki, J. A.; Shuda, Y.; Moore, P. S.; Chang, Y.			Merkel cell polyomavirus small T antigen induces genome instability by E3 ubiquitin ligase targeting	ONCOGENE			English	Article							CENTROSOME OVERDUPLICATION; CHROMOSOMAL INSTABILITY; PROMOTES TUMORIGENESIS; HUMAN PAPILLOMAVIRUSES; MEDIATED DEGRADATION; BINDING PROTEIN-1; E7 ONCOPROTEINS; CYCLE CONTROL; CANCER; ANEUPLOIDY	The formation of a bipolar mitotic spindle is an essential process for the equal segregation of duplicated DNA into two daughter cells during mitosis. As a result of deregulated cellular signaling pathways, cancer cells often suffer a loss of genome integrity that might etiologically contribute to carcinogenesis. Merkel cell polyomavirus (MCV) small T (sT) oncoprotein induces centrosome overduplication, aneuploidy, chromosome breakage and the formation of micronuclei by targeting cellular ligases through a sT domain that also inhibits MCV large T oncoprotein turnover. These results provide important insight as to how centrosome number and chromosomal stability can be affected by the E3 ligase targeting capacity of viral oncoproteins such as MCV sT, which may contribute to Merkel cell carcinogenesis.	[Kwun, H. J.; Wendzicki, J. A.; Shuda, Y.; Moore, P. S.; Chang, Y.] Univ Pittsburgh, Canc Virol Program, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Moore, PS; Chang, Y (corresponding author), Univ Pittsburgh, Canc Inst, Canc Virol Program, 5117 Ctr Ave, Pittsburgh, PA 15213 USA.	psm9@pitt.edu; yc70@pitt.edu	Kwun, Hyun Jin/F-5511-2011; Chang, Yuan/F-4146-2011; Moore, Patrick S./F-3960-2011; Kwun, Hyun Jin/AAH-2706-2020; Kwun, Hyun jin/AAJ-3365-2020; Moore, Patrick/GVR-8294-2022	Kwun, Hyun Jin/0000-0002-8926-746X; Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; Kwun, Hyun jin/0000-0002-8926-746X; 	comprehensive Masonic Cancer Center [P30CA077598]; National Institutes of Health (NIH) [CA136363, CA120726]; NIH [T32AI049820]; UPCI Animal and Cytometry Facilities [P30CA047904]; NATIONAL CANCER INSTITUTE [P30CA077598, P30CA047904, R33CA120726, R01CA136363, R35CA197463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI049820] Funding Source: NIH RePORTER	comprehensive Masonic Cancer Center; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UPCI Animal and Cytometry Facilities; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Gutian Xiao for providing the HA-beta TrCP plasmid, Bert Vogelstein for providing the HCT116 cells, and Megan Lambert and Robin Frederick for assistance in mouse studies, and Meredith Monk for help with the manuscript. The cytogenetic analyses were performed in the Cytogenomics Shared Resource at the University of Minnesota with support from the comprehensive Masonic Cancer Center grant P30CA077598. This study was supported by National Institutes of Health (NIH) grants CA136363 and CA120726 to PSM and YC, who are also supported as American Cancer Society Research Professors. Additional support was provided by the NIH grant T32AI049820 to JAW as a predoctoral trainee. This project used the UPCI Animal and Cytometry Facilities that are supported in part by award P30CA047904.	Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Bonassi S, 2007, CARCINOGENESIS, V28, P625, DOI 10.1093/carcin/bgl177; Busam KJ, 2009, AM J SURG PATHOL, V33, P1378, DOI 10.1097/PAS.0b013e3181aa30a5; Chi YH, 2007, J CELL BIOCHEM, V102, P531, DOI 10.1002/jcb.21484; Cizmecioglu O, 2012, J CELL SCI, V125, P981, DOI 10.1242/jcs.095075; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Desmaze C, 2003, CANCER LETT, V194, P173, DOI 10.1016/S0304-3835(02)00704-8; Duensing A, 2008, VIROLOGY, V372, P157, DOI 10.1016/j.virol.2007.10.030; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Fang X, 2011, SEMIN CELL DEV BIOL, V22, P595, DOI 10.1016/j.semcdb.2011.03.002; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Guderian G, 2010, J CELL SCI, V123, P2163, DOI 10.1242/jcs.068502; Holland AJ, 2010, J CELL BIOL, V188, P191, DOI 10.1083/jcb.200911102; Houben R, 2010, J VIROL, V84, P7064, DOI 10.1128/JVI.02400-09; Iarmarcovai G, 2008, MUTAT RES-REV MUTAT, V658, P215, DOI 10.1016/j.mrrev.2007.10.001; Knight LM, 2015, J VIROL, V89, P35, DOI 10.1128/JVI.02317-14; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Korzeniewski N, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-61; Kwun HJ, 2015, J VIROL, V89, P4191, DOI 10.1128/JVI.00157-15; Kwun HJ, 2013, CELL HOST MICROBE, V14, P125, DOI 10.1016/j.chom.2013.06.008; Kwun HJ, 2009, J VIROL, V83, P12118, DOI 10.1128/JVI.01336-09; Lau AW, 2012, FRONT BIOSCI-LANDMRK, V17, P2197, DOI 10.2741/4045; Li M, 2009, J CELL BIOL, V185, P983, DOI 10.1083/jcb.200904020; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Martin-Lluesma S, 2008, HEPATOLOGY, V48, P1467, DOI 10.1002/hep.22542; Miron K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8094; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Pan HY, 2004, CANCER RES, V64, P4064, DOI 10.1158/0008-5472.CAN-04-0657; Peel Nina, 2013, Worm, V2, pe22497, DOI 10.4161/worm.22497; Peloponese JM, 2005, P NATL ACAD SCI USA, V102, P18974, DOI 10.1073/pnas.0506659103; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rodig SJ, 2012, J CLIN INVEST, V122, P4645, DOI 10.1172/JCI64116; Sahi H, 2014, APMIS, V122, P1157, DOI 10.1111/apm.12274; Shuda M, 2008, P NATL ACAD SCI USA, V105, P16272, DOI 10.1073/pnas.0806526105; Shuda M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142329; Shuda M, 2015, P NATL ACAD SCI USA, V112, P5875, DOI 10.1073/pnas.1505787112; Shuda M, 2011, J CLIN INVEST, V121, P3623, DOI 10.1172/JCI46323; Silverman JS, 2012, TRENDS BIOCHEM SCI, V37, P66, DOI 10.1016/j.tibs.2011.10.004; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Verhaegen ME, 2015, J INVEST DERMATOL, V135, P1415, DOI 10.1038/jid.2014.446; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; White EA, 2012, P NATL ACAD SCI USA, V109, pE260, DOI 10.1073/pnas.1116776109; Witt KL, 2008, MUTAT RES-GEN TOX EN, V649, P101, DOI 10.1016/j.mrgentox.2007.08.004; Yun C, 2004, MOL CANCER RES, V2, P159	50	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6784	6792		10.1038/onc.2017.277	http://dx.doi.org/10.1038/onc.2017.277			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28846109	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000417282500004
J	Shih, CH; Chang, YJ; Huang, WC; Jang, TH; Kung, HJ; Wang, WC; Yang, MH; Lin, MC; Huang, SF; Chou, SW; Chang, E; Chiu, H; Shieh, TY; Chen, YJ; Wang, LH; Chen, L				Shih, C-H; Chang, Y-J; Huang, W-C; Jang, T-H; Kung, H-J; Wang, W-C; Yang, M-H; Lin, M-C; Huang, S-F; Chou, S-W; Chang, E.; Chiu, H.; Shieh, T-Y; Chen, Y-J; Wang, L-H; Chen, L.			EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; AVIAN-SARCOMA VIRUS-UR2; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; FUSION PROTEINS; C-ROS; GENE; EXPRESSION; CAVITY	Current anti-epidermal growth factor receptor (EGFR) therapy for oral cancer does not provide satisfactory efficacy due to drug resistance or reduced EGFR level. As an alternative candidate target for therapy, here we identified an oncogene, ROS1, as an important driver for oral squamous cell carcinoma (OSCC) metastasis. Among tumors from 188 oral cancer patients, upregulated ROS1 expression strongly correlated with metastasis to lung and lymph nodes. Mechanistic studies uncover that the activated ROS1 results from highly expressed ROS1 gene instead of gene rearrangement, a phenomenon distinct from other cancers. Our data further reveal a novel mechanism that reduced histone methyltransferase EZH2 leads to a lower trimethylation of histone H3 lysine 27 suppressive modification, relaxes chromatin, and promotes the accessibility of the transcription factor STAT1 to the enhancer and the intron regions of ROS1 target genes, CXCL1 and GLI1, for upregulating their expressions. Down-regulation of ROS1 in highly invasive OSCC cells, nevertheless, reduces cell proliferation and inhibits metastasis to lung in the tail-vein injection and the oral cavity xenograft models. Our findings highlight ROS1 as a candidate biomarker and therapeutic target for OSCC. Finally, we demonstrate that co-targeting of ROS1 and EGFR could potentially offer an effective oral cancer therapy.	[Shih, C-H; Chang, Y-J; Lin, M-C; Chou, S-W; Chang, E.; Chiu, H.; Chen, L.] Natl Tsing Hua Univ, Inst Mol Med, Hsinchu, Taiwan; [Huang, W-C; Jang, T-H; Kung, H-J; Huang, S-F; Wang, L-H] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan; [Kung, H-J] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA; [Wang, W-C] Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu, Taiwan; [Yang, M-H] Natl Yang Ming Univ, Dept Biotechnol, Taipei, Taiwan; [Yang, M-H] Natl Yang Ming Univ, Lab Sci Med, Taipei, Taiwan; [Shieh, T-Y] Kaohsiung Med Univ, Dept Oral Hyg, Kaohsiung, Taiwan; [Chen, Y-J] MacKay Mem Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Chen, L.] Natl Tsing Hua Univ, Dept Med Sci, Hsinchu, Taiwan; [Wang, L-H] China Med Univ, Presidents Off, Taichung, Taiwan	National Tsing Hua University; National Health Research Institutes - Taiwan; University of California System; University of California Davis; National Tsing Hua University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Kaohsiung Medical University; Mackay Memorial Hospital; National Tsing Hua University; China Medical University Taiwan	Wang, LH (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan.; Chen, L (corresponding author), Natl Tsing Hua Univ, Dept Med Sci, Hsinchu, Taiwan.; Chen, L (corresponding author), Natl Tsing Hua Univ, Inst Mol Med, Hsinchu, Taiwan.; Wang, LH (corresponding author), China Med Univ, Presidents Off, Taichung, Taiwan.	lu-hai.wang@nhri.org.tw; lchen@life.nthu.edu.tw	Chen, Linyi/AAV-2632-2020; Yang, Muh-Hwa/AAE-4691-2020; Wang, Wen-Ching/ABI-2253-2020	Chen, Linyi/0000-0001-7258-8817; Wang, Wen-Ching/0000-0002-7422-3667; Chang, Yu-Jung/0000-0002-4781-0946	Ministry of Science and Technology, Taiwan [NSC 105-2320-B-007-002-MY3, NSC 106-2811-B-007-001]; National Tsing Hua University, Taiwan [104N2739E1, 105N722CV7, 105N183DE1]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Tsing Hua University, Taiwan	This study was supported by grants from Ministry of Science and Technology, Taiwan (NSC 105-2320-B-007-002-MY3) and National Tsing Hua University, Taiwan (104N2739E1 and 105N722CV7) and postdoctoral fellowships from Ministry of Science and Technology, Taiwan (NSC 106-2811-B-007-001 to YJC) and National Tsing Hua University, Taiwan (105N183DE1 to YJC). We thank Professor Rong-Long Pan for commenting on our manuscript.	BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Burke SJ, 2014, AM J PHYSIOL-ENDOC M, V306, pE131, DOI 10.1152/ajpendo.00347.2013; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Davare MA, 2013, P NATL ACAD SCI USA, V110, P19519, DOI 10.1073/pnas.1319583110; Davies KD, 2013, CLIN CANCER RES, V19, P4040, DOI 10.1158/1078-0432.CCR-12-2851; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dionne KR, 2015, INT J CANCER, V136, P503, DOI 10.1002/ijc.28754; Ernani V, 2015, ONCOLOGY-BASEL, V89, P187, DOI 10.1159/000398801; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Ettl T, 2012, HUM PATHOL, V43, P921, DOI 10.1016/j.humpath.2011.08.006; Fan HX, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0041-5; FELDMAN RA, 1982, J VIROL, V42, P228, DOI 10.1128/JVI.42.1.228-236.1982; Filbin MG, 2013, NAT MED, V19, P1518, DOI 10.1038/nm.3328; Huang WC, 2014, CANCER RES, V74, P751, DOI 10.1158/0008-5472.CAN-13-1297; Johnson N W, 2011, Adv Dent Res, V23, P237, DOI 10.1177/0022034511402082; Jun HJ, 2012, CANCER RES, V72, P3764, DOI 10.1158/0008-5472.CAN-11-3990; Jun HJ, 2009, CANCER RES, V69, P2180, DOI 10.1158/0008-5472.CAN-08-3351; Kawanishi H, 2008, CLIN CANCER RES, V14, P2579, DOI 10.1158/1078-0432.CCR-07-1922; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kimura I, 2016, ONCOL LETT, V11, P201, DOI 10.3892/ol.2015.3833; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lin SC, 2004, J ORAL PATHOL MED, V33, P79, DOI 10.1111/j.1600-0714.2004.00034.x; Lu YC, 2012, CANCER PREV RES, V5, P665, DOI 10.1158/1940-6207.CAPR-11-0358; Markopoulos AK, 2012, OPEN DENT J, V6, P126, DOI 10.2174/1874210601206010126; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; Mimeault M, 2010, PHARMACOL REV, V62, P497, DOI 10.1124/pr.109.002329; MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x; Moon C, 2010, EXP BIOL MED, V235, P907, DOI 10.1258/ebm.2009.009181; Nguyen KT, 2002, J BIOL CHEM, V277, P11107, DOI 10.1074/jbc.M108166200; O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285; Okumura K, 1996, J CANCER RES CLIN, V122, P243, DOI 10.1007/BF01209653; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Ryott M, 2009, EUR J CANCER, V45, P1700, DOI 10.1016/j.ejca.2009.02.027; Sashida G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5177; Shaib W, 2012, J ONCOL, V2012, DOI 10.1155/2012/521215; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsien CI, 2013, HEAD NECK-J SCI SPEC, V35, P1323, DOI 10.1002/hed.23128; Uttamsingh S, 2003, J BIOL CHEM, V278, P18798, DOI 10.1074/jbc.M211522200; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; Wang YF, 2012, HEAD NECK-J SCI SPEC, V34, P1556, DOI 10.1002/hed.21958; Warnakulasuriya S, 2010, ORAL ONCOL, V46, P407, DOI 10.1016/j.oraloncology.2010.02.015; Xiong QH, 1996, MOL CELL BIOL, V16, P1509; Yang C C, 2001, Zhonghua Yi Xue Za Zhi (Taipei), V64, P357; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051; Zong CS, 1997, J BIOL CHEM, V272, P1500, DOI 10.1074/jbc.272.3.1500	51	27	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6542	6554		10.1038/onc.2017.262	http://dx.doi.org/10.1038/onc.2017.262			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28759046	Green Published			2022-12-17	WOS:000416049200004
J	Hu, X; Dong, SH; Chen, J; Zhou, XZ; Chen, R; Nair, S; Lu, KP; Chen, LF				Hu, X.; Dong, S-H; Chen, J.; Zhou, X. Z.; Chen, R.; Nair, S.; Lu, K. P.; Chen, L-F			Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4	ONCOGENE			English	Article							RNA-POLYMERASE-II; NF-KAPPA-B; BET BROMODOMAIN PROTEINS; BREAST-CANCER; CELL-PROLIFERATION; PROSTATE-CANCER; GASTRIC-CANCER; P-TEFB; INHIBITION; EXPRESSION	BRD4 has emerged as an important factor in tumorigenesis by promoting the transcription of genes involved in cancer development. However, how BRD4 is regulated in cancer cells remains largely unknown. Here, we report that the stability and functions of BRD4 are positively regulated by prolyl isomerase PIN1 in gastric cancer cells. PIN1 directly binds to phosphorylated threonine (T) 204 of BRD4 as revealed by peptide binding and crystallographic studies and enhances BRD4's stability by inhibiting its ubiquitination. PIN1 also catalyses the isomerization of proline 205 of BRD4 and induces its conformational change, which promotes its interaction with CDK9 and increases BRD4's transcriptional activity. Substitution of BRD4 with PIN1-binding-defective BRD4-T204A mutant in gastric cancer cells reduces BRD4's stability, attenuates BRD4-mediated gene expression by impairing its interaction with CDK9 and suppresses gastric cancer cell proliferation, migration and invasion, and tumor formation. Our results identify BRD4 as a new target of PIN1 and suggest that interfering with their interaction could be a potential therapeutic approach for cancer treatment.	[Hu, X.; Dong, S-H; Chen, J.; Nair, S.; Chen, L-F] Univ Illinois, Dept Biochem, Urbana, IL USA; [Zhou, X. Z.; Lu, K. P.] Harvard Med Sch, BIDMC, Dept Med, Div Translat Therapeut, Boston, MA USA; [Chen, R.] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Lu, K. P.] Fujian Med Univ, Inst Translat Med, Fuzhou, Fujian, Peoples R China; [Chen, L-F] Univ Illinois, Coll Med, Dept Med Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Xiamen University; Fujian Medical University; University of Illinois System; University of Illinois Urbana-Champaign	Chen, LF (corresponding author), Univ Illinois, Dept Biochem, 506 S Mathews Ave,MC-714, Urbana, IL 61801 USA.	lfchen@life.illinois.edu	Nair, Satish/AAY-2510-2021; Dong, Shihui/T-4864-2017		UIUC; NIH [DK085158, CA179511]; Natural Science Foundation of China [81361120386]; NATIONAL CANCER INSTITUTE [R01CA179511, R01CA167677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI117080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK085158] Funding Source: NIH RePORTER	UIUC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members in the Chen lab for discussion. This work is supported in part by fund provided by UIUC (to LFC) and NIH grants DK085158 and CA179511 (to LFC) and Natural Science Foundation of China Grants 81361120386 (to RC).	Ai NP, 2011, NUCLEIC ACIDS RES, V39, P9592, DOI 10.1093/nar/gkr698; Alsarraj J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080746; Alsarraj J, 2011, CANCER RES, V71, P3121, DOI 10.1158/0008-5472.CAN-10-4417; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Atkinson GP, 2009, ONCOGENE, V28, P3735, DOI 10.1038/onc.2009.232; Ayala G, 2003, CANCER RES, V63, P6244; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Basheer F, 2015, EXP HEMATOL, V43, P718, DOI 10.1016/j.exphem.2015.06.004; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Chiang CM, 2009, BIOL REP, V1, P98, DOI DOI 10.3410/B1-98; Chung CW, 2012, PROGR MED CHEM, V51, P1, DOI 10.1016/B978-0-12-396493-9.00001-7; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; Gallagher SJ, 2014, PIGM CELL MELANOMA R, V27, P1126, DOI 10.1111/pcmr.12282; Hsu TI, 2015, ONCOGENE, V34, P826, DOI 10.1038/onc.2014.22; Hu Y, 2015, INT J MOL SCI, V16, P1928, DOI 10.3390/ijms16011928; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jin J, 2013, NEOPLASMA, V60, P92, DOI 10.4149/neo_2013_013; Jung M, 2015, EPIGENOMICS-UK, V7, P487, DOI 10.2217/epi.14.91; Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913; Liou YC, 2011, TRENDS BIOCHEM SCI, V36, P501, DOI 10.1016/j.tibs.2011.07.001; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu ZM, 2014, CELL RES, V24, P1033, DOI 10.1038/cr.2014.109; Ma T, 2014, BIOMED RES INT; Morishita A, 2014, WORLD J GASTROENTERO, V20, P4536, DOI 10.3748/wjg.v20.i16.4536; Muller S, 2011, EXPERT REV MOL MED, V13, P1, DOI 10.1017/S1462399411001992; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Pastori C, 2014, EPIGENETICS-US, V9, P611, DOI 10.4161/epi.27906; Proserpio V, 2013, GENE DEV, V27, P1299, DOI 10.1101/gad.217240.113; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Shi M, 2015, CELL BIOCHEM BIOPHYS, V71, P857, DOI 10.1007/s12013-014-0274-0; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Suizu F, 2006, MOL CELL BIOL, V26, P1463, DOI 10.1128/MCB.26.4.1463-1479.2006; Takahashi K, 2007, ONCOGENE, V26, P3835, DOI 10.1038/sj.onc.1210153; Tsang YHN, 2013, ONCOGENE, V32, P1488, DOI 10.1038/onc.2012.178; Uchida T, 2003, CHEM BIOL, V10, P15, DOI 10.1016/S1074-5521(02)00310-1; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Wu SY, 2016, CELL REP, V16, P1733, DOI 10.1016/j.celrep.2016.07.001; Wu SY, 2013, MOL CELL, V49, P843, DOI 10.1016/j.molcel.2012.12.006; Wu XW, 2013, J BIOL CHEM, V288, P36094, DOI 10.1074/jbc.M113.485029; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Yang S, 2011, J INT MED RES, V39, P2076, DOI 10.1177/147323001103900603; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Yogesha SD, 2014, MOLECULES, V19, P1481, DOI 10.3390/molecules19021481; Zhang Y, 2007, ACS CHEM BIOL, V2, P320, DOI 10.1021/cb7000044; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	56	27	27	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5177	5188		10.1038/onc.2017.137	http://dx.doi.org/10.1038/onc.2017.137			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481868	Green Accepted, Green Submitted			2022-12-17	WOS:000409371100009
J	Nandhu, MS; Kwiatkowska, A; Bhaskaran, V; Hayes, J; Hu, B; Viapiano, MS				Nandhu, M. S.; Kwiatkowska, A.; Bhaskaran, V.; Hayes, J.; Hu, B.; Viapiano, M. S.			Tumor-derived fibulin-3 activates pro-invasive NF-kappa B signaling in glioblastoma cells and their microenvironment	ONCOGENE			English	Article							THERAPEUTIC TARGETS; TISSUE LOCALIZATION; MALIGNANT GLIOMA; GROWTH-FACTOR; STEM-CELLS; ADAM17; RESISTANCE; EXPRESSION; INHIBITOR; EFEMP1	Molecular profiling of glioblastomas has revealed the presence of key signaling hubs that contribute to tumor progression and acquisition of resistance. One of these main signaling mechanisms is the nuclear factor-kappa B (NF-kappa B) pathway, which integrates multiple extracellular signals into transcriptional programs for tumor growth, invasion and maintenance of the tumor-initiating population. We show here that an extracellular protein released by glioblastoma cells, fibulin-3, drives oncogenic NF-kappa B in the tumor and increases NF-kappa B activation in peritumoral astrocytes. Fibulin-3 expression correlates with a NF-kappa B-regulated 'invasive signature' linked to poorer survival, being a possible tissue marker for regions of active tumor progression. Accordingly, fibulin-3 promotes glioblastoma invasion in a manner that requires NF-kappa B activation both in the tumor cells and their microenvironment. Mechanistically, we found that fibulin-3 activates the metalloprotease ADAM17 by competing with its endogenous inhibitor, TIMP3. This results in sustained release of soluble tumor necrosis factor alpha (TNF alpha) by ADAM17, which in turn activates TNF receptors and canonical NF-kappa B signaling. Taken together, our results underscore fibulin-3 as a novel extracellular signal with strong activating effect on NF-kappa B in malignant gliomas. Because fibulin-3 is produced de novo in these tumors and is absent from the normal brain, we propose that targeting the fibulin-3/NF-kappa B axis may provide a novel avenue to disrupt oncogenic NF-kappa B signaling in combination therapies for malignant brain tumors.	[Nandhu, M. S.; Kwiatkowska, A.; Bhaskaran, V.; Viapiano, M. S.] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; [Nandhu, M. S.; Kwiatkowska, A.; Bhaskaran, V.; Viapiano, M. S.] Harvard Med Sch, Boston, MA USA; [Nandhu, M. S.; Viapiano, M. S.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, 505 Irving Ave,Room 4604, Syracuse, NY 13210 USA; [Hayes, J.] Univ Calif San Francisco, Dept Neurol Surg, Helen Diller Family Canc Ctr, San Francisco, CA USA; [Hu, B.] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Hu, B.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University System of Ohio; Ohio State University; Virginia Commonwealth University	Viapiano, MS (corresponding author), SUNY Upstate Med Univ, Dept Neurosci & Physiol, 505 Irving Ave,Room 4604, Syracuse, NY 13210 USA.	viapianm@upstate.edu		Bhaskaran, Vivek/0000-0002-5100-4787	National Institutes of Health [R01CA152065]; National Brain Tumor Society; American Brain Tumor Association; NATIONAL CANCER INSTITUTE [R01CA152065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS091436] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Brain Tumor Society; American Brain Tumor Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the National Institutes of Health (R01CA152065) and the National Brain Tumor Society to MSV, and the Joel Gingras Jr. Research Fellowship from the American Brain Tumor Association to BH.	Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; Baltimore D, 2011, NAT IMMUNOL, V12, P683, DOI 10.1038/ni.2072; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bonavia R, 2012, ONCOGENE, V31, P4054, DOI 10.1038/onc.2011.563; Bozkulak EC, 2009, MOL CELL BIOL, V29, P5679, DOI 10.1128/MCB.00406-09; Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073; Bredel M, 2011, NEW ENGL J MED, V364, P627, DOI 10.1056/NEJMoa1006312; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Camaj P, 2009, BIOL CHEM, V390, P1293, DOI 10.1515/BC.2009.140; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Celiku O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101239; Chen JJ, 2013, MATH PROBL ENG, V2013, DOI 10.1155/2013/768756; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chen XR, 2013, BRAIN RES, V1538, P151, DOI 10.1016/j.brainres.2013.02.025; Chen XR, 2013, NEUROSCI LETT, V537, P44, DOI 10.1016/j.neulet.2013.01.021; Conti Alfredo, 2010, Cancers (Basel), V2, P693, DOI 10.3390/cancers2020693; Creaney J, 2014, THORAX, V69, P895, DOI 10.1136/thoraxjnl-2014-205205; de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Ellert-Miklaszewska A, 2013, GLIA, V61, P1178, DOI 10.1002/glia.22510; Espinosa L, 2010, CANCER CELL, V18, P268, DOI 10.1016/j.ccr.2010.08.006; Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4; Gooz M, 2010, CRIT REV BIOCHEM MOL, V45, P146, DOI 10.3109/10409231003628015; Gray GK, 2014, EXPERT REV NEUROTHER, V14, P1293, DOI 10.1586/14737175.2014.964211; Hiddingh L, 2014, ONCOTARGET, V5, P363, DOI 10.18632/oncotarget.1620; Hu B, 2012, CANCER RES, V72, P3873, DOI 10.1158/0008-5472.CAN-12-1060; Hu B, 2009, MOL CANCER RES, V7, P1756, DOI 10.1158/1541-7786.MCR-09-0207; Hu Yuanjie, 2014, Oncoscience, V1, P205; Hwang CF, 2010, J PATHOL, V222, P367, DOI 10.1002/path.2776; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]; Kim JK, 2014, CANCER LETT, V353, P194, DOI 10.1016/j.canlet.2014.07.034; Kim YJ, 2006, BIOCHEM BIOPH RES CO, V347, P731, DOI 10.1016/j.bbrc.2006.06.149; Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200; Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200; Korkolopoulou P, 2008, HUM PATHOL, V39, P1143, DOI 10.1016/j.humpath.2008.01.020; Kusne Y, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005196; Mathis BJ, 2015, CURR DRUG TARGETS, V16, P284, DOI 10.2174/1389450115666141024152421; Nandhu MS, 2014, CANCER RES, V74, P5435, DOI 10.1158/0008-5472.CAN-14-0685; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Newton RC, 2001, ANN RHEUM DIS, V60, pIII25; Nogueira L, 2011, ONCOTARGET, V2, P646, DOI 10.18632/oncotarget.322; Obaya AJ, 2012, CANCER LETT, V325, P132, DOI 10.1016/j.canlet.2012.06.019; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Ohnishi T, 1998, CANCER RES, V58, P2935; Ostrom QT, 2014, NEUROONCOL S4, V16, piv1; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pass HI, 2012, NEW ENGL J MED, V367, P1417, DOI 10.1056/NEJMoa1115050; Puliyappadamba VT, 2014, MOL CELL ONCOL, V1, DOI 10.4161/23723548.2014.963478; Robe PA, 2004, CLIN CANCER RES, V10, P5595, DOI 10.1158/1078-0432.CCR-03-0392; Rose-John S, 2013, PHARMACOL RES, V71, P19, DOI 10.1016/j.phrs.2013.01.012; Seeliger H, 2009, MOL CANCER RES, V7, P189, DOI 10.1158/1541-7786.MCR-08-0132; Shelest Ekaterina, 2003, In Silico Biology, V3, P71; Song EL, 2011, GYNECOL ONCOL, V121, P174, DOI 10.1016/j.ygyno.2010.11.004; Song EL, 2010, GYNECOL ONCOL, V117, P417, DOI 10.1016/j.ygyno.2009.12.016; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Watkins S, 2012, TRENDS NEUROSCI, V35, P546, DOI 10.1016/j.tins.2012.05.001; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Westhoff MA, 2013, MOL CANCER RES, V11, P1611, DOI 10.1158/1541-7786.MCR-13-0435-T; Wolpert F, 2014, NEURO-ONCOLOGY, V16, P382, DOI 10.1093/neuonc/not232; Zheng XG, 2012, MOL CARCINOGEN, V51, P150, DOI 10.1002/mc.20772; Zong H, 2012, EXPERT REV MOL DIAGN, V12, P383, DOI [10.1586/erm.12.30, 10.1586/ERM.12.30]	66	27	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4875	4886		10.1038/onc.2017.109	http://dx.doi.org/10.1038/onc.2017.109			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28414309	Green Accepted, Green Submitted			2022-12-17	WOS:000408234400005
J	Vivo, M; Fontana, R; Ranieri, M; Capasso, G; Angrisano, T; Pollice, A; Calabro, V; La Mantia, G				Vivo, M.; Fontana, R.; Ranieri, M.; Capasso, G.; Angrisano, T.; Pollice, A.; Calabro, V.; La Mantia, G.			p14ARF interacts with the focal adhesion kinase and protects cells from anoikis	ONCOGENE			English	Article							ARF TUMOR-SUPPRESSOR; DAP-KINASE; MOTOR COMPLEX; DNA-DAMAGE; IN-VIVO; CANCER; SURVIVAL; PHOSPHORYLATION; PROGRESSION; APOPTOSIS	The ARF protein functions as an important sensor of hyper-proliferative stimuli restricting cell proliferation through both p53-dependent and - independent pathways. Although to date the majority of studies on ARF have focused on its anti-proliferative role, few studies have addressed whether ARF may also have pro-survival functions. Here we show for the first time that during the process of adhesion and spreading ARF re-localizes to sites of active actin polymerization and to focal adhesion points where it interacts with the phosphorylated focal adhesion kinase. In line with its recruitment to focal adhesions, we observe that hampering ARF function in cancer cells leads to gross defects in cytoskeleton organization resulting in apoptosis through a mechanism dependent on the Death-Associated Protein Kinase. Our data uncover a novel function for p14ARF in protecting cells from anoikis that may reflect its role in anchorage independence, a hallmark of malignant tumor cells.	[Vivo, M.; Fontana, R.; Ranieri, M.; Capasso, G.; Angrisano, T.; Pollice, A.; Calabro, V.; La Mantia, G.] Univ Naples Federico II, Dipartimento Biol, Via Cinthia, I-80126 Naples, Italy	University of Naples Federico II	Vivo, M; La Mantia, G (corresponding author), Univ Naples Federico II, Dipartimento Biol, Via Cinthia, I-80126 Naples, Italy.	maria.vivo@unina.it; lamantia@unina.it	Vivo, Maria/S-3390-2017; Angrisano, Tiziana/AAC-5353-2022; Calabro, Viola/H-6156-2013; Fontana, Rosa/AAD-7852-2019	Vivo, Maria/0000-0003-2458-4226; Fontana, Rosa/0000-0003-0445-6016; Calabro, Viola/0000-0002-6508-8889; Ranieri, Michela/0000-0002-3833-3594	L.R.5; PO FESR 'DiMo'; PO FESR 'Movie'	L.R.5; PO FESR 'DiMo'; PO FESR 'Movie'	We thank Dr Carlo Di Cristo and Dr Tiziana Parisi for critical revision of the manuscript. We thank Dr Valeria R Villella for providing HeLa cells, Dr Giovanna Benvenuto (Confocal Microscopy Service at the Stazione Zoologica Anton Dohrn, Naples) and Dr Per Guldberg for kindly providing GFP-tagged ARF mutants. This work was supported by grants awarded to GLM and AP from L.R.5 (2007), to VC and GLM from PO FESR 2007-2013 'DiMo' and 'Movie', respectively.	Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Budina-Kolomets A, 2013, AUTOPHAGY, V9, P1553, DOI 10.4161/auto.25831; Chen RH, 2006, J BIOMED SCI, V13, P193, DOI 10.1007/s11373-005-9063-5; Chen ZB, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000053; Chiba K, 1998, TOXICOL IN VITRO, V12, P251, DOI 10.1016/S0887-2333(97)00107-0; Christensen C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6348; Churchman ML, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002157; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Fan HP, 2013, J BIOL CHEM, V288, P3322, DOI 10.1074/jbc.M112.420497; Ferru A, 2006, BRIT J CANCER, V95, P1670, DOI 10.1038/sj.bjc.6603479; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gromley A, 2009, P NATL ACAD SCI USA, V106, P6285, DOI 10.1073/pnas.0902310106; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Humbey O, 2008, CANCER RES, V68, P9608, DOI 10.1158/0008-5472.CAN-08-2263; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Ivanovska J, 2014, APOPTOSIS, V19, P329, DOI 10.1007/s10495-013-0916-5; Johnson CL, 2002, MOL CANCER THER, V1, P861; Kadare G, 2003, J BIOL CHEM, V278, P47434, DOI 10.1074/jbc.M308562200; Kamijo T, 1999, CANCER RES, V59, P2217; Kobayashi T, 2013, MOL CANCER RES, V11, P828, DOI 10.1158/1541-7786.MCR-13-0207; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kotsinas A, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00236; Kuo JC, 2003, J CELL SCI, V116, P4777, DOI 10.1242/jcs.00794; Li CL, 2013, P NATL ACAD SCI USA, V110, pE1112, DOI 10.1073/pnas.1302184110; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Pimkina J, 2009, J BIOL CHEM, V284, P2803, DOI 10.1074/jbc.M804705200; Pollice A, 2008, FEBS LETT, V582, P3257, DOI 10.1016/j.febslet.2008.09.026; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sanchez-Aguilera A, 2002, BLOOD, V99, P1411, DOI 10.1182/blood.V99.4.1411; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Serrels B, 2007, NAT CELL BIOL, V9, P1046, DOI 10.1038/ncb1626; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tancioni I, 2014, MOL CANCER THER, V13, P2050, DOI 10.1158/1535-7163.MCT-13-1063; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Vivo M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117252; Vivo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053631; Vivo M, 2009, CELL CYCLE, V8, P3545, DOI 10.4161/cc.8.21.9954; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Xie YQ, 2014, MOL ONCOL, V8, P1355, DOI 10.1016/j.molonc.2014.05.006; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	55	27	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4913	4928		10.1038/onc.2017.104	http://dx.doi.org/10.1038/onc.2017.104			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436949	hybrid, Green Published			2022-12-17	WOS:000408234400008
J	Comisso, E; Scarola, M; Rosso, M; Piazza, S; Marzinotto, S; Ciani, Y; Orsaria, M; Mariuzzi, L; Schneider, C; Schoeftner, S; Benetti, R				Comisso, E.; Scarola, M.; Rosso, M.; Piazza, S.; Marzinotto, S.; Ciani, Y.; Orsaria, M.; Mariuzzi, L.; Schneider, C.; Schoeftner, S.; Benetti, R.			OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness	ONCOGENE			English	Article							CHROMOSOMAL PASSENGER COMPLEX; AURORA-B KINASE; RETINOBLASTOMA PROTEIN; INITIATING CELLS; SELF-RENEWAL; LUNG-CANCER; STEM; EXPRESSION; INHIBITION; GROWTH	OCT4 (Octamer-binding transcription factor 4) is essential for embryonic stem cell self-renewal. Here we show that OCT4 increases the aggressiveness of high-grade serous ovarian cancer (HG-SOC) by inactivating the Retinoblastoma tumor suppressor pathway and enhancing mitotic stability in cancer cells. OCT4 drives the expression of Nuclear Inhibitor of Protein Phosphatase type 1 (NIPP1) and Cyclin F (CCNF) that together inhibit Protein Phosphatase 1 (PP1). This results in pRB hyper-phosphorylation, accelerated cell proliferation and increased in vitro tumorigenicity of ovarian cancer cells. In parallel, OCT4 and NIPP1/CCNF drive the expression of the central Chromosomal Passenger Complex (CPC) components, Borealin, Survivin and the mitotic kinase Aurora B, promoting the clustering of supernumerary centrosomes to increase mitotic stability. Loss of OCT4 or NIPP1/CCNF results in severe mitotic defects, multipolar spindles and supernumerary centrosomes, finally leading to the induction of apoptosis. These phenotypes were recapitulated in different cancer models indicating general relevance for human cancer. Importantly, activation of these parallel pathways leads to dramatically reduced overall survival of HG-SOC patients. Altogether, our data highlights an unprecedented role for OCT4 as central regulator of mitotic fidelity and RB tumor suppressor pathway activity. Disrupting this pathway represents a promising strategy to target an aggressive subpopulation of HG-SOC cells.	[Comisso, E.; Scarola, M.; Rosso, M.; Piazza, S.; Ciani, Y.; Schneider, C.; Schoeftner, S.; Benetti, R.] LNCIB, Canc Epigenet Grp, Area Sci Pk,Palazzina F3,Padriciano 99, Trieste, Italy; [Comisso, E.; Schneider, C.; Benetti, R.] Univ Udine, Dept Med & Biol Sci, Udine, Italy; [Rosso, M.; Schoeftner, S.] Univ Trieste, Dept Life Sci, Trieste, Italy; [Piazza, S.] Univ Trento CIBIO, Ctr Integrat Biol, Trento, Italy; [Marzinotto, S.; Orsaria, M.; Mariuzzi, L.] Univ Hosp Udine, Inst Anat Pathol, Dept Med & Biol Sci, Udine, Italy; [Scarola, M.; Rosso, M.] LNCIB, Genom Instabil Grp, Area Sci Pk,Padriciano 99, I-34149 Trieste, Italy	University of Udine; University of Trieste; University of Trento; University of Udine; University Hospital of Udine	Benetti, R (corresponding author), LNCIB, Canc Epigenet Grp, Area Sci Pk,Palazzina F3,Padriciano 99, Trieste, Italy.; Schoeftner, S (corresponding author), LNCIB, Genom Instabil Grp, Area Sci Pk,Padriciano 99, I-34149 Trieste, Italy.	stefan.schoeftner@lncib.it; roberta.benetti@lncib.it	Orsaria, Maria/AAH-6310-2021	Piazza, Silvano/0000-0002-7156-5434; Rosso, Massimo/0000-0002-4473-196X; Ciani, Yari/0000-0002-9635-2830	AIRC grant [Rif 17756, Rif 10299]; Rotary Club Bari Sud; Italian Ministry of Education, Universities and Research (MIUR) [CTN01_00177_817708]	AIRC grant(Fondazione AIRC per la ricerca sul cancro); Rotary Club Bari Sud; Italian Ministry of Education, Universities and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	We thank Angelica Feresin and Simone Pisano (University of Udine, Italy) for helping with processing of patient samples and with spindle defects experiments. EC and MS are AIRC post-doctoral fellows. MR is enrolled in the PhD program for Molecular Medicine at the University of Trieste. This work was supported by an AIRC grant (Rif 17756 to RB and Rif 10299 to SS), a financial support by the Rotary Club Bari Sud to RB and a grant from the Italian Ministry of Education, Universities and Research (MIUR) CTN01_00177_817708 to CS.	Amato A, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-79; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Chen ZG, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-10; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Dai XZ, 2013, ONCOL REP, V29, P155, DOI 10.3892/or.2012.2086; Darini CY, 2012, ONCOGENE, V31, P2438, DOI 10.1038/onc.2011.421; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Desjardins M, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-70; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Huang P, 2012, MED ONCOL, V29, P829, DOI 10.1007/s12032-011-9962-4; Iovino F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-38; Kim HJ, 2011, FEBS LETT, V585, P3569, DOI 10.1016/j.febslet.2011.10.022; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Koo BS, 2015, ONCOGENE, V34, P2317, DOI 10.1038/onc.2014.174; Latifi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046858; Leber B, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000915; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Liedtke S, 2008, BIOL CHEM, V389, P845, DOI 10.1515/BC.2008.098; Lieman JH, 2005, J BIOL CHEM, V280, P10484, DOI 10.1074/jbc.M409371200; Linn Douglas E, 2010, Genes Cancer, V1, P908, DOI 10.1177/1947601910388271; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Mitra AK, 2015, GYNECOL ONCOL, V138, P372, DOI 10.1016/j.ygyno.2015.05.040; Ngan VK, 2001, MOL PHARMACOL, V60, P225, DOI 10.1124/mol.60.1.225; Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788; Schoeftner S, 2013, STEM CELLS, V31, P717, DOI 10.1002/stem.1315; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Tantin D, 2013, DEVELOPMENT, V140, P2857, DOI 10.1242/dev.095927; van der Horst A, 2014, CHROMOSOMA, V123, P25, DOI 10.1007/s00412-013-0437-6; Vathipadiekal V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029079; Wang XQ, 2010, HEPATOLOGY, V52, P528, DOI 10.1002/hep.23692; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilkinson RW, 2007, CLIN CANCER RES, V13, P3682, DOI 10.1158/1078-0432.CCR-06-2979; Yu JJ, 2015, ONCOL LETT, V10, P1642, DOI 10.3892/ol.2015.3467; Zhang J, 2010, J CLIN PATHOL, V63, P879, DOI 10.1136/jcp.2009.073593; Zhao Pengpeng, 2012, Nan Fang Yi Ke Da Xue Xue Bao, V32, P643	48	27	27	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4253	4266		10.1038/onc.2017.20	http://dx.doi.org/10.1038/onc.2017.20			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28319064	Green Submitted			2022-12-17	WOS:000406360600003
J	Chen, CH; Fong, LWR; Yu, E; Wu, R; Trott, JF; Weiss, RH				Chen, C-H; Fong, L. W. R.; Yu, E.; Wu, R.; Trott, J. F.; Weiss, R. H.			Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; C-KINASE SUBSTRATE; PATHWAY; PHOSPHORYLATION; RESISTANCE; BIOMARKER; GROWTH; REGORAFENIB; INHIBITORS; PROTEOMICS	Targeted therapeutics, such as those abrogating hypoxia inducible factor (HIF)/vascular endothelial growth factor signaling, are initially effective against kidney cancer (or renal cell carcinoma, RCC); however, drug resistance frequently occurs via subsequent activation of alternative pathways. Through genome-scale integrated analysis of the HIF-alpha network, we identified the major protein kinase C substrate MARCKS (myristoylated alanine-rich C kinase substrate) as a potential target molecule for kidney cancer. In a screen of nephrectomy samples from 56 patients with RCC, we found that MARCKS expression and its phosphorylation are increased and positively correlate with tumor grade. Genetic and pharmacologic suppression of MARCKS in high-grade RCC cell lines in vitro led to a decrease in cell proliferation and migration. We further demonstrated that higher MARCKS expression promotes growth and angiogenesis in vivo in an RCC xenograft tumor. MARCKS acted upstream of the AKT/mTOR pathway, activating HIF-target genes, notably vascular endothelial growth factor-A. Following knockdown of MARCKS in RCC cells, the IC50 of the multikinase inhibitor regorafenib was reduced. Surprisingly, attenuation of MARCKS using the MPS (MARCKS phosphorylation site domain) peptide synergistically interacted with regorafenib treatment and decreased survival of kidney cancer cells through inactivation of AKT and mTOR. Our data suggest a major contribution of MARCKS to kidney cancer growth and provide an alternative therapeutic strategy of improving the efficacy of multikinase inhibitors.	[Chen, C-H; Yu, E.; Trott, J. F.; Weiss, R. H.] Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA; [Chen, C-H; Weiss, R. H.] Univ Calif Davis, Comprehens Canc Ctr, Davis, CA 95616 USA; [Fong, L. W. R.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Yu, E.; Wu, R.] Univ Calif Davis, Dept Internal Med, Div Pulm & Crit Care Med, Davis, CA 95616 USA; [Yu, E.; Wu, R.] Univ Calif Davis, Ctr Comparat Resp Biol & Med, Dept Internal Med, Davis, CA 95616 USA; [Weiss, R. H.] Northern Calif Hlth Care Syst, Dept Vet Affairs, Med Serv, Sacramento, CA USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Davis; University of California System; University of California Davis	Chen, CH; Weiss, RH (corresponding author), Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA.	jchchen@ucdavis.edu; rhweiss@ucdavis.edu		Fong, Lon Wolf/0000-0001-6633-3164	NIH [1R01CA135401-01A1, 1R03CA181837-01, 1R01DK082690-01A1]; Medical Service of the US Department of Veterans' Affairs; Dialysis Clinic, Inc.(DCI) [C-3917]; NATIONAL CANCER INSTITUTE [P30CA093373] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Service of the US Department of Veterans' Affairs; Dialysis Clinic, Inc.(DCI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Mr Muhammad S Arif (Department of Public Health Sciences, University of California at Davis, Davis, CA, USA) for assistance with the experiments; Dr Yu-Ching Lin (UNIMED Healthcare Inc., Taiwan) and Ms Wen-Hsin Chang (Institute of Molecular Medicine, National Taiwan University College of Medicine, Taipei, Taiwan) for technological support in ForteBio system; Dr Guan-Chin Tseng (Department of Pathology, China Medical University Hospital, Taiwan) for useful advice; and the UC Davis Comprehensive Cancer Center Biorepository (University of California at Davis, Davis, CA, USA) for pathology support. This work was supported by NIH grants 1R01CA135401-01A1, 1R03CA181837-01 and 1R01DK082690-01A1, the Medical Service of the US Department of Veterans' Affairs (all to RHW), and a research grant from Dialysis Clinic, Inc. (DCI# C-3917 to C-HC).	ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; Bickeboller M, 2015, ONCOGENE, V34, P1150, DOI 10.1038/onc.2014.40; Brandi J, 2016, J PROTEOMICS, V136, P1, DOI 10.1016/j.jprot.2016.01.017; Brooks G, 1996, CARCINOGENESIS, V17, P683, DOI 10.1093/carcin/17.4.683; Browne BC, 2013, FEBS J, V280, P5237, DOI 10.1111/febs.12441; Chen CH, 2014, ONCOGENE, V33, P3696, DOI 10.1038/onc.2013.336; Chen CH, 2015, ONCOTARGET, V6, P15194, DOI 10.18632/oncotarget.3827; Chen CH, 2014, AM J RESP CRIT CARE, V190, P1127, DOI 10.1164/rccm.201408-1505OC; Chen CH, 2014, AM J RESP CRIT CARE, V189, P1002, DOI 10.1164/rccm.201401-0053LE; Chen XY, 2010, CELL SIGNAL, V22, P1097, DOI 10.1016/j.cellsig.2010.03.003; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Choueiri TK, 2013, CLIN CANCER RES, V19, P5218, DOI 10.1158/1078-0432.CCR-13-0491; Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Domblides C, 2013, EXPERT OPIN EMERG DR, V18, P495, DOI 10.1517/14728214.2013.858697; Dorff TB, 2014, EXPERT REV CLIN PHAR, V7, P67, DOI 10.1586/17512433.2014.862496; Eisen T, 2012, LANCET ONCOL, V13, P1055, DOI 10.1016/S1470-2045(12)70364-9; Ferraro D, 2014, THER ADV MED ONCOL, V6, P222, DOI 10.1177/1758834014544892; Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259; Gross-Goupil M, 2012, CURR UROL REP, V13, P16, DOI 10.1007/s11934-011-0232-y; Gudas LJ, 2014, J MOL MED, V92, P825, DOI 10.1007/s00109-014-1180-z; Han KS, 2015, NEOPLASIA, V17, P805, DOI 10.1016/j.neo.2015.11.001; Hanada S, 2013, CANCER BIOMARK, V13, P289, DOI 10.3233/CBM-130354; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jarboe JS, 2012, CLIN CANCER RES, V18, P3030, DOI 10.1158/1078-0432.CCR-11-3091; Joosten SC, 2015, BBA-REV CANCER, V1855, P1, DOI 10.1016/j.bbcan.2014.11.002; Josic D, 2008, CURR OPIN MOL THER, V10, P116; Kaelin WG, 2004, CLIN CANCER RES, V10, p6290S, DOI 10.1158/1078-0432.CCR-sup-040025; Kalwa H, 2011, J BIOL CHEM, V286, P2320, DOI 10.1074/jbc.M110.196022; Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051; Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142; Maroto P, 2014, CLIN CANCER RES, V20, P2060, DOI 10.1158/1078-0432.CCR-13-1351; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Micallef J, 2009, CANCER RES, V69, P7548, DOI 10.1158/0008-5472.CAN-08-4783; Naboulsi W, 2016, J PROTEOME RES, V15, P38, DOI 10.1021/acs.jproteome.5b00420; Parekh H, 2015, EXPERT REV ANTICANC, V15, P1305, DOI 10.1586/14737140.2015.1090315; Posadas EM, 2013, EXPERT OPIN PHARMACO, V14, P2221, DOI 10.1517/14656566.2013.832202; Rauch ME, 2002, J BIOL CHEM, V277, P14068, DOI 10.1074/jbc.M109572200; Rohrbach TD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140870; Rombouts K, 2013, CANCER LETT, V333, P244, DOI 10.1016/j.canlet.2013.01.040; Sajithlal GB, 2013, MOL PHARMACOL, V84, P562, DOI 10.1124/mol.113.088005; Santoni M, 2014, BBA-REV CANCER, V1845, P221, DOI 10.1016/j.bbcan.2014.01.007; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Su D, 2014, CURR OPIN ONCOL, V26, P321, DOI 10.1097/CCO.0000000000000069; von Roemeling CA, 2014, CANCER RES, V74, P4796, DOI 10.1158/0008-5472.CAN-14-0210; Wettersten HI, 2015, CANCER RES, V75, P2541, DOI 10.1158/0008-5472.CAN-14-1703; Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864; Yang Y, 2014, LEUKEMIA, V29, P715; Zaki K, 2013, CURR ONCOL REP, V15, P91, DOI 10.1007/s11912-013-0292-x; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343; Ziemba BP, 2016, BIOPHYS J, V110, P1811, DOI 10.1016/j.bpj.2016.03.001	52	27	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3588	3598		10.1038/onc.2016.510	http://dx.doi.org/10.1038/onc.2016.510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166200	Green Published, Green Accepted			2022-12-17	WOS:000403878600008
J	Worrall, C; Suleymanova, N; Crudden, C; Drakensjo, IT; Candrea, E; Nedelcu, D; Takahashi, SI; Girnita, L; Girnita, A				Worrall, C.; Suleymanova, N.; Crudden, C.; Drakensjo, I. Trocoli; Candrea, E.; Nedelcu, D.; Takahashi, S-I; Girnita, L.; Girnita, A.			Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma	ONCOGENE			English	Article							GROWTH-FACTOR-I; SMALL-MOLECULE ANTAGONISTS; BETA-ARRESTIN; ULTRAVIOLET-RADIATION; PICROPODOPHYLLIN PPP; MONOCLONAL-ANTIBODY; RECEPTOR IGF-1R; UVEAL MELANOMA; TUMOR INVASION; PHASE-I	Melanoma tumors usually retain wild-type p53; however, its tumor-suppressor activity is functionally disabled, most commonly through an inactivating interaction with mouse double-minute 2 homolog (Mdm2), indicating p53 release from this complex as a potential therapeutic approach. P53 and the tumor-promoter insulin-like growth factor type 1 receptor (IGF-1R) compete as substrates for the E3 ubiquitin ligase Mdm2, making their relative abundance intricately linked. Hence we investigated the effects of pharmacological Mdm2 release from the Mdm2/p53 complex on the expression and function of the IGF-1R. Nutlin-3 treatment increased IGF-1R/Mdm2 association with enhanced IGF-1R ubiquitination and a dual functional outcome: receptor downregulation and selective downstream signaling activation confined to the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. This Nutlin-3 functional selectivity translated into IGF-1-mediated bioactivities with biphasic effects on the proliferative and metastatic phenotype: an early increase and late decrease in the number of proliferative and migratory cells, while the invasiveness was completely inhibited following Nutlin-3 treatment through an impaired IGF-1-mediated matrix metalloproteinases type 2 activation mechanism. Taken together, these experiments reveal the biased agonistic properties of Nutlin-3 for the mitogen-activated protein kinase pathway, mediated by Mdm2 through IGF-1R ubiquitination and provide fundamental insights into destabilizing p53/Mdm2/IGF-1R circuitry that could be developed for therapeutic gain.	[Worrall, C.; Suleymanova, N.; Crudden, C.; Drakensjo, I. Trocoli; Candrea, E.; Nedelcu, D.; Girnita, L.; Girnita, A.] Karolinska Univ Hosp, Karolinska Inst, Dept Oncol & Pathol, Canc Ctr Karolinska, Stockholm, Sweden; [Drakensjo, I. Trocoli; Girnita, A.] Karolinska Univ Hosp, Dermatol Dept, Stockholm, Sweden; [Candrea, E.] Univ Med & Pharm Iuliu Hatieganu Cluj Napoca, Dept Dermatol, Cluj Napoca, Romania; [Takahashi, S-I] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Sci, Tokyo, Japan; [Takahashi, S-I] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo, Japan	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Iuliu Hatieganu University of Medicine & Pharmacy; University of Tokyo; University of Tokyo	Girnita, L; Girnita, A (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, CCK R8 04, S-17196 Stockholm, Sweden.	Leonard.Girnita@ki.se; Ada.Girnita@ki.se	Girnita, Ada/AAC-4518-2020; Girnita, Leonard/A-4168-2008; Crudden, Caitrin/Q-5172-2018	Girnita, Leonard/0000-0003-0280-9500; Crudden, Caitrin/0000-0002-7786-112X; Takahashi, Shin-Ichiro/0000-0002-2323-2010	Swedish Research Council; Swedish Cancer Society; Swedish Childhood Cancer Foundation; Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Stockholm Cancer Society; Stockholm County; JSPS [25221204]; Karolinska Institute	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Childhood Cancer Foundation(European Commission); Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Stockholm Cancer Society; Stockholm County(Stockholm County Council); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Karolinska Institute(Karolinska Institutet)	We thank Professor Rolf Kiessling (CCK, KI) for the BE and DFB cell lines 62, to Juan Castro (CCK, KI) for FACS analysis and to Dr Cath Drummond and Dr Sonia Lain for helpful discussions. Research support was received from the Swedish Research Council, Swedish Cancer Society, The Swedish Childhood Cancer Foundation, Crown Princess Margareta's Foundation for the Visually Impaired, Welander Finsen Foundation, King Gustaf V Jubilee Foundation, Stockholm Cancer Society, Stockholm County and Karolinska Institute. This work was also supported by Grant-in-Aid of Scientific Research (S) no. 25221204, Core-to-core program from JSPS to S-IT group.	Albino AP, 1993, MELANOMA RES, V55, P562; Box NF, 2008, PIGM CELL MELANOMA R, V21, P525, DOI 10.1111/j.1755-148X.2008.00495.x; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Crudden C, 2015, GROWTH HORM IGF RES, V25, P2, DOI 10.1016/j.ghir.2014.10.002; Cummins DL, 2006, MAYO CLIN PROC, V81, P500, DOI 10.4065/81.4.500; Davenport RJ, 2003, SCI SAGE KE, V10, P1126; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Economou MA, 2005, INVEST OPHTH VIS SCI, V46, P4372, DOI 10.1167/iovs.05-0322; Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2620, DOI 10.1167/iovs.07-0742; Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2337, DOI 10.1167/iovs.07-0819; Fahraeus R, 2014, ONCOGENE, V33, P4365, DOI 10.1038/onc.2013.410; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gasbarri A, 2003, MELANOMA RES, V13, P325, DOI 10.1097/00008390-200308000-00001; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Girnita A, 2012, ONCOGENE, V31, P352, DOI 10.1038/onc.2011.239; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2016, PROG MOL BIOL TRANSL, V141, P277, DOI 10.1016/bs.pmbts.2016.04.001; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Girnita L, 2014, CELL MOL LIFE SCI, V71, P2403, DOI 10.1007/s00018-013-1514-y; Gombos A, 2012, INVEST NEW DRUG, V30, P2433, DOI 10.1007/s10637-012-9811-0; Haapajarvi T, 1999, CELL GROWTH DIFFER, V10, P163; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hocker T, 2007, HUM MUTAT, V28, P578, DOI 10.1002/humu.20481; Hongo A, 1996, ONCOGENE, V12, P1231; Houben R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022096; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Ji ZY, 2012, J INVEST DERMATOL, V132, P356, DOI 10.1038/jid.2011.313; Kanavy HE, 2011, SEMIN CUTAN MED SURG, V30, P222, DOI 10.1016/j.sder.2011.08.003; Kanter-Lewensohn L, 1998, MELANOMA RES, V8, P389, DOI 10.1097/00008390-199810000-00002; Karasic TB, 2010, EXP CELL RES, V316, P1994, DOI 10.1016/j.yexcr.2010.04.014; Klein C, 2004, BRIT J CANCER, V91, P1415, DOI 10.1038/sj.bjc.6602164; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Macaulay VM, 2013, ANN ONCOL, V24, P784, DOI 10.1093/annonc/mds511; Mahadevan D, 2014, CANCER CHEMOTH PHARM, V73, P467, DOI 10.1007/s00280-013-2372-x; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Mar VJ, 2013, CLIN CANCER RES, V19, P4589, DOI 10.1158/1078-0432.CCR-13-0398; Molhoek KR, 2011, MELANOMA RES, V21, P274, DOI 10.1097/CMR.0b013e328343a1d6; Neudauer CL, 2003, EXP CELL RES, V286, P128, DOI 10.1016/S0014-4827(03)00049-1; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Puzanov I, 2015, CLIN CANCER RES, V21, P701, DOI 10.1158/1078-0432.CCR-14-0303; SalazarOnfray F, 1997, CANCER RES, V57, P4348; Sehat B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364; Sehat B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000340; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Soussi T, 2011, ADV CANCER RES, V110, P107, DOI 10.1016/B978-0-12-386469-7.00005-0; van Leeuwen IMM, 2011, CELL CYCLE, V10, P1590, DOI 10.4161/cc.10.10.15519; Vasilcanu D, 2006, ONCOGENE, V25, P3186, DOI 10.1038/sj.onc.1209339; Vasilcanu R, 2008, MOL PHARMACOL, V73, P930, DOI 10.1124/mol.107.040014; Vassilev LT, 2004, CELL CYCLE, V3, P419; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Webster NJG, 1996, CANCER RES, V56, P2781; Werner H, 2000, MOL GENET METAB, V71, P315, DOI 10.1006/mgme.2000.3044; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Werner H, 2014, GROWTH HORM IGF RES, V24, P112, DOI 10.1016/j.ghir.2014.03.006; Yeh AH, 2006, ONCOGENE, V25, P6574, DOI 10.1038/sj.onc.1209674; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; Zhang D, 2003, HORM METAB RES, V35, P802; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zheng HY, 2012, P NATL ACAD SCI USA, V109, P20620, DOI 10.1073/pnas.1216348110; Zheng HY, 2012, P NATL ACAD SCI USA, V109, P7055, DOI 10.1073/pnas.1118359109; Zwang YR, 2011, MOL CELL, V42, P524, DOI 10.1016/j.molcel.2011.04.017	68	27	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3274	3286		10.1038/onc.2016.472	http://dx.doi.org/10.1038/onc.2016.472			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28092675	Green Published, hybrid			2022-12-17	WOS:000402869800007
J	Mateo, F; Arenas, EJ; Aguilar, H; Serra-Musach, J; de Garibay, GR; Boni, J; Maicas, M; Du, S; Iorio, F; Herranz-Ors, C; Islam, A; Prado, X; Llorente, A; Petit, A; Vidal, A; Catala, I; Soler, T; Venturas, G; Rojo-Sebastian, A; Serra, H; Cuadras, D; Blanco, I; Lozano, J; Canals, F; Sieuwerts, AM; de Weerd, V; Look, MP; Puertas, S; Garcia, N; Perkins, AS; Bonifaci, N; Skowron, M; Gomez-Baldo, L; Hernandez, V; Martinez-Aranda, A; Martinez-Iniesta, M; Serrat, X; Ceron, J; Brunet, J; Barretina, MP; Gil, M; Falo, C; Fernandez, A; Morilla, I; Pernas, S; Pla, MJ; Andreu, X; Segui, MA; Ballester, R; Castella, E; Nellist, M; Morales, S; Valls, J; Velasco, A; Matias-Guiu, X; Figueras, A; Sanchez-Mut, JV; Sanchez-Cespedes, M; Cordero, A; Gomez-Miragaya, J; Palomero, L; Gomez, A; Gajewski, TF; Cohen, EEW; Jesiotr, M; Bodnar, L; Quintela-Fandino, M; Lopez-Bigas, N; Valdes-Mas, R; Puente, XS; Vinals, F; Casanovas, O; Graupera, M; Hernandez-Losa, J; Cajal, SRY; Garcia-Alonso, L; Saez-Rodriguez, J; Esteller, M; Sierra, A; Martin-Martin, N; Matheu, A; Carracedo, A; Gonzalez-Suarez, E; Nanjundan, M; Cortes, J; Lazaro, C; Odero, MD; Martens, JWM; Moreno-Bueno, G; Barcellos-Hoff, MH; Villanueva, A; Gomis, RR; Pujana, MA				Mateo, F.; Arenas, E. J.; Aguilar, H.; Serra-Musach, J.; de Garibay, G. Ruiz; Boni, J.; Maicas, M.; Du, S.; Iorio, F.; Herranz-Ors, C.; Islam, A.; Prado, X.; Llorente, A.; Petit, A.; Vidal, A.; Catala, I.; Soler, T.; Venturas, G.; Rojo-Sebastian, A.; Serra, H.; Cuadras, D.; Blanco, I.; Lozano, J.; Canals, F.; Sieuwerts, A. M.; de Weerd, V.; Look, M. P.; Puertas, S.; Garcia, N.; Perkins, A. S.; Bonifaci, N.; Skowron, M.; Gomez-Baldo, L.; Hernandez, V.; Martinez-Aranda, A.; Martinez-Iniesta, M.; Serrat, X.; Ceron, J.; Brunet, J.; Barretina, M. P.; Gil, M.; Falo, C.; Fernandez, A.; Morilla, I.; Pernas, S.; Pla, M. J.; Andreu, X.; Segui, M. A.; Ballester, R.; Castella, E.; Nellist, M.; Morales, S.; Valls, J.; Velasco, A.; Matias-Guiu, X.; Figueras, A.; Sanchez-Mut, J. V.; Sanchez-Cespedes, M.; Cordero, A.; Gomez-Miragaya, J.; Palomero, L.; Gomez, A.; Gajewski, T. F.; Cohen, E. E. W.; Jesiotr, M.; Bodnar, L.; Quintela-Fandino, M.; Lopez-Bigas, N.; Valdes-Mas, R.; Puente, X. S.; Vinals, F.; Casanovas, O.; Graupera, M.; Hernandez-Losa, J.; Ramon y Cajal, S.; Garcia-Alonso, L.; Saez-Rodriguez, J.; Esteller, M.; Sierra, A.; Martin-Martin, N.; Matheu, A.; Carracedo, A.; Gonzalez-Suarez, E.; Nanjundan, M.; Cortes, J.; Lazaro, C.; Odero, M. D.; Martens, J. W. M.; Moreno-Bueno, G.; Barcellos-Hoff, M. H.; Villanueva, A.; Gomis, R. R.; Pujana, M. A.			Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition	ONCOGENE			English	Article							BREAST-CANCER; MAMMARY STEM; MESENCHYMAL TRANSITION; EMBRYONIC STEM; SELF-RENEWAL; EXPRESSION; GENES; PATHWAY; TARGET; MOUSE	Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.	[Mateo, F.; Aguilar, H.; Serra-Musach, J.; de Garibay, G. Ruiz; Boni, J.; Herranz-Ors, C.; Prado, X.; Llorente, A.; Garcia, N.; Bonifaci, N.; Skowron, M.; Gomez-Baldo, L.; Palomero, L.; Pujana, M. A.] Bellvitge Inst Biomed Res IDIBELL, Catalan Inst Oncol ICO, Breast Canc & Syst Biol Lab, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain; [Arenas, E. J.; Gomis, R. R.] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Oncol Program, Baldiri Reixac 10, Barcelona 08028, Spain; [Maicas, M.; Odero, M. D.] Univ Navarra, Ctr Appl Med Res CIMA, Pamplona, Spain; [Maicas, M.; Odero, M. D.] Univ Navarra, Dept Biochem & Genet, Pamplona, Spain; [Du, S.; Barcellos-Hoff, M. H.] NYU, Sch Med, Dept Radiat Oncol, New York, NY 10003 USA; [Iorio, F.; Garcia-Alonso, L.; Saez-Rodriguez, J.] European Bioinformat Inst, European Mol Biol Lab, Wellcome Trust Genome Campus, Cambridge, England; [Iorio, F.] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England; [Islam, A.] Univ Dhaka, Dept Genet Engn & Biotechnol, Dhaka, Bangladesh; [Petit, A.; Vidal, A.; Catala, I.; Soler, T.; Venturas, G.] Univ Hosp Bellvitge, IDIBELL, Dept Pathol, Barcelona, Spain; [Rojo-Sebastian, A.] MD Anderson Canc Ctr, Dept Pathol, Madrid, Spain; [Serra, H.; Figueras, A.; Vinals, F.] ICO, Angiogenesis Res Grp, ProCURE, IDIBELL, Barcelona, Spain; [Cuadras, D.] IDIBELL, Stat Unit, Barcelona, Spain; [Blanco, I.; Lazaro, C.] IDIBELL, ICO, Hereditary Canc Programme, Barcelona, Spain; [Lozano, J.] Univ Malaga, Dept Mol Biol & Biochem, Malaga, Spain; [Lozano, J.] Univ Hosp Virgen de la Victoria, Mediterranean Inst Adv Biotechnol & Hlth Res IBIM, Mol Oncol Lab, Malaga, Spain; [Canals, F.] Vall Hebron Univ, Vall Hebron Inst Oncol, ProteoRed Inst Salud Carlos 3, Prote Lab, Barcelona, Spain; [Sieuwerts, A. M.; de Weerd, V.; Look, M. P.; Martens, J. W. M.] Erasmus Univ, Med Ctr, Daniel den Hoed Canc Ctr, Canc Genom Ctr,Dept Med Oncol, Rotterdam, Netherlands; [Puertas, S.; Martinez-Iniesta, M.; Villanueva, A.] IDIBELL, ICO, Chemoresistance & Predict Factors Lab, ProCURE, Barcelona, Spain; [Perkins, A. S.] Univ Rochester, Med Ctr, Sch Med & Dent, Rochester, NY USA; [Hernandez, V.; Martinez-Aranda, A.] IDIBELL, Biol Clues Invas & Metastat Phenotype Lab, Barcelona, Spain; [Serrat, X.; Ceron, J.] IDIBELL, Canc & Human Mol Genet, Barcelona, Spain; [Brunet, J.] Girona Biomed Res Inst IDIBGI, ICO, Hereditary Canc Programme, Girona, Spain; [Barretina, M. P.] IDIBGI, ICO, Dept Med Oncol, Girona, Spain; [Gil, M.; Falo, C.; Fernandez, A.; Morilla, I.; Pernas, S.] IDIBELL, ICO, Dept Med Oncol, Barcelona, Spain; [Pla, M. J.] Univ Hosp Bellvitge, IDIBELL, Dept Gynecol, Barcelona, Spain; [Andreu, X.] Parc Tauli Hosp Consortium, Dept Pathol, Barcelona, Spain; [Segui, M. A.] Parc Tauli Hosp Consortium, Med Oncol Serv, Barcelona, Spain; [Ballester, R.] Univ Hosp Germans Trias & Pujol, Germans Trias & Pujol Res Inst IGTP, ICO, Dept Radiat Oncol, Barcelona, Spain; [Castella, E.] Univ Hosp Germans Trias & Pujol, IGTP, ICO, Dept Pathol, Barcelona, Spain; [Nellist, M.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands; [Valls, J.; Velasco, A.; Matias-Guiu, X.] Univ Lleida, Hosp Arnau de Vilanova, Biomed Res Inst Lleida IRB Lleida, Lleida, Spain; [Sanchez-Mut, J. V.; Sanchez-Cespedes, M.; Cordero, A.; Gomez-Miragaya, J.] IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain; [Gajewski, T. F.] Univ Chicago, Dept Pathol, Chicago, IL 60611 USA; [Gajewski, T. F.] Univ Chicago, Dept Med, Chicago, IL USA; [Cohen, E. E. W.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92037 USA; [Jesiotr, M.] Mil Inst Med, Dept Pathol, Warsaw, Poland; [Bodnar, L.] Mil Inst Med, Dept Oncol, Warsaw, Poland; [Quintela-Fandino, M.] Spanish Natl Canc Res Ctr CNIO, Breast Canc Clin Res Unit, Madrid, Spain; [Lopez-Bigas, N.] Pompeu Fabra Univ UPF, Dept Expt & Hlth Sci, Barcelona Biomed Res Pk, Barcelona, Spain; [Lopez-Bigas, N.; Esteller, M.; Gomis, R. R.] ICREA, Barcelona, Spain; [Valdes-Mas, R.; Puente, X. S.] Univ Oviedo, Univ Inst Oncol Asturias, Dept Biochem & Mol Biol, Oviedo, Spain; [Hernandez-Losa, J.; Ramon y Cajal, S.] Vall Hebron Univ Hosp, Dept Pathol, Barcelona, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain; [Sierra, A.] Cent Univ Catalonia, Univ Vic, Fac Sci & Tech,Mol & Translat Oncol Lab, Biomed Res Inst August Pi & Sunyer IDIBAPS,Biomed, Barcelona, Spain; [Sierra, A.] Cent Univ Catalonia, Univ Vic, Fac Sci & Tech, Syst Biol Dept, Barcelona, Spain; [Martin-Martin, N.; Carracedo, A.] Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain; [Matheu, A.] Biodonostia Res Inst, Oncol Dept, Oncol Sect, San Sebastian, Spain; [Matheu, A.; Carracedo, A.] Basque Fdn Sci, Ikerbasque, Bilbao, Spain; [Carracedo, A.] Univ Basque Country UPV EHU, Dept Biochem & Mol Biol, Bilbao, Spain; [Nanjundan, M.] Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL USA; [Cortes, J.] Vall Hebron Univ Hosp, VHIO, Dept Med Oncol, Barcelona, Spain; [Moreno-Bueno, G.] Autonomous Univ Madrid UAM, Hosp La Paz Inst Hlth Res IdiPAZ, Dept Biochem, Biomed Res Inst Alberto Sols Spanish Natl Res Cou, Madrid, Spain; [Moreno-Bueno, G.] MD Anderson Int Fdn, Madrid, Spain	Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Navarra; University of Navarra; New York University; European Molecular Biology Laboratory (EMBL); Wellcome Trust Sanger Institute; Wellcome Trust Sanger Institute; University of Dhaka; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Texas System; UTMD Anderson Cancer Center; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Universidad de Malaga; Vall d'Hebron Institut d'Oncologia (VHIO); Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; University of Rochester; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP); Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP); Erasmus University Rotterdam; Erasmus MC; Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; University of Chicago; University of Chicago; University of California System; University of California San Diego; Military Institute of Aviation Medicine; Military Institute of Aviation Medicine; Centro Nacional de Investigaciones Oncologicas (CNIO); Pompeu Fabra University; ICREA; University of Oviedo; Instituto Universitario de Oncologia de Asturias; Hospital Universitari Vall d'Hebron; University of Barcelona; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); CIC bioGUNE; Basque Foundation for Science; University of Basque Country; State University System of Florida; University of South Florida; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Texas System; UTMD Anderson Cancer Center	Gomis, RR (corresponding author), Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Oncol Program, Baldiri Reixac 10, Barcelona 08028, Spain.; Gomis, RR (corresponding author), Hosp Duran & Reynals, Catalan Inst Oncol, IDIBELL, ProCURE, Gran via 199, E-08028 Barcelona, Spain.	roger.gomis@irbbarcelona.org; mapujana@iconcologia.net	Casanovas, Alex Cordero/AAA-8157-2020; Vidal, August/N-4662-2016; GARCIA, CONXI LAZARO/Q-2410-2016; Graupera, Mariona/J-1122-2017; Javier, Hernandez Losa/C-1173-2008; Sanchez-Mut, Jose V./A-8651-2019; Petit, Anna/GYU-5229-2022; Ramon y Cajal, Santiago/H-4955-2016; matias-guiu, xavier/C-3039-2009; Puente, Xosé S./ADB-0672-2022; Gonzalez-Suarez, Eva/L-6298-2014; Lozano, José/C-2760-2014; Carracedo, Arkaitz/F-7029-2011; de Garibay, Gorka Ruiz/AAB-6579-2020; Morilla, Idoia/P-6155-2019; Rojo, Alejandro/Y-9674-2019; Saez-Rodriguez, Julio/H-7114-2019; Esteller, Manel/L-5956-2014; Blanco, Ignacio/AAN-5426-2021; Boni, Jacopo/I-9587-2016; MORALES, SERAFIN/L-7216-2019; Odero/ABG-9860-2020; ceron, julian/AAA-8008-2019; Castellà, Eva/K-4140-2017; Sanchez-Cespedes, Montse/H-8485-2012; Valls, Joan/GXM-6532-2022; Mateo, Francesca/K-7746-2015; Iorio, Francesco/H-3284-2019; Skowron, Margaretha/N-6141-2018; Vinals, Francesc/P-6278-2019; Moreno-Bueno, Gema/K-9354-2016; VELASCO, ANA/AGH-3671-2022; Pujana, Miquel Angel/N-3127-2014; Maicas, Miren/A-9836-2017; Lopez-Bigas, Nuria/F-6193-2011; Viñals, Francesc/F-5928-2016; Valdés-Mas, Rafael/AAC-2879-2021; bonifaci, nuria/B-8104-2019; Gomis, Roger R/E-9788-2016; Blanco, Ignacio/D-2565-2013; Casanovas, Oriol/L-5210-2014; Herranz, Carmen/K-1043-2017; Palomero, Luis/K-1058-2017; Brunet, Joan/C-5292-2018	Vidal, August/0000-0001-5727-2099; GARCIA, CONXI LAZARO/0000-0002-7198-5906; Graupera, Mariona/0000-0003-4608-4185; Javier, Hernandez Losa/0000-0003-1526-3201; Sanchez-Mut, Jose V./0000-0002-9292-8521; Ramon y Cajal, Santiago/0000-0002-3867-1390; matias-guiu, xavier/0000-0002-7201-6605; Puente, Xosé S./0000-0001-9525-1483; Gonzalez-Suarez, Eva/0000-0003-0858-8171; Lozano, José/0000-0002-8187-2833; Carracedo, Arkaitz/0000-0001-5957-1260; de Garibay, Gorka Ruiz/0000-0001-9936-8419; Morilla, Idoia/0000-0001-8237-5073; Rojo, Alejandro/0000-0001-6439-3518; Saez-Rodriguez, Julio/0000-0002-8552-8976; Esteller, Manel/0000-0003-4490-6093; Blanco, Ignacio/0000-0002-7414-7481; MORALES, SERAFIN/0000-0001-7445-4193; Odero/0000-0002-8858-2054; Sanchez-Cespedes, Montse/0000-0002-6045-5627; Mateo, Francesca/0000-0002-2342-7010; Iorio, Francesco/0000-0001-7063-8913; Skowron, Margaretha/0000-0003-2152-384X; Moreno-Bueno, Gema/0000-0002-5030-6687; VELASCO, ANA/0000-0003-3142-145X; Pujana, Miquel Angel/0000-0003-3222-4044; Maicas, Miren/0000-0003-1404-5552; Lopez-Bigas, Nuria/0000-0003-4925-8988; Viñals, Francesc/0000-0002-9918-6751; Valdés-Mas, Rafael/0000-0002-0737-5425; bonifaci, nuria/0000-0002-8193-6825; Gomis, Roger R/0000-0001-6473-2858; Blanco, Ignacio/0000-0002-7414-7481; Cuadras, Daniel/0000-0001-8780-1764; Valls, Joan/0000-0002-4806-7568; Martinez-Iniesta, Maria/0000-0001-6252-6671; SEGUI PALMER, MIQUEL ANGEL/0000-0002-5103-6746; Casanovas, Oriol/0000-0002-4298-3995; ARENAS LAHUERTA, ENRIQUE JAVIER/0000-0001-7076-2666; Herranz, Carmen/0000-0002-2866-0321; Sierra, Angels/0000-0003-1023-3492; Llorente, Alicia/0000-0002-6056-0566; Ceron, Julian/0000-0003-4739-2243; Gomez-Miragaya, Jorge/0000-0003-1801-4681; Palomero, Luis/0000-0002-9144-1017; Boni, Jacopo/0000-0003-2626-9393; Islam, Abul/0000-0002-7274-0855; Garcia-Alonso, Luz/0000-0002-7863-9619; Brunet, Joan/0000-0003-1945-3512; quintela-fandino, miguel/0000-0003-1648-1964; Serrat Farran, Xenia/0000-0001-7611-5400	Scientific Foundation 'Asociacion Espanola Contra el Cancer' (AECC, Stable Coordinated Group, Hereditary Cancer); BBVA Foundation; Eugenio Rodriguez Pascual Foundation; Generalitat de Catalunya AGAUR SGR [283, 290, 312, 364, 530, 535]; Spanish Ministry of Health ISCIII FIS [PI10/00057, PI10/00222, PI10/01422, PI12/01528, PI13/00132, PI14/00336]; ISCIII RTICC [RD06/0020/1051, RD12/0036/0007, RD12/0036/0008, RD12/0036/0063]; Spanish Ministry of Science and Innovation, 'Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa', MINECO [SAF2010-20203, SAF2013-46196]; Telemaraton 'Todos Somos Raros, Todos Somos Unicos' [P35]; 'la Caixa' PhD fellowship program; EMBL-EBI; Wellcome Trust Sanger Institute Postdoctoral (ESPOD); NL-B; ME; RRG; ICREA; ICREA Funding Source: Custom	Scientific Foundation 'Asociacion Espanola Contra el Cancer' (AECC, Stable Coordinated Group, Hereditary Cancer); BBVA Foundation(BBVA Foundation); Eugenio Rodriguez Pascual Foundation; Generalitat de Catalunya AGAUR SGR; Spanish Ministry of Health ISCIII FIS(Spanish Government); ISCIII RTICC(Instituto de Salud Carlos III); Spanish Ministry of Science and Innovation, 'Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa', MINECO; Telemaraton 'Todos Somos Raros, Todos Somos Unicos'; 'la Caixa' PhD fellowship program; EMBL-EBI; Wellcome Trust Sanger Institute Postdoctoral (ESPOD); NL-B; ME; RRG; ICREA(ICREA); ICREA(ICREA)	We thank Ander Urruticoechea, Gabriel Capella and George Thomas for helpful discussion; Ana Isabel Extremera, Antoni Xaubet and Julio Ancochea for administrative support; and Sebastien Tosi from the Advanced Digital Microscopy Facility at IRB Barcelona for image analysis. We also thank Xiyun Deng, Yanna Cao, Tien C Ko, Yi Zhang (The University of Texas Health Science Centre at Houston) and Adrian W Moore (RIKEN Brain Science Institute) for their support in evaluating antibodies against EVI1. This study was supported by the following bodies and grants: the Scientific Foundation 'Asociacion Espanola Contra el Cancer' (AECC, Stable Coordinated Group, Hereditary Cancer); the BBVA Foundation; the Eugenio Rodriguez Pascual Foundation grant 2012; Generalitat de Catalunya AGAUR SGR 2012 grants 283, 290 and 312, and SGR 2014 grants 364, 530, and 535; Spanish Ministry of Health ISCIII FIS grants PI10/00057, PI10/00222, PI10/01422, PI12/01528, PI13/00132, and PI14/00336. ISCIII RTICC grants RD06/0020/1051, RD12/0036/0007, RD12/0036/0008 and RD12/0036/0063; Spanish Ministry of Science and Innovation, 'Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa', MINECO grants SAF2010-20203 and SAF2013-46196; and the Telemaraton 2014 'Todos Somos Raros, Todos Somos Unicos' grant P35. EJA was supported by 'la Caixa' PhD fellowship program, F Iorio was supported by a fellowship from the EMBL-EBI and the Wellcome Trust Sanger Institute Postdoctoral (ESPOD) program, and NL-B, ME and RRG were supported by ICREA. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, either in the submission form or the text of the manuscript.	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bard-Chapeau EA, 2013, P NATL ACAD SCI USA, V110, pE2885, DOI 10.1073/pnas.1309310110; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhola NE, 2016, CANCER RES, V76, P440, DOI 10.1158/0008-5472.CAN-15-1640-T; Campone M, 2013, EUR J CANCER, V49, P2621, DOI 10.1016/j.ejca.2013.04.011; Cariati M, 2008, INT J CANCER, V122, P298, DOI 10.1002/ijc.23103; Chandarlapaty S, 2012, CANCER DISCOV, V2, P311, DOI 10.1158/2159-8290.CD-12-0018; Chao CH, 2014, J CLIN INVEST, V124, P3093, DOI 10.1172/JCI73351; Chen L, 2010, NATURE, V464, P1062, DOI 10.1038/nature08978; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Dutta P, 2013, MOL ONCOL, V7, P647, DOI 10.1016/j.molonc.2013.02.008; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hagerstrand D, 2013, CANCER DISCOV, V3, P1044, DOI 10.1158/2159-8290.CD-12-0592; Holder AM, 2015, ONCOTARGET, V6, P19500, DOI 10.18632/oncotarget.3669; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Huang RX, 2015, MOL CELL BIOCHEM, V404, P251, DOI 10.1007/s11010-015-2384-4; Issa A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3379; Janssen EAM, 2003, J PATHOL, V201, P555, DOI 10.1002/path.1475; Kataoka K, 2011, J EXP MED, V208, P2402, DOI 10.1084/jem.20110447; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koren S, 2015, NATURE, V525, P114, DOI 10.1038/nature14669; Kormish JD, 2010, DEV DYNAM, V239, P56, DOI 10.1002/dvdy.22046; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Malhotra GK, 2014, BMC DEV BIOL, V14, DOI 10.1186/s12861-014-0047-4; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Markman B, 2010, ONCOTARGET, V1, P530, DOI 10.18632/oncotarget.188; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Morales M, 2014, EMBO MOL MED, V6, P865, DOI 10.15252/emmm.201303675; Nasr Z, 2013, ONCOGENE, V32, P861, DOI 10.1038/onc.2012.105; Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008-5472.CAN-12-0044; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Pool SE, 2013, CANCER RES, V73, P12, DOI 10.1158/0008-5472.CAN-11-2089; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Rodrik-Outmezguine VS, 2016, NATURE, V534, P272, DOI 10.1038/nature17963; de Garibay GR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132546; Sflomos G, 2016, CANCER CELL, V29, P407, DOI 10.1016/j.ccell.2016.02.002; Stavropoulou V, 2016, CANCER CELL, V30, P43, DOI 10.1016/j.ccell.2016.05.011; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; Witten IH, 1999, P ICONIP ANZIIS ANNE, V99, P192; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Yang ZJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028405; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	59	27	27	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2737	2749		10.1038/onc.2016.427	http://dx.doi.org/10.1038/onc.2016.427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27991928	Green Submitted, Green Published, hybrid			2022-12-17	WOS:000401120900011
J	Omarjee, S; Jacquemetton, J; Poulard, C; Rochel, N; Dejaegere, A; Chebaro, Y; Treilleux, I; Marangoni, E; Corbo, L; Le Romancer, M				Omarjee, S.; Jacquemetton, J.; Poulard, C.; Rochel, N.; Dejaegere, A.; Chebaro, Y.; Treilleux, I.; Marangoni, E.; Corbo, L.; Le Romancer, M.			The molecular mechanisms underlying the ER alpha-36-mediated signaling in breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; REGULATED KINASE; ER-ALPHA; VARIANT; PAXILLIN; PROTEIN; CELLS; RECEPTOR-ALPHA-36; PHOSPHORYLATION; PROLIFERATION	Alterations in estrogen-mediated cellular signaling have largely been implicated in the pathogenesis of breast cancer. Here, we investigated the signaling regulation of a splice variant of the estrogen receptor, namely estrogen receptor (ER alpha-36), associated with a poor prognosis in breast cancers. Coupling in vitro and in vivo approaches we determined the precise sequential molecular events of a new estrogen signaling network in an ERa-negative cell line and in an original patient-derived xenograft. After estrogen treatment, ERa-36 rapidly associates with Src at the level of the plasma membrane, initiating downstream cascades, including MEK1/ERK activation and paxillin phosphorylation on S126, which in turn triggers a higher expression of cyclin D1. Of note, the direct binding of ERa-36 to ERK2 prevents its dephosphorylation by MKP3 and enhances the downstream signaling. These findings improve our understanding of the regulation of non-genomic estrogen signaling and open new avenues for personalized therapeutic approaches targeting Src or MEK in ERa-36-positive patients.	[Omarjee, S.; Jacquemetton, J.; Poulard, C.; Treilleux, I.; Corbo, L.; Le Romancer, M.] Univ Lyon 1, Lyon, France; [Omarjee, S.; Jacquemetton, J.; Poulard, C.; Treilleux, I.; Corbo, L.; Le Romancer, M.] INSERM, Ctr Rech Cancerol Lyon, U1052, Lyon, France; [Omarjee, S.; Jacquemetton, J.; Poulard, C.; Treilleux, I.; Corbo, L.; Le Romancer, M.] CNRS, Ctr Rech Cancerol Lyon, UMR5286, Lyon, France; [Poulard, C.] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Rochel, N.; Dejaegere, A.; Chebaro, Y.] Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; [Rochel, N.; Dejaegere, A.; Chebaro, Y.] CNRS, UMR7104, Illkirch Graffenstaden, France; [Rochel, N.; Dejaegere, A.; Chebaro, Y.] INSERM, U964, Illkirch Graffenstaden, France; [Rochel, N.; Dejaegere, A.; Chebaro, Y.] Univ Strasbourg, Illkirch Graffenstaden, France; [Treilleux, I.] Ctr Leon Berard, Dept Pathol, Lyon, France; [Marangoni, E.] Inst Curie, Translat Res Dept, Paris, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard; University of Southern California; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Le Romancer, M (corresponding author), Ctr Leon Berard, CNRS 5286, INSERM 1052, CRCL, 28 Rue Laennec, F-69373 Lyon, France.	muriel.leromancer@lyon.unicancer.fr	Rochel, Natacha/A-5718-2016; Marangoni, Elisabetta/GSO-3945-2022; Chebaro, Yassmine/M-2174-2019	Rochel, Natacha/0000-0002-3573-5889; Marangoni, Elisabetta/0000-0002-3337-6448; Chebaro, Yassmine/0000-0002-5970-2117; Omarjee, Soleilmane/0000-0001-8686-7286; Poulard, coralie/0000-0003-4821-908X	Fondation Arc Cancer [ANR-10-LABX-0030-INRT]	Fondation Arc Cancer	We thank F Nasri, C. Languilaire, A. Colombe, L Odeyer and F Assayag for technical support, Y Mikaelian (CRCL, Lyon) for the Histone-GFP vector, G Castoria for the PI3K plasmid, Dr Wang for the pCDNA3-ER alpha-36 plasmid, P Chambon for the HEGO plasmid, F Lenfant for the ERa-46 plasmid, B. Manship for the proofreading of the manuscript. Ligue Nationale Contre le Cancer (comite de Saone-et-Loire), 'Fondation Arc Cancer', Canceropole CLARA, INCA and DGOS. 'region Rhone-Alpes' and 'Ligue Contre le Cancer' for SO, French Ministry of Research, 'Fondation Arc Cancer' and NIH for CP. 'Fondation Arc Cancer' for JJ, NR, YC and AD: grant ANR-10-LABX-0030-INRT.	Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025; Cai XM, 2006, MOL CELL BIOL, V26, P2857, DOI 10.1128/MCB.26.7.2857-2868.2006; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chaudhri RA, 2012, J BIOL CHEM, V287, P7169, DOI 10.1074/jbc.M111.292946; Coste I, 2010, J CLIN INVEST, V120, P3663, DOI 10.1172/JCI42771; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gu Y, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-16; Kang LG, 2010, MOL ENDOCRINOL, V24, P709, DOI 10.1210/me.2009-0317; Kong EH, 2003, BIOCHEM SOC T, V31, P56, DOI 10.1042/BST0310056; Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Lee LMJ, 2008, ANTICANCER RES, V28, P479; Levin ER, 2015, ANNU REV MED, V66, P271, DOI 10.1146/annurev-med-050913-021703; Levin ER, 2009, J PHYSIOL-LONDON, V587, P5019, DOI 10.1113/jphysiol.2009.177097; Luo ML, 2015, CELL REP, V11, P111, DOI 10.1016/j.celrep.2015.03.002; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Martin MC, 2008, J BIOL CHEM, V283, P3854, DOI 10.1074/jbc.M705647200; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Poulard C, 2012, EMBO MOL MED, V4, P1200, DOI 10.1002/emmm.201201615; Rao J, 2011, J STEROID BIOCHEM, V127, P231, DOI 10.1016/j.jsbmb.2011.08.004; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Sen A, 2012, J CLIN INVEST, V122, P2469, DOI 10.1172/JCI62044; Sen A, 2010, J BIOL CHEM, V285, P28787, DOI 10.1074/jbc.M110.134064; Shi L, 2009, J CLIN ONCOL, V27, P3423, DOI 10.1200/JCO.2008.17.2254; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Song RXD, 2005, TRENDS ENDOCRIN MET, V16, P347, DOI 10.1016/j.tem.2005.06.010; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tong JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015408; Varricchio L, 2007, MOL CANCER RES, V5, P1213, DOI 10.1158/1541-7786.MCR-07-0150; Wang ZY, 2015, MOL CELL ENDOCRINOL, V418, P193, DOI 10.1016/j.mce.2015.04.017; Wang ZY, 2006, P NATL ACAD SCI USA, V103, P9063, DOI 10.1073/pnas.0603339103; Wang ZY, 2005, BIOCHEM BIOPH RES CO, V336, P1023, DOI 10.1016/j.bbrc.2005.08.226; Yin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107369; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zhang J, 2012, STEROIDS, V77, P666, DOI 10.1016/j.steroids.2012.02.013; Zhang XT, 2011, ONCOGENE, V30, P770, DOI 10.1038/onc.2010.458; Zhang XT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030174	42	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2503	2514		10.1038/onc.2016.415	http://dx.doi.org/10.1038/onc.2016.415			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27941878	Green Published, hybrid			2022-12-17	WOS:000400597300002
J	Capdevila, J; Casanovas, O; Salazar, R; Castellano, D; Segura, A; Fuster, P; Aller, J; Garcia-Carbonero, R; Jimenez-Fonseca, P; Grande, E; Castano, JP				Capdevila, J.; Casanovas, O.; Salazar, R.; Castellano, D.; Segura, A.; Fuster, P.; Aller, J.; Garcia-Carbonero, R.; Jimenez-Fonseca, P.; Grande, E.; Castano, J. P.			Translational research in neuroendocrine tumors: pitfalls and opportunities	ONCOGENE			English	Review							MULTIPLE ENDOCRINE NEOPLASIA; PHASE-II; MULTISTAGE TUMORIGENESIS; DEPOT OCTREOTIDE; GROWTH-FACTOR; MTOR PATHWAY; MOUSE MODEL; CARCINOID-SYNDROME; TARGETED THERAPY; POOR-PROGNOSIS	Interest in research on neuroendocrine tumors (NETs) has grown in the past 10 years, coinciding with improvements in our understanding of the molecular pathogenesis of NETs. In addition, NETs have become one of the most exciting settings for drug development. Two targeted agents for the management of advanced pancreatic NETs have been approved, but the development of targeted agents for NETs is limited by problems with both patient selection and demonstration of activity. In this review, we analyze these limitations and discuss ways to increase the predictive value of preclinical models for target discovery and drug development. The role of translational research and 'omics' methodologies is emphasized, with the final aim of developing personalized medicine. Because NETs usually grow slowly and metastatic tumors are found at easily accessible locations, and owing to improvements in techniques for liquid biopsies, NETs provide a unique opportunity to obtain tumor samples at all stages of the evolution of the disease and to adapt treatment to changes in tumor biology. Combining clinical and translational research is essential to achieve progress in the NET field. Slow growth and genetic stability limit and challenge both the availability and further development of preclinical models of NETs, one of the most crucial unmet research needs in the field. Finally, we suggest some useful approaches for improving clinical drug development for NETs: moving from classical RECIST-based response end points to survival parameters; searching for different criteria to define response rates (for example, antiangiogenic effects and metabolic responses); implementing randomized phase II studies to avoid single-arm phase II studies that produce limited data on drug efficacy; and using predictive biomarkers for patient selection.	[Capdevila, J.] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, VHIO, Med Oncol Dept, Passeig Vall dHebron 119-129, Barcelona 08035, Spain; [Casanovas, O.] Inst Catalan Oncol IDIBELL, ProCURE Res Program, Barcelona, Spain; [Salazar, R.] Univ Barcelona, Catalan Inst Oncol IDIBELL, Oncol Dept, Barcelona, Spain; [Castellano, D.] Hosp Univ 12 Octubre, Oncol Dept, Madrid, Spain; [Segura, A.] Hosp Univ & Politecn La Fe, Oncol Dept, Valencia, Spain; [Fuster, P.] Hosp Univ Son Espases, Oncol Dept, Palma De Mallorca, Spain; [Aller, J.] Puerta de Hierro Univ Hosp, Dept Endocrinol, Madrid, Spain; [Garcia-Carbonero, R.] Hosp Univ Doce Octubre Ctr, Spanish Minist Sci & Innovat, Med Oncol Dept, RTICC,Inst Salud Carlos 3, Madrid, Spain; [Jimenez-Fonseca, P.] Cent Asturias Univ Hosp, Dept Med Oncol, Oviedo, Spain; [Grande, E.] Hosp Univ Ramon y Cajal, Oncol Dept, Madrid, Spain; [Castano, J. P.] Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain; [Castano, J. P.] Reina Sofia Univ Hosp, Cordoba, Spain; [Castano, J. P.] Univ Cordoba, Dept Cell Biol Physiol & Immunol, Cordoba, Spain; [Castano, J. P.] CIBER Fisiopatol Obesidad & Nutr, Cordoba, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Hospital Universitario 12 de Octubre; Hospital Universitari i Politecnic La Fe; Hospital Universitari Son Espases; Hospital Puerta de Hierro-Majadahonda; Hospital Universitario Ramon y Cajal; Hospital Universitario Reina Sofia - Cordoba; Universidad de Cordoba; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN	Capdevila, J (corresponding author), Univ Autonoma Barcelona, Vall dHebron Univ Hosp, VHIO, Med Oncol Dept, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.	jacapdevila@vhebron.net	Miquel, Josep Maria/AAG-3508-2019; Jimenez-Fonseca, Paula/AAA-1272-2020; Castaño, Justo P/A-7124-2010; Casanovas, Oriol/L-5210-2014	Castaño, Justo P/0000-0002-3145-7287; Salazar, Ramon/0000-0001-9419-6232; Garcia-Carbonero, Rocio/0000-0002-3342-397X; Casanovas, Oriol/0000-0002-4298-3995; Aller, Javier/0000-0001-6334-9072	Novartis	Novartis(Novartis)	The authors are grateful to Novartis for the unrestricted grant that made this paper possible and to Javier Mas for editorial support. International networks focused in neuroendocrine tumor management are redesigning the strategies in translational research to optimize preclinical and patient-derived tumor models to better predict efficacy in clinical setting.	Alkatout I, 2015, MODERN PATHOL, V28, P69, DOI 10.1038/modpathol.2014.82; Asa SL, 2011, MODERN PATHOL, V24, pS66, DOI 10.1038/modpathol.2010.127; Banck MS, 2013, J CLIN INVEST, V123, P2502, DOI 10.1172/JCI67963; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Bertolino P, 2003, CANCER RES, V63, P4836; Biondi CA, 2004, MOL CELL BIOL, V24, P3125, DOI 10.1128/MCB.24.8.3125-3131.2004; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Capdevila J, 2011, CANCER DISCOV, V1, P213, DOI 10.1158/2159-8290.CD-11-0151; Capurso G, 2012, J MOL ENDOCRINOL, V49, pR37, DOI 10.1530/JME-12-0069; Castano JP, 2014, CANCER METAST REV, V33, P353, DOI 10.1007/s10555-013-9465-1; Castellano D, 2013, EUR J CANCER, V49, P3780, DOI 10.1016/j.ejca.2013.06.042; Chan J, 2014, CURR TREAT OPTION ON, V15, P365, DOI 10.1007/s11864-014-0294-4; Chan JA, 2012, J CLIN ONCOL, V30, P2963, DOI 10.1200/JCO.2011.40.3147; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CORBETT TH, 1984, CANCER RES, V44, P717; Couderc C, 2015, MOL CELL ENDOCRINOL, V399, P154, DOI 10.1016/j.mce.2014.09.006; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; De Dosso S, 2013, CANCER METAST REV, V32, P465, DOI 10.1007/s10555-013-9421-0; de Wilde RF, 2012, NAT REV GASTRO HEPAT, V9, P199, DOI 10.1038/nrgastro.2012.9; DEVITA VT, 1973, NEW ENGL J MED, V288, P998, DOI 10.1056/NEJM197305102881905; Doroshow JH, 2014, NAT REV CLIN ONCOL, V11, P649, DOI 10.1038/nrclinonc.2014.158; Duran I, 2006, BRIT J CANCER, V95, P1148, DOI 10.1038/sj.bjc.6603419; Duran-Prado M, 2012, ONCOGENE, V31, P2049, DOI 10.1038/onc.2011.389; Elsasser SJ, 2011, SCIENCE, V331, P1145, DOI 10.1126/science.1203280; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Francis JM, 2013, NAT GENET, V45, P1483, DOI 10.1038/ng.2821; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Grande E, 2015, ANN ONCOL, V26, P1987, DOI 10.1093/annonc/mdv252; Grande E, 2013, ASCO M, V31, P4140; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; House MG, 2003, ANN SURG, V238, P423, DOI 10.1097/01.sla.0000086659.49569.9e; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Karpathakis A, 2013, ENDOCR-RELAT CANCER, V20, pR65, DOI 10.1530/ERC-12-0338; Kidd M, 2015, ENDOCR-RELAT CANCER, V22, P561, DOI 10.1530/ERC-15-0092; Kidd M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-595; Kolby L, 2005, BRIT J CANCER, V93, P1144, DOI 10.1038/sj.bjc.6602845; Kolby L, 2001, AM J PATHOL, V158, P745, DOI 10.1016/S0002-9440(10)64017-5; Kulke MH, 2015, NEUROENDOCRINOLOGY, V102, P131; Kulke MH, 2008, J CLIN ONCOL, V26, P3403, DOI 10.1200/JCO.2007.15.9020; Kulke MH, 2009, CLIN CANCER RES, V15, P338, DOI 10.1158/1078-0432.CCR-08-1476; Kulke MH, 2015, ASCO M, V33, P4005, DOI DOI 10.1200/JC0.2015.33.15_; Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056; Meeker A, 2014, MOL CELL ENDOCRINOL, V386, P101, DOI 10.1016/j.mce.2013.07.015; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Meric-Bernstam F, 2012, CLIN CANCER RES, V18, P1777, DOI 10.1158/1078-0432.CCR-11-2123; Missiaglia E, 2010, J CLIN ONCOL, V28, P245, DOI 10.1200/JCO.2008.21.5988; Modlin IM, 2003, CANCER-AM CANCER SOC, V97, P934, DOI 10.1002/cncr.11105; Modlin IM, 2006, J CLIN ENDOCR METAB, V91, P2340, DOI 10.1210/jc.2006-0110; Musunuru S, 2005, J SURG RES, V126, P102, DOI 10.1016/j.jss.2005.01.003; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; NILSSON O, 1992, YALE J BIOL MED, V65, P741; Oberg K, 2012, ANN ONCOL, V23, P124, DOI 10.1093/annonc/mds295; Oberg K, 2013, CLIN CANCER RES, V19, P2842, DOI 10.1158/1078-0432.CCR-12-3458; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; PARANGI S, 1995, CANCER RES, V55, P6071; PAREKH D, 1994, PANCREAS, V9, P83, DOI 10.1097/00006676-199401000-00013; Pavel ME, 2012, J CLIN ONCOL, V30; Pavel ME, 2011, LANCET, V378, P2005, DOI 10.1016/S0140-6736(11)61742-X; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Phan AT, 2015, LANCET ONCOL, V16, P695, DOI 10.1016/S1470-2045(15)70136-1; Qian ZR, 2013, J CLIN ONCOL, V31, P3418, DOI 10.1200/JCO.2012.46.6946; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Raymond E, 2011, NEW ENGL J MED, V364, P501, DOI 10.1056/NEJMoa1003825; Reidy-Lagunes DL, 2012, CANCER-AM CANCER SOC, V118, P4795, DOI 10.1002/cncr.27459; Sampedro-Nunez M, 2016, ONCOTARGET, V7, P6593, DOI 10.18632/oncotarget.6565; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Strosberg JR, 2011, CANCER-AM CANCER SOC, V117, P268, DOI 10.1002/cncr.25425; Yao JC, 2014, ANN ONCOL, V25; Yao JC, 2008, J CLIN ONCOL, V26, P4311, DOI 10.1200/JCO.2008.16.7858; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Yao JC, 2008, J CLIN ONCOL, V26, P1316, DOI 10.1200/JCO.2007.13.6374; Yao JC, 2016, LANCET, V387, P968, DOI 10.1016/S0140-6736(15)00817-X; Yao JC, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.4004; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; Yao JC, 2010, J CLIN ONCOL, V28, P69, DOI 10.1200/JCO.2009.24.2669; Zikusoka MN, 2005, CANCER-AM CANCER SOC, V104, P2292, DOI 10.1002/cncr.21451; Zurita AJ, 2015, BRIT J CANCER, V112, P1199, DOI 10.1038/bjc.2015.73	82	27	27	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1899	1907		10.1038/onc.2016.316	http://dx.doi.org/10.1038/onc.2016.316			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27641330				2022-12-17	WOS:000398898500001
J	Zhou, Q; Wang, X; Yu, Z; Wu, X; Chen, X; Li, J; Zhu, Z; Liu, B; Su, L				Zhou, Q.; Wang, X.; Yu, Z.; Wu, X.; Chen, X.; Li, J.; Zhu, Z.; Liu, B.; Su, L.			Transducin (beta)-like 1 X-linked receptor 1 promotes gastric cancer progression via the ERK1/2 pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; COREPRESSOR COMPLEX; FREQUENT GAIN; ACTIVATION; TBL1XR1; TRANSCRIPTION; GENES; TBLR1; IDENTIFICATION; METASTASIS	Gastric cancer (GC) is one of the most common types of cancer worldwide, and it involves extensive local tumour invasion, metastasis and poor prognosis. Understanding the mechanisms regulating the progression of GC is necessary for the development of effective therapeutic strategies. Transducin (beta)-like 1 X-linked receptor 1 (TBL1XR1) is an important regulator controlling gene activation and repression, which has been thought to be involved in tumorigenesis. However, the role of TBL1XR1 in human GC remains largely unknown. Here, we find that TBL1XR1 is aberrantly expressed in human GC tissues, and TBL1XR1 levels are highly correlated with local tumour invasion, late tumor, lymph node, metastasis (TNM) stage and poor prognosis. Knockdown of TBL1XR1 by shRNA inhibits GC cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT) in vitro, as well as tumorigenesis and peritoneal metastasis in vivo, whereas overexpression of TBL1XR1 produces the opposite effects. These effects are mediated by activation of the ERK1/2 signalling pathway, and inhibition of this pathway with a specific ERK1/2 inhibitor (U0126) significantly impairs the tumour-promoting effects induced by TBL1XR1. Moreover, TBL1XR1 mediated ERK1/2 activation is dependent on the beta-catenin/MMP7/EGFR signalling pathway. In conclusion, TBL1XR1 contributes to GC tumorigenesis and progression through the activation of the beta-catenin/MMP7/EGFR/ERK signalling pathway and may act as a new therapeutic target for GC.	[Zhou, Q.; Wang, X.; Yu, Z.; Wu, X.; Chen, X.; Li, J.; Zhu, Z.; Liu, B.; Su, L.] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai Inst Digest Surg,Dept Surg,Shanghai Key, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University	Liu, B; Su, L (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai Inst Digest Surg,Dept Surg,Shanghai Key, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China.	liubingya@sjtu.edu.cn; suliping@shsmu.edu.cn	Liu, Bingya/GMW-5655-2022	Liu, Bingya/0000-0002-4406-3762	National Natural Science Foundation of China [81572798, 81272749, 91229106, 91529302]; Key Projects in the National Science & Technology Pillar Program of China [2014BAI09B03]; Shanghai Municipal Education Commission [20152505]; Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine [BXJ201318]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Projects in the National Science & Technology Pillar Program of China; Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC)); Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine	We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript. Support: This study was supported by grants from National Natural Science Foundation of China (No. 81572798, No. 81272749, No. 91229106 and No. 91529302), Key Projects in the National Science & Technology Pillar Program of China (No. 2014BAI09B03), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20152505), and Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine (BXJ201318).	Andersson S, 2006, BRIT J CANCER, V95, P331, DOI 10.1038/sj.bjc.6603253; Bandyopadhyay S, 2006, NAT MED, V12, P933, DOI 10.1038/nm1444; Chen SP, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-195; Chen XJ, 2014, CARCINOGENESIS, V35, P1707, DOI 10.1093/carcin/bgu023; Choi HK, 2011, MOL CELL, V43, P203, DOI 10.1016/j.molcel.2011.05.027; Daniels G, 2014, ENDOCR-RELAT CANCER, V21, P127, DOI 10.1530/ERC-13-0293; den Hoed Caroline M, 2016, Curr Gastroenterol Rep, V18, P34, DOI 10.1007/s11894-016-0506-0; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Gao CX, 2015, ELIFE, V4, DOI 10.7554/eLife.10072; Goretsky T, 2016, J BIOL CHEM, V291, P4166, DOI 10.1074/jbc.M115.669416; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Ichikawa K, 2015, MOL CELL, V58, P35, DOI 10.1016/j.molcel.2015.01.023; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kadota M, 2009, CANCER RES, V69, P7357, DOI 10.1158/0008-5472.CAN-09-0064; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Komatsu N, 2015, ONCOGENE, V34, P5607, DOI 10.1038/onc.2015.16; Kuang XJ, 2016, DIGEST DIS SCI, V61, P489, DOI 10.1007/s10620-015-3879-2; Li JY, 2015, AM J CLIN EXP UROL, V3, P13; Li J, 2008, NAT CELL BIOL, V10, P160, DOI 10.1038/ncb1684; Li T, 2015, ONCOL REP, V34, P1469, DOI 10.3892/or.2015.4109; Li XL, 2014, INT J GENOMICS, V2014, DOI 10.1155/2014/870597; Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388; Liu Y, 2007, LUNG CANCER, V56, P307, DOI 10.1016/j.lungcan.2007.01.016; O'Roak BJ, 2012, SCIENCE, V338, P1619, DOI 10.1126/science.1227764; Oganesian A, 2011, P NATL ACAD SCI USA, V108, P19796, DOI 10.1073/pnas.1116271108; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Perissi V, 2008, MOL CELL, V29, P755, DOI 10.1016/j.molcel.2008.01.020; Pons L, 2015, AM J MED GENET A, V167, P164, DOI 10.1002/ajmg.a.36759; Qu Y, 2014, J GASTROENTEROL, V49, P408, DOI 10.1007/s00535-013-0809-y; Saitsu H, 2014, J HUM GENET, V59, P581, DOI 10.1038/jhg.2014.71; Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505; Tabet AC, 2014, AM J MED GENET A, V164, P2335, DOI 10.1002/ajmg.a.36619; Tomita A, 2004, MOL CELL BIOL, V24, P3337, DOI 10.1128/MCB.24.8.3337-3346.2004; Tomita A, 2003, J BIOL CHEM, V278, P30788, DOI 10.1074/jbc.M303309200; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang J, 2014, BRIT J CANCER, V111, P112, DOI 10.1038/bjc.2014.278; Yanaka Y, 2015, CARCINOGENESIS, V36, P1363, DOI 10.1093/carcin/bgv106; Yang YC, 2001, CANCER GENET CYTOGEN, V131, P48, DOI 10.1016/S0165-4608(01)00510-6; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang T, 2009, BLOOD, V114, P4081, DOI 10.1182/blood-2009-05-219881; Zhang XM, 2000, EXP HEMATOL, V28, P1286, DOI 10.1016/S0301-472X(00)00539-7	44	27	27	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1873	1886		10.1038/onc.2016.352	http://dx.doi.org/10.1038/onc.2016.352			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27694893	Green Published, hybrid			2022-12-17	WOS:000398128900012
J	Castagnoli, L; Ghedini, GC; Koschorke, A; Triulzi, T; Dugo, M; Gasparini, P; Casalini, P; Palladini, A; Iezzi, M; Lamolinara, A; Lollini, P; Nanni, P; Chiodoni, C; Tagliabue, E; Pupa, SM				Castagnoli, L.; Ghedini, G. C.; Koschorke, A.; Triulzi, T.; Dugo, M.; Gasparini, P.; Casalini, P.; Palladini, A.; Iezzi, M.; Lamolinara, A.; Lollini, Pl; Nanni, P.; Chiodoni, C.; Tagliabue, E.; Pupa, S. M.			Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MAMMARY-TUMORS; HER2; CELLS; NOTCH; CARCINOMA; MECHANISMS; PATHWAYS; GROWTH; MICE	We have previously shown that the d16HER2 splice variant is linked to HER2-positive breast cancer (BC) tumorigenesis, progression and response to Trastuzumab. However, the mechanisms by which d16HER2 contributes to HER2-driven aggressiveness and targeted therapy susceptibility remain uncertain. Here, we report that the d16HER2-positive mammary tumor cell lines MI6 and MI7, derived from spontaneous lesions of d16HER2 transgenic (tg) mice and resembling the aggressive features of primary lesions, are enriched in the expression of Wnt, Notch and epithelial-mesenchymal transition pathways related genes compared with full-length wild-type (WT) HER2-positive cells (WTHER2_1 and WTHER2_2) derived from spontaneous tumors arising in WTHER2 tg mice. MI6 cells exhibited increased resistance to anoikis and significantly higher mammosphere-forming efficiency (MFE) and self-renewal capability than the WTHER2-positive counterpart. Furthermore, d16HER2-positive tumor cells expressed a higher fraction of CD29(High)/CD24(+)/SCA1(Low) cells and displayed greater in vivo tumor engraftment in serial dilution conditions than WTHER2_1 cells. Accordingly, NOTCH inhibitors impaired mammosphere formation only in MI6 cells. A comparative analysis of stemness-related features driven by d16HER2 and WTHER2 in ad hoc engineered human BC cells (MCF7 and T47D) revealed a higher MFE and aldehyde dehydrogenase-positive staining in d16HER2-vs WTHER2-infected cells, sustaining consistent BC-initiating cell enrichment in the human setting. Moreover, marked CD44 expression was found in MCF7_d16 and T47D_d16 cells vs their WTHER2 and Mock counterparts. Clinically, BC cases from two distinct HER2-positive cohorts characterized by high levels of expression of the activated-d16HER2 metagene were significantly enriched in the Notch family and signal transducer genes vs those with low levels of the metagene.	[Castagnoli, L.; Ghedini, G. C.; Koschorke, A.; Triulzi, T.; Tagliabue, E.; Pupa, S. M.] Fondazione IRCCS Inst Naz Tumori, Mol Targeting Unit, Dept Expt Oncol & Mol Med, Milan, Italy; [Dugo, M.] Fondazione IRCCS Inst Naz Tumori, Funct Genom & Bioinformat Core Facility, Dep Expt Oncol & Mol Med, Milan, Italy; [Gasparini, P.] Fondazione IRCCS Inst Naz Tumori, Tumor Genom, Dep Expt Oncol & Mol Med, Milan, Italy; [Palladini, A.; Lollini, Pl; Nanni, P.] Univ Bologna, Diagnostic & Specialty Med, Dept Expt, Lab Immunol & Biol Metastases, Bologna, Italy; [Iezzi, M.; Lamolinara, A.] Univ G dAnnunzio, Dept Med & Aging Sci, CESI Aging Res Ctr, Chieti, Italy; [Chiodoni, C.] Fondazione IRCSS Inst Natl, Dept Expt Oncol & mol med, Mol Immunol, Milan, Italy	University of Bologna; G d'Annunzio University of Chieti-Pescara	Pupa, SM (corresponding author), Fondazione IRCCS Inst Naz Tumori, Mol Targeting Unit, Dept Expt Oncol & Mol Med, Milan, Italy.	serenella.pupa@istitutotumori.mi.it	Triulzi, Tiziana/C-1070-2017; lamolinara, alessia/AAB-8833-2019; Pupa, Serenella/K-6388-2016; Gasparini, Patrizia/Q-7626-2016; Castagnoli, Lorenzo/J-1893-2014; Iezzi, Manuela/AAB-7939-2019; Tagliabue, Elda/B-9377-2017; Koschorke, Ada/C-5576-2017; Chiodoni, Claudia/C-2172-2017; Dugo, Matteo/H-6860-2014; Lollini, Pier Luigi/A-7644-2008	Triulzi, Tiziana/0000-0003-3050-8676; lamolinara, alessia/0000-0002-7421-4509; Pupa, Serenella/0000-0002-4592-6830; Gasparini, Patrizia/0000-0002-9548-3724; Castagnoli, Lorenzo/0000-0002-0220-6497; Iezzi, Manuela/0000-0002-6296-6498; Tagliabue, Elda/0000-0001-9877-2903; Koschorke, Ada/0000-0002-4828-7405; Chiodoni, Claudia/0000-0002-7644-9969; Dugo, Matteo/0000-0001-9786-2763; Lollini, Pier Luigi/0000-0003-1702-4108	Associazione Italiana Ricerca Cancro (AIRC) [10352, 16918, AIRC 15324]; Ministero Italiano della Salute [RF-2009-1532281];  [15002]	Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero Italiano della Salute(Ministry of Health, Italy); 	We thank Mrs Ghirelli and Mrs Ratti for technical assistance, the Functional Genomics Core Facility and the Flow Cytometry and Cell Sorting Facility of the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan for their support in gene expression profile analyses and in the multiparametric cytofluorimetric analyses, and Mrs Mameli for secretarial assistance. This work was funded by grants from the Associazione Italiana Ricerca Cancro (AIRC) 10352 and 16918 to SM Pupa and AIRC 15324 to PL Lollini; Fellowship 15002 to L Castagnoli; and Ministero Italiano della Salute RF-2009-1532281 to SM Pupa.	Alajati A, 2013, CANCER RES, V73, P5320, DOI 10.1158/0008-5472.CAN-12-3186; Baker AT, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00360; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Campiglio M, 2013, BREAST CANCER RES TR, V141, P101, DOI 10.1007/s10549-013-2658-z; Castagnoli L, 2014, CANCER RES, V74, P6248, DOI 10.1158/0008-5472.CAN-14-0983; Castiglioni F, 2006, ENDOCR-RELAT CANCER, V13, P221, DOI 10.1677/erc.1.01047; Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570; De Giovanni C, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3602; Farahani E, 2014, CARCINOGENESIS, V35, P747, DOI 10.1093/carcin/bgu045; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Farnie G, 2014, CELL CYCLE, V13, P418, DOI 10.4161/cc.27201; Finkle D, 2004, CLIN CANCER RES, V10, P2499, DOI 10.1158/1078-0432.CCR-03-0448; Frisch SM, 2013, J CELL SCI, V126, P21, DOI 10.1242/jcs.120907; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681; Jackson Claire, 2013, Int J Cell Biol, V2013, P973584, DOI 10.1155/2013/973584; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2013, CANCER RES, V73, P3489, DOI 10.1158/0008-5472.CAN-13-0260; Korkaya H, 2009, CLIN CANCER RES, V15, P1845, DOI 10.1158/1078-0432.CCR-08-3087; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Latorre IJ, 2000, MADAME CURIE BIOSCIE; Lindsay J, 2008, CTS-CLIN TRANSL SCI, V1, P107, DOI 10.1111/j.1752-8062.2008.00041.x; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Marchini C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018727; Mitra D, 2009, MOL CANCER THER, V8, P2152, DOI 10.1158/1535-7163.MCT-09-0295; Monteiro J, 2014, CARCINOGENESIS, V35, P2, DOI 10.1093/carcin/bgt279; Ntziachristos P, 2014, CANCER CELL, V25, P318, DOI 10.1016/j.ccr.2014.02.018; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Prat A, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju152; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shao S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0295-3; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Shiu KK, 2014, ONCOGENE, V33, P619, DOI 10.1038/onc.2012.625; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876; Triulzi T, 2015, ONCOTARGET, V6, P28173, DOI 10.18632/oncotarget.4405; Turpin J, 2016, ONCOGENE, V35, P6053, DOI 10.1038/onc.2016.129; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Weigelt B, 2013, CANCER DISCOV, V3, P145, DOI 10.1158/2159-8290.CD-12-0585; Zagozdzon R, 2011, DRUG DISCOV TODAY, V16, P810, DOI 10.1016/j.drudis.2011.06.003; Zhang XJ, 2015, INT J ONCOL, V46, P1141, DOI 10.3892/ijo.2014.2809	45	27	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1721	1732		10.1038/onc.2016.338	http://dx.doi.org/10.1038/onc.2016.338			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27641338	hybrid, Green Published			2022-12-17	WOS:000397460600011
J	Talamillo, A; Grande, L; Ruiz-Ontanon, P; Velasquez, C; Mollinedo, P; Torices, S; Sanchez-Gomez, P; Aznar, A; Esparis-Ogando, A; Lopez-Lopez, C; Lafita, C; Berciano, MT; Montero, JA; Vazquez-Barquero, A; Segura, V; Villagra, NT; Pandiella, A; Lafarga, M; Leon, J; Martinez-Climent, JA; Sanz-Moreno, V; Fernandez-Luna, JL				Talamillo, A.; Grande, L.; Ruiz-Ontanon, P.; Velasquez, C.; Mollinedo, P.; Torices, S.; Sanchez-Gomez, P.; Aznar, A.; Esparis-Ogando, A.; Lopez-Lopez, C.; Lafita, C.; Berciano, M. T.; Montero, J. A.; Vazquez-Barquero, A.; Segura, V.; Villagra, N. T.; Pandiella, A.; Lafarga, M.; Leon, J.; Martinez-Climent, J. A.; Sanz-Moreno, V.; Fernandez-Luna, J. L.			ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; IN-VIVO; INTRACELLULAR DOMAIN; GENE-EXPRESSION; C-MYC; CANCER GENOMICS; GLIOMA; INVASION; GTPASES; ACTIVATION	Long-term survival remains low for most patients with glioblastoma (GBM), which reveals the need for markers of disease outcome and novel therapeutic targets. We describe that ODZ1 (also known as TENM1), a type II transmembrane protein involved in fetal brain development, plays a crucial role in the invasion of GBM cells. Differentiation of glioblastoma stem-like cells drives the nuclear translocation of an intracellular fragment of ODZ1 through proteolytic cleavage by signal peptide peptidase-like 2a. The intracellular fragment of ODZ1 promotes cytoskeletal remodelling of GBM cells and invasion of the surrounding environment both in vitro and in vivo. Absence of ODZ1 by gene deletion or downregulation of ODZ1 by small interfering RNAs drastically reduces the invasive capacity of GBM cells. This activity is mediated by an ODZ1-triggered transcriptional pathway, through the E-box binding Myc protein, that promotes the expression and activation of Ras homolog family member A (RhoA) and subsequent activation of Rho-associated, coiled-coil containing protein kinase (ROCK). Overexpression of ODZ1 in GBM cells reduced survival of xenografted mice. Consistently, analysis of 122 GBM tumour samples revealed that the number of ODZ1-positive cells inversely correlated with overall and progression-free survival. Our findings establish a novel marker of invading GBM cells and consequently a potential marker of disease progression and a therapeutic target in GBM.	[Talamillo, A.; Grande, L.; Ruiz-Ontanon, P.; Mollinedo, P.; Torices, S.; Fernandez-Luna, J. L.] Hosp Valdecilla IDIVAl, Coll Genetica, Santander, Spain; [Velasquez, C.; Vazquez-Barquero, A.] Hosp Valdecilla IDIVAl, Neurosurg Serv, Santander, Spain; [Sanchez-Gomez, P.] Inst Salud Carlos lll, Unit Neuro Oncol, Madrid, Spain; [Aznar, A.; Segura, V.; Martinez-Climent, J. A.] CIMA, Pamplona, Spain; [Esparis-Ogando, A.] Ctr Investigo Canc, Salamanca, Spain; [Lopez-Lopez, C.] Hosp Valdecilla IDIVAL, Service Oncol Media, Santander, Spain; [Lafita, C.; Leon, J.] IBBTEC, CSIC, Coll Cantabria, Santander, Spain; [Berciano, M. T.; Montero, J. A.; Lafarga, M.] Coll Canatbria, Dept Anatomia & Biol Celular, Santander, Spain; [Villagra, N. T.] IDIVAL, Hosp Valdesilla, Serv Anatomia, Santander, Spain; [Sanz-Moreno, V.] Kings Coll london, Sch Biomed & Hlth Serv, Randall Div Cell & Mol Biophys, London, England; [Fernandez-Luna, J. L.] Hosp Valdecilla IDIVAL, Coll Gentica, 39008 Santander, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); University of London; King's College London; Hospital Universitario Marques de Valdecilla (HUMV)	Fernandez-Luna, JL (corresponding author), Hosp Valdecilla IDIVAl, Coll Genetica, Santander, Spain.	fluna@humv.es	Leon, Javier/K-4615-2014; Sánchez-Gómez, Pilar/K-8256-2014; Martinez-Climent, Jose A/I-9199-2012; Lafarga, Miguel/K-3733-2014; Esparís-Ogando, Aucena/O-5326-2017; Talamillo, Ana/AAA-4633-2019; Pandiella, Atanasio/O-5180-2014; Velasquez, Carlos/N-6669-2016; Segura, Victor/E-4531-2010; Teran-Villagra, Nuria/P-3016-2016	Sánchez-Gómez, Pilar/0000-0002-0709-4973; Martinez-Climent, Jose A/0000-0002-7938-3950; Esparís-Ogando, Aucena/0000-0003-4550-4192; Talamillo, Ana/0000-0003-3089-7675; Pandiella, Atanasio/0000-0002-4704-8971; Leon, Javier/0000-0001-5803-0112; Berciano, Maria T./0000-0002-8225-6995; LOPEZ LOPEZ, CARLOS/0000-0002-8901-741X; Lafarga, Miguel/0000-0003-3402-1152; Velasquez, Carlos/0000-0002-4443-5888; Lafita Navarro, Maria del Carmen/0000-0002-7266-651X; Segura, Victor/0000-0002-7740-6290; Sanz-Moreno, Victoria/0000-0002-5096-9456; Teran-Villagra, Nuria/0000-0002-3746-455X	Instituto de Salud Carlos III (ISCIII) [PI13/01760, PI12/00775, SAF2014-53526R]; program Red Tematica de Investigacion Cooperativa en Cancer (RTICC) [RD12/0036/0022, RD12/0036/0027, RD12/0036/0063, RD12/0036/0003, RD12-0036-0033]; Instituto de Investigacion Valdecilla (IDIVAL) grant [APG/03]; Cancer Research UK [C33043/A12065]; Royal Society [RG110591]; Cancer Research UK [12065] Funding Source: researchfish	Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos IIIEuropean Commission); program Red Tematica de Investigacion Cooperativa en Cancer (RTICC); Instituto de Investigacion Valdecilla (IDIVAL) grant; Cancer Research UK(Cancer Research UK); Royal Society(Royal Society of London); Cancer Research UK(Cancer Research UK)	This work was supported by the Instituto de Salud Carlos III (ISCIII), grants PI13/01760 (JLF-L), PI12/00775 (PS-G) and SAF2014-53526R (JL), and program Red Tematica de Investigacion Cooperativa en Cancer (RTICC) grants RD12/0036/0022 (JLF-L), RD12/0036/0027 (PS-G), RD12/0036/0063 (JAM-C), RD12/0036/0003 (AP) and RD12-0036-0033 (JL), Instituto de Investigacion Valdecilla (IDIVAL) grant APG/03 to JLF-L, and Cancer Research UK C33043/A12065 and Royal Society RG110591 to VS-M. We thank R. Galli for kindly providing RG1 cell line. We also thank M.E. Fernandez-Valle for helping with magnetic resonance imaging experiments.	Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bernard D, 2003, J CLIN INVEST, V112, P1724; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Danussi C, 2013, CANCER RES, V73, P5140, DOI 10.1158/0008-5472.CAN-13-1168-T; Deng L, 2010, CANCER BIOL THER, V9, P875, DOI 10.4161/cbt.9.11.11634; Ernst A, 2009, CLIN CANCER RES, V15, P6541, DOI 10.1158/1078-0432.CCR-09-0695; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Grande L, 2012, J BIOL CHEM, V287, P26495, DOI 10.1074/jbc.M112.376319; Grossman SA, 2010, CLIN CANCER RES, V16, P2443, DOI 10.1158/1078-0432.CCR-09-3106; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hirata E, 2012, J CELL SCI, V125, P858, DOI 10.1242/jcs.089995; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Jacquemet G, 2013, J CELL BIOL, V202, P917, DOI 10.1083/jcb.201302041; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jin X, 2013, CANCER LETT, V328, P235, DOI 10.1016/j.canlet.2012.09.005; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kenzelmann D, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-30; Kirkin V, 2007, CELL DEATH DIFFER, V14, P1678, DOI 10.1038/sj.cdd.4402175; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lee KG, 2007, CELL CYCLE, V6, P1487; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Mazzoleni S, 2010, CANCER RES, V70, P7500, DOI 10.1158/0008-5472.CAN-10-2353; Mosca TJ, 2012, NATURE, V484, P237, DOI 10.1038/nature10923; Nogueira L, 2011, ONCOGENE, V30, P3537, DOI 10.1038/onc.2011.74; Nunes SM, 2005, EXP CELL RES, V305, P122, DOI 10.1016/j.yexcr.2004.12.020; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pozo N, 2013, J CLIN INVEST, V123, P2475, DOI 10.1172/JCI63623; Roussel MF, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014308; Ruiz-Ontanon P, 2013, STEM CELLS, V31, P1075, DOI 10.1002/stem.1349; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Scholer J, 2015, J BIOL CHEM, V290, P8154, DOI 10.1074/jbc.M114.615922; Sherry MM, 2009, STEM CELLS, V27, P2383, DOI 10.1002/stem.185; Shervington A, 2006, MOL CELL BIOCHEM, V283, P1, DOI 10.1007/s11010-006-2495-z; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Timpson P, 2011, CANCER RES, V71, P747, DOI 10.1158/0008-5472.CAN-10-2267; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Tucker RP, 2012, MOL BIOL EVOL, V29, P1019, DOI 10.1093/molbev/msr271; Wang H, 2014, ONCOGENE, V33, P1558, DOI 10.1038/onc.2013.97; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Wong SY, 2015, CANCER RES, V75, P1113, DOI 10.1158/0008-5472.CAN-13-3426; Yan B, 2006, NEUROSCI LETT, V407, P124, DOI 10.1016/j.neulet.2006.08.032; Yan K, 2013, CURR OPIN NEUROL, V26, P701, DOI 10.1097/WCO.0000000000000032; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Ying Z, 2013, CANCER RES, V73, P990, DOI 10.1158/0008-5472.CAN-12-2895; Zhang M, 2006, EMBO J, V25, P5284, DOI 10.1038/sj.emboj.7601406; Zhang SY, 2009, MOL CANCER RES, V7, P570, DOI 10.1158/1541-7786.MCR-08-0248; Zhang W, 2014, MOL MED REP, V10, P113, DOI 10.3892/mmr.2014.2152; Zohrabian VM, 2009, ANTICANCER RES, V29, P119	53	27	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1733	1744		10.1038/onc.2016.341	http://dx.doi.org/10.1038/onc.2016.341			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27641332	Green Submitted, Green Accepted			2022-12-17	WOS:000397460600012
J	Wang, L; Zhang, P; Molkentine, DP; Chen, C; Molkentine, JM; Piao, H; Raju, U; Zhang, J; Valdecanas, DR; Tailor, RC; Thames, HD; Buchholz, TA; Chen, J; Ma, L; Mason, KA; Ang, KK; Meyn, RE; Skinner, HD				Wang, L.; Zhang, P.; Molkentine, D. P.; Chen, C.; Molkentine, J. M.; Piao, H.; Raju, U.; Zhang, J.; Valdecanas, D. R.; Tailor, R. C.; Thames, H. D.; Buchholz, T. A.; Chen, J.; Ma, L.; Mason, K. A.; Ang, K-K; Meyn, R. E.; Skinner, H. D.			TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; DOUBLE-STRAND BREAKS; DNA-DAMAGE-RESPONSE; P16 GENE; CANCER GENOMICS; POSITIVE HEAD; NUCLEAR FOCI; 53BP1; EXPRESSION; REPAIR	Patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) have better responses to radiotherapy and higher overall survival rates than do patients with HPV-negative HNSCC, but the mechanisms underlying this phenomenon are unknown. p16 is used as a surrogate marker for HPV infection. Our goal was to examine the role of p16 in HPV-related favorable treatment outcomes and to investigate the mechanisms by which p16 may regulate radiosensitivity. HNSCC cells and xenografts (HPV/p16-positive and -negative) were used. p16-overexpressing and small hairpin RNA-knockdown cells were generated, and the effect of p16 on radiosensitivity was determined by clonogenic cell survival and tumor growth delay assays. DNA double-strand breaks (DSBs) were assessed by immunofluorescence analysis of 53BP1 foci; DSB levels were determined by neutral comet assay; western blotting was used to evaluate protein changes; changes in protein half-life were tested with a cycloheximide assay; gene expression was examined by real-time polymerase chain reaction; and data from The Cancer Genome Atlas HNSCC project were analyzed. p16 overexpression led to downregulation of TRIP12, which in turn led to increased RNF168 levels, repressed DNA damage repair (DDR), increased 53BP1 foci and enhanced radioresponsiveness. Inhibition of TRIP12 expression further led to radiosensitization, and overexpression of TRIP12 was associated with poor survival in patients with HPV-positive HNSCC. These findings reveal that p16 participates in radiosensitization through influencing DDR and support the rationale of blocking TRIP12 to improve radiotherapy outcomes.	[Wang, L.; Zhang, P.; Molkentine, D. P.; Chen, C.; Molkentine, J. M.; Piao, H.; Raju, U.; Zhang, J.; Valdecanas, D. R.; Thames, H. D.; Chen, J.; Ma, L.; Mason, K. A.; Ang, K-K; Meyn, R. E.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Z7-3014,1515 Holcombe Blvd,Unit 1052, Houston, TX 77030 USA; [Piao, H.] Chinese Acad Sci, Dalian Inst Chem Phys, Div Biotechnol, Dalian, Peoples R China; [Tailor, R. C.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA; [Buchholz, T. A.; Ang, K-K; Skinner, H. D.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wang, L (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Z7-3014,1515 Holcombe Blvd,Unit 1052, Houston, TX 77030 USA.	Lwang6@mdanderson.org	Ma, Li/GQR-1313-2022; Skinner, Heath/A-1669-2012	Ma, Li/0000-0001-9965-989X; Buchholz, Thomas/0000-0002-7859-5572; Zhang, Peijing/0000-0003-1586-8710; Skinner, Heath/0000-0003-1836-151X; Molkentine, Jessica/0000-0002-3757-7167	National Cancer Institute [R01CA168485, R01CA181029]; Cancer Prevention Research Institute of Texas [RP150293, P30 NCI CA016672]; MD Anderson Cancer Head and Cancer SPORE Career Development Award; Center for Radiation Oncology Research Development Award; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA181029, R01CA168485] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention Research Institute of Texas; MD Anderson Cancer Head and Cancer SPORE Career Development Award; Center for Radiation Oncology Research Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jeffery Myers and Dr Peter J F Snijders for kindly sharing their cell lines. This work was supported by grants R01CA168485 and R01CA181029 from the National Cancer Institute (REM and KKA) and (LM), respectively, the Gilbert H Fletcher Chair (KKA), Cancer Center Support Grant (P30 NCI CA016672), Individual Investigator Research Award RP150293 from the Cancer Prevention Research Institute of Texas (HDS), an MD Anderson Cancer Head and Cancer SPORE Career Development Award (HDS) and a Center for Radiation Oncology Research Development Award (HDS). The content is solely the responsibility of the authors and does not represent the official views of any grant-awarding agency.	Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Ang KK, 2012, SEMIN RADIAT ONCOL, V22, P128, DOI 10.1016/j.semradonc.2011.12.004; Bauer E, 1998, MUTAT RES-FUND MOL M, V398, P101, DOI 10.1016/S0027-5107(97)00246-7; Bihl MP, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-173; Bohgaki M, 2013, P NATL ACAD SCI USA, V110, P20982, DOI 10.1073/pnas.1320302111; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006; Chou TF, 2011, J BIOL CHEM, V286, P16546, DOI 10.1074/jbc.M110.215319; Collado M, 2010, CANCER CELL, V17, P317, DOI 10.1016/j.ccr.2010.03.015; Dickson MA, 2013, J CLIN ONCOL, V31, P2024, DOI 10.1200/JCO.2012.46.5476; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Dok R, 2014, CANCER RES, V74, P1739, DOI 10.1158/0008-5472.CAN-13-2479; Duan S., 2012, ABSTRACT APPL ANAL, V2012, P1, DOI DOI 10.1109/SPC0M.2012.6290252; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; HALL M, 1995, ONCOGENE, V11, P1581; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Klussmann JP, 2003, AM J PATHOL, V162, P747, DOI 10.1016/S0002-9440(10)63871-0; Lee AWC, 2003, MOL CANCER THER, V2, P961; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Lewis JS, 2010, AM J SURG PATHOL, V34, P1088, DOI 10.1097/PAS.0b013e3181e84652; Li CY, 2013, CELL CYCLE, V12, P923, DOI 10.4161/cc.23882; Li W, 2004, HEAD NECK-J SCI SPEC, V26, P1, DOI 10.1002/hed.10335; Lou-Qian Zhang, 2013, PLoS One, V8, pe54970, DOI 10.1371/journal.pone.0054970; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Matsuda K, 2011, HISTOPATHOLOGY, V59, P441, DOI 10.1111/j.1365-2559.2011.03963.x; Matsumura Y, 1997, CANCER LETT, V115, P91, DOI 10.1016/S0304-3835(97)04714-9; McLaughlin-Drubin ME, 2013, P NATL ACAD SCI USA, V110, P16175, DOI 10.1073/pnas.1310432110; Mirzayans R, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/951574; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Peuscher MH, 2011, NAT CELL BIOL, V13, P1139, DOI 10.1038/ncb2326; Pinato S, 2011, MOL CELL BIOL, V31, P118, DOI 10.1128/MCB.00818-10; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rieckmann T, 2013, RADIOTHER ONCOL, V107, P242, DOI 10.1016/j.radonc.2013.03.013; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shanbhag NM, 2010, CELL, V141, P970, DOI 10.1016/j.cell.2010.04.038; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang L, 2012, MOL MED REP, V6, P904, DOI 10.3892/mmr.2012.1001; Wang L, 2011, ANTICANCER RES, V31, P2141; Westra WH, 2011, HEAD NECK-J SCI SPEC, V34, P459; Xu RB, 2013, CANCER BIOMARK, V13, P215, DOI 10.3233/CBM-130355; Yang ZH, 2014, ASIAN PAC J CANCER P, V15, P3817, DOI 10.7314/APJCP.2014.15.8.3817	50	27	27	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					820	828		10.1038/onc.2016.250	http://dx.doi.org/10.1038/onc.2016.250			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27425591	Green Accepted			2022-12-17	WOS:000394168200009
J	Hung, MH; Chen, YL; Chu, PY; Shih, CT; Yu, HC; Tai, WT; Shiau, CW; Chen, KF				Hung, M-H; Chen, Y-L; Chu, P-Y; Shih, C-T; Yu, H-C; Tai, W-T; Shiau, C-W; Chen, K-F			Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; ACUTE MYELOID-LEUKEMIA; ANTICANCER THERAPY; TUMOR-SUPPRESSOR; CELL-SURVIVAL; OKADAIC ACID; PP2A; INHIBITION; SORAFENIB; CANCER	The SET protein is a potent inhibitor of protein phosphatase 2A (PP2A). Here, we report the oncogenic role of SET in hepatocarcinogenesis, clinical aggressiveness and anti-hepatocellular carcinoma (HCC) therapeutics. By analyzing samples obtained from 147 HCC patients, we found that SET overexpression was detected specifically in 30.6% HCC tumor samples, and was significantly associated with worse clinical features and high p-Akt expression in HCC tumors. Co-expression of SET and Akt predicted shorter post-operative recurrence-free survival in this cohort (P = 0.045). Furthermore, SET was significantly associated with cell growth and hepatosphere formation. To elucidate the anti-HCC potential of targeting SET, we generated a novel SET antagonist, EMQA (N-4-(3-ethynylphenyl)-6,7-dimethoxy-N-2-(4-phenoxyphenyl) quinazoline-2,4-diamine). EMQA enhanced PP2A activity via disrupting SET-PP2Ac (catalytic domain of PP2A) binding in HCC cells, which restored PP2A-mediated p-Akt downregulation and promoted HCC cell death. In HCC cells or recombinant proteins expressing the N- and C-truncated forms of SET, only the C-terminal SET was required for EMQA targeting. Furthermore, combining sorafenib and EMQA showed good synergism in inhibiting HCC survival. Our findings suggested the oncogenic role of SET and the adverse prognostic value of SET overexpression in HCC. This alteration defines a subgroup of HCC patients who could benefit from SET antagonists, such as EMQA.	[Hung, M-H] Taipei Vet Gen Hosp, Dept Oncol, Div Med Oncol, Taipei, Taiwan; [Hung, M-H] Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei, Taiwan; [Hung, M-H] Natl Yang Ming Univ, Sch Life Sci, Program Mol Med, Taipei, Taiwan; [Hung, M-H] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Chen, Y-L] Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan; [Chen, Y-L] Changhua Christian Hosp, Dept Surg, Changhua, Taiwan; [Chu, P-Y] Show Chwan Mem Hosp, Dept Pathol, Changhua, Taiwan; [Chu, P-Y] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan; [Shih, C-T; Yu, H-C; Tai, W-T; Chen, K-F] Natl Taiwan Univ Hosp, Dept Med Res, 7 Chung Shan S Rd, Taipei 100, Taiwan; [Tai, W-T; Chen, K-F] Natl Taiwan Univ Hosp, Natl Ctr Excellence Clin Trial & Res, Taipei, Taiwan; [Shiau, C-W] Natl Yang Ming Univ, Inst Biopharmaceut Sci, 155,Sec 2,Li Nong St, Taipei, Taiwan	Taipei Veterans General Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Kaohsiung Medical University; Changhua Christian Hospital; Show Chwan Memorial Hospital; Fu Jen Catholic University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Yang Ming Chiao Tung University	Chen, KF (corresponding author), Natl Taiwan Univ Hosp, Dept Med Res, 7 Chung Shan S Rd, Taipei 100, Taiwan.; Shiau, CW (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, 155,Sec 2,Li Nong St, Taipei, Taiwan.	cwshiau@ym.edu.tw; kfchen1970@ntu.edu.tw		Chu, Pei-Yi/0000-0001-7336-2465	Ministry of Science and Technology [MOST-104-3113-B-076-001]; Taipei Veterans General Hospital [104DHA0100480, V105B-015]; Taiwan Clinical Oncology Research Foundation; Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Taipei Veterans General Hospital(Taipei Veterans General Hospital); Taiwan Clinical Oncology Research Foundation; Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program	This study is supported by grant MOST-104-3113-B-076-001 from the Ministry of Science and Technology and grant 104DHA0100480 and V105B-015 from Taipei Veterans General Hospital, and partial support from Taiwan Clinical Oncology Research Foundation, Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program.	Agarwal A, 2014, CLIN CANCER RES, V20, P2092, DOI 10.1158/1078-0432.CCR-13-2575; Al-Murrani SWK, 1999, BIOCHEM J, V341, P293, DOI 10.1042/0264-6021:3410293; Arnaud L, 2011, FEBS LETT, V585, P2653, DOI 10.1016/j.febslet.2011.07.020; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bononi A, 2011, ENZYME RES, V2011, DOI [10.4061/2011/329098, DOI 10.4061/2011/329098]; Bruix J, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.4006; Carlson SG, 1998, J AM SOC NEPHROL, V9, P1873; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Chen KF, 2010, ONCOGENE, V29, P6257, DOI 10.1038/onc.2010.357; Chen KF, 2012, BIOORGAN MED CHEM, V20, P6144, DOI 10.1016/j.bmc.2012.08.039; Chen KF, 2011, J PHARMACOL EXP THER, V337, P155, DOI 10.1124/jpet.110.175786; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen WB, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/675429; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Christensen DJ, 2011, J IMMUNOL, V186, P2535, DOI 10.4049/jimmunol.1002847; Cristobal I, 2015, CLIN CANCER RES, V21, P347, DOI 10.1158/1078-0432.CCR-14-0724; Cristobal I, 2012, HAEMATOL-HEMATOL J, V97, P543, DOI 10.3324/haematol.2011.050542; EISENMANN DM, 1994, GENETICS, V137, P647; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Fukukawa C, 2000, CANCER LETT, V161, P89, DOI 10.1016/S0304-3835(00)00598-X; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Issa NP, 2015, NEUROLOGY, V84, P99, DOI 10.1212/WNL.0000000000001109; Janghorban M, 2014, P NATL ACAD SCI USA, V111, P9157, DOI 10.1073/pnas.1317630111; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kubota D, 2014, J PROTEOME RES, V13, P2250, DOI 10.1021/pr400929h; Leopoldino AM, 2012, MOL CELL BIOCHEM, V363, P65, DOI 10.1007/s11010-011-1158-x; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Liu GP, 2012, NEUROBIOL AGING, V33, P254, DOI 10.1016/j.neurobiolaging.2010.01.016; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Muto S, 2007, P NATL ACAD SCI USA, V104, P4285, DOI 10.1073/pnas.0603762104; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Neviani P, 2013, J CLIN INVEST, V123, P4144, DOI 10.1172/JCI68951; Patching SG, 2014, BBA-BIOMEMBRANES, V1838, P43, DOI 10.1016/j.bbamem.2013.04.028; Pelletier D, 2012, NEW ENGL J MED, V366, P339, DOI 10.1056/NEJMct1101691; Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2; Pippa R, 2014, LEUKEMIA, V28, P1915, DOI 10.1038/leu.2014.141; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Switzer CH, 2011, ONCOGENE, V30, P2504, DOI 10.1038/onc.2010.622; Tai WT, 2014, HEPATOLOGY, V59, P190, DOI 10.1002/hep.26640; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Yu HC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.325; Yu HC, 2013, BIOCHEM PHARMACOL, V85, P356, DOI 10.1016/j.bcp.2012.11.009; Zhai B, 2014, MOL CANCER THER, V13, P1589, DOI 10.1158/1535-7163.MCT-13-1043	50	27	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4891	4902		10.1038/onc.2016.21	http://dx.doi.org/10.1038/onc.2016.21			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876205				2022-12-17	WOS:000383330700007
J	Ksionda, O; Melton, AA; Bache, J; Tenhagen, M; Bakker, J; Harvey, R; Winter, SS; Rubio, I; Roose, JP				Ksionda, O.; Melton, A. A.; Bache, J.; Tenhagen, M.; Bakker, J.; Harvey, R.; Winter, S. S.; Rubio, I.; Roose, J. P.			RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEINS; POSITIVE SELECTION; NEUROFIBROMIN 1; P120 RASGAP; LEUKEMIA; PROLIFERATION; STIMULATION; PROCEEDS; REQUIRES; GROWTH	Ras GTPases are activated by RasGEFs and inactivated by RasGAPs, which stimulate the hydrolysis of RasGTP to inactive RasGDP. GTPase-impairing somatic mutations in RAS genes, such as KRAS(G12D), are among the most common oncogenic events in metastatic cancer. A different type of cancer Ras signal, driven by overexpression of the RasGEF RasGRP1 (Ras guanine nucleotide-releasing protein 1), was recently implicated in pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients and murine models, in which RasGRP1 T-ALLs expand in response to treatment with interleukins (ILs) 2, 7 and 9. Here, we demonstrate that IL-2/7/9 stimulation activates Erk and Akt pathways downstream of Ras in RasGRP1 T-ALL but not in normal thymocytes. In normal lymphocytes, RasGRP1 is recruited to the membrane by diacylglycerol (DAG) in a phospholipase C-gamma (PLC gamma)-dependent manner. Surprisingly, we find that leukemic RasGRP1-triggered Ras-Akt signals do not depend on acute activation of PLC gamma to generate DAG but rely on baseline DAG levels instead. In agreement, using three distinct assays that measure different aspects of the RasGTP/GDP cycle, we established that overexpression of RasGRP1 in T-ALLs results in a constitutively high GTP-loading rate of Ras, which is constantly counterbalanced by hydrolysis of RasGTP. KRAS(G12D) T-ALLs do not show constitutive GTP loading of Ras. Thus, we reveal an entirely novel type of leukemogenic Ras signals that is based on a RasGRP1-driven increased in flux through the RasGTP/GDP cycle, which is mechanistically very different from KRAS(G12D) signals. Our studies highlight the dynamic balance between RasGEF and RasGAP in these T-ALLs and put forth a new model in which IL-2/7/9 decrease RasGAP activity.	[Ksionda, O.; Melton, A. A.; Tenhagen, M.; Bakker, J.; Roose, J. P.] Roose Univ Calif, Dept Anat, 513 Parnassus,HSW 1326, San Francisco, CA 94143 USA; [Melton, A. A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Bache, J.; Rubio, I.] Univ Jena, Univ Hosp, Ctr Mol Biomed, Inst Mol Cell Biol, Jena, Germany; [Harvey, R.; Winter, S. S.] Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA; [Rubio, I.] Jena Univ Hosp, CSCC, Integrated Res & Treatment Ctr, Jena, Germany	University of California System; University of California San Francisco; Friedrich Schiller University of Jena; University of New Mexico; Friedrich Schiller University of Jena	Ksionda, O; Roose, JP (corresponding author), Roose Univ Calif, Dept Anat, 513 Parnassus,HSW 1326, San Francisco, CA 94143 USA.	olga.ksionda@ucsf.edu; jeroen.roose@ucsf.edu		Roose, Jeroen/0000-0003-4746-2811	NIH-NCI Physical Science Oncology Center Grant [U54CA143874]; NIH-NIAID Grant (P01 Program) [AI091580]; Gabrielle's Angel Foundation; NIH-NCI Grant [R01-CA187318]; NIH T32 training grant [5T32CA128583-05]; KWF (Dutch Cancer Society); NCI [U10 CA98543, CA180886, U10 CA98413, CA180899, U24 CA114766]; NATIONAL CANCER INSTITUTE [U54CA143874, U10CA180899, P30CA118100, R01CA187318, T32CA128583] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000041, UL1TR001449] Funding Source: NIH RePORTER	NIH-NCI Physical Science Oncology Center Grant; NIH-NIAID Grant (P01 Program); Gabrielle's Angel Foundation; NIH-NCI Grant; NIH T32 training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); KWF (Dutch Cancer Society)(KWF Kankerbestrijding); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank the Roose lab members for helpful comments and Anna Hupalowska for the graphics in Figure 4. Our research was supported by an NIH-NCI Physical Science Oncology Center Grant U54CA143874, an NIH-NIAID Grant (P01 Program Project-AI091580), a Gabrielle's Angel Foundation Grant and NIH-NCI Grant (R01-CA187318) (all to JPR), as well as by an NIH T32 training grant (5T32CA128583-05) and the KWF (Dutch Cancer Society) (MT and JB). This work was also supported by grants from the NCI to the Children's Oncology Group including U10 CA98543 and CA180886 (COG Chair's Grant), U10 CA98413 and CA180899 (COG Statistical Center) and U24 CA114766 (COG Specimen Banking).	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Balgobind BV, 2008, BLOOD, V111, P4322, DOI 10.1182/blood-2007-06-095075; Barata JT, 2004, HAEMATOLOGICA, V89, P1459; Barata JT, 2004, J EXP MED, V200, P659, DOI 10.1084/jem.20040789; Cichowski K, 2003, GENE DEV, V17, P449, DOI 10.1101/gad.1054703; Daley SR, 2013, ELIFE, V2, DOI 10.7554/eLife.01020; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P156; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward Julian, 2003, Biochem J, V376, pe9, DOI 10.1042/BJ20031745; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Feske S, 2012, NAT REV IMMUNOL, V12, P532, DOI 10.1038/nri3233; Gorentla BK, 2011, BLOOD, V117, P4022, DOI 10.1182/blood-2010-08-300731; Hartzell C, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003848; Hennig A, 2015, BIOL CHEM, V396, P831, DOI 10.1515/hsz-2014-0257; Iwig JS, 2013, ELIFE, V2, DOI 10.7554/eLife.00813; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; King PD, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003669; Klinger MB, 2005, ONCOGENE, V24, P2695, DOI 10.1038/sj.onc.1208334; Krutzik PO, 2006, NAT METHODS, V3, P361, DOI 10.1038/NMETH872; Ksionda Olga, 2013, Front Biol (Beijing), V8, P508; Lapinski PE, 2011, J IMMUNOL, V187, P151, DOI 10.4049/jimmunol.1100178; Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773; Lubeck BA, 2015, J IMMUNOL, V195, P31, DOI 10.4049/jimmunol.1402639; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Neumann M, 2013, BLOOD, V121, P4749, DOI 10.1182/blood-2012-11-465138; Oki T, 2011, LEUKEMIA, V26, P1038; Oliver JA, 2013, MOL IMMUNOL, V55, P292, DOI 10.1016/j.molimm.2013.03.005; Roose JP, 2005, MOL CELL BIOL, V25, P4426, DOI 10.1128/MCB.25.11.4426-4441.2005; Rubio I, 2000, CURR BIOL, V10, P1225, DOI 10.1016/S0960-9822(00)00731-4; Rubio I, 2003, BIOCHEM J, V376, P571, DOI 10.1042/BJ20031410; Rubio I, 2006, BIOCHEM J, V398, P243, DOI 10.1042/BJ20060160; Rubio I, 2010, J IMMUNOL, V185, P3536, DOI 10.4049/jimmunol.1000334; Silva A, 2011, CANCER RES, V71, P4780, DOI 10.1158/0008-5472.CAN-10-3606; Stites EC, 2015, CELL REP, V10, P307, DOI 10.1016/j.celrep.2014.12.035; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725	38	27	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3658	3668		10.1038/onc.2015.431	http://dx.doi.org/10.1038/onc.2015.431			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26549032	Green Accepted			2022-12-17	WOS:000379622800005
J	Chakedis, J; French, R; Babicky, M; Jaquish, D; Howard, H; Mose, E; Lam, R; Holman, P; Miyamoto, J; Walterscheid, Z; Lowy, AM				Chakedis, J.; French, R.; Babicky, M.; Jaquish, D.; Howard, H.; Mose, E.; Lam, R.; Holman, P.; Miyamoto, J.; Walterscheid, Z.; Lowy, A. M.			A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells	ONCOGENE			English	Article							MACROPHAGE-STIMULATING PROTEIN; THERAPEUTIC TARGET; CANCER CELLS; TUMORIGENIC ACTIVITIES; PROGNOSTIC MARKER; SPLICING VARIANT; BREAST-CANCER; MET FAMILY; EXPRESSION; IDENTIFICATION	The MST1R gene is overexpressed in pancreatic cancer producing elevated levels of the RON tyrosine kinase receptor protein. While mutations in MST1R are rare, alternative splice variants have been previously reported in epithelial cancers. We report the discovery of a novel RON isoform discovered in human pancreatic cancer. Partial splicing of exons 5 and 6 (P5P6) produces a RON isoform that lacks the first extracellular immunoglobulin-plexin-transcription domain. The splice variant is detected in 73% of xenografts derived from pancreatic adenocarcinoma patients and 71% of pancreatic cancer cell lines. Peptides specific to RON P5P6 detected in human pancreatic cancer specimens by mass spectrometry confirm translation of the protein isoform. The P5P6 isoform is found to be constitutively phosphorylated, present in the cytoplasm, and it traffics to the plasma membrane. Expression of P5P6 in immortalized human pancreatic duct epithelial (HPDE) cells activates downstream AKT, and in human pancreatic epithelial nestin-expressing cells, activates both the AKT and MAPK pathways. Inhibiting RON P5P6 in HPDE cells using a small molecule inhibitor BMS-777607 blocked constitutive activation and decreased AKT signaling. P5P6 transforms NIH3T3 cells and induces tumorigenicity in HPDE cells. Resultant HPDE-P5P6 tumors develop a dense stromal compartment similar to that seen in pancreatic cancer. In summary, we have identified a novel and constitutively active isoform of the RON tyrosine kinase receptor that has transforming activity and is expressed in human pancreatic cancer. These findings provide additional insight into the biology of the RON receptor in pancreatic cancer and are clinically relevant to the study of RON as a potential therapeutic target.	[Chakedis, J.; French, R.; Babicky, M.; Jaquish, D.; Howard, H.; Mose, E.; Lam, R.; Holman, P.; Miyamoto, J.; Walterscheid, Z.; Lowy, A. M.] Univ Calif San Diego, Moores Canc Ctr, Div Surg Oncol, Dept Surg, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Lowy, AM (corresponding author), Univ Calif San Diego, Moores Canc Ctr, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	alowy@ucsd.edu			National Cancer Institute of the National Institutes of Health [R01 CA155620, T32 CA121938]; NCI Cancer Center Support Grant [2 P30 CA023100-23]; NATIONAL CANCER INSTITUTE [R01CA155620, T32CA121938, P30CA023100] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge the generosity of our patients who supported this work through both monetary contributions and/or by allowing tumor tissue to be used for research. Without their contributions, this work would not have been possible. We thank the Tsao and Klemke labs for providing HPDE and HPNE ells, respectively. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01 CA155620 (AML) and T32 CA121938 (JC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. DNA sequencing was performed by the DNA Sequencing Shared Resource, UCSD Moore's Cancer Center, which is funded in part by NCI Cancer Center Support Grant # 2 P30 CA023100-23.	Angeloni D, 2004, J BIOL CHEM, V279, P3726, DOI 10.1074/jbc.M309342200; Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Bardella C, 2004, CANCER RES, V64, P5154, DOI 10.1158/0008-5472.CAN-04-0600; Benight NM, 2012, EXPERT OPIN THER TAR, V16, P921, DOI 10.1517/14728222.2012.710200; Braga E., 2011, Experimental Oncology, V33, P33; Camp ER, 2007, CANCER-AM CANCER SOC, V109, P1030, DOI 10.1002/cncr.22490; Catenacci DVT, 2011, CANCER BIOL THER, V12, P9, DOI 10.4161/cbt.12.1.15747; Chao KLL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041912; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; Eckerich C, 2009, J NEUROCHEM, V109, P969, DOI 10.1111/j.1471-4159.2009.06027.x; Eyob H, 2013, CANCER DISCOV, V3, P751, DOI 10.1158/2159-8290.CD-12-0480; Feres KJ, 2009, ONCOGENE, V28, P279, DOI 10.1038/onc.2008.383; Furukawa T, 1996, AM J PATHOL, V148, P1763; Gurusamy D, 2013, CANCER RES, V73, P1752, DOI 10.1158/0008-5472.CAN-12-2474; Guttman M, 2009, PROTEOMICS, V9, P5016, DOI 10.1002/pmic.200900457; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Kim MP, 2009, NAT PROTOC, V4, P1670, DOI 10.1038/nprot.2009.171; Kumanogoh A, 2013, NAT REV IMMUNOL, V13, P802, DOI 10.1038/nri3545; Liu Xuemei, 2011, Genes Cancer, V2, P753, DOI 10.1177/1947601911421924; Logan-Collins J, 2010, CANCER RES, V70, P1130, DOI 10.1158/0008-5472.CAN-09-0761; Ma Q, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-307; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Neesse A, 2011, GUT, V60, P861, DOI 10.1136/gut.2010.226092; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; Pfaffl M.W., 2004, A Z QUANT PCR, P87; RONSIN C, 1993, ONCOGENE, V8, P1195; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Schroeder GM, 2009, J MED CHEM, V52, P1251, DOI 10.1021/jm801586s; Tactacan CM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-395; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Thomas RM, 2010, PANCREAS, V39, P301, DOI 10.1097/MPA.0b013e3181bb9f73; Wang J, 2009, J BIOL CHEM, V284, P10912, DOI 10.1074/jbc.M809551200; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Wang QR, 2013, CANCER LETT, V340, P43, DOI 10.1016/j.canlet.2013.06.022; Wang X, 2013, CRIT REV IMMUNOL, V33, P549; Xu XM, 2005, J BIOL CHEM, V280, P25087, DOI 10.1074/jbc.M414699200; Yao HP, 2013, CURR CANCER DRUG TAR, V13, P686, DOI 10.2174/15680096113139990038; Yao HP, 2013, NAT REV CANCER, V13, P466, DOI 10.1038/nrc3545; Zeng JY, 2014, MOL CANCER THER, V13, P37, DOI 10.1158/1535-7163.MCT-13-0242; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	42	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3249	3259		10.1038/onc.2015.384	http://dx.doi.org/10.1038/onc.2015.384			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26477314	Green Submitted, Green Accepted			2022-12-17	WOS:000378306400004
J	Rey, C; Faustin, B; Mahouche, I; Ruggieri, R; Brulard, C; Ichas, F; Soubeyran, I; Lartigue, L; De Giorgi, F				Rey, C.; Faustin, B.; Mahouche, I.; Ruggieri, R.; Brulard, C.; Ichas, F.; Soubeyran, I.; Lartigue, L.; De Giorgi, F.			The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer	ONCOGENE			English	Article							MIXED-LINEAGE KINASE; PROTEIN TRIPLE KINASE; TUMOR-CELL INVASION; HYPERTROPHIC GROWTH; EXPRESSION PROFILES; ACTIVATION; PHOSPHORYLATION; GTPASE; RHOGDI; JNK	Often described as a mediator of cell cycle arrest or as a pro-apoptotic factor in stressful conditions, the MAP3K ZAK (Sterile alpha motif and leucine zipper-containing kinase) has also been proven to positively regulate epidermal growth factor receptor (EGFR) and WNT signaling pathways, cancer cell proliferation and cellular neoplastic transformation. Here, we show that both isoforms of ZAK, ZAK-alpha and ZAK-beta are key factors in cancer cell migration. While ZAK depletion reduced cell motility of HeLa and HCT116 cells, its overexpression triggered the activation of all three mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK), c-JUN N-terminal kinase (JNK) and p38, as well as an increase in cell motion. On the contrary, the kinase-dead mutants, ZAK-alpha K45M and ZAK-beta K45M, were not able to provoke such events, and instead exerted a dominant-negative effect on MAPK activation and cell migration. Pharmacological inhibition of ZAK by nilotinib, preventing ZAK-autophosphorylation and thereby auto-activation, led to the same results. Activated by epidermal growth factor (EGF), we further showed that ZAK constitutes an essential element of the EGF/ERK-dependent cell migration pathway. Using public transcriptomic databases and tissue microarrays, we finally established that, as strong factors of the EGFR signaling pathway, ZAK-alpha and/or ZAK-beta transcripts and protein(s) are frequently upregulated in colorectal adenoma and carcinoma patients. Notably, gene set enrichment analysis disclosed a significant correlation between ZAK+ colorectal premalignant lesions and gene sets belonging to the MAPK/ERK and motility-related signaling pathways of the reactome database, strongly suggesting that ZAK induces such pro-tumoral reaction cascades in human cancers.	[Rey, C.; Mahouche, I.; Brulard, C.; Lartigue, L.] Univ Bordeaux 2, Inst Bergonie, Lab Validat & Identificat Nouvelles Cibles Oncol, INSERM U916, 229 Cours Argonne, F-33076 Bordeaux, France; [Faustin, B.] CNRS CIRID, Bordeaux, France; [Ruggieri, R.] Feinstein Inst Med Res, Lab Cell Signaling, Manhasset, NY USA; [Ichas, F.; De Giorgi, F.] Fluofarma, 2 Rue R Escarpit, Pessac, France; [Soubeyran, I.] Inst Bergonie, Dept Biopathol, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; Northwell Health; UNICANCER; Institut Bergonie	Lartigue, L (corresponding author), Univ Bordeaux 2, Inst Bergonie, Lab Validat & Identificat Nouvelles Cibles Oncol, INSERM U916, 229 Cours Argonne, F-33076 Bordeaux, France.	l.lartigue-faustin@bordeaux.unicancer.fr	Ichas, François/ABD-8277-2020	Ichas, François/0000-0001-8184-5248	French National Institute for Medical Research (INSERM); Aquitaine Region; French Ministry of Research; Institut Bergonie; Association for Cancer Research (ARC); Ligue Contre le Cancer; Canceropole Grand Sud-Ouest; 'Agir Cancer' Gironde; French National Research Agency (ANR)	French National Institute for Medical Research (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Aquitaine Region(Region Nouvelle-Aquitaine); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Institut Bergonie; Association for Cancer Research (ARC); Ligue Contre le Cancer(Ligue nationale contre le cancer); Canceropole Grand Sud-Ouest; 'Agir Cancer' Gironde; French National Research Agency (ANR)(French National Research Agency (ANR))	This work was supported by the French National Institute for Medical Research (INSERM), Aquitaine Region, French Ministry of Research, Institut Bergonie, Association for Cancer Research (ARC), the Ligue Contre le Cancer, and Canceropole Grand Sud-Ouest, 'Agir Cancer' Gironde and The French National Research Agency (ANR). We thank Nicolas Faur, Raphael Moustie and Assia Chaibi for their technical help and Pippa McKelvie-Sebileau of Institut Bergonie for medical editorial assistance.	Adler AS, 2014, GENE DEV, V28, P1068, DOI 10.1101/gad.237206.113; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; Bloem LJ, 2001, J MOL CELL CARDIOL, V33, P1739, DOI 10.1006/jmcc.2001.1437; Cho YY, 2004, CANCER RES, V64, P3855, DOI 10.1158/0008-5472.CAN-04-0201; Choi HS, 2005, J BIOL CHEM, V280, P13545, DOI 10.1074/jbc.M410521200; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Griner EM, 2013, ONCOGENE, V32, P1010, DOI 10.1038/onc.2012.124; Gross EA, 2002, J BIOL CHEM, V277, P13873, DOI 10.1074/jbc.M111994200; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang CY, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-56; Huang CY, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-11; Huang CY, 2004, BIOCHEM BIOPH RES CO, V324, P973, DOI 10.1016/j.bbrc.2004.09.156; Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978-1-60761-795-2_1; Korkina O, 2013, J BIOL CHEM, V288, P5364, DOI 10.1074/jbc.M112.414060; Liu JF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4830; Liu TC, 2000, BIOCHEM BIOPH RES CO, V274, P811, DOI 10.1006/bbrc.2000.3236; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Manley PW, 2010, BBA-PROTEINS PROTEOM, V1804, P445, DOI 10.1016/j.bbapap.2009.11.008; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Ray RM, 2012, CELL SIGNAL, V24, P931, DOI 10.1016/j.cellsig.2011.12.016; Reiterer V, 2013, P NATL ACAD SCI USA, V110, pE2934, DOI 10.1073/pnas.1301985110; Rey C, 2013, CELL CYCLE, V12, P1879, DOI 10.4161/cc.24927; Rix U, 2010, LEUKEMIA, V24, P44, DOI 10.1038/leu.2009.228; Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Soubeyran I, 2011, AM J PATHOL, V178, P1986, DOI 10.1016/j.ajpath.2011.01.021; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi M, 2003, J BIOCHEM, V133, P181, DOI 10.1093/jb/mvg022; van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002; Vinayagam A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001699; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang XS, 2005, J BIOL CHEM, V280, P19298, DOI 10.1074/jbc.M413059200; Yang JJ, 2010, CANCER SCI, V101, P1374, DOI 10.1111/j.1349-7006.2010.01537.x; Yang JJ, 2003, BIOCHEM BIOPH RES CO, V301, P71, DOI 10.1016/S0006-291X(02)02980-7; Yang JJ, 2002, BIOCHEM BIOPH RES CO, V297, P105, DOI 10.1016/S0006-291X(02)02123-X; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	45	27	27	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3190	3200		10.1038/onc.2015.379	http://dx.doi.org/10.1038/onc.2015.379			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26522728				2022-12-17	WOS:000378092700010
J	Flashner-Abramson, E; Klein, S; Mullin, G; Shoshan, E; Song, R; Shir, A; Langut, Y; Bar-Eli, M; Reuveni, H; Levitzki, A				Flashner-Abramson, E.; Klein, S.; Mullin, G.; Shoshan, E.; Song, R.; Shir, A.; Langut, Y.; Bar-Eli, M.; Reuveni, H.; Levitzki, A.			Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling	ONCOGENE			English	Article							MONOCLONAL-ANTIBODIES; OVERCOME RESISTANCE; TUMOR PROGRESSION; CANCER; INHIBITOR; ACTIVATION; THERAPIES	It is well known that specific signal transduction inhibitors rarely suffice as anti-cancer agents. In most cases, tumors possess primary drug resistance due to their inherent heterogeneity, or acquire drug resistance due to genomic instability and acquisition of mutations. Here we expand our previous study of the novel compound, NT157, and show that it acts as a dual-targeting agent that invokes the blockage of two signal transduction pathways that are central to the development and maintenance of multiple human cancers. We show that NT157 targets not only IGF1R-IRS1/2, as previously reported, but also the Stat3 signaling pathway and demonstrates remarkable anti-cancer characteristics in A375 human melanoma cells and in a metastatic melanoma model in mice.	[Flashner-Abramson, E.; Klein, S.; Mullin, G.; Shir, A.; Langut, Y.; Reuveni, H.; Levitzki, A.] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel; [Shoshan, E.; Song, R.; Bar-Eli, M.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, Houston, TX 77030 USA; [Reuveni, H.] NovoTyr Ltd, Tel Hai, Israel	Hebrew University of Jerusalem; University of Texas System; UTMD Anderson Cancer Center	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel.; Reuveni, H (corresponding author), TyrNovo Ltd, 8 Abba Eban Ave, IL-4672526 Herzliyya, Israel.	hadas.reuveni@gmail.com; alex.levitzki@mail.huji.ac.il	Mullin, Gerry/H-5294-2019	Mullin, Gerry/0000-0001-5317-6788	ERC Advanced Grant [249898]; NIH Skin Cancer SPORE p50 [CA093459]; Office of the Chief Scientist in the Ministry of Industry, Trade and Labor of Israel; Algen Biopharmaceuticals Ltd; NATIONAL CANCER INSTITUTE [P50CA093459] Funding Source: NIH RePORTER	ERC Advanced Grant; NIH Skin Cancer SPORE p50; Office of the Chief Scientist in the Ministry of Industry, Trade and Labor of Israel; Algen Biopharmaceuticals Ltd; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professor Martin Myers (UMMS) for the Jak2 expression plasmids and Professor Scott Weed (WVU) for the GFP-Src expression plasmids. We thank Professor Ruth Halaban (Yale University) and Yale SPORE in Skin Cancer for providing us with the patient-derived melanoma cells (YUMAC and YUSIK), and Dr Michal Lotem (Hadassah Hospital) for providing us the patient-derived melanoma cells (M571 and M2068). We acknowledge Dr Salim Joubran from our laboratory who was instrumental in the chemistry of NT157. This study was supported by an ERC Advanced Grant (No. 249898) to AL by the NIH Skin Cancer SPORE p50 (No. CA093459), by four grants from the Office of the Chief Scientist in the Ministry of Industry, Trade and Labor of Israel to NovoTyr (HR, 2005-2012) and by Algen Biopharmaceuticals Ltd.	Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; DILLMAN RO, 1984, CRC CR REV ONCOL-HEM, V1, P357, DOI 10.1016/S1040-8428(84)80008-6; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Ibuki N, 2014, MOL CANCER THER, V13, P2827, DOI 10.1158/1535-7163.MCT-13-0842; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Levitzki A, 2006, ANNU REV BIOCHEM, V75, P93, DOI 10.1146/annurev.biochem.75.103004.142657; Levitzki A, 2013, ANNU REV PHARMACOL, V53, P161, DOI 10.1146/annurev-pharmtox-011112-140341; Levitzki A, 2010, MOL ASPECTS MED, V31, P287, DOI 10.1016/j.mam.2010.04.001; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Liu F, 2013, J INVEST DERMATOL, V133, P2041, DOI 10.1038/jid.2013.32; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Mano Y, 2013, PATHOBIOLOGY, V80, P146, DOI 10.1159/000346196; OLDHAM RK, 1983, J CLIN ONCOL, V1, P582, DOI 10.1200/JCO.1983.1.9.582; Page BDG, 2011, EXPERT OPIN THER PAT, V21, P65, DOI 10.1517/13543776.2011.539205; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Qualls J, 2012, J IMMUNOL, V188, P34; Reuveni H, 2013, CANCER RES, V73, P4383, DOI 10.1158/0008-5472.CAN-12-3385; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Stivarou T, 2015, CANCERS, V7, P238, DOI 10.3390/cancers7010238; WARD HWC, 1973, BMJ-BRIT MED J, V1, P13, DOI 10.1136/bmj.1.5844.13; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818	25	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2675	2680		10.1038/onc.2015.229	http://dx.doi.org/10.1038/onc.2015.229			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26119932				2022-12-17	WOS:000376165700014
J	Schumacher, Y; Aparicio, T; Ourabah, S; Baraille, F; Martin, A; Wind, P; Dentin, R; Postic, C; Guilmeau, S				Schumacher, Y.; Aparicio, T.; Ourabah, S.; Baraille, F.; Martin, A.; Wind, P.; Dentin, R.; Postic, C.; Guilmeau, S.			Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth	ONCOGENE			English	Article							COACTIVATOR CRTC1; GENE-EXPRESSION; COLORECTAL-CANCER; BINDING PROTEIN; TRANSCRIPTIONAL COACTIVATOR; MODULATES GLUCONEOGENESIS; CREB ACTIVATION; IL-10; FUSION; CELLS	First identified as a dedicated CREB (cAMP response element-binding protein) co-activator, CRTC1 (CREB-regulated transcription coactivator 1) has been widely implicated in various neuronal functions because of its predominant expression in the brain. However, recent evidences converge to indicate that CRTC1 is aberrantly activated in an expanding number of adult malignancies. In this study, we provide strong evidences of enhanced CRTC1 protein content and transcriptional activity in mouse models of sporadic (APC(min/+) mice) or colitis-associated colon cancer azoxymethane/dextran sulfate sodium (AOM/DSS-treated mice), and in human colorectal tumors specimens compared with adjacent normal mucosa. Among signals that could trigger CRTC1 activation during colonic carcinogenesis, we demonstrate that treatment with cyclooxygenase 2 (COX2) inhibitors reduced nuclear CRTC1 active form levels in colonic tumors of APC(min/+) or AOM/DSS mice. In accordance, prostaglandins E2 (PGE2) exposure to human colon cancer cell lines promoted CRTC1 dephosphorylation and parallel nuclear translocation, resulting in enhanced CRTC1 transcriptional activity, through EP1 and EP2 receptors signaling and consecutive calcineurin and protein kinase A activation. In vitro CRTC1 loss of function in colon cancer cell lines was associated with reduced viability and cell division rate as well as enhanced chemotherapy-induced apoptosis on PGE2 treatment. Conversely, CRTC1 stable overexpression significantly increased colonic xenografts tumor growth, therefore demonstrating the role of CRTC1 signaling in colon cancer progression. Identification of the transcriptional program triggered by enhanced CRTC1 expression during colonic carcinogenesis, revealed some notable pro-tumorigenic CRTC1 target genes including NR4A2, COX2, amphiregulin (AREG) and IL-6. Finally, we demonstrate that COX2, AREG and IL-6 promoter activities triggered by CRTC1 are dependent on functional AP1 and CREB transcriptional partners. Overall, our study establishes CRTC1 as new mediator of PGE2 signaling, unravels the importance of its dysregulation in colon cancer and strengthens its use as a bona fide cancer marker.	[Schumacher, Y.; Ourabah, S.; Baraille, F.; Dentin, R.; Postic, C.; Guilmeau, S.] INSERM, Inst Cochin, U1016, Paris, France; [Schumacher, Y.; Ourabah, S.; Baraille, F.; Dentin, R.; Postic, C.; Guilmeau, S.] CNRS, UMR 8104, Paris, France; [Schumacher, Y.; Ourabah, S.; Baraille, F.; Dentin, R.; Postic, C.; Guilmeau, S.] Univ Paris 05, Paris, France; [Schumacher, Y.] Univ Paris Diderot, Paris, France; [Aparicio, T.] Univ Paris 13, Avicenne Hosp, AP HP, Gastroenterol & Digest Oncol Unit,HUPSSD, Bobigny, France; [Martin, A.] Univ Paris 13, Avicenne Hosp, AP HP, Pathol Unit,HUPSSD, Bobigny, France; [Wind, P.] Univ Paris 13, Avicenne Hosp, AP HP, Digest Surg Unit,HUPSSD, Bobigny, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	Guilmeau, S (corresponding author), Univ Paris 05, Endocrinol Metab & Canc INSERM U1016, 24 Rue Fbg St Jacques, F-75014 Paris, France.	sandra.guilmeau@inserm.fr	Postic, Catherine/P-2271-2017; dentin, Renaud/P-4939-2017; Dentin, Renaud/AAV-5818-2020; Guilmeau, Sandra/P-2318-2017	Postic, Catherine/0000-0002-1875-6960; dentin, Renaud/0000-0003-0988-4458; Dentin, Renaud/0000-0003-0988-4458; Martin, Alberto/0000-0002-0795-0418; Guilmeau, Sandra/0000-0002-8260-1218	Paris Descartes University; INSERM; ARC research foundation against cancer	Paris Descartes University; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ARC research foundation against cancer(Australian Research Council)	We gratefully acknowledge the Canceropole IdF funding source that made Yoann Schumacher PhD work possible. Otherwise, the studies were supported by grants from the Paris Descartes University, INSERM and the ARC research foundation against cancer. The authors are indebted to the Cochin Institute Transcriptomic Facility for technical help. The authors also thank (i) J Mathieu (Institut Cochin, Inserm U1016, Paris, France) for providing mouse BM-derived macrophage-conditioned media, (ii) Y Attie and D Vignjevic for providing human cancer associated fibroblasts conditioned media (Institut Curie, UMR144, Paris, France) and (ii) Ono Pharmaceutical Co. Ltd (Osaka, Japan) for providing PGE2 receptor subtype agonists. The authors are grateful to AF. Burnol (Institut Cochin, Inserm U1016, Paris, France), J Lebihan and M Legall (Centre de Recherche sur l'Inflammation Paris Montmartre, Inserm UMRS 1149, Paris, France), M Moldes (INSERM UMRS 938, Paris, France) and S Thenet (Centre de Recherche des Cordeliers, UMRS 1138, Paris, France) for critical reading of the manuscript.	Altarejos JY, 2008, NAT MED, V14, P1112, DOI 10.1038/nm.1866; Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072; Alvarez Y, 2009, J IMMUNOL, V183, P1471, DOI 10.4049/jimmunol.0900312; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Breuillaud L, 2012, BIOL PSYCHIAT, V72, P528, DOI 10.1016/j.biopsych.2012.04.011; Canettieri G, 2009, P NATL ACAD SCI USA, V106, P1445, DOI 10.1073/pnas.0808749106; Cao Chunxia, 2015, J Natl Cancer Inst, V107, P358, DOI 10.1093/jnci/dju358; Ch'ng TH, 2012, CELL, V150, P207, DOI 10.1016/j.cell.2012.05.027; Chell S, 2006, BBA-REV CANCER, V1766, P104, DOI 10.1016/j.bbcan.2006.05.002; Chen QH, 2013, ADV MECH ENG, DOI 10.1155/2013/589156; Choong E, 2013, JAMA PSYCHIAT, V70, P1011, DOI 10.1001/jamapsychiatry.2013.187; Clark K, 2012, P NATL ACAD SCI USA, V109, P16986, DOI 10.1073/pnas.1215450109; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; de Leng WWJ, 2003, CLIN CANCER RES, V9, P3065; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Eberhard CE, 2013, ENDOCRINOLOGY, V154, P2308, DOI 10.1210/en.2012-2088; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; Feng Y, 2012, CANCER RES, V72, P6502, DOI 10.1158/0008-5472.CAN-12-1909; Finsterwald C, 2011, EUR J NEUROSCI, V34, P1053, DOI 10.1111/j.1460-9568.2011.07839.x; Galizia G, 2002, CLIN IMMUNOL, V102, P169, DOI 10.1006/clim.2001.5163; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Gunderson LL, 2010, J CLIN ONCOL, V28, P264, DOI 10.1200/JCO.2009.24.0952; Guzman Michael J, 2013, J Gastrointest Cancer, V44, P211, DOI 10.1007/s12029-012-9474-2; Holla VR, 2011, J BIOL CHEM, V286, P30003, DOI 10.1074/jbc.M110.184697; Hua M, 2009, P NATL ACAD SCI USA, V106, P3372, DOI 10.1073/pnas.0813306106; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Kim SJ, 2008, MOL CELL BIOL, V28, P1644, DOI 10.1128/MCB.00325-07; Komiya T, 2010, ONCOGENE, V29, P1672, DOI 10.1038/onc.2009.453; Konstantinopoulos PA, 2007, CELL ONCOL, V29, P477; Kovacs KA, 2007, P NATL ACAD SCI USA, V104, P4700, DOI 10.1073/pnas.0607524104; Kucharzik T, 1997, CLIN EXP IMMUNOL, V110, P296; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Li B, 2014, MUCOSAL IMMUNOL, V7, P869, DOI 10.1038/mi.2013.103; Liu Y, 2008, NATURE, V456, P269, DOI 10.1038/nature07349; MacKenzie KF, 2013, J IMMUNOL, V190, P565, DOI 10.4049/jimmunol.1202462; Mocellin S, 2005, J LEUKOCYTE BIOL, V78, P1043, DOI 10.1189/jlb.0705358; Muraoka M, 2009, AM J PHYSIOL-ENDOC M, V296, pE1430, DOI 10.1152/ajpendo.00024.2009; Nagasaki T, 2014, BRIT J CANCER, V110, P469, DOI 10.1038/bjc.2013.748; Park SW, 2011, J PHARMACOL EXP THER, V336, P516, DOI 10.1124/jpet.110.173278; Rasmuson A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029331; Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715; Sakamoto K, 2013, J NEUROSCI, V33, P9021, DOI 10.1523/JNEUROSCI.4202-12.2013; Samarajeewa NU, 2013, HORM CANCER-US, V4, P233, DOI 10.1007/s12672-013-0142-1; Sekeres MJ, 2012, J NEUROSCI, V32, P17857, DOI 10.1523/JNEUROSCI.1419-12.2012; Shouval DS, 2014, ADV IMMUNOL, V122, P177, DOI 10.1016/B978-0-12-800267-4.00005-5; Sinicrope FA, 1999, GASTROENTEROLOGY, V117, P350, DOI 10.1053/gast.1999.0029900350; Siu YT, 2008, MOL BIOL CELL, V19, P4750, DOI 10.1091/mbc.E08-04-0369; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Takeda H, 2004, BRIT J CANCER, V90, P701, DOI 10.1038/sj.bjc.6601584; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Wu ZD, 2006, P NATL ACAD SCI USA, V103, P14379, DOI 10.1073/pnas.0606714103; Yamada Y, 2007, CANCER SCI, V98, P6, DOI 10.1111/j.1349-7006.2006.00348.x; Zagani R, 2009, GASTROENTEROLOGY, V137, P1358, DOI 10.1053/j.gastro.2009.06.039	59	27	28	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2602	2614		10.1038/onc.2015.283	http://dx.doi.org/10.1038/onc.2015.283			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26300003				2022-12-17	WOS:000376165700007
J	Wei, Q; Chen, ZH; Wang, L; Zhang, T; Duan, L; Behrens, C; Wistuba, II; Minna, JD; Gao, B; Luo, JH; Liu, ZP				Wei, Q.; Chen, Z-H; Wang, L.; Zhang, T.; Duan, L.; Behrens, C.; Wistuba, I. I.; Minna, J. D.; Gao, B.; Luo, J-H; Liu, Z. P.			LZTFL1 suppresses lung tumorigenesis by maintaining differentiation of lung epithelial cells	ONCOGENE			English	Article							CANCER; MAINTENANCE; MIGRATION	Lung cancer is the leading cause of cancer-related death in the United States, and metastatic behavior is largely responsible for this mortality. Mutations in multiple 'driver' oncogenes and tumor suppressors are known to contribute to the lung tumorigenesis and in some cases represent therapeutic targets. Leucine Zipper Transcription Factor-like 1 (LZTFL1) is located in the chromosome region 3p21.3 where allelic loss and genetic alterations occur early and frequently in lung cancers. Previously, we found that LZTFL1 is downregulated in epithelial tumors, including lung cancer, and functions as a tumor suppressor in gastric cancers. However, the functional role of LZTFL1 in lung oncogenesis is undefined. We show here that downregulation of LZTFL1 expression in non-small cell lung cancer is associated with recurrence and poor survival, whereas re-expression of LZTFL1 in lung tumor cells inhibited extravasation/colonization of circulating tumor cells to the lung and inhibited tumor growth in vivo. Mechanistically, we found that LZTFL1 is expressed in ciliated human bronchial epithelial cells (HBECs) and its expression correlates with HBEC differentiation. LZTFL1 inhibits transforming growth factor beta-activated mitogen-activated protein kinase and hedgehog signaling. Alteration of intracellular levels of LZTFL1 resulted in changes of expression of genes associated with epithelial-to-mesenchymal transition (EMT). We conclude that LZTFL1 inhibits lung tumorigenesis, possibly by maintaining epithelial cell differentiation and/or inhibition of signalings that lead to EMT and suggest that reactivation of LZTFL1 expression in tumor cells may be a novel lung cancer therapeutic approach.	[Wei, Q.; Chen, Z-H; Wang, L.; Zhang, T.; Duan, L.; Minna, J. D.; Liu, Z. P.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, 6000 Harry Hines Blvd, Dallas, TX 75235 USA; [Wei, Q.] Zhejiang Univ, Sir Run Run Shaw Hosp Coll Med, Dept Surg Oncol, Hangzhou 310003, Zhejiang, Peoples R China; [Wei, Q.] Zhejiang Univ, Sir Run Run Shaw Hosp Coll Med, Inst Clin Med, Hangzhou 310003, Zhejiang, Peoples R China; [Chen, Z-H; Luo, J-H] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou 510275, Guangdong, Peoples R China; [Behrens, C.; Wistuba, I. I.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Behrens, C.; Wistuba, I. I.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Minna, J. D.; Gao, B.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; [Minna, J. D.; Gao, B.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75235 USA; [Liu, Z. P.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Zhejiang University; Zhejiang University; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Liu, ZP (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Internal Med, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.; Luo, JH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou 510275, Guangdong, Peoples R China.; Liu, ZP (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.	luojunh@mail.sysu.edu.cn; Zhi-Ping.Liu@UTsouthwestern.edu			NIHRO1; CPRIT-MIRA [RP120717-P1]; National Natural Science Foundation of China [81101581]; National Cancer Institute Specialized Program of Research Excellence in Lung Cancer Grant [P50CA70907]; Cancer Center Support Grant by National Cancer Institute of the National Institutes of Health [5P30CA142543]; NATIONAL CANCER INSTITUTE [P30CA142543, P50CA070907] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL109471] Funding Source: NIH RePORTER	NIHRO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT-MIRA; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Cancer Institute Specialized Program of Research Excellence in Lung Cancer Grant; Cancer Center Support Grant by National Cancer Institute of the National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work is supported by NIHRO1 and CPRIT-MIRA RP120717-P1 (to ZPL), National Natural Science Foundation of China No. 81101581 (to QW), National Cancer Institute Specialized Program of Research Excellence in Lung Cancer Grant P50CA70907 (to JDM) and Cancer Center Support Grant by the National Cancer Institute of the National Institutes of Health under award number 5P30CA142543.	Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509; Fortier AM, 2013, J BIOL CHEM, V288, P11555, DOI 10.1074/jbc.M112.428920; Gao X, 2013, P NATL ACAD SCI USA, V110, P9356, DOI 10.1073/pnas.1307589110; Gomperts BN, 2013, CANCER PREV RES, V6, P4, DOI 10.1158/1940-6207.CAPR-12-0470; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Huang YJ, 2009, CANCER RES, V69, P7529, DOI 10.1158/0008-5472.CAN-08-4382; Jia YF, 2015, ARCH TOXICOL, V89, P179, DOI 10.1007/s00204-014-1433-1; Kenny PM, 2008, J CLIN ONCOL, V26, P233, DOI 10.1200/JCO.2006.07.7230; Kiss H, 2001, GENOMICS, V73, P10, DOI 10.1006/geno.2000.6498; Kugler MC, 2015, AM J RESP CELL MOL, V52, P1, DOI 10.1165/rcmb.2014-0132TR; Look DC, 2001, AM J PATHOL, V159, P2055, DOI 10.1016/S0002-9440(10)63057-X; Maitah MY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016068; Mendoza A, 2010, J CLIN INVEST, V120, P2979, DOI 10.1172/JCI40252; Minna JD, 2002, CANCER J, V8, pS41; Nanjundan M, 2010, J THORAC ONCOL, V5, P1894, DOI 10.1097/JTO.0b013e3181f2a266; Pacheco-Pinedo EC, 2011, J CLIN INVEST, V121, P1935, DOI 10.1172/JCI44871; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Rock JR, 2011, ANNU REV CELL DEV BI, V27, P493, DOI 10.1146/annurev-cellbio-100109-104040; Sato M, 2012, RESPIROLOGY, V17, P1048, DOI 10.1111/j.1440-1843.2012.02173.x; Seo S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002358; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Uttamsingh S, 2008, ONCOGENE, V27, P2626, DOI 10.1038/sj.onc.1210915; Wang LB, 2014, J CANCER RES CLIN, V140, P1997, DOI 10.1007/s00432-014-1753-9; Watanabe H, 2014, J CLIN INVEST, V124, P1636, DOI 10.1172/JCI71545; Wei Q, 2010, CANCER RES, V70, P2942, DOI 10.1158/0008-5472.CAN-09-3826; Xiao Dakai, 2010, J Thorac Dis, V2, P154, DOI 10.3978/j.issn.2072-1439.2010.02.03.7; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903	31	27	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2655	2663		10.1038/onc.2015.328	http://dx.doi.org/10.1038/onc.2015.328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364604	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000376165700012
J	Yen, SY; Chen, SR; Hsieh, J; Li, YS; Chuang, SE; Chuang, HM; Huang, MH; Lin, SZ; Harn, HJ; Chiou, TW				Yen, S-Y; Chen, S-R; Hsieh, J.; Li, Y-S; Chuang, S-E; Chuang, H-M; Huang, M-H; Lin, S-Z; Harn, H-J; Chiou, T-W			Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; BREAST-CANCER METASTASIS; GLIOBLASTOMA-MULTIFORME; ANGELICA-SINENSIS; HUMAN GLIOMAS; IN-VITRO; BUTYLIDENEPHTHALIDE; GROWTH; CELLS; CHEMOTHERAPY	Glioblastoma multiforme (GBM) is the most common and aggressive brain tumour. The neoplasms are difficult to resect entirely because of their highly infiltration property and leading to the tumour edge is unclear. Gliadel wafer has been used as an intracerebral drug delivery system to eliminate the residual tumour. However, because of its local low concentration and short diffusion distance, patient survival improves non-significantly. Ax1 is an essential regulator in cancer metastasis and patient survival. In this study, we developed a controlled-release polyanhydride polymer loading a novel small molecule, n-butylidenephthalide (BP), which is not only increasing local drug concentration and extending its diffusion distance but also reducing tumour invasion, mediated by reducing Axl expression. First, we determined that BP inhibited the expression of Axl in a dose-and time-dependent manner and reduced the migratory and invasive capabilities of GBM cells. In addition, BP downregulated matrix metalloproteinase activity, which is involved in cancer cell invasion. Furthermore, we demonstrated that BP regulated Axl via the extracellular signal-regulated kinases pathway. Epithelial-to-mesenchymal transition (EMT) is related to epithelial cells in the invasive migratory mesenchymal cells that underlie cancer progression; we demonstrated that BP reduced the expression of EMT-related genes. Furthermore, we used the overexpression of Ax1 in GBM cells to prove that Axl is a crucial target in the inhibition of GBM EMT, migration and invasion. In an in vivo study, we demonstrated that BP inhibited tumour growth and suppressed Axl expression in a dose-dependent manner according to a subcutaneous tumour model. Most importantly, in an intracranial tumour model with BP wafer in situ treatment, we demonstrated that the BP wafer not only significantly increased the survival rate but also decreased Axl expression, and inhibited tumour invasion. These results contribute to the development of a BP wafer for a novel therapeutic strategy for treating GBM invasion and increasing survival in clinical subjects.	[Yen, S-Y; Chen, S-R; Li, Y-S; Chiou, T-W] Natl Dong Hwa Univ, Dept Life Sci, Grad Inst Biotechnol, 1,Sec 2,Da Hsueh Rd, Hualien 97401, Taiwan; [Hsieh, J.] Natl Taiwan Univ, Mol Med Program, Taipei 10764, Taiwan; [Chuang, S-E] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Chuang, H-M; Huang, M-H] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Lin, S-Z] China Med Univ, Grad Inst Immunol, Taichung, Taiwan; [Lin, S-Z] China Med Univ Hosp, Ctr Neuropsychiat, Taichung, Taiwan; [Lin, S-Z] China Med Univ, Beigang Hosp, Dept Neurosurg, Yunlin, Taiwan; [Harn, H-J] China Med Univ Hosp, Dept Pathol, 2 Yude Rd, Taichung 40447, Taiwan; [Chiou, T-W] China Med Univ, Dept Med, Taichung, Taiwan	National Dong Hwa University; National Taiwan University; National Health Research Institutes - Taiwan; National Chung Hsing University; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan	Chiou, TW (corresponding author), Natl Dong Hwa Univ, Dept Life Sci, Grad Inst Biotechnol, 1,Sec 2,Da Hsueh Rd, Hualien 97401, Taiwan.; Harn, HJ (corresponding author), China Med Univ Hosp, Dept Pathol, 2 Yude Rd, Taichung 40447, Taiwan.	duke_harn@yahoo.com.tw; twchiou@mail.ndhu.edu.tw	Lin, Shinn-Zong/AAX-2379-2020		Ministry of Science and Technology, Taiwan [MOST 103-2320-B-039-021-MY3, MOST 103-2221-E-259-035]; Ministry of Economic Affairs [102-EC-17-A-19-I1-0051]; Health and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (Taiwan) [MOHW104-TDU-B-212-124-002]; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]; CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Economic Affairs; Health and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (Taiwan); Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence; CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan	We are grateful to Shuang-En Chuang for sharing the plasmid of pcDNA3.0-Axl. This study was funded by the Ministry of Science and Technology, Taiwan (MOST 103-2320-B-039-021-MY3, MOST 103-2221-E-259-035), Ministry of Economic Affairs (102-EC-17-A-19-I1-0051), Health and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (MOHW104-TDU-B-212-124-002, Taiwan), Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002) and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan.	Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Bezbradica JS, 2009, NAT IMMUNOL, V10, P333, DOI 10.1038/ni.1713; BLACKLOCK JB, 1986, J NEUROSURG, V64, P284, DOI 10.3171/jns.1986.64.2.0284; DOMB AJ, 1987, J POLYM SCI POL CHEM, V25, P3373, DOI 10.1002/pola.1987.080251217; Elliott PJ, 1996, EXP NEUROL, V141, P214, DOI 10.1006/exnr.1996.0156; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Harn HJ CS, 2013, J PHARM PHARMACOL, V1, P36; Harn HJ, 2011, NEURO-ONCOLOGY, V13, P635, DOI 10.1093/neuonc/nor021; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Huang MH, 2014, TUMOR BIOL, V35, P4875, DOI 10.1007/s13277-014-1639-0; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; JELSMAN R, 1967, J NEUROSURG, V27, P388, DOI 10.3171/jns.1967.27.5.0388; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Lin PC, 2008, J NEUROCHEM, V106, P1017, DOI 10.1111/j.1471-4159.2008.05432.x; Lin PC, 2011, ANN SURG ONCOL, V18, P3514, DOI 10.1245/s10434-011-1644-0; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Pierce AM, 2014, BRAIN RES, V1542, P206, DOI 10.1016/j.brainres.2013.10.049; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Rajput S, 2013, MOL CANCER THER, V12, P1676, DOI 10.1158/1535-7163.MCT-12-1019; SHAPIRO WR, 1987, J NEUROSURG, V66, P313; Tsai NM, 2005, CLIN CANCER RES, V11, P3475, DOI 10.1158/1078-0432.CCR-04-1827; Tsai NM, 2006, J NEUROCHEM, V99, P1251, DOI 10.1111/j.1471-4159.2006.04151.x; Tsitlakidis A, 2010, J NEUROSURG, V112, P1020, DOI 10.3171/2009.7.JNS09758; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Verma A, 2011, MOL CANCER THER, V10, P1763, DOI 10.1158/1535-7163.MCT-11-0116; Volk-Draper L, 2014, CANCER RES, V74, P5421, DOI 10.1158/0008-5472.CAN-14-0067; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0	30	27	27	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2156	2165		10.1038/onc.2015.277	http://dx.doi.org/10.1038/onc.2015.277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26257061	hybrid, Green Published			2022-12-17	WOS:000374986000002
J	Zou, M; Baitei, EY; Al-Rijjal, RA; Parhar, RS; Al-Mohanna, FA; Kimura, S; Pritchard, C; Binessa, HA; Alzahrani, AS; Al-Khalaf, HH; Hawwari, A; Akhtar, M; Assiri, AM; Meyer, BF; Shi, Y				Zou, M.; Baitei, E. Y.; Al-Rijjal, R. A.; Parhar, R. S.; Al-Mohanna, F. A.; Kimura, S.; Pritchard, C.; Binessa, H. A.; Alzahrani, A. S.; Al-Khalaf, H. H.; Hawwari, A.; Akhtar, M.; Assiri, A. M.; Meyer, B. F.; Shi, Y.			TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; SERUM TSH; TRANSGENIC MICE; BRAF MUTATIONS; MOUSE MODEL; IN-VIVO; PTEN; CARCINOMA; CELLS; RAS	The BRAF(V600E) mutation is found in approximately 40% of papillary thyroid cancers (PTC). Mice with thyroid-specific expression of BRAF(V600E) (TPO-BRAF(V600E)) develop PTC rapidly with high levels of serum thyroid-stimulating hormone (TSH). It is unclear to what extent the elevated TSH contributes to tumor progression. To investigate the progression of BRAF(V600E)-induced PTC (BVE-PTC) under normal TSH, we transplanted BVE-PTC tumors subcutaneously into nude and TPO-Braf(WT) mice. Regression of the transplanted tumors was observed in both nude and TPO-Braf(WT) mice. They were surrounded by heavy lymphocyte infiltration and oncogene-induced senescence (OIS) was demonstrated by strong beta-gal staining and absence of Ki-67 expression. In contrast, BVE-PTC transplants continued to grow when transplanted into TPO-BRAF(V600E) mice. The expression of Trp53 was increased in tumor transplants undergoing OIS. Trp53 inactivation reversed OIS and enabled tumor transplants to grow in nude mice with characteristic cell morphology of anaplastic thyroid cancer (ATC). PTC-to-ATC transformation was also observed in primary BVE-PTC tumors. ATC cells derived from Trp53 knockout tumors had increased PI3K/AKT signaling and became resistant to BRAF(V600E) inhibitor PLX4720, which could be overcome by combined treatment of PI3K inhibitor LY294002 and PLX4720. In conclusion, BVE-PTC progression could be contained via p53-dependent OIS and TSH is a major disruptor of this balance. Simultaneous targeting of both MAPK and PI3K/AKT pathways offer a better therapeutic outcome against ATC. The current study reinforces the importance of rigorous control of serum TSH in PTC patients.	[Zou, M.; Baitei, E. Y.; Al-Rijjal, R. A.; Binessa, H. A.; Hawwari, A.; Meyer, B. F.; Shi, Y.] King Faisal Specialist Hosp & Res Ctr, Dept Genet, MBC 3,Takhassusi St,POB 3354, Riyadh 11211, Saudi Arabia; [Parhar, R. S.; Al-Mohanna, F. A.] King Faisal Specialist Hosp & Res Ctr, Dept Cell Biol, Riyadh 11211, Saudi Arabia; [Kimura, S.] NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; [Pritchard, C.] Univ Leicester, Dept Biochem, Lancaster Rd, Leicester LE1 7RH, Leics, England; [Alzahrani, A. S.] King Faisal Specialist Hosp & Res Ctr, Dept Med, POB 3354, Riyadh 11211, Saudi Arabia; [Al-Khalaf, H. H.] King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh 11211, Saudi Arabia; [Akhtar, M.] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, POB 3354, Riyadh 11211, Saudi Arabia; [Assiri, A. M.] King Faisal Specialist Hosp & Res Ctr, Dept Comparat Med, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Leicester; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Shi, Y (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Genet, MBC 3,Takhassusi St,POB 3354, Riyadh 11211, Saudi Arabia.	yufei@kfshrc.edu.sa	Shi, Yufei/ABG-5228-2020; Alkhalaf, Huda/Z-5701-2019; Hawwari, Abbas/L-1934-2019	Shi, Yufei/0000-0002-6999-0191; Hawwari, Abbas/0000-0001-9643-6500; Assiri, Abdullah/0000-0002-2753-5238; Assiri, Abdullah/0000-0002-5605-2876; Pritchard, Catrin/0000-0003-1859-4487	KACST [11-BIO1434-20]; Cancer Research UK [13083] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [ZIABC005522] Funding Source: NIH RePORTER	KACST; Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Mr Wilfredo Antiquera for excellent technical support. This study is supported by KACST grant 11-BIO1434-20.	Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Arciuch VGA, 2011, ONCOTARGET, V2, P1109, DOI 10.18632/oncotarget.380; Boelaert K, 2006, J CLIN ENDOCR METAB, V91, P4295, DOI 10.1210/jc.2006-0527; Boelaert K, 2009, ENDOCR-RELAT CANCER, V16, P1065, DOI 10.1677/ERC-09-0150; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Charles RP, 2014, MOL CANCER RES, V12, P979, DOI 10.1158/1541-7786.MCR-14-0158-T; Charles RP, 2011, CANCER RES, V71, P3863, DOI 10.1158/0008-5472.CAN-10-4463; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng JC, 2011, ONCOGENE, V30, P1020, DOI 10.1038/onc.2010.486; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005-2838; Durante C, 2007, J CLIN ENDOCR METAB, V92, P2840, DOI 10.1210/jc.2006-2707; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fiore E, 2010, ENDOCR-RELAT CANCER, V17, P231, DOI 10.1677/ERC-09-0251; Fiore E, 2009, ENDOCR-RELAT CANCER, V16, P1251, DOI 10.1677/ERC-09-0036; Fiore E, 2012, J CLIN ENDOCR METAB, V97, P1134, DOI 10.1210/jc.2011-2735; Franco AT, 2011, P NATL ACAD SCI USA, V108, P1615, DOI 10.1073/pnas.1015557108; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Fujisawa T, 2012, INT J CANCER, V131, P344, DOI 10.1002/ijc.26366; Hagemann T, 2007, MOL CANCER THER, V6, P1993, DOI 10.1158/1535-7163.MCT-07-0118; Haymart MR, 2009, CLIN ENDOCRINOL, V71, P434, DOI 10.1111/j.1365-2265.2008.03489.x; Hollenbeak CS, 2013, EUR J ENDOCRINOL, V168, P549, DOI 10.1530/EJE-12-0848; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Jonklaas J, 2008, THYROID, V18, P943, DOI 10.1089/thy.2008.0061; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Kollmar O, 2008, J SURG RES, V145, P295, DOI 10.1016/j.jss.2007.02.010; Kusakabe T, 2004, GENESIS, V39, P212, DOI 10.1002/gene.20043; Li XY, 2014, ONCOTARGET, V5, P788, DOI 10.18632/oncotarget.1772; Malaguarnera R, 2007, ENDOCR-RELAT CANCER, V14, P43, DOI 10.1677/erc.1.01223; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mazzaferri EL, 2001, J CLIN ENDOCR METAB, V86, P1447, DOI 10.1210/jc.86.4.1447; McFadden DG, 2014, P NATL ACAD SCI USA, V111, pE1600, DOI 10.1073/pnas.1404357111; Mercer K, 2005, CANCER RES, V65, P11493, DOI 10.1158/0008-5472.CAN-05-2211; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Natori T, 2002, BIOCHEM BIOPH RES CO, V297, P1058, DOI 10.1016/S0006-291X(02)02335-5; Romei C, 2008, ENDOCR-RELAT CANCER, V15, P511, DOI 10.1677/ERC-07-0130; Rosivatz E, 2006, ACS CHEM BIOL, V1, P780, DOI 10.1021/cb600352f; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shimamura M, 2013, ENDOCRINOLOGY, V154, P4423, DOI 10.1210/en.2013-1174; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vizioli MG, 2014, ONCOTARGET, V5, P8270, DOI 10.18632/oncotarget.2013; Vizioli MG, 2011, ENDOCR-RELAT CANCER, V18, P743, DOI 10.1530/ERC-11-0240; Wei S, 1999, CANCER RES, V59, P1539; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524; Yoshimura T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058791; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zou M, 2005, BRIT J CANCER, V93, P1277, DOI 10.1038/sj.bjc.6602856; Zou MJ, 2014, THYROID, V24, P1256, DOI 10.1089/thy.2013.0610	59	27	27	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1909	1918		10.1038/onc.2015.253	http://dx.doi.org/10.1038/onc.2015.253			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26477313	Green Accepted			2022-12-17	WOS:000374010300004
J	Fan, YH; Ding, J; Nguyen, S; Liu, XJ; Xu, G; Zhou, HY; Duan, NN; Yang, SM; Zern, MA; Wu, J				Fan, Y-H; Ding, J.; Nguyen, S.; Liu, X-J; Xu, G.; Zhou, H-Y; Duan, N-N; Yang, S-M; Zern, M. A.; Wu, J.			Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; GENE DELIVERY; TARGET GENES; MOUSE MODEL; PATHWAY; METASTASIS; MECHANISMS; COMPONENTS; LDE225	Hepatoma exhibits a series of heterogeneous subpopulations in its cell surface markers, tumorigenicity, invasion and metastatic capability. We previously demonstrated that the CD133(-)/EpCAM(-) hepatoma subpopulation was more metastatic than its counterpart; however, the controlling mechanisms are unexplored. The present study aimed to delineate the significance of aberrant hedgehog (Hh) signaling in the mediation of metastases. Fluorescence-activated cell sorting-enriched CD133(-)/EpCAM(-) (double negative, DN), Huh-7 cells underwent a transwell selection for metastatic cells (transwell-selected, TS). The TS cells displayed much greater metastatic activity as evidenced by an increased invasion rate, extremely upregulated expression of matrix metalloproteinase (MMP)-1/2/9 genes compared with DN and double-positive (DP) subpopulations. In contrast to DP cells, TS cells lost E-cadherin and were all vimentin-positive as shown by immunocytochemistry. There was a transitional increase in Gli-1/2 gene expression levels from DP, DN to TS subpopulations, which was consistent with elevated Gli-1/2 or Twist-1 protein levels in the nuclear fraction. Furthermore, truncated Gli-1 (tGli-1), which transactivates molecules involved in metastasis, was detected in the highly invasive Huh-7 cell subpopulation, but not in less metastatic hepatoma cells or normal hepatocytes. The enhanced metastatic features with increased expression of MMPs as well as the presence of twist and snail genes in TS Huh-7 cells were reversed by LDE225, a potent Smoothened antagonist. In conclusion, the highly metastatic capability of a unique TS subpopulation was highly attributed to significant epithelial-mesenchymal transition, enhanced Hh activity and aberrant occurrence of a tGli-1 variant, which appears to be responsible for the highly invasive behavior.	[Fan, Y-H; Nguyen, S.; Zern, M. A.; Wu, J.] Univ Calif Davis, Med Ctr, Div Gastroenterol & Hepatol, Dept Internal Med, Sacramento, CA 95817 USA; [Fan, Y-H; Yang, S-M] Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing, Peoples R China; [Ding, J.; Liu, X-J; Xu, G.; Zhou, H-Y; Duan, N-N; Wu, J.] Fudan Univ, Shanghai Med Coll, Key Lab Mol Virol, Shanghai 200032, Peoples R China; [Ding, J.] Shanghai Jingan Dist Cent Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Zern, M. A.; Wu, J.] Univ Calif Davis, Med Ctr, Inst Regenerat Cures, Sacramento, CA 95817 USA; [Wu, J.] Fudan Univ, Affiliated Zhongshan Hosp, Shanghai Inst Liver Dis, Shanghai 200032, Peoples R China; [Wu, J.] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA	University of California System; University of California Davis; Army Medical University; Fudan University; University of California System; University of California Davis; Fudan University; University of California System; University of California Davis	Wu, J (corresponding author), Fudan Univ, Shanghai Med Coll, Key Lab Mol Virol, 138 Yixue Yuan Rd,POB 228, Shanghai 200032, Peoples R China.	jdwu@ucdavis.edu	Liu, Xuejing/AAB-5617-2022; Wu, Jian/AAU-5221-2020	Wu, Jian/0000-0001-9933-7364; Zou, Haoyu/0000-0003-0778-4920; Ding, Jia/0000-0002-7391-8520	Natural Science Foundation of China [81272436]; California Institute of Regenerative Medicine [TR0-01857]; China Scholarship Council Award [201207610003]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); California Institute of Regenerative Medicine(California Institute for Regenerative Medicine); China Scholarship Council Award(China Scholarship Council)	This study is partially supported by the Natural Science Foundation of China to Dr Jian Wu (#81272436). Dr Mark A Zern was supported by the California Institute of Regenerative Medicine (#TR0-01857). Ya-Han Fan is the recipient of China Scholarship Council Award (201207610003). The authors are grateful to Bridget McLaughlin for her technical support in the FACS enrichment of hepatoma cell subpopulations at the UC Davis Flow Cytometry Shared Resource, and to Mrs Shu-Hui Sun from Fudan University Shanghai Medical College for her technical assistance in flow cytometric analysis. The abstract of this work was presented in the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, USA, 1-5 November 2013, and published in Hepatology (2013;59:1081A).	Adkins Y, 2013, LAB INVEST, V93, P1313, DOI 10.1038/labinvest.2013.123; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Cabarcas SM, 2011, INT J CANCER, V129, P2315, DOI 10.1002/ijc.26312; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Chen XL, 2010, ARCH MED RES, V41, P315, DOI 10.1016/j.arcmed.2010.06.003; Chen XL, 2011, J HEPATOL, V55, P838, DOI 10.1016/j.jhep.2010.12.043; Chen XL, 2011, TRANSPLANTATION, V91, P293, DOI 10.1097/TP.0b013e318204756c; Eichenmuller M, 2009, HEPATOLOGY, V49, P482, DOI 10.1002/hep.22649; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Fendrich V, 2011, ANN SURG, V254, P818, DOI 10.1097/SLA.0b013e318236bc0f; Fouzas I, 2008, TRANSPL P, V40, P3806, DOI 10.1016/j.transproceed.2008.09.050; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570; Katoh Y, 2008, INT J MOL MED, V22, P271, DOI 10.3892/ijmm_00000019; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Lin TL, 2012, ONCOTARGETS THER, V5, P47, DOI 10.2147/OTT.S21957; Lingala S, 2010, EXP MOL PATHOL, V89, P27, DOI 10.1016/j.yexmp.2010.05.005; Liu L, 2003, GENE THER, V10, P180, DOI 10.1038/sj.gt.3301861; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; McNeill B, 2012, MOL CELL NEUROSCI, V49, P333, DOI 10.1016/j.mcn.2011.12.008; NICOLSON GL, 1984, CANCER METAST REV, V3, P25, DOI 10.1007/BF00047691; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Philips GM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023943; Price John T, 2002, Expert Opin Ther Targets, V6, P217; Riedlinger D, 2014, J HEPATO-BIL-PAN SCI, V21, P607, DOI 10.1002/jhbp.107; Rodon J, 2014, CLIN CANCER RES, V20, P1900, DOI 10.1158/1078-0432.CCR-13-1710; Ruiz I, 2007, TRENDS CELL BIOL, V17, P438, DOI DOI 10.1016/J.TCB.2007.06.007; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki K, 2014, WORLD J SURG, V38, P1147, DOI 10.1007/s00268-013-2374-1; Shimokawa T, 2008, J BIOL CHEM, V283, P14345, DOI 10.1074/jbc.M800299200; Steg AD, 2012, MOL CANCER THER, V11, P1587, DOI 10.1158/1535-7163.MCT-11-1058; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05; Wege H, 2003, GASTROENTEROLOGY, V124, P432, DOI 10.1053/gast.2003.50064; Wu J, 2004, HEPATOLOGY, V40, P195, DOI 10.1002/hep.20288; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2009, HEPATOLOGY, V50, P1464, DOI 10.1002/hep.23221; You N, 2012, ONCOL REP, V28, P2091, DOI 10.3892/or.2012.2035	39	27	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					116	124		10.1038/onc.2015.67	http://dx.doi.org/10.1038/onc.2015.67			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25772244	Green Published			2022-12-17	WOS:000367812400011
J	Roeser, JC; Leach, SD; McAllister, F				Roeser, J. C.; Leach, S. D.; McAllister, F.			Emerging strategies for cancer immunoprevention	ONCOGENE			English	Review							REGULATORY T-CELLS; ALPHA-GALACTOSYLCERAMIDE KRN7000; HEPATITIS-B VACCINATION; SMALL INTERFERING RNA; SUPPRESSOR-CELLS; BREAST-CANCER; MAST-CELLS; NATURAL-KILLER; TUMOR-GROWTH; TRANSCRIPTION FACTOR	The crucial role of the immune system in the formation and progression of tumors has been widely accepted. On one hand, the surveillance role of the immune system plays an important role in endogenous tumor prevention, but on the other hand, in some special circumstances such as in chronic inflammation, the immune system can actually contribute to the formation and progression of tumors. In recent years, there has been an explosion of novel targeted immunotherapies for advanced cancers. In the present manuscript, we explore known and potential various types of cancer prevention strategies and focus on nonvaccine-based cancer preventive strategies targeting the immune system at the early stages of tumorigenesis.	[Roeser, J. C.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA; [Leach, S. D.] Mem Sloan Kettering Canc Ctr, David M Rubenstein Ctr Pancreat Canc Res, New York, NY 10021 USA; [McAllister, F.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA	Johns Hopkins University; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center	McAllister, F (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holcombe, Houston, TX 77030 USA.	fmcallister@mdanderson.org			Pancreatic Cancer Action Network-AACR Career Development Award [14-20-25-MCAL]; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA134292] Funding Source: NIH RePORTER	Pancreatic Cancer Action Network-AACR Career Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by 2014 Pancreatic Cancer Action Network-AACR Career Development Award, grant 14-20-25-MCAL.	Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652; Bar-Natan Michal, 2012, JAKSTAT, V1, P55, DOI 10.4161/jkst.20006; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Becker JC, 2013, CANCER IMMUNOL IMMUN, V62, P1137, DOI 10.1007/s00262-013-1434-6; Blank CU, 2015, INT IMMUNOL, V27, P3, DOI 10.1093/intimm/dxu076; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CDC, VACC INF STAT HPV HU; Chae WJ, 2010, P NATL ACAD SCI USA, V107, P5540, DOI 10.1073/pnas.0912675107; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chang YJ, 2007, P NATL ACAD SCI USA, V104, P10299, DOI 10.1073/pnas.0703824104; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Ciric B, 2009, J IMMUNOL, V182, P5296, DOI 10.4049/jimmunol.0900036; Cuff S, 2010, J IMMUNOL, V184, P607, DOI 10.4049/jimmunol.0804089; Darrasse-Jeze G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00292; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Do JS, 2010, J IMMUNOL, V184, P1675, DOI 10.4049/jimmunol.0903539; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Dwyer MP, 2006, J MED CHEM, V49, P7603, DOI 10.1021/jm0609622; Fagard Remi, 2013, JAKSTAT, V2, pe22882, DOI 10.4161/jkst.22882; Filipazzi P, 2012, CANCER IMMUNOL IMMUN, V61, P255, DOI 10.1007/s00262-011-1161-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Frank DA, 2007, CANCER LETT, V251, P199, DOI 10.1016/j.canlet.2006.10.017; Fuji N, 2000, CLIN CANCER RES, V6, P3380; FUJIMOTO S, 1975, IMMUNOL COMMUN, V4, P201, DOI 10.3109/08820137409055774; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Ghebeh H, 2006, NEOPLASIA, V8, P190, DOI 10.1593/neo.05733; Giaccone G, 2002, CLIN CANCER RES, V8, P3702; Gogas H, 2006, NEW ENGL J MED, V354, P709, DOI 10.1056/NEJMoa053007; Gonsiorek W, 2007, J PHARMACOL EXP THER, V322, P477, DOI 10.1124/jpet.106.118927; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; GRESSER I, 1990, J INVEST DERMATOL, V95, pS66, DOI 10.1111/1523-1747.ep12874776; Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003; Greten TF, 2010, J IMMUNOTHER, V33, P211, DOI 10.1097/CJI.0b013e3181bb499f; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Gu FM, 2011, WORLD J GASTROENTERO, V17, P3922, DOI 10.3748/wjg.v17.i34.3922; Gu-Trantien C, 2013, J CLIN INVEST, V123, P2873, DOI 10.1172/JCI67428; Gwack J, 2011, ASIAN PAC J CANCER P, V12, P2205; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Harvey RD, 2014, CLIN PHARMACOL THER, V96, P214, DOI 10.1038/clpt.2014.74; Hegmans JPJJ, 2014, CURR OPIN PHARMACOL, V17, P17, DOI 10.1016/j.coph.2014.06.007; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hemdan NYA, 2013, IMMUNOL LETT, V149, P123, DOI 10.1016/j.imlet.2012.11.002; Hino R, 2010, CANCER-AM CANCER SOC, V116, P1757, DOI 10.1002/cncr.24899; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Horiguchi A, 2010, BRIT J CANCER, V102, P1592, DOI 10.1038/sj.bjc.6605691; Huang B, 2008, BLOOD, V112, P1269, DOI 10.1182/blood-2008-03-147033; Huang C, 2011, WORLD J GASTROENTERO, V17, P2992, DOI 10.3748/wjg.v17.i25.2992; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Hyun YS, 2012, CARCINOGENESIS, V33, P931, DOI 10.1093/carcin/bgs106; Iwai Y, 2005, INT IMMUNOL, V17, P133, DOI 10.1093/intimm/dxh194; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Johansson A, 2010, AM J PATHOL, V177, P1031, DOI 10.2353/ajpath.2010.100070; Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776; Kilinc MO, 2009, J IMMUNOL, V182, P4217, DOI 10.4049/jimmunol.0802793; Kim YJ, 2010, CANCER PREV RES, V3, P1314, DOI 10.1158/1940-6207.CAPR-09-0272; Kirchberger S, 2013, J EXP MED, V210, P917, DOI 10.1084/jem.20122308; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010; Kurzrock R, 2013, CLIN CANCER RES, V19, P3659, DOI 10.1158/1078-0432.CCR-12-3349; Kusmartsev S, 2004, J IMMUNOL, V172, P989, DOI 10.4049/jimmunol.172.2.989; Ladoire S, 2008, CLIN CANCER RES, V14, P2413, DOI 10.1158/1078-0432.CCR-07-4491; Lai GF, 2008, BIOORG MED CHEM LETT, V18, P1864, DOI 10.1016/j.bmcl.2008.02.010; Lazarevic V, 2013, NAT REV IMMUNOL, V13, P777, DOI 10.1038/nri3536; Lebwohl M, 2012, NEW ENGL J MED, V366, P1010, DOI 10.1056/NEJMoa1111170; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Lewis AM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-48; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Lust JA, 2009, MAYO CLIN PROC, V84, P114, DOI 10.4065/84.2.114; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Markowitz J, 2013, BREAST CANCER RES TR, V140, P13, DOI 10.1007/s10549-013-2618-7; Martin-Orozco N, 2009, CURR OPIN INVEST DR, V10, P543; McAllister F, 2014, CANCER CELL, V25, P621, DOI 10.1016/j.ccr.2014.03.014; McCleland BW, 2007, BIOORG MED CHEM LETT, V17, P1713, DOI 10.1016/j.bmcl.2006.12.067; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; Melillo RM, 2010, ONCOGENE, V29, P6203, DOI 10.1038/onc.2010.348; Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024; Mian BM, 2003, CLIN CANCER RES, V9, P3167; Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794; Mitsunaga S, 2013, BRIT J CANCER, V108, P2063, DOI 10.1038/bjc.2013.174; Molling JW, 2007, J CLIN ONCOL, V25, P862, DOI 10.1200/JCO.2006.08.5787; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Mundy-Bosse BL, 2011, CANCER IMMUNOL IMMUN, V60, P1269, DOI 10.1007/s00262-011-1029-z; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Murdaca G, 2015, EXPERT OPIN DRUG SAF, V14, P571, DOI 10.1517/14740338.2015.1009036; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Murugaiyan G, 2009, J IMMUNOL, V183, P4169, DOI 10.4049/jimmunol.0901017; Najjar YG, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00049; Nakanishi Y, 2011, CARCINOGENESIS, V32, P1333, DOI 10.1093/carcin/bgr128; Nam JS, 2008, CANCER RES, V68, P3915, DOI 10.1158/0008-5472.CAN-08-0206; NANUS DM, 1990, CANCER RES, V50, P4190; Ning Y, 2012, MOL CANCER THER, V11, P1353, DOI 10.1158/1535-7163.MCT-11-0915; Nishimoto N, 2005, BLOOD, V106, P2627, DOI 10.1182/blood-2004-12-4602; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Nowell MA, 2009, J IMMUNOL, V182, P613, DOI 10.4049/jimmunol.182.1.613; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078-0432.CCR-06-2197; Oka T, 2012, LAB INVEST, V92, P1472, DOI 10.1038/labinvest.2012.116; Okazaki T, 2006, TRENDS IMMUNOL, V27, P195, DOI 10.1016/j.it.2006.02.001; Okudaira K, 2009, INT J ONCOL, V35, P741, DOI 10.3892/ijo_00000387; Olive KP, 2006, CLIN CANCER RES, V12, P5277, DOI 10.1158/1078-0432.CCR-06-0436; Onizuka S, 1999, CANCER RES, V59, P3128; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Pardoll DM, 2012, NAT IMMUNOL, V13, P1129, DOI 10.1038/ni.2392; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patterson SL, 2013, CLIN CHEM, V59, P94, DOI 10.1373/clinchem.2012.185389; Pentcheva-Hoang T, 2014, CANCER IMMUNOL RES, V2, P970, DOI 10.1158/2326-6066.CIR-14-0104; Phillips RKS, 2002, GUT, V50, P857, DOI 10.1136/gut.50.6.857; PORTIER M, 1993, BRIT J HAEMATOL, V85, P514; Rabenhorst A, 2012, BLOOD, V120, P2042, DOI 10.1182/blood-2012-03-415638; Rachitskaya AV, 2008, J IMMUNOL, V180, P5167, DOI 10.4049/jimmunol.180.8.5167; Ribas A, 2013, J CLIN ONCOL, V31, P616, DOI 10.1200/JCO.2012.44.6112; Rizza P, 2010, AUTOIMMUNITY, V43, P204, DOI 10.3109/08916930903510880; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schlessinger K, 2005, CANCER RES, V65, P5828, DOI 10.1158/0008-5472.CAN-05-0317; Sen M, 2012, CANCER DISCOV, V2, P694, DOI 10.1158/2159-8290.CD-12-0191; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma RK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073145; SHEIL AGR, 1986, WORLD J SURG, V10, P389; Shields JD, 2010, SCIENCE, V328, P749, DOI 10.1126/science.1185837; Shimizu J, 1999, J IMMUNOL, V163, P5211; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Solomon SD, 2006, CIRCULATION, V114, P1028, DOI 10.1161/CIRCULATIONAHA.106.636746; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; SPRATT JS, 1981, J SURG ONCOL, V18, P219, DOI 10.1002/jso.2930180302; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Steinberg G, 2000, J UROLOGY, V163, P761, DOI 10.1016/S0022-5347(05)67799-3; STUTMAN O, 1974, SCIENCE, V183, P534, DOI 10.1126/science.183.4124.534; Sun M, 2010, NAT REV UROL, V7, P327, DOI 10.1038/nrurol.2010.57; Sylvester RJ, 2011, INT J UROL, V18, P113, DOI 10.1111/j.1442-2042.2010.02678.x; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tachibana T, 2005, CLIN CANCER RES, V11, P7322, DOI 10.1158/1078-0432.CCR-05-0877; Teng MWL, 2008, J LEUKOCYTE BIOL, V84, P988, DOI 10.1189/jlb.1107774; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; vandenBroek MF, 1996, J EXP MED, V184, P1781, DOI 10.1084/jem.184.5.1781; Vicari AP, 2002, SEMIN CANCER BIOL, V12, P33, DOI 10.1006/scbi.2001.0400; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wagsater D, 2006, ANTICANCER RES, V26, P4213; Walker LSK, 2011, NAT REV IMMUNOL, V11, P852, DOI 10.1038/nri3108; Walters I, 2008, BIOORG MED CHEM LETT, V18, P798, DOI 10.1016/j.bmcl.2007.11.039; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wasiuk A, 2012, CANCER IMMUNOL IMMUN, V61, P2273, DOI 10.1007/s00262-012-1276-7; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Wilcox RA, 2012, EUR J HAEMATOL, V88, P465, DOI 10.1111/j.1600-0609.2012.01766.x; Winters MP, 2008, BIOORG MED CHEM LETT, V18, P1926, DOI 10.1016/j.bmcl.2008.01.127; Wojno EDT, 2012, CELL HOST MICROBE, V12, P445, DOI 10.1016/j.chom.2012.10.003; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Yang ZS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008922; Yao C, 2007, INT J CANCER, V121, P1949, DOI 10.1002/ijc.22930; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZEID NA, 1993, PATHOLOGY, V25, P338, DOI 10.3109/00313029309090853; Zhang YQ, 2013, CANCER RES, V73, P6359, DOI 10.1158/0008-5472.CAN-13-1558-T; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	189	27	28	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6029	6039		10.1038/onc.2015.98	http://dx.doi.org/10.1038/onc.2015.98			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	26364615				2022-12-17	WOS:000366113800001
J	Komatsu, N; Fujita, Y; Matsuda, M; Aoki, K				Komatsu, N.; Fujita, Y.; Matsuda, M.; Aoki, K.			mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells	ONCOGENE			English	Article							RAS; ACTIVATION; KINASE; ADDICTION; PATHWAYS; SENSITIVITY; EFFICACY; 3-KINASE; COMPLEX	Cancer cells harboring oncogenic BRaf mutants, but not oncogenic KRas mutants, are sensitive to MEK inhibitors (MEKi). The mechanism underlying the intrinsic resistance to MEKi in KRas-mutant cells is under intensive investigation. Here, we pursued this mechanism by live imaging of extracellular signal-regulated kinases (ERK) and mammalian target of rapamycin complex 1 (mTORC1) activities in oncogenic KRas or BRaf-mutant cancer cells. We established eight cancer cell lines expressing Forster resonance energy transfer (FRET) biosensors for ERK activity and S6K activity, which was used as a surrogate marker for mTORC1 activity. Under increasing concentrations of MEKi, ERK activity correlated linearly with the cell growth rate in BRaf-mutant cancer cells, but not KRas-mutant cancer cells. The administration of PI3K inhibitors resulted in a linear correlation between ERK activity and cell growth rate in KRas-mutant cancer cells. Intriguingly, mTORC1 activity was correlated linearly with the cell growth rate in both BRaf-mutant cancer cells and KRas-mutant cancer cells. These observations suggested that mTORC1 activity had a pivotal role in cell growth and that the mTORC1 activity was maintained primarily by the ERK pathway in BRaf-mutant cancer cells and by both the ERK and PI3K pathways in KRas-mutant cancer cells. FRET imaging revealed that MEKi inhibited mTORC1 activity with slow kinetics, implying transcriptional control of mTORC1 activity by ERK. In agreement with this observation, MEKi induced the expression of negative regulators of mTORC1, including TSC1, TSC2 and Deptor, which occurred more significantly in BRaf-mutant cells than in KRas-mutant cells. These findings suggested that the suppression of mTORC1 activity and induction of negative regulators of mTORC1 in cancer cells treated for at least 1 day could be used as surrogate markers for the MEKi sensitivity of cancer cells.	[Komatsu, N.; Matsuda, M.] Kyoto Univ, Lab Bioimaging & Cell Signaling, Grad Sch Biostudies, Kyoto 6068501, Japan; [Fujita, Y.; Matsuda, M.] Kyoto Univ, Dept Pathol & Biol Dis, Grad Sch Med, Kyoto 6068501, Japan; [Aoki, K.] Kyoto Univ, Imaging Platform Spatio Temporal Informat, Grad Sch Med, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Kyoto University	Aoki, K (corresponding author), Kyoto Univ, Imaging Platform Spatio Temporal Informat, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	k-aoki@lif.kyoto-u.ac.jp	Aoki, Kazuhiro/I-5483-2019; Aoki, Kazuhiro/B-5777-2013	Aoki, Kazuhiro/0000-0001-7263-1555; Aoki, Kazuhiro/0000-0001-7263-1555; Matsuda, Michiyuki/0000-0002-5876-9969; Fujita, Yoshihisa/0000-0002-5086-8188	Research Program of Innovative Cell Biology by Innovative Technology (the 'Cell Innovation' Program); Platform for Dynamic Approaches to Living System from the Ministry of Education, Culture, Sports and Science, Japan;  [23701052]; Grants-in-Aid for Scientific Research [23701052, 26290053] Funding Source: KAKEN	Research Program of Innovative Cell Biology by Innovative Technology (the 'Cell Innovation' Program); Platform for Dynamic Approaches to Living System from the Ministry of Education, Culture, Sports and Science, Japan; ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to the members of the Matsuda Laboratory for their helpful input. Y Inaoka, K Hirano, A Katsumata, N Nishimoto, N Nonaka and A Kawagishi are also to be thanked for their technical assistance. KA and MM were supported by the Research Program of Innovative Cell Biology by Innovative Technology (the 'Cell Innovation' Program) and Platform for Dynamic Approaches to Living System from the Ministry of Education, Culture, Sports and Science, Japan. KA was supported by a Grant-in-Aid for Young Scientists (B) (23701052) and a Grant-in-Aid for Scientific Research (B). NK and YF were supported by a Grant-in-Aid for JSPS Fellows.	Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Aoki K, 2013, MOL CELL, V52, P529, DOI 10.1016/j.molcel.2013.09.015; Aoki K, 2009, NAT PROTOC, V4, P1623, DOI 10.1038/nprot.2009.175; Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483; Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046; Corcoran RB, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005753; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Friday BB, 2008, CANCER RES, V68, P6145, DOI 10.1158/0008-5472.CAN-08-1430; Fujita Y, 2014, FEBS J, V281, P3177, DOI 10.1111/febs.12852; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Kawakami K, 2004, GENETICS, V166, P895, DOI 10.1534/genetics.166.2.895; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Klinger B, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.29; Komatsu N, 2011, MOL BIOL CELL, V22, P4647, DOI 10.1091/mbc.E11-01-0072; LoRusso P, 2012, J CLIN ONCOL, P30; LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Neuzillet C, 2014, PHARMACOL THERAPEUT, V141, P160, DOI 10.1016/j.pharmthera.2013.10.001; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rebucci M, 2013, BIOCHEM PHARMACOL, V85, P1219, DOI 10.1016/j.bcp.2013.02.017; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sos ML, 2009, P NATL ACAD SCI USA, V106, P18351, DOI 10.1073/pnas.0907325106; Speranza G, 2012, J CLIN ONCOL, P30; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yusa K, 2009, NAT METHODS, V6, P363, DOI [10.1038/NMETH.1323, 10.1038/nmeth.1323]	40	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5607	5616		10.1038/onc.2015.16	http://dx.doi.org/10.1038/onc.2015.16			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25703330	Green Submitted			2022-12-17	WOS:000364594300002
J	Xi, S; Inchauste, S; Guo, H; Shan, J; Xiao, Z; Xu, H; Miettenen, M; Zhang, MR; Hong, JA; Raiji, MT; Altorki, NK; Casson, AG; Beer, DG; Robles, AI; Bowman, ED; Harris, CC; Steinberg, SM; Schrump, DS				Xi, S.; Inchauste, S.; Guo, H.; Shan, J.; Xiao, Z.; Xu, H.; Miettenen, M.; Zhang, M. R.; Hong, J. A.; Raiji, M. T.; Altorki, N. K.; Casson, A. G.; Beer, D. G.; Robles, A. I.; Bowman, E. D.; Harris, C. C.; Steinberg, S. M.; Schrump, D. S.			Cigarette smoke mediates epigenetic repression of miR-217 during esophageal adenocarcinogenesis	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; LINEAGE PROGRESSION; MICRORNA EXPRESSION; BARRETTS-ESOPHAGUS; CARCINOMA-CELLS; CANCER; PATHOGENESIS; INVASION; OVEREXPRESSION; KALLIKREIN-7	Although microRNAs (miRs) have been implicated in the pathogenesis of various human malignancies, limited information is available regarding mechanisms by which these noncoding RNAs contribute to initiation and progression of tobacco-induced esophageal cancers. In this study, array and quantitative reverse transcriptase-PCR techniques were used to examine miR expression in immortalized esophageal epithelia (IEE) and esophageal adenocarcinoma (EAC) cells cultured in normal media with or without cigarette smoke condensate (CSC). Under relevant exposure conditions, CSC significantly decreased miR-217 expression in these cells. Endogenous levels of miR-217 expression in cultured EAC cells (EACC)/primary EACs were significantly lower than those observed in IEE/paired normal esophageal tissues. RNA crosslink immunoprecipitation, quantitative reverse transcriptase-PCR (qRT-PCR) and immunoblot experiments demonstrated direct interaction of miR-217 with kallikrein 7 (KLK7), encoding a putative oncogene not previously implicated in EAC. Repression of miR-217 correlated with increased levels of KLK7 in primary EACs, particularly those from smokers. Chromatin and methylated DNA immunoprecipitation experiments demonstrated that CSC-mediated repression of miR-217 coincided with DNMT3b-dependent hypermethylation and decreased occupancy of nuclear factor 1 within the miR-217 genomic locus. Deoxyazacytidine induced miR-217 expression and downregulated KLK7 in EACC; deoxyazacytidine also attenuated CSC-mediated miR-217 repression and upregulation of KLK7 in IEE and EACC. Overexpression of miR-217 significantly decreased, whereas overexpression of KLK7 increased proliferation, invasion and tumorigenicity of EACC. Collectively, these data demonstrate that epigenetic repression of miR-217 contributes to the pathogenesis of EAC via upregulation of KLK7 and suggest that restoration of miR-217 expression may be a novel treatment strategy for these malignancies.	[Xi, S.; Inchauste, S.; Zhang, M. R.; Hong, J. A.; Raiji, M. T.; Schrump, D. S.] NCI, Thorac Surg Sect, Thorac & GI Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Guo, H.] Shandong Tumor Hosp & Inst, Gastrointestinal Surg, Jinan, Shandong, Peoples R China; [Shan, J.] NCI, Adv Biomed Comp Ctr, SAIC Frederick, Frederick, MD 21701 USA; [Xiao, Z.] NCI, Canc & Inflammat Lab, Frederick, MD 21701 USA; [Xu, H.] NCI, Lab Canc Prevent, Frederick, MD 21701 USA; [Miettenen, M.] NCI, Pathol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Altorki, N. K.] Weill Cornell Univ, Med Ctr, Dept Thorac Surg, New York, NY USA; [Casson, A. G.] Univ Saskatchewan, Dept Surg, Saskatoon, SK, Canada; [Beer, D. G.] Univ Michigan, Sect Thorac Surg, Ann Arbor, MI 48109 USA; [Robles, A. I.; Bowman, E. D.; Harris, C. C.] NCI, Lab Human Carcinogenesis, Ctr Canc Res, Bethesda, MD 20892 USA; [Steinberg, S. M.] NCI, Biostat & Data Management Sect, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Shandong First Medical University & Shandong Academy of Medical Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; University of Saskatchewan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrump, DS (corresponding author), NCI, Thorac Surg Sect, Thorac & GI Oncol Branch, Ctr Canc Res, Bldg 10,Room 4-3942,10 Ctr Dr, Bethesda, MD 20892 USA.	David_Schrump@nih.gov		Robles, Ana/0000-0001-5019-4374	NIH intramural funding; Stephen J. Solarz Memorial Fund; NATIONAL CANCER INSTITUTE [ZIABC011492, ZIABC011115, Z01BC005480] Funding Source: NIH RePORTER	NIH intramural funding(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stephen J. Solarz Memorial Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ms Jan Pappas for assistance with manuscript preparation. This study was supported by NIH intramural funding and the Stephen J. Solarz Memorial Fund.	Agrawal N, 2012, CANCER DISCOV, V2, P899, DOI 10.1158/2159-8290.CD-12-0189; [Anonymous], 2013, CURR PROB SURG, V50, P192, DOI 10.1067/j.cpsurg.2013.01.004; Carr Jacquelyn S, 2013, J Gastrointest Cancer, V44, P143, DOI 10.1007/s12029-013-9480-z; Cook MB, 2010, JNCI-J NATL CANCER I, V102, P1344, DOI 10.1093/jnci/djq289; David S, 2011, CURR OPIN PHARMACOL, V11, P612, DOI 10.1016/j.coph.2011.09.006; Devetzi M, 2013, THROMB HAEMOSTASIS, V109, P716, DOI 10.1160/TH12-07-0518; Diaz-Lopez A, 2014, CANCER MANAG RES, V6, P205, DOI 10.2147/CMAR.S38156; Dong Y, 2010, CANCER RES, V70, P2624, DOI 10.1158/0008-5472.CAN-09-3415; Dulak AM, 2012, CANCER RES, V72, P4383, DOI 10.1158/0008-5472.CAN-11-3893; Ek WE, 2013, JNCI-J NATL CANCER I, V105, P1711, DOI 10.1093/jnci/djt303; Fassan M, 2011, INT J CANCER, V129, P1661, DOI 10.1002/ijc.25823; Frankel A, 2014, GENE CHROMOSOME CANC, V53, P324, DOI 10.1002/gcc.22143; Grabowska MM, 2012, FRONT BIOSCI-LANDMRK, V17, P1948, DOI 10.2741/4031; Gu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081032; Hardikar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052192; Iakovlev V, 2012, CANCER EPIDEM BIOMAR, V21, P1135, DOI 10.1158/1055-9965.EPI-11-1079; Johnson SK, 2007, CANCER, V109, P1811, DOI 10.1002/cncr.22606; Kemp CD, 2012, CLIN CANCER RES, V18, P77, DOI 10.1158/1078-0432.CCR-11-0962; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Leidner RS, 2012, GENE CHROMOSOME CANC, V51, P473, DOI 10.1002/gcc.21934; Li H, 2013, NEOPLASMA, V60, P511, DOI 10.4149/neo_2013_066; Mathe EA, 2009, CLIN CANCER RES, V15, P6192, DOI 10.1158/1078-0432.CCR-09-1467; Mayne GC, 2013, CURR PHARM DESIGN, V19, P1211; Mo LJ, 2010, ANTICANCER RES, V30, P3413; Napier KJ, 2014, WORLD J GASTRO ONCOL, V6, P112, DOI 10.4251/wjgo.v6.i5.112; Nishioka C, 2014, CANCER SCI, V105, P297, DOI 10.1111/cas.12339; Prezas P, 2006, BIOL CHEM, V387, P807, DOI 10.1515/BC.2006.102; Prezas P, 2006, BIOL CHEM, V387, P1607, DOI 10.1515/BC.2006.200; Ramani VC, 2011, BBA-MOL CELL RES, V1813, P1525, DOI 10.1016/j.bbamcr.2011.05.007; Ramani VC, 2008, PANCREAS, V37, P399, DOI 10.1097/MPA.0b013e31817f76f7; Rao M, 2011, CANCER RES, V71, P4192, DOI 10.1158/0008-5472.CAN-10-2442; Shaw JLV, 2007, CLIN CHEM, V53, P1423, DOI 10.1373/clinchem.2007.088104; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Spechler SJ, 2013, JAMA-J AM MED ASSOC, V310, P627, DOI 10.1001/jama.2013.226450; Su J, 2014, MOL CELL BIOCHEM, V392, P289, DOI 10.1007/s11010-014-2039-x; Talieri M, 2009, THROMB HAEMOSTASIS, V101, P741, DOI 10.1160/TH08-07-0471; Tramacere I, 2011, EPIDEMIOLOGY, V22, P344, DOI 10.1097/EDE.0b013e31821092cd; Xi SC, 2013, J CLIN INVEST, V123, P1241, DOI 10.1172/JCI61271; Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764; Xu EP, 2013, CARCINOGENESIS, V34, P2750, DOI 10.1093/carcin/bgt286; Zhang Y, 2012, J BIOL CHEM, V287, P21926, DOI 10.1074/jbc.M112.340398; Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108; Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160	43	27	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5548	5559		10.1038/onc.2015.10	http://dx.doi.org/10.1038/onc.2015.10			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25703328	Green Accepted			2022-12-17	WOS:000364594000004
J	Kubic, JD; Little, EC; Lui, JW; Iizuka, T; Lang, D				Kubic, J. D.; Little, E. C.; Lui, J. W.; Iizuka, T.; Lang, D.			PAX3 and ETS1 synergistically activate MET expression in melanoma cells	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; DNA-BINDING MOTIF; C-MET; TRANSCRIPTION FACTOR; UP-REGULATION; RECEPTOR EXPRESSION; MELANOCYTIC LESIONS; MALIGNANT-MELANOMA; TERNARY COMPLEXES; TUMOR PROGRESSION	Melanoma is a highly aggressive disease that is difficult to treat owing to rapid tumor growth, apoptotic resistance and high metastatic potential. The MET proto-oncogene (MET) tyrosine kinase receptor promotes many of these cellular processes, but while MET is often overexpressed in melanoma, the mechanism driving this overexpression is unknown. As the MET gene is rarely mutated or amplified in melanoma, MET overexpression may be driven to increased activation through promoter elements. In this report, we find that transcription factors PAX3 and ETS1 directly interact to synergistically activate MET expression. Inhibition of PAX3 and ETS1 expression in melanoma cells leads to a significant reduction of MET receptor levels. The 300-bp 5' proximal MET promoter contains a PAX3 response element and two ETS1 consensus motifs. Although ETS1 can moderately activate both of these sites without cofactors, robust MET promoter activation of the first site is PAX dependent and requires the presence of PAX3, whereas the second site is PAX independent. The induction of MET by ETS1 via this second site is enhanced by hepatocyte growth factor-dependent ETS1 activation, thereby MET indirectly promotes its own expression. We further find that expression of a dominant-negative ETS1 reduces the ability of melanoma cells to grow both in culture and in vivo. Thus, we discover a pathway where ETS1 advances melanoma through the expression of MET via PAX-dependent and -independent mechanisms.	[Kubic, J. D.; Little, E. C.; Lui, J. W.; Iizuka, T.; Lang, D.] Univ Chicago, Dept Med, Dermatol Sect, Chicago, IL 60637 USA	University of Chicago	Lang, D (corresponding author), Univ Chicago, Dept Med, Dermatol Sect, 5841 South Maryland Ave,MC 5067,Room L536, Chicago, IL 60637 USA.	dlang@medicine.bsd.uchicago.edu		Lang, Deborah/0000-0003-1057-0923	University of Chicago Cancer Center Pilot program [P30-CA014599]; American Cancer Society [RSG-CSM-121505]; Friends of Dermatology-University of Chicago; Wendy Will Chase Foundation; National Institutes of Health [R01CA130202, R01AR062547]; NATIONAL CANCER INSTITUTE [P30CA014599, R01CA130202, R01CA184001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR062547] Funding Source: NIH RePORTER	University of Chicago Cancer Center Pilot program(University of Chicago); American Cancer Society(American Cancer Society); Friends of Dermatology-University of Chicago; Wendy Will Chase Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Drs Ravi Salgia, Eric Svensson and Jonathan Epstein for providing material and/or intellectual support for this project. This work was supported by grants and financial support from the University of Chicago Cancer Center Pilot program (P30-CA014599), American Cancer Society (RSG-CSM-121505), Friends of Dermatology-University of Chicago, The Wendy Will Chase Foundation and the National Institutes of Health (R01CA130202 and R01AR062547).	Beuret L, 2007, J BIOL CHEM, V282, P14140, DOI 10.1074/jbc.M611563200; Bonvin E, 2012, MOL CELL BIOL, V32, P4674, DOI 10.1128/MCB.01067-12; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Dong L, 2011, ONCOGENE, V30, P3716, DOI 10.1038/onc.2011.87; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FISHER RJ, 1991, ONCOGENE, V6, P2249; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Fitzsimmons D, 2009, J MOL BIOL, V392, P452, DOI 10.1016/j.jmb.2009.07.028; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; Gambarotta G, 1996, ONCOGENE, V13, P1911; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; He SJ, 2005, MOL CANCER THER, V4, P996, DOI 10.1158/1535-7163.MCT-04-0252; Holterman CE, 2010, CANCER RES, V70, P730, DOI 10.1158/0008-5472.CAN-09-2090; Horikawa T, 2001, AM J PATHOL, V159, P27, DOI 10.1016/S0002-9440(10)61669-0; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Keehn CA, 2003, MODERN PATHOL, V16, P772, DOI 10.1097/01.MP.0000082395.59356.4F; Kubic JD, 2008, PIGM CELL MELANOMA R, V21, P627, DOI 10.1111/j.1755-148X.2008.00514.x; Lang D, 2003, HUM MOL GENET, V12, P937, DOI 10.1093/hmg/ddg107; Liu F, 2013, J INVEST DERMATOL, V133, P2041, DOI 10.1038/jid.2013.32; Maier H, 2003, NUCLEIC ACIDS RES, V31, P5483, DOI 10.1093/nar/gkg785; Mascarenhas JB, 2010, PIGM CELL MELANOMA R, V23, P225, DOI 10.1111/j.1755-148X.2010.00667.x; Mattia G, 2011, PIGM CELL MELANOMA R, V24, P953, DOI 10.1111/j.1755-148X.2011.00881.x; McGill GG, 2006, J BIOL CHEM, V281, P10365, DOI 10.1074/jbc.M513094200; Medic S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009977; Nakano T, 2000, J CELL PHYSIOL, V184, P255, DOI 10.1002/1097-4652(200008)184:2<255::AID-JCP14>3.0.CO;2-J; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Pinner S, 2009, CANCER RES, V69, P7679; Plummer RS, 2008, MODERN PATHOL, V21, P525, DOI 10.1038/modpathol.3801019; Puri N, 2007, CLIN CANCER RES, V13, P2246, DOI 10.1158/1078-0432.CCR-06-0776; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; Saeki H, 2000, CANCER, V89, P1670, DOI 10.1002/1097-0142(20001015)89:8<1670::AID-CNCR4>3.0.CO;2-J; Sahin A, 2009, INT J ONCOL, V34, P377, DOI 10.3892/ijo_00000161; SAITOH K, 1994, J PATHOL, V174, P191, DOI 10.1002/path.1711740308; Sato T, 2007, J BIOL CHEM, V282, P27702, DOI 10.1074/jbc.M611862200; Scholl FA, 2001, CANCER RES, V61, P823; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Stella MC, 2005, MOL CELL BIOL, V25, P3982, DOI 10.1128/MCB.25.10.3982-3996.2005; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Tomita N, 2003, CIRCULATION, V107, P1411, DOI 10.1161/01.CIR.0000055331.41937.AA; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Wheat W, 1999, MOL CELL BIOL, V19, P2231; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zhang XH, 2005, AM J PHYSIOL-RENAL, V288, pF16, DOI 10.1152/ajprenal.00318.2003	49	27	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4964	4974		10.1038/onc.2014.420	http://dx.doi.org/10.1038/onc.2014.420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531327	Green Accepted			2022-12-17	WOS:000361693000006
J	Nguyen, HN; Yang, JM; Rahdar, M; Keniry, M; Swaney, KF; Parsons, R; Park, BH; Sesaki, H; Devreotes, PN; Iijima, M				Nguyen, H-N; Yang, J-M; Rahdar, M.; Keniry, M.; Swaney, K. F.; Parsons, R.; Park, B. H.; Sesaki, H.; Devreotes, P. N.; Iijima, M.			A new class of cancer-associated PTEN mutations defined by membrane translocation defects	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; BINDING; PHOSPHORYLATION; ACTIVATION; MECHANISM; CELLS	Phosphatase and tensin homolog (PTEN), which negatively regulates tumorigenic phosphatidylinositol (3,4,5)-trisphosphate (PIP3) signaling, is a commonly mutated tumor suppressor. The majority of cancer-associated PTEN mutations block its essential PIP3 phosphatase activity. However, there is a group of clinically identified PTEN mutations that maintain enzymatic activity, and it is unknown how these mutations contribute to tumor pathogenesis. Here, we show that these enzymatically competent PTEN mutants fail to translocate to the plasma membrane where PTEN converts PIP3 to PI(4,5) P2. Artificial membrane tethering of the PTEN mutants effectively restores tumor suppressor activity and represses excess PIP3 signaling in cells. Thus, our findings reveal a novel mechanism of tumorigenic PTEN deficiency.	[Nguyen, H-N; Yang, J-M; Rahdar, M.; Swaney, K. F.; Sesaki, H.; Devreotes, P. N.; Iijima, M.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; [Keniry, M.; Parsons, R.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY USA; [Park, B. H.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins Medicine	Iijima, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.	pnd@jhmi.edu; miijima@jhmi.edu		Parsons, Ramon/0000-0002-6656-3514; Yang, Jr-Ming/0000-0002-6296-8987	NIH [GM084015, GM28007, GM34933, GM089853, NS084154, CA082783, CA155117]; NATIONAL CANCER INSTITUTE [R01CA155117, R01CA082783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028007, R01GM034933, R01GM084015, R01GM089853, T32GM007445, R01GM028007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS084154] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Todd Waldman (Georgetown University School of Medicine) for lentiviral constructs. The mutation data was obtained from the Sanger Institute Catalogue Of Somatic Mutations In Cancer (COSMIC) web site (http://www.sanger.ac.uk/cosmic).<SUP>27</SUP> This work was supported by NIH grants to MI (GM084015), PND (GM28007 and GM34933), HS (GM089853 and NS084154) and to RP (CA082783 and CA155117).	Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Cai HQ, 2011, METHODS MOL BIOL, V757, P451, DOI 10.1007/978-1-61779-166-6_26; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chen CL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002446; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Gericke A, 2013, ADV EXP MED BIOL, V991, P85, DOI 10.1007/978-94-007-6331-9_6; Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106; Han SY, 2000, CANCER RES, V60, P3147; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Nguyen HN, 2014, P NATL ACAD SCI USA, V111, pE2684, DOI 10.1073/pnas.1409433111; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Kamimura Y, 2008, CURR BIOL, V18, P1034, DOI 10.1016/j.cub.2008.06.068; Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248; Kim JS, 2011, MOL CELL BIOL, V31, P2756, DOI 10.1128/MCB.01323-10; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243; Nguyen HN, 2014, ONCOGENE, V33, P5688, DOI 10.1038/onc.2013.507; Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106; Rodriguez-Escudero I, 2011, HUM MOL GENET, V20, P4132, DOI 10.1093/hmg/ddr337; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tan MH, 2012, CLIN CANCER RES, V18, P400, DOI 10.1158/1078-0432.CCR-11-2283; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang GM, 2013, CANCER RES, V73, P3248, DOI 10.1158/0008-5472.CAN-12-1578; Wang Y, 2013, P NATL ACAD SCI USA, V110, pE4723, DOI 10.1073/pnas.1312540110; Wang Y, 2011, MOL BIOL CELL, V22, P2270, DOI 10.1091/mbc.E10-11-0926; Zhang PB, 2010, P NATL ACAD SCI USA, V107, P11829, DOI 10.1073/pnas.1006153107	34	27	27	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3737	3743		10.1038/onc.2014.293	http://dx.doi.org/10.1038/onc.2014.293			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25263454	Green Accepted			2022-12-17	WOS:000357679100011
J	O'Loghlen, A; Martin, N; Krusche, B; Pemberton, H; Alonso, MM; Chandler, H; Brookes, S; Parrinello, S; Peters, G; Gil, J				O'Loghlen, A.; Martin, N.; Krusche, B.; Pemberton, H.; Alonso, M. M.; Chandler, H.; Brookes, S.; Parrinello, S.; Peters, G.; Gil, J.			The nuclear receptor NR2E1/TLX controls senescence	ONCOGENE			English	Article							CELLULAR SENESCENCE; POLYCOMB ORTHOLOGS; STEM-CELLS; CBX7; TLX; EXPRESSION; TAILLESS; CONTRIBUTES; PROGRESSION; INK4A/ARF	The nuclear receptor NR2E1 (also known as TLX or tailless) controls the self-renewal of neural stem cells (NSCs) and has been implied as an oncogene which initiates brain tumors including glioblastomas. Despite NR2E1 regulating targets like p21(CIP1) or PTEN we still lack a full explanation for its role in NSC self-renewal and tumorigenesis. We know that polycomb repressive complexes also control stem cell self-renewal and tumorigenesis, but so far, no formal connection has been established between NR2E1 and PRCs. In a screen for transcription factors regulating the expression of the polycomb protein CBX7, we identified NR2E1 as one of its more prominent regulators. NR2E1 binds at the CBX7 promoter, inducing its expression. Notably CBX7 represses NR2E1 as part of a regulatory loop. Ectopic NR2E1 expression inhibits cellular senescence, extending cellular lifespan in fibroblasts via CBX7-mediated regulation of p16(INK4a) and direct repression of p21(CIP1). In addition NR2E1 expression also counteracts oncogene-induced senescence. The importance of NR2E1 to restrain senescence is highlighted through the process of knocking down its expression, which causes premature senescence in human fibroblasts and epithelial cells. We also confirmed that NR2E1 regulates CBX7 and restrains senescence in NSCs. Finally, we observed that the expression of NR2E1 directly correlates with that of CBX7 in human glioblastoma multiforme. Overall we identified control of senescence and regulation of polycomb action as two possible mechanisms that can join those so far invoked to explain the role of NR2E1 in control of NSC self-renewal and cancer.	[O'Loghlen, A.; Martin, N.; Brookes, S.; Gil, J.] Univ London Imperial Coll Sci Technol & Med, Epigenet Sect, Cell Proliferat Grp, MRC Clin Sci Ctr, London W12 0NN, England; [O'Loghlen, A.; Pemberton, H.; Chandler, H.; Brookes, S.; Peters, G.] CRUK London Res Inst, Mol Oncol Lab, London, England; [Krusche, B.; Parrinello, S.] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Epigenet Sect, Cell Interact & Canc Grp, London W12 0NN, England; [Alonso, M. M.] Univ Hosp Navarra, Dept Med Oncol, Pamplona, Spain	Imperial College London; Cancer Research UK; Imperial College London; Servicio Navarro de Salud - Osasunbidea; University of Navarra	Gil, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Epigenet Sect, Cell Proliferat Grp, MRC Clin Sci Ctr, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	jesus.gil@csc.mrc.ac.uk	Alonso, Marta M/AAI-9457-2020; Gil, Jesus/C-7739-2012; O'Loghlen, Ana/K-9965-2014	Alonso, Marta M/0000-0002-7520-7351; Gil, Jesus/0000-0002-4303-6260; Martin, Nadine/0000-0002-4806-2388; O'Loghlen, Ana/0000-0002-8141-1965	MRC; MRCT; CRUK; AICR; EMBO; Marie Curie fellowships; EMBO Young Investigator Program; Medical Research Council [MC_U120085810, MC_UP_A652_1002] Funding Source: researchfish; MRC [MC_UP_A652_1002, MC_U120085810] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRCT(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); AICR; EMBO(European Molecular Biology Organization (EMBO)); Marie Curie fellowships(European Commission); EMBO Young Investigator Program(European Molecular Biology Organization (EMBO)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to G Dharmalingam and S. Khadayate for help with bioinformatics and to I Farinas and JM Morente for advise and help with NSCs. Core support was received from MRC and grants from MRCT, CRUK and the AICR funded the research in J Gil's laboratory. N Martin was funded by EMBO and Marie Curie fellowships. J Gil is also supported by the EMBO Young Investigator Program.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Forzati F, 2012, CELL CYCLE, V11, P1888, DOI 10.4161/cc.20022; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gui HX, 2011, DEV NEUROSCI-BASEL, V33, P1, DOI 10.1159/000321585; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Karamitopoulou E, 2010, EUR J CANCER, V46, P1438, DOI 10.1016/j.ejca.2010.01.033; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lim DA, 1999, P NATL ACAD SCI USA, V96, P7526, DOI 10.1073/pnas.96.13.7526; Liu HK, 2008, GENE DEV, V22, P2473, DOI 10.1101/gad.479308; Liu HK, 2010, GENE DEV, V24, P683, DOI 10.1101/gad.560310; Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380; Modena P, 2006, J CLIN ONCOL, V24, P5223, DOI 10.1200/JCO.2006.06.3701; Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; Morey L, 2012, CELL STEM CELL, V10, P47, DOI 10.1016/j.stem.2011.12.006; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019; O'Loghlen A, 2012, CELL STEM CELL, V10, P33, DOI 10.1016/j.stem.2011.12.004; Park HJ, 2010, MOL CELLS, V30, P403, DOI 10.1007/s10059-010-0122-z; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pemberton H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r23; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Qu QH, 2010, NAT CELL BIOL, V12, P31, DOI 10.1038/ncb2001; Scheffler B, 2005, P NATL ACAD SCI USA, V102, P9353, DOI 10.1073/pnas.0503965102; Scott CL, 2007, P NATL ACAD SCI USA, V104, P5389, DOI 10.1073/pnas.0608721104; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041; Sun GQ, 2007, P NATL ACAD SCI USA, V104, P15282, DOI 10.1073/pnas.0704089104; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Yokoyama A, 2008, MOL CELL BIOL, V28, P3995, DOI 10.1128/MCB.02030-07; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562; Zhang CL, 2006, GENE DEV, V20, P1308, DOI 10.1101/gad.1413606; Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao C, 2009, NAT STRUCT MOL BIOL, V16, P365, DOI 10.1038/nsmb.1576; Zou YH, 2012, MOL CELL BIOL, V32, P4811, DOI 10.1128/MCB.01122-12	47	27	28	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4069	4077		10.1038/onc.2014.335	http://dx.doi.org/10.1038/onc.2014.335			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25328137	Green Accepted, Green Submitted			2022-12-17	WOS:000358780500005
J	Schoeneberger, H; Belz, K; Schenk, B; Fulda, S				Schoeneberger, H.; Belz, K.; Schenk, B.; Fulda, S.			Impairment of antioxidant defense via glutathione depletion sensitizes acute lymphoblastic leukemia cells for Smac mimetic-induced cell death	ONCOGENE			English	Article							INHIBITOR-MEDIATED SENSITIZATION; KAPPA-B ACTIVATION; APOPTOSIS PROTEINS; BUTHIONINE SULFOXIMINE; MOLECULAR PATHWAYS; LIPID-PEROXIDATION; POTENT INHIBITORS; OXIDATIVE STRESS; REACTIVE OXYGEN; IAP PROTEINS	Evasion of apoptosis in pediatric acute lymphoblastic leukemia (ALL) is linked to aberrant expression of inhibitor of apoptosis (IAP) proteins and dysregulated redox homeostasis, rendering leukemic cells vulnerable to redox-targeting therapies. Here we discover that inhibition of antioxidant defenses via glutathione (GSH) depletion by buthionine sulfoximine (BSO) primes ALL cells for apoptosis induced by the Smac mimetic BV6 that antagonizes IAP proteins. Similarly, BSO cooperates with BV6 to induce cell death in patient-derived primary leukemic samples, underscoring the clinical relevance. In contrast, BSO does not sensitize non-malignant lymphohematopoietic cells from healthy donors toward BV6, pointing to some tumor selectivity. Mechanistically, both agents cooperate to stimulate reactive oxygen species (ROS) production, which is required for BSO/BV6-induced cell death, as ROS inhibitors (that is, N-acetylcysteine, MnTBAP, Trolox) significantly rescue cell death. Further, BSO and BV6 cooperate to trigger lipid peroxidation, which is necessary for cell death, as genetic or pharmacological blockage of lipid peroxidation by GSH peroxidase 4 (GPX4) overexpression or a-tocopherol significantly inhibits BSO/BV6-mediated cell death. Consistently, GPX4 knockdown or GPX4 inhibitor RSL3 enhances lipid peroxidation and cell death by BSO/BV6 cotreatment. The discovery of redox regulation of Smac mimetic-induced cell death has important implications for developing rational Smac mimetic-based combination therapies.	[Schoeneberger, H.; Belz, K.; Schenk, B.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany	Goethe University Frankfurt	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; IUAP VII	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); IUAP VII	We thank D Vucic (Genentech Inc., South San Francisco, CA) for providing BV6, R Brigelius-Flohe for providing the GPX4 vector, T Klingebiel and S Wehner for providing ALL samples, J Leibacher for providing MSCs, PF Angeli and M Conrad for helpful discussions and C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft and IUAP VII (to SF).	Abhari BA, 2013, ONCOGENE, V32, P3263, DOI 10.1038/onc.2012.337; Bailey HH, 1997, J NATL CANCER I, V89, P1789, DOI 10.1093/jnci/89.23.1789; Basit F, 2012, J BIOL CHEM, V287, P38767, DOI 10.1074/jbc.M112.398966; Belz K, 2014, BLOOD, V124, P240, DOI 10.1182/blood-2013-05-500918; Brigelius-Flohe R, 1997, BIOCHEM J, V328, P199, DOI 10.1042/bj3280199; Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020; Caglikulekci M, 2006, J INVEST SURG, V19, P175, DOI 10.1080/08941930600674702; Chen D, 2006, CANCER RES, V66, P11416, DOI 10.1158/0008-5472.CAN-06-0409; CHOU TC, 1980, CARCINOGENESIS, V1, P203, DOI 10.1093/carcin/1.3.203; Curtis J, 2001, HEMAT BLOOD, V40, P257; DAVIES MJ, 1988, BIOCHEM J, V255, P513; Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Eckhardt I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.457; Fakler M, 2009, BLOOD, V113, P1710, DOI 10.1182/blood-2007-09-114314; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107; Franco R, 2008, J BIOL CHEM, V283, P36071, DOI 10.1074/jbc.M807061200; Friesen C, 2004, CELL DEATH DIFFER, V11, pS73, DOI 10.1038/sj.cdd.4401431; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2014, LEUKEMIA, V28, P1414, DOI 10.1038/leu.2014.56; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00003; Fulda S, 2014, CLIN CANCER RES, V20, P289, DOI 10.1158/1078-0432.CCR-13-0227; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Fulda S, 2009, BRIT J HAEMATOL, V145, P441, DOI 10.1111/j.1365-2141.2009.07603.x; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Gomes A, 2005, J BIOCHEM BIOPH METH, V65, P45, DOI 10.1016/j.jbbm.2005.10.003; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hundsdoerfer P, 2010, PEDIATR BLOOD CANCER, V55, P260, DOI 10.1002/pbc.22541; Irwin ME, 2013, ANTIOXID REDOX SIGN, V18, P1349, DOI 10.1089/ars.2011.4258; Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Kearns PR, 2001, BLOOD, V97, P393, DOI 10.1182/blood.V97.2.393; Koopman Werner J H, 2010, Antioxid Redox Signal, V12, P1431, DOI 10.1089/ars.2009.2743; Latchoumycandane C, 2012, J BIOL CHEM, V287, P17693, DOI 10.1074/jbc.M111.300012; Loder S, 2012, LEUKEMIA, V26, P1020, DOI 10.1038/leu.2011.353; MAUNG ZT, 1994, LEUKEMIA, V8, P1487; Naguib YMA, 1998, ANAL BIOCHEM, V265, P290, DOI 10.1006/abio.1998.2931; Ni Y, 2012, CLIN CANCER RES, V18, P4954, DOI 10.1158/1078-0432.CCR-12-1055; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Repetto M, 2012, LIPID PEROXIDATION, P3, DOI 10.5772/45943; Robinson KM, 2006, P NATL ACAD SCI USA, V103, P15038, DOI 10.1073/pnas.0601945103; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Stanulla M, 2009, SEMIN HEMATOL, V46, P52, DOI 10.1053/j.seminhematol.2008.09.007; Tamm I, 2004, CLIN CANCER RES, V10, P3737, DOI 10.1158/1078-0432.CCR-03-0642; Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012; Wuchter C, 2004, HAEMATOLOGICA, V89, P363; Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010	59	27	29	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4032	4043		10.1038/onc.2014.338	http://dx.doi.org/10.1038/onc.2014.338			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25381820				2022-12-17	WOS:000358780500002
J	Archibald, A; Mihai, C; Macara, IG; McCaffrey, L				Archibald, A.; Mihai, C.; Macara, I. G.; McCaffrey, L.			Oncogenic suppression of apoptosis uncovers a Rac1/JNK proliferation pathway activated by loss of Par3	ONCOGENE			English	Article							MAMMARY-GLAND DEVELOPMENT; POLARITY PROTEIN; BREAST-CANCER; RAC; COOPERATE; OVEREXPRESSION; TUMORIGENESIS; OVERGROWTH; GTPASES; GROWTH	Disruption of epithelial organization and loss of growth control are universal features of carcinomas, yet how these features are linked during cancer progression remains poorly understood. Cell polarity proteins control cellular and tissue organization and are emerging as important mediators of cancer progression. The Par3 polarity protein is a molecular scaffold that functions to recruit and spatially organize signaling factors, and was recently identified as a suppressor of breast cancer invasion and metastasis. Here, we show that loss of Par3 in mammary epithelial cells promotes apoptosis, and that oncogenic Notch overcomes the apoptotic signal to reveal an unexpected pro-proliferative role for loss of Par3 in mammary tumors. In this context, loss of Par3 deregulates Rac1 activity to activate Jun N-terminal Kinase-dependent proliferation and tumor growth. Thus, we demonstrate a mechanism by which loss of Par3 promotes proliferation and tumorigenesis, which supports a tumor-suppressive function for Par3 in the mammary epithelium.	[Archibald, A.; Mihai, C.; McCaffrey, L.] McGill Univ, Dept Oncol, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Macara, I. G.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN USA	McGill University; Vanderbilt University	McCaffrey, L (corresponding author), McGill Univ, Dept Oncol, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.	luke.mccaffrey@mcgill.ca			TFRI [1009]; CIHR [MOP-119482]; NATIONAL CANCER INSTITUTE [R01CA132898] Funding Source: NIH RePORTER	TFRI; CIHR(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Didier Trono (Lausanne, Switzerland) for lentivectors. K8 hybridoma, developed by Philippe Brulet and Rolf Kemler, was obtained from the Universtiy of Iowa Developmental Hybridoma Bank. This work was supported by grants from TFRI (Project #1009) and CIHR (MOP-119482) to LM. LM is a FRQS Research Scholar.	Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cellurale C, 2012, CANCER RES, V72, P472, DOI 10.1158/0008-5472.CAN-11-1628; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Durgan J, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.174235; Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Georgiou M, 2010, J CELL SCI, V123, P1089, DOI 10.1242/jcs.060772; Han JS, 2010, ANTICANCER RES, V30, P3407; Hayase J, 2013, J CELL BIOL, V200, P635, DOI 10.1083/jcb.201208150; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Kawazu M, 2013, P NATL ACAD SCI USA, V110, P3029, DOI 10.1073/pnas.1216141110; Kim M, 2007, J CELL SCI, V120, P2309, DOI 10.1242/jcs.007443; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McCaffrey LM, 2011, TRENDS CELL BIOL, V21, P727, DOI 10.1016/j.tcb.2011.06.005; McCaffrey LM, 2009, GENE DEV, V23, P1450, DOI 10.1101/gad.1795909; Morais-de-Sa E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040; Nishimura T, 2005, NAT CELL BIOL, V7, P270, DOI 10.1038/ncb1227; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pegtel DM, 2007, CURR BIOL, V17, P1623, DOI 10.1016/j.cub.2007.08.035; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Simmons MJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3321; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Strumane K, 2009, J CANCER RES CLIN, V135, P69, DOI 10.1007/s00432-008-0437-8; Tepass U, 2012, ANNU REV CELL DEV BI, V28, P655, DOI 10.1146/annurev-cellbio-092910-154033; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Warner SJ, 2010, CURR BIOL, V20, P677, DOI 10.1016/j.cub.2010.03.025; Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011; Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhou C, 2013, ONCOGENE, V32, P903, DOI 10.1038/onc.2012.99	37	27	28	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3199	3206		10.1038/onc.2014.242	http://dx.doi.org/10.1038/onc.2014.242			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25109337	Green Accepted			2022-12-17	WOS:000356101100011
J	Park, JT; Johnson, N; Liu, S; Levesque, M; Wang, YJ; Ho, H; Huso, D; Maitra, A; Parsons, MJ; Prescott, JD; Leach, SD				Park, J. T.; Johnson, N.; Liu, S.; Levesque, M.; Wang, Y. J.; Ho, H.; Huso, D.; Maitra, A.; Parsons, M. J.; Prescott, J. D.; Leach, S. D.			Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey	ONCOGENE			English	Article							K-RAS CODON-12; ZEBRAFISH; CANCER; INDUCTION; NEOPLASIA; ONCOGENES; ABLATION; TUMORS; MICE	Somatic activation of the KRAS proto-oncogene is evident in almost all pancreatic cancers, and appears to represent an initiating event. These mutations occur primarily at codon 12 and less frequently at codons 13 and 61. Although some studies have suggested that different KRAS mutations may have variable oncogenic properties, to date there has been no comprehensive functional comparison of multiple KRAS mutations in an in vivo vertebrate tumorigenesis system. We generated a Gal4/UAS-based zebrafish model of pancreatic tumorigenesis in which the pancreatic expression of UAS-regulated oncogenes is driven by a ptf1a: Gal4-VP16 driver line. This system allowed us to rapidly compare the ability of 12 different KRAS mutations (G12A, G12C, G12D, G12F, G12R, G12S, G12V, G13C, G13D, Q61L, Q61R and A146T) to drive pancreatic tumorigenesis in vivo. Among fish injected with one of five KRAS mutations reported in other tumor types but not in human pancreatic cancer, 2/79 (2.5%) developed pancreatic tumors, with both tumors arising in fish injected with A146T. In contrast, among fish injected with one of seven KRAS mutations known to occur in human pancreatic cancer, 22/106 (20.8%) developed pancreatic cancer. All eight tumorigenic KRAS mutations were associated with downstream MAPK/ERK pathway activation in preneoplastic pancreatic epithelium, whereas nontumorigenic mutations were not. These results suggest that the spectrum of KRAS mutations observed in human pancreatic cancer reflects selection based on variable tumorigenic capacities, including the ability to activate MAPK/ERK signaling.	[Park, J. T.; Johnson, N.; Liu, S.; Levesque, M.; Parsons, M. J.; Prescott, J. D.; Leach, S. D.] Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA; [Wang, Y. J.; Parsons, M. J.; Leach, S. D.] Johns Hopkins Med Inst, Grad Program Human Genet, Baltimore, MD 21205 USA; [Ho, H.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Huso, D.] Johns Hopkins Med Inst, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA; [Parsons, M. J.; Leach, S. D.] Johns Hopkins Med Inst, Inst Med Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Leach, SD (corresponding author), Mem Sloan Kettering Canc Ctr, David M Rubenstein Ctr Pancreat Canc Res, 1275 York Ave,Box 20, New York, NY 10065 USA.	leachs@mskcc.org	Wang, Julia/M-4516-2016	Wang, Julia/0000-0003-2641-6904	NCI [P01 CA134292]; Paul K Neumann Professorship in Pancreatic Cancer at Johns Hopkins University; NATIONAL CANCER INSTITUTE [P01CA134292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007814] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Paul K Neumann Professorship in Pancreatic Cancer at Johns Hopkins University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Mary Chico, Mara Swaim, Anzer Habibullah and Frazer Matthews for expert administrative and technical support. This work was supported by NCI P01 CA134292. SDL was further supported by the Paul K Neumann Professorship in Pancreatic Cancer at Johns Hopkins University.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Auer TO, 2014, GENOME RES, V24, P142, DOI 10.1101/gr.161638.113; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; Charbel C, 2014, J INVEST DERMATOL, V134, P1067, DOI 10.1038/jid.2013.429; Davison JM, 2007, DEV BIOL, V304, P811, DOI 10.1016/j.ydbio.2007.01.033; Er TK, 2014, CANCER LETT, V343, P1, DOI 10.1016/j.canlet.2013.09.012; Fukahori M, 2012, THYROID, V22, P683, DOI 10.1089/thy.2011.0261; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Guerrero S, 2000, CANCER RES, V60, P6750; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hu G, 2011, DEV DYNAM, V240, P2101, DOI 10.1002/dvdy.22699; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Krasinskas AM, 2013, MODERN PATHOL, V26, P1346, DOI 10.1038/modpathol.2013.71; Kraus MC, 2006, INT J ONCOL, V29, P957; Leach SD, 2009, ZEBRAFISH, V6, P317, DOI 10.1089/zeb.2009.9988; Martin P, 2013, J THORAC ONCOL, V8, P530, DOI 10.1097/JTO.0b013e318283d958; Morelli MP, 2012, J CLIN ONCOL, V30, P3565, DOI 10.1200/JCO.2012.43.6535; Mosimann C, 2013, DEV DYNAM, V242, P949, DOI 10.1002/dvdy.23989; Parikh C, 2006, BLOOD, V108, P2349, DOI 10.1182/blood-2004-08-009498; Park SW, 2008, GASTROENTEROLOGY, V134, P2080, DOI 10.1053/j.gastro.2008.02.084; Pisharath Harshan, 2009, V546, P133, DOI 10.1007/978-1-60327-977-2_9; Prior IA, 2012, SEMIN CELL DEV BIOL, V23, P145, DOI 10.1016/j.semcdb.2011.09.002; Roberts JA, 2014, DEVELOPMENT, V141, P715, DOI 10.1242/dev.100347; Yen J, 2014, CURR OPIN GENET DEV, V24, P38, DOI 10.1016/j.gde.2013.11.003; Yoo J, 2000, ARCH PATHOL LAB MED, V124, P836; Zu Y, 2013, NAT METHODS, V10, P329, DOI 10.1038/NMETH.2374	26	27	27	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2801	2806		10.1038/onc.2014.223	http://dx.doi.org/10.1038/onc.2014.223			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25065594	Green Accepted			2022-12-17	WOS:000354979500012
J	Bais, MV; Ozdener, GB; Sonenshein, GE; Trackman, PC				Bais, M. V.; Ozdener, G. B.; Sonenshein, G. E.; Trackman, P. C.			Effects of tumor-suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways	ONCOGENE			English	Article							ATM PROTEIN-KINASE; TRANSFORMED PHENOTYPE; MRE11 NUCLEASE; EXPRESSION; LUNG; ACTIVATION; RESISTANCE; RADIATION; BINDING; CELLS	Lysyl oxidase (LOX) is a multifunctional protein required for normal collagen and elastin biosynthesis and maturation. In addition, LOX has complex roles in cancer in which the lysyl oxidase propeptide (LOX-PP) domain of secreted pro-LOX has tumor-suppressor activity, while the active enzyme promotes metastasis. In prostate cancer cell lines, recombinant LOX-PP (rLOX-PP) inhibits the growth of PC3 cells in vitro by mechanisms that were not characterized, while in DU145 cells rLOX-PP targeted fibroblast growth factor signaling. Because rLOX-PP can enhance effects of a genotoxic chemotherapeutic on breast cancer cell apoptosis, we reasoned that rLOX-PP could target DNA repair pathways typically elevated in cancer. Here we demonstrate for the first time that rLOX-PP inhibits prostate xenograft growth in vivo and that activating phosphorylations of the key DNA repair molecules ataxia-telangiectasia mutated (ATM) and checkpoint kinase 2 (CHK2) are inhibited by rLOX-PP expression in vivo. In addition, in vitro studies showed that rLOX-PP inhibits radiation-induced activating phosphorylations of ATM and CHK2 and that exogenously added rLOX-PP protein can localize to the nucleus in both DU145 and PC3 cells. rLOX-PP pull-down studies resulted in detection of a protein complex with the nuclear DNA repair regulator MRE11 in both cell lines, and rLOX-PP localized to radiation-induced nuclear DNA repair foci. Finally, rLOX-PP was shown to sensitize both DU145 and PC3 cells to radiation-induced cell death determined in colony-formation assays. These data provide evidence that rLOX-PP has a nuclear mechanism of action in which it directly interacts with DNA repair proteins to sensitize prostate cancer cells to the effects of ionizing radiation.	[Bais, M. V.; Ozdener, G. B.; Trackman, P. C.] Boston Univ, Henry M Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; [Sonenshein, G. E.] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA	Boston University; Tufts University	Trackman, PC (corresponding author), Boston Univ, Henry M Goldman Sch Dent Med, Dept Mol & Cell Biol, 700 Albany St,W-201, Boston, MA 02118 USA.	trackman@bu.edu	Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Bais, Manish/0000-0003-4198-7377	NIH [DE R01014066, DOD W81XWH-08-1-0349 PC073646, R01 CA143108]; NATIONAL CANCER INSTITUTE [R01CA143108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014066] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the NIH grants DE R01014066, DOD W81XWH-08-1-0349 PC073646 and R01 CA143108.	Agra N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066281; [Anonymous], 2003, METH MOL B; Bais MV, 2009, BONE, V45, P254, DOI 10.1016/j.bone.2009.04.239; Bais MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031188; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Berlier JE, 2003, J HISTOCHEM CYTOCHEM, V51, P1699, DOI 10.1177/002215540305101214; Bhatti S, 2011, CELL MOL LIFE SCI, V68, P2977, DOI 10.1007/s00018-011-0683-9; Buis J, 2008, CELL, V135, P85, DOI 10.1016/j.cell.2008.08.015; Buscemi G, 2006, MOL CELL BIOL, V26, P7832, DOI 10.1128/MCB.00534-06; Carlessi L, 2007, MOL CANCER THER, V6, P935, DOI 10.1158/1535-7163.MCT-06-0567; Choudhury A, 2006, SEMIN RADIAT ONCOL, V16, P51, DOI 10.1016/j.semradonc.2005.08.007; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; Delia D, 2003, ONCOGENE, V22, P7866, DOI 10.1038/sj.onc.1207086; Eastman A, 2004, J CELL BIOCHEM, V91, P223, DOI 10.1002/jcb.10699; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Hurtado PA, 2008, BIOCHEM BIOPH RES CO, V366, P156, DOI 10.1016/j.bbrc.2007.11.116; Jobson AG, 2007, MOL PHARMACOL, V72, P876, DOI 10.1124/mol.107.035832; Kauffmann A, 2008, ONCOGENE, V27, P565, DOI 10.1038/sj.onc.1210700; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Martinez-Marignac VL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016394; Matos CS, 2012, CURR MED CHEM, V19, P4678; Min CY, 2007, CANCER RES, V67, P1105, DOI 10.1158/0008-5472.CAN-06-3867; Min CY, 2010, J CELL BIOCHEM, V111, P1160, DOI 10.1002/jcb.22828; Mok MTS, 2012, RADIOTHER ONCOL, V103, P415, DOI 10.1016/j.radonc.2012.04.009; Munshi A, 2005, METH MOLEC MED, V110, P21; Nakano D, 2012, J AM SOC NEPHROL, V23, P1847, DOI 10.1681/ASN.2012010078; Neel DS, 2013, CLIN CANCER RES, V19, P3, DOI 10.1158/1078-0432.CCR-12-3232; Olson E, 2007, MOL CELL BIOL, V27, P6053, DOI 10.1128/MCB.00532-07; Oxnard GR, 2012, ARCH PATHOL LAB MED, V136, P1205, DOI 10.5858/arpa.2012-0254-RA; Palamakumbura AH, 2009, ONCOGENE, V28, P3390, DOI 10.1038/onc.2009.203; Palamakumbura AH, 2004, J BIOL CHEM, V279, P40593, DOI 10.1074/jbc.M406639200; Palamakumbura AH, 2003, J BIOL CHEM, V278, P30781, DOI 10.1074/jbc.M305238200; Pallis A, 2011, CURR MED CHEM, V18, P1613, DOI 10.2174/092986711795471383; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Podhorecka M, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/920161; Rainey MD, 2008, CANCER RES, V68, P7466, DOI 10.1158/0008-5472.CAN-08-0763; Ritter M, 2008, SEMIN RADIAT ONCOL, V18, P249, DOI 10.1016/j.semradonc.2008.04.007; Sanchez-Morgan N, 2011, MOL CELL BIOL, V31, P3286, DOI 10.1128/MCB.01426-10; Sarasin A, 2008, MUTAT RES-REV MUTAT, V659, P49, DOI 10.1016/j.mrrev.2007.12.002; Sato S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077288; Sato S, 2011, MOL CELL BIOL, V31, P2683, DOI 10.1128/MCB.01148-10; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Spalding AC, 2002, ONCOGENE, V21, P260, DOI 10.1038/sj.onc.1205048; Stolz A, 2011, CLIN CANCER RES, V17, P401, DOI 10.1158/1078-0432.CCR-10-1215; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Vora SR, 2010, BIOCHEMISTRY-US, V49, P2962, DOI 10.1021/bi902218p; Wang LM, 2008, AM J PHYSIOL-HEART C, V295, pH237, DOI 10.1152/ajpheart.01366.2007; Williams RS, 2008, CELL, V135, P97, DOI 10.1016/j.cell.2008.08.017; Wu M, 2007, CANCER RES, V67, P6278, DOI 10.1158/0008-5472.CAN-07-0776; Yu ZB, 2012, CELL RES, V22, P305, DOI 10.1038/cr.2011.128; Zaorsky NG, 2013, CANCER TREAT REV, V39, P728, DOI 10.1016/j.ctrv.2013.01.008; Zhao YS, 2009, J BIOL CHEM, V284, P1385, DOI 10.1074/jbc.M802612200; Zheng Y, 2014, ONCOL REP, V31, P1669, DOI 10.3892/or.2014.3044	64	27	29	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1928	1937		10.1038/onc.2014.147	http://dx.doi.org/10.1038/onc.2014.147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882580	Green Accepted			2022-12-17	WOS:000352725600007
J	Vigna, E; Comoglio, PM				Vigna, E.; Comoglio, P. M.			Targeting the oncogenic Met receptor by antibodies and gene therapy	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; CELL LUNG-CANCER; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; MONOVALENT ANTIBODY; ANTITUMOR-ACTIVITY; PHASE-II; AMG 102; GEFITINIB RESISTANCE; ONARTUZUMAB METMAB	The receptor for hepatocyte growth factor (HGF), a tyrosine kinase encoded by the Met oncogene, has a crucial role in cancer growth, invasion and metastasis. It is a validated therapeutic target for 'personalized' treatment of a number of malignancies. Therapeutic tools prompting selective, robust and highly effective Met inhibition potentially represent a major step in the battle against cancer. Antibodies targeting either Met or its ligand HGF, although challenging, demonstrate to be endowed with promising features. Here we briefly review and discuss the state of the art in the field.	Univ Torino, Dept Oncol, Candiolo, TO, Italy; IRCCS, FPO, Candiolo Canc Inst, Candiolo, TO, Italy	University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia	Vigna, E (corresponding author), Candiolo Canc Inst, Lab Gene Transfer, KM 3-95,Str Provinciale 142, I-10060 Candiolo, TO, Italy.	elisa.vigna@ircc.it; pcomoglio@gmail.com		Comoglio, Paolo/0000-0002-7056-5328; Vigna, Elisa/0000-0001-9787-5732	AIRC (Italy) [11852]; Metheresis Translational Research SA; University of Torino	AIRC (Italy)(Fondazione AIRC per la ricerca sul cancro); Metheresis Translational Research SA; University of Torino	The original work performed by the authors was supported by an IG grant from the AIRC (Italy) no. 11852 and by a research contract between Metheresis Translational Research SA and the University of Torino. The images are unpublished experiments of Dr Letizia Lanzetti. The invaluable secretarial help of Antonella Cignetto is gratefully acknowledged.	Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Ancot F, 2012, TRAFFIC, V13, P1261, DOI 10.1111/j.1600-0854.2012.01384.x; Bardelli C, 2005, BIOCHEM BIOPH RES CO, V334, P1172, DOI 10.1016/j.bbrc.2005.07.020; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Bendell JC, 2013, CLIN COLORECTAL CANC, V12, P218, DOI 10.1016/j.clcc.2013.04.001; Bertotti A, 2013, JNCI-J NATL CANCER I, V105, P1426, DOI 10.1093/jnci/djt253; Biffi A, 2013, SCIENCE, V341, P864, DOI 10.1126/science.1233158; Buchanan IM, 2011, J CELL MOL MED, V15, P1999, DOI 10.1111/j.1582-4934.2010.01122.x; Burgess T, 2006, CANCER RES, V66, P1721, DOI 10.1158/0008-5472.CAN-05-3329; Burgess TL, 2010, MOL CANCER THER, V9, P400, DOI 10.1158/1535-7163.MCT-09-0824; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Castoldi R, 2013, ONCOGENE, V32, P5593, DOI 10.1038/onc.2013.245; Catenacci DVT, 2011, CANCER DISCOV, V1, P573, DOI 10.1158/2159-8290.CD-11-0175; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; D'Arcangelo M, 2013, BIOL-TARGETS THER, V7, P61, DOI 10.2147/BTT.S28908; De Bacco F, 2012, CANCER RES, V72, P4537, DOI 10.1158/0008-5472.CAN-11-3490; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Duvvuri M, 2005, FRONT BIOSCI-LANDMRK, V10, P1499, DOI 10.2741/1634; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; Galimi F, 2001, J IMMUNOL, V166, P1241, DOI 10.4049/jimmunol.166.2.1241; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gillet Jean-Pierre, 2009, V542, P5, DOI 10.1007/978-1-59745-561-9_1; Goetsch L, 2010, CANC RES S1, V70; Goldman JW, 2013, ASCO M, V31, P8093; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Greenall SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034658; Houghton PJ, 2014, PEDIATR BLOOD CANCER, V61, P380, DOI 10.1002/pbc.24756; Jin HK, 2008, CANCER RES, V68, P4360, DOI 10.1158/0008-5472.CAN-07-5960; Jun HT, 2007, CLIN CANCER RES, V13, P6735, DOI 10.1158/1078-0432.CCR-06-2969; Kim K, 2007, BIOCHEM BIOPH RES CO, V354, P115, DOI 10.1016/j.bbrc.2006.12.164; Kim KJ, 2006, CLIN CANCER RES, V12, P1292, DOI 10.1158/1078-0432.CCR-05-1793; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551; Leiser D, 2014, FEBS LETT, V588, P653, DOI 10.1016/j.febslet.2013.12.025; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Luraghi P, 2014, CANCER RES, V74, P1857, DOI 10.1158/0008-5472.CAN-13-2340-T; Martens T, 2006, CLIN CANCER RES, V12, P6144, DOI 10.1158/1078-0432.CCR-05-1418; Martin LP, 2014, GYNECOL ONCOL, V132, P526, DOI 10.1016/j.ygyno.2013.12.018; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Merchant M, 2013, P NATL ACAD SCI USA, V110, pE2987, DOI 10.1073/pnas.1302725110; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Mittra ES, 2013, CLIN CANCER RES, V19, P5711, DOI 10.1158/1078-0432.CCR-12-1015; Okamoto W, 2010, MOL CANCER THER, V9, P2785, DOI 10.1158/1535-7163.MCT-10-0481; Pacchiana G, 2010, J BIOL CHEM, V285, P36149, DOI 10.1074/jbc.M110.134031; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Perk LR, 2008, EUR J NUCL MED MOL I, V35, P1857, DOI 10.1007/s00259-008-0774-5; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; Rosen PJ, 2010, CLIN CANCER RES, V16, P2677, DOI 10.1158/1078-0432.CCR-09-2862; Ryan CJ, 2013, CLIN CANCER RES, V19, P215, DOI 10.1158/1078-0432.CCR-12-2605; Sadiq AA, 2013, J CLIN ONCOL, V31, P1089, DOI 10.1200/JCO.2012.43.9422; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schoffski P, 2011, BJU INT, V108, P679, DOI 10.1111/j.1464-410X.2010.09947.x; Slordahl TS, 2013, EUR J HAEMATOL, V91, P399, DOI 10.1111/ejh.12185; Stella GM, 2011, HUM MUTAT, V32, P44, DOI 10.1002/humu.21374; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Toschi L, 2008, CLIN CANCER RES, V14, P5941, DOI 10.1158/1078-0432.CCR-08-0071; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; van der Horst E, 2009, NEOPLASIA, V11, P355, DOI 10.1593/neo.81536; Vigna E, 2000, J GENE MED, V2, P308; Vigna E, 2008, CANCER RES, V68, P9176, DOI 10.1158/0008-5472.CAN-08-1688; Vigna E, 2014, J MOL MED, V92, P65, DOI 10.1007/s00109-013-1079-0; Vosjan MJWD, 2012, MOL CANCER THER, V11, P1017, DOI 10.1158/1535-7163.MCT-11-0891; Wang R, 2011, LUNG CANCER, V74, P188, DOI 10.1016/j.lungcan.2011.04.009; Wen PY, 2011, NEURO-ONCOLOGY, V13, P437, DOI 10.1093/neuonc/noq198; Wu XY, 2013, CANCER LETT, V335, P128, DOI 10.1016/j.canlet.2013.02.002; Xin Y, 2013, J CLIN PHARMACOL, V53, P1103, DOI 10.1002/jcph.148; Zeng W, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-2734; Zhao P, 2010, CANCER LETT, V291, P209, DOI 10.1016/j.canlet.2009.10.014; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	83	27	28	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1883	1889		10.1038/onc.2014.142	http://dx.doi.org/10.1038/onc.2014.142			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882574	Green Submitted, Bronze			2022-12-17	WOS:000352725600002
J	Senol, O; Schaaij-Visser, TBM; Erkan, EP; Dorfer, C; Lewandrowski, G; Pham, TV; Piersma, SR; Peerdeman, M; Strobel, T; Tannous, B; Saydam, N; Slavc, I; Knosp, E; Jimenez, CR; Saydam, O				Senol, O.; Schaaij-Visser, T. B. M.; Erkan, E. P.; Dorfer, C.; Lewandrowski, G.; Pham, T. V.; Piersma, S. R.; Peerdeman, M.; Stroebel, T.; Tannous, B.; Saydam, N.; Slavc, I.; Knosp, E.; Jimenez, C. R.; Saydam, O.			miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo	ONCOGENE			English	Article							MYOSIN-II; MESENCHYMAL TRANSITION; INVASION	miR-200a has been implicated in the pathogenesis of meningiomas, one of the most common central nervous system tumors in humans. To identify how miR-200a contributes to meningioma pathogenesis at the molecular level, we used a comparative protein profiling approach using Gel-nanoLC-MS/MS and identified approximately 130 dysregulated proteins in miR-200a-overexpressing meningioma cells. Following the bioinformatic analysis to identify potential genes targeted by miR-200a, we focused on the nonmuscle heavy chain IIb (NMHCIIb), and showed that miR-200a directly targeted NMHCIIb. Considering the key roles of NMHCIIb in cell division and cell migration, we aimed to identify whether miR-200a regulated these processes through NMHCIIb. We found that NMHCIIb overexpression partially rescued miR-200a-mediated inhibition of cell migration, as well as cell growth in vitro and in vivo. Moreover, siRNA-mediated silencing of NMHCIIb expression resulted in a similar migration phenotype in these cells and inhibited meningioma tumor growth in mice. Taken together, these results suggest that NMHCIIb might serve as a novel therapeutic target in meningiomas.	[Senol, O.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol & Radiol, Boston, MA USA; [Schaaij-Visser, T. B. M.; Pham, T. V.; Piersma, S. R.; Jimenez, C. R.] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, OncoProte Lab, Amsterdam, Netherlands; [Erkan, E. P.; Saydam, N.; Slavc, I.; Saydam, O.] Med Univ Vienna, Dept Pediat, Mol Neurooncol Res Unit, A-1090 Vienna, Austria; [Dorfer, C.; Knosp, E.] Med Univ Vienna, Dept Neurosurg, A-1090 Vienna, Austria; [Lewandrowski, G.; Tannous, B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Expt Therapeut & Mol Imaging Lab, Boston, MA USA; [Peerdeman, M.] Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, Amsterdam, Netherlands; [Stroebel, T.] Med Univ Vienna, Inst Neurol, A-1090 Vienna, Austria	Harvard University; Harvard Medical School; Massachusetts General Hospital; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Medical University of Vienna; Medical University of Vienna; Harvard University; Harvard Medical School; Massachusetts General Hospital; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Medical University of Vienna	Saydam, O (corresponding author), Med Univ Vienna, Dept Pediat, Mol Neurooncol Res Unit, A-1090 Vienna, Austria.	okay.saydam@meduniwien.ac.at	Erkan, Erdogan Pekcan/GQR-2513-2022; Jimenez, Connie/AAI-3763-2020; Dorfer, Christian/AAP-1990-2020; Erkan, Erdogan Pekcan/ABI-6822-2020; Saydam, Okay/HDM-4999-2022	Erkan, Erdogan Pekcan/0000-0001-9287-4773; Jimenez, Connie R/0000-0002-3103-4508; Dorfer, Christian/0000-0002-1843-7732	Forschungsgesellschaft for Brain Tumors; EU-FP7-PEOPLE-CIG; Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind'	Forschungsgesellschaft for Brain Tumors; EU-FP7-PEOPLE-CIG; Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind'	Support for this work was provided, in part, by Forschungsgesellschaft for Brain Tumors (to OS, NS), EU-FP7-PEOPLE-2011-CIG (to OS) and Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind' (to OS). We thank Dr Marianne F James for providing us with AC030 cells.	Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Badr CE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000571; Beach JR, 2011, P NATL ACAD SCI USA, V108, P17991, DOI 10.1073/pnas.1106499108; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401; Elson-Schwab I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013176; Figueroa BE, 1999, BRIT J RADIOL, V72, P513, DOI 10.1259/bjr.72.857.10505022; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hu XX, 2009, GYNECOL ONCOL, V114, P457, DOI 10.1016/j.ygyno.2009.05.022; Jacobs K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-255; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2; Pham MH, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1117; Pramesh CS, 2003, JPN J CLIN ONCOL, V33, P86, DOI 10.1093/jjco/hyg022; Ragel Brian, 2003, Cancer Control, V10, P148; Ragel BT, 2008, SURG NEUROL, V70, P295, DOI 10.1016/j.surneu.2007.06.031; Ragel BT, 2010, J NEURO-ONCOL, V99, P315, DOI 10.1007/s11060-010-0381-8; Sandquist JC, 2006, J BIOL CHEM, V281, P35873, DOI 10.1074/jbc.M605343200; Saydam O, 2011, CANCER RES, V71, P852, DOI 10.1158/0008-5472.CAN-10-1219; Saydam O, 2010, J PROTEOME RES, V9, P485, DOI 10.1021/pr900834h; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Sureban SM, 2011, CANCER RES, V71, P2328, DOI 10.1158/0008-5472.CAN-10-2738; Takeda K, 2003, CIRC RES, V93, P330, DOI 10.1161/01.RES.0000089256.00309.CB; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Wilisch-Neumann A, 2013, CLIN CANCER RES, V19, P5402, DOI 10.1158/1078-0432.CCR-12-0299; Wu QH, 2011, GYNECOL ONCOL, V122, P149, DOI 10.1016/j.ygyno.2011.03.026; Xia HP, 2010, BIOCHEM BIOPH RES CO, V391, P535, DOI 10.1016/j.bbrc.2009.11.093	29	27	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1790	1798		10.1038/onc.2014.120	http://dx.doi.org/10.1038/onc.2014.120			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24858044				2022-12-17	WOS:000352158000006
J	Biyanee, A; Ohnheiser, J; Singh, P; Klempnauer, KH				Biyanee, A.; Ohnheiser, J.; Singh, P.; Klempnauer, K-H			A novel mechanism for the control of translation of specific mRNAs by tumor suppressor protein Pdcd4: inhibition of translation elongation	ONCOGENE			English	Article							A-MYB PROTEIN; C-MYB; CODING REGION; BINDING-PROTEIN; EUKARYOTIC TRANSLATION; STRUCTURAL BASIS; GENE-EXPRESSION; CANCER; TRANSFORMATION; TRANSCRIPTION	The tumor suppressor gene Pdcd4 (programmed cell death gene 4) has drawn considerable attention because its downregulation is involved in the development of several types of cancer. Because Pdcd4 interacts with the translation initiation factor eIF4A and inhibits its helicase activity, Pdcd4 has been implicated in the translational suppression of cellular mRNAs containing structured 5'-untranslated regions. However, Pdcd4's role in translation regulation is still poorly understood, because only very few physiological Pdcd4 target mRNAs are known. By using a Pdcd4-deficient clone of the chicken B-cell line DT40, we have discovered that the mRNA of the A-myb proto-oncogene is a novel Pdcd4 target RNA whose translation is suppressed by Pdcd4. Interestingly, the inhibitory effect of Pdcd4 is independent of the Pdcd4-eIF4A interaction, but is dependent on an RNA-binding domain at the N terminus of Pdcd4 and on sequences located within the coding region of A-myb mRNA, indicating that Pdcd4 suppresses A-myb translation by a novel mechanism. Our data show that the Pdcd4 RNA-binding domain preferentially recognizes an RNA secondary structure element formed by the part of the A-myb coding region that mediates Pdcd4-dependent suppression. Previously, we have shown that Pdcd4 also suppresses the translation of the c-myb mRNA by a similar mechanism involving binding of Pdcd4 to RNA secondary structure formed by the c-myb coding region. Surprisingly, our data show that Pdcd4 exerts its inhibitory activity only when the target region of Pdcd4 in A-myb and c-myb mRNA is itself translated, consistent with a mechanism in which Pdcd4 suppresses translation by interfering with translation elongation. Taken together, our work reveals a novel mechanism by which Pdcd4 affects the translational of cellular RNAs. Furthermore, as c-myb and A-myb are members of the Myb proto-oncogene family whose deregulation has been implicated in tumorigenesis, inhibiting their translation might contribute to the tumor-suppressive activity of Pdcd4.	[Biyanee, A.; Ohnheiser, J.; Singh, P.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany; [Biyanee, A.] Univ Munster, GSC MS, D-48149 Munster, Germany	University of Munster; University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Singh, Priyanka/N-1372-2018; Singh, Priyanka/GRF-6098-2022	Singh, Priyanka/0000-0003-0841-1544; Singh, Priyanka/0000-0002-5928-6280	Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft; Graduate School of Chemistry (GSC-MS) at the University of Munster	Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Graduate School of Chemistry (GSC-MS) at the University of Munster	We thank J Golay for the human A-Myb expression vector. This work was supported by a grant from the Deutsche Krebshilfe and the Deutsche Forschungsgemeinschaft. AB and PS were supported by fellowships from the Graduate School of Chemistry (GSC-MS) at the University of Munster.	Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Baltz AG, 2012, MOL CELL, V46, P674, DOI 10.1016/j.molcel.2012.05.021; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; Bitomsky N, 2008, ONCOGENE, V27, P4820, DOI 10.1038/onc.2008.115; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Brummer A, 2013, RNA, V19, P1317, DOI 10.1261/rna.037531.112; Chang JH, 2009, P NATL ACAD SCI USA, V106, P3148, DOI 10.1073/pnas.0808275106; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Drabsch Y, 2007, P NATL ACAD SCI USA, V104, P13762, DOI 10.1073/pnas.0700104104; ErcikanAbali EA, 1997, BIOCHEMISTRY-US, V36, P12317, DOI 10.1021/bi971026e; FOOS G, 1994, ONCOGENE, V9, P2481; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; GOLAY J, 1994, ONCOGENE, V9, P2469; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hogan DJ, 2008, PLOS BIOL, V6, P2297, DOI 10.1371/journal.pbio.0060255; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; Kumar N, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2012.37; Kumarswamy R, 2011, RNA BIOL, V8, P706, DOI 10.4161/rna.8.5.16154; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Lin XK, 2000, NUCLEIC ACIDS RES, V28, P1381, DOI 10.1093/nar/28.6.1381; Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Perez-Leal O, 2012, MOL CELL BIOL, V32, P1453, DOI 10.1128/MCB.06444-11; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Prechtel AT, 2006, J BIOL CHEM, V281, P10912, DOI 10.1074/jbc.M510306200; Ramkissoon LA, 2013, P NATL ACAD SCI USA, V110, P8188, DOI 10.1073/pnas.1300252110; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Schmid T, 2008, CANCER RES, V68, P1254, DOI 10.1158/0008-5472.CAN-07-1719; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shiota M, 2009, CANCER RES, V69, P3148, DOI 10.1158/0008-5472.CAN-08-2334; Singh P, 2011, ONCOGENE, V30, P4864, DOI 10.1038/onc.2011.202; Singh P, 2009, ONCOGENE, V28, P3758, DOI 10.1038/onc.2009.239; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Suzuki C, 2008, P NATL ACAD SCI USA, V105, P3274, DOI 10.1073/pnas.0712235105; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Wedeken L, 2011, J BIOL CHEM, V286, P42855, DOI 10.1074/jbc.M111.269456; Wedeken Lena, 2010, Genes Cancer, V1, P293, DOI 10.1177/1947601910364227; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611; Zhang YY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010618	57	27	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1384	1392		10.1038/onc.2014.83	http://dx.doi.org/10.1038/onc.2014.83			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681950				2022-12-17	WOS:000350806500005
J	Wang, CY; Huang, EYH; Huang, SC; Chung, BC				Wang, C-Y; Huang, E. Y-H; Huang, S-c; Chung, B-c			DNA-PK/Chk2 induces centrosome amplification during prolonged replication stress	ONCOGENE			English	Article							DNA-DAMAGE; S-PHASE; CELLS; ATM; KINASE; PHOSPHORYLATION; ACTIVATION; RADIATION; PK; OVERDUPLICATION	The antineoplastic drug hydroxyurea (HU), when used at subtoxic doses, induces prolonged replication stress and centrosome amplification. This causes genomic instability and increases the malignancy of the recurring tumor. The mechanism of centrosome amplification induced by prolonged replication stress, however, is still unclear. Here, we examined the involvement of ataxia telangiectasia, mutated (ATM), ataxia telangiectasia, mutated and Rad3-related (ATR) and DNA-dependent protein kinase (DNA-PK) and found that HU-induced centrosome amplification was inhibited by the depletion of DNA-PKcs, but not ATM and ATR. Inactivation of ATM/ATR in U2OS cells instead caused aneuploidy and cell death. We found DNA-PKcs depletion also abrogated ATM phosphorylation, indicating that ATM activation during prolonged replication stress depends on DNA-PK. Depletion of DNA-PK abrogated checkpoint kinase (Chk) 2 activation and partially reduced Chk1 activation. Chk2 depletion blocked HU-induced centrosome amplification, indicating a function of Chk2 in centrosome amplification. We further found that Chk2 was phosphorylated at Thr68 on the mother centriole at late G2 and mitosis when unstressed and on all amplified centrioles induced by HU. In summary, we have elucidated that DNA-PK/Chk2 signaling induces centrosome amplification upon long-term HU treatment, therefore increasing our insight into tumor recurrence after initial chemotherapy.	[Wang, C-Y; Huang, E. Y-H; Huang, S-c; Chung, B-c] Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; [Wang, C-Y] Natl Cheng Kung Univ, Coll Med, Dept Cell Biol & Anat, Tainan 70101, Taiwan	Academia Sinica - Taiwan; National Cheng Kung University	Chung, BC (corresponding author), Acad Sinica, Inst Mol Biol, 128 Acad Rd Sect 2, Taipei 115, Taiwan.	mbchung@sinica.edu.tw		Chung, Bon-chu/0000-0002-8612-0219	Academia Sinica [NHRI-EX102-10210SI, NSC102-2923-B-001-003-MY3, NSC102-2320-B-006-051]	Academia Sinica(Academia Sinica - Taiwan)	We would like to thank Ya-Min Lin for technical assistance in FACS analysis. This study was supported by grants from Academia Sinica, NHRI-EX102-10210SI and NSC102-2923-B-001-003-MY3 to B-cC and NSC102-2320-B-006-051 to C-YW.	An J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-32; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Ayene IS, 2005, MOL CANCER THER, V4, P529, DOI 10.1158/1535-7163.MCT-04-0130; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; Bourke E, 2010, ONCOGENE, V29, P616, DOI 10.1038/onc.2009.340; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Golan A, 2010, CELL CYCLE, V9, P2647, DOI 10.4161/cc.9.13.12121; Graser S, 2007, J CELL BIOL, V179, P321, DOI 10.1083/jcb.200707181; Joo K, 2013, P NATL ACAD SCI USA, V110, P5987, DOI 10.1073/pnas.1220927110; Khodjakov A, 2002, J CELL BIOL, V158, P1171, DOI 10.1083/jcb.200205102; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lee KJ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.212969; Liu QH, 2000, GENE DEV, V14, P1448; Nakagawa Y, 2001, MOL BIOL CELL, V12, P1687, DOI 10.1091/mbc.12.6.1687; Prosser SL, 2009, MOL CELL BIOL, V29, P1760, DOI 10.1128/MCB.01124-08; Rampakakis E, 2008, J CELL SCI, V121, P590, DOI 10.1242/jcs.021352; Robinson HMR, 2007, CELL CYCLE, V6, P982, DOI 10.4161/cc.6.8.4111; Sato N, 2000, ONCOGENE, V19, P5281, DOI 10.1038/sj.onc.1203902; Shang ZF, 2010, CANCER RES, V70, P3657, DOI 10.1158/0008-5472.CAN-09-3362; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4; Stehman FB, 1997, GYNECOL ONCOL, V66, P262, DOI 10.1006/gyno.1997.4761; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Wang CY, 2013, MOL CELL BIOL, V33, P476, DOI 10.1128/MCB.01064-12; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	31	27	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1263	1269		10.1038/onc.2014.74	http://dx.doi.org/10.1038/onc.2014.74			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662822				2022-12-17	WOS:000350687100006
J	Whitaker, HC; Shiong, LL; Kay, JD; Gronberg, H; Warren, AY; Seipel, A; Wiklund, F; Thomas, B; Wiklund, P; Miller, JL; Menon, S; Ramos-Montoya, A; Vowler, SL; Massie, C; Egevad, L; Neal, DE				Whitaker, H. C.; Shiong, L. L.; Kay, J. D.; Groenberg, H.; Warren, A. Y.; Seipel, A.; Wiklund, F.; Thomas, B.; Wiklund, P.; Miller, J. L.; Menon, S.; Ramos-Montoya, A.; Vowler, S. L.; Massie, C.; Egevad, L.; Neal, D. E.			N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype	ONCOGENE			English	Article						NAALase; prostate cancer; colon cancer; prognostic; biomarker	PROSTATE-SPECIFIC ANTIGEN; FOCAL ADHESION KINASE; CARBOXYPEPTIDASE-II; CELL-MIGRATION; RADICAL PROSTATECTOMY; RECEPTOR; AGR2; IDENTIFICATION; RECURRENCE; EXPRESSION	N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2) is a member of the glutamate carboxypeptidase II family, best characterized by prostate-specific membrane antigen (PSMA/NAALAD1). Using immunohistochemistry (IHC), we have shown overexpression of NAALADL2 in colon and prostate tumours when compared with benign tissue. In prostate cancer, NAALADL2 expression was associated with stage and Grade, as well as circulating mRNA levels of the NAALADL2 gene. Overexpression of NAALADL2 was shown to predict poor survival following radical prostatectomy. In contrast to PSMA/ NAALAD1, NAALADL2 was localized at the basal cell surface where it promotes adhesion to extracellular matrix proteins. Using stable knockdown and overexpression cell lines, we have demonstrated NAALADL2-dependent changes in cell migration, invasion and colony-forming potential. Expression arrays of the knockdown and overexpression cell lines have identified nine genes that co-expressed with NAALADL2, which included membrane proteins and genes known to be androgen regulated, including the prostate cancer biomarkers AGR2 and SPON2. Androgen regulation was confirmed in a number of these genes, although NAALADL2 itself was not found to be androgen regulated. NAALADL2 was also found to regulate levels of Ser133 phosphorylated C-AMP-binding protein (CREB), a master regulator of a number of cellular processes involved in cancer development and progression. In combination, these data suggest that changes in expression of NAALADL2 can impact upon a number of pro-oncogenic pathways and processes, making it a useful biomarker for both diagnosis and prognosis.	[Whitaker, H. C.; Shiong, L. L.; Kay, J. D.; Thomas, B.; Ramos-Montoya, A.; Massie, C.; Neal, D. E.] Univ Cambridge, Canc Res UK Cambridge Inst, Urooncol Res Grp, Cambridge CB2 0RE, England; [Whitaker, H. C.] Univ Cambridge, Canc Res UK Cambridge Inst, Canc Res UK Biomarker Initiat, Cambridge CB2 0RE, England; [Groenberg, H.; Wiklund, F.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Warren, A. Y.; Miller, J. L.] Univ Cambridge, Canc Res UK Cambridge Inst, Dept Histopathol, Cambridge CB2 0RE, England; [Warren, A. Y.; Miller, J. L.] Univ Cambridge, Canc Res UK Cambridge Inst, ISH Core Facil, Cambridge CB2 0RE, England; [Warren, A. Y.; Miller, J. L.] Cambridge Univ Hosp NHS Fdn Trust, Dept Histopathol, Cambridge, England; [Seipel, A.; Wiklund, P.; Egevad, L.] Karolinska Inst, Dept Pathol, S-10401 Stockholm, Sweden; [Menon, S.; Vowler, S. L.] Univ Cambridge, Canc Res UK Cambridge Inst, Bioinformat Core Facil, Cambridge CB2 0RE, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Karolinska Institutet; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; Karolinska Institutet; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Whitaker, HC (corresponding author), Univ Cambridge, Canc Res UK Cambridge Inst, Canc Res UK Biomarker Initiat, Robinson Way, Cambridge CB2 0RE, England.	Hayley.Whitaker@cruk.cam.ac.uk	Kay, Jonathan/HGE-1248-2022	Massie, Charlie/0000-0003-2314-4843; Neal, David/0000-0002-6033-5086; Wiklund, Peter/0000-0001-6497-4697	University of Cambridge, Cancer Research UK; Hutchison Whampoa Limited; National Institute of Health Research - Cambridge Biomedical Research Centre, Cambridge, UK; National Cancer Research Prostate Cancer: mechanisms of Progression and Treatment (PROMPT) collaborative [G0500966/75466]; Prostate Cancer UK; National Medical Research Council, Singapore; MRC [G0900871] Funding Source: UKRI; Cancer Research UK [22310] Funding Source: researchfish; Medical Research Council [G0900871] Funding Source: researchfish; Prostate Cancer UK [G2012/50] Funding Source: researchfish	University of Cambridge, Cancer Research UK(Cancer Research UKUniversity of Cambridge); Hutchison Whampoa Limited; National Institute of Health Research - Cambridge Biomedical Research Centre, Cambridge, UK; National Cancer Research Prostate Cancer: mechanisms of Progression and Treatment (PROMPT) collaborative; Prostate Cancer UK; National Medical Research Council, Singapore(National Medical Research Council, SingaporeUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Prostate Cancer UK	We would like to acknowledge the support of The University of Cambridge, Cancer Research UK, National Medical Research Council, Singapore and Hutchison Whampoa Limited; the National Institute of Health Research, which funds the Cambridge Biomedical Research Centre, Cambridge, UK; the National Cancer Research Prostate Cancer: mechanisms of Progression and Treatment (PROMPT) collaborative (grant code G0500966/75466), which has funded tissue collections in Cambridge. We would like to thank Prostate Cancer UK for funding a proportion of this work. We are very grateful to the Cancer Research UK Cambridge Institute Genomics Core Facility, Histopathology and ISH Facility, and Bioinformatics and Statistics Core Facility for their assistance with the work in this manuscript. We would also like to thank Erik Sahai (Cancer Research UK London Research Institute) and Ian Mills (Centre for Molecular Medicine Norway) for their helpful discussions in preparing this manuscript.	[Anonymous], 2010, CANC STAT REG; Augustin H, 2013, PROSTATE, V73, P203, DOI 10.1002/pros.22558; Barinka C, 2004, EUR J BIOCHEM, V271, P2782, DOI 10.1111/j.1432-1033.2004.04209.x; Barinka C, 2004, PROTEIN SCI, V13, P1627, DOI 10.1110/ps.04622104; Barrett JA, 2013, J NUCL MED, V54, P380, DOI 10.2967/jnumed.112.111203; Bennett HL, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.50; Botchorishvili G, 2009, CURR OPIN UROL, V19, P221, DOI 10.1097/MOU.0b013e32832a2d10; Brychtova V, 2011, CANCER LETT, V304, P1, DOI 10.1016/j.canlet.2010.12.023; Bu H, 2013, FEBS J, V280, P1249, DOI 10.1111/febs.12118; Burgner D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000319; Cairns JM, 2008, BIOINFORMATICS, V24, P2921, DOI 10.1093/bioinformatics/btn557; Cao KY, 2007, PROSTATE, V67, P1791, DOI 10.1002/pros.20664; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Conkright MD, 2005, TRENDS CELL BIOL, V15, P457, DOI 10.1016/j.tcb.2005.07.007; D'Amico AV, 1999, J CLIN ONCOL, V17, P168, DOI 10.1200/JCO.1999.17.1.168; Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Frigerio B, 2013, EUR J CANCER; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hessels D, 2009, NAT REV UROL, V6, P255, DOI 10.1038/nrurol.2009.40; Ho ME, 2013, MODERN PATHOL, V26, P849, DOI 10.1038/modpathol.2012.238; Hrkach J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003651; Kani K, 2013, PROSTATE, V73, P306, DOI 10.1002/pros.22569; Kattan MW, 1998, JNCI-J NATL CANCER I, V90, P766, DOI 10.1093/jnci/90.10.766; Lee SF, 2011, J BIOL CHEM, V286, P27447, DOI 10.1074/jbc.M111.243154; Liao CH, 2010, ENDOCR-RELAT CANCER, V17, P99, DOI 10.1677/ERC-09-0050; Liu TC, 2012, BIOORG MED CHEM LETT, V22, P3931, DOI 10.1016/j.bmcl.2012.04.110; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mesters JR, 2006, EMBO J, V25, P1375, DOI 10.1038/sj.emboj.7600969; Osborne JR, 2012, UROL ONCOL, V31, P144; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; Powell SM, 2006, BIOCHEM SOC T, V34, P1124, DOI 10.1042/BST0341124; Qian XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037225; Rojas C, 2002, ANAL BIOCHEM, V310, P50, DOI 10.1016/S0003-2697(02)00286-5; Rosario DJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d7894; Silver DA, 1997, CLIN CANCER RES, V3, P81; Smyth G, 2005, LIMMA LINEAR MODELS; Tan SS, 2011, J PATHOL, V223, P81, DOI 10.1002/path.2795; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thirkettle HJ, 2009, CLIN CANCER RES, V15, P3003, DOI 10.1158/1078-0432.CCR-08-2046; Tonkin ET, 2004, HUM GENET, V115, P139, DOI 10.1007/s00439-004-1134-6; Tradonsky A, 2012, AM J CLIN PATHOL, V137, P918, DOI 10.1309/AJCPF3QWIG8FWXIH; Trojan L, 2005, ANTICANCER RES, V25, P183; Tsuchiya N, 1998, J BIOCHEM-TOKYO, V123, P499; Varisli L, 2012, MOL CELL ENDOCRINOL, V350, P107, DOI 10.1016/j.mce.2011.11.027; Varisli L, 2011, DNA CELL BIOL, V30, P419, DOI 10.1089/dna.2010.1128; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Wayner EA, 2012, PROSTATE, V72, P1023, DOI 10.1002/pros.21508; Whitaker HC, 2007, PROSTATE, V67, P943, DOI 10.1002/pros.20580; Whitaker HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013363; Wu YY, 2008, CELL BIOCHEM FUNCT, V26, P467, DOI 10.1002/cbf.1468; Zheng DQ, 1999, CANCER RES, V59, P1655	54	27	32	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5274	5287		10.1038/onc.2013.464	http://dx.doi.org/10.1038/onc.2013.464			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24240687				2022-12-17	WOS:000345120400005
J	Wong, PP; Yeoh, CC; Ahmad, AS; Chelala, C; Gillett, C; Speirs, V; Jones, JL; Hurst, HC				Wong, P-P; Yeoh, C. C.; Ahmad, A. S.; Chelala, C.; Gillett, C.; Speirs, V.; Jones, J. L.; Hurst, H. C.			Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer	ONCOGENE			English	Article							P53-DEPENDENT APOPTOSIS; CANCER/TESTIS ANTIGENS; TUMOR-CELLS; MECHANISMS; PROTEIN; EXPRESSION; REPRESSION; COMPLEXES; DISCOVERY; ARREST	The antiestrogen tamoxifen is a well-tolerated, effective treatment for estrogen receptor-alpha-positive (ER+) breast cancer, but development of resistance eventually limits its use. Here we show that expression of MAGEA2, and related members of this cancertestis antigen family, is upregulated in tamoxifen-resistant tumor cells. Expression of MAGEA2 in tumor lines grown in vitro or as xenografts led to continued proliferation in the presence of tamoxifen. At the molecular level, we demonstrate that MAGEA2 protein localizes to the nucleus and forms complexes with p53 and ER alpha, resulting in repression of the p53 pathway but increased ER-dependent signaling. In a series of ER+, tamoxifen-treated breast cancer patients, we show a highly significant (P = 0.006) association between MAGEA (melanoma-associated antigen) expression and reduced overall survival, confirming the clinical significance of our observations.	[Wong, P-P; Yeoh, C. C.; Jones, J. L.; Hurst, H. C.] Queen Mary Univ London, Barts Canc Inst, Ctr Tumour Biol, London EC1M 6BQ, England; [Ahmad, A. S.] Queen Mary Univ London, Barts Canc Inst, Ctr Epidemiol Math & Stat, London EC1M 6BQ, England; [Chelala, C.] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, London EC1M 6BQ, England; [Gillett, C.] Kings Coll London, Guys Hosp, Breast Pathol Res Grp, London, England; [Speirs, V.] Univ Leeds, Leeds Inst Mol Med, Leeds, W Yorkshire, England	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Leeds	Wong, PP (corresponding author), Queen Mary Univ London, John Vane Sci Ctr, Ctr Tumour Biol, Barts Canc Inst, Charterhouse Sq, London EC1M 6BQ, England.	p.p.wong@qmul.ac.uk; hchurst@btinternet.com	Speirs, Valerie/ABE-7377-2021	Speirs, Valerie/0000-0002-0602-4666; Wong, Ping Pui/0000-0003-1592-4823; chelala, claude/0000-0002-2488-0669; Jones, J Louise/0000-0003-3880-3274	Cancer Research UK; Barts and the London Charity; Cancer Research UK [12008] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Barts and the London Charity; Cancer Research UK(Cancer Research UK)	We are grateful to our colleagues Andrew Clear, Keyur Trivedi and Abeer Shaaban for technical assistance with the TMA for the BLT and Leeds cases, respectively, Dr Yaohe Wang for help with scoring the Immunohistochemistry study, Ian Hart and Steven Robinson for invaluable advice and help with the xenograft study and to Richard Grose for useful comments on the manuscript. We thank Tracey Chapman for expert handling of the Affymetrix arrays and Simak Ali, Dennis McCance and Hinrich Gronemeyer for the generous provision of reagents. This work was funded by Cancer Research UK and Barts and the London Charity.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Atanackovic D, 2008, P NATL ACAD SCI USA, V105, P1650, DOI 10.1073/pnas.0707140104; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Butt AJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1779; Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0021428, 10.1371/journal.pone.0017876, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0027333, 10.1371/journal.pone.0017844, 10.1371/journal.pone.0024144]; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274; Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029; Fentiman IS, 2003, EUR J CANCER, V39, P309, DOI 10.1016/S0959-8049(02)00673-1; Fentiman IS, 2003, EUR J CANCER, V39, P300, DOI 10.1016/S0959-8049(02)00672-X; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Grigoriadis A, 2009, P NATL ACAD SCI USA, V106, P13493, DOI 10.1073/pnas.0906840106; Hughes-Davies L, 2009, BRIT J CANCER, V101, P875, DOI 10.1038/sj.bjc.6605231; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Laios I, 2003, J STEROID BIOCHEM, V87, P207, DOI 10.1016/j.jsbmb.2003.09.011; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; MAAS RA, 1995, CANCER LETT, V97, P107, DOI 10.1016/0304-3835(95)03959-Z; Maraqa L, 2008, CLIN CANCER RES, V14, P405, DOI 10.1158/1078-0432.CCR-07-1363; Marcar L, 2010, CANCER RES, V70, P10362, DOI 10.1158/0008-5472.CAN-10-1341; Markou A, 2011, CLIN CHEM, V57, P421, DOI 10.1373/clinchem.2010.154328; McDonnell DP, 2010, CURR OPIN PHARMACOL, V10, P620, DOI 10.1016/j.coph.2010.09.007; Monte M, 2006, P NATL ACAD SCI USA, V103, P11160, DOI 10.1073/pnas.0510834103; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nardiello T, 2011, CLIN CANCER RES, V17, P4309, DOI 10.1158/1078-0432.CCR-10-1820; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Toillon RA, 2002, BREAST CANCER RES TR, V71, P269, DOI 10.1023/A:1014422101452; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; Williams CMJ, 2009, EMBO J, V28, P3591, DOI 10.1038/emboj.2009.290; Yang B, 2007, CANCER RES, V67, P9954, DOI 10.1158/0008-5472.CAN-07-1478	35	27	27	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4579	4588		10.1038/onc.2014.45	http://dx.doi.org/10.1038/onc.2014.45			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24662835	Green Published, hybrid			2022-12-17	WOS:000342004800005
J	Tan, J; Buache, E; Alpy, F; Daguenet, E; Tomasetto, CL; Ren, GS; Rio, MC				Tan, J.; Buache, E.; Alpy, F.; Daguenet, E.; Tomasetto, C-L; Ren, G-S; Rio, M-C			Stromal matrix metalloproteinase-11 is involved in the mammary gland postnatal development	ONCOGENE			English	Article						mammary gland postnatal development; breast cancer; epithelial-stromal cell crosstalk/interaction; MMP-11; collagen; paracrine function	BRANCHING MORPHOGENESIS; EXTRACELLULAR-MATRIX; DUCTAL MORPHOGENESIS; SIGNALING PATHWAYS; CANCER-CELLS; COLLAGEN-VI; C5 DOMAIN; IN-VIVO; END BUD; STROMELYSIN-3	MMP-11 is a bad prognosis paracrine factor in invasive breast cancers. However, its mammary physiological function remains largely unknown. In the present study we have investigated MMP-11 function during postnatal mammary gland development and function using MMP-11-deficient (MMP-11-/-) mice. Histological and immunohistochemical analyses as well as whole-mount mammary gland staining show alteration of the mammary gland in the absence of MMP-11, where ductal tree, alveolar structures and milk production are reduced. Moreover, a series of transplantation experiments allowed us to demonstrate that MMP-11 exerts an essential local paracrine function that favors mammary gland branching and epithelial cell outgrowth and invasion through adjacent connective tissues. Indeed, MMP-11-/- cleared fat pads are not permissive for wild-type epithelium development, whereasMMP-11-/- epithelium transplants grow normally when implanted in wild-type cleared fat pads. In addition, using primary mammary epithelial organoids, we show in vitro that this MMP-11 pro-branching effect is not direct, suggesting that MMP11 acts via production/release of stroma-associated soluble factor(s). Finally, the lack of MMP-11 leads to decreased periductal collagen content, suggesting that MMP-11 has a role in collagen homeostasis. Thus, local stromal MMP-11 might also regulate mammary epithelial cell behavior mechanically by promoting extracellular matrix stiffness. Collectively, the present data indicate that MMP-11 is a paracrine factor involved during postnatal mammary gland morphogenesis, and support the concept that the stroma strongly impact epithelial cell behavior. Interestingly, stromal MMP-11 has previously been reported to favor malignant epithelial cell survival and promote cancer aggressiveness. Thus, MMP-11 has a paracrine function during mammary gland development that might be harnessed to promote tumor progression, exposing a new link between development and malignancy.	[Tan, J.; Buache, E.; Alpy, F.; Daguenet, E.; Tomasetto, C-L; Rio, M-C] Univ Strasbourg, Inst Natl Sante & Rech Med U964, Ctr Natl Rech Sci UMR 7104, Inst Genet & Biol Mol & Cellulaire,Dept Funct Gen, Strasbourg, France; [Tan, J.; Ren, G-S] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China; [Rio, M-C] Equipe Labellise Ligue Natl Canc, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Chongqing Medical University	Rio, MC (corresponding author), IGBMC, INSERM U964, CNRS UMR 7104, Inst Genet & Biol Mol & Cellulaire, 1 Rue L Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	rio@igbmc.fr	Daguenet, Elisabeth/N-4122-2019; Tomasetto, Catherine Laure/J-2783-2014; Alpy, Fabien/ABD-5893-2020; Daguenet, Elisabeth/K-5507-2015; Alpy, Fabien/H-8941-2016	Daguenet, Elisabeth/0000-0002-6101-1016; Tomasetto, Catherine Laure/0000-0002-1811-5848; Alpy, Fabien/0000-0002-0526-0720; Daguenet, Elisabeth/0000-0002-6101-1016; Alpy, Fabien/0000-0002-0526-0720	Institut National de la Sante et de la Recherche Medicale; Centre National de la Recherche Scientifique; Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer; Ligue Nationale Francaise Contre le Cancer (LNCC; Comites du Haut-Rhin, Bas-Rhin et de la Haute-Savoie); Institut National du Cancer (INCA PL-BIO ADIPOK); Chinese fellowship of National Natural Science Foundation of China [81102008]; LNCC; INCA fellowships	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Francaise Contre le Cancer (LNCC; Comites du Haut-Rhin, Bas-Rhin et de la Haute-Savoie); Institut National du Cancer (INCA PL-BIO ADIPOK)(Institut National du Cancer (INCA) France); Chinese fellowship of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); LNCC; INCA fellowships	We thank Susan Chan and Gerard Gradwohl for helpful discussion, and Corinne Wendling, Laure Nivlet and Olivia Wendling for technical assistance. This work was supported by funds from the Institut National de la Sante et de la Recherche Medicale, the Centre National de la Recherche Scientifique, the Hopital Universitaire de Strasbourg, the Association pour la Recherche sur le Cancer, the Ligue Nationale Francaise Contre le Cancer (LNCC; Comites du Haut-Rhin, Bas-Rhin et de la Haute-Savoie) and the Institut National du Cancer (INCA PL-BIO ADIPOK 2011-2013). JT was a recipient of a Chinese fellowship of National Natural Science Foundation of China (number: 81102008); EB was a recipient of LNCC and INCA fellowships.	Aigner T, 2002, BIOCHEM BIOPH RES CO, V290, P743, DOI 10.1006/bbrc.2001.6227; Andarawewa KL, 2005, CANCER RES, V65, P10862, DOI 10.1158/0008-5472.CAN-05-1231; Basset P, 1997, CRIT REV ONCOL HEMAT, V26, P43, DOI 10.1016/S1040-8428(97)00010-3; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Cannata D, 2010, ENDOCRINOLOGY, V151, P5751, DOI 10.1210/en.2010-0792; Ching S, 2011, J CELL BIOCHEM, V112, P3393, DOI 10.1002/jcb.23273; Couldrey C, 2002, DEV DYNAM, V223, P459, DOI 10.1002/dvdy.10065; DEOME KB, 1959, CANCER RES, V19, P515; Dhimolea E, 2010, BIOMATERIALS, V31, P3622, DOI 10.1016/j.biomaterials.2010.01.077; Edwards PAW, 2000, ADV EXP MED BIOL, V480, P163; Ewald AJ, 2008, DEV CELL, V14, P570, DOI 10.1016/j.devcel.2008.03.003; Fata JE, 2007, DEV BIOL, V306, P193, DOI 10.1016/j.ydbio.2007.03.013; Green KA, 2005, BIOESSAYS, V27, P894, DOI 10.1002/bies.20281; Ha HY, 2001, CANCER RES, V61, P984; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hinck L, 2005, BREAST CANCER RES, V7, P245, DOI 10.1186/bcr1331; Holtz B, 1999, BIOCHEMISTRY-US, V38, P12174, DOI 10.1021/bi990876m; Hovey RC, 2010, J MAMMARY GLAND BIOL, V15, P279, DOI 10.1007/s10911-010-9187-8; Kannan R, 1999, PROTEIN EXPRES PURIF, V16, P76, DOI 10.1006/prep.1999.1068; KEELY PJ, 1995, DIFFERENTIATION, V59, P1, DOI 10.1046/j.1432-0436.1995.5910001.x; Khialeeva E, 2011, DEVELOPMENT, V138, P767, DOI 10.1242/dev.057588; Khokha R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004333; Kren L, 2006, Cesk Patol, V42, P16; Kurley SJ, 2012, DEVELOPMENT, V139, P1754, DOI 10.1242/dev.072769; Kwon YJ, 2011, CLIN EXP METASTAS, V28, P437, DOI 10.1007/s10585-011-9382-z; Lamande SR, 2006, J BIOL CHEM, V281, P16607, DOI 10.1074/jbc.M510192200; Landskroner-Eiger S, 2010, DEV BIOL, V344, P968, DOI 10.1016/j.ydbio.2010.06.019; Lanigan F, 2007, CELL MOL LIFE SCI, V64, P3161, DOI 10.1007/s00018-007-7386-2; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; Lijnen HR, 2002, THROMB HAEMOSTASIS, V87, P530; Lo AT, 2012, J MAMMARY GLAND BIOL, V17, P103, DOI 10.1007/s10911-012-9251-7; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Maskos K, 2003, MOL BIOTECHNOL, V25, P241, DOI 10.1385/MB:25:3:241; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; McCave EJ, 2010, J MAMMARY GLAND BIOL, V15, P291, DOI 10.1007/s10911-010-9190-0; Mori H, 2013, DEVELOPMENT, V140, P343, DOI 10.1242/dev.084236; Motrescu ER, 2008, ONCOGENE, V27, P6347, DOI 10.1038/onc.2008.218; Motrescu ER, 2008, BIOL CHEM, V389, P1037, DOI 10.1515/BC.2008.110; Naylor MJ, 2002, DEV DYNAM, V225, P100, DOI 10.1002/dvdy.10133; Nelson CM, 2006, SCIENCE, V314, P298, DOI 10.1126/science.1131000; Noel A, 2000, ONCOGENE, V19, P1605, DOI 10.1038/sj.onc.1203465; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; Pavlovich AL, 2010, TISSUE ENG PT A, V16, P3719, DOI [10.1089/ten.tea.2009.0836, 10.1089/ten.TEA.2009.0836]; Pedersen G, 2009, CLIN EXP IMMUNOL, V155, P257, DOI 10.1111/j.1365-2249.2008.03836.x; Simian M, 2001, DEVELOPMENT, V128, P3117; Sternlicht MD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1368; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; Tan JX, 2011, INT J DEV BIOL, V55, P851, DOI 10.1387/ijdb.113365jt; Ucar A, 2010, NAT GENET, V42, P1101, DOI 10.1038/ng.709; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; Wolf K, 2011, TRENDS CELL BIOL, V21, P736, DOI 10.1016/j.tcb.2011.09.006; Wu EX, 2001, J CELL BIOCHEM, V82, P549, DOI 10.1002/jcb.1181; Zhao ZS, 2010, HUM PATHOL, V41, P686, DOI 10.1016/j.humpath.2009.10.010	56	27	30	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4050	4059		10.1038/onc.2013.434	http://dx.doi.org/10.1038/onc.2013.434			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24141782	hybrid			2022-12-17	WOS:000340595300004
J	van Oers, JMM; Edwards, Y; Chahwan, R; Zhang, W; Smith, C; Pechuan, X; Schaetzlein, S; Jin, B; Wang, Y; Bergman, A; Scharff, MD; Edelmann, W				van Oers, J. M. M.; Edwards, Y.; Chahwan, R.; Zhang, W.; Smith, C.; Pechuan, X.; Schaetzlein, S.; Jin, B.; Wang, Y.; Bergman, A.; Scharff, M. D.; Edelmann, W.			The MutS beta complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair	ONCOGENE			English	Article						DNA mismatch repair; MSH2-MSH3; DNA double-strand break repair; chromosomal instability; p53; sarcomagenesis	SACCHAROMYCES-CEREVISIAE MSH2; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; SOMATIC HYPERMUTATION; PROTEIN EXPRESSION; HOMOLOGOUS RECOMBINATION; TUMOR SUPPRESSION; DEFICIENT MICE; APC MUTATIONS; COLON-CANCER	Loss of the DNA mismatch repair (MMR) protein MSH3 leads to the development of a variety of tumors in mice without significantly affecting survival rates, suggesting a modulating role for the MutS beta (MSH2-MSH3) complex in late-onset tumorigenesis. To better study the role of MSH3 in tumor progression, we crossed Msh3(-/-) mice onto a tumor predisposing p53-deficient background. Survival of Msh3/p53 mice was not reduced compared with p53 single mutant mice; however, the tumor spectrum changed significantly from lymphoma to sarcoma, indicating MSH3 as a potent modulator of p53-driven tumorigenesis. Interestingly, Msh3(-/-) mouse embryonic fibroblasts displayed increased chromatid breaks and persistence of gamma H2AX foci following ionizing radiation, indicating a defect in DNA double-strand break repair (DSBR). Msh3/p53 tumors showed increased loss of heterozygosity, elevated genome-wide copy-number variation and a moderate microsatellite instability phenotype compared with Msh2/p53 tumors, revealing that MSH2-MSH3 suppresses tumorigenesis by maintaining chromosomal stability. Our results show that the MSH2-MSH3 complex is important for the suppression of late-onset tumors due to its roles in DNA DSBR as well as in DNA MMR. Further, they demonstrate that MSH2-MSH3 suppresses chromosomal instability and modulates the tumor spectrum in p53-deficient tumorigenesis and possibly has a role in other chromosomally unstable tumors as well.	[van Oers, J. M. M.; Edwards, Y.; Chahwan, R.; Schaetzlein, S.; Jin, B.; Wang, Y.; Scharff, M. D.; Edelmann, W.] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; [Zhang, W.] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Smith, C.; Pechuan, X.; Bergman, A.] Albert Einstein Coll Med, Dept Syst & Computat Biol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine	Edelmann, W (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1301 Morris Pk Ave, Bronx, NY 10461 USA.	winfried.edelmann@einstein.yu.edu	Pechuan, Ximo/AAD-7775-2019; Pechuan, Joaquin/H-7327-2015; Chahwan, Richard/AAQ-9381-2021; Smith, Cameron/B-7683-2011	Pechuan, Ximo/0000-0001-8938-7931; Pechuan, Joaquin/0000-0001-8938-7931; Chahwan, Richard/0000-0002-8672-7790; Wang, Yuxun/0000-0002-4252-6102; Smith, Cameron/0000-0002-6347-7506	National Institutes of Health [CA76329, CA93484, CA72649, CA102705]; National Women's Division of the Albert Einstein College of Medicine; NATIONAL CANCER INSTITUTE [R01CA093484, R01CA076329, P30CA013330, R01CA102705, R01CA072649, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI112335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Women's Division of the Albert Einstein College of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Rani Sellers from the Einstein Histotechnology and Comparative Pathology facility for mouse pathology and for reviewing the manuscript. This study was supported by National Institutes of Health grants CA76329 and CA93484 (WE), and CA72649 and CA102705 (MDS). MDS is supported by the Harry Eagle Chair provided by the National Women's Division of the Albert Einstein College of Medicine.	Bardwell PD, 2004, NAT IMMUNOL, V5, P224, DOI 10.1038/ni1031; Benachenhou N, 1998, INT J CANCER, V77, P173, DOI 10.1002/(SICI)1097-0215(19980717)77:2<173::AID-IJC1>3.0.CO;2-N; Benachenhou N, 1999, BRIT J CANCER, V79, P1012, DOI 10.1038/sj.bjc.6690162; Berndt SI, 2007, INT J CANCER, V120, P1548, DOI 10.1002/ijc.22510; Chen PC, 2005, CANCER RES, V65, P8662, DOI 10.1158/0008-5472.CAN-05-0742; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Edelmann W, 2000, CANCER RES, V60, P803; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Harrington JA, 2007, MOL CELL BIOL, V27, P6546, DOI 10.1128/MCB.00855-07; Haugen AC, 2008, CANCER RES, V68, P8465, DOI 10.1158/0008-5472.CAN-08-0002; Hirata H, 2008, J UROLOGY, V179, P2020, DOI 10.1016/j.juro.2008.01.009; Hong Z, 2008, J CELL SCI, V121, P3146, DOI 10.1242/jcs.026393; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacks T, 1996, J CANCER RES CLIN, V122, P319, DOI 10.1007/BF01220798; Kawakami T, 2004, BIOCHEM BIOPH RES CO, V325, P934, DOI 10.1016/j.bbrc.2004.10.114; Kumar C, 2013, J MOL BIOL, V425, P1881, DOI 10.1016/j.jmb.2013.02.024; Kuraguchi M, 2001, CANCER RES, V61, P7934; Lee SY, 2010, GASTROENTEROLOGY, V139, P1519, DOI 10.1053/j.gastro.2010.08.001; Li ZQ, 2006, DNA REPAIR, V5, P675, DOI 10.1016/j.dnarep.2006.02.003; Li ZQ, 2004, J EXP MED, V200, P47, DOI 10.1084/jem.20040355; Lyndaker AM, 2009, BIOESSAYS, V31, P315, DOI 10.1002/bies.200800195; Manley K, 1999, NAT GENET, V23, P471, DOI 10.1038/70598; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Michiels S, 2007, CARCINOGENESIS, V28, P1731, DOI 10.1093/carcin/bgm111; Miura T, 2012, GENETICS, V191, P65, DOI 10.1534/genetics.112.139105; Orimo H, 2000, J HUM GENET, V45, P228, DOI 10.1007/s100380070031; Owen BAL, 2005, NAT STRUCT MOL BIOL, V12, P663, DOI 10.1038/nsmb965; Peled JU, 2010, AM J PATHOL, V177, P2597, DOI 10.2353/ajpath.2010.100234; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Plaschke J, 2004, CANCER RES, V64, P864, DOI 10.1158/0008-5472.CAN-03-2807; Plaschke J, 2012, INT J COLORECTAL DIS, V27, P911, DOI 10.1007/s00384-011-1408-0; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Reynolds MF, 2009, CANCER RES, V69, P1071, DOI 10.1158/0008-5472.CAN-08-2306; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Savouret C, 2003, EMBO J, V22, P2264, DOI 10.1093/emboj/cdg202; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Svetlanov A, 2008, GENETICS, V178, P1937, DOI 10.1534/genetics.107.084798; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Tome S, 2013, DNA REPAIR, V12, P46, DOI 10.1016/j.dnarep.2012.10.006; Tome S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000482; Tomimatsu N, 2012, DNA REPAIR, V11, P441, DOI 10.1016/j.dnarep.2012.01.006; van den Broek WJAA, 2002, HUM MOL GENET, V11, P191, DOI 10.1093/hmg/11.2.191; Varela I, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r100; Wang YX, 2010, P NATL ACAD SCI USA, V107, P5511, DOI 10.1073/pnas.1001223107; Wu XP, 2006, J IMMUNOL, V176, P5426, DOI 10.4049/jimmunol.176.9.5426	52	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3939	3946		10.1038/onc.2013.365	http://dx.doi.org/10.1038/onc.2013.365			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24013230	Green Accepted, Green Submitted			2022-12-17	WOS:000339394700006
J	Huang, J; Stewart, A; Maity, B; Hagen, J; Fagan, RL; Yang, J; Quelle, DE; Brenner, C; Fisher, RA				Huang, J.; Stewart, A.; Maity, B.; Hagen, J.; Fagan, R. L.; Yang, J.; Quelle, D. E.; Brenner, C.; Fisher, R. A.			RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis	ONCOGENE			English	Article						RGS protein; Ras; cellular transformation; Dnmt1; Tip60; apoptosis	PROTEIN SIGNALING 6; HETEROTRIMERIC G-PROTEINS; DNA METHYLTRANSFERASE; PROSTATE-CANCER; P53 ACTIVATION; BREAST-CANCER; CPG ISLANDS; EXPRESSION; CELLS; METHYLATION	The RAS protooncogene has a central role in regulation of cell proliferation, and point mutations leading to oncogenic activation of Ras occur in a large number of human cancers. Silencing of tumor-suppressor genes by DNA methyltransferase 1 (Dnmt1) is essential for oncogenic cellular transformation by Ras, and Dnmt1 is overexpressed in numerous human cancers. Here we provide new evidence that the pleiotropic regulator of G protein signaling (RGS) family member RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated degradation of Dmnt1 and promoting apoptosis. Employing mouse embryonic fibroblasts from wild-type and RGS6(-/-) mice, we found that oncogenic Ras induced upregulation of RGS6, which in turn blocked Ras-induced cellular transformation. RGS6 functions to suppress cellular transformation in response to oncogenic Ras by downregulating Dnmt1 protein expression leading to inhibition of Dnmt1-mediated anti-apoptotic activity. Further experiments showed that RGS6 functions as a scaffolding protein for both Dnmt1 and Tip60 and is required for Tip60-mediated acetylation of Dnmt1 and subsequent Dnmt1 ubiquitylation and degradation. The RGS domain of RGS6, known only for its GTPase-activating protein activity toward G alpha subunits, was sufficient to mediate Tip60 association with RGS6. This work demonstrates a novel signaling action for RGS6 in negative regulation of oncogene-induced transformation and provides new insights into our understanding of the mechanisms underlying Ras-induced oncogenic transformation and regulation of Dnmt1 expression. Importantly, these findings identify RGS6 as an essential cellular defender against oncogenic stress and a potential therapeutic target for developing new cancer treatments.	[Huang, J.; Stewart, A.; Maity, B.; Hagen, J.; Yang, J.; Quelle, D. E.; Fisher, R. A.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; [Fagan, R. L.; Brenner, C.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Fisher, RA (corresponding author), Univ Iowa, Carver Coll Med, Dept Pharmacol, Roy J & Lucille A Carver Coll Med, 2-512 Bowen Sci Bldg, Iowa City, IA 52242 USA.	rory-fisher@uiowa.edu	Brenner, Charles/D-6339-2014	Brenner, Charles/0000-0002-4955-3226; Quelle, Dawn/0000-0001-8776-0122; Fisher, Rory/0000-0003-3108-4836; Stewart, Adele/0000-0003-4968-2471; Switzer, Rebecca/0000-0003-0591-2538	National Cancer Institute [CA161882, HHSN261200433000C, CA075954, CA090367]; American Cancer Society [PF-11-141-01]; NATIONAL CANCER INSTITUTE [R01CA161882, R01CA090367, P30CA086862, R01CA075954] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr John Koland for his careful reading of and useful suggestions for this manuscript, and Sara Reed for identifying effective Tip60 small hairpin RNAs for our assays. This project was supported by National Cancer Institute grants and contracts CA161882 (RAF), HHSN261200433000C (CB), CA075954 (CB), CA090367 (DEQ) and American Cancer Society (PF-11-141-01 (RLF)).	Berman DM, 2004, CANCER RES, V64, P6820, DOI 10.1158/0008-5472.CAN-04-1916; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Cheever ML, 2008, NAT STRUCT MOL BIOL, V15, P155, DOI 10.1038/nsmb.1377; Chen M, 2012, MOL CANCER THER, V11, P370, DOI 10.1158/1535-7163.MCT-11-0458; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Fagan RL, 2013, J BIOL CHEM, V288, P23858, DOI 10.1074/jbc.M113.480517; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; He SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027684; Huang J, 2011, CANCER RES, V71, P6310, DOI 10.1158/0008-5472.CAN-10-3397; Leonhardt H, 2000, J CELL BIOCHEM, P78; Li LC, 2004, BBA-REV CANCER, V1704, P87, DOI 10.1016/j.bbcan.2004.06.001; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Liu ZY, 2004, J BIOL CHEM, V279, P14120, DOI 10.1074/jbc.M309547200; Liu ZY, 2002, J BIOL CHEM, V277, P37832, DOI 10.1074/jbc.M205908200; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Maity B, 2013, CARCINOGENESIS, V34, P1747, DOI 10.1093/carcin/bgt128; Maity B, 2012, J BIOL CHEM, V287, P4972, DOI 10.1074/jbc.M111.297218; Maity B, 2011, J BIOL CHEM, V286, P1409, DOI 10.1074/jbc.M110.186700; Martemyanov KA, 2005, J BIOL CHEM, V280, P5133, DOI 10.1074/jbc.C400596200; Maslov AY, 2012, ONCOGENE, V31, P5172, DOI 10.1038/onc.2012.9; Nakagawa T, 2003, J UROLOGY, V170, P2463, DOI 10.1097/01.ju.0000095919.50869.c9; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; Pakneshan P, 2005, CARCINOGENESIS, V26, P557, DOI 10.1093/carcin/bgi009; Patra SK, 2008, FEBS J, V275, P5217, DOI 10.1111/j.1742-4658.2008.06658.x; Patra SK, 2008, EXP CELL RES, V314, P1193, DOI 10.1016/j.yexcr.2008.01.012; Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033; Peng DF, 2005, CANCER SCI, V96, P403, DOI 10.1111/j.1349-7006.2005.00071.x; Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200; Reu FJ, 2006, J CLIN ONCOL, V24, P3771, DOI 10.1200/JCO.2005.03.4074; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Santourlidis S, 2001, MOL CARCINOGEN, V32, P36, DOI 10.1002/mc.1062; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Syeda F, 2011, J BIOL CHEM, V286, P15344, DOI 10.1074/jbc.M110.209882; Xu M, 2010, MOL MED REP, V3, P699, DOI 10.3892/mmr_00000320; Zhu YM, 2007, INT J COLORECTAL DIS, V22, P661, DOI 10.1007/s00384-006-0224-4	46	27	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3604	3611		10.1038/onc.2013.324	http://dx.doi.org/10.1038/onc.2013.324			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23995786	Green Accepted			2022-12-17	WOS:000338941100012
J	Tan, EH; Morton, JP; Timpson, P; Tucci, P; Melino, G; Flores, ER; Sansom, OJ; Vousden, KH; Muller, PAJ				Tan, E. H.; Morton, J. P.; Timpson, P.; Tucci, P.; Melino, G.; Flores, E. R.; Sansom, O. J.; Vousden, K. H.; Muller, P. A. J.			Functions of TAp63 and p53 in restraining the development of metastatic cancer	ONCOGENE			English	Article						p63; mutant p53; pancreatic tumours; PDAC; metastasis	MUTANT P53; MOUSE MODEL; P63; GAIN; EXPRESSION; TARGET; TUMORIGENESIS; SUPPRESSOR; REGULATOR; MECHANISM	Many tumours harbour mutations in the p53 tumour-suppressor gene that result in the expression of a mutant p53 protein. This mutant p53 protein has, in most cases, lost wild-type transcriptional activity and can also acquire novel functions in promoting invasion and metastasis. One of the mechanisms underlying these novel functions involves the ability of the mutant p53 to interfere with other transcription factors, including the p53 family protein TAp63. To investigate whether simultaneous depletion of both p53 and TAp63 can recapitulate the effect of mutant p53 expression in vivo, we used a mouse model of pancreatic cancer in which the expression of mutant p53 resulted in the rapid appearance of primary tumours and metastases. As shown previously, loss of one allele of wild-type (WT) p53 accelerated tumour development. A change of one WT p53 allele into mutant p53 did not further accelerate tumour development, but did promote the formation of metastasis. By contrast, loss of TAp63 did not significantly accelerate tumour development or metastasis. However, simultaneous depletion of p53 and TAp63 led to both rapid tumour development and metastatic potential, although the incidence of metastases remained lower than that seen in mutant p53-expressing tumours. TAp63/p53-null cells derived from these mice also showed an enhanced ability to scatter and invade in tissue culture as was observed in mutant p53 cells. These data suggest that depletion of TAp63 in a p53-null tumour can promote metastasis and recapitulate-to some extent-the consequences of mutant p53 expression.	[Tan, E. H.; Morton, J. P.; Timpson, P.; Sansom, O. J.; Vousden, K. H.; Muller, P. A. J.] CR UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Timpson, P.] Kinghorn Canc Ctr, Garvan Inst Med Res, Canc Program, Sydney, NSW, Australia; [Tucci, P.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Tucci, P.] Univ Calabria, Dept Pharm Hlth & Nutr Sci, I-87036 Arcavacata Di Rende, CS, Italy; [Melino, G.] IRCCS, Ist Dermopat Immacolata, Biochem Lab, Rome, Italy; [Melino, G.] Univ Roma Tor Vergata, Rome, Italy; [Flores, E. R.] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Beatson Institute; Garvan Institute of Medical Research; University of Leicester; University of Calabria; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Texas System; UTMD Anderson Cancer Center	Vousden, KH (corresponding author), CR UK Beatson Inst, Beatson Inst, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.vousden@beatson.gla.ac.uk; PM292@le.ac.uk	Muller, Patricia AJ/AAH-1888-2019; Timpson, Paul/A-9429-2016; Morton, Jennifer/AAJ-5113-2021; Morton, Jennifer P/E-1633-2011	Muller, Patricia AJ/0000-0002-0926-1499; Morton, Jennifer/0000-0001-5766-9141; Morton, Jennifer P/0000-0001-5766-9141; Sansom, Owen J./0000-0001-9540-3010; TUCCI, PAOLA/0000-0002-9349-5203; Timpson, Paul/0000-0002-5514-7080; Tan, Ee Hong/0000-0002-5971-6455	CRUK; AICR; AIRC [5471, 2011-IG11955]; AIRC 5xmille [9979]; Telethon [GGPO9133]; MRC [MC_U132670600] Funding Source: UKRI; Cancer Research UK [12481, 11650] Funding Source: researchfish; Medical Research Council [MC_U132670600] Funding Source: researchfish; Worldwide Cancer Research [11-0626] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA160394, P30CA016672] Funding Source: NIH RePORTER	CRUK(Cancer Research UK); AICR; AIRC(Fondazione AIRC per la ricerca sul cancro); AIRC 5xmille(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Worldwide Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work in the labs of KHV and OJS was funded by CRUK. Work by PAJM and KHV was sponsored by the AICR. Part of the work was funded by AIRC (# 5471) (2011-IG11955), AIRC 5xmille (# 9979), Telethon Grant GGPO9133, Min. Salute (RF) to GM. We thank Dr N Rath and Dr M Olsen for providing the cDNA of mouse keratinocytes and Dr M Dobbelstein for providing the p63 promoter luciferase construct.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Bergholz J, 2012, CANCER MICROENVIRON, V5, P311, DOI 10.1007/s12307-012-0116-9; Buganim Y, 2010, CANCER RES, V70, P2274, DOI 10.1158/0008-5472.CAN-09-2661; Collisson EA, 2012, CANCER DISCOV, V2, P685, DOI 10.1158/2159-8290.CD-11-0347; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Dong P, 2012, ONCOGENE, V32, P1203; Edward M, 2005, CARCINOGENESIS, V26, P1215, DOI 10.1093/carcin/bgi064; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Koster MI, 2007, P NATL ACAD SCI USA, V104, P3255, DOI 10.1073/pnas.0611376104; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Laurikkala J, 2006, DEVELOPMENT, V133, P1553, DOI 10.1242/dev.02325; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003; Mangiulli M, 2009, NUCLEIC ACIDS RES, V37, P6092, DOI 10.1093/nar/gkp674; Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; Neilsen PM, 2011, ONCOTARGET, V2, P1203; Neuzillet C, 2013, CANCER METAST REV, V32, P147, DOI 10.1007/s10555-012-9396-2; Noll JE, 2012, ONCOGENE, V31, P2836, DOI 10.1038/onc.2011.456; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Quintavalle C, 2013, ONCOGENE, V32, P4001, DOI 10.1038/onc.2012.410; Romano RA, 2007, J INVEST DERMATOL, V127, P1175, DOI 10.1038/sj.jid.5700652; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; SCARPA A, 1993, AM J PATHOL, V142, P1534; Scheel AHJ, 2009, CELL CYCLE, V8, P1426, DOI 10.4161/cc.8.9.8324; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Su XH, 2012, CELL METAB, V16, P511, DOI 10.1016/j.cmet.2012.09.006; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wang W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.97; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546	51	27	28	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3325	3333		10.1038/onc.2013.287	http://dx.doi.org/10.1038/onc.2013.287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23873029	Green Accepted			2022-12-17	WOS:000338443400012
J	Sun, Y; Liu, PY; Scarlett, CJ; Malyukova, A; Liu, B; Marshall, GM; MacKenzie, KL; Biankin, AV; Liu, T				Sun, Y.; Liu, P. Y.; Scarlett, C. J.; Malyukova, A.; Liu, B.; Marshall, G. M.; MacKenzie, K. L.; Biankin, A. V.; Liu, T.			Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc	ONCOGENE			English	Article						N-Myc; neuroblastoma; histone deacetylase 5	EMBRYONIC STEM-CELLS; C-MYC; MUSCLE DIFFERENTIATION; GENOMIC TARGETS; PROTEIN; REPRESSION; HDAC5; TRANSCRIPTION; EXPRESSION; INHIBITORS	The N-Myc oncoprotein induces neuroblastoma, which arises from undifferentiated neuroblasts in the sympathetic nervous system, by modulating gene and protein expression and consequently causing cell differentiation block and cell proliferation. The class Ila histone deacetylase 5 (HDAC5) represses gene transcription, and blocks myoblast, osteoblast and leukemia cell differentiation. Here we showed that N-Myc upregulated HDAC5 expression in neuroblastoma cells. Conversely, HDAC5 repressed the ubiquitin-protein ligase NEDD4 gene expression, increased Aurora A gene expression and consequently upregulated N-Myc protein expression. Genome-wide gene expression analysis and protein co-immunoprecipitation assays revealed that HDAC5 and N-Myc repressed the expression of a common subset of genes by forming a protein complex, whereas HDAC5 and the class III HDAC SIRT2 independently repressed the expression of another common subset of genes without forming a protein complex. Moreover, HDAC5 blocked differentiation and induced proliferation in neuroblastoma cells. Taken together, our data identify HDAC5 as a novel co-factor in N-Myc oncogenesis, and provide the evidence for the potential application of HDAC5 inhibitors in the therapy of N-Myc-induced neuroblastoma and potentially other c-Myc-induced malignancies.	[Sun, Y.; Liu, P. Y.; Malyukova, A.; Liu, B.; Marshall, G. M.; MacKenzie, K. L.; Liu, T.] Childrens Canc Inst Australia Med Res, Randwick, NSW, Australia; [Scarlett, C. J.] Univ Newcastle, Sch Environm & Life Sci, Ourimbah, NSW, Australia; [Scarlett, C. J.; Biankin, A. V.] Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW, Australia; [Liu, B.] Kids Canc Alliance, Randwick, NSW, Australia; [Marshall, G. M.] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia; [Biankin, A. V.] Bankstown Hosp, Dept Surg, Bankstown, NSW, Australia; [Biankin, A. V.] Univ New S Wales, Fac Med, South Western Sydney Clin Sch, Liverpool, NSW, Australia; [Liu, T.] Univ New S Wales, UNSW Med, Sch Womens & Childrens Hlth, Randwick, NSW, Australia	Children's Cancer Institute; University of Newcastle; Garvan Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney	Liu, T (corresponding author), Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Sydney, NSW 2052, Australia.	tliu@unsw.edu.au	Mackenzie, Karen/F-1310-2011; Liu, Tao/A-3922-2015; MacKenzie, Karen/N-5849-2019	Scarlett, Christopher/0000-0002-4140-7785; Biankin, Andrew/0000-0002-0362-5597; MacKenzie, Karen/0000-0003-2996-1617; Liu, Tao/0000-0001-6244-7316	National Health and Medical Research Council [1006002]; Cancer Council NSW project grant; ARC Future Fellowship; Cancer Institute New South Wales Fellowships; Cancer Research UK [17263] Funding Source: researchfish	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW project grant(Cancer Council New South Wales); ARC Future Fellowship(Australian Research Council); Cancer Institute New South Wales Fellowships; Cancer Research UK(Cancer Research UK)	We thank Dr Eric Olsen for the HDAC5 expression constructs. This work was supported by a National Health and Medical Research Council project grant 1006002 (T Liu and CJ Scarlett) and a Cancer Council NSW project grant. T Liu is a recipient of an ARC Future Fellowship, AV Biankin and CJ Scarlett are recipients of Cancer Institute New South Wales Fellowships. Children's Cancer Institute Australia is affiliated with University of New South Wales and Sydney Children's Hospital.	Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Huang EY, 2000, GENE DEV, V14, P45; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kao HY, 2000, GENE DEV, V14, P55; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Liu T, 2007, P NATL ACAD SCI USA, V104, P18682, DOI 10.1073/pnas.0705524104; Liu T, 2009, EUR J CANCER, V45, P1846, DOI 10.1016/j.ejca.2009.03.002; Long XC, 2007, P NATL ACAD SCI USA, V104, P16570, DOI 10.1073/pnas.0708253104; Manji SSM, 2006, J NEUROSCI RES, V83, P181, DOI 10.1002/jnr.20721; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332; Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135; Martin M, 2007, ONCOGENE, V26, P5450, DOI 10.1038/sj.onc.1210613; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Peixoto P, 2012, CELL DEATH DIFFER, V19, P1239, DOI 10.1038/cdd.2012.3; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Renthal W, 2007, NEURON, V56, P517, DOI 10.1016/j.neuron.2007.09.032; Silvagno F, 2002, FEBS LETT, V532, P153, DOI 10.1016/S0014-5793(02)03667-0; SUMMERHILL EM, 1987, MOL BRAIN RES, V2, P99, DOI 10.1016/0169-328X(87)90002-7; Tee AEL, 2010, J BIOL CHEM, V285, P3561, DOI 10.1074/jbc.M109.053041; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Watamoto K, 2003, ONCOGENE, V22, P9176, DOI 10.1038/sj.onc.1206902; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	38	27	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2987	2994		10.1038/onc.2013.253	http://dx.doi.org/10.1038/onc.2013.253			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23812427				2022-12-17	WOS:000337232200005
J	Manning, AL; Benes, C; Dyson, NJ				Manning, A. L.; Benes, C.; Dyson, N. J.			Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation	ONCOGENE			English	Article						heterogeneity; aneuploidy; CIN; retinoblastoma; RB1	GENOMIC INSTABILITY; CLONAL EVOLUTION; GENE-EXPRESSION; HUMAN-CELLS; ANEUPLOIDY; TUMOR; RB; PATHWAY; RETINOBLASTOMA; CANCER	Whole chromosome instability (CIN) is a common feature of cancer cells and has been linked to increased tumor evolution and metastasis. Several studies have shown that the loss of the pRB tumor suppressor causes mitotic defects and chromosome missegregation. pRB is inactivated in many types of cancer and this raises the possibility that the loss of pRB may be a general cause of CIN in tumors. Paradoxically, retinoblastoma tumor cells have a relatively stable karyotype and currently the circumstances in which pRB inactivation causes CIN in human cancers are unclear. Here we utilize a fluorescence in situ hybridization-based approach to score numerical heterogeneity in chromosome copy number as a readout of CIN. Using this technique, we show that high levels of CIN correlate with the combined inactivation of pRB and p53 and that this association is evident in two independent panels of cancer cell lines. Retinoblastoma cell lines characteristically retain a wild-type TP53 gene, providing an opportunity to test the relevance of this functional relationship. We show that retinoblastoma cell lines display mitotic defects similar to those seen when pRB is depleted from non-transformed cells, but that the presence of wild-type p53 suppresses the accumulation of aneuploid cells. A similar synergy between pRB and p53 inactivation was observed in HCT116 cells. These results suggest that the loss of pRB promotes segregation errors, whereas loss of p53 allows tolerance and continued proliferation of the resulting, genomically unstable cancer cells. Hence, it is the cooperative effect of inactivation of both pRB and p53 tumor suppressor pathways that promotes CIN.	[Manning, A. L.; Benes, C.; Dyson, N. J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc Res,Canc Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Dyson, NJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc Res,Canc Ctr, 149 13th St,MB 7330, Charlestown, MA 02129 USA.	dyson@helix.mgh.harvard.edu	Manning, Amity/AAC-8205-2019	Manning, Amity/0000-0003-1332-9086	American Cancer Society Fellowship; NIH [R01 CA155202]; NATIONAL CANCER INSTITUTE [R01CA155202] Funding Source: NIH RePORTER	American Cancer Society Fellowship(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Lees, Dyer and Pellman labs for sharing cell lines, and Neil Ganem for critical reading of the manuscript. This work was supported by a American Cancer Society Fellowship (A.L.M.) and funding from NIH grant R01 CA155202 (to N.J.D). N.J.D. is the James and Shirley Curvey MGH Research Scholar.	Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409; Choi CM, 2009, LUNG CANCER, V64, P66, DOI 10.1016/j.lungcan.2008.07.016; Chung NG, 2012, LEUKEMIA LYMPHOMA, V53, P1234, DOI 10.3109/10428194.2011.645819; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Conklin JF, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2254; Conkrite K, 2012, J CLIN INVEST, V122, P1726, DOI 10.1172/JCI61403; Corson TW, 2007, GENE CHROMOSOME CANC, V46, P617, DOI 10.1002/gcc.20457; Coschi CH, 2012, CELL MOL LIFE SCI, V69, P2009, DOI 10.1007/s00018-011-0910-4; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dimaras H, 2008, HUM MOL GENET, V17, P1363, DOI 10.1093/hmg/ddn024; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002; Gao CF, 2007, P NATL ACAD SCI USA, V104, P8995, DOI 10.1073/pnas.0700631104; Gordon GM, 2011, PROTEIN CELL, V2, P864, DOI 10.1007/s13238-011-1117-z; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heilig CE, 2010, J CELL MOL MED, V14, P895, DOI 10.1111/j.1582-4934.2009.00905.x; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Khan SH, 1998, CANCER RES, V58, P396; Kim MS, 2012, NEOPLASMA, V59, P524, DOI 10.4149/neo_2012_067; Knowlton AL, 2006, CURR BIOL, V16, P1705, DOI 10.1016/j.cub.2006.07.057; KNUDSON AG, 1984, CANCER DETECT PREV, V7, P1; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Manning AL, 2012, NAT REV CANCER, V12, P220, DOI 10.1038/nrc3216; Manning AL, 2011, TRENDS CELL BIOL, V21, P433, DOI 10.1016/j.tcb.2011.05.003; Manning AL, 2010, EMBO J, V29, P3531, DOI 10.1038/emboj.2010.230; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; McClelland SE, 2009, CELL CYCLE, V8, P3262, DOI 10.4161/cc.8.20.9690; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Roschke AV, 2003, CANCER RES, V63, P8634; Roylance R, 2011, CANCER EPIDEM BIOMAR, V20, P2183, DOI 10.1158/1055-9965.EPI-11-0343; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; van den Heuvel S, 2008, NAT REV MOL CELL BIO, V9, P713, DOI 10.1038/nrm2469; Wang ZH, 2004, CANCER RES, V64, P2998, DOI 10.1158/0008-5472.CAN-04-0587; Weglarz L, 2006, ACTA BIOCHIM POL, V53, P349; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733	62	27	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2487	2494		10.1038/onc.2013.201	http://dx.doi.org/10.1038/onc.2013.201			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23792446	Green Accepted			2022-12-17	WOS:000336033600008
J	Mukai, R; Ohshima, T				Mukai, R.; Ohshima, T.			HTLV-1 HBZ positively regulates the mTOR signaling pathway via inhibition of GADD34 activity in the cytoplasm	ONCOGENE			English	Article						HTLV-1; ATL; HBZ; GADD34; nuclear export	CELL LEUKEMIA-VIRUS; BZIP FACTOR HBZ; LEUCINE-ZIPPER-FACTOR; MOLECULAR-MECHANISMS; BINDING-PROTEIN; TYPE-1 TAX; C-JUN; AUTOPHAGY; GENE; TRANSCRIPTION	Human T-cell leukemia virus type-1 (HTLV-1) infection causes adult T-cell leukemia (ATL). Modulation of the transcriptional control of cellular genes by HTLV-1 is thought to be associated with the development of ATL. The viral protein HTLV-1 basic leucine-zipper factor (HBZ) has been shown to dysregulate the activity of cellular transcription factors. Here, we demonstrate that HBZ is exported from the nucleus to the cytoplasm, where it activates the mammalian target of rapamycin (mTOR) signaling pathway through an association with growth arrest and DNA damage gene 34 (GADD34). The N-terminal region of HBZ interacts with the C-terminal region of GADD34. HBZ contains a functional nuclear export signal (NES) sequence within its N-terminal region and it is exported from the nucleus via the CRM1-dependent pathway. Nuclear export of HBZ is essential for its interaction with GADD34 and increased phosphorylation of S6 kinase, which is an established downstream target of the mTOR pathway. Starvation-induced autophagy is significantly suppressed by the overexpression of HBZ. These findings indicate that HBZ is actively exported to the cytoplasm, where it dysregulates the function of cellular factors.	[Mukai, R.; Ohshima, T.] Tokushima Bunri Univ, Fac Engn, Sanuki, Kagawa 7692193, Japan; [Ohshima, T.] Tokushima Bunri Univ, Fac Pharmaceut Sci, Sanuki, Kagawa 7692193, Japan	Tokushima Bunri University; Tokushima Bunri University	Ohshima, T (corresponding author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Kagawa Campus,1314-1 Shido, Sanuki, Kagawa 7692193, Japan.	ohshimat@kph.bunri-u.ac.jp		Mukai, Risa/0000-0003-4669-4100; OHSHIMA, Takayuki/0000-0002-1501-6430	Ministry of Education, Culture, Sports, Science and Technology of Japan; research funds from the Takeda Science Foundation; Suzuken Memorial Foundation; Japanese Leukemia Research Foundation; JSPS	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); research funds from the Takeda Science Foundation; Suzuken Memorial Foundation; Japanese Leukemia Research Foundation; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Dr H. Miyoshi for providing the lentivirus-based transfection system. This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas 'Integrative Research Toward the Conquest of Cancer' from the Ministry of Education, Culture, Sports, Science and Technology of Japan. In addition, this work was supported, in part, by research funds from the Takeda Science Foundation, the Suzuken Memorial Foundation and the Japanese Leukemia Research Foundation. R. Mukai was supported by a Research Fellowship from JSPS for Young Scientists.	Alavian SM, 2011, J VIRAL HEPATITIS, V18, P821, DOI 10.1111/j.1365-2893.2011.01530.x; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; Bender C, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-74; Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76; Cavanagh MH, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-15; Chaumorcel M, 2008, AUTOPHAGY, V4, P46, DOI 10.4161/auto.5184; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Chuluunbaatar U, 2010, GENE DEV, V24, P2627, DOI 10.1101/gad.1978310; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Hagiya K, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-19; Hardt M, 2011, GENES CELLS, V16, P141, DOI 10.1111/j.1365-2443.2010.01482.x; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Hivin P, 2005, J CELL SCI, V118, P1355, DOI 10.1242/jcs.01727; Isono O, 2008, J BIOL CHEM, V283, P34273, DOI 10.1074/jbc.M802527200; Jiang BH, 2008, DRUG RESIST UPDATE, V11, P63, DOI 10.1016/j.drup.2008.03.001; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Kirkegaard K, 2009, CURR TOP MICROBIOL, V335, P323, DOI 10.1007/978-3-642-00302-8_16; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Kudchodkar SB, 2009, REV MED VIROL, V19, P359, DOI 10.1002/rmv.630; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee HK, 2008, CURR OPIN IMMUNOL, V20, P23, DOI 10.1016/j.coi.2008.01.001; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li J, 2011, AM J PHYSIOL-CELL PH, V301, pC213, DOI 10.1152/ajpcell.00067.2011; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Matsumoto J, 2005, ONCOGENE, V24, P1001, DOI 10.1038/sj.onc.1208297; Matsuoka M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-71; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Murata K, 2006, J VIROL, V80, P2495, DOI 10.1128/JVI.80.5.2495-2505.2006; Ohshima T, 2010, J CELL BIOCHEM, V111, P187, DOI 10.1002/jcb.22687; Orvedahl A, 2010, CELL HOST MICROBE, V7, P115, DOI 10.1016/j.chom.2010.01.007; Orvedahl A, 2009, CURR TOP MICROBIOL, V335, P267, DOI 10.1007/978-3-642-00302-8_13; Rende F, 2011, BLOOD, V117, P4855, DOI 10.1182/blood-2010-11-316463; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Simonis N, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-26; Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; Taniguchi Y, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-64; Taylor MP, 2009, AUTOPHAGY, V5, P870, DOI 10.4161/auto.9046; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Uddin MN, 2011, BIOCHEM BIOPH RES CO, V407, P692, DOI 10.1016/j.bbrc.2011.03.077; Watanabe R, 2007, INT J MOL MED, V19, P475; Yasunaga J, 2011, INT J HEMATOL, V94, P435, DOI 10.1007/s12185-011-0937-1; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshida M, 2008, J VIROL, V82, P9359, DOI 10.1128/JVI.00242-08; Yoshita M, 2012, CANCER SCI, V103, P369, DOI 10.1111/j.1349-7006.2011.02123.x; Zhou W, 2011, J BIOL CHEM, V286, P21687, DOI 10.1074/jbc.M110.212787	58	27	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2317	2328		10.1038/onc.2013.181	http://dx.doi.org/10.1038/onc.2013.181			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23708656				2022-12-17	WOS:000335451800005
J	Fernandez, BG; Jezowska, B; Janody, F				Fernandez, B. G.; Jezowska, B.; Janody, F.			Drosophila actin-Capping Protein limits JNK activation by the Src proto-oncogene	ONCOGENE			English	Article						capping protein; Src family kinases; JNK signaling; F-actin; Drosophila wing discs epithelium	REGULATE CELL-PROLIFERATION; RING CANAL MORPHOGENESIS; TUMOR-SUPPRESSOR GENES; FAMILY TYROSINE KINASE; N-TERMINAL KINASE; SMALL GTPASES; F-ACTIN; SIGNALING PATHWAY; DUAL FUNCTION; ORGAN GROWTH	The Src family kinases c-Src, and its downstream effectors, the Rho family of small GTPases RhoA and Jun N-terminal kinase (JNK) have a significant role in tumorigenesis. In this report, using the Drosophila wing disc epithelium as a model system, we demonstrate that the actin-Capping Protein (CP) alpha beta heterodimer, which regulates actin filament (F-actin) polymerization, limits Src-induced apoptosis or tissue overgrowth by restricting JNK activation. We show that overexpressing Src64B drives JNK-independent loss of epithelial integrity and JNK-dependent apoptosis via Btk29A, p120ctn and Rho1. However, when cells are kept alive with the Caspase inhibitor P35, JNK acts as a potent inducer of proliferation via activation of the Yorkie oncogene. Reducing CP levels direct apoptosis of overgrowing Src64B-overexpressing tissues. Conversely, overexpressing capping protein inhibits Src64B and Rho1, but not Rac1-induced JNK signaling. CP requires the actin-binding domain of the alpha-subunit to limit Src64B-induced apoptosis, arguing that the control of F-actin mediates this effect. In turn, JNK directs F-actin accumulation. Moreover, overexpressing capping protein also prevents apoptosis induced by ectopic JNK expression. Our data are consistent with a model in which the control of F-actin by CP limits Src-induced apoptosis or tissue overgrowth by acting downstream of Btk29A, p120ctn and Rho1, but upstream of JNK. In turn, JNK may counteract the effect of CP on F-actin, providing a positive feedback, which amplifies JNK activation. We propose that cytoskeletal changes triggered by misregulation of F-actin modulators may have a significant role in Src-mediated malignant phenotypes during the early stages of cellular transformation.	[Fernandez, B. G.; Jezowska, B.; Janody, F.] Inst Gulbenkian Ciencias, Oeiras, Portugal	Instituto Gulbenkian de Ciencia	Janody, F (corresponding author), Inst Gulbenkian Ciencias, Rua Quinta Grande 6,Apartado 14, P-2780156 Lisbon, Portugal.	fjanody@igc.gulbenkian.pt	Janody, Florence/AAT-1367-2020; Janody, Florence/A-4378-2017	Janody, Florence/0000-0003-4326-0163; Garcia Fernandez, Beatriz/0000-0001-9215-2447	Fundacao para a Ciencia e Tecnologia (FCT) [PTDC/SAU-OBD/73191/2006, PTDC/BIA-BCM/121455/2010]; FCT [SFRH/BPD/35915/2007, SFRH/BD/33215/2007]	Fundacao para a Ciencia e Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	We thank T Xu, B Hay, R Mann, A Laughon, G Morata, J Whited, the Bloomington Drosophila Stock Center, the National Institute of Genetics, The Vienna Drosophila Research Center and the Developmental Studies Hybridoma Bank for fly stocks and reagents. The manuscript was improved by the critical comments of Miguel G. Ferreira, Joana Vaz, Monica Bettencourt Dias and Christen Mirth. This work was supported by grants from Fundacao para a Ciencia e Tecnologia (FCT) (Grants PTDC/SAU-OBD/73191/2006 and PTDC/BIA-BCM/121455/2010). BGF and BJ were the recipients of fellowships from FCT SFRH/BPD/35915/2007 and SFRH/BD/33215/2007, respectively).	Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Brumby AM, 2011, GENETICS, V188, P105, DOI 10.1534/genetics.111.127910; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; Castano J, 2007, MOL CELL BIOL, V27, P1745, DOI 10.1128/MCB.01974-06; Chan HL, 2010, J BIOL CHEM, V285, P4307, DOI 10.1074/jbc.M109.047027; Chang YWE, 2009, RECENT PAT ANTI-CANC, V4, P110, DOI 10.2174/157489209788452830; Chen F, 2012, CANCER RES, V72, P379, DOI 10.1158/0008-5472.CAN-11-1982; Cooper JA, 2008, INT REV CEL MOL BIO, V267, P183, DOI 10.1016/S1937-6448(08)00604-7; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Delalle I, 2005, GENETICS, V171, P1757, DOI 10.1534/genetics.105.049213; Desprat N, 2008, DEV CELL, V15, P470, DOI 10.1016/j.devcel.2008.07.009; Dodson GS, 1998, DEVELOPMENT, V125, P2883; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Enomoto M, 2013, EMBO REP, V14, P65, DOI 10.1038/embor.2012.185; Fan Y, 2010, CELL DEATH DIFFER, V17, P534, DOI 10.1038/cdd.2009.185; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernandez BG, 2011, DEVELOPMENT, V138, P2337, DOI 10.1242/dev.063545; Forster D, 2012, NAT CELL BIOL, V14, P526, DOI 10.1038/ncb2456; Gates J, 2009, DEV BIOL, V333, P90, DOI 10.1016/j.ydbio.2009.06.030; Giannone G, 2006, TRENDS CELL BIOL, V16, P213, DOI 10.1016/j.tcb.2006.02.005; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Harden N, 1999, J CELL SCI, V112, P273; Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Janody F, 2006, DEVELOPMENT, V133, P3349, DOI 10.1242/dev.02511; Jezowska B, 2011, DEV BIOL, V360, P143, DOI 10.1016/j.ydbio.2011.09.016; Khoo P, DIS MODEL MECH; Kim JY, 2009, BIOCHEM PHARMACOL, V79, P431; Kim K, 2004, J CELL BIOL, V164, P567, DOI 10.1083/jcb.200308061; Klein T, 1998, DEV BIOL, V194, P196, DOI 10.1006/dbio.1997.8829; Kulshammer E, 2013, J CELL SCI, V126, P927, DOI 10.1242/jcs.114462; Kurant E, 1998, DEVELOPMENT, V125, P1037; Lee JD, 2001, CURR BIOL, V11, P1147, DOI 10.1016/S0960-9822(01)00323-2; Leong GR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-62; Lu N, 2004, EMBO J, V23, P1089, DOI 10.1038/sj.emboj.7600127; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Magie Craig R., 2002, Development (Cambridge), V129, P3771; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; Mammoto A, 2009, CURR OPIN CELL BIOL, V21, P864, DOI 10.1016/j.ceb.2009.08.001; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Neisch AL, 2010, J CELL BIOL, V189, P311, DOI 10.1083/jcb.200912010; Nelson KS, 2012, NAT CELL BIOL, V14, P518, DOI 10.1038/ncb2467; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oh H, 2008, DEVELOPMENT, V135, P1081, DOI 10.1242/dev.015255; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pedraza LG, 2004, ONCOGENE, V23, P4754, DOI 10.1038/sj.onc.1207635; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Roulier EM, 1998, MOL CELL, V1, P819, DOI 10.1016/S1097-2765(00)80081-7; Rudrapatna VA, DEV DYN, V241, P107; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; SCHAFER DA, 1992, J CELL BIOL, V118, P335, DOI 10.1083/jcb.118.2.335; Shah V, 1998, SOMAT CELL MOLEC GEN, V24, P273, DOI 10.1023/B:SCAM.0000007130.08611.fc; Shindo M, 2008, DEVELOPMENT, V135, P1355, DOI 10.1242/dev.015982; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Smadja-Lamere N, 2008, J BIOL CHEM, V283, P34352, DOI 10.1074/jbc.M803364200; Somogyi K, 2004, MECH DEVELOP, V121, P57, DOI 10.1016/j.mod.2003.10.003; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Spradling AC, 1999, GENETICS, V153, P135; Stewart RA, 2003, ONCOGENE, V22, P6436, DOI 10.1038/sj.onc.1206820; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; Thomas JH, 2004, DEVELOPMENT, V131, P863, DOI 10.1242/dev.00989; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Vidal M, 2007, CANCER RES, V67, P10278, DOI 10.1158/0008-5472.CAN-07-1376; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Warner SJ, 2010, CURR BIOL, V20, P677, DOI 10.1016/j.cub.2010.03.025; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Wear MA, 2004, TRENDS BIOCHEM SCI, V29, P418, DOI 10.1016/j.tibs.2004.06.003; Wear MA, 2004, J BIOL CHEM, V279, P14382, DOI 10.1074/jbc.M313412200; Whited JL, 2004, DEVELOPMENT, V131, P4677, DOI 10.1242/dev.01366; Yamamoto N, 2009, DEVELOPMENT, V136, P1977, DOI 10.1242/dev.030718; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	96	27	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2027	2039		10.1038/onc.2013.155	http://dx.doi.org/10.1038/onc.2013.155			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23644660				2022-12-17	WOS:000334599100003
J	Guo, W; Frenette, PS				Guo, W.; Frenette, P. S.			Alternative CD44 splicing in intestinal stem cells and tumorigenesis	ONCOGENE			English	Editorial Material							CANCER; IDENTIFICATION	As an important player in stem cells and cancer, CD44 is expressed in multiple isoforms via alternative mRNA splicing. Whether, and if so, how various isoforms play distinct roles in normal stem cells and tumorigenesis remains unclear. In this issue of Oncogene, Zeilstra et al. report studies showing that intestinal stem cells express a specific CD44 variant that promotes intestinal tumorigenesis induced by the activation of Wnt signaling, whereas the more commonly expressed standard CD44 isoform is not expressed by stem cells and does not promote tumor formation. This finding demonstrates an isoform-specific function of CD44 in intestinal stem cells and tumorigenesis.	[Guo, W.; Frenette, P. S.] Albert Einstein Coll Med, Ruth L & David S Gottesman Inst Stem Cell & Regen, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Guo, W (corresponding author), Albert Einstein Coll Med, Ruth L & David S Gottesman Inst Stem Cell & Regen, Dept Cell Biol, 1301 Morris Pk,Room 101B, Bronx, NY 10461 USA.	wenjun.guo@einstein.yu.edu; paul.frenette@einstein.yu.edu	Frenette, Paul S/J-8272-2012	Frenette, Paul S/0000-0003-0862-9922	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069438] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL069438] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Katayama Y, 2005, J EXP MED, V201, P1183, DOI 10.1084/jem.20042014; Krause DS, 2006, NAT MED, V12, P1175, DOI 10.1038/nm1489; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	15	27	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					537	538		10.1038/onc.2013.260	http://dx.doi.org/10.1038/onc.2013.260			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23831568				2022-12-17	WOS:000331125100001
J	Lu, H; Wang, X; Urvalek, AM; Li, T; Xie, H; Yu, L; Zhao, J				Lu, H.; Wang, X.; Urvalek, A. M.; Li, T.; Xie, H.; Yu, L.; Zhao, J.			Transformation of human ovarian surface epithelial cells by Kruppel-like factor 8	ONCOGENE			English	Article						KLF8; transformation; human ovarian epithelial cells; human ovarian cancer	FOCAL ADHESION KINASE; CANCER-CELLS; MESENCHYMAL TRANSITION; IONIZING-RADIATION; KLF8 TRANSCRIPTION; GENE-EXPRESSION; UP-REGULATION; HUMAN BREAST; ACTIVATION; PROTEIN	We have previously demonstrated that Kruppel-like factor 8 (KLF8) participates in oncogenic transformation of mouse fibroblasts and is highly overexpressed in human ovarian cancer. In this work, we first correlated KLF8 overexpression with the aggressiveness of ovarian patient tumors and then tested if KLF8 could transform human ovarian epithelial cells. Using the immortalized non-tumorigenic human ovarian surface epithelial cell line T80 and retroviral infection, we generated cell lines that constitutively overexpress KLF8 alone or its combination with the known ovarian oncogenes c-Myc, Stat3c and/or Akt and examined the cell lines for anchorage-independent growth and tumorigenesis. The soft agar clonogenic assay showed that T80/KLF8 cells formed significantly more colonies than the mock cells. Interestingly, the cells expressing both KLF8 and c-Myc formed the largest amounts of colonies, greater than the sum of colonies formed by the cells expressing KLF8 and c-Myc alone. These results suggested that KLF8 might be a weak oncogene that works cooperatively with c-Myc to transform ovarian cells. Surprisingly, overexpression of KLF8 alone was sufficient to induce tumorigenesis in nude mice resulting in short lifespan irrespective of whether the T80/KLF8 cells were injected subcutaneously, intraperitoneally or orthotopically into the ovarian bursa. Histopathological studies confirmed that the T80/KLF8 tumors were characteristic of human serous ovarian carcinomas. Comparative expression profiling and functional studies identified the cell cycle regulators cyclin D1 and USP44 as primary KLF8 targets and effectors for the T80 transformation. Overall, we identified KLF8 overexpression as an important factor in human ovarian carcinoma pathogenesis.	[Lu, H.; Wang, X.; Urvalek, A. M.; Li, T.; Yu, L.; Zhao, J.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA; [Xie, H.] Florida Hosp, Translat Res Inst Metab & Diabet, Orlando, FL USA	State University System of Florida; University of Central Florida; Adventist Health Services; AdventHealth	Zhao, J (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	Jihe.Zhao@ucf.edu	Li, Tianshu/L-6426-2014	Li, Tianshu/0000-0002-9972-4644	NCI [CA132977]; Susan G. Komen for Cure Breast Cancer Foundation [KG090444, KG080616]; American Cancer Society [RSG CCG-111381]; NATIONAL CANCER INSTITUTE [R01CA132977] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G. Komen for Cure Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Alexander Yu Nikitin of Cornell University for helping with the intrabursal implantation techniques. We also thank all the members of Zhao lab for critical discussions and helpful comments. This work was supported by grants from NCI (CA132977), Susan G. Komen for Cure Breast Cancer Foundation (KG090444 and KG080616) and American Cancer Society (RSG CCG-111381) to JZ.	Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Connolly DC, 2003, CANCER RES, V63, P1389; Cox BD, 2006, J CELL BIOCHEM, V99, P36, DOI 10.1002/jcb.20956; Eaton SA, 2008, J BIOL CHEM, V283, P26937, DOI 10.1074/jbc.M804831200; Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Fu WJ, 2010, J CANCER RES CLIN, V136, P1255, DOI 10.1007/s00432-010-0776-0; Gumireddy K, 2009, NAT CELL BIOL, V11, P1297, DOI 10.1038/ncb1974; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Johnson NC, 2004, EXP CELL RES, V298, P9, DOI 10.1016/j.yexcr.2004.04.003; Kang XN, 2010, J CANCER RES CLIN, V136, P1151, DOI 10.1007/s00432-010-0762-6; Lahiri SK, 2012, AM J TRANSL RES, V4, P357; Li JC, 2010, GASTROENTEROLOGY, V139, P2146, DOI 10.1053/j.gastro.2010.08.004; Liu AX, 1998, CANCER RES, V58, P2973; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Liu LL, 2012, TUMOR BIOL, V33, P53, DOI 10.1007/s13277-011-0245-7; Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; Mehta TS, 2009, CELL RES, V19, P1098, DOI 10.1038/cr.2009.64; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Rosen DG, 2006, METHOD ENZYMOL, V407, P660, DOI 10.1016/S0076-6879(05)07052-7; Schnell O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030429; Shan WW, 2009, CELL CYCLE, V8, P731, DOI 10.4161/cc.8.5.7848; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Suresh B, 2010, CELL BIOL INT, V34, P799, DOI 10.1042/CBI20090144; Urvalek AM, 2011, AM J TRANSL RES, V3, P121; Urvalek AM, 2010, CELL CYCLE, V9, P601, DOI 10.4161/cc.9.3.10606; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wan WF, 2012, MOL MED REP, V5, P347, DOI 10.3892/mmr.2011.669; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; Wang X, 2011, ONCOGENE, V30, P1901, DOI 10.1038/onc.2010.563; Wang XH, 2008, J BIOL CHEM, V283, P13934, DOI 10.1074/jbc.M709300200; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Yang F, 2011, MODERN PATHOL, V24, P836, DOI 10.1038/modpathol.2011.44; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yang T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039668; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zhang P, 2005, BLOOD CELL MOL DIS, V35, P227, DOI 10.1016/j.bcmd.2005.04.009; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4; Zheng JF, 2010, CELL CYCLE, V9, P140, DOI 10.4161/cc.9.1.10264; Zhou CY, 2005, BIOCHEM BIOPH RES CO, V336, P952, DOI 10.1016/j.bbrc.2005.08.197; Zhou CY, 2003, ONCOGENE, V22, P2396, DOI 10.1038/sj.onc.1206319; Zhou CY, 2003, BIOCHEM BIOPH RES CO, V303, P130, DOI 10.1016/S0006-291X(03)00318-8	53	27	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					10	18		10.1038/onc.2012.545	http://dx.doi.org/10.1038/onc.2012.545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23222713	Green Accepted			2022-12-17	WOS:000329212000002
J	Ki, MK; Jeoung, MH; Choi, JR; Rho, SS; Kwon, YG; Shim, H; Chung, J; Hong, HJ; Song, BD; Lee, S				Ki, M. K.; Jeoung, M. H.; Choi, J. R.; Rho, S-S; Kwon, Y-G; Shim, H.; Chung, J.; Hong, H. J.; Song, B. D.; Lee, S.			Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro	ONCOGENE			English	Article						Clec14a; C-type lectin-like domain; antibody; angiogenesis; endothelial cell; regulation	METASTATIC COLORECTAL-CANCER; EPIDERMAL-GROWTH-FACTOR; MONOCLONAL-ANTIBODY; INHIBITS ANGIOGENESIS; BEVACIZUMAB; THERAPY; FLUOROURACIL; LEUCOVORIN; CHEMOKINES; VESSELS	It has been suggested that clec14a may be involved in tumor angiogenesis. However, a molecular mechanism has not been clearly identified. In this study, we show for the first time that C-type lectin-like domain (CTLD) of clec14a may be important for regulating cell migration and filopodia formation. Using phage display technology, recombinant human antibodies specific to the CTLDs of human and mouse clec14a (clec14a-CTLD (immunoglobulin G) IgG) were selected. Functional assays using the antibodies showed that clec14a-CTLD IgGs specifically blocked endothelial cell migration and tube formation without affecting cell viability or activation. Further, clec14a-CTLD IgGs inhibited clec14a-mediated cell-cell contact by blocking interaction between CTLDs. Finally, clec14a cross-linking by the clec14a-CTLD IgGs significantly downregulated clec14a expression on the surface of endothelial cells. These results strongly suggest that the clec14a-CTLD may be a key domain in angiogenesis, and that clec14a-CTLD IgGs specifically inhibit angiogenesis by modulating CTLD-mediated cell interactions and clec14a expression on the surface of endothelial cells.	[Ki, M. K.; Jeoung, M. H.; Choi, J. R.; Song, B. D.; Lee, S.] Scripps Korea Antibody Inst, Lab Mol Canc Therapeut, Chunchon 200701, South Korea; [Rho, S-S; Kwon, Y-G] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul 120749, South Korea; [Shim, H.] Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul, South Korea; [Chung, J.] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea; [Hong, H. J.] Kangwon Natl Univ, Dept Syst Immunol, Coll Biomed Sci, Chunchon, South Korea	Yonsei University; Ewha Womans University; Seoul National University (SNU); Kangwon National University	Lee, S (corresponding author), Scripps Korea Antibody Inst, Lab Mol Canc Therapeut, Hyoja 2 Dong, Chunchon 200701, South Korea.	Lees@skai.or.kr			Scripps Korea Antibody Institute; Basic Science Research Program through the National Research Foundation of Korea; Ministry of Education, Science and Technology [2012R1A2A1A01002916]	Scripps Korea Antibody Institute; Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by grants from Scripps Korea Antibody Institute and partly by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012R1A2A1A01002916).	Alon R, 2002, SEMIN IMMUNOL, V14, P93, DOI 10.1006/smim.2001.0346; Barbas C. F., 2001, PHAGE DISPLAY LAB MA; Bergsland E, 2004, ONCOLOGIST, V9, P36, DOI 10.1634/theoncologist.9-suppl_1-36; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Dienstmann R, 2012, CURR CLIN PHARMACOL, V7, P137, DOI 10.2174/157488412800228929; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Huang SM, 2002, MOL CANCER THER, V1, P507; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kim H, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0024749, 10.1371/journal.pone.0019867]; Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502; Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252; Lee SH, 2011, ARCH PHARM RES, V34, P1223, DOI 10.1007/s12272-011-0821-9; Lee S, 2007, INT IMMUNOL, V19, P1349, DOI 10.1093/intimm/dxm104; Leow CC, 2012, INT J ONCOL, V40, P1321, DOI 10.3892/ijo.2012.1366; Lucio-Eterovic AK, 2009, CLIN CANCER RES, V15, P4589, DOI 10.1158/1078-0432.CCR-09-0575; Mura M, 2012, ONCOGENE, V31, P293, DOI 10.1038/onc.2011.233; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Petit AMV, 1997, AM J PATHOL, V151, P1523; Rho SS, 2011, BIOCHEM BIOPH RES CO, V404, P103, DOI 10.1016/j.bbrc.2010.11.075; Sambrook J, 2001, MOL CLONING LAB MANU; Shukla AA, 2007, J CHROMATOGR B, V848, P28, DOI 10.1016/j.jchromb.2006.09.026; Spratlin J, 2011, CURR ONCOL REP, V13, P97, DOI 10.1007/s11912-010-0149-5; Teillaud Jean-Luc, 2012, Methods Mol Biol, V911, P3, DOI 10.1007/978-1-61779-968-6_1; Tortora G, 2004, CURR PHARM DESIGN, V10, P11, DOI 10.2174/1381612043453595; Van Meter KE, 2008, ARCH INSECT BIOCHEM, V69, P107, DOI 10.1002/arch.20271; Vestweber D, 2003, EUR J IMMUNOL, V33, P1361, DOI 10.1002/eji.200324011; Vincenzi B, 2008, CRIT REV ONCOL HEMAT, V68, P93, DOI 10.1016/j.critrevonc.2008.07.006; Zilian Olav, 2012, Hum Vaccin Immunother, V8, P1370, DOI 10.4161/hv.21413	29	27	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5449	5457		10.1038/onc.2013.156	http://dx.doi.org/10.1038/onc.2013.156			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23644659	Green Published, hybrid			2022-12-17	WOS:000327780800002
J	Portela, A; Liz, J; Nogales, V; Setien, F; Villanueva, A; Esteller, M				Portela, A.; Liz, J.; Nogales, V.; Setien, F.; Villanueva, A.; Esteller, M.			DNA methylation determines nucleosome occupancy in the 5 '-CpG islands of tumor suppressor genes	ONCOGENE			English	Article						DNA methylation; tumor suppressor gene; nucleosome; CpG island; DNA methyltransferase	CHROMATIN; PROMOTERS; TISSUES; DNMT3B	Promoter CpG island hypermethylation of tumor suppressor genes is an epigenetic hallmark of human cancer commonly associated with nucleosome occupancy and the transcriptional silencing of the neighboring gene. Nucleosomes can determine the underlying DNA methylation status. Herein, we show that the opposite is also true: DNA methylation can determine nucleosome positioning. Using a cancer model and digital nucleosome positioning techniques, we demonstrate that the induction of DNA hypomethylation events by genetic (DNMT1/DNMT3B deficient cells) or drug (a DNA demethylating agent) approaches is associated with the eviction of nucleosomes from previously hypermethylated CpG islands of tumor suppressor genes. Most importantly, the establishment of a stable cell line that restores DNMT1/DNMT3B deficiency shows that nucleosomes reoccupy their positions in de novo methylated CpG islands. Finally, we extend these results to the genomic level, combining a DNA methylation microarray and the nucleosome positioning technique. Using this global approach, we observe the dependency of nucleosome occupancy upon the DNA methylation status. Thus, our results suggest that there is a close association between hypermethylated CpG islands and the presence of nucleosomes, such that each of these epigenetic mechanisms can determine the recruitment of the other.	[Portela, A.; Liz, J.; Nogales, V.; Setien, F.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain; [Villanueva, A.] Bellvitge Biomed Res Inst IDIBELL, Translat Res Lab, Catalan Inst Oncol, Barcelona, Catalonia, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Avda Gran Via Km 2-7, Barcelona 08908, Catalonia, Spain.	mesteller@idibell.cat	Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Portela, Anna/0000-0003-2184-2584; Nogales, Vanesa/0000-0002-4905-5278	Ministerio de Ciencia e Innovacion (MICINN) [SAF2011-22803]; European Research Council (ERC) Advanced Grant EPINORC; Cellex Foundation; Health and Science Departments of the Catalan Government (Generalitat de Catalunya); Fondo de Investigaciones Sanitarias Grant [PI08-1345]; ICREA Funding Source: Custom	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Research Council (ERC) Advanced Grant EPINORC(European Research Council (ERC)); Cellex Foundation(Foundation CELLEX); Health and Science Departments of the Catalan Government (Generalitat de Catalunya); Fondo de Investigaciones Sanitarias Grant; ICREA(ICREA)	This work was supported by the Ministerio de Ciencia e Innovacion (MICINN), grant number SAF2011-22803 (ME), the European Research Council (ERC) Advanced Grant EPINORC (ME), Cellex Foundation, the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) and a Fondo de Investigaciones Sanitarias Grant PI08-1345 (ME). AP is a Sara Borrell Postdoctoral Fellow. ME is an ICREA Research Professor.	Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445; Cairns BR, 2009, NATURE, V461, P193, DOI 10.1038/nature08450; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; Christensen BC, 2009, CANCER RES, V69, P6315, DOI 10.1158/0008-5472.CAN-09-1073; Davey CS, 2004, NUCLEIC ACIDS RES, V32, P4322, DOI 10.1093/nar/gkh749; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fatemi M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni180; Felle M, 2011, NUCLEIC ACIDS RES, V39, P6956, DOI 10.1093/nar/gkr263; Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110; Gowher H, 2005, BIOCHEMISTRY-US, V44, P9899, DOI 10.1021/bi047634t; Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356; Hodges C, 2009, SCIENCE, V325, P626, DOI 10.1126/science.1172926; Jacinto FV, 2007, CANCER RES, V67, P11481, DOI 10.1158/0008-5472.CAN-07-2687; Carmona FJ, 2012, J PATHOL, V228, P230, DOI 10.1002/path.4011; Jeong S, 2009, MOL CELL BIOL, V29, P5366, DOI 10.1128/MCB.00484-09; Jiang CZ, 2009, NAT REV GENET, V10, P161, DOI 10.1038/nrg2522; Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112; Lee JY, 2012, J AM CHEM SOC, V134, P173, DOI 10.1021/ja210273w; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014; Pandiyan K, 2013, NUCLEIC ACIDS RES, V41, P3973, DOI 10.1093/nar/gkt077; Pennings Sari, 2005, Briefings in Functional Genomics & Proteomics, V3, P351, DOI 10.1093/bfgp/3.4.351; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Sharma S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001286; Shen L, 2007, PLOS GENET, V3, P2023, DOI 10.1371/journal.pgen.0030181; Shen L, 2010, NUCLEIC ACIDS RES, V38, P6054, DOI 10.1093/nar/gkq456; Youssef EM, 2004, CANCER BIOL THER, V3, P82, DOI 10.4161/cbt.3.1.591	34	27	29	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5421	5428		10.1038/onc.2013.162	http://dx.doi.org/10.1038/onc.2013.162			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23686312	hybrid, Green Published			2022-12-17	WOS:000327177600005
J	Thompson-Wicking, K; Francis, RW; Stirnweiss, A; Ferrari, E; Welch, MD; Baker, E; Murch, AR; Gout, AM; Carter, KW; Charles, AK; Phillips, MB; Kees, UR; Beesley, AH				Thompson-Wicking, K.; Francis, R. W.; Stirnweiss, A.; Ferrari, E.; Welch, M. D.; Baker, E.; Murch, A. R.; Gout, A. M.; Carter, K. W.; Charles, A. K.; Phillips, M. B.; Kees, U. R.; Beesley, A. H.			Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma	ONCOGENE			English	Article						BRD4; NUT; carcinoma; NMC; RNA-Seq; transcriptome	T(15-19)(Q15-P13) CHROMOSOME ABNORMALITY; BET BROMODOMAIN INHIBITION; THYMIC CARCINOMA; AGGRESSIVE CARCINOMA; YOUNG-PATIENTS; C-MYC; DIFFERENTIATION; REARRANGEMENT; LEUKEMIA; CHROMATIN	Nuclear protein in testis (NUT)-midline carcinoma (NMC) is a rare, aggressive disease typically presenting with a single t(15; 19) translocation that results in the generation of a bromodomain-containing protein 4 (BRD4)-NUT fusion. PER-624 is a cell line generated from an NMC patient with an unusually complex karyotype that gave no initial indication of the involvement of the NUT locus. Analysis of PER-624 next-generation transcriptome sequencing (RNA-Seq) using the algorithm FusionFinder identified a novel transcript in which Exon 15 of BRD4 was fused to Exon 2 of NUT, therefore differing from all published NMC fusion transcripts. The three additional exons contained in the PER-624 fusion encode a series of polyproline repeats, with one predicted to form a helix. In the NMC cell line PER-403, we identified the 'standard' NMC fusion and two novel isoforms. Knockdown by small interfering RNA in either cell line resulted in decreased proliferation, increased cell size and expression of cytokeratins consistent with epithelial differentiation. These data demonstrate that the novel BRD4-NUT fusion in PER-624 encodes a functional protein that is central to the oncogenic mechanism in these cells. Genomic PCR indicated that in both PER-624 and PER-403, the translocation fuses an intron of BRD4 to a region upstream of the NUT coding sequence. Thus, the generation of BRD4-NUT fusion transcripts through post-translocation RNA-splicing appears to be a common feature of these carcinomas that has not previously been appreciated, with the mechanism facilitating the expression of alternative isoforms of the fusion. Finally, ectopic expression of wild-type NUT, a protein normally restricted to the testis, could be demonstrated in PER-403, indicating additional pathways for aberrant cell signaling in NMC. This study contributes to our understanding of the genetic diversity of NMC, an important step towards finding therapeutic targets for a disease that is refractory to current treatments.	[Thompson-Wicking, K.; Stirnweiss, A.; Ferrari, E.; Welch, M. D.; Gout, A. M.; Kees, U. R.; Beesley, A. H.] Univ Western Australia, Div Childrens Leukaemia & Canc Res, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Francis, R. W.; Carter, K. W.] Univ Western Australia, Div Bioinformat, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Baker, E.; Murch, A. R.] King Edward Mem Hosp Women, PathWest Lab Med, Dept Cytogenet, Perth, WA, Australia; [Murch, A. R.; Charles, A. K.] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia; [Charles, A. K.] PathWest Lab Med, Dept Pathol, Perth, WA, Australia; [Phillips, M. B.] Princess Margaret Hosp Children, Dept Haematol & Oncol, Perth, WA, Australia	Telethon Kids Institute; University of Western Australia; Telethon Kids Institute; University of Western Australia; King Edward Memorial Hospital; University of Western Australia; University of Western Australia	Kees, UR (corresponding author), Telethon Inst Child Hlth Res, Div Childrens Leukaemia & Canc Res, POB 855, Subiaco, WA 6872, Australia.	ursula@ichr.uwa.edu.au	Phillips, Marianne/AAA-4971-2021; Francis, Richard/K-2812-2019; Beesley, Alex H/K-5805-2013	Phillips, Marianne/0000-0002-1963-4543; Francis, Richard/0000-0003-1580-7934; Beesley, Alex H/0000-0002-5742-7270; Charles, Adrian/0000-0002-3193-1065	Children's Leukemia and Cancer Research Foundation (CLCRF, Perth, Western Australia, Australia); Apache Energy Limited; Cancer Council of Western Australia; University of Western Australia; WA State Government Centers of Excellence Program	Children's Leukemia and Cancer Research Foundation (CLCRF, Perth, Western Australia, Australia); Apache Energy Limited; Cancer Council of Western Australia(Cancer Council Western Australia); University of Western Australia; WA State Government Centers of Excellence Program	This work was supported by grants from the Children's Leukemia and Cancer Research Foundation (CLCRF, Perth, Western Australia, Australia), Apache Energy Limited, the Cancer Council of Western Australia, the University of Western Australia and the WA State Government Centers of Excellence Program. We would like to thank Maxine Crook, Senior Medical Scientist, PathWest Laboratory Medicine, Perth, for performing the IHC used in this study.	Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Engleson J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-69; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Francis RW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039987; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; French CA, 2010, J CLIN PATHOL, V63, P492, DOI 10.1136/jcp.2007.052902; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Haruki N, 2005, J MED GENET, V42, P558, DOI 10.1136/jmg.2004.029686; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; KUBONISHI I, 1991, CANCER RES, V51, P3327; KUZUME T, 1992, INT J CANCER, V50, P259, DOI 10.1002/ijc.2910500216; Mertens F, 2007, PEDIATR BLOOD CANCER, V49, P1015, DOI 10.1002/pbc.20755; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; Prinjha RK, 2012, TRENDS PHARMACOL SCI, V33, P146, DOI 10.1016/j.tips.2011.12.002; Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176; Schwartz BE, 2011, CANCER RES, V71, P2686, DOI 10.1158/0008-5472.CAN-10-3513; Shehata BM, 2010, PEDIATR DEVEL PATHOL, V13, P481, DOI 10.2350/09-10-0727-CR.1; Tanaka M, 2012, AM J SURG PATHOL, V36, P381, DOI 10.1097/PAS.0b013e31824230a8; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Vargas SO, 2001, CANCER, V92, P1195, DOI 10.1002/1097-0142(20010901)92:5<1195::AID-CNCR1438>3.0.CO;2-3; Yan JP, 2011, J BIOL CHEM, V286, P27663, DOI 10.1074/jbc.M111.246975; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	30	27	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2013	32	39					4664	4674		10.1038/onc.2012.487	http://dx.doi.org/10.1038/onc.2012.487			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23128391				2022-12-17	WOS:000325072200008
J	Ruggieri, V; Pin, E; Russo, MT; Barone, F; Degan, P; Sanchez, M; Quaia, M; Minoprio, A; Turco, E; Mazzei, F; Viel, A; Bignami, M				Ruggieri, V.; Pin, E.; Russo, M. T.; Barone, F.; Degan, P.; Sanchez, M.; Quaia, M.; Minoprio, A.; Turco, E.; Mazzei, F.; Viel, A.; Bignami, M.			Loss of MUTYH function in human cells leads to accumulation of oxidative damage and genetic instability	ONCOGENE			English	Article						MUTYH variants; 8-oxodG; PIG-A; MUTYH-associated polyposis; DNA glycosylase activity	BASE-EXCISION-REPAIR; ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; DNA-DAMAGE; GLYCOSYLASE ACTIVITY; GERMLINE MUTATIONS; HUMAN HOMOLOG; MYH; HMYH; DEFICIENT	The DNA glycosylase MUTYH (mutY homolog (Escherichia coli)) counteracts the mutagenic effects of 8-oxo-7,8-dihydroguanine (8-oxodG) by removing adenine (A) misincorporated opposite the oxidized purine. Biallelic germline mutations in MUTYH cause the autosomal recessive MUTYH-associated adenomatous polyposis (MAP). Here we designed new tools to investigate the biochemical defects and biological consequences associated with different MUTYH mutations in human cells. To identify phenotype(s) associated with MUTYH mutations, lymphoblastoid cell lines (LCLs) were derived from seven MAP patients harboring missense as well as truncating mutations in MUTYH. These included homozygous p. Arg245His, p. Gly264TrpfsX7 or compound heterozygous variants (p. Gly396Asp/Arg245Cys, p. Gly396Asp/Tyr179Cys, p. Gly396Asp/Glu410GlyfsX43, p. Gly264TrpfsX7/Ala385ProfsX23 and p. Gly264TrpfsX7/ Glu480del). DNA glycosylase assays of MAP LCL extracts confirmed that all these variants were defective in removing A from an 8-oxoG: A DNA substrate, but retained wild-type OGG1 activity. As a consequence of this defect, MAP LCLs accumulated DNA 8-oxodG in their genome and exhibited a fourfold increase in spontaneous mutagenesis at the PIG-A gene compared with LCLs from healthy donors. They were also hypermutable by KBrO3-a source of DNA 8-oxodG-indicating that the relatively modest spontaneous mutator phenotype associated with MUTYH loss can be significantly enhanced by conditions of oxidative stress. These observations identify accumulation of DNA 8-oxodG and a mutator phenotype as likely contributors to the pathogenesis of MUTYH variants.	[Ruggieri, V.; Russo, M. T.; Barone, F.; Minoprio, A.; Turco, E.; Mazzei, F.; Bignami, M.] Ist Super Sanita, Dept Environm & Primary Prevent, I-00161 Rome, Italy; [Pin, E.; Quaia, M.; Viel, A.] IRCCS, Ctr Riferimento Oncol, Div Expt Oncol 1, Aviano, Italy; [Degan, P.] Ist Nazl Ric Cancro IST CBA, Dept Translat Oncol, Genoa, Italy; [Sanchez, M.] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); IRCCS Aviano (CRO); University of Genoa; IRCCS AOU San Martino IST; Istituto Superiore di Sanita (ISS)	Bignami, M (corresponding author), Ist Super Sanita, Dept Environm & Primary Prevent, Viale Regina Elena 299, I-00161 Rome, Italy.	bignami@iss.it	Ruggieri, Vitalba/J-7847-2016; degan, paolo/AAB-6713-2019; Barone, Flavia/N-6983-2017; QUAIA, MICHELE/AAZ-2990-2020; degan, paolo/AAB-4093-2019; Sanchez, Massimo/AAD-1746-2021; Viel, Alessandra/J-7116-2018	Ruggieri, Vitalba/0000-0003-0860-3415; degan, paolo/0000-0003-0855-8896; Barone, Flavia/0000-0002-8929-7749; QUAIA, MICHELE/0000-0002-6656-2597; Sanchez, Massimo/0000-0003-3696-7582; Viel, Alessandra/0000-0003-2804-0840; Turco, Eleonora/0000-0002-5266-4592; PIN, ELISA/0000-0002-2158-2674	NIH/ISS, AIRC; Ministero della Salute Alleanza contro il Cancro	NIH/ISS, AIRC; Ministero della Salute Alleanza contro il Cancro	The authors are grateful to Drs M Fornasarig and D Barana for patient recruitment. This work has been supported by grants to MB from NIH/ISS, AIRC and by Ministero della Salute Alleanza contro il Cancro to AV and MB.	Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Alhopuro Pia, 2005, Hum Mutat, V26, P393, DOI 10.1002/humu.9368; Ali M, 2008, GASTROENTEROLOGY, V135, P499, DOI 10.1053/j.gastro.2008.04.035; Araten DJ, 2005, CANCER RES, V65, P8111, DOI 10.1158/0008-5472.CAN-04-1198; Bai HB, 2007, CANCER LETT, V250, P74, DOI 10.1016/j.canlet.2006.09.016; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Cardoso J, 2006, CANCER RES, V66, P2514, DOI 10.1158/0008-5472.CAN-05-2407; Cheadle JP, 2007, DNA REPAIR, V6, P274, DOI 10.1016/j.dnarep.2006.11.001; Chiera F, 2008, FREE RADICAL BIO MED, V44, P332, DOI 10.1016/j.freeradbiomed.2007.09.018; Cleary SP, 2009, GASTROENTEROLOGY, V136, P1251, DOI 10.1053/j.gastro.2008.12.050; D'Agostino VG, 2010, DNA REPAIR, V9, P700, DOI 10.1016/j.dnarep.2010.03.008; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; Farrington SM, 2005, AM J HUM GENET, V77, P112, DOI 10.1086/431213; Gismondi V, 2004, INT J CANCER, V109, P680, DOI 10.1002/ijc.20054; Glaab WE, 1998, CARCINOGENESIS, V19, P1931, DOI 10.1093/carcin/19.11.1931; Goto M, 2010, HUM MUTAT, V31, pE1861, DOI 10.1002/humu.21363; Gu YS, 2001, NUCLEIC ACIDS RES, V29, P2666, DOI 10.1093/nar/29.12.2666; Hirano S, 2003, J BIOL CHEM, V278, P38121, DOI 10.1074/jbc.C300316200; Isidro Gloria, 2004, Hum Mutat, V24, P353, DOI 10.1002/humu.9282; Jasperson KW, 2010, GASTROENTEROLOGY, V138, P2044, DOI 10.1053/j.gastro.2010.01.054; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; Kundu S, 2009, DNA REPAIR, V8, P1400, DOI 10.1016/j.dnarep.2009.09.009; Lipton L, 2003, CANCER RES, V63, P7595; Molatore S, 2010, HUM MUTAT, V31, P159, DOI 10.1002/humu.21158; Oka S, 2011, CANCER SCI, V102, P677, DOI 10.1111/j.1349-7006.2011.01869.x; Out AA, 2010, HUM MUTAT, V31, P1205, DOI 10.1002/humu.21343; Parker AR, 2005, CARCINOGENESIS, V26, P2010, DOI 10.1093/carcin/bgi166; Peruzzi B, 2010, MUTAT RES-REV MUTAT, V705, P3, DOI 10.1016/j.mrrev.2009.12.004; Pin E, INT J CANCER, DOI [10.1002/ijc.27761, DOI 10.1002/IJC.27761)]; Poulsen MLM, 2008, CURR GENOMICS, V9, P420, DOI 10.2174/138920208785699562; Russo MT, 2009, CANCER RES, V69, P4372, DOI 10.1158/0008-5472.CAN-08-3292; Sansom OJ, 2003, DNA REPAIR, V2, P1029, DOI 10.1016/S1568-7864(03)00111-3; Shi GL, 2006, BIOCHEM J, V400, P53, DOI 10.1042/BJ20060774; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; van Loon B, 2010, DNA REPAIR, V9, P604, DOI 10.1016/j.dnarep.2010.03.004; van Puijenbroek M, 2008, CLIN CANCER RES, V14, P139, DOI 10.1158/1078-0432.CCR-07-1705; Wang L, 2004, GASTROENTEROLOGY, V127, P9, DOI 10.1053/j.gastro.2004.03.070; Xu XXS, 2001, CANCER RES, V61, P3775; Yanaru-Fujisawa R, 2008, CLIN GENET, V73, P545, DOI 10.1111/j.1399-0004.2008.00998.x; Yi FM, 2009, VIROLOGY, V388, P236, DOI 10.1016/j.virol.2009.03.027	41	27	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4500	4508		10.1038/onc.2012.479	http://dx.doi.org/10.1038/onc.2012.479			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108399				2022-12-17	WOS:000324831300005
J	Gery, S; Koeffler, HP				Gery, S.; Koeffler, H. P.			Role of the adaptor protein LNK in normal and malignant hematopoiesis	ONCOGENE			English	Review						cytokine signaling; LNK; hematopoiesis	GENOME-WIDE ASSOCIATION; MYELOPROLIFERATIVE NEOPLASMS; CELIAC-DISEASE; SELF-RENEWAL; GLUCOSE-HOMEOSTASIS; SIGNAL-TRANSDUCTION; PROGENITOR CELLS; DEFICIENT MICE; BLOOD-PRESSURE; STEM-CELLS	The signal transduction pathways, orchestrating the differentiation of hematopoietic stem and progenitor cells in response to cytokine stimulation, are strictly controlled by networks of feedback loops, highly selective protein interactions and finely tuned on/off switches. In hematological malignancies, the aberrant activation of signaling pathways is usually associated with mutations in tyrosine kinases. Recently, the role of negative signaling regulators is increasingly being recognized as an alternative mechanism involved in diseases such as leukemias and myeloproliferative neoplasms (MPNs). The adaptor protein LNK (Src homology 2 (SH2)B3) is a negative regulator of cytokine signaling that has an essential, nonredundant role in normal hematopoiesis. Indeed, LNK-deficient mice show marked expansion of early hematopoietic precursors, more mature myeloid and B-lineage lymphoid cells, as well as enhanced hematopoietic reconstitution. Murine models show that loss of LNK enhances the development of MPNs and may have a role in additional pathologies. LNK mutations were recently identified in patients with MPNs, and studies in animal models and hematopoietic cell lines suggest that LNK controls the aberrant signaling pathways induced by activated oncogenic kinases. In addition, genome-wide studies show that LNK is associated with autoimmune and cardiovascular disorders. These findings have implications for the future study of hematopoiesis, as well as for the development of novel stem cell and disease-specific therapies.	[Gery, S.; Koeffler, H. P.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; [Koeffler, H. P.] Natl Univ Singapore, Canc Sci Inst, Natl Canc Inst, Singapore 117548, Singapore	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National University of Singapore	Gery, S (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	gerys@cshs.org			NIH [R01CA026038-32, U54CA143930]; A * STAR Grant; Mary Barry Foundation; NATIONAL CANCER INSTITUTE [U54CA143930, R01CA026038] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); A * STAR Grant(Agency for Science Technology & Research (A*STAR)); Mary Barry Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study is supported in part by the NIH grants R01CA026038-32 and U54CA143930, as well as A * STAR Grant and the Mary Barry Foundation.	Ahlenius H, 2012, J NEUROSCI, V32, P5151, DOI 10.1523/JNEUROSCI.0474-12.2012; Alcina A, 2010, GENES IMMUN, V11, P439, DOI 10.1038/gene.2010.30; Baran-Marszak F, 2010, BLOOD, V116, P5961, DOI 10.1182/blood-2009-12-256768; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Bersenev A, 2008, J CLIN INVEST, V118, P2832, DOI 10.1172/JCI35808; Bersenev A, 2010, J CLIN INVEST, V120, P2058, DOI 10.1172/JCI42032; Buza-Vidas N, 2006, GENE DEV, V20, P2018, DOI 10.1101/gad.385606; Coenen MJH, 2009, HUM MOL GENET, V18, P4195, DOI 10.1093/hmg/ddp365; Devalliere J, 2011, BIOCHEM PHARMACOL, V82, P1391, DOI 10.1016/j.bcp.2011.06.023; Dhe-Sirano D, 2004, NAT STRUCT MOL BIOL, V11, P968, DOI 10.1038/nsmb829; Dravid G, 2011, MOL THER, V19, P768, DOI 10.1038/mt.2010.281; Ema H, 2005, DEV CELL, V8, P907, DOI 10.1016/j.devcel.2005.03.019; Eriksson N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034442; Gateva V, 2009, NAT GENET, V41, P1228, DOI 10.1038/ng.468; Gery S, 2007, BLOOD, V110, P3360, DOI 10.1182/blood-2007-05-089326; Gery S, 2009, J LEUKOCYTE BIOL, V85, P957, DOI 10.1189/jlb.0908575; Gery S, 2009, EXP HEMATOL, V37, P585, DOI 10.1016/j.exphem.2009.01.009; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Gueller S, 2008, BIOCHEM J, V415, P241, DOI 10.1042/BJ20080102; Gueller S, 2011, EXP HEMATOL, V39, P591, DOI 10.1016/j.exphem.2011.02.001; Gueller S, 2010, J LEUKOCYTE BIOL, V88, P699, DOI 10.1189/jlb.0309185; Ha JS, 2011, AM J HEMATOL, V86, P866, DOI 10.1002/ajh.22107; He XQ, 2000, MOL IMMUNOL, V37, P603, DOI 10.1016/S0161-5890(00)00070-5; Hu JJ, 2005, J BIOL CHEM, V280, P18943, DOI 10.1074/jbc.M414157200; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; Hunt KA, 2008, NAT GENET, V40, P395, DOI 10.1038/ng.102; Hurtado C, 2011, LEUKEMIA RES, V35, P1537, DOI 10.1016/j.leukres.2011.07.009; Jatiani Shashidhar S, 2010, Genes Cancer, V1, P979, DOI 10.1177/1947601910397187; Jiang J, 2012, J CLIN INVEST, V122, P2079, DOI 10.1172/JCI59719; Jin Y, 2012, NAT GENET, V44, P676, DOI 10.1038/ng.2272; Kamei N, 2010, STEM CELLS, V28, P365, DOI 10.1002/stem.243; Koren-Michowitz M, HAEMATOLOGICA; Koren-Michowitz M, 2010, BLOOD, V116; Kurzer JH, 2006, MOL CELL BIOL, V26, P6381, DOI 10.1128/MCB.00570-06; Kwon SM, 2009, CIRC RES, V104, P969, DOI 10.1161/CIRCRESAHA.108.192856; Lasho TL, 2011, LEUKEMIA, V25, P1056, DOI 10.1038/leu.2011.45; Lasho TL, 2010, NEW ENGL J MED, V363, P1189, DOI 10.1056/NEJMc1006966; Lavrikova EY, 2011, PEDIATR DIABETES, V12, P127, DOI 10.1111/j.1399-5448.2010.00656.x; Levy D, 2009, NAT GENET, V41, P677, DOI 10.1038/ng.384; Li M, 2006, ENDOCRINOLOGY, V147, P2163, DOI 10.1210/en.2005-1313; Li YJ, 2000, J IMMUNOL, V164, P5199, DOI 10.4049/jimmunol.164.10.5199; Lin DC, BLOOD; Looi CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023640; Matsumoto T, 2010, J EXP MED, V207, P2207, DOI 10.1084/jem.20100321; Maures TJ, 2007, TRENDS ENDOCRIN MET, V18, P38, DOI 10.1016/j.tem.2006.11.007; McMullin MF, 2011, AM J HEMATOL, V86, P962, DOI 10.1002/ajh.22154; Morris DL, 2010, ENDOCRINOLOGY, V151, P3643, DOI 10.1210/en.2010-0254; Newton-Cheh C, 2009, NAT GENET, V41, P666, DOI 10.1038/ng.361; Nobuhisa I, 2003, MOL CELL BIOL, V23, P8486, DOI 10.1128/MCB.23.23.8486-8494.2003; Oh ST, 2010, BLOOD, V116, P988, DOI 10.1182/blood-2010-02-270108; Pardanani A, 2010, LEUKEMIA, V24, P1713, DOI 10.1038/leu.2010.163; Seita J, 2007, P NATL ACAD SCI USA, V104, P2349, DOI 10.1073/pnas.0606238104; Simon C, 2008, BLOOD, V112, P1039, DOI 10.1182/blood-2008-05-154849; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smyth DJ, 2008, NEW ENGL J MED, V359, P2767, DOI 10.1056/NEJMoa0807917; Takaki S, 2002, J EXP MED, V195, P151, DOI 10.1084/jem.20011170; Takizawa H, 2006, BLOOD, V107, P2968, DOI 10.1182/blood-2005-05-2138; Takizawa H, 2008, EXP HEMATOL, V36, P897, DOI 10.1016/j.exphem.2008.02.004; Takizawa H, 2010, J CLIN INVEST, V120, P179, DOI 10.1172/JCI39503; Tefferi A, 2011, J CLIN ONCOL, V29, P573, DOI 10.1200/JCO.2010.29.8711; Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Tong W, 2005, BLOOD, V105, P4604, DOI 10.1182/blood-2004-10-4093; Tong W, 2004, J EXP MED, V200, P569, DOI 10.1084/jem.20040762; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; Wan MF, 2006, J SURG RES, V136, P53, DOI 10.1016/j.jss.2006.07.004; Wang TC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026433; Zahn JM, 2010, BLOOD, V116; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhernakova A, 2010, AM J HUM GENET, V86, P970, DOI 10.1016/j.ajhg.2010.05.004	72	27	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2013	32	26					3111	3118		10.1038/onc.2012.435	http://dx.doi.org/10.1038/onc.2012.435			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	23045270				2022-12-17	WOS:000321004600001
J	Takahashi, R; Giannini, C; Sarkaria, JN; Schroeder, M; Rogers, J; Mastroeni, D; Scrable, H				Takahashi, R.; Giannini, C.; Sarkaria, J. N.; Schroeder, M.; Rogers, J.; Mastroeni, D.; Scrable, H.			p53 isoform profiling in glioblastoma and injured brain	ONCOGENE			English	Article						gliosis; regeneration; astrocytoma	NEURAL STEM-CELLS; ADULT MAMMALIAN BRAIN; HUMAN CANCERS; SPINAL-CORD; MUTANT P53; EXPRESSION; ASTROCYTES; TUMORS; ZONE; GENE	The tumor suppressor p53 has been found to be the most commonly mutated gene in human cancers; however, the frequency of p53 mutations varies from 10 to 70% across different cancer types. This variability can partly be explained by inactivating mechanisms aside from direct genomic polymorphisms. The p53 gene encodes 12 isoforms, some of which can modulate full-length p53 activity in cancer. In this study, we characterized p53 isoform expression patterns in glioblastoma, gliosis, non-tumor brain and neural progenitor cells by SDS-PAGE, immunoblot, mass spectrometry and reverse transcription-PCR. We found that the most consistently expressed isoform in glioblastoma, Delta 40p53, was uniquely expressed in regenerative processes, such as those involving neural progenitor cells and gliosis compared with tumor samples. Isoform profiling of glioblastoma tissues revealed the presence of both Delta 40p53 and full-length p53, neither of which were detected in non-tumor cerebral cortex. Upon xenograft propagation of tumors, p53 levels increased. The variability of overall p53 expression and relative levels of isoforms suggest fluctuations in subpopulations of cells with greater or lesser capacity for proliferation, which can change as the tumor evolves under different growth conditions.	[Takahashi, R.] Mayo Clin, Med Scientist Training Program, Rochester, MN 55905 USA; [Takahashi, R.; Scrable, H.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Giannini, C.] Mayo Clin, Dept Lab Med & Pathol, Div Anat Pathol, Rochester, MN 55905 USA; [Sarkaria, J. N.; Schroeder, M.] Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA; [Rogers, J.; Mastroeni, D.] Banner Sun Hlth Res Inst, Sun City, AZ USA; [Scrable, H.] Mayo Clin, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; [Scrable, H.] Mayo Clin, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Banner Research; Banner Health; Banner Sun Health Research Institute; Mayo Clinic; Mayo Clinic	Scrable, H (corresponding author), Mayo Clin, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	Scrable.Heidi@mayo.edu	Giannini, Caterina/AAB-7551-2022		PHS [R01AG026094]; Ellison Medical Research Foundation; NCI Cancer Center support grant; Robert and Arlene Kogod Center on Aging at Mayo Clinic; Mayo Brain Tumors SPORE; Mayo Clinic Medical Scientist Training Program; NATIONAL INSTITUTE ON AGING [R01AG026094] Funding Source: NIH RePORTER	PHS(United States Department of Health & Human ServicesUnited States Public Health Service); Ellison Medical Research Foundation(Lawrence Ellison Foundation); NCI Cancer Center support grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Robert and Arlene Kogod Center on Aging at Mayo Clinic; Mayo Brain Tumors SPORE; Mayo Clinic Medical Scientist Training Program; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We would like to thank our Mayo Clinic colleagues for their contributions, in particular, Dr Robert Jenkins for seminal discussions on the etiology of GBM and xenograft biology; Alissa Caron for preparing GBM patient tumor specimens; Dr John Black for CTX samples; Guido Gonzalez for obtaining LNZ308 cells; and Benjamin Madden and the Mayo Clinic Protein Chemistry and Proteomics Shared Resource core for mass spectrometry analysis. We are grateful to past and current members of the Scrable lab for their enduring enthusiasm and abilities, in particular Dr Erica Ungewitter for her invaluable help with p53 antibodies and the work she did as a graduate student that laid the foundation for subsequent studies on p53 in ESCs, and Dr Silvia Medrano, for passing on her expertise with mouse NSC culture and the role of p53 in adult stem cells. This work was supported by PHS award R01AG026094 and a Senior Scholar in Aging award from the Ellison Medical Research Foundation to HS Additional support came from an NCI Cancer Center support grant to the Mayo Clinic Cancer Center, the Robert and Arlene Kogod Center on Aging at Mayo Clinic, the Mayo Brain Tumors SPORE, and the Mayo Clinic Medical Scientist Training Program (RT).	Anensen N, 2006, CLIN CANCER RES, V12, P3985, DOI 10.1158/1078-0432.CCR-05-1970; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butler T, 2010, BLOOD REV, V24, P135, DOI 10.1016/j.blre.2010.03.004; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Carlson BL, 2011, CURR PROTOC PHARM, V52, P1; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Doetsch F, 1997, J NEUROSCI, V17, P5046; GARD AL, 1990, NEURON, V5, P615, DOI 10.1016/0896-6273(90)90216-3; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Globus J.H., 1944, J NEUROPATH EXP NEUR, V3, P1; Globus JH, 1942, ARCH PATHOL, V34, P674; Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784; GRITTI A, 2001, PROTOCOLS NEURAL CEL; Grover R, 2009, ONCOGENE, V28, P2766, DOI 10.1038/onc.2009.138; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Imura T, 2006, GLIA, V53, P277, DOI 10.1002/glia.20281; Imura T, 2003, J NEUROSCI, V23, P2824; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Khoury MP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000927; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Lang B, 2004, NEUROSCIENCE, V128, P775, DOI 10.1016/j.neuroscience.2004.06.033; Laywell ED, 1999, EXP NEUROL, V156, P430, DOI 10.1006/exnr.1999.7029; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Leonard BW, 2009, J COMP NEUROL, V515, P269, DOI 10.1002/cne.22040; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li W, 2006, PATHOLOGY, V38, P287, DOI 10.1080/00313020600817951; Machado-Silva A, 2010, SEMIN CANCER BIOL, V20, P57, DOI 10.1016/j.semcancer.2010.02.005; Marcel V, 2010, FEBS LETT, V584, P4463, DOI 10.1016/j.febslet.2010.10.005; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; Medrano S, 2009, NEUROBIOL AGING, V30, P483, DOI 10.1016/j.neurobiolaging.2007.07.016; Mills AA, 2005, GENE DEV, V19, P2091, DOI 10.1101/gad.1362905; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Philipova T, 2011, INT J ONCOL, V38, P843, DOI 10.3892/ijo.2010.884; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Robles AI, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001016; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sasaki T, 2006, AGING CELL, V5, P413, DOI 10.1111/j.1474-9726.2006.00235.x; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Ungewitter E, 2010, GENE DEV, V24, P2408, DOI 10.1101/gad.1987810; VAN MEIR EG, 1994, CANCER RES, V54, P649; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801	59	27	29	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3165	3174		10.1038/onc.2012.322	http://dx.doi.org/10.1038/onc.2012.322			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22824800	Green Accepted			2022-12-17	WOS:000321004600007
J	Ward, TM; Iorns, E; Liu, X; Hoe, N; Kim, P; Singh, S; Dean, S; Jegg, AM; Gallas, M; Rodriguez, C; Lippman, M; Landgraf, R; Pegram, MD				Ward, T. M.; Iorns, E.; Liu, X.; Hoe, N.; Kim, P.; Singh, S.; Dean, S.; Jegg, A-M; Gallas, M.; Rodriguez, C.; Lippman, M.; Landgraf, R.; Pegram, M. D.			Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5	ONCOGENE			English	Article						ERBB2; truncated; p95; p110; breast cancer; STAT5	HUMAN-BREAST-CANCER; EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODY; TERMINAL FRAGMENTS; SIGNAL TRANSDUCER; TUMOR-CELLS; HER2; RECEPTOR; TRASTUZUMAB; EXPRESSION	Truncated-ERBB2 isoforms (t-ERBB2s), resulting from receptor proteolysis or alternative translation of the ERBB2 mRNA, exist in a subset of human breast tumors. t-ERBB2s lack the receptor extracellular domain targeted by therapeutic anti-ERBB2 antibodies and antibody-drug conjugates, including trastuzumab, trastuzumab-DM1 and pertuzumab. In clinical studies, expression of t-ERBB2 in breast tumors correlates with metastasis as well as trastuzumab resistance. By using a novel immuno-microarray method, we detect a significant t-ERBB2 fraction in 18 of 31 (58%) of immunohistochemistry (IHC)3+ ERBB2+ human tumor specimens, and further show that t-ERBB2 isoforms are phosphorylated in a subset of IHC3+ samples (10 of 31, 32%). We investigated t-ERBB2 biological activity via engineered expression of full-length and truncated ERBB2 isoforms in human mammary epithelial cells (HMECs), including HMEC and MCF10A cells. Expression of p110 t-ERBB2, but not p95m (m = membrane, also 648CTF) or intracellular ERBB2s, significantly enhanced cell migration and invasion in multiple cell types. In addition, only expression of the p110 isoform led to human breast epithelial cell (HMLE) xenograft formation in vivo. Expression of t-ERBB2s did not result in hyperactivation of the phosphoinositide kinase-3/AKT or mitogen-activated protein kinase signaling pathways in these cells; rather, phosphoproteomic array profiling revealed attenuation of phosphorylated signal transducer and activator of transcription 5 (STAT5) in p110-t-ERBB2-expressing cells compared to controls. Short hairpin-mediated silencing of STAT5 phenocopied p110-t-ERBB2-driven cell migration and invasion, while expression of constitutively active STAT5 reversed these effects. Thus, we provide novel evidence that (1) expression of p110 t-ERBB2 is sufficient for full transformation of HMEC, yielding in vivo xenograft formation, and (2) truncated p110 t-ERBB2 expression is associated with decreased phosphorylation of STAT5.	[Ward, T. M.; Jegg, A-M; Gallas, M.; Rodriguez, C.; Pegram, M. D.] Univ Miami, Miller Sch Med, Dept Hematol & Oncol, Miami, FL 33136 USA; [Iorns, E.; Dean, S.; Lippman, M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Liu, X.; Hoe, N.; Kim, P.; Singh, S.] Prometheus Labs, San Diego, CA USA; [Landgraf, R.] Univ Miami, Miller Sch Med, Dept Biochem, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Pegram, MD (corresponding author), Univ Miami, Miller Sch Med, Dept Hematol & Oncol, 1501 North West 10th Ave, Miami, FL 33136 USA.	mpegram@stanford.edu			Young Investigator Award from the Expedition-Inspiration Breast Cancer Research Fund; National Cancer Institute [T32CA119929]; NATIONAL CANCER INSTITUTE [T32CA119929] Funding Source: NIH RePORTER	Young Investigator Award from the Expedition-Inspiration Breast Cancer Research Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Young Investigator Award from the Expedition-Inspiration Breast Cancer Research Fund, and by award T32CA119929 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institute of Health.	Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Arribas J, 2010, CLIN CANCER RES, V16, P4071, DOI 10.1158/1078-0432.CCR-10-1501; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Christianson TA, 1998, CANCER RES, V58, P5123; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Dillon MF, 2008, ENDOCR-RELAT CANCER, V15, P745, DOI 10.1677/ERC-08-0009; Egeblad M, 2001, INT J CANCER, V94, P185, DOI 10.1002/ijc.1459; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Garcia-Castillo J, 2009, J BIOL CHEM, V284, P25302, DOI 10.1074/jbc.M109.001982; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Hatanaka Y, 2001, PATHOL INT, V51, P33, DOI 10.1046/j.1440-1827.2001.01162.x; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Kim P, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-75; KLAPPER MH, 1963, J BIOL CHEM, V238, P3736; Liu PCC, 2006, CANCER BIOL THER, V5, P657, DOI 10.4161/cbt.5.6.2708; Liu PK, 2009, ASCO ANN M ORL FL; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mass R, 2000, SEMIN ONCOL, V27, P46; Molina MA, 2002, CLIN CANCER RES, V8, P347; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P759, DOI 10.1093/jnci/djh133; PUPA SM, 1993, ONCOGENE, V8, P2917; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Saez R, 2006, CLIN CANCER RES, V12, P424, DOI 10.1158/1078-0432.CCR-05-1807; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2010, CLIN CANCER RES, V16, P2688, DOI 10.1158/1078-0432.CCR-09-3407; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sperinde J, 2010, CLIN CANCER RES, V16, P4226, DOI 10.1158/1078-0432.CCR-10-0410; Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Yuan CX, 2003, PROTEIN EXPRES PURIF, V29, P217, DOI 10.1016/S1046-5928(03)00058-5	42	27	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2463	2474		10.1038/onc.2012.256	http://dx.doi.org/10.1038/onc.2012.256			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751112	Green Published, hybrid			2022-12-17	WOS:000318694900010
J	Bambang, IF; Lee, YK; Richardson, DR; Zhang, D				Bambang, I. F.; Lee, Y. K.; Richardson, D. R.; Zhang, D.			Endoplasmic reticulum protein 29 regulates epithelial cell integrity during the mesenchymal-epithelial transition in breast cancer cells	ONCOGENE			English	Article						ERp29; tight junctions; cell polarity; mesenchymal-epithelial transition; epithelial morphogenesis	E-CADHERIN EXPRESSION; TIGHT JUNCTIONS; METASTATIC PROGRESSION; TUMOR PROGRESSION; UP-REGULATION; LIGHT-CHAIN; MYOSIN-II; POLARITY; COMPLEX; ERP29	The epithelial-mesenchymal transition (EMT) correlates with disruption of cell-cell adhesion, loss of cell polarity and development of epithelial cell malignancy. Identifying novel molecules that inhibit EMT has profound potential for developing mechanism-based therapeutics. We previously demonstrated that the endoplasmic reticulum protein 29 (ERp29) is a novel factor that can drive mesenchymal-epithelial transition (MET) and induce cell growth arrest in MDA-MB-231 cells. Here, we show that ERp29 is an important molecule in establishing epithelial cell integrity during the MET. We demonstrate that ERp29 regulates MET in a cell context-dependent manner. ERp29 overexpression induced a complete MET in mesenchymal MDA-MB-231 cells through downregulating the expression of transcriptional repressors (for example, Slug, Snai1, ZEB2 and Twist) of E-cadherin. In contrast, overexpression of ERp29 induces incomplete MET in basal-like BT549 cells in which the expression of EMT-related markers (for example, vimentin; cytokeratin 19 (CK19) and E-cadherin) and the transcriptional repressors of E-cadherin were not altered. However, ERp29 overexpression in both cell-types resulted in loss of filamentous stress fibers, formation of cortical actin and restoration of an epithelial phenotype. Mechanistic studies revealed that overexpression of ERp29 in both cell-types upregulated the expression of TJ proteins (zonula-occludens-1 (ZO-1) and occludin) and the core apical-basal polarity proteins (Par3 and Scribble) at the membrane to enhance cell-cell contact and cell polarization. Knockdown of ERp29 in the epithelial MCF-7 cells decreased the expression of these proteins, leading to the disruption of cell-cell adhesion. Taken together, ERp29 is a novel molecule that regulates MET and epithelial cell integrity in breast cancer cells. Oncogene (2013) 32, 1240-1251; doi:10.1038/onc.2012.149; published online 30 April 2012	[Bambang, I. F.; Zhang, D.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore 117595, Singapore; [Bambang, I. F.; Lee, Y. K.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117595, Singapore; [Richardson, D. R.; Zhang, D.] Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia; [Richardson, D. R.; Zhang, D.] Univ Sydney, Bosch Inst, Iron Metab & Chelat Program, Sydney, NSW 2006, Australia	National University of Singapore; National University of Singapore; University of Sydney; University of Sydney	Zhang, D (corresponding author), Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia.	d.richardson@med.usyd.edu.au; daohai.zhang@sydney.edu.au		Richardson, Des/0000-0002-5506-3274; Richardson, Des/0000-0003-0960-6415	National Health and Medical Research Council of Australia; Agency of Science, Technology and Research-Biomedical Research Council in Singapore (A*STAR-BMRC) [07/1/21/19/496]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Agency of Science, Technology and Research-Biomedical Research Council in Singapore (A*STAR-BMRC)(Agency for Science Technology & Research (A*STAR))	DRR thanks the National Health and Medical Research Council of Australia for a Senior Principal Research Fellowship. This research was performed in DZ's laboratory in the National University of Singapore and was sponsored by an Individual Research Grant awarded to DZ from the Agency of Science, Technology and Research-Biomedical Research Council in Singapore (A*STAR-BMRC 07/1/21/19/496).	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bambang IF, 2009, LAB INVEST, V89, P1229, DOI 10.1038/labinvest.2009.87; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Baryshev M, 2006, BIOCHEM BIOPH RES CO, V340, P617, DOI 10.1016/j.bbrc.2005.12.052; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; Chaffer CL, 2005, CLIN EXP METASTAS, V22, P115, DOI 10.1007/s10585-005-5141-3; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Coradini D, 2011, ACTA PHARMACOL SIN, V32, P552, DOI 10.1038/aps.2011.20; Das S, 2009, MOL BIOL CELL, V20, P2593, DOI 10.1091/mbc.E08-07-0790; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Farmaki E, 2011, BBA-MOL CELL RES, V1813, P1165, DOI 10.1016/j.bbamcr.2011.03.003; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gao DM, 2012, LAB INVEST, V92, P200, DOI 10.1038/labinvest.2011.163; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; Gibson MC, 2003, CURR OPIN CELL BIOL, V15, P747, DOI 10.1016/j.ceb.2003.10.008; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hunter MP, 2010, AM J PHYSIOL-CELL PH, V299, pC21, DOI 10.1152/ajpcell.00543.2009; IMHOF BA, 1983, CELL, V35, P667, DOI 10.1016/0092-8674(83)90099-5; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Katoh K, 2001, AM J PHYSIOL-CELL PH, V280, pC1669, DOI 10.1152/ajpcell.2001.280.6.C1669; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Martin TA, 2004, EUR J CANCER, V40, P2717, DOI 10.1016/j.ejca.2004.08.008; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Qi L, 2012, MED ONCOL, V29, P721, DOI 10.1007/s12032-011-9929-5; Ren XD, 2004, J CELL SCI, V117, P3511, DOI 10.1242/jcs.01205; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Ross DT, 2001, DIS MARKERS, V17, P99, DOI 10.1155/2001/850531; Rothenberg SM, 2010, CANCER RES, V70, P2158, DOI 10.1158/0008-5472.CAN-09-3458; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Shnyder SD, 2008, J PROTEOME RES, V7, P3364, DOI 10.1021/pr800126n; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Tanos B, 2008, ONCOGENE, V27, P6939, DOI 10.1038/onc.2008.345; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Watanabe T, 2007, MOL BIOL CELL, V18, P605, DOI 10.1091/mbc.E06-07-0590; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zen K, 2009, ONCOGENE, V28, P2910, DOI 10.1038/onc.2009.148; Zhang DH, 2010, EXP CELL RES, V316, P3522, DOI 10.1016/j.yexcr.2010.08.014	64	27	30	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1240	1251		10.1038/onc.2012.149	http://dx.doi.org/10.1038/onc.2012.149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543584				2022-12-17	WOS:000316454500005
J	Weiler, M; Pfenning, PN; Thiepold, AL; Blaes, J; Jestaedt, L; Gronych, J; Dittmann, LM; Berger, B; Jugold, M; Kosch, M; Combs, SE; von Deimling, A; Weller, M; Bendszus, M; Platten, M; Wick, W				Weiler, M.; Pfenning, P-N; Thiepold, A-L; Blaes, J.; Jestaedt, L.; Gronych, J.; Dittmann, L. M.; Berger, B.; Jugold, M.; Kosch, M.; Combs, S. E.; von Deimling, A.; Weller, M.; Bendszus, M.; Platten, M.; Wick, W.			Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment	ONCOGENE			English	Article						angiogenesis; glioblastoma; invasion; mammalian target of rapamycin; regulator of G protein signaling	MAMMALIAN TARGET; PHASE-III; CELLS; GLIOBLASTOMA; REGULATOR; PHOSPHORYLATION; RADIOTHERAPY; EXPRESSION; PROTEINS; CCI-779	An essential mode of acquired resistance to radiotherapy (RT) appears to be promotion of tumor cell motility and invasiveness in various cancer types, including glioblastoma, a process resembling 'evasive resistance'. Hence, a logical advancement of RI would be to identify suitable complementary treatment strategies, ideally targeting cell motility. Here we report that the combination of focal RT and mammalian target of rapamycin (mTOR) inhibition using clinically relevant concentrations of temsirolimus (CCI-779) prolongs survival in a syngeneic mouse glioma model through additive cytostatic effects. In vitro, the mTOR inhibitor CCI-779 exerted marked anti-invasive effects, irrespective of the phosphatase and tensin homolog deleted on chromosome 10 status and counteracted the proinvasive effect of sublethal irradiation. Mechanistically, we identified regulator of G-protein signaling 4 (RGS4) as a novel target of mTOR inhibition and a key driver of glioblastoma invasiveness, sensitive to the anti-invasive properties of CCI-779. Notably, suppression of RGS4-dependent glioma cell invasion was signaled through both mTOR complexes, mTORC1 and mTORC2, in a concentration-dependent manner, indicating that high doses of CCI-779 may overcome tumor-cell resistance associated with the sole inhibition of mTORC1. We conclude that combined RT and mTOR inhibition is a promising therapeutic option that warrants further clinical investigation in upfront glioblastoma therapy. Oncogene (2013) 32, 1099-1109; doi:10.103g/onc.2012.137; published online 7 May 2012	[Weiler, M.; Pfenning, P-N; Thiepold, A-L; Blaes, J.; Berger, B.; Wick, W.] German Canc Res Ctr, Clin Cooperat Unit Neurooncol, Heidelberg, Germany; [Weiler, M.; Platten, M.; Wick, W.] Univ Heidelberg Hosp, Dept Neurooncol, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany; [Jestaedt, L.; Bendszus, M.] Univ Heidelberg Hosp, Dept Neuroradiol, D-69120 Heidelberg, Germany; [Gronych, J.; Dittmann, L. M.] German Canc Res Ctr, Project Grp, Small Anim Imaging Ctr, Div Mol Genet, Heidelberg, Germany; [Berger, B.] Univ Heidelberg Hosp, Dept Neurol, D-69120 Heidelberg, Germany; [Jugold, M.] German Canc Res Ctr, Project Grp, Small Anim Imaging Ctr, Div Med Phys Radiol, Heidelberg, Germany; [Kosch, M.] Pfizer, Berlin, Germany; [Combs, S. E.] Univ Heidelberg Hosp, Dept Radiat Oncol, D-69120 Heidelberg, Germany; [von Deimling, A.] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [von Deimling, A.] Univ Heidelberg Hosp, Dept Neuropathol, D-69120 Heidelberg, Germany; [Weller, M.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Platten, M.] German Canc Res Ctr, Helmholtz Grp Expt Neuroimmunol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Pfizer; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Zurich; University Zurich Hospital; Helmholtz Association; German Cancer Research Center (DKFZ)	Wick, W (corresponding author), Univ Heidelberg Hosp, Dept Neurooncol, Natl Ctr Tumor Dis, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	wolfgang.wick@med.uni-heidelberg.de	Thiepold, Anna-Luisa/AAW-8310-2021; Wick, Wolfgang/AAA-2545-2020; von Deimling, Andreas/F-7774-2013; Platten, Michael/F-2902-2013; Gronych, Jan/G-9954-2013	Wick, Wolfgang/0000-0002-6171-634X; von Deimling, Andreas/0000-0002-5863-540X; Platten, Michael/0000-0002-4746-887X; Combs, Stephanie/0000-0002-6934-2864; Weller, Michael/0000-0002-1748-174X	Brain Tumor Network (BTNplus) [10 01GS0883\]; National Genome Research Network (NGFNplus) by the Federal Ministry of Education and Research (BMBF); Charitable Hertie Foundation	Brain Tumor Network (BTNplus); National Genome Research Network (NGFNplus) by the Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Charitable Hertie Foundation	We thank P Rubmann, A-C Klein and N Sims for excellent technical assistance. We also thank the Microscopy Core Facility of the DKFZ and the Nikon Imaging Center at the University of Heidelberg, Heidelberg, Germany. We are grateful to T Wieland, University of Heidelberg, Mannheim, Germany, for providing the pCR3.0-RGS4 expression vector. This work was supported by the Brain Tumor Network (BTNplus), Subproject 10 01GS0883 (WW) and Subproject 4 (JG, LMD) of the National Genome Research Network (NGFNplus) by the Federal Ministry of Education and Research (BMBF), and the Charitable Hertie Foundation. BB is a fellow in the Postdoc Program of the Medical Faculty of the University of Heidelberg.	Bansal G, 2007, PHARMACOL THERAPEUT, V116, P473, DOI 10.1016/j.pharmthera.2007.09.005; Blazer LL, 2010, MOL PHARMACOL, V78, P524, DOI 10.1124/mol.110.065128; Chakravarti A, 2004, J CLIN ONCOL, V22, P1926, DOI 10.1200/JCO.2004.07.193; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Cotton M, 2009, CELL SIGNAL, V21, P1045, DOI 10.1016/j.cellsig.2009.02.008; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Ding J, 2006, NAT NEUROSCI, V9, P832, DOI 10.1038/nn1700; Doherty L, 2006, NEUROLOGY, V67, P156, DOI 10.1212/01.wnl.0000223844.77636.29; Dudkin L, 2001, CLIN CANCER RES, V7, P1758; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Erdely HA, 2004, EUR J NEUROSCI, V19, P3125, DOI 10.1111/j.0953-816X.2004.03364.x; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Geoerger B, 2001, CANCER RES, V61, P1527; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Hess G, 2009, J CLIN ONCOL, V27, P3822, DOI 10.1200/JCO.2008.20.7977; Hooks SB, 2008, BIOCHEM PHARMACOL, V75, P76, DOI 10.1016/j.bcp.2007.07.045; Hu WH, 2009, AM J PHYSIOL-CELL PH, V296, pC1310, DOI 10.1152/ajpcell.00573.2008; Hurst JH, 2009, BIOCHEM PHARMACOL, V78, P1289, DOI 10.1016/j.bcp.2009.06.028; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Levitt P, 2006, BIOL PSYCHIAT, V60, P534, DOI 10.1016/j.biopsych.2006.04.028; Minniti G, 2010, RADIOTHER ONCOL, V97, P377, DOI 10.1016/j.radonc.2010.08.020; Motzer RJ, 2007, J CLIN ONCOL, V25, P3958, DOI 10.1200/JCO.2006.10.5916; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Opitz CA, 2009, STEM CELLS, V27, P909, DOI 10.1002/stem.7; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park IH, 2002, J BIOL CHEM, V277, P31423, DOI 10.1074/jbc.M204080200; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pitter KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014545; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Reardon DA, 2010, J NEURO-ONCOL, V96, P219, DOI 10.1007/s11060-009-9950-0; Rieger J, 2008, J NEUROCHEM, V106, P2436, DOI 10.1111/j.1471-4159.2008.05586.x; Ronellenfitsch MW, 2009, BRAIN, V132, P1509, DOI 10.1093/brain/awp093; Sampson JH, 1997, NEUROSURGERY, V41, P1365, DOI 10.1097/00006123-199712000-00024; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Tabatabai G, 2006, BRAIN, V129, P2426, DOI 10.1093/brain/awl173; Tatenhorst L, 2004, J NEUROPATH EXP NEUR, V63, P210, DOI 10.1093/jnen/63.3.210; Weiler M, 2006, CELL DEATH DIFFER, V13, P1156, DOI 10.1038/sj.cdd.4401786; Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541; Wild-Bode C, 2001, CANCER RES, V61, P2744; Xie Y, 2009, CANCER RES, V69, P5743, DOI 10.1158/0008-5472.CAN-08-3564; Yang L, 2008, CLIN CANCER RES, V14, P3993, DOI 10.1158/1078-0432.CCR-07-4152	49	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1099	1109		10.1038/onc.2012.137	http://dx.doi.org/10.1038/onc.2012.137			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22562250	Green Accepted			2022-12-17	WOS:000316428800004
J	Foskolou, IP; Stellas, D; Rozani, I; Lavigne, MD; Politis, PK				Foskolou, I. P.; Stellas, D.; Rozani, I.; Lavigne, M. D.; Politis, P. K.			Prox1 suppresses the proliferation of neuroblastoma cells via a dual action in p27-Kip1 and Cdc25A	ONCOGENE			English	Article						prospero; cyclinE1; G0/G1-arrest; cell cycle; SH-SY5Y; tet-on	HOMEOBOX TRANSCRIPTION FACTOR; NEURAL STEM-CELLS; SELF-RENEWAL; HUMAN CANCER; CYCLE EXIT; NEURONAL DIFFERENTIATION; SYMPATHETIC-GANGLIA; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; EXPRESSION	Neuroblastoma is a pediatric tumor that originates from precursor cells of the sympathetic nervous system with less than 40% long-term survival in children diagnosed with high-risk disease. These clinical observations underscore the need for novel insights in the mechanisms of malignant transformation and progression. Accordingly, it was recently reported that Prox1, a homeobox transcription regulator, is expressed in higher levels in human neuroblastonna with favorable prognosis. Consistently, we have recently shown that Prox1 exerts a strong antiproliferative effect on neural precursor cells during embryonic development. Thus, Prox1 is a candidate gene with a critical role in suppressing malignant neuroblastoma transformation. Here, we provide evidence that Prox1 strongly suppresses the proliferation of mouse and human neuroblastoma cell lines and blocks the growth of neuroblastoma tumors in SCID mice. Conversely, short hairpin RNA (shRNA) -mediated knockdown of basal Prox1 expression significantly induces proliferation, genomic instability and the ability of neuroblastoma cells to form tumors. Mechanistically, analysis of an inducible Prox1-overexpressing Neuro2A cell line indicates that Prox1 is sufficient to suppress CyclinD1, CyclinA and CyclinB1, consistent with a role in cell cycle arrest. Surprisingly, Prox1 strongly induces CyclinE1 expression in the same system despite its action on blocking cell cycle progression, which could account for the context dependent oncogenic function of Prox1. Most importantly, Prox1 was sufficient to decrease Cdc25A and induce p27-Kip1, but not p21-Cip1 or p53. By alleviating the Prox1 action in Cdc25A and p27-Kip1 expression, we were able to rescue its effect on cell cycle arrest. Together these data suggest that Prox1 negatively regulates neuroblastoma carcinogenesis through suppression of Cdc25A and induction of p27-Kip1 to counteract CyclinE1 overexpression and block cell cycle progression. Furthermore, these observations render Prox1 a candidate target for the treatment of neuroblastoma tumors. Oncogene (2013) 32, 947-960; doi:10.1038/onc.2012.129; published online 16 April 2012	[Foskolou, I. P.; Stellas, D.; Rozani, I.; Lavigne, M. D.; Politis, P. K.] Acad Athens, Biomed Res Fdn, Ctr Basic Res, Athens 11527, Greece	Academy of Athens	Politis, PK (corresponding author), Acad Athens, Biomed Res Fdn, Ctr Basic Res, 4 Soranou Efesiou, Athens 11527, Greece.	ppolitis@bioacademy.gr	Stellas, Dimitris/AAG-2473-2021; Stellas, Dimitris/AAP-8958-2021; Foskolou, Iosifina Petrina/AAY-4662-2021; Politis, Panagiotis/AAO-2423-2020; Foskolou, Iosifina/AAM-5164-2020	Stellas, Dimitris/0000-0002-7787-3921; Lavigne, Matthieu/0000-0003-1543-8745; Foskolou, Iosifina- Petrina/0000-0003-1874-6356; Politis, Panagiotis/0000-0002-2556-2857; Stellas, Dimitris/0000-0002-9587-6288				Airoldi I, 2004, BRIT J CANCER, V90, P2210, DOI 10.1038/sj.bjc.6601842; Akagami M, 2011, ANN SURG ONCOL, V18, P3868, DOI 10.1245/s10434-011-1683-6; Baxter SA, 2011, BBA-MOL CELL RES, V1813, P201, DOI 10.1016/j.bbamcr.2010.10.015; Becker J, 2010, PEDIATR RES, V68, P112, DOI 10.1203/00006450-201011001-00215; Bello B, 2006, DEVELOPMENT, V133, P2639, DOI 10.1242/dev.02429; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Chang HH, 2010, CLIN CANCER RES, V16, P4411, DOI 10.1158/1078-0432.CCR-09-3360; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Choksi SP, 2006, DEV CELL, V11, P775, DOI 10.1016/j.devcel.2006.09.015; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Colonques J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019342; Dudas J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-92; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; Elkouris M, 2011, STEM CELLS, V29, P89, DOI 10.1002/stem.554; Georgopoulou N, 2006, J BIOL CHEM, V281, P33606, DOI 10.1074/jbc.M602689200; GRANA X, 1995, ONCOGENE, V11, P211; Griffiths RL, 2004, EMBO J, V23, P2440, DOI 10.1038/sj.emboj.7600258; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hope KJ, 2011, CURR OPIN HEMATOL, V18, P203, DOI 10.1097/MOH.0b013e328347888a; Hope KJ, 2010, CELL STEM CELL, V7, P101, DOI 10.1016/j.stem.2010.06.007; Itoh Y, 2007, J BIOL CHEM, V282, P390, DOI 10.1074/jbc.M609944200; Kaltezioti V, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000565; Kamiya A, 2008, HEPATOLOGY, V48, P252, DOI 10.1002/hep.22303; Kazenwadel J, 2010, BLOOD, V116, P2395, DOI 10.1182/blood-2009-12-256297; Laerm A, 2007, J HEPATOL, V46, P89, DOI 10.1016/j.jhep.2006.07.033; Lee CY, 2006, DEV CELL, V10, P441, DOI 10.1016/j.devcel.2006.01.017; Li L, 2000, GENE DEV, V14, P147; Liu SC, 2009, CANCER LETT, V286, P240, DOI 10.1016/j.canlet.2009.05.038; Liu TH, 2002, MECH DEVELOP, V112, P25, DOI 10.1016/S0925-4773(01)00626-8; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Nagai H, 2003, GENE CHROMOSOME CANC, V38, P13, DOI 10.1002/gcc.10248; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Pearson ADJ, 2008, LANCET ONCOL, V9, P247, DOI 10.1016/S1470-2045(08)70069-X; Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Politis PK, 2008, FEBS LETT, V582, P741, DOI 10.1016/j.febslet.2008.01.052; Politis PK, 2007, P NATL ACAD SCI USA, V104, P17861, DOI 10.1073/pnas.0610973104; Ribatti D, 2006, BRIT J CANCER, V94, P1845, DOI 10.1038/sj.bjc.6603186; Risebro CA, 2009, DEVELOPMENT, V136, P495, DOI 10.1242/dev.030007; Rodriguez-Niedenfuhr M, 2001, ANAT EMBRYOL, V204, P399, DOI 10.1007/s00429-001-0214-9; Rother K, 2007, ONCOGENE, V26, P1949, DOI 10.1038/sj.onc.1209989; Schneider M, 2006, INT J ONCOL, V28, P883; Schulte JH, 2010, NUCLEIC ACIDS RES, V38, P5919, DOI 10.1093/nar/gkq342; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimoda M, 2006, CLIN CANCER RES, V12, P6005, DOI 10.1158/1078-0432.CCR-06-0712; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Southall TD, 2009, EMBO J, V28, P3799, DOI 10.1038/emboj.2009.309; Stellas D, 2007, CLIN CANCER RES, V13, P1831, DOI 10.1158/1078-0432.CCR-06-1585; Takahashi M, 2006, NEOPLASIA, V8, P1003, DOI 10.1593/neo.06595; Timofeev O, 2010, J BIOL CHEM, V285, P16978, DOI 10.1074/jbc.M109.096552; Tsarovina K, 2008, MOL CELL NEUROSCI, V37, P20, DOI 10.1016/j.mcn.2007.08.010; Versmold B, 2007, INT J CANCER, V121, P547, DOI 10.1002/ijc.22705; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505	60	27	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					947	960		10.1038/onc.2012.129	http://dx.doi.org/10.1038/onc.2012.129			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22508481				2022-12-17	WOS:000316523200002
J	Ley, S; Weigert, A; Weichand, B; Henke, N; Mille-Baker, B; Janssen, RAJ; Brune, B				Ley, S.; Weigert, A.; Weichand, B.; Henke, N.; Mille-Baker, B.; Janssen, R. A. J.; Bruene, B.			The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages	ONCOGENE			English	Article						immunity; sphingolipids; cancer; nerve growth factor; trafficking	NERVE GROWTH-FACTOR; HUMAN MONOCYTES; BREAST-CANCER; RECEPTORS; SPHINGOSINE-1-PHOSPHATE; EXPRESSION; TRANSACTIVATION; INTERLEUKIN-10; PROGRESSION; DISEASE	Tumor-associated macrophages (TAMs) are a major supportive component within neoplasms. Mechanisms of macrophage (M(1)) attraction and differentiation to a tumor-promoting phenotype, which is characterized by pronounced interleukin (IL)-10 production, are under investigation. We report that supernatants of dying cancer cells induced substantial IL-10 release from primary human MOs, dependent on signaling through tyrosine kinase receptor A (TRKA or neurotrophic tyrosine kinase receptor type 1 (NTRK1)). Mechanistically, sphingosine-1-phosphate (SIP) release from apoptotic cancer cells triggered src-dependent shuttling of cytosolic TRKA to the plasma membrane via S1P receptor signaling. Plasma membrane-associated TRKA, which was activated by constitutively autocrine secreted nerve growth factor, used phosphatidylinositol 3-kinase (PI3K)/AKT and p38 mitogen-activated protein kinase (MAPK) signaling to induce IL-10. Interestingly, TRKA-dependent signaling was required for cytokine production by TAMs isolated from primary murine breast cancer tissue. Besides IL-10, this pathway initiated secretion of IL-6, tumor necrosis factor-alpha (TNF-alpha) and monocyte chemotactic protein-1 (MCP-1), indicating relevance in cancer-associated inflammation. Our findings highlight a fine-tuned regulatory system including S1P-dependent TRKA trafficking for executing TAM-like cell function in vitro as well as in vivo. Oncogene (2013) 32, 631-640; doi:10.1038/onc.2012.77; published online 12 March 2012	[Ley, S.; Weigert, A.; Weichand, B.; Henke, N.; Bruene, B.] Goethe Univ Frankfurt, Inst Biochem, I ZAFES, D-60590 Frankfurt, Germany; [Mille-Baker, B.] BioFocus Ltd, Leiden, Netherlands; [Janssen, R. A. J.] Galapagos BV, Leiden, Netherlands	Goethe University Frankfurt; Galapagos NV	Brune, B (corresponding author), Goethe Univ Frankfurt, Inst Biochem, I ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	bruene@pathobiochemie1.de	Weigert, Andreas/E-6540-2010	Weigert, Andreas/0000-0002-7529-1952	DFG [Br999, FOG 784, GRK 757]; Sander Foundation [2007.070.2]; Deutsche Krebshilfe [109599]	DFG(German Research Foundation (DFG)); Sander Foundation; Deutsche Krebshilfe(Deutsche Krebshilfe)	The work was supported by DFG (Br999, FOG 784, GRK 757), Sander Foundation (2007.070.2) and Deutsche Krebshilfe (109599). We are grateful to Yves-Alain Barde for sharing the HA-TRKA expression plasmid and thank Franz Josef Streb, Magarethe Wiebe and Karina Pfister for excellent technical assistance.	Adriaenssens E, 2008, CANCER RES, V68, P346, DOI 10.1158/0008-5472.CAN-07-1183; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Arevalo JC, 2006, CELL MOL LIFE SCI, V63, P1523, DOI 10.1007/s00018-006-6010-1; Barra V, 2011, CELL MOL LIFE SCI, V68, P1815, DOI 10.1007/s00018-010-0537-x; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bracci-Laudiero L, 2005, BLOOD, V106, P3507, DOI 10.1182/blood-2004-10-4055; Chung EY, 2007, IMMUNITY, V27, P952, DOI 10.1016/j.immuni.2007.11.014; Duong CQ, 2004, BBA-MOL CELL BIOL L, V1682, P112; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; El Zein N, 2010, CELL SIGNAL, V22, P1437, DOI 10.1016/j.cellsig.2010.05.012; Gregory CD, 2011, J PATHOL, V223, P177, DOI 10.1002/path.2792; Herr B, 2009, BLOOD, V114, P2140, DOI 10.1182/blood-2009-01-201889; Hughes JE, 2008, CIRC RES, V102, P950, DOI 10.1161/CIRCRESAHA.107.170779; Jung EJ, 2008, EXP MOL MED, V40, P276, DOI 10.3858/emm.2008.40.3.276; Karkoulias G, 2007, CELL SIGNAL, V19, P945, DOI 10.1016/j.cellsig.2006.11.003; Keul P, 2011, CIRC RES, V108, P314, DOI 10.1161/CIRCRESAHA.110.235028; Koh E, 2007, CELL SIGNAL, V19, P1328, DOI 10.1016/j.cellsig.2007.01.005; Kruttgen A, 2006, BRAIN PATHOL, V16, P304, DOI 10.1111/j.1750-3639.2006.00037.x; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Long JS, 2010, J BIOL CHEM, V285, P35957, DOI 10.1074/jbc.M110.117945; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Moises T, 2007, MOL NEUROBIOL, V35, P151, DOI 10.1007/s12035-007-8000-1; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Noga O, 2007, CLIN EXP ALLERGY, V37, P1701, DOI 10.1111/j.1365-2222.2007.02832.x; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; Sandilands E, 2007, EMBO REP, V8, P1162, DOI 10.1038/sj.embor.7401097; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schecterson LC, 2010, DEV NEUROBIOL, V70, P332, DOI 10.1002/dneu.20767; Toman RE, 2004, J CELL BIOL, V166, P381, DOI 10.1083/jcb.200402016; Tsuruda A, 2004, FEBS LETT, V560, P215, DOI 10.1016/S0014-5793(04)00115-2; van Es HHG, 2005, DRUG DISCOV TODAY, V10, P1385, DOI 10.1016/S1359-6446(05)03590-7; Wang WG, 2005, FASEB J, V19, P1731, DOI 10.1096/fj.05-3730fje; Weigert A, 2007, MOL BIOL CELL, V18, P3810, DOI 10.1091/mbc.E06-12-1096; Weigert A, 2010, BLOOD, V115, P3531, DOI 10.1182/blood-2009-10-243444; Weis N, 2009, MOL BIOL CELL, V20, P1280, DOI 10.1091/mbc.E08-10-1005; Wetter JA, 2009, J BIOMOL SCREEN, V14, P1134, DOI 10.1177/1087057109343809; Zweifel LS, 2005, NAT REV NEUROSCI, V6, P615, DOI 10.1038/nrn1727	40	27	30	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2013	32	5					631	640		10.1038/onc.2012.77	http://dx.doi.org/10.1038/onc.2012.77			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22410777				2022-12-17	WOS:000316164700010
J	Bhavsar, PJ; Infante, E; Khwaja, A; Ridley, AJ				Bhavsar, P. J.; Infante, E.; Khwaja, A.; Ridley, A. J.			Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration	ONCOGENE			English	Article						Rho GTPases; acute lymphoblastic leukaemia; Notch1; RhoU; cell migration; cytoskeleton	ACUTE LYMPHOBLASTIC-LEUKEMIA; FAMILY; CANCER; TUMORIGENESIS; INFILTRATION; CYTOSKELETON; INHIBITION; RESISTANCE; REGULATORS; MUTATIONS	NOTCH1 is frequently mutated in T-cell acute lymphoblastic leukaemia (T-ALL), and can stimulate T-ALL cell survival and proliferation. Here we explore the hypothesis that Notch1 also alters T-ALL cell migration. Rho GTPases are well known to regulate cell adhesion and migration. We have analysed the expression levels of Rho GTPases in primary T-ALL samples compared with normal T cells by quantitative PCR. We found that 5 of the 20 human Rho genes are highly and consistently upregulated in T-ALL, and 3 further Rho genes are expressed in T-ALL but not detectable in normal T cells. Of these, RHOU expression is highly correlated with the expression of the Notch1 target DELTEX-1. Inhibition of Notch1 signalling with a gamma-secretase inhibitor (GSI) or Notch1 RNA interference reduced RhoU expression in T-ALL cells, whereas constitutively active Notch1 increased RhoU expression. In addition, Notch1 or RhoU depletion, or GSI treatment, inhibits T-ALL cell adhesion, migration and chemotaxis. These results indicate that NOTCH1 mutation stimulates T-ALL cell migration through RhoU upregulation that could contribute to the leukaemia cell dissemination. Oncogene (2013) 32, 198-208; doi:10.1038/onc.2012.42; published online 20 February 2012	[Bhavsar, P. J.; Infante, E.; Ridley, A. J.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Infante, E.] Guys & St Thomas NHS, Biomed Res Ctr, NIHR, London, England; [Khwaja, A.] UCL, UCL Canc Inst, London, England	University of London; King's College London; University of London; King's College London; University of London; University College London	Ridley, AJ (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	anne.ridley@kcl.ac.uk		Infante, Elvira/0000-0002-9883-8391; Ridley, Anne/0000-0001-8186-5708	Leukaemia and Lymphoma Research UK; Cancer Research UK; King's College London British Heart Foundation Centre of Excellence; Department of Health via National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre; King's College London; King's College Hospital NHS Foundation Trust; Cancer Research UK [15961] Funding Source: researchfish	Leukaemia and Lymphoma Research UK; Cancer Research UK(Cancer Research UK); King's College London British Heart Foundation Centre of Excellence; Department of Health via National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre(National Institute for Health Research (NIHR)); King's College London; King's College Hospital NHS Foundation Trust; Cancer Research UK(Cancer Research UK)	This work was supported by Leukaemia and Lymphoma Research UK, Cancer Research UK and King's College London British Heart Foundation Centre of Excellence. El was supported by the Department of Health via National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre Award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. We are grateful to Sarah Heasman for scientific discussion and guidance; Ritu Garg and Katrina Soderquest for technical assistance; Katherine Lawler for advice on statistical analysis; and Matthew Arno and Estibaliz Aldecoa-otalora Astarloa for assistance and advice on qPCR.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Aspenstrom P, 2007, EXP CELL RES, V313, P3673, DOI 10.1016/j.yexcr.2007.07.022; Aster JC, 2011, J PATHOL, V223, P262, DOI 10.1002/path.2789; Berthold J, 2008, ACTA PHARMACOL SIN, V29, P285, DOI 10.1111/j.1745-7254.2008.00773.x; Berthold J, 2008, EXP CELL RES, V314, P3453, DOI 10.1016/j.yexcr.2008.09.005; Bhojwani D, 2009, CLIN LYMPHOMA MYELOM, V9, pS222, DOI 10.3816/CLM.2009.s.016; Boureux A, 2007, MOL BIOL EVOL, V24, P203, DOI 10.1093/molbev/msl145; Brazier H, 2009, INT J BIOCHEM CELL B, V41, P1391, DOI 10.1016/j.biocel.2008.12.007; Buonamici S, 2009, NATURE, V459, P1000, DOI 10.1038/nature08020; Chang FK, 2006, J MOL BIOL, V364, P302, DOI 10.1016/j.jmb.2006.09.026; Chuang YY, 2007, J CELL SCI, V120, P1927, DOI 10.1242/jcs.03456; Crazzolara R, 2001, BRIT J HAEMATOL, V115, P545, DOI 10.1046/j.1365-2141.2001.03164.x; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Ferrando Adolfo A, 2009, Hematology Am Soc Hematol Educ Program, P353, DOI 10.1182/asheducation-2009.1.353; Fort P, 2011, DEV BIOL, V350, P451, DOI 10.1016/j.ydbio.2010.12.011; Fueller Florian, 2008, Cell Commun Signal, V6, P6, DOI 10.1186/1478-811X-6-6; Graux C, 2006, LEUKEMIA, V20, P1496, DOI 10.1038/sj.leu.2404302; Hayday AC, 2007, NAT IMMUNOL, V8, P137, DOI 10.1038/ni1436; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heasman SJ, 2010, J CELL BIOL, V190, P553, DOI 10.1083/jcb.201002067; Huang M, 2006, HISTOL HISTOPATHOL, V21, P213, DOI 10.14670/HH-21.213; Hubsman MW, 2007, BIOCHEM J, V404, P487, DOI 10.1042/BJ20061696; Infante E, 2011, J LEUKOCYTE BIOL, V89, P577, DOI 10.1189/jlb.0810441; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Palomero T, 2006, BLOOD, V108, P986, DOI 10.1182/blood-2005-08-3482; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Pieters R, 2008, PEDIATR CLIN N AM, V55, P1, DOI 10.1016/j.pcl.2007.11.002; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Riou P, 2010, BIOESSAYS, V32, P986, DOI 10.1002/bies.201000060; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Symons M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-213; Takesono A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008774; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Tybulewicz VLJ, 2009, NAT REV IMMUNOL, V9, P630, DOI 10.1038/nri2606; van Grotel M, 2008, LEUKEMIA, V22, P124, DOI 10.1038/sj.leu.2404957; Van Hennik PB, 2005, ANTIOXID REDOX SIGN, V7, P1440, DOI 10.1089/ars.2005.7.1440; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vicente R, 2010, SEMIN IMMUNOL, V22, P270, DOI 10.1016/j.smim.2010.04.016; Wang H, 2010, CELL SIGNAL, V22, P1022, DOI 10.1016/j.cellsig.2010.02.005; Weerkamp F, 2006, LEUKEMIA, V20, P1197, DOI 10.1038/sj.leu.2404255; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wolfe MS, 2009, SEMIN CELL DEV BIOL, V20, P219, DOI 10.1016/j.semcdb.2008.12.011; Yanez-Mo M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004	53	27	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					198	208		10.1038/onc.2012.42	http://dx.doi.org/10.1038/onc.2012.42			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349824	Green Accepted			2022-12-17	WOS:000314075500008
J	Chaisaingmongkol, J; Popanda, O; Warta, R; Dyckhoff, G; Herpel, E; Geiselhart, L; Claus, R; Lasitschka, F; Campos, B; Oakes, CC; Bermejo, JL; Herold-Mende, C; Plass, C; Schmezer, P				Chaisaingmongkol, J.; Popanda, O.; Warta, R.; Dyckhoff, G.; Herpel, E.; Geiselhart, L.; Claus, R.; Lasitschka, F.; Campos, B.; Oakes, C. C.; Bermejo, J. L.; Herold-Mende, C.; Plass, C.; Schmezer, P.			Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma	ONCOGENE			English	Article						HNSCC; DNA methylation; NEIL1 expression; DNA glycosylase	HYPERMETHYLATION; TUMOR; GLYCOSYLASE; EXPRESSION; HYPOMETHYLATION; INACTIVATION; EXCISION; REVEALS; DAMAGE; METHYLTRANSFERASE	Aberrant promoter methylation of different DNA repair genes has a critical role in the development and progression of various cancer types, including head and neck squamous cell carcinomas (HNSCCs). A systematic analysis of known human repair genes for promoter methylation is however missing. We generated quantitative promoter methylation profiles in single CpG units of 160 human DNA repair genes in a set of DNAs isolated from fresh frozen HNSCC and normal tissues using MassARRAY technology. Ninety-eight percent of these genes contained CpG islands (CGIs) in their promoter region; thus, DNA methylation is a potential regulatory mechanism. Methylation data were obtained for 145 genes, from which 15 genes exhibited more than a 20% difference in methylation levels between tumor and normal tissues, manifested either as hypermethylation or as hypomethylation. Analyses of promoter methylation with mRNA expression identified the DNA glycosylase NEIL1 (nei endonuclease VIII-like 1) as the most prominent candidate gene. NEIL1 promoter hypermethylation was confirmed in additional fresh frozen HNSCC samples, normal mucosa, HNSCC cell lines and primary human skin keratinocytes. The investigation of laser-microdissected tissues further substantiated increased methylation levels in tumor versus matched non-tumor cells. Immunohistological analysis revealed significantly less NEIL1 protein expression in tumor tissues. 5-Aza-2'-deoxycytidine treatment and DNMT1 knockdown resulted in the re-expression of NEIL1 in HNSCC cell lines, which initially carried hypermethylated promoter regions. In conclusion, our results suggest that DNA methylation contributes to the downregulation of NEIL1 expression and might thus have a role in modulating the response to therapies of HNSCC. Oncogene (2012) 31, 5108-5116; doi:10.1038/onc.2011.660; published online 30 January 2012	[Chaisaingmongkol, J.; Popanda, O.; Geiselhart, L.; Claus, R.; Oakes, C. C.; Plass, C.; Schmezer, P.] German Canc Res Ctr, Div Epigen & Canc Risk Factors, D-69120 Heidelberg, Germany; [Warta, R.; Dyckhoff, G.; Herold-Mende, C.] Heidelberg Univ, Dept Otorhinolaryngol Head & Neck Surg, Heidelberg, Germany; [Warta, R.; Campos, B.; Herold-Mende, C.] Heidelberg Univ, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Herpel, E.] Univ Heidelberg Hosp, Inst Pathol, NCT Tissue Bank, Heidelberg, Germany; [Lasitschka, F.] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany; [Bermejo, J. L.] Univ Heidelberg Hosp, Inst Med Biometry & Informat, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Schmezer, P (corresponding author), German Canc Res Ctr, Div Epigen & Canc Risk Factors C010, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.schmezer@dkfz.de	Popanda, Odilia/P-6917-2019; Oakes, Christopher C/H-7288-2014; Plass, Christoph/H-7192-2014; Claus, Rainer/AAZ-5606-2020	Oakes, Christopher C/0000-0001-8000-9694; Claus, Rainer/0000-0003-2617-8766; Chaisaingmongkol, Jittiporn/0000-0001-8019-5562	Royal Thai Government; NIDCR [DE13123]; Deutsche Forschungsgemeinschaft [SFB938 Z2]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER	Royal Thai Government; NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank R Gliniorz, O Muecke, P Waas and O Zelezny ( Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center) and J Scheuerer (Institute of Pathology) for their excellent technical assistance, all other members of the Plass laboratory for their help and thoughtful discussion, M Zucknick (Division of Biostatistics, German Cancer Research Center) for statistical support and P Boukamp (Division of Genetics of Skin Carcinogenesis, German Cancer Research Center) for providing primary human skin keratinocytes. This project was in part supported by a scholarship of The Royal Thai Government to JC. This work was supported in part by NIDCR, grant DE13123 (CP). FL is funded by the Deutsche Forschungsgemeinschaft, grant SFB938 Z2.	Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793; Chan MK, 2009, DNA REPAIR, V8, P786, DOI 10.1016/j.dnarep.2009.03.001; Couve-Privat S, 2007, NUCLEIC ACIDS RES, V35, P5672, DOI 10.1093/nar/gkm592; Das A, 2005, J BIOL CHEM, V280, P35272, DOI 10.1074/jbc.M505526200; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; Dikshit RP, 2007, CANCER-AM CANCER SOC, V110, P1745, DOI 10.1002/cncr.22975; Dokun OY, 2008, INT J CANCER, V123, P2798, DOI 10.1002/ijc.23893; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Doublie S, 2004, P NATL ACAD SCI USA, V101, P10284, DOI 10.1073/pnas.0402051101; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Estecio MRH, 2006, ONCOGENE, V25, P5018, DOI 10.1038/sj.onc.1209509; Esteller M, 2001, CANCER RES, V61, P4689; Freier K, 2010, J ORAL PATHOL MED, V39, P382, DOI 10.1111/j.1600-0714.2009.00864.x; Funke B, 2009, GUT, V58, P483, DOI 10.1136/gut.2008.148908; Guan X, 2007, NUCLEIC ACIDS RES, V35, P2463, DOI 10.1093/nar/gkm075; Ha PK, 2009, ORAL ONCOL, V45, P335, DOI 10.1016/j.oraloncology.2008.05.015; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327; Kraunz KS, 2006, INT J CANCER, V119, P1553, DOI 10.1002/ijc.22013; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Mace-Aime G, 2010, ENVIRON MOL MUTAGEN, V51, P508, DOI 10.1002/em.20548; Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051; Marsit CJ, 2009, CARCINOGENESIS, V30, P416, DOI 10.1093/carcin/bgp006; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Martone T, 2007, CLIN CANCER RES, V13, P5089, DOI 10.1158/1078-0432.CCR-07-0119; Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423; Ninck S, 2003, INT J CANCER, V106, P34, DOI 10.1002/ijc.11188; Pal S, 2010, J GASTROEN HEPATOL, V25, P627, DOI 10.1111/j.1440-1746.2009.06128.x; Poage GM, 2011, CLIN CANCER RES, V17, P3579, DOI 10.1158/1078-0432.CCR-11-0044; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269; Schmezer P, 2008, HNO, V56, P594, DOI 10.1007/s00106-008-1720-3; Seitz HK, 2007, NAT REV CANCER, V7, P599, DOI 10.1038/nrc2191; Seiwert TY, 2007, NAT CLIN PRACT ONCOL, V4, P156, DOI 10.1038/ncponc0750; Sengupta S, 2007, CANCER-AM CANCER SOC, V109, P703, DOI 10.1002/cncr.22430; Shinmura K, 2004, CARCINOGENESIS, V25, P2311, DOI 10.1093/carcin/bgh267; Smith IM, 2010, ORL-J OTO-RHIN-LARYN, V72, P44, DOI 10.1159/000292104; Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102; Vartanian V, 2006, P NATL ACAD SCI USA, V103, P1864, DOI 10.1073/pnas.0507444103; Wiebalk K, 2007, INT J CANCER, V121, P2340, DOI 10.1002/ijc.22981; Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007; Wood RD, 2005, MUTAT RES-FUND MOL M, V577, P275, DOI 10.1016/j.mrfmmm.2005.03.007; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861	48	27	28	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5108	5116		10.1038/onc.2011.660	http://dx.doi.org/10.1038/onc.2011.660			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22286769				2022-12-17	WOS:000312000900007
J	Derocq, D; Prebois, C; Beaujouin, M; Laurent-Matha, V; Pattingre, S; Smith, GK; Liaudet-Coopman, E				Derocq, D.; Prebois, C.; Beaujouin, M.; Laurent-Matha, V.; Pattingre, S.; Smith, G. K.; Liaudet-Coopman, E.			Cathepsin D is partly endocytosed by the LRP1 receptor and inhibits LRP1-regulated intramembrane proteolysis	ONCOGENE			English	Article						cancer; cathepsin D; LRP1; RIP; endocytosis; tyrosine phosphorylation	BREAST-CANCER CELLS; AMYLOID PRECURSOR PROTEIN; HUMAN PROCATHEPSIN-D; INTRACELLULAR DOMAIN; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; CORECEPTOR FUNCTION; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; D INTERACTS	The aspartic protease cathepsin-D (cath-D) is a marker of poor prognosis in breast cancer that is overexpressed and hypersecreted by human breast cancer cells. Secreted pro-cath-D binds to the extracellular domain of the beta-chain of the LDL receptor-related protein-1 (LRP1) in fibroblasts. The LRP1 receptor has an 85-kDa transmembrane beta-chain and a noncovalently attached 515-kDa extracellular alpha-chain. LRP1 acts by (1) internalizing many ligands via its alpha-chain, (2) activating signaling pathways by phosphorylating the LRP1 beta-chain tyrosine and (3) modulating gene transcription by regulated intramembrane proteolysis (RIP) of its beta-chain. LRP1 RIP involves two cleavages: the first liberates the LRP1 ectodomain to give a membrane-associated form, LRP1 beta-CTF, and the second generates the LRP1 beta-intracellular domain, LRP1 beta-ICD, that modulates gene transcription. Here, we investigated the endocytosis of pro-cathD by LRP1 and the effect of pro-cath-D/LRP1 beta interaction on LRP1 beta tyrosine phosphorylation and/or LRP1 beta RIP. Our results indicate that pro-cath-D was partially endocytosed by LRP1 in fibroblasts. However, pro-cath-D and ectopic cath-D did not stimulate phosphorylation of the LRP1 beta-chain tyrosine. Interestingly, ectopic cath-D and its catalytically inactive (D231N)cath-D, and pro-(D231N)cath-D all significantly inhibited LRP1 RIP by preventing LRP1 beta-CTF production. Thus, cath-D inhibits LRP1 RIP independently of its catalytic activity by blocking the first cleavage. As cath-D triggers fibroblast outgrowth by LRP1, we propose that cath-D modulates the growth of fibroblasts by inhibiting LRP1 RIP in the breast tumor microenvironment. Oncogene (2012) 31, 3202-3212; doi:10.1038/onc.2011.501; published online 14 November 2011	[Liaudet-Coopman, E.] INSERM, U896, IRCM Val dAurelle Paul Lamarque, F-34298 Montpellier 5, France; [Derocq, D.; Prebois, C.; Beaujouin, M.; Laurent-Matha, V.; Pattingre, S.; Liaudet-Coopman, E.] IRCM, Montpellier, France; [Derocq, D.; Prebois, C.; Beaujouin, M.; Laurent-Matha, V.; Pattingre, S.; Liaudet-Coopman, E.] Univ Montpellier I, Montpellier, France; [Derocq, D.; Prebois, C.; Beaujouin, M.; Laurent-Matha, V.; Pattingre, S.; Liaudet-Coopman, E.] CRLC Val dAurelle Paul Lamarque, Montpellier, France; [Smith, G. K.] GlaxoSmithKline Inc, Screening & Compound Profiling, Res Triangle Pk, NC USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); GlaxoSmithKline	Liaudet-Coopman, E (corresponding author), INSERM, U896, IRCM Val dAurelle Paul Lamarque, F-34298 Montpellier 5, France.	emmanuelle.liaudet-coopman@inserm.fr	Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Valerie, LAURENT-MATHA/0000-0002-3277-7397; Pattingre, Sophie/0000-0001-6284-6050	Institut National de la Sante et de la Recherche Medicale; University of Montpellier I; ANR Jeunes Chercheuses; Jeunes Chercheurs; Ligue Nationale contre le Cancer; Association pour la Recherche sur le Cancer	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Montpellier I; ANR Jeunes Chercheuses(French National Research Agency (ANR)); Jeunes Chercheurs; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We thank Francoise Berthet and Nadia Kerdjadj for secretarial assistance, and Jean-Yves Cance for the photographs. We also thank Vincent Cavailles for pertinent suggestions for the gene reporter experiments, Herve Emonard for helpful discussions and Owen Parkes for English corrections. This work was supported by the Institut National de la Sante et de la Recherche Medicale, University of Montpellier I, ANR Jeunes Chercheuses, Jeunes Chercheurs and the Ligue Nationale contre le Cancer; the Association pour la Recherche sur le Cancer provided a fellowship for Melanie Beaujouin.	Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Beaujouin M, 2010, J CELL SCI, V123, P3336, DOI 10.1242/jcs.070938; Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Boucher P, 2004, TRENDS CARDIOVAS MED, V14, P55, DOI 10.1016/j.tcm.2003.12.001; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; CAPONY F, 1989, CANCER RES, V49, P3904; CAPONY F, 1994, EXP CELL RES, V215, P154, DOI 10.1006/excr.1994.1327; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Emonard H, 2005, BIOCHIMIE, V87, P369, DOI 10.1016/j.biochi.2004.11.013; Fears CY, 2005, CANCER RES, V65, P9338, DOI 10.1158/0008-5472.CAN-05-1560; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, INT J CANCER, V84, P209, DOI 10.1002/(SICI)1097-0215(19990621)84:3<209::AID-IJC2>3.0.CO;2-9; FUSEK M, 1994, BIOCHEM J, V303, P775, DOI 10.1042/bj3030775; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Glondu M, 2002, ONCOGENE, V21, P5127, DOI 10.1038/sj.onc.1205657; Gonias SL, 2004, THROMB HAEMOSTASIS, V91, P1056, DOI 10.1160/TH04-01-0023; Hass MR, 2009, SEMIN CELL DEV BIOL, V20, P201, DOI 10.1016/j.semcdb.2008.11.014; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI13992; Hu KB, 2006, J BIOL CHEM, V281, P2120, DOI 10.1074/jbc.M504988200; Hu L, 2008, CANCER RES, V68, P4666, DOI 10.1158/0008-5472.CAN-07-6276; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Laurent-Matha V, 2005, J CELL BIOL, V168, P489, DOI 10.1083/jcb.200403078; Laurent-Matha V, 2002, EXP CELL RES, V277, P210, DOI 10.1006/excr.2002.5556; Li YH, 2003, FEBS LETT, V555, P346, DOI 10.1016/S0014-5793(03)01272-9; Liaudet-Coopman E, 2006, CANCER LETT, V237, P167, DOI 10.1016/j.canlet.2005.06.007; Lillis AP, 2005, J THROMB HAEMOST, V3, P1884, DOI 10.1111/j.1538-7836.2005.01371.x; Liu CX, 2007, J BIOL CHEM, V282, P7504, DOI 10.1074/jbc.M608088200; Liu Q, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-17; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; May P, 2007, ANN MED, V39, P219, DOI 10.1080/07853890701214881; Mi KH, 2007, J NEUROCHEM, V101, P517, DOI 10.1111/j.1471-4159.2007.04447.x; Montel V, 2007, CANCER RES, V67, P9817, DOI 10.1158/0008-5472.CAN-07-0683; Newton CS, 2005, J BIOL CHEM, V280, P27872, DOI 10.1074/jbc.M505410200; Ohri SS, 2008, INT J ONCOL, V32, P491; Ohri SS, 2007, CANCER BIOL THER, V6, P1081, DOI 10.4161/cbt.6.7.4325; Polavarapu R, 2008, AM J PATHOL, V172, P1355, DOI 10.2353/ajpath.2008.070975; Quinn KA, 1997, J BIOL CHEM, V272, P23946, DOI 10.1074/jbc.272.38.23946; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; Rodriguez J, 2005, INT J BIOL MARKER, V20, P103, DOI 10.1177/172460080502000204; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Selvais C, 2011, FASEB J, V25, P2770, DOI 10.1096/fj.10-169508; Selvais C, 2009, ENDOCRINOLOGY, V150, P3792, DOI 10.1210/en.2009-0015; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Vashishta A, 2007, INT J ONCOL, V30, P1223; VETVICKA V, 1994, CANCER LETT, V79, P131; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Wu LH, 2005, J CELL BIOCHEM, V96, P1021, DOI 10.1002/jcb.20596; Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje; Zhang HY, 2004, J BIOL CHEM, V279, P2221, DOI 10.1074/jbc.M310679200; Zurhove K, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164263	59	27	30	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	26					3202	3212		10.1038/onc.2011.501	http://dx.doi.org/10.1038/onc.2011.501			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22081071	Green Accepted, Green Submitted			2022-12-17	WOS:000305934400008
J	Xu, N; Libertini, S; Black, EJ; Lao, Y; Hegarat, N; Walker, M; Gillespie, DA				Xu, N.; Libertini, S.; Black, E. J.; Lao, Y.; Hegarat, N.; Walker, M.; Gillespie, D. A.			Cdk-mediated phosphorylation of Chk1 is required for efficient activation and full checkpoint proficiency in response to DNA damage	ONCOGENE			English	Article						Chk1; RPA; Cdk; DNA damage; checkpoint; cell cycle	END RESECTION; HOMOLOGOUS RECOMBINATION; REPAIR; CTIP; SURVIVAL	Here, we show that activation of the checkpoint effector kinase Chk1 in response to irradiation-induced DNA damage is minimal in G1, maximal during S-phase and diminishes as cells enter G2. In addition, formation of irradiation-induced replication protein A (RPA)-coated single-stranded DNA (RPA-ssDNA), a structure required for ATM and Rad3-related (ATR)-Chk1 activation, occurs in a broadly similar pattern. Cyclin-dependent kinase (Cdk) activity is thought to promote RPA-ssDNA formation by stimulating DNA strand resection at double-strand breaks (DSBs), providing one possible mechanism of imposing cell cycle dependence on DNA damage signaling. However, it has recently been shown that Chk1 itself is also subject to Cdk-mediated phosphorylation at serines 286 and 301 (S286 and 301). We show that Chk1 S301 phosphorylation increases as cells progress through S and G2 and that both Cdk1 and Cdk2 are likely to contribute to this modification in vivo. We also find that substitution of S286 and S301 with non-phosphorylatable alanine residues strongly attenuates DNA damage-induced Chk1 activation and G2 checkpoint proficiency, but does not eliminate the underlying cell cycle dependence of Chk1 regulation. Taken together, these data indicate that Cdk activity regulates multiple steps in the DNA damage response pathway including full activation of Chk1 and checkpoint proficiency. Oncogene (2012) 31, 1086-1094; doi:10.1038/onc.2011.310; published online 18 July 2011	[Xu, N.] Tsinghua Univ, Div Life Sci, Grad Sch Shenzhen, Shenzhen 518055, Guang Dong, Peoples R China; [Xu, N.; Libertini, S.; Black, E. J.; Lao, Y.; Walker, M.; Gillespie, D. A.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Gillespie, D. A.] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland	Tsinghua University; University Town of Shenzhen; Tsinghua Shenzhen International Graduate School; Beatson Institute; University of Glasgow	Xu, N (corresponding author), Tsinghua Univ, Div Life Sci, Grad Sch Shenzhen, Room 409,Bldg L,Tsinghua Campus, Shenzhen 518055, Guang Dong, Peoples R China.	xu.naihan@sz.tsinghua.edu.cn; d.gillespie@beatson.gla.ac.uk	Xu, Naihan/C-2778-2018; Libertini, Silvana/A-3531-2011; Gillespie, David/R-4771-2019; , Yuanzhi/D-3936-2015	Libertini, Silvana/0000-0003-2633-1564; Gillespie, David/0000-0002-6338-0544; , Yuanzhi/0000-0002-7803-4484; Lao, Yuanzhi/0000-0002-0994-8303	Cancer Research UK (CR-UK); Medical Research Council of the United Kingdom (MRC); CR-UK China Fellowships; Marie Curie Fellowship	Cancer Research UK (CR-UK)(Cancer Research UK); Medical Research Council of the United Kingdom (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CR-UK China Fellowships; Marie Curie Fellowship(European Commission)	We wish to thank Cancer Research UK (CR-UK) and the Medical Research Council of the United Kingdom (MRC) for financial support. N Xu and Y Lao were the recipients of CR-UK China Fellowships, S Libertini was the recipient of a Marie Curie Fellowship. We thank Helfrid Hochegger for many stimulating discussions.	Bourke E, 2010, ONCOGENE, V29, P616, DOI 10.1038/onc.2009.340; Cerqueira A, 2009, J CELL BIOL, V187, P773, DOI 10.1083/jcb.200903033; Deans AJ, 2006, CANCER RES, V66, P8219, DOI 10.1158/0008-5472.CAN-05-3945; Enomoto M, 2009, J BIOL CHEM, V284, P34223, DOI 10.1074/jbc.C109.051540; Filippo JS, 2008, ANNU REV BIOCHEM, V77, P229, DOI 10.1146/annurev.biochem.77.061306.125255; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Hochegger H, 2007, J CELL BIOL, V178, P257, DOI 10.1083/jcb.200702034; Huertas P, 2008, NATURE, V455, P689, DOI 10.1038/nature07215; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; Ikegami Y, 2008, BIOCHEM BIOPH RES CO, V377, P1227, DOI 10.1016/j.bbrc.2008.10.119; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Rainey MD, 2008, ONCOGENE, V27, P896, DOI 10.1038/sj.onc.1210702; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Satyanarayana A, 2008, MOL BIOL CELL, V19, P65, DOI 10.1091/mbc.E07-06-0525; Shiromizu T, 2006, GENES CELLS, V11, P477, DOI 10.1111/j.1365-2443.2006.00955.x; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Walker M, 2009, ONCOGENE, V28, P2314, DOI 10.1038/onc.2009.102; Wohlbold L, 2009, DNA REPAIR, V8, P1018, DOI 10.1016/j.dnarep.2009.04.009; Xu NH, 2010, J CELL BIOL, V190, P297, DOI 10.1083/jcb.201003004; Yata K, 2009, DNA REPAIR, V8, P6, DOI 10.1016/j.dnarep.2008.09.002; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	27	27	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1086	1094		10.1038/onc.2011.310	http://dx.doi.org/10.1038/onc.2011.310			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21765472				2022-12-17	WOS:000300945900002
J	Arias, A; Lame, MW; Santarelli, L; Hen, R; Greene, LA; Angelastro, JM				Arias, A.; Lame, M. W.; Santarelli, L.; Hen, R.; Greene, L. A.; Angelastro, J. M.			Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas	ONCOGENE			English	Article						ATF5; PDGF-B; tumorigenesis; glioma	GROWTH-FACTOR-B; TRANSCRIPTION FACTOR ATF5; NEURAL PROGENITOR CELLS; GLIAL PROGENITORS; BRAIN-TUMORS; STEM-CELLS; AUTOCRINE STIMULATION; GENE-EXPRESSION; DNA-BINDING; GLIOBLASTOMA	Glioblastomas are among the most incurable cancers. Our past findings indicated that glioblastoma cells, but not neurons or glia, require the transcription factor ATF5 (activating transcription factor 5) for survival. However, it was unknown whether interference with ATF5 function can prevent or promote regression/eradication of malignant gliomas in vivo. To address this issue, we created a mouse model by crossing a human glial fibrillary acidic protein (GFAP) promoter-tetracycline transactivator mouse line with tetracycline operon-dominant negative-ATF5 (d/n-ATF5) mice to establish bi-transgenic mice. In this model, d/n-ATF5 expression is controlled by doxycycline and the promoter for GFAP, a marker for stem/progenitor cells as well as gliomas. Endogenous gliomas were produced with high efficiency by retroviral delivery of platelet-derived growth factor (PDGF)-B and p53-short hairpin RNA (shRNA) in adult bi-transgenic mice in which expression of d/n-ATF5 was spatially and temporally regulated. Induction of d/n-ATF5 before delivery of PDGF-B/p53-shRNA virus greatly reduced the proportion of mice that formed tumors. Moreover, d/n-ATF5 induction after tumor formation led to regression/eradication of detectable gliomas without evident damage to normal brain cells in all 24 mice assessed. Oncogene (2012) 31, 739-751; doi:10.1038/onc.2011.276; published online 4 July 2011	[Arias, A.; Lame, M. W.; Angelastro, J. M.] Univ Calif Davis, Davis Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; [Santarelli, L.; Hen, R.] Columbia Univ, Dept Neurosci, New York, NY USA; [Greene, L. A.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA	University of California System; University of California Davis; Columbia University; Columbia University	Angelastro, JM (corresponding author), Univ Calif Davis, Davis Sch Vet Med, Dept Mol Biosci, 2165 Haring Hall,1 Shields Ave, Davis, CA 95616 USA.	jmangelastro@ucdavis.edu			NIH [NS-33689]; Alexander and Margaret Stewart Trust; NIH-NCI [F31 CA123711-01A1, R21CA126924]; UCD Cancer Center [5P30CA093373-06S1]; NATIONAL CANCER INSTITUTE [R21CA126924, P30CA093373, F31CA123711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033689] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alexander and Margaret Stewart Trust; NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UCD Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by NIH Grant NS-33689 and an award from the Alexander and Margaret Stewart Trust (to LAG); NIH-NCI F31 CA123711-01A1 (to ADA); and in part support of the UCD Cancer Center Support Grant 5P30CA093373-06S1 (to JMA) and in full NIH-NCI R21CA126924 (to JMA). We thank Benjamin Pyles for his technical assistance in management of the mouse colony, genotyping, surgeries and anesthesia, as well as planning experimental end points. We thank Dr Stephen Noctor for the use of the Olympus FV-1000 confocal microscope and Fluoview software. We are indebted to Dr Robert Higgins (Neuropathologist, DVM/PhD) for assessment and evaluation of gliomas in mice with and without induced expression of d/n-ATF5.	Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Angelastro JM, 2003, J NEUROSCI, V23, P4590; Angelastro JM, 2006, ONCOGENE, V25, P907, DOI 10.1038/sj.onc.1209116; Angelastro JM, 2005, J NEUROSCI, V25, P3889, DOI 10.1523/JNEUROSCI.3447-04.2005; Assanah MC, 2009, GLIA, V57, P1835, DOI 10.1002/glia.20895; Assanah M, 2006, J NEUROSCI, V26, P6781, DOI 10.1523/JNEUROSCI.0514-06.2006; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Canoll P, 2008, ACTA NEUROPATHOL, V116, P465, DOI 10.1007/s00401-008-0432-9; Ciaccio NA, 2008, PROTEIN EXPRES PURIF, V62, P235, DOI 10.1016/j.pep.2008.07.011; Ciaccio NA, 2009, MOL PHARMACEUT, V6, P1205, DOI 10.1021/mp900058t; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; Concannon CG, 2001, GENE EXPRESSION, V9, P195, DOI 10.3727/000000001783992605; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Dai CK, 2001, BBA-REV CANCER, V1551, pM19, DOI 10.1016/S0304-419X(01)00027-0; David DJ, 2009, NEURON, V62, P479, DOI 10.1016/j.neuron.2009.04.017; Dluzen D, 2011, J BIOL CHEM, V286, P7705, DOI 10.1074/jbc.M110.207639; Dong SM, 2005, J NEUROPATH EXP NEUR, V64, P948, DOI 10.1097/01.jnen.0000186940.14779.90; Elstrand MB, 2009, INT J GYNECOL PATHOL, V28, P211, DOI 10.1097/PGP.0b013e31818b0f5e; Fiacco TA, 2007, NEURON, V54, P611, DOI 10.1016/j.neuron.2007.04.032; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; Ghashghaei HT, 2007, GENE DEV, V21, P3258, DOI 10.1101/gad.1580407; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; Greene LA, 2009, J NEUROCHEM, V108, P11, DOI 10.1111/j.1471-4159.2008.05749.x; Hede SM, 2009, GLIA, V57, P1143, DOI 10.1002/glia.20837; Hesselager G, 2003, CANCER RES, V63, P4305; Jackson EL, 2008, CELLS TISSUES ORGANS, V188, P212, DOI 10.1159/000114541; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; Li GF, 2009, MOL CANCER RES, V7, P933, DOI 10.1158/1541-7786.MCR-08-0365; Mason JL, 2005, MOL CELL NEUROSCI, V29, P372, DOI 10.1016/j.mcn.2005.03.004; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moll JR, 2000, J BIOL CHEM, V275, P34826, DOI 10.1074/jbc.M004545200; Monaco SE, 2007, INT J CANCER, V120, P1883, DOI 10.1002/ijc.22469; Mu YL, 2010, CURR OPIN NEUROBIOL, V20, P416, DOI 10.1016/j.conb.2010.04.010; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; Riquelme PA, 2008, PHILOS T R SOC B, V363, P123, DOI 10.1098/rstb.2006.2016; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Schrot RJ, 2007, J NEURO-ONCOL, V85, P149, DOI 10.1007/s11060-007-9401-8; Sheng Z, 2010, NAT MED, V16, P671, DOI 10.1038/nm.2158; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Singh SK, 2003, CANCER RES, V63, P5821; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sweger EJ, 2007, J NEUROSCI, V27, P2309, DOI 10.1523/JNEUROSCI.4565-06.2007; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Uhrbom L, 1998, CANCER RES, V58, P5275; Uhrbom L, 2000, INT J CANCER, V85, P398, DOI 10.1002/(SICI)1097-0215(20000201)85:3<398::AID-IJC17>3.0.CO;2-L; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wang H, 2007, CELL BIOL INT, V31, P1309, DOI 10.1016/j.cellbi.2007.05.002; Wang Z, 2010, BBA-REV CANCER, V1806, P122, DOI 10.1016/j.bbcan.2010.04.003; Wei YY, 2010, J BIOCHEM, V148, P171, DOI 10.1093/jb/mvq047	54	27	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					739	751		10.1038/onc.2011.276	http://dx.doi.org/10.1038/onc.2011.276			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725368	hybrid, Green Published			2022-12-17	WOS:000300222100007
J	Xu, J; Wang, B; Xu, Y; Sun, L; Tian, W; Shukla, D; Barod, R; Grillari, J; Grillari-Voglauer, R; Maxwell, PH; Esteban, MA				Xu, J.; Wang, B.; Xu, Y.; Sun, L.; Tian, W.; Shukla, D.; Barod, R.; Grillari, J.; Grillari-Voglauer, R.; Maxwell, P. H.; Esteban, M. A.			Epigenetic regulation of HIF-1 alpha in renal cancer cells involves HIF-1 alpha/2 alpha binding to a reverse hypoxia-response element	ONCOGENE			English	Article						von Hippel-Lindau tumor suppressor gene; hypoxia-inducible factor; renal cancer; epigenetics; histone modifications	TUMOR-SUPPRESSOR PROTEIN; INDUCIBLE FACTOR-I; HISTONE DEMETHYLASES; C-MYC; EXPRESSION; VHL; HIF; CARCINOMA; ALPHA; GENE	Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene underlies the majority of sporadic clear cell renal cell carcinomas (CCRCCs) and is also responsible for the hereditary VHL cancer syndrome. VHL loss of function results in constitutive stabilization of hypoxia-inducible factors (HIF-1 alpha and HIF-2 alpha) due to insufficient proteolysis in the presence of oxygen. This activates multiple genes relevant to tumorigenesis, allowing cells to acquire further mutations and undergo malignant transformation. However, the specific role of each HIF-alpha subunit in CCRCC tumorigenesis is not yet well understood. The current paradigm supports that in the first stages of CCRCC formation the stabilization of HIF-1 alpha is dominant and this limits proliferation, but later on HIF-2 alpha increases and this induces a more aggressive cell behavior. Understanding how this transition happens is highly relevant, as it may provide novel ways to treat these cancers. Here, we show that VHL inactivation in CCRCC cells results in HIF-1 alpha/2 alpha-dependent down-regulation of HIF-1 alpha mRNA through direct binding of either subunit to a reverse hypoxia-response element in the HIF-1 alpha proximal promoter. This binding activates a series of repressive histone modification marks including histone 3 lysine 27 trimethylation (H3K27me3) to make the changes stable, and if overturned reduces CCRCC cell proliferation due to excessive HIF-1 alpha expression level. Our findings thus help understand how HIF-alpha subunits influence each other and also reinforce the idea that epigenetic mechanisms are a key step of CCRCC progression. Oncogene (2012) 31, 1065-1072; doi:10.1038/onc.2011.305; published online 15 August 2011	[Xu, J.; Wang, B.; Xu, Y.; Sun, L.; Tian, W.; Esteban, M. A.] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Stem Cell & Canc Biol Grp,Key Lab Regenerat Biol, S China Inst Stem Cell Biol & Regenerat Med, Guangzhou 510530, Guangdong, Peoples R China; [Shukla, D.; Barod, R.; Maxwell, P. H.] UCL, Rayne Inst, Ctr Cell Signaling & Mol Genet, London, England; [Grillari, J.; Grillari-Voglauer, R.] Univ Nat Resources & Life Sci, Dept Biotechnol Aging & Immortalizat Res, Vienna, Austria	Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; University of London; King's College London; University College London; University of Natural Resources & Life Sciences, Vienna	Esteban, MA (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Stem Cell & Canc Biol Grp,Key Lab Regenerat Biol, S China Inst Stem Cell Biol & Regenerat Med, Guangzhou 510530, Guangdong, Peoples R China.	estebanb@gibh.org	Grillari, Johannes/B-2967-2011; Maxwell, Patrick H/C-5557-2008	Grillari, Johannes/0000-0001-5474-6332; Maxwell, Patrick H/0000-0002-0338-2679; Tian, Weihua/0000-0003-2357-3947; Xu, Yan/0000-0001-5653-291X	Guangzhou Institutes of Biomedicine and Health; Chinese Academy of Sciences [KSCX2-YW-R-244]; National Institute for Health Research [NF-SI-0507-10315] Funding Source: researchfish	Guangzhou Institutes of Biomedicine and Health; Chinese Academy of Sciences(Chinese Academy of Sciences); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was supported by start-up funding from the Guangzhou Institutes of Biomedicine and Health and the Chinese Academy of Sciences Grant KSCX2-YW-R-244 to MAE. We thank Dr Duanqing Pei for his constant support.	Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Christophersen NS, 2010, J EXP MED, V207, P2287, DOI 10.1084/jem.20101438; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Dayan F, 2006, CANCER RES, V66, P3688, DOI 10.1158/0008-5472.CAN-05-4564; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; Esteban MA, 2006, J AM SOC NEPHROL, V17, P1801, DOI 10.1681/ASN.2006020181; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Jeong CH, 2007, J BIOL CHEM, V282, P13672, DOI 10.1074/jbc.M700534200; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koslowski M, 2011, ONCOGENE, V30, P876, DOI 10.1038/onc.2010.481; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Lee KJ, 2010, BBA-MOL CELL RES, V1803, P608, DOI 10.1016/j.bbamcr.2010.01.004; Lin Q, 2011, MOL CANC RES, DOI 10.115811541-7786. MCR-11-0053; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 2002, CANCER RES, V62, P1158; Menrad H, 2010, HEPATOLOGY, V51, P2183, DOI 10.1002/hep.23597; Morris MR, 2011, ONCOGENE, V30, P1390, DOI 10.1038/onc.2010.525; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Xu JY, 2010, J AM SOC NEPHROL, V21, P2041, DOI 10.1681/ASN.2010040345; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930	39	27	28	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	8					1065	1072		10.1038/onc.2011.305	http://dx.doi.org/10.1038/onc.2011.305			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21841824				2022-12-17	WOS:000300709700012
J	Hunter, JE; Willmore, E; Irving, JAE; Hostomsky, Z; Veuger, SJ; Durkacz, BW				Hunter, J. E.; Willmore, E.; Irving, J. A. E.; Hostomsky, Z.; Veuger, S. J.; Durkacz, B. W.			NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699	ONCOGENE			English	Article						PARP-1; NF-kappa B; radio-sensitization; AG-014699; PAR	CHRONIC LYMPHOCYTIC-LEUKEMIA; ADP-RIBOSE POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE-1; IONIZING-RADIATION; TRANSCRIPTION FACTORS; DNA-DAMAGE; BINDING-ACTIVITY; CANCER THERAPY; CELL-LINES; ACTIVATION	The stress-inducible transcription factor, nuclear factor (NF)-kappa B induces genes involved in proliferation and apoptosis. Aberrant NF-kappa B activity is common in cancer and contributes to therapeutic-resistance. Poly(ADPribose) polymerase-1 (PARP-1) is activated during DNA strand break repair and is a known transcriptional co-regulator. Here, we investigated the role of PARP-1 function during NF-kappa B activation using p65 small interfering RNA (siRNA), PARP siRNA or the potent PARP-1 inhibitor, AG-014699. Survival and apoptosis assays showed that NF-kappa B p65(-/-) cells were more sensitive to ionizing radiation (IR) than p65(+/+) cells. Co-incubation with p65 siRNA, PARP siRNA or AG-014699 radio-sensitized p65(+/+), but not p65(-/-) cells, demonstrating that PARP-1 mediates its effects on survival via NF-kappa B. Single-strand break (SSB) repair kinetics, and the effect SSB repair inhibition by AG-014699 were similar in p65(+/+) and p65(-/-) cells. As preventing SSB repair did not radio-sensitize p65(-/-) cells, we conclude that radio-sensitization by AG-014699 is due to downstream inhibition of NF-kappa B activation, and independent of SSB repair inhibition. PARP-1 catalytic activity was essential for IR-induced p65 DNA binding and NF-kappa B-dependent gene transcription, whereas for tumor necrosis factor (TNF)-alpha-treated cells, PARP-1 protein alone was sufficient. We hypothesize that this stimulus-dependent differential is mediated via stimulation of the poly(ADP-ribose) polymer, which was induced following IR, not TNF-alpha. Targeting DNA damage-activated NF-kappa B using AG-014699 may therefore overcome toxicity observed with classical NF-kappa B inhibitors without compromising other vital inflammatory functions. These data highlight the potential of PARP-1 inhibitors to overcome NF-kappa B-mediated therapeutic resistance and widens the spectrum of cancers in which these agents may be utilized. Oncogene (2012) 31, 251-264; doi:10.1038/onc.2011.229; published online 27 June 2011	[Hunter, J. E.; Willmore, E.; Irving, J. A. E.; Veuger, S. J.; Durkacz, B. W.] Newcastle Univ, No Inst Canc Res, Newcastle Canc Ctr, Tyneside, England; [Hostomsky, Z.] Pfizer GRD, La Jolla, CA USA	Newcastle University - UK; Pfizer	Veuger, SJ (corresponding author), Newcastle Univ, Newcastle Canc Ctr, No Inst Canc Res, Sch Med, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	s.j.veuger@ncl.ac.uk	Hostomsky, Zdenek/G-3513-2011; Willmore, Elaine/B-4350-2009	Willmore, Elaine/0000-0002-4762-094X	Pfizer [AG-014699]; Cancer Research UK [C7369/A8048]	Pfizer(Pfizer); Cancer Research UK(Cancer Research UK)	We gratefully acknowledge Pfizer for the supply of AG-014699. This work was supported by Cancer Research UK, grant number C7369/A8048.	ALTHAUS FR, 1994, MOL CELL BIOCHEM, V138, P53, DOI 10.1007/BF00928443; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bonicalzi ME, 2005, CELL MOL LIFE SCI, V62, P739, DOI 10.1007/s00018-004-4505-1; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Daniel RA, 2009, CLIN CANCER RES, V15, P1241, DOI 10.1158/1078-0432.CCR-08-1095; Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509; Drew Y, 2009, DRUG RESIST UPDATE, V12, P153, DOI 10.1016/j.drup.2009.10.001; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Ghosh G., 1999, GENE THER MOL BIOL, V4, P75; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hewamana S, 2008, BLOOD, V111, P4681, DOI 10.1182/blood-2007-11-125278; Hewamana S, 2009, J CLIN ONCOL, V27, P763, DOI 10.1200/JCO.2008.19.1114; Hewamana S, 2008, CLIN CANCER RES, V14, P8102, DOI 10.1158/1078-0432.CCR-08-1673; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; Kanzawa T, 2003, J BIOMED BIOTECHNOL, P25; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Martin-Oliva D, 2006, CANCER RES, V66, P5744, DOI 10.1158/0008-5472.CAN-05-3050; Mulligan EA, 2010, BLOOD, V116, P1477; OGOREK B, 1985, MUTAT RES, V146, P63, DOI 10.1016/0167-8817(85)90056-2; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Plummer ER, 2005, CLIN CANCER RES, V11, P3402, DOI 10.1158/1078-0432.CCR-04-2353; Plummer R, 2005, J CLIN ONCOL, V23, p208S; Plummer R, 2008, CLIN CANCER RES, V14, P7917, DOI 10.1158/1078-0432.CCR-08-1223; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; SAHIJDAK WM, 1994, RADIAT RES, V138, pS47, DOI 10.2307/3578760; Shaw H, 2006, J CLIN ONCOL, V24, p127S; SLAMA JT, 1995, J MED CHEM, V38, P389, DOI 10.1021/jm00002a021; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Stilmann M, 2009, MOL CELL, V36, P365, DOI 10.1016/j.molcel.2009.09.032; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Tschaharganeh D, 2007, PATHOL ONCOL RES, V13, P84, DOI 10.1007/BF02893482; Turco MC, 2004, LEUKEMIA, V18, P11, DOI 10.1038/sj.leu.2403171; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.bi.54.070185.000445; Veuger SJ, 2009, ONCOGENE, V28, P832, DOI 10.1038/onc.2008.439; Veuger SJ, 2003, CANCER RES, V63, P6008; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Zaremba T, 2009, BRIT J CANCER, V101, P256, DOI 10.1038/sj.bjc.6605166	57	27	30	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					251	264		10.1038/onc.2011.229	http://dx.doi.org/10.1038/onc.2011.229			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21706052	Green Accepted			2022-12-17	WOS:000299307400010
J	Belleudi, F; Leone, L; Purpura, V; Cannella, F; Scrofani, C; Torrisi, MR				Belleudi, F.; Leone, L.; Purpura, V.; Cannella, F.; Scrofani, C.; Torrisi, M. R.			HPV16 E5 affects the KGFR/FGFR2b-mediated epithelial growth through alteration of the receptor expression, signaling and endocytic traffic	ONCOGENE			English	Article						HPV16 E5; FGFR2b; KGFR; endocytic pathway; receptor tyrosine kinase; human keratinocytes	HUMAN FORESKIN KERATINOCYTES; LIGAND-DEPENDENT ACTIVATION; DOWN-REGULATION; PROTEIN; ONCOPROTEIN; KGF; EGF; DIFFERENTIATION; CELLS; PROLIFERATION	The E5 oncoprotein of the human papillomavirus type 16 (HPV16 E5) cooperates in cervical carcinogenesis and in epithelial transformation deregulating cell growth, survival and differentiation through the modulation of growth factor receptors. Among the epithelial receptor tyrosine kinases, the keratinocyte growth factor receptor/fibroblast growth factor receptor 2b (KGFR/FGFR2b) is a major paracrine mediator of epithelial homeostasis and appears to have an unique and unusual role in epithelial tissues, exerting a tumor-suppressive function in vitro and in vivo. With the aim to better elucidate the molecular events involved in the pathological activity of 16E5, we investigated if the viral protein would be able to affect the KGFR expression, signaling and turnover by interference with its degradative and recycling endocytic pathways. Quantitative reverse transcriptase-PCR and biochemical approaches on human keratinocytes transfected with 16E5-HA showed that E5 protein is able to induce KGFR down-modulation at both transcript and protein levels. Immunofluorescence microscopy in double-transfected cells expressing both E5 and KGFR revealed that the viral protein alters the receptor endocytic trafficking and triggers its endosomal sorting to the indirect juxtanuclear recycling pathway. The shift from lysosomal degradation to recycling at the plasma membrane correlates with a reduced phosphorylation of the fibroblast growth factor receptor substrate-2 alpha tyrosine 196, the major docking site for Grb2-Cbl complexes responsible for receptor ubiquitination and degradation. 5'-Bromo-deoxyuridine incorporation assay demonstrated that expression of 16E5 induces a decrease in the growth response to the receptor ligands as a consequence of KGFR down-modulation, suggesting that 16E5 might have a role on HPV infection in perturbing the KGFR-mediated physiological behavior of confluent keratinocytes committed to differentiation. Oncogene (2011) 30, 4963-4976; doi:10.1038/onc.2011.203; published online 30 May 2011	[Belleudi, F.; Leone, L.; Purpura, V.; Cannella, F.; Scrofani, C.; Torrisi, M. R.] Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, Dipartimento Med Clin & Mol, I-00161 Rome, Italy; [Torrisi, M. R.] Azienda Osped S Andrea, Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea	Torrisi, MR (corresponding author), Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, Dipartimento Med Clin & Mol, Piazza Sassari 3, I-00161 Rome, Italy.	mara.torrisi@uniroma1.it	Purpura, Valeria/K-3052-2018	PURPURA, VALERIA/0000-0002-1272-313X	MIUR; AIRC-Associazione Italiana per la Ricerca sul Cancro, Italy [IG 10272]	MIUR(Ministry of Education, Universities and Research (MIUR)); AIRC-Associazione Italiana per la Ricerca sul Cancro, Italy(Fondazione AIRC per la ricerca sul cancro)	This work was partially supported by grants from MIUR and from AIRC-Associazione Italiana per la Ricerca sul Cancro (IG 10272), Italy.	Ashrafi GH, 2006, INT J CANCER, V119, P2105, DOI 10.1002/ijc.22089; Ashrafi GH, 2005, INT J CANCER, V113, P276, DOI 10.1002/ijc.20558; Barbaresi S, 2010, J GEN VIROL, V91, P521, DOI 10.1099/vir.0.016295-0; Belleudi F, 2007, TRAFFIC, V8, P1854, DOI 10.1111/j.1600-0854.2007.00651.x; Belleudi F, 2006, FASEB J, V20, P395, DOI 10.1096/fj.05-3934fje; Belleudi F, 2009, EXP CELL RES, V315, P2181, DOI 10.1016/j.yexcr.2009.03.022; Capone A, 2000, CELL GROWTH DIFFER, V11, P607; Ceccarelli S, 2007, EXP CELL RES, V313, P1758, DOI 10.1016/j.yexcr.2007.03.013; Chen SL, 2007, ONCOGENE, V26, P42, DOI 10.1038/sj.onc.1209768; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Feng S, 1997, CANCER RES, V58, P1509; Fey A, 2004, APPL ENVIRON MICROB, V70, P3618, DOI 10.1128/aem.70.6.3618-3623.2004; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Gotoh N, 2008, CANCER SCI, V99, P1319, DOI 10.1111/j.1349-7006.2008.00840.x; Grose R, 2007, EMBO J, V26, P1268, DOI 10.1038/sj.emboj.7601583; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; Kivi N, 2008, ONCOGENE, V27, P2532, DOI 10.1038/sj.onc.1210916; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Lotti LV, 2007, J CELL PHYSIOL, V212, P633, DOI 10.1002/jcp.21056; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; Marchese C, 2001, J INVEST DERMATOL, V116, P623, DOI 10.1046/j.0022-202x.2001.01280.x; Maufort JP, 2007, CANCER RES, V67, P6106, DOI 10.1158/0008-5472.CAN-07-0921; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Pedroza-Saavedra A, 2010, VIROLOGY, V400, P44, DOI 10.1016/j.virol.2010.01.009; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PIM D, 1992, ONCOGENE, V7, P27; Regan JA, 2008, J VIROL, V82, P10042, DOI 10.1128/JVI.01240-08; Rodriguez MI, 2000, ONCOGENE, V19, P3727, DOI 10.1038/sj.onc.1203718; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Suprynowicz FA, 2010, J VIROL, V84, P10619, DOI 10.1128/JVI.00831-10; Talbert-Slagle K, 2009, VIROLOGY, V384, P345, DOI 10.1016/j.virol.2008.09.033; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wakana Y, 2008, MOL BIOL CELL, V19, P1825, DOI 10.1091/mbc.E07-08-0781; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Zhang BY, 2005, ONCOGENE, V24, P2585, DOI 10.1038/sj.onc.1208453; Zhang BY, 2003, VIROLOGY, V310, P100, DOI 10.1016/S0042-6822(03)00103-X; Zhang BY, 2002, J VIROL, V76, P220, DOI 10.1128/JVI.76.1.220-231.2002; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P11336, DOI 10.1073/pnas.191377098	49	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4963	4976		10.1038/onc.2011.203	http://dx.doi.org/10.1038/onc.2011.203			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21625213	Bronze			2022-12-17	WOS:000298346500005
J	Luo, Y; Zhou, H; Liu, L; Shen, T; Chen, W; Xu, B; Han, X; Zhang, F; Scott, RS; Alexander, JS; Alam, A; Huang, S				Luo, Y.; Zhou, H.; Liu, L.; Shen, T.; Chen, W.; Xu, B.; Han, X.; Zhang, F.; Scott, R. S.; Alexander, J. S.; Alam, A.; Huang, S.			The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway	ONCOGENE			English	Article						ciclopirox; lymphatic endothelial cells; tube formation; VEGFR-3; ERK	TUMOR LYMPHANGIOGENESIS; CANDIDA-ALBICANS; VEGF RECEPTOR-3; GROWTH; METASTASIS; PROMOTES; PHOSPHORYLATION; ANGIOGENESIS; LYMPHEDEMA; ACTIVATION	Ciclopirox olamine (CPX), an off-patent antifungal agent used to treat mycoses of skin and nails, has recently been demonstrated to be a potential anticancer agent. However, the underlying mechanism is not well understood. Here, for the first time, we show that CPX inhibited lymphangiogenesis in an in vitro model (tube formation). This effect was, in part, associated with inhibition of vascular endothelial growth factor receptor-3 (VEGFR-3) expression, as overexpression of VEGFR-3 conferred partial resistance to CPX inhibitory effect on tube formation in lymphatic endothelial cells (LECs), whereas downregulation of VEGFR-3 mimicked the effect of CPX, blocking the tube formation. Further study revealed that CPX did not alter mRNA level, but inhibited protein synthesis and promoted protein degradation of VEGFR-3. In addition, we found that CPX inhibited phosphorylation of the extracellular signal-related kinase 1/2 (ERK1/2), a downstream effector of VEGFR-3. Overexpression of VEGFR-3 attenuated CPX inhibition of ERK1/2 phosphorylation, whereas downregulation of VEGFR-3 inhibited ERK1/2 phosphorylation in LECs. Ectopic expression of constitutively active mitogen-activated protein kinase kinase 1 (MKK1) resulted in activation of ERK1/2 and partially prevented CPX inhibition of LEC tube formation. The results suggest that CPX inhibits LEC tube formation at least, in part, through inhibiting VEGFR-3-mediated ERK signaling pathway. Oncogene (2011) 30, 2098-2107; doi:10.1038/onc.2010.590; published online 10 January 2011	[Luo, Y.; Zhou, H.; Liu, L.; Shen, T.; Chen, W.; Xu, B.; Han, X.; Huang, S.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; [Luo, Y.] Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Zhang, F.; Scott, R. S.] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Shreveport, LA 71130 USA; [Alam, A.] Sanofi Aventis R&D, Toulouse, France; [Huang, S.] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Sichuan University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Sanofi-Aventis; Sanofi France; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Huang, S (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	shuan1@lsuhsc.edu	Huang, Shile/I-1632-2019; Chen, Wenxing/GSI-9910-2022; Xu, Baoshan/H-6435-2011; luo, yan/I-5305-2015	Huang, Shile/0000-0002-3239-1072; Xu, Baoshan/0000-0001-8902-1243; Chen, Wenxing/0000-0003-4571-7622	NIH [CA115414]; Louisiana Board of Regents [LEQSF (2006-09)-RD-A-18]; American Cancer Society [RSG-08-135-01-CNE]; NATIONAL CANCER INSTITUTE [R01CA115414] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana Board of Regents; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in part, by the NIH grant CA115414 (SH), Louisiana Board of Regents grant (LEQSF (2006-09)-RD-A-18) (SH), and American Cancer Society grant RSG-08-135-01-CNE (SH). We thank Dr Natalie Ahn for providing MKK1 constructs.	Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Ando T., 2005, Lymphatic Research and Biology, V3, P105, DOI 10.1089/lrb.2005.3.105; Clement PMJ, 2002, INT J CANCER, V100, P491, DOI 10.1002/ijc.10515; Cueni LN, 2006, J INVEST DERMATOL, V126, P2167, DOI 10.1038/sj.jid.5700464; DITTMAR W, 1973, ARZNEIMITTEL-FORSCH, V23, P670; Dixelius J, 2003, J BIOL CHEM, V278, P40973, DOI 10.1074/jbc.M304499200; Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood-2009-03-209965; Fang Changge, 2009, Lymphatic Research and Biology, V7, P189, DOI 10.1089/lrb.2009.0033; Fournier E, 1999, ONCOGENE, V18, P507, DOI 10.1038/sj.onc.1202315; Fritz-Six KL, 2008, J CLIN INVEST, V118, P40, DOI 10.1172/JCI33302; He YL, 2005, CANCER RES, V65, P4739, DOI 10.1158/0008-5472.CAN-04-4576; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Jin DH, 2008, CARDIOVASC RES, V80, P339, DOI 10.1093/cvr/cvn228; JUE SG, 1985, DRUGS, V29, P330, DOI 10.2165/00003495-198529040-00002; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Karpanen T, 2001, CANCER RES, V61, P1786; Karpanen T, 2008, ANNU REV PATHOL-MECH, V3, P367, DOI 10.1146/annurev.pathol.3.121806.151515; Karpanen T, 2006, AM J PATHOL, V169, P708, DOI 10.2353/ajpath.2006.051200; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Lin JM, 2005, CANCER RES, V65, P6901, DOI 10.1158/0008-5472.CAN-05-0408; Linden T, 2003, FASEB J, V17, P761, DOI 10.1096/fj.02-0586fje; Liu L, 2008, ONCOGENE, V27, P4998, DOI 10.1038/onc.2008.137; Liu L, 2006, ONCOGENE, V25, P7029, DOI 10.1038/sj.onc.1209691; Liu L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010578; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Ming J, 2009, PATHOLOGY, V41, P118, DOI 10.1080/00313020802579268; Niewerth M, 2003, ANTIMICROB AGENTS CH, V47, P1805, DOI 10.1128/AAC.47.6.1805-1817.2003; Nisato RE, 2004, AM J PATHOL, V165, P11, DOI 10.1016/S0002-9440(10)63271-3; Pepper MS, 2001, CLIN CANCER RES, V7, P462; Ruggeri B, 2003, CANCER RES, V63, P5978; Salameh A, 2005, BLOOD, V106, P3423, DOI 10.1182/blood-2005-04-1388; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Sigle HC, 2005, J ANTIMICROB CHEMOTH, V55, P663, DOI 10.1093/jac/dki089; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018; Sunavala-Dossabhoy G, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-1; Wissmann C, 2006, CLIN CANCER RES, V12, P6865, DOI 10.1158/1078-0432.CCR-06-1800; Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255	43	27	27	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	18					2098	2107		10.1038/onc.2010.590	http://dx.doi.org/10.1038/onc.2010.590			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21217783	Green Accepted			2022-12-17	WOS:000290249600002
J	Barbash, O; Lee, EK; Diehl, JA				Barbash, O.; Lee, E. K.; Diehl, J. A.			Phosphorylation-dependent regulation of SCFFbx4 dimerization and activity involves a novel component, 14-3-3 epsilon	ONCOGENE			English	Article						cdk4; cyclin D1; Fbx4; 14-3-3	CYCLIN D1; STRUCTURAL BASIS; 14-3-3 PROTEINS; KINASE-ACTIVITY; NUCLEAR EXPORT; UBIQUITINATION; ACTIVATION; 14-3-3-PROTEINS; LOCALIZATION; PROTEOLYSIS	Fbx4 is an F-box constituent of Skp-Cullin-F-box (SCF) ubiquitin ligases that directs ubiquitylation of cyclin D1. Ubiquitylation of cyclin D1 requires phosphorylation of both cyclin D1 and Fbx4 by GSK3 beta. GSK3 beta-mediated phosphorylation of Fbx4 Ser12 during the G1/S transition regulates Fbx4 dimerization, which in turn governs Fbx4-driven E3 ligase activity. In esophageal carcinomas that overexpress cyclin D1, Fbx4 is subject to inactivating mutations that specifically disrupt dimerization, highlighting the biological significance of this regulatory mechanism. In an effort to elucidate the mechanisms that regulate dimerization, we sought to identify proteins that differentially bind to wild-type Fbx4 versus a cancer-derived dimerization-deficient mutant. We provide evidence that phosphorylation of Ser12 generates a docking site for 14-3-3 epsilon. 14-3-3 epsilon binds to endogenous Fbx4 and this association is impaired by mutations that target either Ser8 or Ser12 in Fbx4, suggesting that this N-terminal motif in Fbx4 directs its interaction with 14-3-3 epsilon. Knockdown of 14-3-3 epsilon inhibited Fbx4 dimerization, reduced SCFFbx4 E3 ligase activity and stabilized cyclin D1. Collectively, the current results suggest a model wherein 14-3-3 epsilon binds to Ser12-phosphorylated Fbx4 to mediate dimerization and function. Oncogene (2011) 30, 1995-2002; doi:10.1038/onc.2010.584; published online 17 January 2011	[Barbash, O.; Lee, E. K.; Diehl, J. A.] Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Barbash, O.; Lee, E. K.; Diehl, J. A.] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; [Barbash, O.; Lee, E. K.; Diehl, J. A.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Diehl, JA (corresponding author), Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, 454 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NIH [P01-CA098101]; Leukemia & Lymphoma Scholar award; NATIONAL CANCER INSTITUTE [P30CA016520, P01CA098101, R01CA133154] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Scholar award(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Margarita Romero for excellent technical assistance. This work was supported by a grant from the NIH (P01-CA098101) and a Leukemia & Lymphoma Scholar award (JAD).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Barbash O, 2009, ONCOGENE, V28, P4317, DOI 10.1038/onc.2009.287; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Che XH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-306; Chew EH, 2007, CELL SIGNAL, V19, P1071, DOI 10.1016/j.cellsig.2006.12.002; Dhillon AS, 2009, CELL SIGNAL, V21, P1645, DOI 10.1016/j.cellsig.2009.07.001; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Konishi H, 2002, CANCER RES, V62, P271; KORCHEVA VB, 2010, APPL IMMUNOHISTOCHEM; Li YF, 2010, J BIOL CHEM, V285, P13896, DOI 10.1074/jbc.M110.111518; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Paul G, 2009, GENOMICS, V94, P287, DOI 10.1016/j.ygeno.2009.07.004; Pignataro L, 2005, Acta Otorhinolaryngol Ital, V25, P75; Skaar JR, 2009, CURR OPIN CELL BIOL, V21, P816, DOI 10.1016/j.ceb.2009.08.004; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; van Heusden GPH, 2006, YEAST, V23, P159, DOI 10.1002/yea.1338; Wang J, 2009, J BIOL CHEM, V284, P14011, DOI 10.1074/jbc.M901310200; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng ZX, 2010, DEV CELL, V18, P214, DOI 10.1016/j.devcel.2010.01.007; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang W, 2006, MOL CANCER RES, V4, P935, DOI 10.1158/1541-7786.MCR-06-0253	35	27	27	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					1995	2002		10.1038/onc.2010.584	http://dx.doi.org/10.1038/onc.2010.584			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21242966	Green Accepted			2022-12-17	WOS:000289977400003
J	Dormoy, V; Beraud, C; Lindner, V; Thomas, L; Coquard, C; Barthelmebs, M; Jacqmin, D; Lang, H; Massfelder, T				Dormoy, V.; Beraud, C.; Lindner, V.; Thomas, L.; Coquard, C.; Barthelmebs, M.; Jacqmin, D.; Lang, H.; Massfelder, T.			LIM-class homeobox gene Lim1, a novel oncogene in human renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; developmental LIM class homeobox gene Lim1; growth; migration; VHL tumor suppressor	HORMONE-RELATED PROTEIN; FACTOR-KAPPA-B; IN-VIVO; PROGNOSTIC-SIGNIFICANCE; MICROVESSEL DENSITY; SIGNALING PATHWAYS; KIDNEY DEVELOPMENT; PANCREATIC-CANCER; GROWTH-FACTOR; TENASCIN-C	Human clear cell renal cell carcinoma (CCC) remains resistant to therapies. The transcription factor LIM-class homeobox gene Lim1 is required for normal organogenesis, including nephrogenesis, by regulating cell movements, differentiation and growth. Its expression is controlled partly by the sonic hedgehog-Gli signaling pathway, which we have recently shown to be reactivated in human CCC. So far, no study has assessed whether Lim1 may be associated with tumorigenesis. Using a panel of human CCC cell lines expressing or not the von Hippel-Lindau tumor suppressor gene and 44 tumor/normal tissues pairs, we found that Lim1 is constitutively and exclusively reexpressed in tumors. Through Lim1 silencing or overexpressing, we show that Lim1 is a growth and survival factor in human CCC, at least through the activation of oncogenic pathways including the phosphoinositide kinase-3/Akt and nuclear factor-kappaB pathways. More importantly, in nude mice bearing human CCC tumors, Lim1 silencing abolished tumor growth through the same mechanism as in vitro. In Lim1-depleted cells and tumors, cell movements were substantially impaired because of the inhibition of expression of various proteins involved in metastatic spread, such as paxillin or tenascin-C. These findings establish that the developmental marker Lim1 acts as an oncogene in cancer cells and targeting Lim1 may constitute an innovative therapeutic intervention in human CCC. Oncogene (2011) 30, 1753-1763; doi:10.1038/onc.2010.557; published online 6 December 2010	[Dormoy, V.; Beraud, C.; Thomas, L.; Coquard, C.; Barthelmebs, M.; Massfelder, T.] Univ Strasbourg, INSERM, U682, Sect Kidney Canc & Renal Physiopathol,Sch Med, F-67085 Strasbourg, France; [Lindner, V.] Hop Mulhouse, Dept Pathol, Mulhouse, France; [Jacqmin, D.; Lang, H.] Nouvel Hop Civil Strasbourg, Dept Urol, Strasbourg, France	CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Franche-Comte; CHU Strasbourg	Massfelder, T (corresponding author), Univ Strasbourg, INSERM, U682, Sect Kidney Canc & Renal Physiopathol,Sch Med, F-67085 Strasbourg, France.	thierry.massfelder@medecine.u-strasbg.fr	Massfelder, Thierry/I-1260-2016; Dormoy, Valerian/P-5109-2016	Dormoy, Valerian/0000-0003-1725-371X	INSERM (Institut National de la Sante Et de la Recherche Medicale); University of Strasbourg; French Ligue Contre le Cancer (Comite's du Bas-Rhin et du Haut-Rhin et Comite National)	INSERM (Institut National de la Sante Et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Strasbourg; French Ligue Contre le Cancer (Comite's du Bas-Rhin et du Haut-Rhin et Comite National)	This study was sponsored by INSERM (Institut National de la Sante Et de la Recherche Medicale), by University of Strasbourg and by the French Ligue Contre le Cancer (Comite's du Bas-Rhin et du Haut-Rhin et Comite National, recipient TM). We thank Dr A Donai for helpful suggestions, Dr J Barths for allowing us to perform FACS analysis and RA Hanna for text correction.	Agouni A, 2007, CARCINOGENESIS, V28, P1893, DOI 10.1093/carcin/bgm106; Arsanious A, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-20; Baldewijns MM, 2010, J PATHOL, V221, P125, DOI 10.1002/path.2689; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Chen J, 2009, INT J ONCOL, V34, P1029, DOI 10.3892/ijo_00000228; Clark PE, 2007, CURR OPIN UROL, V17, P331, DOI 10.1097/MOU.0b013e3282c508e0; Dormoy V, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-123; Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511; Escudier B, 2008, BIOL-TARGETS THER, V2, P517; Friedrich CA, 1999, CANCER-AM CANCER SOC, V86, P2478, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Huang D, 2008, CANCER RES, V68, P81, DOI 10.1158/0008-5472.CAN-07-5311; Hueber PA, 2006, KIDNEY INT, V69, P1139, DOI 10.1038/sj.ki.5000136; Hueber PA, 2008, CANCER LETT, V265, P148, DOI 10.1016/j.canlet.2008.02.016; Imao T, 2004, INT J UROL, V11, P948, DOI 10.1111/j.1442-2042.2004.00931.x; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Kawakami K, 2009, CANCER RES, V69, P8603, DOI 10.1158/0008-5472.CAN-09-2534; Kobayashi A, 2005, DEVELOPMENT, V132, P2809, DOI 10.1242/dev.01858; MACLENNAN GT, 1995, UROLOGY, V46, P27, DOI 10.1016/S0090-4295(99)80153-8; Massfelder T, 2004, CANCER RES, V64, P180, DOI 10.1158/0008-5472.CAN-03-1968; Meng XN, 2009, BRIT J CANCER, V101, P327, DOI 10.1038/sj.bjc.6605154; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Nativ O, 1998, UROLOGY, V51, P693, DOI 10.1016/S0090-4295(98)00019-3; Noguelra M, 2008, UROL ONCOL-SEMIN ORI, V26, P113, DOI 10.1016/j.urolonc.2007.03.028; Ohno Y, 2008, ONCOL REP, V20, P511, DOI 10.3892/or_00000035; Reidy KJ, 2009, SEMIN NEPHROL, V29, P321, DOI 10.1016/j.semnephrol.2009.03.009; Ryschich E, 2009, PANCREAS, V38, P804, DOI 10.1097/MPA.0b013e3181b9dfda; Sagalowsky Arthur I, 2002, Curr Opin Urol, V12, P371, DOI 10.1097/00042307-200209000-00001; Schedl A, 2007, NAT REV GENET, V8, P791, DOI 10.1038/nrg2205; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sjolund J, 2008, J CLIN INVEST, V118, P217, DOI 10.1172/JCI32086; Sourbier C, 2007, CANCER RES, V67, P11668, DOI 10.1158/0008-5472.CAN-07-0632; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Tang J, 2008, CELL MOL LIFE SCI, V65, P2933, DOI 10.1007/s00018-008-8315-8; Venegas-Ferrin M, 2010, INT J DEV BIOL, V54, P195, DOI 10.1387/ijdb.092870mv; Yao YZ, 2007, ANN CLIN LAB SCI, V37, P39	38	27	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1753	1763		10.1038/onc.2010.557	http://dx.doi.org/10.1038/onc.2010.557			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21132009				2022-12-17	WOS:000289512200003
J	Morgan, MR; Jazayeri, M; Ramsay, AG; Thomas, GJ; Boulanger, MJ; Hart, IR; Marshall, JF				Morgan, M. R.; Jazayeri, M.; Ramsay, A. G.; Thomas, G. J.; Boulanger, M. J.; Hart, I. R.; Marshall, J. F.			Psoriasin (S100A7) associates with integrin beta 6 subunit and is required for alpha v beta 6-dependent carcinoma cell invasion	ONCOGENE			English	Article						alpha v beta 6; integrins; invasion; psoriasin; cancer; oral SCC	TUMOR PROGRESSION; BINDING-PROTEIN; BREAST-CANCER; TERMINAL DIFFERENTIATION; CYTOPLASMIC DOMAIN; PROMOTES MIGRATION; COLON-CARCINOMA; ORAL-CAVITY; IN-SITU; EXPRESSION	Expression of the integrin alpha v beta 6 is upregulated in a variety of carcinomas where it appears to be involved in malignant progression, although the biology of this integrin is not fully explored. We have generated oral carcinoma cells that express alpha v beta 6 composed of wild-type alpha v and a mutant beta 6 that lacks the unique C-terminal 11 amino acids (aa). We found that these residues, although not required for alpha v beta 6-dependent adhesion or migration, are essential for alpha v beta 6-dependent invasive activity. We have used a proteomic approach to identify novel binding partners for the beta 6 subunit cytoplasmic tail and report that psoriasin (Psor) (S100A7) bound preferentially to the recombinant beta 6 cytoplasmic domain, though not in the absence of the unique C-terminal 11aa. Endogenous cellular Psor co-precipitated with endogenous beta 6 and colocalised with alpha v beta 6 at the cell membrane and intracellular vesicles. Knockdown of Psor, with small interfering RNA, had no effect on alpha v beta 6-dependent adhesion or migration but abrogated alpha v beta 6-mediated oral carcinoma cell invasion both in Transwell and, the more physiologically relevant, organotypic invasion assays, recapitulating the behaviour of the beta 6-mutant cell line. Membrane-permeant Tat-peptides encoding the unique C-terminal residues of beta 6, bound directly to recombinant Psor and inhibited cellular Psor binding to beta 6; this blocked alpha v beta 6-dependent, but not alpha v beta 6-independent, invasion. These data identify a novel interaction between Psor and beta 6 and demonstrate that it is required for alpha v beta 6-dependent invasion by carcinoma cells. Inhibition of this interaction may represent a novel therapeutic strategy to target carcinoma invasion. Oncogene (2011) 30, 1422-1435; doi:10.1038/onc.2010.535; published online 6 December 2010	[Ramsay, A. G.; Marshall, J. F.] Univ London, Barts & London Sch Med & Dent, John Vane Sci Ctr, Inst Canc,Ctr Med Oncol, London EC1M 6BQ, England; [Morgan, M. R.; Jazayeri, M.; Ramsay, A. G.; Thomas, G. J.; Hart, I. R.; Marshall, J. F.] London Sch Med & Dent, John Vane Sci Ctr, Tumor Biol Ctr, London, England; [Boulanger, M. J.] Dept Biochem & Microbiol, Victoria, BC, Canada	University of London; Queen Mary University London; University of London; Queen Mary University London	Marshall, JF (corresponding author), Univ London, Barts & London Sch Med & Dent, John Vane Sci Ctr, Inst Canc,Ctr Med Oncol, Charterhouse Sq, London EC1M 6BQ, England.	j.f.marshall@qmul.ac.uk	Ramsay, Alan G/A-8374-2015	Ramsay, Alan G/0000-0002-0452-0420; Morgan, Mark/0000-0001-7728-9883; Marshall, John/0000-0002-0494-2295				AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Banerjee AG, 2005, MOL CANCER THER, V4, P865, DOI 10.1158/1535-7163.MCT-05-0033; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; BREUSS JM, 1995, J CELL SCI, V108, P2241; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; BUSK M, 1992, J BIOL CHEM, V267, P5790; Clark RAF, 1996, BRIT J DERMATOL, V135, P46; Elayadi AN, 2007, CANCER RES, V67, P5889, DOI 10.1158/0008-5472.CAN-07-0245; Emberley ED, 2005, CANCER RES, V65, P5696, DOI 10.1158/0008-5472.CAN-04-3927; Emberley ED, 2004, BREAST CANCER RES, V6, pR308, DOI 10.1186/bcr791; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Haapasalmi K, 1996, J INVEST DERMATOL, V106, P42, DOI 10.1111/1523-1747.ep12327199; Hazelbag S, 2007, J PATHOL, V212, P316, DOI 10.1002/path.2168; Jiang WG, 2004, INT J ONCOL, V25, P81; Jones J, 1996, ONCOGENE, V12, P119; Jones J, 1997, J ORAL PATHOL MED, V26, P63, DOI 10.1111/j.1600-0714.1997.tb00023.x; Kesting MR, 2009, ORAL ONCOL, V45, P731, DOI 10.1016/j.oraloncology.2008.11.012; Krop I, 2005, CANCER RES, V65, P11326, DOI 10.1158/0008-5472.CAN-05-1523; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Larjava H, 1996, Oral Dis, V2, P77; Leon R, 2009, BIOCHEMISTRY-US, V48, P10591, DOI 10.1021/bi901330g; Li XW, 2003, J BIOL CHEM, V278, P41646, DOI 10.1074/jbc.M306274200; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041; Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Niu J, 2002, INT J CANCER, V99, P529, DOI 10.1002/ijc.10397; Niu J, 2001, INT J CANCER, V92, P40, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1157>3.0.CO;2-B; Nystrom ML, 2006, CANCER RES, V66, P10833, DOI 10.1158/0008-5472.CAN-06-1640; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Paruchuri V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001741; Petersson S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-205; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; Ralhan R, 2008, MOL CELL PROTEOMICS, V7, P1162, DOI 10.1074/mcp.M700500-MCP200; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; Ramsay AG, 2007, CANCER RES, V67, P5275, DOI 10.1158/0008-5472.CAN-07-0318; Regezi JA, 2002, ORAL ONCOL, V38, P332, DOI 10.1016/S1368-8375(01)00062-8; RESKA AA, 1992, J CELL BIOL, V117, P1321; Ruse M, 2003, J INVEST DERMATOL, V121, P132, DOI 10.1046/j.1523-1747.2003.12309.x; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; Thomas GJ, 2006, J ORAL PATHOL MED, V35, P1, DOI 10.1111/j.1600-0714.2005.00374.x; Thomas GJ, 2002, BRIT J CANCER, V87, P859, DOI 10.1038/sj.bjc.6600545; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Thomas GJ, 2001, J INVEST DERMATOL, V116, P898, DOI 10.1046/j.1523-1747.2001.01352.x; Wang J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2105; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wolf R, 2008, J IMMUNOL, V181, P1499, DOI 10.4049/jimmunol.181.2.1499; Zhou G, 2008, ONCOGENE, V27, P3527, DOI 10.1038/sj.onc.1211015	51	27	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1422	1435		10.1038/onc.2010.535	http://dx.doi.org/10.1038/onc.2010.535			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21132011				2022-12-17	WOS:000288743800005
J	Robinson, JP; VanBrocklin, MW; Lastwika, KJ; McKinney, AJ; Brandner, S; Holmen, SL				Robinson, J. P.; VanBrocklin, M. W.; Lastwika, K. J.; McKinney, A. J.; Brandner, S.; Holmen, S. L.			Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo	ONCOGENE			English	Article						MEK; AKT; Ink4a/Arf; glioma; mouse model; targeted therapy	INTEGRATED GENOMIC ANALYSIS; NEURAL PROGENITORS; TUMOR SUPPRESSION; GLIOBLASTOMA; CANCER; GENE; TEMOZOLOMIDE; INHIBITORS; PATHWAYS; MICE	The RAS/RAF mitogen-activated protein kinase pathway (MAPK) is highly active in many tumor types including the majority of high-grade gliomas and expression of activated RAS or RAF in neural progenitor cells combined with either AKT activation or Ink4a/Arf loss leads to the development of high-grade gliomas in vivo. This strongly suggests that this pathway is necessary for glioma formation and maintenance. To further define the role of this pathway in the development of high-grade gliomas, we used the established RCAS/TVA glioma mouse model to test the ability of activated MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK), a RAF effector, to induce tumors in vivo in the context of activated AKT or Ink4a/Arf loss. Although expression of activated MEK alone in neural progenitor cells is not sufficient for tumorigenesis, the combination of activated MEK and AKT or MEK with Ink4a/Arf loss is transforming. The data reveal that activation of the classical RAS/MAPK pathway, which is mediated through MEK, leads to the development of high-grade gliomas in vivo and suggest that MEK may be a relevant target for glioma therapy. To test this, we treated both mouse and human glioma cells with the MEK inhibitor PD0325901. Although this treatment induced apoptosis in a significant percentage of the cells, the effect was enhanced by combined treatment with the phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitor NVP-BEZ235. Our results demonstrate that combined inhibition of MEK and PI3K/mTOR is a rational strategy for the treatment of high-grade gliomas and may be an effective adjuvant therapy for this disease. Oncogene (2011) 30, 1341-1350; doi:10.1038/onc.2010.513; published online 8 November 2010	[Robinson, J. P.; VanBrocklin, M. W.; Lastwika, K. J.; McKinney, A. J.; Holmen, S. L.] Nevada Canc Inst, Drug Dev Dept, Las Vegas, NV 89135 USA; [Brandner, S.] UCL Inst Neurol, Div Neuropathol, London, England	University of California System; University of California San Diego; University of London; University College London	Holmen, SL (corresponding author), Nevada Canc Inst, Drug Dev Dept, 1 Breakthrough Way, Las Vegas, NV 89135 USA.	sholmen@nvcancer.org	Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342; Robinson, James/0000-0002-6585-0116	Nevada Cancer Institute; National Brain Tumor Foundation; American Cancer Society [RSG-06-198-01-TBE]; NATIONAL CANCER INSTITUTE [R01CA121118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073870, R01NS075155] Funding Source: NIH RePORTER	Nevada Cancer Institute(University of California System); National Brain Tumor Foundation; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Han-Mo Koo, Eric Holland and Ronald DePinho for reagents and advice. We thank James Symanowski for assistance with statistical analysis of the data. We also thank Novartis Pharmaceuticals for providing the NVP-BEZ235. This work was supported by the Nevada Cancer Institute, the National Brain Tumor Foundation and RSG-06-198-01-TBE from the American Cancer Society.	Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; Beier D, 2008, CANCER RES, V68, P5706, DOI 10.1158/0008-5472.CAN-07-6878; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; *COUNC NR RES IOL, 1996, GUID CAR US LAB AN; Federspiel Mark J., 1997, V52, P179; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Hu XY, 2005, NEOPLASIA, V7, P356, DOI 10.1593/neo.04595; Ichimura K, 1996, ONCOGENE, V13, P1065; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160; LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883; Lyustikman Y, 2008, NEOPLASIA, V10, P501, DOI 10.1593/neo.08206; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Newlands ES, 1997, CANCER TREAT REV, V23, P35, DOI 10.1016/S0305-7372(97)90019-0; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; QUELLE DE, 1995, CELL, V83, P993; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Robinson JP, 2010, ONCOGENE, V29, P335, DOI 10.1038/onc.2009.333; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Uhrbom L, 2002, CANCER RES, V62, P5551; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang D, 2007, BBA-MOL CELL RES, V1773, P1248, DOI 10.1016/j.bbamcr.2006.11.009; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	35	27	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1341	1350		10.1038/onc.2010.513	http://dx.doi.org/10.1038/onc.2010.513			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057530	Green Accepted			2022-12-17	WOS:000288492100008
J	Schouwey, K; Aydin, IT; Radtke, F; Beermann, F				Schouwey, K.; Aydin, I. T.; Radtke, F.; Beermann, F.			RBP-J kappa-dependent Notch signaling enhances retinal pigment epithelial cell proliferation in transgenic mice	ONCOGENE			English	Article						RPE; transgenic; Notch; eye; melanoma; knockout	EARLY EYE DEVELOPMENT; TUMOR-SUPPRESSOR; EXPRESSION; FATE; TRANSCRIPTION; PATHWAY; GENE; DIFFERENTIATION; MELANOCYTE; MORPHOGENESIS	The Notch signaling pathway is an ubiquitous cell-cell interaction mechanism, which is essential in controlling processes like cell proliferation, cell fate decision, differentiation or stem cell maintenance. Recent data have shown that Notch signaling is RBP-J kappa-dependent in melanocytes, being required for survival of these pigment cells that are responsible for coloration of the skin and hairs in mammals. In addition, Notch is believed to function as an oncogene in melanoma, whereas it is a tumor suppressor in mouse epidermis. In this study, we addressed the implication of the Notch signaling in the development of another population of pigment cells forming the retinal pigment epithelium (RPE) in mammalian eyes. The constitutive activity of Notch in Tyrp1::NotchIC/degrees transgenic mice enhanced RPE cell proliferation, and the resulting RPE-derived pigmented tumor severely affected the overall eye structure. This RPE cell proliferation is dependent on the presence of the transcription factor RBP-J kappa, as it is rescued in mice lacking RBP-J kappa in the RPE. In conclusion, Notch signaling in the RPE uses the canonical pathway, which is dependent on the transcription factor RBP-J kappa. In addition, it is of importance for RPE development, and constitutive Notch activity leads to hyperproliferation and benign tumors of these pigment cells. Oncogene (2011) 30, 313-322; doi:10.1038/onc.2010.428; published online 20 September 2010	[Schouwey, K.; Aydin, I. T.; Radtke, F.; Beermann, F.] Ecole Polytech Fed Lausanne EPFL, Sch Life Sci, Swiss Inst Expt Canc Res ISREC, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research	Beermann, F (corresponding author), Ecole Polytech Fed Lausanne EPFL, Sch Life Sci, Swiss Inst Expt Canc Res ISREC, Stn 19,Batiment SV, CH-1015 Lausanne, Switzerland.	Friedrich.Beermann@epfl.ch	Radtke, Freddy/Q-3198-2017	Radtke, Freddy/0000-0003-4315-4045; Aydin, Iraz Toprak/0000-0001-9608-8577	Oncosuisse; Novartis; Fondation Emma Muschamps; Swiss National Science Foundation	Oncosuisse; Novartis(Novartis); Fondation Emma Muschamps; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	We thank Pierre Chambon, Tatsuko Honjo, Ursula Zimber-Strobl, Lothar Strobl and Ian J Jackson for mouse strains; to Simon Saule, Vince Hearing and Mickey Marks for antibodies; and to Alessandra Solero and Sabrina Guichard for initial help with the Tyrp1::NotchIC construct and mice. The Pax6 antibody developed by A Kawakami was obtained from the Developmental Studies Hybridoma Bank at the University of Iowa. Work in the laboratory of FB was supported by grants from Oncosuisse, Novartis, the Fondation Emma Muschamps and The Swiss National Science Foundation.	Adler R, 1999, MOL VIS, V5; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aubin-Houzelstein G, 2008, J INVEST DERMATOL, V128, P2686, DOI 10.1038/jid.2008.120; Aydin IT, 2009, PIGM CELL MELANOMA R, V22, P854, DOI 10.1111/j.1755-148X.2009.00629.x; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Bao ZZ, 1997, J NEUROSCI, V17, P1425; Baumer N, 2003, DEVELOPMENT, V130, P2903, DOI 10.1242/dev.00450; Besseyrias V, 2007, J EXP MED, V204, P331, DOI 10.1084/jem.20061442; Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x; BODENSTEIN L, 1987, DEV BIOL, V121, P192, DOI 10.1016/0012-1606(87)90152-7; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brennan K, 2002, BIOESSAYS, V24, P405, DOI 10.1002/bies.10089; Bumsted KM, 2000, INVEST OPHTH VIS SCI, V41, P903; Cao TY, 1997, J CELL SCI, V110, P1563; Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255; Dakubo GD, 2008, DEV BIOL, V320, P242, DOI 10.1016/j.ydbio.2008.05.528; Das AV, 2008, DEV NEUROSCI-BASEL, V30, P389, DOI 10.1159/000178017; Defoe DM, 2007, MOL VIS, V13, P273; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Finger PT, 1996, GRAEF ARCH CLIN EXP, V234, pS22, DOI 10.1007/BF02343044; Fuhrmann S, 2000, DEVELOPMENT, V127, P4599; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; GARNER A, 1970, BRIT J OPHTHALMOL, V54, P715, DOI 10.1136/bjo.54.11.715; Gimenez E, 2001, LAB ANIM-UK, V35, P153, DOI 10.1258/0023677011911525; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Haass NK, 2005, J INVEST DERM SYMP P, V10, P153, DOI 10.1111/j.1087-0024.2005.200407.x; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Hingorani M, 1999, OPHTHALMOLOGY, V106, P330, DOI 10.1016/S0161-6420(99)90072-6; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135; Krebs LT, 2000, GENE DEV, V14, P1343; Krebs LT, 2003, GENE DEV, V17, P1207, DOI 10.1101/gad.1084703; Kumano K, 2008, PIGM CELL MELANOMA R, V21, P70, DOI 10.1111/j.1755-148X.2007.00423.x; Lee HY, 2005, DEV BIOL, V284, P464, DOI 10.1016/j.ydbio.2005.06.010; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Lutty G, 1999, MOL VIS, V5; Ma A, 2007, INVEST OPHTH VIS SCI, V48, P3576, DOI 10.1167/iovs.06-1373; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x; Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064; Matt N, 2005, DEVELOPMENT, V132, P4789, DOI 10.1242/dev.02031; May CA, 1996, EXP EYE RES, V63, P75; Mori M, 2002, INVEST OPHTH VIS SCI, V43, P1384; Moriyama M, 2006, J CELL BIOL, V173, P333, DOI 10.1083/jcb.200509084; Murisier F, 2007, DEV BIOL, V303, P838, DOI 10.1016/j.ydbio.2006.11.038; Murisier F, 2006, DEV BIOL, V298, P644, DOI 10.1016/j.ydbio.2006.05.011; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nishikawa SI, 2007, PIGM CELL RES, V20, P263, DOI 10.1111/j.1600-0749.2007.00388.x; Penna D, 1998, ONCOGENE, V17, P2601, DOI 10.1038/sj.onc.1202196; Perron M, 2000, CELL MOL LIFE SCI, V57, P215, DOI 10.1007/PL00000685; Pinnix CC, 2009, CANCER RES, V69, P5312, DOI 10.1158/0008-5472.CAN-08-3767; Porret Andree, 2006, V337, P185; Radtke F, 2005, EMBO REP, V6, P1120, DOI 10.1038/sj.embor.7400585; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7; Rowan S, 2008, DEV BIOL, V321, P111, DOI 10.1016/j.ydbio.2008.06.002; Schmidt A, 1999, INT J CANCER, V80, P600, DOI 10.1002/(SICI)1097-0215(19990209)80:4<600::AID-IJC19>3.0.CO;2-2; Schouwey K, 2008, HISTOL HISTOPATHOL, V23, P609, DOI 10.14670/HH-23.609; Schouwey K, 2007, DEV DYNAM, V236, P282, DOI 10.1002/dvdy.21000; Schouwey K, 2010, PIGM CELL MELANOMA R, V23, P134, DOI 10.1111/j.1755-148X.2009.00651.x; Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shields JA, 2009, OPHTHALMOLOGY, V116, P2213, DOI 10.1016/j.ophtha.2009.04.048; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Vauclair S, 2007, DEV CELL, V13, P242, DOI 10.1016/j.devcel.2007.06.012; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson A, 2006, FEBS LETT, V580, P2860, DOI 10.1016/j.febslet.2006.03.024; Yashiro-Ohtani Y, 2009, GENE DEV, V23, P1665, DOI 10.1101/gad.1793709; Yoshida K, 2004, ANAT EMBRYOL, V208, P145, DOI 10.1007/s00429-004-0382-5; Zhao SL, 2001, MOL VIS, V7, P277; Zheng MH, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-38	85	27	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					313	322		10.1038/onc.2010.428	http://dx.doi.org/10.1038/onc.2010.428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20856205				2022-12-17	WOS:000286418800006
J	Deng, Y; Liu, J; Han, G; Lu, SL; Wang, SY; Malkoski, S; Tan, AC; Deng, C; Wang, XJ; Zhang, Q				Deng, Y.; Liu, J.; Han, G.; Lu, S-L; Wang, S-Y; Malkoski, S.; Tan, A. C.; Deng, C.; Wang, X-J; Zhang, Q.			Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1	ONCOGENE			English	Article						Brca1; CtBP1; NADH; transcription; tumor suppressor; HNSCC	SQUAMOUS-CELL CARCINOMA; TERMINAL BINDING-PROTEIN; FANCONI-ANEMIA; NECK-CANCER; NEGATIVE MODULATION; ANTIOXIDANT TEMPOL; DOWN-REGULATION; BREAST-CANCER; E1A PROTEIN; RAT-LIVER	C-terminal binding protein 1 (CtBP1) is a transcriptional co-repressor and metabolic sensory protein, which often represses tumor suppressor genes. Hence, we sought to determine if CtBP1 affects expression of the tumor suppressor Brca1 in head and neck tissue, as downregulation of Brca1 begins at the early stages of head and neck squamous cell carcinomas (HNSCCs). We found that CtBP1 represses Brca1 transcription by binding to the E2F4 site of the Brca1 promoter. Additionally, the recruitment of CtBP1 to the Brca1 promoter is redox-dependent, that is, increased at high NADH levels in hypoxic conditions. Further, immunostaining using a human HNSCC tissue array revealed that nuclear CtBP1 staining began to accumulate in hyperplasic lesions and HNSCCs, this staining correlated with Brca1 downregulation in these lesions. Pharmacological disruption of CtBP1 binding to Brca1 promoter by the antioxidant Tempol, which reduces NADH levels, relieved CtBP1-mediated repression of Brca1, leading to increased DNA repair in HNSCC cells. As tumor cells are generally hypoxic with increased NADH levels, the dynamic control of Brca1 by a 'metabolic switch' found in this study not only provides an important link between tumor metabolism and tumor suppressor expression but also suggests a potential chemo preventative or therapeutic strategy for HNSCC by blocking NADH-dependent CtBP1 activity at early stages of HNSCC carcinogenesis. Oncogene (2010) 29, 6603-6608; doi:10.1038/onc.2010.406; published online 6 September 2010	[Han, G.; Wang, X-J] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA; [Deng, Y.; Liu, J.; Zhang, Q.] Univ Colorado, Dept Dermatol, Aurora, CO 80045 USA; [Lu, S-L] Univ Colorado, Dept Otolaryngol, Aurora, CO 80045 USA; [Wang, S-Y] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; [Malkoski, S.] Univ Colorado, Dept Med, Div Pulm, Aurora, CO 80045 USA; [Tan, A. C.] Univ Colorado, Dept Med, Div Med Oncol, Aurora, CO 80045 USA; [Deng, C.] NIDDK, NIH, Bethesda, MD USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Oregon Health & Science University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wang, XJ (corresponding author), Univ Colorado, Dept Pathol, Aurora, CO 80045 USA.	xj.wang@UCDenver.edu; Qinghong.Zhang@UCDenver.edu	deng, chuxia/N-6713-2016; Tan, Aik Choon/A-3135-2011	Tan, Aik Choon/0000-0003-2955-8369	NIH [R01DE15953, R01CA115468]; NATIONAL CANCER INSTITUTE [R01CA115468, R01CA087849, K08CA131483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015953] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by Grants from the NIH, R01DE15953 (to X-JW) and R01CA115468 (to QZ). We thank Dr Petra Boukamp for providing the normal human keratinocytes HaCaT cells and Dr James Mitchell for helpful discussions.	Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Berton TR, 2003, ONCOGENE, V22, P5415, DOI 10.1038/sj.onc.1206825; Bindra RS, 2006, CANCER BIOL THER, V5, P1400, DOI 10.4161/cbt.5.10.3454; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; De Siervi A, 2010, CANCER RES, V70, P532, DOI 10.1158/0008-5472.CAN-09-1477; Erker L, 2005, HUM MOL GENET, V14, P1699, DOI 10.1093/hmg/ddi181; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; IANNONE A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P285, DOI 10.1016/0304-4165(90)90052-X; Kim JH, 2009, CELL DEATH DIFFER, V16, P584, DOI 10.1038/cdd.2008.186; Kim JH, 2005, NAT STRUCT MOL BIOL, V12, P423, DOI 10.1038/nsmb924; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; Kutler DI, 2003, ARCH OTOLARYNGOL, V129, P106, DOI 10.1001/archotol.129.1.106; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Metz JM, 2004, CLIN CANCER RES, V10, P6411, DOI 10.1158/1078-0432.CCR-04-0658; Mirnezami AH, 2003, CURR BIOL, V13, P1234, DOI 10.1016/S0960-9822(03)00454-8; Mitchell JB, 2003, FREE RADICAL BIO MED, V34, P93, DOI 10.1016/S0891-5849(02)01193-0; Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schubert R, 2004, HUM MOL GENET, V13, P1793, DOI 10.1093/hmg/ddh189; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Sparano A, 2006, LARYNGOSCOPE, V116, P735, DOI 10.1097/01.mlg.0000205141.54471.7f; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Weber F, 2007, JAMA-J AM MED ASSOC, V297, P187, DOI 10.1001/jama.297.2.187; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; Wreesmann VB, 2007, ORL-J OTO-RHIN-LARYN, V69, P218, DOI 10.1159/000101542; Wu WN, 2007, AM J PHYSIOL-LUNG C, V293, pL952, DOI 10.1152/ajplung.00203.2007; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2002, SCIENCE, V295, P1895; Zhang QS, 2008, CANCER RES, V68, P1601, DOI 10.1158/0008-5472.CAN-07-5186; Zhang QH, 2007, P NATL ACAD SCI USA, V104, P829, DOI 10.1073/pnas.0610590104; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103	44	27	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6603	6608		10.1038/onc.2010.406	http://dx.doi.org/10.1038/onc.2010.406			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20818429	Green Accepted			2022-12-17	WOS:000285380200009
J	Moore, HC; Jordan, LB; Bray, SE; Baker, L; Quinlan, PR; Purdie, CA; Thompson, AM; Bourdon, JC; Fuller-Pace, FV				Moore, H. C.; Jordan, L. B.; Bray, S. E.; Baker, L.; Quinlan, P. R.; Purdie, C. A.; Thompson, A. M.; Bourdon, J-C; Fuller-Pace, F. V.			The RNA helicase p68 modulates expression and function of the Delta 133 isoform(s) of p53, and is inversely associated with Delta 133p53 expression in breast cancer	ONCOGENE			English	Article						breast cancer; p68 RNA helicase; p53; Delta 133p53; gene expression/regulation	TUMOR-SUPPRESSOR P53; ESTROGEN-RECEPTOR-ALPHA; TRANSCRIPTIONAL COACTIVATOR; RIBOSOMAL-RNA; DNA-DAMAGE; BOX; PROTEINS; GENE; DIFFERENTIATION; ACTIVATION	The RNA helicase p68 is a potent co-activator of p53-dependent transcription in response to DNA damage. Previous independent studies have indicated that p68 and the Delta 133p53 isoforms, which modulate the function of full-length p53, are aberrantly expressed in breast cancers. Here we identify a striking inverse association of p68 and Delta 133p53 expression in primary breast cancers. Consistent with these findings, small interfering RNA depletion of p68 in cell lines results in a p53-dependant increase of Delta 133p53 in response to DNA damage, suggesting that increased Delta 133p53 expression could result from downregulation of p68 and provide a potential mechanistic explanation for our observations in breast cancer. Delta 133p53 alpha, which has been shown to negatively regulate the function of full-length p53, reciprocally inhibits the ability of p68 to stimulate p53-dependent transcription from the p21 promoter, suggesting that Delta 133p53 alpha may be competing with p68 to regulate p53 function. This hypothesis is underscored by our observations that p68 interacts with the C-terminal domain of p53, co-immunoprecipitates 133p53 alpha from cell extracts and interacts only with p53 molecules that are able to form tetramers. These data suggest that p68, p53 and 133p53 alpha may form part of a complex feedback mechanism to regulate the expression of Delta 133p53, with consequent modification of p53-mediated transcription, and may modulate the function of p53 in breast and other cancers that harbour wild-type p53. Oncogene (2010) 29, 6475-6484; doi:10.1038/onc.2010.381; published online 6 September 2010	[Moore, H. C.; Baker, L.; Thompson, A. M.; Bourdon, J-C; Fuller-Pace, F. V.] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Oncol & Mol Med, Dundee DD1 9SY, Tayside, Scotland; [Jordan, L. B.; Purdie, C. A.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Pathol, Dundee DD1 9SY, Tayside, Scotland; [Thompson, A. M.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Dundee; University of Dundee; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Fuller-Pace, FV (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Oncol & Mol Med, Dundee DD1 9SY, Tayside, Scotland.	f.v.fullerpace@dundee.ac.uk	JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386; Quinlan, Philip/0000-0002-3012-6646; Purdie, Colin/0000-0002-1258-4010	Tenovus Scotland; Cancer Research UK; Breast Cancer Research Scotland	Tenovus Scotland; Cancer Research UK(Cancer Research UK); Breast Cancer Research Scotland	This work was supported by grants from Tenovus Scotland, Cancer Research UK and Breast Cancer Research Scotland. We thank David Meek for helpful discussions.	Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Balakrishnan SK, 2008, ONCOGENE, V27, P2661, DOI 10.1038/sj.onc.1210935; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bertheau P, 2008, PATHOBIOLOGY, V75, P132, DOI 10.1159/000123851; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bond AT, 2001, MOL CELL BIOL, V21, P7366, DOI 10.1128/MCB.21.21.7366-7379.2001; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caretti G, 2007, CELL CYCLE, V6, P1172, DOI 10.4161/cc.6.10.4228; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Carter S, 2009, CURR OPIN GENET DEV, V19, P18, DOI 10.1016/j.gde.2008.11.010; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Fuller-Pace FV, 2006, NUCLEIC ACIDS RES, V34, P4206, DOI 10.1093/nar/gkl460; Graupner V, 2009, CELL CYCLE, V8, P1238, DOI 10.4161/cc.8.8.8251; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Jensen ED, 2008, J CELL BIOCHEM, V103, P1438, DOI 10.1002/jcb.21526; Liu ZR, 2002, MOL CELL BIOL, V22, P5443, DOI 10.1128/MCB.22.15.5443-5450.2002; Marcel V, 2010, ONCOGENE, V29, P2691, DOI 10.1038/onc.2010.26; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mehta SA, 2007, ONCOGENE, V26, P3329, DOI 10.1038/sj.onc.1210120; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Salzman DW, 2007, J BIOL CHEM, V282, P32773, DOI 10.1074/jbc.M705054200; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhang Jin, 2008, Curr Mol Med, V8, P845, DOI 10.2174/156652408786733748	44	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	49					6475	6484		10.1038/onc.2010.381	http://dx.doi.org/10.1038/onc.2010.381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20818423	Green Accepted			2022-12-17	WOS:000285138900007
J	Rorke, EA; Adhikary, G; Jans, R; Crish, JF; Eckert, RL				Rorke, E. A.; Adhikary, G.; Jans, R.; Crish, J. F.; Eckert, R. L.			AP1 factor inactivation in the suprabasal epidermis causes increased epidermal hyperproliferation and hyperkeratosis but reduced carcinogen-dependent tumor formation	ONCOGENE			English	Article						TAM67; c-jun; keratinocyte differentiation; epidermis; skin cancer	HUMAN INVOLUCRIN PROMOTER; NEGATIVE C-JUN; CONDITIONAL GENE-EXPRESSION; ACTIVATED PROTEIN-KINASES; DISTAL REGULATORY REGION; CELL-PROLIFERATION; MOUSE EPIDERMIS; TRANSGENIC MICE; IN-VIVO; KERATINOCYTE DIFFERENTIATION	Activator protein one (AP1) (jun/fos) factors comprise a family of transcriptional regulators (c-jun, junB, junD, c-fos, FosB, Fra-1 and Fra-2) that are key controllers of epidermal keratinocyte survival and differentiation, and are important drivers of cancer development. Understanding the role of these factors in epidermis is complicated by the fact that each member is expressed in defined cell layers during epidermal differentiation, and because AP1 factors regulate competing processes (that is, proliferation, apoptosis and differentiation). We have proposed that AP1 factors function differently in basal versus suprabasal epidermis. To test this, we inactivated suprabasal AP1 factor function in mouse epidermis by targeted expression of dominant-negative c-jun (TAM67), which inactivates function of all AP1 factors. This produces increased basal keratinocyte proliferation, delayed differentiation and extensive hyperkeratosis. These findings contrast with previous studies showing that basal layer AP1 factor inactivation does not perturb resting epidermis. It is interesting that in spite of extensive keratinocyte hyper-proliferation, susceptibility to carcinogen-dependent tumor induction is markedly attenuated. These novel observations strongly suggest that AP1 factors have distinct roles in the basal versus suprabasal epidermis, confirm that AP1 factor function is required for normal terminal differentiation, and suggest that AP1 factors have a different role in normal epidermis versus cancer progression. Oncogene (2010) 29, 5873-5882; doi:10.1038/onc.2010.315; published online 6 September 2010	[Rorke, E. A.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; [Adhikary, G.; Jans, R.; Eckert, R. L.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Crish, J. F.] Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Obstet & Genecol & Reprod Sci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Rorke, EA (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, 108 N Greene St, Baltimore, MD 21201 USA.	erorke@SOM.umaryland.edu; reckert@umaryland.edu	Jans, Ralph/F-2150-2013		NIH [RO1 AR046494]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049713, R01AR046494] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by NIH RO1 AR046494 (R Eckert).	Adhikary G, 2004, INVEST OPHTH VIS SCI, V45, P1080, DOI 10.1167/iovs.03-1180; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; Bickenbach J R, 2000, Adv Dermatol, V16, P159; BROWN PH, 1994, ONCOGENE, V9, P791; Cooper SJ, 2003, MOL CANCER RES, V1, P848; Crish JF, 2008, J INVEST DERMATOL, V128, P530, DOI 10.1038/sj.jid.5701049; Crish JF, 2006, J INVEST DERMATOL, V126, P305, DOI 10.1038/sj.jid.5700019; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Crish JF, 2002, ONCOGENE, V21, P738, DOI 10.1038/sj.onc.1205038; Cutler TJ, 2004, VET CLIN N AM-EQUINE, V20, pXI, DOI 10.1016/S0749-0739(04)00029-X; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Diamond I, 2000, J INVEST DERMATOL, V115, P788, DOI 10.1046/j.1523-1747.2000.00144.x; Dunnwald M, 2001, EXP DERMATOL, V10, P45, DOI 10.1034/j.1600-0625.2001.100106.x; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Eckert RL, 1996, CELL DEATH DIFFER, V3, P373; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; Florin L, 2006, J INVEST DERMATOL, V126, P902, DOI 10.1038/sj.jid.5700123; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; HEYDEN A, 1994, EPITHELIAL CELL BIOL, V3, P96; HEYDEN A, 1994, DIFFERENTIATION, V57, P187, DOI 10.1046/j.1432-0436.1994.5730187.x; Iizuka H, 2004, J DERMATOL, V31, P271, DOI 10.1111/j.1346-8138.2004.tb00672.x; Jaubert J, 2004, J INVEST DERMATOL, V123, P313, DOI 10.1111/j.0022-202X.2004.23203.x; KAHN CR, 1993, INVEST OPHTH VIS SCI, V34, P3429; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Matthews CP, 2007, CANCER RES, V67, P2430, DOI 10.1158/0008-5472.CAN-06-0522; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Mizuno H, 2006, MOL CARCINOGEN, V45, P1, DOI 10.1002/mc.20160; MOLLOY CJ, 1987, CANCER RES, V47, P4674; Nickoloff B J, 2001, J Invest Dermatol, V117, P1; Nickoloff B J, 1999, Expert Opin Investig Drugs, V8, P393, DOI 10.1517/13543784.8.4.393; Nickoloff BJ, 2002, J INVEST DERM SYMP P, V7, P27, DOI 10.1046/j.1523-1747.2002.19633.x; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Raj D, 2006, J INVEST DERMATOL, V126, P243, DOI 10.1038/sj.jid.5700008; Rutberg SE, 2000, CANCER RES, V60, P6332; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; She QB, 2002, CANCER RES, V62, P1343; Shi B, 2005, EXP DERMATOL, V14, P519, DOI 10.1111/j.0906-6705.2005.00317.x; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SUN TT, 1983, J INVEST DERMATOL, V81, pS109, DOI 10.1111/1523-1747.ep12540831; Sun TT, 1984, CANCER CELLS, V1, P169; Takahashi H, 2002, J DERMATOL SCI, V30, P94, DOI 10.1016/S0923-1811(02)00064-6; Thompson EJ, 2002, CANCER RES, V62, P3044; TOFTGARD R, 1985, CANCER RES, V45, P5845; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Young MR, 2002, MOL CARCINOGEN, V34, P72, DOI 10.1002/mc.10050; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963	70	27	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5873	5882		10.1038/onc.2010.315	http://dx.doi.org/10.1038/onc.2010.315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20818430	Green Accepted			2022-12-17	WOS:000283843400002
J	Brown, JAL; Bourke, E; Liptrot, C; Dockery, P; Morrison, CG				Brown, J. A. L.; Bourke, E.; Liptrot, C.; Dockery, P.; Morrison, C. G.			MCPH1/BRIT1 limits ionizing radiation-induced centrosome amplification	ONCOGENE			English	Article						Mcph1/Brit1; centrosome; DNA damage response; checkpoint; ionizing radiation	DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; HOMOLOGOUS RECOMBINATION; CHROMOSOME CONDENSATION; MITOTIC ENTRY; MICROCEPHALIN; PROTEIN; CANCER; ACTIVATION; CHECKPOINT	Microcephalin (MCPH1/BRIT1) is a potential tumour suppressor that localizes to the centrosome, forms ionizing radiation-induced nuclear foci (IRIF) and is involved in the DNA damage checkpoints that ensure genome stability. Here, we report the impact of Mcph1 disruption in the hyper-recombinogenic DT40 cell line. Mcph1(-/-) cells were viable and proliferated at the same rate as wildtype controls. Mcph1-deficient cells had intact G2-to-M checkpoint responses after ionizing radiation (IR) treatment, but showed moderate radiosensitivity. Light and electron microscopy indicated normal centrosome structures in Mcph1 null cells, but IR induced massive amplification of centrosome numbers in the absence of Mcph1. Mcph1 null cells formed gamma-H2AX and Rad51 IRIF, but resolved them more slowly than wild-type cells. Mcph1 deficiency caused sustained Chk1 phosphorylation after IR, dysregulating Cdk2 activity. These findings show that Mcph1 controls centrosome numbers after DNA damage, which may indicate a novel tumour suppressive mechanism for microcephalin. Oncogene (2010) 29, 5537-5544; doi:10.1038/onc.2010.302; published online 26 July 2010	[Brown, J. A. L.; Bourke, E.; Morrison, C. G.] Natl Univ Ireland Galway, Sch Nat Sci, Ctr Chromosome Biol, Galway, Ireland; [Liptrot, C.; Dockery, P.] Natl Univ Ireland Galway, Sch Med, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway	Morrison, CG (corresponding author), Natl Univ Ireland Galway, Sch Nat Sci, Ctr Chromosome Biol, Univ Rd, Galway, Ireland.	Ciaran.Morrison@nuigalway.ie	Morrison, Ciaran/AAH-2034-2019; Liptrot, Catherine/D-7056-2012; Brown, James/H-3437-2019; Morrison, Ciaran/B-6568-2008	Morrison, Ciaran/0000-0003-2401-7029; Liptrot, Catherine/0000-0003-3882-8084; Brown, James/0000-0002-3155-0334; Morrison, Ciaran/0000-0003-2401-7029; Dockery, Peter/0000-0001-5103-6589; Bourke, Emer/0000-0002-2218-3114	National Biophotonics and Imaging Platform; HEA [PRTLI4]; Health Research Board project [RP/2006/36]; Science Foundation Ireland [08/IN.1/B1029]	National Biophotonics and Imaging Platform; HEA; Health Research Board project; Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We thank William Tsang and Brian Dynlacht for the Cep76 antibody, Andrew Jackson and Andrea Robertson for the MCPH1 mutant lymphoblastoid cells, Tiago Dantas for help with the EM and Noel Lowndes for critical reading of the paper. CL was funded by the National Biophotonics and Imaging Platform funded by the HEA under PRTLI4. This work was supported by the Health Research Board project grant RP/2006/36 and Science Foundation Ireland Principal Investigator award 08/IN.1/B1029.	Alderton GK, 2006, NAT CELL BIOL, V8, P725, DOI 10.1038/ncb1431; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bourke E, 2010, ONCOGENE, V29, P616, DOI 10.1038/onc.2009.340; Bourke E, 2007, EMBO REP, V8, P603, DOI 10.1038/sj.embor.7400962; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brunk K, 2007, J CELL SCI, V120, P3578, DOI 10.1242/jcs.014290; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Jackson AP, 2002, AM J HUM GENET, V71, P136, DOI 10.1086/341283; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jeffers LJ, 2008, ONCOGENE, V27, P139, DOI 10.1038/sj.onc.1210595; Liang YL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000826; Lin SY, 2005, P NATL ACAD SCI USA, V102, P15105, DOI 10.1073/pnas.0507722102; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; LIPTROT C, 1992, ANIMAL CELL TECHNOLOGY : DEVELOPMENTS, PROCESSES AND PRODUCTS, P653; Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Rai R, 2008, CELL CYCLE, V7, P2225, DOI 10.4161/cc.7.14.6303; Rai R, 2006, CANCER CELL, V10, P145, DOI 10.1016/j.ccr.2006.07.002; Rickmyre JL, 2007, J CELL SCI, V120, P3565, DOI 10.1242/jcs.016626; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tibelius A, 2009, J CELL BIOL, V185, P1149, DOI 10.1083/jcb.200810159; Trimborn M, 2004, AM J HUM GENET, V75, P261, DOI 10.1086/422855; Trimborn M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009242; Tsang WY, 2009, DEV CELL, V16, P649, DOI 10.1016/j.devcel.2009.03.004; Wood JL, 2008, J BIOL CHEM, V283, P29586, DOI 10.1074/jbc.M804080200; Wood JL, 2007, J BIOL CHEM, V282, P35416, DOI 10.1074/jbc.M705245200; Wu XL, 2009, CANCER RES, V69, P5531, DOI 10.1158/0008-5472.CAN-08-4834; Xu XZ, 2004, J BIOL CHEM, V279, P34091, DOI 10.1074/jbc.C400139200; Yang SZ, 2008, EMBO REP, V9, P907, DOI 10.1038/embor.2008.128	34	27	29	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	40					5537	5544		10.1038/onc.2010.302	http://dx.doi.org/10.1038/onc.2010.302			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20661222				2022-12-17	WOS:000282945800010
J	El-Kalla, M; Onyskiw, C; Baksh, S				El-Kalla, M.; Onyskiw, C.; Baksh, S.			Functional importance of RASSF1A microtubule localization and polymorphisms	ONCOGENE			English	Article						RASSF1A; microtubule; polymorphism; Tubulin; tumor suppressor gene	TUMOR-SUPPRESSOR RASSF1A; TRANSCRIPTION FACTOR P120(E4F); DEATH INDUCER C19ORF5; CELL-DEATH; BINDING PROTEIN; SPINDLE POLES; GAMMA-TUBULIN; RAS; ASSOCIATION; FAMILY	Ras association domain family protein 1A (RASSF1A) is one of the more heavily methylated genes in human cancers. In addition to promoter-specific methylation, RASSF1A polymorphisms have been identified in cancer patients. RASSF1A is a tumor suppressor protein involved in death receptor-dependent apoptosis and it is localized to microtubules. Currently, the biological importance of RASSF1A microtubule localization and the functional consequences of RASSF1A polymorphisms is not under-stood. In this study, we have investigated both RASSF1A microtubule association and polymorphisms. Loss of RASSF1A microtubule association resulted in the nuclear appearance of RASSF1A and the loss of association with alpha-, gamma-and beta-tubulin. Moreover, the loss of microtubule localization of RASSF1A resulted in enhanced tumor-promoting potential, as determined by a xenograft transplantation model in nude mice. It is surprising that, several RASSF1A polymorphisms also lost the ability to associate with alpha-, gamma-and beta-tubulin and lost the ability to prevent tumor formation in a xenograft nude mouse model when compared with wild-type RASSF1A. Our results demonstrate a role for RASSF1A microtubule localization in eliciting its tumor suppressor function. In addition, some RASSF1A polymorphisms lack the tumor suppressor function of RASSF1A and, if present in patients, may be tumorigenic. Oncogene (2010) 29, 5729-5740; doi:10.1038/onc.2010.316; published online 9 August 2010	[El-Kalla, M.; Onyskiw, C.; Baksh, S.] Univ Alberta, Fac Med & Dent, Dept Pediat, Edmonton, AB T6G 2N8, Canada	University of Alberta	Baksh, S (corresponding author), Univ Alberta, Fac Med & Dent, Dept Pediat, Room B066 Dent Pharm Bldg, Edmonton, AB T6G 2N8, Canada.	sbaksh@ualberta.ca	Baksh, Shairaz/GRX-2106-2022		CIHR [MOP-79494]; Women and Children's Health Research Institute [WCO14]; Stollery Children's Hospital Foundation [PD946]; Alberta Heritage Foundation for Medical Research [G220170170]; Canadian Foundation for Innovation [13118]	CIHR(Canadian Institutes of Health Research (CIHR)); Women and Children's Health Research Institute; Stollery Children's Hospital Foundation; Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric); Canadian Foundation for Innovation(Canada Foundation for Innovation)	We thank Dr Haya Abu Ghazaleh for her helpful discussions, Adrienne DeCorby-Baksh for her excellent technical assistance with our confocal imaging, Dr Victor Yu and Naiyang Fu for the MOAP-1 expression construct. This work was supported by grants from CIHR (MOP-79494) (MEK), the Women and Children's Health Research Institute (WCO14) (MEK), the Stollery Children's Hospital Foundation Donation Grant (PD946) (SB and MEK), Alberta Heritage Foundation for Medical Research (G220170170) (SB), and Canadian Foundation for Innovation/Alberta Small Equipment Grants Program (#13118).	Abu Ghazaleh H, 2010, APOPTOSIS, V15, P117, DOI 10.1007/s10495-009-0451-6; Adachi M, 2003, FEBS LETT, V551, P147, DOI 10.1016/S0014-5793(03)00915-3; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Allen NPC, 2007, ONCOGENE, V26, P6203, DOI 10.1038/sj.onc.1210440; Avruch J, 2009, J BIOL CHEM, V284, P11001, DOI 10.1074/jbc.R800073200; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Bhat KMR, 2007, CLIN CANCER RES, V13, P2849, DOI 10.1158/1078-0432.CCR-06-3040; Brameier M, 2007, BIOINFORMATICS, V23, P1159, DOI 10.1093/bioinformatics/btm066; Cuschieri L, 2007, CELL CYCLE, V6, P2788, DOI 10.4161/cc.6.22.4941; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dallol A, 2007, CANCER RES, V67, P492, DOI 10.1158/0008-5472.CAN-06-3604; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; Foley CJ, 2008, MOL CELL BIOL, V28, P4520, DOI 10.1128/MCB.02011-07; Gao BN, 2008, CANCER RES, V68, P22, DOI 10.1158/0008-5472.CAN-07-5183; Hamilton G, 2009, CURR BIOL, V19, P2020, DOI 10.1016/j.cub.2009.10.040; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu LY, 2005, BIOCHEM BIOPH RES CO, V332, P670, DOI 10.1016/j.bbrc.2005.05.006; Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Moshnikova A, 2006, J BIOL CHEM, V281, P8143, DOI 10.1074/jbc.M511837200; Moshnikova Anna, 2008, BMC Res Notes, V1, P13, DOI 10.1186/1756-0500-1-13; Parvin JD, 2009, ENVIRON MOL MUTAGEN, V50, P649, DOI 10.1002/em.20475; Pihan G, 2003, CANCER CELL, V4, P89, DOI 10.1016/S1535-6108(03)00195-8; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Raynaud-Messina B, 2007, CURR OPIN CELL BIOL, V19, P24, DOI 10.1016/j.ceb.2006.12.008; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Senda Takao, 2005, Anatomical Science International, V80, P121, DOI 10.1111/j.1447-073x.2005.00106.x; Sherwood V, 2008, MOL BIOL CELL, V19, P1772, DOI 10.1091/mbc.E07-07-0652; Song MS, 2005, J BIOL CHEM, V280, P3920, DOI 10.1074/jbc.M409115200; van der Weyden L, 2008, ONCOGENE, V27, P4503, DOI 10.1038/onc.2008.94; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wade RH, 2009, MOL BIOTECHNOL, V43, P177, DOI 10.1007/s12033-009-9193-5	46	27	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5729	5740		10.1038/onc.2010.316	http://dx.doi.org/10.1038/onc.2010.316			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20697344				2022-12-17	WOS:000283262500009
J	Haller, D; Mackiewicz, M; Gerber, S; Beyer, D; Kullmann, B; Schneider, I; Ahmed, JS; Seitzer, U				Haller, D.; Mackiewicz, M.; Gerber, S.; Beyer, D.; Kullmann, B.; Schneider, I.; Ahmed, J. S.; Seitzer, U.			Cytoplasmic sequestration of p53 promotes survival in leukocytes transformed by Theileria	ONCOGENE			English	Article						apoptosis; cytoplasmic sequestration; p53; Theileria annulata	WILD-TYPE P53; PARASITE THEILERIA; NUCLEAR EXCLUSION; COLORECTAL ADENOCARCINOMA; PROTEIN; CELLS; ACTIVATION; PARVA; LYMPHOCYTES; ONCOPROTEIN	The function of the p53 protein as the central effector molecule of the p53 apoptotic pathway was investigated in a reversible model of epigenetic transformation. The infection of bovine leukocytes by the intracellular protozoan parasite Theileria annulata results in parasite-dependent transformation and proliferation of the host cells. We found p53 to be largely localized in the host cell cytoplasm and associated with the parasite membrane of isolated schizonts. Curing infected cells of the parasite with the theilericidal drug buparvaquone resulted in a time-dependent translocation of p53 into the host cell nucleus and the upregulation of the proapoptotic Bax and Apaf-1 and the downregulation of the anti-apoptotic Bcl-2 proteins. Although buparvaquone treatment led to apoptosis of the host cell, inhibition of either p53 or Bax significantly reduced buparvaquone-induced apoptosis of the transformed cells. Thus, the p53 apoptotic pathway of host cells is not induced by infection and transformation with Theileria by a mechanism involving cytoplasmic sequestration of p53. The close association of host cell p53 with the parasite membrane implies that the parasite either interacts directly with p53 or mediates cytoplasmic sequestration of p53 by interacting with other host cell proteins regulating p53 localization. Oncogene (2010) 29, 3079-3086; doi: 10.1038/onc.2010.61; published online 8 March 2010	[Haller, D.; Mackiewicz, M.; Gerber, S.; Beyer, D.; Kullmann, B.; Schneider, I.; Ahmed, J. S.; Seitzer, U.] Res Ctr Borstel, Dept Immunol & Cell Biol, Div Vet Infect Biol & Immunol, D-23845 Borstel, Schleswig Holst, Germany	Forschungszentrum Borstel	Seitzer, U (corresponding author), Res Ctr Borstel, Dept Immunol & Cell Biol, Div Vet Infect Biol & Immunol, Pk Allee 22, D-23845 Borstel, Schleswig Holst, Germany.	useitzer@fz-borstel.de			European Commission [ICA4-CT-2000-30028]	European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was supported in part by a grant from the European Commission INCO-DEV Program (Contract Grant Number: ICA4-CT-2000-30028).	Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Ahmed JS, 1999, PARASITOL RES, V85, P527, DOI 10.1007/s004360050592; AHMED JS, 1989, J VET MED B, V36, P584, DOI 10.1111/j.1439-0450.1989.tb00649.x; Bakheit MA, 2006, PARASITOL RES, V100, P161, DOI 10.1007/s00436-006-0255-3; Bakheit MA, 2006, ANN NY ACAD SCI, V1081, P453, DOI 10.1196/annals.1373.064; BOSARI S, 1995, AM J PATHOL, V147, P790; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; DOBBELAERE DAE, 1988, P NATL ACAD SCI USA, V85, P4730, DOI 10.1073/pnas.85.13.4730; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Galley Y, 1997, P NATL ACAD SCI USA, V94, P5119, DOI 10.1073/pnas.94.10.5119; Gardner MJ, 2005, SCIENCE, V309, P134, DOI 10.1126/science.1110439; Guergnon J, 2003, BIOCHIMIE, V85, P771, DOI 10.1016/j.biochi.2003.09.013; Heussler VT, 2001, CELL MICROBIOL, V3, P537, DOI 10.1046/j.1462-5822.2001.00134.x; Heussler VT, 2002, SCIENCE, V298, P1033, DOI 10.1126/science.1075462; Knippschild U, 1996, ONCOGENE, V12, P1755; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; McHardy N., 1985, Immunization against theileriosis in Africa. Proceedings of a Joint Workshop, 1-5 October 1984, Nairobi, Kenya, ILRAD & FAO., P88; MCHARDY N, 1985, RES VET SCI, V39, P1; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; O'Brate A, 2003, DRUG RESIST UPDATE, V6, P313, DOI 10.1016/j.drup.2003.10.004; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pain A, 2005, SCIENCE, V309, P131, DOI 10.1126/science.1110418; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Schneider I, 2004, PARASITOL RES, V94, P405, DOI 10.1007/s00436-004-1226-1; Seitzer U, 2006, ANN NY ACAD SCI, V1081, P473, DOI 10.1196/annals.1373.069; Shayan P, 1999, PARASITOL RES, V85, P613, DOI 10.1007/s004360050605; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; Toye P, 1996, INFECT IMMUN, V64, P1832, DOI 10.1128/IAI.64.5.1832-1838.1996; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	39	27	30	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	2010	29	21					3079	3086		10.1038/onc.2010.61	http://dx.doi.org/10.1038/onc.2010.61			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20208567				2022-12-17	WOS:000278133100005
J	Yamada, D; Perez-Torrado, R; Filion, G; Caly, M; Jammart, B; Devignot, V; Sasai, N; Ravassard, P; Mallet, J; Sastre-Garau, X; Schmitz, ML; Defossez, PA				Yamada, D.; Perez-Torrado, R.; Filion, G.; Caly, M.; Jammart, B.; Devignot, V.; Sasai, N.; Ravassard, P.; Mallet, J.; Sastre-Garau, X.; Schmitz, M. L.; Defossez, P-A			The human protein kinase HIPK2 phosphorylates and downregulates the methyl-binding transcription factor ZBTB4	ONCOGENE			English	Article						transcription; protein kinase; epigenetics	DNA-DAMAGE; GENE-EXPRESSION; P53 ACTIVITY; APOPTOSIS; CANCER; CELLS; DEGRADATION; ACTIVATION; INTERACTS; SER-46	HIPK2 is a eukaryotic Serine-Threonine kinase that controls cellular proliferation and survival in response to exogenous signals. Here, we show that the human transcription factor ZBTB4 is a new target of HIPK2. The two proteins interact in vitro, colocalize and associate in vivo, and HIPK2 phosphorylates several conserved residues of ZBTB4. Overexpressing HIPK2 causes the degradation of ZBTB4, whereas overexpressing a kinase-deficient mutant of HIPK2 has no effect. The chemical activation of HIPK2 also decreases the amount of ZBTB4 in cells. Conversely, the inhibition of HIPK2 by drugs or by RNA interference causes a large increase in ZBTB4 levels. This negative regulation of ZBTB4 by HIPK2 occurs under normal conditions of cell growth. In addition, the degradation is increased by DNA damage. These findings have two consequences. First, we have recently shown that ZBTB4 inhibits the transcription of p21. Therefore, the activation of p21 by HIPK2 is two-pronged: stimulation of the activator p53, and simultaneous repression of the inhibitor ZBTB4. Second, ZBTB4 is also known to bind methylated DNA and repress methylated sequences. Consequently, our findings raise the possibility that HIPK2 might influence the epigenetic regulation of gene expression at loci that remain to be identified. Oncogene ( 2009) 28, 2535-2544; doi: 10.1038/onc.2009.109; published online 18 May 2009	[Sasai, N.; Defossez, P-A] Univ Paris 07, CNRS, Epigenet & Cell Fate UMR7216, F-75205 Paris 13, France; [Yamada, D.; Perez-Torrado, R.; Filion, G.; Jammart, B.; Devignot, V.; Sasai, N.; Defossez, P-A] Inst Curie, CNRS, UMR218, F-75231 Paris, France; [Caly, M.; Sastre-Garau, X.] Inst Curie, Med Sect, F-75231 Paris, France; [Ravassard, P.; Mallet, J.] Univ Paris 06, CNRS, UMR7091, Paris, France; [Schmitz, M. L.] Univ Giessen, Fac Med, Inst Biochem, Giessen, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Justus Liebig University Giessen	Defossez, PA (corresponding author), Univ Paris 07, CNRS, UMR7216, Batiment Lamarck,Case 7042,35 Rue Helene Brion, F-75205 Paris 13, France.	pierre-antoine.defossez@univ-paris-diderot.fr	Schmitz, M. Lienhard/D-9328-2017; Filion, Guillaume/G-9619-2015; Perez Torrado, Roberto/E-7613-2012	Schmitz, M. Lienhard/0000-0002-6984-7192; Filion, Guillaume/0000-0002-3473-1632; Sastre-Garau, Xavier/0000-0001-5992-2083; ravassard, philippe/0000-0002-0393-9262; Perez Torrado, Roberto/0000-0002-3118-6755; Defossez, Pierre-Antoine/0000-0002-6463-9263	Centre National de la Recherche Scientifique (CNRS); Institut National du Cancer ( ATIP Plus); Association pour la Recherche contre le Cancer [3727, 4859]; Ligue contre le Cancer; Deutsche Forschungsgemeinschaft (DFG)	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National du Cancer ( ATIP Plus)(Institut National du Cancer (INCA) France); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue contre le Cancer(Ligue nationale contre le cancer); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	We thank the following colleagues for reagents: Nelson Dusetti, Roger Tsien, Phillip James, Jacques Camonis, Silvia Soddu. We are especially grateful to Gabriella d'Orazi for the HIPK2 knockdown cells, and to Patricia Le Baccon for her help. DY was supported by postdoctoral fellowships from the Curie Institute, and from Association pour la Recherche contre le Cancer. RPT was supported by a fellowship from Centre National de la Recherche Scientifique (CNRS). The Defossez lab is supported by CNRS ( programme ATIP and programme PICS France-Russie), by Institut National du Cancer ( ATIP Plus), by Association pour la Recherche contre le Cancer ( grants no 3727 and no 4859), and by Ligue contre le Cancer. The work of MLS is supported by the Deutsche Forschungsgemeinschaft (DFG).	Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Clouaire T, 2008, CELL MOL LIFE SCI, V65, P1509, DOI 10.1007/s00018-008-7324-y; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; Defossez PA, 2005, J BIOL CHEM, V280, P43017, DOI 10.1074/jbc.M510802200; Deshmukh H, 2008, ONCOGENE, V27, P4745, DOI 10.1038/onc.2008.110; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Filion GJP, 2006, MOL CELL BIOL, V26, P169, DOI 10.1128/MCB.26.1.169-181.2006; Filion GJP, 2006, ANAL BIOCHEM, V357, P156, DOI 10.1016/j.ab.2006.07.021; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Isono K, 2006, MOL CELL BIOL, V26, P2758, DOI 10.1128/MCB.26.7.2758-2771.2006; James P, 1996, GENETICS, V144, P1425; KANDURI C, 2002, J BIOL CHEM, V4, P4; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Lee W, 2009, DEVELOPMENT, V136, P241, DOI 10.1242/dev.025460; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Moller A, 2003, ONCOGENE, V22, P8731, DOI 10.1038/sj.onc.1207079; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ovcharenko D, 2005, RNA, V11, P985, DOI 10.1261/rna.7288405; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Rinaldo C, 2008, BBA-MOL CELL RES, V1783, P2124, DOI 10.1016/j.bbamcr.2008.06.006; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Roscic A, 2006, MOL CELL, V24, P77, DOI 10.1016/j.molcel.2006.08.004; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; van Roy FM, 2005, NAT REV CANCER, V5, P956, DOI 10.1038/nrc1752; Weber A, 2008, EMBO J, V27, P1563, DOI 10.1038/emboj.2008.85; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Wesierska-Gadek J, 2007, J CELL BIOCHEM, V100, P865, DOI 10.1002/jcb.21211; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102; Zhang QC, 2007, J PROTEOME RES, V6, P4711, DOI 10.1021/pr700571d	40	27	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2535	2544		10.1038/onc.2009.109	http://dx.doi.org/10.1038/onc.2009.109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448668				2022-12-17	WOS:000267806800006
J	Boya, P; Kroemer, G				Boya, P.; Kroemer, G.			Beclin 1: a BH3-only protein that fails to induce apoptosis	ONCOGENE			English	Editorial Material						autophagy; apoptosis; Bcl-2; Beclin-1; endoplasmic reticulum; mitochondria	BCL-XL; AUTOPHAGY; COMPLEX; DOMAIN	Beclin 1 has been recently shown to possess a Bcl-2 homology-3 (BH3) domain that mediates its interaction with antiapoptotic multidomain proteins. Unlike other BH3-only proteins, Beclin 1 fails to stimulate apoptosis when it is overexpressed. In this issue of Oncogene, Ciechomska et al. report the intriguing finding that Bcl-2, as it interacts with Beclin 1, does not lose its anti-apoptotic potential. This finding may have far-reaching implications for the comprehension of the cross-talk between apoptosis and autophagy. Oncogene (2009) 28, 2125-2127; doi: 10.1038/onc.2009.83; published online 27 April 2009	[Boya, P.] Consejo Super Invest Cient, Ctr Invest Biol, Lab 3D, Dept Cellular & Mol Physiopathol, E-28040 Madrid, Spain; [Kroemer, G.] INSERM, U848, Villejuif, France; [Kroemer, G.] Inst Gustave Roussy, F-94805 Villejuif, France; [Kroemer, G.] Univ Paris 11, Villejuif, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Boya, P (corresponding author), Consejo Super Invest Cient, Ctr Invest Biol, Lab 3D, Dept Cellular & Mol Physiopathol, Ramiro Maetzu 9, E-28040 Madrid, Spain.	pboya@cib.csic.es; kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; Boya, Patricia/P-8345-2019; KROEMER, Guido/B-4263-2013; Boya, Patricia/K-2911-2014	Boya, Patricia/0000-0003-3045-951X; KROEMER, Guido/0000-0002-9334-4405; Boya, Patricia/0000-0003-3045-951X				Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; CIECHOMSKA AI, 2009, ONCOGENE IN PRESS; Feng W, 2007, J MOL BIOL, V372, P223, DOI 10.1016/j.jmb.2007.06.069; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Zalckvar E., 2009, EMBO REP, V30, P30	12	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2009	28	21					2125	2127		10.1038/onc.2009.83	http://dx.doi.org/10.1038/onc.2009.83			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19398951				2022-12-17	WOS:000266451300001
J	Umar, S; Sarkar, S; Cowey, S; Singh, P				Umar, S.; Sarkar, S.; Cowey, S.; Singh, P.			Activation of NF-kappa B is required for mediating proliferative and antiapoptotic effects of progastrin on proximal colonic crypts of mice, in vivo	ONCOGENE			English	Article						annexin II; progastrin; NF kappa B; ERKs; Fabp-PG mice; NEMO	INTESTINAL EPITHELIAL-CELLS; TISSUE-PLASMINOGEN ACTIVATOR; ANNEXIN-II; GENE-EXPRESSION; CANCER CELLS; TRANSGENIC MICE; GROWTH; APOPTOSIS; RECEPTOR; BINDING	Mice overexpressing progastrin (PG) in intestinal mucosa (fatty acid-binding protein (Fabp)-PG mice) are at an increased risk of proximal colon carcinogenesis in response to azoxymethane. Here, we report a significant increase in the length of proximal colonic crypts in Fabp-PG mice, associated with potent antiapoptotic effects of PG, which likely contributed to the previously reported increase in colon carcinogenesis in Fabp-PG mice. Phosphorylation of kinase of I kappa B alpha (IKK alpha/beta), inhibitor of kappa B (I kappa B) a and p65NF-kappa B was significantly elevated in proximal colonic crypts of Fabp-PG versus wild-type mice, which was associated with degradation of I kappa B alpha and nuclear translocation/activation of p65. Surprisingly, distal colonic crypt cells were not as responsive to elevated levels of PG in Fabp-PG mice. Annexin II, recently described as a high-affinity receptor for PG, strongly colocalized with PG intracellularly and on basolateral membranes of proximal crypt cells, providing evidence that annexin-II binds PG in situ in colonic crypt cells. Proliferative and antiapoptotic effects of PG on proximal crypts of Fabp-PG mice were attenuated to wild-type levels, on treatment with NEMO peptide (an inhibitor of nuclear factor-kappa B (NF-kappa B) activation), demonstrating for the first time a critical role of NF-kappa B in mediating hyperproliferative affects of PG on colonic crypts of Fabp-PG mice, in vivo. Thus, downregulation of NF-kappa B may significantly reduce the increased risk of colon carcinogenesis in response to PG.	[Sarkar, S.; Cowey, S.; Singh, P.] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; [Umar, S.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Singh, P (corresponding author), Univ Texas Med Branch, Dept Neurosci & Cell Biol, 301 Univ Blvd,Route 1043, Galveston, TX 77555 USA.	posingh@utmb.edu			NATIONAL CANCER INSTITUTE [R01CA114264, R03CA099121, R01CA097959] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114264-04, R03 CA099121, R01 CA097959, R01 CA114264-05, CA97959, R01 CA097959-05, R03 CA099121-03, CA099121, R01 CA097959-06A2, R01 CA114264, CA114264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed S, 2005, PEPTIDES, V26, P1207, DOI 10.1016/j.peptides.2005.02.001; Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; CHICONE L, 1989, BIOCHEM BIOPH RES CO, V164, P512, DOI 10.1016/0006-291X(89)91749-X; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Dasgupta S, 2004, J IMMUNOL, V173, P1344, DOI 10.4049/jimmunol.173.2.1344; Dockray GJ, 1996, PHYSIOL REV, V76, P767, DOI 10.1152/physrev.1996.76.3.767; Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978; Forstner J., 1994, PHYSL GASTROINTESTIN; Fric P, 2000, EUR J CANCER PREV, V9, P265, DOI 10.1097/00008469-200008000-00006; Glebov OK, 2003, CANCER EPIDEM BIOMAR, V12, P755; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hong MY, 1999, CELL GROWTH DIFFER, V10, P749; Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635; Lifshitz S, 2001, CANCER LETT, V163, P229, DOI 10.1016/S0304-3835(00)00624-8; Liu LU, 1999, GUT, V45, P45, DOI 10.1136/gut.45.1.45; Marshman E, 2001, J PATHOL, V195, P285; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mills SJ, 2001, GUT, V48, P41, DOI 10.1136/gut.48.1.41; Muerkoster S, 2005, GASTROENTEROLOGY, V129, P952, DOI 10.1053/j.gastro.2005.06.059; Ortiz-Zapater E, 2007, AM J PATHOL, V170, P1573, DOI 10.2353/ajpath.2007.060850; Ottewell PD, 2005, AM J PHYSIOL-GASTR L, V288, pG541, DOI 10.1152/ajpgi.00268.2004; Ottewell PD, 2003, GASTROENTEROLOGY, V124, P1348, DOI 10.1016/S0016-5085(03)00288-9; Rengifo-Cam W, 2004, CURR PHARM DESIGN, V10, P2345, DOI 10.2174/1381612043383999; Rengifo-Cam W, 2007, CANCER RES, V67, P7266, DOI 10.1158/0008-5472.CAN-07-1206; Sarkar S, 2007, GASTROENTEROLOGY, V132, pA540; SATO M, 1992, ANAT RECORD, V233, P409, DOI 10.1002/ar.1092330308; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Singh P, 2007, ONCOGENE, V26, P425, DOI 10.1038/sj.onc.1209798; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; Singh P, 2003, AM J PHYSIOL-GASTR L, V284, pG328, DOI 10.1152/ajpgi.00351.2002; Singh P, 2007, CANCER LETT, V252, P19, DOI 10.1016/j.canlet.2006.11.012; Song DH, 2003, AM J PHYSIOL-GASTR L, V285, pG217, DOI 10.1152/ajpgi.00516.2002; Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x; Umar S, 2000, AM J PHYSIOL-GASTR L, V279, pG223, DOI 10.1152/ajpgi.2000.279.1.G223; Umar S, 2007, AM J PHYSIOL-GASTR L, V292, pG599, DOI 10.1152/ajpgi.00343.2006; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang Y, 2006, BRIT J PHARMACOL, V148, P814, DOI 10.1038/sj.bjp.0706784; Watanabe T, 2006, CANCER RES, V66, P9804, DOI 10.1158/0008-5472.CAN-06-1163; Wu H, 2003, AM J PHYSIOL-GASTR L, V285, pG1097, DOI 10.1152/ajpgi.00216.2003; Zizzo MG, 2006, BRIT J PHARMACOL, V148, P956, DOI 10.1038/sj.bjp.0706808	44	27	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5599	5611		10.1038/onc.2008.169	http://dx.doi.org/10.1038/onc.2008.169			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18521082	Green Accepted			2022-12-17	WOS:000259280800006
J	Rahman-Roblick, R; Hellman, U; Becker, S; Bader, FG; Auer, G; Wiman, KG; Roblick, UJ				Rahman-Roblick, R.; Hellman, U.; Becker, S.; Bader, F. G.; Auer, G.; Wiman, K. G.; Roblick, U. J.			Proteomic identification of p53-dependent protein phosphorylation	ONCOGENE			English	Article						p53; proteomics; phosphorylation	CELL-DEATH; P53; DJ-1; ACTIVATION; APOPTOSIS; GENE; METASTASIS; REGULATOR; NM23	The p53 tumor suppressor regulates transcription of target genes. We have previously analysed the p53-dependent proteome and identified novel protein targets. Here we have examined p53-dependent phosphorylation using two-dimensional gel electrophoresis and staining with the fluorescent phosphoprotein dye Pro-Q Diamond. We report that p53 induces phosphorylation of a subset of proteins including Nm23, DJ-1, ANXA1 and PrxII. Our identification of p53-dependent phosphorylation of specific target proteins reveals new aspects of the p53-dependent cellular response and suggests that such posttranslational modi. cations may contribute to p53-mediated tumor suppression.	[Wiman, K. G.] Karolinska Inst, Karolinska Univ Hosp R8 04, Canc Ctr Karolinska, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; [Hellman, U.] Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden; [Becker, S.; Bader, F. G.; Auer, G.] Karolinska Inst, Karolinska Biom Ctr, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; [Bader, F. G.; Roblick, U. J.] Univ Schleswig Holstein, Dept Surg, D-23538 Lubeck, Germany	Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research; Uppsala University; Karolinska Institutet; University of Kiel; Schleswig Holstein University Hospital	Wiman, KG (corresponding author), Karolinska Inst, Karolinska Univ Hosp R8 04, Canc Ctr Karolinska, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	klas.wiman@ki.se	Wiman, Klas/AAB-8399-2021; Roblick, Uwe J/F-5906-2011	Wiman, Klas/0000-0002-7113-524X; Auer, Gert/0000-0003-3911-0285				Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bretaud S, 2007, J NEUROCHEM, V100, P1626, DOI 10.1111/j.1471-4159.2006.04291.x; Chen SL, 2003, MOL CARCINOGEN, V36, P204, DOI 10.1002/mc.10110; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Rahman-Roblick R, 2007, P NATL ACAD SCI USA, V104, P5401, DOI 10.1073/pnas.0700794104; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Solito E, 2006, FASEB J, V20, P1498, DOI 10.1096/fj.05-5319fje; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG LM, 1993, CANCER RES, V53, P717	18	27	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4854	4859		10.1038/onc.2008.124	http://dx.doi.org/10.1038/onc.2008.124			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438429				2022-12-17	WOS:000258445100010
J	Hartl, B; Zeller, T; Blanchette, P; Kremmer, E; Dobner, T				Haertl, B.; Zeller, T.; Blanchette, P.; Kremmer, E.; Dobner, T.			Adenovirus type 5 early region 1B 55-kDa oncoprotein can promote cell transformation by a mechanism independent from blocking p53-activated transcription	ONCOGENE			English	Article						E1B-55K; Mre11; PML-NBs; cytoplasmic perinuclear body; CRM1	P53 TUMOR-SUPPRESSOR; E1B 55-KILODALTON ONCOPROTEIN; GENE-EXPRESSION; NUCLEAR EXPORT; MESSENGER-RNAS; PROTEIN; E4ORF6; 1B; PHOSPHORYLATION; REPRESSION	Inhibition of p53-activated transcription is an integral part of the mechanism by which early region 1B 55K oncoprotein (E1B-55K) from adenovirus type 5 (Ad5) contributes to complete cell transformation in combination with Ad E1A. In addition, more recent data suggest that the mode of action of the Ad protein during transformation may involve additional functions and other protein interactions. In the present study, we performed a comprehensive mutational analysis to assign further transforming functions of Ad5 E1B-55K to distinct domains within the viral polypeptide. Results from these studies show that the functions required for transformation are encoded within several patches of the 55K primary sequence, including several clustered cysteine and histidine residues, some of which match the consensus for zinc fingers. In addition, two amino-acid substitutions (C454S/C456S) created a 55K mutant protein, which had substantially reduced transforming activity. Interestingly, the same mutations neither affected binding to p53 nor inhibition of p53-mediated transactivation. Therefore, an activity necessary for efficient transformation of primary rat cells can be separated from functions required for inhibition of p53-stimulated transcription. Our data indicate that this activity is linked to the ability of the Ad5 protein to bind to components of the Mre11/Rad50/NBS1 DNA double-strand break repair complex, and/or its ability to assemble multiprotein aggregates in the cytoplasm and nucleus of transformed rat cells. These results introduce a new function for Ad5 E1B-55K and suggest that the viral protein contributes to cell transformation through p53 transcription-dependent and-independent pathways.	[Haertl, B.; Dobner, T.] Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Virol, D-20251 Hamburg, Germany; [Zeller, T.] Geneart Biopk, Regensburg, Germany; [Blanchette, P.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Kremmer, E.] GSF Inst Mol Immunol, Munich, Germany	Heinrich Pette Institute; McGill University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Dobner, T (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Virol, Martinistr 52, D-20251 Hamburg, Germany.	thomas.dobner@hpi.uni-hamburg.de						ANDERSON CW, 1984, J VIROL, V50, P387, DOI 10.1128/JVI.50.2.387-396.1984; Barral PM, 2005, FEBS LETT, V579, P2752, DOI 10.1016/j.febslet.2005.03.095; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Boivin D, 1999, J VIROL, V73, P1245, DOI 10.1128/JVI.73.2.1245-1253.1999; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Budhu AS, 2005, CELL CYCLE, V4, P1510, DOI 10.4161/cc.4.11.2187; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Carter CC, 2003, VIROLOGY, V315, P224, DOI 10.1016/S0042-6822(03)00526-9; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Flint SJ, 2005, VIROLOGY, V337, P7, DOI 10.1016/j.virol.2005.04.007; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Florin L, 2004, J VIROL, V78, P5546, DOI 10.1128/JVI.78.11.5546-5553.2004; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gabler S, 1998, J VIROL, V72, P7960, DOI 10.1128/JVI.72.10.7960-7971.1998; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; Greenberg RA, 2005, CURR MOL MED, V5, P213, DOI 10.2174/1566524053586590; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Hutton FG, 2000, ONCOGENE, V19, P452, DOI 10.1038/sj.onc.1203316; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kindsmuller K, 2007, P NATL ACAD SCI USA, V104, P6684, DOI 10.1073/pnas.0702158104; Koch P, 2001, CANCER RES, V61, P5941; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Liao DQ, 1999, VIROLOGY, V254, P11, DOI 10.1006/viro.1998.9512; Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005; Lober C, 2002, J GEN VIROL, V83, P2047, DOI 10.1099/0022-1317-83-8-2047; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NEVELS M, 2007, ADENOVIRUS METHODS P, P187; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; Wan YP, 2004, CHINESE MED J-PEKING, V117, P753; Wendt J, 2006, ONCOGENE, V25, P972, DOI 10.1038/sj.onc.1209031; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	51	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3673	3684		10.1038/sj.onc.1211039	http://dx.doi.org/10.1038/sj.onc.1211039			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212738				2022-12-17	WOS:000256659300004
J	Ushmorov, A; Hogarty, MD; Liu, X; Knauss, H; Debatin, KM; Beltinger, C				Ushmorov, A.; Hogarty, M. D.; Liu, X.; Knauss, H.; Debatin, K. M.; Beltinger, C.			N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells	ONCOGENE			English	Article						N-myc; bcl-2; survivin; FLIP(L); neuroblastoma	ADVANCED-STAGE NEUROBLASTOMA; NEURO-BLASTOMA CELLS; ANTI-APOPTOSIS GENE; C-MYC; CASPASE-8 EXPRESSION; MEDIATED APOPTOSIS; ONCOLOGY GROUP; AMPLIFICATION; SURVIVIN; ACTIVATION	N-myc has proapoptotic functions, yet it acts as an oncogene in neuroblastoma. Thus, antiapoptotic mechanisms have to be operative in neuroblastoma cells that antagonize the proapoptotic effects of N-myc. We conditionally activated N-myc in SH-EP neuroblastoma cells subjected to the trophic stress of serum or nutrient deprivation while changing the expression of Bcl-2, survivin and FLIPL, antiapoptotic molecules often over-expressed in poor prognosis neuroblastomas. Bcl-2 protected SH-EP cells from death during nutritional deprivation by activating energetically advantageous oxidative phosphorylation. N-myc overrode the metabolic protection provided by Bcl-2-induced oxidative phosphorylation by reestablishing the glycolytic phenotype and attenuated the antiapoptotic effect of Bcl-2during metabolic stress. Survivin partially antagonized the growth suppressive function of N-myc in SH-EP neuroblastoma cells during serum deprivation whereas FLIPL did not. These findings advance our understanding of the functions of N-myc in neuroblastoma cells.	[Ushmorov, A.; Knauss, H.; Debatin, K. M.; Beltinger, C.] Univ Childrens Hosp, D-89075 Ulm, Germany; [Hogarty, M. D.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Beltinger, C (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	christian.beltinger@uniklinik-ulm.de	Ushmorov, Alexey/AAI-6445-2020; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Ushmorov, Alexey/0000-0003-3724-7253				Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CASTLE VP, 1993, AM J PATHOL, V143, P1543; Chan HSL, 1997, CLIN CANCER RES, V3, P1699; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Cohn SL, 2000, J CLIN ONCOL, V18, P3604, DOI 10.1200/JCO.2000.18.21.3604; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Eggert A, 2001, CANCER RES, V61, P1314; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Fischer M, 2005, J MOL DIAGN, V7, P89, DOI 10.1016/S1525-1578(10)60013-X; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 2006, CANCER RES, V66, P10016, DOI 10.1158/0008-5472.CAN-05-4079; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048; Hogarty MD, 2003, CANCER LETT, V197, P173, DOI 10.1016/S0304-3835(03)00103-4; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kim YH, 2003, MOL CELLS, V16, P67; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; LIU X, 2007, ONCOGENE, V27; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Matthay KK, 2000, J CLIN ONCOL, V18, P3591, DOI 10.1200/JCO.2000.18.21.3591; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Miller MA, 2006, J PEDIAT HEMATOL ONC, V28, P412, DOI 10.1097/01.mph.0000212937.00287.e5; NAKAGAWARA A, 1990, CANCER RES, V50, P3043; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; Papas KK, 1999, FEBS LETT, V446, P338, DOI 10.1016/S0014-5793(99)00240-9; Poulaki V, 2001, CANCER RES, V61, P4864; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; ROSS RA, 1983, J NATL CANCER I, V71, P741; Roth W, 2004, VITAM HORM, V67, P189; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SLAVC I, 1990, CANCER RES, V50, P1459; Song JX, 2005, IMMUNITY, V22, P621, DOI 10.1016/j.immuni.2005.03.012; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tang XX, 2006, CANCER RES, V66, P2826, DOI 10.1158/0008-5472.CAN-05-0854; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E	58	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3424	3434		10.1038/sj.onc.1211017	http://dx.doi.org/10.1038/sj.onc.1211017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193081				2022-12-17	WOS:000256309900007
J	Thaxton, C; Lopera, J; Bott, M; Fernandez-Valle, C				Thaxton, C.; Lopera, J.; Bott, M.; Fernandez-Valle, C.			Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways	ONCOGENE			English	Article						nerve; merlin; beta 1 integrin; ErbB2; Cdc42	MERLIN; PAXILLIN; ACTIVATION; RECEPTORS; ADHESION; LOCALIZATION; MYELINATION; ASSOCIATION; EXPRESSION; GENE	Mutations in the neuro. bromatosis type 2 (NF2) gene cause formation of schwannomas and other tumors in the nervous system. The NF2 protein, Schwannomin/Merlin, is a cytoskeleton-associated tumor suppressor regulated by phosphorylation at serine 518 (S518). Unphosphorylated Schwannomin restricts cell proliferation in part by inhibiting Rac- and p21-activated kinase (Pak). In a negative-feedback loop, Pak phosphorylates Schwannomin inactivating its ability to inhibit Pak. Little is known about receptor mechanisms that promote Pak activity and Schwannomin phosphorylation. Here we demonstrate in primary Schwann cells (SCs) that Schwannomin is rapidly phosphorylated on S518 by Pak following laminin-1 binding to b1 integrin, and by protein kinase A following neuregulin-1b (NRG1b) binding to ErbB2/ErbB3 receptors. These receptors, together with phosphorylated Schwannomin, P-Pak, Cdc42 and paxillin are enriched at the distal tips of SC processes, and can be isolated as a complex using b1 integrin antibody. Dual stimulation with laminin-1 and NRG1 beta does not synergistically increase Schwannomin phosphorylation because ErbB2 kinase partially antagonizes integrin-dependent activation of Pak. These results identify two parallel, but interactive pathways that inactivate the tumor suppressor activity of Schwannomin to allow proliferation of subconfluent SCs. Moreover, they identify ErbB2, ErbB3 and beta 1 integrins as potential therapeutic targets for NF2.	[Thaxton, C.; Lopera, J.; Bott, M.; Fernandez-Valle, C.] Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	State University System of Florida; University of Central Florida	Fernandez-Valle, C (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA.	cfernand@mail.ucf.edu		Thaxton, Courtney/0000-0002-6733-369X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034499] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS034499] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Chen LM, 2000, J NEUROSCI, V20, P3776, DOI 10.1523/JNEUROSCI.20-10-03776.2000; Chen ZL, 2003, J CELL BIOL, V163, P889, DOI 10.1083/jcb.200307068; Chernousov MA, 2000, HISTOL HISTOPATHOL, V15, P593, DOI 10.14670/HH-15.593; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Dubovy P, 1999, Gen Physiol Biophys, V18 Suppl 1, P63; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; Garratt AN, 2000, BIOESSAYS, V22, P987, DOI 10.1002/1521-1878(200011)22:11<987::AID-BIES5>3.0.CO;2-5; Hansen MR, 2004, OTOL NEUROTOL, V25, P155, DOI 10.1097/00129492-200403000-00013; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Iacovelli J, 2007, GLIA, V55, P1638, DOI 10.1002/glia.20578; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kim HA, 1997, J NEUROSCI RES, V49, P236; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lee JW, 2004, MOL CELLS, V17, P188; LOTTI LV, 1992, EXP CELL RES, V202, P274, DOI 10.1016/0014-4827(92)90075-J; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Monje PV, 2006, GLIA, V53, P649, DOI 10.1002/glia.20330; Okada T, 2007, TRENDS CELL BIOL, V17, P222, DOI 10.1016/j.tcb.2007.03.006; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Rosenbaum C, 1997, EXP NEUROL, V148, P604, DOI 10.1006/exnr.1997.6696; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Scoles DR, 2005, BIOCHEM BIOPH RES CO, V335, P385, DOI 10.1016/j.bbrc.2005.07.083; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Taylor AR, 2003, GLIA, V41, P94, DOI 10.1002/glia.10170; Thaxton C, 2007, MOL CELL NEUROSCI, V34, P231, DOI 10.1016/j.mcn.2006.11.003; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Turner CE, 2000, J CELL SCI, V113, P4139; Utermark T, 2003, BRAIN PATHOL, V13, P352; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yang DR, 2005, J CELL BIOL, V168, P655, DOI 10.1083/jcb.200411158	39	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2705	2715		10.1038/sj.onc.1210923	http://dx.doi.org/10.1038/sj.onc.1210923			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998937				2022-12-17	WOS:000255259500005
J	Huang, CC; Wang, JM; Kikkawa, U; Mukai, H; Shen, MR; Morita, I; Chen, BK; Chang, WC				Huang, C-C; Wang, J-M; Kikkawa, U.; Mukai, H.; Shen, M-R; Morita, I.; Chen, B-K; Chang, W-C			Calcineurin-mediated dephosphorylation of c-Jun Ser-243 is required for c-Jun protein stability and cell transformation	ONCOGENE			English	Article						calcineurin; c-jun; dephosphorylation; cell transformation	AP-1 ACTIVITY; DNA-BINDING; KINASE; PHOSPHORYLATION; TUMORIGENESIS; COOPERATION; EXPRESSION; REGULATOR	The proto-oncogene c-Jun plays an important role in regulating tumor progression. We previously reported that the serine/ threonine phosphatase calcineurin ( CaN, also called PP2B) dephosphorylates the C- terminus ( Ser- 243) of c- Jun, resulting in the increase in c- Jun and Sp1 interaction, and subsequent c- Jun- induced gene expression. Here, we demonstrate the interaction of c- Jun and CaN in the nucleus of living cells by fluorescence resonance energy transfer assay and that this interaction is mediated through the calmodulin- binding domain of CaN. Furthermore, c- Jun protein stability was altered by CaN- mediated dephosphorylation at the Ser- 243 site of c-Jun. The half-life of the c-Jun mutant, c-Jun-S243A was longer than that of the wild-type c- Jun. Moreover, silencing of endogenous CaN expression led to increased c- Jun ubiquitination and decreased stability. In 46% of clinical cervical tissue samples obtained from patients with cervical cancer, enhanced c- Jun and CaN expression, as well as decreased phospho-Ser-243 expression levels were detected. Our results suggest that CaN stabilizes c- Jun by dephosphorylating c-Jun at Ser-243 to enhance its tumorigenic ability.	[Wang, J-M; Chen, B-K] Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Biosignal Transduct, Tainan 701, Taiwan; [Huang, C-C; Wang, J-M; Shen, M-R; Chen, B-K; Chang, W-C] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; [Wang, J-M; Shen, M-R; Chen, B-K; Chang, W-C] Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct, Tainan 701, Taiwan; [Kikkawa, U.; Mukai, H.] Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 657, Japan; [Morita, I.] Tokyo Med & Dent Univ, Grad Sch, Dept Cellular Physiol Chem, Bunkyo Ku, Tokyo, Japan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Kobe University; Tokyo Medical & Dental University (TMDU)	Chen, BK (corresponding author), Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Biosignal Transduct, Tainan 701, Taiwan.	bkchen58@mail.ncku.edu.tw; wcchang@mail.ncku.edu.tw	wang, ju-ming/A-1875-2011	Mukai, Hideyuki/0000-0002-0167-8695				Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Chen BK, 2007, MOL BIOL CELL, V18, P1118, DOI 10.1091/mbc.E06-09-0797; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; GOTO S, 1987, CANCER-AM CANCER SOC, V60, P2948, DOI 10.1002/1097-0142(19871215)60:12<2948::AID-CNCR2820601217>3.0.CO;2-N; Hou Q, 2004, FEBS LETT, V577, P294, DOI 10.1016/j.febslet.2004.10.002; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Lakshmikuttyamma A, 2005, J CELL BIOCHEM, V95, P731, DOI 10.1002/jcb.20437; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nomura T, 2002, UROL RES, V30, P102, DOI 10.1007/s00240-002-0239-4; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; WONG WY, 1992, ONCOGENE, V7, P2077	22	27	29	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2422	2429		10.1038/sj.onc.1210888	http://dx.doi.org/10.1038/sj.onc.1210888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17952113				2022-12-17	WOS:000254844900007
J	Sahay, S; Pannucci, NL; Mahon, GM; Rodriguez, PL; Megjugorac, NJ; Kostenko, EV; Ozer, HL; Whitehead, IP				Sahay, S.; Pannucci, N. L.; Mahon, G. M.; Rodriguez, P. L.; Megjugorac, N. J.; Kostenko, E. V.; Ozer, H. L.; Whitehead, I. P.			The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation	ONCOGENE			English	Article						chronic myelogenous leukemia; p210 Bcr-Abl; RhoA; RhoGEF domain; transformation	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; POSITIVE HUMAN LEUKEMIAS; ADAPTER PROTEIN; ONCOGENE; FAMILY; ONCOPROTEIN; SEQUENCES; INTERACTS; GROWTH	The BCR-ABL oncogene encodes an in-frame fusion protein containing N-terminal sequences derived from Bcr and C-terminal sequences derived from Abl. Bcr contains a centrally located Rho-specific guanine nucleotide exchange factor (RhoGEF) domain that is retained within p210 Bcr-Abl. Although this domain is subject to autoinhibition in the context of Bcr, here we show that it is constitutively activated in p210 Bcr-Abl. p210 Bcr-Abl can stimulate RhoA activation independently of its tyrosine kinase activity, and mutations within the RhoGEF domain that are predicted to eliminate RhoGEF activity inhibit RhoA activation. The RhoGEF mutant of p210 Bcr-Abl does not affect the tyrosine kinase activity of the molecule, nor the ability of p210 Bcr-Abl to interact with XPB through the RhoGEF domain. Despite retaining normal levels of tyrosine kinase activity, the RhoGEF mutant of p210 Bcr-Abl is impaired in transforming activity as measured by anchorage-independent growth. However, the mutant is still able to confer the phenotype of growth factor independence in myeloid cells, suggesting that some, but not all parameters of p210 Bcr-Abl transformation, are dependent upon a catalytically active RhoGEF domain. Collectively, these observations identify a gain-of-function activity attributable to the RhoGEF domain of p210 Bcr-Abl that is required to support the transformed phenotype.	[Sahay, S.; Pannucci, N. L.; Mahon, G. M.; Rodriguez, P. L.; Megjugorac, N. J.; Kostenko, E. V.; Ozer, H. L.; Whitehead, I. P.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Univ Hosp Canc Ctr, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Whitehead, IP (corresponding author), UMDNJ, NJMS Canc Ctr H Level, Dept Microbiol & Mol Genet, 205 S Orange Ave, Newark, NJ USA.	whiteip@umdnj.edu			NATIONAL CANCER INSTITUTE [R01CA097066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004821] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA097066, CA097066, R01 CA097066-05A1] Funding Source: Medline; NIA NIH HHS [AG04821, R01 AG004821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Harnois T, 2003, ONCOGENE, V22, P6445, DOI 10.1038/sj.onc.1206626; Korus M, 2002, ONCOGENE, V21, P4601, DOI 10.1038/sj.onc.1205678; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Mahon GM, 2003, CURR BIOL, V13, P437, DOI 10.1016/S0960-9822(03)00090-3; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Olabisi OO, 2006, CANCER RES, V66, P6250, DOI 10.1158/0008-5472.CAN-06-0536; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; TENHOEVE J, 1994, CANCER RES, V54, P2563; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	24	27	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					2064	2071		10.1038/sj.onc.1210841	http://dx.doi.org/10.1038/sj.onc.1210841			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922031	Green Accepted			2022-12-17	WOS:000254359100011
J	Kanda, I; Nishimura, N; Nakatsuji, H; Yamamura, R; Nakanishi, H; Sasaki, T				Kanda, I.; Nishimura, N.; Nakatsuji, H.; Yamamura, R.; Nakanishi, H.; Sasaki, T.			Involvement of Rab13 and JRAB/MICAL-L2 in epithelial cell scattering	ONCOGENE			English	Article						Rab13; JRAB/MICAL-L2; cell scattering	SMALL G-PROTEINS; MDCK CELLS; ADHESION RECEPTORS; BINDING-PROTEINS; TIGHT JUNCTIONS; INTEGRIN BETA-1; OCCLUDIN; RHO; MEMBRANE; CADHERIN	Epithelial cell scattering recapitulates the first steps of carcinoma invasion/metastasis. While the balance between cell-cell adhesive activity and cell motility ultimately determines this process, its molecular mechanisms remain unclear. Adherence junctions and tight junctions (TJs) are primarily responsible for cell-cell adhesive activity and subjected to dynamic remodeling. We previously showed that Rab13 and its effector protein JRAB/MICAL-L2 mediate the endocytic recycling of the integral TJ protein occludin and the assembly of functional TJs. In this study, we examined the role of Rab13 and JRAB/MICAL-L2 in the scattering of Madin-Darby canine kidney (MDCK) cells in response to 12-O-tetradecanoylphorbol-13-acetate (TPA). Knockdown of Rab13 in canine MDCK cells suppressed the TPA-induced scattering, and this phenotype was restored by re-expression of human Rab13. During TPA-induced MDCK cell scattering, Rab13 was transiently activated and returned to its basal level, and both Rab13 and JRAB/MICAL-L2 were colocalized with F-actin at cell-cell contact sites and then accumulated at emerging lamellipodial structures. TPA-induced MDCK cell scattering was also inhibited by knockdown of canine JRAB/MICAL-L2 and rescued by re-expression of mouse JRAB/MICAL-L2. These results indicate that Rab13 and JRAB/MICAL-L2 are involved in epithelial cell scattering.	[Kanda, I.; Nishimura, N.; Nakatsuji, H.; Yamamura, R.; Sasaki, T.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Biochem, Tokushima 7708503, Japan; [Kanda, I.; Nakanishi, H.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Plast & Reconstruct Surg, Tokushima 7708503, Japan	Tokushima University; Tokushima University	Sasaki, T (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Biochem, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	sasaki@basic.med.tokushima-u.ac.jp	Nakanishi, Hiroyuki/AAD-9324-2020	Nakanishi, Hiroyuki/0000-0003-3982-3314; Nakanishi, Hiroyuki/0000-0002-9765-0266				Aijaz S, 2005, DEV CELL, V8, P777, DOI 10.1016/j.devcel.2005.03.003; Ashida S, 2006, CLIN CANCER RES, V12, P2767, DOI 10.1158/1078-0432.CCR-05-1995; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Bertet C, 2004, NATURE, V429, P667, DOI 10.1038/nature02590; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Braga VMM, 2005, CURR OPIN CELL BIOL, V17, P466, DOI 10.1016/j.ceb.2005.08.012; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; Chen X, 2006, CURR OPIN CELL BIOL, V18, P572, DOI 10.1016/j.ceb.2006.07.002; Clarke H, 2000, J CELL SCI, V113, P3187; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Di Giovanni S, 2005, J BIOL CHEM, V280, P2084, DOI 10.1074/jbc.M411975200; Di Giovanni S, 2006, EMBO J, V25, P4084, DOI 10.1038/sj.emboj.7601292; Hickson GRX, 2003, MOL BIOL CELL, V14, P2908, DOI 10.1091/mbc.E03-03-0160; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Jones MC, 2006, CURR OPIN CELL BIOL, V18, P549, DOI 10.1016/j.ceb.2006.08.003; Kimura Y, 1997, AM J PATHOL, V151, P45; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kusumi A, 1999, CURR OPIN CELL BIOL, V11, P582, DOI 10.1016/S0955-0674(99)00020-4; Li J, 2005, DEV CELL, V9, P663, DOI 10.1016/j.devcel.2005.09.012; Marzesco AM, 2002, MOL BIOL CELL, V13, P1819, DOI 10.1091/mbc.02-02-0029; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Morimoto S, 2005, J BIOL CHEM, V280, P2220, DOI 10.1074/jbc.M406906200; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Palacios F, 2003, J BIOL CHEM, V278, P17395, DOI 10.1074/jbc.M300998200; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Suzuki T, 2002, J BIOL CHEM, V277, P14933, DOI 10.1074/jbc.M111842200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Terai T, 2006, MOL BIOL CELL, V17, P2465, DOI 10.1091/mbc.E05-09-0826; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; Troyanovsky RB, 2006, MOL BIOL CELL, V17, P3484, DOI 10.1091/mbc.E06-03-0190; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Wells CD, 2006, CELL, V125, P535, DOI 10.1016/j.cell.2006.02.045; Yamamoto Y, 2003, BIOCHEM BIOPH RES CO, V308, P270, DOI 10.1016/S0006-291X(03)01358-5	42	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1687	1695		10.1038/sj.onc.1210812	http://dx.doi.org/10.1038/sj.onc.1210812			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891173				2022-12-17	WOS:000253962100004
J	Berman-Golan, D; Elson, A				Berman-Golan, D.; Elson, A.			Neu-mediated phosphorylation of protein tyrosine phosphatase epsilon is critical for activation of Src in mammary tumor cells	ONCOGENE			English	Article						tyrosine phosphatase; breast cancer; mammary tumor; Src; Neu	HUMAN BREAST-CANCER; FAMILY KINASES; PTP-ALPHA; C-SRC; RPTP-ALPHA; CYTOPLASMIC FORMS; TRANSGENIC MICE; IN-VIVO; RECEPTOR; PP60(C-SRC)	The receptor-type protein tyrosine phosphatase epsilon (RPTPe) activates c-Src in mammary tumor cells induced in vivo by Neu. Tumor cells lacking RPTPe exhibit reduced c-Src activity, appear less transformed morphologically and proliferate slower in vitro and in vivo. Expression of Src rescues most of these phenotypes, indicating that c-Src activity is important for maintaining the transformed phenotype. However, the molecular mechanisms that control activation of c-Src by RPTPe are unknown. We show that Neu induces phosphorylation of RPTPe exclusively at its C-terminal Y695, and that this phosphorylation is required for activation of c-Src by RPTPe. Phosphorylation of RPTPe does not affect its activity toward another substrate, the voltage-gated potassium channel Kv2.1, suggesting that phosphorylation directs RPTPe activity toward c-Src. Phosphorylation of RPTPe reduces its dimerization at the cell membrane, although this does not affect its activity significantly. RPTPe is subject to strong auto-and trans-dephosphorylation, suggesting that dephosphorylation limits the activation of c-Src downstream of Neu. We conclude that an Neu-RPTP epsilon-Src signaling pathway exists in mammary tumor cells, in which phosphorylation of RPTPe by Neu directs RPTPe to activate c-Src. Reversible phosphorylation of RPTPe at Y695 may thus function as a 'molecular switch', which affects the substrate specificity of the phosphatase.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	ari.elson@weizmann.ac.il		Elson, Ari/0000-0001-9808-9135				Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Bodrikov V, 2005, J CELL BIOL, V168, P127, DOI 10.1083/jcb.200405073; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Cole PA, 2003, CURR OPIN CHEM BIOL, V7, P580, DOI 10.1016/j.cbpa.2003.08.009; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; Gil-Henn H, 2001, J BIOL CHEM, V276, P31772, DOI 10.1074/jbc.M103395200; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Granot-Attas S, 2004, EXP CELL RES, V294, P236, DOI 10.1016/j.yexcr.2003.11.003; Guo SL, 2004, P NATL ACAD SCI USA, V101, P14180, DOI 10.1073/pnas.0405878101; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lau KHW, 2006, J CELL BIOCHEM, V97, P940, DOI 10.1002/jcb.20667; Le Pera I, 2005, ONCOGENE, V24, P3187, DOI 10.1038/sj.onc.1208510; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Maksumova L, 2005, J IMMUNOL, V175, P7947, DOI 10.4049/jimmunol.175.12.7947; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUSTELIN T, 2002, SCI STKE, pPE3; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tiran Z, 2003, J BIOL CHEM, V278, P17509, DOI 10.1074/jbc.M212766200; Toledano-Katchalski H, 1999, ONCOGENE, V18, P5024, DOI 10.1038/sj.onc.1202883; Toledano-Katchalski H, 2003, MOL CELL BIOL, V23, P5460, DOI 10.1128/MCB.23.15.5460-5471.2003; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zheng XM, 2002, J BIOL CHEM, V277, P21922, DOI 10.1074/jbc.M201394200; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	44	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					7028	7037		10.1038/sj.onc.1210505	http://dx.doi.org/10.1038/sj.onc.1210505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486066				2022-12-17	WOS:000250412200008
J	Kucherlapati, M; Nguyen, A; Kuraguchi, M; Yang, K; Fan, K; Bronson, R; Wei, K; Lipkin, M; Edelmann, W; Kucherlapati, R				Kucherlapati, M.; Nguyen, A.; Kuraguchi, M.; Yang, K.; Fan, K.; Bronson, R.; Wei, K.; Lipkin, M.; Edelmann, W.; Kucherlapati, R.			Tumor progression in Apc(1638N) mice with Exo1 and Fen1 deficiencies	ONCOGENE			English	Article						mouse; Apc(1638N); Exo1; Fen1	MISMATCH REPAIR PROTEINS; COLORECTAL-CANCER; GENE; EXONUCLEASE; MUTATIONS; MOUSE; INTERACTS; SYSTEM; MODEL; MSH6	Flap endonuclease 1 (Fen1) and exonuclease 1 (Exo1) have sequence homology and similar nuclease capabilities. Both function in multiple pathways of DNA metabolism, but appear to have distinct in vivo nucleic acid substrates, and therefore distinct metabolic roles. When combined with Apc(1638N), Fen1 promotes tumor progression. Because of functional similarity to Fen1, and because Exo1 is involved in DNA mismatch repair (MMR) by interaction with Msh2 and Mlh1, genes that cause hereditary nonpolyposis colorectal cancer ( HNPCC), we investigated the possibility that Exo1 might also act as a modi. er to Apc(1638N). We present evidence that mice with combined mutations in Apc(1638N) and Exo1 and Apc(1638N), Exo1 and Fen1 genes show moderate increased tumor incidence and multiplicity in comparison to Apc(1638N) siblings, implying a low penetrance role for Exo1 in early gastrointestinal (GI) tumorigenesis. Despite a decrease in median survival (10 months) in Apc(1638N) Exo1 mice, their tumors do not progress any more rapidly than those of Apc(1638N). Instead these animals die from infections that are the result of impaired immune response. Apc(1638N) Exo1 Fen1 mice survive longer (18 months), and therefore appear relatively immune competent. They die of invasive GI tumors that display microsatellite instability (MSI). Our results show that Exo1 has a modest tumor suppressor function.	Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA; Harvard Univ, Sch Med, Rodent Histopathol Core, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA	Harvard University; Harvard Medical School; Rockefeller University; Harvard University; Harvard Medical School; Tufts University; Tufts University; Yeshiva University; Albert Einstein College of Medicine	Kucherlapati, R (corresponding author), Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, 77 Ave Louis Pasteur,NRB 160, Boston, MA 02115 USA.	mkucherlapati@rics.bwh.harvard.edu	Kucherlapati, Raju/ABC-8807-2021		NATIONAL CANCER INSTITUTE [U01CA084301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011040] Funding Source: NIH RePORTER; NCI NIH HHS [CA084301] Funding Source: Medline; NIEHS NIH HHS [ES011040] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam NA, 2003, CANCER GENET CYTOGEN, V147, P121, DOI 10.1016/S0165-4608(03)00196-1; Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Bardwell PD, 2004, NAT IMMUNOL, V5, P224, DOI 10.1038/ni1031; Coletta PL, 2004, BLOOD, V103, P1050, DOI 10.1182/blood-2003-03-0707; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Edelmann L, 2004, AM J MED GENET C, V129C, P91, DOI 10.1002/ajmg.c.30021; Edelmann W, 1999, CANCER RES, V59, P1301; Edelmann W, 2000, CANCER RES, V60, P803; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gounari F, 2005, NAT IMMUNOL, V6, P800, DOI 10.1038/ni1228; Jagmohan-Changur S, 2003, CANCER RES, V63, P154; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Lee B, 2002, NUCLEIC ACIDS RES, V30, P942, DOI 10.1093/nar/30.4.942; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Nielsen FC, 2004, ONCOGENE, V23, P1457, DOI 10.1038/sj.onc.1207265; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Rudolph C, 1998, CURR GENET, V34, P343, DOI 10.1007/s002940050405; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Sokolsky T, 2000, GENETICS, V155, P589; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tran PT, 2004, DNA REPAIR, V3, P1549, DOI 10.1016/j.dnarep.2004.05.015; Tran PT, 2002, DNA REPAIR, V1, P895, DOI 10.1016/S1568-7864(02)00114-3; Tran PT, 2001, P NATL ACAD SCI USA, V98, P9760, DOI 10.1073/pnas.161175998; Wei KC, 2003, GENE DEV, V17, P603, DOI 10.1101/gad.1060603; Wu Y, 2001, GASTROENTEROLOGY, V120, P1580, DOI 10.1053/gast.2001.25117; Yamamoto H, 2005, CARCINOGENESIS, V26, P411, DOI 10.1093/carcin/bgh335	29	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6297	6306		10.1038/sj.onc.1210453	http://dx.doi.org/10.1038/sj.onc.1210453			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452984				2022-12-17	WOS:000249583300006
J	Memezawa, A; Takada, I; Takeyama, K; Igarashi, M; Ito, S; Aiba, S; Kato, S; Kouzmenko, AP				Memezawa, A.; Takada, I.; Takeyama, K.; Igarashi, M.; Ito, S.; Aiba, S.; Kato, S.; Kouzmenko, A. P.			Id2 gene-targeted crosstalk between Wnt and retinoid signaling regulates proliferation in human keratinocytes	ONCOGENE			English	Article						keratinocytes; retinoids; Wnt; proliferation; Id2	BETA-CATENIN; SYNERGISTIC INDUCTION; NUCLEAR RECEPTORS; STEM-CELLS; ACID; PROTEINS; PATHWAY	We investigated the effect of all-trans-retinoic acid (atRA) on proliferation in several human skin cell lines and found that antiproliferative potency of atRA correlated with the endogenous activity of canonical Wnt signaling. In HaCaT keratinocytes, we found that atRA significantly suppressed the expression of Id2, a member of the inhibitor of differentiation family of transcription factors that regulate cell growth and differentiation. However, no apparent change in the expression of other Wnt targets, like c-Myc or cyclin D1, was observed. Retinoid-induced Id2 gene suppression was associated with decreased levels of histone H3 and H4 acetylation and histone H3 Lys-4 methylation, and with recruitment of the LSD1 demethylase at the Wnt-response element (WRE) (TCF/ LEF-binding site), in the Id2 gene promoter. None of such changes was detected at the WRE of c-Myc and cyclin D1 gene promoters. Inhibition of Id2 by short interfering RNA (siRNA) had a similar effect on the proliferation of HaCaT cells as exposure to atRA, whereas anti-beta-catenin siRNA significantly inhibited its antiproliferative effect. These data suggest that downregulation of Id2 gene expression through transcriptional convergence between Wnt and retinoid signaling pathways underlies the antiproliferative effect of retinoids in keratinocytes, and provide evidence of gene-targeted crosstalk between signaling pathways.	Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Tokyo 1130032, Japan; Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, Sendai, Miyagi 980, Japan; Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama, Japan	University of Tokyo; Tohoku University; Japan Science & Technology Agency (JST)	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	uskato@mail.ecc.u-tokyo.ac.jp; alexk@iam.u-tokyo.ac.jp						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Baghdoyan S, 2005, J BIOL CHEM, V280, P15836, DOI 10.1074/jbc.M414216200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Buzzard JJ, 2003, ENDOCRINOLOGY, V144, P3722, DOI 10.1210/en.2003-0379; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Liu T, 2002, J BIOL CHEM, V277, P30887, DOI 10.1074/jbc.M203852200; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; NEUMAN K, 1995, FEBS LETT, V374, P279, DOI 10.1016/0014-5793(95)01128-2; Nigten J, 2005, LEUKEMIA, V19, P799, DOI 10.1038/sj.leu.2403699; Niles RM, 2004, MUTAT RES-FUND MOL M, V555, P81, DOI 10.1016/j.mrfmmm.2004.05.020; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Okuno M, 2004, CURR CANCER DRUG TAR, V4, P285, DOI 10.2174/1568009043333023; Otero JJ, 2004, DEVELOPMENT, V131, P3545, DOI 10.1242/dev.01218; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Simbulan-Rosenthal CM, 2005, ONCOGENE, V24, P5443, DOI 10.1038/sj.onc.1208709; Sundberg M, 2006, J NEUROSCI, V26, P5402, DOI 10.1523/JNEUROSCI.4906-05.2006; Szeto W, 2001, CANCER RES, V61, P4197; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; Wagsater D, 2003, J EXP CLIN CANC RES, V22, P471; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1	32	27	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5038	5045		10.1038/sj.onc.1210320	http://dx.doi.org/10.1038/sj.onc.1210320			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310985				2022-12-17	WOS:000248487400002
J	Cras, A; Darsin-Bettinger, D; Balitrand, N; Cassinat, B; Soulie, A; Toubert, ME; Delva, L; Chomienne, C				Cras, A.; Darsin-Bettinger, D.; Balitrand, N.; Cassinat, B.; Soulie, A.; Toubert, M-E; Delva, L.; Chomienne, C.			Epigenetic patterns of the retinoic acid receptor beta(2) promoter in retinoic acid-resistant thyroid cancer cells	ONCOGENE			English	Article						RAR beta(2) promoter; RA; resistance; thyroid cells; histone acetylation	RECEPTOR-BETA GENE; REDIFFERENTIATION THERAPY; SODIUM/IODIDE SYMPORTER; MYELOID CELLS; RAR-ALPHA; EXPRESSION; CARCINOMA; LINES; TRANSCRIPTION; METHYLATION	Treatment with retinoic acid ( RA) is effective to restore radioactive iodine uptake in metastases of a small fraction of thyroid cancer patients. In order to find predictive markers of response, we took advantage of two thyroid cancer cell lines, FTC133 and FTC238, with low RA-receptor ( RAR)beta expression but differing in their response to RA. We report that in both cell lines, RA signalling pathways are functional, as transactivation of an exogenous RAR beta(2) promoter is effective in the presence of pharmacological concentrations of all-trans RA, and enhanced in RA-resistant FTC238 cells after ectopical expression of RAR beta, suggesting a defective endogenous RAR beta(2) promoter in these cells. Further analyses show that whereas the RAR beta(2) promoter is in an unmethylated permissive status in both FTC133 and FTC238 cells, it failed to be associated with acetylated forms of histones H3 or H4 in FTC238 cells upon RA treatment. Incubation with a histone deacetylase inhibitor, alone or in combination with RA, restored histone acetylation levels and reactivated RAR beta and differentiation marker Na+/I- symporter gene expression. Thus, histone modi. cation patterns may explain RA-refractoriness in differentiated thyroid cancer patients and suggest a potential benefit of combined transcriptional and differentiation therapies.	Hop St Louis, INSERM, UMR S 718, IUH,Unite Biol Cellulaire,AP HP, F-75010 Paris, France; Univ Paris 07, INSERM, UMR S 718, Inst Univ Hematol, Paris, France; Hop St Louis, Nucl Med Serv, AP HP, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Chomienne, C (corresponding author), Hop St Louis, INSERM, UMR S 718, IUH,Unite Biol Cellulaire,AP HP, 1 Ave Claude Vellefaux, F-75010 Paris, France.	christine.chomienne@sls.ap-hop-paris.fr	Cras, Audrey/Q-8784-2017; CASSINAT, BRUNO/N-2752-2017	Cras, Audrey/0000-0002-6894-9584; CASSINAT, BRUNO/0000-0002-6514-3905; DELVA, Laurent/0000-0002-1086-3964; CHOMIENNE, Christine/0000-0001-5513-5752				Bastie JN, 2004, MOL ENDOCRINOL, V18, P2685, DOI 10.1210/me.2003-0412; Carpentier A, 1997, ONCOGENE, V15, P1805, DOI 10.1038/sj.onc.1201335; Carpentier AF, 1999, ANTICANCER RES, V19, P3189; Cassinat B, 2000, LEUKEMIA, V14, P324, DOI 10.1038/sj.leu.2401652; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Delva L, 1999, MOL CELL BIOL, V19, P7158; deThe H, 1996, FASEB J, V10, P955, DOI 10.1096/fasebj.10.9.8801177; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; di Magliano MP, 2000, P NATL ACAD SCI USA, V97, P13144; Filetti S, 1999, EUR J ENDOCRINOL, V141, P443, DOI 10.1530/eje.0.1410443; Goretzki P E, 1990, Recent Results Cancer Res, V118, P48; Grunwald F, 1998, J NUCL MED, V39, P1903; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Idres N, 2002, J BIOL CHEM, V277, P31491, DOI 10.1074/jbc.M205016200; Lazar V, 1999, J CLIN ENDOCR METAB, V84, P3228, DOI 10.1210/jc.84.9.3228; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Niles RM, 2004, MUTAT RES-FUND MOL M, V555, P81, DOI 10.1016/j.mrfmmm.2004.05.020; PINEDA JD, 1995, J CLIN ENDOCR METAB, V80, P1488, DOI 10.1210/jc.80.5.1488; Rochaix P, 1998, HISTOPATHOLOGY, V33, P337, DOI 10.1046/j.1365-2559.1998.00486.x; Rochette-Egly C, 2005, J BIOL CHEM, V280, P32565, DOI 10.1074/jbc.R500008200; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Schmutzler C, 1998, INT J CANCER, V76, P368; Schmutzler C, 1997, BIOCHEM BIOPH RES CO, V240, P832, DOI 10.1006/bbrc.1997.7715; Schmutzler C, 2000, THYROID, V10, P393, DOI 10.1089/thy.2000.10.393; SCHRECK R, 1994, J CLIN ENDOCR METAB, V79, P791, DOI 10.1210/jc.79.3.791; Simon D, 2002, EUR J NUCL MED MOL I, V29, P775, DOI 10.1007/s00259-001-0737-6; Suh YA, 2002, CANCER RES, V62, P3945; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115; Youssef EM, 2004, CLIN CANCER RES, V10, P1733, DOI 10.1158/1078-0432.CCR-0989-3; Youssef EM, 2004, CANCER BIOL THER, V3, P82, DOI 10.4161/cbt.3.1.591	36	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					4018	4024		10.1038/sj.onc.1210178	http://dx.doi.org/10.1038/sj.onc.1210178			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213810				2022-12-17	WOS:000247144500012
J	Yao, JJ; Liu, Y; Lacorazza, HD; Soslow, RA; Scandura, JM; Nimer, SD; Hedvat, CV				Yao, J. J.; Liu, Y.; Lacorazza, H. D.; Soslow, R. A.; Scandura, J. M.; Nimer, S. D.; Hedvat, C. V.			Tumor promoting properties of the ETS protein MEF in ovarian cancer	ONCOGENE			English	Article						MEF; ELF4; RNA interference; ovarian cancer	TRANSCRIPTION FACTOR; EXPRESSION; GENE; PHOSPHORYLATION	We have previously shown that MEF ( myeloid ELF1-like factor, also known as ELF4) functions as a transcriptional activator of the interleukin ( IL)-8, perforin, granulocyte macrophage-colonyst imulating factor ( GM-CSF) and IL-3 genes in hematopoietic cells. MEF is also expressed in non-hematopoietic tissues including certain ovarian cancer cells. To de. ne the function of MEF in these cells, we examined primary human ovarian epithelial tumors and found that MEF is expressed in a significant proportion of ovarian carcinomas, and in the CAOV3 and SKOV3 ovarian cancer cell lines, but not in normal ovarian surface epithelium. Manipulating MEF levels in these cell lines altered their behavior; reducing MEF levels, using short hairpin RNA expressing vectors, significantly inhibited the proliferation of SKOV3 and CAOV3 cells in culture, and impaired the anchorage-independent growth of CAOV3 cells. Overexpression of MEF in SKOV3 cells ( via retroviral transduction) significantly increased their growth rate, enhanced colony formation in soft agar and promoted tumor formation in nude mice. The oncogenic activity of MEF was further shown by the ability of MEF to transform NIH3T3 cells, and induce their tumor formation in nude mice. MEF is an important regulator of the tumorigenic properties of ovarian cancer cells and could be used a therapeutic target in ovarian cancer.	Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Sloan Kettering Inst, Lab Mol Aspects Haematopoiesis, Mol Pharmacol & Chem Program, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, 1275 York Ave, New York, NY 10021 USA.	nimers@mskcc.org		Yao, JinJuan/0000-0003-4692-9969; Soslow, Robert/0000-0002-7269-5898; Scandura, Joseph/0000-0002-9525-143X; HEDVAT, CYRUS/0000-0003-0045-3491	NCI NIH HHS [K01 CA099156, CA052477] Funding Source: Medline; NHLBI NIH HHS [K08 HL4478] Funding Source: Medline; NIDDK NIH HHS [R01 DK052208] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052477, K01CA099156] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aryee DNT, 1998, GENE, V210, P71, DOI 10.1016/S0378-1119(98)00022-5; Choi C, 1997, GENE CHROMOSOME CANC, V20, P234; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; Fukushima T, 2003, LEUKEMIA RES, V27, P387, DOI 10.1016/S0145-2126(02)00214-X; Hedvat CV, 2004, J BIOL CHEM, V279, P6395, DOI 10.1074/jbc.M307524200; Lacorazza HD, 2006, CANCER CELL, V9, P175, DOI 10.1016/j.ccr.2006.02.017; Lacorazza HD, 2003, BLOOD CELL MOL DIS, V31, P342, DOI 10.1016/S1079-9796(03)00162-1; Lacorazza HD, 2002, IMMUNITY, V17, P437, DOI 10.1016/S1074-7613(02)00422-3; Liu Y, 2006, MOL CELL BIOL, V26, P3114, DOI 10.1128/MCB.26.8.3114-3123.2006; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Milde-Langosch K, 2003, INT J GYNECOL PATHOL, V22, P168, DOI 10.1097/00004347-200304000-00009; Miyazaki Y, 2001, J BIOL CHEM, V276, P40528, DOI 10.1074/jbc.M103051200; Miyazaki Y, 1996, ONCOGENE, V13, P1721; Seki Y, 2002, CANCER RES, V62, P6579; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Takai N, 2003, INT J MOL MED, V12, P349; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	19	27	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					4032	4037		10.1038/sj.onc.1210170	http://dx.doi.org/10.1038/sj.onc.1210170			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213815				2022-12-17	WOS:000247144500014
J	Ko, K; Furukawa, K; Takahashi, T; Urano, T; Sanai, Y; Nagino, M; Nimura, Y; Furukawa, K				Ko, K.; Furukawa, K.; Takahashi, T.; Urano, T.; Sanai, Y.; Nagino, M.; Nimura, Y.; Furukawa, K.			Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers	ONCOGENE			English	Article						small interfering RNA; GD3 synthase; lung cancer; GD2; ganglioside	DOUBLE-STRANDED-RNA; CELL-LINES; EXPRESSION; MELANOMA; INVASION; CLONING; MOTILITY; GROWTH	Gangliosides GD3 and GD2 are specifically expressed in neuro-ectoderm-derived tumors, and are considered to play roles in the malignant properties of those cells. We analysed effects of small interfering ( si) RNAs against GD3 synthase gene on the expression of ganglioside GD2 and biological phenotypes of human lung cancer cells expressing GD2. An siRNA could suppress the mRNA level of GD3 synthase gene even by single transfection, whereas repeated transfection was required to suppress GD2express ion on the cell surface. Significant reduction in the cell growth and invasion activity was observed in both lung cancer cell lines examined, when repeatedly transfected with the siRNA twice a week. DNA ladder formation was observed after third transfection, indicating the potent induction of apoptosis. Stable transfection of an RNAi expression vector with H1 RNA promoter was also examined. Transfectant cells with the RNAi expression vector showed almost equivalent suppression of GD2 expression and tumor properties in vitro. Furthermore, the stable transfectant cells showed slower cell growth than the control cells in severe combined immunodeficiency mice. These results suggested that siRNAs and/or RNAi expression vectors to generate siRNAs are promising approach to overcome human lung cancers.	Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol,Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Grad Sch Med, Dept Mol Oncol, Showa Ku, Nagoya, Aichi 4660065, Japan; Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 113, Japan; Chubu Univ, Coll Life & Hlth Sci, Dept Biomed Sci, Kasugai, Aichi 487, Japan	Nagoya University; Nagoya University; Nagoya University; Tokyo Metropolitan Institute of Medical Science; Chubu University	Furukawa, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Nagino, Masato/I-7342-2014; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Urano, Takeshi/0000-0003-3383-3554				Aixinjueluo W, 2005, J BIOL CHEM, V280, P29828, DOI 10.1074/jbc.M414041200; Aoki H, 2004, FEBS LETT, V567, P203, DOI 10.1016/j.febslet.2004.04.060; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Barik S, 2004, ANN MED, V36, P540, DOI 10.1080/07853890410018817; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CARUBIA JM, 1984, BIOCHEM BIOPH RES CO, V120, P500, DOI 10.1016/0006-291X(84)91282-8; Damstrup L, 1998, BRIT J CANCER, V78, P631, DOI 10.1038/bjc.1998.553; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; FURUKAWA K, 1990, ARCH BIOCHEM BIOPHYS, V281, P70, DOI 10.1016/0003-9861(90)90414-T; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hamamura K, 2005, P NATL ACAD SCI USA, V102, P11041, DOI 10.1073/pnas.0503658102; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; Izquierdo M, 2005, CANCER GENE THER, V12, P217, DOI 10.1038/sj.cgt.7700791; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; Okada M, 1996, CANCER RES, V56, P2844; PORTOUKALIAN J, 1979, EUR J BIOCHEM, V94, P19, DOI 10.1111/j.1432-1033.1979.tb12866.x; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; SCHENGRUND CL, 1990, BRAIN RES BULL, V24, P131, DOI 10.1016/0361-9230(90)90297-D; Scherer L, 2004, CURR PHARM BIOTECHNO, V5, P355, DOI 10.2174/1389201043376724; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Yoshida S, 2001, CANCER RES, V61, P4244; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	29	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6924	6935		10.1038/sj.onc.1209683	http://dx.doi.org/10.1038/sj.onc.1209683			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16862187				2022-12-17	WOS:000241732300003
J	Mulherkar, N; Ramaswamy, M; Mordi, DC; Prabhakar, BS				Mulherkar, N.; Ramaswamy, M.; Mordi, D. C.; Prabhakar, B. S.			MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival	ONCOGENE			English	Article						IG20pa; MADD; DENN-SV; shRNA; alternative-splicing; apoptosis	GDP/GTP EXCHANGE PROTEIN; SMALL INTERFERING RNAS; DEATH DOMAIN PROTEIN; INDUCED APOPTOSIS; NEOPLASTIC-CELLS; MAMMALIAN-CELLS; DENN-SV; MADD; EXPRESSION; RECEPTOR	The IG20 gene is overexpressed in human tumors and cancer cell lines, and encodes at least four splice variants (SVs) namely, IG20pa, MADD, IG20-SV2 and DENNSV. Earlier, gain-of-function studies showed that IG20SVs can exhibit diverse functions and play a critical role in cell proliferation and apoptosis. Expression of exogenous IG20pa or DENN-SV rendered cells either susceptible or resistant to induced apoptosis, respectively, whereas MADD and IG20-SV2 had no apparent effect. In order to understand the contrasting effects of the IG20-SVs in a physiologically more relevant system, we expressed exon-specific small hairpin RNAs (shRNAs) to selectively knockdown specific IG20-SVs. Consistent with an earlier study, knockdown of all IG20-SVs resulted in spontaneous apoptosis of HeLa and PA-1 cells. In addition, we unambiguously demonstrated that knockdown of MADD can render cells susceptible to spontaneous apoptosis but had no discernible effect on cell proliferation, colony size or cell cycle progression. Moreover, expression of MADD alone, and not DENN-SV, in the absence of endogenous IG20-SVs was sufficient to prevent spontaneous apoptosis. Our results show the utility of shRNAs for selective knockdown of particular IG20-SVs and their potential therapeutic value in cancer. Further, they demonstrate that MADD alone is sufficient and necessary for cancer cell survival.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; NIAMSD, NIH, Bethesda, MD 20892 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Prabhakar, BS (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, M-C 790,Room E-705,835 S Wolcott Ave, Chicago, IL 60612 USA.	bprabhak@uic.edu		Ramaswamy, Madhu/0000-0001-8870-5328	NATIONAL CANCER INSTITUTE [R01CA107506] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA107506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Brown TL, 1998, CURR BIOL, V8, pR191; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Cullen BR, 2004, VIRUS RES, V102, P3, DOI 10.1016/j.virusres.2004.01.009; CULLEN BR, 2005, GENE THER, V6, P503; Cunningham SJ, 1996, THESIS U TEXAS MED B; Del Villar K, 2004, P NATL ACAD SCI USA, V101, P4210, DOI 10.1073/pnas.0307349101; Efimova E, 2003, CANCER RES, V63, P8768; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Hall J, 2004, NAT REV GENET, V5, P552, DOI 10.1038/nrg1382; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Iwasaki K, 2000, EMBO J, V19, P4806, DOI 10.1093/emboj/19.17.4806; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Levivier E, 2001, BIOCHEM BIOPH RES CO, V287, P688, DOI 10.1006/bbrc.2001.5652; Lim KM, 2004, INT J CANCER, V109, P24, DOI 10.1002/ijc.11660; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Murakami-Mori K, 1999, J IMMUNOL, V162, P3672; Ramaswamy M, 2004, ONCOGENE, V23, P6083, DOI 10.1038/sj.onc.1207804; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Yamaguchi K, 2002, P NATL ACAD SCI USA, V99, P14536, DOI 10.1073/pnas.212511399; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	35	27	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6252	6261		10.1038/sj.onc.1209650	http://dx.doi.org/10.1038/sj.onc.1209650			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16682944				2022-12-17	WOS:000241218200003
J	Nakamura, N; Kobayashi, K; Nakamoto, M; Kohno, T; Sasaki, H; Matsuno, Y; Yokota, J				Nakamura, N.; Kobayashi, K.; Nakamoto, M.; Kohno, T.; Sasaki, H.; Matsuno, Y.; Yokota, J.			Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma	ONCOGENE			English	Article						lung adenocarcinoma; lung epithelial cells; expression pro. le; microdissection; micrometastasis; differential diagnosis	LASER CAPTURE MICRODISSECTION; POLYMERASE-CHAIN-REACTION; CELL 10-KDA PROTEIN; MESSENGER-RNA; PERIPHERAL-BLOOD; EPITHELIAL-CELLS; GENE-EXPRESSION; CANCER; CARCINOMAS; CLASSIFICATION	To identify tumor markers and differentiation markers for lung adenocarcinoma (AdC), we analysed expression profiles of 14 500 genes against three cases of type II alveolar epithelial cells, bronchiolar epithelial cells, and bronchial epithelial cells, respectively, and 10 cases of AdC cells isolated by laser capture microdissection. Hierarchical clustering analysis indicated that AdC cells and noncancerous lung epithelial cells are significantly different in their expression profiles, and that different sets of differentiation markers are expressed among alveolar, bronchiolar and bronchial epithelial cells. Nine genes were identified as being highly expressed in AdC cells, but not expressed in noncancerous lung epithelial cells. Sixteen genes were identified as differentiation markers for lung epithelial cells. Real-time RT-PCR analysis of 45 lung AdC cases further revealed that expression of four tumor markers in AdC cells was significantly higher than that in noncancerous lung cells and that expression of ten differentiation markers was retained in a considerable fraction of lung AdC cases. Five tumor markers and seven differentiation markers were not expressed in peripheral blood cells. Similarities and differences in expression profiles between normal epithelial cells from different lung respiratory compartments and AdC cells demonstrated in this study will be informative for the molecular diagnosis of lung AdC.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp						Aoyagi K, 2003, BIOCHEM BIOPH RES CO, V300, P915, DOI 10.1016/S0006-291X(02)02967-4; Barth PJ, 2000, VIRCHOWS ARCH, V437, P648, DOI 10.1007/s004280000316; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; BROERS JLV, 1992, LAB INVEST, V66, P337; Chhieng DC, 2001, CANCER CYTOPATHOL, V93, P330, DOI 10.1002/cncr.9048; D'Cunha J, 2002, J THORAC CARDIOV SUR, V123, P484, DOI 10.1067/mtc.2002.119883; Egland KA, 2002, MOL CANCER THER, V1, P441; Fischer H, 2001, CARCINOGENESIS, V22, P875, DOI 10.1093/carcin/22.6.875; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Hanaoka J, 2001, CANCER-AM CANCER SOC, V92, P2148, DOI 10.1002/1097-0142(20011015)92:8<2148::AID-CNCR1557>3.0.CO;2-6; Hosch SB, 2001, SEMIN SURG ONCOL, V20, P278, DOI 10.1002/ssu.1045; Kobayashi K, 2004, ONCOGENE, V23, P3089, DOI 10.1038/sj.onc.1207433; Kufer P, 2002, CANCER RES, V62, P251; Matsunaga H, 2002, INT J CANCER, V100, P592, DOI 10.1002/ijc.10534; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; Mitas M, 2003, J MOL DIAGN, V5, P237, DOI 10.1016/S1525-1578(10)60480-1; Miura K, 2002, CANCER RES, V62, P3244; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Naruke T, 2001, ANN THORAC SURG, V71, P1759, DOI 10.1016/S0003-4975(00)02609-6; Otto WR, 2002, J PATHOL, V197, P527, DOI 10.1002/path.1160; Player A, 2004, EXPERT REV MOL DIAGN, V4, P831, DOI 10.1586/14737159.4.6.831; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; SOBIN C, 2002, TNM CLASSIFICATION M, P97; Takamochi K, 2004, EUR J CARDIO-THORAC, V25, P877, DOI 10.1016/j.ejcts.2004.01.049; TenHaveOpbroek AAW, 1997, HISTOL HISTOPATHOL, V12, P319; Tomida S, 2004, ONCOGENE, V23, P5360, DOI 10.1038/sj.onc.1207697; Travis WD, 1999, HISTOLOGICAL TYPING; VIEAU D, 1991, CLIN ENDOCRINOL, V35, P319, DOI 10.1111/j.1365-2265.1991.tb03543.x; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Xu P, 1998, VIRCHOWS ARCH, V432, P17, DOI 10.1007/s004280050129; Zamecnik J, 2002, VIRCHOWS ARCH, V440, P353, DOI 10.1007/s00428-001-0552-2	34	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4245	4255		10.1038/sj.onc.1209442	http://dx.doi.org/10.1038/sj.onc.1209442			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16491115				2022-12-17	WOS:000239004800013
J	Konishi, T; Sasaki, S; Watanabe, T; Kitayama, J; Nagawa, H				Konishi, T.; Sasaki, S.; Watanabe, T.; Kitayama, J.; Nagawa, H.			Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappa B andupregulation of BCL-2 and BCL-XL	ONCOGENE			English	Article						hRFI; apoptosis; 5-FU; colorectal cancer; Bcl-2 family; NF-kappa B	UBIQUITIN-PROTEIN LIGASE; CYTOCHROME-C; TRANSCRIPTIONAL REGULATION; DEATH; EXPRESSION; BCL-X(L); FAMILY; GENE; REGULATORS; MITOCHONDRIA	Resistance to apoptosis is one of the important determinants of resistance to 5-fluorouracil (5-FU) in colorectal cancer cells. Human Ring-Finger homologous to Inhibitor of apoptosis protein type (hRFI) is a newly discovered gene that has been shown to inhibit death receptor-mediated apoptosis in colorectal cancer cells. However, the molecular mechanism of the inhibition of apoptosis is presently unknown. In order to investigate the molecular function of hRFI in the regulation of 5-FU-induced apoptosis in colorectal cancer cells, HCT116 cells were stably transfected with hRFI or LacZ as a control. hRFI overexpression resulted in cellular resistance to 5-FU through an inhibition of the mitochondrial apoptotic pathway and specific upregulation of Bcl-2 and Bcl-XL. Futhermore, hRFI overexpression resulted in the activation of nuclear factor-kappa B (NF-kappa B). Inhibition of NF-kappa B effectively reversed the resistance to apoptosis as well as the upregulation of Bcl-2 and Bcl-XL in the hRFI transfectant, indicating that the activation of NF-kappa B is the key mechanism for all these findings. Overexpression of hRFI in SW480 and COLO320 colorectal cancer cells similarly resulted in resistance to 5-FU with the activation of NF-kappa B and up regulation of Bcl-2 and Bcl-XL. hRFI might be a novel therapeutic target for gene therapy in colorectal cancer.	Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Konishi, T (corresponding author), Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	konishit-sur@h.u-tokyo.ac.jp; sasaki-lsu@h.u-tokyo.ac.jp						BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cusack JC, 2000, CANCER RES, V60, P2323; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang HK, 2000, J BIOL CHEM, V275, P26661; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Kahlenberg MS, 2003, SURG ONCOL, V12, P173, DOI 10.1016/S0960-7404(03)00006-9; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Konishi T, 2005, MOL CANCER THER, V4, P743, DOI 10.1158/1535-7163.MCT-05-0020; KORSMEYER SJ, 1992, BLOOD, V80, P879; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Maurer CA, 1998, DIGEST DIS SCI, V43, P2641, DOI 10.1023/A:1026695025990; MIYASHITA T, 1993, BLOOD, V81, P151; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Nita ME, 2000, JPN J CANCER RES, V91, P825, DOI 10.1111/j.1349-7006.2000.tb01020.x; Nita ME, 1998, BRIT J CANCER, V78, P986, DOI 10.1038/bjc.1998.617; Ogura E, 1999, ONCOL REP, V6, P365; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Panwalkar A, 2004, CANCER-AM CANCER SOC, V100, P1578, DOI 10.1002/cncr.20182; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; Rigas A, 2002, CANCER INVEST, V20, P657, DOI 10.1081/CNV-120002491; Sasaki S, 2004, JPN J CLIN ONCOL, V34, P584, DOI 10.1093/jjco/hyh106; Sasaki S, 2004, J EXP CLIN CANC RES, V23, P507; Sasaki S, 2002, ONCOGENE, V21, P5024, DOI 10.1038/sj.onc.1205627; Sasaki Shin, 2003, Nihon Rinsho, V61 Suppl 7, P242; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Sun YJ, 2002, CANCER RES, V62, P6323; Syken J, 2003, ONCOGENE, V22, P4636, DOI 10.1038/sj.onc.1206569; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Tsujimoto Y, 2000, J NEURAL TRANSM-SUPP, P41; Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146; Voboril R, 2004, J SURG RES, V120, P178, DOI 10.1016/j.jss.2003.11.023; Wang W, 2003, BRIT J CANCER, V88, P624, DOI 10.1038/sj.bjc.6600753; Wang WG, 2003, INT J CANCER, V104, P504, DOI 10.1002/ijc.10972; Yang L, 2003, CANCER RES, V63, P6815; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2003, FASEB J, V17, P790, DOI 10.1096/fj.02-0654rev	50	27	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3160	3169		10.1038/sj.onc.1209342	http://dx.doi.org/10.1038/sj.onc.1209342			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407826				2022-12-17	WOS:000237951000007
J	Abu-Amero, KK; Alzahrani, AS; Zou, M; Shi, Y				Abu-Amero, KK; Alzahrani, AS; Zou, M; Shi, Y			Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome	ONCOGENE			English	Article						mitochondria; mutation; medullary thyroid neoplasm; RET oncogene; multiple endocrine neoplasia	OXIDATIVE STRESS; CLINICAL-FEATURES; SOMATIC MUTATIONS; HIGH-FREQUENCY; RET; CANCER; REPAIR; TUMORS; GENE; ACTIVATION	Medullary thyroid carcinoma (MTC) is a malignant tumour of the calcitonin-secreting parafollicular C cells of the thyroid, and occurs sporadically or as a component of the multiple endocrine neoplasia (MEN) type 2/familial medullary thyroid carcinoma (FMTC) syndromes. In the present study, we investigated the frequency of mtDNA mutations in 26 MTC tumour specimens (13 sporadic and 13 familial MTC) and their matched normal tissues by sequencing the entire coding regions of mitochondrial genome. Nonsynonymous mutations were detected in 20 MTC samples (76.9%): nine out of 13 sporadic MTC (69.2%) and 11 out of 13 (84.6%) familial MTC/MEN2. Both transition and transversion types of mutations were found in the samples. Interestingly, 76.2% (16/21) of transversion mutations were found in FMTC/MEN2 patients, whereas 66.7% (12/18) of transition mutations were in sporadic MTC. Synonymous mutations were found in 12 MTC samples. In total, we identified 27 transversion mutations (21 nonsynonymous and six synonymous) in MTC. Of them, 22 (81.5%) were from FMTC/MEN2, and five (18.5%) were from sporadic MTC. The association of transversion mutation with familial MTC/MEN2 was statistically significant (P = 0.0015, binomial test). Majority of the mutations were involved in the genes located in the complex I of the mitochondrial genome, and were often resulting in a change of a moderately or highly conserved amino acid of their corresponding protein. Mitochondrial respiratory function was also compromised in a TT cell line, which carries mtDNA mutation at nt 4917 and 11 720, and in peripheral lymphocytes of MTC patients with mtDNA mutations. These data suggest that mtDNA mutation may be involved in MTC tumourigenesis and progression. Given that mtDNA mutation spectra are different between sporadic and familial MTC, different mechanisms of oxidative DNA damage may occur in the disease process.	King Faisal Specialist Hosp & Res Ctr, Dept Genet MBC03, Riyadh 11211, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Shi, Y (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Genet MBC03, POB 3354, Riyadh 11211, Saudi Arabia.	yufei@kfshrc.edu.sa	Alzahrani, Ali S/L-3664-2017; Shi, Yufei/ABG-5228-2020; Abu-Amero, Khaled/A-5579-2010	Alzahrani, Ali S/0000-0003-4294-3624; Shi, Yufei/0000-0002-6999-0191; 				Abu-Amero KK, 2005, ONCOGENE, V24, P1455, DOI 10.1038/sj.onc.1208292; ABUAMERO KK, 2005, ARCH PATHOL LABMED, V129, P62; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Benn DE, 2003, ONCOGENE, V22, P1358, DOI 10.1038/sj.onc.1206300; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; BOURGERON T, 1994, J CLIN INVEST, V93, P2514, DOI 10.1172/JCI117261; Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; De Vita G, 2000, CANCER RES, V60, P3727; Elisei R, 2004, J CLIN ENDOCR METAB, V89, P3579, DOI 10.1210/jc.2003-031898; Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; FARID NR, 1995, ENDOCRIN METAB CLIN, V24, P865, DOI 10.1016/S0889-8529(18)30024-0; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Girelli ME, 1998, THYROID, V8, P517, DOI 10.1089/thy.1998.8.517; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hartman P, 2004, MECH AGEING DEV, V125, P417, DOI 10.1016/j.mad.2004.02.007; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Ishii T, 2005, CANCER RES, V65, P203; Jones JB, 2001, CANCER RES, V61, P1299; Kang D, 2003, CLIN CHEM LAB MED, V41, P1281, DOI 10.1515/CCLM.2003.195; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kino K, 2005, MUTAT RES-FUND MOL M, V571, P33, DOI 10.1016/j.mrfmmm.2004.10.010; Kino K, 2001, CHEM BIOL, V8, P369, DOI 10.1016/S1074-5521(01)00019-9; Kiuru M, 2004, CURR MOL MED, V4, P869, DOI 10.2174/1566524043359638; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Kurokawa K, 2003, J INTERN MED, V253, P627, DOI 10.1046/j.1365-2796.2003.01167.x; LeDoux SP, 2001, PROG NUCLEIC ACID RE, V68, P273; Ludwig L, 2001, CANCER RES, V61, P4526; Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8; Marsh DJ, 1997, HORM RES, V47, P168, DOI 10.1159/000185461; Massoll N, 2004, CLIN LAB MED, V24, P49, DOI 10.1016/j.cll.2004.01.006; Maximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; Myers SM, 2004, CANCER RES, V64, P4453, DOI 10.1158/0008-5472.CAN-03-3605; Neeley WL, 2004, J BIOL CHEM, V279, P43568, DOI 10.1074/jbc.M407117200; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Punales MK, 2003, J CLIN ENDOCR METAB, V88, P2644, DOI 10.1210/jc.2002-021422; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Shi Y, 1999, BRIT J CANCER, V79, P1234, DOI 10.1038/sj.bjc.6690198; SHI YF, 1991, CANCER RES, V51, P2690; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Stevnsner T, 2002, EXP GERONTOL, V37, P1189, DOI 10.1016/S0531-5565(02)00142-0; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537; Zhang HX, 2004, ACTA PHARMACOL SIN, V25, P385	54	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					677	684		10.1038/sj.onc.1209094	http://dx.doi.org/10.1038/sj.onc.1209094			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16205644				2022-12-17	WOS:000235068800003
J	Maeno, K; Masuda, A; Yanagisawa, K; Konishi, H; Osada, H; Saito, T; Ueda, R; Takahashi, T				Maeno, K; Masuda, A; Yanagisawa, K; Konishi, H; Osada, H; Saito, T; Ueda, R; Takahashi, T			Altered regulation of c-jun and its involvement in anchorage-independent growth of human lung cancers	ONCOGENE			English	Article						c-jun; lung cancer; anchorage; independent growth; K-ras	BRONCHIAL EPITHELIAL-CELLS; NEOPLASTIC TRANSFORMATION; EMBRYO FIBROBLASTS; RAT-1A CELLS; TARGET GENE; RAT1A CELLS; EXPRESSION; APOPTOSIS; RAS; TRANSACTIVATION	The c-jun oncogene is frequently overexpressed in non-small-cell lung cancers (NSCLC), but its functional involvement in lung cancer development has not been clearly elucidated. In this study, we found that among the immediate-early serum responsible genes, exemplified by c-jun, c-fos and c-myc, induction of c-jun in a human bronchial epithelial cell line, BEAS-2B, was dependent on anchorage, in contrast to clear induction of c-fos and c-myc under both anchorage-dependent and - independent conditions. In fact, forced expression of c-jun in BEAS-2B cells significantly increased cell viability and colony formation in soft agar. Furthermore, we also found that such anchorage-dependent regulation of c-jun was lost in a significant fraction of human lung cancer cell lines. Interestingly, suppressed anchorage-independent but not anchorage-dependent growth was noted by constitutive expression of a dominant-negative c-jun mutant in a lung cancer cell line showing dysregulated and sustained c-jun expression in the absence of anchorage. These findings suggest that dysregulated c-jun expression may be involved in the acquisition of anchorage independence in the process of human lung carcinogenesis.	Nagoya Univ, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Grad Sch Med,Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med, Nagoya, Aichi, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol Sci, Nagoya, Aichi, Japan	Nagoya University; Aichi Cancer Center; Nagoya City University; Nagoya City University	Takahashi, T (corresponding author), Nagoya Univ, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Grad Sch Med,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tak@med.nagoya-u.ac.jp	Yanagisawa, Kiyoshi/I-7263-2014; Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Konishi, Hiroyuki/0000-0003-1131-4905				AMSTAD P, 1988, MOL CARCINOGEN, V1, P151, DOI 10.1002/mc.2940010303; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; BENEZRA JM, 1994, AM J PATHOL, V145, P1036; BROWN PH, 1993, ONCOGENE, V8, P877; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; FUJITA M, 1995, ONCOGENE, V11, P15; HIDA T, 1989, CANCER RES, V49, P4785; Hommura F, 2004, MOL CANCER RES, V2, P305; IKEGAKI N, 1994, CANCER RES, V54, P6; Katabami M, 2005, J BIOL CHEM, V280, P16728, DOI 10.1074/jbc.M413892200; Kinoshita I, 2003, ONCOGENE, V22, P2710, DOI 10.1038/sj.onc.1206371; Lu AP, 2002, J BIOL CHEM, V277, P31364, DOI 10.1074/jbc.M201060200; Masuda A, 1997, CANCER RES, V57, P4898; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Reddel R R, 1988, Oncogene Res, V3, P401; REDDEL RR, 1995, INT J CANCER, V61, P199; REDDEL RR, 1988, CANCER RES, V48, P1904; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Szabo E, 1996, CANCER RES, V56, P305; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; WODRICH W, 1993, CARCINOGENESIS, V14, P1121, DOI 10.1093/carcin/14.6.1121; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	36	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					271	277		10.1038/sj.onc.1209018	http://dx.doi.org/10.1038/sj.onc.1209018			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16158054				2022-12-17	WOS:000234583600011
J	Working, PK; Lin, A; Borellini, F				Working, PK; Lin, A; Borellini, F			Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses	ONCOGENE			English	Review						oncolytic adenovirus; product development; manufacturing	HUMAN CELL-LINE; MOLECULAR CHARACTERIZATION; E1-POSITIVE PARTICLES; TUMOR-CELLS; GM-CSF; REPLICATION; CANCER; VECTORS; AGENTS; RECOMBINATION	Oncolytic adenoviruses have been considered for use as anticancer therapy for decades, and numerous means of conferring tumor selectivity have been developed. As with any new therapy, the trip from the laboratory bench to the clinic has revealed a number of significant development hurdles. Viral therapies are subject to specific regulations and must meet a variety of well-defined criteria for purity, potency, stability, and product characterization prior to their use in the clinic. Published regulatory guidelines, although developed specifically for biotechnology-derived products, are applicable to the production of oncolytic adenoviruses and other cell-based products, and they should be consulted early during development. Most importantly, both the manufacturing process and the development of characterization and release assays should be science-driven, use the best available science and technology, and must consider the unique nature of the product: a living, and mutatable, virus. Potentially significant impacts on product quality and safety stem from the possibility of genetic instability related to overengineering the viruses ( as evidenced by their recombination and/or occasional reversion to wild-type virus during manufacturing). This report provides examples of some of the critical components affecting the development and production of clinical grade material and summarizes the significant progress made in recent years.	Cell Genesys Inc, San Francisco, CA 94080 USA	Cell Genesys Inc	Working, PK (corresponding author), Cell Genesys Inc, 500 Forbes Blvd, San Francisco, CA 94080 USA.	peter.working@cellgenesys.com						Alemany R, 1999, CANCER GENE THER, V6, P21, DOI 10.1038/sj.cgt.7700001; Alemany R, 2001, GENE THER, V8, P1347, DOI 10.1038/sj.gt.3301515; Bernt K, 2002, J VIROL, V76, P10994, DOI 10.1128/JVI.76.21.10994-11002.2002; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bristol JA, 2003, MOL THER, V7, P755, DOI 10.1016/S1525-0016(03)00103-5; Douglas JT, 1999, NAT BIOTECHNOL, V17, P470, DOI 10.1038/8647; Fallaux FJ, 1998, HUM GENE THER, V9, P1909, DOI 10.1089/hum.1998.9.13-1909; FARSON D, 2005, P AM SOC GEN THER AN; FARSON D, 2004, P AM SOC GEN THER AN; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Haviv Yosef S., 2003, Current Gene Therapy, V3, P357, DOI 10.2174/1566523034578311; Hehir KM, 1996, J VIROL, V70, P8459, DOI 10.1128/JVI.70.12.8459-8467.1996; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Hemminki A, 2001, CANCER RES, V61, P6377; Henderson D.R., 2002, ADENOVIRAL VECTORS G, P287; HENDERSON DR, 2001, REPLICATION COMPETEN, P56; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; JONES SD, 2004, PRECLINICA, V2, P301; Kirn D, 2001, GENE THER, V8, P89, DOI 10.1038/sj.gt.3301377; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Lusky M, 2005, HUM GENE THER, V16, P281, DOI 10.1089/hum.2005.16.281; Murakami P, 2004, J VIROL, V78, P6200, DOI 10.1128/JVI.78.12.6200-6208.2004; Murakami P, 2002, HUM GENE THER, V13, P909, DOI 10.1089/10430340252939023; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539; Ryan PC, 2004, CANCER GENE THER, V11, P555, DOI 10.1038/sj.cgt.7700735; SHEN Y, 2003, 12 INT C GEN THER CA; Smith JG, 1999, CANCER GENE THER, V6, P475, DOI 10.1038/sj.cgt.7700062; Suzuki K, 2001, CLIN CANCER RES, V7, P120; Wakimoto H, 2003, GENE THER, V10, P983, DOI 10.1038/sj.gt.3302038; Yu DC, 1999, CANCER RES, V59, P4200; Yu DC, 2001, CANCER RES, V61, P517; Yu DC, 2002, CURR OPIN MOL THER, V4, P435	35	27	32	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2005	24	52					7792	7801		10.1038/sj.onc.1209045	http://dx.doi.org/10.1038/sj.onc.1209045			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299538				2022-12-17	WOS:000233372600014
J	Perez-Losada, J; Wu, D; DelRosario, R; Balmain, A; Mao, JH				Perez-Losada, J; Wu, D; DelRosario, R; Balmain, A; Mao, JH			p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo	ONCOGENE			English	Article						p53; p63; p73; tumor suppressor; radiation; lymphoma	LI-FRAUMENI-SYNDROME; KINASE C-ABL; P53 HOMOLOG; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; INDUCE APOPTOSIS; TUMOR-SUPPRESSOR; TUMORIGENESIS; CARCINOMA; ONCOGENE	p53 is one of the most important tumor suppressor genes in human cancer, but the roles of its homologues p63 and p73 in tumor suppression, alone or in collaboration with p53, remains controversial. Both p63 and p73 can be deregulated after DNA damage, and induce cell cycle arrest and apoptosis, but mice carrying inactive alleles of these genes do not develop spontaneous tumors. Since heterozygous loss of p53 confers strong sensitization to radiation-induced lymphoma development, we investigated the possibility that radiation exposure may reveal previously undetected tumor suppressor properties in p63 or p73, alone or in combination with p53. Animals heterozygous for p63 or p73, as well as both double heterozygous p53/p63 or p53/p73 mice, showed no significant differences in tumor latency, spectrum or frequency after gamma-radiation, compared to their control counterparts. Deletions were found near the p63 locus on chromosome 16 in radiation-induced tumors, but these frequently included the knockout allele. No deletions or LOH involving the p73 gene were detected, and expression of both genes was maintained in the tumors. We conclude that P53 homologues do not contribute to p53 tumor suppressor activity in lymphoma development.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Balmain, A (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu; jmao@cc.ucsf.edu	Pérez-Losada, Jesús/A-5883-2019; Mao, Jian-Hua/EIZ-8595-2022	Pérez-Losada, Jesús/0000-0003-2400-624X; Mao, Jian-Hua/0000-0001-9320-6021	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gong JG, 1999, NATURE, V399, P806; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Liefer KM, 2000, CANCER RES, V60, P4016; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Park JJ, 2000, AM J SURG PATHOL, V24, P1414, DOI 10.1097/00000478-200010000-00012; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257	25	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5521	5524		10.1038/sj.onc.1208799	http://dx.doi.org/10.1038/sj.onc.1208799			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007185				2022-12-17	WOS:000231222300012
J	Li, HB; Sanchez-Torres, J; del Carpio, AF; Nogales-Gonzalez, A; Molina-Ortiz, P; Moreno, MJ; Torok, K; Villalobo, A				Li, HB; Sanchez-Torres, J; del Carpio, AF; Nogales-Gonzalez, A; Molina-Ortiz, P; Moreno, MJ; Torok, K; Villalobo, A			The adaptor Grb7 is a novel calmodulin-binding protein: functional implications of the interaction of calmodulin with Grb7	ONCOGENE			English	Article						adaptor proteins; calmodulin; calmodulin-binding proteins; Grb7; Grb10; Grb14; Mig10; angiogenesis	GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; LIGHT-CHAIN KINASE; CELL-MIGRATION; ESOPHAGEAL-CARCINOMA; LIVING CELLS; ASSOCIATION; CLONING; FAMILY; DOMAIN	We demonstrate using Ca2+-dependent calmodulin (CaM)-affinity chromatography and overlay with biotinylated CaM that the adaptor proteins growth factor receptor bound (Grb) 7 and Grb7V ( a naturally occurring variant lacking the Src homology 2 (SH2) domain) are CaM-binding proteins. Deletion of an amphiphilic basic amino-acid sequence ( residues 243 - 256) predicted to form an alpha-helix located in the proximal region of its pleckstrin homology (PH) domain demonstrates the location of the CaM-binding domain. This site is identical in human and rodents Grb7, and shares great homology with similar regions of Grb10 and Grb14, and the Mig10 protein from Caenorhabditis elegans. We show that Grb7 and Grb7V are present in the cytosol and bound to membranes, while the deletion mutants (Grb7 Delta and Grb7V Delta) have less capacity to be associated to membranes. Grb7D maintains in part the capacity to bind phosphoinositides, and CaM competes for phosphoinositide binding. Activation of ErbB2 by heregulin beta 1 decreases the pool of Grb7 associated to membranes. The cell-permeable CaM antagonist W7 (N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide), but not the CaM-dependent protein kinase II inhibitor KN93, prevents this effect. Highly specific cell-permeable CaM inhibitory peptides decrease the association of Grb7 to membranes. This suggests that CaM regulates the intracellular mobilization of Grb7 in living cells. Direct interaction between enhanced yellow fluorescent protein (EYFP)- Grb7 and enhanced cyan fluorescent protein (ECFP)-CaM chimeras at the plasma membrane of living cells was demonstrated by fluorescence resonance energy transfer ( FRET). The FRET signal dramatically decreased in cells loaded with a cell-permeable Ca2+ chelator, and was significantly attenuated when enhanced yellow fluorescent protein-Grb7 chimera (EYFP-Grb7) Delta instead of EYFP-Grb7 was used. Finally, we show that conditioned media from cells transiently transfected with Grb7 Delta and Grb7V Delta lost its angiogenic activity, in contrast to those from cells transiently transfected with their wild-type counterparts.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, E-28029 Madrid, Spain; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; St George Hosp, Sch Med, Dept Basic Med Sci, Pharmacol & Clin Pharmacol Sect, London SW17 0RE, England; Shijiazhuang Med Sch, Sci & Res Ctr, Shijiazhuang 05008, Hebei, Peoples R China	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; National Research Council Canada; St Georges University London	Villalobo, A (corresponding author), CSIC, Inst Invest Biomed, C Arturo Duperier 4, E-28029 Madrid, Spain.	antonio.villalobo@iib.uam.es	NOGALES, AITOR/AAY-1590-2020; Villalobo, Antonio/O-9621-2019; Villalobo, Antonio/K-2902-2017	NOGALES, AITOR/0000-0002-2424-7900; Villalobo, Antonio/0000-0002-4200-374X; Torok, Katalin/0000-0002-3107-4534				Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cariou B, 2004, FRONT BIOSCI-LANDMRK, V9, P1626, DOI 10.2741/1228; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Feinmesser RL, 1996, ONCOGENE, V12, P2725; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; GOLDENRING JR, 1986, PROG BRAIN RES, V69, P341; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HB, 2004, BIOCHEM J, V381, P257, DOI 10.1042/BJ20040515; Li HB, 2004, FEBS LETT, V559, P175, DOI 10.1016/S0014-5793(04)00067-5; Li HB, 2002, BIOCHEM J, V362, P499, DOI 10.1042/bj3620499; Lim MA, 2004, FRONT BIOSCI-LANDMRK, V9, P387, DOI 10.2741/1226; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Martin-Nieto J, 1998, BIOCHEMISTRY-US, V37, P227, DOI 10.1021/bi971765v; MEANS AR, 1982, ANN NY ACAD SCI, V383, P69, DOI 10.1111/j.1749-6632.1982.tb23162.x; Morrione A, 2003, J CELL PHYSIOL, V197, P307, DOI 10.1002/jcp.10363; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Riedel H, 2004, FRONT BIOSCI-LANDMRK, V9, P603, DOI 10.2741/1227; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Shen TL, 2004, FRONT BIOSCI-LANDMRK, V9, P192, DOI 10.2741/1229; Shen TL, 2002, J BIOL CHEM, V277, P29069, DOI 10.1074/jbc.M203085200; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; Thorogate R, 2004, J CELL SCI, V117, P5923, DOI 10.1242/jcs.01510; Torok K, 1998, BIOCHEMISTRY-US, V37, P6188, DOI 10.1021/bi972773e; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; Torok K, 1998, CURR BIOL, V8, P692, DOI 10.1016/S0960-9822(98)70275-1; Villalobo A, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P287; Villalobo A., 2003, CURR TOPICS BIOCH RE, V5, P105	53	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4206	4219		10.1038/sj.onc.1208591	http://dx.doi.org/10.1038/sj.onc.1208591			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806159				2022-12-17	WOS:000229815300005
J	Marcelain, K; Hayman, MJ				Marcelain, K; Hayman, MJ			The Ski oncoprotein is upregulated and localized at the centrosomes and mitotic spindle during mitosis	ONCOGENE			English	Article						ski oncoprotein; cell cycle regulation; mitosis	ANAPHASE-PROMOTING COMPLEX; ONCOGENIC PROTEIN SKI; C-SKI; CELL-CYCLE; IN-VIVO; REPRESSION; SNON; DEGRADATION; PROTEOLYSIS; EXPRESSION	Ski is an oncoprotein that represses transforming growth factor-beta and nuclear receptor signaling. Despite evidence that relates increased Ski protein levels directly with tumor progression in human cells, the signaling pathways that regulate Ski expression are mostly unidentified. Here we show that the Ski protein levels vary throughout the cell cycle, being lowest at G0/G1. This reduction in Ski protein levels results from proteosomal degradation as suggested by in vivo ubiquitination of Ski and the effects of proteosomal inhibitors. In contrast, an upregulation of the Ski protein was observed in cells going through mitosis. At this stage, we also found that Ski is phosphorylated. In vitro and in vivo data suggest that the phosphorylation of Ski in mitosis is carried out by the main kinase controlling the progression of mitosis, namely cdc2/cyclinB. Interestingly, immunofluorescence experiments, supported by biochemical data, show not only an increase in the Ski protein levels, but also a dramatic redistribution of Ski to the centrosomes and mitotic spindle throughout mitosis. Studies to date on Ski have focused on its role as a transcriptional regulator. However, Ski's increased level and specific relocalization during mitosis suggest that Ski might play a distinct role during this particular phase of the cell cycle.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu	Marcelain, Katherine/I-2791-2013	Marcelain, Katherine/0000-0003-4018-6623	NCI NIH HHS [CA42573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Blomberg-Wirschell M, 1998, METHOD ENZYMOL, V298, P228, DOI 10.1016/S0076-6879(98)98022-3; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Buess M, 2004, NEOPLASIA, V6, P207, DOI 10.1593/neo.03442; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; De Lucia F, 2001, BIOCHEM J, V358, P447, DOI 10.1042/0264-6021:3580447; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Faust M, 2002, CELL MOL LIFE SCI, V59, P2155, DOI 10.1007/s000180200022; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; GRIMES HL, 1993, ONCOGENE, V8, P2863; Hasskarl J, 2004, ONCOGENE, V23, P1930, DOI 10.1038/sj.onc.1207310; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Macdonald M, 2004, ONCOGENE, V23, P5643, DOI 10.1038/sj.onc.1207733; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; NAGASE T, 1993, J BIOL CHEM, V268, P13710; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Reed JA, 2001, CANCER RES, V61, P8074; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; Stroschein SL, 2001, GENE DEV, V15, P2822; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yang R, 1999, MOL CELL BIOL, V19, P2400	40	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4321	4329		10.1038/sj.onc.1208631	http://dx.doi.org/10.1038/sj.onc.1208631			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806149				2022-12-17	WOS:000229976900001
J	Klinger, MB; Guilbault, B; Goulding, RE; Kay, RJ				Klinger, MB; Guilbault, B; Goulding, RE; Kay, RJ			Deregulated expression of RasGRP1 initiates thymic lymphomagenesis independently of T-cell receptors	ONCOGENE			English	Article						T lymphocytes; T-cell receptors; leukemia; lymphoma	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACTIVATED RAS; TCR SIGNALS; THYMOCYTE DIFFERENTIATION; PRE-TCR; GENES; SELECTION; MATURATION; MICE; P53	RasGRP1 is a Ras-specific exchange factor, which is activated by T-cell receptor (TCR) and promotes TCR-dependent positive selection of thymocytes. RasGRP1 is highly expressed on most T lymphocytic leukemias and is a common site of proviral insertion in retrovirus-induced murine T-cell lymphomas. We used RasGRP1 transgenic mice to determine if deregulated expression of RasGRP1 has a causative role in the development of T-cell malignancies. Thymic lymphomas occurred in three different RasGRP1 transgenic mouse lines. Thymocyte transformation correlated with high transgene expression in early stage lymphomas, indicating that deregulated RasGRP1 expression contributed to the initiation of lymphomagenesis. Expression of the positively selectable H-Y TCR accelerated lymphomagenesis in RasGRP1 transgenic mice. However, the transformed thymocytes lacked markers of positive selection and lymphomas occurred when positive selection was precluded by negative selection of the H-Y TCR. Therefore, initiation of lymphomagenesis via RasGRP1 was not associated with TCR-dependent positive selection of thymocytes. Thymic lymphomas occurred in RasGRP1 transgenic/ Rag2(-/-) mice, demonstrating that neither TCR nor pre-TCR were required for RasGRP1-driven lymphomagenesis. The RasGRP1 transgene conferred pre-TCR-independent survival and proliferation of immature thymocytes, suggesting that deregulated expression of RasGRP1 promotes lymphomagenesis by expanding the pool of thymocytes which are susceptible to transformation.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of British Columbia	Kay, RJ (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	rkay@bccrc.ca						Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; AHUJA HG, 1990, BLOOD, V75, P1684; Anderson G, 1999, IMMUNOL TODAY, V20, P463, DOI 10.1016/S0167-5699(99)01524-8; Asnafi V, 2003, BLOOD, V101, P2693, DOI 10.1182/blood-2002-08-2438; Azzam HS, 1998, J EXP MED, V188, P2301, DOI 10.1084/jem.188.12.2301; BIVONA TG, 2003, NATURE, V29, P29; Bruno L, 1996, IMMUNITY, V5, P343, DOI 10.1016/S1074-7613(00)80260-5; Cleverley SC, 2000, ONCOGENE, V19, P13, DOI 10.1038/sj.onc.1203259; Curtis DJ, 1997, ONCOGENE, V15, P2975, DOI 10.1038/sj.onc.1201467; Dailey MO, 1998, CRIT REV IMMUNOL, V18, P153, DOI 10.1615/CritRevImmunol.v18.i3.10; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; Ebinu JO, 2000, BLOOD, V95, P3199; EGERTON M, 1990, INT IMMUNOL, V2, P501, DOI 10.1093/intimm/2.6.501; Erman B, 2002, NAT IMMUNOL, V3, P564, DOI 10.1038/ni800; HAWLEY RG, 1995, ONCOGENE, V11, P1113; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Iritani BM, 1999, IMMUNITY, V10, P713, DOI 10.1016/S1074-7613(00)80070-9; Kawamura M, 1999, LEUKEMIA RES, V23, P115, DOI 10.1016/S0145-2126(98)00146-5; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kruisbeek AM, 2000, IMMUNOL TODAY, V21, P637, DOI 10.1016/S0167-5699(00)01744-8; Layer K, 2003, IMMUNITY, V19, P243, DOI 10.1016/S1074-7613(03)00209-7; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; Norment AM, 2003, J IMMUNOL, V170, P1141, DOI 10.4049/jimmunol.170.3.1141; Ong ST, 2003, CELL IMMUNOL, V221, P64, DOI 10.1016/S0008-8749(03)00065-0; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; Terrence K, 2000, J EXP MED, V192, P537, DOI 10.1084/jem.192.4.537; von Boehmer H, 2003, IMMUNOL REV, V191, P62, DOI 10.1034/j.1600-065X.2003.00010.x; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yokota S, 1998, INT J HEMATOL, V67, P379	37	27	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2695	2704		10.1038/sj.onc.1208334	http://dx.doi.org/10.1038/sj.onc.1208334			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829980				2022-12-17	WOS:000228356700011
J	Joshi, B; Ordonez-Ercan, D; Dasgupta, P; Chellappan, S				Joshi, B; Ordonez-Ercan, D; Dasgupta, P; Chellappan, S			Induction of human metallothionein 1G promoter by VEGF and heavy metals: differential involvement of E2F and metal transcription factors	ONCOGENE			English	Article						VEGF; metallothionein; E2F1; MTF-1; MRE	GENE-EXPRESSION; HISTONE DEACETYLASE; FACTOR-I; TRANSGENIC MICE; FACTOR MTF-1; CELL-LINES; REPRESSES TRANSCRIPTION; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; OXIDATIVE STRESS	The E2F transcription factors induce the expression of many genes in response to specific extracellular stimuli. Here, we show that human metallothionein 1G (hMT1G) promoter is upregulated by E2F1 upon VEGF stimulation of human aortic endothelial cells. Analysis of the hMT1G promoter showed the presence of many potential E2F-binding sites flanked by potential SP1 sites and metal response elements (MREs). hMT1G promoter could be induced by E2F1 in transient transfections; further, deletion analysis suggested that the region spanning the E2F-binding sites was necessary for VEGF-mediated induction. E2Fs 1-5 could bind to the hMT1G promoter in a chromatin immunoprecipitation assay. VEGF stimulation led to an increased binding of E2Fs 1-3 to the endogenous hMT1G promoter; at the same time, the binding of Rb, p107 and p130 to the promoter was abolished. VEGF stimulation also led to the increased acetylation E2F1 as well as the histones in the hMT1G promoter region. Stimulation with metals or VEGF led to dissociation of histone deacetylase 1 (HDAC1) from the promoter, leading to acetylation of histones. Induction of the hMT1G promoter upon exposure to heavy metals such as Zn and Cd is mediated by the MRE. Interestingly, mutation of MRE affected the metal response, but not the VEGF response of the hMT1G promoter. In contrast, deletion of the E2F-binding sites did not affect the metal response. Based on these findings, we conclude that induction of the hMT1G promoter by VEGF and heavy metals occurs through the utilization of different transcription factors.	H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Chellappan, S (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	chellasp@moffitt.usf.edu			NCI NIH HHS [CA63136] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; Benjamin D, 2001, NUCLEIC ACIDS RES, V29, P3603, DOI 10.1093/nar/29.17.3603; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Boccellino M, 2002, LIPIDS, V37, P1047, DOI 10.1007/s11745-002-0999-7; Brehm A, 1999, BRIT J CANCER, V80, P38; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Butler RA, 2001, TOXICOL SCI, V59, P101, DOI 10.1093/toxsci/59.1.101; Cai L, 1998, ANTICANCER RES, V18, P4667; Chaya D, 2001, J BIOL CHEM, V276, P44385, DOI 10.1074/jbc.M108214200; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Favot L, 2003, CARDIOVASC RES, V59, P479, DOI 10.1016/S0008-6363(03)00433-4; Friedline JA, 1998, AM J PATHOL, V152, P23; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Ghoshal K, 1998, J BIOL CHEM, V273, P27904, DOI 10.1074/jbc.273.43.27904; Ghoshal K, 2002, METHOD ENZYMOL, V353, P476; Ghoshal K, 2001, MOL CELL BIOL, V21, P8301, DOI 10.1128/MCB.21.24.8301-8317.2001; Gui CY, 2001, MOL CELL BIOL, V21, P1155, DOI 10.1128/MCB.21.4.1155-1163.2001; Hellemans G, 1999, NEPHRON, V83, P331, DOI 10.1159/000045425; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jacob ST, 1999, GENE EXPRESSION, V7, P301; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KAGI JHR, 1960, J BIOL CHEM, V235, P3460; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kelly EJ, 1996, J NUTR, V126, P1782; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KOJIMA Y, 1991, METHOD ENZYMOL, V205, P419; Kondo Y, 1997, MOL PHARMACOL, V52, P195, DOI 10.1124/mol.52.2.195; LaRochelle O, 2001, BIOCHEM J, V353, P591, DOI 10.1042/0264-6021:3530591; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee DK, 1999, BIOCHEM J, V337, P59, DOI 10.1042/0264-6021:3370059; Levadoux-Martin M, 2001, BIOCHEM J, V355, P473, DOI 10.1042/0264-6021:3550473; Lichtlen P, 2001, SWISS MED WKLY, V131, P647; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584; Majumder S, 1999, ONCOGENE, V18, P6287, DOI 10.1038/sj.onc.1203004; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; Mididoddi S, 1996, TOXICOL LETT, V85, P17, DOI 10.1016/0378-4274(96)03632-6; Moffatt P, 1997, DRUG METAB REV, V29, P261, DOI 10.3109/03602539709037585; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nguyen A, 2000, CANCER LETT, V160, P133, DOI 10.1016/S0304-3835(00)00534-6; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Searle P F, 1987, Experientia Suppl, V52, P407; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; Somji S, 2001, CANCER DETECT PREV, V25, P62; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Wang S, 1999, MOL CELL BIOL, V19, P7447; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	80	27	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2204	2217		10.1038/sj.onc.1208206	http://dx.doi.org/10.1038/sj.onc.1208206			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735762				2022-12-17	WOS:000227857900008
J	Rocchi, P; Muracciole, X; Fina, F; Mulholland, DJ; Karsenty, G; Palmari, J; Ouafik, L; Bladou, F; Martin, PM				Rocchi, P; Muracciole, X; Fina, F; Mulholland, DJ; Karsenty, G; Palmari, J; Ouafik, L; Bladou, F; Martin, PM			Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft	ONCOGENE			English	Article						prostate cancer; androgen-independence; molecular expression analysis; LuCaP 23.1 xenograft	HUMAN-PROSTATE-CANCER; EPIDERMAL-GROWTH-FACTOR; CELL-LINES; RECEPTOR GENE; PLASMINOGEN-ACTIVATOR; FACTOR-ALPHA; TUMOR-MODEL; IN-VIVO; EXPRESSION; CASTRATION	After therapeutic hormone deprivation, most prostate cancer (PrCa) cells develop androgen-independent (AI) growth. PrCa is highly heterogeneous and multifocal, suggesting that several molecular processes or pathways may be contributing to AI. The human LuCaP 23.1 xenograft model retains clinical hallmarks of PrCa, including heterogeneous growth, PSA production, androgen-responsiveness and progression to AI. In this work, we studied the effect of androgen depletion (castration) on the growth of LuCaP 23.1 xenografts. A total of 100 nude mice were implanted and analysed for their growth profiles before and after castration. By 11 and 15 weeks, tumours were harvested and assessed for molecular marker expression specific for PrCa. Prior to castration we found 37 fast growing (FG) tumours (948.9 +/- 76.9 mm(3)) and 63 slow growing (SG) tumours (229.6 +/- 18.4 mm(3)), a previously undescribed result for this PrCa model. Quantitative RT-PCR showed that in comparison to SGs, FGs contained high HER1, uPA and thymidilate synthetase (TS) expression with low levels of 5alpha-reductase 2 mRNA. All FG tumours progressed rapidly to AI growth 5 weeks after castration (FG-P). In SG castrated tumours, 66% of tumours (SG-P) showed retarded progression (by 12 weeks) to AI, whereas 34% responded to castration (SG-R). Molecular analysis permitted us to define distinct molecular profiles integrating different pathways associated with AI progression. FG-P, and a subgroup of SG-P tumours, presented significantly high levels of peptidylglycine alpha-amidating monooxygenase (PAM), HER1, HER2, TS, and uPA mRNA, all of which correlated with AR expression. The second subgroup of SG-P tumours showed overexpression of the antiapoptotic gene Bcl-2. A third subgroup of SG-P tumours showed significant expression of hypoxia-related gene (adrenomedullin) after castration. This work permitted to define distinct molecular profiles related to different AI growth in the LuCaP 23.1 xenograft.	Fac Med Marseille, IFR Jean Roche, APHM,Lab Transfert Oncol Biol, Lab Cancerol Expt EMI 0359, Marseille, France; CHU Timone, APHM, Marseille, France; Hop Salvator, APHM, Serv Urol, Marseille, France; Jack Bell Res Ctr, Prostate Ctr, Vancouver, BC, Canada	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of British Columbia	Rocchi, P (corresponding author), Fac Med Marseille, IFR Jean Roche, APHM,Lab Transfert Oncol Biol, Lab Cancerol Expt EMI 0359, Marseille, France.	procchi@vanhosp.bc.ca	Muracciole, Xavier/P-5640-2016; Rocchi, Palma/P-5455-2014	Rocchi, Palma/0000-0002-4383-4684; Ouafik, L'Houcine/0000-0002-4848-1232; Karsenty, Gilles/0000-0002-9047-3332				Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Bladou F, 1996, INT J CANCER, V67, P785, DOI 10.1002/(SICI)1097-0215(19960917)67:6<785::AID-IJC6>3.0.CO;2-N; Buttyan R, 2000, Curr Opin Urol, V10, P415, DOI 10.1097/00042307-200009000-00009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Dahiya R, 1996, UROLOGY, V48, P963, DOI 10.1016/S0090-4295(96)00376-7; Delos S, 1998, INT J CANCER, V75, P840; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; Ellis WJ, 1996, CLIN CANCER RES, V2, P1039; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; GAYLIS FD, 1989, J UROLOGY, V142, P193, DOI 10.1016/S0022-5347(17)38709-8; Gleave M, 1999, CLIN CANCER RES, V5, P2891; Helenius MA, 2001, CANCER RES, V61, P5340; HOLLAS W, 1992, THROMB HAEMOSTASIS, V68, P662; Huss WJ, 2001, CANCER RES, V61, P2736; JANIK P, 1975, CANCER RES, V35, P3698; Jenster G, 1999, SEMIN ONCOL, V26, P407; Joliffe I T, 1992, Stat Methods Med Res, V1, P69, DOI 10.1177/096228029200100105; Koivisto P, 1997, CANCER RES, V57, P314; LANDSTROM M, 1994, CANCER RES, V54, P4281; Liu AY, 1996, INT J CANCER, V65, P85, DOI 10.1002/(SICI)1097-0215(19960103)65:1<85::AID-IJC15>3.3.CO;2-E; LYON PB, 1995, PROSTATE, V27, P179, DOI 10.1002/pros.2990270402; McGowen R, 2000, CANCER RES, V60, P4771; McLeod DG, 2003, UROLOGY, V61, P3, DOI 10.1016/S0090-4295(02)02393-2; Miyake H, 1999, CANCER RES, V59, P4030; Negri-Cesi P, 1999, PROSTATE, V41, P224, DOI 10.1002/(SICI)1097-0045(19991201)41:4<224::AID-PROS2>3.0.CO;2-Q; Nelson JB, 2000, CANCER INVEST, V18, P87, DOI 10.3109/07357900009023066; Nelson JB, 2000, BJU INT, V85, P45, DOI 10.1046/j.1464-410X.2000.00063.x; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Rocchi P, 2001, CANCER RES, V61, P1196; Ross RK, 1998, CANCER RES, V58, P4497; Scher HI, 1995, CLIN CANCER RES, V1, P545; Scher HI, 2000, J NATL CANCER I, V92, P1866, DOI 10.1093/jnci/92.23.1866; Solit DB, 2002, CLIN CANCER RES, V8, P986; TURKERI LN, 1994, PROSTATE, V25, P199, DOI 10.1002/pros.2990250405; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wen Y, 2000, CANCER RES, V60, P6841; Xing RHM, 1999, ENDOCRINOLOGY, V140, P4056, DOI 10.1210/en.140.9.4056; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zhang LQ, 2003, CANCER RES, V63, P4552; Zudaire E, 2003, REGUL PEPTIDES, V112, P175, DOI 10.1016/S0167-0115(03)00037-5	43	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	2004	23	56					9111	9119		10.1038/sj.onc.1208154	http://dx.doi.org/10.1038/sj.onc.1208154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489889				2022-12-17	WOS:000225492800012
J	Tang, SH; Bhatia, B; Zhou, JJ; Maldonado, CJ; Chandra, D; Kim, E; Fischer, SM; Butler, AP; Friedman, SL; Tang, DG				Tang, SH; Bhatia, B; Zhou, JJ; Maldonado, CJ; Chandra, D; Kim, E; Fischer, SM; Butler, AP; Friedman, SL; Tang, DG			Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells	ONCOGENE			English	Article						15-lipoxygenase 2; gene expression; Sp1; Sp3; prostate cancer; gene regulation	TRANSCRIPTION FACTORS; HISTONE DEACETYLASE; CANCER CELLS; PROMOTER; ACTIVATION; FAMILY; IDENTIFICATION	In this project, we studied the gene regulation of 15-lipoxygenase 2 (15-LOX2), the most abundant arachidonate-metabolizing LOX in adult human prostate and a negative cell-cycle regulator in normal human prostate (NHP) epithelial cells. Through detailed in silico promoter examination and promoter deletion and activity analysis, we found that several Sp1 sites (i.e., three GC boxes and one CACCC box) in the proximal promoter region play a critical role in regulating 15-LOX2 expression in NHP cells. Several pieces of evidence further suggest that the Sp1 and Sp3 proteins play a physiologically important role in positively and negatively regulating the 15-LOX2 gene expression, respectively. First, mutations in the GC boxes affected the 15-LOX2 promoter activity. Second, both Sp1 and Sp3 proteins were detected in the protein complexes that bound the GC boxes revealed by electrophoretic mobility shift assay. Third, importantly, inhibition of Sp1 activity or overexpression of Sp3 both inhibited the endogenous 15-LOX2 mRNA expression. Since 15-LOX2 is normally expressed in the prostate luminal epithelial cells, we subsequently explored whether androgen/androgen receptor may directly regulate its gene expression. The results indicate that androgen does not directly regulate 15-LOX2 gene expression. Together, these observations provide insight on how 15-LOX2 gene expression may be regulated in NHP cells.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; CUNY Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA	University of Texas System; UTMD Anderson Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, 1808 Pk R 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NATIONAL CANCER INSTITUTE [T32CA009480, R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09480-16, R01 CA90297] Funding Source: Medline; NIDDK NIH HHS [R01 DK 37340] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chopra DP, 1996, J CELL PHYSIOL, V169, P269, DOI 10.1002/(SICI)1097-4652(199611)169:2<269::AID-JCP6>3.0.CO;2-M; Frith MC, 2001, BIOINFORMATICS, V17, P878, DOI 10.1093/bioinformatics/17.10.878; Garcia-Ruiz I, 2002, J BIOL CHEM, V277, P30551, DOI 10.1074/jbc.M203368200; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kaluz S, 2003, CANCER RES, V63, P917; Kelavkar U, 1998, MOL BIOL REP, V25, P173, DOI 10.1023/A:1006813009006; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kritzik MR, 1997, BBA-GENE STRUCT EXPR, V1352, P267, DOI 10.1016/S0167-4781(97)00005-5; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; Sambrook JF, 2001, MOL CLONING LAB MANU, V1-3; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; STRACHAN T, 2000, HUM MOL GENET, P169; Tang DG, 1998, CANCER RES, V58, P3466; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698	34	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6942	6953		10.1038/sj.onc.1207913	http://dx.doi.org/10.1038/sj.onc.1207913			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15247906				2022-12-17	WOS:000223750700011
J	Simone, C; Stiegler, P; Forcales, SV; Bagella, L; De Luca, A; Sartorelli, V; Giordano, A; Puri, AL				Simone, C; Stiegler, P; Forcales, SV; Bagella, L; De Luca, A; Sartorelli, V; Giordano, A; Puri, AL			Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300	ONCOGENE			English	Article						deacetylases; acetyltransferases; p300; HDAC; transcription	HISTONE DEACETYLASE; TRANSCRIPTIONAL CONTROL; DNA-BINDING; PROTEINS; MUSCLE; MYOD; CBP; ACETYLATION; PCAF; CHROMATIN	The balance between acetylation and deacetylation of histone and nonhistone proteins controls gene expression in a variety of cellular processes, with transcription being activated by acetyltransferases and silenced by deacetylases. W e report here the formation and enzymatic characterization of a complex between the acetyltransferase p300 and histone deacetylases. The C/ H3 region of p300 was found to co- purify deacetylase activity from nuclear cell extracts. A prototype of class I histone deacetylases, HDAC1, interacts with p300 C/ H3 domain in vitro and in vivo. The p300- binding protein E1A competes with HDAC1 for C/ H3 binding; and, like E1A, HDAC1 overexpression interferes with either activation of Gal4p300 fusion protein or p300- dependent co- activation of two C/ H3- binding proteins, MyoD and p53. The exposure to deacetylase inhibitors could reverse the dominant- negative effect of a C/ H3 fragment insulated from the rest of the molecule, on MyoD- and p53-dependent transcription, whereas inhibition by E1A was resistant to trichostatin A. The se data support the hypothesis that association between acetyltransferases and deacetylases can control the expression of genes implicated in cellular growth and differentiation, and suggest that the dominant- negative effect of the p300 C/ H3 fragment relies on deacetylase recruitment.	Univ Roma La Sapienza, Fdn A Cesalpino, DTI, Gene Express Lab, Rome, Italy; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92093 USA; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; IRCCS Neuromed, I-86077 Pozzilli, IS, Italy; NIAMS, Muscle Biol Lab, Muscle Gene Express Grp, NIH, Bethesda, MD 20892 USA	Sapienza University Rome; Salk Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; IRCCS Neuromed; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Puri, AL (corresponding author), Univ Roma La Sapienza, Fdn A Cesalpino, DTI, Gene Express Lab, Rome, Italy.	plorenzo@salk.edu	Forcales, Sonia/AAU-8996-2020; Giordano, Antonio/F-1927-2010; De Luca, Antonio/AAD-9562-2020; Forcales, Sonia-V./B-2157-2013; Simone, Cristiano/K-3452-2018	Forcales, Sonia/0000-0002-7111-4959; Giordano, Antonio/0000-0002-5959-016X; De Luca, Antonio/0000-0002-3905-6154; Forcales, Sonia-V./0000-0002-7111-4959; Simone, Cristiano/0000-0002-2628-7658; BAGELLA, Luigi/0000-0003-2815-037X; Puri, Pier Lorenzo/0000-0003-4964-0095; Sartorelli, Vittorio/0000-0002-9284-3675	Telethon [GFP01009] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041125] Funding Source: NIH RePORTER	Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, J CELL SCI, V114, P2363; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; COSTANZO A, 2002, MOL CELL, V8, P1243; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goodman RH, 2000, GENE DEV, V14, P1553; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; KOUZARIDES T, 2000, EMBO J, V21, P2383; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Newman BL, 2002, GENETICS, V162, P1675; O'Connor MJ, 1999, J VIROL, V73, P3574; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SATORELLI V, 2001, FRONT BIOSCI, V6, pD1024; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stiegler P, 1998, CANCER RES, V58, P5049; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	64	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2177	2187		10.1038/sj.onc.1207327	http://dx.doi.org/10.1038/sj.onc.1207327			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14968110				2022-12-17	WOS:000220280900007
J	Sheahan, S; Bellamy, COC; Treanor, L; Harrison, DJ; Prost, S				Sheahan, S; Bellamy, COC; Treanor, L; Harrison, DJ; Prost, S			Additive effect of p53, p21 and Rb deletion in triple knockout primary hepatocytes	ONCOGENE			English	Article						polyploidy; proliferation; liver; carcinogenesis; regeneration	KINASE INHIBITOR P21; CELL-CYCLE; INDUCED APOPTOSIS; GENE-EXPRESSION; INDUCTION; GROWTH; POLYPLOIDY; PATHWAY; ROLES; MICE	Using Cre-Lox technology to inducibly delete Rb from wild-type, p21- and/or p53-deficient primary hepatocytes, we investigated the role of p53, p21 and pRb in the regulation of liver cell proliferation, polyploidization and death. These cellular decisions are critical to maintaining liver cell replacement in disease, and in determining the likelihood of carcinogenesis in chronic liver injury. Clearly, the present study shows a complex interplay between p53, p21 and pRb, which regulates the likelihood of hepatocytes stimulated from quiescence, to proliferate, undergo polyploidy or die. It reveals that these proteins act both in concert and independently, demonstrating that a small set of key cellular players is common to diverse cell decisions of fundamental importance to disease.	Univ Edinburgh, Sch Mol & Clin Med, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Prost, S (corresponding author), Univ Edinburgh, Sch Mol & Clin Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	s.prost@ed.ac.uk		harrison, david/0000-0001-9041-9988; prost, sandrine/0000-0002-0140-7115				Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; Goke R, 2001, DIGESTION, V64, P75, DOI 10.1159/000048843; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; NURSE P, 1991, NATURE, V354, P356, DOI 10.1038/354356a0; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Prost S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e80; PURDIE CA, 1994, ONCOGENE, V9, P603; RENTON KW, 1978, MOL PHARMACOL, V14, P672; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vooijs M, 2002, CANCER RES, V62, P1862; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829	56	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1489	1497		10.1038/sj.onc.1207280	http://dx.doi.org/10.1038/sj.onc.1207280			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14647424				2022-12-17	WOS:000189219500001
J	Zhao, LY; Liu, Y; Bertos, NR; Yang, XJ; Liao, DQ				Zhao, LY; Liu, Y; Bertos, NR; Yang, XJ; Liao, DQ			PCAF is a coactivator for p73-mediated transactivation	ONCOGENE			English	Article						transcription coactivator; PCAF; p73; tumor suppressor; acetyltransferase; protein-protein interaction	P53 HOMOLOG P73; KINASE C-ABL; DNA-DAMAGE; INDUCE APOPTOSIS; TRANSCRIPTIONAL ACTIVITIES; P53-RELATED PROTEIN; TUMOR-SUPPRESSOR; BINDING-PROTEIN; TERMINAL DOMAIN; TARGET GENES	The tumor suppressor p53-related p73 shares significant amino-acid sequence identity with p53. Like p53, p73 recognizes canonical p53 DNA-binding sites and activates p53-responsive target genes and induces apoptosis. Moreover, transcription coactivator p300/CBP binds to and coactivates with both p53 and p73 in stimulating the expression of their target genes. Here, we report that coactivator PCAF binds to p73. The N-terminal transactivation domain (TAD) and the conserved oligomerization domain (OD) of p73 are both required for its interaction with PCAF. Conversely, PCAF's HAT-domain is required for and both the N-terminal region and Bromo domain enhance binding of PCAF to p73. Significantly, PCAF stimulates p73-mediated transactivation, and binding of PCAF to p73 is necessary for p73's transactivation activity. PCAF-specific siRNA dramatically reduces p73-mediated transactivation. Stimulation of p73-mediated transactivation by PCAF requires the HAT domain of PCAF and the p53-binding site within the p21 promoter. In vivo, coexpression of wild-type, but not HAT-deficient PCAF with p73beta markedly increases p21 expression. Furthermore, cotransfection of PCAF and p73 leads to increased apoptosis and reduced colony formation. Collectively, these data suggest that p73 recruit PCAF to specific promoters to activate the transcription of p73 target genes.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Sherbrooke, Fac Med, Dept Microbiol & Infect Dis, Sherbrooke, PQ, Canada; McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ, Canada; Univ Florida, UF Shands Canc Ctr, Gainesville, FL USA	State University System of Florida; University of Florida; University of Sherbrooke; McGill University; State University System of Florida; University of Florida	Liao, DQ (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Arch Rd, Gainesville, FL 32610 USA.		Liao, Daiqing/A-8941-2008		NATIONAL CANCER INSTITUTE [R01CA092236] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA92236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gong JG, 1999, NATURE, V399, P806; Gu JJ, 2001, ONCOGENE, V20, P3519, DOI 10.1038/sj.onc.1204454; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harton JA, 2001, J BIOL CHEM, V276, P38715, DOI 10.1074/jbc.M106652200; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; James P, 1996, GENETICS, V144, P1425; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Ozaki T, 1999, CANCER RES, V59, P5902; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Prabhu NS, 1998, INT J ONCOL, V13, P5; Prives C, 1999, J PATHOL, V187, P112; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SCHILTZ RL, 2000, BIOCHIM BIOPHYS ACTA, V1470, P37; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takada N, 1999, CANCER RES, V59, P2810; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Ueda Y, 2001, BIOCHEM J, V356, P859, DOI 10.1042/0264-6021:3560859; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 2001, J BIOL CHEM, V276, P48, DOI 10.1074/jbc.C000722200; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 2001, ONCOGENE, V20, P4050, DOI 10.1038/sj.onc.1204516; Zhu JH, 1998, CANCER RES, V58, P5061	63	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8316	8329		10.1038/sj.onc.1206916	http://dx.doi.org/10.1038/sj.onc.1206916			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614455				2022-12-17	WOS:000186541500010
J	Discenza, MT; He, SJ; Lee, TH; Chu, LL; Bolon, B; Goodyer, P; Eccles, M; Pelletier, J				Discenza, MT; He, SJ; Lee, TH; Chu, LL; Bolon, B; Goodyer, P; Eccles, M; Pelletier, J			WT1 is a modifier of the Pax2 mutant phenotype: cooperation and interaction between WT1 and Pax2	ONCOGENE			English	Article						WT1; Pax2; kidney development; protein-protein interactions	TUMOR SUPPRESSOR GENE; WILMS-TUMOR; KIDNEY DEVELOPMENT; UROGENITAL DEVELOPMENT; EXPRESSION; RECEPTOR; REPRESSION; INHIBITION; MUTATIONS; FAMILY	Metanephric kidney development requires an inductive interaction between the ureteric bud and progenitor mesenchyme, where the early expression of two genes, Wilms' tumour 1 (WT1) and paired box 2 (Pax2), establishes critical but unknown developmental pathways. Indeed, transgenic mice with deregulated overexpression of Pax2 exhibit structural kidney defects and impaired renal function, as do mice harboring targeted disruptions and/or spontaneous mutations of either the Pax2 or WT1 genes. WT1 and Pax2 are thought to regulate each other's expression during renal development. To better de. ne the relationship between WT1 and Pax2, we generated mouse embryos containing heterozygous mutations in both genes. WT1(+/-)/Pax2(1Neu/+) kidneys were 50% smaller than wildtype kidneys. They were characterized by severe attenuation of the renal medulla, and reduced development of calyces and the renal pelvis. Renal cortex development in compound heterozygotes culminated in fewer nephrons than in WT1(+/-), Pax2(1Neu/+) or wild-type mice. Only minor variations in the mesenchymal expression pattern of Pax2 protein, and the mRNA expression levels of Pax2 and WT1, were noted in mutant kidneys. We show that WT1 and Pax2 proteins interact in vitro and in vivo, demonstrating that WT1 and Pax2 can form a molecular complex. Our data suggest that WT1 is a modifier of the Pax2 mutant phenotype.	Univ Otago, Dept Pathol, Dunedin 9015, New Zealand; McGill Univ, Dept Biochem, Montreal, PQ, Canada; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ, Canada	University of Otago; McGill University; Amgen; McGill University; McGill University	Eccles, M (corresponding author), Univ Otago, Dept Pathol, Hercus Bldg,Hanover St,POB 913, Dunedin 9015, New Zealand.		Lee, Tae Ho/AAT-1721-2020					Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Dehbi M, 1996, ONCOGENE, V13, P447; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Eccles MR, 1998, PEDIATR NEPHROL, V12, P712, DOI 10.1007/s004670050533; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EVERS P, 1994, J HISTOCHEM CYTOCHEM, V42, P1555, DOI 10.1177/42.12.7983356; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; GNARRA JR, 1995, CANCER RES, V55, P4092; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Kim J, 2000, FEBS LETT, V474, P121, DOI 10.1016/S0014-5793(00)01590-8; Kreidberg JA, 1999, MOL REPROD DEV, V52, P366, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;366::AID-MRD5&gt;3.0.CO;2-Y; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee TH, 2002, J BIOL CHEM, V277, P44826, DOI 10.1074/jbc.M205667200; Lee TH, 2001, PHYSIOL GENOMICS, V7, P187, DOI 10.1152/physiolgenomics.00046.2001; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; McConnell MJ, 1997, ONCOGENE, V14, P2689, DOI 10.1038/sj.onc.1201114; Moore AW, 1999, DEVELOPMENT, V126, P1845; MURATOVSKA A, 2003, IN PRESS ONCOGENE; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Torres M, 1995, DEVELOPMENT, V121, P4057; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1995, INT J BIOCHEM CELL B, V27, P987, DOI 10.1016/1357-2725(95)00074-Y; Wheat W, 1999, MOL CELL BIOL, V19, P2231	39	27	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8145	8155		10.1038/sj.onc.1206997	http://dx.doi.org/10.1038/sj.onc.1206997			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603255				2022-12-17	WOS:000186403400009
J	Kawasaki, H; Komai, K; Nakamura, M; Yamamoto, E; Ouyang, ZF; Nakashima, T; Morisawa, T; Hashiramoto, A; Shiozawa, K; Ishikawa, H; Kurosaka, M; Shiozawa, S				Kawasaki, H; Komai, K; Nakamura, M; Yamamoto, E; Ouyang, ZF; Nakashima, T; Morisawa, T; Hashiramoto, A; Shiozawa, K; Ishikawa, H; Kurosaka, M; Shiozawa, S			Human wee1 kinase is directly transactivated by and increased in association with c-Fos/AP-1: rheumatoid synovial cells overexpressing these genes go into aberrant mitosis	ONCOGENE			English	Article						c-Fos; AP-1; wee1; rheumatoid arthritis; tumor-like characteristic	C-FOS; PROTEIN-KINASE; CYCLIN-B; ARTHRITIS; EXPRESSION; P34CDC2; PHASE; PHOSPHORYLATION; PROLIFERATION; INFLAMMATION	Wee1 kinase downregulates the M-phase promoting factor, a complex of cdc2 and cyclin B kinase, that controls mitotic cell division. We isolated human wee1 kinase gene promoter and found that it contained one AP-1-binding motif in its promoter region (5'-CGAGTCA-3'; -823/-817), through which wee1 kinase gene was directly transactivated by c-Fos/AP-1. In rheumatoid synovial cells, wee1 kinase was increased in conjunction with the increase of c-Fos/AP-1 and the substrate of wee1, cdc2, was phosphorylated. The amount of wee1 and c-Fos and the phosphorylation of cdc2 were decreased after treatment of the cells with an inhibitor of AP-1, curcumin. A significant proportion of cultured synovial cells of the patients with rheumatoid arthritis, but not those of osteoarthritis, shifted to a tetraploid (4C) state upon long-term culture. Thus, human wee1 kinase gene is directly transactivated by and increased in association with c-Fos/AP-1, and rheumatoid synovial cells over-expressing these genes go into aberrant mitosis.	Kobe Univ, FHS Sch Med, Dept Rheumatol, Suma Ku, Kobe, Hyogo 6540142, Japan; Kobe Univ Hosp, Div Rheumat Dis, Kobe, Hyogo 6500017, Japan; Konan Kakogawa Hosp, Dept Rheumatol, Kakogawa 6758545, Japan; Kobe Univ Hosp, Dept Orthoped Surg, Kobe, Hyogo 6500017, Japan	Kobe University; Kobe University; Kobe University	Shiozawa, S (corresponding author), Kobe Univ, FHS Sch Med, Dept Rheumatol, Suma Ku, 7-10-2 Tomogaoka, Kobe, Hyogo 6540142, Japan.		Komai, Koichiro/L-1633-2019; Shiozawa, Shunichi/W-2992-2019	Komai, Koichiro/0000-0003-0015-5283; 				AICHER WK, 1994, J IMMUNOL, V152, P5940; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Asahara H, 1997, ARTHRITIS RHEUM, V40, P912, DOI 10.1002/art.1780400520; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Fassbender HG, 1998, ARCH ORTHOP TRAUM SU, V117, P2, DOI 10.1007/BF00703430; FASSBENDER HG, 1984, ARTHRITIS RHEUM, V27, P956, DOI 10.1002/art.1780270819; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HINO K, 1995, ARTHRITIS RHEUM-US, V38, P678, DOI 10.1002/art.1780380516; HUNG TS, 1995, CANC LETT, V96, P1; Jacobs RA, 1995, CLIN EXP RHEUMATOL, V13, P717; KAKER SS, 1994, CANC LETT, V87, P85; Kawasaki H, 1999, INT IMMUNOL, V11, P1873, DOI 10.1093/intimm/11.12.1873; Kawasaki H, 2001, EMBO J, V20, P4618, DOI 10.1093/emboj/20.16.4618; KUROKI Y, 1993, J RHEUMATOL, V20, P422; KUROKI Y, 1994, CLIN EXP IMMUNOL, V95, P536; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; Pope RM, 1999, CLIN IMMUNOL, V91, P271, DOI 10.1006/clim.1999.4723; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Schaser K, 1996, Verh Dtsch Ges Pathol, V80, P276; Secchiero P, 1998, BLOOD, V92, P1685, DOI 10.1182/blood.V92.5.1685.417k30_1685_1696; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHIOZAWA S, 1983, ARTHRITIS RHEUM-US, V26, P472, DOI 10.1002/art.1780260404; SHIOZAWA S, 1992, J IMMUNOL, V148, P3100; Shiozawa S, 1997, J CLIN INVEST, V99, P1210, DOI 10.1172/JCI119277; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TRABANDT A, 1992, RHEUMATOL INT, V12, P53, DOI 10.1007/BF00300977; Wakisaka S, 1998, ANN RHEUM DIS, V57, P487, DOI 10.1136/ard.57.8.487; Yamanishi Y, 2001, RHEUM DIS CLIN N AM, V27, P355, DOI 10.1016/S0889-857X(05)70206-4; Zhang Y, 1996, J BIOL CHEM, V271, P4266	35	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6839	6844		10.1038/sj.onc.1206903	http://dx.doi.org/10.1038/sj.onc.1206903			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534529				2022-12-17	WOS:000185843400003
J	Bellan, C; De Falco, G; Lazzi, S; Leoncini, L				Bellan, C; De Falco, G; Lazzi, S; Leoncini, L			Pathologic aspects of AIDS malignancies	ONCOGENE			English	Review						AIDS; HIV; neoplasm; pathology	HUMAN-IMMUNODEFICIENCY-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; EPSTEIN-BARR-VIRUS; TYPE-1 TAT PROTEIN; MULTICENTRIC CASTLEMANS-DISEASE; ACTIVE ANTIRETROVIRAL THERAPY; PRIMARY EFFUSION LYMPHOMA; GROWTH-FACTOR RECEPTOR-3; HIV-I TAT; KAPOSIS-SARCOMA	Since the emergence of the HIV pandemic, a close association between HIV infection and the development of a selected group of cancers has been acknowledged. The introduction of highly active antiretroviral therapy, however, has had a dramatic impact on the incidences of several AIDS-defining malignancies. This suggests the possibility of a direct and indirect role of HIV in HIV-related tumor genesis. The aim of this paper is to review the pathology of AIDS-related malignancies, taking into account the pathogenetic mechanisms and their potential for improving the treatment of these tumors.	Univ Siena, Dept Human Pathol & Oncol, Nuovo Policlin Le Scotte, I-53100 Siena, Italy	University of Siena	Leoncini, L (corresponding author), Univ Siena, Dept Human Pathol & Oncol, Nuovo Policlin Le Scotte, Via Scotte 6, I-53100 Siena, Italy.	leoncinil@unisi.it	leoncini, lorenzo/P-8361-2018; BELLAN, CRISTIANA/ABG-4750-2021; LEONCINI, Lorenzo/U-4413-2019; Lazzi, Stefano/P-8265-2018; BELLAN, CRISTIANA/L-3903-2013	leoncini, lorenzo/0000-0002-7457-300X; BELLAN, CRISTIANA/0000-0001-6119-9007; LEONCINI, Lorenzo/0000-0002-7457-300X; Lazzi, Stefano/0000-0002-2218-3771; BELLAN, CRISTIANA/0000-0001-6119-9007				ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Altavilla G, 1999, AM J PATHOL, V154, P1231, DOI 10.1016/S0002-9440(10)65375-8; Ambinder RF, 2001, EUR J CANCER, V37, P1209, DOI 10.1016/S0959-8049(01)00123-X; Ambrosino C, 2002, J BIOL CHEM, V277, P31448, DOI 10.1074/jbc.M112398200; Babcock GJ, 2000, P NATL ACAD SCI USA, V97, P12250, DOI 10.1073/pnas.200366597; Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002; BEDI GC, 1995, NAT MED, V1, P65, DOI 10.1038/nm0195-65; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Boccalon M, 1996, EUR J CANCER, V32A, P2212, DOI 10.1016/S0959-8049(96)00416-9; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; Cannon M, 2000, SEMIN ONCOL, V27, P409; Carbone A, 2003, LANCET ONCOL, V4, P22, DOI 10.1016/S1470-2045(03)00957-4; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; Clarke B, 2002, J CLIN PATHOL-MOL PA, V55, P19, DOI 10.1136/mp.55.1.19; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CLIN CANCER RES, V6, P754; CORALLINI A, 1993, CANCER RES, V53, P5569; D'OLIVEIRA J J G, 1972, Cancer, V30, P553, DOI 10.1002/1097-0142(197208)30:2<553::AID-CNCR2820300236>3.0.CO;2-W; Dal Maso L, 2001, EUR J CANCER, V37, P1188, DOI 10.1016/S0959-8049(01)00120-4; Dalgleish AG, 2002, ADV CANCER RES, V84, P231, DOI 10.1016/S0065-230X(02)84008-8; de la Fuente C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-14; DEFALCO G, 2003, IN PRESS ONCOGENE; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Du MQ, 2001, BLOOD, V97, P2130, DOI 10.1182/blood.V97.7.2130; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Fiorelli V, 1998, BLOOD, V91, P956; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Gaidano G, 1998, AM J PATHOL, V152, P623; GAIDANO G, 2003, BLOOD           0424; Gates AE, 2002, ONCOLOGY-NY, V16, P657; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Hengge UR, 2002, LANCET INFECT DIS, V2, P344, DOI 10.1016/S1473-3099(02)00288-8; Jussila L, 1998, CANCER RES, V58, P1599; Kaposi M., 1872, ARCH DERMATOL SYPHIL, V4, P265, DOI 10.1007/BF01830024; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; Kersemaekers AMF, 1998, BRIT J CANCER, V77, P192, DOI 10.1038/bjc.1998.33; KIM CM, 1992, ONCOGENE, V7, P1525; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; Knowles DM, 1999, MODERN PATHOL, V12, P200; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; Kundu RK, 1999, BLOOD, V94, P275, DOI 10.1182/blood.V94.1.275.413a30_275_282; Laman H, 2001, MOL CELL BIOL, V21, P624, DOI 10.1128/MCB.21.2.624-635.2001; Lazzi S, 2002, HUM PATHOL, V33, P723, DOI 10.1053/hupa.2002.125372; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; Muliokandov MR, 1996, CANCER RES, V56, P197; Noonan D, 2000, Adv Pharmacol, V48, P229; Olweny C L, 1984, IARC Sci Publ, P543; Prakash O, 2000, JNCI-J NATL CANCER I, V92, P721, DOI 10.1093/jnci/92.9.721; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; Rabkin CS, 2001, EUR J CANCER, V37, P1316, DOI 10.1016/S0959-8049(01)00104-6; ROTH WK, 1992, AIDS, V6, P895, DOI 10.1097/00002030-199209000-00001; Rubartelli A, 1998, IMMUNOL TODAY, V19, P543, DOI 10.1016/S0167-5699(98)01351-6; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; Schulz TF, 2002, VIRUS RES, V82, P115; Schulz TF, 2001, EUR J CANCER, V37, P1217, DOI 10.1016/S0959-8049(01)00115-0; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Stiegler P, 1998, J CELL BIOCHEM, P30; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Tirelli U, 2002, CRIT REV ONCOL HEMAT, V41, P299, DOI 10.1016/S1040-8428(01)00165-2; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; Wallace SVF, 2001, INT J STD AIDS, V12, P283, DOI 10.1258/0956462011923039; Wistuba II, 1999, GYNECOL ONCOL, V74, P519, DOI 10.1006/gyno.1999.5485; ZAULI G, 1995, BLOOD, V86, P3823, DOI 10.1182/blood.V86.10.3823.bloodjournal86103823	76	27	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6639	6645		10.1038/sj.onc.1206815	http://dx.doi.org/10.1038/sj.onc.1206815			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528289				2022-12-17	WOS:000185700700021
J	Lee, MW; Hirai, I; Wang, HG				Lee, MW; Hirai, I; Wang, HG			Caspase-3-mediated cleavage of Rad9 during apoptosis	ONCOGENE			English	Article						caspase-3; Rad9; DNA damage; cell-cycle checkpoint; apoptosis	DNA-DAMAGE; CHECKPOINT COMPLEX; CELL-DEATH; PROTEIN; HRAD9; BCL-2; PHOSPHORYLATION; ACTIVATION; INTERACTS; EVOLUTION	The activation of caspases is a critical event for the execution phase of programmed cell death. Caspases are highly specific in their ability to activate or inhibit many crucial proteins in the cell via cleavage. In this study, we report the identification of several caspase-3-like cleavage sites in the cell-cycle checkpoint protein Rad9. We demonstrate that human Rad9 can be specifically cleaved in cells induced to enter apoptosis by both DNA damage and staurosporine treatment. Indeed, we show that human Rad9 can be effectively cleaved both in vitro and in vivo, which can be inhibited by either a pan-caspase inhibitor or a caspase-3-specific inhibitor. Additionally, no cleavage of Rad9 can be seen in the caspase-3-deficient cell line MCF-7. Site-directed mutagenesis of three of the most conserved cleavage sites dramatically abrogates cleavage of Rad9 by caspase-3 in vitro, and in intact cells after DNA damage. Expression of the cleavage-resistant mutant Rad9 DDD/AAA appears to protect the cell from DNA damage-induced apoptosis. Immunofluorescence studies of Rad9 localization before and after induction of apoptosis show a translocation of Rad9 from the nucleus to the cytosol, concomitant to the appearance of apoptotic morphology. Furthermore, analysis of a truncated Rad9 mutant that corresponds to a putative N-terminal cleavage fragment shows that the N-terminal portion of Rad9 localizes in the cytosol, binds to Bcl-XL, and induces apoptosis. These results support a dual role for cleavage of Rad9: ( 1) the liberation and translocation of the BH3 domain-containing N-terminus of Rad9 to the cytosol, as a means of promoting apoptosis via antagonism of Bcl-XL, and ( 2) the disruption of the Rad9-Rad1-Hus1 DNA damage checkpoint complex.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wang, HG (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NATIONAL CANCER INSTITUTE [R01CA082197, R01CA090315] Funding Source: NIH RePORTER; NCI NIH HHS [CA82197, CA90315] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Caspari T, 2002, CURR BIOL, V12, pR105, DOI 10.1016/S0960-9822(02)00673-5; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hayashi K, 2002, PATHOBIOLOGY, V70, P40, DOI 10.1159/000066002; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Komatsu K, 2000, FEBS LETT, V481, P122, DOI 10.1016/S0014-5793(00)01975-X; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; St Onge RP, 2001, J BIOL CHEM, V276, P41898, DOI 10.1074/jbc.M105152200; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang HG, 1998, HISTOL HISTOPATHOL, V13, P521, DOI 10.14670/HH-13.521; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	27	27	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6340	6346		10.1038/sj.onc.1206729	http://dx.doi.org/10.1038/sj.onc.1206729			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508514				2022-12-17	WOS:000185535300004
J	Gales, C; Sanchez, D; Poirot, M; Pyronnet, S; Buscail, L; Cussac, D; Pradayrol, L; Fourmy, D; Silvente-Poirot, S				Gales, C; Sanchez, D; Poirot, M; Pyronnet, S; Buscail, L; Cussac, D; Pradayrol, L; Fourmy, D; Silvente-Poirot, S			High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor	ONCOGENE			English	Article						CCK2R; constitutively active mutant; gastrin; cancer; nude mice	PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; ORNITHINE DECARBOXYLASE; KAPOSIS-SARCOMA; B RECEPTOR; STRUCTURAL INSTABILITY; CELL-TRANSFORMATION; B/GASTRIN RECEPTOR; ASPARTIC-ACID; ACTIVATION	The cholecystokinin 2 receptor (CCK2R) increases proliferation of normal and neoplastic gastrointestinal cells and activates various mitogenic signaling pathways when stimulated by gastrin. To study the incidence of permanent activation of this receptor in tumorigenicity, a constitutively active mutant was generated by replacing residue Glu151 in the conserved E/DRY motif by Ala. Expression of the E151A-CCK2R mutant in NIH-3T3 cells causes ligand-independent activation of phospholipase C and ornithine decarboxylase, two enzymes critical for mitogenesis. Strikingly, the constitutive activity of this mutant was associated with dramatic alteration of NIH-3T3 cell morphology, enhanced cell proliferation and invasion. Moreover, injection of cells expressing E151A-CCK2R in nude mice resulted in the development of large and rapidly growing tumors. By contrast, none of these effects was observed with cells expressing the wildtype CCK2R, indicating that the tumorigenic properties of the E151A-CCK2R mutant is the result of its constitutive activation. To date, this is the first report that provides evidence for the high tumorigenic effect of a constitutively active CCK2R mutant, thus raising a potential role of the CCK2R in human cancer.	Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France; CHU Rangueil, Inst Louis Bugnard, INSERM, U531, F-31403 Toulouse, France; CHU Rangueil, Inst Louis Bugnard, INSERM, U388, F-31403 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Silvente-Poirot, S (corresponding author), Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.	poirot_s@icr.fnclcc.fr	Fourmy, Daniel/AAE-3703-2019; Cussac, Daniel/AAP-1544-2020; Pyronnet, Stéphane/P-2419-2014; Poirot, Sandrine/D-5448-2017; Poirot, Marc/C-7613-2009; Poirot, Marc/K-3551-2012	Fourmy, Daniel/0000-0001-9910-4827; Poirot, Marc/0000-0002-5711-6624; Poirot, Marc/0000-0002-5711-6624; GALES, Celine/0000-0002-4938-1583; Cussac, Daniel/0000-0002-7227-898X; Silvente-Poirot, Sandrine/0000-0003-2245-9069				ALBINI A, 1987, CANCER RES, V47, P3239; Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Auvinen M, 1997, CANCER RES, V57, P3016; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Burger M, 1999, J IMMUNOL, V163, P2017; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Ding WQ, 2002, CANCER RES, V62, P947; Estep RD, 2003, J VIROL, V77, P1738, DOI 10.1128/JVI.77.3.1738-1746.2003; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Hunyady L, 2003, TRENDS PHARMACOL SCI, V24, P81, DOI 10.1016/S0165-6147(02)00050-0; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; Morin D, 1998, FEBS LETT, V441, P470, DOI 10.1016/S0014-5793(98)01585-3; MORODER L, 1981, H-S Z PHYSIOL CHEM, V362, P929, DOI 10.1515/bchm2.1981.362.2.929; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pagliocca A, 2002, AM J PHYSIOL-GASTR L, V283, pG292, DOI 10.1152/ajpgi.00056.2002; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; Pyronnet S, 1998, ONCOGENE, V16, P2219, DOI 10.1038/sj.onc.1201748; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Reubi JC, 1997, CANCER RES, V57, P1377; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Samama P, 1997, P NATL ACAD SCI USA, V94, P137, DOI 10.1073/pnas.94.1.137; SCEMAMA JL, 1989, AM J PHYSIOL, V256, pG846, DOI 10.1152/ajpgi.1989.256.5.G846; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Silvente-Poirot S, 1999, J BIOL CHEM, V274, P23191, DOI 10.1074/jbc.274.33.23191; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; Smith AM, 2000, GUT, V47, P820, DOI 10.1136/gut.47.6.820; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; TODISCO A, 1995, J BIOL CHEM, V270, P28337; WANG SA, 1998, AM J PHYSIOL, V274, pG607; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	50	27	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6081	6089		10.1038/sj.onc.1206823	http://dx.doi.org/10.1038/sj.onc.1206823			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955087				2022-12-17	WOS:000185137800017
J	Greenbaum, L; Katcoff, DJ; Dou, HY; Gozlan, Y; Malik, Z				Greenbaum, L; Katcoff, DJ; Dou, HY; Gozlan, Y; Malik, Z			A porphobilinogen deaminase (PBGD) Ran-binding protein interaction is implicated in nuclear trafficking of PBGD in differentiating glioma cells	ONCOGENE			English	Article						PBGD; nuclear-localization; RanBPM; porphyrin	PROTOPORPHYRIN-IX ACCUMULATION; INDUCED PORPHYRIN FLUORESCENCE; PHOTODYNAMIC THERAPY; CLINICAL-EXPERIENCE; TRANSFORMED-CELLS; BASIC PRINCIPLES; REGULATORY ROLE; IN-VITRO; CANCER; TRANSPORT	Porphobilinogen deaminase (PBGD) is a rate-limiting enzyme of the heme biosynthesis pathway, whose level is elevated in various human tumors. PBGD was observed in both nuclear and cytoplasmic fractions of C6 glioma cells by immunostaining. During mitosis, chromatids were intensely stained for PBGD in comparison to the interphase chromatin. Using the yeast two-hybrid system, we identified RanBPM, the nuclear Ran-binding protein, as an interacting partner of PBGD. During butyrate-induced differentiation of C6, both nuclear and cytoplasmic PBGD levels declined as did Ran protein and its nucleotide exchange factor RCC1. N,N'-hexamethylene bis-acetamide-dependent differentiation resulted in an increase of the cytoplasmic PBGD, whereas nuclear PBGD, Ran protein and RCC1 remained unchanged. mRNA levels of PBGD remained unchanged during stimulation with both butyrate and N,N'-hexamethylene bis-acetamide. The enzymatic activity of PBGD and protoporphyrin IX synthesis in C6 cells were dependent on the differentiation induction agent. We conclude that PBGD possibly has a nuclear role in addition to its cytosolic enzymatic activity required for heme synthesis, which is related to cell transformation and differentiation.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Malik, Z (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.							ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; ARCANGELI A, 1987, J CELL PHYSIOL, V132, P387, DOI 10.1002/jcp.1041320302; ARCANGELI A, 1993, P NATL ACAD SCI USA, V90, P5858, DOI 10.1073/pnas.90.12.5858; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; BRESLOW R, 1991, P NATL ACAD SCI USA, V88, P5542, DOI 10.1073/pnas.88.13.5542; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; CHUANMAO Z, 1999, J CELL SCI, V112, P2453; Dot J, 2002, NEUROREPORT, V13, P1083, DOI 10.1097/00001756-200206120-00022; Gibson SL, 1998, BRIT J CANCER, V77, P235, DOI 10.1038/bjc.1998.39; Goya L, 1996, INT J DEV NEUROSCI, V14, P409, DOI 10.1016/S0736-5748(96)00026-3; Greenbaum L, 2002, BRIT J CANCER, V86, P1006, DOI 10.1038/sj.bjc.6600173; Hinnen P, 1998, BRIT J CANCER, V78, P679, DOI 10.1038/bjc.1998.559; Ideguchi H, 2002, BIOCHEM J, V367, P87, DOI 10.1042/BJ20011851; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KENNEDY JC, 1990, J PHOTOCH PHOTOBIO B, V6, P143, DOI 10.1016/1011-1344(90)85083-9; Kriegmair M, 1996, J UROLOGY, V155, P105, DOI 10.1016/S0022-5347(01)66559-5; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; LOUIE GV, 1992, NATURE, V359, P33, DOI 10.1038/359033a0; MALIK Z, 1987, BRIT J CANCER, V56, P589, DOI 10.1038/bjc.1987.246; MARKS PA, 1987, CANCER RES, V47, P659; MARKS PA, 1994, P NATL ACAD SCI USA, V91, P10251, DOI 10.1073/pnas.91.22.10251; McLintock Lorna A, 2002, Hematology, V7, P189, DOI 10.1080/1024533021000013906; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Orenstein A, 2000, DERMATOL SURG, V26, P765, DOI 10.1046/j.1524-4725.2000.00056.x; ORENSTEIN A, 1995, CANCER LETT, V93, P227, DOI 10.1016/0304-3835(95)03814-D; Orenstein A, 1998, LASER MED SCI, V13, P112, DOI 10.1007/s101030050063; ORENSTEIN A, 1996, LASERS LIFE SCI, V7, P1; Ortel B, 1998, BRIT J CANCER, V77, P1744, DOI 10.1038/bjc.1998.292; PARKER KK, 1980, SCIENCE, V208, P179, DOI 10.1126/science.6102413; Peng Q, 1997, CANCER-AM CANCER SOC, V79, P2282; Peng Q, 1997, PHOTOCHEM PHOTOBIOL, V65, P235, DOI 10.1111/j.1751-1097.1997.tb08549.x; Ponka P, 1997, BLOOD, V89, P1; Quimby BB, 2001, CELL MOL LIFE SCI, V58, P1766, DOI 10.1007/PL00000816; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; Sazer S, 2000, J CELL SCI, V113, P1111; SCHOENFELD N, 1988, BIOCHEM MED METAB B, V40, P213, DOI 10.1016/0885-4505(88)90121-1; SEGOVIA J, 1994, J NEUROCHEM, V63, P1218; Stepp H, 1998, ENDOSCOPY, V30, P379, DOI 10.1055/s-2007-1001287; Stummer W, 1998, NEUROSURGERY, V42, P518, DOI 10.1097/00006123-199803000-00017; Tunstall RG, 2002, BRIT J CANCER, V87, P246, DOI 10.1038/sj.bjc.6600460; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x	43	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5221	5228		10.1038/sj.onc.1206723	http://dx.doi.org/10.1038/sj.onc.1206723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917623				2022-12-17	WOS:000184734900001
J	Kichina, JV; Rauth, S; Das Gupta, TK; Gudkov, AV				Kichina, JV; Rauth, S; Das Gupta, TK; Gudkov, AV			Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53	ONCOGENE			English	Article						melanoma; p53; Ing1; tumor suppressor; transactivation	TUMOR-SUPPRESSOR P33(ING1); MALIGNANT-MELANOMA; TYROSINASE GENE; MUTANT P53; IN-VITRO; EXPRESSION; LINES; MUTATIONS; MDM2; PROTEIN	Malignant melanomas are frequently characterized by elevated levels of wild-type p53, suggesting that p53 function could be suppressed by a mechanism different from p53 mutation. We analysed the functionality of the p53-signaling pathway in a panel of seven human melanoma cell lines consisting of one p53-deficient line, two lines with mutant p53, and four lines expressing wildtype p53. Only lines with wild-type p53 were characterized by elevated levels of endogenous p21, high activity of p53-responsive reporters and accumulation of p53 in response to genotoxic stress, common properties of functional p53. The presence of wild-type p53 was associated with depletion or loss of p14(ARF) and p16 expression. The levels of p33(ING1b) and p24(ING1c), two major products of Ing1 locus and putative coregulators of p53, were elevated in all cell lines tested; however, ectopic expression of either ING1 isoform had no effect on cell proliferation. All lines retained expression of Apaf-1, and all but one remained sensitive to ectopic expression of retrovirus-transduced p53. Our data indicate that regardless of abnormally high levels of p53 in melanomas, their p53 remains competent in transactivation of its targets, and, if highly overexpressed, capable of growth inhibition. Hence, the p53 pathway in malignant melanomas can be considered for pharmacological targeting and anticancer gene therapy.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER; NCI NIH HHS [CA75179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABARZUA P, 1995, CANCER RES, V55, P3490; *ACS, 2002, CANC FACTS FIG 2002; ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Bae I, 1996, CANCER RES, V56, P840; Bigner S H, 1999, Neuro Oncol, V1, P52, DOI 10.1093/neuonc/1.1.52; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Campos EI, 2002, BRIT J DERMATOL, V146, P574, DOI 10.1046/j.1365-2133.2002.04641.x; Cheung KJJ, 2000, BRIT J CANCER, V83, P1468, DOI 10.1054/bjoc.2000.1464; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; CIRIELLI C, 1995, INT J CANCER, V63, P673, DOI 10.1002/ijc.2910630512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GALLION HH, 1995, CANCER, V76, P1992, DOI 10.1002/1097-0142(19951115)76:10+<1992::AID-CNCR2820761315>3.0.CO;2-U; Garkavtsev I, 1997, HYBRIDOMA, V16, P537, DOI 10.1089/hyb.1997.16.537; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kichina J, 1996, PIGM CELL RES, V9, P85, DOI 10.1111/j.1600-0749.1996.tb00094.x; Leung KM, 2002, CANCER RES, V62, P4890; Loggini B, 2001, TUMORI, V87, P179, DOI 10.1177/030089160108700313; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Mehta RR, 2002, MELANOMA RES, V12, P27, DOI 10.1097/00008390-200202000-00005; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MONTANO X, 1994, ONCOGENE, V9, P1455; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; Nouman GS, 2002, HYBRIDOMA HYBRIDOM, V21, P1, DOI 10.1089/15368590252917584; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ragnarsson-Olding BK, 2002, MELANOMA RES, V12, P453, DOI 10.1097/00008390-200209000-00007; Rass K, 2001, HISTOCHEM J, V33, P459, DOI 10.1023/A:1014472314354; RAUTH S, 1994, IN VITRO CELL DEV-AN, V30A, P79, DOI 10.1007/BF02631396; RAUTH S, 1994, ANTICANCER RES, V14, P2457; RAUTH S, 1993, SOMAT CELL MOLEC GEN, V19, P285, DOI 10.1007/BF01233076; RENZING J, 1995, ONCOGENE, V10, P1865; Salti GI, 2001, MELANOMA RES, V11, P99, DOI 10.1097/00008390-200104000-00003; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Sunamura Makoto, 2002, J Hepatobiliary Pancreat Surg, V9, P32, DOI 10.1007/s005340200002; Tannapfel A, 2001, ONCOGENE, V20, P7104, DOI 10.1038/sj.onc.1204902; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; YAMAMOTO M, 1993, VIRCHOWS ARCH A, V422, P127, DOI 10.1007/BF01607164; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	52	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4911	4917		10.1038/sj.onc.1206741	http://dx.doi.org/10.1038/sj.onc.1206741			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894234				2022-12-17	WOS:000184344600016
J	Szynal, M; Cleuter, Y; Beskorwayne, T; Bagnis, C; Van Lint, C; Kerkhofs, P; Burny, A; Martiat, P; Griebel, P; Van den Broeke, A				Szynal, M; Cleuter, Y; Beskorwayne, T; Bagnis, C; Van Lint, C; Kerkhofs, P; Burny, A; Martiat, P; Griebel, P; Van den Broeke, A			Disruption of B-cell homeostatic control mediated by the BLV-Tax oncoprotein: association with the upregulation of Bcl-2 and signaling through NF-kappa B	ONCOGENE			English	Article						B-cell transformation; tax; complex retrovirus; BLV; Bcl-2; NF-kappa B	BOVINE LEUKEMIA-VIRUS; HTLV-I TAX; TYPE-1 TAX; GENE-EXPRESSION; GERMINAL CENTER; RAS ONCOGENE; PROTEIN; APOPTOSIS; ACTIVATION; TRANSCRIPTION	Transactivating proteins associated with complex oncoretroviruses including human T-cell leukemia virus-1 (HTLV-1) and bovine leukemia virus (BLV) mediate transformation using poorly understood mechanisms. To gain insight into the processes that govern tumor onset and progression, we have examined the impact of BLV-Tax expression on ovine B-cells, the targets of BLV in experimentally infected sheep, using B-cell clones that are dependent on CD154 and gamma(c)-common cytokines. Tax was capable of mediating progression of B-cells from cytokine dependence to cytokine independence, indicating that the transactivator can over-ride signaling pathways typically controlled by cytokine receptor activation in B-cells. When examined in the presence of both CD154 and interleukin-4, Tax had a clear supportive role on B-cell growth, with an impact on B-cell proliferation, cell cycle phase distribution, and survival. Apoptotic B-cell death mediated by growth factor withdrawal, physical insult, and NF-kappaB inhibition was dramatically reduced in the presence of Tax. Furthermore, the expression of Tax was associated with higher Bcl-2 protein levels, providing rationale for the rescue signals mediated by the transactivator. Finally, Tax expression in B-cells led to a dramatic increase of nuclear RelB/p50 and p50/p50 NF-kappaB dimers, indicating that cellular signaling through NF-kappaB is a major contributory mechanism in the disruption of B-cell homeostasis. Although Tax is involved in aspects of pathogenesis that are unique to complex retroviruses, the viral strategies associated with this transactivating oncoprotein may have wide-ranging effects that are relevant to other B-cell malignancies.	Inst Jules Bordet, Lab Expt Hematol, B-1000 Brussels, Belgium; Vet Infect Dis Org, Saskatoon, SK S7H 5E3, Canada; Etab Francais Sang, F-13009 Marseille, France; IBMM, B-6041 Gosselies, Belgium; Coda Cerva, B-1180 Brussels, Belgium	Institut Jules Bordet; University of Saskatchewan; Universite Libre de Bruxelles	Van den Broeke, A (corresponding author), Inst Jules Bordet, Lab Expt Hematol, 121 Blvd Waterloo, B-1000 Brussels, Belgium.	anne_vandenbroeke@compuserve.com						Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Badran BM, 2002, J BIOL CHEM, V277, P47136, DOI 10.1074/jbc.M206330200; Bagnis C, 1997, CANCER GENE THER, V4, P5; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BURNY A, 1994, SYMP SOC GEN MICROBI, V51, P213; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; Feinman R, 1999, BLOOD, V93, P3044; FELBER B K, 1989, New Biologist, V1, P318; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Griebel P, 1999, INT IMMUNOL, V11, P1139, DOI 10.1093/intimm/11.7.1139; Griebel PJ, 2000, J IMMUNOL METHODS, V237, P19, DOI 10.1016/S0022-1759(99)00247-1; HAAS L, 1992, J VIROL, V66, P6223, DOI 10.1128/JVI.66.10.6223-6225.1992; HAURY M, 1993, ONCOGENE, V8, P1257; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Horwitz BH, 1999, J IMMUNOL, V162, P1941; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Keller SA, 2000, BLOOD, V96, P2537; Kerkhofs P, 1998, J VIROL, V72, P2554, DOI 10.1128/JVI.72.3.2554-2559.1998; Kettmann R., 1994, The retroviridae: Volume 3, P39; Kirshenbaum LA, 2000, CLIN INVEST MED, V23, P322; Kistler B, 1998, J IMMUNOL, V160, P2308; Krappmann D, 2001, MOL CELL BIOL, V21, P6640, DOI 10.1128/MCB.21.19.6640-6650.2001; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MAMMERICKX M, 1988, LEUKEMIA, V2, P103; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; MOTYKA B, 1995, IMMUNOLOGY, V84, P383; MURAKAMI K, 1994, AM J VET RES, V55, P72; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Porter LA, 2000, BLOOD, V95, P2645; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Reyes RA, 1998, VIROLOGY, V242, P184, DOI 10.1006/viro.1998.9029; Richardson JH, 1997, BLOOD, V89, P3303, DOI 10.1182/blood.V89.9.3303; Rovnak J, 1999, J VIROL, V73, P8890, DOI 10.1128/JVI.73.10.8890-8897.1999; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schmaltz B, 2000, GNOMON, V72, P633; SchwartzCornil I, 1997, J GEN VIROL, V78, P153, DOI 10.1099/0022-1317-78-1-153; Semmes OJ, 1996, J BIOL CHEM, V271, P9730, DOI 10.1074/jbc.271.16.9730; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Stone DM, 2000, J GEN VIROL, V81, P971, DOI 10.1099/0022-1317-81-4-971; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; Twizere JC, 2000, J VIROL, V74, P9895, DOI 10.1128/JVI.74.21.9895-9902.2000; Van den Broeke A, 1999, J VIROL, V73, P1054, DOI 10.1128/JVI.73.2.1054-1065.1999; Van den Broeke A, 2001, J VIROL, V75, P1095, DOI 10.1128/JVI.75.3.1095-1103.2001; Van Den Broeke Anne, 1997, P2127; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; VANDENBROEKE A, 1988, P NATL ACAD SCI USA, V85, P9263, DOI 10.1073/pnas.85.23.9263; Vernau W, 1997, VET PATHOL, V34, P222, DOI 10.1177/030098589703400307; Wagner EF, 1998, J IMMUNOL, V161, P1123; Warren WD, 1999, MOL IMMUNOL, V36, P31, DOI 10.1016/S0161-5890(98)00114-X; Watanabe T, 1997, INT J HEMATOL, V66, P257; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; Wick KR, 2000, MOL IMMUNOL, V37, P641, DOI 10.1016/S0161-5890(00)00088-2; WILLEMS L, 1987, EMBO J, V6, P3385, DOI 10.1002/j.1460-2075.1987.tb02661.x; WILLEMS L, 1993, J VIROL, V67, P4078, DOI 10.1128/JVI.67.7.4078-4085.1993; WILLEMS L, 1994, P NATL ACAD SCI USA, V91, P11532, DOI 10.1073/pnas.91.24.11532; WILLEMS L, 1990, EMBO J, V9, P1577, DOI 10.1002/j.1460-2075.1990.tb08277.x; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	75	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4531	4542		10.1038/sj.onc.1206546	http://dx.doi.org/10.1038/sj.onc.1206546			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881710	Bronze			2022-12-17	WOS:000184054700009
J	Bader, S; Walker, M; McQueen, HA; Sellar, R; Oei, E; Wopereis, S; Zhu, YH; Peter, A; Bird, AP; Harrison, DJ				Bader, S; Walker, M; McQueen, HA; Sellar, R; Oei, E; Wopereis, S; Zhu, YH; Peter, A; Bird, AP; Harrison, DJ			MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers	ONCOGENE			English	Article						18q21 gene mutations; colon cancer; lung cancer	CPG-BINDING-PROTEIN; HISTONE DEACETYLASE; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; DROSOPHILA-TRITHORAX; MESSENGER-RNA; ALL-1 GENE; DOMAIN; EXPRESSION; DCC	The genes MBD1 and MBD2 encode methyl-CpG binding proteins that suppress transcription from methylated promoters. In contrast, CGBP encodes a protein that binds promoters containing unmethylated CpG and stimulates transcription. All three are located on human chromosome 18q21, a region of frequent loss of heterozygosity in several cancers. These genes therefore represent candidate tumour suppressor genes, whose loss of function could affect the normal regulation of gene expression, whether by lack of complete suppression of genes normally silenced (via loss of MBD1 and MBD2) or by some loss of activation of genes normally expressed (via loss of CGBP), either way contributing to the tumorigenic phenotype. We have confirmed by fluorescent in situ hybridization that MBD1 and MBD2 bracket the DCC locus giving a gene order of MBD1/CGBP-DCC 5'-DCC 3'-MBD2. Mutation analyses by single-stranded conformation polymorphism in colon and lung cancer cell lines and primary tumours revealed a small number of mutations, suggesting only a limited role of these genes in human tumorigenesis.	Univ Edinburgh, Mol Med Ctr, Div Pathol, Sir Alastair Currie Canc Res UK Labs, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Inst Life Sci Technol, NL-7500 KB Enschede, Netherlands	University of Edinburgh; University of Edinburgh	Bader, S (corresponding author), Univ Edinburgh, Mol Med Ctr, Div Pathol, Sir Alastair Currie Canc Res UK Labs, Edinburgh EH4 2XU, Midlothian, Scotland.	s.bader@ed.ac.uk	McQueen, Heather/AAS-3294-2020	McQueen, Heather/0000-0002-4228-6081; Bird, Adrian/0000-0002-8600-0372; harrison, david/0000-0001-9041-9988				Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Carlone DL, 2001, MOL CELL BIOL, V21, P7601, DOI 10.1128/MCB.21.22.7601-7606.2001; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Cross SH, 1999, NUCLEIC ACIDS RES, V27, P2099, DOI 10.1093/nar/27.10.2099; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200; Fabre M, 1999, INT J CANCER, V81, P799, DOI 10.1002/(SICI)1097-0215(19990531)81:5<799::AID-IJC22>3.0.CO;2-W; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Fujita N, 1999, MOL CELL BIOL, V19, P6415; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kanai Y, 1999, BIOCHEM BIOPH RES CO, V264, P962, DOI 10.1006/bbrc.1999.1613; Lanza G, 1998, INT J CANCER, V79, P390, DOI 10.1002/(SICI)1097-0215(19980821)79:4<390::AID-IJC14>3.3.CO;2-M; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Muller-Tidow C, 2001, BRIT J CANCER, V85, P1168, DOI 10.1054/bjoc.2001.2041; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; SHISEKI M, 1994, CANCER RES, V54, P5643; TAKAI K, 1998, CANCER RES, V58, P3700; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	46	27	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3506	3510		10.1038/sj.onc.1206574	http://dx.doi.org/10.1038/sj.onc.1206574			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776203				2022-12-17	WOS:000183128500018
J	Zhang, XW; Chen, Z; Chen, YL; Tong, TJ				Zhang, XW; Chen, Z; Chen, YL; Tong, TJ			Delivering antisense telomerase RNA by a hybrid adenovirus/adeno-associated virus significantly suppresses the malignant phenotype and enhances cell apoptosis of human breast cancer cells	ONCOGENE			English	Article						telomerase RNA; antisense; adenovirus; adeno-associated virus; gene therapy; breast cancer	SITE-SPECIFIC INTEGRATION; CATALYTIC SUBUNIT; IMMORTAL CELLS; HIGH-CAPACITY; GENE-TRANSFER; TUMOR-CELLS; DNA; INDUCTION; VECTORS; INHIBITION	Activated tetomerase is frequently detected in cancer cells and is able to maintain and stabilize the integrity of telomeres; it also contributes to unlimited divisions in cancer cells. Recently, a new generation of selective anticancer strategies is under development targeting the blockage of telomerase activity either at the protein level or telomerase RNA. Here, we report suppression of the malignant phenotype by the expression of the full-length antisense human telomerase RNA (hTR) delivered by a novel hybrid vector recombining adenovirus and adenoassociated virus (vAd-AAV). The hybrid vector vAd-AAV retained the unique traits from two parental viruses, such as high efficiency of gene transfer in mammalian cells and the ability to integrate into the genomic DNA of host cells. The stable expression of antisense hTR in MCF-7, cells significantly suppressed telomerase activity and progressively shortened telomere length for 30 population doublings (PD30). Expression of antisense hTR leads to a telomere-based growth arrest and the induction of spontaneous apoptosis. Antisense hTR decreased soft agar colony formation and reduced the cell proliferation, leading to exit from the cell cycle at G1 at PD15. The expression of antisense hTR also sensitized MCF-7 cells to apoptosis induced by sodium butyrate or serum starvation. Our study demonstrates that delivering antisense hTR by the hybrid Ad/AAV vector is an effective antineoplastic gene therapeutic strategy, which significantly suppresses the malignant phenotype and enhances apoptosis of human breast cancer cells.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Natl Inst Deafness & Commun Disorders, Head & Neck Surg Branch, Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	Peking University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Tong, TJ (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China.							ALI M, 1994, GENE THER, V1, P367; ANDREW NS, 1994, CANCER GENE THER, V1, P165; Avilion AA, 1996, CANCER RES, V56, P645; BERNS KI, 1995, BIOESSAYS, V17, P237, DOI 10.1002/bies.950170310; Bisoffi M, 1998, EUR J CANCER, V34, P1242, DOI 10.1016/S0959-8049(98)00049-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Campisi J, 1999, MOLECULAR BASIS OF CELL CYCLE AND GROWTH CONTROL, P348; Campisi Judith, 1996, P121; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOUGLAS J, 1994, CANCER GENE THER, V1, P51; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; Elenitoba-Johnson KSJ, 2001, AM J PATHOL, V159, P405, DOI 10.1016/S0002-9440(10)61710-5; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; GUILBAUD NF, 1990, J CELL PHYSIOL, V145, P162, DOI 10.1002/jcp.1041450122; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hahn WC, 2001, CLIN CANCER RES, V7, P2953; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Helbing CC, 1998, ONCOGENE, V17, P1491, DOI 10.1038/sj.onc.1202241; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Hiyama E, 2002, ONCOGENE, V21, P643, DOI 10.1038/sj.onc.1205070; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Hsiao RS, 1997, ANTICANCER RES, V17, P827; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; KOTIN RM, 1992, EMBO J, V11, P5071, DOI 10.1002/j.1460-2075.1992.tb05614.x; Kyo S, 1997, CANCER RES, V57, P610; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Li ZD, 2000, ACTA BIOCH BIOPH SIN, V32, P383; Lieber A, 1999, J VIROL, V73, P9314, DOI 10.1128/JVI.73.11.9314-9324.1999; Lu MS, 1996, J VIROL, V70, P8850, DOI 10.1128/JVI.70.12.8850-8857.1996; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Philpott NJ, 2002, J VIROL, V76, P5411, DOI 10.1128/JVI.76.11.5411-5421.2002; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Recchia A, 1999, P NATL ACAD SCI USA, V96, P2615, DOI 10.1073/pnas.96.6.2615; RICHARD JS, 1989, J VIROL, V63, P3822; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Schulick AH, 1997, J CLIN INVEST, V99, P209, DOI 10.1172/JCI119149; Shay J W, 2001, Novartis Found Symp, V235, P116; Shayakhmetov DM, 2002, J VIROL, V76, P1135, DOI 10.1128/JVI.76.3.1135-1143.2002; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Smith R. H., 2002, MOBILE DNA, P905; SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983; Strahl C, 1996, MOL CELL BIOL, V16, P53; Tsao JI, 1997, CLIN CANCER RES, V3, P627; WANG FS, 1997, J BEIJING MED U, V29, P295; WANG WG, 1999, CHIN J BIOCH MOL BIO, V15, P655; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Wright Woodring E., 1996, V16, P153; Yamamoto I, 1996, J BIOCHEM-TOKYO, V119, P1056; 王文恭, 1997, 北京医科大学学报, V29, P490; 张新庆, 2001, 中华神经外科杂志, V17, P395	70	27	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2405	2416		10.1038/sj.onc.1206317	http://dx.doi.org/10.1038/sj.onc.1206317			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717417				2022-12-17	WOS:000182383500003
J	Aoki, M; Sobek, V; Maslyar, DJ; Hecht, A; Vogt, PK				Aoki, M; Sobek, V; Maslyar, DJ; Hecht, A; Vogt, PK			Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes	ONCOGENE			English	Article						beta-catenin; LEF/TCF; target genes; oncogenic transformation	ANCHORAGE-INDEPENDENT GROWTH; NEOPLASTIC TRANSFORMATION; COLORECTAL-CANCER; C-MYC; WNT; IP6; TRANSCRIPTION; ACTIVATION; EXPRESSION; CELLS	Genetic analysis of beta-catenin-induced oncogenic transformation in chicken embryo fibroblasts (CEF) revealed the following prerequisites for oncogenicity: (1) removal of the N terminal phosphorylation sites targeted by glycogen synthase kinase 3beta (GSK3beta), (2) retention of the N terminal transactivation domain, and (3) retention of the armadillo repeats. The C terminal transactivation domain played an ancillary role in the transformation of CEF. There was a rough correlation between the transforming activity of various beta-catenin constructs and their transactivation of the TOPFLASH reporter. Expression levels of the candidate target genes of beta-catenin-LEF, cyclin D1 and myc were not correlated with each other or with the transforming activity of beta-catenin constructs. A new target gene, coding for inositol hexakisphosphate kinase 2 (IP6K2) was identified. Its expression showed concordance with the transforming activity of beta-catenin constructs.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Freiburg, Inst Mol Med & Zellforsch, Freiburg, Germany	Scripps Research Institute; University of Freiburg	Aoki, M (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.	maoki@scripps.edu	Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490; Hecht, Andreas/0000-0003-2262-2575	NCI NIH HHS [CA 78230, CA79616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078230, R01CA079616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Dahmen RP, 2001, CANCER RES, V61, P7039; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Guger KA, 2000, DEV BIOL, V223, P441, DOI 10.1006/dbio.2000.9770; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Nagasawa Y, 1999, CANCER RES, V59, P3539; Norbis F, 1997, J MEMBRANE BIOL, V156, P19, DOI 10.1007/s002329900183; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Safrany ST, 1999, BIOL CHEM, V380, P945, DOI 10.1515/BC.1999.117; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; Shamsuddin AM, 1999, ANTICANCER RES, V19, P3733; Shamsuddin AM, 1999, ANTICANCER RES, V19, P3671; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Vucenik I, 1998, ANTICANCER RES, V18, P4091; Vucenik I, 1998, ANTICANCER RES, V18, P4083; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	43	27	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					6983	6991		10.1038/sj.onc.1205796	http://dx.doi.org/10.1038/sj.onc.1205796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370820				2022-12-17	WOS:000178424900001
J	Day, CH; Fanger, GR; Retter, MW; Hylander, BL; Penetrante, RB; Houghton, RL; Zhang, XQ; McNeill, PD; Maltez, A; Nolasco, M; Badaro, R; Cheever, MA; Reed, SG; Dillon, DC; Watanabe, Y				Day, CH; Fanger, GR; Retter, MW; Hylander, BL; Penetrante, RB; Houghton, RL; Zhang, XQ; McNeill, PD; Maltez, A; Nolasco, M; Badaro, R; Cheever, MA; Reed, SG; Dillon, DC; Watanabe, Y			Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera	ONCOGENE			English	Article						antibody; KLK4; prostase; prostate cancer; protein expression	KALLIKREIN GENE FAMILY; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; SERINE-PROTEASE; ANTIGEN; LOCALIZATION; MEMBER	The ability to identify prostate tumor or prostate tissue specific genes that are expressed at high levels and use their protein products as targets could greatly aid in the diagnosis and treatment of prostate cancer. Using a polymerase chain reaction (PCR)-based subtraction technique, we have recovered the recently described KLK4 (prostase) gene from human prostate cDNA. In this study, KLK4 gene expression in human prostate tumors was further characterized using cDNA quantitative PCR and immunohistochemistry, demonstrating that the gene is specifically expressed at both the mRNA and protein levels in normal human prostate tissue, and in both primary and metastatic prostate tumor samples. Quantitative mRNA analysis also demonstrated low level expression including adrenal gland, salivary gland and thyroid. Finally, it was demonstrated that prostate cancer patient sera contain antibodies that bind specifically to recombinant KLK4 protein. This antibody has been used to detect KLK4-specific peptides in epitope mapping experiments. The relatively specific expression profile and elevated level of KLK4 mRNA and protein in both tumor and normal prostate tissues, in addition to detectable KLK4-specific antibody in cancer patient sera, supports additional efforts to determine if KLK4 can play a role in the diagnosis of prostate cancer, the monitoring of residual disease, or act as a target for immunotherapy.	Corixa Corp, Seattle, WA 98104 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Infect Dis Res Inst, Seattle, WA 98104 USA	Corixa; Roswell Park Cancer Institute; University of Washington; University of Washington Seattle	Day, CH (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.	day@corixa.com			NCI NIH HHS [CA76822] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABIAAD AS, 1992, J UROLOGY, V147, P952, DOI 10.1016/S0022-5347(17)37431-1; Babcook JS, 1996, P NATL ACAD SCI USA, V93, P7843, DOI 10.1073/pnas.93.15.7843; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Daher R, 1998, CLIN CHEM LAB MED, V36, P671, DOI 10.1515/CCLM.1998.120; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dong Y, 2001, CLIN CANCER RES, V7, P2363; DuPont BR, 1999, CYTOGENET CELL GENET, V86, P212, DOI 10.1159/000015340; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Houghton RL, 2001, MOL DIAGN, V6, P79, DOI 10.2165/00066982-200106020-00003; Myers SA, 2001, J CLIN ENDOCR METAB, V86, P2323, DOI 10.1210/jc.86.5.2323; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Obiezu CV, 2001, CLIN CANCER RES, V7, P2380; SISSONS GRJ, 1992, BRIT J RADIOL, V65, P861, DOI 10.1259/0007-1285-65-778-861; Stephenson SA, 1999, J BIOL CHEM, V274, P23210, DOI 10.1074/jbc.274.33.23210; Thiounn N, 1997, UROLOGY, V50, P245, DOI 10.1016/S0090-4295(97)00272-0; Watson MA, 1999, CANCER RES, V59, P3028; Yousef GM, 1999, CANCER RES, V59, P4252	19	27	27	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7114	7120		10.1038/sj.onc.1205786	http://dx.doi.org/10.1038/sj.onc.1205786			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370833				2022-12-17	WOS:000178424900014
J	Sasaki, S; Nakamura, T; Arakawa, H; Mori, M; Watanabe, T; Nagawa, H; Croce, CM				Sasaki, S; Nakamura, T; Arakawa, H; Mori, M; Watanabe, T; Nagawa, H; Croce, CM			Isolation and characterization of a novel gene, hRFI, preferentially expressed in esophageal cancer	ONCOGENE			English	Article						inhibitor of apoptosis protein; TNF-alpha; induced apoptosis; cleavage by caspase-3; Ring Finger domain; esophageal cancer	APOPTOSIS INHIBITORY PROTEIN; CELL-DEATH; BACULOVIRUS GENE; FAMILY; IAP; CASPASES; HOMOLOGS; MOTIF; TID1	hTID1, a human homologue of Drosophila tumor suppressor, I(2)tid regulates the release of cytochrome c from mitochondria and subsequent alteration of caspase-3 activity on apoptosis induced by exogenous stimuli, such as tumor necrosis factor-alpha, and mitomycin C. To search for an interacting molecule with hTid1, we applied two-hybrid yeast screening and isolated a novel gene, which encodes a 46 kDa protein of 373 residues. Within the deduced amino acid sequence, a region showing homology to the Ring Finger domain of X-linked inhibitor of apoptosis protein was identified and the gene was designated as hRFI, standing for human Ring Finger homologous to IAP type. A 2.0 kb hRFI transcript was ubiquitously expressed in all human tissues as well as several cancer cell lines examined. Northern blot analysis showed that in 70% (14 out of 20) of esophageal cancer patients, expression of hRFI in cancerous regions was two or more times higher than in the corresponding normal tissues. HeLa cells transfected with hRFI construct exhibited a tendency to resist TNF-alpha induced apoptosis, suggesting an anti-apoptotic function of the hRFI product. Finally, hRFI protein was shown to be cleaved within the DEDD sequence spanning residues 230 - 233 by caspase-3 during the apoptotic induction.	Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, Tokyo 1138655, Japan; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Technol,Minato Ku, Tokyo 1088639, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Surg, Oita 8740838, Japan	University of Tokyo; Jefferson University; University of Tokyo; Kyushu University	Sasaki, S (corresponding author), Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Young, Richard A/F-6495-2012; Arakawa, Hirofumi/L-3459-2013	Young, Richard A/0000-0001-8855-8647; Arakawa, Hirofumi/0000-0001-6077-0638				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; KOZAK M, 1983, MICROBIOL REV, V47, P1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Merup M, 1997, EUR J HAEMATOL, V58, P174; Pack SD, 1999, GENE CHROMOSOME CANC, V25, P160, DOI 10.1002/(SICI)1098-2264(199906)25:2<160::AID-GCC12>3.0.CO;2-U; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X	25	27	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					5024	5030		10.1038/sj.onc.1205627	http://dx.doi.org/10.1038/sj.onc.1205627			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118383				2022-12-17	WOS:000176874800019
J	Benvenuti, S; Cramer, R; Bruce, J; Waterfield, MD; Jat, PS				Benvenuti, S; Cramer, R; Bruce, J; Waterfield, MD; Jat, PS			Identification of novel candidates for replicative senescence by functional proteomics	ONCOGENE			English	Article						replicative senescence; proteomics; gene expression; mass spectrometry	RESPONSE MEDIATOR PROTEIN-2; LIM-DOMAIN PROTEIN; T-ANTIGEN; CELL-LINES; GENE; GELSOLIN; HOMEODOMAIN; EXPRESSION; DYNAMICS; NEURONS	To identify the underlying mechanisms that limit the mitotic potential of normal somatic cells, we have undertaken a high resolution differential proteomic analysis aimed at identifying proteins that were differentially expressed upon replicative senescence. Since replicative senescence in heterogenous primary fibroblast cultures is asynchronous, we analysed a group of conditionally immortalized rat embryo fibroblast cell lines that have previously been shown to undergo synchronous senescence upon inactivation of SV40 tsA58 T antigen. This identified 43 spots that were differentially expressed in these cell lines. Comparison of the identity of these features with those identified in a complimentary independent differential proteomic analysis of replicative senescence, directly in primary rat embryo fibroblasts upon serial passaging, identified nine features that were in common between the two studies even though they had been conducted entirely separately. None of these proteins have previously been recognized to be involved with replicative senescence. Thus, they represent novel starting points for elucidating the underlying mechanism that regulates the finite mitotic life span of somatic cells and how it can be overcome in cancer cells.	Royal Free & Univ Coll, Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Oxford GlycoSci, Abingdon OX14 3YS, Oxon, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London	Jat, PS (corresponding author), Royal Free & Univ Coll, Sch Med, Ludwig Inst Canc Res, Courtland Bldg,91 Riding House St, London W1W 7BS, England.	parmjit@ludwig.ucl.ac.uk		Benvenuti, Silvia/0000-0002-3041-4429; Cramer, Rainer/0000-0002-8037-2511				AMESS B, 1995, ELECTROPHORESIS, V16, P1255, DOI 10.1002/elps.11501601207; Asch HL, 1996, CANCER RES, V56, P4841; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bauer K, 2000, BLOOD, V96, P4236; Benvenuti S, 2002, MOL CELL PROTEOMICS, V1, P280, DOI 10.1074/mcp.M100028-MCP200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; Campisi J, 1996, EXP GERONTOL, V31, P7, DOI 10.1016/0531-5565(95)02024-1; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Conzen SD, 1995, ONCOGENE, V11, P2295; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; Darmon Alison J., 2000, Molecular Cell Biology Research Communications, V4, P219, DOI 10.1006/mcbr.2001.0281; Dong Y, 1999, INT J CANCER, V81, P930, DOI 10.1002/(SICI)1097-0215(19990611)81:6<930::AID-IJC15>3.0.CO;2-A; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; Gotzmann J, 1999, CRIT REV EUKAR GENE, V9, P257, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.100; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris RA, 2002, PROTEOMICS, V2, P212, DOI 10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Lee HK, 1999, PROSTATE, V40, P14, DOI 10.1002/(SICI)1097-0045(19990615)40:1<14::AID-PROS2>3.0.CO;2-6; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; NAKAJIMA N, 1995, FEBS LETT, V365, P108, DOI 10.1016/0014-5793(95)00453-G; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.3.CO;2-S; Sanchez JC, 1997, ELECTROPHORESIS, V18, P324, DOI 10.1002/elps.1150180305; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shieh DB, 1999, CANCER-AM CANCER SOC, V85, P47, DOI 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; WANG JA, 1996, J CHINA COAL SCI, V1, P16; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592	38	27	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4403	4413		10.1038/sj.onc.1205525	http://dx.doi.org/10.1038/sj.onc.1205525			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080471				2022-12-17	WOS:000176317100006
J	Biroccio, A; Amodei, S; Benassi, B; Scarsella, M; Cianciulli, A; Mottolese, M; Del Bufalo, D; Leonetti, C; Zupi, G				Biroccio, A; Amodei, S; Benassi, B; Scarsella, M; Cianciulli, A; Mottolese, M; Del Bufalo, D; Leonetti, C; Zupi, G			Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones	ONCOGENE			English	Article						c-Myc; telomerase; tumorigenicity; apoptosis; melanoma	TELOMERASE REVERSE-TRANSCRIPTASE; NORMAL HUMAN-CELLS; CATALYTIC SUBUNIT; IN-VITRO; ANTISENSE OLIGODEOXYNUCLEOTIDES; HUMAN FIBROBLASTS; TRANSGENIC MICE; TUMOR-CELLS; LIFE-SPAN; GENE	c-Myc is involved in the control of telomerase activity through its ability to induce the expression of the catalytic subunit of the enzyme, the human telomerase reverse transcriptase (hTERT). Our aim was to study whether telomerase plays a critical role in c-Myc-dependent tumorigenicity of melanoma cells. By using M14-derived clones, expressing low levels of c-Myc, we demonstrated that the down-regulation of c-Myc reduced cell proliferation rate, cloning efficiency and tumorigenicity and increased the apoptotic rate. Decreased tumorigenic potential correlated with reduced hTERT gene expression, telomerase activity and telomere shortening. Introduction of wild-type hTERT into these cells increased their proliferation rate and partially re-established their tumorigenic potential, at early passages, even though the apoptotic rate of the population remained unaltered. After several in vitro passages, hTERT-mediated cell proliferation made the tumorigenic potential of the c-Myc low-expressing clones comparable to that of the M14 parental line. Over-expression of the mutant biologically inactive hTERT did not drive cells to proliferate. In conclusion, our results demonstrate that the reconstitution of high levels of telomerase activity reverses the low tumorigenicity due to low c-Myc expression.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy; Regina Elena Inst Canc Res, Clin & Pathol Labs, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Zupi, G (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy.	zupi@ifo.it	Biroccio, Annamaria/B-2861-2018; Del Bufalo, Donatella/K-8673-2016; Scarsella, Marco/AAA-1486-2020; Leonetti, Carlo/B-2860-2018; Del Bufalo, Donatella/AAC-1594-2021	Biroccio, Annamaria/0000-0003-3198-3532; Del Bufalo, Donatella/0000-0002-3148-6096; Leonetti, Carlo/0000-0002-3526-7827; Del Bufalo, Donatella/0000-0002-3148-6096; Scarsella, Marco/0000-0002-3386-9664				Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CHADENEAU C, 1995, ONCOGENE, V11, P893; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Citro G, 1998, CANCER RES, V58, P283; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	48	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3011	3019		10.1038/sj.onc.1205415	http://dx.doi.org/10.1038/sj.onc.1205415			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082531				2022-12-17	WOS:000175262700008
J	Izutsu, K; Kurokawa, M; Imai, Y; Ichikawa, M; Asai, T; Maki, K; Mitani, K; Hirai, H				Izutsu, K; Kurokawa, M; Imai, Y; Ichikawa, M; Asai, T; Maki, K; Mitani, K; Hirai, H			The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP	ONCOGENE			English	Article						AML1/Evi-1; CtBP; AML1; dominant negative	ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; STIMULATING FACTOR-RECEPTOR; ACUTE MYELOGENOUS LEUKEMIA; AML1 GENE; TRANSCRIPTIONAL REGULATION; CELL-DIFFERENTIATION; GROWTH-FACTOR; CO-REPRESSOR; RUNT DOMAIN	AML1/Evi-1 is a chimeric protein that is derived from t(3;21), found in blastic transformation of chronic myelogenous leukemia. It is composed of the N-terminal AML1 portion with the DNA-binding Runt domain and the C-terminal Evi-1 portion. It has been shown to dominantly repress AML1-induced transactivation. The mechanism for it has been mainly attributed to competition with AML1 for the DNA-binding and for the interaction with PEBP2beta (CBFbeta), a partner protein which heterodimerizes with AML1 It was recently found that Evi-1 interacts with C-terminal binding protein (CtBP) to repress TGFbeta-induced transactivation. Here, we demonstrate that AML1/Evi-1 interacts with CtBP in SKH1 cells, a leukemic cell fine which endogenously overexpresses AML1/Evi-1 and that AML1/Evi-1 requires the interaction with CtBP to repress AML1-induced transactivation. The association with CtBP is also required when AML1/Evi-1 blocks myeloid differentiation of 32Dcl3 cells induced by granulocyte colony-stimulating factor. Taken together, it is suggested that one of the mechanisms for AML1/Evi-1-associated leukemogenesis should be an aberrant recruitment of a corepressor complex by the chimeric protein.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan; Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan	University of Tokyo; Dokkyo Medical University	Hirai, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hhirai-tky@umin.ac.jp	Izutsu, Koji/AAI-1125-2019	Izutsu, Koji/0000-0001-9129-8057; Ichikawa, Motoshi/0000-0001-6497-0848; Imai, Yoichi/0000-0002-2938-6133				BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brannon M, 1999, DEVELOPMENT, V126, P3159; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Ferrara FF, 2001, CANCER RES, V61, P2; Fixe P, 1998, CYTOKINE, V10, P32, DOI 10.1006/cyto.1997.0249; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Guidez F, 2000, BLOOD, V96, P2557; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kosugi H, 1999, LEUKEMIA, V13, P1316, DOI 10.1038/sj.leu.2401508; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; KUROKAWA M, 1995, ONCOGENE, V11, P833; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Mitani K, 1997, LEUKEMIA, V11, P863, DOI 10.1038/sj.leu.2400666; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Zent C, 1996, CURR TOP MICROBIOL, V211, P243; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	58	27	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2695	2703		10.1038/sj.onc.1205356	http://dx.doi.org/10.1038/sj.onc.1205356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965542				2022-12-17	WOS:000174996500009
J	Finkeltov, I; Kuhn, S; Glaser, T; Idelman, G; Wright, JJ; Roberts, CT; Werner, H				Finkeltov, I; Kuhn, S; Glaser, T; Idelman, G; Wright, JJ; Roberts, CT; Werner, H			Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein	ONCOGENE			English	Article						DSRCT; IGF-I receptor; EWS; WT1; translocation	ROUND-CELL TUMOR; HUMAN MYXOID CHONDROSARCOMA; WILMS-TUMOR; EWS GENE; EWINGS-SARCOMA; CHROMOSOME-TRANSLOCATION; PROMOTER ACTIVITY; MALIGNANT-MELANOMA; GENOMIC STRUCTURE; SUPPRESSOR WT1	The EWS family of genes is involved in numerous chromosomal translocations that are characteristic of a variety of sarcomas. A recently described member of this group is desmoplastic small round cell tumor (DSRCT), which is characterized by a recurrent t(11;22)(p13;q12) translocation that fuses the 5' exons of the EWS gene to the 3' exons of the WT1 gene. The originally described chimera comprises exons 1 - 7 of EWS and exons 8 - 10 of WT1. We have previously reported that the WT1 protein represses the expression of the IGF-I receptor gene, whereas the EWS(1 - 7)-WT 1(8 - 10) fusion protein activates IGF-I receptor gene expression. It has recently become apparent that EWS-WT1 chimeras produced in DSCRT are heterogeneous as a result of fusions of different regions of the EWS gene to the WT1 gene. We have recently characterized additional EWS-WT1 translocations that involve the juxtaposition of EWS exons 7 or 8 to WT1 exon 8, and an EWS-WT1 chimera that lacks EWS exon 6. The chimeric transcription factors encoded by these various translocations differ in their DNA-binding characteristics and their ability to transactivate the IGF-I receptor promoter. These data suggest that the molecular pathology of DSRCT is more complex than previously appreciated, and that this diversity may provide the foundation for predictive genotype-phenotype correlations in the future.	Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Ramat Aviv, Israel; NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20889 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Oregon Health & Science University	Werner, H (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Ramat Aviv, Israel.	hwerner@post.tau.ac.il	Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772	NIDDK NIH HHS [DK50810] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050810] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonescu CR, 1998, DIAGN MOL PATHOL, V7, P24, DOI 10.1097/00019606-199802000-00005; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; BRODIE SG, 1995, HUM PATHOL, V26, P1370, DOI 10.1016/0046-8177(95)90303-8; Chan AS, 1999, PEDIATR DEVEL PATHOL, V2, P188, DOI 10.1007/s100249900108; Clark J, 1996, ONCOGENE, V12, P229; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; GANSLER T, 1989, AM J PATHOL, V135, P961; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GILL S, 1995, GENE CHROMOSOME CANC, V12, P307, DOI 10.1002/gcc.2870120412; GONZALEZCRUSSI F, 1990, AM J SURG PATHOL, V14, P633, DOI 10.1097/00000478-199007000-00004; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; JEON IS, 1995, ONCOGENE, V10, P1229; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; KURODA M, 1995, AM J PATHOL, V147, P1221; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LADANYI M, 1994, CANCER RES, V54, P2837; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Liu J, 2000, CLIN CANCER RES, V6, P3522; Maor SB, 2000, MOL GENET METAB, V69, P130, DOI 10.1006/mgme.1999.2958; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; OHNO T, 1994, ONCOGENE, V9, P3087; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; RESNICOFF M, 1995, CANCER RES, V55, P3739; SAWYER JR, 1992, AM J SURG PATHOL, V16, P411, DOI 10.1097/00000478-199204000-00010; Shimizu Y, 1998, CANCER GENET CYTOGEN, V106, P156, DOI 10.1016/S0165-4608(98)00062-4; Tajinda K, 1999, ENDOCRINOLOGY, V140, P4713, DOI 10.1210/en.140.10.4713; WERNER H, 1994, VITAM HORM, V48, P1, DOI 10.1016/S0083-6729(08)60495-1; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Werner H, 1996, J MOL NEUROSCI, V7, P111, DOI 10.1007/BF02736791; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	48	27	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1890	1898		10.1038/sj.onc.1205042	http://dx.doi.org/10.1038/sj.onc.1205042			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896622				2022-12-17	WOS:000174284500012
J	Kukushkin, AN; Abramova, MV; Svetlikova, SB; Darieva, ZA; Pospelova, TV; Pospelov, VA				Kukushkin, AN; Abramova, MV; Svetlikova, SB; Darieva, ZA; Pospelova, TV; Pospelov, VA			Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter	ONCOGENE			English	Article						c-fos repression; Elk-1; histone deacetylase; chromatin; E1A and ras oncogenes	SIGNAL-TRANSDUCTION PATHWAYS; SERUM RESPONSE ELEMENT; P38 MAP KINASE; HISTONE ACETYLATION; PROTEIN-KINASE; JUN PROMOTER; DNA-BINDING; IN-VIVO; INHIBITION; EXPRESSION	REF cells transformed by oncogenes E1A and cHa-ras reveal high and constitutive DNA-binding activity of AP-1 factor lacking in c-Fos protein. Consistently, the transcription of c-fos gene has been found to be downregulated. To elucidate the mechanisms of c-fos downregulation in E1A+cHa-ras transformants, we studied the levels of activity of ERK, JNK/SAPK and p38 kinases and phosphorylation state of Elk-1 transcription factor involved in regulation of c-fos gene. Using two approaches, Western blot analysis with phospho-specific antibodies to MAP kinases and in vitro kinase assay with specific substrates, we show here that ectopic expression of E1A and ras oncogenes leads to a sustained activation of ERK and p38 kinases, whereas JNK/SAPK kinase activity is similar to that in non-transformed REF52 cells. Due to sustained activity of the MAP kinase cascades, Elk-1 transcription factor is being phosphorylated even in serum-starved E1A+cHa-ras cells; moreover, serum does not additionally increase phosphorylation of Elk-1, which is predominant TCF protein bound to SRE region of c-fos gene promoter in these cells. Although the amount of ternary complexes SRE/SRF/TCF estimated by EMSA was similar both in serum-starved and serum-stimulated transformed cells, serum addition still caused a modest activation of c-fos gene transcription at the level of 20% to normal REF cells. In attempt to determine how serum caused the stimulatory effect, we found that PD98059, an inhibitor of MEK/ERK kinase cascade, completely suppressed serum-induced c-fos transcription both in REF and E1A+cHa-ras cells, implicating the ERK as primary kinase for c-fos transcription in these cells. In contrast, SB203580, an inhibitor of p38 kinase, augmented noticeably serum-stimulated transcription of c-fos gene in REF cells, implying the involvement of p38 kinase in negative regulation of c-fos. Furthermore, sodium butyrate, an inhibitor of histone deacetylase activity, was capable of activating c-fos transcription both in serum-stimulated and even in serum-starved E1A+cHa-ras cells. Conversely, serum-starved REF cells fail to respond to sodium butyrate treatment by c-fos activation confirming necessity of prior Elk-1 phosphorylation. Taken together, these data suggest that downregulation of c-fos in E1A+cHa-ras cells seems to occur due to a maintenance of a refractory state that arises in normal REF cells after serum-stimulation. The refractory state of c-fos in E1A+cHa-ras cells is likely a consequence of Ras-induced sustained activation of MAPK (ERK) cascade and persistent phosphorylation of TCF (Elk-1) bound to SRE. Combination of these events eventually does contribute to formation of an inactive chromatin structure at c-fos promoter mediated through recruitment of histone deacetylase activity.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelov, VA (corresponding author), Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia.	vap@link.cytspb.rssi.ru	Igotti, Maria V/U-4868-2017; Kukushkin, Alexander/W-7241-2018	Igotti, Maria/0000-0001-9596-5195				ABRAMOVA MV, 2002, MOL BIOL MOSCOW, V36; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; Ding XZ, 2001, BIOCHEM BIOPH RES CO, V282, P447, DOI 10.1006/bbrc.2001.4595; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Herrera RE, 1997, CHROMOSOMA, V106, P284, DOI 10.1007/s004120050249; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kessler R, 1999, ONCOGENE, V18, P1733, DOI 10.1038/sj.onc.1202484; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LAVARONE A, 1999, MOL CELL BIOL, V19, P916; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Malashicheva AB, 2000, ONCOGENE, V19, P3858, DOI 10.1038/sj.onc.1203736; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pospelova TV, 1999, GENE EXPRESSION, V8, P19; Pospelova TV, 1996, MOL BIOL+, V30, P394; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rosenberger SF, 1999, ONCOGENE, V18, P3626, DOI 10.1038/sj.onc.1202695; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; ROZEK D, 1995, J CELL BIOCHEM, V57, P479, DOI 10.1002/jcb.240570313; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	61	27	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					719	730		10.1038/sj.onc.1205118	http://dx.doi.org/10.1038/sj.onc.1205118			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850800				2022-12-17	WOS:000173427000003
J	Zhao, BH; Bepler, G				Zhao, BH; Bepler, G			Transcript map and complete genomic sequence for the 310 kb region of minimal allele loss on chromosome segment 11p15.5 in non-small-cell lung cancer	ONCOGENE			English	Article						lung cancer; chromosome 11p15.5; transcript map; genomic sequence; SSA/Ro52; RRM1	FULL-LENGTH CDNA; SHORT ARM; RIBONUCLEOTIDE REDUCTASE; GENES; HETEROZYGOSITY; ADENOCARCINOMA; 11P; AMPLIFICATION; ESTABLISHMENT; PROGRESSION	Molecular, functional, and clinical analyses strongly suggest that chromosome segment 11p15.5 contains a gene involved in lung cancer pathogenesis. The critical region of allele loss is 310 kb in size. We used our contig of P1-phage artificial chromosome (PAC) clones together with newly identified bacterial artificial chromosome (BAC) clones and the draft human genome sequence to complete a contiguous string of 380 407 bp. Three PAC clones that span the region were used to identify transcripts by exon trapping. Computational gene prediction algorithms were used to query the sequence for potential genes and exons. Screening for expression was performed with tissue-specific and cell line derived mRNA arrays. The region contains the complete SSA/Ro52 and RRM1 genes, exons 7-12 of the GOK gene, and the psi rad pseudo-gene. A cluster of six nearly identical genes with an intact open reading frame (ORF) of 585 bp that share 75% identity with the HSPC182 gene was found. In addition, five putative novel genes were identified. Sequence tagged sites (STS) and polymorphic markers were used to screen 117 lung cancer cell lines for homozygous deletions and none were identified. These data provide the basis for the identification of a lung cancer suppressor gene on 11p15.5.	Roswell Pk Canc Inst, Dept Med, Lung Canc Program, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Genet, Lung Canc Program, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute	Bepler, G (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, MRC MOLONC, 12902 Magnolia St, Tampa, FL 33612 USA.	beplerg@moffitt.usf.edu			NCI NIH HHS [P30 CA 16056, 5R01 CA 70317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA070317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEPLER G, 1988, DIFFERENTIATION, V37, P158, DOI 10.1111/j.1432-0436.1988.tb00806.x; Bepler G, 1995, CANCER GENET CYTOGEN, V84, P39, DOI 10.1016/0165-4608(95)00063-1; Bepler G, 1998, CANCER DETECT PREV, V22, P14; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bepler G, 1999, GENOMICS, V55, P164, DOI 10.1006/geno.1998.5659; BEPLER G, 1987, J CANCER RES CLIN, V113, P31, DOI 10.1007/BF00389964; BEPLER G, 2000, P AN M AM SOC CLIN, V19, pA485; Bork P, 2001, NATURE, V409, P818, DOI 10.1038/35057274; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; CARNEY DN, 1985, CANCER RES, V45, P2913; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Dickson D, 1999, NATURE, V401, P311, DOI 10.1038/43722; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306; Frengen E, 1999, GENOMICS, V58, P250, DOI 10.1006/geno.1998.5693; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Karnik P, 1998, HUM MOL GENET, V7, P895, DOI 10.1093/hmg/7.5.895; Kim YC, 2000, INT J CANCER, V87, P61, DOI 10.1002/1097-0215(20000701)87:1<61::AID-IJC9>3.0.CO;2-R; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lu KH, 1997, CANCER RES, V57, P387; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; OBriant K, 1997, ANTICANCER RES, V17, P3243; Phelps RM, 1996, J CELL BIOCHEM, P32; Pitterle Diana M., 2000, Current Genomics, V1, P281, DOI 10.2174/1389202003351373; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; RANZANI GN, 1993, HUM GENET, V92, P244; Reese MG, 2000, GENOME RES, V10, P529, DOI 10.1101/gr.10.4.529; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SKINNER MA, 1990, CANCER RES, V50, P2303; Stubbe J, 1998, P NATL ACAD SCI USA, V95, P2723, DOI 10.1073/pnas.95.6.2723; Tran YK, 1996, CANCER RES, V56, P2916; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Uberbacher EC, 1996, METHOD ENZYMOL, V266, P259; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VIEL A, 1992, BRIT J CANCER, V66, P1030, DOI 10.1038/bjc.1992.405; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WINQVIST R, 1993, CANCER RES, V53, P4486; Zhumabayeva B, 1999, BIOTECHNIQUES, V27, P834, DOI 10.2144/99274rr06	49	27	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2001	20	56					8154	8164		10.1038/sj.onc.1205027	http://dx.doi.org/10.1038/sj.onc.1205027			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781830				2022-12-17	WOS:000172396800014
J	Nakamura, T; Kanda, S; Yamamoto, K; Kohno, T; Maeda, K; Matsuyama, T; Kanetake, H				Nakamura, T; Kanda, S; Yamamoto, K; Kohno, T; Maeda, K; Matsuyama, T; Kanetake, H			Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation	ONCOGENE			English	Article						renal carcinoma cells; motility; HGF; HGF receptor; PI3-kinase	FACTOR SCATTER FACTOR; ANCHORAGE-INDEPENDENT GROWTH; SIS-TRANSFORMED-CELLS; CONSTITUTIVE ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; MET PROTOONCOGENE; C-MET; POINT MUTATION; ENDOTHELIAL-CELLS	Dysregulated cell motility is one of the major characteristics of invasion and metastatic potentials of malignant tumor cells. Here, we examined the hepatocyte growth factor (HGF)-induced cell motility of two human renal carcinoma cell lines, ACHN and VMRC-RCW. Scattering and migration was induced in ACHN in an HGF-dependent manner, whereas they were maintained in VMRC-RCW even in the absence of HGF. In VMRC-RCW, HGF receptor (HGFR) tyrosine kinase was constitutively active, and sequence analysis showed N375S, A1209G and V1290L mutations. However, transfection experiments using porcine aortic endothelial (PAE) cells demonstrated that no single mutation or combination of two or three mutations caused HGF-independent constitutive activation. Conversely, the expressed amount of receptor protein had a pivotal role in the basal kinase activity. With respect to downstream signaling molecules of HGFR in ACHN or VMRC-RCW, the Ras-MAPK pathway was downregulated, whereas phosphoinositide 3-kinase (PI3-kinase) was not further activated by HGF-treatment in VMRC-RCW cells. The PI3-kinase inhibitors, wortmannin and LY294002 strongly inhibited spontaneous migration of VMRC-RCW. One transfected PAE cell line with massive overexpression of HGFR demonstrated scattered morphology and increased PI3-kinase activity in association with increased motility, which was partially inhibited by LY294002. Taken together, our results indicate that the overexpression of HGFR causes increase in cellular motility and PI3-kinase shows the important contribution on the increased motility of renal carcinoma cells.	Nagasaki Univ, Sch Med, Dept Urol, Nagasaki 8528501, Japan; Nagasaki Univ, Grad Sch Med, Dept Mol Microbiol & Immunol, Div Cytokine Signaling, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Med, Div Endothelial Cell Biol, Nagasaki 8528501, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Kanda, S (corresponding author), Nagasaki Univ, Grad Sch Med, Dept Mol Microbiol & Immunol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Herrera R, 1998, J CELL SCI, V111, P1039; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; Inoue G, 1996, J BIOL CHEM, V271, P28206, DOI 10.1074/jbc.271.45.28206; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; Kanda S, 2000, J BIOL CHEM, V275, P10105, DOI 10.1074/jbc.275.14.10105; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Lee RCH, 1999, J BIOL CHEM, V274, P10024, DOI 10.1074/jbc.274.15.10024; Levine M D, 1995, EXS, V74, P157; LONGATI P, 1994, ONCOGENE, V9, P49; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakopoulou L, 1997, PATHOL RES PRACT, V193, P299; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; NISHIMURA N, 1992, INT J CANCER, V52, P105, DOI 10.1002/ijc.2910520119; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 1999, CANCER RES, V59, P307; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rusciano D, 1996, J BIOL CHEM, V271, P20763, DOI 10.1074/jbc.271.34.20763; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; TAKAISHI K, 1994, ONCOGENE, V9, P273; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wells A, 2000, ADV CANCER RES, V78, P31; WENNSTROM S, 1994, ONCOGENE, V234, P434; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	76	27	28	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7610	7623		10.1038/sj.onc.1204975	http://dx.doi.org/10.1038/sj.onc.1204975			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753639				2022-12-17	WOS:000172124100004
J	Delarue, FL; Taylor, BS; Sebti, SM				Delarue, FL; Taylor, BS; Sebti, SM			Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase-2 in human normal liver AKN-1 cells and lung cancer A-549 cells	ONCOGENE			English	Article						NOS-2; Ras; RhoA; RhoB; Erk; cytokines	SMOOTH-MUSCLE CELLS; PRIMARY ASTROCYTES; TUMOR-GROWTH; TRANSFORMATION; PROTEIN; EXPRESSION; INDUCTION; GENE; ADENOCARCINOMA; INHIBITION	While both nitric oxide synthase-2 (NOS-2) and low molecular weight GTPases, such as Ras and Rho, have been implicated in malignant transformation, the cross talk between these important proteins is ill understood. In this study we examined the ability of H-Ras, RhoA, RhoB and Rac1 to modulate cytokine-induced NOS2. In the normal human liver AKN-1 cell line and in the human non-small cell lung carcinoma cell line, A-549, the ability of the cytokines (INF-gamma, IL-1 beta and TNF-alpha) to activate NOS-2 was blocked by activated L61-H-Ras whereas dominant negative N17-H-Ras enhanced NOS-2 activation. Consistent with this dominant negative Erk2 as well as a MEK inhibitor also enhanced cytokine activation of NOS-2. Furthermore, activated L63-RhoA blocked whereas activated V14-RhoB enhanced cytokine NOS-2 activation. Activated I115-Rac1 did not affect NOS-2 activation. These results demonstrate that the Ras/Erk and the Ras/RhoA pathways negatively regulate whereas RhoB enhances cytokine-induced NOS-2. This is the first demonstration that genes that promote malignant transformation such as Ras and RhoA inhibit, whereas genes with tumor suppresser activity such as RhoB enhance NOS2 induction.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Oncol, Tampa, FL USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA-67771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; CURLEY SA, 1993, J LEUKOCYTE BIOL, V53, P715, DOI 10.1002/jlb.53.6.715; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DONG ZY, 1994, CANCER RES, V54, P789; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; HER JH, 1993, MOL CELL BIOL, V19, P7519; Juang SH, 1997, CANCER BIOTHER RADIO, V12, P167, DOI 10.1089/cbr.1997.12.167; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LEPOIVRE M, 1989, CANCER RES, V49, P1970; MORDAN LJ, 1993, CARCINOGENESIS, V14, P1555, DOI 10.1093/carcin/14.8.1555; Muniyappa R, 2000, AM J PHYSIOL-HEART C, V278, pH1762, DOI 10.1152/ajpheart.2000.278.6.H1762; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Nussler AK, 1999, IN VITRO CELL DEV-AN, V35, P190, DOI 10.1007/s11626-999-0026-4; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Sambrook J, 1989, MOL CLONING LAB MANU; SCHINI VB, 1992, EUR J PHARMACOL, V216, P379, DOI 10.1016/0014-2999(92)90434-6; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shi Q, 2000, CANCER RES, V60, P2579; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Wang BL, 2001, CANCER RES, V61, P71; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	28	27	29	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6531	6537		10.1038/sj.onc.1204801	http://dx.doi.org/10.1038/sj.onc.1204801			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641777				2022-12-17	WOS:000171404200005
J	Coffin, WF; Erickson, KD; Hoedt-Miller, M; Martin, JM				Coffin, WF; Erickson, KD; Hoedt-Miller, M; Martin, JM			The cytoplasmic amino-terminus of the Latent Membrane Protein-1 of Epstein-Barr Virus: relationship between transmembrane orientation and effector functions of the carboxy-terminus and transmembrane domain	ONCOGENE			English	Article						LMP-1; EBV; transmembrane topology; signaling	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; INTERNAL SIGNAL SEQUENCE; LYMPHOCYTE TRANSFORMATION; CHARGED RESIDUES; C-TERMINUS; 1 ENGAGES; LMP1; EXPRESSION; ACTIVATION	The Latent Membrane Protein 1 (LMP-1) protein of Epstein-Barr virus (EBV) is localized in the plasma membrane of the infected cell. LMP-1 possesses a hydrophobic membrane spanning domain, and charged, intracellular amino- and carboxy-termini. Two models have been proposed for the contribution of the amino-terminus to LMP-l's function: (i) as an effector domain, interacting with cellular proteins, or (ii) as a structural domain dictating the correct orientation of transmembrane domains and thereby positioning LMP-l's critical effector domains (i.e. the carboxy-terminus). However, no studies to date have addressed directly the structural contributions of LMP-1s cytoplasmic amino-terminus to function. This study was designed to determine if LMP-1's cytoplasmic amino-terminus (N-terminus) encodes information required solely for maintenance of proper topological orientation. We have constructed LMP-1 chimeras in which the cytoplasmic N-terminus of LMP-1 is replaced with an unrelated domain of similar size and charge, but of different primary sequence. Retention of the charged amino-terminal (N-terminal) cytoplasmic domain and first predicted transmembrane domain was required for correct transmembrane topology. The absolute primary sequence of the cytoplasmic N-terminus was not critical for LMP-1's cytoskeletal association, turnover, plasma membrane patching, oligomerization, Tumor Necrosis Factor Receptor-associated factor (TRAF) binding, NF-kappaB activation, rodent cell transformation and cytostatic activity. Furthermore, our results point to the hydrophobic transmembrane domain, independent of the cytoplasmic domains, as the primary LMP-1 domain mediating oligomerization, patching and cytoskeletal association. The cytoplasmic amino-terminus provides the structural information whereby proper transmembrane orientation is achieved.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Martin, JM (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Box 347, Boulder, CO 80309 USA.	jm@stripe.colorado.edu	Erickson, Kimberly/AAR-8747-2021	Erickson, Kimberly/0000-0002-6260-282X	NATIONAL CANCER INSTITUTE [R29CA064610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001537] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64610] Funding Source: Medline; NIAID NIH HHS [AI-01537] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; BAICHWAL VR, 1989, ONCOGENE, V4, P67; Bankier A T, 1983, Mol Biol Med, V1, P425; BELTZER JP, 1991, J BIOL CHEM, V266, P973; Bloss T, 1999, J GEN VIROL, V80, P3227, DOI 10.1099/0022-1317-80-12-3227; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Clausse B, 1997, VIROLOGY, V228, P285, DOI 10.1006/viro.1996.8380; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Erickson KD, 2000, J VIROL, V74, P1057, DOI 10.1128/JVI.74.2.1057-1060.2000; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GRATAMA JW, 1991, INT J CANCER, V47, P188, DOI 10.1002/ijc.2910470205; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2276, DOI 10.1073/pnas.80.8.2276; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hatzivassiliou E, 1998, J IMMUNOL, V160, P1116; HEDGE R, 1997, CELL, V28, P575; HEDGE RS, 1999, TRENDS CELL BIOL, V9, P132; HUEN DS, 1995, ONCOGENE, V10, P549; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; KNUTSON VP, 1985, J BIOL CHEM, V260, P4180; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MARTIN J, 1991, CELL GROWTH DIFFER, V2, P653; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MILELR G, 1985, EPSTEIN BARR VIRUS; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; RABSON M, 1983, P NATL ACAD SCI-BIOL, V80, P2762, DOI 10.1073/pnas.80.9.2762; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	76	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5313	5330		10.1038/sj.onc.1204689	http://dx.doi.org/10.1038/sj.onc.1204689			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536044				2022-12-17	WOS:000170575500007
J	Saito, Y; Ochiai, Y; Kodama, Y; Tamura, Y; Togashi, T; Kosugi-Okano, H; Miyazawa, T; Wakabayashi, Y; Hatakeyama, K; Wakana, S; Niwa, O; Kominami, R				Saito, Y; Ochiai, Y; Kodama, Y; Tamura, Y; Togashi, T; Kosugi-Okano, H; Miyazawa, T; Wakabayashi, Y; Hatakeyama, K; Wakana, S; Niwa, O; Kominami, R			Genetic loci controlling susceptibility to gamma-ray-induced thymic lymphoma	ONCOGENE			English	Article						susceptibility gene; genetic mapping; gamma-ray radiation; mouse thymic lymphoma; congenic mouse	INTESTINAL NEOPLASIA; CANCER SUSCEPTIBILITY; SUPPRESSOR GENE; DEFICIENT MICE; COMPLEX TRAITS; MAJOR MODIFIER; COLON-CANCER; MOUSE; RESISTANCE; TUMORS	BALB/c is a susceptible strain for the development of gamma -ray induced mouse thymic lymphoma whereas MSM shows resistance. Association analysis of 220 backcross mice between the two strains using 67 markers was carried out to identify loci involved in the control of susceptibility. The genotype of mice with lymphoma showed excess heterozygosity relative to MSM homozygosity at D2Mit15 and D4Mit12 and was skewed toward MSM-derived alleles at D5Mit5. The P values in Mantel-Cox test were 0.0048 (D2Mit15), 0.0034 (D4Mit12) and 0.0048 (D5Mit5), suggesting association at the three loci in the susceptibility. Cooperative effect on lymphomagenesis was also observed among the three loci. To obtain independent evidence for linkage at D4Mit12, we made partially congenic mice in which a D4Mit12 region in BALB/c was replaced by MSM-derived homolog. Examination for the lymphoma susceptibility in 78 progeny of the congenic mice confirmed the effect of the locus near D4Mit12 (P=0.0037). The result, together with the linkage analysis, shows that the locus near D4Mit12 is regarded as a confirmed linkage but the other two loci as marginally suggestive.	Niigata Univ, Sch Med, Dept Biochem 1, Niigata 9518122, Japan; Niigata Univ, Sch Med, Dept Surg 1, Niigata 9518122, Japan; Kyoto Univ, Inst Phys, Kyoto, Japan; Kyoto Univ, Chem Res Genome Sci Ctr, Kyoto, Japan; Kyoto Univ, Ctr Radiat Biol, Kyoto 606, Japan	Niigata University; Niigata University; Kyoto University; Kyoto University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem 1, Asahimachi 1-757, Niigata 9518122, Japan.							Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; Baross-Francis A, 2000, CARCINOGENESIS, V21, P1259, DOI 10.1093/carcin/21.6.1259; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Demant P, 1992, Semin Cancer Biol, V3, P159; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; MERUELO D, 1981, J EXP MED, V154, P1201, DOI 10.1084/jem.154.4.1201; Moen CJA, 1996, P NATL ACAD SCI USA, V93, P1082, DOI 10.1073/pnas.93.3.1082; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; OKUMOTO M, 1990, CANCER RES, V50, P3848; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; Shisa H, 1996, JPN J CANCER RES, V87, P258, DOI 10.1111/j.1349-7006.1996.tb00214.x; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; van Wezel T, 1999, CANCER RES, V59, P4216; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590	28	27	29	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5243	5247		10.1038/sj.onc.1204675	http://dx.doi.org/10.1038/sj.onc.1204675			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526516				2022-12-17	WOS:000170464000021
J	Hu, JD; Ma, XR; Lindner, DJ; Karra, S; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV				Hu, JD; Ma, XR; Lindner, DJ; Karra, S; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV			Modulation of p53 dependent gene expression and cell death through thioredoxin-thioredoxin reductase by the interferon-retinoid combination	ONCOGENE			English	Article						cytokines; vitamin; growth suppression; apoptosis; redox state	HUMAN TUMOR-CELLS; REDOX REGULATION; DNA-BINDING; MOLECULAR-CLONING; SUPPRESSES GROWTH; INDUCED APOPTOSIS; VITAMIN-A; CANCER; RECEPTOR; PROTEIN	We have shown earlier that the IFN-P and all-trans retinoic acid (RA) combination, but not the single agents, induces death in several tumor cell lines. Employing a genetic technique we have identified several Genes associated with Retinoid-IFN induced Mortality (GRIM), One of the GRIMs was human thioredoxin reductase (TR), a redox enzyme. Since the overexpressed TR augments IFN/RA stimulated cell death, we explored the mechanisms of TR-mediated death, Here we show that TR augments cell death by upregulating the transcriptional activity of p53 tumor suppressor. This process does not involve a physical increase in levels of p53, Using redox inactive mutants of TR and its substrate, thioredoxin (Trx), we demonstrate that IFN/ RA-induced regulation of p53 dependent gene expression requires TR and Trx, In contrast-over-expression of wildtype TR or Trx augment the p53 dependent gene expression in response to IFN/RA treatment. Consistent with these results an increased DNA binding activity of p53 was noted in the presence of TR, These studies identify a novel mechanism of p53 mediated cell death regulation involving redox enzymes.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Greenebaum Canc Ctr,Mol & Cellular Biol Program, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Sci, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Greenebaum Canc Ctr,Mol & Cellular Biol Program, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 71401, CA 78282] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Di Leonardo A, 1997, CANCER RES, V57, P1013; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; FAN SJ, 1995, CANCER RES, V55, P1649; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAINAUT P, 1993, CANCER RES, V53, P4469; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MA X, 2001, IN PRESS J BIOL CHEM; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; MIYASHITA T, 1995, CELL, V80, P293; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALZ HK, 1994, GENETICS, V136, P1075; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Tanioka A, 1997, COLLOID SURFACE B, V9, P17, DOI 10.1016/S0927-7765(97)00006-4; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TSUKADA T, 1993, ONCOGENE, V8, P3313; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103	69	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4235	4248		10.1038/sj.onc.1204585	http://dx.doi.org/10.1038/sj.onc.1204585			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464290				2022-12-17	WOS:000169857200014
J	Ao, Y; Rohde, LH; Naumovski, L				Ao, Y; Rohde, LH; Naumovski, L			p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis	ONCOGENE			English	Article						53BP2; p53; apoptosis; doxorubicin; paclitaxel	P53; PROGRESSION; INTERACTS; DOMAINS; BINDS; DEATH	53BP2 was initially identified as a protein interacting with p53 in a yeast two-hybrid screen and subsequently shown to enhance p53 transcriptional transactivation and induce apoptosis when transiently overexpressed in cell lines. In order to further study the biologically relevant effects of 53BP2, we have constructed HEK293 stable cell lines where 53BP2 expression can be regulated using an ecdysone inducible expression system. Our results indicate that the response of cells is dependent on the amount of 53BP2 that is expressed, High levels of 53BP2 expression(greater than or equal to 140-fold above endogenous) impede cell cycle progression and induce apoptosis, Lower levels of 53BP2 expression (6-11-fold above endogenous) suppress colony formation hut do not lead to detectable perturbations in the cell cycle or apoptosis, Lower levels of 53BP2 expression sensitized cells to apoptosis induced by DNA damaging chemotherapy agents doxorubicin, ara-C and VP16, but not microtubule active agents paclitaxel and vinblastine, Our results demonstrate that high levels of 53BP2 expression have profound biological effects ultimately leading to apoptosis, whereas lower levels of 53BP2 expression have more subtle effects on growth and sensitize cells to some chemotherapy agents.	Stanford Univ, Sch Med, Dept Pediat, Div Hematol Oncol, Stanford, CA 94305 USA	Stanford University	Naumovski, L (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Div Hematol Oncol, 269 Campus Dr,CCSR Rm 1215, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [R01CA076316] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76316] Funding Source: Medline; NHLBI NIH HHS [HL09552] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; NAUMOVSKI L, 1994, BLOOD, V83, P2261; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904	13	27	32	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2720	2725		10.1038/sj.onc.1204352	http://dx.doi.org/10.1038/sj.onc.1204352			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420684				2022-12-17	WOS:000168652600013
J	Vivo, C; Levy, F; Pilatte, Y; Fleury-Feith, J; Chretien, P; Monnet, I; Kheuang, L; Jaurand, MC				Vivo, C; Levy, F; Pilatte, Y; Fleury-Feith, J; Chretien, P; Monnet, I; Kheuang, L; Jaurand, MC			Control of cell cycle progression in human mesothelioma cells treated with gamma interferon	ONCOGENE			English	Article						human mesothelioma cell lines; cell cycle control; cyclin dependent kinase inhibitors; cyclin; r-hu-IFN gamma	MAMMARY EPITHELIAL-CELLS; KINASE INHIBITOR P21; DEPENDENT KINASE; GROWTH ARREST; INDOLEAMINE 2,3-DIOXYGENASE; GENE-EXPRESSION; DNA-DAMAGE; ALPHA; INTERLEUKIN-6; TRANSCRIPTION	Recombinant human interferon gamma (r-hu-IFN gamma) exerts both antitumoral activity in the early stages of human malignant mesothelioma and a cytostatic effect in human mesothelioma (HM) cell lines in vitro. The antiproliferative effect of interferons (IFNs) reported in a variety of cells has been attributed to several mechanisms. In order to progress in the understanding of HM cell growth modulation by r-hu-IFN gamma, modifications of cell cycle progression and expression of key cell cycle regulator proteins in response to r-hu-IFN gamma were examined. Nine HM cell lines were studied, including one resistant to the antiproliferative effect of r-hu-IFN gamma. Except in the resistant cell line r-hu-IFN gamma produced an arrest in the G1 and G2-M phases of the cell cycle, associated with a reduction in both cyclin A and cyclin dependent kinase inhibitors (CDKIs) expression. Moreover cyclin B1/cdc2 activity was decreased. The present study provides the first evidence of a GZ-arrest in r-hu-IFN gamma -treated HM cell lines and indicates that HM cell lines, despite their tumorigenic origin still support cell cycle control. The cell cycle arrest induced by r-hu-IFN gamma seems to depend on cyclin regulation through p21(WAF1/C1P1)- and p27(KiP1)-independent mechanisms and is not directly related to the induced DNA damage.	Univ Paris 12, INSERM U99 09, EA 2345, F-94010 Creteil, France; Hop Tenon, Serv Histol & Biol Tumorale, F-75020 Paris, France; Ctr Hosp Intercommunal, Serv Immunohematol, F-94010 Creteil, France; Ctr Hosp Intercommunal, Serv Pneumol, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil	Jaurand, MC (corresponding author), Univ Paris 12, INSERM U99 09, EA 2345, 8 Rue Gen Sarrail, F-94010 Creteil, France.		JAURAND, MARIE-CLAUDE/S-3538-2017; Pilatte, Yannick/AAD-1943-2019; Pilatte, Yannick/N-4422-2018	JAURAND, MARIE-CLAUDE/0000-0002-0915-6728; 				Astoul P, 1998, CANCER, V83, P2099, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3; BADER T, 1994, P NATL ACAD SCI USA, V91, P11831, DOI 10.1073/pnas.91.25.11831; BIELEFELDTOHMANN H, 1995, CANCER IMMUNOL IMMUN, V40, P241, DOI 10.1007/s002620050169; BIELEFELDTOHMANN H, 1995, J INTERF CYTOK RES, V15, P213, DOI 10.1089/jir.1995.15.213; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BOUTIN C, 1994, CANCER, V74, P2460, DOI 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N; BOWMAN RV, 1991, CANCER CHEMOTH PHARM, V28, P420, DOI 10.1007/BF00685817; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Buard A, 1998, CANCER RES, V58, P840; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHRISTMAS TI, 1993, J INTERFERON RES, V13, P9, DOI 10.1089/jir.1993.13.9; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FITZPATRICK DR, 1995, AM J RESP CELL MOL, V12, P455, DOI 10.1165/ajrcmb.12.5.7742009; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; Grander D, 1997, EUR J HAEMATOL, V59, P129; Grousson J, 2000, J INVEST DERMATOL, V114, P581, DOI 10.1046/j.1523-1747.2000.00905.x; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; HERZINGER T, 1995, ONCOGENE, V11, P2151; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; Jaiswal M, 2000, CANCER RES, V60, P184; JAURAND MC, 1986, MUTAT RES, V169, P141, DOI 10.1016/0165-1218(86)90093-5; Kominsky S, 1998, ONCOGENE, V17, P2973, DOI 10.1038/sj.onc.1202217; KOSAKA C, 1992, ATHEROSCLEROSIS, V97, P75, DOI 10.1016/0021-9150(92)90053-J; Lazutka JR, 1996, MUTAT RES-ENVIR MUTA, V361, P95, DOI 10.1016/S0165-1161(96)00027-1; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; MARTIN DM, 1993, J NEUROSCI RES, V34, P489, DOI 10.1002/jnr.490340502; MONTI G, 1994, CANCER RES, V54, P4419; Moro A, 1998, BIOCHEM BIOPH RES CO, V245, P752, DOI 10.1006/bbrc.1998.8512; OZAKI Y, 1988, P NATL ACAD SCI USA, V85, P1242, DOI 10.1073/pnas.85.4.1242; Peto J, 1999, BRIT J CANCER, V79, P666, DOI 10.1038/sj.bjc.6690105; PhanBich L, 1997, AM J RESP CELL MOL, V16, P178, DOI 10.1165/ajrcmb.16.2.9032125; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Subramaniam PS, 1999, J BIOL CHEM, V274, P403, DOI 10.1074/jbc.274.1.403; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; Ungar S, 1996, BRIT J CANCER, V74, P1534, DOI 10.1038/bjc.1996.585; Urashima M, 1997, BLOOD, V90, P279; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; XU JH, 1995, BLOOD, V86, P2774; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071; ZENG L, 1993, INT J CANCER, V55, P515, DOI 10.1002/ijc.2910550331	52	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1085	1093		10.1038/sj.onc.1204199	http://dx.doi.org/10.1038/sj.onc.1204199			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314045				2022-12-17	WOS:000167232100008
J	Vernucci, M; Cerrato, F; Besnard, N; Casola, S; Pedone, PV; Bruni, CB; Riccio, A				Vernucci, M; Cerrato, F; Besnard, N; Casola, S; Pedone, PV; Bruni, CB; Riccio, A			The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis	ONCOGENE			English	Article						genomic imprinting; hepatocarcinogenesis; insulin-like growth factor; apoptosis	GROWTH-FACTOR-II; INDUCED HEPATOCELLULAR CARCINOMAS; INSULIN-LIKE GROWTH-FACTOR-2; SV40 LARGE T; TRANSGENIC MICE; GENE; EXPRESSION; TUMORIGENESIS; APOPTOSIS; RAT	The expression of the linked but reciprocally imprinted Igf2 and H19 genes is activated in adult liver in the course of tumor development. By in situ hybridization analysis we have shown that both the Igf2 and H19 RNAs are expressed in the majority of the neoplastic nodules, and that hepatocellular carcinomas are developed in an experimental model of liver carcinogenesis. H19 is also highly activated in smaller and less distinct hyperplastic regions, The few neoplastic areas showing Igf2 but no H19 RNA display loss of the maternally inherited allele at the Igf2/H19 locus. These data are compatible with the existence of a common activation mechanism of these two genes during liver carcinogenesis and with a stronger H19 induction in the pre-neoplastic lesions. By using mice carrying a deletion of the H19 endodermal enhancer, we show that this regulatory element is necessary for the activation of the lgf2 and H19 genes upon induction of liver carcinogenesis. Furthermore, multiple sites of the H19 endodermal enhancer region become hypersensitive to DNase I when the carcinogenesis process is induced. Lastly, liver tumors developed in mice paternally inheriting the H19 enhancer deletion are found to have marked growth delays, increased frequency of apoptotic nuclei, and lack of Igf2 mRNA expression, thus indicating that this regulatory element plays a major role in the progression of liver carcinogenesis, since it is required for the activation of the anti-apoptotic lgf2 gene.	CNR, Ctr Endocrinol & Oncol Sperimentale G Salvatore, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; CNR, Ctr Biocristallog, I-80125 Naples, Italy; Univ Naples 2, Dipartimento Sci Ambientali, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Universita della Campania Vanvitelli	Riccio, A (corresponding author), CNR, Ctr Endocrinol & Oncol Sperimentale G Salvatore, Via S Pansini 5, I-80131 Naples, Italy.		Riccio, Andrea/AAY-7571-2020; Riccio, Andrea/A-4991-2015; Casola, Stefano/AAN-8319-2021; Casola, Stefano/O-3922-2014	Riccio, Andrea/0000-0001-7990-3576; Riccio, Andrea/0000-0001-7990-3576; Casola, Stefano/0000-0001-5580-0986; Pedone, Paolo Vincenzo/0000-0002-0828-5843				Allemand I, 1995, ONCOGENE, V11, P2583; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CARICASOLE A, 1993, NUCLEIC ACIDS RES, V21, P1873, DOI 10.1093/nar/21.8.1873; CASOLA S, 1995, ONCOGENE, V11, P711; CHIARIOTTI L, 1988, MOL ENDOCRINOL, V2, P1115, DOI 10.1210/mend-2-11-1115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FEINBERG AP, 1999, CANCER RES, V59, P1743; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haddad R, 1997, CANCER RES, V57, P4615; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Harris TM, 1998, ONCOGENE, V16, P203, DOI 10.1038/sj.onc.1201519; Ishihara K, 2000, GENOME RES, V10, P664, DOI 10.1101/gr.10.5.664; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Li M, 1998, AM J MED GENET, V79, P253; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nardone G, 1996, HEPATOLOGY, V23, P1304, DOI 10.1053/jhep.1996.v23.pm0008675143; NORSTEDT G, 1988, CARCINOGENESIS, V9, P209, DOI 10.1093/carcin/9.2.209; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; RUBIN R, 1995, LAB INVEST, V73, P311; RUTHER U, 1993, ONCOGENE, V8, P87; Sambrook J, 1989, MOL CLONING LAB MANU; Sohda T, 1996, LAB INVEST, V75, P307; Sperandeo MP, 2000, AM J HUM GENET, V66, P841, DOI 10.1086/302811; TAKAGI H, 1992, CANCER RES, V52, P5171; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; UENO T, 1988, CARCINOGENESIS, V9, P1779, DOI 10.1093/carcin/9.10.1779; Ungaro P, 1997, MOL CELL ENDOCRINOL, V135, P153, DOI 10.1016/S0303-7207(97)00201-3; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4; Zhang LJ, 1998, ONCOGENE, V17, P1261, DOI 10.1038/sj.onc.1202050; Zhang LJ, 1996, CANCER RES, V56, P1367	49	27	27	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6376	6385		10.1038/sj.onc.1204024	http://dx.doi.org/10.1038/sj.onc.1204024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175353				2022-12-17	WOS:000166210500022
J	Liu, Y; Zacksenhaus, E				Liu, Y; Zacksenhaus, E			E2F1 mediates ectopic proliferation and stage-specific p53-dependent apoptosis but not aberrant differentiation in the ocular lens of Rb deficient fetuses	ONCOGENE			English	Article						Rb; p53; E2F1; lens; crystallins; filensin	SKELETAL-MUSCLE CELLS; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; MOUSE LENS; TRANSCRIPTION FACTORS; EYE DEVELOPMENT; GROWTH CONTROL; FIBER CELL; IN-VIVO; S-PHASE	The retinoblastoma tumor suppressor, Rb, is a transcription cofactor that controls cell proliferation, survival and differentiation. Mutant mouse embryos lacking Rb exhibit ectopic proliferation and apoptosis that are mediated in some tissues by E2F1, a major partner of Rb, and by the p53 tumor suppressor. Whether E2F1 and p53 also mediate the differentiation defects in Rb mutant embryos is, however, not clear. Here we show that partially rescued mgRb:Rb-/- mutant fetuses exhibit ectopic lens epithelial cell proliferation, apoptosis and severe cataract. The abnormal cell proliferation and apoptosis were significantly suppressed in the lens of compound mutant fetuses lacking both Rb and E2F1 at embryonic day (E) E15.5, Interestingly however, at E18.5, only ectopic proliferation, not apoptosis, was dramatically reduced in mgRb:Rb-/-:E2F1-/- lenses. In contrast, p53 did not exert such a stage-specific effect and apoptosis was invariably suppressed in mgRb:Rb-/-:p53-/- composite mutant lenses throughout embryogenesis. Using RT-PCR and iir situ hybridization analyses, me identified a subset of lens specific genes, most notably the late differentiation marker filensin, which were not properly induced during lens development in mgRb:Rb-/- fetuses. Remarkably, despite the inhibition of cell proliferation and apoptosis, the degeneration of lens fibers and aberrant expression of filensin were only marginally corrected in mgRb:Rb-/-:E2F1-/- fetuses at E15.5 but not at all at E18.5 or in mgRb:Rb-/-:p53-/- mutant fetuses. Thus, inactivation of E2F1 reduces ectopic cell proliferation and stage-specific p53-dependent apoptosis but does not rescue the differentiation defects associated with loss of Rb during lens development.	Univ Toronto, Toronto Gen Hosp, Dept Med, Univ Hlth Network, Toronto, ON M5G 2M1, Canada; Univ Toronto, Toronto Gen Hosp, Inst Res, Dept Med Biophys,Univ Hlth Network, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Zacksenhaus, E (corresponding author), Univ Toronto, Toronto Gen Hosp, Dept Med, Univ Hlth Network, 67 Coll St, Toronto, ON M5G 2M1, Canada.		Zacksenhaus, Eldad/AAD-3584-2020					Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Du W, 2000, DEVELOPMENT, V127, P367; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Francis PJ, 1999, TRENDS GENET, V15, P191, DOI 10.1016/S0168-9525(99)01738-2; Fromm L, 1996, ONCOGENE, V12, P69; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Humbert PO, 2000, GENE DEV, V14, P690; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; JIANG Z, 2000, IN PRESS DEV BIOL; JIANG Z, 2000, IN PRESS J BIOL CHEM; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kondoh H, 1999, CURR OPIN GENET DEV, V9, P301, DOI 10.1016/S0959-437X(99)80045-8; Kumar J, 1997, GENE DEV, V11, P2023, DOI 10.1101/gad.11.16.2023; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Masaki S, 1997, GENE, V201, P11, DOI 10.1016/S0378-1119(97)00419-8; McCaffrey J, 1999, MOL CELL BIOL, V19, P6458; MERDES A, 1991, J CELL BIOL, V115, P397, DOI 10.1083/jcb.115.2.397; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Oliver G, 1997, TRENDS NEUROSCI, V20, P415, DOI 10.1016/S0166-2236(97)01082-5; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sellers WR, 1996, BBA-REV CANCER, V1288, pM1, DOI 10.1016/0304-419X(96)00014-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vitelli L, 2000, MOL CELL BIOL, V20, P5330, DOI 10.1128/MCB.20.14.5330-5342.2000; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876	50	27	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6065	6073		10.1038/sj.onc.1203996	http://dx.doi.org/10.1038/sj.onc.1203996			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146559				2022-12-17	WOS:000165827900014
J	Malashicheva, AB; Kislyakova, TV; Aksenov, ND; Osipov, KA; Pospelov, VA				Malashicheva, AB; Kislyakova, TV; Aksenov, ND; Osipov, KA; Pospelov, VA			F9 embryonal carcinoma cells fail to stop at G1/S boundary of the cell cycle after gamma-irradiation due to p21(WAF1/CIP1) degradation	ONCOGENE			English	Article						p21(WAF1/CIP1); p53; G1 and G2 arrests; teratocarcinoma F9; gamma-irradiation	RADIATION-INDUCED APOPTOSIS; WILD-TYPE P53; DNA-DAMAGE; TERATOCARCINOMA CELLS; SPINDLE DISRUPTION; TRANSFORMED-CELLS; RETINOIC ACID; STEM-CELLS; DIFFERENTIATION; CHECKPOINT	We studied the ability of F9 teratocarcinoma cells to arrest in G1/S and G2/M checkpoints after gamma-irradiation, Wild-type p53 protein was rapidly accumulated in F9 cells after gamma-irradiation, however, this was followed not by a G1/S arrest but by a short and reversible delay of the cell cycle in G2/M. In order to elucidate the reasons of the lack of G1/S arrest in F9 cells, we investigated the expression of p53 downstream target Cdk inhibitor p21(WAF1/CIP1). In spite of p53-dependent activation of p21(WAF1/CIP1) gene promoter and p21(WAF1/CIP1) mRNA accumulation upon irradiation, the p21(WAF1/CIP1) protein was not detected by either immunoblot or immunofluorescence techniques. However, the cells treated with a specific proteasome inhibitor lactacystin revealed the p21(WAF1/CIP1) protein both in non-irradiated and irradiated cells. Therefore we suggest that p21(WAF1/CIP1) protein is degraded by a proteasome-dependent mechanism in F9 cells and the lack of G1/S arrest after gamma-irradiation is due to this degradation. We also examined the expression and activity of cell cycle regulatory proteins: G1- and G2-cyclins and cyclin-dependent kinases, In the absence of functional p21(WAF1/CIP1) inhibitor, the activity of G1 cyclin/Cdk complexes was insufficiently inhibited to cause a G1 arrest, whereas a decrease of cdc2 and cyclin B1-associated kinase activities was enough to contribute to a reversible G2 arrest following gamma-irradiation. After gamma-irradiation, the majority of F9 cells undergo apoptosis implying that wt-p53 likely triggers pro-apoptotic gene expression in DNA damaged cells. Elimination of defected cells might ensure maintenance of genome integrity in the remaining cell population.	Russian Acad Sci, Inst Cytol, Lab Mol Basis Cell Differentiat, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelov, VA (corresponding author), Russian Acad Sci, Inst Cytol, Lab Mol Basis Cell Differentiat, Tikhoretsky 4, St Petersburg 194064, Russia.		Aksenov, Nikolay D/F-1679-2017; Malashicheva, Anna/K-2649-2014	Malashicheva, Anna/0000-0002-0820-2913				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ATENCIA R, 1994, EXP CELL RES, V214, P663, DOI 10.1006/excr.1994.1304; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CARDER P, 1993, ONCOGENE, V8, P1397; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Khan SH, 1998, CANCER RES, V58, P396; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANGLEY RE, 1995, RADIAT RES, V144, P90, DOI 10.2307/3579240; LANGLEY RE, 1993, RADIAT RES, V136, P320, DOI 10.2307/3578543; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Malashicheva A B, 1998, Tsitologiia, V40, P14; Mayo LD, 1996, ONCOGENE, V13, P2315; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Orlovskaya E. I., 1997, Molekulyarnaya Biologiya (Moscow), V31, P224; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PERREAULT J, 1993, J CELL PHYSL, V156, P189; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P2261; SLEIGH MJ, 1992, BIOESSAYS, V14, P769, DOI 10.1002/bies.950141109; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0	43	27	28	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3858	3865		10.1038/sj.onc.1203736	http://dx.doi.org/10.1038/sj.onc.1203736			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951579				2022-12-17	WOS:000088614300004
J	Miller, MA; Malik, IA; Shenk, MA; Steele, RE				Miller, MA; Malik, IA; Shenk, MA; Steele, RE			The Src/Csk regulatory circuit arose early in metazoan evolution	ONCOGENE			English	Article						evolution; metazoan; Src; Csk; protein-tyrosine kinase; Cnidaria	PROTEIN-TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; YEAST; GENE; HYDRA; EXPRESSION; IDENTIFICATION; HOMOLOG; CSK; DNA	We have identified a gene encoding a member of the Csk family of non-receptor protein-tyrosine kinases (PTKs) in the early-diverging metazoan Hydra. In situ hybridization analysis of the distribution of RNA from the Hydra Csk gene indicates that it is expressed in most of the epithelial cells of the adult polyp and in gametogenic cells. Comparison of the expression pattern of Hydra Csk with that of STK, the Hydra Src gene orthologue, reveals that the two genes are largely co-expressed. Such co-expression is consistent with a role for Hydra Csk in regulation of STK activity. This possibility was tested directly by co-expressing Hydra Csk with STK in yeast. Co-expression suppressed the growth inhibition seen when STK alone is expressed in yeast. Suppression was dependent on the presence of the putative regulatory tyrosine in the carboxyl-terminal tail of STK. Phosphotyrosine immunoblot analysis confirmed that expression of Csk resulted in suppression of STK kinase activity. Taken together these data indicate that the regulatory circuit involving Src and Csk PTKs was established prior to the divergence of the phylum Cnidaria from the rest of the metazoans.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dev Biol Ctr, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Steele, RE (corresponding author), Univ Calif Irvine, Dept Biol Chem, 240D Med Sci I, Irvine, CA 92697 USA.			Miller, Michael/0000-0003-4872-7121				BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; CHAN TA, 1994, ONCOGENE, V9, P1253; COOPER JA, 1987, ONCOGENE RES, V1, P297; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Grens A, 1995, DEVELOPMENT, V121, P4027; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LENHOFF H M, 1970, Laboratory Animals (London), V4, P139, DOI 10.1258/002367770781036463; LIU HP, 1992, GENETICS, V132, P665; Martinez DE, 1997, DEV BIOL, V192, P523, DOI 10.1006/dbio.1997.8715; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; OTTILIE S, 1992, ONCOGENE, V7, P1625; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; SARRAS MP, 1994, DEV BIOL, V164, P312, DOI 10.1006/dbio.1994.1201; SIKORSKI RS, 1989, GENETICS, V122, P19; Steele RE, 1996, DEV GENES EVOL, V206, P247, DOI 10.1007/s004270050050; Steele RE, 1999, GENE, V239, P91, DOI 10.1016/S0378-1119(99)00373-X; Suga H, 1999, J MOL EVOL, V48, P646, DOI 10.1007/PL00006508; Swofford D., 1998, PAUP PHYLOGENETIC AN; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	31	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3925	3930		10.1038/sj.onc.1203714	http://dx.doi.org/10.1038/sj.onc.1203714			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951585				2022-12-17	WOS:000088614300011
J	Janji, B; Melchior, C; Vallar, L; Kieffer, N				Janji, B; Melchior, C; Vallar, L; Kieffer, N			Cloning of an isoform of integrin-linked kinase (ILK) that is upregulated in HT-144 melanoma cells following TGF-beta 1 stimulation	ONCOGENE			English	Article						integrin-linked kinase; integrin; TGF-beta; cDNA sequence; melanoma phosphorylation	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR PTEN; PROTEIN-KINASE; REGULATED EXPRESSION; NEGATIVE REGULATION; ADHESION; GENE; IDENTIFICATION; SURVIVAL; MICE	We have shown previously that integrin-linked kinase (ILK) is upregulated in human HT-144 melanoma cells following TGF-beta 1 stimulation, Using mRNA from TGF-beta 1 stimulated HT-144 cells and reverse transcriptase polymerase chain reaction, we have isolated a cDNA encoding a protein highly homologous to ILK. Sequencing of the full-length 1359 base pair cDNA and polypeptide translation revealed that this protein, designated ILK-2, differs from the known ILK (hereafter called ILK-1) by only four amino acids, while the cDNA sequence diverges by 102 nucleotides, thus excluding that ILK-2 is an allelic variant of ILK-1, Expression of ILK2 mRNA was observed in metastatic human HT-144 melanoma and HT-1080 fibrosarcoma tell lines, but not in normal human tissues, Moreover, stimulation of HT-144 cells with TGF-beta 1, but not with EGF, PDGF-AB or insulin, induced a selective overexpression of ILK-2 mRNA as compared to ILK-1 mRNA, Bacterially-expressed GST/ILK-2 autophosphorylated and labeled myelin basic protein as well as a retombinant GST/beta 3 integrin cytoplasmic tail peptide, Transfection of either ILK-2 or ILK-1 cDNA into the non-metastatic melanoma cell line SK-Mel-2, expressing exclusively ILK-1, induced anchorage independent cell growth and cell proliferation, as demonstrated by growth in soft agar, Our data provide evidence that ILK-2 is a new isoform of ILK-1 that is expressed in some highly invasive tumor cell lines but not in normal adult human tissues and whose expression is regulated by TGF-beta 1.	Ctr Univ, Lab Franco Luxembourgeois Rech Biomed, CRP Sante, CNRS, L-1150 Luxembourg, Luxembourg	Luxembourg Institute of Health; University of Luxembourg	Kieffer, N (corresponding author), Ctr Univ, Lab Franco Luxembourgeois Rech Biomed, CRP Sante, CNRS, 162A Ave de la Faiencerie, L-1150 Luxembourg, Luxembourg.			Vallar, Laurent/0000-0002-4404-1010; JANJI, Bassam/0000-0002-9763-0943				Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Gouon V, 1996, INT J CANCER, V68, P650; Gregoire M, 1995, CANCER METAST REV, V14, P339, DOI 10.1007/BF00690602; Hannigan GE, 1997, GENOMICS, V42, P177, DOI 10.1006/geno.1997.4719; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Huang Y, 1999, INT J MOL MED, V3, P563; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Li DM, 1997, CANCER RES, V57, P2124; Li FG, 1997, BBA-MOL CELL RES, V1358, P215, DOI 10.1016/S0167-4889(97)00089-X; Li FG, 1999, J CELL SCI, V112, P4589; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MATSUMOTO K, 1995, CANCER METAST REV, V14, P205, DOI 10.1007/BF00690292; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; REARDEN A, 1994, BIOCHEM BIOPH RES CO, V201, P1124, DOI 10.1006/bbrc.1994.1822; Robertson GP, 1999, CANCER RES, V59, P3596; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Xie W, 1998, AM J PATHOL, V153, P367, DOI 10.1016/S0002-9440(10)65580-0	33	27	30	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3069	3077		10.1038/sj.onc.1203640	http://dx.doi.org/10.1038/sj.onc.1203640			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871859				2022-12-17	WOS:000087903900004
J	Sato, H; Ogata, H; De Luca, LM				Sato, H; Ogata, H; De Luca, LM			Annexin V inhibits the 12-O-tetradecanoylphorbol-13-acetate-induced activation of Ras/extracellular signal-regulated kinase (ERK) signaling pathway upstream of Shc in MCF-7 cells	ONCOGENE			English	Article						annexin V; MAPK; TPA; signal transduction; PKC	BREAST-CANCER CELLS; PROTEIN-KINASE; CARCINOMA-CELLS; MAP KINASE; RAF-1 KINASE; C ACTIVITY; IN-VITRO; RAS; EXPRESSION; PHOSPHORYLATION	Annexin V is a Ca2+-dependent phospholipid binding protein. Although it has been shown to inhibit protein kinase C (PKC) in cell-free systems, its role in the intact cell is unclear, A stable,MCF-7 human breast cancer cell overexpression system was established to investigate the function of annexin V, In these cells, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced phosphorylation and kinase activity of ERK1/2 were suppressed. Morphological changes induced by TPA were reduced by annexin V overexpression as well as by the pan-PKC inhibitor, bisindolylmaleimide I, and by the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) inhibitor, PD98059, TPA-induced MEK1/2 and Raf-l phosphorylation were reduced in these cells, The TP,S-enhanced active Ras, and its association with Raf-1, were reduced. TPA treatment of MCF-7 cells caused an increased association of She with Grb2, However, this increased association was prevented in the annexin V-overexpressors. p21(WAF/CIPI) is responsible for inhibition of cell cycle progression in MICF-7 cells. TPA induced the expression of p21(WAF/CIPI) to a greater extent in MCF-7 parent and control plasmid cells than in annexin V overexpressors, PD98059 inhibited this increase, suggesting that TPA upregulation of p21(WAF/CIPI) occurs via the MEK pathway, and that annexin V overexpression blunts it, This work shows that annexin V overexpression suppresses the TPA-induced Ras/ERK; signaling by inhibiting at/or upstream of She, possibly through the inhibition of PkCs.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	De Luca, LM (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA.							ABE M, 1986, J CELL PHYSIOL, V126, P126, DOI 10.1002/jcp.1041260117; Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; ARITA Y, 1994, INT J CANCER, V56, P229, DOI 10.1002/ijc.2910560215; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Buckland AG, 1998, BBA-LIPID LIPID MET, V1391, P367, DOI 10.1016/S0005-2760(98)00026-5; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COMERA C, 1989, J CELL BIOCHEM, V40, P361, DOI 10.1002/jcb.240400312; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; Dubois T, 1998, BIOCHEM J, V330, P1277, DOI 10.1042/bj3301277; Dubois T, 1996, BBA-MOL CELL RES, V1313, P290, DOI 10.1016/0167-4889(96)00102-4; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; KAPLAN R, 1988, J BIOL CHEM, V263, P8037; KARUBE A, 1995, GYNECOL ONCOL, V58, P295, DOI 10.1006/gyno.1995.1233; KATO S, 1988, EXP CELL RES, V179, P31, DOI 10.1016/0014-4827(88)90345-X; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MENAPACE L, 1987, BIOCHEM BIOPH RES CO, V148, P1295, DOI 10.1016/S0006-291X(87)80274-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Raynal P, 1996, FEBS LETT, V392, P263, DOI 10.1016/0014-5793(96)00827-7; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RAYNAL P, 1993, BIOCHEM J, V292, P759, DOI 10.1042/bj2920759; ROTHHUT B, 1995, EUR J BIOCHEM, V232, P865; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLAEPFER DD, 1992, BIOCHEMISTRY-US, V31, P1886, DOI 10.1021/bi00121a043; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; Shibata S, 1997, GYNECOL ONCOL, V66, P217, DOI 10.1006/gyno.1997.4746; SHIBATA S, 1992, J BIOCHEM-TOKYO, V112, P552, DOI 10.1093/oxfordjournals.jbchem.a123937; SHIBATA S, 1992, TOHOKU J EXP MED, V166, P479, DOI 10.1620/tjem.166.479; SOZERI O, 1992, ONCOGENE, V7, P2259; THEOBALD J, 1994, BBA-MOL CELL RES, V1223, P383, DOI 10.1016/0167-4889(94)90099-X; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Utsumi T, 1992, Nihon Sanka Fujinka Gakkai Zasshi, V44, P793; VALETTE A, 1987, CANCER RES, V47, P1615; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WINKELSTEIN A, 1986, EXP HEMATOL, V14, P1023; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	56	27	29	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2904	2912		10.1038/sj.onc.1203615	http://dx.doi.org/10.1038/sj.onc.1203615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871841				2022-12-17	WOS:000087544500004
J	Bossu, P; Vanoni, M; Wanke, V; Cesaroni, MP; Tropea, F; Melillo, G; Asti, C; Porzio, S; Ruggiero, P; Di Cioccio, V; Maurizi, G; Ciabini, A; Alberghina, L				Bossu, P; Vanoni, M; Wanke, V; Cesaroni, MP; Tropea, F; Melillo, G; Asti, C; Porzio, S; Ruggiero, P; Di Cioccio, V; Maurizi, G; Ciabini, A; Alberghina, L			A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts	ONCOGENE			English	Article						CDC25(Mm); signal transduction therapy; fos-luciferase; oncogenes; GEF	TARGETING SIGNAL-TRANSDUCTION; DEPENDENT ACTIVATION; DISEASE THERAPY; IN-VIVO; PROTEIN; GRB2; EXPRESSION; RECEPTOR; CLONING; FAMILY	Ras proteins are small GTPases playing a pivotal role in cell proliferation and differentiation, Their activation state depends on the competing action of GTPase Activating Proteins (GAP) and Guanine nucleotide Exchange Factors (GEF), A tryptophan residue (Trp1056 in CDC25(Mm)-GEF), conserved in all ras-specific GEFs identified so far has been previously shown to be essential for GEF activity. Its substitution with glutamic acid results in a catalytically inactive mutant, which is able to efficiently displace wild-ty pe GEF from p21(ras) and to originate a stable ras/GEF binary complex due to the reduced affinity of the nucleotide-free ras/GEF complex for the incoming nucleotide, We show here that this 'ras-sequestering property' can be utilized to attenuate ras signal transduction pathways in mouse fibroblasts transformed by oncogenic ras, In fact overexpression of the dominant negative GEF(W1056E), stable transfected cells strongly reduces intracellular ras GTP levels in k-ras transformed fibroblasts. Accordingly, the transfected fibroblasts revert to wild-type phenotype on the basis of morphology, cell cycle and anchorage independent growth. The reversion of the transformed phenotype is accompanied bar DNA endoreduplication, The possible use of dominant negative ras-specific GEFs as a tool to down-regulate tumor growth is discussed.	Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Ctr Ric Dompe, Laquila, Italy	University of Milano-Bicocca; Dompe	Alberghina, L (corresponding author), Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.		Di Cioccio, Vito/N-1296-2013; Bossù, Paola/E-4832-2014; Vanoni, Marco/AAA-3699-2021; Nacmias, Benedetta/J-5084-2018	Di Cioccio, Vito/0000-0002-8063-9650; Bossù, Paola/0000-0002-1432-0078; Vanoni, Marco/0000-0002-8690-2587; Nacmias, Benedetta/0000-0001-9338-9040; Alberghina, Lilia/0000-0003-1694-931X				Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; DHIN L, 1999, NATURE, V400, P468; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Downward J, 1997, CURR BIOL, V7, P258; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; Giglione C, 1998, J BIOL CHEM, V273, P34737, DOI 10.1074/jbc.273.52.34737; Guerrero C, 1996, ONCOGENE, V12, P1097; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; Levitzki A, 1997, MED ONCOL, V14, P83, DOI 10.1007/BF02990952; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Mathiesen I, 1999, GENE THER, V6, P508, DOI 10.1038/sj.gt.3300847; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Park WM, 1997, ONCOGENE, V14, P831, DOI 10.1038/sj.onc.1200893; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vanoni M, 1999, J BIOL CHEM, V274, P36656, DOI 10.1074/jbc.274.51.36656; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D; ZIPPEL R, 1994, INT J ONCOL, V4, P175; Zippel R, 1996, ONCOGENE, V12, P2697; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	49	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2147	2154		10.1038/sj.onc.1203539	http://dx.doi.org/10.1038/sj.onc.1203539			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815806				2022-12-17	WOS:000086728000008
J	Allemand, I; Anglo, A; Jeantet, AY; Cerutti, I; May, E				Allemand, I; Anglo, A; Jeantet, AY; Cerutti, I; May, E			Testicular wild-type p53 expression in transgenic mice induces spermiogenesis alterations ranging from differentiation defects to apoptosis	ONCOGENE			English	Article						p53; transgenic mice; spermatogenesis; apoptosis	TUMOR-SUPPRESSOR P53; GERM-CELL DEATH; DNA-DAMAGE; TERATOCARCINOMA CELLS; FUNCTIONAL DOMAIN; DEFICIENT MICE; IRRADIATED RAT; IN-VIVO; SPERMATOGENESIS; RADIATION	While p53 is dispensable for development, an excess of p53 has dramatic consequences on the embryogenesis and on the cell differentiation. In an attempt to analyse in vivo the effects of p53 activity, we have generated transgenic mice expressing the wild-type p53 under the control of the metallothionein I promoter. In the three transgenic lines established, exogenous p53 is expressed constitutively in the postmeiotic cells of transgenic males and two lines are subfertile, Transgenic males expressing the upper level of p53 produce few spermatozoa since the majority of developing spermatids undergo apoptosis, In the subfertile males exhibiting an intermediate amount of p53, teratozoospermia is obvious suggesting an altered terminal differentiation of postmeiotic cells. In contrast lower level of p53 does not lead the third line to sterility. These results suggest that the activity of p53 is dependent irt vivo on the amount of p53 present within cells, as it has been already demonstrated in vitro.	CEA, DSV, DRR, Lab Cancerogenese Mol,UMR 217,CNRS, F-92265 Fontenay Aux Roses, France; Univ Paris 06, Lab Cytophysiol Analyt, F-75006 Paris, France; Inst Rech Sci Canc, SEAT, F-94801 Villejuif, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Allemand, I (corresponding author), CEA, DSV, DRR, Lab Radiobiol Cellules Germinales, BP6, F-92265 Fontenay Aux Roses, France.			allemand, isabelle/0000-0002-8861-7632				Adachi J, 1998, CELL DEATH DIFFER, V5, P148, DOI 10.1038/sj.cdd.4400325; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Beumer TL, 1997, MOL REPROD DEV, V47, P240, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;240::AID-MRD2&gt;3.0.CO;2-L; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; BlancoRodriguez J, 1996, CELL PROLIFERAT, V29, P13, DOI 10.1046/j.1365-2184.1996.d01-5.x; BRAUN RE, 1989, NATURE, V337, P373, DOI 10.1038/337373a0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chresta CM, 1996, CANCER RES, V56, P1834; DE SK, 1991, MOL ENDOCRINOL, V5, P628, DOI 10.1210/mend-5-5-628; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERSTEN K, 1997, NAT GENET, V378, P378; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gromoll J, 1997, BIOL REPROD, V57, P1312, DOI 10.1095/biolreprod57.6.1312; HALL PA, 1997, CURR BIOL, V7, P144; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hendry JH, 1996, INT J RADIAT BIOL, V70, P677, DOI 10.1080/095530096144563; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lee JW, 1997, ENDOCRINOLOGY, V138, P2081, DOI 10.1210/en.138.5.2081; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MacCallum DE, 1996, ONCOGENE, V13, P2575; MIYASHITA T, 1995, CELL, V80, P293; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Odorisio T, 1998, NAT GENET, V18, P257, DOI 10.1038/ng0398-257; Orlovskaya EI, 1997, MOL BIOL+, V31, P184; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PENG HQ, 1993, CANCER RES, V53, P3574; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; RHEE K, 1995, DEV DYNAM, V204, P406, DOI 10.1002/aja.1002040407; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SassoneCorsi P, 1997, CELL, V88, P163, DOI 10.1016/S0092-8674(00)81834-6; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; Sjoblom T, 1996, ONCOGENE, V12, P2499; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; West A, 1997, INT J RADIAT BIOL, V71, P283, DOI 10.1080/095530097144166; WILLIE AH, 1992, CANCER METAST REV, V11, P95; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zheng H, 1997, INT J RADIAT BIOL, V71, P275, DOI 10.1080/095530097144157; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	61	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6521	6530		10.1038/sj.onc.1203052	http://dx.doi.org/10.1038/sj.onc.1203052			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597255				2022-12-17	WOS:000083709200015
J	Klausner, RD				Klausner, RD			Studying cancer in the mouse	ONCOGENE			English	Article						mouse; cancer; MMHCC; genetics; preclinical models			NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Klausner, RD (corresponding author), NCI, Bldg 31,Room 11A48,31 Ctr Dr,MSC 2590, Bethesda, MD 20892 USA.								0	27	27	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5249	5252		10.1038/sj.onc.1203089	http://dx.doi.org/10.1038/sj.onc.1203089			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498876				2022-12-17	WOS:000082808400002
J	Zhu, X; Pattenden, S; Bremner, R				Zhu, X; Pattenden, S; Bremner, R			PRB is required for interferon-gamma-induction of the MHC class II A beta gene	ONCOGENE			English	Article						retinoblastoma; MHC class II; interferon-gamma; transcription; CIITA	MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN GENE; BARE LYMPHOCYTE SYNDROME; HUMAN-ENDOTHELIAL CELLS; BREAST-CARCINOMA CELLS; RETINOBLASTOMA PROTEIN; TRANSACTIVATOR CIITA; TRANSCRIPTION FACTOR; HLA-DR; CYCLIN D1	PRE is required for IFN-gamma-induction of MHC class II in human tumor cell lines, providing a potential link between tumor suppressors and the immune system. However, other genes, such as cyclin D1, show pRB-dependency only in tumor cells, so by analogy, pRB may not be necessary for cII-regulation in normal cells. Here, we demonstrate that induction of the mouse MHC class II I-A heterodimer is normal in RB+/+ mouse embryonic fibroblasts (MEFs), but deficient in RB-/- MEFs, Inducibility is restored in RB-/- MEFs stably transfected with wild type RE cDNA or infected with an adenovirus expressing pRB. Thus, involvement of pRB in MHC class II expression is conserved in the mouse and is not an aberrant feature of tumorigenic, aneuploid, human tumor cells. Although cII genes are generally induced in a coordinate fashion, suggesting a common mechanism, we found that pRB was specifically required for induction of the A beta, but not A alpha or other MHC cII genes including E beta, Ii and H2-M alpha. Finally, IFN-gamma-induction of class II transactivator (CIITA), was pRB-independent, suggesting that pRB works downstream of this master-regulator of MHC class II expression.	Eye Res Inst Canada, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada	University of Toronto; University of Toronto	Bremner, R (corresponding author), Eye Res Inst Canada, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212				ALBERT SE, 1994, J EXP MED, V180, P233, DOI 10.1084/jem.180.1.233; AMEGLIO F, 1983, INFECT IMMUN, V42, P122, DOI 10.1128/IAI.42.1.122-125.1983; Anderson Donald M., 1992, Molecular Marine Biology and Biotechnology, V1, P89; ANICHINI A, 1988, J IMMUNOL, V140, P183; Armstrong TD, 1997, P NATL ACAD SCI USA, V94, P6886, DOI 10.1073/pnas.94.13.6886; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BARR CL, 1991, J BIOL CHEM, V266, P3475; BARR E, 1994, GENE THER, V1, P51; BASHAM TY, 1983, J IMMUNOL, V130, P1492; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BROWN AM, 1993, J BIOL CHEM, V268, P26328; BROWN AM, 1991, J IMMUNOL, V146, P3183; BURMESTER GR, 1987, J CLIN INVEST, V80, P595, DOI 10.1172/JCI113111; Celada A, 1996, BIOCHEM J, V313, P737, DOI 10.1042/bj3130737; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHEN JZ, 1993, CURR BIOL, V3, P405, DOI 10.1016/0960-9822(93)90347-Q; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GONWA TA, 1984, J CLIN INVEST, V74, P859, DOI 10.1172/JCI111503; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON SP, 1995, CELL IMMUNOL, V166, P207, DOI 10.1006/cimm.1995.9977; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KING DP, 1983, J IMMUNOL, V131, P2814; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; KUBY J, 1994, IMMUNOLOGY, P239; LAMB CA, 1992, J IMMUNOL, V148, P3478; LLOBERAS J, 1995, MOL CELL BIOL, V15, P5092; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LU YM, 1994, ONCOGENE, V9, P1015; LU YM, 1994, MOL IMMUNOL, V31, P1365, DOI 10.1016/0161-5890(94)90055-8; Lu YM, 1996, J IMMUNOL, V156, P2495; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1384; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MANYAK CL, 1988, J IMMUNOL, V140, P3817; Marhin WW, 1996, ONCOGENE, V12, P43; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; Min W, 1996, MOL CELL BIOL, V16, P359; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; MULLER C, 1985, IMMUNOBIOLOGY, V169, P228; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUNCASTER MM, 1992, CANCER RES, V52, P654; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; OSTRANDROSENBERG S, 1994, CURR OPIN IMMUNOL, V6, P722, DOI 10.1016/0952-7915(94)90075-2; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; POBER JS, 1983, J EXP MED, V157, P1339, DOI 10.1084/jem.157.4.1339; RADLEY E, 1994, J BIOL CHEM, V269, P18834; Robinson M. A., 1989, Fundamental immunology., P489; Rohde M, 1996, ONCOGENE, V12, P2393; Scholl T, 1996, J IMMUNOL, V156, P1448; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; SYMINGTON FW, 1985, J IMMUNOL, V135, P1026; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; TSCHICKARDT ME, 1995, INT J CANCER, V62, P461, DOI 10.1002/ijc.2910620417; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westerheide SD, 1997, J IMMUNOL, V158, P4812; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Williams GS, 1998, INT IMMUNOL, V10, P1957, DOI 10.1093/intimm/10.12.1957; WONG GHW, 1984, EUR J IMMUNOL, V14, P52, DOI 10.1002/eji.1830140110; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	91	27	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4940	4947		10.1038/sj.onc.1202876	http://dx.doi.org/10.1038/sj.onc.1202876			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490828				2022-12-17	WOS:000082321700006
J	Loffler, M; Ausserlechner, MJ; Tonko, M; Hartmann, BL; Bernhard, D; Geley, S; Helmberg, A; Kofler, R				Loffler, M; Ausserlechner, MJ; Tonko, M; Hartmann, BL; Bernhard, D; Geley, S; Helmberg, A; Kofler, R			c-Myc does not prevent glucocorticoid-induced apoptosis of human leukemic lymphoblasts	ONCOGENE			English	Article						glucocorticoid; apoptosis; leukemia; c-myc; tetracycline-regulated gene expression	T-CELL HYBRIDOMAS; LINE CCRF-CEM; GENE-EXPRESSION; RECEPTOR; DEATH; RESISTANCE; ALPHA; SUSCEPTIBILITY; PROTOONCOGENES; DEXAMETHASONE	Due to their growth arrest- and apoptosis-inducing ability, glucocorticoids (GC) are widely used in the therapy of various lymphoid malignancies, The signal transduction pathways leading to this clinically-relevant form of apoptosis have, however, not been sufficiently elucidated. GC bind to their specific receptor, a ligand-activated transcription factor of the Zn-finger type, that activates or represses transcription of GC-responsive genes. Previous studies in leukemia cells suggested that transcriptional repression of c-myc expression might be the crucial event in CC-induced apoptosis, although in other systems, c-Myc apparently increased the sensitivity to cell-death inducers. To address this controversy, we stably transfected the GC-sensitive human T-ALL cell Line CEM-C7H2 with constructs allowing tetracycline-regulated expression of c-Myc. Subsequent analyses of these cell lines showed that overexpression of c-Myc per se had little, if any, effect on cell viability, although it rendered the cells more sensitive to apoptosis induced by low serum, confirming the functionality of the expressed transgene, More importantly, however, when the cells were treated with GC in the presence of exogenous c-Myc, they underwent apoptosis exceeding that in cells treated in the absence of transgenic c-Myc. The data indicate that c-myc downregulation is not critical for induction of cell-death by GC in this system, and support the notion that c-Myc sensitizes cells to apoptosis-inducing agents.	Univ Innsbruck, Sch Med, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria	University of Innsbruck	Kofler, R (corresponding author), Univ Innsbruck, Sch Med, Inst Gen & Expt Pathol, Div Mol Pathophysiol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.			Ausserlechner, Michael/0000-0002-1015-2302; Bernhard, David/0000-0002-2383-6607				ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hala M, 1996, INT J CANCER, V68, P663, DOI 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2; Han JW, 1997, CANCER RES, V57, P176; HARTMANN BL, 1998, IN PRESS ONCOGENE, V17; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Kaptein JS, 1996, J BIOL CHEM, V271, P18875, DOI 10.1074/jbc.271.31.18875; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; MA TL, 1992, MOL ENDOCRINOL, V6, P960, DOI 10.1210/me.6.6.960; MIYAZAKI J, 1989, GENE, V79, P269; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; POWERS JH, 1993, CANCER RES, V53, P4059; RHEE K, 1995, CANCER RES, V55, P4188; SCHWEIGERT FJ, 1993, COMP BIOCHEM PHYS A, V105, P347, DOI 10.1016/0300-9629(93)90219-T; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; THULASI R, 1993, J BIOL CHEM, V268, P18306; WOOD AC, 1994, BRIT J CANCER, V69, P663, DOI 10.1038/bjc.1994.128; YUH YS, 1989, J BIOL CHEM, V264, P10904; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4626	4631		10.1038/sj.onc.1202820	http://dx.doi.org/10.1038/sj.onc.1202820			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467407				2022-12-17	WOS:000082018600012
J	Glover, HR; Brewster, CEP; Dilworth, SM				Glover, HR; Brewster, CEP; Dilworth, SM			Association between src-kinases and the polyoma virus oncogene middle T-antigen requires PP2A and a specific sequence motif	ONCOGENE			English	Article						polyoma middle T; pp60(c-src); PP2A; cell transformation	PROTEIN PHOSPHATASE 2A; TUMOR-ANTIGEN; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; 3T3 CELLS; RAT-CELLS; BINDING; PP60C-SRC; ACTIVATION; PURIFICATION	Polyoma virus encodes a potent oncogene, the middle T-antigen (MT), that induces cell transformation by copying the actions of tyrosine kinase associated growth factor receptors, A crucial component of MT transformation is its ability to bind and stimulate the activity of src-family kinases. However, the mechanism by which this is achieved remains unclear. Tyrosine phosphorylation of MT by sr c-kinases then provides binding sites for SH2 and PTB domain containing molecules in a paradigm of receptor action. We present evidence here that the MT/src complex contains equi-molar amounts of PP2A, and that phosphatase activity may be required for the interaction of MT with both PP2A and the src-family. PP2A, then, is a necessary component of the;MT-src complex. We also show that tno motifs in the 185 to 210 region of MT, each consisting of a basic area followed by a serine or threonine, are essential for interaction with sr c-kinases, but not PP2A. The spacing between the serine or threonine and the basic sequence also appears to be important. Substituting a cysteine residue in place of Thr203 in MT has no affect on the binding of pp60(c-src), showing that these sites interact with src-kinases by a novel mechanism that does not require phosphorylation.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Metab Med, London W12 0NN, England	Imperial College London	Dilworth, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Metab Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.							ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cullere X, 1998, J VIROL, V72, P558; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1982, EMBO J, V1, P1319, DOI 10.1002/j.1460-2075.1982.tb01317.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KAMECH N, 1987, J VIROL, V61, P1546, DOI 10.1128/JVI.61.5.1546-1551.1987; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Sambrook J, 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; WALTER G, 1982, P NATL ACAD SCI-BIOL, V79, P4025, DOI 10.1073/pnas.79.13.4025; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	44	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4364	4370		10.1038/sj.onc.1202816	http://dx.doi.org/10.1038/sj.onc.1202816			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439044				2022-12-17	WOS:000081732700009
J	Shinbo, T; Matsuki, A; Matsumoto, Y; Kosugi, S; Takahashi, Y; Niwa, O; Kominami, R				Shinbo, T; Matsuki, A; Matsumoto, Y; Kosugi, S; Takahashi, Y; Niwa, O; Kominami, R			Allelic loss mapping and physical delineation of a region harboring a putative thymic lymphoma suppressor gene on mouse chromosome 12	ONCOGENE			English	Article						tumor suppressor gene; physical mapping; allelic loss (or LOH) analysis; gamma-ray induced thymic lymphoma	ALLELOTYPE ANALYSIS; FREQUENT LOSS; HETEROZYGOSITY; CANCER; LOCI; MICE; CARCINOMAS; GENOME	Our previous allelic loss analasis of gamma-ray induced thymic lymphomas in F-1 hybrid and backcross mice between BALB/c and MSM strains mapped the Tlsr4 region exhibiting a high frequency of allelic loss (62%) to a 2.9 cM interval between the markers D12Mit53 and D12Mit279 on mouse chromosome 12, To narrow further the interval harboring a putative tumor suppressor gene, a high-density scan has been carried out for informative 361 thymic lymphomas, Construction of a physical map of Tlsr4 with 3 YAC and 15 BAC clones and isolation of YAC- and BAC-derived polymorphic probes lead to fine allelic loss mapping. Three successive pola morphic sites within one BAC exhibit the retention of both alleles in seven, one and four lymphomas, suggesting that a common region of allelic loss for Tlsr4 exists within the BAC region. Pulsed-field gel electrophoresis of NotI digests of this and other clones determines that the commonly lost region is a 35 kb interval with a NotI site. NotI sites are frequently associated with coding regions, and our preliminary sequencing has identified ESTs in the region. Thus, the present study facilitates the identification of genes in the Tlsr4 region that mould lead to isolation of a novel tumor suppressor gene.	Niigata Univ, Sch Med, Dept Biochem, Niigata 9518122, Japan; Niigata Univ, Sch Med, Dept Med 2, Niigata 9518122, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyou Ku, Kyoto 6068315, Japan	Niigata University; Niigata University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem, Asahimachi 1-757, Niigata 9518122, Japan.		Kosugi, S./K-5142-2019	Kosugi, Shin-ichi/0000-0002-6602-7412				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bandera CA, 1997, CANCER RES, V57, P513; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BONHOMME F, 1989, GENETIC VARIANTS STR, P658; Brown MA, 1997, TRENDS GENET, V13, P202, DOI 10.1016/S0168-9525(97)01132-3; CHANG WYH, 1995, CANCER RES, V55, P3246; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; HAYASHI T, 1993, GENOMICS, V17, P490, DOI 10.1006/geno.1993.1352; HEGI ME, 1994, CANCER RES, V54, P6257; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; KEMP CJ, 1993, CANCER RES, V53, P6022; KNUDSON AG, 1985, CANCER RES, V45, P1437; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; OKAMOTO M, 1995, CARCINOGENESIS, V16, P2659, DOI 10.1093/carcin/16.11.2659; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Santos J, 1998, ONCOGENE, V17, P925, DOI 10.1038/sj.onc.1202009; Santos J, 1996, ONCOGENE, V12, P669; SUZUKI T, 1989, CANCER RES, V49, P1095; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YOUNG J, 1993, ONCOGENE, V8, P671; Zhuang SM, 1996, CANCER RES, V56, P3338	24	27	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4131	4136		10.1038/sj.onc.1202767	http://dx.doi.org/10.1038/sj.onc.1202767			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435594				2022-12-17	WOS:000081431000010
J	Sun, SY; Yue, P; Shroot, B; Hong, WK; Lotan, R				Sun, SY; Yue, P; Shroot, B; Hong, WK; Lotan, R			Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells	ONCOGENE			English	Article						lung cancer; retinoids; CD437; apoptosis; c-Myc; ODC; cdc25A	MEDIATED APOPTOSIS; CANCER; P53; LINES; PROLIFERATION; ACTIVATION; INDUCTION; RECEPTORS; GROWTH; ARREST	The novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) has been recently identified to be a potent inducer of apoptosis in human non-small cell lung carcinoma (NSCLC) cells through a nuclear retinoic acid receptor independent mechanism. To approach the mechanism by which CD437 induces apoptosis in NSCLC cells, we investigated the involvement of c-Myc in CD437-induced apoptosis, CD437 (1 mu M) up-regulated the expression of c-Myc and of its downstream target genes ornithine decarboxylase (ODC) and cdc25A in all three NSCLC cell lines (i.e., H460, SK-MES-1 and H1792) used. These effects were correlated with cellular susceptibilities to induction of apoptosis by CD437. Furthermore, CD437-induced apoptosis could be blocked by the ODC inhibitor difluoromethylornithine, the caspase inhibitors Z-VAD FMK and Z-DEVD FMK, and c-Myc antisense oligodeoxynucleotide, respectively. These data indicate that c-Myc gene plays an important role in mediating CD437-induced apoptosis in human NSCLC cells.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Galderma Res & Dev, Sophia Antipolis, France	University of Texas System; UTMD Anderson Cancer Center; Galderma R&D SNC	Sun, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [U19 CA68437] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA068437] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Benner S E, 1995, Oncology (Williston Park), V9, P205; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Desbarats L, 1996, EXPERIENTIA, V52, P1123, DOI 10.1007/BF01952111; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Gudas Lorraine J., 1994, P443; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hong Waun Ki, 1994, P597; HSU B, 1995, ONCOGENE, V11, P175; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KIM YH, 1995, CANCER RES, V55, P5603; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Li XS, 1996, CANCER RES, V56, P5055; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LOTAN R, 1995, RETINOIDS ONCOLOGY, P27; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; Sakamuro D, 1995, ONCOGENE, V11, P2411; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1997, CANCER RES, V57, P4931; SUN SY, 1999, IN PRESS ONCOGENE; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817	43	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3894	3901		10.1038/sj.onc.1202771	http://dx.doi.org/10.1038/sj.onc.1202771			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445853				2022-12-17	WOS:000081171700011
J	Low, W; Smith, A; Ashworth, A; Collins, M				Low, W; Smith, A; Ashworth, A; Collins, M			JNK activation is not required for Fas-mediated apoptosis	ONCOGENE			English	Article						caspase; CD95; FADD; M3/6; IL-3	N-TERMINAL KINASE; STRESS-INDUCED APOPTOSIS; MYC-INDUCED APOPTOSIS; HUMAN T-CELLS; SIGNALING COMPLEX; PROTEIN-KINASES; SURFACE-ANTIGEN; CD95 FAS/APO-1; JURKAT CELLS; JUN KINASE	Fas ligation in the presence of cycloheximide induced Jun N-terminal kinase 1 (JNK1) and JNK2 phosphorylation, caspase activation and cell death in the IL-3-dependent cell line BAF3. Fas-mediated apoptosis was prevented by expression of dominant negative FADD but not inhibited by IL-3. To investigate the role of JNK activation in this process, we examined cells overexpressing a JNK-specific phosphatase M3/6. M3/6 prevented Pas stimulation of JNK, but did not affect Pas-mediated caspase activation or cell death, demonstrating that JNK activation is not required for these processes.	UCL, Dept Immunol, London W1P 6DB, England; Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Collins, M (corresponding author), UCL, Dept Immunol, Windeyer Bldg,46 Cleveland St, London W1P 6DB, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cahill MA, 1996, ONCOGENE, V13, P2087; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; delPeso L, 1997, SCIENCE, V278, P687; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Faris M, 1998, J IMMUNOL, V160, P134; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Rudel T, 1998, J IMMUNOL, V160, P7; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	43	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3737	3741		10.1038/sj.onc.1202702	http://dx.doi.org/10.1038/sj.onc.1202702			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391681				2022-12-17	WOS:000081140200007
J	Duyndam, MCA; van Dam, H; Smits, PHM; Verlaan, M; van der Eb, AJ; Zantema, A				Duyndam, MCA; van Dam, H; Smits, PHM; Verlaan, M; van der Eb, AJ; Zantema, A			The N-terminal transactivation domain of ATF2 is a target for the co-operative activation of the c-jun promoter by p300 and 12S E1A	ONCOGENE			English	Article						ATF; Jun; SAPK; CBP; transcription; coactivator	TRANSCRIPTION FACTOR FAMILY; CBP-INDUCED STIMULATION; NUCLEAR-PROTEIN CBP; ADENOVIRUS E1A; HETERODIMER FORMATION; GENE-TRANSCRIPTION; COACTIVATOR P300; RETINOIC ACID; UV RESPONSE; CYCLIC-AMP	The adenovirus EIA proteins activate the c-jun promoter through two Jun/ATF-binding sites, jun1 and jun2. P300, a transcriptional coactivator of several AP1 and ATF transcription factors has been postulated to play a role in this activation, Here,,ve present evidence that p300 can control c-jun transcription by acting as a cofactor for ATF2: (1) Over-expression of p300 mas found to stimulate c-jun transcription both in the presence and absence of EIA. (2) Like E1A, p300 activates the c-jun promoter through the jun1 and jun2 elements and preferentially activates the N-terminal domain of ATF2. (3) Co-immunoprecipitation assays of crude cell extracts indicate that endogenous p300/CBP(-like) proteins and ATF2 proteins are present in a multiprotein complex that can bind specifically to the jun2 element, We further demonstrate that the Stress-Activated-Protein-Kinase (SAPK) target sites of ATF2, Thr69 and Thr71 are not required for the formation of the p300/CBP-ATF2 multiprotein complex. These data indicate that E1A does not inhibit all transcription activation functions of p300, and, in fact, cooperates with p300 in the activation of the ATF2 N-terminus.	Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Zantema, A (corresponding author), Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.			van Dam, Hans/0000-0002-8307-4325				ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V351, P494; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BENBROOK DM, 1990, ONCOGENE, V5, P295; Billon N, 1996, ONCOGENE, V13, P2047; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; Duyndam MCA, 1996, J VIROL, V70, P5852, DOI 10.1128/JVI.70.9.5852-5859.1996; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FLINT KJ, 1991, ONCOGENE, V6, P2019; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Smits PHM, 1996, ONCOGENE, V12, P1529; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1989, ONCOGENE, V4, P1207; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	71	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2311	2321		10.1038/sj.onc.1202584	http://dx.doi.org/10.1038/sj.onc.1202584			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327051				2022-12-17	WOS:000079595500003
J	di Iasio, MG; Calin, G; Tibiletti, MG; Vorechovsky, I; Benediktsson, KP; Taramelli, R; Barbanti-Brodano, G; Negrini, M				di Iasio, MG; Calin, G; Tibiletti, MG; Vorechovsky, I; Benediktsson, KP; Taramelli, R; Barbanti-Brodano, G; Negrini, M			Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region	ONCOGENE			English	Article						LOH at 11q23; breast cancer	ATAXIA-TELANGIECTASIA; CERVICAL-CARCINOMA; OVARIAN-CANCER; MALIGNANT-MELANOMA; ATM MUTATIONS; CHROMOSOME-II; LONG ARM; HETEROZYGOSITY; GENE; TUMORS	Loss of constitutive heterozygosity at 11q23 has been detected in various human solid tumors. Here, we described the analysis of a series of normal and tumor pairs from 110 breast carcinomas for the presence of loss of heterozygosity at 11q23 loci. The overall frequency of LOH was 48%, confirming the importance of deletions at 11q23 in breast tumorigenesis. Previously, we have identified two independent regions of LOH at 11q23, the LOH region 1 at 11q23.1 and the LOH region 2 at 11q23.3. The most telomeric region was recently refined between loci D11S1345 and D11S1316, a region of about 1 Mb. However, the LOH region 1, most centromeric, was still not finely refined: the boundaries were defined by loci D11S2000 and D11S897, separated by about 8 Mb. Here, me refined its boundaries between loci D11S1347 and D11S927, a region of about 2 Mb. We have mapped 11 expressed sequence tags (ESTs) within this region and excluded another 20. This study represents a further step toward the identification of the putative tumor suppressor gene found within the LOH region 1 at 11q23.1.	Univ Ferrara, Dept Mol & Diagnost Med, I-44100 Ferrara, Italy; Univ Pavia, Dept Clin & Biol Sci, I-21100 Varese, Italy; Huddinge Hosp, Dept Surg, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Univ Varese, Dept Struct & Funct Biol, I-21110 Varese, Italy	University of Ferrara; University of Pavia; Karolinska Institutet; University of Insubria	Negrini, M (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Microbiol Sect, Via Luigi Borsari 46, I-44100 Ferrara, Italy.		Calin, George/E-9390-2011; Negrini, Massimo/J-2377-2016	Negrini, Massimo/0000-0002-0007-1920; Calin, George/0000-0001-6704-5615				Arai Y, 1996, GENOMICS, V35, P196, DOI 10.1006/geno.1996.0339; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; CARTER SL, 1994, CANCER RES, V54, P6270; Dahiya R, 1997, INT J CANCER, V72, P283, DOI 10.1002/(SICI)1097-0215(19970717)72:2<283::AID-IJC14>3.0.CO;2-H; Davis M, 1996, CANCER RES, V56, P741; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; Hui ABY, 1996, CANCER RES, V56, P3225; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; LOU WE, 1992, P NATL ACAD SCI USA, V89, P1755; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; RASIO D, 1995, CANCER RES, V55, P3988; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; STILGENBAUER S, 1997, NAT MED, V3, P1115; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Tomlinson IPM, 1996, J PATHOL, V180, P38, DOI 10.1002/(SICI)1096-9896(199609)180:1<38::AID-PATH638>3.0.CO;2-C; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Vorechovsky I, 1996, CANCER RES, V56, P4130; Vorechovsky I, 1996, CANCER RES, V56, P2726; WINQVIST R, 1995, CANCER RES, V55, P2660	33	27	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1635	1638		10.1038/sj.onc.1202453	http://dx.doi.org/10.1038/sj.onc.1202453			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102634				2022-12-17	WOS:000078770700014
J	Giese, H; Dolle, MET; Hezel, A; van Steeg, H; Vijg, J				Giese, H; Dolle, MET; Hezel, A; van Steeg, H; Vijg, J			Accelerated accumulation of somatic mutations in mice deficient in the nucleotide excision repair gene XPA	ONCOGENE			English	Article						nucleotide excision repair; XPA; mutation accumulation; lacZ reporter gene; ageing	ULTRAVIOLET-B; LACKING; TUMORS; LIVER	Inheritable mutations in nucleotide excision repair (NER) genes cause cancer-prone human disorders, such as xeroderma pigmentosum, which are also characterized by symptoms of accelerated ageing. To study the impact of NER deficiency on mutation accumulation iN vivo, mutant frequencies have been determined in liver and brain of 2-16 month old NER deficient XPA(-/-), lacZ hybrid mice. While mutant frequencies in liver of 2-month old XPA(-/-), lacZ mice were comparable to XPA (+/-), lacZ and the lacZ parental strain animals, by 4 months of age mutant frequencies in the XPA-deficient mice were significantly increased by a factor of two and increased further until the age of 16 months. In brain, mutant frequencies were not found to increase with age, These results show that a deficiency in the NER gene XPA causes an accelerated accumulation of somatic mutations in Liver but not in brain. This is in keeping with a higher incidence of spontaneous liver tumors reported earlier for XPA(-/-) mice after about 15 months of age.	Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA; Natl Inst Publ Hlth & Environm, Hlth Effects Res Lab, NL-3720 BA Bilthoven, Netherlands	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Netherlands National Institute for Public Health & the Environment	Vijg, J (corresponding author), Beth Israel Deaconess Med Ctr, 77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL INSTITUTE ON AGING [P30AG013314] Funding Source: NIH RePORTER; NIA NIH HHS [P01 1801 AG10829-01, 1 P30 AG13314-01] Funding Source: Medline; NIEHS NIH HHS [1 RO1 ES/CA 08797-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bootsma D., 1998, GENETIC BASIS HUMAN, P245; BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; de Vries A, 1997, CARCINOGENESIS, V18, P2327, DOI 10.1093/carcin/18.12.2327; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; deVries A, 1997, MOL CARCINOGEN, V19, P46, DOI 10.1002/(SICI)1098-2744(199705)19:1<46::AID-MC7>3.3.CO;2-O; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HART RW, 1979, MECH AGEING DEV, V9, P203, DOI 10.1016/0047-6374(79)90100-3; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; STREHLER BL, 1980, MECH AGEING DEV, V14, P15, DOI 10.1016/0047-6374(80)90103-7; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X	13	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1257	1260		10.1038/sj.onc.1202404	http://dx.doi.org/10.1038/sj.onc.1202404			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022133				2022-12-17	WOS:000078510700016
J	Valge-Archer, V; Forster, A; Rabbitts, TH				Valge-Archer, V; Forster, A; Rabbitts, TH			The LMO1 and LDB1 proteins interact in human T cell acute Leukaemia with the chromosomal translocation t(11;14)(p15;q11)	ONCOGENE			English	Article						leukaemia; dimerization; tumours; chromosomal translocation; transcription	MESSENGER-RNAS; LIM; RHOMBOTIN; ONCOGENE; LEUKEMIA; EXPRESSION; COMPLEX; MOTIF; TTG-1; TAL1	The ectopic expression of LMO1 or LMO2 in T cell acute leukaemias resulting from chromosomal translocations t(11;14)(p15;q11) or t(11;14)(p13;q11) respectively in a causal factor in tumorigenesis. LMO1 has been found as a heterodimer with a 46 Kd protein in a T cell Line derived from a childhood T-acute leukaemia. This 46 Kd protein is the LIM-binding protein LDB1/NLI, The latter is a phosphoprotein and binds to LMO1 in its phosphorylated state and essentially all the LMO1 and LDB1 protein in the T cell line is part of the complex. Therefore, the LMO1-LDB1 interaction is likely to be involved in tumorigenesis after LMO1 is ectopically expressed following chromosomal translocation in T cells prior to development of acute leukaemias.	MRC, Mol Biol Lab, Div Prot & Nucleic Acid Chem, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Div Prot & Nucleic Acid Chem, Hills Rd, Cambridge CB2 2QH, England.		Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145	17	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3199	3202		10.1038/sj.onc.1202353	http://dx.doi.org/10.1038/sj.onc.1202353			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872335				2022-12-17	WOS:000077517400013
J	Hajitou, A; Baramova, EN; Bajou, K; Noe, V; Bruyneel, E; Mareel, M; Collette, J; Foidart, JM; Calberg-Bacq, CM				Hajitou, A; Baramova, EN; Bajou, K; Noe, V; Bruyneel, E; Mareel, M; Collette, J; Foidart, JM; Calberg-Bacq, CM			FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells	ONCOGENE			English	Article						FGF-3; FGF-4; mammary tumors; myoepithelial cells	FIBROBLAST GROWTH-FACTOR; E-CADHERIN EXPRESSION; SMOOTH-MUSCLE ACTIN; HUMAN BREAST-CANCER; TRANSGENIC MICE; TUMOR VIRUS; PROVIRAL INSERTION; FACTOR FAMILY; NUDE-MICE; IN-VITRO	Fibroblast Growth Factors 3 (FGF-3) and 4 (FGF-4) mere compared for the effects they each exert on EF43 mouse cells. This non-transformed mammary cell line appears to be myoepithelial mainly because it expresses cc-smooth muscle actin, The EF43 cells were infected with similar vectors that carry either the short fgf-3 sequence (the product of which goes into the secretory pathway), fgf-4 or the selection gene only as control, In syngeneic animals, EF43,fgf-3 cells were tumorigenic only when orthotopically implanted whereas EF43.fgf-4 cells invariably gave rise to aggressive tumors. However, both tumor types were metastatic as evidenced by the blue micrometastases observed when the implanted cells expressed lacZ. In vitro, the FGF-3 producing cells were strongly invasive in matrigel coated chambers whereas the EF43.fgf-4 cells only were invasive in type I-collagen gels, Interestingly, FGF-3 production greatly stimulated the synthesis of pro-MMP-9 (Matrix Metalloprotease-9) and, to a lesser extent, that of pro-MMP-2, FGF-3 also up-regulated the production of plasminogen activators. In contrast, FGF-4 had no effect on these secretions and the medium conditioned by the EF43.fgf-4 cells displayed the largest plasminogen activator-inhibitor activity, These results show that FGF-3 and FGF-4 have distinct mechanisms of action on myoepithelial cells.	Univ Liege, Lab Fundamental Virol & Immunol, Inst Pathol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol, Med Chem Lab, B-4000 Liege, Belgium; State Univ Ghent, Expt Cancerol Lab, B-9000 Ghent, Belgium	University of Liege; University of Liege; University of Liege; Ghent University	Calberg-Bacq, CM (corresponding author), Univ Liege, Lab Fundamental Virol & Immunol, Inst Pathol, B23, B-4000 Liege, Belgium.			Hajitou, Amin/0000-0003-1119-5686; Bajou, Khalid/0000-0002-5529-9228				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ADAMS LM, 1987, CANCER RES, V47, P4425; ANDERSSON LA, 1994, EXP CELL RES, V219, P389; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BARAMOVA EN, 1994, ANTICANCER RES, V14, P841; BARRACLOUGH R, 1990, J CELL PHYSIOL, V144, P333, DOI 10.1002/jcp.1041440220; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; Deroanne CF, 1997, CANCER RES, V57, P5590; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; FERNIG DG, 1990, J CELL PHYSIOL, V142, P108, DOI 10.1002/jcp.1041420114; FERNIG DG, 1995, INTERCELLULAR SIGNAL, P336; FOIDART JM, 1980, LAB INVEST, V42, P336; FRANKE WW, 1980, J CELL BIOL, V84, P633, DOI 10.1083/jcb.84.3.633; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; GOMM JJ, 1991, CANCER RES, V51, P4685; GUGLIOTTA P, 1988, J HISTOCHEM CYTOCHEM, V36, P659, DOI 10.1177/36.6.3367051; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; HAJITOU A, 1995, INT J CANCER, V63, P702, DOI 10.1002/ijc.2910630516; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; KE Y, 1993, J CELL SCI, V100, P135; Kitsberg DI, 1996, ONCOGENE, V13, P2507; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEPRINCE P, 1989, ANAL BIOCHEM, V177, P341, DOI 10.1016/0003-2697(89)90063-8; LIN WC, 1990, CANCER RES, V50, P2808; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAREEL M M, 1981, Invasion and Metastasis, V1, P195; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Miyake H, 1996, CANCER RES, V56, P2440; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURAKAMI A, 1990, CELL GROWTH DIFFER, V1, P225; NAVARRO P, 1993, J CELL SCI, V105, P923; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RIES C, 1995, BIOL CHEM H-S, V376, P345; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; SATO H, 1992, ONCOGENE, V7, P77; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SMALLEY M, 1995, INTERCELLULAR SIGNALLING IN THE MAMMARY GLAND, P99; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; Spieker N, 1995, EUR J CELL BIOL, V68, P427; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; TANAKA H, 1993, BIOCHEM BIOPH RES CO, V190, P732, DOI 10.1006/bbrc.1993.1110; VAKAET L, 1991, INVAS METAST, V11, P249; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Warburton MJ, 1996, EXP CELL RES, V228, P76, DOI 10.1006/excr.1996.0301; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	63	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2059	2071		10.1038/sj.onc.1202126	http://dx.doi.org/10.1038/sj.onc.1202126			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798677				2022-12-17	WOS:000076540900005
J	Groysman, M; Nagano, M; Shaanan, B; Katzav, S				Groysman, M; Nagano, M; Shaanan, B; Katzav, S			Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation	ONCOGENE			English	Article						vav; SH3; Zyxin; hnRNP-K	AMINO-ACID SUBSTITUTIONS; TYROSINE KINASE-ACTIVITY; PROLINE-RICH PEPTIDES; GTP EXCHANGE FACTOR; PROTOONCOGENE PRODUCT; C-SRC; SIGNAL-TRANSDUCTION; T-CELL; BINDING-PROTEIN; GENE	The vav proto-oncogene encodes a protein with multiple modulae domains that enable it to function as a mediator, linking tyrosine signaling to downstream events in hematopoietic cells, Circumstantial evidence suggests that protein-protein interactions exerted by two of these domains, the Src homology 2 (SH2) and the Src homology 3 (SH3), play an important role in the regulation of Vav activity, To study the relevance of the SH3 domain for the function of vav as a transforming gene, we have created several mutations in the SH3 domain located at its carboxy region. Substitution of the non-conserved aspartic acid 797 (to asparagine, D797N) retained the transforming potential of the vav oncogene, whereas substitutions of five highly conserved amino-acids: alanine 789 (to asparagine, A789N), leucine 801 (to arginine, L801R), tryptophan 821 (to arginine, W821R), glycine 830 (to valine, G830V) and valine 837 (to glutamic acid, V837E) greatly reduced its transforming potential. The mutant proteins resemble Vav in many biochemical properties; however, while the transforming mutant protein (D797N) associates with several unidentified proteins in a manner similar to that of Vav, the non-transforming mutant Vav proteins react very poorly with these proteins, Among the known Vav-interacting proteins, hnRNP-K associates with all mutant proteins except A789N and V837E whereas binding of Zyxin to any of the mutant proteins is not affected. Taken together, our results clearly demonstrate that the SH3 domain has a positive effect on vav activity and is needed for vav transformation, The vavSH3C associating protein(s) that are crucial for its activity as a transforming gene have probably not Set been identified.	Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Katzav, S (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel.		Shaanan, Boaz/F-1202-2012	Shaanan, Boaz/0000-0001-8925-4362; Sherman, Maya/0000-0002-7421-9844				ADAMS JM, 1992, ONCOGENE, V7, P611; BOUGSKI MS, 1993, NATURE, V366, P643; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GALLAND F, 1992, ONCOGENE, V7, P585; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; Hiroaki H, 1996, J BIOMOL NMR, V8, P105; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Hobert O, 1996, ONCOGENE, V12, P1577; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Katzav S, 1995, CRIT REV ONCOGENESIS, V6, P87; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; Morton CJ, 1996, STRUCTURE, V4, P705, DOI 10.1016/S0969-2126(96)00076-7; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Romero F, 1996, MOL CELL BIOL, V16, P37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Wittekind M, 1997, J MOL BIOL, V267, P933, DOI 10.1006/jmbi.1996.0886; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	59	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1597	1606		10.1038/sj.onc.1202074	http://dx.doi.org/10.1038/sj.onc.1202074			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794237				2022-12-17	WOS:000076089900012
J	Niederreither, K; Harbers, M; Chambon, P; Dolle, P				Niederreither, K; Harbers, M; Chambon, P; Dolle, P			Expression of T: G mismatch-specific thymidine-DNA glycosylase and DNA methyl transferase genes during development and tumorigenesis	ONCOGENE			English	Article						in situ hybridization; DNA repair; mouse mammary tumor virus; p53; transgenic mice	SIGNALING PATHWAY; P53 GENE; METHYLTRANSFERASE; CANCER; CELLS; MICE; TUMORS; HYPERMETHYLATION; HYPOMETHYLATION; PROGRESSION	In situ hybridization was used to characterize the expression pattern of the T:G mismatch-specific thymidine-DNA glycosylase (TDG) gene, encoding a DNA repair enzyme which corrects G:T mismatches that result from the hydrolytic deamination of 5-methyl cytosines, TDG transcripts were uniformly and ubiquitously expressed from 7.5-13.5 days post-coitum, but were then markedly enriched in specific tissues of the developing fetus. At 14.5 gestational days, TDG was strongly expressed in the developing nervous system, thymus, lung, liver, kidney and intestine, At later stages, high levels of expression were detected in the thymus, brain, nasal epithelium and within proliferating regions of the intestine, skin, kidney, teeth and bone, This pattern of expression strongly correlated with those of the methyl transferase (MTase) gene, coding for the enzyme which specifically methylates CpG dinucleotides, and the p53 tumour suppressor gene. However, TDG and MTase were differentially expressed during maturation of the male and female germline, We also report that tumors occuring in mice which overexpress MMTV-v-Ha-ras or MMTV-c-myc transgenes or mice heterozygous for p53 gene disruption, all show elevated TDG and MTase expression specific to the transformed tissue.	ULP, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Dolle, P (corresponding author), ULP, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, BP 163,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.		Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090; Harbers, Matthias/0000-0002-5613-7220				Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; ALCIVAR AA, 1992, BIOL REPROD, V46, P201, DOI 10.1095/biolreprod46.2.201; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BENOIT G, 1994, BIOL REPROD, V50, P1312, DOI 10.1095/biolreprod50.6.1312; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CARLSON LL, 1992, GENE DEV, V6, P2536, DOI 10.1101/gad.6.12b.2536; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Heby O, 1995, INT J DEV BIOL, V39, P737; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JacksonGrusby L, 1996, SEMIN CANCER BIOL, V7, P261, DOI 10.1006/scbi.1996.0034; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; Jones PA, 1996, CANCER RES, V56, P2463; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MAKOS M, 1993, CANCER RES, V53, P2715; MAKOS M, 1993, CANCER RES, V53, P2719; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Niederreither K, 1998, METH MOL B, V89, P247; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Pfeifer GP, 1997, BBA-REV CANCER, V1333, pM1, DOI 10.1016/S0304-419X(97)00004-8; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Robertson KD, 1997, AM J HUM GENET, V61, P1220, DOI 10.1086/301658; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SZYF M, 1991, J BIOL CHEM, V266, P10027; TORNALETTI S, 1995, ONCOGENE, V10, P1493; WALTER CA, 1994, SOMAT CELL MOLEC GEN, V20, P451, DOI 10.1007/BF02255837; WIND N, 1995, CELL, V82, P321; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YEBRA MJ, 1995, BIOCHEMISTRY-US, V34, P14752, DOI 10.1021/bi00045a016	43	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1577	1585		10.1038/sj.onc.1202072	http://dx.doi.org/10.1038/sj.onc.1202072			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794235				2022-12-17	WOS:000076089900010
J	Zhang, JS; Nelson, M; McIver, B; Hay, ID; Goellner, JR; Grant, CS; Eberhardt, NL; Smith, DI				Zhang, JS; Nelson, M; McIver, B; Hay, ID; Goellner, JR; Grant, CS; Eberhardt, NL; Smith, DI			Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors	ONCOGENE			English	Article						7q31.2; LOH; thyroid cancer; FRA7G	SUPPRESSOR GENE; ONCOGENE ACTIVATION; BREAST-CANCER; FHIT GENE; CARCINOMAS; MUTATIONS; TUMORIGENESIS; NEOPLASMS; REGION; 3P14.2	We analysed 42 differentiated thyroid tumors including 15 follicular adenomas (FA), 13 papillary thyroid cancers (PTC) and 14 follicular thyroid carcinomas (FTC) with 13 microsatellite markers specific for the long arm of human chromosome 7 within 7q31; this region is deleted frequently in several other tumor types. Overall, 20 of the 42 samples analysed (48%) displayed LOH with one or more of the markers tested. LOH was detected most frequently (78%) in FTC, the most malignant of the thyroid tumors. A smallest common deleted region (SCDR) was defined in this tumor type flanked by markers D7S480 and D7S490, This SCDR is distinct fi:om D7S522, the most commonly deleted locus in many other tumors, which was deleted in only one FTC. D7S522 did show LOH in two of six informative PTCs, None of the PTC and only two of the FAs showed LOH in the FTC SCDR, Since FA is considered a premalignant stage of FTC, our results suggest that inactivation of a putative tumor suppressor at 7q31.2 may be acquired during adenoma to carcinoma progression. The absence of LOH at this locus amongst PTC suggests that inactivation of this tumor suppressor is specific for FTC, In conclusion, LOH at 7q31 is a frequent event in differentiated thyroid cancer, and we have defined a 2 cM SCDR specific for FTC.	Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, 200 1st St SW, Rochester, MN 55905 USA.		Hay, Ian/AAH-8508-2019	Hay, Ian/0000-0002-5527-3909	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achille A, 1996, CANCER RES, V56, P3808; Devilee P, 1997, GENE CHROMOSOME CANC, V18, P193; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; GREBE SK, 1997, W J MED, V165, P156; Grebe SKG, 1997, J CLIN ENDOCR METAB, V82, P3684, DOI 10.1210/jc.82.11.3684; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; HERRMANN MA, 1991, J CLIN INVEST, V88, P1596, DOI 10.1172/JCI115472; HERRMANN ME, 1992, CANCER GENET CYTOGEN, V62, P144, DOI 10.1016/0165-4608(92)90253-5; HICKS DG, 1990, AM J PATHOL, V137, P553; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; ITO T, 1992, CANCER RES, V52, P1369; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; LEMOINE NR, 1989, ONCOGENE, V4, P159; Lin JC, 1996, ONCOGENE, V13, P2001; MATSUO K, 1991, MOL ENDOCRINOL, V5, P1873, DOI 10.1210/mend-5-12-1873; MCCONAHEY WM, 1986, MAYO CLIN PROC, V61, P978, DOI 10.1016/S0025-6196(12)62641-X; NAMBA H, 1990, J CLIN INVEST, V86, P120, DOI 10.1172/JCI114673; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; OAKAHASHI S, 1995, CANCER RES, V55, P4114; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SHRIDHAR V, 1997, IN PRESS ONCOGENE; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUAREZ HG, 1990, ONCOGENE, V5, P565; TEYSSIER JR, 1990, CANCER GENET CYTOGEN, V50, P249, DOI 10.1016/0165-4608(90)90184-C; Umbricht CB, 1997, CANCER RES, V57, P2144; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Williams GH, 1996, BRIT J CANCER, V74, P585, DOI 10.1038/bjc.1996.405; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488; Zedenius J, 1996, HUM GENET, V97, P299, DOI 10.1007/BF02185758; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; ZENKLUSEN JC, 1994, ONCOGENE, V9, P28177	38	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					789	793		10.1038/sj.onc.1201996	http://dx.doi.org/10.1038/sj.onc.1201996			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715281				2022-12-17	WOS:000075337200014
J	Wakeman, JA; Walsh, J; Andrews, PW				Wakeman, JA; Walsh, J; Andrews, PW			Human Wnt-13 is developmentally regulated during the differentiation of NTERA-2 pluripotent human embryonal carcinoma cells	ONCOGENE			English	Article						Wnt-13; teratocarcinoma; human; neuron	PROTO-ONCOGENE INT-1; RETINOIC ACID; XENOPUS EMBRYOS; EXPRESSION; GENE; TERATOCARCINOMA; DROSOPHILA; LINES; POLARITY; HOMOLOG	The Wnt gene family encodes a series of conserved glycoproteins that regulate pattern formation during embryogenesis, in a variety of tissues including the nervous system. As with other genes that control embryonic cell differentiation, members of the Wnt family have also been implicated in tumourigenesis, To search for Wnt genes involved in human teratocarcinomas, with a possible role in human embryogenesis, we used RT-PCR primed with degenerate oligonucleotides to analyse mRNA from differentiating cultures of the pluripotent human embryonal carcinoma (EC) cell line NTERA-2, NTERA-2 EC cells differentiate into neurons and other cell types when induced with retinoic acid. Wnt gene expression was not detected in the undifferentiated EC cells, but Wnt-related PCR fragments were amplified from differentiating cultures, 4-14 days after induction with retinoic acid, The RT-PCR products were composed primarily of DNA fragments corresponding to the recently identified human Wnt-13 gene, No other Wnt-related genes were identified. Northern analysis confirmed induction of Wnt-13 as a 2.4 kb mRNA during the early phases of retinoic acid-induced differentiation, and during differentiation along a non-neural pathway induced by hexamethylene bisacetamide (HMBA), but not in the terminally differentiated neurons, Wnt-13 remained expressed in non-neural differentiated NTERA-2 cells, even several weeks after the induction of differentiation. The time course of induction, its induction by HMBA, and its persistence in differentiated cells indicate that Wnt-13 expression is not dependent upon direct activation by retinoic acid. Wnt-13 was not detected, or only detected at low levels, in other human EC cells, However, it was found to be expressed at a high level in one malignant teratoma cell line, 577MF, that does not exhibit an EC phenotype although it was derived from a testicular teratocarcinoma. At least two members of the human frizzled gene family, thought to encode receptors for Wnt proteins, were also expressed in the NTERA-2 cells, suggesting the presence of a mechanism by which endogenously expressed Wnt-13 could modulate the histogenesis of teratocarcinomas by mediating interactions between subpopulations of differentiating EC cells. We note that Wnt-13 maps to chromosome 1p13, a region reported to be subject to relatively frequent loss of heterozygosity in germ cell tumours, Further analysis indicated that 465 bp of the published Wnt-13 sequence, within the predicted 5' UTR, is incorrect and is possibly derived from a human mitochondrial DNA sequence.	Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Andrews, PW (corresponding author), Univ Sheffield, Dept Biomed Sci, Western Bank, Sheffield S10 2TN, S Yorkshire, England.			Wakeman, Jane/0000-0002-7561-634X; Andrews, Peter/0000-0001-7215-4410	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMAN SL, 1994, MOL BRAIN RES, V25, P157, DOI 10.1016/0169-328X(94)90293-3; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1980, INT J CANCER, V26, P269, DOI 10.1002/ijc.2910260304; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; ANDREWS PW, 1984, LAB INVEST, V50, P147; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Andrews PW, 1996, INT J CANCER, V66, P806, DOI 10.1002/(SICI)1097-0215(19960611)66:6<806::AID-IJC17>3.0.CO;2-0; ANDREWS PW, 1997, IN PRESS ACTA PATH M; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HUGUET EL, 1994, CANCER RES, V54, P2615; Katoh M, 1996, ONCOGENE, V13, P873; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MATHEW S, 1994, CANCER RES, V54, P6265; MATTHAEI KI, 1983, EXP CELL RES, V143, P471, DOI 10.1016/0014-4827(83)90076-9; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MILLER JM, 1996, GENE DEV, V10, P257; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PARR BA, 1993, DEVELOPMENT, V119, P247; PATTILLO RA, 1971, IN VITRO CELL DEV B, V6, P398; PATTILLO RA, 1968, CANCER RES, V28, P1231; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; RAMAKRISHNA NR, 1993, DEVELOPMENT S, V119, P95; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Vider BZ, 1996, ONCOGENE, V12, P153; Wang YS, 1996, J BIOL CHEM, V271, P4468; WOLDA SL, 1992, ONCOGENE, V7, P1941; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060	45	27	29	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					179	186		10.1038/sj.onc.1201942	http://dx.doi.org/10.1038/sj.onc.1201942			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674702				2022-12-17	WOS:000074706700006
J	Fenstermaker, RA; Ciesielski, MJ; Castiglia, GJ				Fenstermaker, RA; Ciesielski, MJ; Castiglia, GJ			Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells	ONCOGENE			English	Article						epidermal growth factor receptor; mutation; genetic recombination; glioma; intron; oncogene	HUMAN GLIOBLASTOMA; EGF-RECEPTOR; MALIGNANT GLIOMAS; BRAIN-TUMORS; FACTOR-ALPHA; C-MYB; GENE; EXPRESSION; TRANSFORMATION; AMPLIFICATION	Amplification and rearrangement of the epidermal growth factor receptor (EGFR) gene occur frequently in malignant gliomas. Rearrangement may also lead to the expression of potentially oncogenic EGFR deletion mutants. Data presented here indicate the existence of a 190 kDa mutant form of the EGFR in A-172 glioma cells that is substantially different from the deletion mutants characterized previously. The EC;FR-like protein is expressed along with the 170 kDa wild type EGFR. It is detectable with antibodies to both extracellular and intracellular regions of the EGFR, but is not crossreactive with other HER-family members, The wild type and mutant receptors undergo phosphorylation in response to treatment with TGF alpha and are associated with expression of both 10.5 kb and 11.5 kb EGFR-related transcripts. Combined reverse transcription-polymerase chain reaction (RT-PCR) identifies a unique transcript in A-172 cells that encodes an in-frame, tandem duplication of both tyrosine kinase and calcium internalization (TK/CAIN) domains (exons 18 through 26). The duplication of these domains is associated with a specific genomic rearrangement between potential v-myb and c-myb consensus binding sites within introns 26 and 17 of the EGFR gene resulting in the formation of a chimeric intron.	Roswell Pk Canc Inst, Dept Neurosurg, Buffalo, NY 14263 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14209 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Fenstermaker, RA (corresponding author), Roswell Pk Canc Inst, Dept Neurosurg, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056-21] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGNES F, 1994, GENE, V145, P283, DOI 10.1016/0378-1119(94)90021-3; BASAU A, 1989, MOL CELL BIOL, V9, P671; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BOGLER O, 1995, CANCER RES, V55, P2746; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; Deng QL, 1996, NUCLEIC ACIDS RES, V24, P766, DOI 10.1093/nar/24.4.766; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Frisa PS, 1996, CELL GROWTH DIFFER, V7, P223; HALEY JD, 1989, ONCOGENE, V4, P273; HernandezMunain C, 1996, J EXP MED, V183, P289, DOI 10.1084/jem.183.1.289; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; HUMPHREY PA, 1988, CANCER RES, V48, P2231; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; MAHALEY MS, 1991, J NEURO-ONCOL, V11, P85, DOI 10.1007/BF02390173; MARUNO M, 1991, J NEUROSURG, V75, P97, DOI 10.3171/jns.1991.75.1.0097; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Moscatello DK, 1996, ONCOGENE, V13, P85; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PANNEERSELVAM K, 1995, EUR J BIOCHEM, V230, P951, DOI 10.1111/j.1432-1033.1995.tb20641.x; PELLEY RJ, 1988, J VIROL, V54, P304; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RASHEED BKA, 1994, CANCER RES, V54, P1324; SCHLEGEL J, 1994, INT J CANCER, V56, P72; STECK PA, 1988, CANCER RES, V48, P5433; SU HHJ, 1997, J BIOL CHEM, V272, P2927; Ueki K, 1996, CANCER RES, V56, P150; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WELTER C, 1990, CANCER LETT, V52, P57, DOI 10.1016/0304-3835(90)90077-B; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMOMOTO T, 1983, CELL, V34, P225; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812	47	27	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3435	3443		10.1038/sj.onc.1202156	http://dx.doi.org/10.1038/sj.onc.1202156			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692551				2022-12-17	WOS:000074544100010
J	Caldas, C; Kim, MH; MacGregor, A; Cain, D; Aparicio, S; Wiedemann, LM				Caldas, C; Kim, MH; MacGregor, A; Cain, D; Aparicio, S; Wiedemann, LM			Isolation and characterization of a Pufferfish MLL (mixed lineage leukemia)-like gene (fMll) reveals evolutionary conservation in vertebrate genes related to Drosophila trithorax	ONCOGENE			English	Article						MLL; HRX; ALL-1; TRX; evolutionary conservation; Fugu rubripes; genomic sequence	11Q23 CHROMOSOMAL TRANSLOCATIONS; ALL-1 GENE; MOLECULAR ANALYSIS; ACTIVATION DOMAIN; SEQUENCE-ANALYSIS; TOPOISOMERASE-II; FUGU RUBRIPES; REGION; BREAKPOINT; ALIGNMENT	The MLL gene is interrupted and fused to a number of partner genes as a result of chromosomal translocations in human leukemias. MLL is a very large protein with a unique domain structure and large regions of homology to Drosophila trx. To define the key structural and functional domains of the MLL protein in vertebrates, me have cloned the genomic region encoding an MLL-like gene in the compact model vertebrate genome of Fugu rubripes. While the similarity between the mouse and human MLL proteins is very high, a lower overall similarity is present between the Fugu and mammalian proteins. Several new highly conserved regions were identified in the portion of the protein included in the MLL leukemia-associated fusion proteins. The conserved nature of regions of similarity between vertebrate forms of MLL and the Drosophila TRX proteins, as well as other domains previously suggested to have a functional role in MLL (including the AT hooks and the DNA methyltransferase domain), was also observed. There; fore, strong evolutionary constraints limited sequence divergence within these domains, The information derived from this comparative analysis will form the basis for the functional study of the MLL protein, particularly as it relates to human leukemogenesis.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Wellcome CRC Inst, Cambridge CB2 1QR, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Wiedemann, LM (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, Fulham Rd, London SW3 6JB, England.		Caldas, Carlos/U-7250-2019; Caldas, Carlos/A-7543-2008; Wiedemann, Leanne/E-3316-2010	Caldas, Carlos/0000-0003-3547-1489; Aparicio, Samuel/0000-0002-0487-9599; Wiedemann, Leanne/0000-0002-0964-4676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APARICIO S, 1995, P NATL ACAD SCI USA, V92, P1684, DOI 10.1073/pnas.92.5.1684; BAXENDALE S, 1995, NAT GENET, V10, P67, DOI 10.1038/ng0595-67; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Bonfield JK, 1996, DNA SEQUENCE, V6, P109, DOI 10.3109/10425179609010197; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; Caldas C, 1998, GENE, V208, P167, DOI 10.1016/S0378-1119(97)00640-9; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; DJABALI M, 1992, NAT GENET, V2, P112; DOMER PH, 1995, LEUKEMIA, V9, P1305; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Greaves MF, 1996, LEUKEMIA, V10, P372; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; Henikoff S, 1997, TRENDS GENET, V13, P293, DOI 10.1016/S0168-9525(97)01219-5; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MACRAE AD, 1995, GENOMICS, V25, P436, DOI 10.1016/0888-7543(95)80044-M; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; MBANGKOLLO D, 1995, DNA CELL BIOL, V14, P475, DOI 10.1089/dna.1995.14.475; Nam DK, 1996, GENE, V178, P169, DOI 10.1016/0378-1119(96)00364-2; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RASIO D, 1996, CANCER RES, V56, P176; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Sathasivam K, 1997, HUM MOL GENET, V6, P2141, DOI 10.1093/hmg/6.12.2141; SCHINDLER U, 1993, PLANT J, V4, P137, DOI 10.1046/j.1365-313X.1993.04010137.x; Schuddekopf K, 1996, P NATL ACAD SCI USA, V93, P9661, DOI 10.1073/pnas.93.18.9661; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Strissel Gbroeker Pamela L., 1996, Blood, V87, P1912; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TILLIB S, 1995, MECH DEVELOP, V53, P113, DOI 10.1016/0925-4773(95)00429-7; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Venkatesh B, 1997, P NATL ACAD SCI USA, V94, P12462, DOI 10.1073/pnas.94.23.12462; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	52	27	27	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3233	3241		10.1038/sj.onc.1201873	http://dx.doi.org/10.1038/sj.onc.1201873			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681821				2022-12-17	WOS:000074343600003
J	Nees, M; van Wijngaarden, E; Bakos, E; Schneider, A; Durst, M				Nees, M; van Wijngaarden, E; Bakos, E; Schneider, A; Durst, M			Identification of novel molecular markers which correlate with HPV-induced tumor progression	ONCOGENE			English	Article						HPV (human papillomavirus); cervical cancer; prognostic markers; differential display; tumor progression	HUMAN PAPILLOMAVIRUS INFECTION; DIFFERENTIAL DISPLAY; TRANSMEMBRANE-4 SUPERFAMILY; EPITHELIAL-CELLS; ALVEOLAR RHABDOMYOSARCOMA; MI-2 AUTOANTIGEN; GENETIC-ANALYSIS; CERVICAL-CANCER; UTERINE CERVIX; MESSENGER-RNAS	High risk HPVs (human papillomaviruses) are causally involved in the development of cervical cancer, However, other factors, such as somatic genetic alterations also play a decisive role in malignant conversion of cervical keratinocytes, Mutations and chromosomal aberrations are known to influence the pattern of gene expression, Therefore we used the recently developed RT-PCR based method of differential display of mRNAs to detect differences in gene expression which correlate with tumorigenicity. Non-tumorigenic HPV16-immortalized human foreskin keratinocytes (HPK IA) were compared with their tumorigenic counterparts and 49 different genes were identified which were either up-or downregulated. The identified genes encode proteins of the cytoskeleton and the extracellular matrix, the nuclear splicing apparatus, transcription regulators and membrane-associated proteins. The expression pattern of all genes was also examined by RNA-RNA in situ hybridization in biopsies of normal cervical epithelium, precancerous lesions and cancers. Two genes, C4.8 and C21.7, are of particular interest because their expression is upregulated in a subset of high grade precancerous lesions and in over 58% of cancers. These two genes may therefore be considered as putative progression markers. C4.8 is a new member of the transmembrane 4 (TM-4) protein family which includes tumor-associated antigens such as CD63 and TAPA-1, whereas C21.7 shows no significant homologies to any known genes or proteins.	Univ Jena, Abt Frauenheilkunde, D-07740 Jena, Germany; Deutsch Krebsforschungszentrum, ATV 0615, D-69120 Heidelberg, Germany	Friedrich Schiller University of Jena; Helmholtz Association; German Cancer Research Center (DKFZ)	Durst, M (corresponding author), Univ Jena, Abt Frauenheilkunde, Bachstr 18, D-07740 Jena, Germany.		Nees, Matthias/W-6596-2018; Nees, Matthias/AAT-5577-2020	Nees, Matthias/0000-0002-9034-301X; 				Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; BAUER D, 1994, PCR METH APPL, V4, P97; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berthod F, 1997, J INVEST DERMATOL, V108, P737, DOI 10.1111/1523-1747.ep12292122; BUIJS A, 1995, ONCOGENE, V10, P1511; CALVIO C, 1995, RNA, V1, P724; CHEN TM, 1993, CANCER RES, V53, P1167; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cuzick J, 1996, EUR J CANCER, V32A, P836, DOI 10.1016/0959-8049(95)00650-8; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; DESPRES N, 1995, J CLIN INVEST, V95, P1891, DOI 10.1172/JCI117870; Durst M, 1995, CANCER GENET CYTOGEN, V85, P105, DOI 10.1016/0165-4608(95)00155-7; DURST M, 1987, ONCOGENE, V1, P251; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Gerecke DR, 1997, GENOMICS, V41, P236, DOI 10.1006/geno.1997.4638; Gress TM, 1996, ONCOGENE, V13, P1819; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Herrington CS, 1996, J CLIN PATHOL, V49, P493, DOI 10.1136/jcp.49.6.493; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HOPPESEYLER F, 1995, J MOL MED, V73, P529; KIVIAT NB, 1992, INT J GYNECOL PATHOL, V11, P197, DOI 10.1097/00004347-199207000-00005; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Londesborough P, 1996, INT J CANCER, V69, P364; Mannion BA, 1996, J IMMUNOL, V157, P2039; Muir C.S., 1987, CANC INCIDENCE 5 CON; Nindl I, 1996, J VIROL METHODS, V62, P81, DOI 10.1016/0166-0934(96)02084-8; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PONTEN J, 1995, INT J CANCER, V63, P317, DOI 10.1002/ijc.2910630229; REID R, 1991, AM J OBSTET GYNECOL, V164, P1461, DOI 10.1016/0002-9378(91)91425-V; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; Schneider A, 1996, AM J OBSTET GYNECOL, V174, P1534, DOI 10.1016/S0002-9378(96)70602-6; SEAGON S, 1994, CANCER RES, V54, P5593; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; TSUTSUMI K, 1992, AM J PATHOL, V140, P255; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531; WOODWORTH CD, 1988, CANCER RES, V48, P4620; WOODWORTH CD, 1989, J VIROL, V57, P572; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; XI LF, 1995, J INFECT DIS, V172, P747, DOI 10.1093/infdis/172.3.747; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854	59	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2447	2458		10.1038/sj.onc.1201785	http://dx.doi.org/10.1038/sj.onc.1201785			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627111				2022-12-17	WOS:000073672300003
J	Webster, MA; Martin-Soudant, N; Nepveu, A; Cardiff, RD; Muller, WJ				Webster, MA; Martin-Soudant, N; Nepveu, A; Cardiff, RD; Muller, WJ			The induction of uterine leiomyomas and mammary tumors in transgenic mice expressing polyomavirus (PyV) large T (LT) antigen is associated with the ability of PyV LT antigen to form specific complexes with retinoblastoma and CUTL1 family members	ONCOGENE			English	Article						polyomavirus LT; CUTL1; leiomyomas; mammary tumors; transgenic	PROTEIN; GENE; PROMOTER; IMMORTALIZATION; TRANSCRIPTION; HYBRIDIZATION; ONCOGENE; BINDING	The inactivation of certain tumor suppressor genes is thought to play an important role in the genesis of a number of tumor types. For example, inactivation of the Retinoblastoma (Rb) tumor suppressor is frequently observed in a proportion of sporadic human breast cancers. While these studies suggest that inactivation of key tumor suppressor genes may play an important role in the induction of mammary cancers, direct evidence supporting this contention is lacking. Because polyomavirus (PyV) Large T (LT) antigen is known to associate with and inactivate certain members of the Rb family (p105Rb, p107, p130), we have derived transgenic mice which express PyV LT antigen in the mammary epithelium, As expected mammary epithelial-specific expression of PyV LT antigen resulted in the induction of mammary tumors which correlated with their capacity to associate with Rb family members. In addition to mammary carcinomas, female transgenic mice expressing the PyV LT transgene frequently develop uterine leiomyomas, Because loss of heterozygosity involving the human CUTL1 (Cut like 1) gene located at chromosomal position 7q22 has been recently implicated in sporadic human uterine leiomyomas, we tested the hypothesis that PyV LT antigen may also form specific complexes with CUTL1, The results of these analyses revealed that specific complexes of CUTL1 and PyV LT antigen could be detected in both leiomyomas and mammary tumors. Taken together, these observations suggest that PyV LT antigen may be involved in inducing these tumors by sequestering both CUTL1 and Rb growth regulatory proteins.	McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada; McGill Univ, Royal Victoria Hosp, Dept Med & Oncol, Montreal, PQ H3A 1A1, Canada; Univ Calif Davis, Sch Med, Dept Med Pathol, Davis, CA USA	McMaster University; McMaster University; McMaster University; McGill University; Royal Victoria Hospital; University of California System; University of California Davis	Muller, WJ (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada.		/AAB-8315-2020					CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEMIEUX N, 1994, GENOMICS, V24, P191, DOI 10.1006/geno.1994.1603; LI M, 1996, CELL GROWTH DIFFER, V1, P3; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OZISIK YY, 1996, CANC GEN CYTOGEN, V71, P1; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; Pilon AA, 1996, J VIROL, V70, P4457, DOI 10.1128/JVI.70.7.4457-4465.1996; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Romagnolo B, 1996, J CLIN INVEST, V98, P777, DOI 10.1172/JCI118850; SARGENT MS, 1994, CANCER GENET CYTOGEN, V77, P65, DOI 10.1016/0165-4608(94)90151-1; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Shibata MA, 1996, CANCER RES, V56, P2998; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VARLEY JM, 1989, ONCOGENE, V4, P725; VONDERHAAR BK, 1979, ENDOCRINOLOGY, V104, P409, DOI 10.1210/endo-104-2-409; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076	34	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1963	1972		10.1038/sj.onc.1201707	http://dx.doi.org/10.1038/sj.onc.1201707			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591780				2022-12-17	WOS:000073079400008
J	Ramaswamy, NT; Ronai, Z; Pelling, JC				Ramaswamy, NT; Ronai, Z; Pelling, JC			Rapid activation of JNK1 in UV-B irradiated epidermal keratinocytes	ONCOGENE			English	Article						UV-B; UV-C; JNK1; keratinocytes; skin cancer and MAPK	P53 PROTEIN; KINASE; LIGHT; RADIATION; SIGNAL; CELLS; SKIN; PHOSPHORYLATION; SPECIFICITY	Jun N-terminal kinase (JNK1) is a member of a family of stress-activated protein kinases which are activated by many forms of stress including UV radiation, resulting in the phosphorylation of c-Jun, ATF-2, Elk-1 and p53, As UV-B radiation is mainly responsible for ultraviolet (UV)-induced skin cancers, we chose to elucidate JNK1 activation in keratinocytes, which represent a UV-relevant system, We have demonstrated rapid activation of JNK1 in a keratinocyte cell Line, C50, in response to multiple doses of UV-B irradiation, JNK1 activation occurred within 1 min, peaked by 10 min and returned to near basal levels within 2 h following the UV-B treatments, Our data provide the first evidence to show that keratinocytes do respond to multiple doses of the physiologically relevant UV-B radiation through rapid activation of the JNK1 pathway.	Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66160 USA; Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Kansas; University of Kansas Medical Center; Icahn School of Medicine at Mount Sinai	Pelling, JC (corresponding author), Univ Kansas, Med Ctr, Dept Pathol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA71040, CA 72987] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Adler V, 1996, CARCINOGENESIS, V17, P2073, DOI 10.1093/carcin/17.9.2073; Berg RJW, 1997, CANCER RES, V57, P581; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; Chatterjee ML, 1996, BIOCHEM BIOPH RES CO, V229, P590, DOI 10.1006/bbrc.1996.1848; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DHANWADA KR, 1995, ONCOGENE, V11, P1947; FITZPATRICK J, 1997, COLOR ATLAS SYNOPSIS, P228; Goldsmith LA, 1996, OTOLARYNG HEAD NECK, V114, P217, DOI 10.1016/S0194-5998(96)70169-9; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL PA, 1993, ONCOGENE, V8, P203; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MATSUI MS, 1995, SKIN CANC MECH HUMAN, P21; MEDRANO EE, 1995, CANCER RES, V55, P4047; Mukhtar H., 1995, SKIN CANC MECH HUMAN, P3; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396	23	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1501	1505		10.1038/sj.onc.1201628	http://dx.doi.org/10.1038/sj.onc.1201628			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525748				2022-12-17	WOS:000072572400014
J	Ivanchuk, SM; Myers, SM; Mulligan, LM				Ivanchuk, SM; Myers, SM; Mulligan, LM			Expression of RET 3 ' splicing variants during human kidney development	ONCOGENE			English	Article						kidney; RET; alternative splicing	MICE LACKING GDNF; TYROSINE KINASE; C-RET; HIRSCHSPRUNG DISEASE; RENAL AGENESIS; CELL-LINE; PROTOONCOGENE; RECEPTOR; DEFECTS; ISOFORMS	The mature mammalian kidney arises through a series of reciprocal inductive interactions between two different cell groups, the ureteric bud epithelium and the metanephric mesenchyme, The RET receptor tyrosine kinase is required for induction and development of the metanephric kidney. Differential splicing at the 3' end of RET results in transcripts encoding three isoforms that differ with respect to their C-terminal 9 (RET9), 51 (RET51) or 43 (RET43) amino acids, In vitro assays have identified differences in the abilities of the RET9 and RET51 isoforms to induce differentiation suggesting functional differences between these proteins. We examined the relative expression levels of the three RET 3' splicing variants in developing human kidney using semi-quantitative RT-PCR. We observed consistent expression of the RET9 and RET43 variants in kidney samples spanning 7.5 through 24 weeks gestation, At early gestational ages (7.5-8.5 weeks), RET51 expression was very low (+/-5%) compared to RET9; however, a rapid seven fold increase in expression was detected by 9 weeks. Our data suggest that RET51 may contribute to differentiation-related events occurring after 8.5 weeks gestation rather than to induction of the human kidney.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Paediat, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Mulligan, LM (corresponding author), Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada.							Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Chakravarti A, 1996, HUM MOL GENET, V5, P303; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durbec PL, 1996, DEVELOPMENT, V122, P349; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; KWOK JBJ, 1993, ONCOGENE, V8, P2575; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Moore, 1982, DEV HUMAN; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MORRISON C, 1994, BBA-GENE STRUCT EXPR, V1219, P493, DOI 10.1016/0167-4781(94)90076-0; MYERS SM, 1995, ONCOGENE, V11, P2039; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Potter EL, 1972, NORMAL ABNORMAL DEV; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1990, ONCOGENE, V5, P1595; Saxen L., 1987, Developmental and Cell Biology Series, V19, P1; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249	34	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					991	996		10.1038/sj.onc.1201622	http://dx.doi.org/10.1038/sj.onc.1201622			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519873	Bronze			2022-12-17	WOS:000072335900005
J	Amariglio, F; Tchang, F; Prioleau, MN; Soussi, T; Cibert, C; Mechali, M				Amariglio, F; Tchang, F; Prioleau, MN; Soussi, T; Cibert, C; Mechali, M			A functional analysis of p53 during early development of Xenopus laevis	ONCOGENE			English	Article						replication; transcription; egg; oocyte	WILD-TYPE P53; TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION DOMAIN; DNA-REPLICATION INVITRO; T-ANTIGEN; GENE AMPLIFICATION; NUCLEAR EXCLUSION; TUMOR-ANTIGEN; EGG EXTRACTS; HOST PROTEIN	p53 is a nuclear protein that acts like a tumor suppressor and is involved in regulation of cellular growth, In Xenopus, the p53 protein is highly expressed during oogenesis and is strictly cytoplasmic in the oocyte, We have analysed its participation in DNA replication and transcription during early development, using the egg and oocyte as model-systems. The injection of sperm nuclei into Xenopus eggs is followed by DNA replication and mitotic events, We show that the endogenous p53 enters the nuclei and moves through a series of discrete subnuclear loci whose distribution is S-phase specific, A specific peripheral nuclear localization of p53 is observed before entry into S-phase, followed by an internal localization which is strictly dependent on ongoing DNA synthesis, At no stage in the cell cycle, however, did we observe any co-localization with RPA or PCNA, which were used as initiation or elongation markers for DNA replication, We also show that injection into the nucleus of the oocyte of small amounts of either Xenopus or human p53 - less than 10% of the cytoplasmic storage - is sufficient to block RNA polymerase II-dependent transcription from a coinjected TATA-box-containing reporter plasmid. Transcription is rescued by microinjection of the TATA-box binding protein (TBP), suggesting that nuclear exclusion of p53 during oogenesis may be necessary for transcription of maternal genes, These characteristics are discussed in relation to the regulation of nuclear activities during early embryogenesis.	CNRS, INST JACQUES MONOD, F-7251 PARID 05, FRANCE; INST CURIE, UMR 218, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)			Prioleau, Marie-Noelle/G-9824-2014; , prioleau/S-6007-2019	, prioleau/0000-0003-2585-4005; soussi, thierry/0000-0001-8184-3293				ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BRAIN R, 1994, ONCOGENE, V9, P1775; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GURDON JB, 1986, J CELL SCI, P287; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; JACKSON P, 1993, ONCOGENE, V8, P589; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIENZLE H, 1989, EUR J BIOCHEM, V184, P181, DOI 10.1111/j.1432-1033.1989.tb15005.x; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAY E, 1991, ONCOGENE, V6, P1363; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; MIYAMOTO N, 1990, BIOCHEM BIOPH RES CO, V168, P604, DOI 10.1016/0006-291X(90)92363-5; MODAK SP, 1993, ONCOGENE, V8, P645; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; PRIOLEAU MN, 1995, EMBO J, V14, P5073, DOI 10.1002/j.1460-2075.1995.tb00189.x; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	67	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2191	2199		10.1038/sj.onc.1201395	http://dx.doi.org/10.1038/sj.onc.1201395			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393977				2022-12-17	WOS:A1997YD01900007
J	Metcalfe, SM; Canman, CE; Milner, J; Morris, RE; Goldman, S; Kastan, MB				Metcalfe, SM; Canman, CE; Milner, J; Morris, RE; Goldman, S; Kastan, MB			Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells	ONCOGENE			English	Article						rapamycin; p53; G1 arrest	ATAXIA-TELANGIECTASIA GENE; P34CDC2 KINASE ACTIVATION; CYCLE CHECKPOINT PATHWAY; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; MESSENGER-RNA; GROWTH ARREST; TARGET	Certain growth regulatory kinases contain domain related to the phospho-inositol 3 (PI-3) kinase catalytic site, These include the ATM gene product, DNA-PKcs, and the target of rapamycin (TOR in yeast: and FRAP in mammalian cells), Rapamycin inhibits growth factor signalling and induces G1 arrest in many cell types, Some growth regulatory PI-3 kinases appear functionally linked to p53 and we have explored potential links between cellular effects induced by rapamycin and p53. In p53 null cells rapamycin inhibited cell cycling but did not induce G1 arrest, In cells which showed selective G1 arrest in response to rapamycin, rapamycin had no effect on basal levels of p53 protein, Similarly p21(WAF1) protein,vas not induced by rapamycin, The kinetics of the cellular p53/p21(WAF1) response to ionising radiation was unaffected by rapamycin; and the ability of growth factor to protect against p53-mediated apoptosis in response to DNA damage was also unaffected by rapamycin. The ATM gene is mutated in the cancer susceptibility syndrome ataxia telangiectasia (AT) but such mutant cells showed a similar sensitivity to rapamycin compared to their normal counterparts, RKO cell lines of common genetic background, but with different levels of functional p53 protein, also responded similarly to rapamycin, Thus, although rapamycin and p53 are each able to induce G1 arrest, they appear to act through independent growth regulatory pathways.	JOHNS HOPKINS UNIV HOSP, CTR ONCOL, BALTIMORE, MD 21287 USA; UNIV YORK, YCRC P53 RES GRP, YORK YO1 5DD, N YORKSHIRE, ENGLAND; STANFORD UNIV, MED CTR,SCH MED,DEPT CARDIOTHORAC SURG, TRANSPLANTAT IMMUNOL LAB, STANFORD, CA 94305 USA	Johns Hopkins University; Johns Hopkins Medicine; University of York - UK; Stanford University	Metcalfe, SM (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT SURG, CAMBRIDGE CB2 2QQ, ENGLAND.			, Christine/0000-0001-8892-7430	NATIONAL CANCER INSTITUTE [R01CA061949, T32CA060441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777, R37ES005777] Funding Source: NIH RePORTER; NCI NIH HHS [CA61949, T32CA60441] Funding Source: Medline; NIEHS NIH HHS [ES05777] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; BARBER NC, 1996, IN PRESS MOL BIOL CE; Beamish H, 1996, ONCOGENE, V13, P963; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANMAN CE, 1994, CANCER RES, V54, P5054; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CAO W, 1995, TRANSPLANTATION, V59, P390, DOI 10.1097/00007890-199502150-00014; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; GORCZYCA W, 1993, CANCER RES, V53, P1945; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hollis CM, 1996, BIOCHEM SOC T, V24, pS66, DOI 10.1042/bst024066s; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; METCALFE S, 1991, TRANSPLANTATION, V51, P1318, DOI 10.1097/00007890-199106000-00039; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PERROTAPPLANAT M, 1995, J CELL SCI, V108, P2037; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHI YF, 1995, CANCER RES, V55, P1982	43	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1635	1642		10.1038/sj.onc.1201341	http://dx.doi.org/10.1038/sj.onc.1201341			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349496				2022-12-17	WOS:A1997XY63100002
J	Hayashi, K; Metzger, R; Salonga, D; Danenberg, K; Leichman, LP; Fink, U; Sendler, A; Kelsen, D; Schwartz, GK; Groshen, S; Lenz, HJ; Danenberg, PV				Hayashi, K; Metzger, R; Salonga, D; Danenberg, K; Leichman, LP; Fink, U; Sendler, A; Kelsen, D; Schwartz, GK; Groshen, S; Lenz, HJ; Danenberg, PV			High frequency of simultaneous loss of p16 and p16 beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach	ONCOGENE			English	Article						p16; p16 beta; gene expression; esophageal tumors	TUMOR-SUPPRESSOR GENE; POLYMERASE CHAIN-REACTION; THYMIDYLATE SYNTHASE; RETINOBLASTOMA PROTEIN; HOMOZYGOUS DELETION; P16/CDKN2 GENE; MESSENGER-RNA; CYCLE ARREST; CDKN2 GENE; MUTATION	Quantitative reverse transcription PCR (RT-PCR) was used to measure gene expressions (relative mRNA levels) of p16 and the alternate transcript p16 beta in esophageal and gastric tumors, p16 gene expression was undetectable in 13 of 25 esophageal squamous cell carcinomas. In 11 of these tumors, p16 beta was simultaneously missing whereas two of the p16-deficient tumors still expressed p16 beta. Among 34 esophageal adenocarcinomas and 11 gastric adenocarcinomas, only one tumor lacked p16 expression and all tumors expressed p16 beta. p16 sequences were not detectable by PCR in genomic DNA from tumors lacking both p16 and p16 beta mRNA, suggesting that the simultaneous loss of both gene expressions resulted from homozygous genomic deletion of the p16 gene. However, DNA from tumors that lacked p16 mRNA but expressed p16 beta did contain the p16 gene, consistent with loss of p16 expression in these tumors by transcriptional suppression. No point mutations in p16 cDNA were detected among 12 that were sequenced, but one p16 cDNA from a squamous cell carcinoma had a 19-base deletion, possibly indicating a splice-site mutation. Among those tumors that expressed p16 mRNA, the gene expression values of both p16 and p16 beta varied over a wide range. In some cases, p16 expression was detectable but low, suggesting that down-regulation of p16 expression may be used in some cases to achieve the funtional equivalent of gene deletion or transcriptional silencing. These results demonstrate that p16 expression patterns differ based on tumor histology and origin. Homozygous deletion of p16 appears to be common in esophageal squamous cell carcinomas but in adenocarcinomas, both gene deletion and transcriptional silencing of p16 were infrequent.	UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,LOS ANGELES,CA 90033; TOKYO WOMENS MED COLL,TOKYO 162,JAPAN; TECH UNIV MUNICH,D-8000 MUNICH,GERMANY; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	University of Southern California; Tokyo Women's Medical University; Technical University of Munich; Memorial Sloan Kettering Cancer Center					PHS HHS [R01-56111] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ATTWOOD SEA, 1992, SURGERY, V111, P503; Bartsch D, 1996, J NATL CANCER I, V88, P680, DOI 10.1093/jnci/88.10.680; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOT WJ, 1993, JAMA-J AM MED ASSOC, V270, P1320, DOI 10.1001/jama.270.11.1320; BLOT WJ, 1994, SEMIN ONCOL, V21, P403; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Galiana C, 1995, MOL CARCINOGEN, V14, P286, DOI 10.1002/mc.2940140409; GERADTS J, 1995, CANCER RES, V55, P6006; Gonzalez MV, 1995, CLIN CANCER RES, V1, P1043; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; Herman J. G., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P595; Heyman M, 1996, J CLIN ONCOL, V14, P1512, DOI 10.1200/JCO.1996.14.5.1512; HORIKOSHI T, 1992, CANCER RES, V52, P108; HUANG Y, 1993, CANCER RES, V53, P1889; Ichimura K, 1996, ONCOGENE, V13, P1065; IGAKI H, 1995, CANCER RES, V55, P3421; IGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090, DOI 10.1006/bbrc.1994.2294; ILSON DH, 1995, CANCER, V75, P2197, DOI 10.1002/1097-0142(19950501)75:9<2197::AID-CNCR2820750902>3.0.CO;2-S; JEN J, 1994, CANCER RES, V54, P6353; JIN XM, 1995, CANCER RES, V55, P3250; JOHNSTON PG, 1995, CANCER RES, V55, P1407; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; Kratzke RA, 1996, CANCER RES, V56, P3415; Kuo DYS, 1996, CLIN CANCER RES, V2, P1981; LARRICK PD, 1995, REVERSE TRANSCRIPTAS, P1; Lenz HJ, 1996, J CLIN ONCOL, V14, P176, DOI 10.1200/JCO.1996.14.1.176; LENZ HJ, 1995, REVERSE TRANSCRIPTAS, P166; Liggett WH, 1996, CANCER RES, V56, P4119; LIU QY, 1995, ONCOGENE, V10, P619; Maesawa C, 1996, CANCER RES, V56, P3875; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; Reed AL, 1996, CANCER RES, V56, P3630; REED JA, 1995, CANCER RES, V55, P2713; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO GI, 1995, CANCER RES, V55, P505; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; SUN Y, 1995, ONCOGENE, V10, P785; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VIGNESWARAN WT, 1993, ANN THORAC SURG, V56, P838, DOI 10.1016/0003-4975(93)90341-E; WYNER EL, 1994, CANCER RES, V54, P5284; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	51	27	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1481	1488		10.1038/sj.onc.1201295	http://dx.doi.org/10.1038/sj.onc.1201295			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333024				2022-12-17	WOS:A1997XW41100012
J	Oh, JW; Katz, A; Harroch, S; Eisenbach, L; Revel, M; Chebath, J				Oh, JW; Katz, A; Harroch, S; Eisenbach, L; Revel, M; Chebath, J			Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells	ONCOGENE			English	Article						interleukin-6; cancer; melanoma; IRF-1; Waf-1; growth control	ACUTE-PHASE RESPONSE; REGULATORY FACTOR-I; INTERLEUKIN-6 RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCER; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS; MOLECULAR-CLONING; STAT FAMILY; IFN-BETA	Interleukin-6 (IL-6) inhibits the growth of melanocytes and of early stage melanoma cells, but not that of advanced melanoma cells. The in vitro IL-6 response can be restored in the highly metastatic melamona B16-F10.9 by addition of recombinant soluble IL-6 receptor alpha-chain (sIL-6R). The F10.9 cells then undergo irreversible growth-arrest and show increased adherence with changes from epithelioid to spindleoid morphology. The sIL-6R is required for IL-6 to induce a sustained activation of the various Stat transcription factors which bind to specific IL-6 inducible enhancers. The sIL-6R and IL-6 combination causes an increase in the level of the anti-oncogenic transcription factor IRF-1 protein and DNA-binding, which remain elevated for 24 h. The promoter activity of the anti-oncogenic p21/Waf-1/Cip-1 gene is induced and accumulation of the p21, protein is observed. These results illustrate the potent agonist activity of sIL-6R on molecular pathways which could mediate the growth-arrest and differentiation of the metastatic melanoma cells. Previously observed antimetastatic effects of IL-6 therapy in mice bearing F10.9 tumors may be at least partly due to direct growth inhibition and differentiation elicited by sIL-6R present in biological fluids.	WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science				Chebath, Judith/0000-0002-8151-7428; Eisenbach, Lea R/0000-0002-4816-1968				Akira S, 1995, ANN NY ACAD SCI, V762, P15; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARMSTRONG CA, 1994, J INVEST DERMATOL, V102, P278, DOI 10.1111/1523-1747.ep12371782; CHEN YQ, 1995, CANCER RES, V55, P4536; CHERNAJOVSKY Y, 1984, DNA-J MOLEC CELL BIO, V3, P297, DOI 10.1089/dna.1.1984.3.297; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COFFER P, 1995, ONCOGENE, V10, P985; COLOMBO MP, 1992, MELANOMA RES, V2, P181, DOI 10.1097/00008390-199209000-00006; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAILLARD JP, 1993, EUR J IMMUNOL, V23, P820, DOI 10.1002/eji.1830230408; Ganapathi MK, 1996, CELL GROWTH DIFFER, V7, P923; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HALIMI H, 1995, EUR CYTOKINE NETW, V6, P135; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARPER JW, 1993, CELL, V75, P805; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HARROCH S, 1993, J BIOL CHEM, V268, P9092; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; KATZ A, 1993, INT J CANCER, V53, P812, DOI 10.1002/ijc.2910530518; KATZ A, 1993, J IMMUNOTHER, V13, P98, DOI 10.1097/00002371-199302000-00004; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; Mackiewicz A, 1995, ANN NY ACAD SCI, V762, P361; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MACKIEWICZ A, 1995, CYTOKINE, V7, P142, DOI 10.1006/cyto.1995.1019; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NOVICK D, 1991, HYBRIDOMA, V10, P137, DOI 10.1089/hyb.1991.10.137; NOVICK D, 1992, CYTOKINE, V4, P6, DOI 10.1016/1043-4666(92)90029-Q; NOVICK D, 1990, J CHROMATOGR, V510, P331, DOI 10.1016/S0021-9673(01)93767-7; Oh JW, 1996, CYTOKINE, V8, P401, DOI 10.1006/cyto.1996.0055; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Revel M, 1995, ANN NY ACAD SCI, V762, P342; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROSEJOHN S, 1993, J BIOL CHEM, V268, P22084; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SILVANI A, 1995, CANCER RES, V55, P2200; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Su Zao-Zhong, 1995, Molecular and Cellular Differentiation, V3, P225; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	69	27	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					569	577		10.1038/sj.onc.1201213	http://dx.doi.org/10.1038/sj.onc.1201213			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247310				2022-12-17	WOS:A1997XN25500008
J	Rizos, H; Becker, TM; Holland, EA; Kefford, RF; Mann, GJ				Rizos, H; Becker, TM; Holland, EA; Kefford, RF; Mann, GJ			Differential expression of p16(INK4a) and p16 beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations	ONCOGENE			English	Article						p16(INK4a); p16 beta; hereditary melanoma	TUMOR-SUPPRESSOR GENE; KINASE-4 INHIBITOR GENE; HOMOZYGOUS DELETIONS; HUMAN CANCERS; P16 GENE; METHYLATION; P16/CDKN2; LOCUS; HYPERMETHYLATION; INACTIVATION	Mutations in the CDKN2A (p16(INK4a)) tumour suppressor gene on chromosome 9p21 are associated with inherited predisposition to melanoma, yet some 9p-linking hereditary melanoma families show no mutations in this gene. Splicing of CDKN2A exons 2 and 3 to an alternative first exon produces a transcript (p16 beta) encoding a protein with cell cycle regulatory properties. We have analysed allele-specific expression levels of both the p16(INK4a) and p16 beta transcripts in B-lymphoblastoid cells from 18 members of hereditary melanoma kindreds including four unrelated control individuals. In 15 of the 18 individuals examined, steady-state levels of each transcript either originated equally from each parental chromosome, or one parental chromosome was dominant for both transcripts. However, in three affected members of two 9p-linking hereditary melanoma kindreds, without exonic CDKN2A mutations, this pattern of coordinate expression was disrupted. In these individuals there was underexpression of the p16 beta transcript, relative to the p16(INK4a) transcript, from the chromosome segregating with disease susceptibility, Loss of coordinate expression of the p16(INK4a) and p16 beta transcripts may be an alternative genetic basis for melanoma susceptibility in certain 9p-linking kindreds.			Rizos, H (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,WESTMEAD INST CANC RES,WESTMEAD,NSW 2145,AUSTRALIA.		Rizos, Helen/AAE-5010-2020; Mann, Graham J/G-4758-2014	Rizos, Helen/0000-0002-2094-9198; Mann, Graham J/0000-0003-1301-405X; Becker, Therese/0000-0002-5636-9902; Kefford, Richard/0000-0001-9251-9229				Borg A, 1996, CANCER RES, V56, P2497; Brown DW, 1996, P NATL ACAD SCI USA, V93, P1418, DOI 10.1073/pnas.93.4.1418; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; COLOMBO P, 1992, P NATL ACAD SCI USA, V89, P6358, DOI 10.1073/pnas.89.14.6358; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GLENDENING JM, 1995, CANCER RES, V55, P5531; GODECKE A, 1991, NUCLEIC ACIDS RES, V19, P5351, DOI 10.1093/nar/19.19.5351; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Hara E, 1996, MOL CELL BIOL, V16, P859; HERMAN JG, 1995, CANCER RES, V55, P4525; HOFFMEYER S, 1995, HUM MOL GENET, V4, P1267, DOI 10.1093/hmg/4.8.1267; Holland EA, 1995, ONCOGENE, V11, P2289; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; IGAKI H, 1995, CANCER RES, V55, P3421; JONES BK, 1995, MOL CELL BIOL, V15, P7010; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEFFORD RF, 1991, CANCER GENET CYTOGEN, V51, P45, DOI 10.1016/0165-4608(91)90007-H; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; LI Y, 1994, CANCER RES, V54, P6078; Liggett WH, 1996, CANCER RES, V56, P4119; LIU L, 1995, ONCOGENE, V11, P405; LUBBERT M, 1992, BRIT J HAEMATOL, V81, P370, DOI 10.1111/j.1365-2141.1992.tb08241.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OTTERSON GA, 1995, ONCOGENE, V11, P1211; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SAKAI T, 1991, AM J HUM GENET, V48, P880; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STONE S, 1995, CANCER RES, V55, P2988; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; YEAGER T, 1995, CANCER RES, V55, P493	46	27	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					515	523		10.1038/sj.onc.1201217	http://dx.doi.org/10.1038/sj.onc.1201217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247305				2022-12-17	WOS:A1997XN25500003
J	Freyaldenhoven, BS; Freyaldenhoven, MP; Iacovoni, JS; Vogt, PK				Freyaldenhoven, BS; Freyaldenhoven, MP; Iacovoni, JS; Vogt, PK			Avian winged helix proteins CWH-1, CWH-2 and CWH-3 repress transcription from Qin binding sites	ONCOGENE			English	Article						winged helix domain; transcriptional repression; DNA binding; repression domain	GENE FORK-HEAD; TUMOR ALVEOLAR RHABDOMYOSARCOMA; FAMILY; MEMBER; ONCOGENE; PAX3; RECOGNITION; BELONGS; FUSION	The chicken winged helix proteins, CWH-1, CWH-2 and CWH-3, were isolated and identified by homology cloning using the winged helix sequence of the retroviral oncogene qin as a probe. The CWH proteins act as growth stimulators in chicken embryo fibroblasts and in this activity resemble the Qin protein. Qin is a transcriptional regulator that functions as a repressor, and its oncogenic potential is correlated with the ability to repress transcription. In this communication we show that CWH proteins are localized in the cell nucleus, recognize the Qin DNA binding site and also function as transcriptional repressors. The repression activity of CWH-3 was mapped to the region of amino acids 211 to 311, a domain that is homologous to the major repression domain of Qin.	SCRIPPS RES INST, DIV ONCOVIROL, BCC239, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BOEGE KA, 1995, GENE CHROMOSOME CANC, V12, P186; Chang HW, 1996, ONCOGENE, V13, P441; CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; FEDERSPIEL MJ, 1994, VIROLOGY, V203, P211, DOI 10.1006/viro.1994.1478; Freyaldenhoven BS, 1997, CANCER RES, V57, P123; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; MADDEN SL, 1993, ONCOGENE, V8, P1713; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J, 1989, MOL CLONING LAB MANU; SHAPIRO DN, 1993, CANCER RES, V53, P5108; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7	29	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					483	488		10.1038/sj.onc.1201189	http://dx.doi.org/10.1038/sj.onc.1201189			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242385				2022-12-17	WOS:A1997XM23800013
J	Roschke, V; Kopantzev, E; Dertzbaugh, M; Rudikoff, S				Roschke, V; Kopantzev, E; Dertzbaugh, M; Rudikoff, S			Chromosomal translocations deregulating c-myc are associated with normal immune responses	ONCOGENE			English	Article						c-myc; chromosomal translocation; B cell malignancy; tumor susceptibility	MURINE PLASMACYTOMAS; MOLECULAR ANALYSIS; CHOLERA-TOXIN; CELLS; LYMPHOMA; MICE; ONCOGENE; SUSCEPTIBILITY; DNA; DIFFERENTIATION	Plasmacytomas induced in BALB/c mice by pristane consistently evidence chromosomal translocations involving the c-myc gene and one of the Ig loci. This obervation has lead to the suggestion that c-myc deregulation is a critical event in the generation of such tumors, However, it is not clear whether c-myc translocation is related to pristane treatment or occurs in normal lymphocyte populations nor whether such translocations occur normally, and at similar frequencies, in strains genetically resistant to plasmacytoma development, such as DBA/2, In order to address these questions, a Long Distance PCR assay with single copy sensitivity was employed to assess the frequency of c-myc/IgA translocations in normal and immunized mice of both plasmacytoma resistant and susceptible lineages in the absence of pristane treatment. Our data demonstrate that spontaneous translocations occur in normal DBA/2 and BALB/c mice with no significant differences in frequency, A 3-5-fold increase in translocation frequency was observed in mice immunized with cholera toxin, a strong stimulator of IgA responses, We conclude that c-myc deregulation by chromosomal translocation is associated with normal physiological processes of B-cell differentiation and, as such, can not be the determining factor leading to malignancy.	NCI,GENET LAB,NIH,BETHESDA,MD 20892; USA,MED RES INST INFECT DIS,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; CHENG S, 1994, NATURE, V369, P684, DOI 10.1038/369684a0; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CRAIG SW, 1971, J EXP MED, V134, P188, DOI 10.1084/jem.134.1.188; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; GARBE C, 1991, J AM ACAD DERMATOL, V24, P584, DOI 10.1016/0190-9622(91)70088-J; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; HILBERT DM, 1993, ONCOGENE, V8, P1993; Husband A J, 1977, Ciba Found Symp, P29; HUSBAND AJ, 1978, J EXP MED, V148, P1146, DOI 10.1084/jem.148.5.1146; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1993, TOXICOL LETT, V67, P237, DOI 10.1016/0378-4274(93)90059-7; JI WZ, 1995, CANCER RES, V55, P2876; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; LIMPENS J, 1995, BLOOD, V85, P2528, DOI 10.1182/blood.V85.9.2528.bloodjournal8592528; LIMPENS J, 1991, ONCOGENE, V6, P2271; LIU YF, 1994, P NATL ACAD SCI USA, V91, P8910, DOI 10.1073/pnas.91.19.8910; LYCKE N, 1989, J IMMUNOL, V142, P3781; LYCKE N, 1986, IMMUNOLOGY, V59, P301; Magrath I, 1992, Semin Cancer Biol, V3, P285; MOCK BA, 1993, P NATL ACAD SCI USA, V90, P9499, DOI 10.1073/pnas.90.20.9499; Muller JR, 1996, CANCER RES, V56, P419; MULLER JR, 1994, P NATL ACAD SCI USA, V91, P12066, DOI 10.1073/pnas.91.25.12066; PAVLIDIS NA, 1992, MED PEDIATR ONCOL, V20, P279, DOI 10.1002/mpo.2950200403; POTTER M, 1994, J NATL CANCER I, V86, P1058, DOI 10.1093/jnci/86.14.1058; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; POTTER M, 1994, CANCER RES, V54, P969; POTTER M, 1984, CANCER SURV, V3, P247; POUSSIER P, 1992, J EXP MED, V176, P187, DOI 10.1084/jem.176.1.187; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; Sokal R. R., 1995, BIOMETRY; SOULIER J, 1995, BLOOD, V86, P1131; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STROBER W, 1991, IMMUNOL RES, V10, P386, DOI 10.1007/BF02919726; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904	43	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3011	3016		10.1038/sj.onc.1201156	http://dx.doi.org/10.1038/sj.onc.1201156			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223664				2022-12-17	WOS:A1997XG10000003
J	Ceccherini, I; Pasini, B; Pacini, F; Gullo, M; Bongarzone, I; Romei, C; Santamasia, G; Matera, I; Mondellini, P; Scopsi, L; Pinchera, A; Pierotti, MA; Romeo, G				Ceccherini, I; Pasini, B; Pacini, F; Gullo, M; Bongarzone, I; Romei, C; Santamasia, G; Matera, I; Mondellini, P; Scopsi, L; Pinchera, A; Pierotti, MA; Romeo, G			Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene	ONCOGENE			English	Article						RET proto-oncogene; MTC patients; somatic mutations; in frame deletions; transformation assay	TYROSINE KINASE DOMAIN; MUTATIONS; PROTOONCOGENE; DISEASE; FMTC; 2A	Somatic RET mutations have been identified in a variable proportion (about 30-70%) of sporadic Medullary Thyroid Carcinoma (MTC) cases. They are represented by the Met918Thr substitution (exon 16) typical of Multiple Endocrine Neoplasia type 2B (MEN2B) and, to a lesser extent, by nucleotide changes occurring at one of five critical cysteine residues (exons 10 and 11) typical of MEN type 2A (MEN2A). An in vitro transforming activity has already been demonstrated for these mutations. A few different MTC somatic mutations have been reported so far whose biological activity has still to be tested, In this paper we report the identification, in two MTC tumor samples, of two interstitial deletions of 48 bp and 6 bp occurred in exons 10 and 11 respectively. Both were somatic heterozygous in frame mutations, not involving any cysteine residue. Moreover, the expression of a full length RET cDNA carrying one of the two deletions demonstrated a strong transforming capacity in NIH3T3 cells.	IST NAZL TUMORI,DIREZ SCI,I-20133 MILAN,ITALY; UNIV PISA,IST ENDOCRINOL,I-56018 TIRRENIA,PISA,ITALY; IST GIANNINA GASLINI,LAB GENET MOL,I-16148 GENOA,ITALY; IST NAZL TUMORI,DIV ANAT PATOL,I-20133 MILAN,ITALY; IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,I-20133 MILAN,ITALY; INT AGCY RES CANC,GENET CANC SUSCEPTIBIL UNIT,F-69372 LYON,FRANCE	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa; University of Genoa; IRCCS Istituto Giannina Gaslini; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; World Health Organization; International Agency for Research on Cancer (IARC)			Santamaria, Giuseppe/AAB-4185-2021; Pasini, Barbara/AHI-2004-2022; Ceccherini, Isabella/P-8195-2014; Pierotti, Marco Alessandro/AAC-4728-2022; Bongarzone, Italia/B-9544-2017	Santamaria, Giuseppe/0000-0002-7686-6703; Pasini, Barbara/0000-0002-4373-1212; Ceccherini, Isabella/0000-0001-8732-1955; Pierotti, Marco Alessandro/0000-0002-7431-8332; Bongarzone, Italia/0000-0003-2530-9170				ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; CECCHERINI I, 1994, ONCOGENE, V9, P3025; Eng C, 1996, CANCER RES, V56, P2167; ENG C, 1995, ONCOGENE, V10, P509; Massague J, 1996, NATURE, V382, P29, DOI 10.1038/382029a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Romei C, 1996, J CLIN ENDOCR METAB, V81, P1619, DOI 10.1210/jc.81.4.1619; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SERI M, IN PRESS HUMAN MUTAT; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0	16	27	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2609	2612		10.1038/sj.onc.1201079	http://dx.doi.org/10.1038/sj.onc.1201079			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191060				2022-12-17	WOS:A1997XA94900012
J	Plummer, SJ; Adams, L; Simmons, JA; Casey, G				Plummer, SJ; Adams, L; Simmons, JA; Casey, G			Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25	ONCOGENE			English	Article						breast cancer; growth suppression; MCF7; microcell mediated chromosome transfer; senescence	CELLULAR SENESCENCE; PROTEIN EXPRESSION; GENETIC-ANALYSIS; OVARIAN-CANCER; P53 GENE; TUMOR; CARCINOMAS; MUTATIONS; REGIONS; TUMORIGENICITY	Chromosome 17 is one of the most frequently altered chromosomes in malignant breast cancer, At least four genes implicated in breast cancer reside on chromosome 17 (p53, 17p13; Her-2/neu/ERBB2, 17q12; BRCA1, 17q21; and nm23, 17q22). In addition, allelic imbalance has been described for at least five regions of chromosome 17, We have previously shown that the introduction of a normal human chromosome 17 into the breast cancer cell line MCF7 by microcell mediated chromosome transfer (MMCT) results in the in vitro growth arrest of these cells within 8 weeks, suggesting the presence of a growth suppressor on chromosome 17, Additionally, we have shown that the tumor suppressor gene p53 is not responsible for this phenotype, as it is wild type in MCF7 cells, and overexpression has no effect on either the in vitro or in vivo growth of these cells, We have further localized this growth suppressor gene to 17q24-q25 by transfer of chromosome 17 hybrids containing defined deletions, Whereas transfer of hybrids that contained an intact 17q (delta 43/A9 and delta 26/A9) resulted in growth arrest, two hybrids with overlapping deletions at 17q24-q25, had no effect on growth of MCF7 cells, Molecular analyses revealed that 50/70 (71%) of the resulting delta 2/MCF7 or delta 624/MCF7 MMCT clones retained an intact introduced chromosome 17, In contrast, only 8/34 (24%) of delta 43/MCF7 revertants (deleted for 17p13.1-pter) which escaped growth arrest showed no breakage of the introduced chromosome 17, We did not observe a preferential loss of an intragenic BRCA1 marker in the MMCT hybrids, excluding BRCA1 as the gene responsible for this growth arrest phenotype, These data therefore implicate a new growth suppressor gene involved in breast cancer that is localized to chromosome 17q24-q25.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NCI NIH HHS [CA58860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058860, U01CA058860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; Casey G, 1996, ONCOGENE, V13, P1971; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PC, 1995, ONCOGENE, V10, P577; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; COUNTER C, 1992, EMBO J, V11, P1919; CROPP CS, 1994, JNCI-J NATL CANCER I, V86, P1167, DOI 10.1093/jnci/86.15.1167; CROPP CS, 1993, CANCER RES, V53, P5617; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; EASTON DF, 1993, AM J HUM GENET, V52, P678; Foster JW, 1996, GENOMICS, V33, P185, DOI 10.1006/geno.1996.0182; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTUREAL PA, 1994, SCIENCE, V266, P120; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GREENBLATT MS, 1994, CANCER RES, V54, P4855; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; LEACH RJ, 1989, GENOMICS, V5, P167, DOI 10.1016/0888-7543(89)90043-8; LEONE A, 1993, ONCOGENE, V8, P2325; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MURAKAMI YS, 1995, CANCER RES, V55, P3389; NAGAI MA, 1994, GENE CHROMOSOME CANC, V11, P58, DOI 10.1002/gcc.2870110109; NEGRINI M, 1994, CANCER RES, V54, P1818; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; OSBORNE CK, 1987, BREAST CANCER RES TR, V9, P111, DOI 10.1007/BF01807363; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; SAITOH S, 1994, ONCOGENE, V9, P2869; Sandhu AK, 1996, ONCOGENE, V12, P247; SASAKI M, 1994, CANCER RES, V54, P6090; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; THIELE M, 1995, ONCOGENE, V10, P439; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570	49	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2339	2345		10.1038/sj.onc.1201073	http://dx.doi.org/10.1038/sj.onc.1201073			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178910				2022-12-17	WOS:A1997WY88300011
J	Rothenberger, S; Bachmann, E; Berger, C; McQuain, C; Odermatt, BF; Knecht, H				Rothenberger, S; Bachmann, E; Berger, C; McQuain, C; Odermatt, BF; Knecht, H			Natural 30 base pair and 69 base pair deletion variants of the LMP1 oncogene do stimulate NF-kappa B-mediated transcription	ONCOGENE			English	Article						Epstein-Barr virus; latent membrane protein 1 (LMP1); NF-kappa B; ICAM-1; lymphoproliferative disorders	EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; HODGKINS-DISEASE; NASOPHARYNGEAL CARCINOMA; CELLS; EXPRESSION; TRANSFORMATION; GENE; ACTIVATION; INDUCTION	An increasing number of reports shows a link between the Epstein-Barr virus (EBV) and lymphoid neoplasia. The latent membrane protein 1 (LMP1) is likely to play a determinant role in this process since this EBV encoded protein has oncogenic properties and is usually expressed in EBV-associated lymphoproliferative diseases (LPD), except Burkitt's lymphoma, We previously identified in LPD patients mutational hot spots and a 30 bp or 69 bp deletion in the LMP1 gene region coding for the C-terminal domain, These deletions are located in an area shown to be important for the activation of the transcription factor NF-kappa B. These findings lead us to test whether these natural deletion variants may have a functional effect, We measured the stimulation of their activity using a luciferase reporter plasmid containing NF-kappa B responsive elements, We tested the NF-kappa B inducing activity of four naturally occurring LMP1 deletion variants, Our results show that these deletion variants activate NF-kappa B to the same level as the wildtype form, indicating that the crucial residues for NF-kappa B activation are conserved among the variants isolated and lie within the last 32 amino acids of the C-terminal domain of the LMP1 oncogene.	UNIV MASSACHUSETTS, MED CTR, CTR CANC, LINK LABS, WORCESTER, MA USA; UNIV ZURICH HOSP, IMMUNOPATHOL LAB, CH-8091 ZURICH, SWITZERLAND; UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND	University of Massachusetts System; University of Massachusetts Worcester; University of Zurich; University Zurich Hospital; University of Lausanne				Rothenberger, Sylvia/0000-0001-8633-2994				BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; HUEN DS, 1995, ONCOGENE, V10, P549; JOSKE D, 1993, BLOOD REV, V7, P215, DOI 10.1016/0268-960X(93)90008-R; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1990, VIROLOGY, P1889; KLEIN C, 1995, BRIT J HAEMATOL, V91, P938, DOI 10.1111/j.1365-2141.1995.tb05416.x; KNECHT H, 1995, ONCOGENE, V10, P523; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1993, LEUKEMIA, V7, P580; Knecht H, 1996, ONCOGENE, V13, P947; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Li SN, 1996, ONCOGENE, V12, P2129; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MILLER G, 1990, VIROLOGY, P1921; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENG M, 1992, ONCOGENE, V7, P1775; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988	35	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	1997	14	17					2123	2126		10.1038/sj.onc.1201032	http://dx.doi.org/10.1038/sj.onc.1201032			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160892				2022-12-17	WOS:A1997WW80900014
J	David, G; Terris, B; Marchio, A; Lavau, C; Dejean, A				David, G; Terris, B; Marchio, A; Lavau, C; Dejean, A			The acute promyelocytic leukemia PML-RAR alpha protein induces hepatic preneoplastic and neoplastic lesions in transgenic mice	ONCOGENE			English	Article						PML-RAR alpha; APL; translocation; hepatocarcinoma; transgenic mice	RETINOIC ACID RECEPTOR; ZINC FINGER GENE; T(1517) TRANSLOCATION; CELL-PROLIFERATION; NUCLEAR RECEPTORS; GROWTH-SUPPRESSOR; FUSION PROTEIN; TGF-ALPHA; HEPATOCARCINOGENESIS; DIFFERENTIATION	The PML-RAR alpha hybrid protein generated by the t(15;17) translocation in acute promyelocytic leukemia (APL) is thought to play a central role in the oncogenic process. However, analysis of the oncogenic activity of the fusion protein in tissue culture assays or in mice has been hampered by its apparent toxicity in multiple murine cells. To circumvent this problem, we generated an inducible line of transgenic mice, MT135, in which the expression of PML-RAR alpha is driven by the metallothionein promoter. After 5 days zinc stimulation, 27 out of 54 mice developed hepatic preneoplasia and neoplasia including foci of basophilic hepatocytes, dysplasia and carcinoma with a significantly higher incidence of lesions in females than in males. The rapid onset of liver pathologies was dependent on overexpression of the transgene since it was not detected in noninduced transgenic animals of the same age. The PML-RAR alpha protein was always present in altered tissues at much higher levels than in the surrounding normal liver tissues. In addition, overexpression of PML-RAR alpha resulted in a strong proliferative response in the hepatocytes. We conclude that overexpression of PML-RAR alpha deregulates cell proliferation and can induce tumorigenic changes in vivo.	INST PASTEUR,UA CNRS,INSERM U163,UNITE RECOMBINAISON & EXPRESS GENET,PARIS,FRANCE; HOP BEAUJON,LAB ANATOMOPATHOL,CLICHY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite			Dejean, Anne/L-5145-2018; Lavau, Catherine/Q-2928-2019; Terris, Benoit/P-1497-2017	Lavau, Catherine/0000-0003-4800-1320; , gregory/0000-0002-3371-4558				ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; BENNOUN M, 1993, AM J PATHOL, V143, P1326; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRENSHAW EB, 1987, CELL, V49, P389, DOI 10.1016/0092-8674(87)90291-1; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FACTOR VM, 1993, EXP TOXICOL PATHOL, V45, P239, DOI 10.1016/S0940-2993(11)80399-4; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUANG SN, 1995, HEPATOLOGY, V21, P620, DOI 10.1002/hep.1840210303; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; Lavau C, 1996, EXP HEMATOL, V24, P544; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TERRIS B, 1995, CANCER RES, V55, P1590; TOSHKOV I, 1990, J CANCER RES CLIN, V116, P581, DOI 10.1007/BF01637078; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEBER E, 1994, CARCINOGENESIS, V15, P1235, DOI 10.1093/carcin/15.6.1235; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	56	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1547	1554		10.1038/sj.onc.1200989	http://dx.doi.org/10.1038/sj.onc.1200989			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129145				2022-12-17	WOS:A1997WQ54800005
J	Kenny, JJ; Knobloch, TJ; Augustus, M; Carter, KC; Rosen, CA; Lang, JC				Kenny, JJ; Knobloch, TJ; Augustus, M; Carter, KC; Rosen, CA; Lang, JC			GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes	ONCOGENE			English	Article						apoptosis; Bcl-2 homologue; leukemia; melanoma; FISH analysis	FOLLICULAR LYMPHOMA; SEQUENCE SIMILARITY; HUMAN MELANOCYTES; HOMOLOG BAK; APOPTOSIS; INDUCTION; ANTIGENS; MEMBRANE; PROTEIN; DEATH	Our laboratory previously described the independent isolation of the fibroblast growth factor 4 (FGF-4) gene by NIH3T3 transformation assay using DNA from a patient with CML leukemia (Lucas et al., 1994). The FGF-4 gene was truncated by DNA rearrangement with a novel gene named GRS. In this manuscript we describe isolation of GRS cDNA and show by sequence comparison that GRS is a novel member of the Bcl-2 gene family. Northern analysis shows expression of the gene in normal human tissue to be largely restricted to the hematopoietic compartment. Analysis of the pattern of gene expression in cancer cell lines demonstrates GRS is expressed in hematopoietic malignancies and in melanoma. The chromosomal location of GRS has also been determined. The gene is positioned on chromosome 15 within bands q24-25.	OHIO STATE UNIV HOSP,ARTHUR G JAMES CANC HOSP & RES INST 1248,COLUMBUS,OH 43210; HUMAN GENOME SCI,ROCKVILLE,MD 20850	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; GlaxoSmithKline; Human Genome Sciences Inc					NCI NIH HHS [CA 63134] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063134] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKHSHI A, 1985, CELL, V41, P889; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, ONCOGENE, V11, P1693; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FRASER JK, 1987, EXP HEMATOL, V15, P406; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOKALJVOKAC N, 1991, CYTOGENET CELL GENET, V57, P11, DOI 10.1159/000133103; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LEARY JF, 1987, LEUKEMIA RES, V11, P807, DOI 10.1016/0145-2126(87)90065-8; LIN EY, 1993, J IMMUNOL, V151, P1979; LUCAS JM, 1994, ONCOL RES, V6, P139; Morris C, 1996, ONCOGENE, V12, P677; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OTLVAI ZN, 1993, CELL, V74, P609; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; Quito FL, 1996, BLOOD, V87, P1282, DOI 10.1182/blood.V87.4.1282.bloodjournal8741282; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M	28	27	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					997	1001		10.1038/sj.onc.1200898	http://dx.doi.org/10.1038/sj.onc.1200898			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050999				2022-12-17	WOS:A1997WK34400013
J	Cosgaya, JM; Perona, R; Aranda, A				Cosgaya, JM; Perona, R; Aranda, A			Retinoic acid induces secretion of transforming growth factors by PC12 pheochromocytoma cells	ONCOGENE			English	Article						retinoic acid; PC12 conditioned medium; TGF-beta 1	FACTOR-BETA; EXPRESSION; FACTOR-BETA-1; GROWTH-FACTOR-BETA-1; DIFFERENTIATION; INDUCTION; RECEPTORS; PROMOTER; LINES; SUPERFAMILY	Conditioned medium from PC12 cells incubated with retinoic acid (RA) increases [H-3]thymidine incorporation in normal rat kidney (NRK) fibroblasts and 3D9 epithelial cells. The medium also causes anchorage-independent growth of NRK cells, which is strongly potentiated either in the presence of EGF or after activation of latent forms of transforming growth factors (TGFs) by acidification. These results suggest that RA regulates the release of more than one growth factor by PC12 cells. Conditioned media from control or NGF-treated PC12 cells causes growth of NRK cells in soft agar only after acidification. An increase in expression of the TGF-beta 1 gene is coincident with NGF-induced neuronal differentiation of PC12 cells. In addition, RA also causes a dose- and time-dependent increase in content of TGF-beta 1 transcripts. This increase is, at least in part, secondary to transcriptional activation. Sequences responsible for the effect of RA and NGF are located in the 5'-flanking region of the TGF-beta 1 gene. The TFG-beta 1 gene has two promoters and in transient transfection assays RA and NGF significantly enhance the activity of constructs containing the second promoter, High-affinity TGF-beta 1 receptors were undetectable in PC12 cells both before and after NGF or RA treatment. RA and NGF decrease PC12 cell proliferation and a neutralizing anti-TGF-beta 1 antibody does not reverse this inhibition. In summary, an increase in expression and secretion of TGF-beta 1 accompanies RA and NGF-induced PC12 cell growth arrest, but TGF-beta 1 does not play an autocrine role in this inhibition.	CSIC, INST INVEST BIOMED, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020; Cosgaya, Jose M/B-4936-2008	Aranda, Ana/0000-0002-8338-9589; Cosgaya, Jose Miguel/0000-0002-6005-2916				ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN PS, 1995, CANCER RES, V55, P2380; Cosgaya JM, 1996, ONCOGENE, V12, P2651; Cosgaya JM, 1996, J NEUROCHEM, V66, P89; COSGAYA JM, 1995, J NEUROCHEM, V65, P2484; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1986, J BIOL CHEM, V261, P4377; FALK LA, 1991, BLOOD, V77, P1248; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KUSUHARA M, 1992, CANCER RES, V52, P3011; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; MONIER S, 1994, CLIN EXP RHEUMATOL, V12, P595; PETERSON EP, 1994, J CELL PHYSIOL, V159, P551, DOI 10.1002/jcp.1041590319; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANZOELEN EJJ, 1993, GROWTH FACTORS, V9, P329, DOI 10.3109/08977199308991593; VANZOELEN EJJ, 1986, J BIOL CHEM, V261, P5003	35	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					579	587		10.1038/sj.onc.1200865	http://dx.doi.org/10.1038/sj.onc.1200865			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053856				2022-12-17	WOS:A1997WF52400009
J	Cheng, NC; Beitsma, M; Chan, A; denCamp, IO; Westerveld, A; Pronk, J; Versteeg, R				Cheng, NC; Beitsma, M; Chan, A; denCamp, IO; Westerveld, A; Pronk, J; Versteeg, R			Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus	ONCOGENE			English	Article						class I HLA; MEMO-1; methylation; neuroblastoma; N-myc; tumour suppressor gene	BLASTOMA CELL-LINES; NEURO-BLASTOMA; ANTIGEN EXPRESSION; LEUKOCYTE ANTIGEN; DNA METHYLATION; C-MYC; GENE; AMPLIFICATION; TUMOR; SEQUENCE	Class I HLA expression is low in neuroblastoma tumours and cell lines. We have recently mapped a modifier of methylation for HLA-C (MEMO-1) to chromosomal bands 1p35-36.1, a region deleted in many neuroblastomas. Hypomethylation of HLA-C is strongly correlated with allelic loss of the MEMO-1 locus. Here, we show that loss of MEMO-1 is associated with hypomethylation of both the 5' and 3' regions of class I KLA loci. We next investigated the relationship between methylation and expression of class I HLA in 28 cell lines of neuroectodermal tumours. Cell lines with hypermethylated HLA-C and HLA-A loci have relatively high expression, while most cell lines with hypomethylated loci have no or a reduced expression. It was reported earlier that high expression of c- or N-myc can suppress class I HLA expression. Remarkably, also N-myc amplification in neuroblastomas is associated with allelic loss of 1p35-36. Therefore, we have analysed the relationships between allelic loss of the MEMO-1 locus, class I HLA methylation and expression, and N-myc amplification and expression. This study shows a tight inter-relationship between these phenomena. Our data suggest a model in which hypomethylation of class I HLA due to loss of the MEMO-1 locus and high N-myc expression could collaborate in the down-regulation of class I HLA expression.	UNIV AMSTERDAM,ACAD MED CTR,DEPT HUMAN GENET,NL-1100 DE AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam			Versteeg, Rogier/AAQ-1765-2020	Versteeg, Rogier/0000-0001-7172-0388				BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BRODEUR GM, 1981, CANCER RES, V41, P4678; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHENG NC, 1995, ONCOGENE, V10, P291; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; COOPER MJ, 1990, CANCER RES, V50, P3694; DAAR AS, 1984, TRANSPLANTATION, V38, P287, DOI 10.1097/00007890-198409000-00018; EMMOUR J, 1991, IMMUNOBIOLOGY, V187, P70; FAVROT MC, 1991, INT J CANCER, V48, P502, DOI 10.1002/ijc.2910480405; FELTNER DE, 1989, J IMMUNOL, V143, P4292; GILBERT F, 1984, CANCER RES, V44, P5444; GROSS N, 1994, INT J CANCER, V59, P141, DOI 10.1002/ijc.2910590124; GUSSOW D, 1987, IMMUNOGENETICS, V25, P313, DOI 10.1007/BF00404424; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; REIN RS, 1987, J IMMUNOL, V138, P1178; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, V2, P291; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SODOYER R, 1984, EMBO J, V3, P879, DOI 10.1002/j.1460-2075.1984.tb01900.x; SUMMERS CW, 1993, EUR J IMMUNOGENET, V20, P201, DOI 10.1111/j.1744-313X.1993.tb00111.x; TANAKA K, 1986, P NATL ACAD SCI USA, V83, P7598, DOI 10.1073/pnas.83.20.7598; TANAKA K, 1983, CELL, V35, P457, DOI 10.1016/0092-8674(83)90179-4; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; VERSTEEG R, 1989, J EXP MED, V170, P621, DOI 10.1084/jem.170.3.621; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416	29	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1737	1744						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895520				2022-12-17	WOS:A1996VM88700019
J	Reddy, UR; Phatak, S; Pleasure, D				Reddy, UR; Phatak, S; Pleasure, D			Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains	ONCOGENE			English	Article						splicing; truncated-Ror1; neural tissues	GROWTH-FACTOR RECEPTOR; HUMAN CELL-LINE; NTERA-2 CELLS; FAMILY; GENE; RNA	Human heart, lung and kidney express a 6 kb mRNA encoding Ror1, a member of the receptor tyrosine kinase (RTK) family with as yet unknown ligand specificity. We used a Ror1 cDNA probe to screen a cDNA library prepared from the human neuronogenic teratocarcinoma line, NTera2, and cloned a 2373 nucleotide transcript, This transcript contains an open reading frame that encodes a 388 amino acid protein identical with the cytosolic, C-terminal region of ror1 but lacking the ror1 transmembrane and entire extracellular domains, Northern blots demonstrate that mRNA encoding this truncated Ror1 ('t-Ror1') is abundantly expressed in fetal and adult human CNS, in human leukemia, lymphoma cell. lines, and in a variety of human cancers derived from neuroectoderm. While previous studies have documented alternative splicing patterns within 5' and 3' regions of mRNAs encoding various RTKs altering their ligand binding specificity or their intracellular signaling, the present report is the first to demonstrate tissue-specific alternative mRNA splicing causing loss of the entire extracellular and transmembrane regions of an RTK.	UNIV PENN,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Reddy, UR (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV NEUROL RES,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS008075, P20NS031102, R01NS025044, P50NS008075] Funding Source: NIH RePORTER; NINDS NIH HHS [NS08075, NS31102, NS25044] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKER DL, 1989, CANCER RES, V49, P4142; BARKER PA, 1993, J BIOL CHEM, V268, P15150; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	18	27	34	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1555	1559						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875995				2022-12-17	WOS:A1996VL38400022
J	Cook, JL; Potter, TA; Bellgrau, D; Routes, BA				Cook, JL; Potter, TA; Bellgrau, D; Routes, BA			E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes	ONCOGENE			English	Article						oncogenes; NK cells; cytotoxic-T-lymphocytes; effector molecules; signaling molecules	NECROSIS-FACTOR-ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGENS; ADENOVIRUS-TRANSFORMED CELLS; CELLULAR CYTO-TOXICITY; MEDIATED CYTOTOXICITY; ACTIVATED MACROPHAGES; SURFACE ANTIGEN; MOUSE CELLS; C-MYC; LYSIS	E1A oncogene expression increases the susceptibility of cells from several species to lysis by natural killer lymphocytes (NK cells), We asked whether this E1A-induced cellular phenotypic conversion is specific for NK cell recognition interactions with target cells or whether it results from an E1A effect that is mediated independently of recognition, E1A-positive and E1A-negative cell pairs were compared for cytolytic susceptibility to other types of killer cells that use recognition mechanisms different from those of NK cells, E1A-positive, NK-susceptible target cells were also preferentially lysed by cytotoxic T lymphocytes (CTL) that recognize only foreign MHC molecules, lymphokine-activated T cells that lack recognition specificity, and CTL whose conventional recognition mechanisms were bypassed by lectin treatment of target cells, E1A expression increased cellular susceptibility to both major mechanisms of killer cell lysis-perforin/granzyme lysis and Fas-dependent lysis, Furthermore, anti-Fas antibody lysed E1A-positive, but not E1A-negative, cells expressing comparable levels of cell surface Fas antigen, These results indicate that a major mechanism by which E1A induces cellular susceptibility to lysis involves a stage in the interaction of killer cells with their targets that follows and is independent of cell surface recognition.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC IMMUNOL,DEPT MED,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,CTR CANC,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cook, JL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,ROBERT W LISLE RES LAB IMMUNOL & TUMOR CELL BIOL,DENVER,CO 80206, USA.				NCI NIH HHS [CA-43187] Funding Source: Medline; NIAID NIH HHS [AI-28115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BELL SM, 1985, EUR J IMMUNOL, V15, P59, DOI 10.1002/eji.1830150112; BELLGRAU D, 1988, J VIROL, V62, P1513, DOI 10.1128/JVI.62.5.1513-1519.1988; BELLGRAU D, 1983, J EXP MED, V157, P1505, DOI 10.1084/jem.157.5.1505; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BONAVIDA B, 1985, J IMMUNOL, V135, P1616; BRADLEY TP, 1984, CELL IMMUNOL, V83, P199, DOI 10.1016/0008-8749(84)90239-9; CHADWICK BS, 1992, J IMMUNOL, V149, P3150; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; COOK JL, 1982, INT J CANCER, V30, P795, DOI 10.1002/ijc.2910300619; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; COOK JL, 1993, ONCOGENE, V8, P625; COOK JL, 1989, J IMMUNOL, V142, P4527; COOK JL, 1987, J VIROL, V61, P2155, DOI 10.1128/JVI.61.7.2155-2161.1987; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; DUERKSENHUGHES PJ, 1991, J VIROL, V65, P1236, DOI 10.1128/JVI.65.3.1236-1244.1991; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GORMAN KC, 1987, J IMMUNOL, V138, P1014; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; HADDADA H, 1986, P NATL ACAD SCI USA, V83, P9684, DOI 10.1073/pnas.83.24.9684; HADDADA H, 1988, ELL, V61, P2755; HUNIG T, 1984, J EXP MED, V159, P551, DOI 10.1084/jem.159.2.551; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KARRE K, 1995, SCIENCE, V267, P978, DOI 10.1126/science.7863341; Karre K, 1993, Semin Immunol, V5, P127, DOI 10.1006/smim.1993.1016; Karre K, 1985, MECHANISMS CYTOTOXIC, P81; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KENYON DJ, 1991, VIROLOGY, V180, P818, DOI 10.1016/0042-6822(91)90099-W; KEREN Z, 1984, CELL IMMUNOL, V89, P458, DOI 10.1016/0008-8749(84)90347-2; KNALL C, 1995, INT IMMUNOL, V7, P995, DOI 10.1093/intimm/7.6.995; KOHL NE, 1987, ONCOGENE, V2, P41; Krantz CK, 1996, VIROLOGY, V217, P23, DOI 10.1006/viro.1996.0089; LEWIS AM, 1985, SCIENCE, V227, P15, DOI 10.1126/science.3843807; LEWIS AM, 1984, CURR TOP MICROBIOL, V110, P1; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OEHM A, 1992, J BIOL CHEM, V267, P10709; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PHILLIPS JH, 1986, J IMMUNOL, V136, P1579; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROUTES JM, 1990, J IMMUNOL, V144, P2763; ROUTES JM, 1995, VIROLOGY, V210, P421, DOI 10.1006/viro.1995.1358; SHANAHAN F, 1986, J IMMUNOL, V137, P723; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; WALKER TA, 1991, P NATL ACAD SCI USA, V88, P6491, DOI 10.1073/pnas.88.15.6491; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	51	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					833	842						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761305				2022-12-17	WOS:A1996VD43300019
J	Harhaj, EW; Maggirwar, SB; Sun, SC				Harhaj, EW; Maggirwar, SB; Sun, SC			Inhibition of p105 processing by NF-kappa B proteins in transiently transfected cells	ONCOGENE			English	Article						NF-kappa B; p105; protein processing; RelA; c-Rel	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; DNA-BINDING SUBUNIT; TRANS-ACTIVATOR PROTEIN; NUCLEAR-LOCALIZATION; PRECURSOR P105; 65-KD SUBUNIT; PHORBOL ESTER; MESSENGER-RNA; REL ONCOGENE	Regulation of the transcription factor NF-kappa B involves proteasome-mediated processing of the NF-kappa B1 p105 precursor protein, which generates the p50 subunit of NF-kappa B. The processing of p105 occurs constitutively in vivo but can be markedly enhanced by various cellular activation agents, although the underlying regulatory mechanism is not yet clear, In the present study, we demonstrate that signal-mediated induction of p105 processing in human T cells is associated with de novo synthesis of this precursor protein, Transient transfection studies performed in COS7 cells revealed that the newly synthesized p105 protein appears to be more rapidly processed compared to its accumulated form that is already associated with the processed product p50, Interestingly, the processing rate of p105 is markedly inhibited in cells co-transfected with p50 or other NF-kappa B subunits, including RelA and c-Rel, that physically interact with p105, These findings suggest that the processing of p105 is subject to negative regulation by the various NF-kappa B subunits, We further demonstrate that p105 undergoes degradation in lipopolysaccharide-stimulated human monocytic cells. However, the inducible degradation of p105 is not coupled with the generation of p50, Together, these studies demonstrate that the processing and inducible degradation of p105 are differentially regulated.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA 68471-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1990, HORMONAL CONTROL REG, P409; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; ZHENG S, 1993, J BIOL CHEM, V268, P17233	38	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2385	2392						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649779				2022-12-17	WOS:A1996UQ22000016
J	Bocco, JL; Bahr, A; Goetz, J; Hauss, C; Kallunki, T; Kedinger, C; Chatton, B				Bocco, JL; Bahr, A; Goetz, J; Hauss, C; Kallunki, T; Kedinger, C; Chatton, B			In vivo association of ATFa with JNK/SAP kinase activities	ONCOGENE			English	Article						ATF; Jun; kinase; interaction	DNA-BINDING PROTEINS; RESPONSE ELEMENT; LEUCINE ZIPPER; CYCLIC-AMP; JUN; FAMILY; ACTIVATION; CELLS; CREB; PHOSPHORYLATION	The human ATFa proteins belong to the CREB/ATF family of transcription factors. We have previously shown that the ATFa proteins may contribute to the modulation of the transcriptional activity of the Jun/Fos complexes (Chatton ed al. (1994). Oncogene, 9, 375-385). We now show that a protein kinase activity is strongly associated with ATFa in vivo, as revealed by coimmunoprecipitation of ATFa/kinase complexes from whole cell extracts, with antibodies against ATFa. Two independent regions were found to be implicated in kinase binding: a major interaction site is located within the N-terminal 82 residues comprising an important metal-chelating element; a weaker binding site corresponds to the basic sequence element preceding the C-terminal leucine-zipper of ATFa. Induction experiments suggest that each of these ATFa domains may interact with different kinases. The major activity is associated with the ATFa N-terminal domain. Based on its response to various inducers, on both in vitro and in vivo binding assays, and on its immunological properties, this activity most likely corresponds to the 54/55 kDa JNK2 protein. Taken together, these observations suggest that the ATFa proteins, among other CREB/ATF proteins, may be important effecters of cell signalling pathways.	ULP,INST GENET & BIOL MOL & CELLULAIRE,INSERM,CNRS,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,CTR MOLEC GENET,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego			CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; Kallunki, Tuula/0000-0002-8571-383X; Bocco, Jose Luis/0000-0002-9682-1270				ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADLER V, 1992, J BIOL CHEM, V267, P17001; BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOCCO JL, 1993, ONCOGENE, V8, P2977; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DAI TN, 1995, ONCOGENE, V10, P849; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLINT KJ, 1991, ONCOGENE, V6, P2019; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE KAW, 1992, J CELL SCI, V103, P9; LIN YS, 1989, NATURE, V338, P39; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1991, ONCOGENE, V6, P627; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TARTAGLIA J, 1992, AIDS RES HUM RETROV, V8, P1445, DOI 10.1089/aid.1992.8.1445; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wiktor T J, 1992, Biotechnology, V24, P508; YAN MH, 1994, NATURE, V372, P798	44	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1971	1980						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649858				2022-12-17	WOS:A1996UK49800016
J	Hu, YL; Bowtell, DDL				Hu, YL; Bowtell, DDL			Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation	ONCOGENE			English	Article						Sos; EGF receptor; Grb2; signal transduction	GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE KINASES; RAS; PROTEIN; ACTIVATION; DOMAIN; BINDS; GENE; SH2	The Son of sevenless (Sos) protein, a guanine nucleotide exchange factor for ras proteins, appears to play a central role in signalling between protein tyrosine kinase receptors and ras. The C-terminal region of Sos binds an adaptor protein, Grb2, which in turn binds to activated receptors including the EGF receptor (EGFR). Although the Sos protein is rapidly phosphorylated following cytokine stimulation, there is no evidence that this alters the enzymatic activity of Sos for ras proteins. Therefore, we investigated whether the ability of Sos1 to form complexes with Grb2 and with the EGF receptor (EGFR) changes following EGF stimulation, as possible mechanism for regulating Sos activity. In contrast to earlier findings, we find that both the association and dissociation of Sos1 with Grb2 is responsive to EGF, Whilst the association of Sos1 and Grb2 following EGF stimulation is not cell type specific, we find that it is dependant on cell density and that the response to EGF differs to that induced by NGF. We find that following EGF stimulation, the Sos1 protein associated with the EGFR is markedly less phosphorylated than the majority of the Sos1 within the cell and there was reduced binding of Grb2 with phosphorylated Sos1 protein in a direct binding assay. A time course analysis showed that Sos1 dissociates from the EGFR more rapidly than does Grb2 following EGF stimulation. Collectively our findings are consistent with the notion that the phosphorylation of Sos1 affects its ability to complex with the EGFR and Grb2.	PETER MACCALLUM CANC INST, TRESCOWTHICK RES CTR, MELBOURNE, VIC 3000, AUSTRALIA; UNIV MELBOURNE, HOWARD FLOREY INST EXPTL PHYSIOL & MED, PARKVILLE, VIC 3052, AUSTRALIA	Peter Maccallum Cancer Center; Florey Institute of Neuroscience & Mental Health; University of Melbourne			Bowtell, David/H-1007-2016; Hu, Yinling/G-5682-2015	Bowtell, David/0000-0001-9089-7525; Hu, Yinling/0000-0002-4795-8537				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU BX, 1993, ONCOGENE, V8, P3081; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165	32	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1865	1872						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649846				2022-12-17	WOS:A1996UK49800004
J	Tobin, D; Nilsson, M; Toftgard, R				Tobin, D; Nilsson, M; Toftgard, R			Ras-independent activation of Rel-family transcription factors by UVB and TPA in cultured keratinocytes	ONCOGENE			English	Article						ultraviolet radiation; NF kappa B; transcription factor; keratinocyte; rasGTPase	NF-KAPPA-B; HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN-KINASE-C; VL30 TRANSCRIPTION; INDUCED EXPRESSION; TYROSINE KINASES; GENE-EXPRESSION; REQUIRES RAF-1; PHORBOL ESTER; PHOSPHORYLATION	UV irradiation of mammalian cells results in the activation of transcription factors which mediate induction of early response genes designed to repair and minimise the damage sustained by the cell. Evidence from studies in HeLa cells suggest that UVC regulates NF-kappa B activity via tyrosine kinases and activation of Ras and Raf kinase. In this study we have used a previously characterized TPA-responsive element (VLTRE) that binds Rel/NF-kappa B proteins and a Ras-responsive element (B10 RRE) to analyse the signalling pathway in UVB-stimulated gene transcription in cultured keratinocytes, We demonstrate that the tumour promoters TPA and WB use different signalling intermediates to activate different sets of Rel/NF-kappa B proteins. UVB transactivation is independent of PKC activity but dependent on tyrosine kinase activity whereas TPA stimulation requires PKC but not tyrosine kinase activity. Furthermore, neither UVB- nor TPA-transactivation is mediated through p21 Ras but both stimuli are dependent on a functional Raf protein. A constitutively active Raf-1 kinase however, was unable to induce transactivation through VLTRE. Thus, Raf has an essential but permissive role in UVB activation of Rel proteins. These findings demonstrate that keratinocytes contain a novel Ras-independent pathway for induction of Rel mediated transcription.	KAROLINSKA INST,NOVUM,CTR NUTR & TOXICOL,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet	Tobin, D (corresponding author), KAROLINSKA INST,NOVUM,DEPT BIOSCI,S-14157 HUDDINGE,SWEDEN.							BOHM S, 1993, J BIOL CHEM, V268, P3952; BOHM S, 1991, J BIOL CHEM, V266, P24834; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSCHER M, 1988, ONCOGENE, V3, P301; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EICHER DM, 1994, J IMMUNOL, V152, P2710; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FINCO TS, 1993, J BIOL CHEM, V268, P17676; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; ISLAM TC, 1993, J BIOL CHEM, V268, P3251; KRUTMANN J, 1990, J INVEST DERMATOL, V95, P127, DOI 10.1111/1523-1747.ep12477839; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MILLER CC, 1994, J BIOL CHEM, V269, P3529; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL G, 1990, NATURE, V344, P178, DOI 10.1038/344178b0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1992, ONCOGENE, V7, P2095; NILSSON M, 1994, J VIROL, V68, P276, DOI 10.1128/JVI.68.1.276-288.1994; NILSSON M, 1995, J BIOL CHEM, V270, P12210, DOI 10.1074/jbc.270.20.12210; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIMON MM, 1994, J INVEST DERMATOL, V102, P422, DOI 10.1111/1523-1747.ep12372194; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STRUHL K, 1990, CURRENT PROTOCOLS S, V11; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; 1992, IARC MONOGRPAHS EVAL, V55	50	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					785	793						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632900				2022-12-17	WOS:A1996TW68600009
J	Santarelli, R; Tzeng, YJ; Zimmermann, C; Guhl, E; Graessmann, A				Santarelli, R; Tzeng, YJ; Zimmermann, C; Guhl, E; Graessmann, A			SV40 T-antigen induces breast cancer formation with a high efficiency in lactating and virgin WAP-SV-T transgenic animals but with a low efficiency in ovariectomized animals	ONCOGENE			English	Article						transgenic animals; SV40-T-antigen; breast cancer; estrogen receptor; progesterone receptor	MOUSE MAMMARY-GLAND; PROGNOSTIC FACTORS; GENE-EXPRESSION; INVOLUTION; RECEPTORS; LECTURE; RAT	The whey acid protein (WAP) is a major mouse milk protein and its gene expression is induced by various lactotrophic hormones leg, estrogen, progesterone). Transgenic animals harboring the early SV40 coding region (T/t-antigen) under the transcriptional control of the WAP promoter develop breast cancer after the first lactation period. The tumor cells synthesize the SV40 T-antigen with a high efficiency indicating that WAP-SV-T expression escapes down-regulation after the lactation period. However about 5-10% of the tumors became T-antigen negative during tumor progession and WAP-SV-T expression was only demonstrable by PCR analysis. Both T-antigen positive and negative tumor cells expressed the estrogen and progesterone receptor at a comparable rate, indicating that hormone receptor levels do not determine expression of the WAP-SV-T transgene, Furthermore, WAP and WAP-SV-T gene expression are not restricted to the pregnancy-lactation period. Virgin animals also express both genes with a low efficiency and about 70% of these animals also developed T-antigen positive breast tumors, The tumor rate however was strongly reduced in ovariectomized animals, indicating that the ovary hormones play a critical role in breast cancer formation.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,D-14195 BERLIN,GERMANY	Free University of Berlin			Santarelli, Roberta/K-5434-2015	Santarelli, Roberta/0000-0002-9416-7594				BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; CLARK GM, 1988, SEMIN ONCOL, V15, P20; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DIELLA F, 1993, LIFE SCI ADV BIOCH, V12, P47; FREEMAN CS, 1978, ENDOCRINOLOGY, V103, P186, DOI 10.1210/endo-103-1-186; FUNQUA SAW, 1991, CANCER RES, V51, P105; GRAESSMANN A, 1981, ADV CANCER RES, V35, P111, DOI 10.1016/S0065-230X(08)60910-0; GRAESSMANN M, 1976, P NATL ACAD SCI USA, V73, P366, DOI 10.1073/pnas.73.2.366; Haslam S. Z., 1987, The mammary gland. Development, regulation, and function., P499; HASLAM SZ, 1980, J CELL BIOL, V86, P730, DOI 10.1083/jcb.86.3.730; HENDERSON BE, 1988, CANCER RES, V48, P246; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KUHN NJ, 1977, COMP ASPECTS LACTATI, P165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER LJ, 1990, CANCER RES, V50, P4177; LI S, 1994, MOL ENDOCRINOL, V8, P1328, DOI 10.1210/me.8.10.1328; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MCGUIRE WL, 1986, CANCER SURV, V5, P527; Muldoon T. G., 1979, Ontogeny of receptors and reproductive hormone action., P225; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; SAMBROOK J, 1989, MOL CLONINGS LABORAT; SENKITI S, 1979, BIOCHIM BIOPHYS ACTA, V582, P79; SHYAMALA G, 1982, HORMONAL REGULATION, V1, P245; STRANGE R, 1992, DEVELOPMENT, V115, P49; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TOPP WC, 1980, DNA TUMOR VIRUSES, P205; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TZENG YJ, 1993, ONCOGENE, V8, P1965; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183	33	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					495	505						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637705				2022-12-17	WOS:A1996TV59700005
J	Lee, JM; Fournel, M; Veillette, A; Branton, PE				Lee, JM; Fournel, M; Veillette, A; Branton, PE			Association of CD45 with Lck and components of the Ras signalling pathway in pervanadate-treated mouse T-cell lines	ONCOGENE			English	Article						CD45; protein tyrosine phosphatase; T-cell activation; Lck; pervanadate	TYROSINE PROTEIN-KINASE; GUANINE-NUCLEOTIDE EXCHANGE; VAV PROTOONCOGENE PRODUCT; LEUKOCYTE-COMMON ANTIGEN; HUMAN LYMPHOCYTES-T; PHOSPHATASE CD45; ADAPTER PROTEIN; SH2 DOMAIN; B-CELLS; ACTIVATION	Pervanadate treatment of a mouse T-cell hybridoma cell line overexpressing an activated form of p56(lck) was shown to result in tyrosine phosphorylation of CD45. Immunoprecipitates prepared under mild lysis conditions using antibodies against CD45 contained a number of other proteins, including p56(lck), that were not evident in the absence of pervanadate treatment or in T cells lacking activated Lck, implying that under these conditions, CD45 is present within complexes containing Lck and other proteins. Analyses involving deletion mutants of p56(lck) indicated that interactions with CD45 did not absolutely require the SH2 and SH3 regions of Lck. Three proteins of the Ras signalling pathway were also shown to associated with CD45: the GTPase-activating protein for Ras (rasGAP), the signalling protein Grb2, and, possibly via complex formation with Grb2, the guanine nucleotide exchange factor mammalian son of sevenless (mSOS). In addition, CD45 was also found in immunoprecipitates prepared from these cells using an antiserum which recognizes Vav, It is possible that rasGAP, Grb2 and Vav bind to phosphotyrosine residues on CD45 via SH2 domains, and such interactions may be specific as other SH2-containing proteins, including phospholipase C alpha (PLC gamma), the p85 subunit of phosphatidylinositol 3-kinase (PI 3-kinase), She and Syp/PTP1D were not detectably associated with CD45 under the same conditions. These data suggested that in addition to its role as a protein tyrosine phosphatase, CD45 may participate in T-cell activation by serving as a membrane docking site for components of the Pas signalling pathway.	MCGILL UNIV, MCGILL CANC CTR, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, MCGILL CANC CTR, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, MCGILL CANC CTR, DEPT ONCOL, MONTREAL, PQ H3G 1Y6, CANADA	McGill University; McGill University; McGill University								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BARBEAU D, 1994, ONCOGENE, V9, P359; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS CM, 1994, J BIOL CHEM, V269, P13594; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IIDA N, 1994, J BIOL CHEM, V269, P28576; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; ROWLEY RB, 1993, CELL MOL BIOL RES, V39, P209; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; SU J, 1994, J BIOL CHEM, V269, P18731; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAKEDA A, 1994, P NATL ACAD SCI USA, V88, P7734; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEIL R, 1994, J BIOL CHEM, V269, P22830; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6836, DOI 10.1073/pnas.81.21.6836; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	72	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					253	263						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570203				2022-12-17	WOS:A1996TR53800005
J	Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Oshimura, M; Miyaki, M				Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Oshimura, M; Miyaki, M			Suppression of tumorigenicity and invasiveness of colon carcinoma cells by introduction of normal chromosome 8p12-pter	ONCOGENE			English	Article						tumor suppressor gene; colon carcinoma; chromosome 8	FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL CARCINOMAS; WILMS-TUMOR; SHORT ARM; GENE; IDENTIFICATION; EXPRESSION; CANCER; LINES; DELETIONS	The development of human colon carcinomas is associated with a number of genetic alterations, A high frequency of deletion of the short arm of chromosome 8 at a late stage of colon carcinogenesis was detected by DNA analysis of colon carcinomas, which suggests the presence of a tumor suppressor gene, We therefore, introduced normal human chromosome 8 into colon carcinoma cells that showed allele loss on 8p21, through microcell hybridization, Five clones of hybrid cells were obtained from independent experiments. Three hybrids exhibited morphological alteration and suppressed tumorigenicity in the subcutis of nude mice, but the other two did not, The difference between the two types of hybrids was the region of the introduced normal chromosome 8: Three hybrids exhibiting morphological alteration and suppressed tumorigenicity had the entire region of the introduced chromosome 8, whereas the other two, exhibiting no change, lacked 8p12-pter from the introduced chromosome, Furthermore, the invasiveness of the hybrids with suppressed tumorigenicity was reduced to one-fifth of that of the parental cells, These results indicate that 8p12-pter carries a gene that contributes to suppression of both tumorigenicity and invasiveness of colon carcinomas.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,FAC MED,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tottori University								ALBINI A, 1987, CANCER RES, V47, P3239; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BROWN PD, 1990, CANCER RES, V50, P6184; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; ICHIKAWA T, 1994, CANCER RES, V54, P2299; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KIKUCHIYANOSHIT.R, 1992, CANCER RES, V53, P3965; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MCGOWAN JI, 1994, CANCER RES, V54, P2568; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHIMIZU M, 1990, ONCOGENE, V5, P185; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TANAKA K, 1993, ONCOGENE, V8, P2253; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WELCH DR, 1994, ONCOGENE, V9, P255; YAMADA H, 1990, ONCOGENE, V5, P1141; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817	41	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					405	410						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570218				2022-12-17	WOS:A1996TR53800020
J	Besser, D; Urich, M; Sakaue, M; Messerschmitt, A; BallmerHofer, K; Nagamine, Y				Besser, D; Urich, M; Sakaue, M; Messerschmitt, A; BallmerHofer, K; Nagamine, Y			Urokinase-type plasminogen activator gene regulation by polyomavirus middle-T antigen	ONCOGENE			English	Article						AP1; middle-T; plasminogen activator; polyomavirus; signal transduction	SIZED TUMOR-ANTIGEN; PHOSPHATIDYLINOSITOL KINASE; ONCOGENIC TRANSFORMATION; CELL-TRANSFORMATION; TYROSINE KINASES; GROWTH-FACTORS; RAT-CELLS; PROTEIN; EXPRESSION; VIRUS	Expression of polyomavirus middle-T antigen (middle-T) is involved in the formation of various tumors in vivo, e,g, hemangiomas and mammary gland tumors, Several genes have been shown to be activated in middle-T-expressing cells, but the underlying mechanisms have only been partially elucidated, Among the genes regulated by middle-T, the urokinase-type plasminogen activator (uPA) gene seems to be of primary importance for the development of the transformed phenotype, We have found that the uPA gene is highly expressed in eEnd2 cells derived from a hemangioma expressing middle-T, NIH3T3 cells show negligible levels of uPA mRNA but its expression was highly induced by infecting with a middle-T-expressing retrovirus, Middle-T did not affect uPA mRNA stability, Transient cotransfection experiments using a uPA-reporter gene construct and a middle-T expression vector showed that high uPA mRNA levels are due to increased uPA promoter activity, Analyses of various signaling molecules by transient cotransfection assays and in vitro kinase assays established that a signaling pathway involving c-Src, SOS, Ras, Raf-l and ERK is activated by middle-T in NIH3T3 cells, resulting in the activation of the uPA gene promoter via PEA3/AP1 elements, In contrast, in eEnd2 cells uPA gene induction is only partially dependent on this pathway, suggesting the involvement of additional signaling molecules in endothelial cells.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	Friedrich Miescher Institute for Biomedical Research; Kobe University			Besser, Daniel/A-8304-2012	Besser, Daniel/0000-0002-4958-9624; Ballmer-Hofer, Kurt/0000-0002-3800-9129				ANDRUS L, 1988, J BIOL CHEM, V263, P6183; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Blasi F, 1990, Semin Cancer Biol, V1, P117; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOTTRAHMEL B, 1992, NEUROREPORT, V3, P1077, DOI 10.1097/00001756-199212000-00011; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ITO Y, 1979, VIROLOGY, V98, P261, DOI 10.1016/0042-6822(79)90545-2; ITO Y, 1980, J VIROL, V35, P219, DOI 10.1128/JVI.35.1.219-232.1980; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE JS, 1994, J BIOL CHEM, V269, P2887; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTE BM, 1995, ONCOGENE, V10, P167; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MUSER J, 1989, ONCOGENE, V4, P1433; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TIENARI J, 1991, CELL REGUL, V2, P285, DOI 10.1091/mbc.2.4.285; Tooze J, 1980, DNA TUMOR VIRUSES; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; URICH M, IN PRESS J BIOL CHEM; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WILLIAMS RL, 1988, CELL, V52, P121; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194	72	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2383	2391						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570190				2022-12-17	WOS:A1995TK70200023
J	SOROKIN, A				SOROKIN, A			ACTIVATION OF THE EGF RECEPTOR BY INSERTIONAL MUTATIONS IN ITS JUXTAMEMBRANE REGIONS	ONCOGENE			English	Article						EGF RECEPTOR; DIMERIZATION; TRANSFORMATION	EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; TRANSMEMBRANE DOMAIN; EXTRACELLULAR DOMAIN; LIGAND-BINDING; SIGNAL TRANSDUCTION; NEU ONCOGENE; SURFACE-RECEPTORS; CARCINOMA-CELLS; POINT MUTATION	Ligand dependent activation of receptor tyrosine kinases is mediated by an allosteric dimerization process that is responsible for the stimulation of protein tyrosine kinase activity and receptor autophosphorylation. In order to gain further insight into the processes which control this process, we have generated EGF receptor mutants that contain inserts of 20-40 amino acids in their juxtamembrane regions, on each side of the receptor's single transmembrane domain. An EGF receptor mutant with an insertion on the cytoplasmic side of the transmembrane domain exhibited typical EGF binding characteristics, ligand-dependent tyrosine autophosphorylation, as web as ligand-induced DNA synthesis. However, an EGF receptor mutant with an insertion on both sides of the transmembrane domain was found to be constitutively activated. This mutant also exhibited dramatically reduced EGF binding, but dimerized and had enhanced tyrosine kinase activity even in the absence of ligand. Moreover, NIH3T3 cells expressing this mutant receptor formed colonies in soft agar in the absence of EGF. This represents a novel example of a constitutively activated receptor, and provides further support for receptor dimerization as a mechanism for activation of EGFR and other receptor tyrosine kinases.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University				Sorokin, Andrey/0000-0002-5660-0190				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; CAO HN, 1992, J BIOL CHEM, V267, P20489; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CARPENTER G, 1989, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COCHET C, 1988, J BIOL CHEM, V263, P3290; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82; HALEY JD, 1989, ONCOGENE, V4, P273; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAZAN R, 1995, J CELL PHYSIOL, V162, P74, DOI 10.1002/jcp.1041620110; HILLMAN GM, 1982, BIOCHEMISTRY-US, V21, P1667, DOI 10.1021/bi00536a030; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1990, CELL REGUL, V1, P173, DOI 10.1091/mbc.1.2.173; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RIZZINO A, 1987, METHOD ENZYMOL, V146, P341; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SOROKIN AB, 1988, DOKL AKAD NAUK SSSR+, V300, P974; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAIMUN L, 1990, P NATL ACAD SCI USA, V87, P7270; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZIDOVETZKI R, 1981, P NATL ACAD SCI-BIOL, V78, P6981, DOI 10.1073/pnas.78.11.6981	54	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1531	1540						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478577				2022-12-17	WOS:A1995TC53500011
J	FUJII, M; IDE, T; WADHWA, R; TAHARA, H; KAUL, SC; MITSUI, Y; OGATA, T; OISHI, M; AYUSAWA, D				FUJII, M; IDE, T; WADHWA, R; TAHARA, H; KAUL, SC; MITSUI, Y; OGATA, T; OISHI, M; AYUSAWA, D			INHIBITORS OF CGMP-DEPENDENT PROTEIN-KINASE BLOCK SENESCENCE INDUCED BY INACTIVATION OF T-ANTIGEN IN SV40-TRANSFORMED IMMORTAL HUMAN FIBROBLASTS	ONCOGENE			English	Article						CGMP DEPENDENT PROTEIN KINASE; INHIBITION; T ANTIGEN; SENESCENCE; MORTALIN	HUMAN-DIPLOID FIBROBLASTS; LARGE-TUMOR-ANTIGEN; INDEFINITE DIVISION; SIMIAN VIRUS-40; SELECTIVE INHIBITOR; CELLULAR SENESCENCE; GENETIC-ANALYSIS; HUMAN-CELLS; POTENT; MOUSE	Immortal human fibroblasts isolated following transfection with thermolabile simian virus 40 T antigen lost division potential upon shift up in temperature due to heat inactivation of the antigen. Such cells showed a concomitant change in the distribution of a mortality marker, mortalin, from a juxtanuclear cap like distribution of immortal cells to a uniform cytosolic distribution of mortal cells. We made an attempt to modulate the above inducible system of cellular senescence using various protein kinase inhibitors. Among the indolocarbazole type inhibitors tested, only KT5823, defined as a specific inhibitor of cGMP-dependent protein kinase, blocked the loss of division potential as determined by cell growth and colony forming ability. This inhibitor also prevented the above change in mortalin distribution due to temperature shift. In addition, the isoquinoline sulfonamide derivatives H8, H9, H88 and H89, all shown to inhibit cGMP-dependent protein kinase, suppressed the senescence. Inhibitors specific to other types of protein kinases, protein phosphatases or tyrosine kinases tested had no effect. Since there was no difference between the effective and non-effective inhibitors in their effects on cell cycle progression, cell cycle arrest by itself cannot account for the above phenomenon. These results suggest that a signaling pathway possibly mediated by cGMP-dependent protein kinase is involved in the induction of cellular senescence.	UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; HIROSHIMA UNIV, SCH MED, DEPT CELLULAR & MOLEC BIOL, HIROSHIMA 734, JAPAN; AGCY IND SCI & TECHNOL, NATL INST BIOSCI & HUMAN TECHNOL, TSUKUBA, IBARAKI 305, JAPAN; NATL INST HLTH, SHINJUKU KU, TOKYO 162, JAPAN	University of Tokyo; Hiroshima University; National Institute of Advanced Industrial Science & Technology (AIST)			Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916				ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AYUSAWA D, 1983, J BIOL CHEM, V258, P2448; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; IDE T, 1983, EXP CELL RES, V143, P343, DOI 10.1016/0014-4827(83)90060-5; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KASE H, 1988, BIOL ACTINOMYCETES 8, P159; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RANDA RL, 1989, MOL CELL BIOL, V9, P3093; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WADHWA R, 1993, J BIOL CHEM, V268, P22239; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1995, EXP CELL RES, V216, P101, DOI 10.1006/excr.1995.1013; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WYATT TA, 1991, J BIOL CHEM, V266, P21274; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	45	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					627	634						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651725				2022-12-17	WOS:A1995RQ46900003
J	CALIFANO, D; MONACO, C; DEVITA, G; DALESSIO, A; DATHAN, NA; POSSENTI, R; VECCHIO, G; FUSCO, A; SANTORO, M; DEFRANCISCIS, V				CALIFANO, D; MONACO, C; DEVITA, G; DALESSIO, A; DATHAN, NA; POSSENTI, R; VECCHIO, G; FUSCO, A; SANTORO, M; DEFRANCISCIS, V			ACTIVATED RET/PTC ONCOGENE ELICITS IMMEDIATE-EARLY AND DELAYED-RESPONSE GENES IN PC12 CELLS	ONCOGENE			English	Article						RET; PHEOCHROMOCYTOMA; TYROSINE KINASE; ONCOGENE; PC12	NERVE GROWTH-FACTOR; NEURON-SPECIFIC ENOLASE; RET PROTO-ONCOGENE; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; TYROSINE KINASE; VGF GENE; EXPRESSION; RAS	The expression of the receptor-like tyrosine kinase RET is associated with tumors, tissues or cell lines of neural crest origin, In addition RET products (Ret) are involved in determining cell fate during the differentiation of the enteric nervous system and during renal organogenesis. However, as yet, no direct evidence exists to indicate that the Ret kinase activity might interfere in a specific way with cellular differentiation, or proliferation, of a neural crest derived cell line. By using two constitutively activated forms of RET (RET/PTC1 and RET/PTC3) in transient transfection experiments, we have obtained evidence that active RET could reprogramme the gene expression pattern in the rat pheochromocytoma PC12 cell line. Transcription driven by gene promoters, such as NGFI-A and vgf, which belong, respectively, to primary and delayed response genes to nerve growth factor (NGF), and by the neuron-specific enolase (NSE) promoter, is rapidly induced by the expression of activated RET oncogenes. This induction is not elicited in other non neural derived cell types tested. We also demonstrate that endogenous vas activity is required for RET induction of these neural markers. Finally, in the RET/PTC transfected PC12 cells, NGF is unable to induce further their transcription. This suggests that RET/PTC could share an intracellular signalling pathway with the NGF-receptor.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; FDN G PASCALE,IST STUDIO & CURA TUMORI,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; CNR,INST NEUROBIOL,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Fondazione Pascale; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR)			Califano, Daniela/Y-6313-2018; De Vita, Gabriella/H-4422-2011	Califano, Daniela/0000-0001-6945-3209; De Vita, Gabriella/0000-0002-7302-1174; Fusco, Alfredo/0000-0003-3332-5197				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ANTORO M, 1994, ONCOGENE, V9, P509; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P1; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BAYBIS M, 1992, FEBS LETT, V308, P202, DOI 10.1016/0014-5793(92)81274-P; BONGARZONE I, 1994, CANCER RES, V54, P2979; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DAHMER MK, 1988, ENDOCRINOLOGY, V122, P2109, DOI 10.1210/endo-122-5-2109; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; HAWLEY RJ, 1992, J NEUROSCI, V12, P2573; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUJUBU DA, 1987, ONCOGENE, V1, P257; LANZI C, 1992, ONCOGENE, V7, P2189; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEVI A, 1980, SCIENCE, V229, P3469; LUKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490; MILLBRANDT J, 1987, SCIENCE, V238, P797; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SCHMECHEL D, 1983, CURRENT METHODS CELL, V1, P1; SCHMECHEL DE, 1980, BRAIN RES, V190, P195, DOI 10.1016/0006-8993(80)91169-5; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOGARI A, 1985, J NEUROSCI, V5, P307; VANDENPOL AN, 1989, J NEUROSCI, V9, P4122; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P133, DOI 10.1016/0304-419X(93)90002-T; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	55	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					107	112						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624117				2022-12-17	WOS:A1995RJ29500013
J	WONG, YH; CHAN, JSC; YUNG, LY; BOURNE, HR				WONG, YH; CHAN, JSC; YUNG, LY; BOURNE, HR			MUTANT ALPHA-SUBUNIT OF G(Z) TRANSFORMS SWISS 3T3 CELLS	ONCOGENE			English	Article						G PROTEINS; NEOPLASTIC TRANSFORMATION; CYCLIC AMP	NUCLEOTIDE-BINDING PROTEIN; CYCLIC-AMP ACCUMULATION; PHOSPHOLIPASE-C; PERTUSSIS TOXIN; ADENYLYL-CYCLASE; INHIBITION; ONCOGENES; RECEPTOR; MITOGENESIS; ACTIVATION	Many hormones and neurotransmitters induce cell proliferation by regulating signaling pathways controlled by heterotimeric G proteins. Mutations that activate the alpha subunits of G(s) and G(i2) produce the gsp and gip2 oncogenes that are found in certain human endocrine tumors. Similar mutations have conferred on other G alpha subunits the ability to promote neoplastic transformation in cultured mammalian cells, G(z), a G protein whose normal signaling function is poorly understood, shares with G(i2) the ability to inhibit adenylyl cyclase. We asked whether mutationally activated alpha(z) can stimulate cell proliferation in a cell line in which stimulation adenylyl cyclase is mitogenic, Swiss 3T3 cells, Stable expression of alpha(z)-Q205L in Swiss 3T3 cells induced focus formation, a faster growth rate with a higher saturation density, anchorage-independent growth in soft agar, and increased [H-3]thymidine incorporation in the absence of growth factors. alpha(z)-Q205L produced a similar but less extensively transformed phenotype in NIH3T3 cells-increased saturation density in culture, a smaller number of foci and few colonies in soft agar. Stimulation of thymidine incorporation by alpha(z)-Q205L in Swiss 3T3 cells was increased by co-treatment with cholera toxin, a stimulator of adenylyl cyclase. Taken together, our results indicate that a(z) stimulates one or more mitogenic pathways in Swiss 3T3 cells, and that effectiveness of these mitogenic pathways does not require reducing the concentration of cellular cAMP.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; HONG KONG UNIV SCI & TECHNOL,DEPT BIOL,KOWLOON,HONG KONG	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hong Kong University of Science & Technology								ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BLOCH DB, 1989, MOL CELL BIOL, V9, P5434, DOI 10.1128/MCB.9.12.5434; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUI Z, 1991, J BIOL CHEM, V266, P20276; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; FAURE M, 1994, J BIOL CHEM, V269, P7852; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VOYNOYASENETSKA.TA, 1994, ONCOGENE, V9, P2559; WANG HY, 1993, J PHARMACOL EXP THER, V267, P1002; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1994, METHOD ENZYMOL, V238, P81; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1; ZIGMAN JM, 1994, ENDOCRINOLOGY, V135, P31, DOI 10.1210/en.135.1.31	31	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1927	1933						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761094				2022-12-17	WOS:A1995QZ92600006
J	ZIMONJIC, DB; ALIMANDI, M; MIKI, T; POPESCU, NC; KRAUS, MH				ZIMONJIC, DB; ALIMANDI, M; MIKI, T; POPESCU, NC; KRAUS, MH			LOCALIZATION OF THE HUMAN HER4/ERBB-4 GENE TO CHROMOSOME-2	ONCOGENE			English	Note						RECEPTOR TYROSINE KINASE; ERBB FAMILY; GENE MAPPING; FISH	FACTOR RECEPTOR FAMILY; FRAGILE SITES; TRANSLOCATION (2-13)(Q37-Q14); ALVEOLAR RHABDOMYOSARCOMA; NERVOUS-SYSTEM; ONCOGENE; MEMBER; HER4/P180(ERBB4); EXPRESSION; HEREGULIN	The HER4/erbB-4 gene has been isolated as the fourth member of the human EGFR subfamily of tyrosine kinases and has been reported to encode a receptor for NDF/heregulin. In the present study we determined the chromosomal location of the HER4/erbB-4 gene within the human genome. Using human cDNA probes in fluorescence in situ hybridization (FISH), we mapped the HER4/erbB-4 gene to human chromosome 2q33.3-34. This finding established that also the HER4/erbB-4 gene is located in close vicinity of homeobox and collagen gene loci, as is the case for the related EGFR, erbB-2/neu and erbB-3. Aberrations of this chromosomal region associated with T cell leukemias and lymphomas as well as alveolar rhabdomyosarcomas raise the possibility that HER4/erbB-4 might be activated in these tumour types.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NCI,BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Zimonjic, Drazen/AAX-7513-2020	Alimandi, Maurizio/0000-0002-1409-6803				CANNIZZARO LA, 1987, AM J HUM GENET, V41, P1; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CRAIGHOLMES AP, 1987, HUM GENET, V76, P134, DOI 10.1007/BF00284909; DANIEL A, 1984, AM J MED GENET, V18, P483, DOI 10.1002/ajmg.1320180318; Di Fiore P P, 1992, Cancer Treat Res, V61, P139; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAI JL, 1987, CANCER GENET CYTOGEN, V25, P371, DOI 10.1016/0165-4608(87)90201-9; LIZARDNACOL S, 1987, CANCER GENET CYTOGEN, V25, P373, DOI 10.1016/0165-4608(87)90202-0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCKUSICK VA, 1993, J MED GENET, V30, P1, DOI 10.1136/jmg.30.1.1; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; POPESCU NC, 1989, GENOMICS, V4, P362, DOI 10.1016/0888-7543(89)90343-1; RABIN M, 1986, P NATL ACAD SCI USA, V83, P9104, DOI 10.1073/pnas.83.23.9104; RETIEF E, 1985, HUM GENET, V69, P304, DOI 10.1007/BF00291646; SEIDAL T, 1982, ACTA PATH MICRO IM A, V90, P345; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; TILLER GE, 1994, GENOMICS, V20, P275, DOI 10.1006/geno.1994.1164; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang-Wuu S, 1988, Cancer Res, V48, P983; WEIL D, 1988, AM J HUM GENET, V42, P435; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; XU J, 1994, CANCER GENET CYTOGEN, V74, P1, DOI 10.1016/0165-4608(94)90020-5; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	31	27	31	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1235	1237						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700649				2022-12-17	WOS:A1995QN35300026
J	VANDEL, L; PFARR, CM; HUGUIER, S; LOISEAU, L; SERGEANT, A; CASTELLAZZI, M				VANDEL, L; PFARR, CM; HUGUIER, S; LOISEAU, L; SERGEANT, A; CASTELLAZZI, M			INCREASED TRANSFORMING ACTIVITY OF JUNB AND JUND BY INTRODUCTION OF AN HETEROLOGOUS HOMODIMERIZATION DOMAIN	ONCOGENE			English	Article						CELLULAR TRANSFORMATION; JUN; DIMERIZATION; BZIP TRANSCRIPTION FACTOR; AP1	CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING PROTEIN; C-JUN; LEUCINE ZIPPER; ONCOGENE JUN; TRANSCRIPTIONAL ACTIVATION; CELLULAR-TRANSFORMATION; SARCOMA VIRUS; FOS PROTEINS; GENE FAMILY	The closely-related proteins c-Jun, JunB and JunD form a family of transcription factors which require dimerization for DNA-binding and transcriptional activity. Dimerization is mediated by a conserved amphipathic a-helix located adjacent to a highly charged DNA-binding domain. The Jun proteins can form both homo and heterodimers within the Jun family and can-also cross-dimerize with the Fos proteins. When expressed at high levels in primary chicken cells, each mouse Jun displays distinct transforming capacities: c-Jun transforms efficiently, JunB transforms poorly, and JunD does not transform at all, The composition of the transforming dimers; however, is unknown. To study the activity of Jun-Jun homodimers we constructed artificial derivatives, denoted Jun(eb1), the naturally occurring dimerization been replaced by an heterologous homodimerization domain from the Epstein-Barr virus transcription factor EB1. These derivatives were introduced into chicken cells and assayed for their ability to affect growth. Unexpectedly, all three Jun(eb1) proteins conferred a transformed phenotype to primary cultures, promoting sustained growth in low-serum medium and colony formation from single cells in agar. These data demonstrate that when forced to accumulate as homodimers, both JunB and JunD can transform cells. They also suggest that the poor transforming activity of JunB and the absence of transforming activity of JunD may be due to their inability to accumulate to high levels as homodimers.	ECOLE NORMALE SUPER LYON,INSERM,U412,UNITE VIROL HUMAINE,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,F-69364 LYON 07,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,CNRS,URA 1644,UNITE VIRUS ONCOGENES,F-75724 PARIS,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite			Pfarr, Curt/HHD-1410-2022	Vandel, Laurence/0000-0002-3692-2942				ANDERSON DD, 1981, J VIROL, V37, P445, DOI 10.1128/JVI.37.1.445-458.1981; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BERGER I, 1991, ONCOGENE, V6, P561; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3241; CHIU R, 1989, CELL, V54, P541; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRISON SC, 1991, NATURE, V363, P715; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1991, ONCOGENE, V6, P1623; HARTL M, 1992, CELL GROWTH DIFFER, V3, P909; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVISTA N, 1994, ONCOL REP, V1, P185; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; METIVIER C, 1993, ONCOGENE, V8, P2311; MORGAN IM, 1992, ONCOGENE, V7, P1119; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TEMIN HM, 1960, VIROLOGY, V10, P182, DOI 10.1016/0042-6822(60)90038-6; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	64	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					495	507						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845674				2022-12-17	WOS:A1995QF64800010
J	OKAZAWA, H; KAMEI, M; IMAFUKU, I; KANAZAWA, I				OKAZAWA, H; KAMEI, M; IMAFUKU, I; KANAZAWA, I			GENE-REGULATION OF TRKB AND TRKC IN THE CHICK RETINA BY LIGHT/DARKNESS EXPOSURE	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; PROTEIN-TYROSINE KINASE; NEUROTROPHIC FACTOR; NEURONAL DEATH; TRANSCRIPTION FACTOR; RAT HIPPOCAMPUS; FACTOR PROMOTES; FACTOR PREVENTS; GANGLION-CELLS	The trk gene family members; the neurotrophic receptors for neurotrophins, are implicated in the survival and the differentiation of neurons. The roles of these protooncogenes have been argued in the pathological conditions and in the specific developmental stage when the programmed cell death occurs to neurons. Here we studied a physiological role of the trk family members in the retina through observations of their gene regulation by light/darkness exposure. Northern blot analysis and immunohistochemistry demonstrate that trkB and trkC are up-regulated by light exposure and down-regulated by darkness in the rod/cone layer, the outer nuclear layer, and the ganglion cell layer. This physiological regulation suggests that these trk family members play a protective role from the damaging effect of light exposure in the retinal neurons.			OKAZAWA, H (corresponding author), UNIV TOKYO, FAC MED, DEPT NEUROL, BUNKYO KU, 7-3-1 HONGO, TOKYO 113, JAPAN.							BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVIES AM, 1985, DEV BIOL, V111, P62, DOI 10.1016/0012-1606(85)90435-X; DECHANT G, 1993, DEVELOPMENT, V119, P545; DUGICHDJORDJEVIC MM, 1992, NEUROSCIENCE, V47, P303, DOI 10.1016/0306-4522(92)90246-X; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HEFTI F, 1986, J NEUROSCI, V6, P2155; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JELSMA TN, 1993, J NEUROBIOL, V24, P1207, DOI 10.1002/neu.480240907; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KORSCHING S, 1993, J NEUROSCI, V13, P2739; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; OKAZAWA H, 1993, FEBS LETT, V329, P171, DOI 10.1016/0014-5793(93)80216-H; OKAZAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P683, DOI 10.1006/bbrc.1993.1876; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RICHTER A, 1975, J PHYSIOL-LONDON, V248, P317, DOI 10.1113/jphysiol.1975.sp010976; RODRIGUEZTEBAR A, 1989, DEV BIOL, V136, P296, DOI 10.1016/0012-1606(89)90256-X; RODRIGUEZTEBAR A, 1993, EUR J BIOCHEM, V211, P789, DOI 10.1111/j.1432-1033.1993.tb17610.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SCHWARTZ EA, 1974, J PHYSIOL-LONDON, V236, P211, DOI 10.1113/jphysiol.1974.sp010431; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SHINTANI A, 1992, BIOCHEM BIOPH RES CO, V182, P325, DOI 10.1016/S0006-291X(05)80148-2; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VAIENZUELLA DM, 1993, NEURON, V10, P963; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YOSHIDA K, 1993, NEURON, V10, P1049, DOI 10.1016/0896-6273(93)90053-T; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	54	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1813	1818						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208527				2022-12-17	WOS:A1994NR68500002
J	MACLEAN, K; ROGAN, EM; WHITAKER, NJ; CHANG, ACM; ROWE, PB; DALLAPOZZA, L; SYMONDS, G; REDDEL, RR				MACLEAN, K; ROGAN, EM; WHITAKER, NJ; CHANG, ACM; ROWE, PB; DALLAPOZZA, L; SYMONDS, G; REDDEL, RR			IN-VITRO TRANSFORMATION OF LI-FRAUMENI SYNDROME FIBROBLASTS BY SV40 LARGE T-ANTIGEN MUTANTS	ONCOGENE			English	Article							HUMAN-DIPLOID FIBROBLASTS; CANCER-PRONE FAMILY; LARGE TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; SIMIAN VIRUS-40; CELL-TRANSFORMATION; P53 GENE; IMMORTALIZATION; SPAN; EXPRESSION	Transfection of SV40 early region DNA into normal human diploid fibroblasts (NHDFs) increases their proliferative potential to a limited extent. We have investigated the roles of the SV40 large T antigen (LTAg) regions responsible for binding to the protein products of the retinoblastoma (Rb) and p53 genes in this temporary escape from senescence. Plasmids encoding LTAg mutants were transfected into NHDFs and into Li-Fraumeni syndrome (LFS) fibroblasts which are heterozygous wild-type (wt)/null-mutant for p53. A LTAg mutated in the p53-binding region (T402DE) had greatly reduced efficiency of focus formation, and a p110(Rb)-binding mutant was unable to induce any foci. T402DE-induced NHDF foci senesced at the same time as untransfected cells, but the equivalent LFS foci all had increased proliferative potentials, with the greatest increase being seen in clones that lost the wt p53 allele. One LFS clone expressed the T402DE mutant during focus formation, but later lost both the T402DE DNA and the wt p53 allele. We conclude that SV40-induced focus formation in NHDFs requires the LTAg p110(Rb)-binding region, and is enhanced by loss of normal p53 function. In contrast, increased proliferative potential is primarily due to loss of p53 function.	CHILDRENS MED RES INST,WESTMEAD,NSW 2145,AUSTRALIA; ROYAL ALEXANDRA HOSP CHILDREN,ONCOL UNIT,CAMPERDOWN,NSW 2050,AUSTRALIA	Children's Medical Research Institute - Australia			Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				BISCHOFF FZ, 1990, CANCER RES, V50, P7979; CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERONDE A, 1989, VIROLOGY, V171, P160; DESILVA R, 1993, CELL MOL BIOL RES, V39, P101; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HAYFLICK L, 1965, EXP CELL RES, V37, P611; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; PEREIRASMITH OM, 1981, SOMAT CELL GENET, V7, P411, DOI 10.1007/BF01542986; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SOUDON J, 1991, LEUKEMIA, V5, P917; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRAUSS M, 1992, ONCOGENE, V7, P769; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WHITAKER NJ, 1992, J VIROL, V66, P1202, DOI 10.1128/JVI.66.2.1202-1206.1992; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	41	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					719	725						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108114				2022-12-17	WOS:A1994MW55100006
J	LIU, BX; WEI, W; BROEK, D				LIU, BX; WEI, W; BROEK, D			THE CATALYTIC DOMAIN OF THE MOUSE SOS1 GENE-PRODUCT ACTIVATES RAS PROTEINS IN-VIVO AND IN-VITRO	ONCOGENE			English	Article							SACCHAROMYCES-CEREVISIAE; ADENYLATE-CYCLASE; CDC25 GENE; IDENTIFICATION; PATHWAY; CLONING; CDNAS	Nucleotide exchange factors (NEFs) which are structurally related to the yeast Saccharomyces cerevisiae CDC25 gene product have recently been identified in mammals. One of these NEFs, cdc25, has been shown to activate RAS in yeast and to promote nucleotide exchange on RAS proteins in vitro. The cdc25 from mammals is expressed at high levels in brain tissue but not in a variety of other tissues examined. The vertebrate sos1 and sos2 gene products have a domain structurally related to the catalytic domain of the yeast CDC25NEF. The expression pattern of sos1 and sos2 is widespread, showing detectable levels of expression in all tissues examined, although the levels vary dramatically in various tissues. In this report we demonstrate that the catalytic domain of SOS1NEF can complement the loss of CDC25 function in yeast, can bind tightly to the nucleotide-free form of H-ras in vitro and can promote nucleotide exchange on the H-ras protein in vitro.	UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Southern California					NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA50261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUET E, 1993, IN PRESS J BIOL CHEM; KIM JH, 1991, MOL CELL BIOL, V11, P3894, DOI 10.1128/MCB.11.8.3894; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; Sambrook J., 1989, MOL CLONING LAB MANU; Sherman F., 1986, METHODS YEAST GENETI; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; White T.J., 1990, PCR PROTOCOLS GUIDE, P315, DOI [10.1016/0307-4412(91), DOI 10.1016/0307-4412(91)]; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	18	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3081	3084						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414509				2022-12-17	WOS:A1993MC09300024
J	MORELLO, D; LAVENU, A; POURNIN, S; BABINET, C				MORELLO, D; LAVENU, A; POURNIN, S; BABINET, C			THE 5' AND 3' NONCODING SEQUENCES OF THE C-MYC GENE, REQUIRED INVITRO FOR ITS POSTTRANSCRIPTIONAL REGULATION, ARE DISPENSABLE INVIVO	ONCOGENE			English	Article							MESSENGER-RNA DEGRADATION; MOUSE-LIVER REGENERATION; CELL-FREE SYSTEM; PROTEIN-SYNTHESIS; TRANSGENIC MICE; PREMATURE TERMINATION; STABILITY INVITRO; LYMPHOMA-CELLS; RAT-LIVER; EXPRESSION	We have previously shown that in vivo the steady-state level of c-myc mRNA in different quiescent organs and its induction in the early stages of hepatic regeneration and after inhibition of protein synthesis are mainly controlled by post-transcriptional mechanisms. In order to localize the target sequences for these mechanisms, transgenic lines expressing various versions of the human c-myc proto-oncogene have been constructed. To avoid all possible transcriptional controls due to the c-mye 5' regulatory region, the c-mye genomic sequences were fused to MHC H-2K(b) class I regulatory sequences, which have previously been shown to be able to drive reporter gene expression in most adult tissues. The transgenes contained either all human c-mye genomic sequences or were deleted for one of the sequences which have been shown in in vitro experiments to play a role in c-mye mRNA stabilization, in particular exon 1, intron 1 and the 3' non-coding region. Several independent transgenic lines were derived for each construct. Using S1 nuclease protection analysis, we have monitored H-2K, mouse c-myc and transgene mRNA expression in several quiescent adult organs, at the start of liver regeneration and after inhibition of protein synthesis in each transgenic line. Our results indicate that the 5' non-coding sequences, including exon 1 and intron 1, and the 3' untranslated region are all dispensable in the different aspects of c-myc post-transcriptional regulation.			MORELLO, D (corresponding author), INST PASTEUR, DEPT IMMUNOL, UNITE GENET MAMMIFERES, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.							AGHIB DF, 1991, ONCOGENE, V6, P2371; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAUER SR, 1989, ONCOGENE, V4, P615; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BONNIEU A, 1990, ONCOGENE, V5, P1585; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1989, ONCOGENE RES, V4, P111; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MORELLO D, 1990, ONCOGENE, V5, P1511; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505	58	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1921	1929						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510935				2022-12-17	WOS:A1993LG68200025
J	TOROK, I; HARTENSTEIN, K; KALMES, A; SCHMITT, R; STRAND, D; MECHLER, BM				TOROK, I; HARTENSTEIN, K; KALMES, A; SCHMITT, R; STRAND, D; MECHLER, BM			THE L(2)GL HOMOLOG OF DROSOPHILA-PSEUDOOBSCURA SUPPRESSES TUMORIGENICITY IN TRANSGENIC DROSOPHILA-MELANOGASTER	ONCOGENE			English	Article							NUCLEOTIDE-SEQUENCE; MOLECULAR EVOLUTION; GENE; REGION; ELEMENTS; PROTEIN; DNA; CLONING; PRODUCT; LOCUS	Mutations in the tumour-suppressor gene lethal(2)giant larvae (l(2)gl) of Drosophila cause malignant transformation of the optic centres of the larval brain and the imaginal discs. We report the cloning and sequencing of the l(2)gl gene from Drosophila pseudoobscura. comparison of this sequence with D. melanogaster reveals a significant sequence conservation within the l(2)gl protein-coding domain and a strong sequence divergence in the 5' promoter region and in the introns. The deduced amino acid sequence of the D. pseudoobscura l(2)gl protein shows 17.7% divergence from D. melanogaster. However, despite these evolutionary differences, the D. pseadoobscura l(2)gl gene can fully suppress tumorigenicity and restore a normal development in l(2)gl-deficient D. melanogaster flies, although the rescued animals display poor viability and fertility. Furthermore, in D. melanogaster transgenic flies, the D. pseudoobscura l(2)gl protein is produced at a similar level as the D. melanogaster l(2)gl protein and displays an identical spatial pattern of expression. This shows that the highly divergent cis-regulatory elements of the D. pseudoobscura transgene can be fully recognized in D. melanogaster and lead to the synthesis of a transgenic protein that has enough specificity conserved for replacing the tumour-suppressor function normally fulfilled by the D. melanogaster l(2)gl protein.			TOROK, I (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT DEV GENET, NEUENHEIMER FELD 280, W-6900 HEIDELBERG, GERMANY.							AGGARWAL SK, 1969, J MORPHOL, V129, P171, DOI 10.1002/jmor.1051290204; AKAIH, 1975, CELL JAPAN, V4, P3841; [Anonymous], 1984, AM NAT; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BLACKMAN RK, 1986, J MOL BIOL, V188, P499, DOI 10.1016/S0022-2836(86)80001-8; BRADY JP, 1990, MOL BIOL EVOL, V7, P525; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BURKE JF, 1984, GENE, V30, P63, DOI 10.1016/0378-1119(84)90105-7; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; FRIEDMAN TB, 1992, J MOL EVOL, V34, P62, DOI 10.1007/BF00163853; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; GATEFF E, 1969, NATL CANCER I MONOGR, P365; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GILLESPIE JH, 1986, ANNU REV ECOL SYST, V17, P637; Gloor H., 1943, Revue Suisse de Zoologie, V50, P339; GLOOR H, 1942, ARCH JUL KLAUS STIFT, V17, P438; GROB H, 1952, Z INDUKT ABSTAMM VER, V84, P320, DOI 10.1007/BF00309474; Hadorn E, 1937, P SOC EXP BIOL MED, V36, P632; HADORN E, 1961, DEV GENETICS LETHAL; HADORN E, 1942, REV SUISSE ZOOL, V49, P228; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENIKOFF S, 1987, GENETICS, V117, P711; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; KLAMBT C, 1989, DEV BIOL, V133, P425, DOI 10.1016/0012-1606(89)90046-8; KRASNEY PA, 1990, MOL BIOL EVOL, V7, P155; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUTZELSCHWAB R, 1987, EMBO J, V6, P1791, DOI 10.1002/j.1460-2075.1987.tb02432.x; MECHLER B, 1989, ACCOMPLISHMENTS CANC, P226; MECHLER BM, 1991, ENVIRON HEALTH PERSP, V93, P63, DOI 10.2307/3431171; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MECHLER BM, 1990, TUMOR SUPPRESSOR GEN, P123; MERZ R, 1990, ENVIRON HEALTH PERSP, V88, P163, DOI 10.2307/3431068; MORIYAMA EN, 1987, JPN J GENET, V62, P139, DOI 10.1266/jjg.62.139; OPPER M, 1987, ONCOGENE, V1, P91; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; RILEY MA, 1989, MOL BIOL EVOL, V6, P33; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAEFFER SW, 1987, GENETICS, V117, P61; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRAND D, 1991, ADV ENZYME REGUL, V31, P339, DOI 10.1016/0065-2571(91)90022-E; SZABAD J, 1991, GENETICS, V127, P525; Throckmorton L.H., 1975, P421; WILDE CD, 1987, EMBO J, V6, P1393, DOI 10.1002/j.1460-2075.1987.tb02380.x; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; Zuckerkandl E, 1962, HORIZONS BIOCH	54	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1537	1549						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389031				2022-12-17	WOS:A1993LE06400017
J	CASTELLAZZI, M; LOISEAU, L; PIU, F; SERGEANT, A				CASTELLAZZI, M; LOISEAU, L; PIU, F; SERGEANT, A			CHIMERIC C-JUN CONTAINING AN HETEROLOGOUS HOMODIMERIZATION DOMAIN TRANSFORMS PRIMARY CHICK-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							DNA-BINDING PROTEIN; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATOR; DIMERIZATION SPECIFICITY; NEGATIVE REGULATION; GENE FAMILY; V-JUN; FOS; ONCOGENE; EXPRESSION	To investigate a possible role for c-Jun homodimers in c-Jun-mediated transformation, we designed two chimeric c-Jun derivatives, called c-Jun(eb1) and c-Jun(gcn4). In these chimeric derivatives the natural dimerization domain of c-Jun was replaced by the heterologous homodimerization domain of the Epstein-Barr virus EB1 or the yeast GCN4 transcription factor. Chick embryo fibroblasts chronically infected with retroviruses expressing c-Jun, c-Jun(eb1) or c-Jun(gcn4) are transformed. Infection with each construction results in sustained growth in low serum and development of colonies from single cells in agar with similar efficiencies. In contrast to c-Jun, c-Jun(eb1) and c-Jun(gcn4) confer additional phenotypic alterations related to in vitro transformation including a condensed cell morphology and ability to develop highly invasive, fast growing colonies in agar. These data suggest that c-Jun homodimers can transform chick embryo fibroblasts and activate cellular functions which influence cell morphology and invasive potential in agar. These findings are consistent with the notion that cellular transformation by c-jun is mediated by c-Jun homodimers.			CASTELLAZZI, M (corresponding author), ECOLE NORMALE SUPER, BIOL MOLEC & CELLULAIRE LAB, CNRS, UMR 49, 46 ALLEE ITALIE, F-69364 LYON, FRANCE.							ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1990, ONCOGENE, V5, P929; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MATSUI M, 1990, ONCOGENE, V5, P249; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN IM, 1992, ONCOGENE, V7, P1119; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEUBERG M, 1991, ONCOGENE, V6, P1325; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1991, ONCOGENE, V6, P1491; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	64	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1149	1160						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479740				2022-12-17	WOS:A1993KY32800006
J	HARA, E; OKAMOTO, S; NAKADA, S; TAYA, Y; SEKIYA, S; ODA, K				HARA, E; OKAMOTO, S; NAKADA, S; TAYA, Y; SEKIYA, S; ODA, K			PROTEIN-PHOSPHORYLATION REQUIRED FOR THE FORMATION OF E2F COMPLEXES REGULATES N-MYC TRANSCRIPTION DURING DIFFERENTIATION OF HUMAN EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; DNA-BINDING PROTEINS; CYCLIN-A; TRANSIENT DECREASE; STEM-CELLS; RB GENE; EXPRESSION; REGION; TRANSACTIVATION; ADENOVIRUS-E1A	The human embryonal carcinoma (EC) cell line NEC14 can be induced to differentiate morphologically by the addition of 10(-2) M N,N'-hexamethylene-bis-acetamide (HMBA). The N-myc gene is expressed at a high level in the undifferentiated cells, but the level decreased steeply after 12-24 h HMBA treatment, returning to its original level after 48 h. The alteration in the N-myc level was well correlated with the formation of complexes with the E2F motif in the N-myc promoter region, and no complex was formed with cell extracts prepared from cells treated with HMBA for 12-24 h. The absence of E2F complexes during this period was caused by an inhibitor generated by a phosphatase reaction. Treatment of the 12-h extract with a cyclic AMP-dependent protein kinase resulted in the formation of E2F complexes, and treatment of the undifferentiated (0 h) and 48-h extracts with a calf intestinal phosphatase abolished complex formation completely. An inhibitor generated by the 0-h extract after treatment with a phosphatase inhibited E2F complex formation by the untreated 0-h extract in the presence of phosphatase inhibitors, okadaic acid and sodium vanadate. One of the two E2F complexes in the undifferentiated cells contained cyclin A, but the complex with similar mobility, formed after the transient decrease in the N-myc level, did not.	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN; SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; CHIBA UNIV,SCH MED,DEPT OBSTET & GYNECOL,CHIBA 280,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Tokyo University of Science; Tokyo University of Science; Chiba University; National Cancer Center - Japan								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FRIEND M, 1981, NUCLEIC ACIDS RES, V9, P6509; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARA E, 1991, NUCLEIC ACIDS RES, V19, P7097, DOI 10.1093/nar/19.25.7097; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HASEGAWA T, 1990, DIFFERENTIATION, V42, P191, DOI 10.1111/j.1432-0436.1990.tb00761.x; HASEGAWA T, 1991, DIFFERENTIATION, V47, P107, DOI 10.1111/j.1432-0436.1991.tb00228.x; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACOBOVITS A, 1985, NATURE, V318, P188; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUNO K, 1989, J BIOL CHEM, V264, P18707; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sambrook J., 1989, MOL CLONING LAB MANU; SEJERSEN T, 1986, J CELL PHYSIOL, V127, P274, DOI 10.1002/jcp.1041270213; SEKIYA S, 1990, GYNECOL ONCOL, V36, P69, DOI 10.1016/0090-8258(90)90111-W; SEKIYA S, 1985, DIFFERENTIATION, V29, P259, DOI 10.1111/j.1432-0436.1985.tb00325.x; SEKIYA S, 1988, INT J GYNECOL PATHOL, V7, P373, DOI 10.1097/00004347-198812000-00008; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Silver L.M., 1983, TERATOCARCINOMA STEM; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKEHANA K, 1991, GENE, V103, P219, DOI 10.1016/0378-1119(91)90276-H; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VELCICH A, 1985, NATURE, V318, P595; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	59	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1023	1032						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384353				2022-12-17	WOS:A1993KT22000026
J	MARSHALL, MS; HETTICH, LA				MARSHALL, MS; HETTICH, LA			CHARACTERIZATION OF RAS EFFECTOR MUTANT INTERACTIONS WITH THE NF1-GAP RELATED DOMAIN	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; ADENYLATE-CYCLASE; SACCHAROMYCES-CEREVISIAE; NEUROFIBROMATOSIS GENE; CATALYTIC DOMAIN; GAP; P21; MUTATIONS; TRANSFORMATION	The GTPase activating proteins Ras GAP and the neurofibromatosis-type 1 (NF1) gene product have been implicated as both potential mediators and regulators of the mitogenic effects of the ras proteins. In this study, the interactions of selected Ras effector mutants with the NF1-GAP related domain (NF1-GRD) were investigated. The NF1-GRD was unable to stimulate the GTPase of Ras[Asn33], Ras[Ser35] or Ras[Asn38], all transformation defective mutants. Each of these mutants had reduced but detectable binding to the NF1-GRD (apparent K(D) of 9 muM, 4 muM and 2 muM respectively, vs 0.5 muM for normal Ha-ras). The NF1-GRD was able to fully stimulate the intrinsic GTPase of the transformation-defective Ras[Gly26Ile27] and Ras[Glu45] mutants, each of which bound the NF1-GRD with wild type affinity or better (K(D)=0.13 muM and 0.4 muM respectively). The transforming Ras[Glu30Lys31] protein showed no GTPase stimulation and bound most poorly to the NF1-GRD (apparent K(D) of 16 muM). The interaction of the NF1-GRD with these specific Ras effector mutations is similar to that observed for Ras GAP. When the relative transforming activity of the valine 12 form of each Ras mutant was plotted against the apparent K(D) for NF1-GRD binding, little correlation was observed. These results support the hypothesis that the NF1 gene product does not function as a downstream effector of Ras in the mitogenic pathway.	WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	Walther Cancer Institute	MARSHALL, MS (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, DIV HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOLDBERG NS, 1991, ARCH DERMATOL, V127, P1705, DOI 10.1001/archderm.127.11.1705; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARSHALL MS, 1988, MOL CELL BIOL, V8, P52, DOI 10.1128/MCB.8.1.52; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SIGAL IS, 1988, COLD SPRING HARB SYM, V53, P863, DOI 10.1101/SQB.1988.053.01.099; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WILLUMSEN BM, 1989, NATO ADV SCI I A-LIF, V165, P165; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	33	27	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					425	431						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426748				2022-12-17	WOS:A1993KN00600022
J	GRIFFITHS, SD; HEALY, LE; FORD, AM; BENNETT, CA; VONCKEN, JW; HEISTERKAMP, N; GROFFEN, J; GREAVES, MF				GRIFFITHS, SD; HEALY, LE; FORD, AM; BENNETT, CA; VONCKEN, JW; HEISTERKAMP, N; GROFFEN, J; GREAVES, MF			CLONAL CHARACTERISTICS OF ACUTE LYMPHOBLASTIC CELLS DERIVED FROM BCR ABL-P190 TRANSGENIC MICE	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; ABL ONCOGENE; BONE-MARROW; GENE; REARRANGEMENT; STIMULATION; EXPRESSION; INVITRO; TRANSLOCATION	The clonal and immunophenotypic characteristics of blood leukemic cells from BCR/ABL p190 transgenic mice were investigated. All cell populations evaluated in vivo and in vitro had B-lymphocyte progenitor immunophenotypes. Immunoglobulin (J(H)) rearrangement patterns provided evidence for clonal diversification at different sites in vivo. Multiple clones were established in vitro from two of these mice (nos. 730 and 753). These cells expressed BCR/ABL p190 protein tyrosine kinase (PTK) and were highly malignant on transfer to secondary recipients. Cells independently cloned in vitro shared identical immunophenotypes and clonal IgH rearrangements, but these were distinct from those of the dominant clones in the mouse from which they were derived. Nevertheless, in vitro clones from mouse no. 753 had an abnormal karyotype (chromosome 14 trisomy) in common with the dominant clone in blood, providing evidence for a hierarchy or clonal selection in vivo and in vitro. Two sets of in vitro clones proliferated independently of exogenous growth factors and stroma and released autocrine interleukin 7 growth factor activity. These data provide evidence for rapid divergent clonal evolution and selection of B-cell progenitors initiated by BCR/ABL p190, followed by other, secondary genetic events mirroring similar changes in the equivalent, highly malignant human leukemia Philadelphia (Ph)-positive/B-precursor acute lymphoblastic leukemia (ALL).	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGNOSIS SECT,LOS ANGELES,CA 90054	Children's Hospital Los Angeles	GRIFFITHS, SD (corresponding author), INST CANC RES,CTR LEUKAEMIA RES FUND,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Healy, Lyn/0000-0002-7044-8789	NATIONAL CANCER INSTITUTE [R01CA050248, R01CA047073] Funding Source: NIH RePORTER; NCI NIH HHS [CA47073, CA50248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BEISHUIZEN A, 1992, LEUKEMIA, V6, P60; BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229; BLOOMFIELD CD, 1989, CANCER GENET CYTOGEN, V40, P171, DOI 10.1016/0165-4608(89)90023-X; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; COOPER MD, 1986, NATURE, V321, P616, DOI 10.1038/321616a0; COWLING GJ, 1985, MODERN TRENDS HUMAN, V6, P385; DEKLEIN A, 1986, BLOOD, V68, P1369; DHUT S, 1991, LEUKEMIA, V5, P49; DOW LW, 1989, BLOOD, V73, P1291; FORD AM, 1983, EMBO J, V2, P997, DOI 10.1002/j.1460-2075.1983.tb01533.x; GIMBLE JM, 1989, BLOOD, V74, P303; GREAVES MF, 1986, CLIN HAEMATOL, V15, P621; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HIRSCHGINSBERG C, 1988, BLOOD, V71, P186; Ishihara K, 1991, Dev Immunol, V1, P149, DOI 10.1155/1991/79721; KALOUSEK DK, 1988, BRIT J HAEMATOL, V70, P5, DOI 10.1111/j.1365-2141.1988.tb02426.x; Kincade P W, 1990, Adv Cancer Res, V54, P235, DOI 10.1016/S0065-230X(08)60813-1; KITANO K, 1988, BRIT J HAEMATOL, V70, P21, DOI 10.1111/j.1365-2141.1988.tb02428.x; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEE G, 1989, J IMMUNOL, V142, P3875; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCNAGNY KM, 1988, J IMMUNOL, V141, P2551; MINOWADA J, 1980, S NEW TRENDS HUMAN I, P188; NAEME PB, 1985, BLOOD, V65, P142; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; OCONNOR R, 1991, BLOOD, V77, P1534; OVERELL RW, 1991, MOL CELL BIOL, V11, P1590, DOI 10.1128/MCB.11.3.1590; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PALUMBO GJ, 1990, CANCER RES, V90, P1917; RIBEIRO RC, 1987, BLOOD, V70, P948; RIEDER H, 1991, CANCER GENET CYTOGEN, V53, P139; RUSSO C, 1991, BLOOD, V77, P1050; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; TURHAN AG, 1988, BLOOD, V71, P1495; VONCKEN JW, 1992, BLOOD, V79, P1029; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	54	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1391	1399						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377812				2022-12-17	WOS:A1992HZ97100018
J	INOUE, J; ITOH, M; AKIZAWA, T; TOYOSHIMA, H; YOSHIDA, M				INOUE, J; ITOH, M; AKIZAWA, T; TOYOSHIMA, H; YOSHIDA, M			HTLV-1 REX PROTEIN ACCUMULATES UNSPLICED RNA IN THE NUCLEUS AS WELL AS IN CYTOPLASM	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; VIRAL MESSENGER-RNA; TRANS-ACTIVATOR GENE; LONG TERMINAL REPEAT; RESPONSIVE ELEMENT; TARGET SEQUENCE; TYPE-1 AFFECTS; EXPRESSION; HIV-1	The Rex protein of human T-cell leukemia viruses (HTLV) is a trans-acting regulator inducing the expression of gag and env mRNA containing the introns. The rex gene can also induce expression of unspliced RNA of human immunodeficiency viruses (HIV). We have analyzed the level of spliced and unspliced RNAs in nucleus and cytoplasm to understand the mechanism by which the Rex protein modulates RNA processing. With the gag gene of HTLV-1, the unspliced RNA was accumulated by Rex protein in both nucleus and cytoplasm. However, the apparent effects on nuclear unspliced RNA depended on the reporter genes: with the env gene of HTLV-1 as well as that of HIV-1, Rex did not accumulate the unspliced RNA in nucleus, but did so only in cytoplasm. These results clearly indicate that Rex protein not only activates the nuclear export of unspliced RNA, but also modulates some steps of RNA processing before the splicing, probably through stabilization of the precursor RNA.	UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research								ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1988, JPN J CANCER RES, V79, P800, DOI 10.1111/j.1349-7006.1988.tb00038.x; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3635; INOUE JI, 1986, FEBS LETT, V209, P187, DOI 10.1016/0014-5793(86)81108-5; ITOH M, 1989, ONCOGENE, V4, P1275; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; ROSENBLATT JD, 1988, SCIENCE, V240, P916, DOI 10.1126/science.2834826; SADAIE MR, 1988, P NATL ACAD SCI USA, V85, P9224, DOI 10.1073/pnas.85.23.9224; SADAIE RM, 1988, SCIENCE, V239, P2910; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; TRONO D, 1990, EMBO J, V9, P4155, DOI 10.1002/j.1460-2075.1990.tb07638.x; YOSHIDA M, 1984, HUMAN T CELL LEUKEMI, P141; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; ZIMM K, 1983, CELL, V34, P865	34	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1753	1757						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923501				2022-12-17	WOS:A1991GX11800005
J	BAETSCHER, M; SCHMIDT, E; SHIMIZU, A; LEDER, P; FISHMAN, MC				BAETSCHER, M; SCHMIDT, E; SHIMIZU, A; LEDER, P; FISHMAN, MC			SV40 T-ANTIGEN TRANSFORMS CALCITONIN CELLS OF THE THYROID BUT NOT CGRP-CONTAINING NEURONS IN TRANSGENIC MICE	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; C-MYC; GENE; EXPRESSION; CARCINOMA; ONCOGENE; BRAIN	Neurons are postmitotic for the adult life of animals. Tumors rarely, if ever, arise from neurons in the adult, although they do from other cells from the same lineage, such as the neuroendocrine C cells of the thyroid. We have found that 2 kb of the calcitonin gene-related peptide (CGRP)/calcitonin gene suffices to target expression to CGRP-containing neurons, such as those in the dorsal root ganglia (DRG), and to the clacitonin-secreting C cells of the thyroid. Using this promoter we have examined the effect of two potentially transforming oncogenes in these two different populations. Overexpression of c-myc for periods of up to two years does not transform either cell type, whereas SV40 Tag causes early onset medullary thyroid carcinoma, but does not transform the dorsal root ganglia neurons. This suggests that as part of the terminal differentiation process of these neurons, the cessation of mitosis is accompanied by a relative refractoriness to oncogenes that may transform other cells of the same lineage.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEV BIOL LAB,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,BOSTON,MA 02114; HOWARD HUGHES MED INST,BOSTON,MA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute	FISHMAN, MC (corresponding author), MASSACHUSETTS GEN HOSP,DEV BIOL LAB,MGH E,149 13TH ST,4TH FLOOR,BOSTON,MA 02129, USA.							AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BARASCH JM, 1987, J NEUROSCI, V7, P2874; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; DEBUSTROS A, 1990, MOL CELL BIOL, V10, P1773, DOI 10.1128/MCB.10.4.1773; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGROOT LJ, 1979, ENDOCRINOLOGY, V2; DeLellis R A, 1981, Methods Achiev Exp Pathol, V10, P190; DELELLIS RA, 1978, AM J CLIN PATHOL, V70, P587, DOI 10.1093/ajcp/70.4.587; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GRAZIADEI PPC, 1979, NEUROSCIENCE, V4, P713, DOI 10.1016/0306-4522(79)90002-2; HAMMANG JP, 1990, NEURON, V4, P775, DOI 10.1016/0896-6273(90)90204-S; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; Hogan B., 1986, MANIPULATING MOUSE E; JOHANNESSEN JV, 1978, HUM PATHOL, V9, P385, DOI 10.1016/S0046-8177(78)80025-2; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; REYNOLDS RK, 1988, P NATL ACAD SCI USA, V85, P3135, DOI 10.1073/pnas.85.9.3135; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; RUPPERT JM, 1986, AM J SURG PATHOL, V10, P513, DOI 10.1097/00000478-198607000-00009; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TRIGGS SM, 1977, ACTA ENDOCRINOL-COP, V85, P84	31	27	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1133	1138						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650439				2022-12-17	WOS:A1991GV26000006
J	DOSAKAAKITA, H; ROSENBERG, RK; MINNA, JD; BIRRER, MJ				DOSAKAAKITA, H; ROSENBERG, RK; MINNA, JD; BIRRER, MJ			A COMPLEX PATTERN OF TRANSLATIONAL INITIATION AND PHOSPHORYLATION IN L-MYC PROTEINS	ONCOGENE			English	Article							CELL LUNG-CANCER; FIBROBLAST GROWTH-FACTOR; CASEIN KINASE-II; NON-AUG CODONS; C-MYC; MESSENGER-RNAS; EMBRYO FIBROBLASTS; GENE FAMILY; LINES; TRANSFORMATION	Molecular analysis of the human proto-oncogene L-myc revealed a complex pattern of gene expression including alternative splicing and polyadenylation site selection of mRNA, giving rise to at least four mRNAs. These mRNAs in turn can code for several proteins. In this report, we characterize and define the origins of the major L-myc proteins. In vitro translation revealed that (i) two L-myc proteins (p59 and p65) were derived through alternative translational initiation at a non-AUG (CUG) site in intron 1 and at an AUC site in exon 2 of L-myc, and that (ii) extensive post-translational phosphorylation of these proteins yielded three additional proteins (p60, p66, and p68). Transfection experiments in rat embryo cells revealed the in vivo existence of this unusual CUG-initiated protein and demonstrated that it possessed transforming activity. Further, immuno-precipitation using high titered anti-L-myc peptide antisera, of two L-myc expressing small-cell lung cancer cell lines revealed three major L-myc proteins (p60, p66 and p68) all of which were derived from extensive phosphorylation of a p59 protein.	NCI,USN,MED ONCOL BRANCH,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA								BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BISTER K, 1987, ONCOGENE, V1, P97; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CARNEY DN, 1985, CANCER RES, V45, P2913; CLEAVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RAMSAY G, 1982, EMBO J, V9, P1111; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SAKSELA K, 1989, INT J CANCER, V44, P182, DOI 10.1002/ijc.2910440132; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					371	378						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849244				2022-12-17	WOS:A1991FT34400004
J	SUTRAVE, P; HUGHES, SH				SUTRAVE, P; HUGHES, SH			THE SKI ONCOGENE	ONCOGENE			English	Review							SEQUENCE; VIRUSES; MUSCLE; CELLS; GENE		NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stavnezer E., 1988, ONCOGENE HDB, P393; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462	13	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					353	356						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011394				2022-12-17	WOS:A1991FT34400001
J	BAKKUS, MHC; PEER, KMJB; MICHIELS, JJ; VANTVEER, MB; BENNER, R				BAKKUS, MHC; PEER, KMJB; MICHIELS, JJ; VANTVEER, MB; BENNER, R			AMPLIFICATION OF THE C-MYC AND THE PVT-LIKE REGION IN HUMAN MULTIPLE-MYELOMA	ONCOGENE			English	Article									DR DANIEL DENHOED CANC CTR,DEPT HEMATOL,ROTTERDAM,NETHERLANDS; ACAD HOSP ROTTERDAM,DEPT IMMUNOL,DIJKZIGT,NETHERLANDS; ACAD HOSP ROTTERDAM,DEPT HEMATOL,DIJKZIGT,NETHERLANDS; ERASMUS UNIV,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam								ADAMS JM, 1986, CURR TOP MICROBIOL, V132, P1; ASKER C, 1988, LEUKEMIA RES, V12, P523, DOI 10.1016/0145-2126(88)90120-8; BANERJEE M, 1985, EMBO J, V4, P3183, DOI 10.1002/j.1460-2075.1985.tb04063.x; BARLOGIE B, 1986, MULTIPLE MYELOMA OTH, P154; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; CROCE CM, 1985, BLOOD, V65, P1; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DEWALD GW, 1985, BLOOD, V66, P380; DURIE BGM, 1985, BLOOD, V66, P548; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERTI A, 1984, CANCER GENET CYTOGEN, V12, P247, DOI 10.1016/0165-4608(84)90036-0; GAZDAR AF, 1986, BLOOD, V67, P1542; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; GRIESSER H, 1986, BLOOD, V68, P592; HUMPHRIES JE, 1989, BLOOD, V74, pA375; JERNBERG H, 1987, BLOOD, V69, P1605; KATAGIRI S, 1985, INT J CANCER, V36, P241, DOI 10.1002/ijc.2910360217; LATREILLE J, 1982, BLOOD, V59, P43; Lewis J P, 1984, Hematol Oncol, V2, P307; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Maniatis T., 1982, MOL CLONING; MELLSTEDT H, 1984, ADV CANCER RES, V41, P257; MELTZER P, 1987, BLOOD, V70, pA985; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; PEGORARO L, 1989, BLOOD, V73, P1020; POTTER M, 1984, CANCER INVEST, V2, P285, DOI 10.3109/07357908409018443; RANNI NS, 1987, CANCER GENET CYTOGEN, V25, P309, DOI 10.1016/0165-4608(87)90192-0; RDL J, 1990, BRIT J CANCER, V61, P276; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SELVANAYAGAM P, 1988, BLOOD, V71, P30; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SHTIVELMAN E, 1990, MOL CELL BIOL, V10, P1835, DOI 10.1128/MCB.10.4.1835; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; SIEGELMAN MH, 1985, J EXP MED, V161, P850, DOI 10.1084/jem.161.4.850; SUMEGI J, 1985, INT J CANCER, V36, P367; TSICHLIS PN, 1989, P NATL ACAD SCI USA, V86, P5487, DOI 10.1073/pnas.86.14.5487; VANDONGEN JJM, 1987, APPLICATION MONOCLON, P87	43	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1359	1364						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216459				2022-12-17	WOS:A1990EC24100012
J	MAVROTHALASSITIS, GJ; WATSON, DK; PAPAS, TS				MAVROTHALASSITIS, GJ; WATSON, DK; PAPAS, TS			THE HUMAN ETS-2 GENE PROMOTER - MOLECULAR DISSECTION AND NUCLEASE HYPERSENSITIVITY	ONCOGENE			English	Article											MAVROTHALASSITIS, GJ (corresponding author), NCI,MOLEC ONCOL LAB,FREDERICK,MD 21701, USA.							BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KIM SJ, 1989, J BIOL CHEM, V264, P402; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; MACE HAF, 1983, NATURE, V304, P555, DOI 10.1038/304555a0; Maniatis T., 1982, MOL CLONING; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PAVLOVIC B, 1988, MOL CELL BIOL, V8, P5513, DOI 10.1128/MCB.8.12.5513; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; THANOS D, 1988, P NATL ACAD SCI USA, V85, P3075, DOI 10.1073/pnas.85.9.3075; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; YU YT, 1986, CELL, V45, P743, DOI 10.1016/0092-8674(86)90788-9; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989	27	27	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1337	1342						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216458				2022-12-17	WOS:A1990EC24100009
J	DASGUPTA, P; REDDY, EP				DASGUPTA, P; REDDY, EP			IDENTIFICATION OF ALTERNATIVELY SPLICED TRANSCRIPTS FOR HUMAN C-MYB - MOLECULAR-CLONING AND SEQUENCE-ANALYSIS OF HUMAN C-MYB EXON-9A SEQUENCES	ONCOGENE			English	Note									WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA044463, P01CA025875] Funding Source: NIH RePORTER; NCI NIH HHS [CA 25875, CA 44463] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; DUDEK H, 1989, ONCOGENE, V4, P1061; DUDEK H, 1989, IN PRESS ONCOGENE, V4; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Maxam A M, 1980, Methods Enzymol, V65, P499; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; REDDY EP, 1988, ONCOGENE HDB, P327; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	23	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1419	1423						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687764				2022-12-17	WOS:A1989CB65900001
J	PANDIELLA, A; LEHVASLAIHO, H; MAGNI, M; ALITALO, K; MELDOLESI, J				PANDIELLA, A; LEHVASLAIHO, H; MAGNI, M; ALITALO, K; MELDOLESI, J			ACTIVATION OF AN EGFR NEU CHIMERIC RECEPTOR - EARLY INTRACELLULAR SIGNALS AND CELL-PROLIFERATION RESPONSES	ONCOGENE			English	Article									UNIV MILANO,SCI INST S RAFFAELE,VIA OLGETTINA 60,I-20132 MILAN,ITALY; UNIV MILAN,CNR,CTR CYTOPHARMACOL,DEPT PHARMACOL,I-20122 MILAN,ITALY; UNIV HELSINKI,DEPT PATHOL,SF-00100 HELSINKI 10,FINLAND; UNIV HELSINKI,DEPT VIROL,SF-00100 HELSINKI 10,FINLAND	University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Helsinki; University of Helsinki			Alitalo, Kari K/J-5013-2014; Pandiella, Atanasio/O-5180-2014	Alitalo, Kari K/0000-0002-7331-0902; Pandiella, Atanasio/0000-0002-4704-8971				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KOCH BD, 1988, J BIOL CHEM, V263, P216; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PANDIELLA A, 1987, EXP CELL RES, V170, P175, DOI 10.1016/0014-4827(87)90127-3; PANDIELLA A, 1989, J BIOL CHEM, V264, P3122; PANDIELLA A, 1988, BIOCHEM J, V254, P223, DOI 10.1042/bj2540223; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; SAWYER ST, 1981, BIOCHEMISTRY-US, V20, P6280, DOI 10.1021/bi00524a057; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WAGGONER AS, 1979, ANNU REV BIOPHYS BIO, V8, P47, DOI 10.1146/annurev.bb.08.060179.000403; WAHL M, 1988, J BIOL CHEM, V263, P7581; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1987, BIOCHEM BIOPH RES CO, V142, P688, DOI 10.1016/0006-291X(87)91469-0; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	30	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1299	1305						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2573029				2022-12-17	WOS:A1989AX65900005
J	NAKAJIMA, H; IKEDA, M; TSUCHIDA, N; NISHIMURA, S; TAYA, Y				NAKAJIMA, H; IKEDA, M; TSUCHIDA, N; NISHIMURA, S; TAYA, Y			INACTIVATION OF THE N-MYC GENE-PRODUCT BY SINGLE AMINO-ACID SUBSTITUTION OF LEUCINE RESIDUES LOCATED IN THE LEUCINE-ZIPPER REGION	ONCOGENE			English	Article									NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,INST STOMATOGNATH SCI,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU)								BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; GARSON JA, 1986, LANCET, V1, P1496; GARSON JA, 1985, LANCET, V2, P718; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IKEDA M, 1987, JPN J CANCER RES, V78, P428; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MITANI K, 1986, JPN J CANCER RES, V77, P1062; MONTGOMERY KT, 1983, P NATL ACAD SCI-BIOL, V80, P5724, DOI 10.1073/pnas.80.18.5724; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; POLLACK R, 1974, P NATL ACAD SCI USA, V71, P4792, DOI 10.1073/pnas.71.12.4792; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; TAYA Y, 1988, J CLIN EXP MED, V145, P410; UENO K, 1988, MOL CELL BIOL, V8, P4529, DOI 10.1128/MCB.8.10.4529; YAMASHITA T, 1986, Tumor Research, V21, P67; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	30	27	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					999	1002						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668849				2022-12-17	WOS:A1989AJ29700008
J	BONNIEU, A; RECH, J; JEANTEUR, P; FORT, P				BONNIEU, A; RECH, J; JEANTEUR, P; FORT, P			REQUIREMENTS FOR C-FOS MESSENGER-RNA DOWN REGULATION IN GROWTH STIMULATED MURINE CELLS	ONCOGENE			English	Article									UNIV MONTPELLIER 2, BIOL MOLEC LAB, CNRS, UA 1191, F-34060 MONTPELLIER, FRANCE; CTR PAUL LAMARQUE, BIOCHIM LAB, F-34094 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier			Bonnieu, Anne/ABA-7182-2020; Fort, Philippe/M-9498-2015	Fort, Philippe/0000-0001-5997-8722				ADAMSON ED, 1985, EMBO J, V4, P941, DOI 10.1002/j.1460-2075.1985.tb03722.x; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BONNIEU A, 1988, ONCOGENE RES, V3, P155; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; DEVILLIERS J, 1981, NUCLEIC ACIDS RES, V9, P6251, DOI 10.1093/nar/9.23.6251; deVilliers J., 1983, TECHNIQUES LIFE SCI, P1; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREEENBERG ME, 1985, J BIOL CHEM, V206, P14101; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; MARX JL, 1987, SCIENCE, V237, P854, DOI 10.1126/science.3039659; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOLDERS H, 1987, ONCOGENE, V82, P4987; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RECH J, 1989, IN PRESS NUCLEIC ACI; RENZ M, 1985, EMBO J, V4, P3711, DOI 10.1002/j.1460-2075.1985.tb04139.x; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANOOYEN A, 1979, SCIENCE, V206, P337, DOI 10.1126/science.482942; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WATSON RJ, 1988, ONCOGENE, V2, P267; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	62	27	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1989	4	7					881	888						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2502753				2022-12-17	WOS:A1989AE58400010
J	LINDBERG, RA; THOMPSON, DP; HUNTER, T				LINDBERG, RA; THOMPSON, DP; HUNTER, T			IDENTIFICATION OF CDNA CLONES THAT CODE FOR PROTEIN-TYROSINE KINASES BY SCREENING EXPRESSION LIBRARIES WITH ANTIBODIES AGAINST PHOSPHOTYROSINE	ONCOGENE			English	Article									UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	LINDBERG, RA (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92138, USA.				NATIONAL CANCER INSTITUTE [R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FOULKES JG, 1985, J BIOL CHEM, V260, P8070; GILMER TM, 1981, NATURE, V294, P771, DOI 10.1038/294771a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; HUNTER T, 1988, IN PRESS COLD SPRING, V53; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; LETWIN K, 1988, ONCOGENE, V3, P621; Maniatis T., 1982, MOL CLONING; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCGRATH JP, 1982, NATURE, V295, P423, DOI 10.1038/295423a0; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RUTA M, 1988, ONCOGENE, V3, P9; SADOWSKI I, 1987, ONCOGENE, V1, P181; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; STREBHARDT K, 1987, P NATL ACAD SCI USA, V84, P8778, DOI 10.1073/pnas.84.24.8778; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WANG JYJ, 1982, J BIOL CHEM, V257, P13181; WANG JYJ, 1985, J BIOL CHEM, V260, P64; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	41	27	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					629	633						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2485256				2022-12-17	WOS:A1988R646000002
J	PARK, RE; HASELTINE, WA; ROSEN, CA				PARK, RE; HASELTINE, WA; ROSEN, CA			A NUCLEAR FACTOR IS REQUIRED FOR TRANSACTIVATION OF HTLV-I GENE-EXPRESSION	ONCOGENE			English	Article									ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL,NUTLEY,NJ 07110; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHOL,BOSTON,MA 02115	Roche Holding; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								BLATTNER WA, 1982, INT J CANCER, V30, P257, DOI 10.1002/ijc.2910300302; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FUJISAWA J, 1985, P NATL ACAD SCI US, V82, P2276; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; INOUE J, 1986, EMBO J, V5, P2882; JOSEPHS SF, 1984, VIROLOGY, V1139, P340; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE TH, 1984, SCIENCE, V226, P57, DOI 10.1126/science.6089350; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; PASHKALIS H, 1986, P NATL ACAD SCI US, V83, P6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; RUBEN S, IN PRESS SCIENCE; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXON A, 1978, J IMMUNOL, V120, P777; SAXON A, 1978, ANN INTERN MED, V88, P323, DOI 10.7326/0003-4819-88-3-323; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467	39	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					275	279						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2849741				2022-12-17	WOS:A1988Q436700005
J	BROWNELL, E; RUSCETTI, FW; SMITH, RG; RICE, NR				BROWNELL, E; RUSCETTI, FW; SMITH, RG; RICE, NR			DETECTION OF REL-RELATED RNA AND PROTEIN IN HUMAN LYMPHOID-CELLS	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,BIONET RES INC,BASIC RES PROGRAM,MOLEC VIROL & CARCINOGENESIS LAB,FREDERICK,MD 21701; NCI,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21701; UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas								ABE H, 1986, J IMMUNOL METHODS, V90, P111, DOI 10.1016/0022-1759(86)90391-1; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1988, ONCOGENE, V2, P527; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND JL, 1987, J IMMUNOL, V138, P3495; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HERZOG NK, 1986, J VIROL, V57, P371, DOI 10.1128/JVI.57.1.371-375.1986; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; MAGE M, 1981, EUR J IMMUNOL, V11, P228, DOI 10.1002/eji.1830110312; Maniatis T, 1982, MOL CLONING LABORATO; MINOWADA J, 1975, COMP LEUKEMIA RES 19, P251; MINOWADA J, 1982, MALIGNANT LYMPHOMAS, P53; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1980, J VIROL, V33, P320, DOI 10.1128/JVI.33.1.320-329.1980; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SMITH RG, 1981, J IMMUNOL, V126, P596; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; TIMONEN T, 1980, J IMMUNOL METHODS, V36, P285, DOI 10.1016/0022-1759(80)90133-7; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WONG TC, 1981, VIROLOGY, V111, P289, DOI 10.1016/0042-6822(81)90674-7; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	41	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					93	98						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400013
J	Wood, GE; Hockings, H; Hilton, DM; Kermorgant, S				Wood, Georgina E.; Hockings, Helen; Hilton, Danielle M.; Kermorgant, Stephanie			The role of MET in chemotherapy resistance	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; TARGETING C-MET; LUNG-CANCER; BREAST-CANCER; SOMATIC MUTATIONS; SCATTER-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CISPLATIN RESISTANCE	Chemotherapy remains the mainstay of treatment in the majority of solid and haematological malignancies. Resistance to cytotoxic chemotherapy is a major clinical problem and substantial research is ongoing into potential methods of overcoming this resistance. One major target, the receptor tyrosine kinase MET, has generated increasing interest with multiple clinical trials in progress. Overexpression of MET is frequently observed in a range of different cancers and is associated with poor prognosis. Studies have shown that MET promotes resistance to targeted therapies, including those targeting EGFR, BRAF and MEK. More recently, several reports suggest that MET also contributes to cytotoxic chemotherapy resistance. Here we review the preclinical evidence of MET's role in chemotherapy resistance, the mechanisms by which this resistance is mediated and the translational relevance of MET inhibitor therapy for patients with chemotherapy resistant disease.	[Wood, Georgina E.; Hockings, Helen; Hilton, Danielle M.; Kermorgant, Stephanie] Queen Mary Univ London, Barts Canc Inst, John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England	University of London; Queen Mary University London	Wood, GE; Kermorgant, S (corresponding author), Queen Mary Univ London, Barts Canc Inst, John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England.	georgina.wood3@nhs.net; s.kermorgant@qmul.ac.uk	Kermorgant, Stephanie/AAB-4931-2020	Kermorgant, Stephanie/0000-0001-5921-479X; Wood, Georgina/0000-0003-2610-3545	MRC [G0501003] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abraham J, 2015, LEUKEMIA LYMPHOMA, V56, P26, DOI 10.3109/10428194.2014.907890; Avan A, 2013, CURR PHARM DESIGN, V19, P940, DOI 10.2174/138161213804547312; Barrow-McGee R, 2014, INT J BIOCHEM CELL B, V49, P69, DOI 10.1016/j.biocel.2014.01.009; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Beviglia L, 1999, INT J CANCER, V83, P640, DOI 10.1002/(SICI)1097-0215(19991126)83:5<640::AID-IJC13>3.0.CO;2-D; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Bowers DC, 2000, CANCER RES, V60, P4277; Brandes F, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1064-9; Caenepeel S, 2017, ONCOTARGET, V8, P17795, DOI 10.18632/oncotarget.14855; Canadas I, 2014, CLIN CANCER RES, V20, P938, DOI 10.1158/1078-0432.CCR-13-1330; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1; Cattley Russell C, 2004, Toxicol Pathol, V32 Suppl 1, P116, DOI 10.1080/01926230490426507; Chen JT, 2008, AM J RESP CELL MOL, V38, P559, DOI 10.1165/rcmb.2007-0001OC; Chen QY, 2016, ONCOTARGET, V7, P24510, DOI 10.18632/oncotarget.8229; Choi SW, 2010, SMALL, V6, P1492, DOI 10.1002/smll.201000544; Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470-2045(16)30107-3; Chu SH, 2010, ONCOL REP, V24, P189, DOI 10.3892/or_00000845; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Copin MC, 2016, LUNG CANCER, V101, P59, DOI 10.1016/j.lungcan.2016.09.009; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Cosse JP, 2008, ANTI-CANCER AGENT ME, V8, P790, DOI 10.2174/187152008785914798; Delitto D, 2014, WORLD J GASTROENTERO, V20, P8458, DOI 10.3748/wjg.v20.i26.8458; delPeso L, 1997, SCIENCE, V278, P687; Desbats MA, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00281; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Duval K, 2017, PHYSIOLOGY, V32, P266, DOI 10.1152/physiol.00036.2016; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Finisguerra V, 2015, NATURE, V522, P349, DOI 10.1038/nature14407; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Glodde N, 2017, IMMUNITY, V47, P789, DOI 10.1016/j.immuni.2017.09.012; Hage C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.158; Hara T, 2019, ANN SURG ONCOL, V26, P899, DOI 10.1245/s10434-018-07126-5; Hervieu A, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00086; Huang MG, 2016, J CLIN INVEST, V126, P1801, DOI 10.1172/JCI84876; Huang XX, 2017, AM J TRANSL RES, V9, P1667; Hughes Veronica S, 2019, Oncotarget, V10, P184, DOI 10.18632/oncotarget.26546; Hughes VS, 2018, TRENDS CANCER, V4, P94, DOI 10.1016/j.trecan.2017.11.009; Hung TH, 2015, CANCER GENE THER, V22, P262, DOI 10.1038/cgt.2015.15; Iveson T, 2014, LANCET ONCOL, V15, P1007, DOI 10.1016/S1470-2045(14)70023-3; Jia LZ, 2018, MED SCI MONITOR, V24, P8239, DOI 10.12659/MSM.913514; Jiang WG, 2001, CLIN CANCER RES, V7, P2555; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Jung KA, 2015, MOL PHARMACOL, V87, P465, DOI 10.1124/mol.114.096065; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; Ko B, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.09; Koch JP, 2020, ONCOGENE, V39, P2845, DOI 10.1038/s41388-020-1193-8; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Lasagna N, 2006, CANCER RES, V66, P2673, DOI 10.1158/0008-5472.CAN-05-2290; Lee CT, 2008, DIS COLON RECTUM, V51, P1268, DOI 10.1007/s10350-008-9297-1; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Li EZ, 2016, TUMOR BIOL, V37, P7843, DOI 10.1007/s13277-015-4318-x; Li M, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0420-2; Litman T, 2000, J CELL SCI, V113, P2011; Lu W, 2019, DEV CELL, V49, P361, DOI 10.1016/j.devcel.2019.04.010; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Marchion DC, 2013, ONCOL REP, V29, P2011, DOI 10.3892/or.2013.2329; Martin LP, 2014, GYNECOL ONCOL, V132, P526, DOI 10.1016/j.ygyno.2013.12.018; Matsumoto K, 1993, EXS, V65, P225; Medova Michaela, 2010, Genes Cancer, V1, P1053, DOI 10.1177/1947601910388030; Menard L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4907; Meng QH, 2000, BIOCHEM BIOPH RES CO, V274, P772, DOI 10.1006/bbrc.2000.3199; Moschetta M, 2013, CLIN CANCER RES, V19, P4371, DOI 10.1158/1078-0432.CCR-13-0039; Neklason DW, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-424; Nunes T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124036; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Organ Shawna Leslie, 2011, Ther Adv Med Oncol, V3, pS7, DOI 10.1177/1758834011422556; Ozasa H, 2014, CANCER SCI, V105, P1032, DOI 10.1111/cas.12447; Park WS, 1999, CANCER RES, V59, P307; Petterson SA, 2015, J NEURO-ONCOL, V122, P517, DOI 10.1007/s11060-015-1723-3; Pothula SP, 2017, ONCOTARGET, V8, P76722, DOI 10.18632/oncotarget.20822; Que WZ, 2011, MOL MED REP, V4, P343, DOI 10.3892/mmr.2011.426; Rajadurai CV, 2012, J CELL SCI, V125, P2940, DOI 10.1242/jcs.100834; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Rucki AA, 2017, MOL CANCER THER, V16, P2399, DOI 10.1158/1535-7163.MCT-16-0452; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Siegfried JM, 1998, ANN THORAC SURG, V66, P1915, DOI 10.1016/S0003-4975(98)01165-5; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Stacy AE, 2013, MOL PHARMACOL, V84, P655, DOI 10.1124/mol.113.088609; Sun S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166058; Tang MKS, 2010, NEOPLASIA, V12, P128, DOI 10.1593/neo.91438; Tang XL, 2017, J PHARMACOL SCI, V135, P1, DOI 10.1016/j.jphs.2017.06.006; Tovar EA, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.03.64; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Vaidyanathan A, 2016, BRIT J CANCER, V115, P431, DOI 10.1038/bjc.2016.203; van Leenders GJLH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026753; Wang J, 2017, CLIN EXP PHARMACOL P, V44, P79, DOI 10.1111/1440-1681.12672; Wang J, 2016, GENES DIS, V3, P3, DOI 10.1016/j.gendis.2016.01.002; Wang KL, 2012, ARCH BIOCHEM BIOPHYS, V526, P38, DOI 10.1016/j.abb.2012.07.003; Watermann I, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0362-5; Wei DY, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160470; Wolf J, 2019, J CLIN ONCOL, V37; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Yashiro M, 2013, BRIT J CANCER, V109, P2619, DOI 10.1038/bjc.2013.638; Yu ZR, 2012, INT J BIOCHEM CELL B, V44, P2144, DOI 10.1016/j.biocel.2012.08.022; Zhang QM, 2020, INT J NANOMED, V15, P2323, DOI 10.2147/IJN.S231214; Zhou H, 2011, J BIOL CHEM, V286, P25687, DOI 10.1074/jbc.M110.212944; Zhou JB, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00343	105	26	26	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					1927	1941		10.1038/s41388-020-01577-5	http://dx.doi.org/10.1038/s41388-020-01577-5		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33526881	hybrid, Green Published			2022-12-17	WOS:000613601600001
J	Yousefi, H; Vatanmakanian, M; Mahdiannasser, M; Mashouri, L; Alahari, NV; Monjezi, MR; Ilbeigi, S; Alahari, SK				Yousefi, Hassan; Vatanmakanian, Mousa; Mahdiannasser, Mojdeh; Mashouri, Ladan; Alahari, Nikhilesh V.; Monjezi, Mohammad Rafiee; Ilbeigi, Shahrzad; Alahari, Suresh K.			Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance	ONCOGENE			English	Review							BINDING PROTEIN NISCHARIN; ALPHA-V INTEGRINS; CELL-ADHESION; CLINICAL-SIGNIFICANCE; MONOCLONAL-ANTIBODY; TUMOR ANGIOGENESIS; LINKED KINASE; UP-REGULATION; PROMOTES RESISTANCE; THERAPEUTIC TARGETS	Integrins are cell adhesion receptors, which are typically transmembrane glycoproteins that connect to the extracellular matrix (ECM). The function of integrins regulated by biochemical events within the cells. Understanding the mechanisms of cell growth by integrins is important in elucidating their effects on tumor progression. One of the major events in integrin signaling is integrin binding to extracellular ligands. Another event is distant signaling that gathers chemical signals from outside of the cell and transmit the signals upon cell adhesion to the inside of the cell. In normal breast tissue, integrins function as checkpoints to monitor effects on cell proliferation, while in cancer tissue these functions altered. The combination of tumor microenvironment and its associated components determines the cell fate. Hypoxia can increase the expression of several integrins. The exosomal integrins promote the growth of metastatic cells. Expression of certain integrins is associated with increased metastasis and decreased prognosis in cancers. In addition, integrin-binding proteins promote invasion and metastasis in breast cancer. Targeting specific integrins and integrin-binding proteins may provide new therapeutic approaches for breast cancer therapies. This review will examine the current knowledge of integrins' role in breast cancer.	[Yousefi, Hassan; Vatanmakanian, Mousa; Alahari, Suresh K.] LSUHSC, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Mahdiannasser, Mojdeh] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran; [Mashouri, Ladan] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Alahari, Nikhilesh V.] Louisiana State Univ, Baton Rouge, LA 70803 USA; [Monjezi, Mohammad Rafiee] Shiraz Univ Med Sci, Dept Immunol, T Cell Memory Lab, Shiraz, Iran; [Ilbeigi, Shahrzad] Shiraz Univ Med Sci, Dept Med Genet, Shiraz, Iran	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Tehran University of Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Louisiana State University System; Louisiana State University; Shiraz University of Medical Science; Shiraz University of Medical Science	Alahari, SK (corresponding author), LSUHSC, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	salaha@lsuhsc.edu	Monjezi, Mohammad Rafiee/AAU-4322-2021	rafiee monjezi, mohammad/0000-0002-6765-9868; ilbeigi, Shahrzad/0000-0001-5143-7614				Abou Faycal C, 2018, BRIT J CANCER, V118, P1596, DOI 10.1038/s41416-018-0128-4; Adorno-Cruz V, 2019, BIORXIV, DOI 10.1101/583062; Ahmed KM, 2013, CANCER RES, V73, P3737, DOI 10.1158/0008-5472.CAN-12-3537; Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Alanko J, 2015, NAT CELL BIOL, V17, P1412, DOI 10.1038/ncb3250; Alday-Parejo B, 2019, CANCERS, V11, DOI 10.3390/cancers11070978; Alghisi GC, 2006, ENDOTHELIUM-J ENDOTH, V13, P113, DOI 10.1080/10623320600698037; Allan AL, 2006, AM J PATHOL, V169, P233, DOI 10.2353/ajpath.2006.051152; Aluwihare P, 2009, J CELL SCI, V122, P227, DOI 10.1242/jcs.035246; Annis MG, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0936-8; Aoudjit Fawzi, 2012, Chemother Res Pract, V2012, P283181, DOI 10.1155/2012/283181; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Ata R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010189; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Badaoui M, 2017, ONCOTARGET, V9, P24653, DOI DOI 10.18632/ONCOTARGET.19065; Bahrami A, 2018, J CELL BIOCHEM, V119, P213, DOI 10.1002/jcb.26136; Baltes F, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118663; Baranwal S, 2011, J NATL CANCER I, V103, P1513, DOI 10.1093/jnci/djr350; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Barnawi R, 2019, INT J CANCER, V145, P830, DOI 10.1002/ijc.32183; BARROWMCGEE R, 2016, NAT COMMUN, V7; Bendeck MP, 2000, ARTERIOSCL THROM VAS, V20, P1467, DOI 10.1161/01.ATV.20.6.1467; Berardi DE, 2017, CANCER RES TREAT, V49, P869, DOI 10.4143/crt.2016.378; Bianchi-Smiraglia A, 2013, ONCOGENE, V32, P3049, DOI 10.1038/onc.2012.320; Bierie B, 2017, P NATL ACAD SCI USA, V114, pE2337, DOI 10.1073/pnas.1618298114; Bill A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041179; Blandin AF, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00279; Boudreau N, 2003, BREAST CANCER RES, V5, P140, DOI 10.1186/bcr589; Brezillon S, 2013, FEBS J, V280, P2369, DOI 10.1111/febs.12210; Brooks DLP, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0510-x; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Campbell PS, 2019, J CELL PHYSIOL, V234, P108, DOI 10.1002/jcp.27013; Cao ZY, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0248-8; Casalou Cristina, 2016, Small GTPases, V7, P270; Cen JY, 2019, CANCERS, V11, DOI 10.3390/cancers11121946; Chen J, 2015, MOL MED REP, V12, P77, DOI 10.3892/mmr.2015.3373; Chen Q, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003257; Cheng Y, 2019, EUR J PHARM SCI, V128, P8, DOI 10.1016/j.ejps.2018.11.023; Chia WJ, 2009, BBA-REV CANCER, V1795, P110, DOI 10.1016/j.bbcan.2008.10.001; Chikina AS, 2019, BIOL CELL, V111, P245, DOI 10.1111/boc.201800078; Chiu YC, 2009, CARCINOGENESIS, V30, P1651, DOI 10.1093/carcin/bgp156; Choi J, 2015, LUNG CANCER, V90, P22, DOI 10.1016/j.lungcan.2015.06.023; Chung AH, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0740-2; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Clark AG, 2015, CURR OPIN CELL BIOL, V36, P13, DOI 10.1016/j.ceb.2015.06.004; Cooper J, 2019, CANCER CELL, V35, P347, DOI 10.1016/j.ccell.2019.01.007; Cordone I, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0827-4; Costa RLB, 2018, BREAST CANCER RES TR, V169, P397, DOI 10.1007/s10549-018-4697-y; Cui HX, 2011, ONCOL REP, V25, P1365, DOI 10.3892/or.2011.1192; da Silva RG, 2010, AM J PATHOL, V177, P1534, DOI 10.2353/ajpath.2010.100043; Danhier F, 2012, MOL PHARMACEUT, V9, P2961, DOI 10.1021/mp3002733; Davis PJ, 2016, NAT REV ENDOCRINOL, V12, P111, DOI 10.1038/nrendo.2015.205; De Franceschi N, 2015, J CELL SCI, V128, P839, DOI 10.1242/jcs.161653; Uzair ID, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00139; Desgrosellier JS, 2014, DEV CELL, V30, P295, DOI 10.1016/j.devcel.2014.06.005; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dewangan J, 2018, LIFE SCI, V193, P9, DOI 10.1016/j.lfs.2017.11.045; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; Ding YM, 2008, MOL CELL BIOL, V28, P3742, DOI 10.1128/MCB.01832-07; Dome B, 2005, INT J CANCER, V116, P27, DOI 10.1002/ijc.20991; Donate F, 2008, CLIN CANCER RES, V14, P2137, DOI 10.1158/1078-0432.CCR-07-4530; Dong SL, 2020, INT J CANCER, V146, P2576, DOI 10.1002/ijc.32690; Doolittle E, 2015, ACS NANO, V9, P8012, DOI 10.1021/acsnano.5b01552; dos Santos PB, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-104; Eastlack SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198945; Elaimy AL, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aau1165; EREMO AG, 2020, SCI REP UK, V10; Fang RP, 2020, ONCOGENE, V39, P2290, DOI 10.1038/s41388-019-1146-2; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; Foubert P, 2011, METHODS MOL BIOL, V757, P471, DOI 10.1007/978-1-61779-166-6_27; Fournier HN, 2002, J BIOL CHEM, V277, P20895, DOI 10.1074/jbc.M200200200; Freeman TC, 2013, BIOCHEMISTRY-US, V52, P7082, DOI 10.1021/bi400678y; Gajbhiye KR, 2019, J DRUG TARGET, V27, P111, DOI 10.1080/1061186X.2018.1473409; Gamble JR, 2009, AM J PATHOL, V175, P2217, DOI 10.2353/ajpath.2009.090076; Geiger C, 2000, EMBO J, V19, P2525, DOI 10.1093/emboj/19.11.2525; Germain M, 2010, J PATHOL, V220, P370, DOI 10.1002/path.2654; Ghatak S, 2016, AM J PATHOL, V186, P3011, DOI 10.1016/j.ajpath.2016.06.021; Gil-Bazo I, 2003, Rev Med Univ Navarra, V47, P22; Glenisson Mathilde, 2012, Genes Cancer, V3, P63, DOI 10.1177/1947601912449832; Gligorijevic B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001995; Glukhova MA, 2013, CURR OPIN CELL BIOL, V25, P633, DOI 10.1016/j.ceb.2013.06.010; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Goel HL, 2012, CELL ADHES MIGR, V6, P554, DOI 10.4161/cam.22419; Goodman SL, 2012, TRENDS PHARMACOL SCI, V33, P405, DOI 10.1016/j.tips.2012.04.002; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hamidi H, 2019, NAT REV CANCER, V19, P179, DOI 10.1038/s41568-019-0112-1; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanker AB, 2017, CANCER RES, V77, P3280, DOI 10.1158/0008-5472.CAN-16-2808; Hassan H, 2013, FEBS J, V280, P2216, DOI 10.1111/febs.12111; Hayashi H, 2008, J BIOL CHEM, V283, P23791, DOI 10.1074/jbc.M800190200; Hedrick E, 2017, MOL CARCINOGEN, V56, P2066, DOI 10.1002/mc.22662; Hersey P, 2010, CANCER-AM CANCER SOC, V116, P1526, DOI 10.1002/cncr.24821; Hirota S, 2015, DEVELOPMENT, V142, P4363, DOI 10.1242/dev.113746; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Hong IK, 2012, J BIOL CHEM, V287, P32027, DOI 10.1074/jbc.M111.314443; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hou S, 2016, SCI REP-UK, V6, DOI 10.1038/srep18430; Hsu EC, 2016, CARCINOGENESIS, V37, P430, DOI 10.1093/carcin/bgw020; Hsu EC, 2015, NEOPLASIA, V17, P497, DOI 10.1016/j.neo.2015.06.001; Huang R, 2018, DRUG DELIV, V25, P757, DOI 10.1080/10717544.2018.1446474; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098; Hussain M, 2016, CLIN CANCER RES, V22, P3192, DOI 10.1158/1078-0432.CCR-15-2512; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ibrahim SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085737; Indira Chandran Vineesh, 2015, Oncoscience, V2, P207; Flamini MI, 2017, HORM CANCER-US, V8, P16, DOI 10.1007/s12672-016-0280-3; Ivanova IA, 2013, ONCOGENE, V32, P5582, DOI 10.1038/onc.2013.277; Ivaska J, 2011, ANNU REV CELL DEV BI, V27, P291, DOI 10.1146/annurev-cellbio-092910-154017; Jain P, 2013, J BIOL CHEM, V288, P15495, DOI 10.1074/jbc.M112.418103; Jakubzig B, 2018, CANCERS, V10, DOI 10.3390/cancers10120495; Jiang L, 2017, BRIT J CANCER, V117, P695, DOI 10.1038/bjc.2017.214; Jin H, 2006, CANCER RES, V66, P2146, DOI 10.1158/0008-5472.CAN-05-2704; Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162; Ju JLA, 2017, MOL CANCER RES, V15, P723, DOI 10.1158/1541-7786.MCR-16-0338; Juliano R, 2004, INTEGRIN REGULATION; Kale S, 2015, ONCOGENE, V34, P5408, DOI 10.1038/onc.2015.315; Kapp TG, 2013, EXPERT OPIN THER PAT, V23, P1273, DOI 10.1517/13543776.2013.818133; Katoh D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.27; Katz E, 2007, INT J BIOCHEM CELL B, V39, P715, DOI 10.1016/j.biocel.2006.11.004; Keely S, 2009, FASEB J, V23, P1338, DOI 10.1096/fj.08-125344; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Koike T, 2004, P NATL ACAD SCI USA, V101, P8132, DOI 10.1073/pnas.0402088101; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Kovacheva M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194918; Kracun D, 2014, ANTIOXID REDOX SIGN, V20, P1964, DOI 10.1089/ars.2013.5286; Kwon A, 2020, J CELL PHYSIOL, V235, P4494, DOI 10.1002/jcp.29326; Kwon MJ, 2012, BRIT J CANCER, V106, P923, DOI 10.1038/bjc.2012.11; Lee JW, 2014, BMB REP, V47, P483, DOI 10.5483/BMBRep.2014.47.9.146; Lee SA, 2011, FRONT BIOSCI-LANDMRK, V16, P1752, DOI 10.2741/3818; Li DS, 2004, MOL CELL BIOL, V24, P3838, DOI 10.1128/MCB.24.9.3838-3848.2004; Li LQ, 2017, ONCOTARGET, V8, P106876, DOI 10.18632/oncotarget.22449; Li WT, 2015, ONCOL REP, V34, P1345, DOI 10.3892/or.2015.4103; Li YF, 2019, BIOMATERIALS, V188, P160, DOI 10.1016/j.biomaterials.2018.10.019; Li ZQ, 2018, ENDOCRINOLOGY, V159, P285, DOI 10.1210/en.2017-00693; Lin HY, 2016, STEROIDS, V114, P59, DOI 10.1016/j.steroids.2016.05.006; Lin HY, 2009, AM J PHYSIOL-CELL PH, V296, pC980, DOI 10.1152/ajpcell.00305.2008; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Liu Z, 2013, CURR MOL MED, V13, P1487, DOI 10.2174/1566524013666131111115347; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Loges Sonja, 2010, Genes Cancer, V1, P12, DOI 10.1177/1947601909356574; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Castiglioni JL, 2016, J APPL LOGIC, V15, P1, DOI [10.1016/j.jal.2015.11.001, 10.4103/1477-3163.176223]; Luo J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0694-6; Malek-Hosseini Z, 2017, BREAST CANCER-TOKYO, V24, P742, DOI 10.1007/s12282-017-0773-0; Maltsev OV, 2016, ANGEW CHEM INT EDIT, V55, P1535, DOI 10.1002/anie.201508709; Mardilovich K, 2009, CANCER RES, V69, P8894, DOI 10.1158/0008-5472.CAN-09-1152; Marelli UK, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00222; Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8; Marsico G, 2018, TRENDS CANCER, V4, P537, DOI 10.1016/j.trecan.2018.05.009; Martin TA, 2014, ONCOL REP, V31, P262, DOI 10.3892/or.2013.2813; Maziveyi M, 2019, CANCER RES, V79, P2152, DOI 10.1158/0008-5472.CAN-18-0842; Maziveyi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0764-6; Metwaly HA, 2018, ARCH BIOCHEM BIOPHYS, V652, P50, DOI 10.1016/j.abb.2018.06.007; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Momeny M., 2017, SCI REP, V7; Mon NN, 2017, ONCOL LETT, V13, P955, DOI 10.3892/ol.2016.5521; Moral MEG, 2017, CURR TOP MED CHEM, V17, P3425, DOI 10.2174/1568026618666180118154514; Moreno-Layseca P, 2019, NAT CELL BIOL, V21, P122, DOI 10.1038/s41556-018-0223-z; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; Moschos SJ, 2010, J IMMUNOTHER, V33, P316, DOI 10.1097/CJI.0b013e3181c1f216; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; Moule AP, 2014, BIOCHEM J, V464, P301, DOI 10.1042/BJ20141047; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Naik MU, 2011, INT J BIOCHEM CELL B, V43, P120, DOI 10.1016/j.biocel.2010.10.003; Naik MU, 2011, INT J CANCER, V128, P587, DOI 10.1002/ijc.25388; Nam JM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3454; Nam K, 2017, ONCOTARGET, V8, P35804, DOI 10.18632/oncotarget.16208; Nistico P, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0459-x; Novitskaya V, 2014, ONCOGENE, V33, P2779, DOI 10.1038/onc.2013.231; O'Day SJ, 2012, INVEST NEW DRUG, V30, P1074, DOI 10.1007/s10637-011-9639-z; Oh S, 2017, BMB REP, V50, P132, DOI 10.5483/BMBRep.2017.50.3.189; Ohtoshi A, 2000, BIOCHEM BIOPH RES CO, V267, P947, DOI 10.1006/bbrc.1999.2007; Pang MF, 2016, CANCER RES, V76, P5277, DOI 10.1158/0008-5472.CAN-16-0579; Park HJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56276-3; Patsialou A., 2013, INTRAVITAL, V2; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Peeney D, 2020, CARCINOGENESIS, V41, P313, DOI 10.1093/carcin/bgz172; Peng WJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53984-8; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Pio GM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177640; Porter HA, 2013, CANCER LETT, V338, P239, DOI 10.1016/j.canlet.2013.03.030; Pramanik D, 2008, J MED CHEM, V51, P7298, DOI 10.1021/jm800915y; Raab-Westphal S, 2017, CANCERS, V9, DOI 10.3390/cancers9090110; Radisky ES, 2015, FRONT BIOSCI-LANDMRK, V20, P1144, DOI 10.2741/4364; Ramovs V, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1146-8; Ranjan A, 2016, CANCER RES, V76, P877, DOI 10.1158/0008-5472.CAN-15-1233; Ratcliffe CDH, 2019, J CELL BIOL, V218, P285, DOI 10.1083/jcb.201804106; Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x; Ria T, 2002, HAEMATOLOGICA, V87, P836; Ricart AD, 2008, CLIN CANCER RES, V14, P7924, DOI 10.1158/1078-0432.CCR-08-0378; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; Rose A, 2011, ROLE GPNMB BREAST TU; Ruegg C, 2010, RECENT RESULTS CANC, V180, P83, DOI 10.1007/978-3-540-78281-0_6; Ruegg C, 2004, BBA-REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003; Ryu MH, 2010, BIOCHEM BIOPH RES CO, V393, P11, DOI 10.1016/j.bbrc.2010.01.060; Sainio Annele, 2014, Mol Cell Ther, V2, P14, DOI 10.1186/2052-8426-2-14; Sato H, 2015, CLIN EXP METASTAS, V32, P405, DOI 10.1007/s10585-015-9705-6; Sayyad MR, 2019, BREAST CANCER RES TR, V178, P35, DOI 10.1007/s10549-019-05347-0; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Senese R, 2014, J ENDOCRINOL, V221, pR1, DOI 10.1530/JOE-13-0573; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Sese M, 2017, ONCOTARGET, V8, P114856, DOI 10.18632/oncotarget.23145; Shahidi M, 2018, MED MOL MORPHOL, V51, P21, DOI 10.1007/s00795-017-0168-5; Shao N, 2015, CANCER LETT, V364, P165, DOI 10.1016/j.canlet.2015.05.009; Sharma C, 2012, CELL MOL LIFE SCI, V69, P2233, DOI 10.1007/s00018-012-0924-6; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Shen M, 2019, CANCER CELL, V35, P64, DOI 10.1016/j.ccell.2018.11.016; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Siddharth S, 2018, INT J BIOCHEM CELL B, V102, P151, DOI 10.1016/j.biocel.2018.07.011; Sin S, 2011, J NATL CANCER I, V103, P1323, DOI 10.1093/jnci/djr290; Singh C, 2018, BIOCHEM BIOPH RES CO, V499, P374, DOI 10.1016/j.bbrc.2018.03.169; Smuczek B, 2017, EXP CELL RES, V358, P323, DOI 10.1016/j.yexcr.2017.07.005; Sorensen BH, 2015, CELL PHYSIOL BIOCHEM, V36, P111, DOI 10.1159/000374057; Stewart RL, 2015, LAB INVEST, V95, P976, DOI 10.1038/labinvest.2015.82; Stipp CS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001355; Sun ZQ, 2019, NAT CELL BIOL, V21, P25, DOI 10.1038/s41556-018-0234-9; Tai YL, 2015, SCI REP-UK, V5, DOI 10.1038/srep16408; Tang CH, 2009, PROSTATE, V69, P1781, DOI 10.1002/pros.21029; Thomas GJ, 2001, J INVEST DERMATOL, V116, P898, DOI 10.1046/j.1523-1747.2001.01352.x; Tolomelli A, 2017, CANCERS, V9, DOI 10.3390/cancers9070078; Touihri-Barakati I, 2017, EUR J PHARMACOL, V797, P153, DOI 10.1016/j.ejphar.2017.01.006; Travis MA, 2003, TRENDS PHARMACOL SCI, V24, P192, DOI 10.1016/S0165-6147(03)00069-5; Trepat X, 2012, COMPR PHYSIOL, V2, P2369, DOI 10.1002/cphy.c110012; van der Flier A, 2010, DEVELOPMENT, V137, P2439, DOI 10.1242/dev.049551; Vicente-Manzanares M, 2018, CURR OPIN CELL BIOL, V55, P17, DOI 10.1016/j.ceb.2018.05.010; Villanueva J, 2008, CURR ONCOL REP, V10, P439, DOI 10.1007/s11912-008-0067-y; Vlahakis NE, 2007, J BIOL CHEM, V282, P15187, DOI 10.1074/jbc.M609323200; Wang PB, 2011, J CELL BIOL, V195, P499, DOI 10.1083/jcb.201104128; Wang XW, 2017, CELL PHYSIOL BIOCHEM, V43, P1413, DOI 10.1159/000481873; Wang ZS, 2019, INT J CANCER, V145, P2767, DOI 10.1002/ijc.32359; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wei R, 2017, J CANCER, V8, P2173, DOI 10.7150/jca.20480; Wirth M, 2014, EUR UROL, V65, P897, DOI 10.1016/j.eururo.2013.05.051; Yang L, 2015, ONCOTARGET, V6, P25755, DOI 10.18632/oncotarget.4697; Yang XWH, 2008, CANCER RES, V68, P3204, DOI 10.1158/0008-5472.CAN-07-2949; Yao HR, 2016, BREAST CANCER RES TR, V157, P489, DOI 10.1007/s10549-016-3844-6; Yin HL, 2016, INT J MOL SCI, V17; Yom CK, 2011, BREAST CANCER RES TR, V128, P647, DOI 10.1007/s10549-010-1150-2; You WK, 2014, ANGIOGENESIS, V17, P61, DOI 10.1007/s10456-013-9378-1; Yuan J, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0579-y; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang WZ, 2011, BRAZ J MED BIOL RES, V44, P642, DOI [10.1590/S0100-879X2011007500072, 10.1590/S0100-879X2011000700005]; Zhang Y, 2018, CELL PHYSIOL BIOCHEM, V46, P1737, DOI 10.1159/000489249; Zhu W, 2017, ONCOGENE, V36, P2619, DOI 10.1038/onc.2016.428; Zhu WY, 2017, CANCER RES, V77, P4823, DOI 10.1158/0008-5472.CAN-17-0025	253	26	27	5	31	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1043	1063		10.1038/s41388-020-01588-2	http://dx.doi.org/10.1038/s41388-020-01588-2		JAN 2021	21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33420366				2022-12-17	WOS:000607346000015
J	Gao, QZ; Zhou, R; Meng, Y; Duan, RF; Wu, L; Li, R; Deng, FL; Lin, C; Zhao, L				Gao, Qingzu; Zhou, Rui; Meng, Yuan; Duan, Rongfei; Wu, Ling; Li, Rui; Deng, Fengliu; Lin, Chuang; Zhao, Liang			Long noncoding RNA CMPK2 promotes colorectal cancer progression by activating the FUBP3-c-Myc axis	ONCOGENE			English	Article							FAR UPSTREAM ELEMENT; C-MYC; TRANSCRIPTION; PROTEINS; LNCRNA; LIM	Long noncoding RNAs (lncRNAs) have been shown to play crucial roles in cancer long noncoding RNAs (lncRNAs) have been known to play crucial roles in cancer development and progression by regulating chromatin dynamics and gene expression. However, only a few lncRNAs with annotated functions in the progression of colorectal cancer (CRC) have been identified to date. In the present study, the expression of lncCMPK2 was upregulated in CRC tissues and positively correlated with clinical stages and lymphatic metastasis. The overexpression of lncCMPK2 promoted the proliferation and cell cycle transition of CRC cells. Conversely, the silencing of lncCMPK2 restricted cell proliferation both in vitro and in vivo. lncCMPK2 was localized to the nucleus of CRC cells, bound to far upstream element binding protein 3 (FUBP3), and guided FUBP3 to the far upstream element (FUSE) of the c-Myc gene to activate transcription. lncCMPK2 also stabilized FUBP3. These results provide novel insights into the functional mechanism of lncCMPK2 in CRC progression and highlight its potential as a biomarker of advanced CRC and therapeutic target.	[Gao, Qingzu; Zhou, Rui; Meng, Yuan; Wu, Ling; Li, Rui; Deng, Fengliu; Lin, Chuang; Zhao, Liang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China; [Gao, Qingzu] Xinxiang Med Univ, Dept Pathol, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China; [Gao, Qingzu; Zhou, Rui; Wu, Ling; Li, Rui; Deng, Fengliu; Zhao, Liang] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China; [Meng, Yuan] Second Peoples Hosp Longgang Dist, Dept Pathol, Shenzhen, Peoples R China; [Duan, Rongfei] Xinxiang Med Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Peoples R China	Southern Medical University - China; Xinxiang Medical University; Southern Medical University - China; Xinxiang Medical University	Zhao, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China.	liangsmu@foxmail.com			National Natural Science Foundation of China [81572813, 81773082, 81702903, 81872423]; Guangdong Natural Science Foundation [2016A030313626, 2017A030310038, 2018B030311036]; Fork Ying Tung Education Foundation [161035]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Fork Ying Tung Education Foundation	This work was supported by the National Natural Science Foundation of China (nos. 81572813, 81773082, 81702903, and 81872423), Guangdong Natural Science Foundation (2016A030313626, 2017A030310038, 2018B030311036), and Fork Ying Tung Education Foundation (161035).	Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Beckedorff FC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003705; Bhan A, 2014, CHEMMEDCHEM, V9, P1932, DOI 10.1002/cmdc.201300534; Chen Q, 2018, CLIN CANCER RES, V24, P684, DOI 10.1158/1078-0432.CCR-17-0605; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Gonzalez V, 2010, ANNU REV PHARMACOL, V50, P111, DOI 10.1146/annurev.pharmtox.48.113006.094649; Gu J, 2018, CELL PHYSIOL BIOCHEM, V48, P194, DOI 10.1159/000491718; Hajjari M, 2015, CANCER BIOL MED, V12, P1, DOI 10.7497/j.issn.2095-3941.2015.0006; Han QR, 2019, ONCOGENE, V38, P3019, DOI 10.1038/s41388-018-0614-4; Huang HI, 2016, PROTEOMICS, V16, P2351, DOI 10.1002/pmic.201600098; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Kambara H, 2014, NUCLEIC ACIDS RES, V42, P10668, DOI 10.1093/nar/gku713; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112; Liu JH, 2017, FRONT BIOSCI-LANDMRK, V22, P66, DOI 10.2741/4472; Liu TY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0873-2; Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392; Malakar P, 2019, CANCER RES, V79, P2480, DOI 10.1158/0008-5472.CAN-18-1432; Mariotti B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00100; Munschauer M, 2018, NATURE, V561, P132, DOI 10.1038/s41586-018-0453-z; Naxerova K, 2017, SCIENCE, V357, P55, DOI 10.1126/science.aai8515; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Quinn LM, 2017, TRANSCR-AUSTIN, V8, P185, DOI 10.1080/21541264.2017.1293595; Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Silva JM, 2011, RNA BIOL, V8, P496, DOI 10.4161/rna.8.3.14800; Wang H, 2014, CLIN CANCER RES, V20, P5835, DOI 10.1158/1078-0432.CCR-14-0485; Wang ZH, 2018, CANCER CELL, V33, P706, DOI 10.1016/j.ccell.2018.03.006; Weber A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-369; Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739; Zheng P, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0216-3; Zubaidah RM, 2008, PROTEOMICS, V8, P5086, DOI 10.1002/pmic.200800322	41	26	26	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3926	3938		10.1038/s41388-020-1266-8	http://dx.doi.org/10.1038/s41388-020-1266-8		MAR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203166				2022-12-17	WOS:000520826900001
J	Janiszewska, M				Janiszewska, Michalina			The microcosmos of intratumor heterogeneity: the space-time of cancer evolution	ONCOGENE			English	Review							SINGLE-CELL ANALYSIS; BREAST-CANCER; BRANCHED EVOLUTION; IN-SITU; REVEALS; RESISTANCE; MUTATIONS; AMPLIFICATION; METASTASIS; RNA	The Cancer Genome Atlas consortium brought us terabytes of information about genetic alterations in different types of human tumors. While many cancer-driver genes have been identified through these efforts, interrogating cancer genomes has also shed new light on tumor complexity. Mutations were found to vary tremendously in their allelic frequencies within the same tumor. Based on those variant allelic frequencies grouping, an estimate of genetically distinct "clones" of cancer cells can be determined for each tumor. It was estimated that 4-8 clones are present in every human tumor. Presence of distinct clones, cells that differ in their genotype and/or phenotype, is one of the roots for the major challenge of effectively curing cancer patients. Any given treatment applied to a heterogeneous mixture of cancer cells will yield distinct responses in different cells and may be ineffective in killing particular clones. Moreover, in highly heterogeneous tumors, stochastically, there is a higher chance of presence of traits, such as point mutations in key receptor tyrosine kinases, that drive drug resistance. Thus, intratumor heterogeneity is like an arsenal, providing a variety of weapons for self-defense against cancer-targeted therapy. However, in this arsenal the supplies are constantly changing, as cancer cells are accumulating new mutations. What is also changing is the battlefield-the tumor microenvironment including all noncancerous cells within the tumor and surrounding tissue, which also contribute to the diversification of cancer's forces. In order to design more effective therapies that would target this ever-changing landscape, we need to learn more about the two elusive variables that shape the tumor ecosystem: the space-how could we exploit the organization of tumor microenvironment? and the time-how could we predict the changes in heterogeneous tumors?	[Janiszewska, Michalina] Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA	Scripps Research Institute	Janiszewska, M (corresponding author), Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA.	mjaniszewska@scripps.edu			NIH [R00 CA201606-01A1]; Scripps Research Institute	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Scripps Research Institute	I thank Dr Joseph Kissil (The Scripps Research Institute) and the Janiszewska lab members for insightful discussions. This work is supported by NIH R00 CA201606-01A1 and the startup funds provided by the Scripps Research Institute.	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; Angelo M, 2014, NAT MED, V20, P436, DOI 10.1038/nm.3488; Baker AM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02295-5; Ben-David U, 2018, NATURE, V560, P325, DOI 10.1038/s41586-018-0409-3; Berglund E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04724-5; Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841; Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Casasent AK, 2018, CELL, V172, P205, DOI 10.1016/j.cell.2017.12.007; Chevrier S, 2017, CELL, V169, P736, DOI 10.1016/j.cell.2017.04.016; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Gaiti F, 2019, NATURE, V569, P576, DOI 10.1038/s41586-019-1198-z; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gerdes MJ, 2013, P NATL ACAD SCI USA, V110, P11982, DOI 10.1073/pnas.1300136110; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giaretti W, 1996, AM J PATHOL, V149, P237; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/NMETH.2869, 10.1038/nmeth.2869]; Haber DA, 2014, CANCER DISCOV, V4, P650, DOI 10.1158/2159-8290.CD-13-1014; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hernandez L, 2012, J PATHOL, V227, P42, DOI 10.1002/path.3990; Hinohara K, 2019, TRENDS CELL BIOL, V29, P569, DOI 10.1016/j.tcb.2019.03.003; Hinohara K, 2019, CANCER CELL, V35, P330, DOI 10.1016/j.ccell.2019.01.012; Janiszewska M, 2019, NAT CELL BIOL, V21, P879, DOI 10.1038/s41556-019-0346-x; Janiszewska M, 2015, NAT GENET, V47, P1212, DOI 10.1038/ng.3391; Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P273, DOI 10.1038/nrclinonc.2016.25; KONISHI N, 1995, AM J PATHOL, V147, P1112; Lan XY, 2017, NATURE, V549, P227, DOI 10.1038/nature23666; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee CH, 2018, TRENDS IMMUNOL, V39, P536, DOI 10.1016/j.it.2018.04.005; Lee JH, 2014, SCIENCE, V343, P1360, DOI 10.1126/science.1250212; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Miller AM, 2019, NATURE, V565, P654, DOI 10.1038/s41586-019-0882-3; Miller CA, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003665; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Prager BC, 2019, CELL STEM CELL, V24, P41, DOI 10.1016/j.stem.2018.12.009; Reeves MQ, 2018, NAT CELL BIOL, V20, DOI 10.1038/s41556-018-0109-0; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]; Rye IH, 2018, MOL ONCOL, V12, P1838, DOI 10.1002/1878-0261.12375; Seol H, 2012, MODERN PATHOL, V25, P938, DOI 10.1038/modpathol.2012.36; Shema E, 2019, NAT GENET, V51, P19, DOI 10.1038/s41588-018-0290-x; Siegel MB, 2018, J CLIN INVEST, V128, P1371, DOI 10.1172/JCI96153; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Soucheray M, 2015, CANCER RES, V75, P4372, DOI 10.1158/0008-5472.CAN-15-0377; Stachler MD, 2015, NAT GENET, V47, P1047, DOI 10.1038/ng.3343; Stahl PL, 2016, SCIENCE, V353, P78, DOI 10.1126/science.aaf2403; Sun RP, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a028381; Tanay A, 2017, NATURE, V541, P331, DOI 10.1038/nature21350; Thrane K, 2018, CANCER RES, V78, P5970, DOI 10.1158/0008-5472.CAN-18-0747; Tsujikawa T, 2017, CELL REP, V19, P203, DOI 10.1016/j.celrep.2017.03.037; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Vogelstein B, 2015, NEW ENGL J MED, V373, P1895, DOI 10.1056/NEJMp1508811; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yizhak K, 2019, SCIENCE, V364, P970, DOI 10.1126/science.aaw0726; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930	69	26	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2031	2039		10.1038/s41388-019-1127-5	http://dx.doi.org/10.1038/s41388-019-1127-5			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31784650	Green Accepted			2022-12-17	WOS:000518584000001
J	Bessou, M; Lopez, J; Gadet, R; Deygas, M; Popgeorgiev, N; Poncet, D; Nougarede, A; Billard, P; Mikaelian, I; Gonzalo, P; Rimokh, R; Gillet, G				Bessou, Margaux; Lopez, Jonathan; Gadet, Rudy; Deygas, Mathieu; Popgeorgiev, Nikolay; Poncet, Delphine; Nougarede, Adrien; Billard, Pauline; Mikaelian, Ivan; Gonzalo, Philippe; Rimokh, Ruth; Gillet, Germain			The apoptosis inhibitor Bcl-xL controls breast cancer cell migration through mitochondria-dependent reactive oxygen species production	ONCOGENE			English	Article							ANION CHANNEL; ENDOPLASMIC-RETICULUM; CYTOCHROME-C; BH4 DOMAIN; BCL-X(L); FAMILY; CALCIUM; VDAC; METASTASIS; RELEASE	The Bcl-xL apoptosis inhibitor plays a major role in vertebrate development. In addition to its effect on apoptosis, Bcl-xL is also involved in cell migration and mitochondrial metabolism. These effects may favour the onset and dissemination of metastasis. However, the underlying molecular mechanisms remain to be fully understood. Here we focus on the control of cell migration by Bcl-xL in the context of breast cancer cells. We show that Bcl-xL silencing led to migration defects in Hs578T and MDA-MB231 cells. These defects were rescued by re-expressing mitochondria-addressed, but not endoplasmic reticulum-addressed, Bcl-xL. The use of BH3 mimetics, such as ABT-737 and WEHI-539 confirmed that the effect of Bcl-xL on migration did not depend on interactions with BH3-containing death accelerators such as Bax or BH3-only proteins. In contrast, the use of a BH4 peptide that disrupts the Bcl-xL/VDAC1 complex supports that Bcl-xL by acting on VDAC1 permeability contributes to cell migration through the promotion of reactive oxygen species production by the electron transport chain. Collectively our data highlight the key role of Bcl-xL at the interface between cell metabolism, cell death, and cell migration, thus exposing the VDAC1/Bcl-xL interaction as a promising target for anti-tumour therapy in the context of metastatic breast cancer.	[Bessou, Margaux; Lopez, Jonathan; Gadet, Rudy; Deygas, Mathieu; Popgeorgiev, Nikolay; Poncet, Delphine; Nougarede, Adrien; Billard, Pauline; Mikaelian, Ivan; Gonzalo, Philippe; Rimokh, Ruth; Gillet, Germain] Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, Ctr Leon Berard,INSERM 1052,CNRS 5286, F-69008 Lyon, France; [Lopez, Jonathan; Poncet, Delphine] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Ctr Biol Sud, Chemin Grand Revoyet, F-69495 Pierre Benite, France; [Gonzalo, Philippe] CHU St Etienne, Lab Biochim, F-42000 St Etienne, France; [Gillet, Germain] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Lab Anat & Cytol Pathol, Chemin Grand Revoyet, F-69495 Pierre Benite, France; [Deygas, Mathieu] Inst Curie, CNRS, UMR144, 6 Rue Jean Calvin, F-75005 Paris, France; [Nougarede, Adrien] CEA LETI, 17 Ave Martyrs, F-38000 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; CHU Lyon; CHU de St Etienne; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; CEA	Rimokh, R; Gillet, G (corresponding author), Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, Ctr Leon Berard,INSERM 1052,CNRS 5286, F-69008 Lyon, France.; Gillet, G (corresponding author), Hosp Civils Lyon, Ctr Hosp Lyon Sud, Lab Anat & Cytol Pathol, Chemin Grand Revoyet, F-69495 Pierre Benite, France.	ruth.rimokh@inserm.fr; germain.gillet@univ-lyon1.fr	gillet, germain/A-9095-2013; Poncet, Delphine A/A-7190-2016; Billard, Pauline/AAS-5731-2020	Poncet, Delphine A/0000-0003-0446-5262; Billard, Pauline/0000-0002-3255-0192; LOPEZ, Jonathan/0000-0003-3768-2378; Popgeorgiev, Nikolay/0000-0002-4835-5201; GILLET, Germain/0000-0002-1514-327X	AFM telethon [20269]; Fondation ARC [PGA1 RF20180206799, PJA 20161204606]	AFM telethon(Association Francaise contre les Myopathies); Fondation ARC	We would like to thank Stephane Borel for technical assistance, Julien Prudent for critical reading of the manuscript, Brigitte Manship for manuscript editing, Isabelle Goddard for skilful technical assistance regarding studies in mice (LMT, Lyon), and CIQLE core facility (SFR Sante Lyon-Est) for videomicroscopy. This work was supported by AFM telethon (to GG, grant #20269) and Fondation ARC to GG (grant #PGA1 RF20180206799) and JL (grant #PJA 20161204606).	Angelova PR, 2016, FREE RADICAL BIO MED, V100, P81, DOI 10.1016/j.freeradbiomed.2016.06.005; Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025; Ben-Hail D, 2016, BBA-MOL CELL RES, V1863, P1612, DOI 10.1016/j.bbamcr.2016.04.002; Bonneau B, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004480; Bonneau B, 2013, BBA-MOL CELL RES, V1833, P1755, DOI 10.1016/j.bbamcr.2013.01.021; Chen YB, 2011, J CELL BIOL, V195, P263, DOI 10.1083/jcb.201108059; Choi SY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10384; Dogterom M, 2019, NAT REV MOL CELL BIO, V20, P38, DOI 10.1038/s41580-018-0067-1; Du YCN, 2007, PLOS BIOL, V5, P2255, DOI 10.1371/journal.pbio.0050276; Eno CO, 2012, MOL BIOL CELL, V23, P2605, DOI 10.1091/mbc.E12-02-0090; Fernandez Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662; Fouque A, 2016, CELL DEATH DIFFER, V23, P1702, DOI 10.1038/cdd.2016.61; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Griffiths EJ, 2009, BBA-BIOENERGETICS, V1787, P1324, DOI 10.1016/j.bbabio.2009.01.019; Hager JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004455; Hardwick JM, 2012, TRENDS CELL BIOL, V22, P318, DOI 10.1016/j.tcb.2012.03.005; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Huang HY, 2013, J BIOL CHEM, V288, P19870, DOI 10.1074/jbc.M112.448290; Hwang KT, 2012, INT J CANCER, V131, pE1109, DOI 10.1002/ijc.27539; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Karczmarek-Borowska B, 2006, LUNG CANCER, V51, P61, DOI 10.1016/j.lungcan.2005.08.010; Kastl L, 2014, FEBS LETT, V588, P175, DOI 10.1016/j.febslet.2013.11.033; Keitel U, 2014, ONCOTARGET, V5, P11778, DOI 10.18632/oncotarget.2634; Lessene G, 2013, NAT CHEM BIOL, V9, P390, DOI [10.1038/nchembio.1246, 10.1038/NCHEMBIO.1246]; Li C, 2007, P NATL ACAD SCI USA, V104, P12565, DOI 10.1073/pnas.0702489104; Lim SK, 2012, CLIN EXP METASTAS, V29, P901, DOI 10.1007/s10585-012-9479-z; Lopez J, 2015, BRIT J CANCER, V112, P957, DOI 10.1038/bjc.2015.85; Ludin A, 2014, ANTIOXID REDOX SIGN, V21, P1605, DOI 10.1089/ars.2014.5941; Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595; Monaco G, 2015, J BIOL CHEM, V290, P9150, DOI 10.1074/jbc.M114.622514; Mookerjee SA, 2017, J BIOL CHEM, V292, P7189, DOI 10.1074/jbc.M116.774471; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nguyen MHT, 2005, ANN NY ACAD SCI, V1047, P127, DOI 10.1196/annals.1341.012; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Paupe V, 2018, BIOCHEM BIOPH RES CO, V500, P75, DOI 10.1016/j.bbrc.2017.05.039; Popgeorgiev N, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00013; Popgeorgiev N, 2011, DEV CELL, V20, P663, DOI 10.1016/j.devcel.2011.03.016; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Prudent J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3330; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rostovtseva TK, 2005, J BIOENERG BIOMEMBR, V37, P129, DOI 10.1007/s10863-005-6566-8; Schmitt E, 2007, ONCOGENE, V26, P5851, DOI 10.1038/sj.onc.1210396; Senju Y, 2019, CURR OPIN CELL BIOL, V56, P7, DOI 10.1016/j.ceb.2018.08.003; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Suzuki J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5153; Tan WZ, 2007, BBA-BIOMEMBRANES, V1768, P2510, DOI 10.1016/j.bbamem.2007.06.002; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Vander Heiden MG, 1999, MOL CELL, V3, P159; Vervliet T, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00075; Vogler M, 2011, BLOOD, V117, P7145, DOI 10.1182/blood-2011-03-344812; Watanabe J, 2002, INT J ONCOL, V21, P515; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Yang J, 2016, P NATL ACAD SCI USA, V113, pE1953, DOI 10.1073/pnas.1517935113; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308	58	26	26	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3056	3074		10.1038/s41388-020-1212-9	http://dx.doi.org/10.1038/s41388-020-1212-9		FEB 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32066881	Green Submitted			2022-12-17	WOS:000514052700002
J	Shen, JJ; Zhai, J; You, Q; Zhang, GX; He, MF; Yao, XQ; Shen, LZ				Shen, Jiajia; Zhai, Jing; You, Qiang; Zhang, Guoxin; He, Mingfang; Yao, Xuequan; Shen, Lizong			Cancer-associated fibroblasts-derived VCAM1 induced by H. pylori infection facilitates tumor invasion in gastric cancer	ONCOGENE			English	Article							CELL-ADHESION MOLECULE-1; HELICOBACTER-PYLORI; EXPRESSION; PROGNOSIS	Cancer-associated fibroblasts (CAFs) play a major role in the progression of stomach cancer, but the related mechanisms are not fully understood. H. pylori infection is recognized as one of the strongest risk factors for gastric carcinoma, but its effects on CAFs remain unknown. We aimed to determine the causative relationship between H. pylori infection in fibroblasts and the promoted cancer pathogenesis and progression in gastric cancer. Primary CAFs and normal activated fibroblasts (NAFs) were generated from gastric cancer patients. Gene signature of H. pylori-infected human stomach fibroblasts was performed using the RNA-seq analysis. Spheroid cell invasion assay and zebrafish cell line-derived xenograft (zCDX) model were introduced to evaluate tumor invasion induced by CAFs. The molecule interactions were determined using the kinetic binding analysis with the Biolayer Interferometry (BLI). Clinical significance and relevance were also assessed using the database analyses. H. pylori infection activated stomach fibroblasts and caused multiple gene alterations, including vascular adhesion molecule 1 (VCAM1). H. pylori infection increased VCAM1 expression in CAFs in gastric carcinoma via activation of JAK/STAT1 signaling pathway, and VCAM1 levels were positively associated with tumor progression and dismal prognosis in stomach cancer patients. Furthermore, CAFs-derived VCAM1 molecularly interacted with integrin alpha v beta 1/5 in gastric cancer cells facilitated tumor invasion in vitro and in vivo. Our results identify a novel mechanism underlying CAFs to promote tumor invasion during H. pylori infection. These studies facilitate us for a better understanding of the molecular process of gastric carcinoma progression, and provide the potential strategies for gastric cancer therapy.	[Shen, Jiajia; Shen, Lizong] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Div Gastrointestinal Surg, Nanjing 210029, Peoples R China; [Zhai, Jing; Yao, Xuequan] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Surg Oncol, Nanjing 210029, Peoples R China; [You, Qiang] Nanjing Med Univ, Affiliated Hosp 2, Dept Geriatr, Nanjing 210003, Peoples R China; [Zhang, Guoxin] Nanjing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanjing 210029, Peoples R China; [He, Mingfang] Nanjing Tech Univ, Coll Biotechnol & Pharmaceut Engn, Inst Translat Med, Nanjing 211800, Peoples R China	Nanjing Medical University; Nanjing University of Chinese Medicine; Nanjing Medical University; Nanjing Medical University; Nanjing Tech University	Shen, LZ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Div Gastrointestinal Surg, Nanjing 210029, Peoples R China.	shenlz@njmu.edu.cn		You, Qiang/0000-0003-3308-4127	National Natural Science Foundation of China [81272711, 81871959]; Priority Academic Program Development of Jiangsu Higher Education Institutions [JX10231801]; Key Medical Talents Program of Jiangsu Province [ZDRCA2016014]; Key R&D Program of Jiangsu Province (Social Development) [BE2018758]; Programs of Jiangsu Province Hospital of Chinese Medicine [Y2018RC14, Y2018CX71]; Jiangsu Graduate Research Innovation Program [KYCX18_1479]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions; Key Medical Talents Program of Jiangsu Province; Key R&D Program of Jiangsu Province (Social Development); Programs of Jiangsu Province Hospital of Chinese Medicine; Jiangsu Graduate Research Innovation Program	This work was supported by the National Natural Science Foundation of China (Grant Nos. 81272711 and 81871959 to LS), the Priority Academic Program Development of Jiangsu Higher Education Institutions (JX10231801 to LS), the Key Medical Talents Program of Jiangsu Province (ZDRCA2016014 to LS), the Key R&D Program of Jiangsu Province (Social Development, BE2018758 to LS), the Programs of Jiangsu Province Hospital of Chinese Medicine (Y2018RC14 to LS and Y2018CX71 to JZ), and the Jiangsu Graduate Research Innovation Program (KYCX18_1479 to JS).	Attieh Y, 2017, J CELL BIOL, V216, P3509, DOI 10.1083/jcb.201702033; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cerutti C, 2017, EXP CELL RES, V358, P31, DOI 10.1016/j.yexcr.2017.06.003; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Coburn N, 2018, CANCER TREAT REV, V63, P104, DOI 10.1016/j.ctrv.2017.12.006; Crowe SE, 2019, NEW ENGL J MED, V380, P1158, DOI 10.1056/NEJMcp1710945; Fujii S, 2015, CANCER MED-US, V4, P1667, DOI 10.1002/cam4.515; Galamb O, 2008, HELICOBACTER, V13, P112, DOI 10.1111/j.1523-5378.2008.00584.x; Horvat A, 2018, ONCOGENE, V37, P5054, DOI 10.1038/s41388-018-0343-8; Huelsken J, 2018, CELL, V172, P643, DOI 10.1016/j.cell.2018.01.028; Ishimoto T, 2017, GASTROENTEROLOGY, V153, P191, DOI 10.1053/j.gastro.2017.03.046; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karakasheva TA, 2018, CANCER RES, V78, P4957, DOI 10.1158/0008-5472.CAN-17-2268; Kiga K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5497; Kong DH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041057; Krzysiek-Maczka G, 2013, J PHYSIOL PHARMACOL, V64, P77; Krzysiek-Maczka G, 2018, HELICOBACTER, V23, DOI 10.1111/hel.12538; LeBleu VS, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.029447; Liu CJ, 2018, CANCERS, V10, DOI 10.3390/cancers10120479; Liu YS, 2017, ONCOGENE, V36, P5006, DOI 10.1038/onc.2017.129; Maeda M, 2020, GUT, V69, P243, DOI 10.1136/gutjnl-2018-317645; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; Satoyoshi R, 2015, ONCOGENE, V34, P650, DOI 10.1038/onc.2013.584; Scalici JM, 2017, CANCER-AM CANCER SOC, V123, P977, DOI 10.1002/cncr.30415; Schlesinger M, 2015, INT J CANCER, V136, P2504, DOI 10.1002/ijc.28927; Sharma R, 2017, CELL ONCOL, V40, P199, DOI 10.1007/s13402-017-0324-x; Sigal M, 2017, NATURE, V548, P451, DOI 10.1038/nature23642; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Terai S, 2015, GASTRIC CANCER, V18, P306, DOI 10.1007/s10120-014-0380-0; Tichet M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7993; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Velikova G, 1997, BRIT J CANCER, V76, P1398, DOI 10.1038/bjc.1997.569; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang XF, 2017, INT J CANCER, V141, P998, DOI 10.1002/ijc.30801; Wen JF, 2018, ONCOGENE, V37, P3549, DOI 10.1038/s41388-018-0208-1; Wu JQ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0631-0; Yang L, 2018, CHINESE J CANCER RES, V30, P291, DOI 10.21147/j.issn.1000-9604.2018.03.01; Zhai J, 2019, CANCER LETT, V454, P37, DOI 10.1016/j.canlet.2019.04.002	42	26	28	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2961	2974		10.1038/s41388-020-1197-4	http://dx.doi.org/10.1038/s41388-020-1197-4		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034307				2022-12-17	WOS:000511752600001
J	Xiao, Y; Liu, GD; Sun, Y; Gao, Y; Ouyang, XW; Chang, CS; Gong, LS; Yeh, SY				Xiao, Yao; Liu, Guodong; Sun, Yin; Gao, Yuan; Ouyang, Xiwu; Chang, Chawnshang; Gong, Liansheng; Yeh, Shuyuan			Targeting the estrogen receptor alpha (ER alpha)-mediated circ-SMG1.72/miR-141-3p/Gelsolin signaling to better suppress the HCC cell invasion	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CIRCULAR RNA; GENDER DISPARITY; CANCER; PROLIFERATION; GELSOLIN; EXPRESSION; GROWTH; OVEREXPRESSION; MECHANISMS	Early studies indicated that estrogen receptor alpha (ER alpha) might impact the progression of hepatocellular carcinoma (HCC). However, the detailed mechanisms, especially its linkage to the gelsolin (GSN)-mediated cell invasion, remain unclear. Here we found that ER alpha could decrease HCC cell invasion via suppressing the circular RNA-SMG1.72 (circRNA-SMG1.72) expression via transcriptional regulation through directly binding to the 5 ' promoter region of its host gene SMG1, We showed that ER alpha-suppressed circ-SMG1.72 could sponge and inhibit the expression of the microRNA (miRNA, miR), miR-141-3p, which could then result in increasing the GSN messenger RNA translation via reduced miR binding to its 3 ' untranslated region (3 ' UTR). The preclinical study using an in vivo mouse model with orthotopic xenografts of HCC cells confirmed the in vitro data, and the human HCC clinical sample survey and tissue staining also confirmed the linkage of ER alpha/miR-141-3p/GSN signaling to the HCC progression. Together, our findings suggest that ER alpha can suppress HCC cell invasion via altering the ER alpha/circRNA-SMG1.72/miR-141-3p/GSN signaling, and targeting this newly identified signaling with small molecules may help in the development of novel therapies to better suppress the HCC progression.	[Xiao, Yao; Liu, Guodong; Gong, Liansheng] Cent South Univ, Xiangya Hosp, Dept Hepatobiliary & Pancreat Surg, Changsha 410008, Peoples R China; [Xiao, Yao; Liu, Guodong; Sun, Yin; Gao, Yuan; Ouyang, Xiwu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; [Xiao, Yao; Liu, Guodong; Sun, Yin; Gao, Yuan; Ouyang, Xiwu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; [Xiao, Yao; Liu, Guodong; Sun, Yin; Gao, Yuan; Ouyang, Xiwu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA; [Xiao, Yao; Liu, Guodong; Sun, Yin; Gao, Yuan; Ouyang, Xiwu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, Wilmot Canc Ctr Inst, Rochester, NY 14642 USA	Central South University; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Gong, LS (corresponding author), Cent South Univ, Xiangya Hosp, Dept Hepatobiliary & Pancreat Surg, Changsha 410008, Peoples R China.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Ctr Inst, Rochester, NY 14642 USA.	gongliansheng8280@163.com; Shuyuan_Yeh@URMC.Rochester.edu	xiao, yao/AEX-1775-2022	Chang, Chawnshang/0000-0001-8510-3516; Xiao, Yao/0000-0002-4638-4148; Liu, Guodong/0000-0003-1922-2538	George Whipple Professorship Endowment; National Natural Science Foundation of China [81903004]; The 12th Five-year Key Discipline Construction in Hunan Province (Biomedical Engineering)	George Whipple Professorship Endowment; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); The 12th Five-year Key Discipline Construction in Hunan Province (Biomedical Engineering)	This work was supported by George Whipple Professorship Endowment, National Natural Science Foundation of China (81903004) and The 12th Five-year Key Discipline Construction in Hunan Province (Biomedical Engineering). We thank Karen Wolf for help preparing the manuscript.	Ahlbory-Dieker DL, 2009, MOL ENDOCRINOL, V23, P1544, DOI 10.1210/me.2009-0045; Bai RX, 2018, CARBOHYD POLYM, V190, P255, DOI 10.1016/j.carbpol.2018.02.059; Chen CF, 2010, HEPATOLOGY, V52, P1690, DOI 10.1002/hep.23847; Chen JJ, 2015, ONCOL REP, V33, P792, DOI 10.3892/or.2014.3647; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; Chen Q, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.142; Chow PKH, 2002, HEPATOLOGY, V36, P1221, DOI 10.1053/jhep.2002.36824; Deng BA, 2015, GENE, V571, P292, DOI 10.1016/j.gene.2015.06.083; Deng L, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0248-0; Deng RZ, 2015, ONCOL LETT, V9, P2129, DOI 10.3892/ol.2015.3002; Ding M, 2018, J CELL BIOCHEM, V119, P9974, DOI 10.1002/jcb.27326; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; El-Serag HB, 2001, HEPATOLOGY, V33, P62, DOI 10.1053/jhep.2001.21041; Fu LY, 2017, ONCOTARGET, V8, P58405, DOI 10.18632/oncotarget.16881; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gu J, 2018, CELL PHYSIOL BIOCHEM, V48, P194, DOI 10.1159/000491718; Gu J, 2018, CANCER LETT, V434, P1, DOI 10.1016/j.canlet.2018.06.039; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jiang SY, 1995, J HEPATOL, V23, P712, DOI 10.1016/0168-8278(95)80038-7; Kavoosi Fraidoon, 2016, Adv Biomed Res, V5, P133, DOI 10.4103/2277-9175.187395; Kramer MC, 2015, GENE DEV, V29, P2168, DOI 10.1101/gad.270421.115; Lader AS, 2005, EXP CELL RES, V307, P153, DOI 10.1016/j.yexcr.2005.03.001; Li GH, 2012, MED RES REV, V32, P999, DOI 10.1002/med.20231; Li Z, 2012, CELL, V148, P72, DOI 10.1016/j.cell.2011.11.026; Liao CJ, 2011, GYNECOL ONCOL, V120, P135, DOI 10.1016/j.ygyno.2010.10.005; Liu CH, 2018, MOL THER, V26, P2267, DOI 10.1016/j.ymthe.2018.06.019; Liu CH, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0619-z; Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029; Maynadier M, 2008, FASEB J, V22, P671, DOI 10.1096/fj.07-9322com; Megger DA, 2013, MOL CELL PROTEOMICS, V12, P2006, DOI 10.1074/mcp.M113.028027; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Nathan S, 2017, BREAST CANCER RES TR, V166, P681, DOI 10.1007/s10549-017-4442-y; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Njei B, 2018, OBES SURG, V28, P3880, DOI 10.1007/s11695-018-3431-5; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; Sayeed A, 2007, CANCER RES, V67, P7746, DOI 10.1158/0008-5472.CAN-06-3724; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Tang YY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0825-x; Tian MQ, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22281; Treiber T, 2012, THROMB HAEMOSTASIS, V107, P605, DOI 10.1160/TH11-12-0836; Villa E, 2002, MOL CELL ENDOCRINOL, V193, P65, DOI 10.1016/S0303-7207(02)00097-7; Wang SH, 2015, J GASTROEN HEPATOL, V30, P1237, DOI 10.1111/jgh.12934; Wang SH, 2012, GASTROENTEROLOGY, V142, P989, DOI 10.1053/j.gastro.2011.12.045; Wu H, 2017, J HEPATOL, V66, P1193, DOI 10.1016/j.jhep.2017.01.030; Yang W, 2016, ONCOGENE, V35, P3919, DOI 10.1038/onc.2015.460; Yin WB, 2018, CLIN CHIM ACTA, V487, P363, DOI 10.1016/j.cca.2017.10.011; Yu MW, 2003, HEPATOLOGY, V38, P1393, DOI 10.1016/j.hep.2003.09.041; Zhou JC, 2013, ONCOL REP, V30, P1622, DOI 10.3892/or.2013.2610; Zlotorynski E, 2015, NAT REV MOL CELL BIO, V16, DOI 10.1038/nrm4079; Zuo QF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.573	54	26	26	5	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2493	2508		10.1038/s41388-019-1150-6	http://dx.doi.org/10.1038/s41388-019-1150-6		JAN 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31996784				2022-12-17	WOS:000510136400001
J	Singh, JP; Qian, K; Lee, JS; Zhou, JF; Han, XM; Zhang, BC; Ong, QX; Ni, WM; Jiang, MZ; Ruan, HB; Li, MD; Zhang, KS; Ding, ZB; Lee, P; Singh, K; Wu, J; Herzog, RI; Kaech, S; Wendel, HG; Yates, III; Han, WP; Sherwin, RS; Nie, YZ; Yang, XY				Singh, Jay Prakash; Qian, Kevin; Lee, Jeong-Sang; Zhou, Jinfeng; Han, Xuemei; Zhang, Bichen; Ong, Qunxiang; Ni, Weiming; Jiang, Mingzuo; Ruan, Hai-Bin; Li, Min-Dian; Zhang, Kaisi; Ding, Zhaobing; Lee, Philip; Singh, Kamini; Wu, Jing; Herzog, Raimund, I; Kaech, Susan; Wendel, Hans-Guido; Yates, John R., III; Han, Weiping; Sherwin, Robert S.; Nie, Yongzhan; Yang, Xiaoyong			O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth	ONCOGENE			English	Article							CANCER METABOLISM; TRANSFERASE; PROMOTES; PROTEIN; ACETYLTRANSFERASE; GENERATION; ISOFORM; NEURONS; DOMAIN; CELLS	Cancer cells are known to adopt aerobic glycolysis in order to fuel tumor growth, but the molecular basis of this metabolic shift remains largely undefined. O-GlcNAcase (OGA) is an enzyme harboring O-linked beta-N-acetylglucosamine (O-GlcNAc) hydrolase and cryptic lysine acetyltransferase activities. Here, we report that OGA is upregulated in a wide range of human cancers and drives aerobic glycolysis and tumor growth by inhibiting pyruvate kinase M2 (PKM2). PKM2 is dynamically O-GlcNAcylated in response to changes in glucose availability. Under high glucose conditions, PKM2 is a target of OGA-associated acetyltransferase activity, which facilitates O-GlcNAcylation of PKM2 by O-GlcNAc transferase (OGT). O-GlcNAcylation inhibits PKM2 catalytic activity and thereby promotes aerobic glycolysis and tumor growth. These studies define a causative role for OGA in tumor progression and reveal PKM2 O-GlcNAcylation as a metabolic rheostat that mediates exquisite control of aerobic glycolysis.	[Singh, Jay Prakash; Qian, Kevin; Lee, Jeong-Sang; Zhang, Bichen; Ong, Qunxiang; Ni, Weiming; Ruan, Hai-Bin; Li, Min-Dian; Zhang, Kaisi; Wu, Jing; Yang, Xiaoyong] Yale Univ, Sch Med, Program Integrat Cell Signaling & Neurobiol Metab, 333 Cedar St, New Haven, CT 06519 USA; [Singh, Jay Prakash; Qian, Kevin; Lee, Jeong-Sang; Zhang, Bichen; Ong, Qunxiang; Ni, Weiming; Ruan, Hai-Bin; Li, Min-Dian; Zhang, Kaisi; Wu, Jing; Yang, Xiaoyong] Yale Univ, Dept Comparat Med, Sch Med, 333 Cedar St, New Haven, CT 06519 USA; [Qian, Kevin; Li, Min-Dian; Zhang, Kaisi; Yang, Xiaoyong] Yale Univ, Dept Cellular & Mol Physiol, Sch Med, 333 Cedar St, New Haven, CT 06519 USA; [Zhou, Jinfeng; Jiang, Mingzuo; Nie, Yongzhan] Fourth Mil Med Univ, Xijing Hosp Digest Dis, State Key Lab Canc Biol, 127 West Changle Rd, Xian 710032, Shaanxi, Peoples R China; [Han, Xuemei; Yates, John R., III] Scripps Res Inst, Dept Chem Physiol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA; [Ong, Qunxiang; Ding, Zhaobing; Lee, Philip; Han, Weiping] Singapore Bioimaging Consortium, Singapore, Singapore; [Singh, Kamini; Wendel, Hans-Guido] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Wu, Jing] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Xian 710049, Shaanxi, Peoples R China; [Herzog, Raimund, I; Sherwin, Robert S.] Yale Univ, Dept Med, Sch Med, 333 Cedar St, New Haven, CT 06519 USA; [Kaech, Susan] Yale Univ, Dept Immunobiol, Sch Med, 333 Cedar St, New Haven, CT 06519 USA	Yale University; Yale University; Yale University; Air Force Military Medical University; Scripps Research Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Bioengineering & Bioimaging (IBB); A*STAR - Singapore Bioimaging Consortium (SBIC); Memorial Sloan Kettering Cancer Center; Xi'an Jiaotong University; Yale University; Yale University	Yang, XY (corresponding author), Yale Univ, Sch Med, Program Integrat Cell Signaling & Neurobiol Metab, 333 Cedar St, New Haven, CT 06519 USA.; Yang, XY (corresponding author), Yale Univ, Dept Comparat Med, Sch Med, 333 Cedar St, New Haven, CT 06519 USA.; Yang, XY (corresponding author), Yale Univ, Dept Cellular & Mol Physiol, Sch Med, 333 Cedar St, New Haven, CT 06519 USA.	xiaoyong.yang@yale.edu	Zhang, Bichen/ABH-3118-2020; Li, Min-Dian/F-1721-2015; Ruan, Hai-Bin/AAN-7777-2021	Li, Min-Dian/0000-0002-3650-1507; Ruan, Hai-Bin/0000-0002-3858-1272; Zhang, Bichen/0000-0002-0150-1267; Ding, Zhaobing/0000-0002-8812-298X	NIH [R01 DK089098, P01 DK057751]; Yale Comprehensive Cancer Center Pilot Grant; American Cancer Society Research Scholar Grant	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yale Comprehensive Cancer Center Pilot Grant; American Cancer Society Research Scholar Grant(American Cancer Society)	We thank Dr. Jinbo Yang for providing the Flag-PKM2 plasmid and shPKM2 lentivirus. We thank Dr. Julie T. Feldstein for helping with immunohistochemical analysis of human cancer tissues. We thank Dr. Neeraj Tiwari for helping with sucrose density gradient ultracentrifugation. This work was supported by NIH R01 DK089098, P01 DK057751, Yale Comprehensive Cancer Center Pilot Grant, and American Cancer Society Research Scholar Grant to XY.	Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; ASHIZAWA K, 1991, J BIOL CHEM, V266, P16842; Bond MR, 2013, ANNU REV NUTR, V33, P205, DOI 10.1146/annurev-nutr-071812-161240; Bowe DB, 2006, MOL CELL BIOL, V26, P8539, DOI 10.1128/MCB.01053-06; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hayakawa K, 2013, J BIOL CHEM, V288, P17099, DOI 10.1074/jbc.M113.455899; He Y, 2014, ACTA CRYSTALLOGR D, V70, P186, DOI 10.1107/S1399004713029155; Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Krzeslak A, 2012, CLIN EXP MED, V12, P61, DOI 10.1007/s10238-011-0138-5; Li MD, 2013, CELL METAB, V17, P303, DOI 10.1016/j.cmet.2012.12.015; Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135; Lv L, 2013, MOL CELL, V52, P340, DOI 10.1016/j.molcel.2013.09.004; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Ong QX, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00599; Patel AB, 2005, P NATL ACAD SCI USA, V102, P5588, DOI 10.1073/pnas.0501703102; Qian KV, 2018, J BIOL CHEM, V293, P13989, DOI 10.1074/jbc.RA118.004709; Rao FV, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.130021; Ruan HB, 2014, CELL, V159, P306, DOI 10.1016/j.cell.2014.09.010; Ruan HB, 2013, TRENDS ENDOCRIN MET, V24, P301, DOI 10.1016/j.tem.2013.02.002; Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006; Singh JP, 2015, CANCER LETT, V356, P244, DOI 10.1016/j.canlet.2014.04.014; Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Toleman C, 2004, J BIOL CHEM, V279, P53665, DOI 10.1074/jbc.M410406200; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whisenhunt TR, 2006, GLYCOBIOLOGY, V16, P551, DOI 10.1093/glycob/cwj096; Yang WW, 2013, CANCER LETT, V339, P153, DOI 10.1016/j.canlet.2013.06.008; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang XY, 2008, NATURE, V451, P964, DOI 10.1038/nature06668; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22; Yang YR, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.24; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278; Zhang KS, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00221	41	26	26	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					560	573		10.1038/s41388-019-0975-3	http://dx.doi.org/10.1038/s41388-019-0975-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31501520	Green Accepted			2022-12-17	WOS:000509718300006
J	Yang, SS; Ren, XL; Liang, YS; Yan, YR; Zhou, YS; Hu, JL; Wang, ZZ; Song, FY; Wang, FF; Liao, WJ; Liao, WT; Ding, YQ; Liang, L				Yang, Shaoshan; Ren, Xiaoli; Liang, Yunshi; Yan, Yongrong; Zhou, Yangshu; Hu, Jinlong; Wang, Zhizhi; Song, Fuyao; Wang, Feifei; Liao, Wangjun; Liao, Wenting; Ding, Yanqing; Liang, Li			KNK437 restricts the growth and metastasis of colorectal cancer via targeting DNAJA1/CDC45 axis	ONCOGENE			English	Article							SHOCK-PROTEIN 27; CELL LUNG-CANCER; EMERGING ROLES; DNAJ HOMOLOG; HEAT; INHIBITOR; IDENTIFICATION; GANETESPIB; EXPRESSION; RESISTANCE	As an inhibitor of heat shock proteins (HSPs), KNK437 has been reported to play an anti-tumor role in several cancers. But its therapeutic effect and mechanisms in colorectal cancer (CRC) remain unclear. Here, KNK437 sharply inhibited the level of DnaJ heat shock protein family (Hsp40) member A1 (DNAJA1), followed by DNAJB1, but had little effect on the levels of HSP27, HSP105, HSP90, and HSP70 in CRC cells. DNAJA1 promoted CRC cell proliferation in vitro and tumor growth and metastasis in vivo. Mechanistically, DNAJA1 was activated by E2F transcription factor 1 (E2F1) and then promoted cell cycle by stabilizing cell division cycle protein 45 (CDC45), which could be reversed by KNK437. DNAJA1 was significantly upregulated in CRC tissues and positively correlated with serosa invasion, lymph node metastasis. High level of DNAJA1 predicted poor prognosis for CRC patients. Its expression was highly linked with E2F1 and CDC45 in CRC tissues. More importantly, KNK437 significantly suppressed the growth of DNAJA1 expressing tumor in vivo. The combined treatment of KNK437 with 5-FU/L-OHP chemotherapy reduced liver metastasis of CRC. These data reveal a novel mechanism of KNK437 in anti-tumor therapy of CRC and provides a newly therapeutic strategy with potential translation to the CRC patients.	[Yang, Shaoshan; Ren, Xiaoli; Liang, Yunshi; Yan, Yongrong; Zhou, Yangshu; Hu, Jinlong; Wang, Zhizhi; Song, Fuyao; Wang, Feifei; Liao, Wenting; Ding, Yanqing; Liang, Li] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Yang, Shaoshan; Ren, Xiaoli; Liang, Yunshi; Yan, Yongrong; Zhou, Yangshu; Hu, Jinlong; Wang, Zhizhi; Song, Fuyao; Wang, Feifei; Liao, Wenting; Ding, Yanqing; Liang, Li] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Yang, Shaoshan] Shantou Univ, Med Coll, Affiliated Hosp 2, Dept Pathol, Shantou 515041, Guangdong, Peoples R China; [Liao, Wangjun] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Shantou University; Southern Medical University - China	Liang, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.; Liang, L (corresponding author), Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China.	lli@fimmu.com	Liao, Yulin/AAP-6315-2021; liang, li/AAB-9126-2022		National key R&D program of China [2017YFC1309002]; National Basic Research Program of China (973 Program) [2015CB554002]; National Natural Science Foundation of China [81672821, 81472313, 81773101, 81272759, 81401927, 81302151, 81802306]; China Postdoctoral Science Foundation [2018M633081, 2018M633079]; Natural Science Foundation of Guangdong Province [2018A030310457]	National key R&D program of China; National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This work was supported by the National key R&D program of China (2017YFC1309002), National Basic Research Program of China (973 Program, 2015CB554002), National Natural Science Foundation of China (81672821, 81472313, 81773101, 81272759, 81401927, 81302151, and 81802306), Project funded by China Postdoctoral Science Foundation (2018M633081 and 2018M633079), Natural Science Foundation of Guangdong Province (2018A030310457).	Ban HS, 2016, BIOCONJUGATE CHEM, V27, P1911, DOI 10.1021/acs.bioconjchem.6b00305; Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Barrio S, 2013, BRIT J HAEMATOL, V161, P667, DOI 10.1111/bjh.12308; Bauerschmidt C, 2007, GENES CELLS, V12, P745, DOI 10.1111/j.1365-2443.2007.01090.x; Bodoor Khaldon, 2016, Asian Pac J Cancer Prev, V17, P3929; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Gibbs SJ, 2008, NEUROBIOL DIS, V32, P196, DOI 10.1016/j.nbd.2008.07.016; Hadchity E, 2009, MOL THER, V17, P1387, DOI 10.1038/mt.2009.90; Haggerty TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114506; Haider S, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0105-3; Hardy CFJ, 1997, GENE, V187, P239, DOI 10.1016/S0378-1119(96)00761-5; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Jagadish N, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0425-9; Jhaveri K, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0879-5; Kimura A, 2017, WORLD J GASTROENTERO, V23, P7541, DOI 10.3748/wjg.v23.i42.7541; Kotlarz A, 2013, CELL STRESS CHAPERON, V18, P653, DOI 10.1007/s12192-013-0407-1; Kudryavtsev VA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173640; Kuramitsu Y, 2012, ANTICANCER RES, V32, P2295; Lee HG, 2017, ONCOL LETT, V13, P2817, DOI 10.3892/ol.2017.5794; Li HY, 2017, NEOPLASMA, V64, P22, DOI 10.4149/neo_2017_103; Matijasevic Z, 1998, ONCOL RES, V10, P605; Meshalkina DA, 2016, ONCOTARGET, V7, P22050, DOI 10.18632/oncotarget.7872; Nasheuer HP, 2002, PROG NUCLEIC ACID RE, V72, P41, DOI 10.1016/S0079-6603(02)72067-9; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Oommen D, 2012, BIOCHEM BIOPH RES CO, V421, P538, DOI 10.1016/j.bbrc.2012.04.040; Parrales A, 2016, NAT CELL BIOL, V18, P1233, DOI 10.1038/ncb3427; Qiu XB, 2006, CELL MOL LIFE SCI, V63, P2560, DOI 10.1007/s00018-006-6192-6; Ramalingam S, 2015, ANN ONCOL, V26, P1741, DOI 10.1093/annonc/mdv220; Sahin E, 2011, INT J HYPERTHER, V27, P63, DOI 10.3109/02656736.2010.528139; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sonna LA, 2002, J APPL PHYSIOL, V92, P1725, DOI 10.1152/japplphysiol.01143.2001; Stark JL, 2014, BIOCHEMISTRY-US, V53, P1360, DOI 10.1021/bi401329a; Sun J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705342; Taba K, 2011, CHEMOTHERAPY, V57, P12, DOI 10.1159/000321019; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tane S, 2015, CANCER SCI, V106, P1625, DOI 10.1111/cas.12770; Terada K, 2005, EMBO J, V24, P611, DOI 10.1038/sj.emboj.7600549; Thorsteinsdottir J, 2017, J NEURO-ONCOL, V135, P443, DOI 10.1007/s11060-017-2600-z; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Wang CC, 2006, CANCER RES, V66, P6756, DOI 10.1158/0008-5472.CAN-06-0185; Wang YF, 2016, CLIN CANCER RES, V22, P5876, DOI 10.1158/1078-0432.CCR-15-2190; Yokota S, 2000, CANCER RES, V60, P2942	43	26	26	3	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					249	261		10.1038/s41388-019-0978-0	http://dx.doi.org/10.1038/s41388-019-0978-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477839				2022-12-17	WOS:000507766400001
J	Chen, DC; Li, YC; Zhang, XW; Wu, HY; Wang, Q; Cai, J; Cui, YM; Liu, HL; Lan, P; Wang, JP; Yang, ZH; Wang, L				Chen, Daici; Li, Yichen; Zhang, Xiaowen; Wu, Haiyong; Wang, Qian; Cai, Jian; Cui, Yanmei; Liu, Huanliang; Lan, Ping; Wang, Jianping; Yang, Zihuan; Wang, Lei			Ubiquitin ligase TRIM65 promotes colorectal cancer metastasis by targeting ARHGAP35 for protein degradation	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; TUMOR-CELL-MIGRATION; GENETICS; POLARITY; FASCIN; RHOA	Tripartite motif-containing protein 65 (TRIM65) is an E3 ubiquitin ligase and a critical regulator of a variety of cellular processes as well as tumor progression. Therefore, more substrates must be identified in the physiology or disease context. Here, we found that TRIM65 is upregulated and associated with poor survival in colorectal cancer (CRC). More specifically, high expression of TRIM65 is associated with CRC metastasis and recurrence. Ectopic overexpression of TRIM65 in CRC cell lines enhanced proliferation, invasion, and migration, while knockdown of TRIM65 expression had the opposite effects. Furthermore, we identified a new substrate of TRIM65, namely ARHGAP35, a Rho GTPase-activating protein (GAP) that is involved in polarized cell migration. Phenotypically, forced expression of TRIM65 induces increased production of migration-related structures, focal adhesions, and/or filopodia and enhances CRC metastasis to the liver or the lung in a mouse model. Mechanistic studies revealed that TRIM65 mediates ubiquitination of ARHGAP35, whose degradation leads to elevated Rho GTPase activity. In addition, we identified several phosphorylation sites on TRIM65. In sum, we reveal a novel TRIM65-GAP-Rho regulatory axis that modulates the actin cytoskeleton and the migration behavior of CRC cells, and the TRIM65-ARHGAP35 interaction might be a valuable therapeutic target in CRC.	[Chen, Daici; Li, Yichen; Zhang, Xiaowen; Wu, Haiyong; Wang, Qian; Cui, Yanmei; Liu, Huanliang; Lan, Ping; Wang, Jianping; Yang, Zihuan; Wang, Lei] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou, Guangdong, Peoples R China; [Chen, Daici; Li, Yichen; Zhang, Xiaowen; Wu, Haiyong; Wang, Qian; Cui, Yanmei; Liu, Huanliang; Lan, Ping; Wang, Jianping; Yang, Zihuan; Wang, Lei] Guangdong Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Cai, Jian; Lan, Ping; Wang, Jianping; Wang, Lei] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Chen, DC; Yang, ZH; Wang, L (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou, Guangdong, Peoples R China.; Chen, DC; Yang, ZH; Wang, L (corresponding author), Guangdong Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China.; Wang, L (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China.	chendc3@mail.sysu.edu.cn; yzhuan@mail.sysu.edu.cn; wangl9@mail.sysu.edu.cn	Chen, Daici/AAI-7285-2020	Chen, Daici/0000-0002-8872-0592; Cai, Jian/0000-0001-5687-2009; Liu, Huanliang/0000-0002-1006-6666	Natural Science Foundation of China [81573078, 81872386]; Natural Science Foundation of Guangdong Province [2017A030313805, 2016A030311021]; Guangzhou Science and Technology Program Key Projects [201604020174, 201604020005]; National Key Clinical Discipline	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Program Key Projects; National Key Clinical Discipline	This work was financially supported by Natural Science Foundation of China (Grant No. 81573078 and 81872386), Natural Science Foundation of Guangdong Province (Grant No. 2017A030313805 and 2016A030311021), and Guangzhou Science and Technology Program Key Projects (Grant No. 201604020174 and 201604020005). The authors thank group members of Professor Lei Wang for inspirational discussion, and support by National Key Clinical Discipline and the Program of Introducing Talents of Discipline to Universities in general.	Ali MRK, 2017, P NATL ACAD SCI USA, V114, pE5655, DOI 10.1073/pnas.1703151114; Bartolome RA, 2008, CANCER RES, V68, P8221, DOI 10.1158/0008-5472.CAN-08-0561; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Chen L, 2010, NATURE, V464, P1062, DOI 10.1038/nature08978; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fang LK, 2015, CANCER CELL, V28, P183, DOI 10.1016/j.ccell.2015.07.004; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fornage M, 2011, ANN NEUROL, V69, P928, DOI 10.1002/ana.22403; Freudenberger P, 2012, J NEUROL SCI, V322, P82, DOI 10.1016/j.jns.2012.06.016; Han SQ, 2016, MOL ONCOL, V10, P966, DOI 10.1016/j.molonc.2016.03.006; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kamanova J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005552; Keck JM, 2011, SCIENCE, V332, P1557, DOI 10.1126/science.1205193; Lang XT, 2017, J EXP MED, V214, P459, DOI 10.1084/jem.20160592; Li ST, 2014, P NATL ACAD SCI USA, V111, P6970, DOI 10.1073/pnas.1322545111; Li Y, 2016, BIOCHEM BIOPH RES CO, V473, P278, DOI 10.1016/j.bbrc.2016.03.093; Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Schmidt H, 2012, EXP GERONTOL, V47, P873, DOI 10.1016/j.exger.2012.06.003; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Short KM, 2006, J BIOL CHEM, V281, P8970, DOI 10.1074/jbc.M512755200; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wei WS, 2018, CANCER LETT, V435, P10, DOI 10.1016/j.canlet.2018.07.036; William WN, 2009, NAT REV DRUG DISCOV, V8, P213, DOI 10.1038/nrd2663; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yang YF, 2017, J CELL SCI, V130, P3108, DOI 10.1242/jcs.206623; Zajac O, 2018, NAT CELL BIOL, V20, P296, DOI 10.1038/s41556-017-0027-6; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	29	26	26	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2019	38	37					6429	6444		10.1038/s41388-019-0891-6	http://dx.doi.org/10.1038/s41388-019-0891-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6FR	31332286	hybrid, Green Published			2022-12-17	WOS:000485778800003
J	Lee, CF; Dang, A; Hernandez, E; Pong, RC; Chen, B; Sonavane, R; Raj, G; Kapur, P; Lin, HY; Wu, SR; Ko, CJ; Lo, UG; Lee, HY; Hsieh, JT; Lee, MS				Lee, Cheng-Fan; Dang, Andrew; Hernandez, Elizabeth; Pong, Rey-Chen; Chen, Benjamin; Sonavane, Rajni; Raj, Ganesh; Kapur, Payal; Lin, Hsin-Ying; Wu, Shang-Ru; Ko, Chun-Jung; Lo, U-Ging; Lee, Hsin-yu; Hsieh, Jer-Tsong; Lee, Ming-Shyue			Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase	ONCOGENE			English	Article							C-REACTIVE PROTEIN; NF-KAPPA-B; HUMAN OVARIAN-CANCER; GROWTH-FACTOR; MATRIPTASE ACTIVATION; SIGNALING PATHWAY; PLASMA-MEMBRANE; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; MIGRATION	Gram-negative bacteria have been found to be a major population in prostatitis and prostate cancer (PCa) tissues. Lipopolysaccharide (LPS), a major compound of Gram-negative bacteria, with stimulatory activities in some cancer types, but has not been fully studied in PCa. In this study, we examined the effect of LPS on the invasion of PCa cells. Interestingly, LPS can enhance the invasiveness of PCa, but had no significant effect on PCa cell viability. Using protease inhibitor screening and biochemical analyses, matriptase, a member of the membrane-anchored serine protease family, is found to play a key role in LPS-induced PCa cell invasion. Mechanistically, Toll-like receptor 4 (TLR4, LPS receptor)sphingosine kinase 1 (SphK1) signaling underlies LPS-induced matriptase activation and PCa cell invasion. Specifically, LPS induced the S225 phosphorylation of SphK1 and the translocation of SphK1 to plasma membrane, leading to the production of sphingosine 1-phosphate (S1P), ERK1/2 and matriptase activation via S1P receptor 4 (S1PR4). This phenomenon is further validated using the patient-derived explant (PDE) model. Indeed, there is a significant correlation among the elevated SphK1 levels, the Gleason grades of PCa specimens, and the poor survival of PCa patients. Taken together, this study demonstrates a potential impact of LPS on PCa progression. Our results provide not only a new finding of the role of bacterial infection in PCa progression but also potential therapeutic target(s) associated with PCa metastasis.	[Lee, Cheng-Fan; Lin, Hsin-Ying; Wu, Shang-Ru; Ko, Chun-Jung; Lee, Ming-Shyue] Natl Taiwan Univ, Dept Biochem & Mol Biol, Coll Med, Taipei, Taiwan; [Lee, Cheng-Fan; Dang, Andrew; Hernandez, Elizabeth; Pong, Rey-Chen; Sonavane, Rajni; Raj, Ganesh; Lo, U-Ging; Hsieh, Jer-Tsong] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Chen, Benjamin] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA; [Kapur, Payal] Univ Texas Southwestern Med Ctr Dallas, Urol & Pathol, Dallas, TX 75390 USA; [Ko, Chun-Jung] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Lee, Hsin-yu] Natl Taiwan Univ, Dept Life Sci, Taipei, Taiwan	National Taiwan University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; National Taiwan University	Lee, MS (corresponding author), Natl Taiwan Univ, Dept Biochem & Mol Biol, Coll Med, Taipei, Taiwan.; Hsieh, JT (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA.	jt.hsieh@utsouthwestern.edu; mslee2006@ntu.edu.tw	Ko, Chun-Jung/AAA-6187-2022	Ko, Chun-Jung/0000-0001-6565-7060	United States Army [W81XWH-11-1-0491, W81XWH-16-1-0474]; Taiwan National Science Council [NSC 100-2628-B-002-004-MY4]; National Health Research Institutes Grant [NHRI-EX102-9909BC, NHRI-EX106-10401BI]; National Taiwan University [NTU-CESRP-104R7602C4, 107L890504]; Ministry of Science and Technology [MOST 103-2321-B-002-096, MOST 104-2320B-002-044- MY3, MOST 104-2911-I-002-578, MOST 105-2911-I-002-521, MOST 106-2320-B-002-046-MY3]	United States Army(United States Department of DefenseUnited States Army); Taiwan National Science Council(Ministry of Science and Technology, Taiwan); National Health Research Institutes Grant; National Taiwan University(National Taiwan University); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This work was supported in part by grants from the United States Army (W81XWH-11-1-0491 and W81XWH-16-1-0474) to Jer-Tsong Hsieh, and by Taiwan National Science Council Grant NSC 100-2628-B-002-004-MY4, Ministry of Science and Technology Grants (MOST 103-2321-B-002-096, MOST 104-2320B-002-044- MY3, MOST 104-2911-I-002-578, MOST 105-2911-I-002-521 and MOST 106-2320-B-002-046-MY3), National Health Research Institutes Grant (NHRI-EX102-9909BC and NHRI-EX106-10401BI), and National Taiwan University Grant NTU-CESRP-104R7602C4 and 107L890504 to Ming-Shyue Lee. We thank Dr. Bink W. Wattenberg at James Graham Brown Cancer Center for SphK1 plasmid, Dr. Ming-Fong Lin at the University of Nebraska Medical Center for human prostate cancer cell lines, Dr. Chen-Yong Lin at the Georgetown University for his gifts of antibodies and I-Wen Huang and Kuan-Jin Yu for their technical supports.	Adams DR, 2016, TRENDS BIOCHEM SCI, V41, P395, DOI 10.1016/j.tibs.2016.02.007; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Asghar MY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196992; Balthasar S, 2006, BIOCHEM J, V398, P547, DOI 10.1042/BJ20060299; Beach JA, 2016, ONCOTARGET, V7, P4167, DOI 10.18632/oncotarget.6703; Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Bi Y, 2014, AM J PATHOL, V184, P2791, DOI 10.1016/j.ajpath.2014.06.023; Cheng JC, 2013, J CLIN INVEST, V123, P4344, DOI 10.1172/JCI64791; Datta A, 2014, ONCOTARGET, V5, P5920, DOI 10.18632/oncotarget.1874; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Devine KM, 2008, GYNECOL ONCOL, V110, P237, DOI 10.1016/j.ygyno.2008.04.013; Fleming JK, 2016, J LIPID RES, V57, P1737, DOI 10.1194/jlr.D068866; Gebhardt C, 2009, J VET EMERG CRIT CAR, V19, P450, DOI 10.1111/j.1476-4431.2009.00462.x; Gonzalez-Reyes S, 2011, CANCER IMMUNOL IMMUN, V60, P217, DOI 10.1007/s00262-010-0931-0; Guo YX, 2015, INT J CLIN EXP MED, V8, P20349; Illuzzi G, 2010, J BIOL CHEM, V285, P18594, DOI 10.1074/jbc.M109.072801; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kalhori V, 2015, MOL CELL ENDOCRINOL, V404, P113, DOI 10.1016/j.mce.2015.01.037; Kim ES, 2011, J CELL SCI, V124, P2220, DOI 10.1242/jcs.076794; Kiyomiya KI, 2006, AM J PHYSIOL-CELL PH, V291, pC40, DOI 10.1152/ajpcell.00351.2005; Ko CJ, 2017, ONCOGENE, V36, P4597, DOI 10.1038/onc.2017.82; Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297; Koh E, 2007, CELL SIGNAL, V19, P1328, DOI 10.1016/j.cellsig.2007.01.005; Lanoix JP, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-183; Lee MS, 2006, J CANC MOL, V2, P183; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lehrer S, 2005, BJU INT, V95, P961, DOI 10.1111/j.1464-410X.2005.05447.x; Li J, 2017, ANAT REC, V300, P1219, DOI 10.1002/ar.23590; Li MH, 2009, CANCER LETT, V276, P171, DOI 10.1016/j.canlet.2008.11.025; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Lin CY, 2008, FRONT BIOSCI-LANDMRK, V13, P621, DOI 10.2741/2707; Lipsky BA, 2010, CLIN INFECT DIS, V50, P1641, DOI 10.1086/652861; Liu XX, 2017, BIOMED PHARMACOTHER, V92, P429, DOI 10.1016/j.biopha.2017.05.102; Ma D, 2017, BIOCHEM BIOPH RES CO, V482, P366, DOI 10.1016/j.bbrc.2016.11.069; Maceyka M, 2014, NATURE, V510, P58, DOI 10.1038/nature13475; Malavaud B, 2010, EUR J CANCER, V46, P3417, DOI 10.1016/j.ejca.2010.07.053; Miller AV, 2008, MOL CELL BIOL, V28, P4142, DOI 10.1128/MCB.01465-07; Mukhopadhyay P, 2015, BREAST CANCER MANAG, V4, P241, DOI 10.2217/bmt.15.20; Nagahashi M., 2014, BIOMED RES INT, V2014, P1; Nakajima M, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699133; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Nunes J, 2012, BRIT J CANCER, V106, P909, DOI 10.1038/bjc.2012.14; Ohotski J, 2012, BRIT J CANCER, V106, P1453, DOI 10.1038/bjc.2012.98; Park KS, 2007, BIOCHEM BIOPH RES CO, V356, P239, DOI 10.1016/j.bbrc.2007.02.112; Pchejetski D, 2011, NAT REV UROL, V8, P569, DOI 10.1038/nrurol.2011.117; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Proia RL, 2015, J CLIN INVEST, V125, P1379, DOI 10.1172/JCI76369; Pyne Nigel J., 2015, Advances in Biological Regulation, V60, P151, DOI 10.1016/j.jbior.2015.09.001; Pyne NJ, 2012, BIOCHEM SOC T, V40, P94, DOI 10.1042/BST20110602; Rosenberg AJ, 2015, APPL RADIAT ISOTOPES, V102, P5, DOI 10.1016/j.apradiso.2015.04.010; Salama MF, 2015, FASEB J, V29, P2803, DOI 10.1096/fj.15-270413; Sevenich L, 2014, GENE DEV, V28, P2331, DOI 10.1101/gad.250647.114; Shida D, 2008, CANCER RES, V68, P6569, DOI 10.1158/0008-5472.CAN-08-0411; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Simons BW, 2015, J PATHOL, V235, P478, DOI 10.1002/path.4472; Sordillo LA, 2016, ANTICANCER RES, V36, P2085; St Hill CA, 2015, FRONT CHEM, V3, DOI 10.3389/fchem.2015.00055; Syed SN, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/7510496; Szajnik M, 2009, ONCOGENE, V28, P4353, DOI 10.1038/onc.2009.289; Taitt HE, 2018, AM J MENS HEALTH, V12, P1807, DOI 10.1177/1557988318798279; Tan YH, 2014, MOL CELL, V54, P212, DOI 10.1016/j.molcel.2014.03.012; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thamilselvan V, 2002, IN VITRO CELL DEV-AN, V38, P246; Tsai CH, 2014, ONCOGENE, V33, P4643, DOI 10.1038/onc.2013.412; Vaarala MH, 2016, ONCOL LETT, V12, P1149, DOI 10.3892/ol.2016.4702; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023; Wang D, 2008, MOL CANCER THER, V7, P1993, DOI 10.1158/1535-7163.MCT-08-0088; Watson C, 2010, AM J PATHOL, V177, P2205, DOI 10.2353/ajpath.2010.100220; Weichand B, 2017, J EXP MED, V214, P2695, DOI 10.1084/jem.20160392; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wu SR, 2010, AM J PATHOL, V177, P3145, DOI 10.2353/ajpath.2010.100228; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yatomi Y, 2008, BBA-GEN SUBJECTS, V1780, P606, DOI 10.1016/j.bbagen.2007.10.006; Young N, 2009, MOL CANCER RES, V7, P23, DOI 10.1158/1541-7786.MCR-08-0061; Zeng Y, 2016, ONCOL LETT, V12, P379, DOI 10.3892/ol.2016.4661; Zhan ZZ, 2014, AUTOPHAGY, V10, P257, DOI 10.4161/auto.27162; Zhu GW, 2016, CELL PHYSIOL BIOCHEM, V39, P1665, DOI 10.1159/000447868; Ziaee S, 2015, TRANSL ANDROL UROL, V4, P438, DOI 10.3978/j.issn.2223-4683.2015.04.10	80	26	27	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5580	5598		10.1038/s41388-019-0833-3	http://dx.doi.org/10.1038/s41388-019-0833-3			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31152147				2022-12-17	WOS:000474845100003
J	Hu, JW; Mirshahidi, S; Simental, A; Lee, SC; Filho, PAD; Peterson, NR; Duerksen-Hughes, P; Yuan, XP				Hu, Jinwei; Mirshahidi, Saied; Simental, Alfred; Lee, Steve C.; Filho, Pedro A. De Andrade; Peterson, Nathaniel R.; Duerksen-Hughes, Penelope; Yuan, Xiangpeng			Cancer stem cell self-renewal as a therapeutic target in human oral cancer	ONCOGENE			English	Article							TUMOR-GROWTH; BMI-1; HEAD; IDENTIFICATION; KINASE; METASTASES; MITOPHAGY; PROMOTES; SURVIVAL; SITES	Tumor recurrence following treatment remains a major clinical challenge in oral cavity cancer. Cancer stem cells (CSCs) have been isolated from human oral cancers and been considered as the driving force of tumor recurrence and metastasis. However, it still remains unclear whether targeting CSCs in oral cancer is a clinically relevant strategy to combat cancer recurrence and metastasis. Here, using clinical cancer specimens and patient-derived xenografts, we show that the self-renewal regulator BMI1 is highly expressed in CSCs of oral cavity squamous cell carcinoma. Inhibition of BMI1 decreases oral CSCs' self-renewal and tumor-initiating potential. Treatment of pre-established human oral cancer xenografts with a BMI1 inhibitor resulted in abrogation of tumor progression and reduced the frequency of CSCs in the xenografts. Remarkably, the BMI1 inhibitor has therapeutic effects in cisplatin-resistant tumors and can reduce metastases initiated by circulating CSCs. Mechanistically, BMI1-inhibition leads to oral CSC necroptotic cell death, which underlies the self-renewal impairment after inhibiting BMIl. Our data provide a pre-clinical proof-of-concept that targeting BMI1-related CSC self-renewal is a clinically relevant anti-cancer therapy in human oral cavity squamous cell carcinoma.	[Hu, Jinwei; Simental, Alfred; Lee, Steve C.; Filho, Pedro A. De Andrade; Peterson, Nathaniel R.; Yuan, Xiangpeng] Loma Linda Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Loma Linda, CA 92354 USA; [Mirshahidi, Saied] Loma Linda Univ, Canc Ctr Biospecimen Lab, Med Ctr, Loma Linda, CA 92354 USA; [Mirshahidi, Saied; Duerksen-Hughes, Penelope; Yuan, Xiangpeng] Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA 92354 USA; [Hu, Jinwei] Kaiser Permanente, Fontana Med Ctr, Dept Head & Neck Surg, Fontana, CA 92335 USA	Loma Linda University; Loma Linda University; Loma Linda University; Kaiser Permanente	Yuan, XP (corresponding author), Loma Linda Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Loma Linda, CA 92354 USA.; Yuan, XP (corresponding author), Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA 92354 USA.	xyuan@llu.edu		Duerksen-Hughes, Penelope/0000-0002-0998-2157; Lee, Steve/0000-0002-4460-4303	Department of Otolaryngology-Head & Neck Surgery and Cancer Center at Loma Linda University;  [GCAT 2140225];  [GRASP 2140307];  [GCAT 2150204]	Department of Otolaryngology-Head & Neck Surgery and Cancer Center at Loma Linda University; ; ; 	This work was supported in parts by the Department of Otolaryngology-Head & Neck Surgery and Cancer Center at Loma Linda University, and by institutional grants GCAT 2140225, GCAT 2150204, and GRASP 2140307.	Ablett MP, 2014, ONCOTARGET, V5, P599, DOI 10.18632/oncotarget.1169; Bansal N, 2016, CLIN CANCER RES, V22, P6176, DOI 10.1158/1078-0432.CCR-15-3107; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883; Chen DM, 2017, CELL STEM CELL, V20, P621, DOI 10.1016/j.stem.2017.02.003; Clay MR, 2010, HEAD NECK-J SCI SPEC, V32, P1195, DOI 10.1002/hed.21315; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Dey A, 2016, AUTOPHAGY, V12, P659, DOI 10.1080/15548627.2016.1147670; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Du JJ, 2010, MED ONCOL, V27, P1273, DOI 10.1007/s12032-009-9373-y; Ferlito A, 2001, ORL-J OTO-RHIN-LARYN, V63, P202, DOI 10.1159/000055740; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14; Hu JW, 2006, CANCER RES, V66, P8887, DOI 10.1158/0008-5472.CAN-05-3448; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Krishnamurthy S, 2010, CANCER RES, V70, P9969, DOI 10.1158/0008-5472.CAN-10-1712; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Li DW, 2010, J CANCER RES CLIN, V136, P997, DOI 10.1007/s00432-009-0745-7; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lim YC, 2014, ORAL ONCOL, V50, P633, DOI 10.1016/j.oraloncology.2014.04.004; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mandal P, 2014, MOL CELL, V56, P481, DOI 10.1016/j.molcel.2014.10.021; Mirshahidi S, 2018, EXP CELL RES, V362, P515, DOI 10.1016/j.yexcr.2017.12.017; Mizumura K, 2014, J CLIN INVEST, V124, P3987, DOI 10.1172/JCI74985; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nor C, 2014, NEOPLASIA, V16, P137, DOI 10.1593/neo.131744; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Song J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011456; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tehranchi R, 2010, NEW ENGL J MED, V363, P1025, DOI 10.1056/NEJMoa0912228; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Trumpp A, 2008, NAT CLIN PRACT ONCOL, V5, P337, DOI 10.1038/ncponc1110; Wang JCY, 2007, CELL STEM CELL, V1, P497, DOI 10.1016/j.stem.2007.10.005; White RA, 2013, J CLIN INVEST, V123, P4390, DOI 10.1172/JCI65856; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	52	26	27	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5440	5456		10.1038/s41388-019-0800-z	http://dx.doi.org/10.1038/s41388-019-0800-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30936460				2022-12-17	WOS:000473842500008
J	Huang, CC; Cheng, SH; Wu, CH; Li, WY; Wang, JS; Kung, ML; Chu, TH; Huang, ST; Feng, CT; Huang, SC; Tai, MH				Huang, Chao-Cheng; Cheng, Shih-Hsuan; Wu, Chen-Hsuan; Li, Wen-Yuan; Wang, Jiang-Shiang; Kung, Mei-Lang; Chu, Tian-Huei; Huang, Shih-Tsung; Feng, Chien-Ting; Huang, Shih-Chung; Tai, Ming-Hong			Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling	ONCOGENE			English	Article							STEM-CELLS; GROWTH-FACTOR; DLK1; EXPRESSION; CANCER; GENE; PROTEIN; INHIBITOR; PATHWAY; PREF-1	Ovarian carcinoma is the most lethal type of gynecologic malignancies. Alterations of Notch pathway are prevalent in ovarian carcinogenesis. This study investigated the expression profile and function of delta-like 1 homolog (DLK1), a non-canonical Notch ligand, during ovarian carcinogenesis. Tissue microarray (TMA) consisting of surgically resected samples from 221 patients with ovarian carcinoma was constructed for DLK1 expression. DLK1 overexpression or knockdown was achieved by adenovirus gene delivery to evaluate the effect of DLK1 on the oncogenic behaviors in ovarian cancer cells and in xenografted tumors. TMA analysis revealed that elevated DLK1 expression was correlated with stages, lymph node metastasis and E-cadherin downregulation. Despite no influence on survival among ovarian carcinoma patients, DLK1 overexpression was specially associated with overall survival and progression free survival in high-grade serous carcinoma (HGSC) patients, constituting an independent prognostic factor for these patients. By adenovirus gene delivery, it was found modulation of cellular DLK1 level regulated the tumorigenic behaviors and epithelial-mesenchymal transition (EMT) in vitro and in vivo. Immunohistochemical analysis further showed that DLK1 overexpression resulted in escalated proliferation, angiogenesis, EMT and Notch activities. Application of recombinant DLK1 extracellular domain (rDLK1-EC) recapitulated the tumorigenic behaviors of DLK1 in ovarian cancer cells. By using neutralizing antibody or pharmaceutical inhibitor, blockade of Notch signaling attenuated the tumorigenic behaviors evoked by DLK1 overexpression. The present study indicates that DLK1 overexpression participates in ovarian carcinogenesis through Notch activation and EMT induction. Moreover, DLK1 may constitute a novel diagnostic biomarker and therapeutic target for HGSC.	[Huang, Chao-Cheng; Cheng, Shih-Hsuan; Wang, Jiang-Shiang] Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung, Taiwan; [Huang, Chao-Cheng; Cheng, Shih-Hsuan; Wu, Chen-Hsuan; Wang, Jiang-Shiang] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Huang, Chao-Cheng; Wang, Jiang-Shiang] Kaohsiung Chang Gung Mem Hosp, Biobank & Tissue Bank, Kaohsiung, Taiwan; [Cheng, Shih-Hsuan; Chu, Tian-Huei; Feng, Chien-Ting; Huang, Shih-Chung; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan; [Wu, Chen-Hsuan] Kaohsiung Chang Gung Mem Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan; [Wu, Chen-Hsuan] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Tao Yuan, Taiwan; [Li, Wen-Yuan] Fooyin Univ Hosp, Dept Pathol, Pingtung, Taiwan; [Li, Wen-Yuan; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung, Taiwan; [Kung, Mei-Lang] Natl Sun Yat Sen Univ, Dept Chem, Kaohsiung, Taiwan; [Chu, Tian-Huei; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung, Taiwan; [Huang, Shih-Tsung] Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung, Taiwan; [Huang, Shih-Tsung] Acad Sinica, Doctoral Degree Program Marine Biotechnol, Taipei, Taiwan; [Huang, Shih-Chung] Kaohsiung Armed Forces Gen Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Tai, Ming-Hong] Kaohsiung Med Univ, Grad Inst Clin Sci, Kaohsiung 807, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; National Sun Yat Sen University; Chang Gung Memorial Hospital; Chang Gung University; National Sun Yat Sen University; National Sun Yat Sen University; National Sun Yat Sen University; National Sun Yat Sen University; Academia Sinica - Taiwan; Kaohsiung Medical University	Huang, CC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung, Taiwan.; Huang, CC (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.; Huang, CC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Biobank & Tissue Bank, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Kaohsiung Med Univ, Grad Inst Clin Sci, Kaohsiung 807, Taiwan.	huangcc@cgmh.org.tw; minghongtai@gmail.com		Chu, Tian-Huei/0000-0003-1197-5754	Ministry of Science and Technology, Taiwan [NSC101-2320-B-182-009, NSC102-2320-B-182-011, MOST103-2320-B-182-005-MY3, MOST105-2325-B-110-001]; Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital Tissue Bank [CLRPG8E0161, CLRPG8F1701]; Kaohsiung Armed Forces General Hospital, Taiwan [107-10]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, TaiwanMinistry of Science, ICT & Future Planning, Republic of Korea); Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital Tissue Bank; Kaohsiung Armed Forces General Hospital, Taiwan	This work was supported by grants from the Ministry of Science and Technology, Taiwan (NSC101-2320-B-182-009, NSC102-2320-B-182-011, MOST103-2320-B-182-005-MY3 to C.C.H., and MOST105-2325-B-110-001 to M.H.T.). We thank Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital Tissue Bank (CLRPG8E0161 and CLRPG8F1701), and the Kaohsiung Armed Forces General Hospital, Taiwan (107-10) for technical support.	Abdallah BM, 2007, J BIOL CHEM, V282, P7339, DOI 10.1074/jbc.M607530200; Baladron V, 2005, EXP CELL RES, V303, P343, DOI 10.1016/j.yexcr.2004.10.001; Baladron V, 2001, FRONT BIOSCI-LANDMRK, V6, pA25, DOI 10.2741/baladron; Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Ceder JA, 2008, EUR UROL, V54, P1344, DOI 10.1016/j.eururo.2008.03.006; Chen X, 2012, CANCER RES, V72, P2294, DOI 10.1158/0008-5472.CAN-11-2181; Chen X, 2010, ONCOTARGET, V1, P210, DOI 10.18632/oncotarget.127; Choi JH, 2008, CANCER RES, V68, P5716, DOI 10.1158/0008-5472.CAN-08-0001; Deng JL, 2016, ONCOTARGET, V7, P55771, DOI 10.18632/oncotarget.9908; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Falix FA, 2012, BBA-MOL BASIS DIS, V1822, P988, DOI 10.1016/j.bbadis.2012.02.003; Gasperowicz M, 2008, PLACENTA, V29, P651, DOI 10.1016/j.placenta.2008.06.004; Guseh JS, 2009, DEVELOPMENT, V136, P1751, DOI 10.1242/dev.029249; Haga CL, 2012, J BIOL CHEM, V287, P42695, DOI 10.1074/jbc.M112.387761; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Hu TH, 2003, CANCER-AM CANCER SOC, V98, P1444, DOI 10.1002/cncr.11653; Hu W, 2014, CANCER RES, V74, P3282, DOI 10.1158/0008-5472.CAN-13-2066; Huang CC, 2018, ANGIOGENESIS, V21, P901, DOI 10.1007/s10456-018-9615-8; Huang CC, 2018, ANGIOGENESIS, V21, P299, DOI 10.1007/s10456-018-9596-7; Huang J, 2007, CARCINOGENESIS, V28, P1094, DOI 10.1093/carcin/bgl215; Jung JG, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004751; Kawakami T, 2006, HUM MOL GENET, V15, P821, DOI 10.1093/hmg/ddl001; Kim YS, 2016, BIOCHEM BIOPH RES CO, V480, P254, DOI 10.1016/j.bbrc.2016.10.041; Kim Y, 2009, CANCER RES, V69, P9271, DOI 10.1158/0008-5472.CAN-09-1605; Klymenko Y, 2017, CANCERS, V9, P1; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095912; Liu GY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142680; Liu Yu, 2010, Zhongguo Fei Ai Za Zhi, V13, P923, DOI 10.3779/j.issn.1009-3419.2010.10.12; Ma Z, 2017, BIOCHEM BIOPH RES CO, V490, P309, DOI 10.1016/j.bbrc.2017.06.041; Nueda ML, 2008, J MOL BIOL, V379, P428, DOI 10.1016/j.jmb.2008.03.070; Nueda ML, 2017, FASEB J, V31, P3484, DOI 10.1096/fj.201601341RRR; Nueda ML, 2014, BBA-MOL CELL RES, V1843, P2674, DOI 10.1016/j.bbamcr.2014.07.015; Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; Park JT, 2010, AM J PATHOL, V177, P1087, DOI 10.2353/ajpath.2010.100316; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Rodriguez P, 2012, CARDIOVASC RES, V93, P232, DOI 10.1093/cvr/cvr296; Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Smas CM, 1997, CRIT REV EUKAR GENE, V7, P281, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.10; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang YH, 2006, MOL CELL BIOL, V26, P5421, DOI 10.1128/MCB.02437-05; Wu JC, 2016, PROSTATE, V76, P1469, DOI 10.1002/pros.23230; Xu J, 2016, AM J CANCER RES, V6, P2700; Yanai H, 2010, J BIOCHEM, V148, P85, DOI 10.1093/jb/mvq034; Yin D, 2006, ONCOGENE, V25, P1852, DOI 10.1038/sj.onc.1209219; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zhang S S, 2016, Zhonghua Zhong Liu Za Zhi, V38, P510, DOI 10.3760/cma.j.issn.0253-3766.2016.07.006	54	26	26	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3201	3215		10.1038/s41388-018-0658-5	http://dx.doi.org/10.1038/s41388-018-0658-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30626939				2022-12-17	WOS:000465557200007
J	Wiesweg, M; Kasper, S; Worm, K; Herold, T; Reis, H; Sara, L; Metzenmacher, M; Abendroth, A; Darwiche, K; Aigner, C; Wedemeyer, HH; Helfritz, FA; Stuschke, M; Schumacher, B; Markus, P; Paul, A; Rahmann, S; Schmid, KW; Schuler, M				Wiesweg, Marcel; Kasper, Stefan; Worm, Karl; Herold, Thomas; Reis, Henning; Sara, Linda; Metzenmacher, Martin; Abendroth, Annalena; Darwiche, Kaid; Aigner, Clemens; Wedemeyer, Heiner H.; Helfritz, Fabian A.; Stuschke, Martin; Schumacher, Brigitte; Markus, Peter; Paul, Andreas; Rahmann, Sven; Schmid, Kurt W.; Schuler, Martin			Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer	ONCOGENE			English	Article							SIDED COLON-CANCER; DNA-DAMAGE; KRAS MUTATIONS; BRAF MUTANTS; ADENOCARCINOMA; SENSITIVITY; EGFR; CHEMOTHERAPY; MECHANISMS; INHIBITION	Mutated RAS onco-proteins are key drivers across many cancers. The distribution of somatic RAS mutations varies between cancer entities. Retrospective analyses have associated some RAS mutations with distinct clinical outcomes. However, the clinical impact of the full spectrum of RAS mutations in their disease contextuality remains to be defined. To improve upon this situation, we studied genomically and clinically annotated, prospectively recruited cohorts of patients with RAS-mutated metastatic lung cancer and colorectal cancer. Mutational spectra were compared with predictions derived from analyzing the mutagenic impact at the genome level for each entity. Interestingly, we found concordance of predicted signatures with those actually observed in our patients. Thus, composition of the functionally active RAS mutational subtypes is primarily determined by the mutagenic context. Most RAS mutations seemed dominant oncogenic drivers with entity-dependent clinical outcomes. RAS comutations were enriched in tumors harboring class 2/3 BRAF mutations, highlighting the functional dependency of some mutated BRAF isoforms on RAS. With our dataset, we established a probabilistic model for cross-entity comparison of the prognostic impact of specific RAS mutational subtypes. The resulting prognostic clusters showed largely consistent clinical categorizations in both entities. This suggests mutant subtype-specific functional properties leading to similar clinical effects. A notable exception is KRAS G12C, which imparted an adverse prognosis only in colorectal cancer. Our findings provide a framework for risk stratification of specific RAS mutations across several cancer entities, which is required to guide the analysis of clinical findings in patients treated with direct RAS inhibitors or agents targeting downstream pathways.	[Wiesweg, Marcel; Kasper, Stefan; Sara, Linda; Metzenmacher, Martin; Abendroth, Annalena; Schuler, Martin] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Hufelandstr 55, D-45122 Essen, Germany; [Wiesweg, Marcel; Rahmann, Sven] Univ Duisburg Essen, Univ Hosp Essen, Inst Human Genet, Genome Informat, Hufelandstr 55, D-45122 Essen, Germany; [Kasper, Stefan; Stuschke, Martin; Schmid, Kurt W.; Schuler, Martin] Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Hufelandstr 55, D-45122 Essen, Germany; [Worm, Karl; Herold, Thomas; Reis, Henning; Schmid, Kurt W.] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Inst Pathol, Hufelandstr 55, D-45122 Essen, Germany; [Darwiche, Kaid] Univ Duisburg Essen, Ruhrlandklin Univ Hosp Essen, Sect Intervent Pneumol, Dept Pulm Med, Tuschener Weg 40, D-45239 Essen, Germany; [Aigner, Clemens] Univ Duisburg Essen, Ruhrlandklin Univ Hosp Essen, Dept Thorac Surg & Endoscopy, Tuschener Weg 40, D-45239 Essen, Germany; [Wedemeyer, Heiner H.] Univ Duisburg Essen, Dept Gastroenterol & Hepatol, West German Canc Ctr, Univ Hosp Essen, Hufelandstr 55, D-45122 Essen, Germany; [Helfritz, Fabian A.; Paul, Andreas] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Gen Visceral & Transplantat Surg, Hufelandstr 55, D-45122 Essen, Germany; [Stuschke, Martin] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Radiotherapy, Hufelandstr 55, D-45122 Essen, Germany; [Schumacher, Brigitte] Elisabeth Hosp Essen, Dept Gastroenterol, Klara Kopp Weg 1, D-45138 Essen, Germany; [Markus, Peter] Elisabeth Hosp Essen, Dept Gen Visceral & Trauma Surg, Klara Kopp Weg 1, D-45138 Essen, Germany; [Schuler, Martin] Univ Duisburg Essen, Ruhrlandklin Univ Hosp Essen, Div Thorac Oncol, Tuschener Weg 40, D-45239 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen	Schuler, M (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Hufelandstr 55, D-45122 Essen, Germany.; Schuler, M (corresponding author), Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Hufelandstr 55, D-45122 Essen, Germany.; Schuler, M (corresponding author), Univ Duisburg Essen, Ruhrlandklin Univ Hosp Essen, Div Thorac Oncol, Tuschener Weg 40, D-45239 Essen, Germany.	martin.schuler@uk-essen.de	Reis, Henning/AAX-9545-2020; Kasper, Stefan/I-4521-2015; Aigner, Clemens/A-7284-2019	Reis, Henning/0000-0003-1373-5295; Kasper, Stefan/0000-0002-5947-8733; Aigner, Clemens/0000-0002-7787-991X; Wiesweg, Marcel/0000-0002-9698-9559	Oncology Center of Excellence Program of the Deutsche Krebshilfe [110534]; German Federal government via the German Cancer Consortium (DKTK); Novartis Pharma AG; Medical Faculty of the University Duisburg-Essen (IFORES fellowship); North Rhine-Westphalian State government via the German Cancer Consortium (DKTK)	Oncology Center of Excellence Program of the Deutsche Krebshilfe; German Federal government via the German Cancer Consortium (DKTK); Novartis Pharma AG; Medical Faculty of the University Duisburg-Essen (IFORES fellowship); North Rhine-Westphalian State government via the German Cancer Consortium (DKTK)	This work was supported by the Oncology Center of Excellence Program of the Deutsche Krebshilfe (grant number 110534); the German Federal and North Rhine-Westphalian State governments via the German Cancer Consortium (DKTK); Novartis Pharma AG (research grant); the Medical Faculty of the University Duisburg-Essen (IFORES fellowship to M.W.). The funding sources had no influence on the analysis and interpretation of data, and contents of the manuscript.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ambrogio C, 2018, CELL, V172, P857, DOI 10.1016/j.cell.2017.12.020; Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175; Blanpain C, 2011, CELL STEM CELL, V8, P16, DOI 10.1016/j.stem.2010.12.012; Blons H, 2014, ANN ONCOL, V25, P2378, DOI 10.1093/annonc/mdu464; Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349; Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7; Castellucci E, 2017, ONCOLOGIST, V22, P497, DOI 10.1634/theoncologist.2017-0034; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cserepes M, 2014, EUR J CANCER, V50, P1819, DOI 10.1016/j.ejca.2014.04.001; Deihimi S, 2017, ONCOTARGET, V8, P39945, DOI 10.18632/oncotarget.18098; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dion V, 2014, TRENDS GENET, V30, P220, DOI 10.1016/j.tig.2014.04.005; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garassino MC, 2011, ANN ONCOL, V22, P235, DOI 10.1093/annonc/mdq680; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guerrero S, 2000, CANCER RES, V60, P6750; Haigis KM, 2017, TRENDS CANCER, V3, P686, DOI 10.1016/j.trecan.2017.08.006; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hunter JC, 2015, MOL CANCER RES, V13, P1325, DOI 10.1158/1541-7786.MCR-15-0203; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Iyama T, 2013, DNA REPAIR, V12, P620, DOI 10.1016/j.dnarep.2013.04.015; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394; Jones RP, 2017, BRIT J CANCER, V116, P923, DOI 10.1038/bjc.2017.37; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Karahalil B, 2002, FASEB J, V16, P1895, DOI 10.1096/fj.02-0463com; Kerner GSMA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070346; Kuong KJ, 2013, NAT GENET, V45, P964, DOI 10.1038/ng.2736; Kwak MS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007882; Lans H, 2015, DNA REPAIR, V32, P141, DOI 10.1016/j.dnarep.2015.04.025; Larki P, 2017, CELL J, V19, P113, DOI 10.22074/cellj.2017.5123; Lee GH, 2015, EJSO-EUR J SURG ONC, V41, P300, DOI 10.1016/j.ejso.2014.11.001; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; Messner I, 2013, J CANCER RES CLIN, V139, P201, DOI 10.1007/s00432-012-1319-7; Metro G, 2012, LUNG CANCER, V78, P81, DOI 10.1016/j.lungcan.2012.06.005; Nan XL, 2015, P NATL ACAD SCI USA, V112, P7996, DOI 10.1073/pnas.1509123112; Oh Bo-Young, 2011, J Korean Soc Coloproctol, V27, P127, DOI 10.3393/jksc.2011.27.3.127; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Ostrow SL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21927; Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105; Petrelli F, 2017, JAMA ONCOL, V3, P211, DOI 10.1001/jamaoncol.2016.4227; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Sahin IH, 2013, J CANCER, V4, P320, DOI 10.7150/jca.3619; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Shepherd FA, 2013, J CLIN ONCOL, V31, P2173, DOI 10.1200/JCO.2012.48.1390; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Takamochi K, 2013, ONCOL LETT, V6, P1207, DOI 10.3892/ol.2013.1551; Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797; Tejpar S, 2012, J CLIN ONCOL, V30, P3570, DOI 10.1200/JCO.2012.42.2592; Toyooka S, 2007, CLIN CANCER RES, V13, P3431, DOI 10.1158/1078-0432.CCR-07-0070; Vitale I, 2017, MOL CELL, V66, P306, DOI 10.1016/j.molcel.2017.04.006; Vittal A, 2017, CASE REP ONCOL MED, V2017, DOI 10.1155/2017/2321052; Wiesweg M, 2018, CLIN COLORECTAL CANC, V17, pE331, DOI 10.1016/j.clcc.2018.02.003; Wiesweg M, 2017, J THORAC ONCOL, V12, P54, DOI 10.1016/j.jtho.2016.08.137; Wiesweg M, 2013, EUR J CANCER, V49, P3076, DOI 10.1016/j.ejca.2013.06.014; Xing KL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0036-2; Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Yu HA, 2015, J THORAC ONCOL, V10, P431, DOI 10.1097/JTO.0000000000000432; Zhao H, 2014, ELIFE, V3, DOI 10.7554/eLife.02725; Zheng G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1811-y	66	26	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2953	2966		10.1038/s41388-018-0634-0	http://dx.doi.org/10.1038/s41388-018-0634-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30568222				2022-12-17	WOS:000465167600006
J	Fletcher, JS; Springer, MG; Choi, K; Jousma, E; Rizvi, TA; Dombi, E; Kim, MO; Wu, JQ; Ratner, N				Fletcher, Jonathan S.; Springer, Mitchell G.; Choi, Kwangmin; Jousma, Edwin; Rizvi, Tilat A.; Dombi, Eva; Kim, Mi-Ok; Wu, Jianqiang; Ratner, Nancy			STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma	ONCOGENE			English	Article							SCHWANN-CELLS; TARGETING STAT3; BONE-MARROW; NF1 LOSS; PLEXIFORM; ROLES; CCR2; ANGIOGENESIS; RECRUITMENT; DIAGNOSIS	Plexiform neurofibroma, a benign peripheral nerve tumor, is associated with the biallelic loss of function of the NF1 tumor suppressor in Schwann cells. Here, we show that FLLL32, a small molecule inhibitor of JAK2/STAT3 signaling, reduces neurofibroma growth in mice with conditional, biallelic deletion of Nf1 in the Schwann cell lineage. FLLL32 treatment or Stat3 deletion in tumor cells reduced inflammatory cytokine expression and tumor macrophage numbers in neurofibroma. Although STAT3 inhibition downregulated the chemokines CCL2 and CCL12, which can signal through CCR2 to recruit macrophages to peripheral nerves, deletion of Ccr2 did not improve survival or reduce macrophage numbers in neurofibroma-bearing mice. Interestingly, Iba1+; F4/80+;CD11b+ macrophages accounted for similar to 20-40% of proliferating cells in untreated tumors. FLLL32 suppressed macrophage proliferation, implicating STAT3-dependent, local proliferation in neurofibroma macrophage accumulation, and decreased Schwann cell proliferation and increased Schwann cell death. The functions of STAT3 signaling in neurofibroma Schwann cells and macrophages, and its relevance as a therapeutic target in neurofibroma, merit further investigation.	[Fletcher, Jonathan S.; Springer, Mitchell G.; Choi, Kwangmin; Jousma, Edwin; Rizvi, Tilat A.; Wu, Jianqiang; Ratner, Nancy] Univ Cincinnati, Div Expt Hematol & Canc Biol, Cincinnati Childrens Hosp, Dept Pediat,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Fletcher, Jonathan S.] Univ Cincinnati, Coll Med, Grad Program Immunol, Cincinnati, OH 45229 USA; [Dombi, Eva] NCI, Ctr Canc Res, Bldg 10,Room 1-5750, Bethesda, MD 20892 USA; [Kim, Mi-Ok] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Epidemiol & Biostat, UCS F Box 0128, San Francisco, CA 94143 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Wu, JQ; Ratner, N (corresponding author), Univ Cincinnati, Div Expt Hematol & Canc Biol, Cincinnati Childrens Hosp, Dept Pediat,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Jianqiang.Wu@cchmc.org; Nancy.Ratner@cchmc.org		RATNER, NANCY/0000-0001-5030-9354; Kim, Mi-Ok/0000-0002-7712-3653	DOD [W81XWH-11-1-0057, W81XWH-11-1-0259]; Neurofibromatosis Therapeutic Acceleration Program (NTAP) at Johns Hopkins University;  [R01 NS28840];  [5 F30 NS096796]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS096796, R01NS028840] Funding Source: NIH RePORTER	DOD(United States Department of Defense); Neurofibromatosis Therapeutic Acceleration Program (NTAP) at Johns Hopkins University; ; ; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank James Fuchs and Jiayuh Lin (The Ohio State University) for providing FLLL32, and the Imaging Resource Center at Cincinnati Children's Hospital Medical Center (R. Scott Dunn) for MRI Imaging. This work was supported by R01 NS28840 (to NR and JW), and DOD W81XWH-11-1-0057 (to NR), DOD W81XWH-11-1-0259 (to JW), and RNA-Seq by an Agreement with the Neurofibromatosis Therapeutic Acceleration Program (NTAP) at Johns Hopkins University (to NR). JSF was the recipient of 5 F30 NS096796.	Beert E, 2012, GENE CHROMOSOME CANC, V51, P852, DOI 10.1002/gcc.21969; Bournazou Eirini, 2013, JAKSTAT, V2, pe23828, DOI 10.4161/jkst.23828; Campana L, 2018, J IMMUNOL, V200, P1169, DOI 10.4049/jimmunol.1701247; Choi K, 2017, SCI REP-UK, V7, DOI 10.1038/srep43315; Cortez-Retamozo V, 2012, P NATL ACAD SCI USA, V109, P2491, DOI 10.1073/pnas.1113744109; Ferner RE, 2007, J MED GENET, V44, P81, DOI 10.1136/jmg.2006.045906; Ferner RE, 2013, HAND CLINIC, V115, P939, DOI 10.1016/B978-0-444-52902-2.00053-9; Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945; Gauri P, 2016, HISTOPATHOLOGY, V70, P946; Gazzaniga S, 2007, J INVEST DERMATOL, V127, P2031, DOI 10.1038/sj.jid.5700827; Herrmann A, 2010, CANCER RES, V70, P7455, DOI 10.1158/0008-5472.CAN-10-0736; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; KIM HA, 1995, ONCOGENE, V11, P325; Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213; Lederle W, 2011, INT J CANCER, V128, P2803, DOI 10.1002/ijc.25621; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Lin L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-217; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Muller M, 2008, GLIA, V56, P1005, DOI 10.1002/glia.20674; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Oberlander M, 2010, MOL CELL NEUROSCI, V45, P59, DOI 10.1016/j.mcn.2010.05.009; Pemov A, 2017, ONCOGENE, V36, P3168, DOI 10.1038/onc.2016.464; Prada CE, 2013, ACTA NEUROPATHOL, V125, P159, DOI 10.1007/s00401-012-1056-7; Prada CE, 2012, J PEDIATR-US, V160, P461, DOI 10.1016/j.jpeds.2011.08.051; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Siebert H, 2000, J NEUROIMMUNOL, V110, P177, DOI 10.1016/S0165-5728(00)00343-X; Staser K, 2010, BLOOD, V116, P157, DOI 10.1182/blood-2009-09-242875; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Wu J, 2017, ONCOGENE, V36, P1669, DOI 10.1038/onc.2016.386; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang J, 2010, JNCI-J NATL CANCER I, V102, P522, DOI 10.1093/jnci/djq044; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	39	26	27	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2876	2884		10.1038/s41388-018-0600-x	http://dx.doi.org/10.1038/s41388-018-0600-x			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542122	Green Accepted			2022-12-17	WOS:000464121600015
J	Renziehausen, A; Wang, HX; Rao, B; Weir, L; Lo Nigro, C; Lattanzio, L; Merlano, M; Vega-Rioja, A; Fernandez-Carranco, MD; Hajji, N; Matin, R; Harwood, C; Li, S; Sim, VR; O'Neill, K; Evans, A; Thompson, A; Szlosarek, P; Fleming, C; Stebbing, J; Proby, C; Tzakos, AG; Syed, N; Crook, T				Renziehausen, Alexander; Wang, Hexiao; Rao, Bhavya; Weir, Lynda; Lo Nigro, Cristiana; Lattanzio, Laura; Merlano, Marco; Vega-Rioja, Antonio; del Carmen Fernandez-Carranco, Maria; Hajji, Nabil; Matin, Rubeta; Harwood, Catherine; Li, Su; Sim, Van Ren; O'Neill, Kevin; Evans, Alan; Thompson, Alastair; Szlosarek, Peter; Fleming, Colin; Stebbing, Justin; Proby, Charlotte; Tzakos, Andreas G.; Syed, Nelofer; Crook, Tim			The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention	ONCOGENE			English	Article							CONVERTING-ENZYME-INHIBITORS; II TYPE-1 RECEPTOR; IMPROVED SURVIVAL; BREAST-CANCER; SERUM; TUMOR; ANGIOGENESIS; ANTAGONIST; BIOMARKER; AGTR1	Despite emergence of new systemic therapies, metastatic melanoma remains a challenging and often fatal form of skin cancer. The renin-angiotensin system (RAS) is a major physiological regulatory pathway controlling salt-water equilibrium, intravascular volume and blood pressure. Biological effects of the RAS are mediated by the vasoactive hormone angiotensin II (AngII) via two receptor subtypes, AT1R (encoded by AGTR1) and AT2R (encoded by AGTR2). We report decreasing expression and increasing CpG island methylation of AGTR1 in metastatic versus primary melanoma and detection in serum of methylated genomic DNA from the AGTR1 CpG island in metastatic melanoma implying that AGTR1 encodes a tumour suppressor function in melanoma. Consistent with this hypothesis, antagonism of AT1R using losartan or shRNA-mediated knockdown in melanoma cell lines expressing AGTR1 resulted in acquisition of the ability to proliferate in serum-free conditions. Conversely, ectopic expression of AGTR1 in cell lines lacking endogenous expression inhibits proliferation irrespective of the presence of AngII implying a ligand-independent suppressor function for AT1R. Treatment of melanoma cell lines expressing endogenous AT2R with either AngII or the AT2R-selective agonist Y6AII induces proliferation in serum-free conditions whereas the AT2R-specific antagonists PD123319 and EMA401 inhibit melanoma growth and angiogenesis and potentiate inhibitors of BRAF and MEK in cells with BRAF V600 mutations. Our results demonstrate that the RAS has both oncogenic and tumour suppressor functions in melanoma. Pharmacological inhibition of AT2R may provide therapeutic opportunities in melanomas expressing this receptor and AGTR1 CpG island methylation in serum may serve as a novel biomarker of metastatic melanoma.	[Renziehausen, Alexander; Hajji, Nabil; Syed, Nelofer] Imperial Coll London, Div Brain Sci, John Fulcher Neurooncol Lab, London, England; [Wang, Hexiao] China Med Univ, Dept Dermatol, Hosp 1, Shenyang, Liaoning, Peoples R China; [Rao, Bhavya; Weir, Lynda; Proby, Charlotte] Ninewells Hosp, Med Res Inst, Dundee, Scotland; [Rao, Bhavya; Weir, Lynda; Proby, Charlotte] Med Sch, Dundee, Scotland; [Lo Nigro, Cristiana; Lattanzio, Laura; Merlano, Marco] Osped San Croce & Carle, Dept Oncol, Cuneo, Italy; [Vega-Rioja, Antonio; del Carmen Fernandez-Carranco, Maria] Hosp Univ Virgen Macarena, Seville, Spain; [Matin, Rubeta; Harwood, Catherine] Barts & London Queen Marys Sch Med & Dent, London, England; [Li, Su] Royal Marsden Hosp, Fulham Rd, London, England; [Sim, Van Ren] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone ME16 9QQ, Kent, England; [O'Neill, Kevin] Charing Cross Hosp, Dept Neurosurg, London, England; [Evans, Alan] Ninewells Hosp, Dept Pathol, Dundee, Scotland; [Thompson, Alastair] MD Anderson Canc Ctr, Breast Surg Oncol, Houston, TX USA; [Szlosarek, Peter] Barts Canc Ctr, Dept Med Oncol, London, England; [Fleming, Colin; Proby, Charlotte] Ninewells Hosp, Dept Dermatol, Dundee, Scotland; [Stebbing, Justin] Imperial Coll, London, England; [Tzakos, Andreas G.] Univ Ioannina, Dept Chem, Ioannina, Greece; [Crook, Tim] St Lukes Canc Ctr, Guildford, Surrey, England	Imperial College London; China Medical University; University of Dundee; University of Dundee; Hospital Universitario Virgen Macarena; University of London; Queen Mary University London; Royal Marsden NHS Foundation Trust; Imperial College London; University of Dundee; University of Texas System; UTMD Anderson Cancer Center; University of Dundee; Imperial College London; University of Ioannina	Syed, N (corresponding author), Imperial Coll London, Div Brain Sci, John Fulcher Neurooncol Lab, London, England.; Crook, T (corresponding author), St Lukes Canc Ctr, Guildford, Surrey, England.	N.syed@imperial.ac.uk; timothycrook@nhs.net	tzakos, Andreas/V-9624-2019; Renziehausen, Alexander/AAE-4907-2020; hajji, nabil/AAV-1435-2020; Matin, Rubeta/AAB-1515-2019	Matin, Rubeta/0000-0002-9695-5412; Stebbing, Justin/0000-0002-1117-6947; Tzakos, Andreas/0000-0001-6391-0288; Vega Rioja, Antonio/0000-0003-4698-9697	Anonymous Trust; Tenovus Scotland; Melanoma Focus; Leng Foundation; Brain Tumour Research Campaign; Economica y Competitividad [SAF2014-60649-JN]; Fondo Europeo de Regional-FEDER	Anonymous Trust; Tenovus Scotland; Melanoma Focus; Leng Foundation; Brain Tumour Research Campaign; Economica y Competitividad; Fondo Europeo de Regional-FEDER	The work was supported by They The Anonymous Trust, Tenovus Scotland (to Dr. T.C.), Melanoma Focus (to C.P.), The Leng Foundation (to C.P.) and The Brain Tumour Research Campaign (to N.S.). Antonio Vega-Rioja is under contract Proyectos I + D + I para jovenes investigadores from de Economica y Competitividad (SAF2014-60649-JN) and co-funded by Fondo Europeo de Regional-FEDER. Tim Crook is a Scottish Senior Clinical Fellow in Medical Oncology.	Anand U, 2013, EUR J PAIN, V17, P1012, DOI 10.1002/j.1532-2149.2012.00269.x; Ateeq B, 2009, CELL CYCLE, V8, P3794, DOI 10.4161/cc.8.23.9976; Bar J, 2015, CLIN LUNG CANCER, V16, pE189, DOI 10.1016/j.cllc.2015.05.002; Beaumont KA, 2014, HEALTHCARE-BASEL, V2, P27, DOI 10.3390/healthcare2010027; Brunner D, 2010, ALTEX-ALTERN ANIM EX, V27, P53; Campbell DJ, 1996, CLIN EXP PHARMACOL P, V23, pS125, DOI 10.1111/j.1440-1681.1996.tb03073.x; Carpentier AF, 2012, EUR J NEUROL, V19, P1337, DOI 10.1111/j.1468-1331.2012.03766.x; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen XS, 2013, CANCER LETT, V328, P318, DOI 10.1016/j.canlet.2012.10.006; Corkery DP, 2011, BRIT J HAEMATOL, V153, P786, DOI 10.1111/j.1365-2141.2011.08661.x; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty Keith T, 2011, F1000 Med Rep, V3, P8, DOI 10.3410/M3-8; Guo RD, 2015, IUBMB LIFE, V67, P42, DOI 10.1002/iub.1342; Hanaizi Z, 2012, EUR J CANCER, V48, P237, DOI 10.1016/j.ejca.2011.09.018; Hatzimichael E, 2014, EXPERT REV MOL DIAGN, V14, P639, DOI 10.1586/14737159.2014.928204; Hesselink JMK, 2017, J PAIN RES, V10, P439, DOI 10.2147/JPR.S128520; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoshimoto S, 2012, J INVEST DERMATOL, V132, P1689, DOI 10.1038/jid.2012.36; Karnik SS, 2015, PHARMACOL REV, V67, P754, DOI 10.1124/pr.114.010454; Lo Nigro C, 2013, J INVEST DERMATOL, V133, P1278, DOI 10.1038/jid.2012.493; Magnani F, 2014, ACS CHEM BIOL, V9, P1420, DOI 10.1021/cb500063y; Miura S, 2005, J BIOL CHEM, V280, P18237, DOI 10.1074/jbc.M500639200; Moreno BH, 2015, SEMIN ONCOL, V42, P466, DOI 10.1053/j.seminoncol.2015.02.008; Moreno-Munoz D, 2015, EUR J CLIN INVEST, V45, P1325, DOI 10.1111/eci.12557; Nussberger J, 2002, HYPERTENSION, V39, pE1, DOI 10.1161/hy0102.102293; Otake AH, 2010, CANCER CHEMOTH PHARM, V66, P79, DOI 10.1007/s00280-009-1136-0; Patton EE, 2010, PIGM CELL MELANOMA R, V23, P314, DOI 10.1111/j.1755-148X.2010.00693.x; Reis IM, 2015, BRIT J CANCER, V113, P460, DOI 10.1038/bjc.2015.240; Rhodes DR, 2009, P NATL ACAD SCI USA, V106, P10284, DOI 10.1073/pnas.0900351106; Shah R, 2009, BRIT J CANCER, V100, P1687, DOI 10.1038/sj.bjc.6605042; Sullivan RJ, 2015, CLIN CANCER RES, V21, P2424, DOI 10.1158/1078-0432.CCR-14-1650; Syed N, 2006, BLOOD, V107, P250, DOI 10.1182/blood-2005-03-1194; Wolchok JD, 2015, CELL, V162, P937, DOI 10.1016/j.cell.2015.07.045; Yoon C, 2011, CAN MED ASSOC J, V183, pE1073, DOI 10.1503/cmaj.101497; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	35	26	26	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2320	2336		10.1038/s41388-018-0563-y	http://dx.doi.org/10.1038/s41388-018-0563-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478450	Green Accepted			2022-12-17	WOS:000462588000007
J	Weng, CC; Ding, PY; Liu, YH; Hawse, JR; Subramaniam, M; Wu, CC; Lin, YC; Chen, CY; Hung, WC; Cheng, KH				Weng, Ching-Chieh; Ding, Pei-Ya; Liu, Yu-Hsuan; Hawse, John R.; Subramaniam, Malayannan; Wu, Chia-Chen; Lin, Yu-Chun; Chen, Chiao-Yun; Hung, Wen-Chun; Cheng, Kuang-Hung			Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis	ONCOGENE			English	Article							P-SELECTIN; POOR-PROGNOSIS; ADVANCED-STAGE; EXPRESSION; GROWTH; ACTIVATION; ANTIGEN; CELLS; RAF; ADENOCARCINOMA	Prostate cancer (PCA), one of the most common malignant tumors in men, is the second leading cause of cancer deaths in males worldwide. We report here that PCA models harboring conditional LSL/Kras(G12D) or BRAF(F-V600E) allele with prostate-specific abrogated p53 function recapitulate human PCA precursor lesions, histopathology, and clinical behaviors. We found that the development of reprogrammed EMT-like phenotypes and skeleton metastatic behavior requires concurrent activated Kras and p53 depletion in PCA. Microarray analyses of primary PCA cells derived from these models identified several cancer stemness genes including CD24, EpCAM, and CD133 upregulated by KRAS(G12D). Among these stemness markers, we identified CD24 as a key driver of tumorigenesis and metastasis in vivo. These data demonstrate that specific factors involved in cancer stemness are critical for metastatic conversion of PCA and may be ideal targets for therapeutic intervention.	[Weng, Ching-Chieh; Ding, Pei-Ya; Liu, Yu-Hsuan; Wu, Chia-Chen; Lin, Yu-Chun; Cheng, Kuang-Hung] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan; [Hawse, John R.; Subramaniam, Malayannan] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Chen, Chiao-Yun] Kaohsiung Med Univ Hosp, Dept Med Imaging, Kaohsiung, Taiwan; [Hung, Wen-Chun; Cheng, Kuang-Hung] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Cheng, Kuang-Hung] Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan	National Sun Yat Sen University; Mayo Clinic; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Health Research Institutes - Taiwan; Kaohsiung Medical University	Cheng, KH (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan.; Cheng, KH (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan.; Cheng, KH (corresponding author), Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan.	khcheng@faculty.nsysu.edu.tw			MOST from the Ministry of Science and Technology, Taiwan, ROC [105-2320-B-110-004, 105-2321-B-400-010]; Kaohsiung Medical University, Kaohsiung, Taiwan [KMU-TP105G00]	MOST from the Ministry of Science and Technology, Taiwan, ROC; Kaohsiung Medical University, Kaohsiung, Taiwan	Supported by MOST grants 105-2320-B-110-004 and 105-2321-B-400-010 (to K.H. Cheng) from the Ministry of Science and Technology, Taiwan, ROC, and grant KMU-TP105G00 (to K.H. Cheng) from Kaohsiung Medical University, Kaohsiung, Taiwan.	Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; ARGUELLO F, 1988, CANCER RES, V48, P6876; Bedard PW, 2008, J PHARMACOL EXP THER, V324, P497, DOI 10.1124/jpet.107.128124; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; D'Amico AV, 2002, INT J RADIAT ONCOL, V53, P581, DOI 10.1016/S0360-3016(02)02797-9; Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008-5472.CAN-07-6541; Dong JT, 2006, J CELL BIOCHEM, V97, P433, DOI 10.1002/jcb.20696; Dosch JS, 2015, CANCER RES, V75, P4582, DOI 10.1158/0008-5472.CAN-14-2793; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Gao JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102590; Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35; Gires O, 2009, NAT REV CANCER, V9, P143, DOI 10.1038/nrc2499-c1; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gu Z, 2000, ONCOGENE, V19, P1288, DOI 10.1038/sj.onc.1203426; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; ISAACS WB, 1991, CANCER RES, V51, P4716; Jeong JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003949; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; KANO J, 1994, J CELL PHYSIOL, V161, P358, DOI 10.1002/jcp.1041610221; Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325; Kristiansen G, 2004, PROSTATE, V58, P183, DOI 10.1002/pros.10324; Lee JW, 2012, J NAT MED-TOKYO, V66, P8, DOI 10.1007/s11418-011-0537-7; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin CW, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0080883, 10.1371/journal.pone.0056499, 10.1371/journal.pone.0070187, 10.1371/journal.pone.0065734]; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Nubel T, 2009, MOL CANCER RES, V7, P285, DOI 10.1158/1541-7786.MCR-08-0200; Overdevest JB, 2012, P NATL ACAD SCI USA, V109, pE3588, DOI 10.1073/pnas.1113960109; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sagiv E, 2008, CANCER RES, V68, P2803, DOI 10.1158/0008-5472.CAN-07-6463; Salmaninejad A, 2015, CLIN LAB, V61, P749, DOI 10.7754/Clin.Lab.2014.141210; Silan F, 2012, MOL BIOL REP, V39, P1595, DOI 10.1007/s11033-011-0898-8; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67; Thudi NK, 2011, PROSTATE, V71, P615, DOI 10.1002/pros.21277; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Weng CC, 2017, ONCOGENE, V36, P5532, DOI 10.1038/onc.2017.155; Weng CC, 2016, PANCREAS, V45, P443, DOI 10.1097/MPA.0000000000000460; Yang CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099412; Yang XR, 2009, CLIN CANCER RES, V15, P5518, DOI 10.1158/1078-0432.CCR-09-0151	50	26	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2005	2019		10.1038/s41388-018-0575-7	http://dx.doi.org/10.1038/s41388-018-0575-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30467381	Green Published, hybrid			2022-12-17	WOS:000461822600002
J	Song, ZY; Wang, F; Cui, SX; Gao, ZH; Qu, XJ				Song, Zhi-Yu; Wang, Feng; Cui, Shu-Xiang; Gao, Zu-Hua; Qu, Xian-Jun			CXCR7/CXCR4 heterodimer-induced histone demethylation: a new mechanism of colorectal tumorigenesis	ONCOGENE			English	Article							SUPPRESSOR-CELLS; CHEMOKINE RECEPTOR; BETA-ARRESTIN; CANCER; CXCR7; REGULATORS; IMMUNE; TRIMETHYLATION; ACTIVATION; METASTASES	Both chemokine receptors (CXCRs) 7 and 4 can facilitate immune cell migration and mediate a vast array of physiological and pathological events. Herein we report, in both human and animal studies, that these two CXCRs can form heterodimers in vivo and promote colorectal tumorigenesis through histone demethylation. Compared with adjacent non-neoplastic tissue, human colorectal cancer (CRC) tissue showed a significant higher expression of CXCR4 and CXCR7, which was colocalized in the cancer cell epithelium. The CXCR/CXCR4 heterodimerization was associated with increased histone demethylase JMJD2A. Villin-CXCR7-CXCR4 transgenic mice demonstrated a greater degree of exacerbated colitis and tumorigenesis than villin-CXCR7 and villin-CXCR4 mice. The CXCR7/CXCR4 heterodimerization also promoted APC mutation-driven colorectal tumorigenesis in APC(Min/+)/villin-CXCR7-CXCR4 mice. Further analysis showed that the CXCR7/CXCR4 heterodimer induced nuclear beta arr1 recruitment and histone demethylase JMJD2A, leading to histone demethylation and resulting in transcription of inflammatory factors and oncogenes. This study uncovered a novel mechanism of colorectal tumorigenesis through the CXCR7/CXCR4 heterodimer-induced histone demethylation. Inhibition of CXCR7/CXCR4 heterodimer-induced histone demethylation could be an effective strategy for the prevention and treatment of colorectal cancer.	[Song, Zhi-Yu; Qu, Xian-Jun] Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China; [Wang, Feng; Cui, Shu-Xiang] McGill Univ, Dept Pathol, Montreal, PQ, Canada; [Gao, Zu-Hua] Capital Med Univ, Sch Publ Hlth, Toxicol & Sanit Chem, Beijing, Peoples R China; [Song, Zhi-Yu] Henan Prov Peoples Hosp, Dept Pharm, Zhengzhou, Henan, Peoples R China	Capital Medical University; McGill University; Capital Medical University; Zhengzhou University	Qu, XJ (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China.; Gao, ZH (corresponding author), Capital Med Univ, Sch Publ Hlth, Toxicol & Sanit Chem, Beijing, Peoples R China.	zu-hua.gao@mcgill.ca; quxj@ccmu.edu.cn			Natural Science Foundation of China [81673449, 91629303]; Beijing Natural Science Foundation Program and Scientific Research Program of Municipal Commission of Education [KZ201710025020, KZ201810025033]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation Program and Scientific Research Program of Municipal Commission of Education	This work was supported by Natural Science Foundation of China (81673449 and 91629303) and Beijing Natural Science Foundation Program and Scientific Research Program of Municipal Commission of Education (KZ201710025020 and KZ201810025033).	Atreya I, 2008, EXPERT REV ANTICANC, V8, P561, DOI 10.1586/14737140.8.4.561; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Beaulieu JM, 2005, CELL, V123, P755, DOI 10.1016/j.cell.2005.11.010; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; COOPER HS, 1993, LAB INVEST, V69, P238; Decaillot FM, 2011, J BIOL CHEM, V286, P32188, DOI 10.1074/jbc.M111.277038; Dhayalan A, 2010, J BIOL CHEM, V285, P26114, DOI 10.1074/jbc.M109.089433; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Graham GJ, 2009, EUR J IMMUNOL, V39, P342, DOI 10.1002/eji.200838858; Guerra-Calderas L, 2015, CANCER GENET-NY, V208, P215, DOI 10.1016/j.cancergen.2014.11.001; Haile LA, 2008, GASTROENTEROLOGY, V135, P871, DOI 10.1053/j.gastro.2008.06.032; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618; Liu XQ, 2017, BIOMATERIALS, V127, P61, DOI 10.1016/j.biomaterials.2017.02.035; Luker KE, 2010, ONCOGENE, V29, P4599, DOI 10.1038/onc.2010.212; Meidenbauer JJ, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-23; Saleiro D, 2012, INT J CANCER, V131, P2553, DOI 10.1002/ijc.27578; Salifou K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10174; Sanchez-Martin L, 2013, TRENDS MOL MED, V19, P12, DOI 10.1016/j.molmed.2012.10.004; Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; Sun CC, 2014, PATHOL RES PRACT, V210, P668, DOI 10.1016/j.prp.2014.06.016; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Werner L, 2013, THERANOSTICS, V3, P40, DOI 10.7150/thno.5135; Werner L, 2011, J LEUKOCYTE BIOL, V90, P583, DOI 10.1189/jlb.0111101; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wu T, 2016, ONCOTARGET, V7, P19548, DOI 10.18632/oncotarget.6969; Xu GL, 2015, J BIOL CHEM, V290, P5414, DOI 10.1074/jbc.M114.610345; Yang D, 2015, INT J CLIN EXP PATHO, V8, P13051; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang L, 2016, ONCOGENE, V35, P5641, DOI 10.1038/onc.2016.100; Zhang SS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-85; Zhou ZH, 2015, J PATHOL, V236, P467, DOI 10.1002/path.4541	42	26	26	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1560	1575		10.1038/s41388-018-0519-2	http://dx.doi.org/10.1038/s41388-018-0519-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30337690				2022-12-17	WOS:000459945800014
